{
  "$schema": "folio-library-document/v1",
  "id": "10665-381036",
  "title": "WHO consolidated guidelines on tuberculosis: module 3: diagnosis: web annex B: evidence synthesis and analysis",
  "variant": "pdf",
  "pages": 1169,
  "tocSource": "undetermined",
  "tocMethod": "contents",
  "toc": [],
  "sections": [
    {
      "id": "page-001",
      "number": null,
      "title": "Page 1",
      "level": 1,
      "pageStart": 1,
      "pageEnd": 1,
      "labelStart": null,
      "labelEnd": null,
      "words": 15,
      "summary": {
        "text": "The title page of Web Annex B (evidence synthesis and analysis) to WHO's consolidated tuberculosis guidelines, Module 3: Diagnosis.",
        "status": "draft"
      },
      "keywords": [],
      "extract": "WHO consolidated guidelines on tuberculosis. Module 3: Diagnosis Web Annex B. Evidence synthesis and analysis",
      "extractCut": false,
      "blocks": [
        "library/10665-381036/blocks/prose-page-001"
      ]
    },
    {
      "id": "page-002",
      "number": null,
      "title": "Page 2",
      "level": 1,
      "pageStart": 2,
      "pageEnd": 2,
      "labelStart": null,
      "labelEnd": null,
      "words": 537,
      "summary": {
        "text": "The copyright and cataloguing page, with Creative Commons licence terms, noting that the annex supports the TB diagnosis guideline and is published for transparency. It also lists the usual WHO disclaimers on third-party materials and liability.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "creative commons",
          "heading": false
        },
        {
          "term": "suggested citation",
          "heading": false
        },
        {
          "term": "licence",
          "heading": false
        },
        {
          "term": "igo",
          "heading": false
        },
        {
          "term": "health organization",
          "heading": false
        },
        {
          "term": "world health",
          "heading": false
        },
        {
          "term": "consolidated guidelines",
          "heading": false
        },
        {
          "term": "work",
          "heading": false
        }
      ],
      "extract": "© World Health Organization 2025 Some rights reserved. This work is available under the Creative Commons Attribution-NonCommercial- ShareAlike 3.0 IGO licence (CC BY-NC-SA 3.0 IGO; https://creativecommons.org/licenses/by-nc- sa/3.0/igo). Under the terms of this licence, you may copy, redistribute and adapt the work for non-commercial purposes, provided the work is appropriately cited, as indicated below. In any use",
      "extractCut": true,
      "blocks": [
        "library/10665-381036/blocks/prose-page-002"
      ]
    },
    {
      "id": "page-003",
      "number": null,
      "title": "Page 3",
      "level": 1,
      "pageStart": 3,
      "pageEnd": 3,
      "labelStart": "ii",
      "labelEnd": "ii",
      "words": 477,
      "summary": {
        "text": "The first page of the table of contents, listing web annexes B.1 onwards that cover reviews of low complexity automated NAATs, other diagnostic tests and qualitative syntheses on targeted next-generation sequencing.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "web annex",
          "heading": false
        },
        {
          "term": "acid amplification",
          "heading": false
        },
        {
          "term": "nucleic acid",
          "heading": false
        },
        {
          "term": "automated nucleic",
          "heading": false
        },
        {
          "term": "automated naats",
          "heading": false
        },
        {
          "term": "amplification tests",
          "heading": false
        },
        {
          "term": "extrapulmonary tuberculosis",
          "heading": false
        },
        {
          "term": "complexity automated",
          "heading": false
        }
      ],
      "extract": "ii Web Annex B.1. Low complexity automated nucleic acid amplification tests (LC-aNAATs) for detection of pulmonary TB and resistance to isoniazid/rifampicin in adults and adolescents: a systematic review of diagnostic accuracy ........................................................................................... 1 Web Annex B.2. Low complexity automated NAATs for pulmonary and extrapulmonary tuberculosis and",
      "extractCut": true,
      "blocks": [
        "library/10665-381036/blocks/prose-page-003"
      ]
    },
    {
      "id": "page-004",
      "number": null,
      "title": "Page 4",
      "level": 1,
      "pageStart": 4,
      "pageEnd": 4,
      "labelStart": "iii",
      "labelEnd": "iii",
      "words": 69,
      "summary": {
        "text": "The final page of the table of contents, listing annexes B.20 to B.23 on the accuracy, safety, cost-effectiveness and economic modelling of TB antigen-based skin tests.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "antigen-based skin",
          "heading": false
        },
        {
          "term": "tuberculosis antigen-based",
          "heading": false
        },
        {
          "term": "mycobacterium tuberculosis",
          "heading": false
        }
      ],
      "extract": "iii Web Annex B20. Accuracy of Mycobacterium tuberculosis antigen-based skin tests: a systematic review and meta-analysis ................................................................................................................ 920 Web Annex B 21. Safety of Mycobacterium tuberculosis antigen-based skin tests: a systematic review and meta-analysis",
      "extractCut": true,
      "blocks": [
        "library/10665-381036/blocks/prose-page-004"
      ]
    },
    {
      "id": "page-005",
      "number": null,
      "title": "Page 5",
      "level": 1,
      "pageStart": 5,
      "pageEnd": 5,
      "labelStart": "iv",
      "labelEnd": "iv",
      "words": 39,
      "summary": {
        "text": "A brief acknowledgement thanking the experts who carried out the systematic reviews in the web annex.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "invaluable",
          "heading": false
        },
        {
          "term": "affiliations",
          "heading": false
        },
        {
          "term": "wishes",
          "heading": false
        }
      ],
      "extract": "iv Acknowledgements The World Health Organization (WHO) wishes to acknowledge the invaluable contributions made by all the experts who carried out the systematic reviews included in this web annex. Their names and affiliations are included in the sections concerned.",
      "extractCut": false,
      "blocks": [
        "library/10665-381036/blocks/prose-page-005"
      ]
    },
    {
      "id": "page-006",
      "number": null,
      "title": "Page 6",
      "level": 1,
      "pageStart": 6,
      "pageEnd": 6,
      "labelStart": "1",
      "labelEnd": "1",
      "words": 184,
      "summary": {
        "text": "The title, author list and affiliations for Web Annex B.1, a systematic review of how accurately low complexity automated nucleic acid amplification tests (LC-aNAATs) detect pulmonary TB and isoniazid or rifampicin resistance in adults and adolescents.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "tropical medicine",
          "heading": false
        },
        {
          "term": "liverpool school",
          "heading": false
        },
        {
          "term": "infectious diseases",
          "heading": false
        },
        {
          "term": "usa",
          "heading": false
        },
        {
          "term": "division",
          "heading": false
        },
        {
          "term": "critical care",
          "heading": false
        },
        {
          "term": "seattle",
          "heading": false
        },
        {
          "term": "university",
          "heading": false
        }
      ],
      "extract": "Web Annex B.1. Low complexity automated nucleic acid amplification tests (LC-aNAATs) for detection of pulmonary TB and resistance to isoniazid/rifampicin in adults and adolescents: a systematic review of diagnostic accuracy David J. Horne1, Leeberk Raja Inbaraj2, Jerry S. Zifodya3, Adrienne E. Shapiro4, Adhin Bhaskar2, E. Chandler Church5, Jefferson Daniel6, Alexander W. Kay7, Jonah Kreniske8, Vittoria Lutje9,",
      "extractCut": true,
      "blocks": [
        "library/10665-381036/blocks/prose-page-006"
      ]
    },
    {
      "id": "page-007",
      "number": null,
      "title": "Page 7",
      "level": 1,
      "pageStart": 7,
      "pageEnd": 7,
      "labelStart": "2",
      "labelEnd": "2",
      "words": 543,
      "summary": {
        "text": "Gives background for the LC-aNAAT review, citing 2022 global estimates of TB incidence and rifampicin-resistant TB and WHO's recommendation of rapid molecular tests as initial diagnostics. It explains WHO's grouping of tests into classes and the clinical importance of detecting rifampicin and isoniazid resistance.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "truenat mtb",
          "heading": false
        },
        {
          "term": "genexpert mtb",
          "heading": false
        },
        {
          "term": "mtb rif",
          "heading": false
        },
        {
          "term": "rifampicin resistance",
          "heading": false
        },
        {
          "term": "drug resistance",
          "heading": false
        },
        {
          "term": "molecular tests",
          "heading": false
        },
        {
          "term": "rr-tb",
          "heading": false
        },
        {
          "term": "second-line drugs",
          "heading": false
        }
      ],
      "extract": "Background There were an estimated 10.6 million people who newly developed tuberculosis (TB) in 2022 and of the 7.5 million reported cases, 83% involved the lungs (WHO Global Tuberculosis Report 2023). In 2022, there were about 410,000 new cases of rifampicin-resistant or multidrug resistant TB. Several rapid molecular tests are recommended by the WHO as the initial diagnostic test for TB, some of which can detect",
      "extractCut": true,
      "blocks": [
        "library/10665-381036/blocks/prose-page-007"
      ]
    },
    {
      "id": "page-008",
      "number": null,
      "title": "Page 8",
      "level": 1,
      "pageStart": 8,
      "pageEnd": 8,
      "labelStart": "3",
      "labelEnd": "3",
      "words": 457,
      "summary": {
        "text": "Lists the index tests in the LC-aNAAT class and describes the Xpert MTB/RIF Ultra and Truenat assays, including how they detect TB, report semi-quantitative results and target the rpoB gene for rifampicin resistance.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "mtb detected",
          "heading": false
        },
        {
          "term": "truenat mtb",
          "heading": false
        },
        {
          "term": "resistance detected",
          "heading": false
        },
        {
          "term": "detected medium",
          "heading": false
        },
        {
          "term": "mtb rif",
          "heading": false
        },
        {
          "term": "truenat mtb-rif",
          "heading": false
        },
        {
          "term": "truenat assays",
          "heading": false
        },
        {
          "term": "resistance indeterminate",
          "heading": false
        }
      ],
      "extract": "Index tests The individual LC-aNAATs are: ● GeneXpert MTB/RIF Ultra; ● Truenat (Truenat MTB Plus and Truenat MTB‐RIF Dx); ● STANDARD M10, SD Biosensor; ● IRON-qPCR, BIONEER For ease of reference, we will refer to GeneXpert MTB/RIF Ultra as Xpert Ultra and the two Truenat assays as Truenat except where necessary to refer to a specific assay. Xpert Ultra, Cepheid, USA Xpert Ultra is a NAAT that functions as an",
      "extractCut": true,
      "blocks": [
        "library/10665-381036/blocks/prose-page-008"
      ]
    },
    {
      "id": "page-009",
      "number": null,
      "title": "Page 9",
      "level": 1,
      "pageStart": 9,
      "pageEnd": 9,
      "labelStart": "4",
      "labelEnd": "4",
      "words": 471,
      "summary": {
        "text": "Describes the STANDARD M10 molecular system and its TB assays, then outlines the review's methods, including literature searches carried out in October 2023 across several databases.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "iron qpcr",
          "heading": false
        },
        {
          "term": "mtb ntm",
          "heading": false
        },
        {
          "term": "simultaneous detection",
          "heading": false
        },
        {
          "term": "smear status",
          "heading": false
        },
        {
          "term": "ultra trace",
          "heading": false
        },
        {
          "term": "standard mdr-tb",
          "heading": false
        },
        {
          "term": "test accuracy",
          "heading": false
        },
        {
          "term": "molecular diagnostics",
          "heading": false
        }
      ],
      "extract": "The STANDARD M10 is an in vitro molecular diagnostics system that automatically extracts and amplifies nucleic acids (DNA, RNA) from the collected samples, and analyses the data from amplification in real-time, by combining the processes of isothermal amplification and real-time PCR in a single platform using all-in-one cartridge systems. There are two variations currently available for TB detection: STANDARD™ M10",
      "extractCut": true,
      "blocks": [
        "library/10665-381036/blocks/prose-page-009"
      ]
    },
    {
      "id": "page-010",
      "number": null,
      "title": "Page 10",
      "level": 1,
      "pageStart": 10,
      "pageEnd": 10,
      "labelStart": "5",
      "labelEnd": "5",
      "words": 493,
      "summary": {
        "text": "Lists further sources searched for the LC-aNAAT review, including trial registries, dissertations and a WHO public call for data, and sets out eligibility criteria. It introduces the two reference standards used, culture and a composite reference standard.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "bronchial wash",
          "heading": false
        },
        {
          "term": "tracheal aspirate",
          "heading": false
        },
        {
          "term": "reference standards",
          "heading": false
        },
        {
          "term": "composite reference",
          "heading": false
        },
        {
          "term": "index test",
          "heading": false
        },
        {
          "term": "rifampicin resistance",
          "heading": false
        },
        {
          "term": "test technologies",
          "heading": false
        },
        {
          "term": "xpert ultra",
          "heading": false
        }
      ],
      "extract": "Cochrane Library, issue 10, October 2023; MEDLINE (Ovid); Embase (Ovid); Science Citation Index and Biosis previews (ISI Web of Knowledge); WHO Global Index Medicus; and SCOPUS (Elsevier). VL searched ClinicalTrials.gov (clinicaltrials.gov/) and the WHO Clinical Trials Registry platform (www.who.int/trialsearch) to identify ongoing trials. VL also searched for relevant dissertations in ProQuest Dissertations &",
      "extractCut": true,
      "blocks": [
        "library/10665-381036/blocks/prose-page-010"
      ]
    },
    {
      "id": "page-011",
      "number": null,
      "title": "Page 11",
      "level": 1,
      "pageStart": 11,
      "pageEnd": 11,
      "labelStart": "6",
      "labelEnd": "6",
      "words": 483,
      "summary": {
        "text": "Defines the culture and composite reference standards, then describes data extraction, quality assessment with QUADAS-2 and planned meta-analyses of sensitivity and specificity by subgroup such as smear and HIV status.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "summary estimate",
          "heading": false
        },
        {
          "term": "assay lies",
          "heading": false
        },
        {
          "term": "point estimate",
          "heading": false
        },
        {
          "term": "drug resistance",
          "heading": false
        },
        {
          "term": "percentage points",
          "heading": false
        },
        {
          "term": "composite reference",
          "heading": false
        },
        {
          "term": "drug resistant",
          "heading": false
        },
        {
          "term": "overall point",
          "heading": false
        }
      ],
      "extract": "Culture (microbiological reference standard) Culture is considered the best reference standard for TB using either automated liquid culture or solid culture methods. Since both culture methods are used interchangeably in clinical practice (Moreira 2015), a positive result either alone or in combination was accepted as a diagnosis of TB while all negative cultures indicated no TB. Composite reference standard (CRS)",
      "extractCut": true,
      "blocks": [
        "library/10665-381036/blocks/prose-page-011"
      ]
    },
    {
      "id": "page-012",
      "number": null,
      "title": "Page 12",
      "level": 1,
      "pageStart": 12,
      "pageEnd": 12,
      "labelStart": "7",
      "labelEnd": "7",
      "words": 350,
      "summary": {
        "text": "Explains the class pooling criteria and bivariate meta-analysis models used for the LC-aNAAT review, then reports search results for Xpert Ultra, yielding 33 included studies.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "remaining reports",
          "heading": false
        },
        {
          "term": "pooling criteria",
          "heading": false
        },
        {
          "term": "diagnostic studies",
          "heading": false
        },
        {
          "term": "zar",
          "heading": false
        },
        {
          "term": "mishra",
          "heading": false
        },
        {
          "term": "schünemann",
          "heading": false
        },
        {
          "term": "nicol",
          "heading": false
        },
        {
          "term": "class",
          "heading": false
        }
      ],
      "extract": "LC-aNAAT class, we applied the pooling criteria that was developed by the WHO Global TB Programme and Guideline Development Group (GDG) members for a previous GDG meeting. The class pooling criteria is given in the Box above. We performed meta-analysis using the bivariate model to estimate summary sensitivity and specificity. When there was sparse data, we simplified the model to a univariate random effects or fixed",
      "extractCut": true,
      "blocks": [
        "library/10665-381036/blocks/prose-page-012"
      ]
    },
    {
      "id": "page-013",
      "number": null,
      "title": "Page 13",
      "level": 1,
      "pageStart": 13,
      "pageEnd": 13,
      "labelStart": "8",
      "labelEnd": "8",
      "words": 8,
      "summary": {
        "text": "A caption for the study flow diagram for Xpert Ultra.",
        "status": "draft"
      },
      "keywords": [],
      "extract": "Figure 1. Study flow diagram for Xpert Ultra",
      "extractCut": false,
      "blocks": [
        "library/10665-381036/blocks/prose-page-013",
        "library/10665-381036/blocks/figure-img-p013-1"
      ]
    },
    {
      "id": "page-014",
      "number": null,
      "title": "Page 14",
      "level": 1,
      "pageStart": 14,
      "pageEnd": 14,
      "labelStart": "9",
      "labelEnd": "9",
      "words": 87,
      "summary": {
        "text": "Reports search results for the Truenat assays, with five reports included in the review, and captions the corresponding study flow diagram.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "truenat",
          "heading": false
        },
        {
          "term": "articles",
          "heading": false
        },
        {
          "term": "meta-analysis",
          "heading": false
        }
      ],
      "extract": "Search Results: Truenat We identified 1175 research articles for screening from searches of electronic sources. After removing duplicate studies (n=524), we screened the titles and abstracts of 651 unique articles and excluded 617. We identified four reports through citation searching and WHO call for data. We performed full- text screening of 38 articles and included five reports of which four contributed to the",
      "extractCut": true,
      "blocks": [
        "library/10665-381036/blocks/prose-page-014",
        "library/10665-381036/blocks/figure-img-p014-1"
      ]
    },
    {
      "id": "page-015",
      "number": null,
      "title": "Page 15",
      "level": 1,
      "pageStart": 15,
      "pageEnd": 15,
      "labelStart": "10",
      "labelEnd": "10",
      "words": 243,
      "summary": {
        "text": "Reports that no eligible studies were found for STANDARD M10 or other new LC-aNAATs and summarizes the 36 included studies, mostly of Xpert Ultra, with eleven assessing rifampicin resistance detection.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "evaluated truenat",
          "heading": false
        },
        {
          "term": "truenat mtb",
          "heading": false
        },
        {
          "term": "xpert ultra",
          "heading": false
        },
        {
          "term": "mtb plus",
          "heading": false
        },
        {
          "term": "evaluated both",
          "heading": false
        },
        {
          "term": "gomathi",
          "heading": false
        },
        {
          "term": "penn-nicholson",
          "heading": false
        },
        {
          "term": "jose",
          "heading": false
        }
      ],
      "extract": "Search Results: STANDARD M10 and other index tests We screened 34 titles and abstracts and excluded 32. We assessed the full texts of two articles and found none eligible for this review (Figure 3). Figure 3. Study flow diagram for STANDARD M10 and other new LC-aNAATs Characteristics of included studies There were 36 included studies: 31 that only evaluated Xpert Ultra (including one study based on two reports—Nicol",
      "extractCut": true,
      "blocks": [
        "library/10665-381036/blocks/prose-page-015",
        "library/10665-381036/blocks/figure-img-p015-1"
      ]
    },
    {
      "id": "page-016",
      "number": null,
      "title": "Page 16",
      "level": 1,
      "pageStart": 16,
      "pageEnd": 16,
      "labelStart": "11",
      "labelEnd": "11",
      "words": 111,
      "summary": {
        "text": "Describes the respiratory specimen types used in the included studies, mainly sputum, with some using bronchoalveolar lavage or pooled samples.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "sputum samples",
          "heading": false
        },
        {
          "term": "xpert ultra",
          "heading": false
        },
        {
          "term": "bal",
          "heading": false
        },
        {
          "term": "sava",
          "heading": false
        }
      ],
      "extract": "Respiratory specimen types Most included studies used sputum for their evaluation of LC-aNAATs. Three studies exclusively evaluated Xpert Ultra testing of BAL samples (Chien 2020, Park 2019, Zhang 2021) while one study included BAL in addition to sputum samples (Sava 2023). One study (Penn-Nicholson 2021) pooled multiple sputum specimens per participant in the reference laboratory and used unpooled sputum in the",
      "extractCut": true,
      "blocks": [
        "library/10665-381036/blocks/prose-page-016"
      ]
    },
    {
      "id": "page-017",
      "number": null,
      "title": "Page 17",
      "level": 1,
      "pageStart": 17,
      "pageEnd": 17,
      "labelStart": "12",
      "labelEnd": "12",
      "words": 270,
      "summary": {
        "text": "The first page of Table 1, giving characteristics of the Xpert Ultra studies, such as reference standard, design, share of people with HIV, setting, age group, country and specimen type.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "fresh sputum",
          "heading": false
        },
        {
          "term": "solid liquid",
          "heading": false
        },
        {
          "term": "inpatient outpatient",
          "heading": false
        },
        {
          "term": "liquid culture",
          "heading": false
        },
        {
          "term": "frozen sputum",
          "heading": false
        },
        {
          "term": "prospective cohort",
          "heading": false
        },
        {
          "term": "rsa",
          "heading": false
        },
        {
          "term": "yes",
          "heading": false
        }
      ],
      "extract": "12 Table 1. Xpert Ultra: Characteristics of included studies Study Reference standard Study design Proportion of PLHIV Clinical setting Age group Country High TB burden? Specimen type Xpert Ultra non-determinate for detection of MTBa % (number/total) Aguilera-Alonso 2022 Solid & liquid – 1 to 3 specimens Prospective Cohort None Inpatient Adolescents Spain No Fresh sputum NR Berhanu 2018 Solid (LJ) & liquid",
      "extractCut": true,
      "blocks": [
        "library/10665-381036/blocks/prose-page-017",
        "library/10665-381036/blocks/table-001"
      ]
    },
    {
      "id": "page-018",
      "number": null,
      "title": "Page 18",
      "level": 1,
      "pageStart": 18,
      "pageEnd": 18,
      "labelStart": "13",
      "labelEnd": "13",
      "words": 305,
      "summary": {
        "text": "Continues Table 1 of Xpert Ultra study characteristics, covering further studies from South Africa, Malawi, Switzerland, China and elsewhere.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "fresh sputum",
          "heading": false
        },
        {
          "term": "solid liquid",
          "heading": false
        },
        {
          "term": "inpatient outpatient",
          "heading": false
        },
        {
          "term": "frozen sputum",
          "heading": false
        },
        {
          "term": "outpatient adults",
          "heading": false
        },
        {
          "term": "outpatient adolescents",
          "heading": false
        },
        {
          "term": "cross-sectional",
          "heading": false
        },
        {
          "term": "yes",
          "heading": false
        }
      ],
      "extract": "13 Study Reference standard Study design Proportion of PLHIV Clinical setting Age group Country High TB burden? Specimen type Xpert Ultra non-determinate for detection of MTBa % (number/total) Mishra 2020b Liquid Cross-sectional 44% (152/346) Unknown Adults RSA Yes Fresh sputum NR Moodley 2022 Liquid Cross-sectional 38% (298/789) Outpatient Adults RSA Yes Fresh sputum <1% (1/789) Mukoka 2023 Solid & liquid RCT 100%",
      "extractCut": true,
      "blocks": [
        "library/10665-381036/blocks/prose-page-018"
      ]
    },
    {
      "id": "page-019",
      "number": null,
      "title": "Page 19",
      "level": 1,
      "pageStart": 19,
      "pageEnd": 19,
      "labelStart": "14",
      "labelEnd": "14",
      "words": 104,
      "summary": {
        "text": "Ends Table 1 of Xpert Ultra study characteristics, with abbreviations for culture media and other terms.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "rsa",
          "heading": false
        },
        {
          "term": "liquid",
          "heading": false
        },
        {
          "term": "fresh",
          "heading": false
        },
        {
          "term": "inpatient",
          "heading": false
        }
      ],
      "extract": "14 Study Reference standard Study design Proportion of PLHIV Clinical setting Age group Country High TB burden? Specimen type Xpert Ultra non-determinate for detection of MTBa % (number/total) cohort & adults sputum Wang 2022 Liquid Cross-sectional 0% (0/1079) Inpatient Adolescents & adults China Yes Fresh sputum <0.1% (4/1079) Zar 2019 Liquid - 2 specimens Prospective cohort 0% (0/5) Inpatient Adolescents RSA Yes",
      "extractCut": true,
      "blocks": [
        "library/10665-381036/blocks/prose-page-019"
      ]
    },
    {
      "id": "page-020",
      "number": null,
      "title": "Page 20",
      "level": 1,
      "pageStart": 20,
      "pageEnd": 20,
      "labelStart": "15",
      "labelEnd": "15",
      "words": 180,
      "summary": {
        "text": "Table 2, giving characteristics of the Truenat studies, conducted mainly in India and several African and Asia-Pacific countries, including rates of non-determinate results.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "fresh sputum",
          "heading": false
        },
        {
          "term": "reported outpatients",
          "heading": false
        },
        {
          "term": "repeat testing",
          "heading": false
        },
        {
          "term": "mgit",
          "heading": false
        },
        {
          "term": "yes",
          "heading": false
        },
        {
          "term": "tertiary",
          "heading": false
        },
        {
          "term": "plhiv",
          "heading": false
        }
      ],
      "extract": "15 Table 2. Truenat assays: Characteristics of included studies Study Reference standard Study design Proportion of PLHIV Clinical setting Age group Country High TB burden Specimen type Truenat non- determinate % (number/total) Jose 2024 LJ & MGIT Cross- sectional (Retrospective) Not reported Outpatients & inpatients from tertiary care hospital Adolescents & adults India Yes Fresh Not reported Gomathi 2020 MGIT",
      "extractCut": true,
      "blocks": [
        "library/10665-381036/blocks/prose-page-020",
        "library/10665-381036/blocks/table-002"
      ]
    },
    {
      "id": "page-021",
      "number": null,
      "title": "Page 21",
      "level": 1,
      "pageStart": 21,
      "pageEnd": 21,
      "labelStart": "16",
      "labelEnd": "16",
      "words": 302,
      "summary": {
        "text": "Summarizes the risk of bias and applicability assessment for the included LC-aNAAT studies, listing those judged high risk or of concern and why.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "applicability concern",
          "heading": false
        },
        {
          "term": "tertiary referral",
          "heading": false
        },
        {
          "term": "patient selection",
          "heading": false
        },
        {
          "term": "concern based",
          "heading": false
        },
        {
          "term": "referral hospital",
          "heading": false
        },
        {
          "term": "applicability assessment",
          "heading": false
        },
        {
          "term": "reference standard",
          "heading": false
        },
        {
          "term": "bias",
          "heading": false
        }
      ],
      "extract": "Methodological quality Figure 4 summarises the results of the risk of bias and applicability assessment for each of the included studies. The following studies were assessed as “high” risk of bias and/or applicability concern: ● Aguilera-Alonso 2022 - Patient selection, applicability concern; Reference standard applicability concern based on recruitment of participants exclusively from tertiary referral hospitals",
      "extractCut": true,
      "blocks": [
        "library/10665-381036/blocks/prose-page-021"
      ]
    },
    {
      "id": "page-022",
      "number": null,
      "title": "Page 22",
      "level": 1,
      "pageStart": 22,
      "pageEnd": 22,
      "labelStart": "17",
      "labelEnd": "17",
      "words": 13,
      "summary": {
        "text": "A caption for the summary figure of risk of bias and applicability across studies of respiratory specimens.",
        "status": "draft"
      },
      "keywords": [],
      "extract": "Figure 5. Risk of bias and applicability summary: respiratory specimens and microbiological reference",
      "extractCut": false,
      "blocks": [
        "library/10665-381036/blocks/prose-page-022",
        "library/10665-381036/blocks/figure-img-p022-1"
      ]
    },
    {
      "id": "page-023",
      "number": null,
      "title": "Page 23",
      "level": 1,
      "pageStart": 23,
      "pageEnd": 23,
      "labelStart": "18",
      "labelEnd": "18",
      "words": 423,
      "summary": {
        "text": "Begins the findings of the LC-aNAAT review, introducing Table 3 of summary sensitivity and specificity estimates for the class and individual tests. The table rows cover analyses by reference standard, specimen and smear status.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "mrs",
          "heading": false
        },
        {
          "term": "xpert ultra",
          "heading": false
        },
        {
          "term": "lc-anaats",
          "heading": false
        },
        {
          "term": "smear",
          "heading": false
        },
        {
          "term": "diagnostic accuracy",
          "heading": false
        },
        {
          "term": "plhiv",
          "heading": false
        },
        {
          "term": "appendix",
          "heading": false
        }
      ],
      "extract": "standard. Review authors' judgements about each domain presented as percentages across included studies. The numbers shown on each bar indicate the number of studies in each judgement category. Findings Summary estimates of diagnostic accuracy Table 3 summarises the results of the meta-analyses for LC-aNAATs and each index test in the class, including sensitivity and subgroup analyses. Main results are presented",
      "extractCut": true,
      "blocks": [
        "library/10665-381036/blocks/prose-page-023",
        "library/10665-381036/blocks/figure-img-p023-1",
        "library/10665-381036/blocks/table-003"
      ]
    },
    {
      "id": "page-024",
      "number": null,
      "title": "Page 24",
      "level": 1,
      "pageStart": 24,
      "pageEnd": 24,
      "labelStart": "19",
      "labelEnd": "19",
      "words": 479,
      "summary": {
        "text": "Continues Table 3 of LC-aNAAT diagnostic accuracy, giving pooled sensitivity, specificity and predictive values by history of TB, age group, HIV status and for rifampicin resistance. Predictive values are calculated at an assumed 10% pre-test probability.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "truenat mtb",
          "heading": false
        },
        {
          "term": "xpert ultra",
          "heading": false
        },
        {
          "term": "mrs",
          "heading": false
        },
        {
          "term": "smear",
          "heading": false
        },
        {
          "term": "lc-anaats",
          "heading": false
        },
        {
          "term": "plus",
          "heading": false
        }
      ],
      "extract": "No. Analysis Number of studies Number of participants (cases) Summary sensitivity (95% CI) Summary specificity (95% CI) PPV (95% CI)1 NPV (95% CI)1 14 Xpert Ultra, MRS, history of TB 9 809 (152) 84.8 (78.2 to 89.7) 86.2 (78.9 to 91.3) 40.7 (29.1 to 53.5) 98.1 (97.0 to 98.8) 15 Xpert Ultra, MRS, no history of TB 9 3423 (1134) 91.5 (87.9 to 94.1) 95.1 (91.6 to 97.1) 67.4 (53.9 to 78.5) 99.0 (98.6 to 99.3) 16 Xpert",
      "extractCut": true,
      "blocks": [
        "library/10665-381036/blocks/prose-page-024"
      ]
    },
    {
      "id": "page-025",
      "number": null,
      "title": "Page 25",
      "level": 1,
      "pageStart": 25,
      "pageEnd": 25,
      "labelStart": "20",
      "labelEnd": "20",
      "words": 553,
      "summary": {
        "text": "Gives footnotes to the accuracy table explaining the statistical models used, then discusses studies with lower sensitivity. One example is a Malawi trial enrolling only people with HIV.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "truenat mtb",
          "heading": false
        },
        {
          "term": "xpert ultra",
          "heading": false
        },
        {
          "term": "mtb plus",
          "heading": false
        },
        {
          "term": "mtb rif",
          "heading": false
        },
        {
          "term": "microbiological reference",
          "heading": false
        },
        {
          "term": "mrs",
          "heading": false
        },
        {
          "term": "reference standard",
          "heading": false
        },
        {
          "term": "estimable",
          "heading": false
        }
      ],
      "extract": "sensitivity and specificity and their 95% CIs. 2We performed meta-analysis of sensitivity using univariate fixed effect logistic regression because there was little variation in estimates of sensitivity between studies and in many studies, there were zero false positives and true negatives (i.e. zero non-cases) so a bivariate meta-analysis was not feasible. 3Same results for LC-aNAATs because no adolescent only data",
      "extractCut": true,
      "blocks": [
        "library/10665-381036/blocks/prose-page-025"
      ]
    },
    {
      "id": "page-026",
      "number": null,
      "title": "Page 26",
      "level": 1,
      "pageStart": 26,
      "pageEnd": 26,
      "labelStart": "21",
      "labelEnd": "21",
      "words": 232,
      "summary": {
        "text": "Discusses studies with lower specificity, such as those enrolling people previously treated for TB, and introduces the analysis against a composite reference standard, done only for Xpert Ultra.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "prior history",
          "heading": false
        },
        {
          "term": "composite reference",
          "heading": false
        },
        {
          "term": "xpert ultra",
          "heading": false
        },
        {
          "term": "reference standard",
          "heading": false
        },
        {
          "term": "naat",
          "heading": false
        },
        {
          "term": "false",
          "heading": false
        },
        {
          "term": "plot",
          "heading": false
        }
      ],
      "extract": "performed on the second sample. Both liquid and solid media were used for culture. Description of studies with lower specificity: Mishra 2020b: Participants were exclusively persons with a history of treated TB in the past two years. Likely, many of these participants would have had residual DNA from M. tuberculosis leading to a positive NAAT and negative TB culture. Wang 2019: This study had a high rate of Xpert",
      "extractCut": true,
      "blocks": [
        "library/10665-381036/blocks/prose-page-026",
        "library/10665-381036/blocks/figure-img-p026-1"
      ]
    },
    {
      "id": "page-027",
      "number": null,
      "title": "Page 27",
      "level": 1,
      "pageStart": 27,
      "pageEnd": 27,
      "labelStart": "22",
      "labelEnd": "22",
      "words": 5,
      "summary": {
        "text": "A blank page with no extracted text.",
        "status": "draft"
      },
      "keywords": [],
      "extract": "_(no text on this page)_",
      "extractCut": false,
      "blocks": [
        "library/10665-381036/blocks/prose-page-027"
      ]
    },
    {
      "id": "page-028",
      "number": null,
      "title": "Page 28",
      "level": 1,
      "pageStart": 28,
      "pageEnd": 28,
      "labelStart": "23",
      "labelEnd": "23",
      "words": 408,
      "summary": {
        "text": "Table 4, listing the composite reference standard definitions used in each Xpert Ultra study, with a caption for the related risk-of-bias figure.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "crs definition",
          "heading": false
        },
        {
          "term": "culture confirmed",
          "heading": false
        },
        {
          "term": "crs based",
          "heading": false
        },
        {
          "term": "radiological findings",
          "heading": false
        },
        {
          "term": "immunological evidence",
          "heading": false
        },
        {
          "term": "bal samples",
          "heading": false
        },
        {
          "term": "anti-tb treatment",
          "heading": false
        },
        {
          "term": "unconfirmed",
          "heading": false
        }
      ],
      "extract": "Table 4. CRS Definitions Study CRS Definition Aguilera-Alonso 2022 Adolescents; CRS definition: (1) Confirmed TB: >1 respiratory specimen positive for MTB (culture or PCR); (2) Unconfirmed TB: without bacteriological evidence who met >1 (if immunological evidence of MTB) or 2 (immunological evidence absent) criteria: symptoms/signs suggestive of TB, CXR consistent with TB, close TB exposure, response to TB",
      "extractCut": true,
      "blocks": [
        "library/10665-381036/blocks/prose-page-028",
        "library/10665-381036/blocks/figure-vfig-p028",
        "library/10665-381036/blocks/table-004"
      ]
    },
    {
      "id": "page-029",
      "number": null,
      "title": "Page 29",
      "level": 1,
      "pageStart": 29,
      "pageEnd": 29,
      "labelStart": "24",
      "labelEnd": "24",
      "words": 188,
      "summary": {
        "text": "Reports that against a composite reference standard, LC-aNAATs had a summary sensitivity of about 70% and specificity of about 99%, with illustrative numbers per 1000 people tested. It then introduces the analysis for people living with HIV.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "composite reference",
          "heading": false
        },
        {
          "term": "xpert ultra",
          "heading": false
        },
        {
          "term": "reference standard",
          "heading": false
        },
        {
          "term": "pulmonary",
          "heading": false
        },
        {
          "term": "false",
          "heading": false
        }
      ],
      "extract": "The sensitivities in the 10 studies (2127 participants) were between 0% and 96% and the specificities were between 96% and 100% (Figure 8). The summary sensitivity (95% CI) was 69.9% (52.7 to 82.9) and the summary specificity was 98.8% (96.2 to 99.7). For a population of 1000 adults and adolescents where 100 have pulmonary tuberculosis on a composite reference standard, 80 would be LC-aNAAT-positive and 10 (13%)",
      "extractCut": true,
      "blocks": [
        "library/10665-381036/blocks/prose-page-029",
        "library/10665-381036/blocks/figure-img-p029-1",
        "library/10665-381036/blocks/figure-img-p029-2"
      ]
    },
    {
      "id": "page-030",
      "number": null,
      "title": "Page 30",
      "level": 1,
      "pageStart": 30,
      "pageEnd": 30,
      "labelStart": "25",
      "labelEnd": "25",
      "words": 187,
      "summary": {
        "text": "Summarizes the twelve studies of sputum testing in people living with HIV, giving the range of sensitivities and specificities, with captions for the related figures.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "plhiv",
          "heading": false
        },
        {
          "term": "microbiological reference",
          "heading": false
        },
        {
          "term": "reference standard",
          "heading": false
        },
        {
          "term": "plot",
          "heading": false
        },
        {
          "term": "lc-anaat-positive",
          "heading": false
        }
      ],
      "extract": "included studies. As previously noted, there are applicability concerns in patient selection for Park 2019 based on recruitment of inpatients exclusively from a tertiary referral hospital. Figure 9. Risk of bias and applicability concern for each study: respiratory specimens and microbiological reference standard in PLHIV Twelve studies (2016 participants) evaluated sputum specimens from PLHIV (Figure 10). The",
      "extractCut": true,
      "blocks": [
        "library/10665-381036/blocks/prose-page-030",
        "library/10665-381036/blocks/figure-img-p030-1",
        "library/10665-381036/blocks/figure-img-p030-2"
      ]
    },
    {
      "id": "page-031",
      "number": null,
      "title": "Page 31",
      "level": 1,
      "pageStart": 31,
      "pageEnd": 31,
      "labelStart": "26",
      "labelEnd": "26",
      "words": 279,
      "summary": {
        "text": "Introduces the analysis of LC-aNAATs in HIV-negative adults and adolescents and then describes the frequency of Xpert Ultra trace results across studies.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "microbiological reference",
          "heading": false
        },
        {
          "term": "trace",
          "heading": false
        },
        {
          "term": "against microbiological",
          "heading": false
        },
        {
          "term": "reference standard",
          "heading": false
        },
        {
          "term": "xpert ultra",
          "heading": false
        },
        {
          "term": "adolescents",
          "heading": false
        },
        {
          "term": "pulmonary",
          "heading": false
        },
        {
          "term": "adults",
          "heading": false
        }
      ],
      "extract": "Should LC-aNAATs on respiratory samples be used to diagnose pulmonary TB in HIV negative adults and adolescents with signs and symptoms or screened positive for pulmonary TB, against a microbiological reference standard? Figure 11 summarises the results of the risk of bias and applicability assessment for each of the six included studies. As previously noted, there are applicability concerns in patient selection for",
      "extractCut": true,
      "blocks": [
        "library/10665-381036/blocks/prose-page-031",
        "library/10665-381036/blocks/figure-img-p031-1",
        "library/10665-381036/blocks/figure-img-p031-2"
      ]
    },
    {
      "id": "page-032",
      "number": null,
      "title": "Page 32",
      "level": 1,
      "pageStart": 32,
      "pageEnd": 32,
      "labelStart": "27",
      "labelEnd": "27",
      "words": 186,
      "summary": {
        "text": "Reports how classifying Xpert Ultra trace results as positive or negative changes pooled sensitivity and specificity, and introduces the rifampicin resistance analysis.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "rifampicin resistance",
          "heading": false
        },
        {
          "term": "applicability concerns",
          "heading": false
        },
        {
          "term": "trace",
          "heading": false
        },
        {
          "term": "reclassified",
          "heading": false
        },
        {
          "term": "lc-anaats",
          "heading": false
        }
      ],
      "extract": "ranged between 0% and 81.8%. Trace results were considered test positives in the primary analysis of 34 studies of LC-aNAATs for pulmonary TB giving a summary sensitivity (95% CI) of 90.3% (87.7 to 92.4) and summary specificity of 94.9% (93.1 to 96.3). In a sensitivity analysis with trace results reclassified as test negatives, the summary estimates (95% CI) of sensitivity and specificity from the 34 studies were",
      "extractCut": true,
      "blocks": [
        "library/10665-381036/blocks/prose-page-032",
        "library/10665-381036/blocks/figure-img-p032-1"
      ]
    },
    {
      "id": "page-033",
      "number": null,
      "title": "Page 33",
      "level": 1,
      "pageStart": 33,
      "pageEnd": 33,
      "labelStart": "28",
      "labelEnd": "28",
      "words": 162,
      "summary": {
        "text": "Reports a pooled sensitivity of about 95% and specificity of about 98% for LC-aNAAT detection of rifampicin resistance, with evidence graded high certainty.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "rifampicin resistance",
          "heading": false
        },
        {
          "term": "plot",
          "heading": false
        },
        {
          "term": "estimable",
          "heading": false
        },
        {
          "term": "lc-anaat",
          "heading": false
        }
      ],
      "extract": "Of the 13 (2553 participants) studies that evaluated sputum specimens, sensitivity was not estimable for two studies (Figure 14). The sensitivities in the remaining 11 studies (2540 participants) included in the meta-analysis were between 53% and 100% and the specificities were between 97% and 100%. The summary sensitivity (95% CI) was 95.1% (83.1 to 98.7) and the summary specificity was 98.1% (97.0 to 98.7). The",
      "extractCut": true,
      "blocks": [
        "library/10665-381036/blocks/prose-page-033",
        "library/10665-381036/blocks/figure-img-p033-1",
        "library/10665-381036/blocks/figure-img-p033-2"
      ]
    },
    {
      "id": "page-034",
      "number": null,
      "title": "Page 34",
      "level": 1,
      "pageStart": 34,
      "pageEnd": 34,
      "labelStart": "29",
      "labelEnd": "29",
      "words": 478,
      "summary": {
        "text": "Notes that no eligible studies assessed rifampicin resistance detection in people living with HIV, then begins the review's discussion and main conclusions, including the effect of how trace results are interpreted.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "summary sensitivity",
          "heading": false
        },
        {
          "term": "summary specificity",
          "heading": false
        },
        {
          "term": "rifampicin resistance",
          "heading": false
        },
        {
          "term": "respiratory specimens",
          "heading": false
        },
        {
          "term": "lc-anaat accuracy",
          "heading": false
        },
        {
          "term": "ultra trace",
          "heading": false
        },
        {
          "term": "xpert ultra",
          "heading": false
        },
        {
          "term": "found lc-anaats",
          "heading": false
        }
      ],
      "extract": "true positive. Should LC-aNAATs on respiratory samples be used to diagnose rifampicin resistance in PLHIV (adults and adolescents) with signs and symptoms or screened positive for pulmonary TB against a microbiological reference standard? We identified no studies on this topic that met inclusion criteria. Several studies in Figure 14 either did not include PLHIV or did not report participants’ HIV status",
      "extractCut": true,
      "blocks": [
        "library/10665-381036/blocks/prose-page-034"
      ]
    },
    {
      "id": "page-035",
      "number": null,
      "title": "Page 35",
      "level": 1,
      "pageStart": 35,
      "pageEnd": 35,
      "labelStart": "30",
      "labelEnd": "30",
      "words": 482,
      "summary": {
        "text": "Concludes the main findings on LC-aNAAT accuracy for TB and rifampicin resistance, discusses strengths, limitations and implications, and states authors' contributions.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "ultra trace",
          "heading": false
        },
        {
          "term": "xpert ultra",
          "heading": false
        },
        {
          "term": "aes",
          "heading": false
        },
        {
          "term": "trace positives",
          "heading": false
        },
        {
          "term": "summary sensitivity",
          "heading": false
        },
        {
          "term": "summary specificity",
          "heading": false
        },
        {
          "term": "sabi",
          "heading": false
        },
        {
          "term": "rifampicin resistance",
          "heading": false
        }
      ],
      "extract": "o Consistent with summary estimates in this meta-analysis, if Xpert Ultra trace positives are considered “positive”: summary sensitivity 90.7% (88.2 to 92.7) and summary specificity 94.8% (92.8 to 96.3) o If Xpert Ultra trace positives are considered “negative”, summary sensitivity 87.9% (85.2 to 90.3) and summary specificity 96.5% (94.8 to 97.6). ● LC-aNAAT for the detection of rifampicin resistance had a summary",
      "extractCut": true,
      "blocks": [
        "library/10665-381036/blocks/prose-page-035"
      ]
    },
    {
      "id": "page-036",
      "number": null,
      "title": "Page 36",
      "level": 1,
      "pageStart": 36,
      "pageEnd": 36,
      "labelStart": "31",
      "labelEnd": "31",
      "words": 588,
      "summary": {
        "text": "The start of the reference list of included Xpert Ultra studies for the LC-aNAAT review.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "xpert ultra",
          "heading": false
        },
        {
          "term": "rif ultra",
          "heading": false
        },
        {
          "term": "xpert mtb",
          "heading": false
        },
        {
          "term": "pulmonary tuberculosis",
          "heading": false
        },
        {
          "term": "mycobacterium tuberculosis",
          "heading": false
        },
        {
          "term": "infect dis",
          "heading": false
        },
        {
          "term": "prospective multicentre",
          "heading": false
        },
        {
          "term": "accuracy study",
          "heading": false
        }
      ],
      "extract": "References Included Xpert Ultra Studies 1. Aguilera-Alonso, D.; Solis-Garcia, G.; Noguera-Julian, A.; Gonzalez-Martin, J.; Roman Cobena, A.; Baquero-Artigao, F.; Toro Rueda, C.; Rodriguez-Molino, P.; Bloise Sanchez, I.; Vallmanya, T.; Bernet-Sanchez, A.; Minguell Domingo, L.; Rubio, A.; Saavedra-Lozano, J.; Ruiz-Serrano, M. J.; Blazquez-Gamero, D.; Lopez-Roa, P.; Gomez-Pastrana, D.; Lopez Prieto, M. D.; Lopez",
      "extractCut": true,
      "blocks": [
        "library/10665-381036/blocks/prose-page-036"
      ]
    },
    {
      "id": "page-037",
      "number": null,
      "title": "Page 37",
      "level": 1,
      "pageStart": 37,
      "pageEnd": 37,
      "labelStart": "32",
      "labelEnd": "32",
      "words": 634,
      "summary": {
        "text": "Continues the reference list of included Xpert Ultra studies, citing diagnostic accuracy studies from various countries.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "rif ultra",
          "heading": false
        },
        {
          "term": "xpert ultra",
          "heading": false
        },
        {
          "term": "mtb rif",
          "heading": false
        },
        {
          "term": "pulmonary tuberculosis",
          "heading": false
        },
        {
          "term": "tuberculosis diagnosis",
          "heading": false
        },
        {
          "term": "eur respir",
          "heading": false
        },
        {
          "term": "clin microbiol",
          "heading": false
        },
        {
          "term": "accuracy study",
          "heading": false
        }
      ],
      "extract": "MTB/RIF Ultra and digital chest radiography for the diagnosis and treatment of TB in people living with HIV: a randomised controlled trial (XACT-TB). Trans R Soc Trop Med Hyg. 2023;117(1):28-37. 16. Nicol MP, Workman L, Prins M, Bateman L, Ghebrekristos Y, Mbhele S, et al. Accuracy of Xpert Mtb/Rif Ultra for the Diagnosis of Pulmonary Tuberculosis in Children. Pediatr Infect Dis J. 2018;37(10):e261-e3. 17. Opota O,",
      "extractCut": true,
      "blocks": [
        "library/10665-381036/blocks/prose-page-037"
      ]
    },
    {
      "id": "page-038",
      "number": null,
      "title": "Page 38",
      "level": 1,
      "pageStart": 38,
      "pageEnd": 38,
      "labelStart": "33",
      "labelEnd": "33",
      "words": 242,
      "summary": {
        "text": "Ends the Xpert Ultra references and lists included Truenat studies, among them an unpublished South African evaluation.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "truenat mtb",
          "heading": false
        },
        {
          "term": "xpert mtb",
          "heading": false
        },
        {
          "term": "pulmonary tuberculosis",
          "heading": false
        },
        {
          "term": "xpert ultra",
          "heading": false
        },
        {
          "term": "mtb plus",
          "heading": false
        },
        {
          "term": "mtb rif",
          "heading": false
        },
        {
          "term": "diagnostic accuracy",
          "heading": false
        },
        {
          "term": "gomathi",
          "heading": false
        }
      ],
      "extract": "Children Using Xpert Ultra on Different Respiratory Specimens. Am J Respir Crit Care Med. 2019;200(12):1531-8. 33. Zhang P, Liu H, Wang H, Wu Y, Sun L, Rao M, et al. Performance of Xpert MTB/RIF Ultra for the Diagnosis of Pulmonary Tuberculosis Using Bronchoalveolar Lavage Samples in People Living with HIV/AIDS (PLWHA) in China: A Prospective Study. HIV AIDS (Auckl). 2021;13:905-16. Included Truenat MTB Plus and",
      "extractCut": true,
      "blocks": [
        "library/10665-381036/blocks/prose-page-038"
      ]
    },
    {
      "id": "page-039",
      "number": null,
      "title": "Page 39",
      "level": 1,
      "pageStart": 39,
      "pageEnd": 39,
      "labelStart": "34",
      "labelEnd": "34",
      "words": 317,
      "summary": {
        "text": "Appendix 1, giving the detailed MEDLINE search strategy for the LC-aNAAT review.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "adj resistant",
          "heading": false
        },
        {
          "term": "fluoroquinolone adj",
          "heading": false
        },
        {
          "term": "ethionamide adj",
          "heading": false
        },
        {
          "term": "amikacin adj",
          "heading": false
        },
        {
          "term": "tuberculosis adj",
          "heading": false
        },
        {
          "term": "adj resistance",
          "heading": false
        },
        {
          "term": "isoniazid adj",
          "heading": false
        },
        {
          "term": "drug adj",
          "heading": false
        }
      ],
      "extract": "Appendix Appendix 1. Detailed search strategies Ovid MEDLINE(R) ALL <1946 to October 13, 2023> 1 pulmonary Tuberculosis/ 2 mycobacterium tuberculosis.mp. or Mycobacterium tuberculosis/ 3 Tuberculosis, Multidrug-Resistant/ 4 Extensively Drug-Resistant Tuberculosis/ 5 (((tuberculosis or TB) adj3 (lung* or pulmonic or bronchial or pulmonary)) or ((tuberculosis or TB) adj3 (respiratory or respirational))).mp. 6",
      "extractCut": true,
      "blocks": [
        "library/10665-381036/blocks/prose-page-039"
      ]
    },
    {
      "id": "page-040",
      "number": null,
      "title": "Page 40",
      "level": 1,
      "pageStart": 40,
      "pageEnd": 40,
      "labelStart": "35",
      "labelEnd": "35",
      "words": 338,
      "summary": {
        "text": "Continues the search strategies, covering MEDLINE terms for the index tests and searches in Web of Science and Scopus.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "title-abs-key",
          "heading": false
        },
        {
          "term": "resistant tuberculosis",
          "heading": false
        },
        {
          "term": "xpert ultra",
          "heading": false
        },
        {
          "term": "multidrug resistant",
          "heading": false
        },
        {
          "term": "drug resistant",
          "heading": false
        },
        {
          "term": "biosensor",
          "heading": false
        },
        {
          "term": "iron-qpcr",
          "heading": false
        },
        {
          "term": "xdr-tb",
          "heading": false
        }
      ],
      "extract": "15 (Xpert* or GeneXpert or cepheid or near* patient).tw. 16 ultra.tw. 17 15 and 16 18 14 and 17 19 (Truenat* or Molbio or TruRif).mp. 20 14 and 19 21 (STANDARD M10 or SD Biosensor or IRON-qPCR or BIONEER).mp. 22 14 and 21 Web of Science Search Strategy (Science Citation index-Expanded and Biosis Previews) #1 Search: (tuberculosis or TB) and (lung or pulmonary) (Topic) OR multidrug resistant tuberculosis or",
      "extractCut": true,
      "blocks": [
        "library/10665-381036/blocks/prose-page-040"
      ]
    },
    {
      "id": "page-041",
      "number": null,
      "title": "Page 41",
      "level": 1,
      "pageStart": 41,
      "pageEnd": 41,
      "labelStart": "36",
      "labelEnd": "36",
      "words": 137,
      "summary": {
        "text": "Gives the search strategies used in the Cochrane Central Register and ProQuest dissertations.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "mesh descriptor",
          "heading": false
        },
        {
          "term": "resistant tuberculosis",
          "heading": false
        },
        {
          "term": "explode",
          "heading": false
        },
        {
          "term": "trees",
          "heading": false
        }
      ],
      "extract": "Search Name: Cochrane Central Register of Controlled Trials Issue 10 of 12, October 2023 #1 MeSH descriptor: [Tuberculosis] explode all trees #2 MeSH descriptor: [Mycobacterium tuberculosis] explode all trees #3 ((tuberculosis or TB or MDR-TB or XDR-TB)):ti,ab,kw #4 MeSH descriptor: [Tuberculosis, Multidrug-Resistant] explode all trees #5 extensively drug resistant tuberculosis #6 MeSH descriptor: [Extensively",
      "extractCut": true,
      "blocks": [
        "library/10665-381036/blocks/prose-page-041"
      ]
    },
    {
      "id": "page-042",
      "number": null,
      "title": "Page 42",
      "level": 1,
      "pageStart": 42,
      "pageEnd": 42,
      "labelStart": "37",
      "labelEnd": "37",
      "words": 453,
      "summary": {
        "text": "Appendix 2, summary of findings tables for LC-aNAATs in diagnosing pulmonary TB and rifampicin resistance, giving pooled accuracy and certainty of evidence.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "sensitivity ranged",
          "heading": false
        },
        {
          "term": "false negatives",
          "heading": false
        },
        {
          "term": "true negatives",
          "heading": false
        },
        {
          "term": "false positives",
          "heading": false
        },
        {
          "term": "summary specificity",
          "heading": false
        },
        {
          "term": "diagnose pulmonary",
          "heading": false
        },
        {
          "term": "respiratory samples",
          "heading": false
        },
        {
          "term": "appendix table",
          "heading": false
        }
      ],
      "extract": "Appendix 2. Summary of findings tables Appendix Table 1. Should LC-aNAATs on respiratory samples be used to diagnose pulmonary TB in adults and adolescents with signs and symptoms or screened positive for pulmonary TB, against a microbiological reference standard? In the 34 studies (14840 participants) included in the meta- analysis, sensitivity ranged between 54% and 100% and specificity between 71% and 100%. The",
      "extractCut": true,
      "blocks": [
        "library/10665-381036/blocks/prose-page-042"
      ]
    },
    {
      "id": "page-043",
      "number": null,
      "title": "Page 43",
      "level": 1,
      "pageStart": 43,
      "pageEnd": 43,
      "labelStart": "38",
      "labelEnd": "38",
      "words": 106,
      "summary": {
        "text": "Ends a summary of findings table with expected true and false results per 1,000 people tested at several prevalences, graded high certainty.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "negatives",
          "heading": false
        },
        {
          "term": "positives",
          "heading": false
        },
        {
          "term": "prevalence",
          "heading": false
        }
      ],
      "extract": "evidence for both sensitivity and specificity was graded as high. Test result Number of results per 1,000 patients tested (95% CI) Number of participants (studies) Certainty of the Evidence (GRADE) Prevalence2% Typically seen in Prevalence10% Typically seen in Prevalence15% Typically seen in True positives 19 (17 to 20) 95 (83 to 99) 143 (125 to 148) 491 (11) ⨁⨁⨁⨁ High False negatives 1 (0 to 3) 5 (1 to 17) 7 (2 to",
      "extractCut": true,
      "blocks": [
        "library/10665-381036/blocks/prose-page-043"
      ]
    },
    {
      "id": "page-044",
      "number": null,
      "title": "Page 44",
      "level": 1,
      "pageStart": 44,
      "pageEnd": 44,
      "labelStart": "39",
      "labelEnd": "39",
      "words": 161,
      "summary": {
        "text": "Introduces Appendix 3, additional forest plots of LC-aNAATs by brand and subgroup, and explains how head-to-head studies were handled to avoid double counting.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "sputum samples",
          "heading": false
        },
        {
          "term": "truenat mtb",
          "heading": false
        },
        {
          "term": "xpert ultra",
          "heading": false
        },
        {
          "term": "mtb plus",
          "heading": false
        },
        {
          "term": "brand",
          "heading": false
        }
      ],
      "extract": "Appendix 3. Additional forest plots Appendix Figures 1 to 11 summarise currently available data for LC-aNAATs by brand and subgroups. Two studies (Penn-Nicholson 2021 and Theron 2024) compared the accuracy of Xpert Ultra and Truenat MTB Plus. Note that for the class level meta-analyses of LC-aNAATs presented in Table 3, to avoid double counting, we selected the data for Truenat MTB Plus for inclusion in the",
      "extractCut": true,
      "blocks": [
        "library/10665-381036/blocks/prose-page-044",
        "library/10665-381036/blocks/figure-img-p044-1"
      ]
    },
    {
      "id": "page-045",
      "number": null,
      "title": "Page 45",
      "level": 1,
      "pageStart": 45,
      "pageEnd": 45,
      "labelStart": "40",
      "labelEnd": "40",
      "words": 39,
      "summary": {
        "text": "Captions for forest plots of LC-aNAAT accuracy by brand among people living with HIV and HIV-negative people.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "forest plot",
          "heading": false
        },
        {
          "term": "sputum specimen",
          "heading": false
        },
        {
          "term": "microbiological reference",
          "heading": false
        }
      ],
      "extract": "Appendix Figure 2. Forest plot of LC-aNAATs for pulmonary TB by brand: PLHIV, sputum specimen and microbiological reference standard Appendix Figure 3. Forest plot of LC-aNAATs for pulmonary TB by brand: HIV negative, sputum specimen and microbiological reference standard",
      "extractCut": false,
      "blocks": [
        "library/10665-381036/blocks/prose-page-045",
        "library/10665-381036/blocks/figure-img-p045-1",
        "library/10665-381036/blocks/figure-img-p045-2"
      ]
    },
    {
      "id": "page-046",
      "number": null,
      "title": "Page 46",
      "level": 1,
      "pageStart": 46,
      "pageEnd": 46,
      "labelStart": "41",
      "labelEnd": "41",
      "words": 40,
      "summary": {
        "text": "Captions for forest plots of LC-aNAAT accuracy by brand in smear-positive and smear-negative people.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "forest plot",
          "heading": false
        },
        {
          "term": "sputum specimen",
          "heading": false
        },
        {
          "term": "microbiological reference",
          "heading": false
        }
      ],
      "extract": "Appendix Figure 4. Forest plot of LC-aNAATs for pulmonary TB by brand: smear positive, sputum specimen and microbiological reference standard Appendix Figure 5. Forest plot of LC-aNAATs for pulmonary TB by brand: smear negative, sputum specimen and microbiological reference standard",
      "extractCut": false,
      "blocks": [
        "library/10665-381036/blocks/prose-page-046",
        "library/10665-381036/blocks/figure-img-p046-1",
        "library/10665-381036/blocks/figure-img-p046-2"
      ]
    },
    {
      "id": "page-047",
      "number": null,
      "title": "Page 47",
      "level": 1,
      "pageStart": 47,
      "pageEnd": 47,
      "labelStart": "42",
      "labelEnd": "42",
      "words": 43,
      "summary": {
        "text": "Captions for forest plots of LC-aNAAT accuracy by brand in people with and without a history of TB.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "forest plot",
          "heading": false
        },
        {
          "term": "sputum specimen",
          "heading": false
        },
        {
          "term": "microbiological reference",
          "heading": false
        }
      ],
      "extract": "Appendix Figure 6. Forest plot of LC-aNAATs for pulmonary TB by brand: history of TB, sputum specimen and microbiological reference standard Appendix Figure 7. Forest plot of LC-aNAATs for pulmonary TB by brand: no history of TB, sputum specimen and microbiological reference standard",
      "extractCut": false,
      "blocks": [
        "library/10665-381036/blocks/prose-page-047",
        "library/10665-381036/blocks/figure-img-p047-1",
        "library/10665-381036/blocks/figure-img-p047-2"
      ]
    },
    {
      "id": "page-048",
      "number": null,
      "title": "Page 48",
      "level": 1,
      "pageStart": 48,
      "pageEnd": 48,
      "labelStart": "43",
      "labelEnd": "43",
      "words": 49,
      "summary": {
        "text": "Captions for forest plots of rifampicin resistance detection by brand and of Xpert Ultra accuracy in adolescents.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "forest plot",
          "heading": false
        },
        {
          "term": "appendix figure",
          "heading": false
        },
        {
          "term": "brand",
          "heading": false
        }
      ],
      "extract": "Appendix Figure 8. Forest plot of LC-aNAATs for rifampicin resistance by brand: sputum specimen Appendix Figure 9. Forest plot of Xpert Ultra: adolescents only See characteristics of these studies in Table 1 and the summary estimates in Table 3. Adolescent only data were not available for Truenat MTB Plus.",
      "extractCut": false,
      "blocks": [
        "library/10665-381036/blocks/prose-page-048",
        "library/10665-381036/blocks/figure-img-p048-1",
        "library/10665-381036/blocks/figure-img-p048-2"
      ]
    },
    {
      "id": "page-049",
      "number": null,
      "title": "Page 49",
      "level": 1,
      "pageStart": 49,
      "pageEnd": 49,
      "labelStart": "44",
      "labelEnd": "44",
      "words": 22,
      "summary": {
        "text": "Captions for forest plots of LC-aNAAT accuracy in adults and of rifampicin resistance detection by smear status.",
        "status": "draft"
      },
      "keywords": [],
      "extract": "Appendix Figure 10. Forest plot of LC-aNAATs: adult only Appendix Figure 11. Forest plot of LC-aNAATs for rifampicin resistance by smear status",
      "extractCut": false,
      "blocks": [
        "library/10665-381036/blocks/prose-page-049",
        "library/10665-381036/blocks/figure-img-p049-1",
        "library/10665-381036/blocks/figure-img-p049-2"
      ]
    },
    {
      "id": "page-050",
      "number": null,
      "title": "Page 50",
      "level": 1,
      "pageStart": 50,
      "pageEnd": 50,
      "labelStart": "45",
      "labelEnd": "45",
      "words": 334,
      "summary": {
        "text": "Appendix 4, a table of Xpert Ultra trace results per study and the share that were true positives, with summary estimates when trace results are treated as negative. The page ends with the title of the next annex, B.2.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "ultra trace",
          "heading": false
        },
        {
          "term": "xpert ultra",
          "heading": false
        },
        {
          "term": "complexity automated",
          "heading": false
        },
        {
          "term": "mrs",
          "heading": false
        },
        {
          "term": "appendix table",
          "heading": false
        },
        {
          "term": "reclassified",
          "heading": false
        }
      ],
      "extract": "Appendix 4. Analyses of Xpert Ultra results Appendix Table 4. Summary of Xpert Ultra trace results Study ID TP trace result (a) FP trace result (b) Number of trace results (a + b) Number of participants (n) Percentage of true positive trace results [a/(a + b)] Percentage of trace results [(a + b)/n] Aguilera-Alonso 2022 0 0 0 5 − 0.0 Berhanu 2018 2 4 6 237 33.3 2.5 Boyles 2020 1 1 2 207 50.0 1.0 Calderwood 2023 13",
      "extractCut": true,
      "blocks": [
        "library/10665-381036/blocks/prose-page-050"
      ]
    },
    {
      "id": "page-051",
      "number": null,
      "title": "Page 51",
      "level": 1,
      "pageStart": 51,
      "pageEnd": 51,
      "labelStart": "46",
      "labelEnd": "46",
      "words": 169,
      "summary": {
        "text": "The title, author list and affiliations for Web Annex B.2, a systematic review of the diagnostic accuracy of low complexity automated NAATs for pulmonary and extrapulmonary TB and rifampicin resistance in children.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "baylor college",
          "heading": false
        },
        {
          "term": "alexander kay",
          "heading": false
        },
        {
          "term": "texas",
          "heading": false
        },
        {
          "term": "houston",
          "heading": false
        },
        {
          "term": "birmingham",
          "heading": false
        },
        {
          "term": "pediatrics",
          "heading": false
        },
        {
          "term": "liverpool",
          "heading": false
        }
      ],
      "extract": "pulmonary and extrapulmonary tuberculosis and rifampicin resistance in children: a systematic review of diagnostic accuracy Alexander W Kay1,2,3*, Maia Madison1,2,3,4, Katie Scandrett5, Tara Ness1,2, Pauline Amuge6, Leeberk Raja Inbaraj7, Jefferson Daniel8, Mukesh Kumar Sathyanarayanan7, Vignes Anand Srinivasalu7, Adhin Bhaskar7, Anna M Mandalakas1,2, Karen R Steingart9, Yemisi Takwoingi5 1. The Global Tuberculosis",
      "extractCut": true,
      "blocks": [
        "library/10665-381036/blocks/prose-page-051"
      ]
    },
    {
      "id": "page-052",
      "number": null,
      "title": "Page 52",
      "level": 1,
      "pageStart": 52,
      "pageEnd": 52,
      "labelStart": "47",
      "labelEnd": "47",
      "words": 550,
      "summary": {
        "text": "Gives background on the paediatric TB burden, citing 2022 estimates of cases and deaths among children under 15, and the challenges of diagnosing TB in children. It then begins the methods, listing the databases searched in October 2023.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "xpert ultra",
          "heading": false
        },
        {
          "term": "xpert mtb",
          "heading": false
        },
        {
          "term": "extrapulmonary tuberculosis",
          "heading": false
        },
        {
          "term": "complexity automated",
          "heading": false
        },
        {
          "term": "tuberculosis report",
          "heading": false
        },
        {
          "term": "truenat mtb",
          "heading": false
        },
        {
          "term": "automated naats",
          "heading": false
        },
        {
          "term": "mtb rif",
          "heading": false
        }
      ],
      "extract": "BACKGROUND Tuberculosis is one of the top 10 causes of death and a leading cause from a single infectious agent, with an estimated 1.1 million deaths in 2022 (WHO Global Tuberculosis Report 2023). Globally during that year, an estimated 10.6 million people developed tuberculosis disease, including around 1.1 million children younger than 15 years and 214,000 children who died of the disease (WHO Global Tuberculosis",
      "extractCut": true,
      "blocks": [
        "library/10665-381036/blocks/prose-page-052"
      ]
    },
    {
      "id": "page-053",
      "number": null,
      "title": "Page 53",
      "level": 1,
      "pageStart": 53,
      "pageEnd": 53,
      "labelStart": "48",
      "labelEnd": "48",
      "words": 578,
      "summary": {
        "text": "Completes the search methods of the paediatric LC-aNAAT review, including trial registries, reference lists and dissertations, and describes study selection, data extraction and risk-of-bias assessment. It also explains the meta-analysis approach and the use of GRADE to rate certainty separately for sensitivity and specificity.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "gastric aspirate",
          "heading": false
        },
        {
          "term": "xpert ultra",
          "heading": false
        },
        {
          "term": "nasopharyngeal aspirate",
          "heading": false
        },
        {
          "term": "ultra trace",
          "heading": false
        },
        {
          "term": "aspirate specimens",
          "heading": false
        },
        {
          "term": "allowed culture",
          "heading": false
        },
        {
          "term": "extrapulmonary tuberculosis",
          "heading": false
        },
        {
          "term": "mycobacterium tuberculosis",
          "heading": false
        }
      ],
      "extract": "Index Medicus; and SCOPUS (Elsevier). VL also searched ClinicalTrials.gov (clinicaltrials.gov/) and the WHO Clinical Trials Registry Platform (www.who.int/trialsearch) to identify ongoing trials. The review authors examined the reference lists of included articles and relevant review articles identified through electronic searches. VL also searched for relevant dissertations in ProQuest Dissertations & Theses A&I.",
      "extractCut": true,
      "blocks": [
        "library/10665-381036/blocks/prose-page-053"
      ]
    },
    {
      "id": "page-054",
      "number": null,
      "title": "Page 54",
      "level": 1,
      "pageStart": 54,
      "pageEnd": 54,
      "labelStart": "49",
      "labelEnd": "49",
      "words": 135,
      "summary": {
        "text": "Reports that 23 studies evaluated Xpert Ultra in children using sputum, gastric aspirate, nasopharyngeal aspirate, stool or extrapulmonary specimens, and summarizes their settings and reference standards.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "xpert ultra",
          "heading": false
        },
        {
          "term": "extrapulmonary tuberculosis",
          "heading": false
        },
        {
          "term": "evaluated xpert",
          "heading": false
        },
        {
          "term": "prisma diagram",
          "heading": false
        },
        {
          "term": "ultra against",
          "heading": false
        }
      ],
      "extract": "Study Identification and Characteristics For pulmonary and extrapulmonary tuberculosis detection, we identified 23 studies that evaluated the diagnostic accuracy of Xpert Ultra in sputum, gastric aspirate, nasopharyngeal aspirate, stool or extrapulmonary specimens. Table 1 describes the study characteristics, and the PRISMA diagram is displayed in Figure 1 (Page 2021). Figure 1. PRISMA Diagram Of the 23 studies",
      "extractCut": true,
      "blocks": [
        "library/10665-381036/blocks/prose-page-054",
        "library/10665-381036/blocks/figure-img-p054-1",
        "library/10665-381036/blocks/figure-vfig-p054"
      ]
    },
    {
      "id": "page-055",
      "number": null,
      "title": "Page 55",
      "level": 1,
      "pageStart": 55,
      "pageEnd": 55,
      "labelStart": "50",
      "labelEnd": "50",
      "words": 273,
      "summary": {
        "text": "The first page of Table 1, listing key characteristics of included paediatric Xpert Ultra studies, such as country, TB burden, setting, specimen type, design and reference standard.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "gastric aspirate",
          "heading": false
        },
        {
          "term": "prospective cohort",
          "heading": false
        },
        {
          "term": "consecutive",
          "heading": false
        },
        {
          "term": "cross sectional",
          "heading": false
        },
        {
          "term": "yes",
          "heading": false
        },
        {
          "term": "npa",
          "heading": false
        },
        {
          "term": "stool",
          "heading": false
        },
        {
          "term": "inpatient",
          "heading": false
        }
      ],
      "extract": "Study Countries High TB burden/high TB/HIV burden Clinical setting Type of specimen Study design Patient selection Number of cultures Composi te reference standard Aguilera- Alonso 2022 Spain No/No Undefined Sputum, gastric aspirate Prospective cohort Consecutive Unclear Yes Aurilio 2022 Brazil Yes/Yes Undefined Extrapulmonary Prospective cohort Consecutive Unclear Yes Babo 2023 Ethiopia Yes/Yes Outpatient Stool",
      "extractCut": true,
      "blocks": [
        "library/10665-381036/blocks/prose-page-055"
      ]
    },
    {
      "id": "page-056",
      "number": null,
      "title": "Page 56",
      "level": 1,
      "pageStart": 56,
      "pageEnd": 56,
      "labelStart": "51",
      "labelEnd": "51",
      "words": 459,
      "summary": {
        "text": "Completes the table of paediatric study characteristics and summarizes the risk of bias and applicability judgements for studies using sputum specimens.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "gastric aspirate",
          "heading": false
        },
        {
          "term": "prospective cohort",
          "heading": false
        },
        {
          "term": "xpert ultra",
          "heading": false
        },
        {
          "term": "judged",
          "heading": false
        },
        {
          "term": "yes",
          "heading": false
        },
        {
          "term": "consecutive",
          "heading": false
        },
        {
          "term": "respiratory specimens",
          "heading": false
        },
        {
          "term": "regarding applicability",
          "heading": false
        }
      ],
      "extract": "Study Countries High TB burden/high TB/HIV burden Clinical setting Type of specimen Study design Patient selection Number of cultures Composi te reference standard Parigi 2021 Italy No/No Inpatient Gastric aspirate Prospective cohort Unclear Multiple Yes Pradhan 2022 India Yes/No Inpatient CSF Prospective cohort Consecutive Single Yes Sabi 2018 Tanzania No/Yes Inpatient and outpatient Sputum Prospective cohort",
      "extractCut": true,
      "blocks": [
        "library/10665-381036/blocks/prose-page-056"
      ]
    },
    {
      "id": "page-057",
      "number": null,
      "title": "Page 57",
      "level": 1,
      "pageStart": 57,
      "pageEnd": 57,
      "labelStart": "52",
      "labelEnd": "52",
      "words": 569,
      "summary": {
        "text": "Summarizes risk-of-bias and applicability judgements for paediatric Xpert Ultra studies using sputum, gastric aspirate and stool specimens, domain by domain.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "gastric aspirate",
          "heading": false
        },
        {
          "term": "xpert ultra",
          "heading": false
        },
        {
          "term": "selection domain",
          "heading": false
        },
        {
          "term": "because xpert",
          "heading": false
        },
        {
          "term": "aspirate specimens",
          "heading": false
        },
        {
          "term": "judged",
          "heading": false
        },
        {
          "term": "regarding applicability",
          "heading": false
        },
        {
          "term": "timing domain",
          "heading": false
        }
      ],
      "extract": "and a high risk of bias for one study (1/15, 6.7%) because in this study many children were excluded from the analysis (Liu 2021). Studies evaluating Xpert Ultra on gastric aspirate specimens (12 studies) In the patient selection domain, for MRS, we judged the risk of bias as low for most studies (10/12, 83.3%) and high-risk two studies (16.6%) because the manner of participant selection was a retrospective",
      "extractCut": true,
      "blocks": [
        "library/10665-381036/blocks/prose-page-057"
      ]
    },
    {
      "id": "page-058",
      "number": null,
      "title": "Page 58",
      "level": 1,
      "pageStart": 58,
      "pageEnd": 58,
      "labelStart": "53",
      "labelEnd": "53",
      "words": 582,
      "summary": {
        "text": "Completes the quality assessment for stool and other specimens, then begins a table of summary diagnostic accuracy of Xpert Ultra in children by specimen type and reference standard. The table rows cover sputum and gastric aspirate against culture or a composite standard.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "xpert ultra",
          "heading": false
        },
        {
          "term": "because xpert",
          "heading": false
        },
        {
          "term": "judged",
          "heading": false
        },
        {
          "term": "gastric aspirate",
          "heading": false
        },
        {
          "term": "pulmonary tuberculosis",
          "heading": false
        },
        {
          "term": "regarding applicability",
          "heading": false
        },
        {
          "term": "reference standard",
          "heading": false
        },
        {
          "term": "crs",
          "heading": false
        }
      ],
      "extract": "high concern for one study (10%) because participants with a definite diagnosis of tuberculosis were excluded (Liu 2021). Regarding applicability, we judged low concern for most studies (8/10, 80%). We judged high concern for one study (10%) because the patients were exclusively inpatients in a tertiary/specialized hospital, and unclear for one study (10%) because the setting was undefined. In the index test domain,",
      "extractCut": true,
      "blocks": [
        "library/10665-381036/blocks/prose-page-058"
      ]
    },
    {
      "id": "page-059",
      "number": null,
      "title": "Page 59",
      "level": 1,
      "pageStart": 59,
      "pageEnd": 59,
      "labelStart": "54",
      "labelEnd": "54",
      "words": 236,
      "summary": {
        "text": "Continues the paediatric accuracy table for nasopharyngeal aspirate and stool, then begins reporting results for sputum against culture, with eleven studies meta-analysed.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "nasopharyngeal aspirate",
          "heading": false
        },
        {
          "term": "predictive values",
          "heading": false
        },
        {
          "term": "microbiological reference",
          "heading": false
        },
        {
          "term": "pulmonary tuberculosis",
          "heading": false
        },
        {
          "term": "reference standard",
          "heading": false
        }
      ],
      "extract": "7 Nasopharyngeal aspirate; MRS 6 1353 (94) 46.2 (34.9 to 57.9) 97.5 (95.1 to 98.7) 67.2 (44.3 to 83.5) 94.2 (92.9 to 95.5) 8 Nasopharyngeal aspirate; CRS 4 676 (465) 12.7 (09.2 to 17.3) 100.0 (98.3 to 100.0) 100.0 (37.2 to 100.0) 91.2 (90.7 to 91.6) 9 Stool; MRS 10 2885 (255) 68.0 (50.3 to 81.7) 98.2 (96.3 to 99.1) 80.9 (60.4 to 91.3) 96.5 (94.6 to 98.0) 10 Stool; CRS 6 1778 (510) 31.4 (17.2 to 50.2) 99.0 (97.4 to",
      "extractCut": true,
      "blocks": [
        "library/10665-381036/blocks/prose-page-059",
        "library/10665-381036/blocks/figure-img-p059-1",
        "library/10665-381036/blocks/figure-vfig-p059"
      ]
    },
    {
      "id": "page-060",
      "number": null,
      "title": "Page 60",
      "level": 1,
      "pageStart": 60,
      "pageEnd": 60,
      "labelStart": "55",
      "labelEnd": "55",
      "words": 133,
      "summary": {
        "text": "Reports that Xpert Ultra on children's sputum had a summary sensitivity of about 75% and specificity of about 96% against culture, with high-certainty evidence and illustrative figures per 1,000 children.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "pulmonary tuberculosis",
          "heading": false
        },
        {
          "term": "xpert ultra",
          "heading": false
        },
        {
          "term": "false",
          "heading": false
        },
        {
          "term": "true",
          "heading": false
        }
      ],
      "extract": "(68.9 to 80.8) and the summary specificity (95% CI) was 95.9% (92.3 to 97.9) (high-certainty (sensitivity and specificity) evidence). For a population of 1,000 children where 100 have tuberculosis on culture, 112 would be Xpert Ultra positive; of these, 75 would have pulmonary tuberculosis (true positives) and 37 would not have pulmonary tuberculosis (false positives); 888 would be Xpert Ultra negative; of these 863",
      "extractCut": true,
      "blocks": [
        "library/10665-381036/blocks/prose-page-060",
        "library/10665-381036/blocks/figure-img-p060-1"
      ]
    },
    {
      "id": "page-061",
      "number": null,
      "title": "Page 61",
      "level": 1,
      "pageStart": 61,
      "pageEnd": 61,
      "labelStart": "56",
      "labelEnd": "56",
      "words": 148,
      "summary": {
        "text": "Reports a much lower summary sensitivity of about 24% for Xpert Ultra on children's sputum against a composite reference standard, with specificity of 100%.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "pulmonary tuberculosis",
          "heading": false
        },
        {
          "term": "composite reference",
          "heading": false
        },
        {
          "term": "xpert ultra",
          "heading": false
        },
        {
          "term": "reference standard",
          "heading": false
        }
      ],
      "extract": "Figure 4. Risk of bias and applicability summary for pulmonary tuberculosis: sputum specimen and composite reference standard Eleven studies (2,824 participants) evaluating sputum against a CRS were included with sensitivities between 17% and 63% and specificities all 100% (Figure 5). Ten studies (2,823 participants) were included in the meta-analysis. The summary sensitivity (95% CI) was 23.5% (20.3 to 27.0) and",
      "extractCut": true,
      "blocks": [
        "library/10665-381036/blocks/prose-page-061",
        "library/10665-381036/blocks/figure-img-p061-1",
        "library/10665-381036/blocks/figure-img-p061-2"
      ]
    },
    {
      "id": "page-062",
      "number": null,
      "title": "Page 62",
      "level": 1,
      "pageStart": 62,
      "pageEnd": 62,
      "labelStart": "57",
      "labelEnd": "57",
      "words": 198,
      "summary": {
        "text": "Introduces the analysis of Xpert Ultra on sputum in children living with HIV against culture, with illustrative numbers of true and false results per 1,000 children.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "pulmonary tuberculosis",
          "heading": false
        },
        {
          "term": "clhiv",
          "heading": false
        },
        {
          "term": "xpert ultra",
          "heading": false
        },
        {
          "term": "microbiological reference",
          "heading": false
        },
        {
          "term": "false",
          "heading": false
        }
      ],
      "extract": "The studies are sorted on the plot by decreasing sensitivity. FN: false negative; FP: false positive; TN: true negative; TP: true positive. 3. Should LC-aNAATs on respiratory samples be used to diagnose pulmonary tuberculosis in children living with HIV (CLHIV) with signs and symptoms or screened positive for pulmonary tuberculosis, against a microbiological reference standard? Figure 6. Risk of bias and",
      "extractCut": true,
      "blocks": [
        "library/10665-381036/blocks/prose-page-062",
        "library/10665-381036/blocks/figure-img-p062-1"
      ]
    },
    {
      "id": "page-063",
      "number": null,
      "title": "Page 63",
      "level": 1,
      "pageStart": 63,
      "pageEnd": 63,
      "labelStart": "58",
      "labelEnd": "58",
      "words": 149,
      "summary": {
        "text": "Reports that, against a composite reference standard, Xpert Ultra on sputum from children living with HIV had a summary sensitivity of about 19% and specificity of 100%.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "clhiv",
          "heading": false
        },
        {
          "term": "pulmonary tuberculosis",
          "heading": false
        },
        {
          "term": "composite reference",
          "heading": false
        },
        {
          "term": "seven studies",
          "heading": false
        },
        {
          "term": "reference standard",
          "heading": false
        }
      ],
      "extract": "Figure 7. LC-aNAATs for pulmonary tuberculosis in CLHIV using sputum and a microbiological reference standard The studies are sorted on the plot by decreasing sensitivity. FN: false negative; FP: false positive; TN: true negative; TP: true positive. 4. Should LC-aNAATs on respiratory samples be used to diagnose pulmonary tuberculosis in CLHIV with signs and symptoms or screened positive for pulmonary tuberculosis,",
      "extractCut": true,
      "blocks": [
        "library/10665-381036/blocks/prose-page-063",
        "library/10665-381036/blocks/figure-img-p063-1",
        "library/10665-381036/blocks/figure-img-p063-2"
      ]
    },
    {
      "id": "page-064",
      "number": null,
      "title": "Page 64",
      "level": 1,
      "pageStart": 64,
      "pageEnd": 64,
      "labelStart": "59",
      "labelEnd": "59",
      "words": 141,
      "summary": {
        "text": "Gives illustrative results per 1,000 children living with HIV against the composite standard and introduces the analysis of gastric aspirate specimens.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "pulmonary tuberculosis",
          "heading": false
        },
        {
          "term": "gastric aspirate",
          "heading": false
        },
        {
          "term": "xpert ultra",
          "heading": false
        },
        {
          "term": "clhiv",
          "heading": false
        }
      ],
      "extract": "For a population of 1,000 CLHIV where 400 have tuberculosis on CRS, 74 would be Xpert Ultra positive; of these, 74 would have pulmonary tuberculosis (true positives) and 0 would not have pulmonary tuberculosis (false positives); 926 would be Xpert Ultra negative; of these 600 would not have pulmonary tuberculosis (true negatives) and 326 would have pulmonary tuberculosis (false- negatives). Figure 9. LC-aNAATs for",
      "extractCut": true,
      "blocks": [
        "library/10665-381036/blocks/prose-page-064",
        "library/10665-381036/blocks/figure-img-p064-1",
        "library/10665-381036/blocks/figure-img-p064-2"
      ]
    },
    {
      "id": "page-065",
      "number": null,
      "title": "Page 65",
      "level": 1,
      "pageStart": 65,
      "pageEnd": 65,
      "labelStart": "60",
      "labelEnd": "60",
      "words": 191,
      "summary": {
        "text": "Reports a summary sensitivity of about 70% and specificity of about 91% for Xpert Ultra on gastric aspirate against culture in children, with moderate-certainty evidence.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "gastric aspirate",
          "heading": false
        },
        {
          "term": "pulmonary tuberculosis",
          "heading": false
        },
        {
          "term": "xpert ultra",
          "heading": false
        },
        {
          "term": "microbiological reference",
          "heading": false
        },
        {
          "term": "reference standard",
          "heading": false
        }
      ],
      "extract": "microbiological reference standard Twelve studies (1959 participants) evaluating gastric aspirate against a MRS were included with sensitivities between 0% and 100% and specificities between 67% and 100% (Figure 11). All 12 studies were included in the meta-analysis. The summary sensitivity (95% CI) was 69.6% (60.3 to 77.6) and the summary specificity (95% CI) was 91.0% (82.5 to 95.6) (moderate-certainty",
      "extractCut": true,
      "blocks": [
        "library/10665-381036/blocks/prose-page-065",
        "library/10665-381036/blocks/figure-img-p065-1"
      ]
    },
    {
      "id": "page-066",
      "number": null,
      "title": "Page 66",
      "level": 1,
      "pageStart": 66,
      "pageEnd": 66,
      "labelStart": "61",
      "labelEnd": "61",
      "words": 194,
      "summary": {
        "text": "Reports a summary sensitivity of about 49% and specificity of about 99% for Xpert Ultra on gastric aspirate against a composite reference standard in children.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "gastric aspirate",
          "heading": false
        },
        {
          "term": "pulmonary tuberculosis",
          "heading": false
        },
        {
          "term": "xpert ultra",
          "heading": false
        },
        {
          "term": "composite reference",
          "heading": false
        },
        {
          "term": "seven studies",
          "heading": false
        }
      ],
      "extract": "Figure 12. Risk of bias and applicability summary for pulmonary tuberculosis: gastric aspirate and composite reference standard Seven studies (1,057 participants) evaluating gastric aspirate against a CRS were included with sensitivities between 19% and 83% and specificities 91% to 100% (Figure 13). All seven studies were included in the meta-analysis. The summary sensitivity (95% CI) was 48.8% (31.4 to 63.7) and",
      "extractCut": true,
      "blocks": [
        "library/10665-381036/blocks/prose-page-066",
        "library/10665-381036/blocks/figure-img-p066-1",
        "library/10665-381036/blocks/figure-img-p066-2"
      ]
    },
    {
      "id": "page-067",
      "number": null,
      "title": "Page 67",
      "level": 1,
      "pageStart": 67,
      "pageEnd": 67,
      "labelStart": "62",
      "labelEnd": "62",
      "words": 175,
      "summary": {
        "text": "Reports that Xpert Ultra on nasopharyngeal aspirate had a summary sensitivity of about 46% against culture in children, with illustrative numbers per 1,000 tested.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "nasopharyngeal aspirate",
          "heading": false
        },
        {
          "term": "pulmonary tuberculosis",
          "heading": false
        },
        {
          "term": "xpert ultra",
          "heading": false
        },
        {
          "term": "microbiological reference",
          "heading": false
        },
        {
          "term": "reference standard",
          "heading": false
        }
      ],
      "extract": "screened positive for pulmonary tuberculosis, against a microbiological reference standard? Figure 14. Risk of bias and applicability summary for pulmonary tuberculosis: nasopharyngeal aspirate and microbiological reference standard Seven studies (1,355 participants) evaluating nasopharyngeal aspirate against a MRS were included with sensitivities between 33% and 67% and specificities between 50% and 99% (Figure",
      "extractCut": true,
      "blocks": [
        "library/10665-381036/blocks/prose-page-067",
        "library/10665-381036/blocks/figure-img-p067-1",
        "library/10665-381036/blocks/figure-img-p067-2"
      ]
    },
    {
      "id": "page-068",
      "number": null,
      "title": "Page 68",
      "level": 1,
      "pageStart": 68,
      "pageEnd": 68,
      "labelStart": "63",
      "labelEnd": "63",
      "words": 220,
      "summary": {
        "text": "Reports low sensitivity for Xpert Ultra on nasopharyngeal aspirate against a composite reference standard and introduces the analysis of stool specimens against culture.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "nasopharyngeal aspirate",
          "heading": false
        },
        {
          "term": "pulmonary tuberculosis",
          "heading": false
        },
        {
          "term": "diagnose pulmonary",
          "heading": false
        },
        {
          "term": "composite reference",
          "heading": false
        },
        {
          "term": "xpert ultra",
          "heading": false
        },
        {
          "term": "reference standard",
          "heading": false
        }
      ],
      "extract": "8. Should LC-aNAATs on nasopharyngeal aspirate specimens be used to diagnose pulmonary tuberculosis in children with signs and symptoms or screened positive for pulmonary tuberculosis, against a composite reference standard? Figure 16. Risk of bias and applicability summary for pulmonary tuberculosis: nasopharyngeal aspirate and composite reference standard Four studies (676 participants) evaluating nasopharyngeal",
      "extractCut": true,
      "blocks": [
        "library/10665-381036/blocks/prose-page-068",
        "library/10665-381036/blocks/figure-img-p068-1",
        "library/10665-381036/blocks/figure-img-p068-2"
      ]
    },
    {
      "id": "page-069",
      "number": null,
      "title": "Page 69",
      "level": 1,
      "pageStart": 69,
      "pageEnd": 69,
      "labelStart": "64",
      "labelEnd": "64",
      "words": 198,
      "summary": {
        "text": "Reports a summary sensitivity of about 68% and specificity of about 98% for Xpert Ultra on stool in children against a microbiological reference standard.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "pulmonary tuberculosis",
          "heading": false
        },
        {
          "term": "xpert ultra",
          "heading": false
        },
        {
          "term": "summary specificity",
          "heading": false
        },
        {
          "term": "summary sensitivity",
          "heading": false
        },
        {
          "term": "ten studies",
          "heading": false
        }
      ],
      "extract": "Figure 18. Risk of bias and applicability summary for pulmonary tuberculosis: stool and microbiological reference standard Ten studies (2885 participants) evaluating stool against a MRS of culture or Xpert Ultra on sputum or gastric aspirate were included with sensitivities between 26% and 100% and specificities between 89% and 100% (Figure 19). All ten studies were included in the meta-analysis. The summary",
      "extractCut": true,
      "blocks": [
        "library/10665-381036/blocks/prose-page-069",
        "library/10665-381036/blocks/figure-img-p069-1"
      ]
    },
    {
      "id": "page-070",
      "number": null,
      "title": "Page 70",
      "level": 1,
      "pageStart": 70,
      "pageEnd": 70,
      "labelStart": "65",
      "labelEnd": "65",
      "words": 201,
      "summary": {
        "text": "Introduces the analysis of Xpert Ultra on stool against a composite reference standard, with illustrative numbers of true and false results per 1,000 children.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "pulmonary tuberculosis",
          "heading": false
        },
        {
          "term": "xpert ultra",
          "heading": false
        },
        {
          "term": "composite reference",
          "heading": false
        },
        {
          "term": "reference standard",
          "heading": false
        },
        {
          "term": "stool",
          "heading": false
        },
        {
          "term": "six studies",
          "heading": false
        }
      ],
      "extract": "Figure 19. Xpert Ultra for pulmonary tuberculosis using stool and a microbiological reference standard. The studies are sorted on the plot by decreasing sensitivity. FN: false negative; FP: false positive; TN: true negative; TP: true positive. 10. Should LC-aNAATs on stool be used to diagnose pulmonary tuberculosis in children with signs and symptoms or screened positive for pulmonary tuberculosis, against a",
      "extractCut": true,
      "blocks": [
        "library/10665-381036/blocks/prose-page-070",
        "library/10665-381036/blocks/figure-img-p070-1",
        "library/10665-381036/blocks/figure-img-p070-2"
      ]
    },
    {
      "id": "page-071",
      "number": null,
      "title": "Page 71",
      "level": 1,
      "pageStart": 71,
      "pageEnd": 71,
      "labelStart": "66",
      "labelEnd": "66",
      "words": 172,
      "summary": {
        "text": "Describes subgroup analyses by HIV status, age and nutritional status and reports sparse data on Xpert Ultra detection of rifampicin resistance in children's sputum.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "rifampicin resistance",
          "heading": false
        },
        {
          "term": "appendix summarizes",
          "heading": false
        },
        {
          "term": "reference standard",
          "heading": false
        },
        {
          "term": "pulmonary tuberculosis",
          "heading": false
        },
        {
          "term": "analyses",
          "heading": false
        },
        {
          "term": "sensitivity",
          "heading": false
        }
      ],
      "extract": "Figure 21. Xpert Ultra for pulmonary tuberculosis using stool and a composite reference standard. The studies are sorted on the plot by decreasing sensitivity. FN: false negative; FP: false positive; TN: true negative; TP: true positive. Subgroup analyses Appendix 3 summarizes the sensitivity and specificity of the studies included for different specimen types by HIV status (living with HIV and HIV negative), age",
      "extractCut": true,
      "blocks": [
        "library/10665-381036/blocks/prose-page-071",
        "library/10665-381036/blocks/figure-img-p071-1",
        "library/10665-381036/blocks/figure-img-p071-2"
      ]
    },
    {
      "id": "page-072",
      "number": null,
      "title": "Page 72",
      "level": 1,
      "pageStart": 72,
      "pageEnd": 72,
      "labelStart": "67",
      "labelEnd": "67",
      "words": 198,
      "summary": {
        "text": "Begins the results on extrapulmonary TB in children, reporting on Xpert Ultra accuracy in cerebrospinal fluid for tuberculous meningitis against culture.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "tuberculosis meningitis",
          "heading": false
        },
        {
          "term": "tuberculous meningitis",
          "heading": false
        },
        {
          "term": "extrapulmonary tuberculosis",
          "heading": false
        },
        {
          "term": "xpert ultra",
          "heading": false
        },
        {
          "term": "microbiological reference",
          "heading": false
        },
        {
          "term": "csf",
          "heading": false
        }
      ],
      "extract": "Figure 23. Xpert Ultra for detection of rifampicin resistance. FN: false negative; FP: false positive; TN: true negative; TP: true positive. Detection of extrapulmonary tuberculosis 12. Should LC-aNAATs on cerebrospinal fluid (CSF) be used to diagnose tuberculous meningitis in children with signs and symptoms of tuberculous meningitis, against a microbiological reference standard? Figure 24. Risk of bias and",
      "extractCut": true,
      "blocks": [
        "library/10665-381036/blocks/prose-page-072",
        "library/10665-381036/blocks/figure-img-p072-1",
        "library/10665-381036/blocks/figure-img-p072-2",
        "library/10665-381036/blocks/figure-img-p072-3"
      ]
    },
    {
      "id": "page-073",
      "number": null,
      "title": "Page 73",
      "level": 1,
      "pageStart": 73,
      "pageEnd": 73,
      "labelStart": "68",
      "labelEnd": "68",
      "words": 202,
      "summary": {
        "text": "Reports two small studies of Xpert Ultra on cerebrospinal fluid against a composite reference standard, with low sensitivity, and introduces the lymph node analysis.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "tuberculosis meningitis",
          "heading": false
        },
        {
          "term": "tuberculous meningitis",
          "heading": false
        },
        {
          "term": "lymph node",
          "heading": false
        },
        {
          "term": "extrapulmonary tuberculosis",
          "heading": false
        },
        {
          "term": "composite reference",
          "heading": false
        },
        {
          "term": "reference standard",
          "heading": false
        }
      ],
      "extract": "13. Should LC-aNAATs on CSF be used to diagnose tuberculous meningitis in children with signs and symptoms of tuberculous meningitis, against a composite reference standard? Figure 26. Risk of bias and applicability summary for extrapulmonary tuberculosis using CSF and a composite reference standard Two studies (67 participants) were included with sensitivities of 12% to 19% and all had a specificity of 100% (Figure",
      "extractCut": true,
      "blocks": [
        "library/10665-381036/blocks/prose-page-073",
        "library/10665-381036/blocks/figure-img-p073-1",
        "library/10665-381036/blocks/figure-img-p073-2"
      ]
    },
    {
      "id": "page-074",
      "number": null,
      "title": "Page 74",
      "level": 1,
      "pageStart": 74,
      "pageEnd": 74,
      "labelStart": "69",
      "labelEnd": "69",
      "words": 185,
      "summary": {
        "text": "Reports two small studies of Xpert Ultra on lymph node tissue and aspirates against culture, with high sensitivity and variable specificity; no meta-analysis was performed.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "lymph node",
          "heading": false
        },
        {
          "term": "node tuberculosis",
          "heading": false
        },
        {
          "term": "node tissue",
          "heading": false
        },
        {
          "term": "extrapulmonary tuberculosis",
          "heading": false
        },
        {
          "term": "xpert ultra",
          "heading": false
        }
      ],
      "extract": "Figure 28. Risk of bias and applicability summary for extrapulmonary tuberculosis using lymph node tissue or aspirates and a microbiological reference standard Two studies (58 participants) were included all with a sensitivity of 100% and specificities between 33% and 82% (Figure 29). Meta-analysis was not performed due to the small number of cases and studies. For a population of 1,000 children where 200 have",
      "extractCut": true,
      "blocks": [
        "library/10665-381036/blocks/prose-page-074",
        "library/10665-381036/blocks/figure-img-p074-1",
        "library/10665-381036/blocks/figure-img-p074-2"
      ]
    },
    {
      "id": "page-075",
      "number": null,
      "title": "Page 75",
      "level": 1,
      "pageStart": 75,
      "pageEnd": 75,
      "labelStart": "70",
      "labelEnd": "70",
      "words": 242,
      "summary": {
        "text": "Reports small studies of Xpert Ultra on lymph node specimens against a composite reference standard and on other extrapulmonary specimens, too few for meta-analysis. The text contains a typographical error in the sensitivity range.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "lymph node",
          "heading": false
        },
        {
          "term": "node tuberculosis",
          "heading": false
        },
        {
          "term": "extrapulmonary tuberculosis",
          "heading": false
        },
        {
          "term": "composite reference",
          "heading": false
        },
        {
          "term": "study evaluated",
          "heading": false
        },
        {
          "term": "reference standard",
          "heading": false
        },
        {
          "term": "performed due",
          "heading": false
        }
      ],
      "extract": "Figure 30. Risk of bias and applicability summary for extrapulmonary tuberculosis using lymph node tissue and aspirates and a composite reference standard Two studies (58 participants) were included with sensitivities of 50% to 805 and a sensitivity of 100% (Figure 31). Meta-analysis was not performed due to the small number of studies and participants. For a population of 1,000 children where 200 have tuberculosis",
      "extractCut": true,
      "blocks": [
        "library/10665-381036/blocks/prose-page-075",
        "library/10665-381036/blocks/figure-img-p075-2"
      ]
    },
    {
      "id": "page-076",
      "number": null,
      "title": "Page 76",
      "level": 1,
      "pageStart": 76,
      "pageEnd": 76,
      "labelStart": "71",
      "labelEnd": "71",
      "words": 319,
      "summary": {
        "text": "Summarizes the main results of the paediatric review, giving Xpert Ultra sensitivity and specificity by specimen type and reference standard. It notes that sensitivity was similar for sputum, gastric aspirate and stool.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "gastric aspirate",
          "heading": false
        },
        {
          "term": "nasopharyngeal aspirate",
          "heading": false
        },
        {
          "term": "aspirate specimens",
          "heading": false
        },
        {
          "term": "against mrs",
          "heading": false
        },
        {
          "term": "extrapulmonary tuberculosis",
          "heading": false
        },
        {
          "term": "xpert ultra",
          "heading": false
        },
        {
          "term": "specimen types",
          "heading": false
        },
        {
          "term": "sensitivity",
          "heading": false
        }
      ],
      "extract": "Figure 32. LC-aNAATs for extrapulmonary tuberculosis using a microbiological reference standard. EPTB: extrapulmonary tuberculosis; FN: false negative; FP: false positive; TN: true negative; TP: true positive. SUMMARY OF MAIN RESULTS ● For sputum, sensitivity was 75.3% (95% CI 68.9 to 80.8) and specificity was 95.9% (95% CI 92.3 to 97.9) in children 0 to 9 years, against MRS. ● For sputum, sensitivity was 70.4% (95%",
      "extractCut": true,
      "blocks": [
        "library/10665-381036/blocks/prose-page-076",
        "library/10665-381036/blocks/figure-img-p076-1"
      ]
    },
    {
      "id": "page-077",
      "number": null,
      "title": "Page 77",
      "level": 1,
      "pageStart": 77,
      "pageEnd": 77,
      "labelStart": "72",
      "labelEnd": "72",
      "words": 451,
      "summary": {
        "text": "Concludes that Xpert Ultra specificity exceeded 90% for each specimen type, though formal comparisons were not made, then gives acknowledgements and begins the list of included study references.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "xpert ultra",
          "heading": false
        },
        {
          "term": "rif ultra",
          "heading": false
        },
        {
          "term": "xpert mtb",
          "heading": false
        },
        {
          "term": "haas",
          "heading": false
        },
        {
          "term": "lung disease",
          "heading": false
        },
        {
          "term": "stool",
          "heading": false
        },
        {
          "term": "tropical medicine",
          "heading": false
        },
        {
          "term": "barcellini",
          "heading": false
        }
      ],
      "extract": "formal comparisons were performed, and it is difficult to draw conclusions about comparative accuracy. The Xpert Ultra specificity for each specimen type was greater than 90%. ACKNOWLEDGEMENTS We would like to thank the authorship team of the Cochrane Review that accompanies this update: Sabine Verkuijl, Kerri Viney, Tiziana Mazini, Annemieke BRANDS, Lucia González Fernández, Michael Eisenhut, Karen Steingart, and",
      "extractCut": true,
      "blocks": [
        "library/10665-381036/blocks/prose-page-077"
      ]
    },
    {
      "id": "page-078",
      "number": null,
      "title": "Page 78",
      "level": 1,
      "pageStart": 78,
      "pageEnd": 78,
      "labelStart": "73",
      "labelEnd": "73",
      "words": 353,
      "summary": {
        "text": "Continues the references of included paediatric Xpert Ultra studies.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "nct",
          "heading": false
        },
        {
          "term": "pediatric tuberculosis",
          "heading": false
        },
        {
          "term": "rif ultra",
          "heading": false
        },
        {
          "term": "xpert mtb",
          "heading": false
        },
        {
          "term": "stool processing",
          "heading": false
        },
        {
          "term": "pulmonary tuberculosis",
          "heading": false
        },
        {
          "term": "unpublished data",
          "heading": false
        },
        {
          "term": "ultra assay",
          "heading": false
        }
      ],
      "extract": "Enimil 2022 Enimil, A. K.; Nuttall, J. J. C.; Centner, C. M.; Beylis, N.; Eley, B. S.. Xpert MTB/RIF Ultra and mycobacterial culture in routine clinical care at a paediatric hospital. Southern African Journal of Infectious Diseases 20 June 2022;2313-1810. [DOI: https://doi.org/10.4102/sajid.v37i1.398] Jaganath 2021 Jaganath D, Wambi P, Reza TF, Nakafeero J, Aben EO, Kiconco E, et al. A prospective evaluation of",
      "extractCut": true,
      "blocks": [
        "library/10665-381036/blocks/prose-page-078"
      ]
    },
    {
      "id": "page-079",
      "number": null,
      "title": "Page 79",
      "level": 1,
      "pageStart": 79,
      "pageEnd": 79,
      "labelStart": "74",
      "labelEnd": "74",
      "words": 404,
      "summary": {
        "text": "Ends the included study references and begins the list of excluded studies, each with its reason for exclusion.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "xpert ultra",
          "heading": false
        },
        {
          "term": "rif ultra",
          "heading": false
        },
        {
          "term": "xpert mtb",
          "heading": false
        },
        {
          "term": "international journal",
          "heading": false
        },
        {
          "term": "pulmonary tuberculosis",
          "heading": false
        },
        {
          "term": "ultra assay",
          "heading": false
        },
        {
          "term": "lung disease",
          "heading": false
        },
        {
          "term": "sabi",
          "heading": false
        }
      ],
      "extract": "MTB/RIF Ultra for the diagnosis of pulmonary tuberculosis in children. Paediatric Infectious Disease Journal 2018;37(10):e261-3. [CRS ID: 14396201] Parigi 2021 Parigi S, Venturini E, Galli L, Chiappini E. Xpert MTB/RIF Ultra performance in diagnosing paediatric pulmonary TB in gastric aspirates. International Journal of Tuberculosis and Lung Disease 2021;25(1):75-7. Pradhan 2022 Pradhan, N. N.; Paradkar, M. S.;",
      "extractCut": true,
      "blocks": [
        "library/10665-381036/blocks/prose-page-079"
      ]
    },
    {
      "id": "page-080",
      "number": null,
      "title": "Page 80",
      "level": 1,
      "pageStart": 80,
      "pageEnd": 80,
      "labelStart": "75",
      "labelEnd": "75",
      "words": 405,
      "summary": {
        "text": "Continues the list of excluded studies, citing reasons such as adult populations, inability to separate data for children under 10, or unpublished data.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "mtb rif",
          "heading": false
        },
        {
          "term": "xpert mtb",
          "heading": false
        },
        {
          "term": "rif ultra",
          "heading": false
        },
        {
          "term": "ultra assay",
          "heading": false
        },
        {
          "term": "pulmonary tuberculosis",
          "heading": false
        },
        {
          "term": "adult study",
          "heading": false
        },
        {
          "term": "international journal",
          "heading": false
        },
        {
          "term": "ijid",
          "heading": false
        }
      ],
      "extract": "10.1016/j.ijid.2021.11.010; Unable to disaggregate data to children 0-9 years of age ChiCTR1800015075 Diagnositc accuracy of Xpert MTB/RIF Ultra assay on diagnosing pediatric pulmonary tuberculosis 2018;():2018; Data is unpublished and incomplete Christopher 2021 Christopher, D. J.; Coelho, V.; Ebby, G. S.; Shankar, D.; Gupta, R.; Thangakunam, B. Incremental yield of Xpert® MTB/RIF Ultra over Xpert® MTB/RIF in the",
      "extractCut": true,
      "blocks": [
        "library/10665-381036/blocks/prose-page-080"
      ]
    },
    {
      "id": "page-081",
      "number": null,
      "title": "Page 81",
      "level": 1,
      "pageStart": 81,
      "pageEnd": 81,
      "labelStart": "76",
      "labelEnd": "76",
      "words": 425,
      "summary": {
        "text": "Continues the excluded studies list with reasons, including registered trials whose data were unpublished or incomplete.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "disaggregate data",
          "heading": false
        },
        {
          "term": "adult study",
          "heading": false
        },
        {
          "term": "mycobacterium tuberculosis",
          "heading": false
        },
        {
          "term": "doi",
          "heading": false
        },
        {
          "term": "kagujje",
          "heading": false
        },
        {
          "term": "mekkaoui",
          "heading": false
        },
        {
          "term": "diagnostic accuracy",
          "heading": false
        },
        {
          "term": "rif ultra",
          "heading": false
        }
      ],
      "extract": "Gutierrez, N.; Cherif, G. F.; Williams, C. M.; Wisniewska, A.; Barer, M. R.; Rigouts, L.; de Jong, B. C. Annals of Clinical Microbiology and Antimicrobials 2023;22(1) (no pagination)(81): 2023; DOI: 10.1186/s12941-023-00633-8; Adult study population Kagujje 2023 Kagujje, M.; Nyangu, S.; Maimbolwa, M. M.; Shuma, B.; Mutti, L.; Somwe, P.; Sanjase, N.; Chungu, C.; Kerkhoff, A. D.; Muyoyeta, M. Face mask sampling (FMS)",
      "extractCut": true,
      "blocks": [
        "library/10665-381036/blocks/prose-page-081"
      ]
    },
    {
      "id": "page-082",
      "number": null,
      "title": "Page 82",
      "level": 1,
      "pageStart": 82,
      "pageEnd": 82,
      "labelStart": "77",
      "labelEnd": "77",
      "words": 405,
      "summary": {
        "text": "Continues the excluded studies list, including TB-Speed trials and studies not designed to assess diagnostic accuracy.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "fujifilm silvamp",
          "heading": false
        },
        {
          "term": "nct",
          "heading": false
        },
        {
          "term": "pulmonary tuberculosis",
          "heading": false
        },
        {
          "term": "shi",
          "heading": false
        },
        {
          "term": "data duplicated",
          "heading": false
        },
        {
          "term": "disaggregate data",
          "heading": false
        },
        {
          "term": "novel urine",
          "heading": false
        },
        {
          "term": "infect dis",
          "heading": false
        }
      ],
      "extract": "NCT03831906. TB-Speed Pneumonia. clinicaltrials.gov/show/NCT03831906 (first received 6 February 2019); data were unpublished and incomplete NCT04038632 NCT04038632. TB-Speed Decentralisation Study. clinicaltrials.gov/show/NCT04038632 (first received 2 August 2019); data were unpublished and incomplete. NCT05818059 https://clinicaltrials.gov/show/NCT05818059 2023;(): 2023; Not a diagnostic accuracy study Nicol 2020",
      "extractCut": true,
      "blocks": [
        "library/10665-381036/blocks/prose-page-082"
      ]
    },
    {
      "id": "page-083",
      "number": null,
      "title": "Page 83",
      "level": 1,
      "pageStart": 83,
      "pageEnd": 83,
      "labelStart": "78",
      "labelEnd": "78",
      "words": 429,
      "summary": {
        "text": "Continues the excluded studies list, mostly studies that could not separate data for young children or enrolled adults.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "rif ultra",
          "heading": false
        },
        {
          "term": "mtb rif",
          "heading": false
        },
        {
          "term": "genexpert mtb",
          "heading": false
        },
        {
          "term": "xpert mtb",
          "heading": false
        },
        {
          "term": "pulmonary tuberculosis",
          "heading": false
        },
        {
          "term": "data duplicated",
          "heading": false
        },
        {
          "term": "disaggregate data",
          "heading": false
        },
        {
          "term": "sabi",
          "heading": false
        }
      ],
      "extract": "Quan 2023 Quan, S.; Zou, T.; Duan, L.; Tian, X.; Wang, Y.; Zhu, Y.; Fang, M.; Shi, Y.; Wan, C.; Sun, L.; Shen, A.; Clinical Characteristics of Pulmonary Tuberculosis in Children Tested by Xpert MTB/RIF Ultra. Pediatr Infect Dis J ;42(5):389-395; DOI: 10.1097/INF.0000000000003866; Unable to disaggregate data to children 0-9 years of age Rekart 2023 Rekart, M. L.; Aung, A.; Cullip, T.; Mulanda, W.; Mun, L.;",
      "extractCut": true,
      "blocks": [
        "library/10665-381036/blocks/prose-page-083"
      ]
    },
    {
      "id": "page-084",
      "number": null,
      "title": "Page 84",
      "level": 1,
      "pageStart": 84,
      "pageEnd": 84,
      "labelStart": "79",
      "labelEnd": "79",
      "words": 454,
      "summary": {
        "text": "Continues the excluded studies list with reasons for each exclusion.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "rif ultra",
          "heading": false
        },
        {
          "term": "mtb rif",
          "heading": false
        },
        {
          "term": "xpert mtb",
          "heading": false
        },
        {
          "term": "multicenter cohort",
          "heading": false
        },
        {
          "term": "sun",
          "heading": false
        },
        {
          "term": "pulmonary tuberculosis",
          "heading": false
        },
        {
          "term": "wang",
          "heading": false
        },
        {
          "term": "ultra assay",
          "heading": false
        }
      ],
      "extract": "Sun 2022 Sun, L.; Liu, Y.; Fang, M.; Chen, Y.; Zhu, Y.; Xia, C.; Jia, J.; Quan, S.; Wang, Y.; Tian, X.; Shi, Y.; Duan, L.; Shi, X.; Liao, Q.; Wan, C.; Shen, A.; Use of Xpert MTB/RIF Ultra assay on stool and gastric aspirate samples to diagnose pulmonary tuberculosis in children in a high-tuberculosis-burden but resource-limited area of China. Int J Infect Dis 2022;114():236-243; 2022; DOI:",
      "extractCut": true,
      "blocks": [
        "library/10665-381036/blocks/prose-page-084"
      ]
    },
    {
      "id": "page-085",
      "number": null,
      "title": "Page 85",
      "level": 1,
      "pageStart": 85,
      "pageEnd": 85,
      "labelStart": "80",
      "labelEnd": "80",
      "words": 380,
      "summary": {
        "text": "Ends the excluded studies list and begins the other references, citing GRADE guidance on certainty of test accuracy evidence.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "tuberculosis lymphadenitis",
          "heading": false
        },
        {
          "term": "rif ultra",
          "heading": false
        },
        {
          "term": "mtb rif",
          "heading": false
        },
        {
          "term": "xpert mtb",
          "heading": false
        },
        {
          "term": "lymphadenitis diagnosis",
          "heading": false
        },
        {
          "term": "pulmonary tuberculosis",
          "heading": false
        },
        {
          "term": "infectious diseases",
          "heading": false
        },
        {
          "term": "schünemann",
          "heading": false
        }
      ],
      "extract": "Yao 2023 Yao, L.; Chen, S.; Sha, W.; Gu, Y. The diagnostic performance of endobronchial ultrasound with Xpert MTB/RIF Ultra in smear-negative pulmonary tuberculosis. BMC Infectious Diseases 2023;23(1) (no pagination)(107): 2023; DOI: 10.1186/s12879-023-08073-7; Adult study population Yenew 2023 Yenew, B.; de Haas, P.; Diriba, G.; Kebede, A.; Sherefdin, B.; Demissie, Y.; Bedru, A.; Sahile, M.; Mengesha, E.; Dememew,",
      "extractCut": true,
      "blocks": [
        "library/10665-381036/blocks/prose-page-085"
      ]
    },
    {
      "id": "page-086",
      "number": null,
      "title": "Page 86",
      "level": 1,
      "pageStart": 86,
      "pageEnd": 86,
      "labelStart": "81",
      "labelEnd": "81",
      "words": 169,
      "summary": {
        "text": "Ends the other references, citing GRADE guidance and WHO consolidated guidelines and handbooks on TB diagnosis.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "tuberculosis report",
          "heading": false
        },
        {
          "term": "health organization",
          "heading": false
        },
        {
          "term": "world health",
          "heading": false
        },
        {
          "term": "global tuberculosis",
          "heading": false
        },
        {
          "term": "operational handbook",
          "heading": false
        },
        {
          "term": "rapid diagnostics",
          "heading": false
        }
      ],
      "extract": "Schünemann HJ, Mustafa R, Brozek J, Steingart KR, Leeflang M, Murad MH, et al. GRADE guidelines: 21 part 2. Inconsistency, Imprecision, publication bias and other domains for rating the certainty of evidence for test accuracy and presenting it in evidence profiles and summary of findings tables. Journal of Clinical Epidemiology 2020;122:142-52. WHO Consolidated Guidelines (Module 3) 2020 World Health Organization.",
      "extractCut": true,
      "blocks": [
        "library/10665-381036/blocks/prose-page-086"
      ]
    },
    {
      "id": "page-087",
      "number": null,
      "title": "Page 87",
      "level": 1,
      "pageStart": 87,
      "pageEnd": 87,
      "labelStart": "82",
      "labelEnd": "82",
      "words": 166,
      "summary": {
        "text": "Appendix 1, the MEDLINE search strategy for the paediatric LC-aNAAT review, combining TB, child and test name terms.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "lymph node",
          "heading": false
        },
        {
          "term": "exp",
          "heading": false
        },
        {
          "term": "mening",
          "heading": false
        },
        {
          "term": "extrapulmonary",
          "heading": false
        }
      ],
      "extract": "APPENDIX Appendix 1: Detailed search strategies Ovid MEDLINE(R) ALL <1946 to October 03, 2023> 1 Mycobacterium tuberculosis/ 2 Tuberculosis, Pulmonary/ 3 Extensively Drug-Resistant Tuberculosis/ 4 Tuberculosis, Multidrug-Resistant/ 5 (tuberculosis or TB).tw. 6 ((extrapulmonary or lymph node* or mening* or pulmonary) and TB).ti. or ((extrapulmonary or lymph node* or mening* or pulmonary) and TB).ab. 7 exp",
      "extractCut": true,
      "blocks": [
        "library/10665-381036/blocks/prose-page-087"
      ]
    },
    {
      "id": "page-088",
      "number": null,
      "title": "Page 88",
      "level": 1,
      "pageStart": 88,
      "pageEnd": 88,
      "labelStart": "83",
      "labelEnd": "83",
      "words": 215,
      "summary": {
        "text": "Gives the Embase and Web of Science search strategies for the paediatric review.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "lymph node",
          "heading": false
        },
        {
          "term": "resistant tuberculosis",
          "heading": false
        },
        {
          "term": "drug resistant",
          "heading": false
        },
        {
          "term": "exp",
          "heading": false
        },
        {
          "term": "mening",
          "heading": false
        }
      ],
      "extract": "1 Mycobacterium tuberculosis/ 2 Lung Tuberculosis/ 3 extensively drug resistant tuberculosis/ 4 drug resistant tuberculosis/ 5 (tuberculosis or TB).tw. 6 ((extrapulmonary or lymph node* or mening* or pulmonary) and TB).ti. or ((extrapulmonary or lymph node* or mening* or pulmonary) and TB).ab. 7 exp extrapulmonary tuberculosis/ 8 5 and 6 9 1 or 2 or 3 or 4 or 7 or 8 10 (child or children* or childhood or infan* or",
      "extractCut": true,
      "blocks": [
        "library/10665-381036/blocks/prose-page-088"
      ]
    },
    {
      "id": "page-089",
      "number": null,
      "title": "Page 89",
      "level": 1,
      "pageStart": 89,
      "pageEnd": 89,
      "labelStart": "84",
      "labelEnd": "84",
      "words": 378,
      "summary": {
        "text": "Gives the Web of Science, Scopus and regional database search strategies for the paediatric review.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "title-abs-key",
          "heading": false
        },
        {
          "term": "xpert ultra",
          "heading": false
        },
        {
          "term": "adolescen",
          "heading": false
        },
        {
          "term": "infan",
          "heading": false
        },
        {
          "term": "neonat",
          "heading": false
        },
        {
          "term": "toddler",
          "heading": false
        },
        {
          "term": "paediatr",
          "heading": false
        },
        {
          "term": "mening",
          "heading": false
        }
      ],
      "extract": "#5 Search: #3 AND #4 #6 Search: (Xpert* or GeneXpert* or cepheid) and Ultra (Topic) #7 Search: #5 AND #6 #8 Search: (Truenat* or Molbio or TruRif) (Topic) #9 Search: #5 AND #8 #10 Search: (STANDARD M10 or SD Biosensor or IRON-qPCR or BIONEER) (Topic) Search: #5 AND #10 Scopus (Elseviers) ( TITLE-ABS-KEY ( ( standard AND m10 OR sd AND biosensor OR iron-qpcr OR bioneer ) ) ) AND ( ( TITLE-ABS-KEY ( ( child OR",
      "extractCut": true,
      "blocks": [
        "library/10665-381036/blocks/prose-page-089"
      ]
    },
    {
      "id": "page-090",
      "number": null,
      "title": "Page 90",
      "level": 1,
      "pageStart": 90,
      "pageEnd": 90,
      "labelStart": "85",
      "labelEnd": "85",
      "words": 166,
      "summary": {
        "text": "Gives the Cochrane library and trial registry search strategies for the paediatric review.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "mesh descriptor",
          "heading": false
        },
        {
          "term": "tuberculosis child",
          "heading": false
        },
        {
          "term": "explode",
          "heading": false
        },
        {
          "term": "trees",
          "heading": false
        }
      ],
      "extract": "Search Name: Cochrane Database of Systematic Reviews Issue 10 of 12, October 2023 ID Search Hits #1 MeSH descriptor: [Tuberculosis] explode all trees #2 MeSH descriptor: [Mycobacterium tuberculosis] explode all trees #3 ((tuberculosis or TB or MDR-TB or XDR-TB)):ti,ab,kw #4 #1 or #2 or #3 #5 extrapulmonary tuberculosis #6 MeSH descriptor: [Tuberculosis, Extrapulmonary] explode all trees #7 PTB or EPTB #8 #4 or #5 or",
      "extractCut": true,
      "blocks": [
        "library/10665-381036/blocks/prose-page-090"
      ]
    },
    {
      "id": "page-091",
      "number": null,
      "title": "Page 91",
      "level": 1,
      "pageStart": 91,
      "pageEnd": 91,
      "labelStart": "86",
      "labelEnd": "86",
      "words": 24,
      "summary": {
        "text": "Appendix 2, PRISMA diagram captions for Truenat and for STANDARD M10 and IRON-qPCR in the paediatric review.",
        "status": "draft"
      },
      "keywords": [],
      "extract": "Appendix 2. PRISMA diagram for other LC-aNAATs A. Truenat ( Truenat MTB Plus, and Truenat MTB‐RIF Dx) B. STANDARD M10, SD Biosensor; IRON-qPCR, BIONEER",
      "extractCut": false,
      "blocks": [
        "library/10665-381036/blocks/prose-page-091",
        "library/10665-381036/blocks/figure-img-p091-1"
      ]
    },
    {
      "id": "page-092",
      "number": null,
      "title": "Page 92",
      "level": 1,
      "pageStart": 92,
      "pageEnd": 92,
      "labelStart": "87",
      "labelEnd": "87",
      "words": 5,
      "summary": {
        "text": "A blank page with no extracted text.",
        "status": "draft"
      },
      "keywords": [],
      "extract": "_(no text on this page)_",
      "extractCut": false,
      "blocks": [
        "library/10665-381036/blocks/prose-page-092",
        "library/10665-381036/blocks/figure-img-p092-1"
      ]
    },
    {
      "id": "page-093",
      "number": null,
      "title": "Page 93",
      "level": 1,
      "pageStart": 93,
      "pageEnd": 93,
      "labelStart": "88",
      "labelEnd": "88",
      "words": 676,
      "summary": {
        "text": "Appendix 3, the start of a table of Xpert Ultra subgroup accuracy for paediatric pulmonary TB by HIV status, age group and specimen type. It also covers reference standard, giving pooled sensitivity, specificity and predictive values.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "crs",
          "heading": false
        },
        {
          "term": "mrs",
          "heading": false
        },
        {
          "term": "sam",
          "heading": false
        },
        {
          "term": "yrs",
          "heading": false
        },
        {
          "term": "sputum",
          "heading": false
        }
      ],
      "extract": "Appendix 3. Diagnostic accuracy of LC-aNAATs (Xpert Ultra) for detection of pulmonary tuberculosis: subgroup analyses No. Subgroup Specimen, reference standard Studies Total (cases) Summary sensitivity (95% CI) Summary specificity (95% CI) PPV (95% CI)* NPV (95% CI)* 1 CLHIV Sputum, MRS 7 400 (57) 70.4 (56.0 to 81.7) 95.6 (89.9 to 98.2) 64.2 (38.0 to 83.4) 96.7 (94.8 to 98.0) 2 CLHIV Sputum, CRS 7 317 (242) 18.6",
      "extractCut": true,
      "blocks": [
        "library/10665-381036/blocks/prose-page-093"
      ]
    },
    {
      "id": "page-094",
      "number": null,
      "title": "Page 94",
      "level": 1,
      "pageStart": 94,
      "pageEnd": 94,
      "labelStart": "89",
      "labelEnd": "89",
      "words": 605,
      "summary": {
        "text": "Continues the subgroup accuracy table for children aged 1–4 years and other subgroups by specimen and reference standard.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "yrs",
          "heading": false
        },
        {
          "term": "mrs",
          "heading": false
        },
        {
          "term": "crs",
          "heading": false
        },
        {
          "term": "npa",
          "heading": false
        },
        {
          "term": "predictive values",
          "heading": false
        },
        {
          "term": "stool",
          "heading": false
        }
      ],
      "extract": "28 1-4 yrs NPA, MRS 5 799 (57) 49.3 (36.2 to 62.5) 98.7 (96.6 to 99.5) 81.0 (54.5 to 93.5) 94.6 (93.2 to 96.0) 29 1-4 yrs NPA, CRS 4 446 (310) 11.0 (06.9 to 17.1) 100.0 (97.3 to 100.0) 100.0 (22.4 to 100.0) 91.0 (90.4 to 91.6) 30 1-4 yrs Stool, MRS 7 1420 (154) 74.6 (63.1 to 83.4) 95.3 (92.3 to 97.2) 63.8 (47.6 to 76.6) 97.1 (95.7 to 98.1) 31 1-4 yrs Stool, CRS 5 746 (199) 28.3 (12.0 to 53.3) 99.3 (97.4 to 99.8)",
      "extractCut": true,
      "blocks": [
        "library/10665-381036/blocks/prose-page-094"
      ]
    },
    {
      "id": "page-095",
      "number": null,
      "title": "Page 95",
      "level": 1,
      "pageStart": 95,
      "pageEnd": 95,
      "labelStart": "90",
      "labelEnd": "90",
      "words": 112,
      "summary": {
        "text": "Ends the subgroup accuracy table with nasopharyngeal aspirate and stool results and abbreviations; some confidence intervals in the stool row appear misprinted in the source.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "predictive values",
          "heading": false
        },
        {
          "term": "npa",
          "heading": false
        },
        {
          "term": "crs",
          "heading": false
        }
      ],
      "extract": "12 NPA, CRS 3 534 (370) 13.4 (07.0 to 24.2) 100.0 (97.8 to 100.0) 100.0 (25.9 to 100.0) 91.2 (90.4 to 92.2) 13 Stool, MRS 4 2242 (100) 62.1 (48.7 to 48.7) 99.0 (97.7 to 99.6) 87.8 (70.5 to 93.1) 95.9 (94.5 to 94.6) 14 Stool, CRS 2 916 (193) 26.8 (05.4 to 70.3) 99.3 (98.3 to 99.7) 81.1 (26.5 to 96.4) 92.4 (90.3 to 96.8) * Predictive values were calculated at a pre-test probability of 10%. Sensitivity, specificity and",
      "extractCut": true,
      "blocks": [
        "library/10665-381036/blocks/prose-page-095"
      ]
    },
    {
      "id": "page-096",
      "number": null,
      "title": "Page 96",
      "level": 1,
      "pageStart": 96,
      "pageEnd": 96,
      "labelStart": "91",
      "labelEnd": "91",
      "words": 137,
      "summary": {
        "text": "The title, authors and affiliations of Web Annex B.3, a systematic review of LC-aNAAT accuracy for extrapulmonary TB and rifampicin resistance in adults and adolescents.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "india dept",
          "heading": false
        },
        {
          "term": "icmr national",
          "heading": false
        },
        {
          "term": "chennai",
          "heading": false
        },
        {
          "term": "national institute",
          "heading": false
        },
        {
          "term": "clinical research",
          "heading": false
        },
        {
          "term": "review lead",
          "heading": false
        }
      ],
      "extract": "Web Annex B.3. Accuracy of LC-aNAATs for extrapulmonary tuberculosis and rifampicin resistance in adults and adolescents: a systematic review Mikashmi Kohli1, Leeberk Raja Inbaraj2, Angela Salomon3, Jefferson Daniel4, Mukesh Kumar Sathya Narayanan5, Vignes Anand Srinivasalu2, Adhin Bhaskar6, Katie Scandrett7, Karen R Steingart8, Yemisi Takwoingi7 1Xpert Ultra review lead 2Truenat review lead 1 FIND, Geneva,",
      "extractCut": true,
      "blocks": [
        "library/10665-381036/blocks/prose-page-096"
      ]
    },
    {
      "id": "page-097",
      "number": null,
      "title": "Page 97",
      "level": 1,
      "pageStart": 97,
      "pageEnd": 97,
      "labelStart": "92",
      "labelEnd": "92",
      "words": 482,
      "summary": {
        "text": "Gives background on extrapulmonary TB, which made up a fifth of notified TB cases in 2022, and on rifampicin-resistant TB. It describes Xpert Ultra's improved detection limit compared with Xpert MTB/RIF and its new trace result category.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "xpert ultra",
          "heading": false
        },
        {
          "term": "xpert mtb",
          "heading": false
        },
        {
          "term": "rif ultra",
          "heading": false
        },
        {
          "term": "truenat mtb",
          "heading": false
        },
        {
          "term": "extrapulmonary tuberculosis",
          "heading": false
        },
        {
          "term": "tuberculosis detection",
          "heading": false
        },
        {
          "term": "complexity automated",
          "heading": false
        },
        {
          "term": "tuberculosis report",
          "heading": false
        }
      ],
      "extract": "Background Globally, extrapulmonary tuberculosis accounted for 20% of the 7.4 million cases of tuberculosis notified in 2022, ranging from 8% in the WHO Western Pacific Region to 24% in the Eastern Mediterranean Region (WHO Global Tuberculosis Report 2023). In 2022, there were about 520,000 new cases of rifampicin-resistant tuberculosis; of these cases, 78% had multidrug-resistant tuberculosis (WHO Global",
      "extractCut": true,
      "blocks": [
        "library/10665-381036/blocks/prose-page-097"
      ]
    },
    {
      "id": "page-098",
      "number": null,
      "title": "Page 98",
      "level": 1,
      "pageStart": 98,
      "pageEnd": 98,
      "labelStart": "93",
      "labelEnd": "93",
      "words": 486,
      "summary": {
        "text": "Explains how Xpert Ultra trace results should be interpreted and describes the other index tests, including Truenat, STANDARD M10 and the multiplex IRON-qPCR platform.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "truenat mtb",
          "heading": false
        },
        {
          "term": "truenat assays",
          "heading": false
        },
        {
          "term": "mtb ntm",
          "heading": false
        },
        {
          "term": "truenat mtb-rif",
          "heading": false
        },
        {
          "term": "xpert mtb",
          "heading": false
        },
        {
          "term": "standard mtb",
          "heading": false
        },
        {
          "term": "real-time pcr",
          "heading": false
        },
        {
          "term": "melting temperature",
          "heading": false
        }
      ],
      "extract": "that corresponds to the lowest bacillary load for M. tuberculosis detection. This new category is reported as 'MTB trace DETECTED'. Interpreting a trace call result requires a reassessment of clinical symptoms and history of prior tuberculosis. No rifampicin resistance results are available (indeterminate) for people with trace results. As with Xpert MTB/RIF, Xpert Ultra detects both live and dead bacteria. To",
      "extractCut": true,
      "blocks": [
        "library/10665-381036/blocks/prose-page-098"
      ]
    },
    {
      "id": "page-099",
      "number": null,
      "title": "Page 99",
      "level": 1,
      "pageStart": 99,
      "pageEnd": 99,
      "labelStart": "94",
      "labelEnd": "94",
      "words": 411,
      "summary": {
        "text": "Describes the IRON-qPCR kit for detecting TB and resistance to many drugs, then sets out the review's methods for analysing results per participant and by type of extrapulmonary TB.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "qpcr rfia",
          "heading": false
        },
        {
          "term": "iron qpcr",
          "heading": false
        },
        {
          "term": "extrapulmonary tuberculosis",
          "heading": false
        },
        {
          "term": "electronic searches",
          "heading": false
        },
        {
          "term": "pulmonary tuberculosis",
          "heading": false
        },
        {
          "term": "review authors",
          "heading": false
        },
        {
          "term": "extracted data",
          "heading": false
        },
        {
          "term": "searched",
          "heading": false
        }
      ],
      "extract": "in 40 minutes. The IRON qPCR RFIA kit is a cartridge-based assay that detects M. tuberculosis and resistance to 11 drugs: rifampicin, isoniazid, fluoroquinolones (levofloxacin, moxifloxacin, gatifloxacin and ofloxacin), aminoglycosides (kanamycin, amikacin, capreomycin), prothionamide and ethionamide. It uses IRON qPCR, which is a single instrument for extraction and amplification and detection. Two modules are",
      "extractCut": true,
      "blocks": [
        "library/10665-381036/blocks/prose-page-099"
      ]
    },
    {
      "id": "page-100",
      "number": null,
      "title": "Page 100",
      "level": 1,
      "pageStart": 100,
      "pageEnd": 100,
      "labelStart": "95",
      "labelEnd": "95",
      "words": 339,
      "summary": {
        "text": "Explains the meta-analysis approach for the extrapulmonary review, including bivariate models and analyses by reference standard, and introduces the search results.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "assay lies",
          "heading": false
        },
        {
          "term": "summary estimate",
          "heading": false
        },
        {
          "term": "point estimate",
          "heading": false
        },
        {
          "term": "percentage points",
          "heading": false
        },
        {
          "term": "overall point",
          "heading": false
        },
        {
          "term": "drug resistance",
          "heading": false
        },
        {
          "term": "drug resistant",
          "heading": false
        },
        {
          "term": "fitted",
          "heading": false
        }
      ],
      "extract": "diagnosis), and rifampicin resistance. We also performed analyses separately by type of reference standard (microbiological or composite). Sensitivity and specificity were estimated for each included study with 95% confidence intervals (CIs) and these estimates were presented on forest plots and in receiver operating characteristic (ROC) space on summary ROC (SROC) plots. We used a bivariate random-effects model to",
      "extractCut": true,
      "blocks": [
        "library/10665-381036/blocks/prose-page-100"
      ]
    },
    {
      "id": "page-101",
      "number": null,
      "title": "Page 101",
      "level": 1,
      "pageStart": 101,
      "pageEnd": 101,
      "labelStart": "96",
      "labelEnd": "96",
      "words": 201,
      "summary": {
        "text": "The study flow diagram for the extrapulmonary LC-aNAAT review, showing records identified, screened, excluded and included, with a PRISMA reference.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "reports excluded",
          "heading": false
        },
        {
          "term": "reports sought",
          "heading": false
        },
        {
          "term": "records removed",
          "heading": false
        },
        {
          "term": "reports assessed",
          "heading": false
        },
        {
          "term": "records identified",
          "heading": false
        },
        {
          "term": "retrieved",
          "heading": false
        }
      ],
      "extract": "96 Figure 1. Study flow diagram for LC-aNAATs Records identified from: Databases (n =1776) Records removed before screening: Duplicate records removed (n =871 ) Records screened (n = 905) Records excluded (n = 794) Reports sought for retrieval (n = 111) Reports not retrieved (n = 0) Reports assessed for eligibility (n = 111) Reports excluded:86 (See reasons for each test in supplementary figures 1-3) Records",
      "extractCut": true,
      "blocks": [
        "library/10665-381036/blocks/prose-page-101",
        "library/10665-381036/blocks/figure-vfig-p101"
      ]
    },
    {
      "id": "page-102",
      "number": null,
      "title": "Page 102",
      "level": 1,
      "pageStart": 102,
      "pageEnd": 102,
      "labelStart": "97",
      "labelEnd": "97",
      "words": 347,
      "summary": {
        "text": "Table 1 of a systematic review on low-complexity automated nucleic acid amplification tests (LC-aNAATs) for extrapulmonary TB, listing included Xpert Ultra studies by country, reference standard, share of people with HIV, setting and specimen type. Most studies are from tertiary centres in high-burden countries such as South Africa, Uganda and India.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "cerebrospinal fluid",
          "heading": false
        },
        {
          "term": "pleural fluid",
          "heading": false
        },
        {
          "term": "pericardial fluid",
          "heading": false
        },
        {
          "term": "tertiary care",
          "heading": false
        },
        {
          "term": "node biopsy",
          "heading": false
        },
        {
          "term": "lymph node",
          "heading": false
        },
        {
          "term": "node aspirate",
          "heading": false
        },
        {
          "term": "mgit",
          "heading": false
        }
      ],
      "extract": "97 Table 1. Key characteristics of included studies Study Country Reference standard PLHIV % Clinical setting High TB burden High HIV-TB burden country Specimen type Xpert Ultra Alomatu 2023 South Africa MGIT 52.6 Tertiary care centre Yes Yes Pericardial fluid Antel 2020 South Africa MGIT 51 Tertiary care centre Yes Yes Lymph node aspirate and biopsy Bahr 2017 Uganda MGIT 100 Tertiary care centre Yes Yes",
      "extractCut": true,
      "blocks": [
        "library/10665-381036/blocks/prose-page-102"
      ]
    },
    {
      "id": "page-103",
      "number": null,
      "title": "Page 103",
      "level": 1,
      "pageStart": 103,
      "pageEnd": 103,
      "labelStart": "98",
      "labelEnd": "98",
      "words": 328,
      "summary": {
        "text": "Continues Table 1 of included studies, adding studies from Colombia, Spain, Uganda, China and India with their reference standards and specimen types. Footnotes define the culture methods and abbreviations.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "cerebrospinal fluid",
          "heading": false
        },
        {
          "term": "pleural fluid",
          "heading": false
        },
        {
          "term": "peritoneal fluid",
          "heading": false
        },
        {
          "term": "node aspirate",
          "heading": false
        },
        {
          "term": "node biopsy",
          "heading": false
        },
        {
          "term": "pericardial fluid",
          "heading": false
        },
        {
          "term": "lymph node",
          "heading": false
        },
        {
          "term": "tertiary care",
          "heading": false
        }
      ],
      "extract": "98 Study Country Reference standard PLHIV % Clinical setting High TB burden High HIV-TB burden country Specimen type Penata 2021 Colombia MGIT and LJ 26 University hospital No No Cerebrospinal fluid, pleural fluid, bone or joint aspirate, pericardial fluid, peritoneal fluid, urine, lymph node biopsy Perez-Risco 2018 Spain MGIT and LJ Unknown Referral laboratory No No Cerebrospinal fluid, pleural fluid, bone or joint",
      "extractCut": true,
      "blocks": [
        "library/10665-381036/blocks/prose-page-103"
      ]
    },
    {
      "id": "page-104",
      "number": null,
      "title": "Page 104",
      "level": 1,
      "pageStart": 104,
      "pageEnd": 104,
      "labelStart": "99",
      "labelEnd": "99",
      "words": 345,
      "summary": {
        "text": "Reports that 36 Xpert Ultra studies and three Truenat MTB Plus studies were included, with no eligible studies for other index tests, so pooled estimates come from Xpert Ultra only. It notes that GRADE summary of findings tables are in an appendix and presents a risk of bias and applicability summary figure.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "xpert ultra",
          "heading": false
        },
        {
          "term": "extrapulmonary tuberculosis",
          "heading": false
        },
        {
          "term": "judged risk",
          "heading": false
        },
        {
          "term": "standard domain",
          "heading": false
        },
        {
          "term": "truenat mtb",
          "heading": false
        },
        {
          "term": "tuberculosis hiv",
          "heading": false
        },
        {
          "term": "specimen type",
          "heading": false
        },
        {
          "term": "reference standard",
          "heading": false
        }
      ],
      "extract": "Findings We included 36 studies for Xpert Ultra and three studies for Truenat MTB plus. We found no eligible studies for the other index tests. For a class level analysis for each specimen type across different technologies, we could only include studies from Xpert Ultra based on the criteria in Box 1. Therefore, the summary estimates in Table 2 were obtained from only studies of Xpert Ultra. We present the findings",
      "extractCut": true,
      "blocks": [
        "library/10665-381036/blocks/prose-page-104",
        "library/10665-381036/blocks/figure-img-p104-1"
      ]
    },
    {
      "id": "page-105",
      "number": null,
      "title": "Page 105",
      "level": 1,
      "pageStart": 105,
      "pageEnd": 105,
      "labelStart": "100",
      "labelEnd": "100",
      "words": 288,
      "summary": {
        "text": "Table 2 gives pooled sensitivity, specificity and predictive values of LC-aNAATs for extrapulmonary TB by specimen and reference standard, with cerebrospinal fluid showing 88.2% sensitivity against microbiological reference. Pleural fluid and urine show lower sensitivity against a composite reference standard.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "pleural fluid",
          "heading": false
        },
        {
          "term": "node fluid",
          "heading": false
        },
        {
          "term": "pleural tissue",
          "heading": false
        },
        {
          "term": "lymph node",
          "heading": false
        },
        {
          "term": "cerebrospinal fluid",
          "heading": false
        }
      ],
      "extract": "Figure 2b. Summary of risk of bias and applicability assessment for each Truenat MTB plus study The estimates of the diagnostic accuracy of LC-aNAATs for each form of extrapulmonary tuberculosis is given in Table 2. Table 2. Diagnostic accuracy of LC-aNAATs for detection of extrapulmonary tuberculosis in adults and adolescents EPTB specimen Reference standard Number of studies Number of participants (cases) Summary",
      "extractCut": true,
      "blocks": [
        "library/10665-381036/blocks/prose-page-105",
        "library/10665-381036/blocks/figure-img-p105-1"
      ]
    },
    {
      "id": "page-106",
      "number": null,
      "title": "Page 106",
      "level": 1,
      "pageStart": 106,
      "pageEnd": 106,
      "labelStart": "101",
      "labelEnd": "101",
      "words": 336,
      "summary": {
        "text": "Completes Table 2 with estimates for urine, bone or joint fluid, pericardial, peritoneal and blood specimens, where bone or joint fluid shows high sensitivity. It then introduces the results for tuberculous meningitis.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "cerebrospinal fluid",
          "heading": false
        },
        {
          "term": "peritoneal fluid",
          "heading": false
        },
        {
          "term": "joint fluid",
          "heading": false
        },
        {
          "term": "lymph node",
          "heading": false
        },
        {
          "term": "node aspirate",
          "heading": false
        },
        {
          "term": "microbiological reference",
          "heading": false
        },
        {
          "term": "predictive values",
          "heading": false
        },
        {
          "term": "reference standard",
          "heading": false
        }
      ],
      "extract": "EPTB specimen Reference standard Number of studies Number of participants (cases) Summary sensitivity (95% CI) Summary specificity (95% CI) Positive predictive value (95% CI)* Negative predictive value (95% CI)* Urine CRS 3 693 (159) 23.0 (14.7 to 34.1) 98.9 (89.7 to 99.9) 70.7 (13.7 to 97.4) 92.0 (90.4 to 93.2) Bone or joint fluid MRS 3 126 (58) 96.6 (87.2 to 99.1) 91.1 (80.8 to 96.2) 54.8 (33.6 to 74.2) 99.6 (98.3",
      "extractCut": true,
      "blocks": [
        "library/10665-381036/blocks/prose-page-106"
      ]
    },
    {
      "id": "page-107",
      "number": null,
      "title": "Page 107",
      "level": 1,
      "pageStart": 107,
      "pageEnd": 107,
      "labelStart": "102",
      "labelEnd": "102",
      "words": 130,
      "summary": {
        "text": "Reports that Xpert Ultra on cerebrospinal fluid had 88.2% sensitivity and 96.0% specificity against a microbiological reference and 60.3% sensitivity against a composite reference for tuberculous meningitis.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "tuberculous meningitis",
          "heading": false
        },
        {
          "term": "cerebrospinal fluid",
          "heading": false
        },
        {
          "term": "diagnose tuberculous",
          "heading": false
        },
        {
          "term": "moderate certainty",
          "heading": false
        }
      ],
      "extract": "Figure 3. Risk of bias and applicability summary for each study: tuberculous meningitis in cerebrospinal fluid Should LC-aNAATs be used to diagnose tuberculous meningitis in cerebrospinal fluid in adults with signs and symptoms of tuberculous meningitis, against a microbiological reference standard? LC-aNAAT summary sensitivity and specificity (95%) were 88.2% (83.7 to 91.6) and 96.0% (86.8 to 98.9) based on 16",
      "extractCut": true,
      "blocks": [
        "library/10665-381036/blocks/prose-page-107",
        "library/10665-381036/blocks/figure-img-p107-1"
      ]
    },
    {
      "id": "page-108",
      "number": null,
      "title": "Page 108",
      "level": 1,
      "pageStart": 108,
      "pageEnd": 108,
      "labelStart": "103",
      "labelEnd": "103",
      "words": 72,
      "summary": {
        "text": "A figure caption for forest plots of LC-aNAAT accuracy in cerebrospinal fluid, followed by an introduction to results for lymph node TB.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "lymph node",
          "heading": false
        },
        {
          "term": "cerebrospinal fluid",
          "heading": false
        },
        {
          "term": "node tuberculosis",
          "heading": false
        }
      ],
      "extract": "Figure 4. LC-aNAATs for tuberculous meningitis in cerebrospinal fluid The studies are ordered by decreasing sensitivity. CRS: composite reference standard; CSF: cerebrospinal fluid; FN: false negative; FP: false positive; TB: tuberculosis; TN: true negative; TP: true positive. Detection of lymph node tuberculosis The methodological quality assessment results are summarised in Figure 5 and study estimates of",
      "extractCut": true,
      "blocks": [
        "library/10665-381036/blocks/prose-page-108",
        "library/10665-381036/blocks/figure-img-p108-1",
        "library/10665-381036/blocks/figure-img-p108-2",
        "library/10665-381036/blocks/figure-img-p108-3",
        "library/10665-381036/blocks/figure-img-p108-4"
      ]
    },
    {
      "id": "page-109",
      "number": null,
      "title": "Page 109",
      "level": 1,
      "pageStart": 109,
      "pageEnd": 109,
      "labelStart": "104",
      "labelEnd": "104",
      "words": 144,
      "summary": {
        "text": "Reports pooled Xpert Ultra accuracy on lymph node aspirate, with 85.3% sensitivity and 74.1% specificity against a microbiological reference and 71.3% sensitivity against a composite reference, with low to very low certainty.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "lymph node",
          "heading": false
        },
        {
          "term": "node aspirate",
          "heading": false
        },
        {
          "term": "node tuberculosis",
          "heading": false
        },
        {
          "term": "diagnose lymph",
          "heading": false
        },
        {
          "term": "lc-anaats summary",
          "heading": false
        }
      ],
      "extract": "Figure 5. Risk of bias and applicability summary for each study: lymph node tuberculosis in lymph node aspirate Should LC-aNAATs be used to diagnose lymph node tuberculosis in lymph node aspirate in adults and adolescents with signs and symptoms of lymph node tuberculosis, against a microbiological reference standard? LC-aNAATs summary sensitivity and specificity (95% CI) were 85.3% (73.4 to 92.4) and 74.1% (63.5 to",
      "extractCut": true,
      "blocks": [
        "library/10665-381036/blocks/prose-page-109",
        "library/10665-381036/blocks/figure-img-p109-1"
      ]
    },
    {
      "id": "page-110",
      "number": null,
      "title": "Page 110",
      "level": 1,
      "pageStart": 110,
      "pageEnd": 110,
      "labelStart": "105",
      "labelEnd": "105",
      "words": 69,
      "summary": {
        "text": "A figure caption for lymph node aspirate forest plots, introducing results for lymph node tissue.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "lymph node",
          "heading": false
        },
        {
          "term": "node tuberculosis",
          "heading": false
        },
        {
          "term": "ordered",
          "heading": false
        }
      ],
      "extract": "Figure 6. LC-aNAATs for lymph node tuberculosis in lymph node aspirate The studies are ordered by decreasing sensitivity. CRS: composite reference standard; FN: false negative; FP: false positive; LN: lymph node; TB: tuberculosis; TN: true negative; TP: true positive. The methodological quality assessment results are summarised in Figure 7 and study estimates of sensitivity and specificity are presented in Figure 8",
      "extractCut": true,
      "blocks": [
        "library/10665-381036/blocks/prose-page-110",
        "library/10665-381036/blocks/figure-img-p110-1",
        "library/10665-381036/blocks/figure-img-p110-2",
        "library/10665-381036/blocks/figure-img-p110-3"
      ]
    },
    {
      "id": "page-111",
      "number": null,
      "title": "Page 111",
      "level": 1,
      "pageStart": 111,
      "pageEnd": 111,
      "labelStart": "106",
      "labelEnd": "106",
      "words": 141,
      "summary": {
        "text": "Reports pooled Xpert Ultra accuracy on lymph node tissue, with 96.5% sensitivity and 79.4% specificity against a microbiological reference and lower sensitivity against a composite reference.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "lymph node",
          "heading": false
        },
        {
          "term": "node tissue",
          "heading": false
        },
        {
          "term": "node tuberculosis",
          "heading": false
        },
        {
          "term": "diagnose lymph",
          "heading": false
        },
        {
          "term": "lc-anaats summary",
          "heading": false
        }
      ],
      "extract": "Figure 7. Risk of bias and applicability summary for each study: lymph node tuberculosis in lymph node tissue Should LC-aNAATs be used to diagnose lymph node tuberculosis in lymph node tissue in adults and adolescents with signs and symptoms of lymph node tuberculosis, against a microbiological reference standard? LC-aNAATs summary sensitivity and specificity (95% CI) were 96.5% (84.7 to 99.3) and 79.4% (65.4 to",
      "extractCut": true,
      "blocks": [
        "library/10665-381036/blocks/prose-page-111",
        "library/10665-381036/blocks/figure-img-p111-1"
      ]
    },
    {
      "id": "page-112",
      "number": null,
      "title": "Page 112",
      "level": 1,
      "pageStart": 112,
      "pageEnd": 112,
      "labelStart": "107",
      "labelEnd": "107",
      "words": 80,
      "summary": {
        "text": "A figure caption for lymph node tissue results, introducing the risk of bias summary for pleural TB in pleural fluid.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "pleural tuberculosis",
          "heading": false
        },
        {
          "term": "pleural fluid",
          "heading": false
        },
        {
          "term": "lymph node",
          "heading": false
        }
      ],
      "extract": "Figure 8. LC-aNAATs for lymph node tuberculosis in lymph node tissue The studies are ordered by decreasing sensitivity. FN: false negative; FP: false positive; TB: tuberculosis; TN: true negative; TP: true positive Detection of pleural tuberculosis The methodological quality assessment results are summarised in Figure 9 and study estimates of sensitivity and specificity are presented in Figure 10 for pleural",
      "extractCut": true,
      "blocks": [
        "library/10665-381036/blocks/prose-page-112",
        "library/10665-381036/blocks/figure-img-p112-1",
        "library/10665-381036/blocks/figure-img-p112-2",
        "library/10665-381036/blocks/figure-img-p112-3",
        "library/10665-381036/blocks/figure-img-p112-4"
      ]
    },
    {
      "id": "page-113",
      "number": null,
      "title": "Page 113",
      "level": 1,
      "pageStart": 113,
      "pageEnd": 113,
      "labelStart": "108",
      "labelEnd": "108",
      "words": 175,
      "summary": {
        "text": "Reports Xpert Ultra accuracy for pleural TB in pleural fluid, with 74.0% sensitivity and 88.1% specificity from 13 studies against a microbiological reference. It also gives estimates against a composite reference and introduces results for pleural tissue.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "pleural fluid",
          "heading": false
        },
        {
          "term": "pleural tuberculosis",
          "heading": false
        },
        {
          "term": "diagnose pleural",
          "heading": false
        },
        {
          "term": "lc-anaats summary",
          "heading": false
        },
        {
          "term": "summary sensitivity",
          "heading": false
        }
      ],
      "extract": "Should LC-aNAATs be used to diagnose pleural tuberculosis in pleural fluid in adults and adolescents with signs and symptoms of pleural tuberculosis, against a microbiological reference standard? LC-aNAATs summary sensitivity and specificity (95% CI) were 74.0% (60.8 to 83.9) and 88.1% (78.8 to 93.6) from 13 Xpert Ultra studies (1041 participants); low certainty (sensitivity) and very low certainty (specificity)",
      "extractCut": true,
      "blocks": [
        "library/10665-381036/blocks/prose-page-113",
        "library/10665-381036/blocks/figure-img-p113-1",
        "library/10665-381036/blocks/figure-img-p113-2",
        "library/10665-381036/blocks/figure-img-p113-3"
      ]
    },
    {
      "id": "page-114",
      "number": null,
      "title": "Page 114",
      "level": 1,
      "pageStart": 114,
      "pageEnd": 114,
      "labelStart": "109",
      "labelEnd": "109",
      "words": 185,
      "summary": {
        "text": "Reports that two studies on pleural tissue showed sensitivities of 80–100% and specificities of 75–86% against a microbiological reference, with low or very low certainty. It also covers composite reference results and introduces genitourinary TB in urine.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "pleural tissue",
          "heading": false
        },
        {
          "term": "pleural tuberculosis",
          "heading": false
        },
        {
          "term": "diagnose pleural",
          "heading": false
        },
        {
          "term": "genitourinary tuberculosis",
          "heading": false
        },
        {
          "term": "lc-anaats sensitivities",
          "heading": false
        },
        {
          "term": "xpert ultra",
          "heading": false
        }
      ],
      "extract": "Figure 11. Risk of bias and applicability summary for each study: pleural tuberculosis in pleural tissue Should LC-aNAATs be used to diagnose pleural tuberculosis in pleural tissue in adults and adolescents with signs and symptoms of pleural tuberculosis, against a microbiological reference standard? LC-aNAATs sensitivities were 80% and 100% and specificities were 75% and 86% from two Xpert Ultra studies (105",
      "extractCut": true,
      "blocks": [
        "library/10665-381036/blocks/prose-page-114",
        "library/10665-381036/blocks/figure-img-p114-1",
        "library/10665-381036/blocks/figure-img-p114-2",
        "library/10665-381036/blocks/figure-img-p114-3"
      ]
    },
    {
      "id": "page-115",
      "number": null,
      "title": "Page 115",
      "level": 1,
      "pageStart": 115,
      "pageEnd": 115,
      "labelStart": "110",
      "labelEnd": "110",
      "words": 152,
      "summary": {
        "text": "Reports that Xpert Ultra on urine had 100% sensitivity in three studies but widely varying specificity against a microbiological reference, with low sensitivity against a composite reference. It introduces results for bone or joint TB.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "genitourinary tuberculosis",
          "heading": false
        },
        {
          "term": "diagnose genitourinary",
          "heading": false
        },
        {
          "term": "lc-anaats",
          "heading": false
        },
        {
          "term": "urine",
          "heading": false
        },
        {
          "term": "reference standard",
          "heading": false
        }
      ],
      "extract": "Figure 13. Risk of bias and applicability summary for each study: genitourinary tuberculosis in urine Should LC-aNAATs be used to diagnose genitourinary tuberculosis in urine in adults and adolescents with signs and symptoms of genitourinary tuberculosis, against a microbiological reference standard? LC-aNAATs sensitivities were all 100% (3 studies) and specificities were between 28% and 100% (6 studies, 232",
      "extractCut": true,
      "blocks": [
        "library/10665-381036/blocks/prose-page-115",
        "library/10665-381036/blocks/figure-img-p115-1",
        "library/10665-381036/blocks/figure-img-p115-2",
        "library/10665-381036/blocks/figure-img-p115-3",
        "library/10665-381036/blocks/figure-img-p115-4",
        "library/10665-381036/blocks/figure-img-p115-5"
      ]
    },
    {
      "id": "page-116",
      "number": null,
      "title": "Page 116",
      "level": 1,
      "pageStart": 116,
      "pageEnd": 116,
      "labelStart": "111",
      "labelEnd": "111",
      "words": 174,
      "summary": {
        "text": "Reports Xpert Ultra accuracy for bone or joint TB, with 96.6% sensitivity and 91.1% specificity from three studies against a microbiological reference. A single study against a composite reference gave 90% sensitivity and 97% specificity.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "diagnose bone",
          "heading": false
        },
        {
          "term": "joint tuberculosis",
          "heading": false
        },
        {
          "term": "joint aspirate",
          "heading": false
        },
        {
          "term": "joint fluid",
          "heading": false
        },
        {
          "term": "xpert ultra",
          "heading": false
        }
      ],
      "extract": "The methodological quality assessment results are summarised in Figure 15 and study estimates of sensitivity and specificity are presented in Figure 16 for detection of bone or joint tuberculosis in bone or joint fluid. Figure 15. Risk of bias and applicability summary for each study: bone or joint tuberculosis in bone of joint fluid Should LC-aNAATs be used to diagnose bone or joint tuberculosis in bone or joint",
      "extractCut": true,
      "blocks": [
        "library/10665-381036/blocks/prose-page-116",
        "library/10665-381036/blocks/figure-img-p116-1"
      ]
    },
    {
      "id": "page-117",
      "number": null,
      "title": "Page 117",
      "level": 1,
      "pageStart": 117,
      "pageEnd": 117,
      "labelStart": "112",
      "labelEnd": "112",
      "words": 141,
      "summary": {
        "text": "Reports Xpert Ultra accuracy for pericardial TB in pericardial fluid, with 84.0% sensitivity and 86.6% specificity from three studies, at low certainty.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "pericardial fluid",
          "heading": false
        },
        {
          "term": "pericardial tuberculosis",
          "heading": false
        },
        {
          "term": "bone",
          "heading": false
        },
        {
          "term": "sensitivity",
          "heading": false
        },
        {
          "term": "lc-anaats",
          "heading": false
        }
      ],
      "extract": "Figure 16. LC-aNAATs for bone or joint tuberculosis in bone or joint fluid The studies are ordered by decreasing sensitivity. FN: false negative; FP: false positive; TB: tuberculosis; TN: true negative; TP: true positive. Detection of pericardial tuberculosis The methodological quality assessment results are summarised in Figure 17 and study estimates of sensitivity and specificity are presented in Figure 18 for",
      "extractCut": true,
      "blocks": [
        "library/10665-381036/blocks/prose-page-117",
        "library/10665-381036/blocks/figure-img-p117-1",
        "library/10665-381036/blocks/figure-img-p117-2",
        "library/10665-381036/blocks/figure-img-p117-3",
        "library/10665-381036/blocks/figure-img-p117-4"
      ]
    },
    {
      "id": "page-118",
      "number": null,
      "title": "Page 118",
      "level": 1,
      "pageStart": 118,
      "pageEnd": 118,
      "labelStart": "113",
      "labelEnd": "113",
      "words": 140,
      "summary": {
        "text": "Reports that Xpert Ultra sensitivity for peritoneal TB in peritoneal fluid ranged from 33% to 67% with specificities of 94–100% in three small studies, at very low to low certainty.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "peritoneal fluid",
          "heading": false
        },
        {
          "term": "peritoneal tuberculosis",
          "heading": false
        },
        {
          "term": "disseminated tuberculosis",
          "heading": false
        },
        {
          "term": "sensitivity",
          "heading": false
        },
        {
          "term": "lc-anaats",
          "heading": false
        }
      ],
      "extract": "Figure 18. LC-aNAATs for pericardial, peritoneal and disseminated tuberculosis The studies are ordered by decreasing sensitivity. FN: false negative; FP: false positive; TN: true negative; TP: true positive. Detection of peritoneal tuberculosis The methodological quality assessment results are summarised in Figure 19 and study estimates of sensitivity and specificity are presented in Figure 18 for detection of",
      "extractCut": true,
      "blocks": [
        "library/10665-381036/blocks/prose-page-118",
        "library/10665-381036/blocks/figure-img-p118-1",
        "library/10665-381036/blocks/figure-img-p118-2",
        "library/10665-381036/blocks/figure-img-p118-3",
        "library/10665-381036/blocks/figure-img-p118-4",
        "library/10665-381036/blocks/figure-img-p118-5"
      ]
    },
    {
      "id": "page-119",
      "number": null,
      "title": "Page 119",
      "level": 1,
      "pageStart": 119,
      "pageEnd": 119,
      "labelStart": "114",
      "labelEnd": "114",
      "words": 246,
      "summary": {
        "text": "Reports that one study of Xpert Ultra on blood for disseminated TB found 38% sensitivity and 98% specificity. It introduces subgroup analyses comparing concentrated and unconcentrated cerebrospinal fluid.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "tuberculous meningitis",
          "heading": false
        },
        {
          "term": "cerebrospinal fluid",
          "heading": false
        },
        {
          "term": "disseminated tuberculosis",
          "heading": false
        },
        {
          "term": "study estimates",
          "heading": false
        },
        {
          "term": "against microbiological",
          "heading": false
        },
        {
          "term": "xpert ultra",
          "heading": false
        },
        {
          "term": "microbiological reference",
          "heading": false
        },
        {
          "term": "lc-anaat",
          "heading": false
        }
      ],
      "extract": "The methodological quality assessment results are summarised in Figure 20 and study estimates of sensitivity and specificity are presented in Figure 18 for detection of disseminated tuberculosis in blood. Figure 20. Risk of bias and applicability summary for each study: disseminated tuberculosis in blood Should LC-aNAATs be used to diagnose disseminated tuberculosis in blood in adults and adolescents with signs and",
      "extractCut": true,
      "blocks": [
        "library/10665-381036/blocks/prose-page-119",
        "library/10665-381036/blocks/figure-img-p119-1",
        "library/10665-381036/blocks/figure-img-p119-2"
      ]
    },
    {
      "id": "page-120",
      "number": null,
      "title": "Page 120",
      "level": 1,
      "pageStart": 120,
      "pageEnd": 120,
      "labelStart": "115",
      "labelEnd": "115",
      "words": 310,
      "summary": {
        "text": "Table 3 shows higher Xpert Ultra sensitivity on concentrated than unconcentrated cerebrospinal fluid. A further table lists starting volumes, concentration and accuracy by study.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "concentrated csf",
          "heading": false
        },
        {
          "term": "cerebrospinal fluid",
          "heading": false
        },
        {
          "term": "starting cerebrospinal",
          "heading": false
        },
        {
          "term": "fluid volumes",
          "heading": false
        },
        {
          "term": "unconcentrated",
          "heading": false
        }
      ],
      "extract": "Table 3. Impact of concentration on diagnostic accuracy of LC-aNAATs for CSF Subgroup Studies (specimens) Summary sensitivity (95% CI) Summary specificity (95% CI) Microbiological reference standard Concentrated CSF 5 (781) 92.8 (87.5 to 96.0) 93.6 (70.8 to 98.9) Unconcentrated CSF 6 (470) 81.0 (68.0 to 89.5) 85.8 (68.9 to 94.3) Composite reference standard Concentrated CSF 5 (828) 70.0 (64.7 to 74.7) 99.9 (81.8 to",
      "extractCut": true,
      "blocks": [
        "library/10665-381036/blocks/prose-page-120"
      ]
    },
    {
      "id": "page-121",
      "number": null,
      "title": "Page 121",
      "level": 1,
      "pageStart": 121,
      "pageEnd": 121,
      "labelStart": "116",
      "labelEnd": "116",
      "words": 176,
      "summary": {
        "text": "Notes there were too few data to meta-analyse pleural fluid by concentration and tabulates starting volumes and accuracy by study. It then introduces results for detection of rifampicin resistance.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "pleural fluid",
          "heading": false
        },
        {
          "term": "starting volume",
          "heading": false
        },
        {
          "term": "concentration",
          "heading": false
        },
        {
          "term": "rifampicin resistance",
          "heading": false
        }
      ],
      "extract": "Impact of concentration and starting volume of pleural fluid on accuracy There were insufficient data to perform meta-analyses for pleural fluid by concentration. Table 5 provides the available information for concentration and starting volume from studies. Table 5. Starting volumes and concentration for pleural fluid and diagnostic accuracy Study, year Pleural fluid volume Concentration Sensitivity (95% CI)",
      "extractCut": true,
      "blocks": [
        "library/10665-381036/blocks/prose-page-121",
        "library/10665-381036/blocks/table-005"
      ]
    },
    {
      "id": "page-122",
      "number": null,
      "title": "Page 122",
      "level": 1,
      "pageStart": 122,
      "pageEnd": 122,
      "labelStart": "117",
      "labelEnd": "117",
      "words": 130,
      "summary": {
        "text": "Reports that Xpert Ultra on extrapulmonary specimens detected rifampicin resistance with 100% sensitivity and 99.4% specificity in 13 studies, at high certainty.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "rifampicin resistance",
          "heading": false
        },
        {
          "term": "predictive value",
          "heading": false
        },
        {
          "term": "specificity",
          "heading": false
        },
        {
          "term": "lc-anaat",
          "heading": false
        }
      ],
      "extract": "Figure 22. Risk of bias and applicability summary for each study: rifampicin resistance Should LC-aNAAT in extrapulmonary specimens be used to diagnose rifampicin resistance in adults and adolescents with presumed extrapulmonary tuberculosis? LC-aNAAT summary sensitivity and specificity (95% CI) were 100.0% (93.4 to 100.0) and 99.4% (92.1 to 100.0) from 13 Xpert Ultra studies (446 participants; Table 6); high",
      "extractCut": true,
      "blocks": [
        "library/10665-381036/blocks/prose-page-122",
        "library/10665-381036/blocks/figure-img-p122-1",
        "library/10665-381036/blocks/figure-vfig-p122",
        "library/10665-381036/blocks/table-006"
      ]
    },
    {
      "id": "page-123",
      "number": null,
      "title": "Page 123",
      "level": 1,
      "pageStart": 123,
      "pageEnd": 123,
      "labelStart": "118",
      "labelEnd": "118",
      "words": 20,
      "summary": {
        "text": "A figure caption for forest plots of LC-aNAAT accuracy for detecting rifampicin resistance.",
        "status": "draft"
      },
      "keywords": [],
      "extract": "Figure 23. LC-aNAATs for detection of rifampicin resistance FN: false negative; FP: false positive; TN: true negative; TP: true positive.",
      "extractCut": false,
      "blocks": [
        "library/10665-381036/blocks/prose-page-123",
        "library/10665-381036/blocks/figure-img-p123-1"
      ]
    },
    {
      "id": "page-124",
      "number": null,
      "title": "Page 124",
      "level": 1,
      "pageStart": 124,
      "pageEnd": 124,
      "labelStart": "119",
      "labelEnd": "119",
      "words": 417,
      "summary": {
        "text": "The discussion notes that accuracy varied by disease site and specimen, with sensitivity lowest for peritoneal fluid and highest for lymph node tissue against a microbiological reference. It calls for studies of other LC-aNAATs and notes high-certainty evidence of very high accuracy for rifampicin resistance.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "lymph node",
          "heading": false
        },
        {
          "term": "node aspirate",
          "heading": false
        },
        {
          "term": "node tuberculosis",
          "heading": false
        },
        {
          "term": "node tissue",
          "heading": false
        },
        {
          "term": "extrapulmonary tuberculosis",
          "heading": false
        },
        {
          "term": "summary specificity",
          "heading": false
        },
        {
          "term": "summary sensitivity",
          "heading": false
        },
        {
          "term": "trace",
          "heading": false
        }
      ],
      "extract": "Discussion The sensitivity and specificity of LC-aNAATs for detection of extrapulmonary tuberculosis varied with site of disease and specimen type. Based on a microbiological reference standard, sensitivity was lowest for detection of peritoneal tuberculosis using peritoneal fluid with a summary sensitivity (95% CI) of 50.0% (20.0 to 80.0) and summary specificity (95% CI) of 98.4% (89.3 to 99.8). Conversely,",
      "extractCut": true,
      "blocks": [
        "library/10665-381036/blocks/prose-page-124"
      ]
    },
    {
      "id": "page-125",
      "number": null,
      "title": "Page 125",
      "level": 1,
      "pageStart": 125,
      "pageEnd": 125,
      "labelStart": "120",
      "labelEnd": "120",
      "words": 424,
      "summary": {
        "text": "Begins the review's reference list, citing manufacturer information, meta-analysis methods, the Global TB Report and a Cochrane review, followed by included studies of Xpert Ultra.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "rif ultra",
          "heading": false
        },
        {
          "term": "mtb rif",
          "heading": false
        },
        {
          "term": "xpert mtb",
          "heading": false
        },
        {
          "term": "clin epidemiol",
          "heading": false
        },
        {
          "term": "accessed september",
          "heading": false
        },
        {
          "term": "maartens",
          "heading": false
        },
        {
          "term": "diagnostic accuracy",
          "heading": false
        },
        {
          "term": "antel",
          "heading": false
        }
      ],
      "extract": "References Bioneer Corporation. IRON-qPCR™. 2023. Available at: eng.bioneer.com/20-a-2600.html (accessed 19 September 2023). Chu H, Cole SR. Bivariate meta-analysis of sensitivity and specificity with sparse data: a generalized linear mixed model approach. J Clin Epidemiol. 2006;59(12):1331-2. Global TB Report, 2023. WHO, Geneva, Switzerland Kohli M, Schiller I, Dendukuri N, Yao M, Dheda K, Denkinger CM, et al.",
      "extractCut": true,
      "blocks": [
        "library/10665-381036/blocks/prose-page-125"
      ]
    },
    {
      "id": "page-126",
      "number": null,
      "title": "Page 126",
      "level": 1,
      "pageStart": 126,
      "pageEnd": 126,
      "labelStart": "121",
      "labelEnd": "121",
      "words": 500,
      "summary": {
        "text": "Continues the reference list of included studies on Xpert Ultra and Truenat MTB Plus for extrapulmonary TB in specimens such as cerebrospinal fluid, blood and pleural fluid.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "rif ultra",
          "heading": false
        },
        {
          "term": "mtb rif",
          "heading": false
        },
        {
          "term": "hoel ida",
          "heading": false
        },
        {
          "term": "xpert mtb",
          "heading": false
        },
        {
          "term": "tuberculous meningitis",
          "heading": false
        },
        {
          "term": "ida marie",
          "heading": false
        },
        {
          "term": "extrapulmonary tuberculosis",
          "heading": false
        },
        {
          "term": "lancet infectious",
          "heading": false
        }
      ],
      "extract": "tuberculosis to detect and measure Mycobacterium tuberculosis blood stream infection: a diagnostic and disease biomarker cohort study. Lancet Microbe 2022;3(7):e521-e532. [DOI: doi: 10.1016/S2666-5247(22)00062-3] Chin JH, Musubire AK, Morgan N, Pellinen J, Grossman S, Bhatt JM, et al. Xpert MTB/RIF Ultra for detection of Mycobacterium tuberculosis in cerebrospinal fluid. Journal of Clinical Microbiology",
      "extractCut": true,
      "blocks": [
        "library/10665-381036/blocks/prose-page-126"
      ]
    },
    {
      "id": "page-127",
      "number": null,
      "title": "Page 127",
      "level": 1,
      "pageStart": 127,
      "pageEnd": 127,
      "labelStart": "122",
      "labelEnd": "122",
      "words": 519,
      "summary": {
        "text": "Continues the reference list with included diagnostic accuracy studies of Xpert Ultra from various countries and settings.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "sharma kusum",
          "heading": false
        },
        {
          "term": "sharma megha",
          "heading": false
        },
        {
          "term": "shree ritu",
          "heading": false
        },
        {
          "term": "rif ultra",
          "heading": false
        },
        {
          "term": "xpert ultra",
          "heading": false
        },
        {
          "term": "tuberculous meningitis",
          "heading": false
        },
        {
          "term": "mtb rif",
          "heading": false
        },
        {
          "term": "infect dis",
          "heading": false
        }
      ],
      "extract": "tuberculosis. Afr J Thorac Crit Care Med 2019;31. [DOI: 10.7196/AJTCCM.2019.v25i2.011] Mansfield M, McLaughlin AM, Roycroft E, Montgomery L, Keane J, Fitzgibbon MM, Rogers TR. Diagnostic Performance of Xpert MTB/RIF Ultra Compared with Predecessor Test, Xpert MTB/RIF, in a Low TB Incidence Setting: a Retrospective Service Evaluation. . Microbiol Spectr 2022;10(3):e0234521. [DOI: 10.1128/spectrum.02345-21] Mekkaoui",
      "extractCut": true,
      "blocks": [
        "library/10665-381036/blocks/prose-page-127"
      ]
    },
    {
      "id": "page-128",
      "number": null,
      "title": "Page 128",
      "level": 1,
      "pageStart": 128,
      "pageEnd": 128,
      "labelStart": "123",
      "labelEnd": "123",
      "words": 327,
      "summary": {
        "text": "Ends the reference list with studies comparing Truenat MTB Plus and Xpert Ultra and evaluating Xpert Ultra in Saudi Arabia, China and elsewhere.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "sharma aman",
          "heading": false
        },
        {
          "term": "rif ultra",
          "heading": false
        },
        {
          "term": "mtb rif",
          "heading": false
        },
        {
          "term": "xpert mtb",
          "heading": false
        },
        {
          "term": "genexpert ultra",
          "heading": false
        },
        {
          "term": "extrapulmonary tuberculosis",
          "heading": false
        },
        {
          "term": "international journal",
          "heading": false
        },
        {
          "term": "cohort study",
          "heading": false
        }
      ],
      "extract": "Sharma Aman. Determining the diagnostic potential of Truenat MTB Plus for Tubercular lymphadenitis and detection of drug resistance and a comparison with GeneXpert Ultra. Tuberculosis 2023/09/01;142:102379. [DOI: https://doi.org/10.1016/j.tube.2023.102379] Slail Mousa J, Booq Rayan Y, Al-Ahmad Ibrahim H, Alharbi Arwa A, Alharbi Shafi F, Alotaibi Mutlaq Z, Aljubran Abdulaziz M, Aldossary Ahmad M, Memish Ziad A,",
      "extractCut": true,
      "blocks": [
        "library/10665-381036/blocks/prose-page-128"
      ]
    },
    {
      "id": "page-129",
      "number": null,
      "title": "Page 129",
      "level": 1,
      "pageStart": 129,
      "pageEnd": 129,
      "labelStart": "124",
      "labelEnd": "124",
      "words": 206,
      "summary": {
        "text": "Appendix 1 gives the detailed literature search strategy, beginning with Ovid MEDLINE and Embase search terms for extrapulmonary TB and the index tests.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "resistant tuberculosis",
          "heading": false
        },
        {
          "term": "multidrug resistant",
          "heading": false
        },
        {
          "term": "mycobacterium tuberculosis",
          "heading": false
        },
        {
          "term": "drug resistant",
          "heading": false
        },
        {
          "term": "extra pulmonary",
          "heading": false
        }
      ],
      "extract": "Appendix Appendix 1. Detailed search strategies Ovid MEDLINE(R) ALL <1946 to October 10, 2023> 1 Mycobacterium tuberculosis/ 2 Tuberculosis/ 3 Tuberculosis, Multidrug-Resistant/ 4 Extensively Drug-Resistant Tuberculosis/ 5 (Tuberculosis or TB or MDR TB or XDR TB or \"Multidrug Resistant Tuberculosis\" or \"Extensively Drug Resistant Tuberculosis\" or tuberculous).tw. 6 (extrapulmonary or extra pulmonary or EPTB).tw. 7",
      "extractCut": true,
      "blocks": [
        "library/10665-381036/blocks/prose-page-129"
      ]
    },
    {
      "id": "page-130",
      "number": null,
      "title": "Page 130",
      "level": 1,
      "pageStart": 130,
      "pageEnd": 130,
      "labelStart": "125",
      "labelEnd": "125",
      "words": 257,
      "summary": {
        "text": "Continues the search strategies with remaining Embase lines and the Web of Science and Cochrane Library searches.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "intra ocular",
          "heading": false
        },
        {
          "term": "resistant tuberculosis",
          "heading": false
        },
        {
          "term": "search",
          "heading": false
        },
        {
          "term": "mening",
          "heading": false
        },
        {
          "term": "topic",
          "heading": false
        },
        {
          "term": "pleur",
          "heading": false
        }
      ],
      "extract": "7 (lymphadenitis or disseminated or miliary or pleur* or skeletal or spine or mening* or intracranial or intra ocular or ocular or abdominal or splenic or genitourinary or pericardial).ti,ab. 8 extrapulmonary tuberculosis/ 9 1 or 2 or 3 or 4 or 5 10 6 or 7 11 9 and 10 12 8 or 11 13 Xpert*.tw. and Ultra.mp. 14 (GeneXpert or cepheid).tw. and ultra.mp. 15 near* patient.tw. and Ultra.mp. 16 13 or 14 or 15 17 12 and 16",
      "extractCut": true,
      "blocks": [
        "library/10665-381036/blocks/prose-page-130"
      ]
    },
    {
      "id": "page-131",
      "number": null,
      "title": "Page 131",
      "level": 1,
      "pageStart": 131,
      "pageEnd": 131,
      "labelStart": "126",
      "labelEnd": "126",
      "words": 381,
      "summary": {
        "text": "Continues the search strategies for the Cochrane Library, Global Index Medicus, Scopus and ClinicalTrials.gov.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "extrapulmonary tuberculosis",
          "heading": false
        },
        {
          "term": "title-abs-key",
          "heading": false
        },
        {
          "term": "ocular",
          "heading": false
        },
        {
          "term": "mening",
          "heading": false
        },
        {
          "term": "pleur",
          "heading": false
        },
        {
          "term": "splenic",
          "heading": false
        },
        {
          "term": "skeletal",
          "heading": false
        },
        {
          "term": "intracranial",
          "heading": false
        }
      ],
      "extract": "#4 ((lymphadenitis or disseminated or miliary or pleur* or skeletal or spine or mening* or intracranial or intra ocular or ocular or abdominal or splenic or genitourinary or pericardial)):ti,ab,kw #5 #3 and #4 #6 MeSH descriptor: [Tuberculosis, Extrapulmonary] explode all trees #7 EPTB or extrapulmonary tuberculosis #8 #5 or #6 or #7 #9 (Xpert* or GeneXpert* or cepheid) and Ultra #10 #8 and #9 #11 Truenat* or Molbio",
      "extractCut": true,
      "blocks": [
        "library/10665-381036/blocks/prose-page-131"
      ]
    },
    {
      "id": "page-132",
      "number": null,
      "title": "Page 132",
      "level": 1,
      "pageStart": 132,
      "pageEnd": 132,
      "labelStart": "127",
      "labelEnd": "127",
      "words": 64,
      "summary": {
        "text": "Ends the search strategies with the WHO trials registry and ProQuest dissertation searches.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "title",
          "heading": false
        },
        {
          "term": "biosensor",
          "heading": false
        },
        {
          "term": "extrapulmonary",
          "heading": false
        }
      ],
      "extract": "(STANDARD M10 or SD Biosensor or IRON-qPCR or BIONEER) | Extrapulmonary Tuberculosis WHO ICTRP tuberculosis and extrapulmonary and (Xpert* or truenat or STANDARD M10 or SD Biosensor or IRON-qPCR or NAAT*) Proquest Dissertation and Thesis S1 title(tuberculosis) AND title (extrapulmonary) AND (STANDARD M10 or SD Biosensor or IRON- qPCR or BIONEER) S2 title(tuberculosis) AND title(extrapulmonary) AND Truenat S3",
      "extractCut": true,
      "blocks": [
        "library/10665-381036/blocks/prose-page-132"
      ]
    },
    {
      "id": "page-133",
      "number": null,
      "title": "Page 133",
      "level": 1,
      "pageStart": 133,
      "pageEnd": 133,
      "labelStart": "128",
      "labelEnd": "128",
      "words": 255,
      "summary": {
        "text": "Appendix 2 begins the GRADE summary of findings tables, showing Xpert Ultra on cerebrospinal fluid for TB meningitis against a microbiological reference, with results per 1,000 people at different prevalences. It explains downgrading for imprecision.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "false positives",
          "heading": false
        },
        {
          "term": "meningitis",
          "heading": false
        },
        {
          "term": "downgraded",
          "heading": false
        },
        {
          "term": "mrs",
          "heading": false
        },
        {
          "term": "specificity",
          "heading": false
        },
        {
          "term": "negatives",
          "heading": false
        }
      ],
      "extract": "128 Appendix 2. Summary of findings tables 1. Should LC-aNAAT on CSF be used to diagnose TB meningitis in adults and adolescents with signs and symptoms of TB meningitis, MRS? Patient or population: adults and adolescents with signs and symptoms of TB meningitis, MRS Pooled sensitivity:0.88 (95% CI: 0.84 to 0.92)| Pooled specificity:0.96 (95% CI: 0.87 to 0.99) Test result Number of results per 1,000 patients tested",
      "extractCut": true,
      "blocks": [
        "library/10665-381036/blocks/prose-page-133"
      ]
    },
    {
      "id": "page-134",
      "number": null,
      "title": "Page 134",
      "level": 1,
      "pageStart": 134,
      "pageEnd": 134,
      "labelStart": "129",
      "labelEnd": "129",
      "words": 183,
      "summary": {
        "text": "A GRADE summary of findings table for Xpert Ultra on cerebrospinal fluid for TB meningitis against a composite reference standard, with pooled sensitivity of 0.60. It explains downgrading for inconsistency given widely varying sensitivities.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "meningitis",
          "heading": false
        },
        {
          "term": "ninan",
          "heading": false
        },
        {
          "term": "crs",
          "heading": false
        },
        {
          "term": "negatives",
          "heading": false
        }
      ],
      "extract": "129 2. Should LC-aNAAT on CSF be used to diagnose TB meningitis in adults and adolescents with signs and symptoms of TB meningitis, CRS? Patient or population: adults and adolescents with signs and symptoms of TB meningitis, CRS Pooled sensitivity:0.60 (95% CI: 0.51 to 0.69)| Pooled specificity:0.99 (95% CI: 0.98 to 1.00) Test result Number of results per 1,000 patients tested (95% CI) Number of participants",
      "extractCut": true,
      "blocks": [
        "library/10665-381036/blocks/prose-page-134"
      ]
    },
    {
      "id": "page-135",
      "number": null,
      "title": "Page 135",
      "level": 1,
      "pageStart": 135,
      "pageEnd": 135,
      "labelStart": "130",
      "labelEnd": "130",
      "words": 215,
      "summary": {
        "text": "A GRADE summary of findings table for Xpert Ultra on cerebrospinal fluid for TB meningitis in people living with HIV, with pooled sensitivity of 0.89 and specificity of 0.91. Footnotes explain judgements on imprecision.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "false negatives",
          "heading": false
        },
        {
          "term": "false positives",
          "heading": false
        },
        {
          "term": "confidence limits",
          "heading": false
        },
        {
          "term": "around false",
          "heading": false
        },
        {
          "term": "different decisions",
          "heading": false
        }
      ],
      "extract": "130 3. Should LC-aNAAT on CSF be used to diagnose TB meningitis in PLHIV with signs and symptoms of TB meningitis, MRS? Patient or population: PLHIV with signs and symptoms of TB meningitis, MRS Pooled sensitivity:0.89 (95% CI: 0.77 to 0.95) | Pooled specificity:0.91 (95% CI: 0.87 to 0.93) Test result Number of results per 1,000 patients tested (95% CI) Number of participants (studies) Certainty of the Evidence",
      "extractCut": true,
      "blocks": [
        "library/10665-381036/blocks/prose-page-135"
      ]
    },
    {
      "id": "page-136",
      "number": null,
      "title": "Page 136",
      "level": 1,
      "pageStart": 136,
      "pageEnd": 136,
      "labelStart": "131",
      "labelEnd": "131",
      "words": 289,
      "summary": {
        "text": "A GRADE summary of findings table for Xpert Ultra on lymph node aspirate against a microbiological reference, with pooled sensitivity of 0.85 and specificity of 0.74. Footnotes explain downgrading for risk of bias and imprecision.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "lymph node",
          "heading": false
        },
        {
          "term": "false negatives",
          "heading": false
        },
        {
          "term": "true negatives",
          "heading": false
        },
        {
          "term": "false positives",
          "heading": false
        },
        {
          "term": "confidence limits",
          "heading": false
        },
        {
          "term": "around true",
          "heading": false
        },
        {
          "term": "decisions depending",
          "heading": false
        }
      ],
      "extract": "131 4. Should LC-aNAAT on lymph node aspirate be used to diagnose lymph node TB in adults and adolescents with signs and symptoms of lymph node TB, MRS? Patient or population: adults and adolescents with signs and symptoms of lymph node TB, MRS Pooled sensitivity:0.85 (95% CI: 0.73 to 0.92)| Pooled specificity:0.74 (95% CI: 0.64 to 0.82) Test result Number of results per 1,000 patients tested (95% CI) Number of",
      "extractCut": true,
      "blocks": [
        "library/10665-381036/blocks/prose-page-136"
      ]
    },
    {
      "id": "page-137",
      "number": null,
      "title": "Page 137",
      "level": 1,
      "pageStart": 137,
      "pageEnd": 137,
      "labelStart": "132",
      "labelEnd": "132",
      "words": 8,
      "summary": {
        "text": "A continuation line from the previous table's footnotes on downgrading for imprecision.",
        "status": "draft"
      },
      "keywords": [],
      "extract": "132 assumed. We downgraded two levels for imprecision.",
      "extractCut": false,
      "blocks": [
        "library/10665-381036/blocks/prose-page-137"
      ]
    },
    {
      "id": "page-138",
      "number": null,
      "title": "Page 138",
      "level": 1,
      "pageStart": 138,
      "pageEnd": 138,
      "labelStart": "133",
      "labelEnd": "133",
      "words": 291,
      "summary": {
        "text": "A GRADE summary of findings table for Xpert Ultra on lymph node aspirate against a composite reference, with pooled sensitivity of 0.71 and specificity of 0.97. Footnotes explain downgrading for inconsistency and imprecision.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "lymph node",
          "heading": false
        },
        {
          "term": "true negatives",
          "heading": false
        },
        {
          "term": "false positives",
          "heading": false
        },
        {
          "term": "downgraded",
          "heading": false
        },
        {
          "term": "crs",
          "heading": false
        },
        {
          "term": "indirectness",
          "heading": false
        },
        {
          "term": "prevalence",
          "heading": false
        }
      ],
      "extract": "133 5. Should LC-aNAAT on lymph node aspirate be used to diagnose lymph node TB in adults and adolescents with signs and symptoms of lymph node TB, CRS? Patient or population: adults and adolescents with signs and symptoms of lymph node TB, CRS Pooled sensitivity:0.71 (95% CI: 0.64 to 0.77)|Pooled specificity:0.97 (95% CI: 0.82 to 1.00) Test result Number of results per 1,000 patients tested (95% CI) Number of",
      "extractCut": true,
      "blocks": [
        "library/10665-381036/blocks/prose-page-138"
      ]
    },
    {
      "id": "page-139",
      "number": null,
      "title": "Page 139",
      "level": 1,
      "pageStart": 139,
      "pageEnd": 139,
      "labelStart": "134",
      "labelEnd": "134",
      "words": 1,
      "summary": {
        "text": "A page bearing only a page number.",
        "status": "draft"
      },
      "keywords": [],
      "extract": "134",
      "extractCut": false,
      "blocks": [
        "library/10665-381036/blocks/prose-page-139"
      ]
    },
    {
      "id": "page-140",
      "number": null,
      "title": "Page 140",
      "level": 1,
      "pageStart": 140,
      "pageEnd": 140,
      "labelStart": "135",
      "labelEnd": "135",
      "words": 288,
      "summary": {
        "text": "A GRADE summary of findings table for Xpert Ultra on lymph node tissue against a microbiological reference, with pooled sensitivity of 0.96 and specificity of 0.79. Footnotes explain downgrading for inconsistency and imprecision.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "lymph node",
          "heading": false
        },
        {
          "term": "true negatives",
          "heading": false
        },
        {
          "term": "false positives",
          "heading": false
        },
        {
          "term": "downgraded",
          "heading": false
        },
        {
          "term": "inconsistency",
          "heading": false
        },
        {
          "term": "tissue",
          "heading": false
        },
        {
          "term": "mrs",
          "heading": false
        }
      ],
      "extract": "135 6. Should LC-aNAAT on lymph node tissue be used to diagnose lymph node TB in adults and adolescents with signs and symptoms of lymph node TB, MRS? Patient or population: adults and adolescents with signs and symptoms of lymph node TB, MRS Pooled sensitivity:0.96 (95% CI: 0.85 to 0.99)|Pooled specificity:0.79 (95% CI: 0.65 to 0.89) Test result Number of results per 1,000 patients tested (95% CI) Number of",
      "extractCut": true,
      "blocks": [
        "library/10665-381036/blocks/prose-page-140"
      ]
    },
    {
      "id": "page-141",
      "number": null,
      "title": "Page 141",
      "level": 1,
      "pageStart": 141,
      "pageEnd": 141,
      "labelStart": "136",
      "labelEnd": "136",
      "words": 280,
      "summary": {
        "text": "A GRADE summary of findings table for Xpert Ultra on lymph node tissue against a composite reference, with pooled sensitivity of 0.61 and specificity of 0.97. It begins the next table on pleural fluid.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "lymph node",
          "heading": false
        },
        {
          "term": "false negatives",
          "heading": false
        },
        {
          "term": "true positives",
          "heading": false
        },
        {
          "term": "downgraded",
          "heading": false
        },
        {
          "term": "lowa",
          "heading": false
        },
        {
          "term": "pleural",
          "heading": false
        },
        {
          "term": "signs",
          "heading": false
        }
      ],
      "extract": "136 7. Should LC-aNAAT on lymph node tissue be used to diagnose lymph node TB in adults and adolescents with signs and symptoms of lymph node TB, CRS? Patient or population: adults and adolescents with signs and symptoms of lymph node TB, CRS Pooled sensitivity:0.61 (95% CI: 0.47 to 0.74)| Pooled specificity:0.97 (95% CI: 0.92 to 0.99) Test result Number of results per 1,000 patients tested (95% CI) Number of",
      "extractCut": true,
      "blocks": [
        "library/10665-381036/blocks/prose-page-141"
      ]
    },
    {
      "id": "page-142",
      "number": null,
      "title": "Page 142",
      "level": 1,
      "pageStart": 142,
      "pageEnd": 142,
      "labelStart": "137",
      "labelEnd": "137",
      "words": 271,
      "summary": {
        "text": "A GRADE summary of findings table for Xpert Ultra on pleural fluid against a microbiological reference, with pooled sensitivity of 0.74 and specificity of 0.88. Footnotes explain downgrading, and the next table on the composite reference begins.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "true negatives",
          "heading": false
        },
        {
          "term": "false positives",
          "heading": false
        },
        {
          "term": "studies varied",
          "heading": false
        },
        {
          "term": "pleural",
          "heading": false
        },
        {
          "term": "downgraded",
          "heading": false
        },
        {
          "term": "mrs",
          "heading": false
        }
      ],
      "extract": "137 symptoms of pleural TB, MRS? Patient or population: adults and adolescents with signs and symptoms of pleural TB, MRS Pooled sensitivity:0.74 (95% CI: 0.61 to 0.84) |Pooled specificity:0.88 (95% CI: 0.79 to 0.94) Test result Number of results per 1,000 patients tested (95% CI) Number of participants (studies) Certainty of the Evidence (GRADE) Prevalence2.5% Typically seen in Prevalence10% Typically seen in",
      "extractCut": true,
      "blocks": [
        "library/10665-381036/blocks/prose-page-142"
      ]
    },
    {
      "id": "page-143",
      "number": null,
      "title": "Page 143",
      "level": 1,
      "pageStart": 143,
      "pageEnd": 143,
      "labelStart": "138",
      "labelEnd": "138",
      "words": 238,
      "summary": {
        "text": "A GRADE summary of findings table for Xpert Ultra on pleural fluid against a composite reference, with pooled sensitivity of 0.44 and specificity of 0.99. Footnotes explain downgrading for imprecision and risk of bias.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "false negatives",
          "heading": false
        },
        {
          "term": "true positives",
          "heading": false
        },
        {
          "term": "downgraded",
          "heading": false
        },
        {
          "term": "lowa",
          "heading": false
        },
        {
          "term": "pleural",
          "heading": false
        },
        {
          "term": "crs",
          "heading": false
        }
      ],
      "extract": "138 symptoms of pleural TB, CRS? Patient or population: adults and adolescents with signs and symptoms of pleural TB, CRS Pooled sensitivity:0.44 (95% CI: 0.33 to 0.55)| Pooled specificity:0.99 (95% CI: 0.95 to 1.00) Test result Number of results per 1,000 patients tested (95% CI) Number of participants (studies) Certainty of the Evidence (GRADE) Prevalence2.5% Typically seen in Prevalence10% Typically seen in",
      "extractCut": true,
      "blocks": [
        "library/10665-381036/blocks/prose-page-143"
      ]
    },
    {
      "id": "page-144",
      "number": null,
      "title": "Page 144",
      "level": 1,
      "pageStart": 144,
      "pageEnd": 144,
      "labelStart": "139",
      "labelEnd": "139",
      "words": 251,
      "summary": {
        "text": "A GRADE summary of findings table for Xpert Ultra on pleural tissue against a microbiological reference, with sensitivities of 0.80–1.00 from two studies. It begins the next table on the composite reference.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "pleural tissue",
          "heading": false
        },
        {
          "term": "diagnose pleural",
          "heading": false
        },
        {
          "term": "lowa",
          "heading": false
        },
        {
          "term": "downgraded",
          "heading": false
        },
        {
          "term": "signs",
          "heading": false
        },
        {
          "term": "mrs",
          "heading": false
        }
      ],
      "extract": "139 10. Should LC-aNAAT on pleural tissue be used to diagnose pleural TB in adults and adolescents with signs and symptoms of pleural TB, MRS? Patient or population: adults and adolescents with signs and symptoms of pleural TB, MRS Range of sensitivities:0.80 to 1.00| Range of specificities:0.75 to 0.86 Test result Number of results per 1,000 patients tested (95% CI) Number of participants (studies) Certainty of the",
      "extractCut": true,
      "blocks": [
        "library/10665-381036/blocks/prose-page-144"
      ]
    },
    {
      "id": "page-145",
      "number": null,
      "title": "Page 145",
      "level": 1,
      "pageStart": 145,
      "pageEnd": 145,
      "labelStart": "140",
      "labelEnd": "140",
      "words": 248,
      "summary": {
        "text": "A GRADE summary of findings table for Xpert Ultra on pleural tissue against a composite reference, with sensitivities of 0.54–0.81. It begins the table on urine for genitourinary TB.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "downgraded",
          "heading": false
        },
        {
          "term": "genitourinary",
          "heading": false
        },
        {
          "term": "lowa",
          "heading": false
        },
        {
          "term": "pleural",
          "heading": false
        },
        {
          "term": "crs",
          "heading": false
        },
        {
          "term": "symptoms",
          "heading": false
        }
      ],
      "extract": "140 symptoms of pleural TB, CRS? Patient or population: adults and adolescents with signs and symptoms of pleural TB, CRS Range of sensitivities:0.54 to 0.81| Range of specificities:0.94 to 0.97 Test result Number of results per 1,000 patients tested (95% CI) Number of participants (studies) Certainty of the Evidence (GRADE) Prevalence2.5% Typically seen in Prevalence10% Typically seen in Prevalence20% Typically",
      "extractCut": true,
      "blocks": [
        "library/10665-381036/blocks/prose-page-145"
      ]
    },
    {
      "id": "page-146",
      "number": null,
      "title": "Page 146",
      "level": 1,
      "pageStart": 146,
      "pageEnd": 146,
      "labelStart": "141",
      "labelEnd": "141",
      "words": 248,
      "summary": {
        "text": "A GRADE summary of findings table for Xpert Ultra on urine against a microbiological reference, with 100% sensitivity but specificity ranging from 0.28 to 1.00, at very low certainty. It begins the composite reference table.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "genitourinary",
          "heading": false
        },
        {
          "term": "downgraded",
          "heading": false
        },
        {
          "term": "lowa",
          "heading": false
        },
        {
          "term": "signs",
          "heading": false
        },
        {
          "term": "crs",
          "heading": false
        },
        {
          "term": "symptoms",
          "heading": false
        }
      ],
      "extract": "141 Patient or population: adults and adolescents with signs and symptoms of genitourinary TB, MRS Range of sensitivities:1.00 to 1.00| Range of specificities:0.28 to 1.00 Test result Number of results per 1,000 patients tested (95% CI) Number of participants (studies) Certainty of the Evidence (GRADE) Prevalence2.5% Typically seen in Prevalence10% Typically seen in Prevalence20% Typically seen in True positives 25",
      "extractCut": true,
      "blocks": [
        "library/10665-381036/blocks/prose-page-146"
      ]
    },
    {
      "id": "page-147",
      "number": null,
      "title": "Page 147",
      "level": 1,
      "pageStart": 147,
      "pageEnd": 147,
      "labelStart": "142",
      "labelEnd": "142",
      "words": 252,
      "summary": {
        "text": "A GRADE summary of findings table for Xpert Ultra on urine against a composite reference, with pooled sensitivity of 0.23 and specificity of 0.99. It begins the table on bone or joint TB.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "pooled sensitivity",
          "heading": false
        },
        {
          "term": "pooled specificity",
          "heading": false
        },
        {
          "term": "bone",
          "heading": false
        },
        {
          "term": "joint",
          "heading": false
        },
        {
          "term": "downgraded",
          "heading": false
        },
        {
          "term": "mrs",
          "heading": false
        }
      ],
      "extract": "142 Pooled sensitivity:0.23 (95% CI: 0.15 to 0.34)| Pooled specificity:0.99 (95% CI: 0.90 to 1.00) Test result Number of results per 1,000 patients tested (95% CI) Number of participants (studies) Certainty of the Evidence (GRADE) Prevalence2.5% Typically seen in Prevalence10% Typically seen in Prevalence20% Typically seen in True positives 6 (4 to 9) 23 (15 to 34) 46 (29 to 68) 159 (3) ⨁⨁◯◯ Lowa,b False negatives",
      "extractCut": true,
      "blocks": [
        "library/10665-381036/blocks/prose-page-147"
      ]
    },
    {
      "id": "page-148",
      "number": null,
      "title": "Page 148",
      "level": 1,
      "pageStart": 148,
      "pageEnd": 148,
      "labelStart": "143",
      "labelEnd": "143",
      "words": 245,
      "summary": {
        "text": "A GRADE summary of findings table for Xpert Ultra on bone or joint fluid against a microbiological reference, with footnotes on indirectness and imprecision. It begins the composite reference table based on a single study.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "true negatives",
          "heading": false
        },
        {
          "term": "false positives",
          "heading": false
        },
        {
          "term": "bone",
          "heading": false
        },
        {
          "term": "downgraded",
          "heading": false
        },
        {
          "term": "lowa",
          "heading": false
        },
        {
          "term": "single study",
          "heading": false
        }
      ],
      "extract": "143 Test result Number of results per 1,000 patients tested (95% CI) Number of participants (studies) Certainty of the Evidence (GRADE) Prevalence2.5% Typically seen in Prevalence10% Typically seen in Prevalence20% Typically seen in True positives 24 (22 to 25) 97 (87 to 99) 193 (174 to 198) 58 (3) ⨁⨁◯◯ Lowa,b False negatives 1 (0 to 3) 3 (1 to 13) 7 (2 to 26) True negatives 888 (788 to 938) 820 (727 to 866) 729",
      "extractCut": true,
      "blocks": [
        "library/10665-381036/blocks/prose-page-148"
      ]
    },
    {
      "id": "page-149",
      "number": null,
      "title": "Page 149",
      "level": 1,
      "pageStart": 149,
      "pageEnd": 149,
      "labelStart": "144",
      "labelEnd": "144",
      "words": 192,
      "summary": {
        "text": "Completes the GRADE table for bone or joint TB against a composite reference from a single Chinese study, noting it may not be representative. Footnotes explain downgrading for imprecision.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "true negatives",
          "heading": false
        },
        {
          "term": "false positives",
          "heading": false
        },
        {
          "term": "extrapulmonary tuberculosis",
          "heading": false
        },
        {
          "term": "moderatea",
          "heading": false
        }
      ],
      "extract": "144 Test result Number of results per 1,000 patients tested (95% CI) Number of participants (studies) Certainty of the Evidence (GRADE) Prevalence2.5% Typically seen in Prevalence10% Typically seen in Prevalence20% Typically seen in True positives 24 (23 to 25) 96 (91 to 99) 192 (182 to 198) 111 (1) ⨁⨁⨁◯ Moderatea False negatives 1 (0 to 2) 4 (1 to 9) 8 (2 to 18) True negatives 946 (829 to 975) 873 (765 to 900) 776",
      "extractCut": true,
      "blocks": [
        "library/10665-381036/blocks/prose-page-149"
      ]
    },
    {
      "id": "page-150",
      "number": null,
      "title": "Page 150",
      "level": 1,
      "pageStart": 150,
      "pageEnd": 150,
      "labelStart": "145",
      "labelEnd": "145",
      "words": 273,
      "summary": {
        "text": "A GRADE summary of findings table for Xpert Ultra on peritoneal fluid, with sensitivities of 0.33–0.67 and very low certainty. Footnotes explain downgrading for indirectness, inconsistency and imprecision.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "peritoneal",
          "heading": false
        },
        {
          "term": "selection domain",
          "heading": false
        },
        {
          "term": "downgraded",
          "heading": false
        },
        {
          "term": "extrapulmonary tuberculosis",
          "heading": false
        },
        {
          "term": "patient selection",
          "heading": false
        },
        {
          "term": "mrs",
          "heading": false
        },
        {
          "term": "bias",
          "heading": false
        }
      ],
      "extract": "145 16. Should LC-aNAAT on peritoneal fluid be used to diagnose peritoneal TB in adults and adolescents with signs and symptoms of peritoneal TB, MRS? Patient or population: adults and adolescents with signs and symptoms of peritoneal TB, MRS Range of sensitivities:0.33 to 0.67|Range of specificities:0.94 to 1.00 Test result Number of results per 1,000 patients tested (95% CI) Number of participants (studies)",
      "extractCut": true,
      "blocks": [
        "library/10665-381036/blocks/prose-page-150"
      ]
    },
    {
      "id": "page-151",
      "number": null,
      "title": "Page 151",
      "level": 1,
      "pageStart": 151,
      "pageEnd": 151,
      "labelStart": "146",
      "labelEnd": "146",
      "words": 2,
      "summary": {
        "text": "A continuation of the previous table's footnote on imprecision.",
        "status": "draft"
      },
      "keywords": [],
      "extract": "146 imprecision.",
      "extractCut": false,
      "blocks": [
        "library/10665-381036/blocks/prose-page-151"
      ]
    },
    {
      "id": "page-152",
      "number": null,
      "title": "Page 152",
      "level": 1,
      "pageStart": 152,
      "pageEnd": 152,
      "labelStart": "147",
      "labelEnd": "147",
      "words": 228,
      "summary": {
        "text": "A GRADE summary of findings table for Xpert Ultra on pericardial fluid, with pooled sensitivity of 0.84 and specificity of 0.87. Footnotes explain downgrading for indirectness and imprecision.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "pericardial",
          "heading": false
        },
        {
          "term": "lowa",
          "heading": false
        },
        {
          "term": "downgraded",
          "heading": false
        },
        {
          "term": "mrs",
          "heading": false
        },
        {
          "term": "negatives",
          "heading": false
        }
      ],
      "extract": "147 17. Should LC-aNAAT on pericardial fluid be used to diagnose pericardial TB in adults and adolescents with signs and symptoms of pericardial TB, MRS? Patient or population: adults and adolescents with signs and symptoms of pericardial TB, MRS Pooled sensitivity:0.84 (95% CI: 0.74 to 0.91)| Pooled specificity:0.87 (95% CI: 0.80 to 0.92) Test result Number of results per 1,000 patients tested (95% CI) Number of",
      "extractCut": true,
      "blocks": [
        "library/10665-381036/blocks/prose-page-152"
      ]
    },
    {
      "id": "page-153",
      "number": null,
      "title": "Page 153",
      "level": 1,
      "pageStart": 153,
      "pageEnd": 153,
      "labelStart": "148",
      "labelEnd": "148",
      "words": 241,
      "summary": {
        "text": "A GRADE summary of findings table for Xpert Ultra on blood for disseminated TB from a single study, with sensitivity of 0.38 and specificity of 0.98. It begins the table on rifampicin resistance.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "single study",
          "heading": false
        },
        {
          "term": "lowa",
          "heading": false
        },
        {
          "term": "disseminated",
          "heading": false
        },
        {
          "term": "mrs",
          "heading": false
        },
        {
          "term": "lc-anaat",
          "heading": false
        }
      ],
      "extract": "148 18. Should LC-aNAAT in blood be used to diagnose disseminated TB in adults and adolescents with signs and symptoms of disseminated TB, MRS? Patient or population: adults and adolescents with signs and symptoms of disseminated TB, MRS Single study sensitivity:0.38 (95% CI: 0.33 to 0.43)| Single study specificity:0.98 (95% CI: 0.94 to 1.00) Test result Number of results per 1,000 patients tested (95% CI) Number of",
      "extractCut": true,
      "blocks": [
        "library/10665-381036/blocks/prose-page-153"
      ]
    },
    {
      "id": "page-154",
      "number": null,
      "title": "Page 154",
      "level": 1,
      "pageStart": 154,
      "pageEnd": 154,
      "labelStart": "149",
      "labelEnd": "149",
      "words": 132,
      "summary": {
        "text": "A GRADE summary of findings table showing pooled sensitivity of 1.00 and specificity of 0.99 for detecting rifampicin resistance in extrapulmonary specimens, at high certainty.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "eptb",
          "heading": false
        },
        {
          "term": "mrs",
          "heading": false
        },
        {
          "term": "negatives",
          "heading": false
        }
      ],
      "extract": "149 signs and symptoms of EPTB, MRS? Patient or population: adults and adolescents with signs and symptoms of EPTB, MRS Pooled sensitivity:1.00 (95% CI: 0.93 to 1.00)|Pooled specificity:0.99 (95% CI: 0.92 to 1.00) Test result Number of results per 1,000 patients tested (95% CI) Number of participants (studies) Certainty of the Evidence (GRADE) Prevalence2% Typically seen in Prevalence10% Typically seen in",
      "extractCut": true,
      "blocks": [
        "library/10665-381036/blocks/prose-page-154"
      ]
    },
    {
      "id": "page-155",
      "number": null,
      "title": "Page 155",
      "level": 1,
      "pageStart": 155,
      "pageEnd": 155,
      "labelStart": "150",
      "labelEnd": "150",
      "words": 237,
      "summary": {
        "text": "PRISMA study flow diagrams for the Xpert Ultra and Truenat MTB Plus searches, showing records screened, excluded with reasons and included.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "reports excluded",
          "heading": false
        },
        {
          "term": "reports sought",
          "heading": false
        },
        {
          "term": "records removed",
          "heading": false
        },
        {
          "term": "reports assessed",
          "heading": false
        },
        {
          "term": "records identified",
          "heading": false
        },
        {
          "term": "supplementary figure",
          "heading": false
        },
        {
          "term": "flow diagram",
          "heading": false
        }
      ],
      "extract": "150 Supplementary Figures and Tables Supplementary Figure 1. Study flow diagram for Xpert Ultra Supplementary Figure 2. Study flow diagram for Truenat MTB plus a Records identified from: Databases (n =564) Records removed before screening: Duplicate records removed (n = 344 ) Records screened (n = 220) Records excluded (n = 145) Reports sought for retrieval (n = 75) Reports not retrieved (n = 0) Reports assessed for",
      "extractCut": true,
      "blocks": [
        "library/10665-381036/blocks/prose-page-155"
      ]
    },
    {
      "id": "page-156",
      "number": null,
      "title": "Page 156",
      "level": 1,
      "pageStart": 156,
      "pageEnd": 156,
      "labelStart": "151",
      "labelEnd": "151",
      "words": 205,
      "summary": {
        "text": "A PRISMA flow diagram for STANDARD M10 and other tests, with a note that the manufacturer will discontinue Truenat MTB kits internationally from 2024.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "reports excluded",
          "heading": false
        },
        {
          "term": "reports sought",
          "heading": false
        },
        {
          "term": "records removed",
          "heading": false
        },
        {
          "term": "reports assessed",
          "heading": false
        },
        {
          "term": "records identified",
          "heading": false
        },
        {
          "term": "truenat mtb",
          "heading": false
        }
      ],
      "extract": "151 Supplementary Figure 3. Study flow diagram for STANDARD M10 and others * Manufacturer to discontinue Truenat MTB kits from the international market from 2024 From: Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ 2021;372:n71. doi: 10.1136/bmj.n71. For more information, visit:",
      "extractCut": true,
      "blocks": [
        "library/10665-381036/blocks/prose-page-156"
      ]
    },
    {
      "id": "page-157",
      "number": null,
      "title": "Page 157",
      "level": 1,
      "pageStart": 157,
      "pageEnd": 157,
      "labelStart": "152",
      "labelEnd": "152",
      "words": 148,
      "summary": {
        "text": "A PRISMA flow diagram showing that no studies were included for one index test search after two reports were excluded for addressing pulmonary TB.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "reports excluded",
          "heading": false
        },
        {
          "term": "reports sought",
          "heading": false
        },
        {
          "term": "records removed",
          "heading": false
        },
        {
          "term": "reports assessed",
          "heading": false
        }
      ],
      "extract": "152 From: Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ 2021;372:n71. doi: 10.1136/bmj.n71. For more information, visit: http://www.prisma-statement.org/ Records identified from*: Databases (n =37) Records removed before screening: Duplicate records removed (n = 3) Records screened (n = 34) Records",
      "extractCut": true,
      "blocks": [
        "library/10665-381036/blocks/prose-page-157"
      ]
    },
    {
      "id": "page-158",
      "number": null,
      "title": "Page 158",
      "level": 1,
      "pageStart": 158,
      "pageEnd": 158,
      "labelStart": "153",
      "labelEnd": "153",
      "words": 214,
      "summary": {
        "text": "Supplementary Table 1 gives certainty of evidence and effect estimates per 1,000 people for each specimen type, beginning with cerebrospinal fluid and lymph node fluid. The extracted table text is jumbled.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "cerebrospinal fluid",
          "heading": false
        },
        {
          "term": "mrs",
          "heading": false
        },
        {
          "term": "eptb",
          "heading": false
        }
      ],
      "extract": "Supplementary Table 1: Certainty of evidence for all forms of EPTB. EPTB specimen Reference standard # studies Participants (cases) Summary sensitivity (95% CI) Summary specificity (95% CI) Effect Estimates Low Medium Cerebrospinal fluid MRS 16 1687 (287) 88.2 (83.7 to 91.6) 96.0 (86.8 to 98.9) TP: 22(21-23) FN: 3 (2-4) TN: 936 (846- 964) FP: 39 (11-129) TP: 88 (84-92) FN: 12(8-16) TN: 864(781- 890) FP: 36(10-119) T",
      "extractCut": true,
      "blocks": [
        "library/10665-381036/blocks/prose-page-158"
      ]
    },
    {
      "id": "page-159",
      "number": null,
      "title": "Page 159",
      "level": 1,
      "pageStart": 159,
      "pageEnd": 159,
      "labelStart": "154",
      "labelEnd": "154",
      "words": 284,
      "summary": {
        "text": "Continues the certainty of evidence table for lymph node, pleural fluid and pleural tissue specimens. The extracted table text is jumbled.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "pleural tissue",
          "heading": false
        },
        {
          "term": "pleural fluid",
          "heading": false
        },
        {
          "term": "node tissue",
          "heading": false
        }
      ],
      "extract": "Lymph node fluid CRS 6 461 (243) 71.3 (64.3 to 77.4) 97.4 (82.2 to 99.7) TP: 18 (16-19) FN: 7 (6-9) TN: 950 (801- 972) FP: 25 (3-174) TP: 71 (64-77) FN: 29 (23-36) TN: 877 (740- 897) FP: 23 (3-160) T F T 7 F Lymph node tissue MRS 8 578 (97) 96.5 (84.7 to 99.3) 79.4 (65.4 to 88.8) TP: 24 (21-25) FN: 1 (0-4) TN: 774 (638- 866) FP: 201 (109- 337) TP: 97 (85-99) FN: 3 (1-15) TN: 715 (589- 799) FP: 185 (101- 311) T 1 F T",
      "extractCut": true,
      "blocks": [
        "library/10665-381036/blocks/prose-page-159"
      ]
    },
    {
      "id": "page-160",
      "number": null,
      "title": "Page 160",
      "level": 1,
      "pageStart": 160,
      "pageEnd": 160,
      "labelStart": "155",
      "labelEnd": "155",
      "words": 261,
      "summary": {
        "text": "Continues the certainty of evidence table for urine, synovial, peritoneal and pericardial fluid specimens. The extracted table text is jumbled.",
        "status": "draft"
      },
      "keywords": [],
      "extract": "105 (53) FN: 5-11 TN: 917- 946 FP: 29-58 FN: 19-46 TN: 846- 873 FP: 27-54 F T F Urine MRS 6 232 (14) 100% 28% to 100% TP: 25-25 FN: 0- 0 TN: 273-975 FP: 0-702 TP: 100-100 FN: 0-0 TN: 252-900 FP: 0- 648 T F T F Urine CRS 3 693 (159) 23.0 (14.7 to 34.1) 98.9 (89.7 to 99.9) TP: 6 (4-9) FN: 19 ( 16-21) TN: 964 (875- 974) FP: 11 (1-100) TP: 23 ( 15-34) FN: 77 (66-85) TN: 890 (807- 899) FP: 10 (1-93) T F 1 T 7 F Synovial",
      "extractCut": true,
      "blocks": [
        "library/10665-381036/blocks/prose-page-160"
      ]
    },
    {
      "id": "page-161",
      "number": null,
      "title": "Page 161",
      "level": 1,
      "pageStart": 161,
      "pageEnd": 161,
      "labelStart": "156",
      "labelEnd": "156",
      "words": 96,
      "summary": {
        "text": "Completes the certainty of evidence table with blood and rifampicin resistance results.",
        "status": "draft"
      },
      "keywords": [],
      "extract": "FP: 131 (83- 200) F Blood MRS 1 578 (423) 38% (33% to 43%) 98% (94% to 100%) TP: 10 (8-11) FN: 15 (14-17) TN: 956 (917- 975) FP: 19 (0-58) TP: 38 (33-43) FN: 62 (57-67) TN: 882 (846- 900) FP: 18 (0-54) T F 1 T 8 F RIF resistance MRS 13 446 (54) 100.0 (93.4 to 100.0) 99.4 (92.1 to 100.0) TP: 20 (19-20) FN: 0 (0-1) TN: 974 (903- 980) FP: 6 (0-77) TP: 100 (93-100) FN: 0 (0-7) TN: 895 (829- 900) FP: 5 (0-71) T 1 F T 8 F",
      "extractCut": false,
      "blocks": [
        "library/10665-381036/blocks/prose-page-161"
      ]
    },
    {
      "id": "page-162",
      "number": null,
      "title": "Page 162",
      "level": 1,
      "pageStart": 162,
      "pageEnd": 162,
      "labelStart": "157",
      "labelEnd": "157",
      "words": 152,
      "summary": {
        "text": "The title page of Web Annex B.4, a 2024 systematic review on the impact of rapid nucleic acid amplification tests for TB on patient outcomes, listing its authors and their affiliations. It was prepared for a WHO guideline meeting in May 2024.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "eleanor ochodo",
          "heading": false
        },
        {
          "term": "research fellow",
          "heading": false
        },
        {
          "term": "united kingdom",
          "heading": false
        },
        {
          "term": "acid amplification",
          "heading": false
        },
        {
          "term": "nucleic acid",
          "heading": false
        },
        {
          "term": "kemri",
          "heading": false
        },
        {
          "term": "health research",
          "heading": false
        }
      ],
      "extract": "Web Annex B.4. Impact of Rapid Nucleic Acid Amplification Tests for Tuberculosis on Patient Outcomes: A Systematic Review Date: 15 April 2024 Review authors and affiliations: Eleanor Ochodo (Review Lead), Centre for Global Health Research, Kenya Medical Research Institute (KEMRI), Kenya/Centre for Evidence-based Health Care, Stellenbosch University, South Africa Lisa Were, Centre for Global Health Research, KEMRI,",
      "extractCut": true,
      "blocks": [
        "library/10665-381036/blocks/prose-page-162"
      ]
    },
    {
      "id": "page-163",
      "number": null,
      "title": "Page 163",
      "level": 1,
      "pageStart": 163,
      "pageEnd": 163,
      "labelStart": "158",
      "labelEnd": "158",
      "words": 132,
      "summary": {
        "text": "A list of abbreviations used in the review of rapid nucleic acid amplification tests and patient outcomes.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "complexity-automated nucleic",
          "heading": false
        },
        {
          "term": "acid amplification",
          "heading": false
        },
        {
          "term": "amplification tests",
          "heading": false
        },
        {
          "term": "randomized controlled",
          "heading": false
        },
        {
          "term": "controlled trial",
          "heading": false
        },
        {
          "term": "guideline development",
          "heading": false
        }
      ],
      "extract": "List of Abbreviations cRCT CI Cluster Randomized Controlled Trial Confidence Interval DR-TB Drug-resistant Tuberculosis DS-TB Drug-susceptible Tuberculosis EPTB Extrapulmonary Tuberculosis FQ Fluoroquinolone GDG Guideline Development Group GDT Guideline Development Tool GRADE Grading of Recommendations, Assessment, Development, and Evaluations ICC Interclass Correlation Coefficient iRCT Individual Randomized",
      "extractCut": true,
      "blocks": [
        "library/10665-381036/blocks/prose-page-163"
      ]
    },
    {
      "id": "page-164",
      "number": null,
      "title": "Page 164",
      "level": 1,
      "pageStart": 164,
      "pageEnd": 164,
      "labelStart": "159",
      "labelEnd": "159",
      "words": 293,
      "summary": {
        "text": "The executive summary explains that WHO recommends rapid NAATs as initial TB tests and that the review assessed their impact on patient outcomes compared with smear microscopy or culture. It reports trial results on time to diagnosis and treatment, with moderate certainty.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "smear microscopy",
          "heading": false
        },
        {
          "term": "patient outcomes",
          "heading": false
        },
        {
          "term": "randomised",
          "heading": false
        },
        {
          "term": "naats",
          "heading": false
        },
        {
          "term": "complexity",
          "heading": false
        },
        {
          "term": "certainty",
          "heading": false
        },
        {
          "term": "moderate",
          "heading": false
        },
        {
          "term": "trials",
          "heading": false
        }
      ],
      "extract": "Executive Summary Background WHO recommends Rapid nucleic acid amplification tests (NAATs) as the initial diagnostic test for tuberculosis (TB), some of which can detect drug resistance simultaneously. They have higher diagnostic accuracy than smear microscopy and have fast turnaround times that may lead to a positive impact on patient outcomes. Objective To assess the impact of low complexity (LC) and moderate",
      "extractCut": true,
      "blocks": [
        "library/10665-381036/blocks/prose-page-164"
      ]
    },
    {
      "id": "page-165",
      "number": null,
      "title": "Page 165",
      "level": 1,
      "pageStart": 165,
      "pageEnd": 165,
      "labelStart": "160",
      "labelEnd": "160",
      "words": 52,
      "summary": {
        "text": "Concludes that Xpert Ultra may shorten time to diagnosis and treatment but that evidence of its effect on patient-important outcomes is limited.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "xpert ultra",
          "heading": false
        },
        {
          "term": "patient-important",
          "heading": false
        },
        {
          "term": "conclude",
          "heading": false
        }
      ],
      "extract": "Conclusions The use of Xpert Ultra may decrease the time to TB diagnosis and improve the time to TB treatment initiation. However, we found that compared to smear microscopy or culture, there is limited evidence with moderate certainty of evidence to confidently conclude that Xpert Ultra has an impact on patient-important outcomes.",
      "extractCut": false,
      "blocks": [
        "library/10665-381036/blocks/prose-page-165"
      ]
    },
    {
      "id": "page-166",
      "number": null,
      "title": "Page 166",
      "level": 1,
      "pageStart": 166,
      "pageEnd": 166,
      "labelStart": "161",
      "labelEnd": "161",
      "words": 324,
      "summary": {
        "text": "Gives background on TB, noting 10.6 million cases and about 1.3 million deaths in 2022, and describes pulmonary and extrapulmonary forms. It introduces drug-resistant TB as a major global health security threat.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "eptb",
          "heading": false
        },
        {
          "term": "million people",
          "heading": false
        },
        {
          "term": "ptb",
          "heading": false
        },
        {
          "term": "adult-type",
          "heading": false
        },
        {
          "term": "affects",
          "heading": false
        },
        {
          "term": "drug resistance",
          "heading": false
        },
        {
          "term": "spread",
          "heading": false
        },
        {
          "term": "extrapulmonary",
          "heading": false
        }
      ],
      "extract": "Background Description of the condition TB is one of the leading causes of death worldwide and affects all ages (1). TB is caused by Mycobacterium tuberculosis (M. tuberculosis) bacteria. TB primarily affects the respiratory system causing pulmonary TB (PTB) but can also affect other organ systems in the form of extrapulmonary TB (EPTB). While TB is preventable and largely curable, an estimated 10.6 million people",
      "extractCut": true,
      "blocks": [
        "library/10665-381036/blocks/prose-page-166"
      ]
    },
    {
      "id": "page-167",
      "number": null,
      "title": "Page 167",
      "level": 1,
      "pageStart": 167,
      "pageEnd": 167,
      "labelStart": "162",
      "labelEnd": "162",
      "words": 339,
      "summary": {
        "text": "Explains detection and classification of drug-resistant TB, including rifampicin-resistant, MDR, pre-XDR and XDR-TB. It then lists the classes of NAATs reviewed, such as Xpert Ultra, Truenat, STANDARD M10 and IRON-qPCR.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "truenat mtb",
          "heading": false
        },
        {
          "term": "drug resistance",
          "heading": false
        },
        {
          "term": "pre-xdr-tb",
          "heading": false
        },
        {
          "term": "second-line drugs",
          "heading": false
        },
        {
          "term": "mtb rif",
          "heading": false
        },
        {
          "term": "tuberculosis strains",
          "heading": false
        },
        {
          "term": "rr-tb",
          "heading": false
        },
        {
          "term": "molecular tests",
          "heading": false
        }
      ],
      "extract": "and testing for drug resistance using rapid molecular tests, culture methods or sequencing technologies. Resistance to rifampicin—the most effective first-line drug—is of greatest concern. Resistance to rifampicin and isoniazid is defined as multidrug-resistant TB (MDR-TB). Both MDR-TB and rifampicin-resistant TB (RR-TB) require treatment with second-line drugs (3). WHO uses five categories to classify cases of",
      "extractCut": true,
      "blocks": [
        "library/10665-381036/blocks/prose-page-167"
      ]
    },
    {
      "id": "page-168",
      "number": null,
      "title": "Page 168",
      "level": 1,
      "pageStart": 168,
      "pageEnd": 168,
      "labelStart": "163",
      "labelEnd": "163",
      "words": 293,
      "summary": {
        "text": "Lists further NAAT classes, including TB-LAMP and FluoroType XDR-TB, and describes Xpert Ultra as an automated PCR system usable with minimal expertise, citing its reported accuracy. It also describes Truenat assays and their possible results.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "truenat mtb",
          "heading": false
        },
        {
          "term": "mtb rif",
          "heading": false
        },
        {
          "term": "xpert mtb",
          "heading": false
        },
        {
          "term": "mtb plus",
          "heading": false
        },
        {
          "term": "rif ultra",
          "heading": false
        },
        {
          "term": "molbio diagnostics",
          "heading": false
        },
        {
          "term": "high-certainty evidence",
          "heading": false
        },
        {
          "term": "rifampicin resistance",
          "heading": false
        }
      ],
      "extract": "● LC-mNAATs: TB-LAMP ● MC-aNAATs: FluoroType XDR-TB LC-aNAATs Xpert MTB/RIF Ultra, Cepheid, USA For ease of reference, we refer to Xpert MTB/RIF Ultra as Xpert Ultra. Xpert Ultra is a NAAT that functions as an automated closed system that performs real-time polymerase chain reaction (PCR). Xpert Ultra can be used for diagnosing TB and RR-TB. Xpert Ultra can be performed by operators with minimal technical expertise",
      "extractCut": true,
      "blocks": [
        "library/10665-381036/blocks/prose-page-168"
      ]
    },
    {
      "id": "page-169",
      "number": null,
      "title": "Page 169",
      "level": 1,
      "pageStart": 169,
      "pageEnd": 169,
      "labelStart": "164",
      "labelEnd": "164",
      "words": 263,
      "summary": {
        "text": "Describes result categories of rifampicin resistance testing and the STANDARD M10 and IRON-qPCR molecular platforms, as part of the index test descriptions for a review of NAAT impact on patient outcomes.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "mtb ntm",
          "heading": false
        },
        {
          "term": "inh resistance",
          "heading": false
        },
        {
          "term": "resistance detected",
          "heading": false
        },
        {
          "term": "mtbc",
          "heading": false
        },
        {
          "term": "rif resistance",
          "heading": false
        },
        {
          "term": "standard mdr-tb",
          "heading": false
        },
        {
          "term": "simultaneous detection",
          "heading": false
        },
        {
          "term": "assay aids",
          "heading": false
        }
      ],
      "extract": "• RIF Resistance DETECTED • Indeterminate or ERROR STANDARD M10, SD Biosensor, Republic of Korea The STANDARD M10 is an in vitro molecular diagnosis system that automatically extracts and amplifies nucleic acids (DNA, RNA) from the collected samples, and analyses the data from amplification in real-time, by combining the processes of isothermal amplification and real- time PCR in a single platform using all-in-one",
      "extractCut": true,
      "blocks": [
        "library/10665-381036/blocks/prose-page-169"
      ]
    },
    {
      "id": "page-170",
      "number": null,
      "title": "Page 170",
      "level": 1,
      "pageStart": 170,
      "pageEnd": 170,
      "labelStart": "165",
      "labelEnd": "165",
      "words": 376,
      "summary": {
        "text": "Describes the IRON-qPCR kit for detecting TB and resistance to 11 drugs, then explains how rapid near-patient NAATs could improve outcomes by cutting loss to follow-up before diagnosis and treatment.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "qpcr rfia",
          "heading": false
        },
        {
          "term": "iron qpcr",
          "heading": false
        },
        {
          "term": "smear microscopy",
          "heading": false
        },
        {
          "term": "lamp",
          "heading": false
        },
        {
          "term": "lzd",
          "heading": false
        },
        {
          "term": "amk",
          "heading": false
        },
        {
          "term": "higher sensitivity",
          "heading": false
        },
        {
          "term": "emb",
          "heading": false
        }
      ],
      "extract": "qPCR ™ has a high multiplexing capacity of up to 40 targets in a single test and provides results in 40 minutes. The IRON qPCR RFIA kit is a cartridge-based assay that detects M. tuberculosis and resistance to 11 drugs: rifampicin, isoniazid, fluoroquinolones (levofloxacin, moxifloxacin, gatifloxacin and ofloxacin), aminoglycosides (kanamycin, amikacin, capreomycin), prothionamide and ethionamide. It uses IRON qPCR,",
      "extractCut": true,
      "blocks": [
        "library/10665-381036/blocks/prose-page-170"
      ]
    },
    {
      "id": "page-171",
      "number": null,
      "title": "Page 171",
      "level": 1,
      "pageStart": 171,
      "pageEnd": 171,
      "labelStart": "166",
      "labelEnd": "166",
      "words": 299,
      "summary": {
        "text": "Argues that reducing pre-treatment loss to follow-up may lower mortality and that rapid drug resistance detection could speed appropriate therapy, and states the review's objective of assessing NAAT impact on patient outcomes.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "automated naats",
          "heading": false
        },
        {
          "term": "complexity automated",
          "heading": false
        },
        {
          "term": "patient outcomes",
          "heading": false
        },
        {
          "term": "xpert mtb",
          "heading": false
        },
        {
          "term": "review assessed",
          "heading": false
        },
        {
          "term": "mtb rif",
          "heading": false
        },
        {
          "term": "mc-anaats",
          "heading": false
        },
        {
          "term": "ltfu",
          "heading": false
        }
      ],
      "extract": "perhaps, reduce time to treatment. Pre‐treatment loss to follow‐up (LTFU) is associated with high mortality rates, and thus, its reduction may lead to reduced mortality (22). A larger proportion of people with true TB may receive effective therapy, and fewer individuals may be falsely diagnosed with the disease on clinical grounds alone, and incorrectly treated. Rapid detection of drug resistance may lead to more",
      "extractCut": true,
      "blocks": [
        "library/10665-381036/blocks/prose-page-171"
      ]
    },
    {
      "id": "page-172",
      "number": null,
      "title": "Page 172",
      "level": 1,
      "pageStart": 172,
      "pageEnd": 172,
      "labelStart": "167",
      "labelEnd": "167",
      "words": 5,
      "summary": {
        "text": "A fragment completing the review objective, referring to people being investigated for TB.",
        "status": "draft"
      },
      "keywords": [],
      "extract": "people being investigated for TB.",
      "extractCut": false,
      "blocks": [
        "library/10665-381036/blocks/prose-page-172"
      ]
    },
    {
      "id": "page-173",
      "number": null,
      "title": "Page 173",
      "level": 1,
      "pageStart": 173,
      "pageEnd": 173,
      "labelStart": "168",
      "labelEnd": "168",
      "words": 186,
      "summary": {
        "text": "Sets out the methods for the review of NAAT impact, following Cochrane and PRISMA guidance, including randomized trials and primary outcomes of all-cause mortality and cure, with loss to follow-up and time to diagnosis as secondary outcomes.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "aged years",
          "heading": false
        },
        {
          "term": "diagnostic strategies",
          "heading": false
        },
        {
          "term": "truenat",
          "heading": false
        },
        {
          "term": "types",
          "heading": false
        },
        {
          "term": "outcomes",
          "heading": false
        },
        {
          "term": "criteria",
          "heading": false
        }
      ],
      "extract": "Methods This review was written following the recommended methodology described in the Cochrane Handbook for Systematic Reviews of Interventions (23) and the PRISMA 2020 statement (24). The protocol for the review is available on the Open Source Repository. Criteria for considering studies for this review Types of studies We included cluster and individually randomised controlled trials (RCTs) that met our inclusion",
      "extractCut": true,
      "blocks": [
        "library/10665-381036/blocks/prose-page-173"
      ]
    },
    {
      "id": "page-174",
      "number": null,
      "title": "Page 174",
      "level": 1,
      "pageStart": 174,
      "pageEnd": 174,
      "labelStart": "169",
      "labelEnd": "169",
      "words": 387,
      "summary": {
        "text": "Adds time to treatment as an outcome and presents WHO's updated TB treatment outcome definitions in a table, then begins describing the October 2023 literature searches.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "bacteriological conversion",
          "heading": false
        },
        {
          "term": "bacteriological response",
          "heading": false
        },
        {
          "term": "consecutive cultures",
          "heading": false
        },
        {
          "term": "treatment outcome",
          "heading": false
        },
        {
          "term": "whose treatment",
          "heading": false
        },
        {
          "term": "ds-tb",
          "heading": false
        },
        {
          "term": "days apart",
          "heading": false
        },
        {
          "term": "least days",
          "heading": false
        }
      ],
      "extract": "• Time to treatment For all outcomes, we used the WHO definitions outlined in Table 1 below. The WHO consulted on the definitions of DR-TB treatment outcomes in 2020. Following this consultation, the WHO proposed new definitions of TB treatment outcomes that apply to the assessment of treatment outcomes of all forms of TB (25). Table 1: TB treatment outcome deﬁnitions for both drug‐resistant and drug‐susceptible TB",
      "extractCut": true,
      "blocks": [
        "library/10665-381036/blocks/prose-page-174"
      ]
    },
    {
      "id": "page-175",
      "number": null,
      "title": "Page 175",
      "level": 1,
      "pageStart": 175,
      "pageEnd": 175,
      "labelStart": "170",
      "labelEnd": "170",
      "words": 318,
      "summary": {
        "text": "Lists the databases and trial registries searched and describes study selection and independent data extraction by two review authors.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "review authors",
          "heading": false
        },
        {
          "term": "senior review",
          "heading": false
        },
        {
          "term": "dissertations",
          "heading": false
        },
        {
          "term": "searched",
          "heading": false
        },
        {
          "term": "covidence",
          "heading": false
        },
        {
          "term": "disagreements",
          "heading": false
        },
        {
          "term": "clinicaltrials",
          "heading": false
        },
        {
          "term": "articles",
          "heading": false
        }
      ],
      "extract": "Cochrane Central Register of Controlled Trials (CENTRAL), using the Cochrane Library, issue 10, October 2023; MEDLINE (Ovid); Embase (Ovid); Science Citation Index and Biosis previews (ISI Web of Knowledge); WHO Global Index Medicus; and SCOPUS (Elsevier). VL also searched ClinicalTrials.gov (clinicaltrials.gov/) and the WHO Clinical Trials Registry Platform (www.who.int/trialsearch) to identify ongoing trials.",
      "extractCut": true,
      "blocks": [
        "library/10665-381036/blocks/prose-page-175"
      ]
    },
    {
      "id": "page-176",
      "number": null,
      "title": "Page 176",
      "level": 1,
      "pageStart": 176,
      "pageEnd": 176,
      "labelStart": "171",
      "labelEnd": "171",
      "words": 361,
      "summary": {
        "text": "Describes the data extracted for binary and time-to-event outcomes, adjustments for cluster trials and risk-of-bias assessment, and introduces GRADE assessment of certainty.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "hazard ratios",
          "heading": false
        },
        {
          "term": "odds ratios",
          "heading": false
        },
        {
          "term": "review authors",
          "heading": false
        },
        {
          "term": "extracted",
          "heading": false
        },
        {
          "term": "adjusted",
          "heading": false
        },
        {
          "term": "rob",
          "heading": false
        },
        {
          "term": "binary",
          "heading": false
        },
        {
          "term": "adjustment",
          "heading": false
        }
      ],
      "extract": "participant characteristics, intervention, control, each outcome measured and how it was measured, covariates outcomes were adjusted for, length of follow‐up, and measure of effect, with standard errors or 95% CIs. For binary outcomes, we extracted the 2x2 data or relative measures of effect (risk or odds ratios) if available. For time‐to‐event outcomes, we extracted hazard ratios if available. In addition, for",
      "extractCut": true,
      "blocks": [
        "library/10665-381036/blocks/prose-page-176"
      ]
    },
    {
      "id": "page-177",
      "number": null,
      "title": "Page 177",
      "level": 1,
      "pageStart": 177,
      "pageEnd": 177,
      "labelStart": "172",
      "labelEnd": "172",
      "words": 251,
      "summary": {
        "text": "Explains the GRADE domains and certainty levels used, then reports that two trials, one individually randomized and one cluster randomized, met the inclusion criteria.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "effect estimate",
          "heading": false
        },
        {
          "term": "true effect",
          "heading": false
        },
        {
          "term": "excluded studies",
          "heading": false
        },
        {
          "term": "rct",
          "heading": false
        },
        {
          "term": "confident",
          "heading": false
        },
        {
          "term": "screened",
          "heading": false
        },
        {
          "term": "criteria",
          "heading": false
        }
      ],
      "extract": "important outcome as described by Balshem 2011 (31). Drawing on valid reasons we downgraded the level of certainty in the evidence within the following five domains: risk of bias, inconsistency, indirectness, imprecision and publication bias. The following criteria were applied to interpret the findings: ● High: we were very confident that the true effect lies close to that of the estimate of the effect. ● Moderate:",
      "extractCut": true,
      "blocks": [
        "library/10665-381036/blocks/prose-page-177"
      ]
    },
    {
      "id": "page-178",
      "number": null,
      "title": "Page 178",
      "level": 1,
      "pageStart": 178,
      "pageEnd": 178,
      "labelStart": "173",
      "labelEnd": "173",
      "words": 180,
      "summary": {
        "text": "The PRISMA flow chart for the patient outcomes review, showing records screened and two studies included.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "ineligible comparator",
          "heading": false
        },
        {
          "term": "ineligible study",
          "heading": false
        },
        {
          "term": "records removed",
          "heading": false
        },
        {
          "term": "reports excluded",
          "heading": false
        },
        {
          "term": "reports sought",
          "heading": false
        }
      ],
      "extract": "173 Figure 1: The PRISMA 2020 ﬂow chart illustrating the study selection process (24) *Details are provided for these studies in Appendix 3. Records identified from*: Databases and registers (n =1067) Records removed before screening: Duplicate records removed (n = 6) Records marked as ineligible by automation tools (n = 1) Records removed for other reasons (n = 0) Records screened (n = 1060) Records excluded** (n =",
      "extractCut": true,
      "blocks": [
        "library/10665-381036/blocks/prose-page-178",
        "library/10665-381036/blocks/figure-vfig-p178"
      ]
    },
    {
      "id": "page-179",
      "number": null,
      "title": "Page 179",
      "level": 1,
      "pageStart": 179,
      "pageEnd": 179,
      "labelStart": "174",
      "labelEnd": "174",
      "words": 190,
      "summary": {
        "text": "Describes the two included trials, a Ugandan cluster trial of a multicomponent Xpert Ultra strategy and a South African mobile-clinic trial comparing Xpert Ultra with smear microscopy, noting neither reported mortality or cure.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "same-day smear",
          "heading": false
        },
        {
          "term": "smear microscopy",
          "heading": false
        },
        {
          "term": "xpert ultra",
          "heading": false
        },
        {
          "term": "receive xpert",
          "heading": false
        },
        {
          "term": "aged years",
          "heading": false
        },
        {
          "term": "on-site",
          "heading": false
        }
      ],
      "extract": "Characteristics of included studies The characteristics of the two included RCTs are summarised in Table 2. Of note, no study reported all-cause mortality and cure as outcomes. Cattamanchi 2021 (32) conducted a cRCT amongst adults aged ≥18 years in Ugandan community health centres for TB diagnosis. They compared a multicomponent diagnostic strategy (on-site Xpert Ultra testing, guided restructuring of clinic",
      "extractCut": true,
      "blocks": [
        "library/10665-381036/blocks/prose-page-179"
      ]
    },
    {
      "id": "page-180",
      "number": null,
      "title": "Page 180",
      "level": 1,
      "pageStart": 180,
      "pageEnd": 180,
      "labelStart": "175",
      "labelEnd": "175",
      "words": 209,
      "summary": {
        "text": "Table 2, giving key characteristics of the two included trials, such as design, country, setting, population, index and comparator tests, and outcomes.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "african region",
          "heading": false
        },
        {
          "term": "smear microscopy",
          "heading": false
        },
        {
          "term": "randomised controlled",
          "heading": false
        },
        {
          "term": "sample type",
          "heading": false
        },
        {
          "term": "controlled trial",
          "heading": false
        },
        {
          "term": "xpert ultra",
          "heading": false
        },
        {
          "term": "primary outcome",
          "heading": false
        },
        {
          "term": "irct",
          "heading": false
        }
      ],
      "extract": "175 Table 2: Key characteristics of included studies Author, year Study design Country (WHO region) Facility (geographical area) Target population Condition Index test (sample type) Comparator test (sample type) Outcomes Esmail 2023 (33) Parallel iRCT with 2 arms (single- centre) South Africa (African region) Community- based scalable mobile clinic (per-urban area) 588 adults >18 years, at least one TB symptom for 2",
      "extractCut": true,
      "blocks": [
        "library/10665-381036/blocks/prose-page-180"
      ]
    },
    {
      "id": "page-181",
      "number": null,
      "title": "Page 181",
      "level": 1,
      "pageStart": 181,
      "pageEnd": 181,
      "labelStart": "176",
      "labelEnd": "176",
      "words": 148,
      "summary": {
        "text": "Table 3, giving outcome results of the two trials, showing shorter times to TB diagnosis and treatment with Xpert Ultra.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "hazard ratio",
          "heading": false
        },
        {
          "term": "adjusted geometric",
          "heading": false
        },
        {
          "term": "geometric mean",
          "heading": false
        },
        {
          "term": "culture-based treatment",
          "heading": false
        }
      ],
      "extract": "176 Table 3: Outcome results Author, year (study design) Type of analysis & sample size Lost-to-follow-up (n/N, %) Patient outcome results Intervention arm Comparison arm Overall (at study endpoint) Primary Secondary Esmail 2023 (iRCT) (33) Modified ITT N = 584 I = 288 C = 296 Not reported Not reported Not reported Time to TB treatment, days: Same-day and/or culture-based treatment: Hazard ratio: 2.3 (95% CI:",
      "extractCut": true,
      "blocks": [
        "library/10665-381036/blocks/prose-page-181"
      ]
    },
    {
      "id": "page-182",
      "number": null,
      "title": "Page 182",
      "level": 1,
      "pageStart": 182,
      "pageEnd": 182,
      "labelStart": "177",
      "labelEnd": "177",
      "words": 145,
      "summary": {
        "text": "Summarizes risk of bias, judged low for the South African trial and of some concern for the Ugandan cluster trial owing to recruitment and unspecified analyses.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "bias assessment",
          "heading": false
        },
        {
          "term": "irct",
          "heading": false
        },
        {
          "term": "outcome",
          "heading": false
        },
        {
          "term": "randomisation",
          "heading": false
        }
      ],
      "extract": "Methodological quality assessment Figure 2 summarises the results of the risk of bias assessment for one outcome from an iRCT. There was a low risk of bias across all domains for Esmail 2023 for the time to treatment outcome (33). Figure 2: Summary of risk of bias assessment for iRCT per outcome For Cattamanchi 2021 there were some risk of bias concerns for both outcomes because participants were screened for",
      "extractCut": true,
      "blocks": [
        "library/10665-381036/blocks/prose-page-182",
        "library/10665-381036/blocks/figure-img-p182-1",
        "library/10665-381036/blocks/figure-img-p182-2"
      ]
    },
    {
      "id": "page-183",
      "number": null,
      "title": "Page 183",
      "level": 1,
      "pageStart": 183,
      "pageEnd": 183,
      "labelStart": "178",
      "labelEnd": "178",
      "words": 243,
      "summary": {
        "text": "Reports that neither trial measured mortality, cure or loss to follow-up, and presents evidence that Xpert Ultra shortened time to diagnosis and to treatment compared with smear microscopy.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "adjusted geometric",
          "heading": false
        },
        {
          "term": "geometric mean",
          "heading": false
        },
        {
          "term": "hazard ratio",
          "heading": false
        },
        {
          "term": "mean time",
          "heading": false
        },
        {
          "term": "ratio comparing",
          "heading": false
        },
        {
          "term": "treatment initiation",
          "heading": false
        },
        {
          "term": "xpert ultra",
          "heading": false
        }
      ],
      "extract": "Findings of the synthesis Primary outcomes Both studies did not report our primary outcomes of all-cause mortality and cure. Secondary outcomes Both studies did not report LTFU. Time to TB diagnosis Cattamanchi 2021 (32) was the only study to report time to TB diagnosis and calculated an adjusted geometric mean ratio (0.49, 95% CI: 0.39−0.62) (Figure 4). The adjusted geometric mean ratio suggested that the mean time",
      "extractCut": true,
      "blocks": [
        "library/10665-381036/blocks/prose-page-183",
        "library/10665-381036/blocks/figure-vfig-p183"
      ]
    },
    {
      "id": "page-184",
      "number": null,
      "title": "Page 184",
      "level": 1,
      "pageStart": 184,
      "pageEnd": 184,
      "labelStart": "179",
      "labelEnd": "179",
      "words": 123,
      "summary": {
        "text": "Concludes that Xpert Ultra appears to shorten time to treatment initiation compared with smear microscopy, and notes that certainty of evidence was rated moderate for all outcomes.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "favours xpert",
          "heading": false
        },
        {
          "term": "favours control",
          "heading": false
        },
        {
          "term": "plot showing",
          "heading": false
        },
        {
          "term": "forest plot",
          "heading": false
        }
      ],
      "extract": "1.2−7.7) (33). Therefore, it appears the use of Xpert Ultra improves the time to TB treatment initiation when compared to smear microscopy, regardless of whether treatment was initiated due to a positive TB culture. Figure 5: Forest plot showing adjusted geometric mean ratio for time to TB treatment initiation (N – number of participants included for the outcome) Figure 6: Forest plot showing hazard ratios for time",
      "extractCut": true,
      "blocks": [
        "library/10665-381036/blocks/prose-page-184",
        "library/10665-381036/blocks/figure-vfig-p184"
      ]
    },
    {
      "id": "page-185",
      "number": null,
      "title": "Page 185",
      "level": 1,
      "pageStart": 185,
      "pageEnd": 185,
      "labelStart": "180",
      "labelEnd": "180",
      "words": 354,
      "summary": {
        "text": "The GRADE table giving certainty of evidence for time to diagnosis and treatment with low and moderate complexity NAATs, followed by references to the two included trials.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "geometric mean",
          "heading": false
        },
        {
          "term": "adjusted geometric",
          "heading": false
        },
        {
          "term": "randomise trials",
          "heading": false
        },
        {
          "term": "trials seriousa",
          "heading": false
        },
        {
          "term": "mean ratio",
          "heading": false
        },
        {
          "term": "confidence interval",
          "heading": false
        },
        {
          "term": "serious",
          "heading": false
        },
        {
          "term": "hazard",
          "heading": false
        }
      ],
      "extract": "Table 4: GRADE table for certainty of the evidence Certainty assessment № of patients Effect Certainty Importanc e № of studie s Study design Risk of bias Inconsistenc y Indirectnes s Imprecisio n Other consideration s Low and Moderate Complexit y NAATS Smear microscopy/cultu re Relativ e (95% CI) Absolut e (95% CI) Time to diagnosis 11 randomise d trials seriousa not serious not serious not seriousb none The",
      "extractCut": true,
      "blocks": [
        "library/10665-381036/blocks/prose-page-185"
      ]
    },
    {
      "id": "page-186",
      "number": null,
      "title": "Page 186",
      "level": 1,
      "pageStart": 186,
      "pageEnd": 186,
      "labelStart": "181",
      "labelEnd": "181",
      "words": 361,
      "summary": {
        "text": "Discusses the findings of the review, which included two trials of Xpert Ultra in adults reporting secondary outcomes only, along with its strengths and limitation that no trials of other NAAT classes were found.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "xpert ultra",
          "heading": false
        },
        {
          "term": "hazard ratio",
          "heading": false
        },
        {
          "term": "adjusted geometric",
          "heading": false
        },
        {
          "term": "geometric mean",
          "heading": false
        },
        {
          "term": "treatment initiation",
          "heading": false
        },
        {
          "term": "all-cause mortality",
          "heading": false
        },
        {
          "term": "marcy",
          "heading": false
        },
        {
          "term": "mc-anaats",
          "heading": false
        }
      ],
      "extract": "Discussion Summary of findings This review assessed the impact of LC-aNAATs, LC-mNAATs and MC-aNAATs on patient outcomes in people being investigated for TB. We included two RCTs published between 2021 and 2023 (one iRCT and one pragmatic cRCT) assessing the impact of Xpert Ultra, a type of LC-aNAAT (32, 33). Both studies involved adult participants. Data were available for two of the three secondary outcomes of",
      "extractCut": true,
      "blocks": [
        "library/10665-381036/blocks/prose-page-186"
      ]
    },
    {
      "id": "page-187",
      "number": null,
      "title": "Page 187",
      "level": 1,
      "pageStart": 187,
      "pageEnd": 187,
      "labelStart": "182",
      "labelEnd": "182",
      "words": 186,
      "summary": {
        "text": "Calls for high-quality trials of NAAT impact on patient outcomes, including outside the African region, and concludes that evidence that Xpert Ultra improves diagnosis and treatment times is limited.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "all-cause mortality",
          "heading": false
        },
        {
          "term": "xpert ultra",
          "heading": false
        },
        {
          "term": "lc-anaats",
          "heading": false
        },
        {
          "term": "patient outcomes",
          "heading": false
        },
        {
          "term": "lc-mnaats",
          "heading": false
        }
      ],
      "extract": "Implications for future research There is a need for high-quality trials that assess the impact of LC-aNAATs, LC-mNAATs and MC-aNAATs against relevant comparators on important patient outcomes to confidently inform policy decisions. Studies included in this review were conducted within the WHO African region. Evidence from other WHO regions with high TB incidence such as South-East Asia and Western Pacific regions",
      "extractCut": true,
      "blocks": [
        "library/10665-381036/blocks/prose-page-187"
      ]
    },
    {
      "id": "page-188",
      "number": null,
      "title": "Page 188",
      "level": 1,
      "pageStart": 188,
      "pageEnd": 188,
      "labelStart": "183",
      "labelEnd": "183",
      "words": 184,
      "summary": {
        "text": "Appendix 1, the start of the detailed MEDLINE search strategy for the patient outcomes review.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "lymph node",
          "heading": false
        },
        {
          "term": "exp",
          "heading": false
        },
        {
          "term": "mening",
          "heading": false
        },
        {
          "term": "tuberculosis",
          "heading": false
        },
        {
          "term": "extrapulmonary",
          "heading": false
        }
      ],
      "extract": "Appendices Appendix 1: Detailed search strategies Ovid MEDLINE(R) ALL <1946 to October 16, 2023,> 1 Mycobacterium tuberculosis/ or tuberculosis.ti. 2 Tuberculosis, Pulmonary/ or Extensively Drug-Resistant Tuberculosis/ or Tuberculosis, Multidrug-Resistant/ 3 (tuberculosis or TB).tw. 4 (extrapulmonary or lymph node* or mening* or pulmonary).ti. or (extrapulmonary or lymph node* or mening* or pulmonary).ab. 5 3 and 4",
      "extractCut": true,
      "blocks": [
        "library/10665-381036/blocks/prose-page-188"
      ]
    },
    {
      "id": "page-189",
      "number": null,
      "title": "Page 189",
      "level": 1,
      "pageStart": 189,
      "pageEnd": 189,
      "labelStart": "184",
      "labelEnd": "184",
      "words": 170,
      "summary": {
        "text": "Continues the search strategies, completing MEDLINE and beginning Embase.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "lymph node",
          "heading": false
        },
        {
          "term": "resistant tuberculosis",
          "heading": false
        },
        {
          "term": "exp",
          "heading": false
        },
        {
          "term": "drug resistant",
          "heading": false
        }
      ],
      "extract": "28 23 or 24 or 25 or 26 29 7 and 18 30 27 and 29 31 30 and 28 32 Follow Up Studies/ or cohort. mp. 33 (before and after studies).mp. 34 exp Cohort Studies/ 35 32 or 33 or 34 36 30 and 35 37 36 or 31 Ovid Embase 1947-Present, updated daily 1 Mycobacterium tuberculosis/ or tuberculosis.ti. 2 Lung Tuberculosis/ or extensively drug resistant tuberculosis/ or drug resistant tuberculosis/ 3 (tuberculosis or TB).tw. 4",
      "extractCut": true,
      "blocks": [
        "library/10665-381036/blocks/prose-page-189"
      ]
    },
    {
      "id": "page-190",
      "number": null,
      "title": "Page 190",
      "level": 1,
      "pageStart": 190,
      "pageEnd": 190,
      "labelStart": "185",
      "labelEnd": "185",
      "words": 280,
      "summary": {
        "text": "Continues the Embase search strategy and gives the Web of Science search.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "blind procedure",
          "heading": false
        },
        {
          "term": "randomized trial",
          "heading": false
        },
        {
          "term": "clinical trial",
          "heading": false
        },
        {
          "term": "topic",
          "heading": false
        },
        {
          "term": "time series",
          "heading": false
        },
        {
          "term": "resistant tuberculosis",
          "heading": false
        },
        {
          "term": "placebo",
          "heading": false
        }
      ],
      "extract": "20 exp Survival/ 21 Time-to-Treatment/ or exp Diagnostic Error/ 22 18 or 19 or 20 or 21 23 8 or 9 or 10 or 11 or 12 or 13 or 14 or 15 or 16 or 17 24 7 and 22 and 23 25 (random* or factorial* or placebo* or assign* or allocat* or crossover*).tw. 26 ((blind* or mask*) and (single or double or triple or treble)).tw. 27 crossover procedure/ 28 double blind procedure/ or single blind procedure/ 29 randomization/ or",
      "extractCut": true,
      "blocks": [
        "library/10665-381036/blocks/prose-page-190"
      ]
    },
    {
      "id": "page-191",
      "number": null,
      "title": "Page 191",
      "level": 1,
      "pageStart": 191,
      "pageEnd": 191,
      "labelStart": "186",
      "labelEnd": "186",
      "words": 293,
      "summary": {
        "text": "Gives the Scopus, regional database and trial registry search strategies for the patient outcomes review.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "mesh descriptor",
          "heading": false
        },
        {
          "term": "iron qpcr",
          "heading": false
        },
        {
          "term": "biosensor",
          "heading": false
        },
        {
          "term": "naat",
          "heading": false
        },
        {
          "term": "truenat",
          "heading": false
        },
        {
          "term": "title-abs-key",
          "heading": false
        },
        {
          "term": "explode",
          "heading": false
        }
      ],
      "extract": "#7 Search: #5 OR #6 #8 Search: #7 AND #4 Scopus (Elsevier) ((TITLE-ABS-KEY (tuberculosis OR tb OR mdr-tb OR xdr-tb ) AND TITLE-ABS-KEY ( ( xpert* OR genexpert* OR cepheid ) OR ( truenat* OR molbio OR trurif ) OR tb-lamp* OR loopamp* OR fluorotype* OR ( standard AND m10 OR sd AND biosensor OR iron-qpcr OR bioneer ) OR naat* ) AND ABS ( treatment OR effect* OR outcome* OR mortality OR impact* OR survival OR error* ) )",
      "extractCut": true,
      "blocks": [
        "library/10665-381036/blocks/prose-page-191"
      ]
    },
    {
      "id": "page-192",
      "number": null,
      "title": "Page 192",
      "level": 1,
      "pageStart": 192,
      "pageEnd": 192,
      "labelStart": "187",
      "labelEnd": "187",
      "words": 209,
      "summary": {
        "text": "Appendix 2, the first part of a table of excluded studies, listing reasons such as duplicates, inaccessible full texts and ineligible index tests.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "ineligible index",
          "heading": false
        },
        {
          "term": "index test",
          "heading": false
        },
        {
          "term": "inaccessible full",
          "heading": false
        },
        {
          "term": "duplicate",
          "heading": false
        },
        {
          "term": "full text",
          "heading": false
        },
        {
          "term": "nct",
          "heading": false
        }
      ],
      "extract": "Appendix 2: Table of characteristics of excluded studies Study ID Reason for exclusion 1. Auld 2016 (39) Duplicate 2. Lessells 2017 (40) Duplicate 3. Durovni 2014 (41) Duplicate 4. Theron 2014 (42) Duplicate 5. Churchyard 2015 (43) Duplicate 6. NCT02043080 2014 (44) Inaccessible full text 7. NCT03187964 2017 (45) Inaccessible full text 8. NCT03168945 2016 (46) Inaccessible full text 9. Lessells 2011 (40, 47)",
      "extractCut": true,
      "blocks": [
        "library/10665-381036/blocks/prose-page-192"
      ]
    },
    {
      "id": "page-193",
      "number": null,
      "title": "Page 193",
      "level": 1,
      "pageStart": 193,
      "pageEnd": 193,
      "labelStart": "188",
      "labelEnd": "188",
      "words": 215,
      "summary": {
        "text": "Continues the list of excluded studies, with reasons such as ineligible population, study design or study type.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "ineligible study",
          "heading": false
        },
        {
          "term": "ineligible population",
          "heading": false
        },
        {
          "term": "study design",
          "heading": false
        },
        {
          "term": "study type",
          "heading": false
        },
        {
          "term": "auld",
          "heading": false
        },
        {
          "term": "santos",
          "heading": false
        }
      ],
      "extract": "30. Agizew 2019 (66) Ineligible population 31. Blanc 2020 (67) (68) Ineligible population 32. Ngwira 2019 (69) Ineligible population 33. Santos 2021 (70) Ineligible population 34. Auld 2020 (71) Ineligible population 35. Mupfumi 2014 (72) Ineligible population 36. Gupta-Wright 2018 (73) Ineligible population 37. VanRie 2013 (74) Ineligible study design 38. Alvarez 2015 (75) Ineligible study design 39. Cadavid 2022",
      "extractCut": true,
      "blocks": [
        "library/10665-381036/blocks/prose-page-193"
      ]
    },
    {
      "id": "page-194",
      "number": null,
      "title": "Page 194",
      "level": 1,
      "pageStart": 194,
      "pageEnd": 194,
      "labelStart": "189",
      "labelEnd": "189",
      "words": 53,
      "summary": {
        "text": "Ends the list of excluded studies, including three trials excluded for having ineligible comparators.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "ineligible comparator",
          "heading": false
        },
        {
          "term": "ineligible study",
          "heading": false
        },
        {
          "term": "study type",
          "heading": false
        }
      ],
      "extract": "61. Lessells 2015 (98) Ineligible study type 62. Bonnet 2020 (99) Ineligible study type 63. Nathavitharana 2021 (100) Ineligible study type 64. Ochodo 2019 (101) Ineligible study type 65. Haraka 2021 (21) Ineligible study type 66. Marcy 2023 (35) Ineligible comparator 67. Mukoka 2023 (36) Ineligible comparator 68. Leukes 2024 (37) Ineligible comparator",
      "extractCut": false,
      "blocks": [
        "library/10665-381036/blocks/prose-page-194"
      ]
    },
    {
      "id": "page-195",
      "number": null,
      "title": "Page 195",
      "level": 1,
      "pageStart": 195,
      "pageEnd": 195,
      "labelStart": "190",
      "labelEnd": "190",
      "words": 430,
      "summary": {
        "text": "Appendix 3 describes three relevant but ineligible trials, including a multi-country stepped-wedge trial of Xpert Ultra in young children with severe pneumonia and a trial in people with HIV in Malawi.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "chest x-ray",
          "heading": false
        },
        {
          "term": "control arm",
          "heading": false
        },
        {
          "term": "xpert ultra",
          "heading": false
        },
        {
          "term": "x-ray group",
          "heading": false
        },
        {
          "term": "xpert mtb",
          "heading": false
        },
        {
          "term": "numbers lost",
          "heading": false
        },
        {
          "term": "mtb rif",
          "heading": false
        },
        {
          "term": "smear microscopy",
          "heading": false
        }
      ],
      "extract": "Appendix 3: Details of ineligible but relevant RCTs Characteristics of excluded but relevant RCTs These have been summarised in Appendix Table 1 and 2 below. Marcy 2023 (35) included 2,570 children aged <5 years in a stepped-wedge cRCT comparing the WHO standard of care for severe pneumonia (n=1401) to Xpert Ultra (n=1,169). The trial was conducted in 16 hospitals across six countries in Africa. In the 12-week",
      "extractCut": true,
      "blocks": [
        "library/10665-381036/blocks/prose-page-195"
      ]
    },
    {
      "id": "page-196",
      "number": null,
      "title": "Page 196",
      "level": 1,
      "pageStart": 196,
      "pageEnd": 196,
      "labelStart": "191",
      "labelEnd": "191",
      "words": 17,
      "summary": {
        "text": "A fragment ending a description of a trial outcome on starting treatment within seven days and median time to treatment.",
        "status": "draft"
      },
      "keywords": [],
      "extract": "7 days of their first visit. The study also reported on the median time to treatment initiation.",
      "extractCut": false,
      "blocks": [
        "library/10665-381036/blocks/prose-page-196"
      ]
    },
    {
      "id": "page-197",
      "number": null,
      "title": "Page 197",
      "level": 1,
      "pageStart": 197,
      "pageEnd": 197,
      "labelStart": "192",
      "labelEnd": "192",
      "words": 300,
      "summary": {
        "text": "Appendix Table 1, giving characteristics of the three ineligible but relevant trials, such as design, countries, settings, tests and outcomes.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "african region",
          "heading": false
        },
        {
          "term": "xpert ultra",
          "heading": false
        },
        {
          "term": "truenat mtb",
          "heading": false
        },
        {
          "term": "multi centre",
          "heading": false
        },
        {
          "term": "severe pneumonia",
          "heading": false
        },
        {
          "term": "participants lost",
          "heading": false
        },
        {
          "term": "primary outcome",
          "heading": false
        },
        {
          "term": "sample type",
          "heading": false
        }
      ],
      "extract": "192 Appendix Table 1: Key characteristics of ineligible but relevant RCTs Author, year Study design Country (WHO region) Facility (geographical area) Target population Condition Index test (sample type) Comparator test (sample type) Outcomes Marcy 2023 (35) Pragmatic stepped wedge cRCT with 2 arms (multi- centre) Cambodia (Western Pacific region) Cameroon, Côte d'Ivoire, Mozambique, Uganda, Zambia (African region)",
      "extractCut": true,
      "blocks": [
        "library/10665-381036/blocks/prose-page-197"
      ]
    },
    {
      "id": "page-198",
      "number": null,
      "title": "Page 198",
      "level": 1,
      "pageStart": 198,
      "pageEnd": 198,
      "labelStart": "193",
      "labelEnd": "193",
      "words": 204,
      "summary": {
        "text": "Appendix Table 2, outcome results for the ineligible trials, including odds ratios for mortality and hazard ratios for time to treatment in the paediatric pneumonia trial.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "comparison arm",
          "heading": false
        },
        {
          "term": "odds ratio",
          "heading": false
        },
        {
          "term": "intervention arm",
          "heading": false
        },
        {
          "term": "xpert ultra",
          "heading": false
        },
        {
          "term": "xpert mtb",
          "heading": false
        },
        {
          "term": "randomised controlled",
          "heading": false
        }
      ],
      "extract": "193 using smear microscopy iRCT: Individual randomised controlled trial cRCT: Cluster randomised controlled trial HIV: Human Immunodeficiency Virus PLHIV: people living with HIV WHO: World Health Organization N: Total sample size I: Intervention arm C: Comparison arm *Outcome not relevant to our review. Appendix Table 2: Outcome results for ineligible but relevant RCTs Author, year (study design) Type of analysis &",
      "extractCut": true,
      "blocks": [
        "library/10665-381036/blocks/prose-page-198"
      ]
    },
    {
      "id": "page-199",
      "number": null,
      "title": "Page 199",
      "level": 1,
      "pageStart": 199,
      "pageEnd": 199,
      "labelStart": "194",
      "labelEnd": "194",
      "words": 98,
      "summary": {
        "text": "Completes the outcome results table with the Leukes 2024 cluster trial and footnotes on analyses and sputum testing.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "itt",
          "heading": false
        },
        {
          "term": "censored",
          "heading": false
        },
        {
          "term": "intention",
          "heading": false
        }
      ],
      "extract": "194 Leukes 2024 (37) Modified intention to treat N= 3983 I= 2003 C= 1980 Not reported Not reported Not reported *Not relevant Time to TB treatment initiation: Coxme Model Output for pTB bacteriologically confirmed population censored at 60 days= Hazard ratio: 6.0 (95% CI: Not reported) ITT: Intention to treat analysis *Non-patient outcomes reported i Results of the sensitivity analyses for the primary end",
      "extractCut": true,
      "blocks": [
        "library/10665-381036/blocks/prose-page-199"
      ]
    },
    {
      "id": "page-200",
      "number": null,
      "title": "Page 200",
      "level": 1,
      "pageStart": 200,
      "pageEnd": 200,
      "labelStart": "195",
      "labelEnd": "195",
      "words": 243,
      "summary": {
        "text": "Reports findings from the ineligible trials, with only the paediatric pneumonia trial reporting all-cause mortality and a hazard ratio for time to treatment that the text interprets as favouring Xpert Ultra.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "odds ratios",
          "heading": false
        },
        {
          "term": "adjusted odds",
          "heading": false
        },
        {
          "term": "marcy reported",
          "heading": false
        },
        {
          "term": "forest plot",
          "heading": false
        },
        {
          "term": "all-cause mortality",
          "heading": false
        },
        {
          "term": "xpert ultra",
          "heading": false
        },
        {
          "term": "numbers lost",
          "heading": false
        }
      ],
      "extract": "Findings All-cause mortality Appendix Figure 1 shows the forest plot for all-cause mortality. Only Marcy 2023 reported all- cause mortality. Note that raw numbers were not used to calculate risk ratios because dividing numbers by the design effect is not an appropriate adjustment for results of stepped- wedge trials (21). Instead, the adjusted odds ratios as calculated by the study authors are presented. In the",
      "extractCut": true,
      "blocks": [
        "library/10665-381036/blocks/prose-page-200"
      ]
    },
    {
      "id": "page-201",
      "number": null,
      "title": "Page 201",
      "level": 1,
      "pageStart": 201,
      "pageEnd": 201,
      "labelStart": "196",
      "labelEnd": "196",
      "words": 28,
      "summary": {
        "text": "A caption for the forest plot of hazard ratios for time to TB treatment initiation.",
        "status": "draft"
      },
      "keywords": [],
      "extract": "Appendix Figure 2: Forest plot showing hazard ratio for time to TB treatment initiation (N – number of participants included for the outcome) Favours control Favours Xpert Ultra",
      "extractCut": false,
      "blocks": [
        "library/10665-381036/blocks/prose-page-201"
      ]
    },
    {
      "id": "page-202",
      "number": null,
      "title": "Page 202",
      "level": 1,
      "pageStart": 202,
      "pageEnd": 202,
      "labelStart": "197",
      "labelEnd": "197",
      "words": 495,
      "summary": {
        "text": "The start of the reference list for the patient outcomes review, citing TB burden reports and diagnostic studies.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "pulmonary tuberculosis",
          "heading": false
        },
        {
          "term": "world bank",
          "heading": false
        },
        {
          "term": "tuberculosis report",
          "heading": false
        },
        {
          "term": "loop-mediated isothermal",
          "heading": false
        },
        {
          "term": "health organisation",
          "heading": false
        },
        {
          "term": "isothermal amplification",
          "heading": false
        },
        {
          "term": "global tuberculosis",
          "heading": false
        },
        {
          "term": "syst rev",
          "heading": false
        }
      ],
      "extract": "References 1. Bloom BR, Atun R, Cohen T, Dye C, Fraser H, Gomez GB, et al. Tuberculosis. In: Holmes KK, Bertozzi S, Bloom BR, Jha P, editors. Major Infectious Diseases. Washington (DC): The International Bank for Reconstruction and Development / The World Bank © 2017 International Bank for Reconstruction and Development / The World Bank.; 2017. 2. World Health Organisation. Global tuberculosis report 2023 2023",
      "extractCut": true,
      "blocks": [
        "library/10665-381036/blocks/prose-page-202"
      ]
    },
    {
      "id": "page-203",
      "number": null,
      "title": "Page 203",
      "level": 1,
      "pageStart": 203,
      "pageEnd": 203,
      "labelStart": "198",
      "labelEnd": "198",
      "words": 592,
      "summary": {
        "text": "Continues the reference list, citing studies of LAMP and other molecular assays and of TB detection trials.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "higgins jpt",
          "heading": false
        },
        {
          "term": "gradepro gdt",
          "heading": false
        },
        {
          "term": "sterne jac",
          "heading": false
        },
        {
          "term": "cochrane syst",
          "heading": false
        },
        {
          "term": "updated august",
          "heading": false
        },
        {
          "term": "cochrane handbook",
          "heading": false
        },
        {
          "term": "page",
          "heading": true
        },
        {
          "term": "pulmonary tuberculosis",
          "heading": false
        }
      ],
      "extract": "18. Fan L, Guan B, Cheng M, Liu C, Tian Y, Li R, et al. A Comprehensive Evaluation of a Loop- Mediated Isothermal Amplification Assay for the Diagnosis of Pulmonary Tuberculosis in Children Using Bronchoalveolar Lavage Fluid. Infect Drug Resist. 2022;15:975-87. 19. Iwamoto T, Sonobe T, Hayashi K. Loop-mediated isothermal amplification for direct detection of Mycobacterium tuberculosis complex, M. avium, and M.",
      "extractCut": true,
      "blocks": [
        "library/10665-381036/blocks/prose-page-203"
      ]
    },
    {
      "id": "page-204",
      "number": null,
      "title": "Page 204",
      "level": 1,
      "pageStart": 204,
      "pageEnd": 204,
      "labelStart": "199",
      "labelEnd": "199",
      "words": 534,
      "summary": {
        "text": "Continues the reference list, citing randomized trials of Xpert testing and case-finding strategies.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "cluster-randomized trial",
          "heading": false
        },
        {
          "term": "mtb rif",
          "heading": false
        },
        {
          "term": "xpert mtb",
          "heading": false
        },
        {
          "term": "med hyg",
          "heading": false
        },
        {
          "term": "controlled trial",
          "heading": false
        },
        {
          "term": "infect dis",
          "heading": false
        },
        {
          "term": "bmc infect",
          "heading": false
        },
        {
          "term": "trop med",
          "heading": false
        }
      ],
      "extract": "36. Mukoka M, Twabi HH, Msefula C, Semphere R, Ndhlovu G, Lipenga T, et al. Utility of Xpert MTB/RIF Ultra and digital chest radiography for the diagnosis and treatment of TB in people living with HIV: a randomised controlled trial (XACT-TB). Trans R Soc Trop Med Hyg. 2023;117(1):28-37. 37. Leukes VN, Hella J, Sabi I, Cossa M, Khosa C, Erkosar B, et al. Study protocol: a pragmatic, cluster-randomized controlled",
      "extractCut": true,
      "blocks": [
        "library/10665-381036/blocks/prose-page-204"
      ]
    },
    {
      "id": "page-205",
      "number": null,
      "title": "Page 205",
      "level": 1,
      "pageStart": 205,
      "pageEnd": 205,
      "labelStart": "200",
      "labelEnd": "200",
      "words": 600,
      "summary": {
        "text": "Continues the reference list, citing trials of case-finding strategies and of Xpert testing in South Africa, Botswana and elsewhere.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "randomised trial",
          "heading": false
        },
        {
          "term": "infect dis",
          "heading": false
        },
        {
          "term": "randomised controlled",
          "heading": false
        },
        {
          "term": "mtb rif",
          "heading": false
        },
        {
          "term": "stepped wedge",
          "heading": false
        },
        {
          "term": "rif versus",
          "heading": false
        },
        {
          "term": "xpert mtb",
          "heading": false
        },
        {
          "term": "tuberculosis treatment",
          "heading": false
        }
      ],
      "extract": "52. Hanrahan CF, Nonyane BAS, Mmolawa L, West NS, Siwelana T, Lebina L, et al. Contact tracing versus facility-based screening for active TB case finding in rural South Africa: A pragmatic cluster-randomized trial (Kharitode TB). PLos Med. 2019;16(4):14. 53. Ershova JV, Volchenkov GV, Somova TR, Kuznetsova TA, Kaunetis NV, Kaminski D, et al. Impact of GeneXpert MTB/RIF R on treatment initiation and outcomes of",
      "extractCut": true,
      "blocks": [
        "library/10665-381036/blocks/prose-page-205"
      ]
    },
    {
      "id": "page-206",
      "number": null,
      "title": "Page 206",
      "level": 1,
      "pageStart": 206,
      "pageEnd": 206,
      "labelStart": "201",
      "labelEnd": "201",
      "words": 595,
      "summary": {
        "text": "Continues the reference list, citing trials of empirical versus test-guided TB treatment in people with HIV and studies of Xpert and late diagnosis.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "mtb rif",
          "heading": false
        },
        {
          "term": "xpert mtb",
          "heading": false
        },
        {
          "term": "van rie",
          "heading": false
        },
        {
          "term": "rif assay",
          "heading": false
        },
        {
          "term": "pulmonary tuberculosis",
          "heading": false
        },
        {
          "term": "randomized trial",
          "heading": false
        },
        {
          "term": "tuberc lung",
          "heading": false
        },
        {
          "term": "cluster randomized",
          "heading": false
        }
      ],
      "extract": "67. Blanc FX, Badje AD, Bonnet M, Gabillard D, Messou E, Muzoora C, et al. Systematic or Test- Guided Treatment for Tuberculosis in HIV-Infected Adults. N Engl J Med. 2020;382(25):2397-410. 68. Nct. Systematic Empirical vs. Test-guided Anti-TB Treatment Impact in Severely Immunosuppressed HIV-infected Adults Initiating ART With CD4 Cell Counts &lt;100/mm3. 2014. 69. Ngwira LG, Corbett EL, Khundi M, Barnes GL, Nkhoma",
      "extractCut": true,
      "blocks": [
        "library/10665-381036/blocks/prose-page-206"
      ]
    },
    {
      "id": "page-207",
      "number": null,
      "title": "Page 207",
      "level": 1,
      "pageStart": 207,
      "pageEnd": 207,
      "labelStart": "202",
      "labelEnd": "202",
      "words": 593,
      "summary": {
        "text": "Continues the reference list, citing studies on Xpert impact, loss to follow-up and Cochrane reviews.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "mtb rif",
          "heading": false
        },
        {
          "term": "xpert mtb",
          "heading": false
        },
        {
          "term": "rif assay",
          "heading": false
        },
        {
          "term": "rif ultra",
          "heading": false
        },
        {
          "term": "pulmonary tuberculosis",
          "heading": false
        },
        {
          "term": "lung dis",
          "heading": false
        },
        {
          "term": "tuberc lung",
          "heading": false
        },
        {
          "term": "pragmatic clinical",
          "heading": false
        }
      ],
      "extract": "84. Mwansa-Kambafwile J, Maitshotlo B, Black A. Microbiologically Confirmed Tuberculosis: Factors Associated with Pre-Treatment Loss to Follow-Up, and Time to Treatment Initiation. PLoS ONE. 2017;12(1):e0168659. 85. Chaisson LH, Roemer M, Cantu D, Haller B, Millman AJ, Cattamanchi A, et al. Impact of GeneXpert MTB/RIF assay on triage of respiratory isolation rooms for inpatients with presumed tuberculosis: a",
      "extractCut": true,
      "blocks": [
        "library/10665-381036/blocks/prose-page-207"
      ]
    },
    {
      "id": "page-208",
      "number": null,
      "title": "Page 208",
      "level": 1,
      "pageStart": 208,
      "pageEnd": 208,
      "labelStart": "203",
      "labelEnd": "203",
      "words": 41,
      "summary": {
        "text": "The final reference in the patient outcomes review, a systematic review of Xpert MTB/RIF effects on mortality.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "kalema",
          "heading": false
        },
        {
          "term": "mallett",
          "heading": false
        },
        {
          "term": "wellcome",
          "heading": false
        }
      ],
      "extract": "101. Ochodo EA, Kalema N, Schumacher S, Steingart K, Young T, Mallett S, et al. Variation in the observed effect of Xpert MTB/RIF testing for tuberculosis on mortality: A systematic review and analysis of trial design considerations. Wellcome Open Res. 2019;4:173.",
      "extractCut": false,
      "blocks": [
        "library/10665-381036/blocks/prose-page-208"
      ]
    },
    {
      "id": "page-209",
      "number": null,
      "title": "Page 209",
      "level": 1,
      "pageStart": 209,
      "pageEnd": 209,
      "labelStart": "204",
      "labelEnd": "204",
      "words": 103,
      "summary": {
        "text": "The title, authors and affiliations of Web Annex B.5, a systematic review of the diagnostic accuracy of low complexity manual NAATs (LC-mNAATs) for pulmonary and extrapulmonary TB in adults and adolescents.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "leeberk raja",
          "heading": false
        },
        {
          "term": "raja inbaraj",
          "heading": false
        },
        {
          "term": "icmr national",
          "heading": false
        },
        {
          "term": "united kingdom",
          "heading": false
        },
        {
          "term": "chennai",
          "heading": false
        }
      ],
      "extract": "Web Annex B.5. LC-mNAATs for detection of pulmonary and extrapulmonary tuberculosis in adults and adolescents: a systematic review of diagnostic accuracy Leeberk Raja Inbaraj1, Jefferson Daniel2, Vignes Anand Srinivasalu1, Mukesh Kumar Sathyanarayanan1, Adhin Bhaskar1, Katie Scandrett3, Karen Steingart4 , Yemisi Takwoingi3 1. ICMR- National Institute for Research in Tuberculosis, Chennai, India 2. Christian Medical",
      "extractCut": true,
      "blocks": [
        "library/10665-381036/blocks/prose-page-209"
      ]
    },
    {
      "id": "page-210",
      "number": null,
      "title": "Page 210",
      "level": 1,
      "pageStart": 210,
      "pageEnd": 210,
      "labelStart": "205",
      "labelEnd": "205",
      "words": 612,
      "summary": {
        "text": "Gives background for the LC-mNAAT review, citing 2022 TB diagnoses and deaths and the problem of diagnostic delay, and describes the TB-LAMP test as the class's index test. Methods follow a generic protocol shared by six diagnostic accuracy reviews.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "smear microscopy",
          "heading": false
        },
        {
          "term": "amplification process",
          "heading": false
        },
        {
          "term": "lc-mnaats",
          "heading": false
        },
        {
          "term": "tb-lamp",
          "heading": false
        },
        {
          "term": "diagnostic accuracy",
          "heading": false
        },
        {
          "term": "primers",
          "heading": false
        },
        {
          "term": "index test",
          "heading": false
        },
        {
          "term": "minutes",
          "heading": false
        }
      ],
      "extract": "Background Tuberculosis (TB) is one of the deadliest diseases with high mortality and morbidity. Globally, in 2022, 7.5 million people were newly diagnosed with TB and 1.3 million died due to TB. (WHO Global TB Report 2023). One of the major obstacles to the elimination of TB is the delay in accurate diagnosis. Over the years, various rapid molecular tests have been recommended by WHO (mWRD) as the initial",
      "extractCut": true,
      "blocks": [
        "library/10665-381036/blocks/prose-page-210"
      ]
    },
    {
      "id": "page-211",
      "number": null,
      "title": "Page 211",
      "level": 1,
      "pageStart": 211,
      "pageEnd": 211,
      "labelStart": "206",
      "labelEnd": "206",
      "words": 543,
      "summary": {
        "text": "Describes the October 2023 searches, eligibility criteria and culture reference standard for the LC-mNAAT review.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "unpublished studies",
          "heading": false
        },
        {
          "term": "excluded studies",
          "heading": false
        },
        {
          "term": "culture methods",
          "heading": false
        },
        {
          "term": "electronic searches",
          "heading": false
        },
        {
          "term": "reference standards",
          "heading": false
        },
        {
          "term": "index test",
          "heading": false
        },
        {
          "term": "review authors",
          "heading": false
        },
        {
          "term": "diagnostic accuracy",
          "heading": false
        }
      ],
      "extract": "Search methods Electronic searches The Cochrane Infectious Diseases Group Information Specialist (Vittoria Lutje (VL)) performed literature searches between 2nd and 3rd October 2023, without language restrictions, in the following databases, using the search terms in Appendix 1: Cochrane Central Register of Controlled Trials (CENTRAL), included in the Cochrane Library, issue 10, October 2023; MEDLINE (Ovid); Embase",
      "extractCut": true,
      "blocks": [
        "library/10665-381036/blocks/prose-page-211"
      ]
    },
    {
      "id": "page-212",
      "number": null,
      "title": "Page 212",
      "level": 1,
      "pageStart": 212,
      "pageEnd": 212,
      "labelStart": "207",
      "labelEnd": "207",
      "words": 391,
      "summary": {
        "text": "Defines the composite reference standard and outlines analysis methods, then reports that 29 studies were included, 27 on pulmonary TB and three on extrapulmonary TB.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "study authors",
          "heading": false
        },
        {
          "term": "composite reference",
          "heading": false
        },
        {
          "term": "review authors",
          "heading": false
        },
        {
          "term": "mks",
          "heading": false
        },
        {
          "term": "primary study",
          "heading": false
        },
        {
          "term": "reference standard",
          "heading": false
        },
        {
          "term": "clinical characteristics",
          "heading": false
        },
        {
          "term": "level data",
          "heading": false
        }
      ],
      "extract": "of TB while a negative culture indicated no TB. Composite reference standard We defined a composite reference standard as a positive culture or a clinical decision to initiate treatment for TB (i.e., clinically diagnosed TB). The composite reference standard may be based on the results of microbiological tests, culture or NAATs other than the index test being evaluated; imaging studies; histology; and clinical",
      "extractCut": true,
      "blocks": [
        "library/10665-381036/blocks/prose-page-212"
      ]
    },
    {
      "id": "page-213",
      "number": null,
      "title": "Page 213",
      "level": 1,
      "pageStart": 213,
      "pageEnd": 213,
      "labelStart": "208",
      "labelEnd": "208",
      "words": 321,
      "summary": {
        "text": "The study flow diagram for the LC-mNAAT review, with an introduction to the characteristics of included studies.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "records removed",
          "heading": false
        },
        {
          "term": "reports excluded",
          "heading": false
        },
        {
          "term": "reports sought",
          "heading": false
        },
        {
          "term": "reports assessed",
          "heading": false
        },
        {
          "term": "records identified",
          "heading": false
        },
        {
          "term": "dta",
          "heading": false
        },
        {
          "term": "unknown age",
          "heading": false
        }
      ],
      "extract": "208 Figure 1. Study flow diagram *One study contributed data for both pulmonary TB (PTB) and extrapulmonary TB (EPTB). DTA = diagnostic test accuracy Characteristics of included studies Key characteristics of the 27 included studies for detection of pulmonary TB and the three studies for detection of extrapulmonary TB are described in Table Records identified from: Databases (n = 2806) Registers (n = 0) Records",
      "extractCut": true,
      "blocks": [
        "library/10665-381036/blocks/prose-page-213",
        "library/10665-381036/blocks/figure-vfig-p213"
      ]
    },
    {
      "id": "page-214",
      "number": null,
      "title": "Page 214",
      "level": 1,
      "pageStart": 214,
      "pageEnd": 214,
      "labelStart": "209",
      "labelEnd": "209",
      "words": 308,
      "summary": {
        "text": "States that all included studies were cross-sectional evaluations of TB-LAMP against culture, and begins Table 1 of study characteristics by country, HIV prevalence, setting and specimen.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "expectorated sputum",
          "heading": false
        },
        {
          "term": "mgit",
          "heading": false
        },
        {
          "term": "lymph node",
          "heading": false
        },
        {
          "term": "outpatient",
          "heading": false
        },
        {
          "term": "danfack",
          "heading": false
        },
        {
          "term": "peripheral",
          "heading": false
        },
        {
          "term": "cameroon",
          "heading": false
        },
        {
          "term": "yes",
          "heading": false
        }
      ],
      "extract": "209 1. All the studies were cross-sectional and assessed TB-LAMP using a microbiological reference standard. No study used a composite reference standard. Table 1. Characteristics of included studies Study Country Reference standard Proportion of PLHIV Clinical setting Laboratory type High TB burden Specimen type Proportion smear positive participants Bojang 2016 Gambia MGIT 2/50 (4%) Outpatient Central No",
      "extractCut": true,
      "blocks": [
        "library/10665-381036/blocks/prose-page-214"
      ]
    },
    {
      "id": "page-215",
      "number": null,
      "title": "Page 215",
      "level": 1,
      "pageStart": 215,
      "pageEnd": 215,
      "labelStart": "210",
      "labelEnd": "210",
      "words": 322,
      "summary": {
        "text": "Continues the table of TB-LAMP study characteristics, covering studies from China, multi-country sites and others, with abbreviations.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "expectorated sputum",
          "heading": false
        },
        {
          "term": "gastric aspirate",
          "heading": false
        },
        {
          "term": "mgit",
          "heading": false
        },
        {
          "term": "lymph node",
          "heading": false
        },
        {
          "term": "node tissue",
          "heading": false
        },
        {
          "term": "yes",
          "heading": false
        },
        {
          "term": "outpatient",
          "heading": false
        },
        {
          "term": "danfack",
          "heading": false
        }
      ],
      "extract": "210 Study Country Reference standard Proportion of PLHIV Clinical setting Laboratory type High TB burden Specimen type Proportion smear positive participants Ou 2016 China MGIT Not reported Outpatient Central Yes Expectorated sputum 187/1519 (12%) Ou 2019 China LJ Not reported Outpatient Central Yes Expectorated sputum 267/3126 (9%) Pham 20183 Peru, South Africa, Brazil, and Vietnam LJ/MGIT 96/964 (10%) Not reported",
      "extractCut": true,
      "blocks": [
        "library/10665-381036/blocks/prose-page-215"
      ]
    },
    {
      "id": "page-216",
      "number": null,
      "title": "Page 216",
      "level": 1,
      "pageStart": 216,
      "pageEnd": 216,
      "labelStart": "211",
      "labelEnd": "211",
      "words": 322,
      "summary": {
        "text": "Describes the pulmonary TB studies, most in high-burden settings, and how multi-sample and smear-negative studies were handled, and summarizes risk of bias and applicability judgements.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "selection domain",
          "heading": false
        },
        {
          "term": "standard domain",
          "heading": false
        },
        {
          "term": "domain due",
          "heading": false
        },
        {
          "term": "unclear risk",
          "heading": false
        },
        {
          "term": "sputum samples",
          "heading": false
        },
        {
          "term": "judged",
          "heading": false
        },
        {
          "term": "patient selection",
          "heading": false
        },
        {
          "term": "reference standard",
          "heading": false
        }
      ],
      "extract": "Detection of pulmonary tuberculosis Of the 27 studies included, 62.9% (17/27) were conducted in high TB burden settings. One of the studies (Getahun 2017) assessed only smear negative patients and so was not included in the main analysis for detection of pulmonary TB. One study (Pham 2018) collected two sputum samples per participant and each sample was tested with TB-LAMP. The primary analysis reported by the study",
      "extractCut": true,
      "blocks": [
        "library/10665-381036/blocks/prose-page-216"
      ]
    },
    {
      "id": "page-217",
      "number": null,
      "title": "Page 217",
      "level": 1,
      "pageStart": 217,
      "pageEnd": 217,
      "labelStart": "212",
      "labelEnd": "212",
      "words": 13,
      "summary": {
        "text": "A caption for the figure of risk of bias and applicability for each pulmonary TB study.",
        "status": "draft"
      },
      "keywords": [],
      "extract": "Figure 2. Risk of bias and applicability summary for each study: pulmonary TB",
      "extractCut": false,
      "blocks": [
        "library/10665-381036/blocks/prose-page-217",
        "library/10665-381036/blocks/figure-img-p217-1"
      ]
    },
    {
      "id": "page-218",
      "number": null,
      "title": "Page 218",
      "level": 1,
      "pageStart": 218,
      "pageEnd": 218,
      "labelStart": "213",
      "labelEnd": "213",
      "words": 37,
      "summary": {
        "text": "A caption for the summary figure of risk of bias and applicability across pulmonary TB studies.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "bar",
          "heading": false
        },
        {
          "term": "percentages",
          "heading": false
        },
        {
          "term": "judgement",
          "heading": false
        }
      ],
      "extract": "Figure 3. Risk of bias and applicability summary: pulmonary TB Review authors' judgements about each domain presented as percentages across included studies. The numbers shown on each bar indicate the number of studies in each judgement category.",
      "extractCut": false,
      "blocks": [
        "library/10665-381036/blocks/prose-page-218",
        "library/10665-381036/blocks/figure-img-p218-1"
      ]
    },
    {
      "id": "page-219",
      "number": null,
      "title": "Page 219",
      "level": 1,
      "pageStart": 219,
      "pageEnd": 219,
      "labelStart": "214",
      "labelEnd": "214",
      "words": 325,
      "summary": {
        "text": "Presents Table 2 of LC-mNAAT diagnostic accuracy for pulmonary TB, giving pooled sensitivity and specificity for sputum and subgroups.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "forest plots",
          "heading": false
        },
        {
          "term": "lc-mnaats",
          "heading": false
        },
        {
          "term": "gastric",
          "heading": false
        },
        {
          "term": "plhiv",
          "heading": false
        },
        {
          "term": "pulmonary",
          "heading": false
        }
      ],
      "extract": "214 Findings Table 2 summarises the results for LC-mNAATs for pulmonary TB. Results are presented below with additional forest plots provided in Appendix 2. Table 2. Diagnostic accuracy of LC-mNAATs for pulmonary TB in adults and adolescents Analysis Studies Total (cases) Summary sensitivity (95% CI) Summary specificity (95% CI) PPV (95% CI)* NPV (95% CI)* Detection of pulmonary TB Sputum 26 18297 (4108) 84.1 (78.3",
      "extractCut": true,
      "blocks": [
        "library/10665-381036/blocks/prose-page-219"
      ]
    },
    {
      "id": "page-220",
      "number": null,
      "title": "Page 220",
      "level": 1,
      "pageStart": 220,
      "pageEnd": 220,
      "labelStart": "215",
      "labelEnd": "215",
      "words": 218,
      "summary": {
        "text": "Reports that across 26 studies of sputum, TB-LAMP sensitivity ranged widely and gives the summary estimates, then introduces the analysis in people living with HIV.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "diagnose pulmonary",
          "heading": false
        },
        {
          "term": "respiratory samples",
          "heading": false
        },
        {
          "term": "against microbiological",
          "heading": false
        },
        {
          "term": "lc-mnaats",
          "heading": false
        },
        {
          "term": "microbiological reference",
          "heading": false
        },
        {
          "term": "reference standard",
          "heading": false
        }
      ],
      "extract": "Should LC-mNAATs on respiratory samples be used to diagnose pulmonary TB in adults and adolescents with signs and symptoms of pulmonary TB, against a microbiological reference standard? Twenty-six (18297 participants) studies assessed diagnostic accuracy using sputum specimens. The sensitivities were between 55% and 100% and the specificities were between 70% and 100% (Figure 4). The summary sensitivity (95% CI) was",
      "extractCut": true,
      "blocks": [
        "library/10665-381036/blocks/prose-page-220",
        "library/10665-381036/blocks/figure-img-p220-1"
      ]
    },
    {
      "id": "page-221",
      "number": null,
      "title": "Page 221",
      "level": 1,
      "pageStart": 221,
      "pageEnd": 221,
      "labelStart": "216",
      "labelEnd": "216",
      "words": 240,
      "summary": {
        "text": "Reports a summary sensitivity of about 77% and specificity of about 96% for LC-mNAATs in people living with HIV, and lower sensitivity in those with CD4 counts below 200.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "moderate certainty",
          "heading": false
        },
        {
          "term": "plhiv",
          "heading": false
        },
        {
          "term": "respiratory samples",
          "heading": false
        },
        {
          "term": "pulmonary",
          "heading": false
        },
        {
          "term": "lc-mnaats",
          "heading": false
        },
        {
          "term": "count",
          "heading": false
        }
      ],
      "extract": "Figure 5. Risk of bias and applicability for each study: pulmonary TB detection in PLHIV The sensitivities in the eight studies (2991 participants) included in the meta-analysis ranged between 52% and 100% and the specificities between 27% and 100% (Figure 6). The summary sensitivity (95% CI) was 77.1% (60.8 to 87.9) and the summary specificity was 95.9% (84.9 to 99.0); low certainty (sensitivity) and moderate",
      "extractCut": true,
      "blocks": [
        "library/10665-381036/blocks/prose-page-221",
        "library/10665-381036/blocks/figure-img-p221-1",
        "library/10665-381036/blocks/figure-img-p221-2"
      ]
    },
    {
      "id": "page-222",
      "number": null,
      "title": "Page 222",
      "level": 1,
      "pageStart": 222,
      "pageEnd": 222,
      "labelStart": "217",
      "labelEnd": "217",
      "words": 255,
      "summary": {
        "text": "Part of a web annex systematic review on low-complexity manual nucleic acid amplification tests (LC-mNAATs, TB-LAMP) for TB, giving a forest plot for people with HIV by CD4 count and results for HIV-negative adults and adolescents. Three low-risk studies gave a summary sensitivity of about 77% and specificity of about 99% for pulmonary TB, followed by the start of additional analyses by smear status.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "forest plot",
          "heading": false
        },
        {
          "term": "respiratory samples",
          "heading": false
        },
        {
          "term": "lc-mnaats",
          "heading": false
        },
        {
          "term": "pulmonary",
          "heading": false
        },
        {
          "term": "false",
          "heading": false
        },
        {
          "term": "true",
          "heading": false
        }
      ],
      "extract": "Figure 7. Forest plot of LC-mNAATs for detection of pulmonary TB: PLHIV by CD4 count FN: false negative; FP: false positive; TN: true negative; TP: true positive. Should LC-mNAATs on respiratory samples be used to diagnose pulmonary TB in HIV negative adults and adolescents with signs and symptoms of pulmonary TB, against a microbiological reference standard? Figure 8 summarises the results of the risk of bias and",
      "extractCut": true,
      "blocks": [
        "library/10665-381036/blocks/prose-page-222",
        "library/10665-381036/blocks/figure-img-p222-1",
        "library/10665-381036/blocks/figure-img-p222-2",
        "library/10665-381036/blocks/figure-img-p222-3"
      ]
    },
    {
      "id": "page-223",
      "number": null,
      "title": "Page 223",
      "level": 1,
      "pageStart": 223,
      "pageEnd": 223,
      "labelStart": "218",
      "labelEnd": "218",
      "words": 257,
      "summary": {
        "text": "Reports LC-mNAAT accuracy for pulmonary TB by sputum smear status: in smear-positive people sensitivity was about 96% but specificity only about 44%. For smear-negative people, results per 1000 tested show fewer false positives but more missed cases.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "microbiological reference",
          "heading": false
        },
        {
          "term": "against microbiological",
          "heading": false
        },
        {
          "term": "summary specificity",
          "heading": false
        },
        {
          "term": "summary sensitivity",
          "heading": false
        },
        {
          "term": "lc-mnaat-negative",
          "heading": false
        },
        {
          "term": "sputum specimens",
          "heading": false
        }
      ],
      "extract": "against a microbiological reference standard? Twenty-one (1908 participants) studies evaluated sputum specimens, but specificity was not estimable for five studies. The sensitivities in the remaining 16 studies (1568 participants) included in the meta-analysis were between 64% and 100% and the specificities were between 0% and 100% (Figure 10). The summary sensitivity (95% CI) was 95.9% (92.2 to 97.9) and the",
      "extractCut": true,
      "blocks": [
        "library/10665-381036/blocks/prose-page-223",
        "library/10665-381036/blocks/figure-img-p223-1"
      ]
    },
    {
      "id": "page-224",
      "number": null,
      "title": "Page 224",
      "level": 1,
      "pageStart": 224,
      "pageEnd": 224,
      "labelStart": "219",
      "labelEnd": "219",
      "words": 172,
      "summary": {
        "text": "Gives the forest plot for smear-negative samples and begins the results for extrapulmonary TB, noting unclear risk of bias in two of three studies and introducing the question on lymph node TB.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "lymph node",
          "heading": false
        },
        {
          "term": "microbiological reference",
          "heading": false
        },
        {
          "term": "lc-mnaats",
          "heading": false
        },
        {
          "term": "reference standard",
          "heading": false
        },
        {
          "term": "extrapulmonary",
          "heading": false
        }
      ],
      "extract": "Figure 11. Forest plot of LC-mNAATs for detection of pulmonary TB: smear negative, respiratory samples and microbiological reference standard Studies are sorted on the plot by sensitivity, specificity and study. FN: false negative; FP: false positive; TN: true negative; TP: true positive. Detection of extrapulmonary tuberculosis Methodological quality Of the three studies included for extrapulmonary TB (Figure 12),",
      "extractCut": true,
      "blocks": [
        "library/10665-381036/blocks/prose-page-224",
        "library/10665-381036/blocks/figure-img-p224-1",
        "library/10665-381036/blocks/figure-img-p224-2"
      ]
    },
    {
      "id": "page-225",
      "number": null,
      "title": "Page 225",
      "level": 1,
      "pageStart": 225,
      "pageEnd": 225,
      "labelStart": "220",
      "labelEnd": "220",
      "words": 340,
      "summary": {
        "text": "Reports LC-mNAAT accuracy for lymph node TB on biopsy tissue, with summary sensitivity about 94% and specificity 90% from low-certainty evidence, and illustrates outcomes per 1000 people tested. It also mentions data from aspirate and pus and introduces two small studies on abdominal TB in ascitic fluid.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "lymph node",
          "heading": false
        },
        {
          "term": "ascitic fluid",
          "heading": false
        },
        {
          "term": "cerebrospinal fluid",
          "heading": false
        },
        {
          "term": "microbiological reference",
          "heading": false
        },
        {
          "term": "lc-mnaats",
          "heading": false
        },
        {
          "term": "against microbiological",
          "heading": false
        },
        {
          "term": "forest plot",
          "heading": false
        },
        {
          "term": "reference standard",
          "heading": false
        }
      ],
      "extract": "node TB using lymph node tissue from biopsy and a microbiological reference standard (Figure 13). The estimated sensitivities were between 93% and 100% and specificities were between 88% and 100%. The summary sensitivity (95% CI) was 94.3% (79.8 to 98.6) and the summary specificity was 90.0% (79.5 to 95.4). For illustration at a 10% prevalence, the estimated positive and negative predictive values are 51.2% (30.2 to",
      "extractCut": true,
      "blocks": [
        "library/10665-381036/blocks/prose-page-225",
        "library/10665-381036/blocks/figure-img-p225-1",
        "library/10665-381036/blocks/figure-img-p225-2"
      ]
    },
    {
      "id": "page-226",
      "number": null,
      "title": "Page 226",
      "level": 1,
      "pageStart": 226,
      "pageEnd": 226,
      "labelStart": "221",
      "labelEnd": "221",
      "words": 300,
      "summary": {
        "text": "Reports small-study results for LC-mNAATs in extrapulmonary TB, including abdominal TB in ascitic fluid, pleural TB in pleural fluid and bone or joint TB. It ends introducing a single study on genitourinary TB in urine.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "pleural fluid",
          "heading": false
        },
        {
          "term": "synovial fluid",
          "heading": false
        },
        {
          "term": "microbiological reference",
          "heading": false
        },
        {
          "term": "lc-mnaats",
          "heading": false
        },
        {
          "term": "forest plot",
          "heading": false
        },
        {
          "term": "estimated specificities",
          "heading": false
        },
        {
          "term": "against microbiological",
          "heading": false
        },
        {
          "term": "reference standard",
          "heading": false
        }
      ],
      "extract": "sensitivities were 17% and 100% and estimated specificities were 94% and 95%. Figure 15. Forest plot of LC-mNAATs for detection of abdominal TB in ascitic fluid FN = false negative; FP = false positive; TN = true negative; TP = true positive. Should LC-mNAATs on pleural fluid be used to diagnose pleural TB in adults and adolescents with signs and symptoms of pleural TB, against a microbiological reference standard?",
      "extractCut": true,
      "blocks": [
        "library/10665-381036/blocks/prose-page-226",
        "library/10665-381036/blocks/figure-img-p226-1",
        "library/10665-381036/blocks/figure-img-p226-2",
        "library/10665-381036/blocks/figure-img-p226-3"
      ]
    },
    {
      "id": "page-227",
      "number": null,
      "title": "Page 227",
      "level": 1,
      "pageStart": 227,
      "pageEnd": 227,
      "labelStart": "222",
      "labelEnd": "222",
      "words": 336,
      "summary": {
        "text": "Completes the genitourinary TB result and discusses the review's findings, noting a pooled sensitivity of about 84% and specificity of about 96% for pulmonary TB, lower sensitivity than Xpert MTB/RIF Ultra but similar specificity. It ends with acknowledgements to the study authors who supplied data.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "summary specificity",
          "heading": false
        },
        {
          "term": "rif ultra",
          "heading": false
        },
        {
          "term": "danfack",
          "heading": false
        },
        {
          "term": "mtb rif",
          "heading": false
        },
        {
          "term": "summary sensitivity",
          "heading": false
        },
        {
          "term": "xpert mtb",
          "heading": false
        },
        {
          "term": "odume",
          "heading": false
        },
        {
          "term": "tb-lamp",
          "heading": false
        }
      ],
      "extract": "specificity were 50% and 100%. Figure 18. Forest plot of LC-mNAATs for detection of genitourinary TB in urine FN = false negative; FP = false positive; TN = true negative; TP = true positive. Discussion Our review included 27 studies that assessed pulmonary TB and three studies assessed extrapulmonary TB. The estimated summary sensitivity (95% CI) was 84.1% (78.3 to 88.6) and the summary specificity was 96.1% (94.2",
      "extractCut": true,
      "blocks": [
        "library/10665-381036/blocks/prose-page-227",
        "library/10665-381036/blocks/figure-img-p227-1"
      ]
    },
    {
      "id": "page-228",
      "number": null,
      "title": "Page 228",
      "level": 1,
      "pageStart": 228,
      "pageEnd": 228,
      "labelStart": "223",
      "labelEnd": "223",
      "words": 582,
      "summary": {
        "text": "The reference list of included studies for the adult TB-LAMP review, citing diagnostic accuracy studies from The Gambia, Cambodia, Cameroon, Nigeria and China.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "loop-mediated isothermal",
          "heading": false
        },
        {
          "term": "isothermal amplification",
          "heading": false
        },
        {
          "term": "mediated isothermal",
          "heading": false
        },
        {
          "term": "amplification assay",
          "heading": false
        },
        {
          "term": "pulmonary tuberculosis",
          "heading": false
        },
        {
          "term": "tb-lamp among",
          "heading": false
        },
        {
          "term": "tuberculosis complex",
          "heading": false
        },
        {
          "term": "mycobacterium tuberculosis",
          "heading": false
        }
      ],
      "extract": "References Included studies Bojang AL, Mendy FS, Tientcheu LD, Otu J, Antonio M, Kampmann B, et al. Comparison of TB-LAMP, GeneXpert MTB/RIF and culture for diagnosis of pulmonary tuberculosis in The Gambia. Journal of Infection [Internet]. 2016 Mar 1 [cited 2020 Sep 30];72(3):332–7. Cheng S, Pheng SH, Heng S, Marks GB, Bañuls AL, Mao TE, et al. Evaluation of Loopamp Assay for the Diagnosis of Pulmonary Tuberculosis",
      "extractCut": true,
      "blocks": [
        "library/10665-381036/blocks/prose-page-228"
      ]
    },
    {
      "id": "page-229",
      "number": null,
      "title": "Page 229",
      "level": 1,
      "pageStart": 229,
      "pageEnd": 229,
      "labelStart": "224",
      "labelEnd": "224",
      "words": 593,
      "summary": {
        "text": "Continues the reference list for the adult TB-LAMP review, citing studies from China, multicentre and paediatric evaluations, and GRADE guidance on rating test accuracy evidence.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "loop-mediated isothermal",
          "heading": false
        },
        {
          "term": "isothermal amplification",
          "heading": false
        },
        {
          "term": "mycobacterium tuberculosis",
          "heading": false
        },
        {
          "term": "tb-lamp assay",
          "heading": false
        },
        {
          "term": "pulmonary tuberculosis",
          "heading": false
        },
        {
          "term": "international journal",
          "heading": false
        },
        {
          "term": "detecting mycobacterium",
          "heading": false
        },
        {
          "term": "reddy",
          "heading": false
        }
      ],
      "extract": "Pulmonary Tuberculosis at the County-Level Laboratory in China. Cattamanchi A, editor. PLoS ONE. 2014 May 1;9(5):e94544. Ou X, Wang S, Dong H, Pang Y, Li Q, Xia H, et al. Multicenter evaluation of a real-time loop-mediated isothermal amplification (RealAmp) test for rapid diagnosis of Mycobacterium tuberculosis. Journal of Microbiological Methods. 2016 Oct 1;129:39–43. Ou XC, Li H, Liu DX, Xia H, Ma XG, Wang SH, et",
      "extractCut": true,
      "blocks": [
        "library/10665-381036/blocks/prose-page-229"
      ]
    },
    {
      "id": "page-230",
      "number": null,
      "title": "Page 230",
      "level": 1,
      "pageStart": 230,
      "pageEnd": 230,
      "labelStart": "225",
      "labelEnd": "225",
      "words": 98,
      "summary": {
        "text": "The end of the reference list, citing WHO TB-LAMP policy guidance, the Global tuberculosis report 2023 and a Cochrane review of Xpert Ultra.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "cited mar",
          "heading": false
        },
        {
          "term": "pulmonary tuberculosis",
          "heading": false
        },
        {
          "term": "health organization",
          "heading": false
        },
        {
          "term": "world health",
          "heading": false
        }
      ],
      "extract": "Journal of Clinical Epidemiology. 2020 Jun;122:142–52. World Health Organization. The use of loop-mediated isothermal amplification (TB-LAMP) for the diagnosis of pulmonary tuberculosis: policy guidance [Internet]. iris.who.int. Geneva: World Health Organization; 2016 [cited 2024 Mar 13]. Available from: https://iris.who.int/handle/10665/249154 World Health Organization. Global tuberculosis report 2023 [Internet].",
      "extractCut": true,
      "blocks": [
        "library/10665-381036/blocks/prose-page-230"
      ]
    },
    {
      "id": "page-231",
      "number": null,
      "title": "Page 231",
      "level": 1,
      "pageStart": 231,
      "pageEnd": 231,
      "labelStart": "226",
      "labelEnd": "226",
      "words": 266,
      "summary": {
        "text": "Appendix 1 giving the detailed literature search strategies for the TB-LAMP review in databases such as MEDLINE and Embase.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "lymph node",
          "heading": false
        },
        {
          "term": "loop-mediated isothermal",
          "heading": false
        },
        {
          "term": "resistant tuberculosis",
          "heading": false
        },
        {
          "term": "isothermal amplification",
          "heading": false
        },
        {
          "term": "mycobacterium tuberculosis",
          "heading": false
        },
        {
          "term": "mening",
          "heading": false
        }
      ],
      "extract": "Appendix Appendix 1. Detailed search strategies Ovid MEDLINE(R) ALL <1946 to September 29, 2023> 1 Mycobacterium tuberculosis/ 2 Tuberculosis, Pulmonary/ 3 Extensively Drug-Resistant Tuberculosis/ 4 Tuberculosis, Multidrug-Resistant/ 5 (tuberculosis or TB).tw. 6 ((extrapulmonary or lymph node* or mening* or pulmonary) and TB).ti. or ((extrapulmonary or lymph node* or mening* or pulmonary) and TB).ab. 7 exp",
      "extractCut": true,
      "blocks": [
        "library/10665-381036/blocks/prose-page-231"
      ]
    },
    {
      "id": "page-232",
      "number": null,
      "title": "Page 232",
      "level": 1,
      "pageStart": 232,
      "pageEnd": 232,
      "labelStart": "227",
      "labelEnd": "227",
      "words": 234,
      "summary": {
        "text": "Continues the search strategies, listing queries used in Scopus, ProQuest, the Cochrane Central Register, trial registries and Global Index Medicus.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "loop-mediated isothermal",
          "heading": false
        },
        {
          "term": "isothermal amplification",
          "heading": false
        },
        {
          "term": "mesh descriptor",
          "heading": false
        },
        {
          "term": "title-abs-key",
          "heading": false
        },
        {
          "term": "explode",
          "heading": false
        },
        {
          "term": "tb-lamp",
          "heading": false
        }
      ],
      "extract": "#10 Search: #6 AND #9 Scopus Elsevier ( ( TITLE-ABS-KEY ( loop-mediated AND isothermal AND amplification ) ) OR ( TITLE-ABS-KEY ( loop AND mediated AND isothermal AND amplification ) ) OR ( TITLE-ABS-KEY ( tb-lamp* OR loopamp* ) ) ) AND ( ( TITLE-ABS-KEY ( ( tuberculosis OR tb ) AND ( extrapulmonary OR lymph AND node* OR mening* OR pulmonary ) ) ) OR ( TITLE-ABS-KEY ( ( multidrug AND resistant AND tuberculosis ) OR",
      "extractCut": true,
      "blocks": [
        "library/10665-381036/blocks/prose-page-232"
      ]
    },
    {
      "id": "page-233",
      "number": null,
      "title": "Page 233",
      "level": 1,
      "pageStart": 233,
      "pageEnd": 233,
      "labelStart": "228",
      "labelEnd": "228",
      "words": 111,
      "summary": {
        "text": "Appendix 2 introducing additional forest plots for other specimen types, such as bronchoalveolar lavage and gastric samples, and for laboratory settings.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "forest plot",
          "heading": false
        },
        {
          "term": "ptb pulmonary",
          "heading": false
        },
        {
          "term": "appendix figure",
          "heading": false
        },
        {
          "term": "bal",
          "heading": false
        }
      ],
      "extract": "Appendix 2. Additional forest plots Appendix Figures 1 to 3 summarise currently available data for other sample types and subgroups. Appendix Figure 1. Forest plot of LC-mNAATs for pulmonary TB: BAL, gastric aspirate and gastric lavage specimens Studies are sorted on the plot by study. BAL= bronchoalveolar lavage; FN = false negative; FP = false positive; PTB = pulmonary TB; TN = true negative; TP = true positive.",
      "extractCut": true,
      "blocks": [
        "library/10665-381036/blocks/prose-page-233",
        "library/10665-381036/blocks/figure-img-p233-1",
        "library/10665-381036/blocks/figure-img-p233-2"
      ]
    },
    {
      "id": "page-234",
      "number": null,
      "title": "Page 234",
      "level": 1,
      "pageStart": 234,
      "pageEnd": 234,
      "labelStart": "229",
      "labelEnd": "229",
      "words": 44,
      "summary": {
        "text": "Caption of an appendix forest plot of TB test accuracy for pulmonary TB in high-burden settings.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "plot",
          "heading": false
        },
        {
          "term": "false",
          "heading": false
        },
        {
          "term": "true",
          "heading": false
        }
      ],
      "extract": "Appendix Figure 3. Forest plot of LC-aNAATs for pulmonary TB: high burden setting Studies are sorted on the plot by sensitivity, specificity and study. FN = false negative; FP = false positive; PTB = pulmonary TB; TN = true negative; TP = true positive.",
      "extractCut": false,
      "blocks": [
        "library/10665-381036/blocks/prose-page-234",
        "library/10665-381036/blocks/figure-img-p234-1"
      ]
    },
    {
      "id": "page-235",
      "number": null,
      "title": "Page 235",
      "level": 1,
      "pageStart": 235,
      "pageEnd": 235,
      "labelStart": "230",
      "labelEnd": "230",
      "words": 373,
      "summary": {
        "text": "Summary of findings tables for LC-mNAATs in adults, giving numbers of true and false results per 1000 tested at several prevalence levels with GRADE certainty. Pulmonary TB on respiratory samples is rated high certainty, with the table for people with HIV and explanatory notes on downgrading following.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "false negatives",
          "heading": false
        },
        {
          "term": "false positives",
          "heading": false
        },
        {
          "term": "true negatives",
          "heading": false
        },
        {
          "term": "diagnose ptb",
          "heading": false
        },
        {
          "term": "pooled specificity",
          "heading": false
        },
        {
          "term": "pooled sensitivity",
          "heading": false
        },
        {
          "term": "confidence interval",
          "heading": false
        },
        {
          "term": "respiratory samples",
          "heading": false
        }
      ],
      "extract": "Page 230 of 1168 Appendix 3. Summary of findings tables 1. Should LC-mNAAT on respiratory samples be used to diagnose PTB in adults and adolescents with signs and symptoms of PTB, MRS? Patient or population: adults and adolescents with signs and symptoms of PTB, MRS Pooled sensitivity: 0.84 (95% CI: 0.78 to 0.89) Pooled specificity: 0.96 (95% CI: 0.94 to 0.97) Test result Number of results per 1,000 patients tested",
      "extractCut": true,
      "blocks": [
        "library/10665-381036/blocks/prose-page-235"
      ]
    },
    {
      "id": "page-236",
      "number": null,
      "title": "Page 236",
      "level": 1,
      "pageStart": 236,
      "pageEnd": 236,
      "labelStart": "231",
      "labelEnd": "231",
      "words": 393,
      "summary": {
        "text": "Continues the summary of findings tables, with notes on inconsistency and imprecision and a table for people with HIV with CD4 below 200, rated very low certainty. It begins the table for lymph node TB.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "lymph node",
          "heading": false
        },
        {
          "term": "false negatives",
          "heading": false
        },
        {
          "term": "true positives",
          "heading": false
        },
        {
          "term": "study contributed",
          "heading": false
        },
        {
          "term": "single study",
          "heading": false
        },
        {
          "term": "downgraded",
          "heading": false
        },
        {
          "term": "mrs",
          "heading": false
        },
        {
          "term": "lc-mnaat",
          "heading": false
        }
      ],
      "extract": "Page 231 of 1168 c. The point estimates of individual studies ranged from 27% to 100% and 95% Cis did not overlap for a few studies. We downgraded one level for inconsistency. d. The 95% CI was wide (84.9 to 99.0) for the specificity. The number of participants contributing to the estimation of specificity was large (2531 participants). This was a judgement, and we did not downgrade for imprecision. 3. Should",
      "extractCut": true,
      "blocks": [
        "library/10665-381036/blocks/prose-page-236"
      ]
    },
    {
      "id": "page-237",
      "number": null,
      "title": "Page 237",
      "level": 1,
      "pageStart": 237,
      "pageEnd": 237,
      "labelStart": "232",
      "labelEnd": "232",
      "words": 166,
      "summary": {
        "text": "Completes the summary of findings table for lymph node TB, explaining that the evidence was downgraded two levels for very serious imprecision due to few participants.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "true negatives",
          "heading": false
        },
        {
          "term": "false positives",
          "heading": false
        },
        {
          "term": "confidence limits",
          "heading": false
        },
        {
          "term": "serious imprecision",
          "heading": false
        }
      ],
      "extract": "Page 232 of 1168 Test result Number of results per 1,000 patients tested (95% CI) Number of participants (studies) Certainty of the Evidence (GRADE) Prevalence 2.5% Prevalence 10% Prevalence 20% True negatives 878 (780 to 926) 810 (720 to 855) 720 (640 to 760) 60 (3) ⨁⨁◯◯ Lowb False positives 97 (49 to 195) 90 (45 to 180) 80 (40 to 160) CI: confidence interval Explanations a. There were very few cases (35) with",
      "extractCut": true,
      "blocks": [
        "library/10665-381036/blocks/prose-page-237"
      ]
    },
    {
      "id": "page-238",
      "number": null,
      "title": "Page 238",
      "level": 1,
      "pageStart": 238,
      "pageEnd": 238,
      "labelStart": "233",
      "labelEnd": "233",
      "words": 201,
      "summary": {
        "text": "Summary of findings table for LC-mNAATs on cerebrospinal fluid for TB meningitis, rated very low to low certainty because of inconsistent sensitivity and very few cases.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "serious imprecision",
          "heading": false
        },
        {
          "term": "meningitis",
          "heading": false
        },
        {
          "term": "downgraded",
          "heading": false
        },
        {
          "term": "lowc",
          "heading": false
        },
        {
          "term": "mrs",
          "heading": false
        }
      ],
      "extract": "Page 233 of 1168 5. Should LC-mNAAT on CSF be used to diagnose TB meningitis in adults and adolescents with signs and symptoms of TB meningitis, MRS? Patient or population: adults and adolescents with signs and symptoms of TB meningitis, MRS Range of sensitivities:0.01 to 0.9 Range of specificities:0.97 to 0.99 Test result Number of results per 1,000 patients tested (95% CI) Number of participants (studies)",
      "extractCut": true,
      "blocks": [
        "library/10665-381036/blocks/prose-page-238"
      ]
    },
    {
      "id": "page-239",
      "number": null,
      "title": "Page 239",
      "level": 1,
      "pageStart": 239,
      "pageEnd": 239,
      "labelStart": "234",
      "labelEnd": "234",
      "words": 94,
      "summary": {
        "text": "Title page of Web Annex B.6, a systematic review of LC-mNAATs for detecting pulmonary and extrapulmonary TB in children, listing authors from ICMR, Christian Medical College and the University of Birmingham.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "leeberk raja",
          "heading": false
        },
        {
          "term": "raja inbaraj",
          "heading": false
        },
        {
          "term": "icmr national",
          "heading": false
        },
        {
          "term": "chennai",
          "heading": false
        }
      ],
      "extract": "Page 234 of 1168 Web Annex B.6. LC-mNAATs for detection of pulmonary and extrapulmonary tuberculosis in children: a systematic review of diagnostic accuracy Leeberk Raja Inbaraj1*, Mukesh Kumar Sathyanarayanan1, Jefferson Daniel2, Vignes Anand Srinivasalu1 Adhin Bhaskar1, Katie Scandrett3, Yemisi Takwoingi3 1. ICMR- National Institute for Research in Tuberculosis, Chennai, India 2. Christian Medical College,",
      "extractCut": true,
      "blocks": [
        "library/10665-381036/blocks/prose-page-239"
      ]
    },
    {
      "id": "page-240",
      "number": null,
      "title": "Page 240",
      "level": 1,
      "pageStart": 240,
      "pageEnd": 240,
      "labelStart": "235",
      "labelEnd": "235",
      "words": 593,
      "summary": {
        "text": "Gives the background to the paediatric TB-LAMP review, citing WHO estimates of 1.3 million children with TB in 2022 and the difficulty of diagnosis in children. It describes the TB-LAMP test, which takes about an hour in three steps and gives no information on drug resistance.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "smear microscopy",
          "heading": false
        },
        {
          "term": "amplification process",
          "heading": false
        },
        {
          "term": "tb-lamp",
          "heading": false
        },
        {
          "term": "primers",
          "heading": false
        },
        {
          "term": "ongoing transmission",
          "heading": false
        },
        {
          "term": "lc-mnaat",
          "heading": false
        },
        {
          "term": "minutes",
          "heading": false
        },
        {
          "term": "pulmonary",
          "heading": false
        }
      ],
      "extract": "Page 235 of 1168 Background The World Health Organization (WHO) estimated 1.3 million children (aged 0–14 years) were affected by tuberculosis (TB) in 2022. Globally, paediatric TB contributed to 16% of deaths among HIV-negative children in the same year. Multiple factors contribute to diagnostic delays and the consequent rise in incidence and mortality among children. The unique pathophysiology and clinical",
      "extractCut": true,
      "blocks": [
        "library/10665-381036/blocks/prose-page-240"
      ]
    },
    {
      "id": "page-241",
      "number": null,
      "title": "Page 241",
      "level": 1,
      "pageStart": 241,
      "pageEnd": 241,
      "labelStart": "236",
      "labelEnd": "236",
      "words": 447,
      "summary": {
        "text": "Sets out the review's objectives, to assess TB-LAMP accuracy by disease site in children and explore heterogeneity, and refers to a generic protocol informing the 2024 WHO guideline update. It describes the search methods and eligibility criteria, including children under 10 and respiratory specimens.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "unpublished studies",
          "heading": false
        },
        {
          "term": "electronic searches",
          "heading": false
        },
        {
          "term": "diagnostic accuracy",
          "heading": false
        },
        {
          "term": "review authors",
          "heading": false
        },
        {
          "term": "dissertations",
          "heading": false
        },
        {
          "term": "searched",
          "heading": false
        },
        {
          "term": "clinicaltrials",
          "heading": false
        },
        {
          "term": "ovid",
          "heading": false
        }
      ],
      "extract": "Page 236 of 1168 drugs. Objectives 1. To assess the diagnostic accuracy of LC-mNAATs for detection of pulmonary and extrapulmonary TB by the site of disease in children with presumptive TB. 2. To investigate the potential sources of heterogeneity. For detection of pulmonary TB, we aimed to investigate the effect of smear microscopy status (smear positive/smear negative), HIV status (positive/negative), and the",
      "extractCut": true,
      "blocks": [
        "library/10665-381036/blocks/prose-page-241"
      ]
    },
    {
      "id": "page-242",
      "number": null,
      "title": "Page 242",
      "level": 1,
      "pageStart": 242,
      "pageEnd": 242,
      "labelStart": "237",
      "labelEnd": "237",
      "words": 495,
      "summary": {
        "text": "Continues the methods, covering specimen types for extrapulmonary TB, exclusion criteria and handling of mixed-age data. It defines the index test, the culture and composite reference standards and the use of GRADE to assess certainty.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "study authors",
          "heading": false
        },
        {
          "term": "composite reference",
          "heading": false
        },
        {
          "term": "reference standard",
          "heading": false
        },
        {
          "term": "culture methods",
          "heading": false
        },
        {
          "term": "review authors",
          "heading": false
        },
        {
          "term": "index test",
          "heading": false
        },
        {
          "term": "mks",
          "heading": false
        },
        {
          "term": "primary study",
          "heading": false
        }
      ],
      "extract": "Page 237 of 1168 aspirate, nasopharyngeal aspirate). For extrapulmonary TB, we included non-respiratory specimens such as cerebrospinal fluid (CSF), pleural fluid, lymph node aspirate or tissue. We considered blood for disseminated TB. We only included studies that provided at least five specimens for a given form of extrapulmonary TB. We excluded studies designed to find people with active TB in community settings.",
      "extractCut": true,
      "blocks": [
        "library/10665-381036/blocks/prose-page-242"
      ]
    },
    {
      "id": "page-243",
      "number": null,
      "title": "Page 243",
      "level": 1,
      "pageStart": 243,
      "pageEnd": 243,
      "labelStart": "238",
      "labelEnd": "238",
      "words": 74,
      "summary": {
        "text": "Reports the search results: 1138 unique records screened, 151 full texts reviewed and four studies included for pulmonary TB, one also covering extrapulmonary TB.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "articles",
          "heading": false
        },
        {
          "term": "screening",
          "heading": false
        },
        {
          "term": "page",
          "heading": true
        }
      ],
      "extract": "Page 238 of 1168 Results of the search We identified 2806 research articles for screening from searches of electronic sources and screened the titles and abstracts of 1138 unique articles. Of the 1138 articles, we excluded 988. We performed full-text screening of 151 articles. We included four studies for pulmonary TB and one of them for both pulmonary and extrapulmonary TB. Figure 1 shows the flow of studies",
      "extractCut": true,
      "blocks": [
        "library/10665-381036/blocks/prose-page-243"
      ]
    },
    {
      "id": "page-244",
      "number": null,
      "title": "Page 244",
      "level": 1,
      "pageStart": 244,
      "pageEnd": 244,
      "labelStart": "239",
      "labelEnd": "239",
      "words": 277,
      "summary": {
        "text": "A study flow diagram for the paediatric TB-LAMP review, showing records identified, screened and excluded with reasons such as case-control design or in-house kits.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "records removed",
          "heading": false
        },
        {
          "term": "reports excluded",
          "heading": false
        },
        {
          "term": "reports sought",
          "heading": false
        },
        {
          "term": "reports assessed",
          "heading": false
        },
        {
          "term": "records identified",
          "heading": false
        },
        {
          "term": "unknown age",
          "heading": false
        },
        {
          "term": "satisfied",
          "heading": false
        }
      ],
      "extract": "Page 239 of 1168 Figure.1 Study flow diagram *One study contributed to both pulmonary TB (PTB) and extrapulmonary TB (EPTB). DTA= diagnostic test accuracy. Records identified from: Databases (n =2806) Registers (n = 0) Records removed before screening: Duplicate records removed (n = 1668 ) Records marked as ineligible by automation tools (n = 0) Records removed for other reasons (n = 0) Records screened (n = 1138)",
      "extractCut": true,
      "blocks": [
        "library/10665-381036/blocks/prose-page-244"
      ]
    },
    {
      "id": "page-245",
      "number": null,
      "title": "Page 245",
      "level": 1,
      "pageStart": 245,
      "pageEnd": 245,
      "labelStart": "240",
      "labelEnd": "240",
      "words": 270,
      "summary": {
        "text": "Describes the four included cross-sectional studies from The Gambia, Thailand, India and Cameroon, with a table of their reference standards, settings and specimen types. It notes risk of bias concerns and high applicability concern for one inpatient study.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "gastric aspirate",
          "heading": false
        },
        {
          "term": "gastric lavage",
          "heading": false
        },
        {
          "term": "nasopharyngeal aspirate",
          "heading": false
        },
        {
          "term": "expectorated sputum",
          "heading": false
        },
        {
          "term": "induced sputum",
          "heading": false
        },
        {
          "term": "mgit",
          "heading": false
        },
        {
          "term": "promsena",
          "heading": false
        },
        {
          "term": "reference standard",
          "heading": false
        }
      ],
      "extract": "Page 240 of 1168 Characteristics of included studies Key characteristics of the four included studies for detection of pulmonary TB are described in Table 1. One of the studies also assessed extrapulmonary TB (Promsena 2022). All studies were cross- sectional in design and assessed TB-LAMP using a microbiological reference standard in central laboratories. No study used a composite reference standard. None of the",
      "extractCut": true,
      "blocks": [
        "library/10665-381036/blocks/prose-page-245"
      ]
    },
    {
      "id": "page-246",
      "number": null,
      "title": "Page 246",
      "level": 1,
      "pageStart": 246,
      "pageEnd": 246,
      "labelStart": "241",
      "labelEnd": "241",
      "words": 145,
      "summary": {
        "text": "Introduces findings for the paediatric review, with sensitivities from 50% to 100% and specificities from 67% to 100% across four studies; no meta-analysis was done because of mixed specimens and sparse data. A risk of bias figure is partly extracted as garbled text.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "ence stan",
          "heading": false
        },
        {
          "term": "atient selection",
          "heading": false
        },
        {
          "term": "test ence",
          "heading": false
        },
        {
          "term": "specimen types",
          "heading": false
        }
      ],
      "extract": "Page 241 of 1168 Figure 2. Risk of bias and applicability summary for each study Findings Main results are presented below with additional forest plots provided in Appendix 2 and summary of findings tables in Appendix 3. Figure 3 summarises the sensitivity and specificity of the studies included across and for each specimen type. Four studies (314 participants) assessed diagnostic accuracy using different specimen",
      "extractCut": true,
      "blocks": [
        "library/10665-381036/blocks/prose-page-246",
        "library/10665-381036/blocks/figure-vfig-p246"
      ]
    },
    {
      "id": "page-247",
      "number": null,
      "title": "Page 247",
      "level": 1,
      "pageStart": 247,
      "pageEnd": 247,
      "labelStart": "242",
      "labelEnd": "242",
      "words": 803,
      "summary": {
        "text": "Gives the forest plot by specimen type and reports that three studies on respiratory samples showed sensitivities of 60–100% and specificities of 95–100%, with very low to low certainty. Results for stool and other specimens follow. Much of the forest plot data was extracted as garbled text with missing letters.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "aspirate tudy",
          "heading": false
        },
        {
          "term": "ensitivity",
          "heading": false
        },
        {
          "term": "pecificity",
          "heading": false
        },
        {
          "term": "gastric aspirate",
          "heading": false
        },
        {
          "term": "tracheal aspirate",
          "heading": false
        },
        {
          "term": "sena",
          "heading": false
        },
        {
          "term": "esti",
          "heading": false
        },
        {
          "term": "diagnose pulmonary",
          "heading": false
        }
      ],
      "extract": "Page 242 of 1168 Figure 3. Forest plot of LC-mNAATs for detection of pulmonary TB by specimen type BAL= bronchoalveolar lavage; FN: false negative; FP: false positive; NPA = nasopharyngeal aspirate; PTB = pulmonary TB; TN: true negative; TP: true positive. Should LC-mNAATs on respiratory samples be used to diagnose pulmonary TB in children with signs and symptoms of pulmonary TB, against a microbiological reference",
      "extractCut": true,
      "blocks": [
        "library/10665-381036/blocks/prose-page-247"
      ]
    },
    {
      "id": "page-248",
      "number": null,
      "title": "Page 248",
      "level": 1,
      "pageStart": 248,
      "pageEnd": 248,
      "labelStart": "243",
      "labelEnd": "243",
      "words": 340,
      "summary": {
        "text": "Reports paediatric TB-LAMP results for gastric aspirate, tracheal aspirate and nasopharyngeal aspirate, mostly from single small studies. It then introduces extrapulmonary TB results and their quality assessment.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "detecting pulmonary",
          "heading": false
        },
        {
          "term": "microbiological reference",
          "heading": false
        },
        {
          "term": "diagnose pulmonary",
          "heading": false
        },
        {
          "term": "against microbiological",
          "heading": false
        },
        {
          "term": "nasopharyngeal aspirate",
          "heading": false
        },
        {
          "term": "reference standard",
          "heading": false
        },
        {
          "term": "lc-mnaats",
          "heading": false
        },
        {
          "term": "methodological quality",
          "heading": false
        }
      ],
      "extract": "Page 243 of 1168 children with signs and symptoms of pulmonary TB, against a microbiological reference standard? Three studies (176 participants including 14 with pulmonary TB) assessed the accuracy of LC- mNAATs for detecting pulmonary TB using gastric aspirate and a microbiological reference standard (Figure 3). Sensitivity was not estimable for two studies and was 64% in the third study. The specificities were",
      "extractCut": true,
      "blocks": [
        "library/10665-381036/blocks/prose-page-248"
      ]
    },
    {
      "id": "page-249",
      "number": null,
      "title": "Page 249",
      "level": 1,
      "pageStart": 249,
      "pageEnd": 249,
      "labelStart": "244",
      "labelEnd": "244",
      "words": 257,
      "summary": {
        "text": "Reports a single small study of TB-LAMP on lymph node tissue in children and discusses that the evidence is limited by few, small studies, calling for adequately powered research. Acknowledgements and a partly garbled forest plot follow.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "lymph node",
          "heading": false
        },
        {
          "term": "node tissue",
          "heading": false
        },
        {
          "term": "ensitivity",
          "heading": false
        },
        {
          "term": "pecificity",
          "heading": false
        },
        {
          "term": "lc-mnaats",
          "heading": false
        },
        {
          "term": "microbiological reference",
          "heading": false
        },
        {
          "term": "reference standard",
          "heading": false
        }
      ],
      "extract": "Page 244 of 1168 Figure 5. Risk of bias and applicability summary for detection of extrapulmonary TB Review authors' judgements about each domain presented per study. Findings Should LC-mNAATs be used to diagnose lymph node TB in lymph node tissue in children with signs and symptoms of lymph node TB, against a microbiological reference standard? One study (nine participants) assessed the accuracy of LC-mNAATs for",
      "extractCut": true,
      "blocks": [
        "library/10665-381036/blocks/prose-page-249",
        "library/10665-381036/blocks/figure-img-p249-1"
      ]
    },
    {
      "id": "page-250",
      "number": null,
      "title": "Page 250",
      "level": 1,
      "pageStart": 250,
      "pageEnd": 250,
      "labelStart": "245",
      "labelEnd": "245",
      "words": 383,
      "summary": {
        "text": "The reference list for the paediatric TB-LAMP review, citing included studies from The Gambia, Cameroon, Thailand and India and background literature on childhood TB diagnosis.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "loop-mediated isothermal",
          "heading": false
        },
        {
          "term": "childhood tuberculosis",
          "heading": false
        },
        {
          "term": "pulmonary tuberculosis",
          "heading": false
        },
        {
          "term": "isothermal amplification",
          "heading": false
        },
        {
          "term": "pubmed",
          "heading": false
        },
        {
          "term": "accessed december",
          "heading": false
        },
        {
          "term": "infectious diseases",
          "heading": false
        },
        {
          "term": "doi",
          "heading": false
        }
      ],
      "extract": "Page 245 of 1168 References Included studies Bojang AL, Mendy FS, Tientcheu LD, Otu J, Antonio M, Kampmann B, et al. Comparison of TB-LAMP, GeneXpert MTB/RIF and culture for diagnosis of pulmonary tuberculosis in The Gambia. Journal of Infection. 2016 Mar;72(3):332-7. doi: 10.1016/j.jinf.2015.11.011. Epub 2015 Dec 24. PMID: 26724771 Donfack VD et al. Performance Evaluation of TB-LAMP in children. 2024 (Unpublished)",
      "extractCut": true,
      "blocks": [
        "library/10665-381036/blocks/prose-page-250"
      ]
    },
    {
      "id": "page-251",
      "number": null,
      "title": "Page 251",
      "level": 1,
      "pageStart": 251,
      "pageEnd": 251,
      "labelStart": "246",
      "labelEnd": "246",
      "words": 268,
      "summary": {
        "text": "Appendix 1 giving detailed search strategies for the paediatric TB-LAMP review in MEDLINE, Embase and Web of Science.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "lymph node",
          "heading": false
        },
        {
          "term": "loop-mediated isothermal",
          "heading": false
        },
        {
          "term": "resistant tuberculosis",
          "heading": false
        },
        {
          "term": "isothermal amplification",
          "heading": false
        },
        {
          "term": "detailed search",
          "heading": false
        },
        {
          "term": "mycobacterium tuberculosis",
          "heading": false
        }
      ],
      "extract": "Page 246 of 1168 Appendix Appendix 1. Detailed search strategies Detailed search strategies Ovid MEDLINE(R) ALL <1946 to September 29, 2023> 1 Mycobacterium tuberculosis/ 2 Tuberculosis, Pulmonary/ 3 Extensively Drug-Resistant Tuberculosis/ 4 Tuberculosis, Multidrug-Resistant/ 5 (tuberculosis or TB).tw. 6 ((extrapulmonary or lymph node* or mening* or pulmonary) and TB).ti. or ((extrapulmonary or lymph node* or",
      "extractCut": true,
      "blocks": [
        "library/10665-381036/blocks/prose-page-251"
      ]
    },
    {
      "id": "page-252",
      "number": null,
      "title": "Page 252",
      "level": 1,
      "pageStart": 252,
      "pageEnd": 252,
      "labelStart": "247",
      "labelEnd": "247",
      "words": 243,
      "summary": {
        "text": "Continues the search strategies, listing queries in Scopus, ProQuest, the Cochrane Central Register, trial registries and Global Index Medicus.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "loop-mediated isothermal",
          "heading": false
        },
        {
          "term": "isothermal amplification",
          "heading": false
        },
        {
          "term": "mesh descriptor",
          "heading": false
        },
        {
          "term": "title-abs-key",
          "heading": false
        },
        {
          "term": "explode",
          "heading": false
        },
        {
          "term": "tb-lamp",
          "heading": false
        }
      ],
      "extract": "Page 247 of 1168 #9 Search: #7 OR #8 #10 Search: #6 AND #9 Scopus Elseviers ( ( TITLE-ABS-KEY ( loop-mediated AND isothermal AND amplification ) ) OR ( TITLE-ABS-KEY ( loop AND mediated AND isothermal AND amplification ) ) OR ( TITLE-ABS-KEY ( tb-lamp* OR loopamp* ) ) ) AND ( ( TITLE-ABS-KEY ( ( tuberculosis OR tb ) AND ( extrapulmonary OR lymph AND node* OR mening* OR pulmonary ) ) ) OR ( TITLE-ABS-KEY ( (",
      "extractCut": true,
      "blocks": [
        "library/10665-381036/blocks/prose-page-252"
      ]
    },
    {
      "id": "page-253",
      "number": null,
      "title": "Page 253",
      "level": 1,
      "pageStart": 253,
      "pageEnd": 253,
      "labelStart": "248",
      "labelEnd": "248",
      "words": 1032,
      "summary": {
        "text": "Appendix forest plots of paediatric TB-LAMP accuracy by age group and respiratory specimen type. The plot data was extracted as garbled text with missing letters and is largely unreadable.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "npa tudy",
          "heading": false
        },
        {
          "term": "lavage tudy",
          "heading": false
        },
        {
          "term": "aspirate tudy",
          "heading": false
        },
        {
          "term": "sputum tudy",
          "heading": false
        },
        {
          "term": "ensitivity",
          "heading": false
        },
        {
          "term": "pecificity",
          "heading": false
        },
        {
          "term": "esti",
          "heading": false
        }
      ],
      "extract": "Page 248 of 1168 Appendix 2. Additional forest plots Appendix Figures 1 to 3 summarise available data for different subgroups. Appendix Figure 1. Forest plot of LC-mNAATs for pulmonary TB by age group for respiratory specimen types T A P for PT , 1 year, sputum tudy TP FP FN TN ensitivity (95% CI) pecificity (95% CI) ensitivity (95% CI) pecificity (95% CI) a a 2021 0 0 0 2 ot esti a le 1 00 0 16 1 00 0 0 2 0 4 0 6 0",
      "extractCut": true,
      "blocks": [
        "library/10665-381036/blocks/prose-page-253"
      ]
    },
    {
      "id": "page-254",
      "number": null,
      "title": "Page 254",
      "level": 1,
      "pageStart": 254,
      "pageEnd": 254,
      "labelStart": "249",
      "labelEnd": "249",
      "words": 293,
      "summary": {
        "text": "Appendix forest plots of paediatric TB-LAMP accuracy by age group for stool and by HIV status. Much of the plot data was extracted as garbled text.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "stool tudy",
          "heading": false
        },
        {
          "term": "ensitivity",
          "heading": false
        },
        {
          "term": "pecificity",
          "heading": false
        },
        {
          "term": "ptb pulmonary",
          "heading": false
        },
        {
          "term": "npa nasopharyngeal",
          "heading": false
        }
      ],
      "extract": "Page 249 of 1168 BAL= bronchoalveolar lavage; FN: false negative; FP: false positive; NPA = nasopharyngeal aspirate; PTB = pulmonary TB; TN: true negative; TP: true positive. Appendix Figure 2. Forest plot of LC-mNAATs for pulmonary TB by age group for stool specimen type FN: false negative; FP: false positive; PTB = pulmonary TB; TN: true negative; TP: true positive. Appendix Figure 3. Forest plot of LC-mNAATs for",
      "extractCut": true,
      "blocks": [
        "library/10665-381036/blocks/prose-page-254",
        "library/10665-381036/blocks/figure-img-p254-1"
      ]
    },
    {
      "id": "page-255",
      "number": null,
      "title": "Page 255",
      "level": 1,
      "pageStart": 255,
      "pageEnd": 255,
      "labelStart": "250",
      "labelEnd": "250",
      "words": 433,
      "summary": {
        "text": "Summary of findings tables for TB-LAMP in children, giving true and false results per 1000 tested at different prevalence levels, with very low to moderate certainty and notes on downgrading.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "diagnose ptb",
          "heading": false
        },
        {
          "term": "false negatives",
          "heading": false
        },
        {
          "term": "true negatives",
          "heading": false
        },
        {
          "term": "false positives",
          "heading": false
        },
        {
          "term": "serious imprecision",
          "heading": false
        },
        {
          "term": "single study",
          "heading": false
        },
        {
          "term": "confidence interval",
          "heading": false
        },
        {
          "term": "tuberculosis contributing",
          "heading": false
        }
      ],
      "extract": "250 Appendix 3. Summary of findings tables 1. Should LC-mNAAT on respiratory samples be used to diagnose PTB in children with signs and symptoms of PTB, MRS? Patient or population: Children with signs and symptoms of PTB, MRS Range of sensitivities: 0.60 to 0.99 Range of specificities: 0.95 to 0.99 Test result Number of results per 1,000 patients tested (95% CI) Number of participants (studies) Certainty of the",
      "extractCut": true,
      "blocks": [
        "library/10665-381036/blocks/prose-page-255"
      ]
    },
    {
      "id": "page-256",
      "number": null,
      "title": "Page 256",
      "level": 1,
      "pageStart": 256,
      "pageEnd": 256,
      "labelStart": "251",
      "labelEnd": "251",
      "words": 49,
      "summary": {
        "text": "Explanatory notes completing the summary of findings table, citing downgrading for indirectness, inconsistency and imprecision.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "downgraded",
          "heading": false
        },
        {
          "term": "serious",
          "heading": false
        },
        {
          "term": "level",
          "heading": false
        }
      ],
      "extract": "251 tuberculosis burden country. We downgraded one level for indirectness due to applicability concerns in other settings. b. The study had a wide 95% CI (59-100%) for sensitivity. We downgraded one level for serious inconsistency. c. Too few children with pulmonary tuberculosis. We downgraded one level for serious imprecision.",
      "extractCut": false,
      "blocks": [
        "library/10665-381036/blocks/prose-page-256"
      ]
    },
    {
      "id": "page-257",
      "number": null,
      "title": "Page 257",
      "level": 1,
      "pageStart": 257,
      "pageEnd": 257,
      "labelStart": "252",
      "labelEnd": "252",
      "words": 424,
      "summary": {
        "text": "Title page of Web Annex B.7, a systematic review of parallel use of automated nucleic acid amplification tests on respiratory samples and stool, with or without urine LF-LAM, to detect pulmonary TB in children, listing authors and affiliations.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "medicine odense",
          "heading": false
        },
        {
          "term": "mcgill university",
          "heading": false
        },
        {
          "term": "southern denmark",
          "heading": false
        },
        {
          "term": "cochrane denmark",
          "heading": false
        },
        {
          "term": "denmark centre",
          "heading": false
        },
        {
          "term": "lmu university",
          "heading": false
        },
        {
          "term": "brittney sweetser",
          "heading": false
        },
        {
          "term": "university hospital",
          "heading": false
        }
      ],
      "extract": "252 Web Annex B.7. Parallel use of low-complexity automated nucleic acid amplification tests on respiratory samples and stool with or without lateral flow urine lipoarabinomannan assays to detect pulmonary tuberculosis disease in children Laura Olbrich*, Stephanie Bjerrum, Bada Yang, Hayley Poore, Alia Razid, Brittney Sweetser, Johanna Åhsberg, Mathias Weis Damkjær, Alexander Kay, Andreas Lundh, Ruvandhi",
      "extractCut": true,
      "blocks": [
        "library/10665-381036/blocks/prose-page-257"
      ]
    },
    {
      "id": "page-258",
      "number": null,
      "title": "Page 258",
      "level": 1,
      "pageStart": 258,
      "pageEnd": 258,
      "labelStart": "253",
      "labelEnd": "253",
      "words": 534,
      "summary": {
        "text": "Begins the executive summary of the review of parallel TB testing in children, explaining that automated NAATs and urine LF-LAM have mostly been assessed separately though used together in practice. It sets out the questions and reports that parallel testing of respiratory samples and stool increased sensitivity with a small loss of specificity.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "respiratory samples",
          "heading": false
        },
        {
          "term": "parallel testing",
          "heading": false
        },
        {
          "term": "percentage points",
          "heading": false
        },
        {
          "term": "pulmonary tuberculosis",
          "heading": false
        },
        {
          "term": "tuberculosis disease",
          "heading": false
        },
        {
          "term": "cri",
          "heading": false
        },
        {
          "term": "diagnostic accuracy",
          "heading": false
        },
        {
          "term": "stool",
          "heading": false
        }
      ],
      "extract": "253 EXECUTIVE SUMMARY Background Low complexity automated nucleic acid amplification tests (LC-aNAATs) are part of the molecular World Health Organization (WHO)-recommended rapid diagnostics widely used to diagnose tuberculosis disease. They are recommended as the first test for symptomatic children presenting with presumptive tuberculosis disease. The lateral flow urine lipoarabinomannan (LF-LAM) antigen test is",
      "extractCut": true,
      "blocks": [
        "library/10665-381036/blocks/prose-page-258"
      ]
    },
    {
      "id": "page-259",
      "number": null,
      "title": "Page 259",
      "level": 1,
      "pageStart": 259,
      "pageEnd": 259,
      "labelStart": "254",
      "labelEnd": "254",
      "words": 700,
      "summary": {
        "text": "Continues the executive summary with pooled accuracy for parallel respiratory and stool testing against a composite reference standard and results for children with HIV. It concludes that parallel testing improves sensitivity and may be most beneficial in high-prevalence settings, with greater risk of false positives and overtreatment where prevalence is low.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "percentage points",
          "heading": false
        },
        {
          "term": "stool alone",
          "heading": false
        },
        {
          "term": "respiratory samples",
          "heading": false
        },
        {
          "term": "parallel testing",
          "heading": false
        },
        {
          "term": "cri",
          "heading": false
        },
        {
          "term": "points lower",
          "heading": false
        },
        {
          "term": "pooled specificity",
          "heading": false
        },
        {
          "term": "points higher",
          "heading": false
        }
      ],
      "extract": "254 participant, tuberculosis prevalence 40.9% [1,464/3,579]), the estimated diagnostic accuracy of the parallel use of LC-aNAAT on respiratory samples and stool had a pooled sensitivity of 29.0% (95% CrI 17.3 to 44.7) and a pooled specificity of 99.1% (95% CrI 96.1 to 99.8). Compared to LC-aNAAT on respiratory samples alone, parallel testing had 4.7 (95% CrI 2.1 to 8.9) percentage points higher sensitivity and -0.5",
      "extractCut": true,
      "blocks": [
        "library/10665-381036/blocks/prose-page-259"
      ]
    },
    {
      "id": "page-260",
      "number": null,
      "title": "Page 260",
      "level": 1,
      "pageStart": 260,
      "pageEnd": 260,
      "labelStart": "255",
      "labelEnd": "255",
      "words": 256,
      "summary": {
        "text": "Discusses that the sensitivity gain from parallel testing was smaller in children with HIV and that adding urine LF-LAM increased sensitivity further. It notes LF-LAM may be the only test available in some settings and that building capacity or referral for molecular testing should be considered.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "parallel test",
          "heading": false
        },
        {
          "term": "incremental increase",
          "heading": false
        },
        {
          "term": "lc-anaat",
          "heading": false
        },
        {
          "term": "lf-lam",
          "heading": false
        },
        {
          "term": "chiv",
          "heading": false
        },
        {
          "term": "test strategy",
          "heading": false
        },
        {
          "term": "sensitivity",
          "heading": false
        },
        {
          "term": "stool",
          "heading": false
        }
      ],
      "extract": "255 recommendation to consider repeat molecular testing in children if the pre-test probability of pulmonary TB is 5% or more. Among CHIV, the incremental increase in sensitivity of parallel stool and respiratory LC-aNAAT was lower than among children without HIV. This likely reflects the lower sensitivity in general of molecular TB testing in people living with HIV given their paucibacillary disease. The urine",
      "extractCut": true,
      "blocks": [
        "library/10665-381036/blocks/prose-page-260"
      ]
    },
    {
      "id": "page-261",
      "number": null,
      "title": "Page 261",
      "level": 1,
      "pageStart": 261,
      "pageEnd": 261,
      "labelStart": "256",
      "labelEnd": "256",
      "words": 386,
      "summary": {
        "text": "Describes childhood TB as the review's target condition, with about 1.2 million cases in children annually and high mortality from missed diagnosis. It explains the limits of clinical and radiographic diagnosis and outlines WHO-recommended rapid tests, with a figure summarising tests by specimen type.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "tuberculosis disease",
          "heading": false
        },
        {
          "term": "health organization",
          "heading": false
        },
        {
          "term": "world health",
          "heading": false
        },
        {
          "term": "mwrd",
          "heading": false
        },
        {
          "term": "chiv",
          "heading": false
        },
        {
          "term": "children",
          "heading": false
        },
        {
          "term": "kay",
          "heading": false
        },
        {
          "term": "dependent",
          "heading": false
        }
      ],
      "extract": "256 1. BACKGROUND 1.1 Target condition being diagnosed Of the approximately 10 million annual tuberculosis cases worldwide, an estimated 1.2 million occur in children [World Health Organization 2022a]. Tuberculosis remains among the top ten causes of mortality in children, accounting for 14% and 11% of tuberculosis-related deaths in HIV-negative people and people with HIV, respectively, largely due to missed",
      "extractCut": true,
      "blocks": [
        "library/10665-381036/blocks/prose-page-261"
      ]
    },
    {
      "id": "page-262",
      "number": null,
      "title": "Page 262",
      "level": 1,
      "pageStart": 262,
      "pageEnd": 262,
      "labelStart": "257",
      "labelEnd": "257",
      "words": 294,
      "summary": {
        "text": "Describes clinical scores and the treatment decision algorithms recommended by WHO in 2022, which favour sensitivity over specificity, and the need for better tests. It defines the parallel testing strategy and introduces the two index tests.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "stool samples",
          "heading": false
        },
        {
          "term": "decision algorithms",
          "heading": false
        },
        {
          "term": "index tests",
          "heading": false
        },
        {
          "term": "respiratory",
          "heading": false
        },
        {
          "term": "health organization",
          "heading": false
        },
        {
          "term": "world health",
          "heading": false
        },
        {
          "term": "lc-anaat",
          "heading": false
        },
        {
          "term": "treatment decision",
          "heading": false
        }
      ],
      "extract": "257 Several clinical scores have been proposed to aid in establishing a diagnosis, especially at lower levels of health care where most children present [World Health Organization 2018]. In 2022, the WHO recommended the use of treatment decision algorithms for the interim, with evidence of its performance to be reviewed in 2024 [World Health Organization 2022b]. To be broadly applicable across a range of health care",
      "extractCut": true,
      "blocks": [
        "library/10665-381036/blocks/prose-page-262",
        "library/10665-381036/blocks/figure-img-p262-1"
      ]
    },
    {
      "id": "page-263",
      "number": null,
      "title": "Page 263",
      "level": 1,
      "pageStart": 263,
      "pageEnd": 263,
      "labelStart": "258",
      "labelEnd": "258",
      "words": 625,
      "summary": {
        "text": "Describes the automated NAATs assessed, including Xpert MTB/RIF and Ultra, Truenat, STANDARD M10 and IRON-qPCR, and the only commercial LF-LAM test. It explains methods for processing stool samples, such as the simple one-step and sucrose flotation methods.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "genexpert mtb",
          "heading": false
        },
        {
          "term": "truenat mtb",
          "heading": false
        },
        {
          "term": "mtb rif",
          "heading": false
        },
        {
          "term": "stool processing",
          "heading": false
        },
        {
          "term": "rif ultra",
          "heading": false
        },
        {
          "term": "xpert mtb",
          "heading": false
        },
        {
          "term": "gastric aspirate",
          "heading": false
        },
        {
          "term": "molbio diagnostics",
          "heading": false
        }
      ],
      "extract": "258 urine. LC-aNAAT includes the Xpert MTB/RIF and Xpert MTB/RIF Ultra (Cepheid, Sunnyvale, United States of America [USA]); Truenat MTB and MTB Plus (Molbio Diagnostics, Goa, India); STANDARD M10 (SD Biosensor, Republic of Korea); and IRON-qPCR (BIONEER, Republic of Korea). For LF-LAM, Determine TB LAM Ag (DetermineTM TB LAM Ag; Abbott, Chicago, IL, USA) is currently the only commercially available LF-LAM test.",
      "extractCut": true,
      "blocks": [
        "library/10665-381036/blocks/prose-page-263"
      ]
    },
    {
      "id": "page-264",
      "number": null,
      "title": "Page 264",
      "level": 1,
      "pageStart": 264,
      "pageEnd": 264,
      "labelStart": "259",
      "labelEnd": "259",
      "words": 638,
      "summary": {
        "text": "Describes the stool processing kit method and a head-to-head comparison of stool methods with similar sensitivity, then explains how the urine LF-LAM test detects a mycobacterial cell wall component. It argues there may be added value in combining WHO-recommended rapid tests for children with and without HIV.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "lf-lam test",
          "heading": false
        },
        {
          "term": "lf-lam testing",
          "heading": false
        },
        {
          "term": "extrapulmonary tuberculosis",
          "heading": false
        },
        {
          "term": "tuberculosis disease",
          "heading": false
        },
        {
          "term": "respiratory specimens",
          "heading": false
        },
        {
          "term": "diagnostic accuracy",
          "heading": false
        },
        {
          "term": "bjerrum",
          "heading": false
        },
        {
          "term": "lam",
          "heading": false
        }
      ],
      "extract": "259 Kit (SPK) containing several plastic consumables (filter device, stool transfer supplies) can be used jointly with a specially prepared buffer [Banada 2016; Walters 2018]. Following preparation, the sample is filtered instead of using sedimentation. A recently presented head-to-head comparison demonstrated a similar sensitivity with estimates ranging from 46.8% for the OSF and 48.3% for SOS to 52.1% for SPK,",
      "extractCut": true,
      "blocks": [
        "library/10665-381036/blocks/prose-page-264"
      ]
    },
    {
      "id": "page-265",
      "number": null,
      "title": "Page 265",
      "level": 1,
      "pageStart": 265,
      "pageEnd": 265,
      "labelStart": "260",
      "labelEnd": "260",
      "words": 497,
      "summary": {
        "text": "States the review's aim to estimate the change in accuracy from parallel use of automated NAATs on respiratory samples and stool and urine LF-LAM, to inform WHO guidelines. It lists the PICO questions, including effects on patient-important outcomes such as cure, mortality and time to diagnosis.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "lc-anaat stool",
          "heading": false
        },
        {
          "term": "pulmonary tuberculosis",
          "heading": false
        },
        {
          "term": "presumptive tuberculosis",
          "heading": false
        },
        {
          "term": "respiratory sample",
          "heading": false
        },
        {
          "term": "detecting pulmonary",
          "heading": false
        },
        {
          "term": "tuberculosis disease",
          "heading": false
        },
        {
          "term": "children years",
          "heading": false
        },
        {
          "term": "parallel testing",
          "heading": false
        }
      ],
      "extract": "260 supported from past studies in children that have shown improved accuracy of parallel LC-aNAAT with different respiratory sample types [Song 2021; Zar 2019]. This systematic review will estimate the change in diagnostic accuracy of parallel use of LC-aNAATs (from respiratory specimens and stool) and LF-LAM compared to using each of the tests alone to diagnose pulmonary tuberculosis among children with and",
      "extractCut": true,
      "blocks": [
        "library/10665-381036/blocks/prose-page-265"
      ]
    },
    {
      "id": "page-266",
      "number": null,
      "title": "Page 266",
      "level": 1,
      "pageStart": 266,
      "pageEnd": 266,
      "labelStart": "261",
      "labelEnd": "261",
      "words": 497,
      "summary": {
        "text": "Begins the methods of a systematic review on parallel testing for pulmonary tuberculosis in children, defining eligible comparative diagnostic accuracy studies of low-complexity automated NAATs (LC-aNAATs) on respiratory samples and stool, plus urine LF-LAM for children with HIV. Table 5 sets out the primary comparisons and minimum study design requirements.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "lc-anaat stool",
          "heading": false
        },
        {
          "term": "lc-anaat respiratory",
          "heading": false
        },
        {
          "term": "lc-anaat urine",
          "heading": false
        },
        {
          "term": "lf-lam respiratory",
          "heading": false
        },
        {
          "term": "lc-anaat reference",
          "heading": false
        },
        {
          "term": "respiratory specimen",
          "heading": false
        },
        {
          "term": "ipd available",
          "heading": false
        },
        {
          "term": "index test",
          "heading": false
        }
      ],
      "extract": "261 treatment initiation. 3. METHODS This review was based on a protocol, which was informed by methodology used in previous reviews and other protocols in the field [Inbaraj 2023; Zifodya 2021; Kohli 2021; Shapiro 2021; Bjerrum 2019b; Shah 2016b]. 3.1. Criteria for considering studies for this review 3.1.1. Types of studies For children who were HIV negative or with unknown HIV status, we included comparative",
      "extractCut": true,
      "blocks": [
        "library/10665-381036/blocks/prose-page-266"
      ]
    },
    {
      "id": "page-267",
      "number": null,
      "title": "Page 267",
      "level": 1,
      "pageStart": 267,
      "pageEnd": 267,
      "labelStart": "262",
      "labelEnd": "262",
      "words": 575,
      "summary": {
        "text": "Explains that fully paired studies were included even when some participants lacked a sample or result, since samples are hard to obtain from children, and describes eligible participants and index tests. It notes the stool processing methods considered and begins listing the automated outputs of Xpert MTB/RIF and Xpert Ultra.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "urinary lf-lam",
          "heading": false
        },
        {
          "term": "stool processing",
          "heading": false
        },
        {
          "term": "respiratory samples",
          "heading": false
        },
        {
          "term": "index tests",
          "heading": false
        },
        {
          "term": "xpert mtb",
          "heading": false
        },
        {
          "term": "weight gain",
          "heading": false
        },
        {
          "term": "poor weight",
          "heading": false
        },
        {
          "term": "mtb rif",
          "heading": false
        }
      ],
      "extract": "262 two-by-two table data). Additionally, we reviewed fully paired studies that were originally designed to assess the accuracy of LF-LAM or LC-aNAAT on stool, with LC-aNAAT and microbiological culture on respiratory specimens for the reference standard. We included these studies if data were made available for reanalysis and estimation of comparative diagnostic accuracy. We included studies with an attempt to",
      "extractCut": true,
      "blocks": [
        "library/10665-381036/blocks/prose-page-267"
      ]
    },
    {
      "id": "page-268",
      "number": null,
      "title": "Page 268",
      "level": 1,
      "pageStart": 268,
      "pageEnd": 268,
      "labelStart": "263",
      "labelEnd": "263",
      "words": 485,
      "summary": {
        "text": "Lists the result categories of the Xpert assays, Truenat, MTB Plus, STANDARD M10, IRON-qPCR and LF-LAM, noting that Ultra 'trace' results were counted as positive in children. It then describes the microbiological reference standard and how its quality was assessed with QUADAS-2.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "mtb detected",
          "heading": false
        },
        {
          "term": "tuberculosis culture",
          "heading": false
        },
        {
          "term": "tuberculosis disease",
          "heading": false
        },
        {
          "term": "liquid culture",
          "heading": false
        },
        {
          "term": "pulmonary tuberculosis",
          "heading": false
        },
        {
          "term": "mycobacterium tuberculosis",
          "heading": false
        },
        {
          "term": "reference standard",
          "heading": false
        },
        {
          "term": "solid culture",
          "heading": false
        }
      ],
      "extract": "263 1. MTB (Mycobacterium tuberculosis complex) DETECTED; RIF (rifampicin) resistance DETECTED 2. MTB DETECTED; Rif resistance NOT DETECTED 3. MTB DETECTED; Rif resistance INDETERMINATE 4. MTB NOT DETECTED 5. INVALID/ERROR/NO RESULT Invalid, error, and no result indicate that the presence or absence of M tuberculosis cannot be determined [A. W. Kay 2020]. Xpert MTB/ RIF Ultra also incorporates a semi-quantitative",
      "extractCut": true,
      "blocks": [
        "library/10665-381036/blocks/prose-page-268"
      ]
    },
    {
      "id": "page-269",
      "number": null,
      "title": "Page 269",
      "level": 1,
      "pageStart": 269,
      "pageEnd": 269,
      "labelStart": "264",
      "labelEnd": "264",
      "words": 503,
      "summary": {
        "text": "Defines the composite reference standard, combining microbiological tests on any sample type with study-defined clinical criteria, and how TB presence or absence was classified. It then outlines the electronic literature search, limited to studies published after 2010.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "pulmonary tuberculosis",
          "heading": false
        },
        {
          "term": "clinical criteria",
          "heading": false
        },
        {
          "term": "citation index",
          "heading": false
        },
        {
          "term": "index tests",
          "heading": false
        },
        {
          "term": "tuberculosis disease",
          "heading": false
        },
        {
          "term": "crs",
          "heading": false
        },
        {
          "term": "clinical characteristics",
          "heading": false
        },
        {
          "term": "mrs",
          "heading": false
        }
      ],
      "extract": "264 We included studies using a CRS consisting of a combination of microbiological tests and clinical criteria, including M. tuberculosis culture, NAATs on any sample type (pulmonary and extrapulmonary), or clinical criteria specified by the primary study authors. We included NAATs on non-respiratory sample types as children who have pulmonary tuberculosis often also have extrapulmonary TB. Clinical criteria to",
      "extractCut": true,
      "blocks": [
        "library/10665-381036/blocks/prose-page-269"
      ]
    },
    {
      "id": "page-270",
      "number": null,
      "title": "Page 270",
      "level": 1,
      "pageStart": 270,
      "pageEnd": 270,
      "labelStart": "265",
      "labelEnd": "265",
      "words": 503,
      "summary": {
        "text": "Describes other search sources, such as expert groups and a WHO call for data, and how two reviewers independently screened records in Covidence and extracted data, including individual-participant data shared by study authors.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "study authors",
          "heading": false
        },
        {
          "term": "review authors",
          "heading": false
        },
        {
          "term": "non determinate",
          "heading": false
        },
        {
          "term": "resolved disagreements",
          "heading": false
        },
        {
          "term": "study selection",
          "heading": false
        },
        {
          "term": "data extraction",
          "heading": false
        },
        {
          "term": "specimen type",
          "heading": false
        },
        {
          "term": "disagreements through",
          "heading": false
        }
      ],
      "extract": "265 We examined reference lists of included studies, relevant reviews, studies, commentaries, and editorials and searched the WHO websites related to HIV and tuberculosis. We contacted experts in the field and leading research groups working on new diagnostics such as SMART4TB, STOP TB and FIND (Foundation for Innovative New Diagnostics). In addition, we reviewed studies submitted after a WHO call for literature.",
      "extractCut": true,
      "blocks": [
        "library/10665-381036/blocks/prose-page-270"
      ]
    },
    {
      "id": "page-271",
      "number": null,
      "title": "Page 271",
      "level": 1,
      "pageStart": 271,
      "pageEnd": 271,
      "labelStart": "266",
      "labelEnd": "266",
      "words": 564,
      "summary": {
        "text": "Explains that data were managed in Excel and Review Manager and that study quality was assessed independently with the QUADAS-2 and QUADAS-C tools. It begins describing the statistical analysis, in which any positive result counted as positive for the parallel strategy.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "mean logit-transformed",
          "heading": false
        },
        {
          "term": "testing minus",
          "heading": false
        },
        {
          "term": "binomial distribution",
          "heading": false
        },
        {
          "term": "summary difference",
          "heading": false
        },
        {
          "term": "parallel testing",
          "heading": false
        },
        {
          "term": "bivariate random-effects",
          "heading": false
        },
        {
          "term": "uniform distribution",
          "heading": false
        },
        {
          "term": "component test",
          "heading": false
        }
      ],
      "extract": "266 involved in any of the included studies did not participate in data extraction of their own study. We extracted the data and recorded it using Microsoft® Excel and entered it into Review Manager Web directly [Collaboration 2020]. 3.3.3 Assessment of methodological quality We assessed the methodological quality of included studies using QUADAS-2 [Whiting 2011] and QUADAS-C [Yang 2021a] tools (Appendices 2 and 3).",
      "extractCut": true,
      "blocks": [
        "library/10665-381036/blocks/prose-page-271"
      ]
    },
    {
      "id": "page-272",
      "number": null,
      "title": "Page 272",
      "level": 1,
      "pageStart": 272,
      "pageEnd": 272,
      "labelStart": "267",
      "labelEnd": "267",
      "words": 505,
      "summary": {
        "text": "Explains that participants with missing or invalid index test results were treated as test-negative in the primary analysis, with a sensitivity analysis excluding them. It also defines investigations of heterogeneity, including subgroups by danger signs of serious illness in children with and without HIV.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "non-determinate index",
          "heading": false
        },
        {
          "term": "non determinate",
          "heading": false
        },
        {
          "term": "count versus",
          "heading": false
        },
        {
          "term": "cell count",
          "heading": false
        },
        {
          "term": "years old",
          "heading": false
        },
        {
          "term": "children years",
          "heading": false
        },
        {
          "term": "hiv years",
          "heading": false
        },
        {
          "term": "nasopharyngeal aspirate",
          "heading": false
        }
      ],
      "extract": "267 testing pathway were regarded as ‘not positive’. This included (a) participants with an inadequate or unavailable specimen for testing and (b) participants with an invalid or technical failure (i.e. non- determinate test results). For the primary analysis, we analysed participants with a ‘not positive’ as test negative. We performed a sensitivity analysis in which those participants with at least one missing or",
      "extractCut": true,
      "blocks": [
        "library/10665-381036/blocks/prose-page-272",
        "library/10665-381036/blocks/table-007"
      ]
    },
    {
      "id": "page-273",
      "number": null,
      "title": "Page 273",
      "level": 1,
      "pageStart": 273,
      "pageEnd": 273,
      "labelStart": "268",
      "labelEnd": "268",
      "words": 497,
      "summary": {
        "text": "Lists the sensitivity analyses performed and explains why publication bias was not formally assessed and how certainty of evidence was graded with GRADE. It begins the results, reporting that 155 unique records were screened and 42 full texts assessed.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "certainty rating",
          "heading": false
        },
        {
          "term": "rating risk",
          "heading": false
        },
        {
          "term": "log odds",
          "heading": false
        },
        {
          "term": "publication bias",
          "heading": false
        },
        {
          "term": "true difference",
          "heading": false
        },
        {
          "term": "patient-important outcomes",
          "heading": false
        },
        {
          "term": "confidence intervals",
          "heading": false
        },
        {
          "term": "distributions",
          "heading": false
        }
      ],
      "extract": "268 3.3.7 Sensitivity analysis We performed the following sensitivity analyses by limiting inclusion in the meta-analysis based on the following criteria: • Only participants screening positive for tuberculosis using CXR • Exclusion of studies at high or unclear risk of bias (QUADAS-C) and high concerns regarding applicability (QUADAS-2) in at least one domain • Alterative prior distributions which are less",
      "extractCut": true,
      "blocks": [
        "library/10665-381036/blocks/prose-page-273"
      ]
    },
    {
      "id": "page-274",
      "number": null,
      "title": "Page 274",
      "level": 1,
      "pageStart": 274,
      "pageEnd": 274,
      "labelStart": "269",
      "labelEnd": "269",
      "words": 99,
      "summary": {
        "text": "Reports that 36 studies were included but none reported parallel-testing accuracy or patient-important outcomes, so authors re-analysed data for 14 studies across the two review questions.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "lc-anaat",
          "heading": false
        },
        {
          "term": "studies",
          "heading": false
        },
        {
          "term": "picos",
          "heading": false
        }
      ],
      "extract": "269 six studies. We included 36 unique studies, all of which had data on a parallel strategy of LC-aNAAT on respiratory specimens and LC-aNAAT on stool, and additionally LF-LAM in CHIV; however, none of the included studies reported on parallel accuracy. We did not identify studies on impact/patient-important outcomes. Data extraction directly from the publication was not feasible for any of the included studies. On",
      "extractCut": true,
      "blocks": [
        "library/10665-381036/blocks/prose-page-274"
      ]
    },
    {
      "id": "page-275",
      "number": null,
      "title": "Page 275",
      "level": 1,
      "pageStart": 275,
      "pageEnd": 275,
      "labelStart": "270",
      "labelEnd": "270",
      "words": 270,
      "summary": {
        "text": "Shows the study flow diagram (Figure 2) and introduces the QUADAS-2 risk-of-bias and applicability figures for studies of children without HIV and children with HIV.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "studies assessed",
          "heading": false
        },
        {
          "term": "studies excluded",
          "heading": false
        },
        {
          "term": "duplicates identified",
          "heading": false
        },
        {
          "term": "applicability concerns",
          "heading": false
        },
        {
          "term": "wrong",
          "heading": false
        },
        {
          "term": "pico",
          "heading": false
        },
        {
          "term": "index test",
          "heading": false
        }
      ],
      "extract": "270 Figure 2: Flow of studies in the review. 4.2 Methodological quality of included studies 4.2.1. QUADAS- 2 – PICO 1 Figure 3a show risk of bias and applicability concerns for each of the 12 included studies for children without HIV or with HIV status unknown, while Figure 3b shows the same for the seven studies included for CHIV. Figure 3: Risk of bias and applicability concerns related to single test accuracy",
      "extractCut": true,
      "blocks": [
        "library/10665-381036/blocks/prose-page-275",
        "library/10665-381036/blocks/figure-vfig-p275"
      ]
    },
    {
      "id": "page-276",
      "number": null,
      "title": "Page 276",
      "level": 1,
      "pageStart": 276,
      "pageEnd": 276,
      "labelStart": "271",
      "labelEnd": "271",
      "words": 441,
      "summary": {
        "text": "Reports QUADAS-2 judgements for PICO 1, finding most studies at low risk of bias in patient selection, with applicability concerns for those recruiting only inpatients. It also covers the index test, reference standard and flow and timing domains.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "judged studies",
          "heading": false
        },
        {
          "term": "unclear concern",
          "heading": false
        },
        {
          "term": "unclear risk",
          "heading": false
        },
        {
          "term": "eight studies",
          "heading": false
        },
        {
          "term": "donkeng",
          "heading": false
        },
        {
          "term": "selection domain",
          "heading": false
        },
        {
          "term": "concern because",
          "heading": false
        },
        {
          "term": "regarding applicability",
          "heading": false
        }
      ],
      "extract": "271 For children without HIV or HIV unknown, in the patient selection domain, we judged 11 studies (91.6%) to have low risk of bias. One study (8.3%; [Donkeng 2022]) had unclear risk of bias. Regarding applicability, eight studies (66.7%) had low concern because the studies included the appropriate participants and settings [Ainan 2021; Babo 2023; Hanrahan 2018; Hasan 2017; Jaganath 2024; Olbrich 2024; M. P. Nicol",
      "extractCut": true,
      "blocks": [
        "library/10665-381036/blocks/prose-page-276",
        "library/10665-381036/blocks/figure-img-p276-1"
      ]
    },
    {
      "id": "page-277",
      "number": null,
      "title": "Page 277",
      "level": 1,
      "pageStart": 277,
      "pageEnd": 277,
      "labelStart": "272",
      "labelEnd": "272",
      "words": 113,
      "summary": {
        "text": "Completes the flow and timing judgements for PICO 1 and introduces Figure 4, the QUADAS-C assessment of bias in the comparative accuracy estimates.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "comparative accuracy",
          "heading": false
        },
        {
          "term": "accuracy estimates",
          "heading": false
        },
        {
          "term": "quadas-c",
          "heading": false
        }
      ],
      "extract": "272 participants were included in the analysis. Four studies had unclear risk of bias as we could not determine if all index tests were collected at the same time as the reference standard (33.3%; [Ainan 2021; Chabala 2024; Orikiriza 2021; Wobudeya 2024]). 4.2.2. QUADAS-C – PICO 1 Figure 4a show risk of bias in the comparative accuracy estimates for each of the 12 studies comparing the parallel use of LC-aNAAT on",
      "extractCut": true,
      "blocks": [
        "library/10665-381036/blocks/prose-page-277"
      ]
    },
    {
      "id": "page-278",
      "number": null,
      "title": "Page 278",
      "level": 1,
      "pageStart": 278,
      "pageEnd": 278,
      "labelStart": "273",
      "labelEnd": "273",
      "words": 341,
      "summary": {
        "text": "Reports QUADAS-C judgements for PICO 1, finding most studies at low risk of bias for patient selection and index tests. Studies using a composite reference standard that included the index NAATs were judged at high risk of bias in that domain.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "judged eleven",
          "heading": false
        },
        {
          "term": "unclear risk",
          "heading": false
        },
        {
          "term": "donkeng",
          "heading": false
        },
        {
          "term": "index tests",
          "heading": false
        },
        {
          "term": "chiv",
          "heading": false
        },
        {
          "term": "jaganath",
          "heading": false
        },
        {
          "term": "bias",
          "heading": false
        },
        {
          "term": "both index",
          "heading": false
        }
      ],
      "extract": "273 All studies for the purpose of this review used a paired diagnostic accuracy design. In the patient selection domain, we judged eleven studies (91.7%) for studies in children without HIV and five (71.4%) for CHIV to have low risk of bias [Chipinduro 2017; Jaganath 2024; LaCourse 2018; Olbrich 2024; Orikiriza 2021]. One study (8.3%,[Donkeng 2022]) for children without HIV and two (28.6% [Donkeng 2022; Hanrahan",
      "extractCut": true,
      "blocks": [
        "library/10665-381036/blocks/prose-page-278",
        "library/10665-381036/blocks/figure-img-p278-1"
      ]
    },
    {
      "id": "page-279",
      "number": null,
      "title": "Page 279",
      "level": 1,
      "pageStart": 279,
      "pageEnd": 279,
      "labelStart": "274",
      "labelEnd": "274",
      "words": 508,
      "summary": {
        "text": "Completes the QUADAS-C flow and timing results for PICO 1 and introduces Figure 5, the QUADAS-2 assessment for the six PICO 2 studies, including the figure's risk-of-bias grid.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "unclear risk",
          "heading": false
        },
        {
          "term": "index test",
          "heading": false
        },
        {
          "term": "chipinduro",
          "heading": false
        },
        {
          "term": "applicability concerns",
          "heading": false
        },
        {
          "term": "lacourse",
          "heading": false
        },
        {
          "term": "hanrahan",
          "heading": false
        },
        {
          "term": "jaganath",
          "heading": false
        },
        {
          "term": "judged",
          "heading": false
        }
      ],
      "extract": "274 were judged to have a high risk of bias. In the flow and timing domain, we judged nine studies (75.0 %, [Ainan 2021; Babo 2023; Hanrahan 2018; Hasan 2017; Jaganath 2024; Kabir 2021; M. P. Nicol 2013; Olbrich 2024; Orikiriza 2021]) for children without HIV and five (71.4%, [Chipinduro 2017; Jaganath 2024; LaCourse 2018; Olbrich 2024; Orikiriza 2021]) for CHIV to have low risk of bias for the comparison, as all",
      "extractCut": true,
      "blocks": [
        "library/10665-381036/blocks/prose-page-279",
        "library/10665-381036/blocks/figure-vfig-p279"
      ]
    },
    {
      "id": "page-280",
      "number": null,
      "title": "Page 280",
      "level": 1,
      "pageStart": 280,
      "pageEnd": 280,
      "labelStart": "275",
      "labelEnd": "275",
      "words": 140,
      "summary": {
        "text": "Notes low applicability concerns for reference standards in PICO 2 studies and introduces Figure 6, the QUADAS-C assessment comparing parallel NAAT plus LF-LAM testing with each test alone.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "comparative accuracy",
          "heading": false
        },
        {
          "term": "accuracy estimates",
          "heading": false
        },
        {
          "term": "orikiriza",
          "heading": false
        },
        {
          "term": "quadas-c",
          "heading": false
        }
      ],
      "extract": "275 Olbrich 2024; Orikiriza 2021]. Regarding applicability of the reference standard, we thought that all studies had low concerns as all performed a test to identify M tuberculosis species (speciation) for the MRS, and appropriate criteria for CRS. In the flow and timing domain, we judged five studies (83.3%) to be at low risk of bias noting that all participants were included in the analysis. One study had unclear",
      "extractCut": true,
      "blocks": [
        "library/10665-381036/blocks/prose-page-280"
      ]
    },
    {
      "id": "page-281",
      "number": null,
      "title": "Page 281",
      "level": 1,
      "pageStart": 281,
      "pageEnd": 281,
      "labelStart": "276",
      "labelEnd": "276",
      "words": 439,
      "summary": {
        "text": "Reports QUADAS-C judgements for PICO 2, with high risk of bias for composite reference standards that included NAATs, and begins the description of key study characteristics, followed by the risk-of-bias grid.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "judged five",
          "heading": false
        },
        {
          "term": "involving participant",
          "heading": false
        },
        {
          "term": "studies evaluated",
          "heading": false
        },
        {
          "term": "lc-anaat alone",
          "heading": false
        },
        {
          "term": "tuberculosis prevalence",
          "heading": false
        },
        {
          "term": "respiratory sample",
          "heading": false
        },
        {
          "term": "stool compared",
          "heading": false
        },
        {
          "term": "unclear risk",
          "heading": false
        }
      ],
      "extract": "276 All studies for the purpose of this review used a paired diagnostic accuracy design. In the index test domain, we judged five studies (83.3%) to have low risk of bias as the risk of bias for each index test was judged low in QUADAS-2, while we could not tell for one study (16.7%; [Chipinduro 2017]), and thus judged unclear risk of bias. In the reference standard domain, we judged all studies based on a MRS to",
      "extractCut": true,
      "blocks": [
        "library/10665-381036/blocks/prose-page-281"
      ]
    },
    {
      "id": "page-282",
      "number": null,
      "title": "Page 282",
      "level": 1,
      "pageStart": 282,
      "pageEnd": 282,
      "labelStart": "277",
      "labelEnd": "277",
      "words": 33,
      "summary": {
        "text": "States that most studies recruited in sub-Saharan Africa and that all enrolled symptomatic children, some also by chest X-ray, serious illness or advanced HIV.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "cxr",
          "heading": false
        },
        {
          "term": "abnormalities",
          "heading": false
        },
        {
          "term": "recruited",
          "heading": false
        }
      ],
      "extract": "277 (eight, 66.7%) recruited from 10 countries within Sub-Saharan Africa. All 14 studies included symptomatic, but five studies also enrolled participants based on CXR abnormalities, being seriously ill or with advanced HIV disease.",
      "extractCut": false,
      "blocks": [
        "library/10665-381036/blocks/prose-page-282"
      ]
    },
    {
      "id": "page-283",
      "number": null,
      "title": "Page 283",
      "level": 1,
      "pageStart": 283,
      "pageEnd": 283,
      "labelStart": "278",
      "labelEnd": "278",
      "words": 471,
      "summary": {
        "text": "Presents PICO 1 results against a microbiological reference standard, describing the eight studies comparing parallel respiratory and stool NAAT testing with either sample alone. It reports study numbers and TB prevalence and includes forest plots of sensitivity and specificity.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "lc-anaats combined",
          "heading": false
        },
        {
          "term": "respiratory sample",
          "heading": false
        },
        {
          "term": "status unknown",
          "heading": false
        },
        {
          "term": "either respiratory",
          "heading": false
        },
        {
          "term": "eight studies",
          "heading": false
        },
        {
          "term": "hiv status",
          "heading": false
        },
        {
          "term": "seven studies",
          "heading": false
        },
        {
          "term": "pulmonary tuberculosis",
          "heading": false
        }
      ],
      "extract": "278 4.4. PICO 1: What is the incremental diagnostic accuracy of parallel use of LC- aNAATs on a respiratory sample and stool for diagnosis of pulmonary tuberculosis disease in children that are HIV negative or unknown HIV status with signs and symptoms or screened positive for pulmonary tuberculosis, compared to use of the LC-aNAAT on one sample type (either respiratory or stool)? 4.4.1 Comparative diagnostic",
      "extractCut": true,
      "blocks": [
        "library/10665-381036/blocks/prose-page-283"
      ]
    },
    {
      "id": "page-284",
      "number": null,
      "title": "Page 284",
      "level": 1,
      "pageStart": 284,
      "pageEnd": 284,
      "labelStart": "279",
      "labelEnd": "279",
      "words": 52,
      "summary": {
        "text": "Begins reporting the range of sensitivity and specificity of NAAT on respiratory samples alone in children without HIV or with unknown status.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "lc-anaat",
          "heading": false
        },
        {
          "term": "respiratory",
          "heading": false
        },
        {
          "term": "hanrahan",
          "heading": false
        }
      ],
      "extract": "279 Diagnostic accuracy of the component tests: LC-aNAAT on respiratory sample or LC-aNAAT on stool based on the microbiological reference standard For children without HIV or HIV status unknown, the sensitivity of LC-aNAAT on respiratory samples alone ranged from 47.8% [Olbrich 2024] to 100% [Hanrahan 2018] and specificity from 84.5% [M. P.",
      "extractCut": false,
      "blocks": [
        "library/10665-381036/blocks/prose-page-284",
        "library/10665-381036/blocks/figure-img-p284-1",
        "library/10665-381036/blocks/figure-img-p284-2"
      ]
    },
    {
      "id": "page-285",
      "number": null,
      "title": "Page 285",
      "level": 1,
      "pageStart": 285,
      "pageEnd": 285,
      "labelStart": "280",
      "labelEnd": "280",
      "words": 428,
      "summary": {
        "text": "Reports pooled accuracy of NAAT on respiratory samples alone and on stool alone, against a microbiological reference standard, for children without HIV and with HIV. It then gives the pooled gain in sensitivity and small loss of specificity from parallel testing compared with respiratory testing alone.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "stool alone",
          "heading": false
        },
        {
          "term": "alone ranged",
          "heading": false
        },
        {
          "term": "versus lc-anaat",
          "heading": false
        },
        {
          "term": "pooled sensitivity",
          "heading": false
        },
        {
          "term": "samples alone",
          "heading": false
        },
        {
          "term": "pooled difference",
          "heading": false
        },
        {
          "term": "cri",
          "heading": false
        },
        {
          "term": "respiratory samples",
          "heading": false
        }
      ],
      "extract": "280 Nicol 2013] to 100% [Donkeng 2022] between studies. The pooled sensitivity and specificity for LC- aNAAT on respiratory samples alone were 72.6% (95% CrI 59.0 to 84.6) and 95.0% (95% CrI 90.6 to 97.7). The sensitivity of LC-aNAAT on stool alone ranged from 0.0% [Hanrahan 2018] to 85.7% [Hasan 2017] and specificity from 89.2% [M. P. Nicol 2013] to 100% [Hanrahan 2018; Hasan 2017; Donkeng 2022] between studies.",
      "extractCut": true,
      "blocks": [
        "library/10665-381036/blocks/prose-page-285"
      ]
    },
    {
      "id": "page-286",
      "number": null,
      "title": "Page 286",
      "level": 1,
      "pageStart": 286,
      "pageEnd": 286,
      "labelStart": "281",
      "labelEnd": "281",
      "words": 135,
      "summary": {
        "text": "Caption for Figure 8, forest plots of the difference in accuracy between parallel NAAT testing and respiratory-sample testing alone in children without HIV, with notes on the confidence intervals.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "study-specific",
          "heading": false
        },
        {
          "term": "black",
          "heading": false
        },
        {
          "term": "difference",
          "heading": false
        },
        {
          "term": "risk-of-bias",
          "heading": false
        }
      ],
      "extract": "281 Figure 8: Forest plots of study-specific and summary estimates of difference in accuracy between the parallel use of LC-aNAATs combined versus LC-aNAAT on respiratory samples alone for tuberculosis in children that are HIV negative or unknown HIV status with presumed pulmonary tuberculosis by MRS. The black squares represent the point estimate of one study, the black horizontal line its 95% confidence interval",
      "extractCut": true,
      "blocks": [
        "library/10665-381036/blocks/prose-page-286",
        "library/10665-381036/blocks/figure-img-p286-1"
      ]
    },
    {
      "id": "page-287",
      "number": null,
      "title": "Page 287",
      "level": 1,
      "pageStart": 287,
      "pageEnd": 287,
      "labelStart": "282",
      "labelEnd": "282",
      "words": 164,
      "summary": {
        "text": "Captions for Figures 9 and 10, forest plots of pooled sensitivity and specificity by index test for children without HIV and children with HIV.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "pooled difference",
          "heading": false
        },
        {
          "term": "pooled sensitivity",
          "heading": false
        },
        {
          "term": "squares represent",
          "heading": false
        },
        {
          "term": "pooled single",
          "heading": false
        },
        {
          "term": "line connecting",
          "heading": false
        }
      ],
      "extract": "282 Figure 9: Forest plot of pooled sensitivity and specificity for all studie in children without HIV or HIV unknown, by each index test. The squares represent the pooled sensitivity and specificity, the black horizontal line its 95% credible interval (CrI). The pooled difference in sensitivity and specificity between parallel testing and LC-aNAAT alone is indicated by a line connecting two squares. This pooled",
      "extractCut": true,
      "blocks": [
        "library/10665-381036/blocks/prose-page-287",
        "library/10665-381036/blocks/figure-img-p287-1",
        "library/10665-381036/blocks/figure-img-p287-2"
      ]
    },
    {
      "id": "page-288",
      "number": null,
      "title": "Page 288",
      "level": 1,
      "pageStart": 288,
      "pageEnd": 288,
      "labelStart": "283",
      "labelEnd": "283",
      "words": 196,
      "summary": {
        "text": "Reports that, against a microbiological reference standard, parallel testing raised pooled sensitivity by about 23.5% over stool testing alone in children without HIV, with a small specificity loss, and by about 8.5% in children with HIV.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "lc-anaat alone",
          "heading": false
        },
        {
          "term": "lc-anaats combined",
          "heading": false
        },
        {
          "term": "stool alone",
          "heading": false
        },
        {
          "term": "incremental accuracy",
          "heading": false
        },
        {
          "term": "pooled difference",
          "heading": false
        }
      ],
      "extract": "283 Incremental diagnostic accuracy of parallel use of LC-aNAATs combined versus LC-aNAAT on stool alone based on the microbiological reference standard In children without HIV or HIV status unknown, incremental difference in sensitivity for parallel use of LC-aNAATs versus LC-aNAAT on stool alone ranged from 6.7% [Chabala 2024] to 31.7% [Jaganath 2024] between studies. The difference in specificity ranged from 0%",
      "extractCut": true,
      "blocks": [
        "library/10665-381036/blocks/prose-page-288"
      ]
    },
    {
      "id": "page-289",
      "number": null,
      "title": "Page 289",
      "level": 1,
      "pageStart": 289,
      "pageEnd": 289,
      "labelStart": "284",
      "labelEnd": "284",
      "words": 133,
      "summary": {
        "text": "Caption for Figure 11, forest plots of the difference in accuracy between parallel NAAT testing and stool testing alone in children without HIV.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "study-specific",
          "heading": false
        },
        {
          "term": "black",
          "heading": false
        },
        {
          "term": "difference",
          "heading": false
        },
        {
          "term": "risk-of-bias",
          "heading": false
        }
      ],
      "extract": "284 Figure 11: Forest plots of study-specific and summary estimates of difference in accuracy between the parallel use of LC-aNAATs versus LC-aNAAT on stool alone for tuberculosis in children that are HIV negative or unknown HIV status with presumed pulmonary tuberculosis by MRS. The black squares represent the point estimate of one study, the black horizontal line its 95% confidence interval (CI). The QUADAS-C",
      "extractCut": true,
      "blocks": [
        "library/10665-381036/blocks/prose-page-289",
        "library/10665-381036/blocks/figure-img-p289-1"
      ]
    },
    {
      "id": "page-290",
      "number": null,
      "title": "Page 290",
      "level": 1,
      "pageStart": 290,
      "pageEnd": 290,
      "labelStart": "285",
      "labelEnd": "285",
      "words": 477,
      "summary": {
        "text": "Begins the PICO 1 analysis against a composite reference standard, describing 12 studies in children without HIV and seven in children with HIV, with TB prevalence ranging widely. It notes that composite reference definitions varied and includes forest plots of accuracy.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "lc-anaats ranged",
          "heading": false
        },
        {
          "term": "lc-anaats combined",
          "heading": false
        },
        {
          "term": "lc-anaat alone",
          "heading": false
        },
        {
          "term": "donkeng",
          "heading": false
        },
        {
          "term": "status unknown",
          "heading": false
        },
        {
          "term": "hanrahan",
          "heading": false
        },
        {
          "term": "seven studies",
          "heading": false
        },
        {
          "term": "hiv status",
          "heading": false
        }
      ],
      "extract": "285 4.4.2 Comparative diagnostic accuracy against a composite reference standard Summary of Findings Tables for the incremental diagnostic accuracy of the parallel use of LC-aNAATs combined versus each LC-aNAAT alone using the CRS can be found in Appendix 12. Description of included studies We identified 12 studies that compared the accuracy of a parallel strategy of LC-aNAATs combined versus each LC-aNAAT alone in",
      "extractCut": true,
      "blocks": [
        "library/10665-381036/blocks/prose-page-290"
      ]
    },
    {
      "id": "page-291",
      "number": null,
      "title": "Page 291",
      "level": 1,
      "pageStart": 291,
      "pageEnd": 291,
      "labelStart": "286",
      "labelEnd": "286",
      "words": 67,
      "summary": {
        "text": "Begins reporting the sensitivity and specificity ranges of respiratory-sample NAAT testing against the composite reference standard in children without HIV.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "lc-anaat",
          "heading": false
        },
        {
          "term": "donkeng",
          "heading": false
        },
        {
          "term": "respiratory",
          "heading": false
        }
      ],
      "extract": "286 Diagnostic accuracy of the component tests: LC-aNAAT on respiratory sample or LC-aNAAT on stool based on the composite reference standard In children without HIV or HIV status unknown, the sensitivity of LC-aNAAT on respiratory samples alone ranged from 44.6% ([Hanrahan 2018]) to 81.2% [Donkeng 2022] between studies, and specificity was at 100% for all studies except one study where specificity was 78.4%",
      "extractCut": true,
      "blocks": [
        "library/10665-381036/blocks/prose-page-291",
        "library/10665-381036/blocks/figure-img-p291-1",
        "library/10665-381036/blocks/figure-img-p291-2"
      ]
    },
    {
      "id": "page-292",
      "number": null,
      "title": "Page 292",
      "level": 1,
      "pageStart": 292,
      "pageEnd": 292,
      "labelStart": "287",
      "labelEnd": "287",
      "words": 422,
      "summary": {
        "text": "Reports pooled sensitivity and specificity of respiratory and stool NAAT testing against the composite reference standard, which gives much lower sensitivity estimates than the microbiological standard. It then gives the pooled differences for parallel testing versus respiratory testing alone in children with and without HIV.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "versus lc-anaat",
          "heading": false
        },
        {
          "term": "alone ranged",
          "heading": false
        },
        {
          "term": "stool alone",
          "heading": false
        },
        {
          "term": "respiratory samples",
          "heading": false
        },
        {
          "term": "cri",
          "heading": false
        },
        {
          "term": "pooled sensitivity",
          "heading": false
        },
        {
          "term": "pooled difference",
          "heading": false
        },
        {
          "term": "hanrahan",
          "heading": false
        }
      ],
      "extract": "287 sensitivity was 21.7% (95% CrI 12.8 to 34.4) and the specificity 99.8% (95% CrI 97.9 to 100), (12 studies; 3,579 participants, 1,464 [40.9%] with tuberculosis). The sensitivity of LC-aNAAT on stool alone ranged from 0.0% [Hanrahan 2018] to 68.8% [Donkeng 2022] and specificity from 93.5% [Olbrich 2024] to 100% [Ainan 2021; Chabala 2024; Donkeng 2022; Hanrahan 2018; Kabir 2021; Orikiriza 2021; Wobudeya 2024]",
      "extractCut": true,
      "blocks": [
        "library/10665-381036/blocks/prose-page-292"
      ]
    },
    {
      "id": "page-293",
      "number": null,
      "title": "Page 293",
      "level": 1,
      "pageStart": 293,
      "pageEnd": 293,
      "labelStart": "288",
      "labelEnd": "288",
      "words": 139,
      "summary": {
        "text": "Caption for Figure 13, forest plots of the difference in accuracy between parallel NAAT testing and respiratory testing alone against a composite reference standard.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "black",
          "heading": false
        },
        {
          "term": "difference",
          "heading": false
        },
        {
          "term": "study-specific",
          "heading": false
        },
        {
          "term": "risk-of-bias",
          "heading": false
        }
      ],
      "extract": "288 Figure 13: Forest plots of study-specific and summary estimates of difference in accuracy between the parallel use of LC-aNAATs combined versus LC-aNAAT on respiratory samples alone for tuberculosis in children that are (a) HIV negative or unknown HIV status and (b) CHIV with presumed pulmonary tuberculosis by a CRS. The black squares represent the point estimate of one study, the black horizontal line its 95%",
      "extractCut": true,
      "blocks": [
        "library/10665-381036/blocks/prose-page-293",
        "library/10665-381036/blocks/figure-img-p293-1"
      ]
    },
    {
      "id": "page-294",
      "number": null,
      "title": "Page 294",
      "level": 1,
      "pageStart": 294,
      "pageEnd": 294,
      "labelStart": "289",
      "labelEnd": "289",
      "words": 255,
      "summary": {
        "text": "Reports that, against a composite reference standard, parallel testing increased pooled sensitivity by about 10.5% over stool testing alone in children without HIV with almost no loss of specificity, and gives the corresponding results for children with HIV.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "lc-anaat alone",
          "heading": false
        },
        {
          "term": "stool alone",
          "heading": false
        },
        {
          "term": "versus lc-anaat",
          "heading": false
        },
        {
          "term": "lc-anaats combined",
          "heading": false
        },
        {
          "term": "incremental accuracy",
          "heading": false
        },
        {
          "term": "pooled difference",
          "heading": false
        }
      ],
      "extract": "289 Incremental accuracy of the parallel use of LC-aNAATs combined versus LC- aNAAT on stool alone based on the composite reference standard For children without HIV or HIV status unknown, within studies, incremental difference in sensitivity for parallel use of LC-aNAATs combined versus LC-aNAAT on stool alone ranged from 4.1% [Orikiriza 2021] to 31.8% [Chabala 2024]. The difference in specificity for parallel use",
      "extractCut": true,
      "blocks": [
        "library/10665-381036/blocks/prose-page-294"
      ]
    },
    {
      "id": "page-295",
      "number": null,
      "title": "Page 295",
      "level": 1,
      "pageStart": 295,
      "pageEnd": 295,
      "labelStart": "290",
      "labelEnd": "290",
      "words": 133,
      "summary": {
        "text": "Caption for Figure 14, forest plots of the difference in accuracy between parallel NAAT testing and stool testing alone against a composite reference standard.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "study-specific",
          "heading": false
        },
        {
          "term": "black",
          "heading": false
        },
        {
          "term": "difference",
          "heading": false
        },
        {
          "term": "risk-of-bias",
          "heading": false
        }
      ],
      "extract": "290 Figure 14: Forest plots of study-specific and summary estimates of difference in accuracy between the parallel use of LC-aNAATs combined versus LC-aNAAT on stool alone for tuberculosis in children that are HIV negative or unknown HIV status with presumed pulmonary tuberculosis by a CRS. The black squares represent the point estimate of one study, the black horizontal line its 95% confidence interval (CI). The",
      "extractCut": true,
      "blocks": [
        "library/10665-381036/blocks/prose-page-295",
        "library/10665-381036/blocks/figure-img-p295-1"
      ]
    },
    {
      "id": "page-296",
      "number": null,
      "title": "Page 296",
      "level": 1,
      "pageStart": 296,
      "pageEnd": 296,
      "labelStart": "291",
      "labelEnd": "291",
      "words": 383,
      "summary": {
        "text": "Lists subgroup analyses for PICO 1, such as inpatients, age group, sample type and severe acute malnutrition, and reports the low rates of invalid NAAT results. It also gives sensitivity-analysis results that exclude participants with missing or invalid results.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "pooled difference",
          "heading": false
        },
        {
          "term": "zero invalid",
          "heading": false
        },
        {
          "term": "respiratory samples",
          "heading": false
        },
        {
          "term": "reported invalid",
          "heading": false
        },
        {
          "term": "stool alone",
          "heading": false
        },
        {
          "term": "sensitivity comparing",
          "heading": false
        },
        {
          "term": "cri",
          "heading": false
        },
        {
          "term": "parallel testing",
          "heading": false
        }
      ],
      "extract": "291 4.4.3 Subgroup analyses using a microbiological reference standard The diagnostic accuracy of the parallel use of LC-aNAAT combined, LC-aNAAT on respiratory samples, and LC-aNAAT on stool in children without HIV or HIV status unknown is shown for the following subgroups against a MRS in Appendix 16: inpatient setting; symptomatic participants; age 0-4 versus 5-9 years; sample type NPA versus other respiratory",
      "extractCut": true,
      "blocks": [
        "library/10665-381036/blocks/prose-page-296"
      ]
    },
    {
      "id": "page-297",
      "number": null,
      "title": "Page 297",
      "level": 1,
      "pageStart": 297,
      "pageEnd": 297,
      "labelStart": "292",
      "labelEnd": "292",
      "words": 338,
      "summary": {
        "text": "Introduces PICO 2 on parallel respiratory and stool NAAT plus urine LF-LAM testing in children with HIV, describing six studies with 653 participants. Its forest-plot caption refers to adults and adolescents, which seems inconsistent with the child population.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "lc-anaats combined",
          "heading": false
        },
        {
          "term": "respiratory sample",
          "heading": false
        },
        {
          "term": "lf-lam",
          "heading": false
        },
        {
          "term": "chipinduro",
          "heading": false
        },
        {
          "term": "lacourse",
          "heading": false
        },
        {
          "term": "pulmonary tuberculosis",
          "heading": false
        },
        {
          "term": "microbiological reference",
          "heading": false
        },
        {
          "term": "parallel",
          "heading": false
        }
      ],
      "extract": "292 4.5. PICO 2: What is the incremental diagnostic accuracy of parallel use of LC- aNAATs on a respiratory sample and stool and LF-LAM on urine for diagnosis of pulmonary tuberculosis disease in children with HIV with signs and symptoms or screened positive for pulmonary tuberculosis, compared to any of the tests (either LC-aNAATs combined or LF-LAM) alone? 4.5.1 Comparative diagnostic accuracy against a",
      "extractCut": true,
      "blocks": [
        "library/10665-381036/blocks/prose-page-297"
      ]
    },
    {
      "id": "page-298",
      "number": null,
      "title": "Page 298",
      "level": 1,
      "pageStart": 298,
      "pageEnd": 298,
      "labelStart": "293",
      "labelEnd": "293",
      "words": 296,
      "summary": {
        "text": "Reports pooled accuracy for combined NAATs alone and for LF-LAM alone in children with HIV, against a microbiological reference standard, and the pooled gain in sensitivity and loss of specificity from adding LF-LAM.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "lc-anaats combined",
          "heading": false
        },
        {
          "term": "combined alone",
          "heading": false
        },
        {
          "term": "lf-lam alone",
          "heading": false
        },
        {
          "term": "alone ranged",
          "heading": false
        },
        {
          "term": "lf-lam versus",
          "heading": false
        },
        {
          "term": "pooled sensitivity",
          "heading": false
        },
        {
          "term": "cri",
          "heading": false
        }
      ],
      "extract": "293 Diagnostic accuracy of the component tests: LC-aNAATs combined or urine LF- LAM based on the microbiological reference standard The sensitivity of LC-aNAATs combined alone ranged from 25.0% [Orikiriza 2021] to 85.7% [Jaganath 2024] and the specificity from 90.0% ([Olbrich 2024]) to 100% [Hanrahan 2018; Orikiriza 2021] between studies. The pooled sensitivity and specificity for LC-aNAATs combined alone were 69.3%",
      "extractCut": true,
      "blocks": [
        "library/10665-381036/blocks/prose-page-298",
        "library/10665-381036/blocks/figure-img-p298-1"
      ]
    },
    {
      "id": "page-299",
      "number": null,
      "title": "Page 299",
      "level": 1,
      "pageStart": 299,
      "pageEnd": 299,
      "labelStart": "294",
      "labelEnd": "294",
      "words": 127,
      "summary": {
        "text": "Caption for Figure 16, forest plots of the difference in accuracy between combined NAATs plus LF-LAM and combined NAATs alone in children with HIV.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "lc-anaats combined",
          "heading": false
        },
        {
          "term": "study-specific",
          "heading": false
        },
        {
          "term": "black",
          "heading": false
        },
        {
          "term": "difference",
          "heading": false
        }
      ],
      "extract": "294 Figure 16: Forest plots of study-specific and summary estimates of difference in accuracy between the parallel use of LC-aNAATs combined and LF-LAM versus LC-aNAATs combined alone for tuberculosis in children with HIV with presumed pulmonary tuberculosis by MRS. The black squares represent the point estimate of one study, the black horizontal line its 95% confidence interval (CI). The QUADAS-C risk-of-bias",
      "extractCut": true,
      "blocks": [
        "library/10665-381036/blocks/prose-page-299",
        "library/10665-381036/blocks/figure-img-p299-1"
      ]
    },
    {
      "id": "page-300",
      "number": null,
      "title": "Page 300",
      "level": 1,
      "pageStart": 300,
      "pageEnd": 300,
      "labelStart": "295",
      "labelEnd": "295",
      "words": 346,
      "summary": {
        "text": "Caption for Figure 17, then reports that parallel testing raised sensitivity by about 50% over LF-LAM alone, and gives component test accuracy against a composite reference standard.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "lf-lam alone",
          "heading": false
        },
        {
          "term": "lf-lam versus",
          "heading": false
        },
        {
          "term": "pooled difference",
          "heading": false
        },
        {
          "term": "lc-anaats combined",
          "heading": false
        },
        {
          "term": "pooled sensitivity",
          "heading": false
        },
        {
          "term": "plus lc-anaat",
          "heading": false
        },
        {
          "term": "cri",
          "heading": false
        },
        {
          "term": "composite reference",
          "heading": false
        }
      ],
      "extract": "295 Figure 17: Forest plot of pooled sensitivity and specificity for all studies, by each index test. The squares represent the pooled sensitivity and specificity, the black horizontal line its 95% credible interval (CrI). The pooled difference in sensitivity and specificity between parallel testing and LC-aNAAT alone is indicated by a line connecting two squares. This pooled difference may not correspond to the",
      "extractCut": true,
      "blocks": [
        "library/10665-381036/blocks/prose-page-300",
        "library/10665-381036/blocks/figure-img-p300-1"
      ]
    },
    {
      "id": "page-301",
      "number": null,
      "title": "Page 301",
      "level": 1,
      "pageStart": 301,
      "pageEnd": 301,
      "labelStart": "296",
      "labelEnd": "296",
      "words": 348,
      "summary": {
        "text": "Caption for Figure 18 and pooled accuracy of combined NAATs and LF-LAM alone against a composite reference standard, with the incremental accuracy of adding LF-LAM.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "lc-anaats combined",
          "heading": false
        },
        {
          "term": "combined alone",
          "heading": false
        },
        {
          "term": "anaats combined",
          "heading": false
        },
        {
          "term": "alone ranged",
          "heading": false
        },
        {
          "term": "lf-lam versus",
          "heading": false
        },
        {
          "term": "pooled sensitivity",
          "heading": false
        },
        {
          "term": "cri",
          "heading": false
        },
        {
          "term": "hanrahan",
          "heading": false
        }
      ],
      "extract": "296 Figure 18: Forest plots the parallel use of LC-aNAAT on respiratory sample and LC-aNAAT on stool. Sensitivity and specificity for tuberculosis in children without HIV or HIV status unknown using a MRS. The squares represent the sensitivity and specificity of one study, the black line its confidence interval (CI). TP = true positive; FP = false positive; FN = false negative; TN = true negative Diagnostic accuracy",
      "extractCut": true,
      "blocks": [
        "library/10665-381036/blocks/prose-page-301",
        "library/10665-381036/blocks/figure-img-p301-1"
      ]
    },
    {
      "id": "page-302",
      "number": null,
      "title": "Page 302",
      "level": 1,
      "pageStart": 302,
      "pageEnd": 302,
      "labelStart": "297",
      "labelEnd": "297",
      "words": 37,
      "summary": {
        "text": "A short fragment pointing to the summary-of-findings appendices for PICO 2.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "lc-anaats",
          "heading": false
        },
        {
          "term": "pico",
          "heading": false
        },
        {
          "term": "urinary",
          "heading": false
        }
      ],
      "extract": "297 participants, MRS (PICO 1) See Appendix 23: Summary of findings of incremental accuracy for parallel use of LC-aNAATs on respiratory samples and stool and urinary LF-LAM versus LC-aNAATs combined alone for all participants, CRS (PICO 1)",
      "extractCut": false,
      "blocks": [
        "library/10665-381036/blocks/prose-page-302"
      ]
    },
    {
      "id": "page-303",
      "number": null,
      "title": "Page 303",
      "level": 1,
      "pageStart": 303,
      "pageEnd": 303,
      "labelStart": "298",
      "labelEnd": "298",
      "words": 124,
      "summary": {
        "text": "Caption for Figure 19, forest plots of the accuracy difference for combined NAATs plus LF-LAM against a composite reference standard in children with HIV.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "study-specific",
          "heading": false
        },
        {
          "term": "black",
          "heading": false
        },
        {
          "term": "difference",
          "heading": false
        },
        {
          "term": "risk-of-bias",
          "heading": false
        }
      ],
      "extract": "298 Figure 19: Forest plots of study-specific and summary estimates of difference in accuracy between the parallel use of LC-aNAATs combined and LF-LAM for tuberculosis in children with HIV with presumed pulmonary tuberculosis by a CRS. The black squares represent the point estimate of one study, the black horizontal line its 95% confidence interval (CI). The QUADAS-C risk-of-bias judgements by study are included on",
      "extractCut": true,
      "blocks": [
        "library/10665-381036/blocks/prose-page-303",
        "library/10665-381036/blocks/figure-img-p303-1"
      ]
    },
    {
      "id": "page-304",
      "number": null,
      "title": "Page 304",
      "level": 1,
      "pageStart": 304,
      "pageEnd": 304,
      "labelStart": "299",
      "labelEnd": "299",
      "words": 339,
      "summary": {
        "text": "Reports the incremental accuracy of parallel testing over LF-LAM alone against a composite reference standard, and lists the PICO 2 subgroup analyses, including advanced HIV disease and low CD4 count.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "lc-anaats combined",
          "heading": false
        },
        {
          "term": "lf-lam versus",
          "heading": false
        },
        {
          "term": "lf-lam ranged",
          "heading": false
        },
        {
          "term": "comparative accuracy",
          "heading": false
        },
        {
          "term": "estimates ranged",
          "heading": false
        },
        {
          "term": "advanced hiv",
          "heading": false
        },
        {
          "term": "comparative diagnostic",
          "heading": false
        },
        {
          "term": "specificity estimates",
          "heading": false
        }
      ],
      "extract": "Incremental diagnostic accuracy of LC-aNAATs combined and LF-LAM versus LF-LAM alone based on the composite reference standard The pooled difference in accuracy of the parallel use of LC-aNAATs combined and LF-LAM versus LF- LAM alone was 10.1% (95% CrI 5.1 to 17.2; PI 20.3 to 79.1) for sensitivity and -3.5% (95% CrI -21.6 to -4.9; PI -16.2 to -3.4) for specificity. 4.5.3 Subgroup analyses using a microbiological",
      "extractCut": true,
      "blocks": [
        "library/10665-381036/blocks/prose-page-304"
      ]
    },
    {
      "id": "page-305",
      "number": null,
      "title": "Page 305",
      "level": 1,
      "pageStart": 305,
      "pageEnd": 305,
      "labelStart": "300",
      "labelEnd": "300",
      "words": 445,
      "summary": {
        "text": "Presents Table 4, summarising sensitivity and specificity for combined NAATs, LF-LAM and parallel testing in all participants and in subgroups such as advanced HIV disease. It also reports sensitivity analyses that change the estimated gains and losses.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "combined lf-lam",
          "heading": false
        },
        {
          "term": "lc-anaats combined",
          "heading": false
        },
        {
          "term": "zero invalid",
          "heading": false
        },
        {
          "term": "reported invalid",
          "heading": false
        },
        {
          "term": "observed zero",
          "heading": false
        },
        {
          "term": "pooled difference",
          "heading": false
        },
        {
          "term": "hanrahan",
          "heading": false
        },
        {
          "term": "studies observed",
          "heading": false
        }
      ],
      "extract": "Table 4: Summary accuracy for subgroups of interest. Summary accuracy by test with the difference between the parallel use (LC-aNAAT and LF-LAM) versus LC-aNAAT alone for detection of tuberculosis against a MRS Studies (participants) Summary sensitivity 95% CrI Summary specificity 95% CrI Primary analysis (MRS), all participants LC-aNAATs combined 6 (653) 69.3% 49.9, 84.0 95.4% 91.1, 98.0 LF-LAM 27.4% 13.5, 47.5",
      "extractCut": true,
      "blocks": [
        "library/10665-381036/blocks/prose-page-305"
      ]
    },
    {
      "id": "page-306",
      "number": null,
      "title": "Page 306",
      "level": 1,
      "pageStart": 306,
      "pageEnd": 306,
      "labelStart": "301",
      "labelEnd": "301",
      "words": 85,
      "summary": {
        "text": "Reports that excluding participants with missing or invalid results gave a slightly larger sensitivity gain and a larger specificity loss for parallel testing than the primary analysis.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "pooled difference",
          "heading": false
        },
        {
          "term": "cri",
          "heading": false
        },
        {
          "term": "non-determinate",
          "heading": false
        }
      ],
      "extract": "(95% CrI −6.9 to −1.3). When excluding participants with at least one unavailable or non-determinate index test result (6 studies, 548 participants), pooled difference in sensitivity comparing the accuracy of parallel testing to LC-aNAAT combined was 8.4% (95% CrI 1.9 to 24.4) while pooled difference in specificity was - 11.6% (95% CrI -21.2 to -5.9), compared to the primary analysis with a pooled difference in",
      "extractCut": true,
      "blocks": [
        "library/10665-381036/blocks/prose-page-306"
      ]
    },
    {
      "id": "page-307",
      "number": null,
      "title": "Page 307",
      "level": 1,
      "pageStart": 307,
      "pageEnd": 307,
      "labelStart": "302",
      "labelEnd": "302",
      "words": 509,
      "summary": {
        "text": "Opens the discussion by summarising the evidence base of 12 and six fully paired studies for the two review questions. It then begins setting out the main PICO 1 results as expected outcomes per 1000 children.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "stool alone",
          "heading": false
        },
        {
          "term": "pulmonary tuberculosis",
          "heading": false
        },
        {
          "term": "true positives",
          "heading": false
        },
        {
          "term": "pooled difference",
          "heading": false
        },
        {
          "term": "parallel testing",
          "heading": false
        },
        {
          "term": "respiratory samples",
          "heading": false
        },
        {
          "term": "presumptive pulmonary",
          "heading": false
        },
        {
          "term": "parallel strategy",
          "heading": false
        }
      ],
      "extract": "5. DISCUSSION This systematic review summarizes the evidence on the parallel use of LC-aNAAT on respiratory samples and LC-aNAAT on stool in children without HIV with presumptive pulmonary tuberculosis disease, compared to each test alone, based on 12 fully paired comparative diagnostic accuracy studies. Furthermore, it summarises the evidence on the parallel use of LC-aNAAT on respiratory samples plus LC-aNAAT on",
      "extractCut": true,
      "blocks": [
        "library/10665-381036/blocks/prose-page-307"
      ]
    },
    {
      "id": "page-308",
      "number": null,
      "title": "Page 308",
      "level": 1,
      "pageStart": 308,
      "pageEnd": 308,
      "labelStart": "303",
      "labelEnd": "303",
      "words": 514,
      "summary": {
        "text": "Translates pooled accuracy of parallel respiratory and stool NAAT testing into numbers of true and false positives and negatives per 1000 children. It also shows how many extra children would be correctly or wrongly identified compared with each test alone.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "pulmonary tuberculosis",
          "heading": false
        },
        {
          "term": "true positives",
          "heading": false
        },
        {
          "term": "pooled difference",
          "heading": false
        },
        {
          "term": "false positives",
          "heading": false
        },
        {
          "term": "stool alone",
          "heading": false
        },
        {
          "term": "true negatives",
          "heading": false
        },
        {
          "term": "parallel testing",
          "heading": false
        },
        {
          "term": "parallel strategy",
          "heading": false
        }
      ],
      "extract": "• Pooled sensitivity: 70.2% (51.1 to 84.7) | Pooled specificity: 95.4% (91.7 to 97.8) ➔ For a population of 1,000 children where 400 have tuberculosis on culture, 308 would test positive using the parallel testing strategy; of these, 281 would have pulmonary tuberculosis (true positives) and 11 would not have pulmonary tuberculosis (false positives); 692 would test negative by the parallel testing strategy; of these",
      "extractCut": true,
      "blocks": [
        "library/10665-381036/blocks/prose-page-308"
      ]
    },
    {
      "id": "page-309",
      "number": null,
      "title": "Page 309",
      "level": 1,
      "pageStart": 309,
      "pageEnd": 309,
      "labelStart": "304",
      "labelEnd": "304",
      "words": 503,
      "summary": {
        "text": "Continues the per-1000-children estimates for parallel testing compared with stool testing alone and for children with HIV, then opens the discussion of PICO 1.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "pulmonary tuberculosis",
          "heading": false
        },
        {
          "term": "true positives",
          "heading": false
        },
        {
          "term": "stool alone",
          "heading": false
        },
        {
          "term": "pooled difference",
          "heading": false
        },
        {
          "term": "true negatives",
          "heading": false
        },
        {
          "term": "false positives",
          "heading": false
        },
        {
          "term": "samples alone",
          "heading": false
        },
        {
          "term": "respiratory samples",
          "heading": false
        }
      ],
      "extract": "test negative; of these, 3 would not have pulmonary tuberculosis (true negatives) and 14 would have pulmonary tuberculosis (false-negatives). Compared to LC-aNAAT on stool alone, difference in accuracy is: • Pooled difference in sensitivity: 10.5% (6.9 to 15.0) • Pooled difference in specificity: -0.1% (-0.7 to 0) ➔ For a population of 1,000 children where 100 have tuberculosis on culture, compared to testing with",
      "extractCut": true,
      "blocks": [
        "library/10665-381036/blocks/prose-page-309"
      ]
    },
    {
      "id": "page-310",
      "number": null,
      "title": "Page 310",
      "level": 1,
      "pageStart": 310,
      "pageEnd": 310,
      "labelStart": "305",
      "labelEnd": "305",
      "words": 436,
      "summary": {
        "text": "Discusses that parallel testing in children without HIV raised sensitivity modestly over respiratory testing and more over stool testing, with small specificity losses, suggesting the two sample types complement each other. It notes that the sensitivity analyses gave similar overall estimates.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "parallel testing",
          "heading": false
        },
        {
          "term": "respiratory testing",
          "heading": false
        },
        {
          "term": "remained similar",
          "heading": false
        },
        {
          "term": "added sensitivity",
          "heading": false
        },
        {
          "term": "denominator decreased",
          "heading": false
        },
        {
          "term": "individual testing",
          "heading": false
        },
        {
          "term": "among children",
          "heading": false
        },
        {
          "term": "pulmonary tuberculosis",
          "heading": false
        }
      ],
      "extract": "testing had a sensitivity of 79.9% and specificity of 93.4% for detection of pulmonary tuberculosis based on the MRS. Sensitivity estimates ranged from 60-100% in the includes studies and may reflect that three of the eight included studies had less than 10 children each who were culture- positive, mostly due to low tuberculosis prevalence. However, the estimated difference in sensitivity between parallel and",
      "extractCut": true,
      "blocks": [
        "library/10665-381036/blocks/prose-page-310"
      ]
    },
    {
      "id": "page-311",
      "number": null,
      "title": "Page 311",
      "level": 1,
      "pageStart": 311,
      "pageEnd": 311,
      "labelStart": "306",
      "labelEnd": "306",
      "words": 473,
      "summary": {
        "text": "Summarises the PICO 2 results, giving pooled accuracy of parallel NAAT and LF-LAM testing in children with HIV and translating it into per-1000 estimates. These show that adding LF-LAM detects more cases but produces many more false positives.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "pulmonary tuberculosis",
          "heading": false
        },
        {
          "term": "lc-anaats combined",
          "heading": false
        },
        {
          "term": "true positives",
          "heading": false
        },
        {
          "term": "combined alone",
          "heading": false
        },
        {
          "term": "false positives",
          "heading": false
        },
        {
          "term": "pooled difference",
          "heading": false
        },
        {
          "term": "parallel testing",
          "heading": false
        },
        {
          "term": "true negatives",
          "heading": false
        }
      ],
      "extract": "5.3 Summary of main results of PICO 2 ___________________________________________________________________________ See Appendix 22 and 23. Summary table, comparative accuracy for parallel use of LC-aNAATs combined and LF-LAM versus LC-aNAATs combined alone using a MRS, presented for all participants, by subgroups, and sensitivity analyses. ___________________________________________________________________________",
      "extractCut": true,
      "blocks": [
        "library/10665-381036/blocks/prose-page-311"
      ]
    },
    {
      "id": "page-312",
      "number": null,
      "title": "Page 312",
      "level": 1,
      "pageStart": 312,
      "pageEnd": 312,
      "labelStart": "307",
      "labelEnd": "307",
      "words": 697,
      "summary": {
        "text": "Reports diagnostic accuracy results from a systematic review on tuberculosis testing in children with HIV, finishing the single-test example and then presenting parallel use of rapid molecular tests on respiratory and stool samples together with urine LF-LAM. Parallel testing showed a sensitivity of about 78% and specificity of 84%, with wide variation between studies, and sensitivity rose compared with molecular tests alone. Subgroup comparisons by age and CD4 count are also discussed, with overlapping credible intervals.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "lf-lam testing",
          "heading": false
        },
        {
          "term": "specificity ranged",
          "heading": false
        },
        {
          "term": "parallel testing",
          "heading": false
        },
        {
          "term": "culture-negative tuberculosis",
          "heading": false
        },
        {
          "term": "sensitivity estimates",
          "heading": false
        },
        {
          "term": "lf-lam increased",
          "heading": false
        },
        {
          "term": "chiv",
          "heading": false
        },
        {
          "term": "respiratory culture-negative",
          "heading": false
        }
      ],
      "extract": "46 would not have pulmonary tuberculosis (true negatives) and 61 would have pulmonary tuberculosis (false-negatives). 5.4 Parallel use of LC-aNAAT on respiratory samples plus stool and LF-LAM for diagnosis of tuberculosis compared to each assay alone (PICO 2) For the parallel use of LC-aNAATS combined and LF-LAM in CHIV, the overall diagnostic accuracy of parallel testing was estimated at a sensitivity of 77.6% and",
      "extractCut": true,
      "blocks": [
        "library/10665-381036/blocks/prose-page-312"
      ]
    },
    {
      "id": "page-313",
      "number": null,
      "title": "Page 313",
      "level": 1,
      "pageStart": 313,
      "pageEnd": 313,
      "labelStart": "308",
      "labelEnd": "308",
      "words": 688,
      "summary": {
        "text": "Discusses the strengths of the review, such as comprehensive searching and data from study authors, and its weaknesses, including unpublished re-analysed data and that fewer than half of eligible studies contributed. It compares the findings with earlier reviews in adults and with Cochrane estimates for single tests.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "lc-anaat alone",
          "heading": false
        },
        {
          "term": "childhood tuberculosis",
          "heading": false
        },
        {
          "term": "diagnostic accuracy",
          "heading": false
        },
        {
          "term": "systematic review",
          "heading": false
        },
        {
          "term": "review focused",
          "heading": false
        },
        {
          "term": "index test",
          "heading": false
        },
        {
          "term": "parallel testing",
          "heading": false
        },
        {
          "term": "estimations",
          "heading": false
        }
      ],
      "extract": "older than five years with a CD4-count lower than 200 per microliter. 5.5 Strengths and weaknesses of the review This review represents the first estimations of incremental accuracy using parallel- compared to single-test strategies in children, based on comprehensive searching, strict inclusion, and standardized data extraction. For both review questions, sample sizes were large and comparative accuracy study",
      "extractCut": true,
      "blocks": [
        "library/10665-381036/blocks/prose-page-313"
      ]
    },
    {
      "id": "page-314",
      "number": null,
      "title": "Page 314",
      "level": 1,
      "pageStart": 314,
      "pageEnd": 314,
      "labelStart": "309",
      "labelEnd": "309",
      "words": 41,
      "summary": {
        "text": "Compares the review's LF-LAM accuracy estimates with an earlier meta-analysis, noting lower sensitivity but higher specificity.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "seid",
          "heading": false
        },
        {
          "term": "versus",
          "heading": false
        },
        {
          "term": "kay",
          "heading": false
        }
      ],
      "extract": "Kay 2022]. For LF-LAM, estimated sensitivity in this review was lower compared to a previous systematic review and meta-analysis (27.4% versus 46.59%) but with a higher specificity (88.2% versus 76.45%); however, methodologies including reference standard definitions may have varied [Seid 2022].",
      "extractCut": false,
      "blocks": [
        "library/10665-381036/blocks/prose-page-314"
      ]
    },
    {
      "id": "page-315",
      "number": null,
      "title": "Page 315",
      "level": 1,
      "pageStart": 315,
      "pageEnd": 315,
      "labelStart": "310",
      "labelEnd": "310",
      "words": 663,
      "summary": {
        "text": "Sets out the authors' conclusions on testing children for tuberculosis, stressing the large gap in case detection and the priority given to sensitivity over specificity. It discusses the benefits of microbiological confirmation and of parallel testing on several sample types, and identifies research needs including extrapulmonary disease and drug-resistance detection.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "parallel lc-anaat",
          "heading": false
        },
        {
          "term": "parallel testing",
          "heading": false
        },
        {
          "term": "stool samples",
          "heading": false
        },
        {
          "term": "tuberculosis prevalence",
          "heading": false
        },
        {
          "term": "tuberculosis disease",
          "heading": false
        },
        {
          "term": "extrapulmonary tuberculosis",
          "heading": false
        },
        {
          "term": "respiratory specimens",
          "heading": false
        },
        {
          "term": "overtreatment",
          "heading": false
        }
      ],
      "extract": "6. Author’s conclusions 6.1 Implications for practice Almost half of the estimated tuberculosis cases in children and two-thirds among children less than 5 years old are not reported to public health programs worldwide [World Health Organization 2023]. Underdiagnosis is the main contributor to this case detection gap, and leads to delays in treatment initiation [World Health Organization 2023]. As most children who",
      "extractCut": true,
      "blocks": [
        "library/10665-381036/blocks/prose-page-315"
      ]
    },
    {
      "id": "page-316",
      "number": null,
      "title": "Page 316",
      "level": 1,
      "pageStart": 316,
      "pageEnd": 316,
      "labelStart": "311",
      "labelEnd": "311",
      "words": 65,
      "summary": {
        "text": "Concludes the research implications, calling for studies on other molecular platforms, implementation research and data on patient outcomes of parallel testing in children.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "children",
          "heading": false
        },
        {
          "term": "xpert",
          "heading": false
        },
        {
          "term": "facilitators",
          "heading": false
        }
      ],
      "extract": "limited to use of Xpert MTB/RIF and Xpert Ultra, and further research is needed on other LC-aNAAT platforms for children. There is an urgent need for implementation research to understand the barriers and facilitators to guide the best strategies for tuberculosis testing in children, and there is a lack of data on the impact of parallel testing on patient outcomes for children with presumptive tuberculosis.",
      "extractCut": false,
      "blocks": [
        "library/10665-381036/blocks/prose-page-316"
      ]
    },
    {
      "id": "page-317",
      "number": null,
      "title": "Page 317",
      "level": 1,
      "pageStart": 317,
      "pageEnd": 317,
      "labelStart": "312",
      "labelEnd": "312",
      "words": 372,
      "summary": {
        "text": "Acknowledges help with the search strategy, describes each author's contribution to the review and lists declarations of interest.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "primary studies",
          "heading": false
        },
        {
          "term": "authors",
          "heading": false
        },
        {
          "term": "wrote",
          "heading": false
        },
        {
          "term": "review",
          "heading": false
        },
        {
          "term": "health organization",
          "heading": false
        },
        {
          "term": "consultant",
          "heading": false
        },
        {
          "term": "protocol",
          "heading": false
        },
        {
          "term": "financial",
          "heading": false
        }
      ],
      "extract": "Acknowledgements We are grateful to Vittoria Lutje, the CIDG Information Specialist, for help with the search strategy. We thank all authors of primary studies for answering our questions and providing data. Contributions of authors All authors contributed significantly to this review. LO, SB, BY, JÅ, AK, AL, MS, and DJ wrote the protocol. LO and DJ performed the majority of the screening and data extraction with",
      "extractCut": true,
      "blocks": [
        "library/10665-381036/blocks/prose-page-317"
      ]
    },
    {
      "id": "page-318",
      "number": null,
      "title": "Page 318",
      "level": 1,
      "pageStart": 318,
      "pageEnd": 318,
      "labelStart": "313",
      "labelEnd": "313",
      "words": 514,
      "summary": {
        "text": "The start of the reference list for the review of parallel TB testing in children, citing studies of stool and urine testing and methodological sources.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "nandini dendukuri",
          "heading": false
        },
        {
          "term": "urine lipoarabinomannan",
          "heading": false
        },
        {
          "term": "lipoarabinomannan assay",
          "heading": false
        },
        {
          "term": "mikashmi kohli",
          "heading": false
        },
        {
          "term": "ian schiller",
          "heading": false
        },
        {
          "term": "pulmonary tuberculosis",
          "heading": false
        },
        {
          "term": "active tuberculosis",
          "heading": false
        },
        {
          "term": "rif assay",
          "heading": false
        }
      ],
      "extract": "References Abbott. \"Determine TB LAM Package Insert.\" Ainan, S., F. F. Furia, F. Mhimbira, N. P. Mnyambwa, N. Mgina, et al. 2021. \"Xpert R MTB/RIF assay testing on stool for the diagnosis of paediatric pulmonary TB in Tanzania.\" Public Health in Action 11 (2): 75-79. Babo, Y., B. Seremolo, M. Bogale, A. Bedru, Y. Wabe, et al. 2023. \"Comparison of Xpert MTB/RIF Ultra Results of Stool and Sputum in Children with",
      "extractCut": true,
      "blocks": [
        "library/10665-381036/blocks/prose-page-318"
      ]
    },
    {
      "id": "page-319",
      "number": null,
      "title": "Page 319",
      "level": 1,
      "pageStart": 319,
      "pageEnd": 319,
      "labelStart": "314",
      "labelEnd": "314",
      "words": 628,
      "summary": {
        "text": "Continuation of the reference list, citing studies on stool processing methods, clinical scoring and Xpert assays for tuberculosis.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "mtb rif",
          "heading": false
        },
        {
          "term": "xpert mtb",
          "heading": false
        },
        {
          "term": "rif ultra",
          "heading": false
        },
        {
          "term": "pediatric tuberculosis",
          "heading": false
        },
        {
          "term": "pulmonary tuberculosis",
          "heading": false
        },
        {
          "term": "cochrane database",
          "heading": false
        },
        {
          "term": "stool processing",
          "heading": false
        },
        {
          "term": "database syst",
          "heading": false
        }
      ],
      "extract": "de Haas, P., B. Yenew, E. Mengesha, A. Slyzkyi, Z. Gashu, et al. 2021. \"The Simple One-Step (SOS) Stool Processing Method for Use with the Xpert MTB/RIF Assay for a Child-Friendly Diagnosis of Tuberculosis Closer to the Point of Care.\" J Clin Microbiol 59 (8): e0040621. DiNardo, A. R., A. Detjen, P. Ustero, K. Ngo, J. Bacha, et al. 2016. \"Culture is an imperfect and heterogeneous reference standard in pediatric",
      "extractCut": true,
      "blocks": [
        "library/10665-381036/blocks/prose-page-319"
      ]
    },
    {
      "id": "page-320",
      "number": null,
      "title": "Page 320",
      "level": 1,
      "pageStart": 320,
      "pageEnd": 320,
      "labelStart": "315",
      "labelEnd": "315",
      "words": 609,
      "summary": {
        "text": "Continuation of the reference list, citing studies on smear positivity and urine LAM testing in children and adults with HIV.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "tb-lam lateral",
          "heading": false
        },
        {
          "term": "infect dis",
          "heading": false
        },
        {
          "term": "determine tb-lam",
          "heading": false
        },
        {
          "term": "stool processing",
          "heading": false
        },
        {
          "term": "pulmonary tuberculosis",
          "heading": false
        },
        {
          "term": "stool xpert",
          "heading": false
        },
        {
          "term": "clin infect",
          "heading": false
        },
        {
          "term": "urine lipoarabinomannan",
          "heading": false
        }
      ],
      "extract": "Kunkel, Amber, Pia Abel Zur Wiesch, Ruvandhi R Nathavitharana, Florian M Marx, Helen E Jenkins, et al. 2016. \"Smear positivity in paediatric and adult tuberculosis: systematic review and meta- analysis.\" BMC infectious diseases 16 (1): 1-9. LaCourse, S. M., P. B. Pavlinac, L. M. Cranmer, I. N. Njuguna, C. Mugo, et al. 2018. \"Stool Xpert MTB/RIF and urine lipoarabinomannan for the diagnosis of tuberculosis in",
      "extractCut": true,
      "blocks": [
        "library/10665-381036/blocks/prose-page-320"
      ]
    },
    {
      "id": "page-321",
      "number": null,
      "title": "Page 321",
      "level": 1,
      "pageStart": 321,
      "pageEnd": 321,
      "labelStart": "316",
      "labelEnd": "316",
      "words": 589,
      "summary": {
        "text": "Continuation of the reference list, citing paediatric TB diagnostic trials, Truenat assays and Cochrane methodological guidance.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "urine-based lipoarabinomannan",
          "heading": false
        },
        {
          "term": "urine lipoarabinomannan",
          "heading": false
        },
        {
          "term": "petra clowes",
          "heading": false
        },
        {
          "term": "lipoarabinomannan assay",
          "heading": false
        },
        {
          "term": "pulmonary tuberculosis",
          "heading": false
        },
        {
          "term": "pediatric tuberculosis",
          "heading": false
        },
        {
          "term": "diagnosing tuberculosis",
          "heading": false
        },
        {
          "term": "database syst",
          "heading": false
        }
      ],
      "extract": "Olbrich, L. 2024. \"Rapid and Accurate Diagnosis of Pediatric Tuberculosis Disease (RaPaed-TB). NCT03734172.\" Orikiriza, P., J. Smith, B. Ssekyanzi, D. Nyehangane, I. Mugisha Taremwa, et al. 2021. \"Tuberculosis diagnostic accuracy of stool Xpert MTB/RIF and urine AlereLAM in vulnerable children.\" European Respiratory Journal 59 (1): 01. Penn-Nicholson, A., S. N. Gomathi, C. Ugarte-Gil, A. Meaza, E. Lavu, et al. 2021.",
      "extractCut": true,
      "blocks": [
        "library/10665-381036/blocks/prose-page-321"
      ]
    },
    {
      "id": "page-322",
      "number": null,
      "title": "Page 322",
      "level": 1,
      "pageStart": 322,
      "pageEnd": 322,
      "labelStart": "317",
      "labelEnd": "317",
      "words": 508,
      "summary": {
        "text": "Continuation of the reference list, citing studies on LF-LAM, stool molecular detection and tools for assessing diagnostic accuracy studies.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "tuberculosis detection",
          "heading": false
        },
        {
          "term": "world health",
          "heading": false
        },
        {
          "term": "health organization",
          "heading": false
        },
        {
          "term": "ann intern",
          "heading": false
        },
        {
          "term": "intern med",
          "heading": false
        },
        {
          "term": "lipoarabinomannan assay",
          "heading": false
        },
        {
          "term": "lateral flow",
          "heading": false
        },
        {
          "term": "consolidated guidelines",
          "heading": false
        }
      ],
      "extract": "Thit, Swe Swe, Ne Myo Aung, Zaw Win Htet, Mark A. Boyd, Htin Aung Saw, et al. 2017. \"The clinical utility of the urine-based lateral flow lipoarabinomannan assay in HIV-infected adults in Myanmar: an observational study.\" BMC Medicine 15 (1): 145. Thomas, T. A. 2019. \"Tuberculosis in Children.\" Thorac Surg Clin 29 (1): 109-121. Covidence systematic review software., , Melbourne, Australia. Available at",
      "extractCut": true,
      "blocks": [
        "library/10665-381036/blocks/prose-page-322"
      ]
    },
    {
      "id": "page-323",
      "number": null,
      "title": "Page 323",
      "level": 1,
      "pageStart": 323,
      "pageEnd": 323,
      "labelStart": "318",
      "labelEnd": "318",
      "words": 108,
      "summary": {
        "text": "The final entries of the reference list, citing studies on molecular diagnosis of tuberculosis in children and Xpert Ultra in adults.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "lesley workman",
          "heading": false
        },
        {
          "term": "pulmonary tuberculosis",
          "heading": false
        },
        {
          "term": "xpert ultra",
          "heading": false
        },
        {
          "term": "heather",
          "heading": false
        }
      ],
      "extract": "Zar, Heather J, Lesley Workman, Washiefa Isaacs, Jacinta Munro, Faye Black, et al. 2012. \"Rapid molecular diagnosis of pulmonary tuberculosis in children using nasopharyngeal specimens.\" Clinical infectious diseases 55 (8): 1088-1095. Zar, Heather J, Lesley J Workman, Margaretha Prins, Linda J Bateman, Slindile P Mbhele, et al. 2019. \"Tuberculosis diagnosis in children using Xpert Ultra on different respiratory",
      "extractCut": true,
      "blocks": [
        "library/10665-381036/blocks/prose-page-323"
      ]
    },
    {
      "id": "page-324",
      "number": null,
      "title": "Page 324",
      "level": 1,
      "pageStart": 324,
      "pageEnd": 324,
      "labelStart": "319",
      "labelEnd": "319",
      "words": 470,
      "summary": {
        "text": "The title page and author list of Web Annex B.8, a systematic review of parallel use of rapid molecular tests and urine LF-LAM to detect tuberculosis in adults and adolescents with HIV, with author affiliations and corresponding author.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "heidelberg university",
          "heading": false
        },
        {
          "term": "mcgill university",
          "heading": false
        },
        {
          "term": "lmu university",
          "heading": false
        },
        {
          "term": "southern denmark",
          "heading": false
        },
        {
          "term": "university hospital",
          "heading": false
        },
        {
          "term": "copenhagen university",
          "heading": false
        },
        {
          "term": "tropical medicine",
          "heading": false
        },
        {
          "term": "denmark centre",
          "heading": false
        }
      ],
      "extract": "Web Annex B.8. Parallel use of low-complexity automated nucleic acid amplification tests and lateral flow urine lipoarabinomannan assay to detect tuberculosis disease in adults and adolescents with HIV: a systematic review Stephanie Bjerrum*, Bada Yang, Johanna Åhsberg, Laura Olbrich, Mathias Weis Damkjær, Ruvandhi Nathavitharana, Tobias Broger, Ioana Diana Olaru, Brittney Sweetser, Hayley Poore, Alia Razid,",
      "extractCut": true,
      "blocks": [
        "library/10665-381036/blocks/prose-page-324"
      ]
    },
    {
      "id": "page-325",
      "number": null,
      "title": "Page 325",
      "level": 1,
      "pageStart": 325,
      "pageEnd": 325,
      "labelStart": "320",
      "labelEnd": "320",
      "words": 557,
      "summary": {
        "text": "The executive summary's background, objective and methods for the review of parallel molecular and LF-LAM testing in people with HIV. It reports results on patient outcomes, including an uncertain effect of parallel testing on mortality in inpatient settings.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "respiratory lc-anaat",
          "heading": false
        },
        {
          "term": "urine lf-lam",
          "heading": false
        },
        {
          "term": "lc-anaat alone",
          "heading": false
        },
        {
          "term": "parallel testing",
          "heading": false
        },
        {
          "term": "percentage points",
          "heading": false
        },
        {
          "term": "tuberculosis disease",
          "heading": false
        },
        {
          "term": "composite reference",
          "heading": false
        },
        {
          "term": "points lower",
          "heading": false
        }
      ],
      "extract": "EXCECUTIVE SUMMARY Background Low complexity automated nucleic acid amplification tests (LC-aNAATs) are part of the molecular World Health Organization (WHO)-recommended rapid diagnostics widely used to diagnose tuberculosis disease. The lateral flow urine lipoarabinomannan (LF-LAM) test is recommended by WHO to assist in diagnosing tuberculosis disease among people with HIV. Previous systematic reviews have",
      "extractCut": true,
      "blocks": [
        "library/10665-381036/blocks/prose-page-325"
      ]
    },
    {
      "id": "page-326",
      "number": null,
      "title": "Page 326",
      "level": 1,
      "pageStart": 326,
      "pageEnd": 326,
      "labelStart": "321",
      "labelEnd": "321",
      "words": 432,
      "summary": {
        "text": "Continues the executive summary, noting that parallel testing likely increases microbiologically confirmed diagnoses and treatment starts and concluding that the two tests may be complementary. The page then begins the table of contents of the review.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "parallel testing",
          "heading": false
        },
        {
          "term": "urine lf-lam",
          "heading": false
        },
        {
          "term": "respiratory lc-anaat",
          "heading": false
        },
        {
          "term": "lc-anaat alone",
          "heading": false
        },
        {
          "term": "index tests",
          "heading": false
        },
        {
          "term": "testing strategy",
          "heading": false
        },
        {
          "term": "target condition",
          "heading": false
        },
        {
          "term": "risk ratio",
          "heading": false
        }
      ],
      "extract": "reporting higher overall mortality in the parallel testing group; this trial differed from the other two in having lower baseline antiretroviral therapy coverage, higher rates of comorbidities, and was conducted during the COVID-19 pandemic which may have affected overall care. The parallel testing strategy likely increases the proportion with a microbiologically test positive tuberculosis diagnosis (risk ratio 3.06",
      "extractCut": true,
      "blocks": [
        "library/10665-381036/blocks/prose-page-326"
      ]
    },
    {
      "id": "page-327",
      "number": null,
      "title": "Page 327",
      "level": 1,
      "pageStart": 327,
      "pageEnd": 327,
      "labelStart": "322",
      "labelEnd": "322",
      "words": 342,
      "summary": {
        "text": "Part of the table of contents of the review, listing methods, results, discussion and conclusion sections.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "adult inpatients",
          "heading": false
        },
        {
          "term": "urine lf-lam",
          "heading": false
        },
        {
          "term": "respiratory lc-anaats",
          "heading": false
        },
        {
          "term": "microbiological reference",
          "heading": false
        },
        {
          "term": "comparative diagnostic",
          "heading": false
        },
        {
          "term": "reference standard",
          "heading": false
        },
        {
          "term": "diagnostic accuracy",
          "heading": false
        },
        {
          "term": "methodological quality",
          "heading": false
        }
      ],
      "extract": "3.2.2 Searching other resources. ................................................................................................ 332 3.3 Data collection and analysis ....................................................................................................... 332 3.3.1 Selection of studies ............................................................................................................ 332",
      "extractCut": true,
      "blocks": [
        "library/10665-381036/blocks/prose-page-327"
      ]
    },
    {
      "id": "page-328",
      "number": null,
      "title": "Page 328",
      "level": 1,
      "pageStart": 328,
      "pageEnd": 328,
      "labelStart": "323",
      "labelEnd": "323",
      "words": 12,
      "summary": {
        "text": "The final lines of the table of contents, listing acknowledgements, author contributions, declarations of interest and references.",
        "status": "draft"
      },
      "keywords": [],
      "extract": "Acknowledgements 367 Contributions of authors 367 Declarations of interest 367 References 367",
      "extractCut": false,
      "blocks": [
        "library/10665-381036/blocks/prose-page-328"
      ]
    },
    {
      "id": "page-329",
      "number": null,
      "title": "Page 329",
      "level": 1,
      "pageStart": 329,
      "pageEnd": 329,
      "labelStart": "324",
      "labelEnd": "324",
      "words": 631,
      "summary": {
        "text": "Describes tuberculosis as the leading cause of death among people with HIV and explains the higher rates of extrapulmonary disease and diagnostic difficulty in this group. It introduces urine LF-LAM, noting that its sensitivity increases with greater immunosuppression.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "extrapulmonary tuberculosis",
          "heading": false
        },
        {
          "term": "tuberculosis disease",
          "heading": false
        },
        {
          "term": "pulmonary tuberculosis",
          "heading": false
        },
        {
          "term": "disseminated tuberculosis",
          "heading": false
        },
        {
          "term": "among people",
          "heading": false
        },
        {
          "term": "lf-lam test",
          "heading": false
        },
        {
          "term": "paucibacillary pulmonary",
          "heading": false
        },
        {
          "term": "deaths among",
          "heading": false
        }
      ],
      "extract": "1. BACKGROUND 1.1 Target condition being diagnosed Tuberculosis remains a challenge to diagnose particularly in people with HIV. Diagnosis is often missed or delayed resulting in worse prognosis and patient outcomes. Globally, tuberculosis resulted in 1.1 million deaths among people without HIV and 167,000 deaths among people with HIV in 2022, and is the leading cause of death among people with HIV [Organization",
      "extractCut": true,
      "blocks": [
        "library/10665-381036/blocks/prose-page-329"
      ]
    },
    {
      "id": "page-330",
      "number": null,
      "title": "Page 330",
      "level": 1,
      "pageStart": 330,
      "pageEnd": 330,
      "labelStart": "325",
      "labelEnd": "325",
      "words": 684,
      "summary": {
        "text": "Summarizes previous reviews that assessed molecular tests and LF-LAM separately, including evidence that combining them raised sensitivity, and gives earlier pooled LF-LAM accuracy estimates. It also begins to describe WHO's guidance on using LF-LAM by patient setting.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "urine lf-lam",
          "heading": false
        },
        {
          "term": "band intensity",
          "heading": false
        },
        {
          "term": "lf-lam test",
          "heading": false
        },
        {
          "term": "tuberculosis disease",
          "heading": false
        },
        {
          "term": "scale card",
          "heading": false
        },
        {
          "term": "xpert mtb",
          "heading": false
        },
        {
          "term": "mtb rif",
          "heading": false
        },
        {
          "term": "extrapulmonary tuberculosis",
          "heading": false
        }
      ],
      "extract": "Previous reviews have traditionally assessed diagnostic accuracy of LC-aNAATs and LF-LAM each in isolation for detection of tuberculosis including Xpert MTB/RIF and Xpert Ultra assays (Cepheid, Sunnyvale, USA) for pulmonary tuberculosis [Zifodya 2021; Shapiro 2021] and extrapulmonary tuberculosis [Kohli 2021a] and urine LF-LAM for people with HIV [Bjerrum 2019c]. Some studies have found that urine LF-LAM and",
      "extractCut": true,
      "blocks": [
        "library/10665-381036/blocks/prose-page-330"
      ]
    },
    {
      "id": "page-331",
      "number": null,
      "title": "Page 331",
      "level": 1,
      "pageStart": 331,
      "pageEnd": 331,
      "labelStart": "326",
      "labelEnd": "326",
      "words": 549,
      "summary": {
        "text": "Describes WHO criteria for LF-LAM use in inpatient and outpatient settings and introduces the molecular index tests, Xpert MTB/RIF, Xpert Ultra and Truenat, and how they work.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "truenat mtb",
          "heading": false
        },
        {
          "term": "xpert mtb",
          "heading": false
        },
        {
          "term": "mtb rif",
          "heading": false
        },
        {
          "term": "xpert ultra",
          "heading": false
        },
        {
          "term": "mtb plus",
          "heading": false
        },
        {
          "term": "tuberculosis complex",
          "heading": false
        },
        {
          "term": "ultra versus",
          "heading": false
        },
        {
          "term": "cell count",
          "heading": false
        }
      ],
      "extract": "i.e. inpatient and outpatient settings [World Health Organization. 2021a]. In inpatient settings, LF- LAM is recommended in people with HIV if: with signs and symptoms of tuberculosis; advanced HIV disease; seriously ill; or with a CD4 cell count of less than or equal to 200 cells/mm3, irrespective of signs and symptoms of tuberculosis. In outpatient settings, LF-LAM is suggested in people with HIV if: with signs",
      "extractCut": true,
      "blocks": [
        "library/10665-381036/blocks/prose-page-331"
      ]
    },
    {
      "id": "page-332",
      "number": null,
      "title": "Page 332",
      "level": 1,
      "pageStart": 332,
      "pageEnd": 332,
      "labelStart": "327",
      "labelEnd": "327",
      "words": 352,
      "summary": {
        "text": "Explains the intended role of LF-LAM as an add-on test and molecular tests as initial tests, and the rationale for estimating the change in accuracy when both are used in parallel to inform WHO guidelines.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "broger",
          "heading": false
        },
        {
          "term": "lc-anaat",
          "heading": false
        },
        {
          "term": "lf-lam",
          "heading": false
        },
        {
          "term": "diagnostic accuracy",
          "heading": false
        },
        {
          "term": "lam",
          "heading": false
        },
        {
          "term": "tuberculosis",
          "heading": false
        },
        {
          "term": "systematic review",
          "heading": false
        },
        {
          "term": "yield",
          "heading": false
        }
      ],
      "extract": "1.3 Role of the tests The WHO operational handbook on tuberculosis states that “Urine LF-LAM should be used as an add-on to clinical judgement in combination with other tests. It should not be used as a replacement or triage test” [World Health Organization. 2021c]. For LC-aNAAT, the suggested role is an initial test replacing smear microscopy for the diagnosis of tuberculosis [World Health Organization. 2021a]. LF-",
      "extractCut": true,
      "blocks": [
        "library/10665-381036/blocks/prose-page-332"
      ]
    },
    {
      "id": "page-333",
      "number": null,
      "title": "Page 333",
      "level": 1,
      "pageStart": 333,
      "pageEnd": 333,
      "labelStart": "328",
      "labelEnd": "328",
      "words": 394,
      "summary": {
        "text": "Lists the review questions on the incremental accuracy of parallel testing in adults and adolescents with HIV, the subgroups of interest and the patient-important outcomes such as mortality and time to treatment.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "presumptive tuberculosis",
          "heading": false
        },
        {
          "term": "respiratory lc-anaats",
          "heading": false
        },
        {
          "term": "chest x-ray",
          "heading": false
        },
        {
          "term": "tuberculosis disease",
          "heading": false
        },
        {
          "term": "mwrd",
          "heading": false
        },
        {
          "term": "cell count",
          "heading": false
        },
        {
          "term": "advanced hiv",
          "heading": false
        },
        {
          "term": "crp",
          "heading": false
        }
      ],
      "extract": "2. Review questions We addressed the following PICO (population, intervention, comparison, outcome) questions. See Appendix 1: PICO questions. 1. What is the incremental diagnostic accuracy of parallel use of respiratory LC-aNAATs and urine LF-LAM for diagnosis of tuberculosis disease in adults and adolescents with HIV who present with presumptive tuberculosis, compared to any of the tests alone? In addition, we",
      "extractCut": true,
      "blocks": [
        "library/10665-381036/blocks/prose-page-333"
      ]
    },
    {
      "id": "page-334",
      "number": null,
      "title": "Page 334",
      "level": 1,
      "pageStart": 334,
      "pageEnd": 334,
      "labelStart": "329",
      "labelEnd": "329",
      "words": 588,
      "summary": {
        "text": "Begins the methods, setting out the types of comparative diagnostic accuracy studies eligible and excluded and the inclusion of adults and adolescents with HIV and presumptive tuberculosis.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "urinary lf-lam",
          "heading": false
        },
        {
          "term": "respiratory lc-anaat",
          "heading": false
        },
        {
          "term": "respiratory samples",
          "heading": false
        },
        {
          "term": "accuracy studies",
          "heading": false
        },
        {
          "term": "ipd available",
          "heading": false
        },
        {
          "term": "index tests",
          "heading": false
        },
        {
          "term": "diagnostic accuracy",
          "heading": false
        },
        {
          "term": "comparative diagnostic",
          "heading": false
        }
      ],
      "extract": "3. METHODS The methodology of this review is similar to those used in previous reviews and protocols in the field [Shah 2016a; Bjerrum 2019c; Shapiro 2021; Kohli 2021a; Zifodya 2021; Inbaraj 2023a; Inbaraj 2023b]. 3.1 Criteria for considering studies for this review 3.1.1 Types of studies We included comparative diagnostic accuracy studies that evaluated the accuracy of a parallel combination of respiratory",
      "extractCut": true,
      "blocks": [
        "library/10665-381036/blocks/prose-page-334",
        "library/10665-381036/blocks/table-008"
      ]
    },
    {
      "id": "page-335",
      "number": null,
      "title": "Page 335",
      "level": 1,
      "pageStart": 335,
      "pageEnd": 335,
      "labelStart": "330",
      "labelEnd": "330",
      "words": 602,
      "summary": {
        "text": "Further defines eligible participants, including those with positive screening tests or unselected people with HIV in high-prevalence settings, and describes the index tests and the target condition of any form of tuberculosis.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "mtb detected",
          "heading": false
        },
        {
          "term": "urinary lf-lam",
          "heading": false
        },
        {
          "term": "mtb rif",
          "heading": false
        },
        {
          "term": "xpert mtb",
          "heading": false
        },
        {
          "term": "respiratory lc-anaat",
          "heading": false
        },
        {
          "term": "pulmonary tuberculosis",
          "heading": false
        },
        {
          "term": "rif resistance",
          "heading": false
        },
        {
          "term": "xpert ultra",
          "heading": false
        }
      ],
      "extract": "symptoms compatible with tuberculosis (e.g., a positive WHO four-symptom screen). We also included participants with a positive screening test for tuberculosis (e.g., abnormal chest X-ray findings, elevated C-reactive protein or positive screening mWRD). We included participants from studies that evaluated the index tests in people with HIV irrespective of tuberculosis symptoms, for example, studies of people with",
      "extractCut": true,
      "blocks": [
        "library/10665-381036/blocks/prose-page-335"
      ]
    },
    {
      "id": "page-336",
      "number": null,
      "title": "Page 336",
      "level": 1,
      "pageStart": 336,
      "pageEnd": 336,
      "labelStart": "331",
      "labelEnd": "331",
      "words": 514,
      "summary": {
        "text": "Defines the microbiological and composite reference standards used to determine whether participants had tuberculosis disease.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "microbiological reference",
          "heading": false
        },
        {
          "term": "reference standard",
          "heading": false
        },
        {
          "term": "composite reference",
          "heading": false
        },
        {
          "term": "sputum culture",
          "heading": false
        },
        {
          "term": "respiratory lc-anaat",
          "heading": false
        },
        {
          "term": "tuberculosis disease",
          "heading": false
        },
        {
          "term": "microbiological tests",
          "heading": false
        },
        {
          "term": "standard domain",
          "heading": false
        }
      ],
      "extract": "tuberculosis were not regarded as separate target conditions. 3.1.5 Reference standards We required studies to ascertain the presence or absence of tuberculosis disease using at least one of the following two reference standards: 3.1.5.1 Microbiological Reference Standard For a microbiological reference standard • Presence of tuberculosis disease was defined as a positive M. tuberculosis culture on any sample type",
      "extractCut": true,
      "blocks": [
        "library/10665-381036/blocks/prose-page-336"
      ]
    },
    {
      "id": "page-337",
      "number": null,
      "title": "Page 337",
      "level": 1,
      "pageStart": 337,
      "pageEnd": 337,
      "labelStart": "332",
      "labelEnd": "332",
      "words": 500,
      "summary": {
        "text": "Discusses how composite reference standards that include index tests may bias accuracy estimates, then describes the search methods and the process for screening titles, abstracts and full texts.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "composite reference",
          "heading": false
        },
        {
          "term": "literature search",
          "heading": false
        },
        {
          "term": "reference standard",
          "heading": false
        },
        {
          "term": "citation index",
          "heading": false
        },
        {
          "term": "index tests",
          "heading": false
        },
        {
          "term": "review authors",
          "heading": false
        },
        {
          "term": "uploaded",
          "heading": false
        },
        {
          "term": "dissertations",
          "heading": false
        }
      ],
      "extract": "Some composite reference standards may include one or more index tests (LF-LAM, respiratory LC- aNAATs, or both) as part of the reference standard; for example, if the decision to start tuberculosis treatment directly depended on the results of respiratory LC-aNAAT. This will likely lead to overestimation of diagnostic specificity. If the reference standard incorporated any of the index tests, we considered the risk",
      "extractCut": true,
      "blocks": [
        "library/10665-381036/blocks/prose-page-337"
      ]
    },
    {
      "id": "page-338",
      "number": null,
      "title": "Page 338",
      "level": 1,
      "pageStart": 338,
      "pageEnd": 338,
      "labelStart": "333",
      "labelEnd": "333",
      "words": 555,
      "summary": {
        "text": "Describes study selection, independent data extraction on study, participant, test and reference standard characteristics, quality assessment with QUADAS tools and the Bayesian statistical model for comparing accuracy.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "resolved disagreements",
          "heading": false
        },
        {
          "term": "study authors",
          "heading": false
        },
        {
          "term": "review authors",
          "heading": false
        },
        {
          "term": "bivariate random-effects",
          "heading": false
        },
        {
          "term": "data extraction",
          "heading": false
        },
        {
          "term": "summary difference",
          "heading": false
        },
        {
          "term": "extraction form",
          "heading": false
        },
        {
          "term": "absolute summary",
          "heading": false
        }
      ],
      "extract": "articles. We resolved disagreements through discussion and, if necessary, involved a third review author as arbiter. We listed reasons for exclusion. Review authors who co-authored any of the included studies did not participate in assessment or data extraction of their own study [Cochrane Library Content.]. We illustrated the study selection process in a PRISMA diagram [Page 2021]. 3.3.2 Data extraction and",
      "extractCut": true,
      "blocks": [
        "library/10665-381036/blocks/prose-page-338"
      ]
    },
    {
      "id": "page-339",
      "number": null,
      "title": "Page 339",
      "level": 1,
      "pageStart": 339,
      "pageEnd": 339,
      "labelStart": "334",
      "labelEnd": "334",
      "words": 582,
      "summary": {
        "text": "Explains the statistical approach for modelling differences in sensitivity and specificity between parallel and single testing, the prior distributions used and the handling of non-determinate results. It begins listing subgroup analyses for heterogeneity.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "non-determinate index",
          "heading": false
        },
        {
          "term": "mean logit-transformed",
          "heading": false
        },
        {
          "term": "testing minus",
          "heading": false
        },
        {
          "term": "parallel testing",
          "heading": false
        },
        {
          "term": "binomial distribution",
          "heading": false
        },
        {
          "term": "index test",
          "heading": false
        },
        {
          "term": "uniform distribution",
          "heading": false
        },
        {
          "term": "component test",
          "heading": false
        }
      ],
      "extract": "accomplished by assuming that difference in TP (TP of parallel testing minus TP of component test) and difference in TN (TN of parallel testing minus TN of component test) both follow a binomial distribution. This approach naturally accounts for the dependence between the two tests being compared (i.e. the parallel testing strategy and the component test) and ensures that difference in sensitivity cannot be lower",
      "extractCut": true,
      "blocks": [
        "library/10665-381036/blocks/prose-page-339"
      ]
    },
    {
      "id": "page-340",
      "number": null,
      "title": "Page 340",
      "level": 1,
      "pageStart": 340,
      "pageEnd": 340,
      "labelStart": "335",
      "labelEnd": "335",
      "words": 489,
      "summary": {
        "text": "Lists the remaining subgroup analyses and the sensitivity analyses, such as restricting to seriously ill patients, advanced HIV or Xpert Ultra. It then explains how data on health impact outcomes were identified from trials and related reviews.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "certainty rating",
          "heading": false
        },
        {
          "term": "rating risk",
          "heading": false
        },
        {
          "term": "publication bias",
          "heading": false
        },
        {
          "term": "log odds",
          "heading": false
        },
        {
          "term": "true difference",
          "heading": false
        },
        {
          "term": "accuracy review",
          "heading": false
        },
        {
          "term": "test accuracy",
          "heading": false
        },
        {
          "term": "diagnostic accuracy",
          "heading": false
        }
      ],
      "extract": "• CD4 cell count (CD4 ≤ 200 versus CD4 > 200) • Clinical setting (inpatient versus outpatient) • Type of LC-aNAAT. However, there was data only for Xpert MTB/RIF and Xpert MTB/RIF Ultra. This analysis was restricted to within-study comparisons 3.3.7 Sensitivity analysis We performed the following sensitivity analyses by limiting inclusion in the meta-analysis based on the following criteria: • Only screening",
      "extractCut": true,
      "blocks": [
        "library/10665-381036/blocks/prose-page-340"
      ]
    },
    {
      "id": "page-341",
      "number": null,
      "title": "Page 341",
      "level": 1,
      "pageStart": 341,
      "pageEnd": 341,
      "labelStart": "336",
      "labelEnd": "336",
      "words": 451,
      "summary": {
        "text": "Describes the methods for the part of the systematic review on how testing strategies affect patient outcomes, including only randomized trials that compared parallel respiratory LC-aNAAT and urine LF-LAM testing with either test alone. It lists outcomes such as cure, mortality and time to diagnosis or treatment, and notes that pooled risk ratios were estimated by random-effects meta-analysis.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "lc-anaat alone",
          "heading": false
        },
        {
          "term": "proportion treated",
          "heading": false
        },
        {
          "term": "proportion diagnosed",
          "heading": false
        },
        {
          "term": "mortality assessment",
          "heading": false
        },
        {
          "term": "controlled trials",
          "heading": false
        },
        {
          "term": "lf-lam",
          "heading": false
        },
        {
          "term": "confirmed tuberculosis",
          "heading": false
        },
        {
          "term": "review author",
          "heading": false
        }
      ],
      "extract": "on Impact of LF-LAM on patient outcomes [Nathavitharana 2021]; all articles with data on impact were further reviewed for inclusion by review author RRN. We included randomized controlled trials that assessed the effect of test strategies on the following patient important outcomes: cure, mortality, loss-to-follow-up, time to diagnosis, and time to treatment initiation. Trials that included participants as described",
      "extractCut": true,
      "blocks": [
        "library/10665-381036/blocks/prose-page-341"
      ]
    },
    {
      "id": "page-342",
      "number": null,
      "title": "Page 342",
      "level": 1,
      "pageStart": 342,
      "pageEnd": 342,
      "labelStart": "337",
      "labelEnd": "337",
      "words": 228,
      "summary": {
        "text": "Reports the search results of the systematic review: 457 records screened, 130 full texts assessed and 31 studies included, all comparing parallel respiratory LC-aNAAT and urine LF-LAM with either test alone. It explains that most data came from authors or from re-analysis of shared individual participant data.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "data re-analysed",
          "heading": false
        },
        {
          "term": "huerga",
          "heading": false
        },
        {
          "term": "participant data",
          "heading": false
        },
        {
          "term": "individual participant",
          "heading": false
        },
        {
          "term": "broger",
          "heading": false
        },
        {
          "term": "studies",
          "heading": false
        }
      ],
      "extract": "4. RESULTS 4.1 Results of the search We identified and screened a total of 457 records for inclusion in this systematic review. Of these, we assessed 130 full-text reports against our inclusion criteria. We excluded 99 records and provided reasons. Figure 1 shows the flow of studies in the review. We recorded the excluded studies (n=99) and the reasons for their exclusion. We included 31 unique studies: all studies",
      "extractCut": true,
      "blocks": [
        "library/10665-381036/blocks/prose-page-342"
      ]
    },
    {
      "id": "page-343",
      "number": null,
      "title": "Page 343",
      "level": 1,
      "pageStart": 343,
      "pageEnd": 343,
      "labelStart": "338",
      "labelEnd": "338",
      "words": 8,
      "summary": {
        "text": "A caption for the figure showing the flow of studies through the review.",
        "status": "draft"
      },
      "keywords": [],
      "extract": "Figure 8. Flow of studies in the review.",
      "extractCut": false,
      "blocks": [
        "library/10665-381036/blocks/prose-page-343",
        "library/10665-381036/blocks/figure-img-p343-1"
      ]
    },
    {
      "id": "page-344",
      "number": null,
      "title": "Page 344",
      "level": 1,
      "pageStart": 344,
      "pageEnd": 344,
      "labelStart": "339",
      "labelEnd": "339",
      "words": 119,
      "summary": {
        "text": "Begins the assessment of study quality using QUADAS-2, noting that 11 of 31 studies were at high risk of bias in patient selection, mostly because they excluded people unable to give sputum or urine samples.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "applicability concerns",
          "heading": false
        },
        {
          "term": "index test",
          "heading": false
        },
        {
          "term": "quadas",
          "heading": false
        },
        {
          "term": "bias",
          "heading": false
        }
      ],
      "extract": "4.2 Methodological quality of included studies 4.2.1 QUADAS-2 Figure 9 shows risk of bias and applicability concerns for each of the 31 studies included. In the patient selection domain, we considered 11 studies (35%) to be at high risk of bias for the following reasons: nine studies excluded participants who could not produce sputum samples (and/or urine)[Benjamin 2019; Bjerrum 2015; Broger-Cohort4 2020; Calligaro",
      "extractCut": true,
      "blocks": [
        "library/10665-381036/blocks/prose-page-344",
        "library/10665-381036/blocks/figure-img-p344-1"
      ]
    },
    {
      "id": "page-345",
      "number": null,
      "title": "Page 345",
      "level": 1,
      "pageStart": 345,
      "pageEnd": 345,
      "labelStart": "340",
      "labelEnd": "340",
      "words": 729,
      "summary": {
        "text": "Continues the QUADAS-2 assessment, describing other sources of bias such as enrolling people already on tuberculosis treatment or selecting known Xpert-positive cases. It reports that most studies raised low applicability concerns, explains the few with high concern, and notes that nine studies were at high risk of bias for flow and timing.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "unclear concern",
          "heading": false
        },
        {
          "term": "reference standard",
          "heading": false
        },
        {
          "term": "concern because",
          "heading": false
        },
        {
          "term": "study enrolled",
          "heading": false
        },
        {
          "term": "composite reference",
          "heading": false
        },
        {
          "term": "unclear risk",
          "heading": false
        },
        {
          "term": "microbiological reference",
          "heading": false
        },
        {
          "term": "extrapulmonary samples",
          "heading": false
        }
      ],
      "extract": "Peter 2015a; J.G. Peter 2016; Shah 2014; Stead 2023]; one study enrolled participants who had started tuberculosis treatment before index testing [de Vasconcellos 2021]; and one study enrolled a subset of participants with a known positive sputum Xpert ultra result for convenience that could have inflated sensitivity [Shapiro 2022]. Regarding applicability, 26 studies (84%) had low concern because the studies",
      "extractCut": true,
      "blocks": [
        "library/10665-381036/blocks/prose-page-345"
      ]
    },
    {
      "id": "page-346",
      "number": null,
      "title": "Page 346",
      "level": 1,
      "pageStart": 346,
      "pageEnd": 346,
      "labelStart": "341",
      "labelEnd": "341",
      "words": 670,
      "summary": {
        "text": "Completes the QUADAS-2 assessment and begins the QUADAS-C comparative risk-of-bias assessment of the 31 paired studies comparing parallel testing with LC-aNAAT alone. It notes issues such as non-determinate or invalid results, reported as generally low.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "huerga",
          "heading": false
        },
        {
          "term": "unclear risk",
          "heading": false
        },
        {
          "term": "considered studies",
          "heading": false
        },
        {
          "term": "standard domain",
          "heading": false
        },
        {
          "term": "index test",
          "heading": false
        },
        {
          "term": "studies because",
          "heading": false
        },
        {
          "term": "reference standard",
          "heading": false
        },
        {
          "term": "stead",
          "heading": false
        }
      ],
      "extract": "Wright 2018; Huerga 2017a; Huerga 2021; Liu 2022; Spooner 2022; Stead 2023] or because not all participants were included in the two-by-two tables [de Vasconcellos 2021; Huerga 2019; Liu 2022]. Three studies had unclear risk of bias [Huerga 2023a; Huerga 2020; Van Hoving 2019]. We judged the remaining 19 studies (61%) to be at low risk of bias noting that all participants were included in the analysis. 4.2.2",
      "extractCut": true,
      "blocks": [
        "library/10665-381036/blocks/prose-page-346"
      ]
    },
    {
      "id": "page-347",
      "number": null,
      "title": "Page 347",
      "level": 1,
      "pageStart": 347,
      "pageEnd": 347,
      "labelStart": "342",
      "labelEnd": "342",
      "words": 23,
      "summary": {
        "text": "Introduces the findings section with the caption of the figure on comparative risk of bias (QUADAS-C) for each study.",
        "status": "draft"
      },
      "keywords": [],
      "extract": "4.3 Findings Figure 10: Risk of bias in comparative accuracy estimates (QUADAS C) Review authors' judgements about each domain for each included study.",
      "extractCut": false,
      "blocks": [
        "library/10665-381036/blocks/prose-page-347",
        "library/10665-381036/blocks/figure-img-p347-1"
      ]
    },
    {
      "id": "page-348",
      "number": null,
      "title": "Page 348",
      "level": 1,
      "pageStart": 348,
      "pageEnd": 348,
      "labelStart": "343",
      "labelEnd": "343",
      "words": 618,
      "summary": {
        "text": "Describes the 31 included studies, carried out in 19 countries, mostly in sub-Saharan Africa and in high TB/HIV burden settings. It notes major differences between studies in target condition, CD4 counts, tuberculosis prevalence and setting, from inpatient wards to outpatient clinics and community screening.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "microbiological reference",
          "heading": false
        },
        {
          "term": "reference standard",
          "heading": false
        },
        {
          "term": "composite reference",
          "heading": false
        },
        {
          "term": "pulmonary tuberculosis",
          "heading": false
        },
        {
          "term": "accuracy against",
          "heading": false
        },
        {
          "term": "tuberculosis prevalence",
          "heading": false
        },
        {
          "term": "diagnostic accuracy",
          "heading": false
        },
        {
          "term": "sputum culture",
          "heading": false
        }
      ],
      "extract": "The 31 studies were conducted in 19 different countries, four (21%) in low-income countries, 10 (53%) in lower middle-income countries and five (26%) in upper middle-income countries. Fourteen countries (74%) were high burden countries for tuberculosis/HIV [World Health Organization. 2021b]. A majority of studies, 27 (87%), enrolled participants from 12 countries within Sub-Saharan Africa. We noted substantial",
      "extractCut": true,
      "blocks": [
        "library/10665-381036/blocks/prose-page-348"
      ]
    },
    {
      "id": "page-349",
      "number": null,
      "title": "Page 349",
      "level": 1,
      "pageStart": 349,
      "pageEnd": 349,
      "labelStart": "344",
      "labelEnd": "344",
      "words": 175,
      "summary": {
        "text": "Gives the pooled accuracy of parallel respiratory LC-aNAAT and urine LF-LAM testing against a microbiological reference standard: sensitivity about 78% and specificity about 89% across 27 studies, with a related forest plot.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "microbiological reference",
          "heading": false
        },
        {
          "term": "parallel",
          "heading": false
        },
        {
          "term": "lc-anaat",
          "heading": false
        },
        {
          "term": "reference standard",
          "heading": false
        },
        {
          "term": "cri",
          "heading": false
        }
      ],
      "extract": "screening setting, and one in primary health care facilities. For the remaining two studies, the setting was unclear. The median CD4 cell count ranged from 42 to 317 cells per µL. See Appendix 9: Characteristics of individual studies. Diagnostic accuracy of parallel use of respiratory LC-aNAAT and urine LF- LAM based on the microbiological reference standard The sensitivity of the parallel use of LC-aNAAT on",
      "extractCut": true,
      "blocks": [
        "library/10665-381036/blocks/prose-page-349",
        "library/10665-381036/blocks/figure-img-p349-2"
      ]
    },
    {
      "id": "page-350",
      "number": null,
      "title": "Page 350",
      "level": 1,
      "pageStart": 350,
      "pageEnd": 350,
      "labelStart": "345",
      "labelEnd": "345",
      "words": 264,
      "summary": {
        "text": "Reports pooled accuracy of the component tests on their own, with LC-aNAAT alone at about 68% sensitivity and 97% specificity and LF-LAM alone at about 39% sensitivity and 92% specificity. It also gives the pooled gain in sensitivity and loss in specificity from parallel testing compared with LC-aNAAT alone.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "lc-anaat alone",
          "heading": false
        },
        {
          "term": "respiratory lc-anaat",
          "heading": false
        },
        {
          "term": "versus lc-anaat",
          "heading": false
        },
        {
          "term": "lf-lam alone",
          "heading": false
        },
        {
          "term": "alone ranged",
          "heading": false
        },
        {
          "term": "urine lf-lam",
          "heading": false
        },
        {
          "term": "pooled difference",
          "heading": false
        }
      ],
      "extract": "Diagnostic accuracy of the component tests, respiratory LC-aNAAT and urine LF-LAM, based on the microbiological reference standard The sensitivity of respiratory LC-aNAAT alone ranged from 24% to 100%, and specificity from 91% to 100%. The pooled sensitivity LC-aNAAT alone was 68.0% (95% CrI 60.8 to 74.9) and specificity 96.7% (95% CrI 95.7 to 97.6), (27 studies; 12,651 participants, 2,368 (18.7%) with",
      "extractCut": true,
      "blocks": [
        "library/10665-381036/blocks/prose-page-350"
      ]
    },
    {
      "id": "page-351",
      "number": null,
      "title": "Page 351",
      "level": 1,
      "pageStart": 351,
      "pageEnd": 351,
      "labelStart": "346",
      "labelEnd": "346",
      "words": 110,
      "summary": {
        "text": "Caption for a forest plot of study-level differences in sensitivity and specificity between parallel testing and LC-aNAAT alone, noting why some confidence intervals include impossible values.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "study-specific",
          "heading": false
        },
        {
          "term": "black",
          "heading": false
        },
        {
          "term": "lc-anaat",
          "heading": false
        }
      ],
      "extract": "346 Figure 12. Forest plot of study-specific estimates of difference in sensitivity and specificity between the parallel use of LC-aNAAT and LF-LAM versus LC-aNAAT alone for tuberculosis in adults and adolescents with HIV, based on the microbiological reference standard. The black squares represent the point estimate of one study, the black horizontal line its 95% confidence interval (CI). The QUADAS-C risk-of-bias",
      "extractCut": true,
      "blocks": [
        "library/10665-381036/blocks/prose-page-351",
        "library/10665-381036/blocks/figure-img-p351-1"
      ]
    },
    {
      "id": "page-352",
      "number": null,
      "title": "Page 352",
      "level": 1,
      "pageStart": 352,
      "pageEnd": 352,
      "labelStart": "347",
      "labelEnd": "347",
      "words": 95,
      "summary": {
        "text": "Caption for a forest plot of pooled sensitivity and specificity for LF-LAM, LC-aNAAT and parallel testing, with the pooled differences between them.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "pooled difference",
          "heading": false
        },
        {
          "term": "squares",
          "heading": false
        },
        {
          "term": "reference standard",
          "heading": false
        }
      ],
      "extract": "347 Figure 13. Forest plot of pooled difference in sensitivity and specificity (all studies combined) by index test: LF-LAM, LC-aNAAT, and their parallel use. The squares represent the pooled sensitivity and specificity, the black horizontal line its 95% credible interval (CrI). The pooled difference in sensitivity and specificity between parallel testing and LC-aNAAT alone is indicated by a line connecting two",
      "extractCut": true,
      "blocks": [
        "library/10665-381036/blocks/prose-page-352",
        "library/10665-381036/blocks/figure-img-p352-1"
      ]
    },
    {
      "id": "page-353",
      "number": null,
      "title": "Page 353",
      "level": 1,
      "pageStart": 353,
      "pageEnd": 353,
      "labelStart": "348",
      "labelEnd": "348",
      "words": 551,
      "summary": {
        "text": "Reports that parallel testing raised sensitivity by about 36 percentage points over LF-LAM alone with a small loss of specificity, using the microbiological reference standard. It then presents the comparative accuracy based on a composite reference standard from 23 studies.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "lf-lam alone",
          "heading": false
        },
        {
          "term": "lc-anaat alone",
          "heading": false
        },
        {
          "term": "lf-lam versus",
          "heading": false
        },
        {
          "term": "urine lf-lam",
          "heading": false
        },
        {
          "term": "composite reference",
          "heading": false
        },
        {
          "term": "respiratory lc-anaat",
          "heading": false
        },
        {
          "term": "pooled difference",
          "heading": false
        },
        {
          "term": "parallel testing",
          "heading": false
        }
      ],
      "extract": "Incremental accuracy of parallel testing versus LF-LAM alone based on the microbiological reference standard The study-specific estimates of difference in accuracy between the parallel use of respiratory LC-aNAAT and urine LF-LAM versus LF-LAM alone for tuberculosis in adults and adolescents with HIV, based on the microbiological reference standard, are shown in Appendix 15. The pooled difference in sensitivity and",
      "extractCut": true,
      "blocks": [
        "library/10665-381036/blocks/prose-page-353"
      ]
    },
    {
      "id": "page-354",
      "number": null,
      "title": "Page 354",
      "level": 1,
      "pageStart": 354,
      "pageEnd": 354,
      "labelStart": "349",
      "labelEnd": "349",
      "words": 566,
      "summary": {
        "text": "Introduces subgroup analyses of parallel testing versus either test alone, by symptoms, CD4 count, inpatient or outpatient status, positive TB screening, advanced HIV and serious illness. It gives results for symptomatic and asymptomatic people and begins the results for people with CD4 counts of 200 or less.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "between-subgroup difference",
          "heading": false
        },
        {
          "term": "pooled difference",
          "heading": false
        },
        {
          "term": "asymptomatic participants",
          "heading": false
        },
        {
          "term": "symptomatic participants",
          "heading": false
        },
        {
          "term": "versus asymptomatic",
          "heading": false
        },
        {
          "term": "summary difference",
          "heading": false
        },
        {
          "term": "pooled sensitivity",
          "heading": false
        },
        {
          "term": "parallel testing",
          "heading": false
        }
      ],
      "extract": "4.4.3 Subgroup analyses based on the microbiological reference standard The comparative diagnostic accuracy for the parallel use of respiratory LC-aNAAT and LF-LAM versus any of the tests alone is shown for the following subgroups: symptomatic versus asymptomatic, CD4 cell count ≤ 200 versus > 200, and inpatients versus outpatients. We also show results limited to the following subgroups: screening positive for",
      "extractCut": true,
      "blocks": [
        "library/10665-381036/blocks/prose-page-354",
        "library/10665-381036/blocks/table-009"
      ]
    },
    {
      "id": "page-355",
      "number": null,
      "title": "Page 355",
      "level": 1,
      "pageStart": 355,
      "pageEnd": 355,
      "labelStart": "350",
      "labelEnd": "350",
      "words": 549,
      "summary": {
        "text": "Continues the subgroup results, giving the sensitivity gain and specificity loss of parallel testing in people with CD4 counts of 200 or less, and noting few data above 200. Tables summarize pooled accuracy by CD4 count and by inpatient or outpatient setting.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "between-subgroup difference",
          "heading": false
        },
        {
          "term": "pooled difference",
          "heading": false
        },
        {
          "term": "versus lc-anaat",
          "heading": false
        },
        {
          "term": "summary difference",
          "heading": false
        },
        {
          "term": "lc-anaat alone",
          "heading": false
        },
        {
          "term": "parallel testing",
          "heading": false
        },
        {
          "term": "pooled specificity",
          "heading": false
        },
        {
          "term": "pooled sensitivity",
          "heading": false
        }
      ],
      "extract": "between parallel testing and LC-aNAAT was 9.2% (95% CrI 4.0 to 17.4; 95% PI 0.6 to 57.4) and -9.4% (95% CrI -14.7 to -5.6; 95% PI -40.0 to -1.6). Two studies reported data for participants with CD4 > 200, involving 148 participants, 11 (7%) with tuberculosis. Table 10: Summary accuracy by CD4. Pooled test accuracy along with difference between the parallel use (LC-aNAAT and LF-LAM) versus LC-aNAAT alone for",
      "extractCut": true,
      "blocks": [
        "library/10665-381036/blocks/prose-page-355",
        "library/10665-381036/blocks/table-010",
        "library/10665-381036/blocks/table-011"
      ]
    },
    {
      "id": "page-356",
      "number": null,
      "title": "Page 356",
      "level": 1,
      "pageStart": 356,
      "pageEnd": 356,
      "labelStart": "351",
      "labelEnd": "351",
      "words": 549,
      "summary": {
        "text": "Reports evidence that the benefit in sensitivity and the loss in specificity from parallel testing are larger for inpatients than outpatients. It then gives results for people screening positive for tuberculosis by chest X-ray or CRP and for seriously ill participants.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "between-subgroup difference",
          "heading": false
        },
        {
          "term": "pooled difference",
          "heading": false
        },
        {
          "term": "summary difference",
          "heading": false
        },
        {
          "term": "pooled specificity",
          "heading": false
        },
        {
          "term": "pooled sensitivity",
          "heading": false
        },
        {
          "term": "parallel testing",
          "heading": false
        },
        {
          "term": "ill participants",
          "heading": false
        },
        {
          "term": "cri",
          "heading": false
        }
      ],
      "extract": "There was evidence that the difference in sensitivity among inpatients exceeds that of outpatients (probability that between-subgroup difference > 0 was 98%). Regarding difference in specificity, there was also evidence of between-subgroup difference (probability that between-subgroup difference < 0 was 97%). Comparative accuracy in participants screening positive for tuberculosis Six studies reported data for",
      "extractCut": true,
      "blocks": [
        "library/10665-381036/blocks/prose-page-356",
        "library/10665-381036/blocks/table-012",
        "library/10665-381036/blocks/table-013",
        "library/10665-381036/blocks/table-014"
      ]
    },
    {
      "id": "page-357",
      "number": null,
      "title": "Page 357",
      "level": 1,
      "pageStart": 357,
      "pageEnd": 357,
      "labelStart": "352",
      "labelEnd": "352",
      "words": 383,
      "summary": {
        "text": "Tabulates accuracy among seriously ill participants and reports additional analyses, including studies that used Xpert Ultra and the proportion of unavailable or non-determinate test results.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "non determinate",
          "heading": false
        },
        {
          "term": "xpert ultra",
          "heading": false
        },
        {
          "term": "pooled difference",
          "heading": false
        },
        {
          "term": "determinate index",
          "heading": false
        },
        {
          "term": "summary difference",
          "heading": false
        },
        {
          "term": "pooled specificity",
          "heading": false
        },
        {
          "term": "pooled sensitivity",
          "heading": false
        },
        {
          "term": "parallel testing",
          "heading": false
        }
      ],
      "extract": "Summary accuracy by test with the difference between the parallel use (LC-aNAAT and LF-LAM) versus LC-aNAAT alone for detection of tuberculosis against a microbiological reference standard Participants Studies (participants) Pooled sensitivity (95% CrI) Pooled specificity (95% CrI) Seriously ill LF-LAM 6 (577) 47.8% (30.6 to 67.0) 82.4% (71.4 to 90.6) LC-aNAAT 6 (577) 67.9% (47.8 to 85.0) 94.0% (89.4 to 97.1)",
      "extractCut": true,
      "blocks": [
        "library/10665-381036/blocks/prose-page-357",
        "library/10665-381036/blocks/figure-img-p357-1",
        "library/10665-381036/blocks/table-015",
        "library/10665-381036/blocks/table-016"
      ]
    },
    {
      "id": "page-358",
      "number": null,
      "title": "Page 358",
      "level": 1,
      "pageStart": 358,
      "pageEnd": 358,
      "labelStart": "353",
      "labelEnd": "353",
      "words": 299,
      "summary": {
        "text": "Reports sensitivity analyses: excluding high-risk studies raised the sensitivity gain of parallel testing to about 10 points, while excluding participants with missing or non-determinate results lowered it to about 4 points. A table summarizes the results.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "pooled difference",
          "heading": false
        },
        {
          "term": "summary difference",
          "heading": false
        },
        {
          "term": "excluding participants",
          "heading": false
        },
        {
          "term": "excluding studies",
          "heading": false
        },
        {
          "term": "cri",
          "heading": false
        },
        {
          "term": "non-determinate index",
          "heading": false
        }
      ],
      "extract": "Peter 2015a; Van Hoving 2019] 4.6 Sensitivity analyses When excluding studies at high of bias (QUADAS-C) and with high or unclear concerns regarding applicability (QUADAS-2), the pooled difference in sensitivity increased to 10.0% (95% CrI 4.9 to 17.6) and pooled difference in specificity to -10.8 (95% CrI -20.6 to -5.4) (8 studies, 4,304 participants). See Table 17. When excluding participants with at least one",
      "extractCut": true,
      "blocks": [
        "library/10665-381036/blocks/prose-page-358",
        "library/10665-381036/blocks/table-017"
      ]
    },
    {
      "id": "page-359",
      "number": null,
      "title": "Page 359",
      "level": 1,
      "pageStart": 359,
      "pageEnd": 359,
      "labelStart": "354",
      "labelEnd": "354",
      "words": 523,
      "summary": {
        "text": "Turns to the second question, on the effect of parallel testing on patient-important outcomes, identifying three trials with 4602 participants that reported mortality and time to diagnosis and treatment. It describes the trial settings and the risk-of-bias assessment, noting possible bias from limited enrolment hours.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "urine lf-lam",
          "heading": false
        },
        {
          "term": "urine xpert",
          "heading": false
        },
        {
          "term": "mtb rif",
          "heading": false
        },
        {
          "term": "respiratory lc-anaats",
          "heading": false
        },
        {
          "term": "sputum xpert",
          "heading": false
        },
        {
          "term": "group participants",
          "heading": false
        },
        {
          "term": "intervention group",
          "heading": false
        },
        {
          "term": "gupta-wright",
          "heading": false
        }
      ],
      "extract": "4.7 PICO 2 on impact PICO 2: What is the effect of parallel use of respiratory LC-aNAATs and urine LF- LAM on patient important outcomes in adults and adolescents with HIV who present with presumptive tuberculosis, compared to respiratory LC-aNAAT alone? We identified three trials (n=4602 participants) with data on the impact of parallel use of respiratory LC- aNAATs and urine LF-LAM for clinical decision-making on",
      "extractCut": true,
      "blocks": [
        "library/10665-381036/blocks/prose-page-359"
      ]
    },
    {
      "id": "page-360",
      "number": null,
      "title": "Page 360",
      "level": 1,
      "pageStart": 360,
      "pageEnd": 360,
      "labelStart": "355",
      "labelEnd": "355",
      "words": 201,
      "summary": {
        "text": "Reports that across three trials in adult inpatients with HIV, parallel testing had a pooled mortality risk ratio of 0.93 with wide confidence intervals and high heterogeneity. It contrasts one trial showing a 4% absolute mortality reduction with another reporting higher mortality in the intervention arm.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "urine lf-lam",
          "heading": false
        },
        {
          "term": "respiratory lc-anaat",
          "heading": false
        },
        {
          "term": "lc-anaat alone",
          "heading": false
        },
        {
          "term": "study directed",
          "heading": false
        },
        {
          "term": "parallel testing",
          "heading": false
        },
        {
          "term": "absolute risk",
          "heading": false
        }
      ],
      "extract": "4.7.1 Impact of respiratory LC-aNAATs and urine LF-LAM on mortality in adult inpatients with HIV Three trials provided data on the impact of parallel testing with respiratory LC-aNAAT and urine LF-LAM on mortality, compared to respiratory LC-aNAAT alone, with differences in trial specific intervention characteristics (Table 11). The pooled risk ratio for the impact of parallel testing of LF-LAM and respiratory",
      "extractCut": true,
      "blocks": [
        "library/10665-381036/blocks/prose-page-360",
        "library/10665-381036/blocks/figure-img-p360-1",
        "library/10665-381036/blocks/figure-img-p360-3"
      ]
    },
    {
      "id": "page-361",
      "number": null,
      "title": "Page 361",
      "level": 1,
      "pageStart": 361,
      "pageEnd": 361,
      "labelStart": "356",
      "labelEnd": "356",
      "words": 298,
      "summary": {
        "text": "Tabulates the three trials' populations, designs, timing and mortality results, and begins describing how mortality differed by CD4 count.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "adult inpatients",
          "heading": false
        },
        {
          "term": "median haemoglobin",
          "heading": false
        },
        {
          "term": "respiratory lc-anaats",
          "heading": false
        },
        {
          "term": "urine lf-lam",
          "heading": false
        },
        {
          "term": "randomized controlled",
          "heading": false
        },
        {
          "term": "lam test",
          "heading": false
        },
        {
          "term": "controlled trial",
          "heading": false
        },
        {
          "term": "cells",
          "heading": false
        }
      ],
      "extract": "Table 18. Comparison of mortality in randomized trials evaluating interventions that included respiratory LC-aNAATs and urine LF-LAM in adult inpatients with HIV. Study Population Illness severity metrics Design Time of mortality assessment Mortality analysis Mortality in intervention Mortality in control Other key findings Peter 2016 1609 HIV- positive adults, inpatients (with TB symptoms) Median CD4 84 cells per",
      "extractCut": true,
      "blocks": [
        "library/10665-381036/blocks/prose-page-361",
        "library/10665-381036/blocks/figure-img-p361-1",
        "library/10665-381036/blocks/figure-vfig-p361",
        "library/10665-381036/blocks/table-018"
      ]
    },
    {
      "id": "page-362",
      "number": null,
      "title": "Page 362",
      "level": 1,
      "pageStart": 362,
      "pageEnd": 362,
      "labelStart": "357",
      "labelEnd": "357",
      "words": 555,
      "summary": {
        "text": "Describes mortality by CD4 count, with one trial showing a significant mortality reduction from adding LF-LAM only in people with CD4 counts under 100. It then begins reporting the effect of parallel testing on the proportion diagnosed with tuberculosis, with forest plots.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "urine lf-lam",
          "heading": false
        },
        {
          "term": "standard-of-care group",
          "heading": false
        },
        {
          "term": "urine lc-anaat",
          "heading": false
        },
        {
          "term": "respiratory lc-anaats",
          "heading": false
        },
        {
          "term": "adult inpatients",
          "heading": false
        },
        {
          "term": "proportion diagnosed",
          "heading": false
        },
        {
          "term": "åhsberg reported",
          "heading": false
        },
        {
          "term": "lc-anaat alone",
          "heading": false
        }
      ],
      "extract": "2018 reported that in their trial of adult inpatients with HIV, use of urine LF-LAM in conjunction with other tests including respiratory LC-aNAAT (Xpert MTB/RIF) and urine LC-aNAAT (Xpert MTB/RIF) was associated with an adjusted risk difference of -0.1 (-3.3 to 3.1, P = 0.96) in patients with a CD4 count ≥ 100 cells per µL, and with an adjusted risk difference of -7.1 (-13.7 to -0.4, P = 0.036) in patients with a",
      "extractCut": true,
      "blocks": [
        "library/10665-381036/blocks/prose-page-362"
      ]
    },
    {
      "id": "page-363",
      "number": null,
      "title": "Page 363",
      "level": 1,
      "pageStart": 363,
      "pageEnd": 363,
      "labelStart": "358",
      "labelEnd": "358",
      "words": 402,
      "summary": {
        "text": "Reports that trials found more inpatients received a microbiologically confirmed tuberculosis diagnosis when LF-LAM was added to LC-aNAAT testing. In one trial LF-LAM was the only positive test in 41% of diagnosed cases.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "urine lf-lam",
          "heading": false
        },
        {
          "term": "standard-of-care group",
          "heading": false
        },
        {
          "term": "urine xpert",
          "heading": false
        },
        {
          "term": "gupta-wright reported",
          "heading": false
        },
        {
          "term": "tuberculosis diagnosis",
          "heading": false
        },
        {
          "term": "respiratory lc-anaats",
          "heading": false
        },
        {
          "term": "xpert mtb",
          "heading": false
        },
        {
          "term": "microbiological test",
          "heading": false
        }
      ],
      "extract": "Gupta-Wright 2018 reported that the proportion of participants with a microbiological test positive tuberculosis diagnosis (including LF-LAM result) was higher in the intervention group that included use of respiratory and urine LC-aNAAT (Xpert MTB/RIF) and LF-LAM compared to the standard-of-care group that included LC-aNAAT but not LF-LAM (16% [210/1287] versus 7% [85/1287]; adjusted risk difference 9.9% [95% CI",
      "extractCut": true,
      "blocks": [
        "library/10665-381036/blocks/prose-page-363",
        "library/10665-381036/blocks/figure-img-p363-1",
        "library/10665-381036/blocks/figure-img-p363-2"
      ]
    },
    {
      "id": "page-364",
      "number": null,
      "title": "Page 364",
      "level": 1,
      "pageStart": 364,
      "pageEnd": 364,
      "labelStart": "359",
      "labelEnd": "359",
      "words": 356,
      "summary": {
        "text": "Reports trial findings on time to tuberculosis treatment and the proportion treated, with bedside LF-LAM shortening time from enrolment to treatment in one trial. Another trial noted that fewer than half of those tested with LF-LAM started treatment.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "urine lf-lam",
          "heading": false
        },
        {
          "term": "standard-of-care group",
          "heading": false
        },
        {
          "term": "åhsberg reported",
          "heading": false
        },
        {
          "term": "respiratory lc-anaats",
          "heading": false
        },
        {
          "term": "proportion treated",
          "heading": false
        },
        {
          "term": "iqr",
          "heading": false
        },
        {
          "term": "tuberculosis compared",
          "heading": false
        },
        {
          "term": "gupta-wright reported",
          "heading": false
        }
      ],
      "extract": "sputum Xpert MTB/RIF alone. 4.7.4 Impact of respiratory LC-aNAATs and urine LF-LAM on time to treatment and proportion treated for tuberculosis in adult inpatients with HIV Two trials evaluated time to diagnosis, reporting median and interquartile ranges, which precluded meta-analysis of mean differences. Using bedside urine LF-LAM and study directed treatment recommendation, Peter 2016 reported that the time from",
      "extractCut": true,
      "blocks": [
        "library/10665-381036/blocks/prose-page-364",
        "library/10665-381036/blocks/figure-img-p364-1"
      ]
    },
    {
      "id": "page-365",
      "number": null,
      "title": "Page 365",
      "level": 1,
      "pageStart": 365,
      "pageEnd": 365,
      "labelStart": "360",
      "labelEnd": "360",
      "words": 499,
      "summary": {
        "text": "Opens the discussion by summarizing the evidence from 31 paired accuracy studies and three randomized trials on parallel respiratory LC-aNAAT and urine LF-LAM testing in adults and adolescents with HIV. It restates key pooled accuracy results, including for seriously ill participants.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "respiratory lc-anaat",
          "heading": false
        },
        {
          "term": "lc-anaat alone",
          "heading": false
        },
        {
          "term": "sensitivity difference",
          "heading": false
        },
        {
          "term": "urine lf-lam",
          "heading": false
        },
        {
          "term": "specificity difference",
          "heading": false
        },
        {
          "term": "cri",
          "heading": false
        },
        {
          "term": "lf-lam against",
          "heading": false
        },
        {
          "term": "microbiological reference",
          "heading": false
        }
      ],
      "extract": "5. DISCUSSION This systematic review summarizes the evidence from 31 fully paired comparative accuracy studies on the parallel use of respiratory LC-aNAAT and urine LF-LAM for detection of tuberculosis disease in adults and adolescents with HIV presenting with signs and symptoms of tuberculosis or screen positive, compared to each test alone. We identified three randomized controlled trials that evaluated the impact",
      "extractCut": true,
      "blocks": [
        "library/10665-381036/blocks/prose-page-365"
      ]
    },
    {
      "id": "page-366",
      "number": null,
      "title": "Page 366",
      "level": 1,
      "pageStart": 366,
      "pageEnd": 366,
      "labelStart": "361",
      "labelEnd": "361",
      "words": 556,
      "summary": {
        "text": "Continues the summary of results with accuracy estimates for inpatients and outpatients and notes that the estimated sensitivity gain of parallel testing was larger with a composite reference standard.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "respiratory lc-anaat",
          "heading": false
        },
        {
          "term": "lc-anaat alone",
          "heading": false
        },
        {
          "term": "microbiological reference",
          "heading": false
        },
        {
          "term": "specificity difference",
          "heading": false
        },
        {
          "term": "sensitivity difference",
          "heading": false
        },
        {
          "term": "composite reference",
          "heading": false
        },
        {
          "term": "cri",
          "heading": false
        },
        {
          "term": "reference standard",
          "heading": false
        }
      ],
      "extract": "o Specificity difference -14.4% (95% CrI -24.2 to -7.4) For the subgroup of inpatients, the diagnostic accuracy of the parallel use of respiratory LC-aNAAT and urine LF-LAM using a microbiological reference standard is: • Sensitivity 77.7% (95% CrI 68.5 to 85.9) and specificity 87.2% (95% CrI 81.3 to 91.6) Compared to respiratory LC-aNAAT alone, difference in accuracy is: o Sensitivity difference 11.7% (95% CrI 4.6",
      "extractCut": true,
      "blocks": [
        "library/10665-381036/blocks/prose-page-366"
      ]
    },
    {
      "id": "page-367",
      "number": null,
      "title": "Page 367",
      "level": 1,
      "pageStart": 367,
      "pageEnd": 367,
      "labelStart": "362",
      "labelEnd": "362",
      "words": 624,
      "summary": {
        "text": "Discusses how reference standards and study quality influenced estimates, with the largest sensitivity gains in studies that enrolled people regardless of their ability to produce sputum. It also notes that Xpert Ultra has largely replaced Xpert MTB/RIF and is expected to be more sensitive.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "parallel testing",
          "heading": false
        },
        {
          "term": "respiratory lc-anaat",
          "heading": false
        },
        {
          "term": "lc-anaat alone",
          "heading": false
        },
        {
          "term": "testing compared",
          "heading": false
        },
        {
          "term": "microbiological reference",
          "heading": false
        },
        {
          "term": "individual testing",
          "heading": false
        },
        {
          "term": "reference standard",
          "heading": false
        },
        {
          "term": "sensitivity estimate",
          "heading": false
        }
      ],
      "extract": "microbiological reference standard (16.0 % vs. 6.7%), despite an overall estimated sensitivity of parallel testing (67.6%) that was lower than the sensitivity estimate with an microbiological reference standard (77.5%). Study quality may influence estimates of diagnostic accuracy. Comparing parallel testing with respiratory LC-aNAAT alone, the increase in sensitivity was highest in studies at low risk of bias in the",
      "extractCut": true,
      "blocks": [
        "library/10665-381036/blocks/prose-page-367"
      ]
    },
    {
      "id": "page-368",
      "number": null,
      "title": "Page 368",
      "level": 1,
      "pageStart": 368,
      "pageEnd": 368,
      "labelStart": "363",
      "labelEnd": "363",
      "words": 685,
      "summary": {
        "text": "Notes that sensitivity analyses found no difference between Xpert Ultra and Xpert MTB/RIF in parallel testing, and explains how this review differs from earlier Cochrane reviews by assessing tests in combination. It then turns to the trials on patient outcomes and how they differed in implementing LF-LAM.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "xpert mtb",
          "heading": false
        },
        {
          "term": "mtb rif",
          "heading": false
        },
        {
          "term": "xpert ultra",
          "heading": false
        },
        {
          "term": "rif alone",
          "heading": false
        },
        {
          "term": "parallel testing",
          "heading": false
        },
        {
          "term": "evaluated xpert",
          "heading": false
        },
        {
          "term": "lf-lam",
          "heading": false
        },
        {
          "term": "systematic review",
          "heading": false
        }
      ],
      "extract": "in sensitivity. Overall, nine studies in this review evaluated Xpert Ultra and 21 evaluated Xpert MTB/RIF. In sensitivity analysis, there were no differences in the estimated sensitivity and specificity of parallel testing using Xpert Ultra or Xpert MTB/RIF with urinary LF-LAM, compared to either test alone. 5.3 Parallel testing - differences to previous Cochrane systematic review Systematic reviews and",
      "extractCut": true,
      "blocks": [
        "library/10665-381036/blocks/prose-page-368"
      ]
    },
    {
      "id": "page-369",
      "number": null,
      "title": "Page 369",
      "level": 1,
      "pageStart": 369,
      "pageEnd": 369,
      "labelStart": "364",
      "labelEnd": "364",
      "words": 642,
      "summary": {
        "text": "Summarizes that in inpatients with HIV parallel testing has an uncertain effect on mortality but likely increases the share diagnosed and probably the share treated for tuberculosis. It also discusses limitations of the evidence and its relevance for decision makers.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "urine lf-lam",
          "heading": false
        },
        {
          "term": "sputum lc-anaat",
          "heading": false
        },
        {
          "term": "parallel testing",
          "heading": false
        },
        {
          "term": "tuberculosis diagnostic",
          "heading": false
        },
        {
          "term": "routine tuberculosis",
          "heading": false
        },
        {
          "term": "tuberculosis treatment",
          "heading": false
        },
        {
          "term": "inpatient settings",
          "heading": false
        },
        {
          "term": "diagnostic strategies",
          "heading": false
        }
      ],
      "extract": "parallel testing with sputum LC-aNAAT and urine LF-LAM has an uncertain effect on mortality (risk ratio 0.93; 95% CI 0.74 to 1.17) at eight weeks in people with HIV compared to routine tuberculosis diagnostic testing without LF-LAM; however, there was heterogeneity between individual trial interventions and effect estimates and the pooled results were statistically imprecise. Parallel testing with sputum LC- aNAAT",
      "extractCut": true,
      "blocks": [
        "library/10665-381036/blocks/prose-page-369"
      ]
    },
    {
      "id": "page-370",
      "number": null,
      "title": "Page 370",
      "level": 1,
      "pageStart": 370,
      "pageEnd": 370,
      "labelStart": "365",
      "labelEnd": "365",
      "words": 626,
      "summary": {
        "text": "Sets out the authors' conclusions for practice, describing respiratory LC-aNAAT as the usual first test and urine LF-LAM as a complementary add-on that can detect more HIV-associated tuberculosis, including in people unable to give sputum. It calls for implementation research on barriers and enablers that affect clinical decisions.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "urine lf-lam",
          "heading": false
        },
        {
          "term": "parallel test",
          "heading": false
        },
        {
          "term": "non-site-specific test",
          "heading": false
        },
        {
          "term": "parallel testing",
          "heading": false
        },
        {
          "term": "extrapulmonary tuberculosis",
          "heading": false
        },
        {
          "term": "test strategy",
          "heading": false
        },
        {
          "term": "future studies",
          "heading": false
        },
        {
          "term": "patients unable",
          "heading": false
        }
      ],
      "extract": "6. Author’s conclusions 6.1 Implications for practice LC-aNAAT on respiratory sample is often the initial test to detect tuberculosis disease. Urine LF-LAM is an add on test that is in combination with clinical judgement and other tests (parallel use) for the diagnosis of HIV-associated tuberculosis. Respiratory LC-aNAAT and urine LF-LAM may be complementary when performed as part of a parallel testing strategy to",
      "extractCut": true,
      "blocks": [
        "library/10665-381036/blocks/prose-page-370"
      ]
    },
    {
      "id": "page-371",
      "number": null,
      "title": "Page 371",
      "level": 1,
      "pageStart": 371,
      "pageEnd": 371,
      "labelStart": "366",
      "labelEnd": "366",
      "words": 26,
      "summary": {
        "text": "Notes further research gaps, including the lack of outcome data for parallel testing in children and in outpatient settings.",
        "status": "draft"
      },
      "keywords": [],
      "extract": "Other notable research gaps include the lack of data on the effect of parallel use diagnostic strategies on patient-important outcomes in children and in outpatient settings.",
      "extractCut": false,
      "blocks": [
        "library/10665-381036/blocks/prose-page-371"
      ]
    },
    {
      "id": "page-372",
      "number": null,
      "title": "Page 372",
      "level": 1,
      "pageStart": 372,
      "pageEnd": 372,
      "labelStart": "367",
      "labelEnd": "367",
      "words": 569,
      "summary": {
        "text": "Gives the review's acknowledgements and authors' contributions, followed by the start of its reference list.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "infectious diseases",
          "heading": false
        },
        {
          "term": "systematic review",
          "heading": false
        },
        {
          "term": "primary studies",
          "heading": false
        },
        {
          "term": "authors",
          "heading": false
        },
        {
          "term": "wrote",
          "heading": false
        },
        {
          "term": "health organization",
          "heading": false
        },
        {
          "term": "consultant",
          "heading": false
        },
        {
          "term": "world health",
          "heading": false
        }
      ],
      "extract": "Acknowledgements We are grateful to Vittoria Lutje, the CIDG Information Specialist, for help with the search strategy. We thank all authors of primary studies for answering our questions and providing data. Contributions of authors All authors contributed significantly to this review. SB, BY, and JÅ wrote the review sections. RN wrote the sections related to impact review. SB and JÅ performed the majority of the",
      "extractCut": true,
      "blocks": [
        "library/10665-381036/blocks/prose-page-372"
      ]
    },
    {
      "id": "page-373",
      "number": null,
      "title": "Page 373",
      "level": 1,
      "pageStart": 373,
      "pageEnd": 373,
      "labelStart": "368",
      "labelEnd": "368",
      "words": 567,
      "summary": {
        "text": "Part of the review's reference list, citing studies on diagnostic search strategies and the accuracy of urine LAM tests for tuberculosis in people with HIV.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "urine lipoarabinomannan",
          "heading": false
        },
        {
          "term": "lipoarabinomannan assay",
          "heading": false
        },
        {
          "term": "lipoarabinomannan test",
          "heading": false
        },
        {
          "term": "point-of-care urine",
          "heading": false
        },
        {
          "term": "flow urine",
          "heading": false
        },
        {
          "term": "database syst",
          "heading": false
        },
        {
          "term": "syst rev",
          "heading": false
        },
        {
          "term": "sputum tuberculosis",
          "heading": false
        }
      ],
      "extract": "Beynon, R., M. M. Leeflang, S. McDonald, A. Eisinga, R. L. Mitchell, et al. 2013. \"Search strategies to identify diagnostic accuracy studies in MEDLINE and EMBASE.\" Cochrane Database Syst Rev 2013 (9): MR000022. BIONEER. 2022. \"IRON-qPCR.\" https://eng.bioneer.com/20-a-2600.html. Bjerrum, S., T. Broger, R. Szekely, S. Mitarai, J. A. Opintan, et al. 2020. \"Diagnostic Accuracy of a Novel and Rapid Lipoarabinomannan",
      "extractCut": true,
      "blocks": [
        "library/10665-381036/blocks/prose-page-373"
      ]
    },
    {
      "id": "page-374",
      "number": null,
      "title": "Page 374",
      "level": 1,
      "pageStart": 374,
      "pageEnd": 374,
      "labelStart": "369",
      "labelEnd": "369",
      "words": 533,
      "summary": {
        "text": "Part of the review's reference list, citing trials and accuracy studies of tuberculosis diagnostics, Xpert product pages and statistical methods papers.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "accessed november",
          "heading": false
        },
        {
          "term": "cochrane library",
          "heading": false
        },
        {
          "term": "lancet hiv",
          "heading": false
        },
        {
          "term": "randomised controlled",
          "heading": false
        },
        {
          "term": "truenat mtb",
          "heading": false
        },
        {
          "term": "tuberculosis screening",
          "heading": false
        },
        {
          "term": "mtb rif",
          "heading": false
        },
        {
          "term": "library content",
          "heading": false
        }
      ],
      "extract": "Calligaro, G. L., L. S. Zijenah, J. G. Peter, G. Theron, V. Buser, et al. 2017. \"Effect of new tuberculosis diagnostic technologies on community-based intensified case finding: a multicentre randomised controlled trial.\" The Lancet Infectious Diseases 17 (4): 441-450. Cepheid. 2023a. \"Xpert MTB/RIF \". Accessed November 12 https://www.cepheid.com/en-US/tests/tb- emerging-infectious-diseases/xpert-mtb-rif.html.",
      "extractCut": true,
      "blocks": [
        "library/10665-381036/blocks/prose-page-374"
      ]
    },
    {
      "id": "page-375",
      "number": null,
      "title": "Page 375",
      "level": 1,
      "pageStart": 375,
      "pageEnd": 375,
      "labelStart": "370",
      "labelEnd": "370",
      "words": 584,
      "summary": {
        "text": "Part of the review's reference list, citing Cochrane reviews of Xpert assays and studies of the FujiLAM assay in people with HIV.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "mathabire rucker",
          "heading": false
        },
        {
          "term": "ambulatory hiv-positive",
          "heading": false
        },
        {
          "term": "fujilam assay",
          "heading": false
        },
        {
          "term": "ambulatory patients",
          "heading": false
        },
        {
          "term": "novel fujilam",
          "heading": false
        },
        {
          "term": "lipoarabinomannan assay",
          "heading": false
        },
        {
          "term": "determine-tb lam",
          "heading": false
        },
        {
          "term": "mtb rif",
          "heading": false
        }
      ],
      "extract": "Horne, D. J., M. Kohli, J. S. Zifodya, I. Schiller, N. Dendukuri, et al. 2019. \"Xpert MTB/RIF and Xpert MTB/RIF Ultra for pulmonary tuberculosis and rifampicin resistance in adults.\" Cochrane Database Syst Rev 6 (6): CD009593. Huerga, H., M. Bastard, A. V. Lubega, M. Akinyi, N. T. Antabak, et al. 2023a. \"Novel FujiLAM assay to detect tuberculosis in HIV-positive ambulatory patients in four African countries: a",
      "extractCut": true,
      "blocks": [
        "library/10665-381036/blocks/prose-page-375"
      ]
    },
    {
      "id": "page-376",
      "number": null,
      "title": "Page 376",
      "level": 1,
      "pageStart": 376,
      "pageEnd": 376,
      "labelStart": "371",
      "labelEnd": "371",
      "words": 587,
      "summary": {
        "text": "Part of a reference list citing mainly diagnostic accuracy studies and Cochrane reviews of Xpert assays and urine LAM tests for TB in people with HIV.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "urine lipoarabinomannan",
          "heading": false
        },
        {
          "term": "lam lateral",
          "heading": false
        },
        {
          "term": "infect dis",
          "heading": false
        },
        {
          "term": "hiv-infected outpatients",
          "heading": false
        },
        {
          "term": "lateral flow",
          "heading": false
        },
        {
          "term": "pediatric tuberculosis",
          "heading": false
        },
        {
          "term": "diagnostic accuracy",
          "heading": false
        },
        {
          "term": "cochrane database",
          "heading": false
        }
      ],
      "extract": "Kohli, M., I. Schiller, N. Dendukuri, M. Yao, K. Dheda, et al. 2021b. \"Xpert MTB/RIF Ultra and Xpert MTB/RIF assays for extrapulmonary tuberculosis and rifampicin resistance in adults.\" Cochrane Database Syst Rev 1 (1): CD012768. Lawn, S. D., A. D. Kerkhoff, R. Burton, C. Schutz, A. Boulle, et al. 2017a. \"Diagnostic accuracy, incremental yield and prognostic value of Determine TB-LAM for routine diagnostic testing",
      "extractCut": true,
      "blocks": [
        "library/10665-381036/blocks/prose-page-376"
      ]
    },
    {
      "id": "page-377",
      "number": null,
      "title": "Page 377",
      "level": 1,
      "pageStart": 377,
      "pageEnd": 377,
      "labelStart": "372",
      "labelEnd": "372",
      "words": 568,
      "summary": {
        "text": "Continues a reference list of TB diagnostic studies, meta-analysis methods, manufacturer information on STANDARD M10 and Cochrane handbook chapters.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "fujifilm silvamp",
          "heading": false
        },
        {
          "term": "urine lipoarabinomannan",
          "heading": false
        },
        {
          "term": "lipoarabinomannan assay",
          "heading": false
        },
        {
          "term": "reveals lot",
          "heading": false
        },
        {
          "term": "database syst",
          "heading": false
        },
        {
          "term": "adolescent tuberculosis",
          "heading": false
        },
        {
          "term": "lot variability",
          "heading": false
        },
        {
          "term": "syst rev",
          "heading": false
        }
      ],
      "extract": "antiretroviral therapy initiators: a prospective diagnostic accuracy study.\" MedRxiv : the Preprint Server for Health Sciences 05: 05. Reitsma, J. B., A. S. Glas, A. W. Rutjes, R. J. Scholten, P. M. Bossuyt, and A. H. Zwinderman. 2005. \"Bivariate analysis of sensitivity and specificity produces informative summary measures in diagnostic reviews.\" J Clin Epidemiol 58 (10): 982-90. SD BIOSENSOR. 2021. \"STANDARD M M10",
      "extractCut": true,
      "blocks": [
        "library/10665-381036/blocks/prose-page-377"
      ]
    },
    {
      "id": "page-378",
      "number": null,
      "title": "Page 378",
      "level": 1,
      "pageStart": 378,
      "pageEnd": 378,
      "labelStart": "373",
      "labelEnd": "373",
      "words": 466,
      "summary": {
        "text": "Ends a reference list of studies on urine LAM testing and Xpert Ultra for TB diagnosis.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "urine lipoarabinomannan",
          "heading": false
        },
        {
          "term": "ann intern",
          "heading": false
        },
        {
          "term": "pulmonary tuberculosis",
          "heading": false
        },
        {
          "term": "lipoarabinomannan assay",
          "heading": false
        },
        {
          "term": "tuberculosis detection",
          "heading": false
        },
        {
          "term": "intern med",
          "heading": false
        },
        {
          "term": "health organization",
          "heading": false
        },
        {
          "term": "world health",
          "heading": false
        }
      ],
      "extract": "Thit, S. S., N. M. Aung, Z. W. Htet, M. A. Boyd, H. A. Saw, et al. 2017. \"The clinical utility of the urine- based lateral flow lipoarabinomannan assay in HIV-infected adults in Myanmar: an observational study.\" BMC Medicine 15 (1): 145. Van Hoving, D. J., S. Lahri, H. J. Lategan, M. P. Nicol, G. Maartens, and G. Meintjes. 2019. \"Brief Report: Real-World Performance and Interobserver Agreement of Urine",
      "extractCut": true,
      "blocks": [
        "library/10665-381036/blocks/prose-page-378"
      ]
    },
    {
      "id": "page-379",
      "number": null,
      "title": "Page 379",
      "level": 1,
      "pageStart": 379,
      "pageEnd": 379,
      "labelStart": "374",
      "labelEnd": "374",
      "words": 5,
      "summary": {
        "text": "A blank page with no extracted text.",
        "status": "draft"
      },
      "keywords": [],
      "extract": "_(no text on this page)_",
      "extractCut": false,
      "blocks": [
        "library/10665-381036/blocks/prose-page-379"
      ]
    },
    {
      "id": "page-380",
      "number": null,
      "title": "Page 380",
      "level": 1,
      "pageStart": 380,
      "pageEnd": 380,
      "labelStart": "375",
      "labelEnd": "375",
      "words": 88,
      "summary": {
        "text": "The title page of Web Annex B.9, a systematic review of economic evidence on low- and moderate-complexity nucleic acid amplification tests for TB diagnosis and drug resistance, prepared for a WHO guideline meeting in May 2024, with authors and affiliations.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "alice zwerling",
          "heading": false
        },
        {
          "term": "ottawa",
          "heading": false
        },
        {
          "term": "bango",
          "heading": false
        },
        {
          "term": "funeka",
          "heading": false
        }
      ],
      "extract": "Web Annex B.9. Systematic Review of Economic Evidence Around Low and Moderate Complexity Nucleic Acid Amplification Tests for TB Diagnosis and Detection of Resistance Prepared for WHO Global TB Programme, Guideline Development Group Meeting May 6th to 11th 2024 Funeka Bango1, Suvesh Shrestha2, Pushpita Samina3, Olivia D’Silva2, Alice Zwerling2 1 Health Systems Research Unit, South African Medical Research Council,",
      "extractCut": true,
      "blocks": [
        "library/10665-381036/blocks/prose-page-380"
      ]
    },
    {
      "id": "page-381",
      "number": null,
      "title": "Page 381",
      "level": 1,
      "pageStart": 381,
      "pageEnd": 381,
      "labelStart": "376",
      "labelEnd": "376",
      "words": 127,
      "summary": {
        "text": "A list of abbreviations used in the economic review of TB nucleic acid amplification tests.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "throughput systems",
          "heading": false
        },
        {
          "term": "acid amplification",
          "heading": false
        },
        {
          "term": "nucleic acid",
          "heading": false
        },
        {
          "term": "amplification tests",
          "heading": false
        },
        {
          "term": "life years",
          "heading": false
        },
        {
          "term": "who-recommended",
          "heading": false
        }
      ],
      "extract": "Abbreviations ART Antiretroviral therapy CLHIV Children living with HIV CXR Chest X-ray DALYs Disability-adjusted life years DR Drugs-resistant DS Drug-susceptible DST Drugs susceptibility testing FIND Foundation for Innovative New Diagnostics HIV Human immunodeficiency viruses HT High throughput systems ICER Incremental cost effectiveness ratio LC-NAATs Low complexity automated nucleic acid amplification tests",
      "extractCut": true,
      "blocks": [
        "library/10665-381036/blocks/prose-page-381"
      ]
    },
    {
      "id": "page-382",
      "number": null,
      "title": "Page 382",
      "level": 1,
      "pageStart": 382,
      "pageEnd": 382,
      "labelStart": "377",
      "labelEnd": "377",
      "words": 419,
      "summary": {
        "text": "Gives background noting that TB caused 1.3 million deaths in 2022 and that WHO recommends rapid molecular tests as initial diagnostics. It explains that access remains limited in high-burden areas because of costs, infrastructure and staff shortages.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "million people",
          "heading": false
        },
        {
          "term": "molecular diagnostic",
          "heading": false
        },
        {
          "term": "drug resistance",
          "heading": false
        },
        {
          "term": "diagnostic tests",
          "heading": false
        },
        {
          "term": "mwrds",
          "heading": false
        },
        {
          "term": "drug-resistant",
          "heading": false
        },
        {
          "term": "mdr-tb",
          "heading": false
        },
        {
          "term": "medium",
          "heading": false
        }
      ],
      "extract": "1. BACKGROUND In 2022, Tuberculosis (TB) was the second leading cause of death from a single infectious agent after COVID-19 globally(1). TB resulted in 1.3 million deaths in 2022 with more than 10.6 million people who fell ill with TB, and of the 6.2 million people diagnosed with pulmonary TB worldwide, 63% were bacteriologically confirmed. The World Health Organization (WHO) recommends using rapid molecular",
      "extractCut": true,
      "blocks": [
        "library/10665-381036/blocks/prose-page-382"
      ]
    },
    {
      "id": "page-383",
      "number": null,
      "title": "Page 383",
      "level": 1,
      "pageStart": 383,
      "pageEnd": 383,
      "labelStart": "378",
      "labelEnd": "378",
      "words": 349,
      "summary": {
        "text": "Describes the classes of NAATs, including Xpert, Xpert Ultra and Truenat, moderate-complexity automated tests and TB-LAMP. It notes that economic evidence for the newer tests is limited and has not been recently reviewed.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "xpert ultra",
          "heading": false
        },
        {
          "term": "economic evidence",
          "heading": false
        },
        {
          "term": "initial detection",
          "heading": false
        },
        {
          "term": "mtb rif",
          "heading": false
        },
        {
          "term": "tb-lamp",
          "heading": false
        },
        {
          "term": "mc-anaats",
          "heading": false
        },
        {
          "term": "truenat",
          "heading": false
        },
        {
          "term": "lc-mnaats",
          "heading": false
        }
      ],
      "extract": "Low-complexity automated nucleic acid amplification tests (LC-aNAATs) are a class of TB diagnostics included in the mWRDs that can be used for TB diagnosis. They include Xpert® MTB/RIF (Xpert), Xpert® MTB/RIF Ultra (Ultra) (Cepheid, USA), and TrueNat™ (11). These tests provide initial detection of TB and resistance to rifampicin detection. Moderate complexity automated NAATs (MC-aNAATs) offer a high sample",
      "extractCut": true,
      "blocks": [
        "library/10665-381036/blocks/prose-page-383"
      ]
    },
    {
      "id": "page-384",
      "number": null,
      "title": "Page 384",
      "level": 1,
      "pageStart": 384,
      "pageEnd": 384,
      "labelStart": "379",
      "labelEnd": "379",
      "words": 341,
      "summary": {
        "text": "States the review's aim of summarising economic evidence on three NAAT classes and begins describing the methods. It sets out inclusion criteria and excludes studies of active case-finding or triage before testing.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "studies assessing",
          "heading": false
        },
        {
          "term": "systematic review",
          "heading": false
        },
        {
          "term": "complexity automated",
          "heading": false
        },
        {
          "term": "naats",
          "heading": false
        },
        {
          "term": "lc-anaats",
          "heading": false
        },
        {
          "term": "cost-effectiveness",
          "heading": false
        },
        {
          "term": "economic",
          "heading": false
        },
        {
          "term": "classes",
          "heading": false
        }
      ],
      "extract": "The overall aim of the present review is to identify, evaluate, and summarize the findings of available economic evidence on three classes of NAATs: • Low complexity automated nucleic acid amplification tests (LC-aNAATs) for TB diagnosis and detection of drug resistance. • Low-complexity manual NAAT (LC-mNAAT) TB-LAMP for TB diagnosis. • Moderate complexity automated NAATs (MC-aNAATs). 2. METHODS This systematic",
      "extractCut": true,
      "blocks": [
        "library/10665-381036/blocks/prose-page-384"
      ]
    },
    {
      "id": "page-385",
      "number": null,
      "title": "Page 385",
      "level": 1,
      "pageStart": 385,
      "pageEnd": 385,
      "labelStart": "380",
      "labelEnd": "380",
      "words": 269,
      "summary": {
        "text": "Specifies the study populations, specimen types and economic outcomes eligible for the review, such as cost per test and cost per QALY gained. It introduces the search strategies developed with information specialists.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "adjusted life",
          "heading": false
        },
        {
          "term": "search strategies",
          "heading": false
        },
        {
          "term": "life years",
          "heading": false
        },
        {
          "term": "unit test",
          "heading": false
        },
        {
          "term": "naats",
          "heading": false
        },
        {
          "term": "comparator",
          "heading": false
        },
        {
          "term": "class",
          "heading": false
        },
        {
          "term": "study population",
          "heading": false
        }
      ],
      "extract": "For the remaining classes of NAATs (LC-mNAATs and MC-aNAATs), the inclusion criteria for each class of NAATs included in the review are specified below. 2.2. Study Population & Specimen Type: The study population may include any of the following: All people who screen positive, with signs and symptoms of TB, or with abnormal chest X-rays, people living with HIV (PLHIV), and children with signs or symptoms of TB.",
      "extractCut": true,
      "blocks": [
        "library/10665-381036/blocks/prose-page-385"
      ]
    },
    {
      "id": "page-386",
      "number": null,
      "title": "Page 386",
      "level": 1,
      "pageStart": 386,
      "pageEnd": 386,
      "labelStart": "381",
      "labelEnd": "381",
      "words": 354,
      "summary": {
        "text": "Describes dual independent screening and data extraction, with disagreements resolved by a third reviewer. It lists the key economic outcomes extracted, such as cost per patient tested and incremental cost-effectiveness ratios.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "identified articles",
          "heading": false
        },
        {
          "term": "published studies",
          "heading": false
        },
        {
          "term": "review articles",
          "heading": false
        },
        {
          "term": "additional studies",
          "heading": false
        },
        {
          "term": "resolved through",
          "heading": false
        },
        {
          "term": "mc-anaat",
          "heading": false
        },
        {
          "term": "inclusion criteria",
          "heading": false
        },
        {
          "term": "key identified",
          "heading": false
        }
      ],
      "extract": "reviewers screened titles and abstracts retrieved using the search strategies according to the inclusion criteria. Following this, full texts of studies assessed to meet the inclusion criteria were independently assessed for eligibility by two reviewers. All disagreements were resolved through discussion and the involvement of a third reviewer if a consensus could not be reached. Overall, the search strategy",
      "extractCut": true,
      "blocks": [
        "library/10665-381036/blocks/prose-page-386"
      ]
    },
    {
      "id": "page-387",
      "number": null,
      "title": "Page 387",
      "level": 1,
      "pageStart": 387,
      "pageEnd": 387,
      "labelStart": "382",
      "labelEnd": "382",
      "words": 280,
      "summary": {
        "text": "Explains that costs were converted to 2024 US dollars and that reporting quality was assessed with a modified CHEERS checklist. Studies were also summarised by population, HIV status, type of TB, level of care and sample type.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "missing data",
          "heading": false
        },
        {
          "term": "costing studies",
          "heading": false
        },
        {
          "term": "economic evaluation",
          "heading": false
        },
        {
          "term": "cheers",
          "heading": false
        },
        {
          "term": "unit test",
          "heading": false
        },
        {
          "term": "currency",
          "heading": false
        },
        {
          "term": "heterogeneity",
          "heading": false
        },
        {
          "term": "checklist",
          "heading": false
        }
      ],
      "extract": "were inflated to 2024 in the local currency and converted to 2024 USD (United States Dollars) using the online currency exchange rate (17). Assessing the Quality of Evidence: The quality of reporting for complete economic evaluation studies included in the review were assessed using a modified version of the Consolidated Health Economic Evaluation Reporting Standards (CHEERS) checklist (18). As some items do not",
      "extractCut": true,
      "blocks": [
        "library/10665-381036/blocks/prose-page-387"
      ]
    },
    {
      "id": "page-388",
      "number": null,
      "title": "Page 388",
      "level": 1,
      "pageStart": 388,
      "pageEnd": 388,
      "labelStart": "383",
      "labelEnd": "383",
      "words": 200,
      "summary": {
        "text": "Reports that 29 studies on LC-aNAATs were included from 1,534 records identified, and shows the PRISMA flow diagram with reasons for exclusion.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "duplicates removed",
          "heading": false
        },
        {
          "term": "studies excluded",
          "heading": false
        },
        {
          "term": "cost-effectiveness analyses",
          "heading": false
        },
        {
          "term": "systematic review",
          "heading": false
        },
        {
          "term": "anaats",
          "heading": false
        },
        {
          "term": "truenat",
          "heading": false
        }
      ],
      "extract": "3.1. Systematic review of LC aNAATs (Xpert, Ultra and TrueNat) Summary of Findings: A total of 1534 studies were identified in the original search, after removing duplicates, 736 potentially relevant studies were screened. Of these, 107 were assigned for full-text review and were evaluated against the inclusion and exclusion criteria, and 29 studies were included in the final systematic review (Figure 1). Of the 29",
      "extractCut": true,
      "blocks": [
        "library/10665-381036/blocks/prose-page-388"
      ]
    },
    {
      "id": "page-389",
      "number": null,
      "title": "Page 389",
      "level": 1,
      "pageStart": 389,
      "pageEnd": 389,
      "labelStart": "384",
      "labelEnd": "384",
      "words": 470,
      "summary": {
        "text": "Describes the ten cost-effectiveness studies of Xpert across countries at all income levels and the studies of Xpert Ultra. Some compared Ultra with smear microscopy and Xpert, while others assessed parallel use with LAM or whole-genome sequencing.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "smear microscopy",
          "heading": false
        },
        {
          "term": "study compared",
          "heading": false
        },
        {
          "term": "cost-effectiveness studies",
          "heading": false
        },
        {
          "term": "another study",
          "heading": false
        },
        {
          "term": "studies focused",
          "heading": false
        },
        {
          "term": "study assessed",
          "heading": false
        },
        {
          "term": "respiratory samples",
          "heading": false
        },
        {
          "term": "smear-negative patients",
          "heading": false
        }
      ],
      "extract": "General characteristics of included full economic evaluation studies. Xpert cost-effectiveness studies (n=10) Ten cost-effectiveness analyses evaluated Xpert (19–28). These were conducted across various settings covering all income levels, including one study from the USA, one each from Brazil and South Africa, two from Thailand, and Uganda and one each from Columbia, Egypt, and Ethiopia (Table 1). Most of the",
      "extractCut": true,
      "blocks": [
        "library/10665-381036/blocks/prose-page-389"
      ]
    },
    {
      "id": "page-390",
      "number": null,
      "title": "Page 390",
      "level": 1,
      "pageStart": 390,
      "pageEnd": 390,
      "labelStart": "385",
      "labelEnd": "385",
      "words": 38,
      "summary": {
        "text": "Notes that one study in India evaluated the cost-effectiveness of Truenat in children compared with smear and Xpert.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "truenat",
          "heading": false
        },
        {
          "term": "designated",
          "heading": false
        },
        {
          "term": "microscopy",
          "heading": false
        }
      ],
      "extract": "TrueNat (n=1) One full economic evaluation study conducted in India evaluated the cost-effectiveness of TrueNat in designated microscopy centers compared to smear and Xpert in children below 15 years of age for drug- sensitive and resistant TB (40).",
      "extractCut": false,
      "blocks": [
        "library/10665-381036/blocks/prose-page-390"
      ]
    },
    {
      "id": "page-391",
      "number": null,
      "title": "Page 391",
      "level": 1,
      "pageStart": 391,
      "pageEnd": 391,
      "labelStart": "386",
      "labelEnd": "386",
      "words": 131,
      "summary": {
        "text": "Table 1 begins listing the included full economic evaluations, with country, population, type of TB, setting, intervention, comparator and sample type.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "follow-on test",
          "heading": false
        },
        {
          "term": "ssm",
          "heading": false
        },
        {
          "term": "xpert mtb",
          "heading": false
        },
        {
          "term": "mtb rif",
          "heading": false
        },
        {
          "term": "initial diagnostic",
          "heading": false
        }
      ],
      "extract": "386 Table 1. General characteristics of included full economic evaluation studies. Citation Country Study population Type of TB disease Study Setting Diagnostic Intervention Diagnostic Comparator Type of sample Xpert Chitpim et al., 2022(41) Thailand Adults (≥15 years old) DS and DT- TB Not reported Xpert MTB/RIF Initial (As an initial diagnostic test in all patients or instead of SSM) Xpert MTB/RIF Add-on (In",
      "extractCut": true,
      "blocks": [
        "library/10665-381036/blocks/prose-page-391"
      ]
    },
    {
      "id": "page-392",
      "number": null,
      "title": "Page 392",
      "level": 1,
      "pageStart": 392,
      "pageEnd": 392,
      "labelStart": "387",
      "labelEnd": "387",
      "words": 155,
      "summary": {
        "text": "Continues Table 1 with economic evaluations of Xpert from Colombia, Brazil, several African countries, Ethiopia and Uganda.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "years old",
          "heading": false
        },
        {
          "term": "lam",
          "heading": false
        },
        {
          "term": "xpert",
          "heading": false
        },
        {
          "term": "sputum",
          "heading": false
        },
        {
          "term": "unspecified",
          "heading": false
        },
        {
          "term": "ds-tb",
          "heading": false
        }
      ],
      "extract": "387 Cadavid et al., 2022(29) Colombia Children and adults DS and DR- TB Specialised lab Xpert SSM MGIT culture Respiratory samples Da Silva et al., 2021(43) Brazil Adults (≥18 years old) DR-TB Unclear Xpert Bactec MGIT 960 System Sputum Esmail et al., 2020(30,31) South Africa, Tanzania, Zambia, and Zimbabwe Adults (≥18 years old) Unspecified Hospital Concurrent LAM + Xpert Sequential Xpert followed by LAM Sequential",
      "extractCut": true,
      "blocks": [
        "library/10665-381036/blocks/prose-page-392"
      ]
    },
    {
      "id": "page-393",
      "number": null,
      "title": "Page 393",
      "level": 1,
      "pageStart": 393,
      "pageEnd": 393,
      "labelStart": "388",
      "labelEnd": "388",
      "words": 135,
      "summary": {
        "text": "Continues Table 1 with studies from Thailand and Egypt and economic evaluations of Xpert Ultra in South Africa, several other countries, Ethiopia and Indonesia.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "sputum microscopy",
          "heading": false
        },
        {
          "term": "sputum smear",
          "heading": false
        },
        {
          "term": "fujilam",
          "heading": false
        },
        {
          "term": "alerelam",
          "heading": false
        },
        {
          "term": "ultra",
          "heading": false
        }
      ],
      "extract": "388 Khumsri et al., 2020(46) Thailand Adults (≥18 years old) DS and DR- TB Hospital Xpert Sputum AFB smear Sputum Sedrak et al., 2022(47) Egypt HIV-negative adults DS and DR- TB Hospital Xpert + sputum microscopy Sputum microscopy and culture Sputum Ultra Fekadu, Wang & You, 2023 (48) South Africa Adult HIV- infected individuals with signs and symptoms of TB disease. DS and DR - TB Outpatients and inpatients Ultra",
      "extractCut": true,
      "blocks": [
        "library/10665-381036/blocks/prose-page-393"
      ]
    },
    {
      "id": "page-394",
      "number": null,
      "title": "Page 394",
      "level": 1,
      "pageStart": 394,
      "pageEnd": 394,
      "labelStart": "389",
      "labelEnd": "389",
      "words": 121,
      "summary": {
        "text": "Completes Table 1 with Ultra studies from England and Wales, South Africa and Uganda and the Truenat study in India.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "wgs",
          "heading": false
        },
        {
          "term": "ds-tb",
          "heading": false
        },
        {
          "term": "ultra",
          "heading": false
        },
        {
          "term": "irisa-tb",
          "heading": false
        },
        {
          "term": "deaminase",
          "heading": false
        }
      ],
      "extract": "389 Mugwagwa, Abubakar & White, 2021(50) England and Wales South-Asian and Black-African ethnic/social groups DS and DR- TB Inpatient and outpatient Ultra Simultaneous Ultra and WGS Xpert Replacing the culture-based DST with WGS Simultaneously doing WGS and Xpert Sputum Pooran et al., 2022 (51) South Africa Suspected TB cases DS-TB Primary care clinics Ultra Smear microscopy MGIT Adenosine deaminase Interferon-",
      "extractCut": true,
      "blocks": [
        "library/10665-381036/blocks/prose-page-394"
      ]
    },
    {
      "id": "page-395",
      "number": null,
      "title": "Page 395",
      "level": 1,
      "pageStart": 395,
      "pageEnd": 395,
      "labelStart": "390",
      "labelEnd": "390",
      "words": 7,
      "summary": {
        "text": "A table fragment naming Xpert in designated microscopy centres as a comparator.",
        "status": "draft"
      },
      "keywords": [],
      "extract": "390 GeneXpert MTB in Designated Microscopy Centre",
      "extractCut": false,
      "blocks": [
        "library/10665-381036/blocks/prose-page-395"
      ]
    },
    {
      "id": "page-396",
      "number": null,
      "title": "Page 396",
      "level": 1,
      "pageStart": 396,
      "pageEnd": 396,
      "labelStart": "391",
      "labelEnd": "391",
      "words": 206,
      "summary": {
        "text": "Summarises the methods of the full economic evaluations, most of which took a provider perspective and used cost-effectiveness or cost-utility analysis with sensitivity analyses. The Truenat study used a decision tree model with DALYs as the outcome.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "cost-effectiveness studies",
          "heading": false
        },
        {
          "term": "provider perspective",
          "heading": false
        },
        {
          "term": "decision tree",
          "heading": false
        },
        {
          "term": "evaluation studies",
          "heading": false
        },
        {
          "term": "life years",
          "heading": false
        },
        {
          "term": "dalys",
          "heading": false
        }
      ],
      "extract": "3.1.1. Methodological characteristics of included full economic evaluation studies. Xpert cost-effectiveness studies (n=10) Seven of the ten studies were done from the provider perspective (20–24,27,28), one from a clinical trial perspective (26) and two from a societal perspective (19,25). All full economic evaluation studies performed a variation of cost-effectiveness analyses (CEA), four presenting utility",
      "extractCut": true,
      "blocks": [
        "library/10665-381036/blocks/prose-page-396"
      ]
    },
    {
      "id": "page-397",
      "number": null,
      "title": "Page 397",
      "level": 1,
      "pageStart": 397,
      "pageEnd": 397,
      "labelStart": "392",
      "labelEnd": "392",
      "words": 140,
      "summary": {
        "text": "Table 2 begins listing the methodological characteristics of the economic evaluations, including perspective, analysis type, currency, outcome and model.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "decision tree",
          "heading": false
        },
        {
          "term": "sensitivity analysis",
          "heading": false
        },
        {
          "term": "cea",
          "heading": false
        },
        {
          "term": "yes",
          "heading": false
        },
        {
          "term": "provider",
          "heading": false
        }
      ],
      "extract": "392 Table 2. Methodological characteristics of full economic evaluation studies Citation Perspective Type of economic analysis Year of analysis Currency Primary outcome Primary costing Modelling Type of model used Sensitivity analysis Xpert Chitpim et al., 2022(41) Societal CUA 2021 ฿ (Thai Baht) QALYs No Yes A hybrid decision tree Markov model One-way sensitivity analysis and probability sensitivity analysis Ejalu",
      "extractCut": true,
      "blocks": [
        "library/10665-381036/blocks/prose-page-397"
      ]
    },
    {
      "id": "page-398",
      "number": null,
      "title": "Page 398",
      "level": 1,
      "pageStart": 398,
      "pageEnd": 398,
      "labelStart": "393",
      "labelEnd": "393",
      "words": 142,
      "summary": {
        "text": "Continues Table 2 with the methods of economic studies of Xpert, including outcomes, models and sensitivity analyses.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "decision tree",
          "heading": false
        },
        {
          "term": "cea",
          "heading": false
        },
        {
          "term": "healthcare provider",
          "heading": false
        },
        {
          "term": "scenario analysis",
          "heading": false
        },
        {
          "term": "one-way",
          "heading": false
        }
      ],
      "extract": "393 the sixth month of follow-up. Esmail et al., 2020 (30) Healthcare provider CEA 2018 US$ Culture-positive case diagnosed and started on treatment Unclear Yes Not specified One-way Hickey et al., 2022 (31) Healthcare provider CEA Unspecifi ed US$ Hospital length- of-stay Unclear Yes Decision-analytic model in a decision tree with three arms comparing 3 AFB smears (3-AFB), a single Xpert test (1- Xpert), and 2",
      "extractCut": true,
      "blocks": [
        "library/10665-381036/blocks/prose-page-398"
      ]
    },
    {
      "id": "page-399",
      "number": null,
      "title": "Page 399",
      "level": 1,
      "pageStart": 399,
      "pageEnd": 399,
      "labelStart": "394",
      "labelEnd": "394",
      "words": 149,
      "summary": {
        "text": "Continues Table 2 with the methods of studies from Egypt and of Xpert Ultra evaluations, including decision tree and transmission models.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "tree model",
          "heading": false
        },
        {
          "term": "decision tree",
          "heading": false
        },
        {
          "term": "healthcare provider",
          "heading": false
        },
        {
          "term": "probabilistic",
          "heading": false
        },
        {
          "term": "dalys",
          "heading": false
        }
      ],
      "extract": "394 Sedrak et al., 2022 (47) Healthcare provider CEA 2017 E£ DALYs diagnostic costs, devices and test costs, treatment costs, patient costs Yes Decision tree analysis model Deterministic and probabilistic sensitivity analysis Ultra Fekadu, Wang & You, 2023 (48) Healthcare provider CUA 2023 US$ DALYs No Yes Decision tree model One-way, probabilistic, and scenario analysis Iem et al., 2023 (49) Healthcare provider",
      "extractCut": true,
      "blocks": [
        "library/10665-381036/blocks/prose-page-399"
      ]
    },
    {
      "id": "page-400",
      "number": null,
      "title": "Page 400",
      "level": 1,
      "pageStart": 400,
      "pageEnd": 400,
      "labelStart": "395",
      "labelEnd": "395",
      "words": 71,
      "summary": {
        "text": "Completes Table 2 with methods of a Ugandan Ultra study and the Indian Truenat cost-utility study.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "healthcare provider",
          "heading": false
        },
        {
          "term": "per-patient",
          "heading": false
        },
        {
          "term": "per-test",
          "heading": false
        }
      ],
      "extract": "395 diagnosed and initiated on treatment Thompson et al., 2023 (52) Healthcare provider Cost + CEA 2019 US$ Cost outcomes: per-patient and per-test cost Cost- effectiveness outcomes: incremental patient with microbiologically confirmed tuberculosis disease initiating treatment within 14 days of initial presentation Yes No Modelling used for statistical analysis One-way and probabilistic TrueNat Bhatia et al., 2023",
      "extractCut": true,
      "blocks": [
        "library/10665-381036/blocks/prose-page-400"
      ]
    },
    {
      "id": "page-401",
      "number": null,
      "title": "Page 401",
      "level": 1,
      "pageStart": 401,
      "pageEnd": 401,
      "labelStart": "396",
      "labelEnd": "396",
      "words": 367,
      "summary": {
        "text": "Describes quality assessment with an 18-item modified CHEERS checklist. It begins reporting cost-effectiveness results, including ICERs for Xpert and LAM strategies in hospitalized people with HIV.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "xpert omni",
          "heading": false
        },
        {
          "term": "xpert cost-effectiveness",
          "heading": false
        },
        {
          "term": "compared xpert",
          "heading": false
        },
        {
          "term": "reporting quality",
          "heading": false
        },
        {
          "term": "cost-effectiveness studies",
          "heading": false
        },
        {
          "term": "lam",
          "heading": false
        },
        {
          "term": "secondary costing",
          "heading": false
        },
        {
          "term": "overall score",
          "heading": false
        }
      ],
      "extract": "Quality assessment Two reviewers independently evaluated the reporting quality of each included study, and any disagreement was resolved by discussion. An 18-item modified Consolidated Health Economic Evaluation Reporting Standards (CHEERS) statement was used. The CHEERS statement is not a tool for assessing the quality of methods and does not provide an overall score. Instead, it assesses the quality of reporting.",
      "extractCut": true,
      "blocks": [
        "library/10665-381036/blocks/prose-page-401"
      ]
    },
    {
      "id": "page-402",
      "number": null,
      "title": "Page 402",
      "level": 1,
      "pageStart": 402,
      "pageEnd": 402,
      "labelStart": "397",
      "labelEnd": "397",
      "words": 328,
      "summary": {
        "text": "Reports further cost-effectiveness results, such as Xpert's low cost per additional case compared with smear in Ethiopia and in Colombia. It also reports that pooling sputum for Ultra or Xpert reduced costs per test and per confirmed case.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "lam xpert",
          "heading": false
        },
        {
          "term": "compared xpert",
          "heading": false
        },
        {
          "term": "parallel lam",
          "heading": false
        },
        {
          "term": "smear",
          "heading": false
        },
        {
          "term": "lamp",
          "heading": false
        },
        {
          "term": "icer",
          "heading": false
        },
        {
          "term": "cost-effectiveness studies",
          "heading": false
        },
        {
          "term": "empiric",
          "heading": false
        }
      ],
      "extract": "Xpert. For parallel LAM + Xpert, the ICER was $2338. Despite this, parallel testing was the preferred strategy for identifying more cases. Kaso & Hailu, 2021 compared Xpert to smear, and the ICER was $28 per additional case diagnosed (44). Cadavid et al., 2022 compared Xpert to smear and culture in adults & children and found Xpert to be more cost-effective with an ICER of $1017 compared to $1039 for culture (29).",
      "extractCut": true,
      "blocks": [
        "library/10665-381036/blocks/prose-page-402"
      ]
    },
    {
      "id": "page-403",
      "number": null,
      "title": "Page 403",
      "level": 1,
      "pageStart": 403,
      "pageEnd": 403,
      "labelStart": "398",
      "labelEnd": "398",
      "words": 350,
      "summary": {
        "text": "Reports that pooled sputum testing could save resources and summarises studies of Ultra for pleural TB and in children's stool in Ethiopia and Indonesia, with ICERs per DALY averted. It introduces a study of whole-genome sequencing in England and Wales.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "decentralised testing",
          "heading": false
        },
        {
          "term": "centralised testing",
          "heading": false
        },
        {
          "term": "cost-effective strategy",
          "heading": false
        },
        {
          "term": "irisa-tb",
          "heading": false
        },
        {
          "term": "fujilam",
          "heading": false
        },
        {
          "term": "cost-effectiveness",
          "heading": false
        },
        {
          "term": "averted",
          "heading": false
        },
        {
          "term": "pleural",
          "heading": false
        }
      ],
      "extract": "pooling. The study concluded that pooled sputum testing could be a cost-effective strategy for diagnosing TB, resulting in significant resource savings, as it could increase testing capacity and affordability in resource-limited settings. Pooran et al., 2022 determined the cost-effectiveness of five different testing strategies [Smear microscopy, MGIT, Adenosine deaminase, Interferon-gamma Release Immuno-Suspension",
      "extractCut": true,
      "blocks": [
        "library/10665-381036/blocks/prose-page-403"
      ]
    },
    {
      "id": "page-404",
      "number": null,
      "title": "Page 404",
      "level": 1,
      "pageStart": 404,
      "pageEnd": 404,
      "labelStart": "399",
      "labelEnd": "399",
      "words": 220,
      "summary": {
        "text": "Reports that whole-genome sequencing could shorten time to drug susceptibility results and save costs. It also states that Truenat was found more cost-effective than Xpert and smear microscopy in India.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "inb",
          "heading": false
        },
        {
          "term": "shortens",
          "heading": false
        },
        {
          "term": "study showed",
          "heading": false
        },
        {
          "term": "wgs",
          "heading": false
        },
        {
          "term": "molecular testing",
          "heading": false
        },
        {
          "term": "truenat",
          "heading": false
        },
        {
          "term": "low-burden",
          "heading": false
        }
      ],
      "extract": "sensitivity testing, compared to using Ultra or the simultaneous use of WGS and Ultra for routine TB diagnosis (50). The study showed that WGS shortens the time to drug-sensitivity testing and treatment modification where necessary, reducing treatment and hospitalisation costs, with an Incremental Net benefit (INB) of £11.1M. Molecular testing shortens the time to TB diagnosis and treatment. While this causes an",
      "extractCut": true,
      "blocks": [
        "library/10665-381036/blocks/prose-page-404"
      ]
    },
    {
      "id": "page-405",
      "number": null,
      "title": "Page 405",
      "level": 1,
      "pageStart": 405,
      "pageEnd": 405,
      "labelStart": "400",
      "labelEnd": "400",
      "words": 118,
      "summary": {
        "text": "Table 3 begins listing cost components and costs per test in 2024 US dollars for Xpert studies in Brazil, Uganda and southern and eastern African countries.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "xpert",
          "heading": false
        },
        {
          "term": "lam",
          "heading": false
        },
        {
          "term": "sequential",
          "heading": false
        },
        {
          "term": "ejalu",
          "heading": false
        }
      ],
      "extract": "400 Table 3. Cost components included in full economic evaluation studies Class of LC- aNAAT Citation Country Costs included in the analysis Cost per test (2024 US$) Staff Lab space Equipment Consumables Overhead Transport Xpert Primary costing Da Silva et al., 2021(43) Brazil ✓ ✓ ✓ ✓ X X Xpert with subsidy = $41.46 Xpert without subsidy $217.03 Ejalu et al., 2022 (42) Uganda ✓ ✓ ✓ ✓ ✓ ✓ Total cost per test Xpert",
      "extractCut": true,
      "blocks": [
        "library/10665-381036/blocks/prose-page-405"
      ]
    },
    {
      "id": "page-406",
      "number": null,
      "title": "Page 406",
      "level": 1,
      "pageStart": 406,
      "pageEnd": 406,
      "labelStart": "401",
      "labelEnd": "401",
      "words": 137,
      "summary": {
        "text": "Continues Table 3 with costs per test for Xpert in Ethiopia, Thailand, Egypt, Uganda and Colombia, and for pooled Ultra testing.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "xpert mtb",
          "heading": false
        },
        {
          "term": "cost analyses",
          "heading": false
        },
        {
          "term": "mtb rif",
          "heading": false
        }
      ],
      "extract": "401 Kaso & Hailu, 2021. (44) Ethiopia ✓ ✓ ✓ ✓ ✓ X Cost per patient tested Xpert $28.06 (ranging from $27.60 to $28.76) Khumsri et al., 2020 (46) Thailand ✓ ✓ ✓ ✓ ✓ X Xpert $53.78 Sedrak et al., 2022 (47) Egypt ✓ X ✓ ✓ X X Secondary cost analyses Chitpim et al., 2022 (41) Thailand ✓ ✓ ✓ ✓ ✓ ✓ Xpert unit costs $1,001.61 (SE $100.16) Keim-Malpass et al., 2023 (45) Uganda ✓ ✓ ✓ ✓ X X Xpert MTB/Rif $23.06 Hickey et al.,",
      "extractCut": true,
      "blocks": [
        "library/10665-381036/blocks/prose-page-406"
      ]
    },
    {
      "id": "page-407",
      "number": null,
      "title": "Page 407",
      "level": 1,
      "pageStart": 407,
      "pageEnd": 407,
      "labelStart": "402",
      "labelEnd": "402",
      "words": 87,
      "summary": {
        "text": "Completes Table 3 with costs per Ultra test in South Africa, Uganda, England and Wales, Ethiopia and Indonesia.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "south africa",
          "heading": false
        },
        {
          "term": "indonesia",
          "heading": false
        },
        {
          "term": "ethiopia",
          "heading": false
        }
      ],
      "extract": "402 Pooran et al., 2022 (51,52) South Africa ✓ ✓ ✓ ✓ X Xpert ULTRA baseline test - $12.19 Thompson et al., 2023 (52) Uganda ✓ ✓ ✓ ✓ ✓ Centralised = $20.69 Decentralised = $28.05 Secondary cost analyses Fekadu et al., 2023 (48) South Africa ✓ ✓ ✓ ✓ X X $27.00 Mugwagwa et al., 2021 (50) England and Wales ✓ ✓ ✓ ✓ X X $167.52 Mafirakureva et al., 2022 (39) Ethiopia Indonesia ✓ ✓ X ✓ X X Ethiopia = $46.39 Indonesia =",
      "extractCut": true,
      "blocks": [
        "library/10665-381036/blocks/prose-page-407"
      ]
    },
    {
      "id": "page-408",
      "number": null,
      "title": "Page 408",
      "level": 1,
      "pageStart": 408,
      "pageEnd": 408,
      "labelStart": "403",
      "labelEnd": "403",
      "words": 145,
      "summary": {
        "text": "Describes twelve cost analyses of Xpert, mostly from lower-middle-income countries and a provider perspective, and the cost components they included.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "costing studies",
          "heading": false
        },
        {
          "term": "cost components",
          "heading": false
        },
        {
          "term": "consumables",
          "heading": false
        },
        {
          "term": "human resources",
          "heading": false
        },
        {
          "term": "perspective",
          "heading": false
        }
      ],
      "extract": "Xpert cost analyses (n=12) Twelve studies assessed the cost per test of Xpert (54–65). Most of these studies (46%) were done in lower-middle-income countries. Most studies (92%) were done from a provider perspective, and only one was done from a societal perspective. The studies were conducted in various settings, and Xpert was compared to several different comparators. Table 4 outlines the study characteristics of",
      "extractCut": true,
      "blocks": [
        "library/10665-381036/blocks/prose-page-408"
      ]
    },
    {
      "id": "page-409",
      "number": null,
      "title": "Page 409",
      "level": 1,
      "pageStart": 409,
      "pageEnd": 409,
      "labelStart": "404",
      "labelEnd": "404",
      "words": 162,
      "summary": {
        "text": "Table 4 begins describing the included Xpert cost analyses in countries such as Benin, the Philippines, South Africa and Brazil.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "smear microscopy",
          "heading": false
        },
        {
          "term": "specified population",
          "heading": false
        },
        {
          "term": "xpert",
          "heading": false
        },
        {
          "term": "outpatient",
          "heading": false
        },
        {
          "term": "cxr",
          "heading": false
        },
        {
          "term": "dr-tb",
          "heading": false
        }
      ],
      "extract": "404 Table 4. Description of included cost analyses Citation Country Study population Type of TB disease Study Setting Diagnostic Intervention Diagnostic Comparator Xpert Adjobimey et al., 2022 (66) Benin Pregnant woman DS-TB Health centers Xpert No comparator Capeding et al., 2022 (67) Philippines No specified population DS and DR-TB Primary care facilities and hospitals Xpert Smear microscopy ZN Cassim et al., 2021",
      "extractCut": true,
      "blocks": [
        "library/10665-381036/blocks/prose-page-409"
      ]
    },
    {
      "id": "page-410",
      "number": null,
      "title": "Page 410",
      "level": 1,
      "pageStart": 410,
      "pageEnd": 410,
      "labelStart": "405",
      "labelEnd": "405",
      "words": 201,
      "summary": {
        "text": "Continues Table 4 with Xpert cost analyses in India, Indonesia, Brazil and other settings, including centralized and decentralized testing.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "x-ray",
          "heading": false
        },
        {
          "term": "ds-tb",
          "heading": false
        },
        {
          "term": "symptom screen",
          "heading": false
        },
        {
          "term": "smear microscopy",
          "heading": false
        },
        {
          "term": "xpert",
          "heading": false
        },
        {
          "term": "lpa",
          "heading": false
        }
      ],
      "extract": "405 Muniyandi et al., 2021 (72) India Unclear DS TB and DR- TB Primary care facilities, outpatients, and inpatients ZN, x-ray, and Xpert ZN, x-ray, Xpert and LPA FM, x-ray and Xpert FM, x-ray, Xpert and LPA ZN ZN, x-ray and LPA ZN and x-ray FM FM and x-ray FM, x-ray and LPA Nadjib et al., 2022 (73) Indonesia Adults (≥15 years) DS-TB and DR- TB TB diagnostics facilities Xpert Sputum smear microscopy SSM + chest x-ray",
      "extractCut": true,
      "blocks": [
        "library/10665-381036/blocks/prose-page-410"
      ]
    },
    {
      "id": "page-411",
      "number": null,
      "title": "Page 411",
      "level": 1,
      "pageStart": 411,
      "pageEnd": 411,
      "labelStart": "406",
      "labelEnd": "406",
      "words": 23,
      "summary": {
        "text": "Notes defining the abbreviations used in Table 4.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "microscopy",
          "heading": false
        },
        {
          "term": "diode",
          "heading": false
        },
        {
          "term": "neelsen",
          "heading": false
        }
      ],
      "extract": "406 Note: SSM (Sputum smear microscopy), Xpert (GeneXpert MTB/RIF), FM (Fluorescence microscopy), ZN (Ziehl–Neelsen microscopy), LED‑FM (light‑emitting diode‑fluorescent microscopy), DST (drug susceptibility testing)",
      "extractCut": false,
      "blocks": [
        "library/10665-381036/blocks/prose-page-411"
      ]
    },
    {
      "id": "page-412",
      "number": null,
      "title": "Page 412",
      "level": 1,
      "pageStart": 412,
      "pageEnd": 412,
      "labelStart": "407",
      "labelEnd": "407",
      "words": 170,
      "summary": {
        "text": "Table 5 begins listing cost components and unit costs from Xpert cost analyses, with costs per test mostly between about $13 and $32 and costs per case detected in Cambodia.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "xpert mtb",
          "heading": false
        },
        {
          "term": "unit costs",
          "heading": false
        },
        {
          "term": "mtb rif",
          "heading": false
        },
        {
          "term": "health system",
          "heading": false
        }
      ],
      "extract": "407 Table 5. Cost components and unit costs Citation Analysis Perspective Costs included in the analysis Cost per test (2024US$) Staff Building/ Infrastructure Equipment Consumables Overhead Transport Xpert Adjobimey et al., 2022 (66) Health system ✓ X ✓ ✓ ✓ ✓ Xpert MTB/RIF (per sample) $23.14 Capeding et al., 2022 (67) Health system ✓ ✓ ✓ ✓ ✓ X Xpert MTB/RIF testing $24.69 (23.29– 25.95) Bottom-up, and $28.4",
      "extractCut": true,
      "blocks": [
        "library/10665-381036/blocks/prose-page-412"
      ]
    },
    {
      "id": "page-413",
      "number": null,
      "title": "Page 413",
      "level": 1,
      "pageStart": 413,
      "pageEnd": 413,
      "labelStart": "408",
      "labelEnd": "408",
      "words": 153,
      "summary": {
        "text": "Continues Table 5 with Xpert costs per test or person from Tajikistan, India, Indonesia and Brazil, including societal costs.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "societal lab",
          "heading": false
        },
        {
          "term": "direct non-medical",
          "heading": false
        },
        {
          "term": "health system",
          "heading": false
        },
        {
          "term": "xpert",
          "heading": false
        }
      ],
      "extract": "408 Cost per screening $13 Cost per Xpert test $22.79 Cost per TB case detected (Xpert) $434.24 Lopes et al., 2020 (71) Health system Unclear Xpert Muniyandi et al., 2021 (72) Health system ✓ ✓ ✓ ✓ ✓ ? GeneXpert MTB/RIF $ 19.88 Nadjib et al., 2022 (73) Societal ✓ ✓ ✓ ✓ ? ? Ave cost/person tested Health system$33.04 Societal - Lab only + direct non-medical $47.06 Societal - Lab + direct non-medical + indirect $85.16",
      "extractCut": true,
      "blocks": [
        "library/10665-381036/blocks/prose-page-413"
      ]
    },
    {
      "id": "page-414",
      "number": null,
      "title": "Page 414",
      "level": 1,
      "pageStart": 414,
      "pageEnd": 414,
      "labelStart": "409",
      "labelEnd": "409",
      "words": 20,
      "summary": {
        "text": "Completes Table 5 with a laboratory-perspective Xpert cost per test from India.",
        "status": "draft"
      },
      "keywords": [],
      "extract": "409 Yadav, Verma & Kaushik, 2022 (77) Laboratory Perspective ✓ ? ✓ ✓ ✓ ? Cost per test - $18.07",
      "extractCut": false,
      "blocks": [
        "library/10665-381036/blocks/prose-page-414"
      ]
    },
    {
      "id": "page-415",
      "number": null,
      "title": "Page 415",
      "level": 1,
      "pageStart": 415,
      "pageEnd": 415,
      "labelStart": "410",
      "labelEnd": "410",
      "words": 213,
      "summary": {
        "text": "Reports that six studies were included in the review of TB-LAMP after screening, and shows the PRISMA flow diagram with reasons for exclusion.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "studies excluded",
          "heading": false
        },
        {
          "term": "economic evaluation",
          "heading": false
        },
        {
          "term": "containing information",
          "heading": false
        },
        {
          "term": "systematic review",
          "heading": false
        },
        {
          "term": "duplicates",
          "heading": false
        },
        {
          "term": "tb-lamp",
          "heading": false
        }
      ],
      "extract": "3.2. Systematic review of LC-mNAAT (TB-LAMP): 3.2.1. Summary of Findings: After eliminating 638 duplicates, our search found 1,990 studies. Six studies were included in the final systematic review, as seen in Figure 2. Studies that did not involve people with TB, used LAMP as a diagnostic intervention, or did not contain cost data were excluded. Of the six included studies, one performed a cost-utility analysis",
      "extractCut": true,
      "blocks": [
        "library/10665-381036/blocks/prose-page-415"
      ]
    },
    {
      "id": "page-416",
      "number": null,
      "title": "Page 416",
      "level": 1,
      "pageStart": 416,
      "pageEnd": 416,
      "labelStart": "411",
      "labelEnd": "411",
      "words": 101,
      "summary": {
        "text": "Describes the countries, years, settings and specimen types of the TB-LAMP studies, which mostly used sputum from presumptive TB cases.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "inmates",
          "heading": false
        },
        {
          "term": "baikunje",
          "heading": false
        },
        {
          "term": "jaroenram",
          "heading": false
        }
      ],
      "extract": "(81) and Cameroon (79), respectively. The studies were conducted over a range of years, from 2014 to 2021. The studies were conducted across various settings, including outpatient departments at health centers (83), peripheral laboratories (80), a laboratory setting for the development of modified TB-LAMP (82), and all prisons and villages involving inmates and refugees (79). Jaroenram et al. (2020) used the sputum",
      "extractCut": true,
      "blocks": [
        "library/10665-381036/blocks/prose-page-416"
      ]
    },
    {
      "id": "page-417",
      "number": null,
      "title": "Page 417",
      "level": 1,
      "pageStart": 417,
      "pageEnd": 417,
      "labelStart": "412",
      "labelEnd": "412",
      "words": 157,
      "summary": {
        "text": "Table 6 lists general characteristics of the TB-LAMP economic studies, such as setting, currency, population, strategies, perspective and type of analysis. The extracted table text is broken up.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "perspe ctive",
          "heading": false
        },
        {
          "term": "analysi",
          "heading": false
        },
        {
          "term": "diagno",
          "heading": false
        },
        {
          "term": "societa",
          "heading": false
        },
        {
          "term": "outco",
          "heading": false
        },
        {
          "term": "ies",
          "heading": false
        }
      ],
      "extract": "412 Table 6: General characteristics of included full economic evaluation studies Manus cript Countr y setting Setting Curren cy Year of cost valuati on Study popula tion Diagno stic strateg ies Refere nce diagno stic strateg ies Analysi s perspe ctive (health care or societa l) Type of econo mic evaluat ion Type of model if applica ble Primar y outco me Second ary outco me(s) Source of costing Baikunj e 2019 (81)",
      "extractCut": true,
      "blocks": [
        "library/10665-381036/blocks/prose-page-417"
      ]
    },
    {
      "id": "page-418",
      "number": null,
      "title": "Page 418",
      "level": 1,
      "pageStart": 418,
      "pageEnd": 418,
      "labelStart": "413",
      "labelEnd": "413",
      "words": 49,
      "summary": {
        "text": "A fragment of Table 6 describing TB-LAMP and Xpert testing strategies and ICER per QALY outcomes.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "dst",
          "heading": false
        },
        {
          "term": "xray",
          "heading": false
        },
        {
          "term": "positiv",
          "heading": false
        }
      ],
      "extract": "413 above 15 years ( with sympto ms or abnor mal chest Xray) -on test to SSM) TB- LAMP Initial (If positiv e, the first- line DST (FL- DST) and second -line DST (SL- DST) would Xpert MTB/RI F Add- on Xpert MTB/RI F Initial ICER per QALY gained",
      "extractCut": false,
      "blocks": [
        "library/10665-381036/blocks/prose-page-418"
      ]
    },
    {
      "id": "page-419",
      "number": null,
      "title": "Page 419",
      "level": 1,
      "pageStart": 419,
      "pageEnd": 419,
      "labelStart": "414",
      "labelEnd": "414",
      "words": 100,
      "summary": {
        "text": "Continues Table 6 with TB-LAMP studies in Cameroonian prisons and refugee villages and in Thailand.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "mentio ned",
          "heading": false
        },
        {
          "term": "lamp",
          "heading": false
        },
        {
          "term": "usd",
          "heading": false
        }
      ],
      "extract": "414 be utilized .) Donken g-Donf ack 2022 (79) Camer oon All inmate s and refuge es in 34 prisons and 3 villages USD 2019 Presum ptive TB cases from prisons and refuge e camps. TB LAMP, followe d by Gene Xpert Gene Xpert only Not mentio ned Cost Benefit Analysi s N/A Amoun t of USD saved literatu re, GDF, NTP Jaroenr am 2020 (82) Thailan d USD 2019 Known TB cases TB- LAMP potenti ostat (TB LAMP- EC) Culture and",
      "extractCut": true,
      "blocks": [
        "library/10665-381036/blocks/prose-page-419"
      ]
    },
    {
      "id": "page-420",
      "number": null,
      "title": "Page 420",
      "level": 1,
      "pageStart": 420,
      "pageEnd": 420,
      "labelStart": "415",
      "labelEnd": "415",
      "words": 103,
      "summary": {
        "text": "Continues Table 6 with TB-LAMP costing studies in Malawi and Viet Nam.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "presum ptive",
          "heading": false
        },
        {
          "term": "lamp",
          "heading": false
        },
        {
          "term": "laborat",
          "heading": false
        },
        {
          "term": "primar",
          "heading": false
        }
      ],
      "extract": "415 Nliwasa 2016 (83) Malawi LAMP was done at primar y care facility wherea s Xpert and micros copy in a researc h laborat ory. USD Octobe r 2013 to March 2014 Presum ptive TB cases above 15 years TB- LAMP Culture , SSM, Xpert MTB/RI F Not mentio ned Costing N/A Cost of TB- LAMP Literat ure Sohn 2019 (80) Malawi and Vietna m periph eral laborat ories USD Februa ry to April of 2015 Presum ptive TB cases TB LAMP GeneX",
      "extractCut": true,
      "blocks": [
        "library/10665-381036/blocks/prose-page-420"
      ]
    },
    {
      "id": "page-421",
      "number": null,
      "title": "Page 421",
      "level": 1,
      "pageStart": 421,
      "pageEnd": 421,
      "labelStart": "416",
      "labelEnd": "416",
      "words": 5,
      "summary": {
        "text": "A table fragment naming Xpert testing.",
        "status": "draft"
      },
      "keywords": [],
      "extract": "416 analysi s Xpert test",
      "extractCut": false,
      "blocks": [
        "library/10665-381036/blocks/prose-page-421"
      ]
    },
    {
      "id": "page-422",
      "number": null,
      "title": "Page 422",
      "level": 1,
      "pageStart": 422,
      "pageEnd": 422,
      "labelStart": "417",
      "labelEnd": "417",
      "words": 400,
      "summary": {
        "text": "Reports that TB-LAMP costs per test ranged from $1 to $19, with the lowest estimates giving little or partial costing detail. It describes a Thai cost-utility study's methods, including direct medical and non-medical costs.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "non-medical costs",
          "heading": false
        },
        {
          "term": "ssm followed",
          "heading": false
        },
        {
          "term": "lowest cost",
          "heading": false
        },
        {
          "term": "direct medical",
          "heading": false
        },
        {
          "term": "cost-utility analysis",
          "heading": false
        },
        {
          "term": "diagnostic algorithms",
          "heading": false
        },
        {
          "term": "formal care",
          "heading": false
        },
        {
          "term": "mtb rif",
          "heading": false
        }
      ],
      "extract": "3.1.3. Economic Evidence Around LC-mNAAT (TB-LAMP): Diagnostic Cost per Sample: According to the costing studies, the cost per test ranged from $1 to $19 (all values in 2024 USD currency). The lowest cost of $1 did not provide any details on the cost calculation (81), while the second lowest cost of $2 included the cost of equipment, reagents, and consumables in a laboratory setting (82). The study integrated LAMP",
      "extractCut": true,
      "blocks": [
        "library/10665-381036/blocks/prose-page-422"
      ]
    },
    {
      "id": "page-423",
      "number": null,
      "title": "Page 423",
      "level": 1,
      "pageStart": 423,
      "pageEnd": 423,
      "labelStart": "418",
      "labelEnd": "418",
      "words": 343,
      "summary": {
        "text": "Reports Thai findings that TB-LAMP followed by drug susceptibility testing was cost-saving compared with smear and culture, alongside ICERs for other strategies. It begins describing a Cameroonian cost-benefit analysis of mass screening.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "tb-lamp followed",
          "heading": false
        },
        {
          "term": "ssm followed",
          "heading": false
        },
        {
          "term": "mtb rif",
          "heading": false
        },
        {
          "term": "dst costed",
          "heading": false
        },
        {
          "term": "gained compared",
          "heading": false
        },
        {
          "term": "xpert mtb",
          "heading": false
        },
        {
          "term": "genexpert mtb",
          "heading": false
        },
        {
          "term": "screening campaigns",
          "heading": false
        }
      ],
      "extract": "The conventional method, SSM followed by Culture/DST (Smear, Culture, and Sensitivity Testing), was established as the baseline for comparison. This approach incurred a cost of $212.90 and resulted in a QALY of 24.24. Next, the study evaluated alternative strategies: • SSM followed by TB-LAMP and DST costed $237.20 with a QALY of 25.02. The ICER was calculated to be $29.93 per additional QALY gained compared to the",
      "extractCut": true,
      "blocks": [
        "library/10665-381036/blocks/prose-page-423"
      ]
    },
    {
      "id": "page-424",
      "number": null,
      "title": "Page 424",
      "level": 1,
      "pageStart": 424,
      "pageEnd": 424,
      "labelStart": "419",
      "labelEnd": "419",
      "words": 221,
      "summary": {
        "text": "Reports that combining TB-LAMP and Xpert in Cameroon cut turnaround time by about three-quarters and saved money from the second year. It also compares TB-LAMP and GeneXpert budget needs relative to national TB programme budgets in Malawi and Viet Nam.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "annual budget",
          "heading": false
        },
        {
          "term": "ntp annual",
          "heading": false
        },
        {
          "term": "budget allocation",
          "heading": false
        },
        {
          "term": "same labs",
          "heading": false
        },
        {
          "term": "xpert mtb",
          "heading": false
        },
        {
          "term": "spread across",
          "heading": false
        },
        {
          "term": "mtb rif",
          "heading": false
        }
      ],
      "extract": "printer, air conditioners, consumables, maintenance, and human resources. It revealed that combined TB- LAMP and Xpert MTB/RIF significantly reduced turnaround time (TAT) by 73.23% in prisons and 74.92% in villages. Moreover, the algorithm demonstrated cost benefits from the second year of implementation: about $16,986 and $18,654 were saved for years 2 and 3, respectively, in prison (15,699 prisoners) and $1879 and",
      "extractCut": true,
      "blocks": [
        "library/10665-381036/blocks/prose-page-424"
      ]
    },
    {
      "id": "page-425",
      "number": null,
      "title": "Page 425",
      "level": 1,
      "pageStart": 425,
      "pageEnd": 425,
      "labelStart": "420",
      "labelEnd": "420",
      "words": 103,
      "summary": {
        "text": "Table 7 gives TB-LAMP unit costs in Malawi and Viet Nam by batch size, falling from $13–19 for two tests to $8–11 for 14 tests.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "batch tests",
          "heading": false
        },
        {
          "term": "malawi tests",
          "heading": false
        },
        {
          "term": "yes",
          "heading": false
        }
      ],
      "extract": "420 Table 7: Cost of TB LAMP Author Included cost Unit test cost (USD) Equipment Consumables Staff Overhead Equipment warranty Nliwasa et al. 2016 (83) Yes Yes Yes Yes Yes Malawi 2 tests per batch $13 4 tests per batch $10 10 tests per batch $8 14 tests per batch $8 Sohn et al. 2019 (80) Yes Yes Yes Yes Yes Malawi 2 tests per batch $15 4 tests per batch $11 10 tests per batch $8 14 tests per batch $8 Vietnam 2 tests",
      "extractCut": true,
      "blocks": [
        "library/10665-381036/blocks/prose-page-425"
      ]
    },
    {
      "id": "page-426",
      "number": null,
      "title": "Page 426",
      "level": 1,
      "pageStart": 426,
      "pageEnd": 426,
      "labelStart": "421",
      "labelEnd": "421",
      "words": 83,
      "summary": {
        "text": "Completes Table 7 and presents Table 8 on costs, QALYs and ICERs of TB-LAMP and Xpert algorithms from the Thai study.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "ssm followed",
          "heading": false
        },
        {
          "term": "mtb rif",
          "heading": false
        },
        {
          "term": "xpert mtb",
          "heading": false
        }
      ],
      "extract": "421 Baikunje et al. 2019 (81) No Yes No No No $1 Jaroenram et al. 2020 (82) Yes Yes No No No $2 Table 8: Cost of TB LAMP and other algorithms from Chitipim et al. 2022(41) Cost ($USD) QALY ICER per QALY gained SSM followed by Culture/DST $212.9 24.24 Comparator SSM followed by TB-LAMP if positive DST $237.2 25.02 $29.93 TB-LAMP followed by DST $204.2 25.17 Cost saving SSM followed by Xpert MTB/RIF $277.6 24.77",
      "extractCut": true,
      "blocks": [
        "library/10665-381036/blocks/prose-page-426"
      ]
    },
    {
      "id": "page-427",
      "number": null,
      "title": "Page 427",
      "level": 1,
      "pageStart": 427,
      "pageEnd": 427,
      "labelStart": "422",
      "labelEnd": "422",
      "words": 127,
      "summary": {
        "text": "Reports quality scores of the TB-LAMP studies and that only one study was included in the review of moderate-complexity automated NAATs.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "mc-anaat",
          "heading": false
        },
        {
          "term": "systematic review",
          "heading": false
        },
        {
          "term": "cheers",
          "heading": false
        },
        {
          "term": "quality",
          "heading": false
        }
      ],
      "extract": "3.2.4. Quality of included studies: Our quality of health economic studies extraction form was used to evaluate the quality of included manuscripts. This contained 18 questions and was adapted from a modified CHEERS, as described earlier. Quality scores varied from 11/18 to 17/18, with an average quality score of 14/21 among. 3.3 Systematic review of MC-aNAAT 3.3.1. Summary of Findings: We identified 108 records",
      "extractCut": true,
      "blocks": [
        "library/10665-381036/blocks/prose-page-427"
      ]
    },
    {
      "id": "page-428",
      "number": null,
      "title": "Page 428",
      "level": 1,
      "pageStart": 428,
      "pageEnd": 428,
      "labelStart": "423",
      "labelEnd": "423",
      "words": 124,
      "summary": {
        "text": "Describes the single included study, which estimated costs of low- and high-throughput moderate-complexity NAAT systems in a hypothetical laboratory in a low- or middle-income country.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "throughput",
          "heading": false
        },
        {
          "term": "batch",
          "heading": false
        },
        {
          "term": "activity-based",
          "heading": false
        },
        {
          "term": "malhotra",
          "heading": false
        }
      ],
      "extract": "3.3.2. General characteristics of included full economic evaluation studies The systematic review included a study conducted by Malhotra et al. in 2023, which estimated the costs associated with two moderate complexities automated NAATs with low throughput (LT) and high throughput (HT) systems (85). The selected study was conducted in a hypothetical laboratory in resource- limited setting in a low- or middle-income",
      "extractCut": true,
      "blocks": [
        "library/10665-381036/blocks/prose-page-428",
        "library/10665-381036/blocks/figure-img-p428-1"
      ]
    },
    {
      "id": "page-429",
      "number": null,
      "title": "Page 429",
      "level": 1,
      "pageStart": 429,
      "pageEnd": 429,
      "labelStart": "424",
      "labelEnd": "424",
      "words": 271,
      "summary": {
        "text": "Explains the study's cost components and data sources and reports base-case costs per test for low- and high-throughput systems. It notes a quality score of 17 out of 18.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "naat equipment",
          "heading": false
        },
        {
          "term": "per-test cost",
          "heading": false
        },
        {
          "term": "test kit",
          "heading": false
        },
        {
          "term": "sensitivity analysis",
          "heading": false
        },
        {
          "term": "price",
          "heading": false
        },
        {
          "term": "cost-effective",
          "heading": false
        },
        {
          "term": "score",
          "heading": false
        },
        {
          "term": "lower",
          "heading": false
        }
      ],
      "extract": "equipment, test kit (consumables), staff, building, and overhead costs captured in 2019 US dollars. The sources of costing information included time-and-motion (TAM) studies conducted by Foundation for Innovative New Diagnostics (FIND), manufacturer’s data, and certain assumptions derived from earlier FIND studies in LMICs. 3.3.3. Cost Estimates and sensitivity analysis: In the base case the per-test cost of was",
      "extractCut": true,
      "blocks": [
        "library/10665-381036/blocks/prose-page-429"
      ]
    },
    {
      "id": "page-430",
      "number": null,
      "title": "Page 430",
      "level": 1,
      "pageStart": 430,
      "pageEnd": 430,
      "labelStart": "425",
      "labelEnd": "425",
      "words": 137,
      "summary": {
        "text": "Table 9 describes the included moderate-complexity NAAT study, and Table 10 gives its unit test costs of $22.48 for low-throughput and $18.66 for high-throughput systems.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "costing study",
          "heading": false
        },
        {
          "term": "malhotra",
          "heading": false
        },
        {
          "term": "yes",
          "heading": false
        },
        {
          "term": "unit test",
          "heading": false
        },
        {
          "term": "diagnostic strategies",
          "heading": false
        }
      ],
      "extract": "425 Table 9: Characteristics of included study on systematic revise of MC-aNAAT Manuscript Country setting Setting Currency Year of cost valuation Study population Diagnostic strategies Reference diagnostic strategies Analysis perspective Type of economic evaluation Type of model if applicable Primary outcome Secondary outcome(s) Source of costing Malhotra et al., 2023 (85) Hypothetical resource limited setting in",
      "extractCut": true,
      "blocks": [
        "library/10665-381036/blocks/prose-page-430"
      ]
    },
    {
      "id": "page-431",
      "number": null,
      "title": "Page 431",
      "level": 1,
      "pageStart": 431,
      "pageEnd": 431,
      "labelStart": "426",
      "labelEnd": "426",
      "words": 440,
      "summary": {
        "text": "Discusses the 29 LC-aNAAT studies, including 17 cost-effectiveness analyses and 12 cost analyses, all of the latter on Xpert. It contrasts this with an earlier review that found no Ultra studies and notes that only one Truenat study exists.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "seventeen cost-effectiveness",
          "heading": false
        },
        {
          "term": "cost-effectiveness analyses",
          "heading": false
        },
        {
          "term": "assessed parallel",
          "heading": false
        },
        {
          "term": "cost analyses",
          "heading": false
        },
        {
          "term": "parallel testing",
          "heading": false
        },
        {
          "term": "twelve cost",
          "heading": false
        },
        {
          "term": "preferred strategy",
          "heading": false
        },
        {
          "term": "averted",
          "heading": false
        }
      ],
      "extract": "4. DISCUSSION LC-aNAAT discussion: Through a systematic review of published literature on LC aNAATs, we identified 29 studies that met our inclusion criteria. These included seventeen cost-effectiveness analyses and twelve cost analyses. Of the seventeen cost-effectiveness analyses, ten were on Xpert, six on Ultra and one on TrueNat. All twelve cost analyses were on Xpert. We did not find any cost analyses for Ultra",
      "extractCut": true,
      "blocks": [
        "library/10665-381036/blocks/prose-page-431"
      ]
    },
    {
      "id": "page-432",
      "number": null,
      "title": "Page 432",
      "level": 1,
      "pageStart": 432,
      "pageEnd": 432,
      "labelStart": "427",
      "labelEnd": "427",
      "words": 314,
      "summary": {
        "text": "Discusses TB-LAMP evidence, noting that batch size and setting affect costs. It adds that a recent fall in TB-LAMP's price may improve its cost-effectiveness and affordability.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "implementing tb-lamp",
          "heading": false
        },
        {
          "term": "per-test costs",
          "heading": false
        },
        {
          "term": "diverse settings",
          "heading": false
        },
        {
          "term": "mtb rif",
          "heading": false
        },
        {
          "term": "cost-affordability",
          "heading": false
        },
        {
          "term": "xpert mtb",
          "heading": false
        },
        {
          "term": "underscores",
          "heading": false
        },
        {
          "term": "cost-utility",
          "heading": false
        }
      ],
      "extract": "LC-nNAAT discussion: The present systematic review provides an in-depth analysis of the economic and cost-effectiveness of implementing TB-LAMP in diverse settings. Through a range of economic analyses, including cost-utility, cost-benefit, and cost-affordability assessments, this study contributes valuable insights into the potential role of TB-LAMP in tuberculosis diagnostics. The reviewed studies reveal that",
      "extractCut": true,
      "blocks": [
        "library/10665-381036/blocks/prose-page-432"
      ]
    },
    {
      "id": "page-433",
      "number": null,
      "title": "Page 433",
      "level": 1,
      "pageStart": 433,
      "pageEnd": 433,
      "labelStart": "428",
      "labelEnd": "428",
      "words": 357,
      "summary": {
        "text": "Concludes that TB-LAMP shows promise within diagnostic algorithms in resource-limited settings and that evidence on moderate-complexity NAATs is limited to one study. It begins the overall conclusion that Xpert was generally cost-effective compared with smear or culture.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "per-test costs",
          "heading": false
        },
        {
          "term": "naat systems",
          "heading": false
        },
        {
          "term": "equipment costs",
          "heading": false
        },
        {
          "term": "testing volumes",
          "heading": false
        },
        {
          "term": "drug-resistant tuberculosis",
          "heading": false
        },
        {
          "term": "testing frequency",
          "heading": false
        },
        {
          "term": "hypothetical",
          "heading": false
        },
        {
          "term": "lmic",
          "heading": false
        }
      ],
      "extract": "In conclusion, the collective findings suggest that TB-LAMP holds promise as a cost-effective and efficient diagnostic tool for tuberculosis when integrated into broader diagnostic algorithms, particularly in resource-constrained settings. The results of this study have important implications for policymakers and healthcare professionals involved in the diagnosis and management of tuberculosis. MC-aNAAT discussion:",
      "extractCut": true,
      "blocks": [
        "library/10665-381036/blocks/prose-page-433"
      ]
    },
    {
      "id": "page-434",
      "number": null,
      "title": "Page 434",
      "level": 1,
      "pageStart": 434,
      "pageEnd": 434,
      "labelStart": "429",
      "labelEnd": "429",
      "words": 359,
      "summary": {
        "text": "Concludes that Ultra was generally cost-effective compared with smear and that Truenat was cost-effective in one study, so LC-aNAATs are likely cost-effective in many settings. The reference list then begins.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "multidrug-resistant tuberculosis",
          "heading": false
        },
        {
          "term": "mycobacterium tuberculosis",
          "heading": false
        },
        {
          "term": "cost-effective compared",
          "heading": false
        },
        {
          "term": "parallel testing",
          "heading": false
        },
        {
          "term": "susceptibility testing",
          "heading": false
        },
        {
          "term": "drug susceptibility",
          "heading": false
        },
        {
          "term": "assessed parallel",
          "heading": false
        },
        {
          "term": "apr",
          "heading": false
        }
      ],
      "extract": "heterogeneity in the cost-effectiveness results regarding Ultra, it was generally cost-effective compared to sputum smear microscopy. TrueNat cost-effectiveness was reported in only one study but was found to be cost-effective compared to Xpert amongst children in India. In general LC aNAATs are likely to be cost-effective across a variety of settings when compared with SSM and/or culture. Few studies assessed",
      "extractCut": true,
      "blocks": [
        "library/10665-381036/blocks/prose-page-434"
      ]
    },
    {
      "id": "page-435",
      "number": null,
      "title": "Page 435",
      "level": 1,
      "pageStart": 435,
      "pageEnd": 435,
      "labelStart": "430",
      "labelEnd": "430",
      "words": 608,
      "summary": {
        "text": "Part of the reference list, citing TB diagnostics research, WHO guidance and economic evaluations of Xpert in various countries.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "pulmonary tuberculosis",
          "heading": false
        },
        {
          "term": "mycobacterium tuberculosis",
          "heading": false
        },
        {
          "term": "mtb rif",
          "heading": false
        },
        {
          "term": "xpert mtb",
          "heading": false
        },
        {
          "term": "genexpert mtb",
          "heading": false
        },
        {
          "term": "cost-effectiveness analysis",
          "heading": false
        },
        {
          "term": "united nations",
          "heading": false
        },
        {
          "term": "mar",
          "heading": false
        }
      ],
      "extract": "10. García JI, Allué-Guardia A, Tampi RP, Restrepo BI, Torrelles JB. New Developments and Insights in the Improvement of Mycobacterium tuberculosis Vaccines and Diagnostics Within the End TB Strategy. Curr Epidemiol Rep. 2021 Apr 7;8(2):33–45. 11. World Health Organization. Update on the use of nucleic acid amplification tests to detect TB and drug resistant TB: rapid communication. Geneva ; 2021. 12. Nandlal L,",
      "extractCut": true,
      "blocks": [
        "library/10665-381036/blocks/prose-page-435"
      ]
    },
    {
      "id": "page-436",
      "number": null,
      "title": "Page 436",
      "level": 1,
      "pageStart": 436,
      "pageEnd": 436,
      "labelStart": "431",
      "labelEnd": "431",
      "words": 558,
      "summary": {
        "text": "Continues the reference list with economic evaluations of Xpert and Ultra in countries such as the US, Colombia and Uganda.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "model-based cost-effectiveness",
          "heading": false
        },
        {
          "term": "cost-effectiveness analysis",
          "heading": false
        },
        {
          "term": "low-burden setting",
          "heading": false
        },
        {
          "term": "genexpert mtb",
          "heading": false
        },
        {
          "term": "jul",
          "heading": false
        },
        {
          "term": "mtb rif",
          "heading": false
        },
        {
          "term": "diagnose tuberculosis",
          "heading": false
        },
        {
          "term": "hosp epidemiol",
          "heading": false
        }
      ],
      "extract": "Available from: https://ejhm.journals.ekb.eg/ 28. Hickey AJ, Cummings MJ, Zafari Z, Louh IK, Li J, O’Donnell MR. Evaluation of screening strategies for pulmonary tuberculosis among hospitalized patients in a low-burden setting: Cost-effectiveness of GeneXpert MTB/RIF compared to smear microscopy. Infect Control Hosp Epidemiol. 2022 Jul 21;43(7):892–7. 29. Cadavid C, Realpe T, Mejía GI, Zapata E, Hernández M, Robledo",
      "extractCut": true,
      "blocks": [
        "library/10665-381036/blocks/prose-page-436"
      ]
    },
    {
      "id": "page-437",
      "number": null,
      "title": "Page 437",
      "level": 1,
      "pageStart": 437,
      "pageEnd": 437,
      "labelStart": "432",
      "labelEnd": "432",
      "words": 599,
      "summary": {
        "text": "Continues the reference list with cost and cost-effectiveness studies of Xpert and other TB tests from Brazil, Ethiopia, India and elsewhere.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "tuberculosis diagnosis",
          "heading": false
        },
        {
          "term": "cost-effectiveness analysis",
          "heading": false
        },
        {
          "term": "pulmonary tuberculosis",
          "heading": false
        },
        {
          "term": "soc bras",
          "heading": false
        },
        {
          "term": "xpert mtb",
          "heading": false
        },
        {
          "term": "med trop",
          "heading": false
        },
        {
          "term": "mtb rif",
          "heading": false
        },
        {
          "term": "rev soc",
          "heading": false
        }
      ],
      "extract": "BMJ Open. 2022 Aug 23;12(8):e059823. 43. Silva SCA da, Vater MC, Ramalho DM de P, Almeida IN de, Miranda SS de, Kritski A. Cost-effectiveness of Xpert®MTB/RIF in the diagnosis of tuberculosis: pragmatic study. Rev Soc Bras Med Trop. 2021;54. 44. Kaso AW, Hailu A. Costs and cost-effectiveness of Gene Xpert compared to smear microscopy for the diagnosis of pulmonary tuberculosis using real-world data from Arsi zone,",
      "extractCut": true,
      "blocks": [
        "library/10665-381036/blocks/prose-page-437"
      ]
    },
    {
      "id": "page-438",
      "number": null,
      "title": "Page 438",
      "level": 1,
      "pageStart": 438,
      "pageEnd": 438,
      "labelStart": "433",
      "labelEnd": "433",
      "words": 623,
      "summary": {
        "text": "Part of a reference list for a review of costs of tuberculosis nucleic acid amplification tests (NAATs), citing costing and affordability studies of Xpert MTB/RIF, line probe assays and screening algorithms in countries such as India, Indonesia, Brazil and Uganda.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "soc bras",
          "heading": false
        },
        {
          "term": "bras med",
          "heading": false
        },
        {
          "term": "tuberculosis diagnosis",
          "heading": false
        },
        {
          "term": "rev soc",
          "heading": false
        },
        {
          "term": "med trop",
          "heading": false
        },
        {
          "term": "tuberculosis elimination",
          "heading": false
        },
        {
          "term": "costs incurred",
          "heading": false
        },
        {
          "term": "genotype mtbdrplus",
          "heading": false
        }
      ],
      "extract": "costs incurred under the National Tuberculosis Elimination Programme: A costing study from Tamil Nadu, South India. Int Health. 2021 Nov 1;13(6):536–44. 61. Nadjib M, Dewi RK, Setiawan E, Miko TY, Putri S, Hadisoemarto PF, et al. Cost and affordability of scaling up tuberculosis diagnosis using Xpert MTB/RIF testing in West Java, Indonesia. PLoS One. 2022 Mar 1;17(3 March). 62. Santos ADS, De Oliveira RD, Lemos EF,",
      "extractCut": true,
      "blocks": [
        "library/10665-381036/blocks/prose-page-438"
      ]
    },
    {
      "id": "page-439",
      "number": null,
      "title": "Page 439",
      "level": 1,
      "pageStart": 439,
      "pageEnd": 439,
      "labelStart": "434",
      "labelEnd": "434",
      "words": 308,
      "summary": {
        "text": "The end of the reference list for the TB NAAT costing review, citing cost and cost-effectiveness studies of case finding, TB-LAMP, Xpert and moderate-complexity drug susceptibility testing.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "loop-mediated isothermal",
          "heading": false
        },
        {
          "term": "isothermal amplification",
          "heading": false
        },
        {
          "term": "placement decisions",
          "heading": false
        },
        {
          "term": "infect dis",
          "heading": false
        },
        {
          "term": "complexity naats",
          "heading": false
        },
        {
          "term": "tuberculosis drug",
          "heading": false
        },
        {
          "term": "determining cost",
          "heading": false
        },
        {
          "term": "dec",
          "heading": false
        }
      ],
      "extract": "diagnosis of presumptive multidrug-resistant tuberculosis patients. J Glob Infect Dis. 2022;14(3):93. 78. Jo Y, Kagujje M, Johnson K, Dowdy D, Hangoma P, Chiliukutu L, et al. Costs and cost-effectiveness of a comprehensive tuberculosis case finding strategy in Zambia. PLoS One. 2021 Sep 9;16(9):e0256531. 79. Donkeng-Donfack VF, Tchatchueng-Mbougua JB, Abanda NN, Ongboulal SM, Djieugoue YJ, Kamdem Simo Y, et al. A",
      "extractCut": true,
      "blocks": [
        "library/10665-381036/blocks/prose-page-439"
      ]
    },
    {
      "id": "page-440",
      "number": null,
      "title": "Page 440",
      "level": 1,
      "pageStart": 440,
      "pageEnd": 440,
      "labelStart": "435",
      "labelEnd": "435",
      "words": 138,
      "summary": {
        "text": "The start of an annex table assessing the quality of economic studies of TB NAATs, scoring studies of TrueNat and Xpert Ultra against checklist questions on population, comparators, design, time horizon, perspective and costing.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "appropriat",
          "heading": false
        },
        {
          "term": "relevant costs",
          "heading": false
        },
        {
          "term": "alternati",
          "heading": false
        }
      ],
      "extract": "435 Annex Annex Table 1. Quality assessment (Part 1) Citation Is the study populati on clearly describe d? Are competin g alternativ es clearly described ? Is a well- defined research question posed in answerab le form? Is the economic study design appropria te to the stated objective ? Is the chosen time horizon appropriate to include relevant costs and consequenc es? Is the chosen perspectiv e appropriat e? Are",
      "extractCut": true,
      "blocks": [
        "library/10665-381036/blocks/prose-page-440"
      ]
    },
    {
      "id": "page-441",
      "number": null,
      "title": "Page 441",
      "level": 1,
      "pageStart": 441,
      "pageEnd": 441,
      "labelStart": "436",
      "labelEnd": "436",
      "words": 110,
      "summary": {
        "text": "Continues the quality assessment table (part 1) for economic studies of TB NAATs, listing further Ultra and Xpert studies with mostly positive ratings.",
        "status": "draft"
      },
      "keywords": [],
      "extract": "436 Mafirakure va et al., 2022 ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ Mugwagw a, Abubakar & White, 2021 ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ Thompson et al., 2023 ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ Pooran et al., 2022 ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ Xpert Cadavid et al., 2022 ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ Chitpim et al., 2022 ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ Da Silva et al., 2021 ✓ ✓ ✓ ✓ x ✓ ✓ ✓ ✓ Ejalu et al., 2022 ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓",
      "extractCut": false,
      "blocks": [
        "library/10665-381036/blocks/prose-page-441"
      ]
    },
    {
      "id": "page-442",
      "number": null,
      "title": "Page 442",
      "level": 1,
      "pageStart": 442,
      "pageEnd": 442,
      "labelStart": "437",
      "labelEnd": "437",
      "words": 80,
      "summary": {
        "text": "Continues the quality assessment table (part 1) for Xpert economic studies, with a few studies falling short on time horizon or perspective.",
        "status": "draft"
      },
      "keywords": [],
      "extract": "437 Esmail et al., 2020 ✓ ✓ ✓ ✓ x ✓ ✓ ✓ ✓ Hickey et al., 2022 ✓ ✓ ✓ ✓ x x ✓ ✓ ✓ Kaso & Hailu, 2021 ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ Keim- Malpass et al., 2023 ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ Khumsri et al., 2020 ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ Sedrak et al., 2022 ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓",
      "extractCut": false,
      "blocks": [
        "library/10665-381036/blocks/prose-page-442"
      ]
    },
    {
      "id": "page-443",
      "number": null,
      "title": "Page 443",
      "level": 1,
      "pageStart": 443,
      "pageEnd": 443,
      "labelStart": "438",
      "labelEnd": "438",
      "words": 149,
      "summary": {
        "text": "The start of the second part of the quality assessment of TB NAAT economic studies, rating outcomes, incremental analysis, discounting, sensitivity analysis, conclusions, generalizability and conflicts of interest.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "appropriat",
          "heading": false
        },
        {
          "term": "alternati",
          "heading": false
        },
        {
          "term": "alternativ",
          "heading": false
        },
        {
          "term": "incremen",
          "heading": false
        }
      ],
      "extract": "438 Annex Table 2. Quality assessment (Part 2) Citation Are all importa nt and relevant outcome s for each alternati ve identifie d? Are all outcomes measured appropriat ely in physical units? Are outcomes valued appropriate ly? Is an incremen tal analysis of costs and outcome s of alternativ es performe d? Are all future costs and outcomes discounted appropriate ly? Are all important variables, whose values are",
      "extractCut": true,
      "blocks": [
        "library/10665-381036/blocks/prose-page-443"
      ]
    },
    {
      "id": "page-444",
      "number": null,
      "title": "Page 444",
      "level": 1,
      "pageStart": 444,
      "pageEnd": 444,
      "labelStart": "439",
      "labelEnd": "439",
      "words": 97,
      "summary": {
        "text": "Continues the part 2 quality assessment table for TrueNat, Ultra and Xpert economic studies, with most criteria met.",
        "status": "draft"
      },
      "keywords": [],
      "extract": "439 Fekadu, Wang & You, 2023 ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ Mafirakur eva et al., 2022 ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ Mugwagw a, Abubakar & White, 2021 ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ Thompson et al., 2023 ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ Pooran et al., 2022 ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ Xpert Cadavid et al., 2022 ✓ ✓ ✓ ✓ ✓ x ✓ ✓ ✓ Chitpim et al., 2022 ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓",
      "extractCut": false,
      "blocks": [
        "library/10665-381036/blocks/prose-page-444"
      ]
    },
    {
      "id": "page-445",
      "number": null,
      "title": "Page 445",
      "level": 1,
      "pageStart": 445,
      "pageEnd": 445,
      "labelStart": "440",
      "labelEnd": "440",
      "words": 113,
      "summary": {
        "text": "Completes the part 2 quality assessment table for Xpert economic studies and introduces a quality assessment table for low-complexity manual NAAT studies.",
        "status": "draft"
      },
      "keywords": [],
      "extract": "440 Da Silva et al., 2021 ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ Ejalu et al., 2022 ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ Esmail et al., 2020 ✓ ✓ ✓ x ✓ ✓ ✓ ✓ ✓ Hickey et al., 2022 ✓ ✓ ✓ ✓ x ✓ ✓ ✓ ✓ Kaso & Hailu, 2021 ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ Keim- Malpass et al., 2023 ✓ ✓ ✓ ✓ x ✓ ✓ ✓ ✓ Khumsri et al., 2020 ✓ ✓ ✓ ✓ x ✓ ✓ ✓ ✓ Sedrak et al., 2022 ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ Annex Table 3. Quality assessment LC-mNAAT",
      "extractCut": false,
      "blocks": [
        "library/10665-381036/blocks/prose-page-445"
      ]
    },
    {
      "id": "page-446",
      "number": null,
      "title": "Page 446",
      "level": 1,
      "pageStart": 446,
      "pageEnd": 446,
      "labelStart": "441",
      "labelEnd": "441",
      "words": 180,
      "summary": {
        "text": "Quality assessment tables for economic studies of low-complexity manual NAATs and moderate-complexity automated NAATs, giving yes/no ratings per criterion and total scores ranging from 46% to 100%.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "yes",
          "heading": false
        },
        {
          "term": "costs valued",
          "heading": false
        },
        {
          "term": "costs measured",
          "heading": false
        },
        {
          "term": "competing alternatives",
          "heading": false
        },
        {
          "term": "time horizon",
          "heading": false
        },
        {
          "term": "relevant costs",
          "heading": false
        },
        {
          "term": "study perspective",
          "heading": false
        },
        {
          "term": "total score",
          "heading": false
        }
      ],
      "extract": "441 Study population Competing alternatives Research question Study design Time horizon Study perspective Relevant costs Costs measured Costs valued Discounting Sensitivity analysis Conclusions Generalizability Conflict of interest Total score Nliwasa 2016 Yes Yes Yes Yes N/A Yes Yes Yes Yes No No Yes Yes Yes 85% Baikunje 2019 No N/A No No No No No Yes No Yes 46% Sohn 2019 Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes",
      "extractCut": true,
      "blocks": [
        "library/10665-381036/blocks/prose-page-446"
      ]
    },
    {
      "id": "page-447",
      "number": null,
      "title": "Page 447",
      "level": 1,
      "pageStart": 447,
      "pageEnd": 447,
      "labelStart": "442",
      "labelEnd": "442",
      "words": 119,
      "summary": {
        "text": "The literature search strategy for the systematic review of costs of moderate-complexity automated TB NAATs, combining terms for tuberculosis, named test products and manufacturers, and cost analysis.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "text word",
          "heading": false
        },
        {
          "term": "cost analys",
          "heading": false
        },
        {
          "term": "fields",
          "heading": false
        },
        {
          "term": "title abstract",
          "heading": false
        },
        {
          "term": "abbott realtime",
          "heading": false
        },
        {
          "term": "mesh terms",
          "heading": false
        }
      ],
      "extract": "442 Annex 5: MC-aNAAT systematic review search strategy Concept #1 \"tuberculosis\"[MeSH Terms] OR \"tuberculosis\"[Title/Abstract] OR \"TB\"[Title/Abstract] OR \"tuberculous\"[Title/Abstract] OR \"mycobacterium tuberculosis\"[MeSH Terms] Concept #2 \"Abbott RealTime MTB\"[All Fields] OR \"Abbott RealTime MTB RIF/INH\"[All Fields] OR \"FluoroType MTBDR\"[All Fields] OR \"FluoroType MTB\"[All Fields] OR \"Hain Lifescience\"[All Fields]",
      "extractCut": true,
      "blocks": [
        "library/10665-381036/blocks/prose-page-447"
      ]
    },
    {
      "id": "page-448",
      "number": null,
      "title": "Page 448",
      "level": 1,
      "pageStart": 448,
      "pageEnd": 448,
      "labelStart": "443",
      "labelEnd": "443",
      "words": 89,
      "summary": {
        "text": "The cover note of Web Annex B.10, a qualitative evidence synthesis of user perspectives on TB NAATs dated April 2024, giving WHO and author contact details.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "eleanor",
          "heading": false
        },
        {
          "term": "ochodo",
          "heading": false
        },
        {
          "term": "alexei",
          "heading": false
        },
        {
          "term": "korobitsyn",
          "heading": false
        }
      ],
      "extract": "443 Web Annex B.10. Nucleic acid amplification tests (NAATs) for tuberculosis and tuberculosis drug resistance: A qualitative evidence synthesis of user perspectives Date: 07 April 2024 To: Dr. Alexei Korobitsyn World Health Organization (WHO) Avenue Appia 20 1211 Geneva Switzerland korobitsyna@who.int Names, affiliations, and address of the contact person: Eleanor Ochodo Kenya Medical Research Institute, Center for",
      "extractCut": true,
      "blocks": [
        "library/10665-381036/blocks/prose-page-448"
      ]
    },
    {
      "id": "page-449",
      "number": null,
      "title": "Page 449",
      "level": 1,
      "pageStart": 449,
      "pageEnd": 449,
      "labelStart": "444",
      "labelEnd": "444",
      "words": 131,
      "summary": {
        "text": "The title page of the qualitative evidence synthesis on user perspectives of NAATs for TB and drug-resistant TB, listing authors from Kenya, South Africa and the Netherlands and noting it was prepared for a WHO guideline meeting in May 2024.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "acid amplification",
          "heading": false
        },
        {
          "term": "nucleic acid",
          "heading": false
        },
        {
          "term": "amplification tests",
          "heading": false
        },
        {
          "term": "faculty",
          "heading": false
        },
        {
          "term": "global health",
          "heading": false
        }
      ],
      "extract": "444 Nucleic acid amplification tests (NAATs) for tuberculosis and tuberculosis drug resistance: A qualitative evidence synthesis of user perspectives Ochodo EA1, 2, Mulaku NM1, 2, 3, Karanja PW4, Engel N5, 1. Centre for Global Health Research, Kenya Medical Research Institute, Kisumu, Kenya 2. Centre for Evidence-Based Health Care, Department of Global Health, Faculty of Medicine & Health Sciences, Stellenbosch",
      "extractCut": true,
      "blocks": [
        "library/10665-381036/blocks/prose-page-449"
      ]
    },
    {
      "id": "page-450",
      "number": null,
      "title": "Page 450",
      "level": 1,
      "pageStart": 450,
      "pageEnd": 450,
      "labelStart": "445",
      "labelEnd": "445",
      "words": 161,
      "summary": {
        "text": "A list of abbreviations used in the qualitative evidence synthesis on TB NAATs, covering test types, databases and review methods such as GRADE-CERQual and PRISMA.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "complexity-automated nucleic",
          "heading": false
        },
        {
          "term": "acid amplification",
          "heading": false
        },
        {
          "term": "amplification test",
          "heading": false
        },
        {
          "term": "resistant tuberculosis",
          "heading": false
        },
        {
          "term": "qualitative research",
          "heading": false
        },
        {
          "term": "central",
          "heading": false
        },
        {
          "term": "reviews",
          "heading": false
        }
      ],
      "extract": "445 List of Abbreviations CB-NAAT Cartridge Based- Nucleic Acid Amplification Test CENTRAL Cochrane Central Register of Controlled Trials CERQual Confidence in the Evidence from Reviews of Qualitative research DR-TB Drug Resistant Tuberculosis EPPI Evidence for Policy and Practice Information and coordinating Centre tool ENTREQ Enhancing transparency in reporting the synthesis of qualitative research GRADE Grading",
      "extractCut": true,
      "blocks": [
        "library/10665-381036/blocks/prose-page-450"
      ]
    },
    {
      "id": "page-451",
      "number": null,
      "title": "Page 451",
      "level": 1,
      "pageStart": 451,
      "pageEnd": 451,
      "labelStart": "446",
      "labelEnd": "446",
      "words": 372,
      "summary": {
        "text": "Opens the executive summary of the qualitative synthesis, explaining that newer NAATs are replacing standard Xpert MTB/RIF as initial TB tests and that evidence on their feasibility, acceptability and equity will inform WHO guidelines. It states the objectives and notes that 49 qualitative studies were included, 17 from an updated search.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "complexity naats",
          "heading": false
        },
        {
          "term": "complexity automated",
          "heading": false
        },
        {
          "term": "moderate complexity",
          "heading": false
        },
        {
          "term": "user perspectives",
          "heading": false
        },
        {
          "term": "end user",
          "heading": false
        },
        {
          "term": "synthesize provider",
          "heading": false
        },
        {
          "term": "xpert mtb",
          "heading": false
        },
        {
          "term": "mtb rif",
          "heading": false
        }
      ],
      "extract": "446 Executive Summary Background The WHO has introduced different classes of Nucleic Acid Amplification Tests (NAATs) depending on their infrastructure needs and mode of conduct. Latter NAATs are replacing standard Xpert MTB/RIF as initial diagnostic tests for Tuberculosis (TB) due to their high accuracy, rapid results and impact on patient important outcomes. Evidence on perspectives on the use, feasibility,",
      "extractCut": true,
      "blocks": [
        "library/10665-381036/blocks/prose-page-451"
      ]
    },
    {
      "id": "page-452",
      "number": null,
      "title": "Page 452",
      "level": 1,
      "pageStart": 452,
      "pageEnd": 452,
      "labelStart": "447",
      "labelEnd": "447",
      "words": 410,
      "summary": {
        "text": "Continues the executive summary, noting that included studies came from high TB burden settings in Africa, Asia and Eastern Europe, mostly on Xpert MTB/RIF, with two on Xpert Ultra and none on parallel testing or moderate-complexity NAATs. It summarizes 19 review findings grouped into what users value, related challenges and equity concerns, including Ultra's speed and accuracy but also infrastructure problems and fear of false results.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "valued xpert",
          "heading": false
        },
        {
          "term": "xpert ultra",
          "heading": false
        },
        {
          "term": "providers valued",
          "heading": false
        },
        {
          "term": "xpert mtb",
          "heading": false
        },
        {
          "term": "mtb rif",
          "heading": false
        },
        {
          "term": "eastern europe",
          "heading": false
        },
        {
          "term": "review findings",
          "heading": false
        },
        {
          "term": "diagnostic testing",
          "heading": false
        }
      ],
      "extract": "447 settings in Africa, Asia and Eastern Europe. Two studies were on perspectives about Xpert Ultra and the rest about Xpert MTB/RIF or rapid NAATs. The studies about Xpert Ultra were conducted in Africa and Eastern Europe and focused on all people with presumptive TB, drug resistant TB (DR-TB) and extrapulmonary TB (EPTB). All studies focused on perspectives about single tests and neither covered parallel testing",
      "extractCut": true,
      "blocks": [
        "library/10665-381036/blocks/prose-page-452"
      ]
    },
    {
      "id": "page-453",
      "number": null,
      "title": "Page 453",
      "level": 1,
      "pageStart": 453,
      "pageEnd": 453,
      "labelStart": "448",
      "labelEnd": "448",
      "words": 225,
      "summary": {
        "text": "Summarizes access and equity concerns in the executive summary, such as funding, platform maintenance, referral weaknesses and costs. It concludes that qualitative evidence on newer NAATs is limited, that challenges mirror those of Xpert MTB/RIF, and recommends studies on parallel testing.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "latter naats",
          "heading": false
        },
        {
          "term": "xpert mtb",
          "heading": false
        },
        {
          "term": "mtb rif",
          "heading": false
        },
        {
          "term": "xpert ultra",
          "heading": false
        },
        {
          "term": "standard xpert",
          "heading": false
        },
        {
          "term": "limited availability",
          "heading": false
        },
        {
          "term": "ease",
          "heading": false
        },
        {
          "term": "health facilities",
          "heading": false
        }
      ],
      "extract": "448 Concerns for access and equity Findings about Xpert MTB/RIF demonstrated concerns about sustainable funding, restrictions by donors, maintenance of the testing platforms, poor referral systems and dependence on outreach workers limiting access. Also protracted diagnostic delays, test underutilization, unavailability of community TB diagnostic facilities and too many eligibility restrictions limited access to",
      "extractCut": true,
      "blocks": [
        "library/10665-381036/blocks/prose-page-453"
      ]
    },
    {
      "id": "page-454",
      "number": null,
      "title": "Page 454",
      "level": 1,
      "pageStart": 454,
      "pageEnd": 454,
      "labelStart": "449",
      "labelEnd": "449",
      "words": 406,
      "summary": {
        "text": "Sets out the background to the review, citing the 2023 Global TB Report figures of 10.3 million cases and 1.3 million deaths and the need for prompt, accurate diagnosis. It describes WHO's classes of NAATs and introduces parallel testing as an alternative to sequential algorithms.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "million deaths",
          "heading": false
        },
        {
          "term": "automated naats",
          "heading": false
        },
        {
          "term": "million people",
          "heading": false
        },
        {
          "term": "microbiological detection",
          "heading": false
        },
        {
          "term": "complexity automated",
          "heading": false
        },
        {
          "term": "guiding appropriate",
          "heading": false
        },
        {
          "term": "mtb rif",
          "heading": false
        },
        {
          "term": "diagnostic tests",
          "heading": false
        }
      ],
      "extract": "449 Background Tuberculosis (TB) continues to be among the world’s top causes of mortality while drug resistant TB (DR- TB) is the leading cause of death due to anti-microbial resistant disease and poses a global security risk.1 2 According to the WHO Global Tuberculosis Report published in 2023,1 about 10.3 million people developed TB and 410,000 people developed multidrug rifampicin resistant TB (MDR-TB/RR-TB)",
      "extractCut": true,
      "blocks": [
        "library/10665-381036/blocks/prose-page-454"
      ]
    },
    {
      "id": "page-455",
      "number": null,
      "title": "Page 455",
      "level": 1,
      "pageStart": 455,
      "pageEnd": 455,
      "labelStart": "450",
      "labelEnd": "450",
      "words": 425,
      "summary": {
        "text": "Gives examples of studies where parallel testing, such as Xpert with LAM or culture, increased sensitivity, and notes End TB Strategy targets. It explains that the review was updated to cover newer NAAT classes and parallel testing in children and people with HIV ahead of the WHO guideline meeting.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "complexity naats",
          "heading": false
        },
        {
          "term": "xpert mtb",
          "heading": false
        },
        {
          "term": "plus xpert",
          "heading": false
        },
        {
          "term": "rapid tests",
          "heading": false
        },
        {
          "term": "parallel testing",
          "heading": false
        },
        {
          "term": "molecular rapid",
          "heading": false
        },
        {
          "term": "rapid diagnostics",
          "heading": false
        },
        {
          "term": "recommended rapid",
          "heading": false
        }
      ],
      "extract": "450 demonstrated increased sensitivities. For example, Fan and colleagues 8 showed that parallel test algorithms using culture plus Xpert MTB/RIF plus Simultaneous Amplification and Testing method for TB (SAT-TB), culture plus Xpert, or culture plus SAT-TB achieved higher sensitivities compared with all three single test models. A cross sectional study by Esmail and colleagues 9 evaluating five different diagnostic",
      "extractCut": true,
      "blocks": [
        "library/10665-381036/blocks/prose-page-455"
      ]
    },
    {
      "id": "page-456",
      "number": null,
      "title": "Page 456",
      "level": 1,
      "pageStart": 456,
      "pageEnd": 456,
      "labelStart": "451",
      "labelEnd": "451",
      "words": 324,
      "summary": {
        "text": "States the review objectives and explains that methods followed Cochrane guidance for qualitative research, building on an earlier Cochrane review of low-complexity NAATs. It sets out inclusion criteria for qualitative and mixed-methods studies and the types of publications excluded.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "complexity naats",
          "heading": false
        },
        {
          "term": "moderate complexity",
          "heading": false
        },
        {
          "term": "qualitative research",
          "heading": false
        },
        {
          "term": "qualitative data",
          "heading": false
        },
        {
          "term": "xpert mtb",
          "heading": false
        },
        {
          "term": "mtb rif",
          "heading": false
        },
        {
          "term": "user perspectives",
          "heading": false
        },
        {
          "term": "synthesize provider",
          "heading": false
        }
      ],
      "extract": "451 Review objectives • To synthesize provider and end user perspectives on low complexity and moderate complexity NAATs for diagnosis of tuberculosis and tuberculosis drug resistance (DR-TB). • To synthesize provider and end user perspectives on parallel use of NAATs or of different specimens on NAATs in children and PLHIV. Methods The methods for study inclusion, data collection and analysis were based on the",
      "extractCut": true,
      "blocks": [
        "library/10665-381036/blocks/prose-page-456"
      ]
    },
    {
      "id": "page-457",
      "number": null,
      "title": "Page 457",
      "level": 1,
      "pageStart": 457,
      "pageEnd": 457,
      "labelStart": "452",
      "labelEnd": "452",
      "words": 289,
      "summary": {
        "text": "Defines the review's population of test recipients and providers and the interventions covered, describing classes of low-complexity manual and automated NAATs and the products in each.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "complexity naats",
          "heading": false
        },
        {
          "term": "manual naats",
          "heading": false
        },
        {
          "term": "complexity automated",
          "heading": false
        },
        {
          "term": "moderate complexity",
          "heading": false
        },
        {
          "term": "similar technologies",
          "heading": false
        },
        {
          "term": "recipient",
          "heading": false
        },
        {
          "term": "detection",
          "heading": false
        },
        {
          "term": "classes",
          "heading": false
        }
      ],
      "extract": "452 commentaries, or non-research editorials. Population We included studies about users or potential users of low and moderate complexity NAATs. Users at recipient level were children, adolescents, adults and people living with HIV with signs and symptoms of TB and/or screened positive for TB or their caregivers. Users at provider level were health care providers (clinicians, nurses, laboratory technicians), TB",
      "extractCut": true,
      "blocks": [
        "library/10665-381036/blocks/prose-page-457"
      ]
    },
    {
      "id": "page-458",
      "number": null,
      "title": "Page 458",
      "level": 1,
      "pageStart": 458,
      "pageEnd": 458,
      "labelStart": "453",
      "labelEnd": "453",
      "words": 215,
      "summary": {
        "text": "Describes moderate-complexity automated NAATs for detecting resistance to second-line drugs, the target conditions and outcome measures on user views. It notes reporting standards and that literature searches were run in October 2023.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "naats",
          "heading": false
        },
        {
          "term": "searches",
          "heading": false
        },
        {
          "term": "search",
          "heading": false
        },
        {
          "term": "presented",
          "heading": false
        },
        {
          "term": "intervention",
          "heading": false
        },
        {
          "term": "health",
          "heading": false
        }
      ],
      "extract": "453 rifampicin, isoniazid and 2nd line anti-TB agents) (LC-aNAATs)* Moderate complexity automated NAATs for the detection of MTB-complex (MTBC) and its resistance to the anti-tuberculosis (TB) drugs fluoroquinolones (FLQ; levofloxacin and moxifloxacin), amikacin (AMK), ethambutol (EMB), and linezolid (LZD)) (MC-aNAATs) The LiquidArray MTB-XDR VER 1.0. *Xpert MTB/RIF belongs to the LC-aNAAT class but has been",
      "extractCut": true,
      "blocks": [
        "library/10665-381036/blocks/prose-page-458"
      ]
    },
    {
      "id": "page-459",
      "number": null,
      "title": "Page 459",
      "level": 1,
      "pageStart": 459,
      "pageEnd": 459,
      "labelStart": "454",
      "labelEnd": "454",
      "words": 343,
      "summary": {
        "text": "Lists the databases searched for the qualitative synthesis and explains that no date limit was applied, plus reference checking. It describes how studies were selected and sampled, including Xpert MTB/RIF studies as supporting evidence when direct evidence on newer tests was lacking.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "conference proceedings",
          "heading": false
        },
        {
          "term": "complexity naats",
          "heading": false
        },
        {
          "term": "articles identified",
          "heading": false
        },
        {
          "term": "full texts",
          "heading": false
        },
        {
          "term": "search",
          "heading": false
        },
        {
          "term": "richness",
          "heading": false
        },
        {
          "term": "duplicate",
          "heading": false
        },
        {
          "term": "eligible",
          "heading": false
        }
      ],
      "extract": "454 using the search terms described in Appendix 1: Cochrane Central Register of Controlled Trials (CENTRAL), included in the Cochrane Library, issue 10, October 2023; MEDLINE (Ovid); Embase (Ovid); Social Science Citation Index (ISI Web of Knowledge); WHO Global Index Medicus; and CINAHL (EBSCOhost). Though this was an update, we did not limit the search date from the date of the last search in our previous",
      "extractCut": true,
      "blocks": [
        "library/10665-381036/blocks/prose-page-459"
      ]
    },
    {
      "id": "page-460",
      "number": null,
      "title": "Page 460",
      "level": 1,
      "pageStart": 460,
      "pageEnd": 460,
      "labelStart": "455",
      "labelEnd": "455",
      "words": 368,
      "summary": {
        "text": "Describes duplicate data extraction in Covidence, the study, intervention and finding details extracted, and the approach to appraising methodological limitations and ethics reporting.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "methodological limitations",
          "heading": false
        },
        {
          "term": "ethical clearance",
          "heading": false
        },
        {
          "term": "extracted data",
          "heading": false
        },
        {
          "term": "rigor",
          "heading": false
        },
        {
          "term": "data extraction",
          "heading": false
        },
        {
          "term": "data collection",
          "heading": false
        },
        {
          "term": "centre tool",
          "heading": false
        },
        {
          "term": "review authors",
          "heading": false
        }
      ],
      "extract": "455 Three review authors (EO, MM and PK) independently performed data extraction in duplicate using the Covidence platform.17 We resolved any disagreements by discussion and consensus. The platform for data extraction was designed and piloted on at least two studies before use. We extracted data findings in a narrative form including themes and supporting quotations. We extracted data about: Study characteristics:",
      "extractCut": true,
      "blocks": [
        "library/10665-381036/blocks/prose-page-460"
      ]
    },
    {
      "id": "page-461",
      "number": null,
      "title": "Page 461",
      "level": 1,
      "pageStart": 461,
      "pageEnd": 461,
      "labelStart": "456",
      "labelEnd": "456",
      "words": 266,
      "summary": {
        "text": "Lists the appraisal questions used to assess rigour in sampling, data collection and analysis in the included qualitative studies, with attention to participant anonymity.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "rigor",
          "heading": false
        },
        {
          "term": "data collection",
          "heading": false
        },
        {
          "term": "data analysis",
          "heading": false
        },
        {
          "term": "study context",
          "heading": false
        },
        {
          "term": "method",
          "heading": false
        },
        {
          "term": "sampling",
          "heading": false
        },
        {
          "term": "qualitative",
          "heading": false
        },
        {
          "term": "participants",
          "heading": false
        }
      ],
      "extract": "456 work, we ensured that participants could not be recognized by readers. We extracted the following information across the five domains: Rigor in sampling: • Was the sampling strategy appropriate to the questions posed in the study? (e.g. was the strategy well-reasoned and justified?) • Were attempts made to obtain a diverse sample of the population in question? (Considering populations excluded and those with",
      "extractCut": true,
      "blocks": [
        "library/10665-381036/blocks/prose-page-461"
      ]
    },
    {
      "id": "page-462",
      "number": null,
      "title": "Page 462",
      "level": 1,
      "pageStart": 462,
      "pageEnd": 462,
      "labelStart": "457",
      "labelEnd": "457",
      "words": 308,
      "summary": {
        "text": "Continues the appraisal criteria, covering how well findings are grounded in data and the breadth and depth of findings. It introduces the GRADE-CERQual approach used to rate confidence in each review finding.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "review findings",
          "heading": false
        },
        {
          "term": "data presented",
          "heading": false
        },
        {
          "term": "themes",
          "heading": false
        },
        {
          "term": "identified codes",
          "heading": false
        },
        {
          "term": "breadth",
          "heading": false
        },
        {
          "term": "grade-cerqual",
          "heading": false
        },
        {
          "term": "depth",
          "heading": false
        },
        {
          "term": "grounded",
          "heading": false
        }
      ],
      "extract": "457 preliminary results to participants, asking a colleague to review the data, or reflexivity; in quantitative research this may be done by, for example, significance testing). Extent to which findings are grounded in/supported by the data: • Were enough data presented to show how the authors arrived at their findings? • Were the data presented fit the interpretation/support claims about patterns in data? • Were",
      "extractCut": true,
      "blocks": [
        "library/10665-381036/blocks/prose-page-462"
      ]
    },
    {
      "id": "page-463",
      "number": null,
      "title": "Page 463",
      "level": 1,
      "pageStart": 463,
      "pageEnd": 463,
      "labelStart": "458",
      "labelEnd": "458",
      "words": 393,
      "summary": {
        "text": "Explains how GRADE-CERQual confidence ratings were made across four components and summarized in tables. It describes the thematic synthesis method and the reviewers' steps to manage reflexivity and bias.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "review finding",
          "heading": false
        },
        {
          "term": "supporting review",
          "heading": false
        },
        {
          "term": "review question",
          "heading": false
        },
        {
          "term": "data contributing",
          "heading": false
        },
        {
          "term": "findings tables",
          "heading": false
        },
        {
          "term": "methodological limitations",
          "heading": false
        },
        {
          "term": "primary studies",
          "heading": false
        },
        {
          "term": "cogent",
          "heading": false
        }
      ],
      "extract": "458 assesses confidence in the review evidence on four main components including methodological limitations of included studies, coherence of review findings, adequacy of data contributing to review findings and relevance of the included studies to the review question. We rated our confidence of the evidence as either high (not downgraded), moderate, low, or very low for each of the four domains and made a judgment",
      "extractCut": true,
      "blocks": [
        "library/10665-381036/blocks/prose-page-463"
      ]
    },
    {
      "id": "page-464",
      "number": null,
      "title": "Page 464",
      "level": 1,
      "pageStart": 464,
      "pageEnd": 464,
      "labelStart": "459",
      "labelEnd": "459",
      "words": 349,
      "summary": {
        "text": "Gives reflexivity statements describing the review authors' backgrounds and potential influences on their views. It begins the results, reporting 49 included studies, 17 newly identified and 32 from the earlier Cochrane review.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "tuberculosis diagnostics",
          "heading": false
        },
        {
          "term": "tuberculosis tests",
          "heading": false
        },
        {
          "term": "pre-treatment loss",
          "heading": false
        },
        {
          "term": "she",
          "heading": false
        },
        {
          "term": "qualitative evidence",
          "heading": false
        },
        {
          "term": "evidence synthesis",
          "heading": false
        },
        {
          "term": "cartridge-based",
          "heading": false
        },
        {
          "term": "systematic reviews",
          "heading": false
        }
      ],
      "extract": "459 EO is a public health physician and methodologist. She has 12 years' experience in evidence synthesis specializing in methodology, systematic reviews, and meta-analysis of diagnostic tests. She has conducted diagnostic test accuracy and qualitative systematic reviews on tuberculosis tests, some of which have informed WHO guidelines on tuberculosis tests. She is also an academic editor with the Cochrane",
      "extractCut": true,
      "blocks": [
        "library/10665-381036/blocks/prose-page-464"
      ]
    },
    {
      "id": "page-465",
      "number": null,
      "title": "Page 465",
      "level": 1,
      "pageStart": 465,
      "pageEnd": 465,
      "labelStart": "460",
      "labelEnd": "460",
      "words": 437,
      "summary": {
        "text": "Reports that only two included studies concerned Xpert Ultra and none addressed moderate-complexity or other newer low-complexity NAATs. It describes the Ultra studies in Kenya, Eswatini and Belarus and the settings and uses of the Xpert MTB/RIF studies.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "xpert ultra",
          "heading": false
        },
        {
          "term": "xpert mtb",
          "heading": false
        },
        {
          "term": "mtb rif",
          "heading": false
        },
        {
          "term": "program coordinators",
          "heading": false
        },
        {
          "term": "complexity naats",
          "heading": false
        },
        {
          "term": "studies reported",
          "heading": false
        },
        {
          "term": "program officers",
          "heading": false
        },
        {
          "term": "rapid naats",
          "heading": false
        }
      ],
      "extract": "460 studies were about Xpert Ultra published in 2020 and 2022 and the rest were about Xpert MTB/RIF or rapid NAATs published between 2012 and 2023. No qualitative studies on moderate complexity NAATs or other newer low complexity NAATs (apart from Xpert Ultra) were identified. An overview of included and excluded studies can be found in Annex 3 and 4 respectively. Description of the studies Studies about Xpert Ultra",
      "extractCut": true,
      "blocks": [
        "library/10665-381036/blocks/prose-page-465"
      ]
    },
    {
      "id": "page-466",
      "number": null,
      "title": "Page 466",
      "level": 1,
      "pageStart": 466,
      "pageEnd": 466,
      "labelStart": "461",
      "labelEnd": "461",
      "words": 367,
      "summary": {
        "text": "Summarizes the methodological quality of included studies, judged very good for the Ultra studies and mostly good for others. It introduces the 19 review findings and describes what providers and laboratory staff valued about Xpert, such as accuracy, speed and low patient costs.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "xpert ultra",
          "heading": false
        },
        {
          "term": "xpert mtb",
          "heading": false
        },
        {
          "term": "complexity naats",
          "heading": false
        },
        {
          "term": "rapid naats",
          "heading": false
        },
        {
          "term": "review findings",
          "heading": false
        },
        {
          "term": "methodological quality",
          "heading": false
        },
        {
          "term": "towards methodological",
          "heading": false
        },
        {
          "term": "thorough attempt",
          "heading": false
        }
      ],
      "extract": "461 perspectives of single tests and not parallel testing. Methodological limitations of the studies A summary of our assessment for methodological quality can be found in Annex 5. Briefly: The two studies30 31 about Xpert Ultra were overall of very good quality having undertaken several steps or fairly thorough attempt towards methodological quality across the assessed components. Studies about Xpert MTB/RIF or",
      "extractCut": true,
      "blocks": [
        "library/10665-381036/blocks/prose-page-466"
      ]
    },
    {
      "id": "page-467",
      "number": null,
      "title": "Page 467",
      "level": 1,
      "pageStart": 467,
      "pageEnd": 467,
      "labelStart": "462",
      "labelEnd": "462",
      "words": 482,
      "summary": {
        "text": "Describes what patients and providers valued about Xpert and Ultra, including Ultra's better detection in hard-to-diagnose groups such as children and extrapulmonary TB. It summarizes challenges limiting these benefits, such as weak systems, outdated guidelines and over-reliance on test results.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "xpert ultra",
          "heading": false
        },
        {
          "term": "xpert mtb",
          "heading": false
        },
        {
          "term": "mtb rif",
          "heading": false
        },
        {
          "term": "sereda",
          "heading": false
        },
        {
          "term": "providers valued",
          "heading": false
        },
        {
          "term": "diagnose patients",
          "heading": false
        },
        {
          "term": "sputum microscopy",
          "heading": false
        },
        {
          "term": "among patients",
          "heading": false
        }
      ],
      "extract": "462 staff satisfaction compared to sputum microscopy. People with TB valued an accurate diagnosis, avoiding diagnostic delays and low costs associated with diagnostic testing. Compared to Xpert MTB/RIF, providers valued Xpert Ultra‘s capacity to improve TB case detection among these hard-to-diagnose patients (EPTB, pediatric TB and TB patients who are co-infected with COVID-19) and detecting more cases. By building",
      "extractCut": true,
      "blocks": [
        "library/10665-381036/blocks/prose-page-467"
      ]
    },
    {
      "id": "page-468",
      "number": null,
      "title": "Page 468",
      "level": 1,
      "pageStart": 468,
      "pageEnd": 468,
      "labelStart": "463",
      "labelEnd": "463",
      "words": 560,
      "summary": {
        "text": "Notes uncertainty among providers about Ultra's accuracy and infrastructure barriers to its use. It presents detailed findings on patient reluctance to test due to stigma, staffing and training gaps, and workload, illustrated with participant quotations.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "xpert ultra",
          "heading": false
        },
        {
          "term": "sereda",
          "heading": false
        },
        {
          "term": "xpert mtb",
          "heading": false
        },
        {
          "term": "xpert testing",
          "heading": false
        },
        {
          "term": "staff shortages",
          "heading": false
        },
        {
          "term": "sputum collection",
          "heading": false
        },
        {
          "term": "mtb rif",
          "heading": false
        },
        {
          "term": "enough trained",
          "heading": false
        }
      ],
      "extract": "463 processes also led to underutilization. Providers’ acceptability of Xpert Ultra seemed high but there was uncertainty about its accuracy, potentially leading to reduced trust and litigation should there be a false diagnosis. Like Xpert MTB/RIF, its implementation could also be hindered by Infrastructural issues such as power outages, staff shortages. Limited sputum transportation and limited availability of",
      "extractCut": true,
      "blocks": [
        "library/10665-381036/blocks/prose-page-468"
      ]
    },
    {
      "id": "page-469",
      "number": null,
      "title": "Page 469",
      "level": 1,
      "pageStart": 469,
      "pageEnd": 469,
      "labelStart": "464",
      "labelEnd": "464",
      "words": 445,
      "summary": {
        "text": "Presents the finding that health workers accept some test uncertainty but fear litigation and loss of trust from false diagnoses with Ultra. It then summarizes access and equity concerns and begins the discussion, restating the 19 findings in three categories.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "complexity naats",
          "heading": false
        },
        {
          "term": "automated naats",
          "heading": false
        },
        {
          "term": "xpert ultra",
          "heading": false
        },
        {
          "term": "xpert mtb",
          "heading": false
        },
        {
          "term": "sereda",
          "heading": false
        },
        {
          "term": "eastern europe",
          "heading": false
        },
        {
          "term": "presented perspectives",
          "heading": false
        },
        {
          "term": "mtb rif",
          "heading": false
        }
      ],
      "extract": "464 Finding 7: Health workers accept a measure of uncertainty of tests but fear that false diagnosis can still lead to litigation and diminished trust in test results (Moderate confidence, Mwaura 202030). The reduced specificity of Xpert Ultra included the risk of litigation from patients for a false diagnosis and reduced trust in the healthcare system by sharing through word of mouth, within a patient’s network,",
      "extractCut": true,
      "blocks": [
        "library/10665-381036/blocks/prose-page-469"
      ]
    },
    {
      "id": "page-470",
      "number": null,
      "title": "Page 470",
      "level": 1,
      "pageStart": 470,
      "pageEnd": 470,
      "labelStart": "465",
      "labelEnd": "465",
      "words": 449,
      "summary": {
        "text": "Discusses the review's high overall confidence, its strengths such as duplicate screening, and its main limitation, the scarcity of direct evidence on newer NAATs. It compares findings with other literature and concludes that newer NAATs are valued for accuracy and integration with existing GeneXpert platforms.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "newer naats",
          "heading": false
        },
        {
          "term": "complexity naats",
          "heading": false
        },
        {
          "term": "xpert ultra",
          "heading": false
        },
        {
          "term": "xpert mtb",
          "heading": false
        },
        {
          "term": "mtb rif",
          "heading": false
        },
        {
          "term": "rapid naats",
          "heading": false
        },
        {
          "term": "qualitative evidence",
          "heading": false
        },
        {
          "term": "qualitative studies",
          "heading": false
        }
      ],
      "extract": "465 access and equity. Of these findings, nine also applied to Xpert Ultra. Overall, we had high confidence in the review findings. The strengths of our review included utilizing a robust study search and selection process and building on a previously utilized framework for our thematic analysis. Studies were screened and appraised in duplicate to minimize bias. We also strengthened the limited evidence on Xpert",
      "extractCut": true,
      "blocks": [
        "library/10665-381036/blocks/prose-page-470"
      ]
    },
    {
      "id": "page-471",
      "number": null,
      "title": "Page 471",
      "level": 1,
      "pageStart": 471,
      "pageEnd": 471,
      "labelStart": "466",
      "labelEnd": "466",
      "words": 91,
      "summary": {
        "text": "Concludes that challenges for newer NAATs mirror those of Xpert MTB/RIF, followed by acknowledgements, WHO funding and a no-conflicts statement.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "naats",
          "heading": false
        },
        {
          "term": "lutje",
          "heading": false
        },
        {
          "term": "vittoria",
          "heading": false
        }
      ],
      "extract": "466 and their ease in integrating with rapid testing for other diseases. Overall, we had high confidence in the review findings. Challenges limiting the realization of these values for latter NAATs are similar to Xpert MTB/RIF and comprise weak infrastructure, fragmented systems, heavy workload and limited availability of NAATs and their supplies. Acknowledgements We acknowledge the efforts of the information",
      "extractCut": true,
      "blocks": [
        "library/10665-381036/blocks/prose-page-471"
      ]
    },
    {
      "id": "page-472",
      "number": null,
      "title": "Page 472",
      "level": 1,
      "pageStart": 472,
      "pageEnd": 472,
      "labelStart": "467",
      "labelEnd": "467",
      "words": 408,
      "summary": {
        "text": "The start of the reference list for the qualitative synthesis on TB NAATs, citing WHO TB reports and strategies and Cochrane methods guidance.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "united nations",
          "heading": false
        },
        {
          "term": "nations general",
          "heading": false
        },
        {
          "term": "world health",
          "heading": false
        },
        {
          "term": "health organization",
          "heading": false
        },
        {
          "term": "mtb rif",
          "heading": false
        },
        {
          "term": "switzerland",
          "heading": false
        },
        {
          "term": "doi",
          "heading": false
        },
        {
          "term": "tuberculosis",
          "heading": false
        }
      ],
      "extract": "467 References 1. WHO. Global Tuberculosis Report. Geneva, Switzerland: World Health Organization.2023. Available at https://www.who.int/teams/global-tuberculosis-programme/tb-reports/global-tuberculosis- report-2023. 2. WHO. Status Update: Reaching the targets in the political declaration of the United Nations General Assembly High-level Meeting on the fight against tuberculosis. September 2023. Geneva,",
      "extractCut": true,
      "blocks": [
        "library/10665-381036/blocks/prose-page-472"
      ]
    },
    {
      "id": "page-473",
      "number": null,
      "title": "Page 473",
      "level": 1,
      "pageStart": 473,
      "pageEnd": 473,
      "labelStart": "468",
      "labelEnd": "468",
      "words": 461,
      "summary": {
        "text": "Continues the reference list of the qualitative synthesis, citing qualitative reporting standards, PRISMA and GRADE-CERQual methods papers.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "applying grade-cerqual",
          "heading": false
        },
        {
          "term": "implement sci",
          "heading": false
        },
        {
          "term": "qualitative evidence",
          "heading": false
        },
        {
          "term": "qualitative research",
          "heading": false
        },
        {
          "term": "evidence synthesis",
          "heading": false
        },
        {
          "term": "synthesis findings",
          "heading": false
        },
        {
          "term": "res methodol",
          "heading": false
        },
        {
          "term": "doi",
          "heading": false
        }
      ],
      "extract": "468 13. Tong A, Flemming K, McInnes E, et al. Enhancing transparency in reporting the synthesis of qualitative research: ENTREQ. BMC Med Res Methodol 2012;12:181. doi: 10.1186/1471-2288- 12-181 14. Murad MH, Chang SM, Fiordalisi CV, et al. Improving the utility of evidence synthesis for decision makers in the face of insufficient evidence. J Clin Epidemiol 2021;135:170-75. doi: 10.1016/j.jclinepi.2021.02.028 15.",
      "extractCut": true,
      "blocks": [
        "library/10665-381036/blocks/prose-page-473"
      ]
    },
    {
      "id": "page-474",
      "number": null,
      "title": "Page 474",
      "level": 1,
      "pageStart": 474,
      "pageEnd": 474,
      "labelStart": "469",
      "labelEnd": "469",
      "words": 527,
      "summary": {
        "text": "Continues the reference list of the qualitative synthesis with included studies on Xpert Ultra and Xpert MTB/RIF implementation in countries such as Kenya, Belarus, Cambodia and Uganda.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "infect dis",
          "heading": false
        },
        {
          "term": "doi",
          "heading": false
        },
        {
          "term": "tuberculosis control",
          "heading": false
        },
        {
          "term": "pone",
          "heading": false
        },
        {
          "term": "mtb rif",
          "heading": false
        },
        {
          "term": "qualitative study",
          "heading": false
        },
        {
          "term": "xpert mtb",
          "heading": false
        },
        {
          "term": "journal",
          "heading": false
        }
      ],
      "extract": "469 30. Mwaura M, Kao K, Wambugu J, et al. Situating trade-offs: Stakeholder perspectives on overtreatment versus missed diagnosis in transition to Xpert MTB/RIF Ultra in Kenya and Swaziland. PLoS One 2020;15(2):e0228669. doi: 10.1371/journal.pone.0228669 31. Sereda Y, Korotych O, Klimuk D, et al. Tuberculosis Co-Infection Is Common in Patients Requiring Hospitalization for COVID-19 in Belarus: Mixed-Methods Study.",
      "extractCut": true,
      "blocks": [
        "library/10665-381036/blocks/prose-page-474"
      ]
    },
    {
      "id": "page-475",
      "number": null,
      "title": "Page 475",
      "level": 1,
      "pageStart": 475,
      "pageEnd": 475,
      "labelStart": "470",
      "labelEnd": "470",
      "words": 513,
      "summary": {
        "text": "Continues the reference list of the qualitative synthesis, citing studies on drug-resistant TB care and Xpert roll-out in countries including Nigeria and India.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "mycobact dis",
          "heading": false
        },
        {
          "term": "serv res",
          "heading": false
        },
        {
          "term": "clin tuberc",
          "heading": false
        },
        {
          "term": "tuberc lung",
          "heading": false
        },
        {
          "term": "int tuberc",
          "heading": false
        },
        {
          "term": "doi",
          "heading": false
        },
        {
          "term": "tuberculosis diagnosis",
          "heading": false
        },
        {
          "term": "resistant tuberculosis",
          "heading": false
        }
      ],
      "extract": "470 46. Oga-Omenka C, Boffa J, Kuye J, et al. Understanding the gaps in DR-TB care cascade in Nigeria: A sequential mixed-method study. J Clin Tuberc Other Mycobact Dis 2020;21:100193. doi: 10.1016/j.jctube.2020.100193 47. Creswell J, Codlin AJ, Andre E, et al. Results from early programmatic implementation of Xpert MTB/RIF testing in nine countries. BMC Infect Dis 2014;14:2. doi: 10.1186/1471-2334-14-2 48. England",
      "extractCut": true,
      "blocks": [
        "library/10665-381036/blocks/prose-page-475"
      ]
    },
    {
      "id": "page-476",
      "number": null,
      "title": "Page 476",
      "level": 1,
      "pageStart": 476,
      "pageEnd": 476,
      "labelStart": "471",
      "labelEnd": "471",
      "words": 498,
      "summary": {
        "text": "Continues the reference list of the qualitative synthesis, citing implementation studies of molecular TB testing in Mongolia, India, South Africa, Nepal and elsewhere.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "int tuberc",
          "heading": false
        },
        {
          "term": "mixed-methods study",
          "heading": false
        },
        {
          "term": "tuberc lung",
          "heading": false
        },
        {
          "term": "epidemiol glob",
          "heading": false
        },
        {
          "term": "trop med",
          "heading": false
        },
        {
          "term": "lung dis",
          "heading": false
        },
        {
          "term": "tuberculosis patients",
          "heading": false
        },
        {
          "term": "tuberculosis diagnostic",
          "heading": false
        }
      ],
      "extract": "471 63. Rendell NL, Bekhbat S, Ganbaatar G, et al. Implementation of the Xpert MTB/RIF assay for tuberculosis in Mongolia: a qualitative exploration of barriers and enablers. PeerJ 2017;5:e3567. doi: 10.7717/peerj.3567 64. Vijayageetha M, Kumar AM, Ramakrishnan J, et al. Tuberculosis screening among pregnant women attending a tertiary care hospital in Puducherry, South India: is it worth the effort? Glob Health",
      "extractCut": true,
      "blocks": [
        "library/10665-381036/blocks/prose-page-476"
      ]
    },
    {
      "id": "page-477",
      "number": null,
      "title": "Page 477",
      "level": 1,
      "pageStart": 477,
      "pageEnd": 477,
      "labelStart": "472",
      "labelEnd": "472",
      "words": 515,
      "summary": {
        "text": "Continues the reference list of the qualitative synthesis, citing studies on clinic flow, Xpert implementation lessons and health system factors in TB management.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "tuberc lung",
          "heading": false
        },
        {
          "term": "lung dis",
          "heading": false
        },
        {
          "term": "int tuberc",
          "heading": false
        },
        {
          "term": "mtb rif",
          "heading": false
        },
        {
          "term": "xpert mtb",
          "heading": false
        },
        {
          "term": "doi",
          "heading": false
        },
        {
          "term": "ijtld",
          "heading": false
        },
        {
          "term": "cowan",
          "heading": false
        }
      ],
      "extract": "472 78. Stime KJ, Garrett N, Sookrajh Y, et al. Clinic flow for STI, HIV, and TB patients in an urban infectious disease clinic offering point-of-care testing services in Durban, South Africa. BMC Health Serv Res 2018;18(1):363. doi: 10.1186/s12913-018-3154-2 79. Adam P, Pai M. Implementation of Xpert((R)) MTB/RIF in high-burden countries: voices from the field matter. Public Health Action 2019;9(3):78-79. doi:",
      "extractCut": true,
      "blocks": [
        "library/10665-381036/blocks/prose-page-477"
      ]
    },
    {
      "id": "page-478",
      "number": null,
      "title": "Page 478",
      "level": 1,
      "pageStart": 478,
      "pageEnd": 478,
      "labelStart": "473",
      "labelEnd": "473",
      "words": 511,
      "summary": {
        "text": "Continues the reference list of the qualitative synthesis, citing studies on diagnostic implementation, TB-LAMP feasibility and health worker knowledge.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "multidrug-resistant tuberculosis",
          "heading": false
        },
        {
          "term": "pulmonary tuberculosis",
          "heading": false
        },
        {
          "term": "doi",
          "heading": false
        },
        {
          "term": "mtb rif",
          "heading": false
        },
        {
          "term": "rapid molecular",
          "heading": false
        },
        {
          "term": "mbelele",
          "heading": false
        },
        {
          "term": "molecular diagnostic",
          "heading": false
        },
        {
          "term": "treatment initiation",
          "heading": false
        }
      ],
      "extract": "473 95. Dominique JK, Ortiz-Osorno AA, Fitzgibbon J, et al. Implementation of HIV and Tuberculosis Diagnostics: The Importance of Context. Clin Infect Dis 2015;61Suppl 3(Suppl 3):S119-25. doi: 10.1093/cid/civ552 96. Gray CM, Katamba A, Narang P, et al. Feasibility and Operational Performance of Tuberculosis Detection by Loop-Mediated Isothermal Amplification Platform in Decentralized Settings: Results from a",
      "extractCut": true,
      "blocks": [
        "library/10665-381036/blocks/prose-page-478"
      ]
    },
    {
      "id": "page-479",
      "number": null,
      "title": "Page 479",
      "level": 1,
      "pageStart": 479,
      "pageEnd": 479,
      "labelStart": "474",
      "labelEnd": "474",
      "words": 342,
      "summary": {
        "text": "Continues the reference list of the qualitative synthesis, citing work on health system barriers to molecular diagnostics and access to drug-resistant TB services.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "bmj glob",
          "heading": false
        },
        {
          "term": "molecular diagnostics",
          "heading": false
        },
        {
          "term": "doi",
          "heading": false
        },
        {
          "term": "glob health",
          "heading": false
        },
        {
          "term": "health research",
          "heading": false
        },
        {
          "term": "oga-omenka",
          "heading": false
        },
        {
          "term": "qualitative study",
          "heading": false
        },
        {
          "term": "public health",
          "heading": false
        }
      ],
      "extract": "474 113. Ntinginya NE, Kuchaka D, Orina F, et al. Unlocking the health system barriers to maximise the uptake and utilisation of molecular diagnostics in low-income and middle-income country setting. BMJ Glob Health 2021;6(8) doi: 10.1136/bmjgh-2021-005357 114. Ochodo EA, Naidoo S, Schumacher S, et al. Improving the design of studies evaluating the impact of diagnostic tests for tuberculosis on health outcomes: a",
      "extractCut": true,
      "blocks": [
        "library/10665-381036/blocks/prose-page-479"
      ]
    },
    {
      "id": "page-480",
      "number": null,
      "title": "Page 480",
      "level": 1,
      "pageStart": 480,
      "pageEnd": 480,
      "labelStart": "475",
      "labelEnd": "475",
      "words": 313,
      "summary": {
        "text": "Annex 1 of the qualitative synthesis, describing the database searches and beginning the detailed Ovid MEDLINE search strategy with terms on acceptability, equity and barriers.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "resistant tuberculosis",
          "heading": false
        },
        {
          "term": "drug resistant",
          "heading": false
        },
        {
          "term": "electronic searches",
          "heading": false
        },
        {
          "term": "search strategies",
          "heading": false
        },
        {
          "term": "adj",
          "heading": false
        },
        {
          "term": "ovid",
          "heading": false
        },
        {
          "term": "attitude",
          "heading": false
        },
        {
          "term": "mdr",
          "heading": false
        }
      ],
      "extract": "475 Annexes Annex 1: Search strategies Search methods for identification of studies Electronic searches The Cochrane Infectious Diseases Group Information Specialist (VL) performed literature searches between 9th-13th October 2023, without language restrictions, in the following databases, using the search terms described in Appendix xx: Cochrane Central Register of Controlled Trials (CENTRAL), included in the",
      "extractCut": true,
      "blocks": [
        "library/10665-381036/blocks/prose-page-480"
      ]
    },
    {
      "id": "page-481",
      "number": null,
      "title": "Page 481",
      "level": 1,
      "pageStart": 481,
      "pageEnd": 481,
      "labelStart": "476",
      "labelEnd": "476",
      "words": 297,
      "summary": {
        "text": "Continues the MEDLINE search strategy for the qualitative synthesis, listing terms for implementation outcomes, qualitative methods and named NAAT products.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "resistant tuberculosis",
          "heading": false
        },
        {
          "term": "mixed methods",
          "heading": false
        },
        {
          "term": "drug resistant",
          "heading": false
        },
        {
          "term": "adj",
          "heading": false
        },
        {
          "term": "focus group",
          "heading": false
        },
        {
          "term": "mdr",
          "heading": false
        },
        {
          "term": "facilitator",
          "heading": false
        }
      ],
      "extract": "476 29 patient retention*.mp. 30 health personnel attitude/ or providers experience*.mp. 31 Clinical Pathway/ 32 facilitator*.ab. or facilitator*.ti. or (implement* or adoption).tw. 33 (Appropriateness or feasibility or readiness or penetration or reach).tw. 34 Sustainability.tw. or cost effectiveness.mp. or Cost-Benefit Analysis/ 35 23 or 24 or 25 or 26 or 27 or 28 or 29 or 30 or 31 or 32 or 33 or 34 36 22 and 35",
      "extractCut": true,
      "blocks": [
        "library/10665-381036/blocks/prose-page-481"
      ]
    },
    {
      "id": "page-482",
      "number": null,
      "title": "Page 482",
      "level": 1,
      "pageStart": 482,
      "pageEnd": 482,
      "labelStart": "477",
      "labelEnd": "477",
      "words": 334,
      "summary": {
        "text": "Part of the literature search strategy for a qualitative review on TB nucleic acid amplification tests, listing database search lines on acceptability, equity, preferences, barriers and implementation, followed by the start of the CINAHL search.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "mixed methods",
          "heading": false
        },
        {
          "term": "grounded theory",
          "heading": false
        },
        {
          "term": "qualitative research",
          "heading": false
        },
        {
          "term": "phenomenolog",
          "heading": false
        },
        {
          "term": "topic",
          "heading": false
        },
        {
          "term": "resistant tuberculosis",
          "heading": false
        },
        {
          "term": "attitude",
          "heading": false
        }
      ],
      "extract": "477 21 7 or 8 or 9 or 10 or 11 or 12 or 13 or 14 or 15 or 16 or 17 or 18 or 19 or 20 22 6 and 21 23 Patient attitude/ or acceptability.mp. or acceptance.mp. 24 Health Equity/ or equity.mp. or health care access/ 25 Patient Preference/ or preference*.mp. 26 Patient Satisfaction/ or Attitude to Health/ 27 barrier*.mp. 28 challenge*.mp. 29 patient retention*.mp. 30 health personnel attitude/ or providers",
      "extractCut": true,
      "blocks": [
        "library/10665-381036/blocks/prose-page-482"
      ]
    },
    {
      "id": "page-483",
      "number": null,
      "title": "Page 483",
      "level": 1,
      "pageStart": 483,
      "pageEnd": 483,
      "labelStart": "478",
      "labelEnd": "478",
      "words": 378,
      "summary": {
        "text": "Continues the search strategies for the qualitative review, giving CINAHL and other database queries combining TB test names such as Xpert, Truenat and LAMP with terms on attitudes, equity and feasibility, ending with the WHO Global Index Medicus search.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "mesh descriptor",
          "heading": false
        },
        {
          "term": "mycobacterium tuberculosis",
          "heading": false
        },
        {
          "term": "resistant tuberculosis",
          "heading": false
        },
        {
          "term": "amplification techniques",
          "heading": false
        },
        {
          "term": "healthcare professionals",
          "heading": false
        },
        {
          "term": "acid amplification",
          "heading": false
        },
        {
          "term": "attitude",
          "heading": false
        },
        {
          "term": "health equity",
          "heading": false
        }
      ],
      "extract": "478 framework analysis ) S5 S3 AND S4 S4 TX ( patient* and (attitude* or satisfaction or preference* or retention) ) OR TX ( (health personnel or healthcare professionals or healthcare workers) and (attitude* or satisfaction or preference*) ) OR TX ( Health Equity or equity or health care access ) OR TX ( (Appropriateness or feasibility or readiness or penetration or reach) ) OR TX ( Sustainability or cost",
      "extractCut": true,
      "blocks": [
        "library/10665-381036/blocks/prose-page-483"
      ]
    },
    {
      "id": "page-484",
      "number": null,
      "title": "Page 484",
      "level": 1,
      "pageStart": 484,
      "pageEnd": 484,
      "labelStart": "479",
      "labelEnd": "479",
      "words": 1,
      "summary": {
        "text": "A page containing only a page number.",
        "status": "draft"
      },
      "keywords": [],
      "extract": "479",
      "extractCut": false,
      "blocks": [
        "library/10665-381036/blocks/prose-page-484"
      ]
    },
    {
      "id": "page-485",
      "number": null,
      "title": "Page 485",
      "level": 1,
      "pageStart": 485,
      "pageEnd": 485,
      "labelStart": "480",
      "labelEnd": "480",
      "words": 152,
      "summary": {
        "text": "A PRISMA flow chart for study selection, showing 3892 records screened, 104 assessed in full text and 49 studies included, two on Xpert Ultra and 47 on Xpert MTB/RIF.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "duplicates identified",
          "heading": false
        },
        {
          "term": "studies excluded",
          "heading": false
        },
        {
          "term": "commentaries",
          "heading": false
        },
        {
          "term": "ineligible",
          "heading": false
        }
      ],
      "extract": "480 Annex 2: PRISMA Flow chart for study selection Identification References from other sources (n =0 ) Citation searching (n =0) Grey literature (n =0) Studies screened (n = 3891) Studies sought for retrieval (n = 104) Studies assessed for eligibility (n = 104) References removed (n = 1) Duplicates identified manually (n = 0) Duplicates identified by Covidence (n = 1) Marked as ineligible by automation tools (n =",
      "extractCut": true,
      "blocks": [
        "library/10665-381036/blocks/prose-page-485"
      ]
    },
    {
      "id": "page-486",
      "number": null,
      "title": "Page 486",
      "level": 1,
      "pageStart": 486,
      "pageEnd": 486,
      "labelStart": "481",
      "labelEnd": "481",
      "words": 250,
      "summary": {
        "text": "The start of a table describing the studies included in the qualitative review, giving country, income and TB burden, facility type, test, population, participants and data collection methods; the page carries a stray form placeholder line.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "mtb rif",
          "heading": false
        },
        {
          "term": "xpert mtb",
          "heading": false
        },
        {
          "term": "xpert ultra",
          "heading": false
        },
        {
          "term": "income",
          "heading": false
        },
        {
          "term": "health centers",
          "heading": false
        },
        {
          "term": "lower middle",
          "heading": false
        },
        {
          "term": "care providers",
          "heading": false
        },
        {
          "term": "complexity automated",
          "heading": false
        }
      ],
      "extract": "Click or tap here to enter text. 481 Annex 3: Table of included studies Table 2: Table of characteristics of included studies Study ID Country, Income classification, TB Burden Type of health facility Diagnostic technology Target population of test Type & number of participants Data collection methods Low Complexity automated NAATs – Xpert Ultra test or cartridges Mwaura 202030 Kenya, Swaziland Lower Middle Income",
      "extractCut": true,
      "blocks": [
        "library/10665-381036/blocks/prose-page-486"
      ]
    },
    {
      "id": "page-487",
      "number": null,
      "title": "Page 487",
      "level": 1,
      "pageStart": 487,
      "pageEnd": 487,
      "labelStart": "482",
      "labelEnd": "482",
      "words": 215,
      "summary": {
        "text": "Continues the table of included qualitative studies on TB molecular testing, covering studies in South Africa, Brazil, Tanzania and elsewhere with their participants and methods.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "middle income",
          "heading": false
        },
        {
          "term": "upper middle",
          "heading": false
        },
        {
          "term": "mtb rif",
          "heading": false
        },
        {
          "term": "xpert mtb",
          "heading": false
        },
        {
          "term": "program officers",
          "heading": false
        },
        {
          "term": "care providers",
          "heading": false
        },
        {
          "term": "interviews",
          "heading": false
        },
        {
          "term": "unclear",
          "heading": false
        }
      ],
      "extract": "Click or tap here to enter text. 482 Bangladesh, Cambodia, Davids 201571 South Africa Upper middle income High Burden Primary health care clinics POC TB test People with presumptive TB Primary health care providers (n=400) Interviews, questionnaire and recorded anecdotal notes De Camargo 201572 Brazil Upper middle income High burden Clinics Xpert MTB/RIF Presumptive cases of TB and DR TB Laboratory technician (11),",
      "extractCut": true,
      "blocks": [
        "library/10665-381036/blocks/prose-page-487"
      ]
    },
    {
      "id": "page-488",
      "number": null,
      "title": "Page 488",
      "level": 1,
      "pageStart": 488,
      "pageEnd": 488,
      "labelStart": "483",
      "labelEnd": "483",
      "words": 236,
      "summary": {
        "text": "Continues the table of included studies, with entries from Lesotho, Viet Nam, East African countries, China and Nepal among others.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "middle income",
          "heading": false
        },
        {
          "term": "mtb rif",
          "heading": false
        },
        {
          "term": "xpert mtb",
          "heading": false
        },
        {
          "term": "lower middle",
          "heading": false
        },
        {
          "term": "health staff",
          "heading": false
        },
        {
          "term": "interviews",
          "heading": false
        },
        {
          "term": "fgds",
          "heading": false
        },
        {
          "term": "presumptive",
          "heading": false
        }
      ],
      "extract": "Click or tap here to enter text. 483 †Gwaza 202343 Lesotho Low Income High Burden Hospital, Clinic Xpert MTB/RIF People with presumptive TB and DR-TB Health care providers and Ministry of health staff (n=44) Interviews Hoang 201574 Vietnam Lower middle income High Burden District health centre /hospital Xpert MTB/RIF Patients at high risk for MDR-TB TB provincial staff members & health staff at central, provincial",
      "extractCut": true,
      "blocks": [
        "library/10665-381036/blocks/prose-page-488"
      ]
    },
    {
      "id": "page-489",
      "number": null,
      "title": "Page 489",
      "level": 1,
      "pageStart": 489,
      "pageEnd": 489,
      "labelStart": "484",
      "labelEnd": "484",
      "words": 231,
      "summary": {
        "text": "Continues the table of included studies, listing studies from Indonesia, India, Tanzania and other countries with their settings, participants and interview or focus group methods.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "middle income",
          "heading": false
        },
        {
          "term": "xpert mtb",
          "heading": false
        },
        {
          "term": "mtb rif",
          "heading": false
        },
        {
          "term": "lower-middle",
          "heading": false
        },
        {
          "term": "lower middle",
          "heading": false
        },
        {
          "term": "private clinics",
          "heading": false
        },
        {
          "term": "household contacts",
          "heading": false
        },
        {
          "term": "interviews",
          "heading": false
        }
      ],
      "extract": "Click or tap here to enter text. 484 Lower middle income primary health centres, district public health office laboratory living with HIV (PLHIV); severe forms of TB; and in presumptive MDR TB †Juliasih 202034 Indonesia Lower-Middle Income High Burden Primary Health Centre Rapid molecular test/Unspecified NAAT People with presumptive DR- TB TB Officers (n=not reported) Interviews, Observations †Kanakaraju 202035",
      "extractCut": true,
      "blocks": [
        "library/10665-381036/blocks/prose-page-489"
      ]
    },
    {
      "id": "page-490",
      "number": null,
      "title": "Page 490",
      "level": 1,
      "pageStart": 490,
      "pageEnd": 490,
      "labelStart": "485",
      "labelEnd": "485",
      "words": 239,
      "summary": {
        "text": "Continues the table of included studies, covering studies in Ethiopia, India, South Africa and Kenya, including some focused on children and extrapulmonary TB.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "middle income",
          "heading": false
        },
        {
          "term": "mtb rif",
          "heading": false
        },
        {
          "term": "xpert mtb",
          "heading": false
        },
        {
          "term": "lower middle",
          "heading": false
        },
        {
          "term": "interviews",
          "heading": false
        },
        {
          "term": "lower-middle",
          "heading": false
        },
        {
          "term": "burden",
          "heading": false
        },
        {
          "term": "presumptive",
          "heading": false
        }
      ],
      "extract": "Click or tap here to enter text. 485 Mohammed 202051 Ethiopia Low income High burden OPD, HIV clinic, diabetic and maternal child health clinics Xpert MTB/RIF Presumptive TB patients Head of each health facility and a focal health care provider (n=35) Interviews & document reviews †Nagar 202036 India Lower-Middle Income High Burden Hospital, Clinic, Private nursing home, Government medical college, Xpert MTB/RIF or",
      "extractCut": true,
      "blocks": [
        "library/10665-381036/blocks/prose-page-490"
      ]
    },
    {
      "id": "page-491",
      "number": null,
      "title": "Page 491",
      "level": 1,
      "pageStart": 491,
      "pageEnd": 491,
      "labelStart": "486",
      "labelEnd": "486",
      "words": 224,
      "summary": {
        "text": "Continues the table of included studies, with entries from Myanmar, Nepal and Cambodia among others.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "middle income",
          "heading": false
        },
        {
          "term": "mtb rif",
          "heading": false
        },
        {
          "term": "xpert mtb",
          "heading": false
        },
        {
          "term": "lower middle",
          "heading": false
        },
        {
          "term": "household contacts",
          "heading": false
        },
        {
          "term": "interviews",
          "heading": false
        },
        {
          "term": "township",
          "heading": false
        },
        {
          "term": "presumptive",
          "heading": false
        }
      ],
      "extract": "Click or tap here to enter text. 486 clinicians, laboratory technologists (n=40) Oo 201961 Myanmar Lower Middle income High Burden Township TB centre Xpert MTB/RIF Presumptive DR- TB patients Township TB coordinators & lab techs (n=32) Interviews †Paudel 202137 Nepal Lower-Middle Income High Burden Hospital Xpert MTB/RIF People with presumptive TB Health care providers, hospital managers, district focal persons,",
      "extractCut": true,
      "blocks": [
        "library/10665-381036/blocks/prose-page-491"
      ]
    },
    {
      "id": "page-492",
      "number": null,
      "title": "Page 492",
      "level": 1,
      "pageStart": 492,
      "pageEnd": 492,
      "labelStart": "487",
      "labelEnd": "487",
      "words": 229,
      "summary": {
        "text": "The final rows of the included studies table, covering studies from India such as those involving people with HIV and pregnant women, with a note marking studies from the updated search.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "mtb rif",
          "heading": false
        },
        {
          "term": "xpert mtb",
          "heading": false
        },
        {
          "term": "lower-middle",
          "heading": false
        },
        {
          "term": "laboratory professionals",
          "heading": false
        },
        {
          "term": "income",
          "heading": false
        },
        {
          "term": "interviews",
          "heading": false
        },
        {
          "term": "care providers",
          "heading": false
        },
        {
          "term": "officers",
          "heading": false
        }
      ],
      "extract": "Click or tap here to enter text. 487 High Burden hospital and health centres officers, nurses, laboratory staff, and TB officers (n=26) Saria 202054 India Lower-Middle Income High Burden not clear, some private clinics and informal providers Xpert MTB/RIF Presumptive TB patients Formal and informal health providers Interviews and shadowing formal health careproviders †Shrestha 202339 India Lower-Middle Income High",
      "extractCut": true,
      "blocks": [
        "library/10665-381036/blocks/prose-page-492"
      ]
    },
    {
      "id": "page-493",
      "number": null,
      "title": "Page 493",
      "level": 1,
      "pageStart": 493,
      "pageEnd": 493,
      "labelStart": "488",
      "labelEnd": "488",
      "words": 63,
      "summary": {
        "text": "The start of a table of studies excluded from the qualitative review, listing the first five with reasons such as study type or non-qualitative design.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "ardizzoni",
          "heading": false
        },
        {
          "term": "study type",
          "heading": false
        },
        {
          "term": "excluded studies",
          "heading": false
        }
      ],
      "extract": "Click or tap here to enter text. 488 Annex 4: Table of excluded studies Table 3: Excluded studies and reasons for exclusion No. Study ID Reason for exclusion 1. †Adam 201979 Study type (Editorial) 2. Adepoyibi 201880 Not a qualitative study design 3. Albert 201681 Study type (Review article) 4. Ardizzoni 201582 Data not analysed using qualitative analysis methods 5. Ardizzoni 201582 Duplicate",
      "extractCut": false,
      "blocks": [
        "library/10665-381036/blocks/prose-page-493"
      ]
    },
    {
      "id": "page-494",
      "number": null,
      "title": "Page 494",
      "level": 1,
      "pageStart": 494,
      "pageEnd": 494,
      "labelStart": "489",
      "labelEnd": "489",
      "words": 151,
      "summary": {
        "text": "Continues the table of excluded studies, giving reasons such as reviews, letters, non-qualitative designs or not addressing the topic.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "qualitative study",
          "heading": false
        },
        {
          "term": "address phenomenon",
          "heading": false
        },
        {
          "term": "study type",
          "heading": false
        },
        {
          "term": "study design",
          "heading": false
        },
        {
          "term": "qualitative analysis",
          "heading": false
        }
      ],
      "extract": "Click or tap here to enter text. 489 6. †Boulanger 202083 Did not address phenomenon of interest 7. †Brown 202184 Study type (systematic review) 8. †Cash 201385 Study type (Review) 9. Charoensook 201886 Data not analysed using qualitative analysis methods 10. Chalwa 201687 Not a qualitative study design 11. †Clouse 201288 Study type (review) 12. †Cowan 201389 Did not address phenomenon of interest 13. †Daftary",
      "extractCut": true,
      "blocks": [
        "library/10665-381036/blocks/prose-page-494"
      ]
    },
    {
      "id": "page-495",
      "number": null,
      "title": "Page 495",
      "level": 1,
      "pageStart": 495,
      "pageEnd": 495,
      "labelStart": "490",
      "labelEnd": "490",
      "words": 139,
      "summary": {
        "text": "Continues the list of excluded studies with reasons for exclusion, such as conference abstracts and lack of qualitative analysis.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "address phenomenon",
          "heading": false
        },
        {
          "term": "qualitative study",
          "heading": false
        },
        {
          "term": "study type",
          "heading": false
        },
        {
          "term": "conference abstract",
          "heading": false
        },
        {
          "term": "qualitative analysis",
          "heading": false
        }
      ],
      "extract": "Click or tap here to enter text. 490 24. †Kedia 201599 Study type (conference abstract) 25. †Kondo 2021100 Not a qualitative study design 26. †Lemaire 2010101 Study type (Debate) 27. Lorent 2016102 Did not address phenomenon of interest 28. Maraba 2018103 Did not address phenomenon of interest 29. †Mbelele 2018104 Study type (Meta-narrative review) 30. †Mistry 2016105 Did not address phenomenon of interest 31.",
      "extractCut": true,
      "blocks": [
        "library/10665-381036/blocks/prose-page-495"
      ]
    },
    {
      "id": "page-496",
      "number": null,
      "title": "Page 496",
      "level": 1,
      "pageStart": 496,
      "pageEnd": 496,
      "labelStart": "491",
      "labelEnd": "491",
      "words": 129,
      "summary": {
        "text": "The last entries in the excluded studies table, with reasons including duplicates, conference abstracts and very thin data.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "address phenomenon",
          "heading": false
        },
        {
          "term": "conference abstract",
          "heading": false
        },
        {
          "term": "study type",
          "heading": false
        },
        {
          "term": "oga-omenka",
          "heading": false
        }
      ],
      "extract": "Click or tap here to enter text. 491 41. Ochodo 2019114 Did not address phenomenon of interest 42. †Oga-Omenka 2020115 Did not address phenomenon of interest 43. †Oga-Omenka 2020116 Study type (systematic review) 44. †Palamountain 2012117 Study type (Review) 45. Palupi 2019118 Not a qualitative study design 46. †Pamba 2022119 Study type (conference abstract) 47. †Parcell 2012120 Study type (Conference abstract) 48.",
      "extractCut": true,
      "blocks": [
        "library/10665-381036/blocks/prose-page-496"
      ]
    },
    {
      "id": "page-497",
      "number": null,
      "title": "Page 497",
      "level": 1,
      "pageStart": 497,
      "pageEnd": 497,
      "labelStart": "492",
      "labelEnd": "492",
      "words": 424,
      "summary": {
        "text": "A table assessing the methodological rigour of included studies with the EPPI-Centre tool, rating sampling, data collection, analysis and grounding of findings, beginning with the Xpert Ultra studies.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "thorough attempt",
          "heading": false
        },
        {
          "term": "few steps",
          "heading": false
        },
        {
          "term": "yes",
          "heading": false
        },
        {
          "term": "increase rigour",
          "heading": false
        },
        {
          "term": "complexity naats",
          "heading": false
        },
        {
          "term": "methodological",
          "heading": false
        },
        {
          "term": "xpert",
          "heading": false
        },
        {
          "term": "data",
          "heading": false
        }
      ],
      "extract": "492 Annex 5: Assessment of methodological quality Table 4: Assessment of methodological limitations of the included studies using EPPI -Centre tool No. Study ID Were steps taken to increase rigour in sampling? Were steps taken to increase rigour in the data collected? Were steps taken to increase rigour in the analysis of the data? Were the findings of the study grounded in/supported by the data? Low complexity",
      "extractCut": true,
      "blocks": [
        "library/10665-381036/blocks/prose-page-497"
      ]
    },
    {
      "id": "page-498",
      "number": null,
      "title": "Page 498",
      "level": 1,
      "pageStart": 498,
      "pageEnd": 498,
      "labelStart": "493",
      "labelEnd": "493",
      "words": 435,
      "summary": {
        "text": "Continues the EPPI-Centre quality assessment table, rating rigour in sampling, data collection and analysis for further included studies.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "can't tell",
          "heading": false
        },
        {
          "term": "stated can't",
          "heading": false
        },
        {
          "term": "thorough attempt",
          "heading": false
        },
        {
          "term": "few steps",
          "heading": false
        },
        {
          "term": "yes",
          "heading": false
        }
      ],
      "extract": "493 13. †Pongpeeradech 202238 Yes, a few steps were taken Yes, a few steps were taken Yes, a few steps were taken Yes, a few steps were taken 14. †Shrestha 202339 Yes, a few steps were taken Yes, a few steps were taken Yes, a few steps were taken Yes, several steps were taken 15. †Singh 202140 Yes, a few steps were taken Yes, several steps were taken Yes, several steps were taken Yes, a fairly thorough attempt was",
      "extractCut": true,
      "blocks": [
        "library/10665-381036/blocks/prose-page-498"
      ]
    },
    {
      "id": "page-499",
      "number": null,
      "title": "Page 499",
      "level": 1,
      "pageStart": 499,
      "pageEnd": 499,
      "labelStart": "494",
      "labelEnd": "494",
      "words": 427,
      "summary": {
        "text": "Continues the methodological quality assessment table for included studies, with ratings ranging from no steps taken to fairly thorough attempts.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "can't tell",
          "heading": false
        },
        {
          "term": "stated can't",
          "heading": false
        },
        {
          "term": "thorough attempt",
          "heading": false
        },
        {
          "term": "few steps",
          "heading": false
        },
        {
          "term": "yes",
          "heading": false
        }
      ],
      "extract": "494 was made 30. McDowell 201856 Yes, a fairly thorough attempt was made Yes, few steps were taken Yes, a fairly thorough attempt was made Yes, a fairly thorough attempt was made 31. Medina-Morino 202165 Yes, several steps were taken Yes, few steps were taken Yes, several steps were taken Yes, a fairly thorough attempt was made 32. Mnyambwa 201857 Yes, few steps were taken Yes, few steps were taken No, not at",
      "extractCut": true,
      "blocks": [
        "library/10665-381036/blocks/prose-page-499"
      ]
    },
    {
      "id": "page-500",
      "number": null,
      "title": "Page 500",
      "level": 1,
      "pageStart": 500,
      "pageEnd": 500,
      "labelStart": "495",
      "labelEnd": "495",
      "words": 378,
      "summary": {
        "text": "Finishes the quality assessment table and begins a table of qualitative review findings on Xpert Ultra, giving CERQual confidence ratings and explanations, starting with what users value.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "minor concerns",
          "heading": false
        },
        {
          "term": "moderate concerns",
          "heading": false
        },
        {
          "term": "few steps",
          "heading": false
        },
        {
          "term": "methodological limitations",
          "heading": false
        },
        {
          "term": "methodological quality",
          "heading": false
        },
        {
          "term": "review finding",
          "heading": false
        },
        {
          "term": "xpert ultra",
          "heading": false
        },
        {
          "term": "steps towards",
          "heading": false
        }
      ],
      "extract": "495 47. Viyageetha 201964 Yes, few steps were taken Yes, few steps were taken Yes, few steps were taken Yes, few steps were taken † Studies identified in updated search Annex 6: Summary of review findings (Xpert Ultra) Table 5: Summary table of qualitative findings for Xpert Ultra studies Finding # Review finding Methodological limitations Coherence Relevance Adequacy CERQual assessment of confidence in the evidence",
      "extractCut": true,
      "blocks": [
        "library/10665-381036/blocks/prose-page-500"
      ]
    },
    {
      "id": "page-501",
      "number": null,
      "title": "Page 501",
      "level": 1,
      "pageStart": 501,
      "pageEnd": 501,
      "labelStart": "496",
      "labelEnd": "496",
      "words": 526,
      "summary": {
        "text": "Continues the Xpert Ultra findings table with CERQual assessments, covering challenges such as patients' reluctance to test because of stigma linked to TB and low socioeconomic status.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "minor concerns",
          "heading": false
        },
        {
          "term": "refs finding",
          "heading": false
        },
        {
          "term": "xpert refs",
          "heading": false
        },
        {
          "term": "moderate concerns",
          "heading": false
        },
        {
          "term": "evidence confirms",
          "heading": false
        },
        {
          "term": "standard xpert",
          "heading": false
        },
        {
          "term": "methodological limitations",
          "heading": false
        },
        {
          "term": "methodological quality",
          "heading": false
        }
      ],
      "extract": "496 (n=13) with albeit a good variety of users Challenges to realizing these values 3 Patients can be reluctant to test for TB/MDR-TB because of stigma related to the association of TB with low socioeconomic status No/very minor concerns- One study which had fairly good methodological quality across all four components No concerns - good fit of finding with primary study Moderate concerns, varied participants from",
      "extractCut": true,
      "blocks": [
        "library/10665-381036/blocks/prose-page-501"
      ]
    },
    {
      "id": "page-502",
      "number": null,
      "title": "Page 502",
      "level": 1,
      "pageStart": 502,
      "pageEnd": 502,
      "labelStart": "497",
      "labelEnd": "497",
      "words": 481,
      "summary": {
        "text": "Continues the Xpert Ultra findings table, including a finding that adding Xpert Ultra without adjusting staffing increases laboratory workload and lowers health worker motivation.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "minor concerns",
          "heading": false
        },
        {
          "term": "moderate concerns",
          "heading": false
        },
        {
          "term": "finding though",
          "heading": false
        },
        {
          "term": "towards richness",
          "heading": false
        },
        {
          "term": "towards methodological",
          "heading": false
        },
        {
          "term": "methodological limitations",
          "heading": false
        },
        {
          "term": "steps towards",
          "heading": false
        },
        {
          "term": "country contributes",
          "heading": false
        }
      ],
      "extract": "497 6 The introduction of Xpert Ultra increases workload of laboratory staff if added onto existing work without adjusting staffing arrangements, decreasing motivation of health workers who may be hesitant to accept testing with Xpert Ultra No/very minor concerns - only one study which took several steps towards methodological quality across all the four domains] No/very minor concerns - finding captures the primary",
      "extractCut": true,
      "blocks": [
        "library/10665-381036/blocks/prose-page-502"
      ]
    },
    {
      "id": "page-503",
      "number": null,
      "title": "Page 503",
      "level": 1,
      "pageStart": 503,
      "pageEnd": 503,
      "labelStart": "498",
      "labelEnd": "498",
      "words": 208,
      "summary": {
        "text": "Ends the Xpert Ultra findings with lack of testing in nearby facilities limiting access for vulnerable groups, then introduces a table of findings for all included NAATs integrated with an earlier Cochrane qualitative review.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "minor concerns",
          "heading": false
        },
        {
          "term": "moderate concerns",
          "heading": false
        },
        {
          "term": "review finding",
          "heading": false
        },
        {
          "term": "steps towards",
          "heading": false
        },
        {
          "term": "naats",
          "heading": false
        },
        {
          "term": "took",
          "heading": false
        },
        {
          "term": "hospitals",
          "heading": false
        }
      ],
      "extract": "498 9 Lack of Xpert testing in surrounding health facilities hamper access to prompt and accurate testing and treatment particularly for vulnerable groups. No or very minor concerns - only one study contributed to this review finding however, the study took several steps towards increasing quality No concerns - captures the data from primary studies Moderate concerns- good variety of users, only hospital set- up,",
      "extractCut": true,
      "blocks": [
        "library/10665-381036/blocks/prose-page-503"
      ]
    },
    {
      "id": "page-504",
      "number": null,
      "title": "Page 504",
      "level": 1,
      "pageStart": 504,
      "pageEnd": 504,
      "labelStart": "499",
      "labelEnd": "499",
      "words": 1003,
      "summary": {
        "text": "A table of qualitative findings for all included NAATs with CERQual confidence ratings, opening with what patients in high-burden settings value, such as an accurate diagnosis and avoiding delays. Further findings cover what health workers and programme staff value from rapid molecular testing. Each finding lists methodological, coherence, relevance and adequacy concerns and contributing studies.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "minor concerns",
          "heading": false
        },
        {
          "term": "finding minor",
          "heading": false
        },
        {
          "term": "moderate concerns",
          "heading": false
        },
        {
          "term": "rich studies",
          "heading": false
        },
        {
          "term": "concerns because",
          "heading": false
        },
        {
          "term": "concerns synthesis",
          "heading": false
        },
        {
          "term": "concerns across",
          "heading": false
        },
        {
          "term": "methodological quality",
          "heading": false
        }
      ],
      "extract": "499 Finding # Review finding Methodological limitations Coherence Relevance Adequacy CERQual assessment of confidence in the evidence Eplanation of CERQual assessment Studies contribut review finding 1 Patients in high-burden TB settings value 1) getting an accurate diagnosis and reaching diagnostic closure (finally knowing what is wrong with me), 2) avoiding diagnostic delays as they exacerbate existing financial",
      "extractCut": true,
      "blocks": [
        "library/10665-381036/blocks/prose-page-504"
      ]
    },
    {
      "id": "page-505",
      "number": null,
      "title": "Page 505",
      "level": 1,
      "pageStart": 505,
      "pageEnd": 505,
      "labelStart": "500",
      "labelEnd": "500",
      "words": 979,
      "summary": {
        "text": "Continues the NAAT qualitative findings table, including patients' reluctance to test owing to stigma, fear of side effects, inability to produce sputum and travel costs. It also covers how clinic workflows and patient flows affect use of the tests. Parts of the extracted text are garbled, with words broken into fragments.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "minor concerns",
          "heading": false
        },
        {
          "term": "countries minor",
          "heading": false
        },
        {
          "term": "half took",
          "heading": false
        },
        {
          "term": "took few",
          "heading": false
        },
        {
          "term": "rich studies",
          "heading": false
        },
        {
          "term": "concerns descriptive",
          "heading": false
        },
        {
          "term": "towards richness",
          "heading": false
        },
        {
          "term": "few steps",
          "heading": false
        }
      ],
      "extract": "500 7 Patients can be reluctant to test for TB/MDR-TB because of stigma related to MDR-TB or related to having interrupted treatment in the past or relatd to association of TB with low socioeconomic status, because of fears of side effects, the failure to recognize symptoms, the inability to produce sputum and the cost, distance and travel concerns related to (repeat) clinic visits. no/very minor concerns- six out",
      "extractCut": true,
      "blocks": [
        "library/10665-381036/blocks/prose-page-505"
      ]
    },
    {
      "id": "page-506",
      "number": null,
      "title": "Page 506",
      "level": 1,
      "pageStart": 506,
      "pageEnd": 506,
      "labelStart": "501",
      "labelEnd": "501",
      "words": 1099,
      "summary": {
        "text": "Continues the NAAT findings table, covering how stock-outs, poor logistics, lack of power, space and maintenance raise test failure and underuse. It also includes findings on access and equity concerns. Most findings are rated with moderate or high confidence.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "minor concerns",
          "heading": false
        },
        {
          "term": "concerns captures",
          "heading": false
        },
        {
          "term": "concerns rich",
          "heading": false
        },
        {
          "term": "methodologica richness",
          "heading": false
        },
        {
          "term": "moderate concerns",
          "heading": false
        },
        {
          "term": "concerns because",
          "heading": false
        },
        {
          "term": "took few",
          "heading": false
        },
        {
          "term": "towards richness",
          "heading": false
        }
      ],
      "extract": "501 11 The lack of sufficient resources and of ensuring maintenance (i.e. stock-outs; unreliable logistics; lack of funding, electricity, space, air conditioners, and sputum containers; dusty environment, and delayed or absent local repair option) leads to higher test failure rates and underutilization and negatively influences uptake and impact of LC- NAAT. minor concerns - of 25 studies contributing to the",
      "extractCut": true,
      "blocks": [
        "library/10665-381036/blocks/prose-page-506"
      ]
    },
    {
      "id": "page-507",
      "number": null,
      "title": "Page 507",
      "level": 1,
      "pageStart": 507,
      "pageEnd": 507,
      "labelStart": "502",
      "labelEnd": "502",
      "words": 336,
      "summary": {
        "text": "Notes that studies on Xpert Ultra contributed to highlighted findings and gives lists of the review's tables and figures, with some repeated table text.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "minor concerns",
          "heading": false
        },
        {
          "term": "concerns captures",
          "heading": false
        },
        {
          "term": "concerns rich",
          "heading": false
        },
        {
          "term": "rich studies",
          "heading": false
        },
        {
          "term": "summary table",
          "heading": false
        },
        {
          "term": "summary findings",
          "heading": false
        },
        {
          "term": "took few",
          "heading": false
        },
        {
          "term": "qualitative findings",
          "heading": false
        }
      ],
      "extract": "502 ٭ Studies on Xpert Ultra contributed to reviews findings in yellow rows. List of Tables Table 1: Classes of NAATs for detection of TB and DR-TB Table 2: Table of characteristics of included studies Table 3: Excluded studies and reasons for their exclusion Table 4: Assessment of methodological limitations of included studies using the EPPI-Centre tools Table 5: Summary table of qualitative findings for Xpert",
      "extractCut": true,
      "blocks": [
        "library/10665-381036/blocks/prose-page-507"
      ]
    },
    {
      "id": "page-508",
      "number": null,
      "title": "Page 508",
      "level": 1,
      "pageStart": 508,
      "pageEnd": 508,
      "labelStart": "503",
      "labelEnd": "503",
      "words": 1,
      "summary": {
        "text": "A page containing only a page number.",
        "status": "draft"
      },
      "keywords": [],
      "extract": "503",
      "extractCut": false,
      "blocks": [
        "library/10665-381036/blocks/prose-page-508"
      ]
    },
    {
      "id": "page-509",
      "number": null,
      "title": "Page 509",
      "level": 1,
      "pageStart": 509,
      "pageEnd": 509,
      "labelStart": "504",
      "labelEnd": "504",
      "words": 94,
      "summary": {
        "text": "The title page of Web Annex B.11, a December 2020 systematic review of the diagnostic accuracy of moderate-complexity automated NAATs for TB and rifampicin and isoniazid resistance, with authors and affiliations.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "mcgill university",
          "heading": false
        },
        {
          "term": "samuel",
          "heading": false
        },
        {
          "term": "schumacher",
          "heading": false
        },
        {
          "term": "heidelberg",
          "heading": false
        }
      ],
      "extract": "504 Web Annex B.11. Moderate complexity automated NAATs: Diagnostic accuracy for TB detection and detection of resistance to rifampicin and isoniazid. A systematic review and meta-analysis December 2020 Authors: Mikashmi Kohli1,2; Emily MacLean1,2; Madhukar Pai1,2; Claudia M. Denkinger3,4; Samuel G. Schumacher3 Corresponding author: Samuel Schumacher PhD Evidence & Policy Lead at FIND Geneva, Switzerland Email:",
      "extractCut": true,
      "blocks": [
        "library/10665-381036/blocks/prose-page-509"
      ]
    },
    {
      "id": "page-510",
      "number": null,
      "title": "Page 510",
      "level": 1,
      "pageStart": 510,
      "pageEnd": 510,
      "labelStart": "505",
      "labelEnd": "505",
      "words": 363,
      "summary": {
        "text": "The opening of the executive summary for the review of moderate-complexity NAATs, giving the global TB and drug-resistant TB burden in 2017 and describing the review methods, including pooled meta-analysis in Stata.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "resistance detection",
          "heading": false
        },
        {
          "term": "drug resistance",
          "heading": false
        },
        {
          "term": "mtb detection",
          "heading": false
        },
        {
          "term": "reference standard",
          "heading": false
        },
        {
          "term": "diagnostic companies",
          "heading": false
        },
        {
          "term": "phenotypic",
          "heading": false
        },
        {
          "term": "molecular",
          "heading": false
        },
        {
          "term": "studies",
          "heading": false
        }
      ],
      "extract": "505 EXECUTIVE SUMMARY Background The World Health Organization (WHO) estimates that in 2017, 10 million people became ill with TB globally. Drug-resistant TB is an enormous threat. In 2017, an estimated 558,000 people were newly diagnosed with rifampicin-resistant TB, 468,720 of whom had multidrug-resistant TB (MDR-TB). MDR-TB is caused by infection with M. tuberculosis bacteria that are resistant to at least",
      "extractCut": true,
      "blocks": [
        "library/10665-381036/blocks/prose-page-510"
      ]
    },
    {
      "id": "page-511",
      "number": null,
      "title": "Page 511",
      "level": 1,
      "pageStart": 511,
      "pageEnd": 511,
      "labelStart": "506",
      "labelEnd": "506",
      "words": 303,
      "summary": {
        "text": "Summarises the review results: 36 studies from central laboratories gave 39 datasets, with limited patient data, and the tests showed accuracy for TB, rifampicin and isoniazid resistance detection comparable to WHO-recommended molecular tests.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "pooled sensitivity",
          "heading": false
        },
        {
          "term": "resistant specimens",
          "heading": false
        },
        {
          "term": "pooled specificity",
          "heading": false
        },
        {
          "term": "resistance detection",
          "heading": false
        },
        {
          "term": "index tests",
          "heading": false
        },
        {
          "term": "diagnostic accuracy",
          "heading": false
        },
        {
          "term": "hiv status",
          "heading": false
        },
        {
          "term": "reference standard",
          "heading": false
        }
      ],
      "extract": "506 A total of 36 studies contributed to 39 unique datasets (four studies provided data for more than one index test). All the studies were performed in central laboratories as the index tests require sophisticated laboratory infrastructure. For most studies, samples were included in the study on arrival into the laboratory, as a result there was limited data on the demographics of the included patient population,",
      "extractCut": true,
      "blocks": [
        "library/10665-381036/blocks/prose-page-511"
      ]
    },
    {
      "id": "page-512",
      "number": null,
      "title": "Page 512",
      "level": 1,
      "pageStart": 512,
      "pageEnd": 512,
      "labelStart": "507",
      "labelEnd": "507",
      "words": 352,
      "summary": {
        "text": "Gives background on the TB and MDR-TB burden and on molecular tests already recommended by WHO, such as Xpert, line-probe assays, LAMP and Truenat.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "inh resistance",
          "heading": false
        },
        {
          "term": "mtb bacteria",
          "heading": false
        },
        {
          "term": "resistance detection",
          "heading": false
        },
        {
          "term": "drug resistance",
          "heading": false
        },
        {
          "term": "mutations",
          "heading": false
        },
        {
          "term": "genes",
          "heading": false
        },
        {
          "term": "rif",
          "heading": false
        },
        {
          "term": "genotype",
          "heading": false
        }
      ],
      "extract": "507 Background Tuberculosis (TB) is caused by Mycobacterium tuberculosis (Mtb) bacteria. TB causes tremendous suffering worldwide and has surpassed HIV/AIDS as the world’s leading infectious cause of death. The World Health Organization (WHO) estimates that in 2017, 10 million people became ill with TB globally. Approximately, 1.3 million HIV-negative people and 300,000 HIV-positive people died from TB (WHO 2018).",
      "extractCut": true,
      "blocks": [
        "library/10665-381036/blocks/prose-page-512"
      ]
    },
    {
      "id": "page-513",
      "number": null,
      "title": "Page 513",
      "level": 1,
      "pageStart": 513,
      "pageEnd": 513,
      "labelStart": "508",
      "labelEnd": "508",
      "words": 396,
      "summary": {
        "text": "Describes high-throughput centralised molecular platforms for TB and resistance detection, such as Abbott RealTime and Roche Cobas, and the Bruker-Hain FluoroType assays with their extraction and detection systems.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "rif inh",
          "heading": false
        },
        {
          "term": "fluorotype mtbdr",
          "heading": false
        },
        {
          "term": "realtime mtb",
          "heading": false
        },
        {
          "term": "inh resistance",
          "heading": false
        },
        {
          "term": "mtb assay",
          "heading": false
        },
        {
          "term": "resistance detection",
          "heading": false
        },
        {
          "term": "dna extraction",
          "heading": false
        },
        {
          "term": "cfu",
          "heading": false
        }
      ],
      "extract": "508 Recently, several companies have developed molecular tests for TB and RIF/INH resistance detection on centralized platforms, many of which have been established as multi-disease platforms, primarily for detection of Human immunodeficiency virus (HIV), Human Papillomavirus (HPV) and Hepatitis C Virus. On these high-throughput platforms a large number of patient specimens can be tested in a shorter amount of time.",
      "extractCut": true,
      "blocks": [
        "library/10665-381036/blocks/prose-page-513"
      ]
    },
    {
      "id": "page-514",
      "number": null,
      "title": "Page 514",
      "level": 1,
      "pageStart": 514,
      "pageEnd": 514,
      "labelStart": "509",
      "labelEnd": "509",
      "words": 318,
      "summary": {
        "text": "Describes the BD MAX MDR-TB assay and its genetic targets and detection limits, then sets out the review's eligible study types, including case-control studies and data from a WHO public call.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "assay detects",
          "heading": false
        },
        {
          "term": "mdr-tb assay",
          "heading": false
        },
        {
          "term": "mtb detection",
          "heading": false
        },
        {
          "term": "cfu",
          "heading": false
        },
        {
          "term": "lod",
          "heading": false
        },
        {
          "term": "genes",
          "heading": false
        },
        {
          "term": "reference standard",
          "heading": false
        },
        {
          "term": "cobas",
          "heading": false
        }
      ],
      "extract": "509 Becton Dickinson (BD) has developed a multiplexed real-time PCR (BD MAXTM MDR-TB, CE-marked since 2018) assay for the detection of Mtb and resistance to both RIF and INH. The platform utilizes 5- colour detection (UNITAID 2017). For Mtb detection, this assay detects multicopy genomic targets IS6110 and IS1081 as well as a single copy genomic target. For resistance, the assay detects rpoB, inhA promoter and katG",
      "extractCut": true,
      "blocks": [
        "library/10665-381036/blocks/prose-page-514"
      ]
    },
    {
      "id": "page-515",
      "number": null,
      "title": "Page 515",
      "level": 1,
      "pageStart": 515,
      "pageEnd": 515,
      "labelStart": "510",
      "labelEnd": "510",
      "words": 292,
      "summary": {
        "text": "Sets out the review's participants, the four index test families, the target conditions and the reference standards, including a composite standard combining phenotypic testing and sequencing.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "realtime mtb",
          "heading": false
        },
        {
          "term": "cobas mtb",
          "heading": false
        },
        {
          "term": "mtb rif",
          "heading": false
        },
        {
          "term": "conventional dst",
          "heading": false
        },
        {
          "term": "composite reference",
          "heading": false
        },
        {
          "term": "roche cobas",
          "heading": false
        },
        {
          "term": "dst showed",
          "heading": false
        },
        {
          "term": "abbott realtime",
          "heading": false
        }
      ],
      "extract": "510 Types of participants Patients of all age groups presumed of having or confirmed with pulmonary TB or MDR-TB, in all settings and all countries, were included. Specimen types were limited to pulmonary TB specimens (such as sputum, bronchoalveolar lavage, tracheal aspirate etc.). Index tests 1. Abbott RealTime MTB and Abbott RealTime MTB RIF/INH 2. Bruker-Hain FluoroType MTB and FluoroType MTBDR 3. BD Max MDR-TB",
      "extractCut": true,
      "blocks": [
        "library/10665-381036/blocks/prose-page-515"
      ]
    },
    {
      "id": "page-516",
      "number": null,
      "title": "Page 516",
      "level": 1,
      "pageStart": 516,
      "pageEnd": 516,
      "labelStart": "511",
      "labelEnd": "511",
      "words": 311,
      "summary": {
        "text": "Explains how discordant composite reference results were handled, defines sensitivity and specificity outcomes, and describes the search and screening by two review authors.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "demonstrating rif",
          "heading": false
        },
        {
          "term": "mtb detection",
          "heading": false
        },
        {
          "term": "composite reference",
          "heading": false
        },
        {
          "term": "index test",
          "heading": false
        },
        {
          "term": "specificity refers",
          "heading": false
        },
        {
          "term": "sensitivity refers",
          "heading": false
        },
        {
          "term": "reference standard",
          "heading": false
        },
        {
          "term": "isolates",
          "heading": false
        }
      ],
      "extract": "511 low-level heteroresistance, below the limit of detection of the sequencing technologies used; e.g. Sanger). The composite reference standard was constructed without knowledge of the index test results. Outcome measures For Mtb detection, sensitivity refers to the proportion of specimens or isolates with a culture positive for Mtb that were detected as Mtb-positive by the index test. For RIF- or INH-resistance",
      "extractCut": true,
      "blocks": [
        "library/10665-381036/blocks/prose-page-516"
      ]
    },
    {
      "id": "page-517",
      "number": null,
      "title": "Page 517",
      "level": 1,
      "pageStart": 517,
      "pageEnd": 517,
      "labelStart": "512",
      "labelEnd": "512",
      "words": 343,
      "summary": {
        "text": "Describes resolution of screening disagreements, data extraction and quality assessment, noting that publication bias tests were not done and unpublished data were included.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "data extraction",
          "heading": false
        },
        {
          "term": "review authors",
          "heading": false
        },
        {
          "term": "index test",
          "heading": false
        },
        {
          "term": "publication bias",
          "heading": false
        },
        {
          "term": "quadas",
          "heading": false
        },
        {
          "term": "stata",
          "heading": false
        },
        {
          "term": "resolved",
          "heading": false
        },
        {
          "term": "statistical",
          "heading": false
        }
      ],
      "extract": "criteria (Screen 2). In Screen 2, any discrepancies were resolved by discussion between the review authors, and for any study that were not resolved by the review authors, were then decided by a third review author (SS). If a study contributed data to more than one analysis (e.g. two different index tests in one study, on the same or different specimens), it was considered as two or more datasets. Data extraction We",
      "extractCut": true,
      "blocks": [
        "library/10665-381036/blocks/prose-page-517"
      ]
    },
    {
      "id": "page-518",
      "number": null,
      "title": "Page 518",
      "level": 1,
      "pageStart": 518,
      "pageEnd": 518,
      "labelStart": "513",
      "labelEnd": "513",
      "words": 304,
      "summary": {
        "text": "Describes the bivariate random-effects meta-analysis methods in Stata, investigation of heterogeneity and the use of GRADE to assess certainty of evidence.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "pooled estimate",
          "heading": false
        },
        {
          "term": "assay lies",
          "heading": false
        },
        {
          "term": "point estimate",
          "heading": false
        },
        {
          "term": "pooling criteria",
          "heading": false
        },
        {
          "term": "prediction region",
          "heading": false
        },
        {
          "term": "forest plots",
          "heading": false
        },
        {
          "term": "overall point",
          "heading": false
        },
        {
          "term": "index tests",
          "heading": false
        }
      ],
      "extract": "Meta-analysis was after pooling the dataset from all the index tests together. We also visually saw the results from each index test by forest plots. Bivariate random effects meta-analyses were performed (Chu 2006; Reitsma 2005) using the metandi programme in Stata for index tests with enough studies that included data to calculate sensitivity, specificity, and 95% confidence intervals for each of these. Summary and",
      "extractCut": true,
      "blocks": [
        "library/10665-381036/blocks/prose-page-518"
      ]
    },
    {
      "id": "page-519",
      "number": null,
      "title": "Page 519",
      "level": 1,
      "pageStart": 519,
      "pageEnd": 519,
      "labelStart": "514",
      "labelEnd": "514",
      "words": 398,
      "summary": {
        "text": "Explains how evidence quality was rated using GRADE, then reports the number of studies for each index test for TB detection, all using culture as the reference.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "points subtracted",
          "heading": false
        },
        {
          "term": "fluorotype mtbdr",
          "heading": false
        },
        {
          "term": "cobas mtb",
          "heading": false
        },
        {
          "term": "utilized specimens",
          "heading": false
        },
        {
          "term": "realtime mtb",
          "heading": false
        },
        {
          "term": "abbott realtime",
          "heading": false
        },
        {
          "term": "high-income countries",
          "heading": false
        },
        {
          "term": "mtb assay",
          "heading": false
        }
      ],
      "extract": "Summary of Findings tables. As recommended, we rated the quality of evidence as high (no points subtracted), moderate (one point subtracted), low (two points subtracted), or very low greater than two points subtracted) based on five factors: risk of bias, indirectness, inconsistency, imprecision, and other considerations. We subtracted one point when there was a serious issue identified or two points when there was",
      "extractCut": true,
      "blocks": [
        "library/10665-381036/blocks/prose-page-519"
      ]
    },
    {
      "id": "page-520",
      "number": null,
      "title": "Page 520",
      "level": 1,
      "pageStart": 520,
      "pageEnd": 520,
      "labelStart": "515",
      "labelEnd": "515",
      "words": 197,
      "summary": {
        "text": "Summarises QUADAS-2 risk of bias for TB detection, noting that over half of the 29 studies had high or unclear risk in patient selection, and reports pooled sensitivity of 93.0% and specificity of 97.7%.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "unclear risk",
          "heading": false
        },
        {
          "term": "index test",
          "heading": false
        },
        {
          "term": "reference standard",
          "heading": false
        },
        {
          "term": "pooled",
          "heading": false
        },
        {
          "term": "bias",
          "heading": false
        }
      ],
      "extract": "Figure 2: QUADAS-2 assessment for TB detection Patient selection Risk of bias Of the total 29 studies, 16 (55%) had high or unclear risk of bias as they either did prior testing before including specimens in the study or used convenience sampling or the method of participant selection was not reported. Applicability concern Only 45% of the studies were conducted in high TB/MDR TB burden country. Index test As all",
      "extractCut": true,
      "blocks": [
        "library/10665-381036/blocks/prose-page-520",
        "library/10665-381036/blocks/figure-img-p520-1"
      ]
    },
    {
      "id": "page-521",
      "number": null,
      "title": "Page 521",
      "level": 1,
      "pageStart": 521,
      "pageEnd": 521,
      "labelStart": "516",
      "labelEnd": "516",
      "words": 64,
      "summary": {
        "text": "A forest plot caption followed by the smear-positive subgroup analysis, with pooled sensitivity of 98.8%.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "smear status",
          "heading": false
        },
        {
          "term": "specimens",
          "heading": false
        },
        {
          "term": "stratified",
          "heading": false
        }
      ],
      "extract": "Figure 3: Forest plot of included studies for TB detection Subgroup analysis: Smear status There were 26 studies that provided information for TB detection stratified by smear status. A total of 2880 smear positive and 9447 smear negative specimens were evaluated. The sensitivity for smear positive specimens ranged from 93% to 100%. The pooled sensitivity was 98.8% (93.7 to 99.7) (Table 2b) (Figure 4).",
      "extractCut": false,
      "blocks": [
        "library/10665-381036/blocks/prose-page-521",
        "library/10665-381036/blocks/figure-img-p521-1"
      ]
    },
    {
      "id": "page-522",
      "number": null,
      "title": "Page 522",
      "level": 1,
      "pageStart": 522,
      "pageEnd": 522,
      "labelStart": "517",
      "labelEnd": "517",
      "words": 71,
      "summary": {
        "text": "Reports pooled sensitivity of 86.1% and specificity of 96.4% for TB detection in smear-negative specimens, with forest plot captions.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "forest plot",
          "heading": false
        },
        {
          "term": "smear",
          "heading": false
        },
        {
          "term": "ranged",
          "heading": false
        }
      ],
      "extract": "Figure 4: Forest plot of included studies for TB detection in smear positive specimens. For smear negative the sensitivity ranged from 22% to 100%, and specificity ranged from 68% to 100%. Meta-analysis of the data provided a pooled sensitivity of 86.1% (73.4 to 93.2) and the pooled specificity was 96.4% (93.6 to 98.0) (Table 2b) (Figure 5). Figure 5: Forest plot of included studies for TB detection in smear",
      "extractCut": true,
      "blocks": [
        "library/10665-381036/blocks/prose-page-522",
        "library/10665-381036/blocks/figure-img-p522-1",
        "library/10665-381036/blocks/figure-img-p522-2"
      ]
    },
    {
      "id": "page-523",
      "number": null,
      "title": "Page 523",
      "level": 1,
      "pageStart": 523,
      "pageEnd": 523,
      "labelStart": "518",
      "labelEnd": "518",
      "words": 284,
      "summary": {
        "text": "Describes a sensitivity analysis excluding four manufacturer-driven studies for TB detection and introduces head-to-head comparisons of the tests with Xpert on the same specimens.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "head-to head",
          "heading": false
        },
        {
          "term": "head comparisons",
          "heading": false
        },
        {
          "term": "manufacturer driven",
          "heading": false
        },
        {
          "term": "sensitivity analysis",
          "heading": false
        },
        {
          "term": "index test",
          "heading": false
        },
        {
          "term": "four studies",
          "heading": false
        },
        {
          "term": "diagnostic accuracy",
          "heading": false
        },
        {
          "term": "excluded",
          "heading": false
        }
      ],
      "extract": "Sensitivity analysis: Manufacturer driven There were four studies which were manufacturer driven in this dataset for TB detection. We excluded these studies and performed a sensitivity analysis to evaluate the diagnostic accuracy of these class of tests for TB detection. The definition of manufacturer driven was that we removed studies which were provided by the manufacturers’ during the public call. Additionally,",
      "extractCut": true,
      "blocks": [
        "library/10665-381036/blocks/prose-page-523",
        "library/10665-381036/blocks/figure-img-p523-1"
      ]
    },
    {
      "id": "page-524",
      "number": null,
      "title": "Page 524",
      "level": 1,
      "pageStart": 524,
      "pageEnd": 524,
      "labelStart": "519",
      "labelEnd": "519",
      "words": 81,
      "summary": {
        "text": "Presents head-to-head comparisons with Xpert for TB detection, noting low specificity for both Abbott RealTime and Xpert in one study and differing results for FluoroType and Xpert in another.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "xpert",
          "heading": false
        },
        {
          "term": "fluorotype",
          "heading": false
        },
        {
          "term": "head",
          "heading": false
        }
      ],
      "extract": "BD Max Cobas MTB Figure 6: Head- to head comparisons of cNATs and Xpert for TB detection In the study by Wang 2016, a lower specificity was observed for both Abbott RealTime MTB assay (84%) and the Xpert assay (90%) for pulmonary TB specimens. Obasanya 2017 used Xpert in the study for pulmonary specimens. The study reported lower sensitivity of 79% for Xpert in comparison to the FluoroType (sensitivity of 89%),",
      "extractCut": true,
      "blocks": [
        "library/10665-381036/blocks/prose-page-524",
        "library/10665-381036/blocks/figure-img-p524-1",
        "library/10665-381036/blocks/figure-img-p524-2",
        "library/10665-381036/blocks/figure-img-p524-4",
        "library/10665-381036/blocks/figure-img-p524-8"
      ]
    },
    {
      "id": "page-525",
      "number": null,
      "title": "Page 525",
      "level": 1,
      "pageStart": 525,
      "pageEnd": 525,
      "labelStart": "520",
      "labelEnd": "520",
      "words": 312,
      "summary": {
        "text": "Discusses possible cross-contamination from manual extraction as a reason for low FluoroType specificity, and reports pooled rifampicin resistance detection with sensitivity of 96.7% and specificity of 98.9%.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "phenotypic dst",
          "heading": false
        },
        {
          "term": "rifampicin resistance",
          "heading": false
        },
        {
          "term": "inh assay",
          "heading": false
        },
        {
          "term": "resistance detection",
          "heading": false
        },
        {
          "term": "rif inh",
          "heading": false
        },
        {
          "term": "fluorotype",
          "heading": false
        },
        {
          "term": "index test",
          "heading": false
        },
        {
          "term": "reference standard",
          "heading": false
        }
      ],
      "extract": "was substantially improved (94% versus 60% for the FluoroType). Considering the possible reasons mentioned about for the low specificity of the FluoroType, and from the head-to-head comparison results, it is possible that the manual DNA extraction method used in this study for performing FluoroType MTB assay could have led to substantially high cross-contamination than a fully automated Xpert assay. For Paradis",
      "extractCut": true,
      "blocks": [
        "library/10665-381036/blocks/prose-page-525",
        "library/10665-381036/blocks/figure-img-p525-1"
      ]
    },
    {
      "id": "page-526",
      "number": null,
      "title": "Page 526",
      "level": 1,
      "pageStart": 526,
      "pageEnd": 526,
      "labelStart": "521",
      "labelEnd": "521",
      "words": 126,
      "summary": {
        "text": "Covers isoniazid resistance detection against phenotypic drug susceptibility testing, reporting pooled sensitivity of 86.4% and high specificity, with forest plot captions.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "phenotypic dst",
          "heading": false
        },
        {
          "term": "isoniazid resistance",
          "heading": false
        },
        {
          "term": "forest plot",
          "heading": false
        },
        {
          "term": "rifampicin resistance",
          "heading": false
        }
      ],
      "extract": "Figure 8: Forest plot for rifampicin resistance detection with phenotypic DST as the reference standard 3. PICO question: Among people with bacteriologically-confirmed PTB (adults, PLHIV, children) should cNAT assays on sputum be used to detect isoniazid resistance using phenotypic DST as reference standard ? Isoniazid resistance The overall sensitivity for rifampicin resistance in these 18 studies ranged from 58%",
      "extractCut": true,
      "blocks": [
        "library/10665-381036/blocks/prose-page-526",
        "library/10665-381036/blocks/figure-img-p526-1",
        "library/10665-381036/blocks/figure-img-p526-2"
      ]
    },
    {
      "id": "page-527",
      "number": null,
      "title": "Page 527",
      "level": 1,
      "pageStart": 527,
      "pageEnd": 527,
      "labelStart": "522",
      "labelEnd": "522",
      "words": 239,
      "summary": {
        "text": "Reports rifampicin and isoniazid resistance detection against a composite reference standard, with pooled rifampicin sensitivity of 96.7% and specificity of 98.7%.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "rifampicin resistance",
          "heading": false
        },
        {
          "term": "pooled estimates",
          "heading": false
        },
        {
          "term": "isoniazid resistance",
          "heading": false
        },
        {
          "term": "bacteriologically-confirmed ptb",
          "heading": false
        },
        {
          "term": "composite reference",
          "heading": false
        },
        {
          "term": "cnat assays",
          "heading": false
        },
        {
          "term": "discrepant mutations",
          "heading": false
        }
      ],
      "extract": "Pooled Analysis: Composite reference standard 4. PICO question: Among people with bacteriologically-confirmed PTB (adults, PLHIV, children) should cNAT assays on sputum be used to detect rifampicin resistance using composite reference standard ? Rifampicin resistance The overall sensitivity for rifampicin resistance in these 9 studies ranged from 92% to 100% and the specificity ranged from 95% to 100%. The pooled",
      "extractCut": true,
      "blocks": [
        "library/10665-381036/blocks/prose-page-527",
        "library/10665-381036/blocks/figure-img-p527-1",
        "library/10665-381036/blocks/figure-img-p527-2"
      ]
    },
    {
      "id": "page-528",
      "number": null,
      "title": "Page 528",
      "level": 1,
      "pageStart": 528,
      "pageEnd": 528,
      "labelStart": "523",
      "labelEnd": "523",
      "words": 240,
      "summary": {
        "text": "Reports a sensitivity analysis excluding three manufacturer-driven studies for resistance detection, with similar results, followed by acknowledgements.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "resistance detection",
          "heading": false
        },
        {
          "term": "manufacturer driven",
          "heading": false
        },
        {
          "term": "sensitivity analysis",
          "heading": false
        },
        {
          "term": "kostera",
          "heading": false
        },
        {
          "term": "assays",
          "heading": false
        },
        {
          "term": "promising",
          "heading": false
        },
        {
          "term": "thank",
          "heading": false
        }
      ],
      "extract": "Sensitivity analysis: Manufacturer driven There were three studies which were manufacturer driven in this dataset for TB detection. We performed a sensitivity analysis excluding these studies driven by manufacturers to assess whether this would affect the results. We excluded Kostera 2016, Kostera 2018 and Paradis 2018. The pooled estimate for this sensitivity analysis for rifampicin was sensitivity of 97.6% (93.3",
      "extractCut": true,
      "blocks": [
        "library/10665-381036/blocks/prose-page-528"
      ]
    },
    {
      "id": "page-529",
      "number": null,
      "title": "Page 529",
      "level": 1,
      "pageStart": 529,
      "pageEnd": 529,
      "labelStart": "524",
      "labelEnd": "524",
      "words": 84,
      "summary": {
        "text": "The first table of the review, giving the number of included studies for each index test and purpose, marked as prepared for the WHO Global TB Programme and not for further distribution.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "flurotype mtbdr",
          "heading": false
        },
        {
          "term": "abbott realtime",
          "heading": false
        },
        {
          "term": "resistance detection",
          "heading": false
        }
      ],
      "extract": "This report has been prepared for the WHO Global TB Programme. Do not distribute further. 524 TABLES Table 1: Number of included studies for each index test INDEX TEST PURPOSE NUMBER OF STUDIES ABBOTT REALTIME MTB TB detection 12 ABBOTT REALTIME RIF/INH Resistance detection 9 FLUOROTYPE MTB TB detection 6 FLUROTYPE MTBDR TB detection 4 FLUROTYPE MTBDR Resistance detection 3 BD MAX MDR-TB TB detection 5 BD MAX MDR-TB",
      "extractCut": true,
      "blocks": [
        "library/10665-381036/blocks/prose-page-529"
      ]
    },
    {
      "id": "page-530",
      "number": null,
      "title": "Page 530",
      "level": 1,
      "pageStart": 530,
      "pageEnd": 530,
      "labelStart": "525",
      "labelEnd": "525",
      "words": 232,
      "summary": {
        "text": "Tabulates pooled accuracy of centralized nucleic acid assays for detecting tuberculosis across 29 studies, overall about 93% sensitivity and 98% specificity, with results for each assay such as Abbott RealTime MTB, FluoroType and BD Max. The page carries a note that the report was prepared for WHO's Global TB Programme and is not for further distribution.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "pooled spec",
          "heading": false
        },
        {
          "term": "pooled sens",
          "heading": false
        },
        {
          "term": "roche cobas",
          "heading": false
        },
        {
          "term": "cobas mtb",
          "heading": false
        },
        {
          "term": "max",
          "heading": false
        }
      ],
      "extract": "This report has been prepared for the WHO Global TB Programme. Do not distribute further. 525 Table 2a: Diagnostic accuracy of each index test- TB detection Parameter Point estimate CI TB+ TB - Overall (N = 29) Overall sens 93.0 90.9 to 94.7 4767 9085 Overall spec 97.7 95.6 to 98.8 Abbott RealTime MTB (N= 12) Pooled sens 96.1 89.9 to 98.5 1274 4162 Pooled spec 97.6 94.8 to 98.9 FluoroType MTB (N= 6) Pooled sens 91.3",
      "extractCut": true,
      "blocks": [
        "library/10665-381036/blocks/prose-page-530",
        "library/10665-381036/blocks/table-019",
        "library/10665-381036/blocks/table-020"
      ]
    },
    {
      "id": "page-531",
      "number": null,
      "title": "Page 531",
      "level": 1,
      "pageStart": 531,
      "pageEnd": 531,
      "labelStart": "526",
      "labelEnd": "526",
      "words": 229,
      "summary": {
        "text": "Tabulates the accuracy of the centralized assays for tuberculosis detection by smear status, with near-complete sensitivity in smear-positive and about 86% in smear-negative specimens, broken down by assay.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "pooled spec",
          "heading": false
        },
        {
          "term": "pooled sens",
          "heading": false
        },
        {
          "term": "roche cobas",
          "heading": false
        },
        {
          "term": "cobas mtb",
          "heading": false
        }
      ],
      "extract": "This report has been prepared for the WHO Global TB Programme. Do not distribute further. 526 Parameter Point estimate CI Point estimate CI Smear positive (N = 26; 2880 specimens) Smear negative (N = 26; 9947 specimens) Overall sens 98.8% 93.7 to 99.7 86.1% 73.4 to 93.2 Overall spec - - 96.4% 93.6 to 98.0 Abbott RealTime MTB(N= 11) Pooled sens 99.7% 97.3 to 99.9 85.7% 65.5 to 95.0 Pooled spec - - 99.2% 96.4 to 99.1",
      "extractCut": true,
      "blocks": [
        "library/10665-381036/blocks/prose-page-531"
      ]
    },
    {
      "id": "page-532",
      "number": null,
      "title": "Page 532",
      "level": 1,
      "pageStart": 532,
      "pageEnd": 532,
      "labelStart": "527",
      "labelEnd": "527",
      "words": 245,
      "summary": {
        "text": "Tabulates the accuracy of each centralized assay for detecting rifampicin and isoniazid resistance against phenotypic drug susceptibility testing, with pooled sensitivity of about 97% for rifampicin and 86% for isoniazid and high specificity.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "pooled spec",
          "heading": false
        },
        {
          "term": "pooled sens",
          "heading": false
        },
        {
          "term": "rif inh",
          "heading": false
        },
        {
          "term": "overall pooled",
          "heading": false
        },
        {
          "term": "roche cobas",
          "heading": false
        }
      ],
      "extract": "This report has been prepared for the WHO Global TB Programme. Do not distribute further. 527 Table 3a: Diagnostic accuracy of each index test - resistance detection with phenotypic DST as reference standard Overall Pooled RIF (N = 18) Overall Pooled INH (N = 18) Pooled Sens 96.7 (93.1 to 98.4) Pooled sens 86.4 (82.8 to 89.3) Pooled Spec 98.9 (97.5 to 99.5) Pooled spec 99.2 (98.1 to 99.7) Abbott (RIF) N = 9 Abbott",
      "extractCut": true,
      "blocks": [
        "library/10665-381036/blocks/prose-page-532",
        "library/10665-381036/blocks/table-021"
      ]
    },
    {
      "id": "page-533",
      "number": null,
      "title": "Page 533",
      "level": 1,
      "pageStart": 533,
      "pageEnd": 533,
      "labelStart": "528",
      "labelEnd": "528",
      "words": 144,
      "summary": {
        "text": "Tabulates resistance detection accuracy against a composite reference standard and gives a sensitivity analysis for tuberculosis, rifampicin and isoniazid resistance detection.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "pooled spec",
          "heading": false
        },
        {
          "term": "pooled sens",
          "heading": false
        },
        {
          "term": "overall pooled",
          "heading": false
        },
        {
          "term": "overall sensitivity",
          "heading": false
        }
      ],
      "extract": "This report has been prepared for the WHO Global TB Programme. Do not distribute further. 528 Table 3b : Diagnostic accuracy of each index test - resistance detection with composite reference standard Overall Pooled RIF (N = 9) Overall Pooled INH (N = 8) Pooled sens 96.7 (92.9 to 98.5) Pooled sens 86.4 (82.1 to 89.8) Pooled spec 98.7 (97.1 to 99.4) Pooled spec 99.8 (98.3 to 99.8) Data are presented as point estimate",
      "extractCut": true,
      "blocks": [
        "library/10665-381036/blocks/prose-page-533",
        "library/10665-381036/blocks/table-022"
      ]
    },
    {
      "id": "page-534",
      "number": null,
      "title": "Page 534",
      "level": 1,
      "pageStart": 534,
      "pageEnd": 534,
      "labelStart": "529",
      "labelEnd": "529",
      "words": 238,
      "summary": {
        "text": "A summary-of-findings table on the accuracy of centralized nucleic acid tests for tuberculosis detection, showing expected true and false results per 1000 people at different prevalence levels with GRADE certainty and reasons for downgrading.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "cri",
          "heading": false
        },
        {
          "term": "prevalence",
          "heading": false
        },
        {
          "term": "negatives",
          "heading": false
        },
        {
          "term": "cnats",
          "heading": false
        },
        {
          "term": "positives",
          "heading": false
        }
      ],
      "extract": "This report has been prepared for the WHO Global TB Programme. Do not distribute further. 529 Table 5: Summary of findings: TB detection What is the diagnostic accuracy of cNATs for TB detection? Patient or population: Participants with presumptive pulmonary TB Setting: outpatient and inpatient Reference standard: culture Pooled sensitivity: 0.93 (95% CI: 0.91 to 0.95) Pooled specificity: 0.98 (95% CI: 0.96 to 0.99)",
      "extractCut": true,
      "blocks": [
        "library/10665-381036/blocks/prose-page-534"
      ]
    },
    {
      "id": "page-535",
      "number": null,
      "title": "Page 535",
      "level": 1,
      "pageStart": 535,
      "pageEnd": 535,
      "labelStart": "530",
      "labelEnd": "530",
      "words": 246,
      "summary": {
        "text": "A summary-of-findings table on centralized tests for detecting rifampicin resistance, giving expected results per 1000 people tested at several prevalence levels and the GRADE certainty of evidence.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "rifampicin resistance",
          "heading": false
        },
        {
          "term": "cnats",
          "heading": false
        },
        {
          "term": "prevalence",
          "heading": false
        },
        {
          "term": "negatives",
          "heading": false
        },
        {
          "term": "positives",
          "heading": false
        }
      ],
      "extract": "This report has been prepared for the WHO Global TB Programme. Do not distribute further. 530 Table 6: Summary of findings: cNATs for rifampicin resistance What is the diagnostic accuracy of cNATs for RIF resistance detection? Patient or population: Participants with presumptive MDR-TB Setting: outpatient and inpatient Reference standard: culture Pooled sensitivity: 0.97 (95% CI: 0.93 to 0.98) | Pooled specificity :",
      "extractCut": true,
      "blocks": [
        "library/10665-381036/blocks/prose-page-535"
      ]
    },
    {
      "id": "page-536",
      "number": null,
      "title": "Page 536",
      "level": 1,
      "pageStart": 536,
      "pageEnd": 536,
      "labelStart": "531",
      "labelEnd": "531",
      "words": 258,
      "summary": {
        "text": "A summary-of-findings table on centralized tests for detecting isoniazid resistance, with pooled sensitivity of 0.86 and specificity of 0.99, results per 1000 people and notes on GRADE judgements.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "cnats assay",
          "heading": false
        },
        {
          "term": "inh resistance",
          "heading": false
        },
        {
          "term": "downgrade",
          "heading": false
        },
        {
          "term": "cri",
          "heading": false
        },
        {
          "term": "prevalence",
          "heading": false
        },
        {
          "term": "negatives",
          "heading": false
        }
      ],
      "extract": "531 Table 7: Summary of findings: cNATs assay for isoniazid resistance What is the diagnostic accuracy of cNATs assay for INH resistance detection? Patient or population: Participants with presumptive MDR-TB Setting: outpatient and inpatient Reference standard: culture Pooled sensitivity: 0.86 (95% CI: 0.83 to 0.89) | Pooled specificity : 0.99 (95% CI: 0.98 to 1.00) Test result Number of results per 1,000 patients",
      "extractCut": true,
      "blocks": [
        "library/10665-381036/blocks/prose-page-536"
      ]
    },
    {
      "id": "page-537",
      "number": null,
      "title": "Page 537",
      "level": 1,
      "pageStart": 537,
      "pageEnd": 537,
      "labelStart": "532",
      "labelEnd": "532",
      "words": 239,
      "summary": {
        "text": "A summary-of-findings table on rifampicin resistance detection against a composite reference standard of phenotypic testing and sequencing, with results per 1000 people and GRADE certainty.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "rif resistance",
          "heading": false
        },
        {
          "term": "cnats",
          "heading": false
        },
        {
          "term": "cri",
          "heading": false
        },
        {
          "term": "prevalence",
          "heading": false
        },
        {
          "term": "crs",
          "heading": false
        }
      ],
      "extract": "532 Table 8: Summary of findings table: cNATs for RIF resistance: CRS What is the diagnostic accuracy of cNATs for RIF resistance detection? Patient or population: Participants with presumptive pulmonary TB Setting: outpatient and inpatient Reference standard: CRS: phenotypic DST (solid or liquid) and gene sequencing, where at least one test is resistant Pooled sensitivity : 0.97 (95% CI: 0.93 to 0.98) | Pooled",
      "extractCut": true,
      "blocks": [
        "library/10665-381036/blocks/prose-page-537"
      ]
    },
    {
      "id": "page-538",
      "number": null,
      "title": "Page 538",
      "level": 1,
      "pageStart": 538,
      "pageEnd": 538,
      "labelStart": "533",
      "labelEnd": "533",
      "words": 251,
      "summary": {
        "text": "A summary-of-findings table on isoniazid resistance detection against a composite reference standard, with results per 1000 people and GRADE certainty.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "inh resistance",
          "heading": false
        },
        {
          "term": "cnats",
          "heading": false
        },
        {
          "term": "cri",
          "heading": false
        },
        {
          "term": "prevalence",
          "heading": false
        },
        {
          "term": "crs",
          "heading": false
        },
        {
          "term": "negatives",
          "heading": false
        }
      ],
      "extract": "533 Table 9: Summary of findings table: cNATs for INH resistance: CRS What is the diagnostic accuracy of cNATs for INH resistance detection? Patient or population: Participants with presumptive pulmonary TB Setting: outpatient and inpatient Reference standard: CRS: phenotypic DST (solid or liquid) and gene sequencing, where at least one test is resistant Pooled sensitivity : 0.86 (95% CI: 0.82 to 0.90) | Pooled",
      "extractCut": true,
      "blocks": [
        "library/10665-381036/blocks/prose-page-538"
      ]
    },
    {
      "id": "page-539",
      "number": null,
      "title": "Page 539",
      "level": 1,
      "pageStart": 539,
      "pageEnd": 539,
      "labelStart": "534",
      "labelEnd": "534",
      "words": 107,
      "summary": {
        "text": "A PRISMA flow diagram showing 878 citations screened, 133 full papers reviewed and 36 studies (39 datasets) included, broken down by assay.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "abbott realtime",
          "heading": false
        },
        {
          "term": "excluded screen",
          "heading": false
        },
        {
          "term": "fluorotype",
          "heading": false
        },
        {
          "term": "mdrtb",
          "heading": false
        }
      ],
      "extract": "Figures Figure 1. PRISMA diagram of studies included in the review Potentially relevant citations identified from electronic databases: 878 Excluded Screen One: 638 Reason: Not relevant based on assessment of title and abstract Full papers retrieved for more detailed evaluation: 133 Excluded Screen Two: 57 Reasons: Inappropriate index test: 48 Abstract: 4 Not pulmonary specimens: 2 Case report: 1 Case-control: 1 Not",
      "extractCut": true,
      "blocks": [
        "library/10665-381036/blocks/prose-page-539"
      ]
    },
    {
      "id": "page-540",
      "number": null,
      "title": "Page 540",
      "level": 1,
      "pageStart": 540,
      "pageEnd": 540,
      "labelStart": "535",
      "labelEnd": "535",
      "words": 24,
      "summary": {
        "text": "The caption for a figure summarizing QUADAS-2 risk of bias and applicability concerns for studies of assays for tuberculosis detection.",
        "status": "draft"
      },
      "keywords": [],
      "extract": "Appendix A: Quallity assessment Figure A. Risk of Bias and Applicability Concerns summary for QUADAS-2 domains in each study evaluating assays for TB detection",
      "extractCut": false,
      "blocks": [
        "library/10665-381036/blocks/prose-page-540",
        "library/10665-381036/blocks/figure-img-p540-1"
      ]
    },
    {
      "id": "page-541",
      "number": null,
      "title": "Page 541",
      "level": 1,
      "pageStart": 541,
      "pageEnd": 541,
      "labelStart": "536",
      "labelEnd": "536",
      "words": 20,
      "summary": {
        "text": "The caption for a figure summarizing QUADAS-2 risk of bias and applicability concerns for studies of resistance detection.",
        "status": "draft"
      },
      "keywords": [],
      "extract": "Figure B: Risk of Bias and Applicability Concerns summary for QUADAS-2 domains in each study evaluating assays for resistance detection",
      "extractCut": false,
      "blocks": [
        "library/10665-381036/blocks/prose-page-541",
        "library/10665-381036/blocks/figure-img-p541-1"
      ]
    },
    {
      "id": "page-542",
      "number": null,
      "title": "Page 542",
      "level": 1,
      "pageStart": 542,
      "pageEnd": 542,
      "labelStart": "537",
      "labelEnd": "537",
      "words": 403,
      "summary": {
        "text": "Sets out the review's QUADAS-2 protocol, explaining how each signalling question on patient selection and the index test was scored. It notes that the centralized assays give automated results with prespecified thresholds, leaving no room for subjective interpretation.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "signaling question",
          "heading": false
        },
        {
          "term": "scored yes",
          "heading": false
        },
        {
          "term": "inappropriate exclusions",
          "heading": false
        },
        {
          "term": "study enrolled",
          "heading": false
        },
        {
          "term": "patients presumed",
          "heading": false
        },
        {
          "term": "introduced bias",
          "heading": false
        },
        {
          "term": "mdr-tb burden",
          "heading": false
        },
        {
          "term": "index test",
          "heading": false
        }
      ],
      "extract": "Appendix B. QUADAS-2 Protocol Domain 1 Patient Selection: Risk of Bias: Could the selection of patients have introduced bias? • Signaling question 1: Was a consecutive or random sample of patients or specimens enrolled? o We scored ‘yes’ if the study enrolled a consecutive or random sample of eligible patients; ‘no’ if the study selected patients by convenience, and ‘unclear’ if the study did not report the manner",
      "extractCut": true,
      "blocks": [
        "library/10665-381036/blocks/prose-page-542"
      ]
    },
    {
      "id": "page-543",
      "number": null,
      "title": "Page 543",
      "level": 1,
      "pageStart": 543,
      "pageEnd": 543,
      "labelStart": "538",
      "labelEnd": "538",
      "words": 401,
      "summary": {
        "text": "Continues the QUADAS-2 protocol with criteria for applicability of the index test and for judging risk of bias in the reference standard, including blinding to index test results.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "scored yes",
          "heading": false
        },
        {
          "term": "scored unclear",
          "heading": false
        },
        {
          "term": "signaling question",
          "heading": false
        },
        {
          "term": "reference standard",
          "heading": false
        },
        {
          "term": "liquid culture",
          "heading": false
        },
        {
          "term": "index test",
          "heading": false
        },
        {
          "term": "quality reference",
          "heading": false
        },
        {
          "term": "rifampicin resistance",
          "heading": false
        }
      ],
      "extract": "o As the threshold is prespecified in all centralized molecular DST assay in this review, we answered this question \"yes\" for all studies. Applicability: Are there concerns that the index test, its conduct, or its interpretation differ from the review question? Variations in test technology, execution, or interpretation may affect estimates of the diagnostic accuracy of a test. We judged ‘low concern’ if the test",
      "extractCut": true,
      "blocks": [
        "library/10665-381036/blocks/prose-page-543"
      ]
    },
    {
      "id": "page-544",
      "number": null,
      "title": "Page 544",
      "level": 1,
      "pageStart": 544,
      "pageEnd": 544,
      "labelStart": "539",
      "labelEnd": "539",
      "words": 452,
      "summary": {
        "text": "Continues the QUADAS-2 protocol with an added question for rifampicin resistance on blinding of the reference standard, and criteria for applicability and for the flow and timing domain.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "scored yes",
          "heading": false
        },
        {
          "term": "signaling question",
          "heading": false
        },
        {
          "term": "paired specimens",
          "heading": false
        },
        {
          "term": "reference standard",
          "heading": false
        },
        {
          "term": "liquid culture",
          "heading": false
        },
        {
          "term": "same reference",
          "heading": false
        },
        {
          "term": "solid culture",
          "heading": false
        },
        {
          "term": "participants received",
          "heading": false
        }
      ],
      "extract": "o We added a signaling question for rifampicin resistance detection. We scored \"yes\" if the reference test provided an automated result (for example, MGIT 960), blinding was explicitly stated, or it was clear that the reference standard was performed at a separate laboratory or performed by different people, or both. We scored \"no\" if the study stated that the reference standard result was interpreted with knowledge",
      "extractCut": true,
      "blocks": [
        "library/10665-381036/blocks/prose-page-544"
      ]
    },
    {
      "id": "page-545",
      "number": null,
      "title": "Page 545",
      "level": 1,
      "pageStart": 545,
      "pageEnd": 545,
      "labelStart": "540",
      "labelEnd": "540",
      "words": 80,
      "summary": {
        "text": "Completes the QUADAS-2 protocol and begins Appendix C, which lists forest plots of tuberculosis detection for each assay.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "fluorotype mtbdr",
          "heading": false
        },
        {
          "term": "fluorotype mtb",
          "heading": false
        },
        {
          "term": "mtbdr assay",
          "heading": false
        }
      ],
      "extract": "analysis and there was no explanation given; and 'unclear ' if not enough information was given to assess whether participants were excluded from the analysis Appendix C: Data by different technologies TB detection 1. Abbott RealTime MTB assay Figure A: Forest plot of TB detection by Abbott RealTime MTB assay 2. FluoroType MTB assay Figure B: Forest plot of TB detection by FluoroType MTB assay 3. FluoroType MTBDR",
      "extractCut": true,
      "blocks": [
        "library/10665-381036/blocks/prose-page-545",
        "library/10665-381036/blocks/figure-img-p545-1",
        "library/10665-381036/blocks/figure-img-p545-2",
        "library/10665-381036/blocks/figure-img-p545-3"
      ]
    },
    {
      "id": "page-546",
      "number": null,
      "title": "Page 546",
      "level": 1,
      "pageStart": 546,
      "pageEnd": 546,
      "labelStart": "541",
      "labelEnd": "541",
      "words": 43,
      "summary": {
        "text": "Lists further forest plot captions for tuberculosis detection by BD Max and Cobas assays and for rifampicin resistance detection by the Abbott assay.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "max mdr-tb",
          "heading": false
        },
        {
          "term": "cobas mtb",
          "heading": false
        },
        {
          "term": "forest plot",
          "heading": false
        }
      ],
      "extract": "4. BD Max MDR-TB Figure D: Forest plot of TB detection by BD Max MDR-TB assay 5. Cobas 6800/8800 MTB assay Figure E: Forest plot of TB detection by Cobas MTB assay Resistance detection Figure: RIF resistance detection by Abbott RealTIme RIF/INH resistance",
      "extractCut": false,
      "blocks": [
        "library/10665-381036/blocks/prose-page-546",
        "library/10665-381036/blocks/figure-img-p546-1",
        "library/10665-381036/blocks/figure-img-p546-2",
        "library/10665-381036/blocks/figure-img-p546-3"
      ]
    },
    {
      "id": "page-547",
      "number": null,
      "title": "Page 547",
      "level": 1,
      "pageStart": 547,
      "pageEnd": 547,
      "labelStart": "542",
      "labelEnd": "542",
      "words": 25,
      "summary": {
        "text": "Lists forest plot captions for isoniazid and rifampicin resistance detection by the Abbott and FluoroType MTBDR assays.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "flurotype mtbdr",
          "heading": false
        },
        {
          "term": "inh resistance",
          "heading": false
        },
        {
          "term": "resistance detection",
          "heading": false
        }
      ],
      "extract": "Figure: INH resistance detection by Abbott RealTIme RIF/INH resistance Figure: RIF resistance detection by FluroType MTBDR resistance Figure: INH resistance detection by FluroType MTBDR resistance",
      "extractCut": false,
      "blocks": [
        "library/10665-381036/blocks/prose-page-547",
        "library/10665-381036/blocks/figure-img-p547-1",
        "library/10665-381036/blocks/figure-img-p547-2",
        "library/10665-381036/blocks/figure-img-p547-3"
      ]
    },
    {
      "id": "page-548",
      "number": null,
      "title": "Page 548",
      "level": 1,
      "pageStart": 548,
      "pageEnd": 548,
      "labelStart": "543",
      "labelEnd": "543",
      "words": 21,
      "summary": {
        "text": "Lists forest plot captions for rifampicin and isoniazid resistance detection by the BD Max and Cobas assays.",
        "status": "draft"
      },
      "keywords": [],
      "extract": "Figure: RIF and INH resistance detection by BD Max MDR-TB assay Figure: RIF and INH resistance detection by Cobas MTB-DR assay",
      "extractCut": false,
      "blocks": [
        "library/10665-381036/blocks/prose-page-548",
        "library/10665-381036/blocks/figure-img-p548-1",
        "library/10665-381036/blocks/figure-img-p548-2"
      ]
    },
    {
      "id": "page-549",
      "number": null,
      "title": "Page 549",
      "level": 1,
      "pageStart": 549,
      "pageEnd": 549,
      "labelStart": "544",
      "labelEnd": "544",
      "words": 316,
      "summary": {
        "text": "Appendix D explains how the composite reference standard was applied in three studies with sequencing data, including how discordant results tied to particular mutations were classified. It also notes resistance mutations that some assays failed to detect.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "phenotypic dst",
          "heading": false
        },
        {
          "term": "inha promoter",
          "heading": false
        },
        {
          "term": "promoter region",
          "heading": false
        },
        {
          "term": "rif resistance",
          "heading": false
        },
        {
          "term": "mutation",
          "heading": false
        },
        {
          "term": "sequencing",
          "heading": false
        },
        {
          "term": "composite reference",
          "heading": false
        },
        {
          "term": "crs",
          "heading": false
        }
      ],
      "extract": "544 Appendix D Composite reference standard Three studies (Hofmann Thiel, 2018; Kostera 2016 and Tam 2017) evaluated sequencing and provided information on the mutations to assess results using CRS for RIF resistance. In the study by Hofmann Thiel 2018, three specimens which were susceptible by phenotypic DST but resistant by Abbott, had a L511P mutation as confirmed by sequencing. As there is limited confidence",
      "extractCut": true,
      "blocks": [
        "library/10665-381036/blocks/prose-page-549"
      ]
    },
    {
      "id": "page-550",
      "number": null,
      "title": "Page 550",
      "level": 1,
      "pageStart": 550,
      "pageEnd": 550,
      "labelStart": "545",
      "labelEnd": "545",
      "words": 173,
      "summary": {
        "text": "The start of the review's reference list, citing manufacturer product pages and studies on tuberculosis drug resistance and diagnosis.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "bruker-hain diagnostics",
          "heading": false
        },
        {
          "term": "abbott realtime",
          "heading": false
        },
        {
          "term": "mycobacteria tuberculosis",
          "heading": false
        },
        {
          "term": "microbiology mycobacteria",
          "heading": false
        },
        {
          "term": "mycobacterium tuberculosis",
          "heading": false
        },
        {
          "term": "products microbiology",
          "heading": false
        }
      ],
      "extract": "545 References Abbott 2019a Abbott. Abbott RealTime MTB. https://www.molecular.abbott/int/en/products/infectious- disease/realtime-mtb 2019. Abbott 2019b Abbott. Abbott RealTime RIF/INH. https://www.molecular.abbott/int/en/products/infectious- disease/realtime-mtb-rif-inh-resistance 2019. Almeida Da Silva 2011 Almeida Da Silva PE and Palomino JC. Molecular basis and mechanisms of drug resistance in Mycobacterium",
      "extractCut": true,
      "blocks": [
        "library/10665-381036/blocks/prose-page-550"
      ]
    },
    {
      "id": "page-551",
      "number": null,
      "title": "Page 551",
      "level": 1,
      "pageStart": 551,
      "pageEnd": 551,
      "labelStart": "546",
      "labelEnd": "546",
      "words": 250,
      "summary": {
        "text": "Part of the review's reference list, citing statistical methods, the Cochrane diagnostic review handbook and studies of molecular tuberculosis diagnostics.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "miotto",
          "heading": false
        },
        {
          "term": "mycobacterium tuberculosis",
          "heading": false
        },
        {
          "term": "mtb rif",
          "heading": false
        },
        {
          "term": "xpert mtb",
          "heading": false
        },
        {
          "term": "dicks",
          "heading": false
        },
        {
          "term": "friedrich",
          "heading": false
        },
        {
          "term": "systematic reviews",
          "heading": false
        },
        {
          "term": "horne",
          "heading": false
        }
      ],
      "extract": "546 Chu H and Cole SR. Bivariate meta-analysis of sensitivity and specificity with sparse data: a generalized linear mixed model approach. J Clin Epidemiol 2006;59(12):1331-1332. Cochrane 2008 The Cochrane Collaboration. Cochrane Handbook for Systematic Reviews of Diagnostic Test Accuracy. 2008. Dicks 2019 Dicks KV and Stout JE. Molecular Diagnostics for Mycobacterium tuberculosis Infection [Annual Review of",
      "extractCut": true,
      "blocks": [
        "library/10665-381036/blocks/prose-page-551"
      ]
    },
    {
      "id": "page-552",
      "number": null,
      "title": "Page 552",
      "level": 1,
      "pageStart": 552,
      "pageEnd": 552,
      "labelStart": "547",
      "labelEnd": "547",
      "words": 274,
      "summary": {
        "text": "Part of the review's reference list, citing meta-analyses of line probe assays, bivariate methods, GRADE papers and studies of false-positive Xpert results.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "schünemann",
          "heading": false
        },
        {
          "term": "subbaraman",
          "heading": false
        },
        {
          "term": "somoskovi",
          "heading": false
        },
        {
          "term": "nathavitharana",
          "heading": false
        },
        {
          "term": "jclinepi",
          "heading": false
        },
        {
          "term": "steingart",
          "heading": false
        },
        {
          "term": "murad",
          "heading": false
        },
        {
          "term": "reitsma",
          "heading": false
        }
      ],
      "extract": "547 Nathavitharana 2017 Nathavitharana RR, Cudahy PG, Schumacher SG, Steingart KR, Pai M, Denkinger CM. Accuracy of line probe assays for the diagnosis of pulmonary and multidrug-resistant tuberculosis: a systematic review and meta-analysis. The European respiratory journal 2017;49(1):1601075. DOI: 10.1183/13993003.01075-2016 Reitsma 2005 Reitsma JB, Glas AS, Rutjes AW, Scholten RJ, Bossuyt PM, Zwinderman AH.",
      "extractCut": true,
      "blocks": [
        "library/10665-381036/blocks/prose-page-552"
      ]
    },
    {
      "id": "page-553",
      "number": null,
      "title": "Page 553",
      "level": 1,
      "pageStart": 553,
      "pageEnd": 553,
      "labelStart": "548",
      "labelEnd": "548",
      "words": 231,
      "summary": {
        "text": "The end of the review's reference list, including studies of false-positive Xpert results and WHO tuberculosis reports and guidelines.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "previous tuberculosis",
          "heading": false
        },
        {
          "term": "mtb rif",
          "heading": false
        },
        {
          "term": "distinguish true",
          "heading": false
        },
        {
          "term": "xpert mtb",
          "heading": false
        },
        {
          "term": "theron",
          "heading": false
        },
        {
          "term": "clinical infectious",
          "heading": false
        },
        {
          "term": "health organization",
          "heading": false
        },
        {
          "term": "world health",
          "heading": false
        }
      ],
      "extract": "548 in Patients With Previous Tuberculosis: Can We Distinguish True From False Positive Results?. Clinical Infectious Diseases 2016;62 (8):995–1001. Theron 2016 Theron G, Venter R, Calligaro G, Smith L, Limberis J, Meldau R, et al. Xpert MTB/RIF Results in Patients With Previous Tuberculosis: Can We Distinguish True From False Positive Results?. Clinical Infectious Diseases 2016;62 (8):995–1001. Theron 2018 Theron",
      "extractCut": true,
      "blocks": [
        "library/10665-381036/blocks/prose-page-553"
      ]
    },
    {
      "id": "page-554",
      "number": null,
      "title": "Page 554",
      "level": 1,
      "pageStart": 554,
      "pageEnd": 554,
      "labelStart": "549",
      "labelEnd": "549",
      "words": 68,
      "summary": {
        "text": "The title page of Web Annex B.12, a systematic review of economic evidence on nucleic acid amplification tests for detecting TB and drug-resistant TB, prepared by University of Ottawa authors for a December 2020 WHO guideline meeting and marked not for distribution.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "ottawa",
          "heading": false
        },
        {
          "term": "brianna",
          "heading": false
        },
        {
          "term": "empringham",
          "heading": false
        }
      ],
      "extract": "549 Web Annex B.12. Systematic Literature Review of Economic Evidence for Nucleic acid amplification tests (NAATs) to detect TB and DR-TB in adults and children Produced in Preparation for the WHO guideline development group meeting Dec. 7-18, 2020 Final Report: PLEASE DO NOT DISTRIBUTE December 2020 Alice Zwerling, Sazia Naz & Brianna Empringham School of Epidemiology & Public Health Faculty of Medicine, University",
      "extractCut": true,
      "blocks": [
        "library/10665-381036/blocks/prose-page-554"
      ]
    },
    {
      "id": "page-555",
      "number": null,
      "title": "Page 555",
      "level": 1,
      "pageStart": 555,
      "pageEnd": 555,
      "labelStart": "550",
      "labelEnd": "550",
      "words": 366,
      "summary": {
        "text": "Sets out the background to the economic evidence review, which summarizes cost data on three classes of nucleic acid amplification tests for TB and drug-resistant TB, starting with centralized end-to-end platforms such as Abbott RealTime, FluoroType, BD Max and Roche Cobas. It describes the database search strategy and its cost-related search terms.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "naats classes",
          "heading": false
        },
        {
          "term": "abbott realtime",
          "heading": false
        },
        {
          "term": "pza lpa",
          "heading": false
        },
        {
          "term": "economic evidence",
          "heading": false
        },
        {
          "term": "acid amplification",
          "heading": false
        },
        {
          "term": "nucleic acid",
          "heading": false
        },
        {
          "term": "search strategy",
          "heading": false
        },
        {
          "term": "current economic",
          "heading": false
        }
      ],
      "extract": "550 BACKGROUND In preparation for the upcoming guideline development group meeting “Nucleic acid amplification tests to detect TB and DR-TB” scheduled for 7-11 December, 2020, there is a need to summarize the current economic evidence on the following three classes of NAATs: 1) Centralized assays that present end-to-end (E2E) solutions for detection of pulmonary TB and resistance to rifampicin and isoniazid;",
      "extractCut": true,
      "blocks": [
        "library/10665-381036/blocks/prose-page-555"
      ]
    },
    {
      "id": "page-556",
      "number": null,
      "title": "Page 556",
      "level": 1,
      "pageStart": 556,
      "pageEnd": 556,
      "labelStart": "551",
      "labelEnd": "551",
      "words": 464,
      "summary": {
        "text": "Explains that because direct evidence was scarce, further searches looked for indirect cost evidence from the same platforms in other diseases and from line probe assays. It describes study selection and data extraction and an unpublished costing study that used time-and-motion observations in a South African laboratory to estimate unit test costs for BD Max and Hain.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "motion studies",
          "heading": false
        },
        {
          "term": "e2e",
          "heading": false
        },
        {
          "term": "diagnostic scenarios",
          "heading": false
        },
        {
          "term": "indirect evidence",
          "heading": false
        },
        {
          "term": "study selection",
          "heading": false
        },
        {
          "term": "unit test",
          "heading": false
        },
        {
          "term": "hain",
          "heading": false
        },
        {
          "term": "searches",
          "heading": false
        }
      ],
      "extract": "551 Due to limited direct evidence, several subsequent searches were performed in the same 4 databases as of late November to identify indirect evidence using these platforms in non-TB disease areas. Search strategies were run with the specific platform names but without the following search term for TB: (tuberculosis OR TB OR mycobacterium). Additional searches were also run with additional search terms for",
      "extractCut": true,
      "blocks": [
        "library/10665-381036/blocks/prose-page-556"
      ]
    },
    {
      "id": "page-557",
      "number": null,
      "title": "Page 557",
      "level": 1,
      "pageStart": 557,
      "pageEnd": 557,
      "labelStart": "552",
      "labelEnd": "552",
      "words": 369,
      "summary": {
        "text": "Explains the bottom-up ingredients approach to unit test costing and the simplifying assumptions behind the estimates, such as half of laboratory work being for TB and a minimum daily throughput. A table breaks down BD Max costs by overhead, building, staff, equipment and test kits, at about US$ 18.50 per test in the main estimate.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "unit test",
          "heading": false
        },
        {
          "term": "unpublished find",
          "heading": false
        },
        {
          "term": "test costs",
          "heading": false
        },
        {
          "term": "staff costs",
          "heading": false
        },
        {
          "term": "find sohn",
          "heading": false
        },
        {
          "term": "data courtesy",
          "heading": false
        },
        {
          "term": "test kit",
          "heading": false
        },
        {
          "term": "parameter values",
          "heading": false
        }
      ],
      "extract": "552 of staff conducting various activities to capture discrete time estimates that can be attributed to each activity and used to construct personnel cost per activity. Those staff costs are then used in the bottom- up ingredients approach where component costs (staff, consumables, equipment, etc.) are added up to create a total unit cost. Several important simplifying assumptions were made that may limit",
      "extractCut": true,
      "blocks": [
        "library/10665-381036/blocks/prose-page-557"
      ]
    },
    {
      "id": "page-558",
      "number": null,
      "title": "Page 558",
      "level": 1,
      "pageStart": 558,
      "pageEnd": 558,
      "labelStart": "553",
      "labelEnd": "553",
      "words": 205,
      "summary": {
        "text": "Gives the cost breakdown for the Hain test, about US$ 15.40 per test in the main estimate, and notes that test kits were the largest cost except in a higher-cost scenario where equipment dominated. It adds that Hain's unit cost would probably fall further if run at full capacity.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "per-test cost",
          "heading": false
        },
        {
          "term": "hain",
          "heading": false
        },
        {
          "term": "samples run",
          "heading": false
        },
        {
          "term": "largest single",
          "heading": false
        },
        {
          "term": "equipment costs",
          "heading": false
        },
        {
          "term": "max",
          "heading": false
        }
      ],
      "extract": "553 Type of test: Hain Resource Type PE Low High Overhead $1.95 $0.64 $5.00 Building $0.33 $0.05 $1.69 Staff $1.66 $0.69 $3.11 Equipment $2.43 $1.62 $15.60 Test Kits $9.00 $6.60 $12.00 Total $15.37 $9.61 $37.40 Data courtesy of FIND/H Sohn, unpublished. PE: Primary estimate The cost of the test kit was the largest single cost contributor across both tests (~$4 less for Hain kit) however under conditions with higher",
      "extractCut": true,
      "blocks": [
        "library/10665-381036/blocks/prose-page-558",
        "library/10665-381036/blocks/figure-img-p558-1",
        "library/10665-381036/blocks/figure-img-p558-2"
      ]
    },
    {
      "id": "page-559",
      "number": null,
      "title": "Page 559",
      "level": 1,
      "pageStart": 559,
      "pageEnd": 559,
      "labelStart": "554",
      "labelEnd": "554",
      "words": 304,
      "summary": {
        "text": "Reports that per-test cost was very sensitive to annual testing volume below 5000 tests and stabilized above about 10 000 tests. It notes that further searches found little additional data and that evidence on variation across sites and countries is limited.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "per-test cost",
          "heading": false
        },
        {
          "term": "kit costs",
          "heading": false
        },
        {
          "term": "test costs",
          "heading": false
        },
        {
          "term": "testing volume",
          "heading": false
        },
        {
          "term": "unit test",
          "heading": false
        },
        {
          "term": "cost data",
          "heading": false
        },
        {
          "term": "tests year",
          "heading": false
        },
        {
          "term": "one-way sensitivity",
          "heading": false
        }
      ],
      "extract": "554 In one-way sensitivity analyses, annual testing volumes were varied from <5,000 to >25,000 tests/year (Figure 3). Per-test cost was highly sensitive to testing volume when fewer than 5000 tests were conducted per year, but unit test costs begin to stabilize between 5,000 and 10,000 tests /year, and above 10,000 test per year, unit cost estimate was robust. When equipment can be multiplexed and used at capacity,",
      "extractCut": true,
      "blocks": [
        "library/10665-381036/blocks/prose-page-559",
        "library/10665-381036/blocks/figure-img-p559-1"
      ]
    },
    {
      "id": "page-560",
      "number": null,
      "title": "Page 560",
      "level": 1,
      "pageStart": 560,
      "pageEnd": 560,
      "labelStart": "555",
      "labelEnd": "555",
      "words": 492,
      "summary": {
        "text": "States that no cost-effectiveness studies were found for the centralized end-to-end platforms and that extrapolating from other tests is not appropriate. It calls for economic modelling across settings and gives the same caution for the Xpert MTB/XDR test.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "colour modules",
          "heading": false
        },
        {
          "term": "mtb xdr",
          "heading": false
        },
        {
          "term": "xpert xdr",
          "heading": false
        },
        {
          "term": "xdr cartridge",
          "heading": false
        },
        {
          "term": "colour system",
          "heading": false
        },
        {
          "term": "xdr assay",
          "heading": false
        },
        {
          "term": "mtb rif",
          "heading": false
        },
        {
          "term": "e2e solutions",
          "heading": false
        }
      ],
      "extract": "555 No studies were identified that assessed cost-effectiveness analyses for any of the E2E solutions and extrapolation was not appropriate given differences in standard of care, different care cascades and associated costs, operational conditions, testing volume and diagnostic accuracy. Implementation considerations such as test placement, lab network, and ability of program to initiate treatment quickly will all",
      "extractCut": true,
      "blocks": [
        "library/10665-381036/blocks/prose-page-560"
      ]
    },
    {
      "id": "page-561",
      "number": null,
      "title": "Page 561",
      "level": 1,
      "pageStart": 561,
      "pageEnd": 561,
      "labelStart": "556",
      "labelEnd": "556",
      "words": 554,
      "summary": {
        "text": "Discusses factors likely to shape the cost-effectiveness of Xpert MTB/XDR, including its accuracy relative to the local standard of care, its place in the diagnostic algorithm and its results in under 90 minutes. It notes that total costs and budget impact will depend on testing volume, XDR prevalence and current practice.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "mtb xdr",
          "heading": false
        },
        {
          "term": "xpert mtb",
          "heading": false
        },
        {
          "term": "resource requirements",
          "heading": false
        },
        {
          "term": "diagnostic accuracy",
          "heading": false
        },
        {
          "term": "algorithm",
          "heading": false
        }
      ],
      "extract": "556 Several factors that are likely influential on cost-effectiveness of Xpert MTB/XDR include diagnostic accuracy which may lead to more or fewer individuals being diagnosed compared with the standard of care, and this will vary by region depending on what the standard of care is across different regions. Along with diagnostic accuracy associated with the test itself, the diagnostic algorithm and placement of the",
      "extractCut": true,
      "blocks": [
        "library/10665-381036/blocks/prose-page-561"
      ]
    },
    {
      "id": "page-562",
      "number": null,
      "title": "Page 562",
      "level": 1,
      "pageStart": 562,
      "pageEnd": 562,
      "labelStart": "557",
      "labelEnd": "557",
      "words": 483,
      "summary": {
        "text": "Notes that manufacturer prices cover cartridges and equipment but not staff, overhead and operating costs of Xpert MTB/XDR, which vary by setting. It then turns to line probe assays for pyrazinamide resistance, citing a multi-country study comparing per-sample costs of line probe assays with other drug susceptibility methods.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "pza lpa",
          "heading": false
        },
        {
          "term": "genoscholar pza-tb",
          "heading": false
        },
        {
          "term": "mtb xdr",
          "heading": false
        },
        {
          "term": "line probe",
          "heading": false
        },
        {
          "term": "costs associated",
          "heading": false
        },
        {
          "term": "probe assay",
          "heading": false
        },
        {
          "term": "operational costs",
          "heading": false
        },
        {
          "term": "xpert mtb",
          "heading": false
        }
      ],
      "extract": "557 Direct costs related to cartridge and machinery are provided from the manufacturer while several important items related to resource use including staff time, overhead and operational costs associated with implementing Xpert MTB/XDR have not been investigated. Differences in resource use between Xpert MTB/XDR and existing approaches will vary across settings using different phenotypic and genotypic DST.",
      "extractCut": true,
      "blocks": [
        "library/10665-381036/blocks/prose-page-562"
      ]
    },
    {
      "id": "page-563",
      "number": null,
      "title": "Page 563",
      "level": 1,
      "pageStart": 563,
      "pageEnd": 563,
      "labelStart": "558",
      "labelEnd": "558",
      "words": 512,
      "summary": {
        "text": "Reports that line probe assay costs varied widely between countries and were driven by test volume, batch size and staff wages, and cites a study from China where the assay cost more than conventional testing. It repeats that operating cost data are limited and vary across settings.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "genoscholar pza",
          "heading": false
        },
        {
          "term": "pza lpa",
          "heading": false
        },
        {
          "term": "test costs",
          "heading": false
        },
        {
          "term": "operational costs",
          "heading": false
        },
        {
          "term": "staff wages",
          "heading": false
        },
        {
          "term": "unit test",
          "heading": false
        },
        {
          "term": "test kit",
          "heading": false
        },
        {
          "term": "testing volume",
          "heading": false
        }
      ],
      "extract": "558 sample for LPA ranged across countries from $33.73 in Moldova to $100.50 in South Africa. LPAs became less expensive than PSQ if testing volume and batch size were maximized. Key drivers of cost included test volume, batch size and staff wages, with South African sites driving higher average test costs due to low volume and high staff wages. Li et al described the performance and costs of the Genotype MTBDRplus",
      "extractCut": true,
      "blocks": [
        "library/10665-381036/blocks/prose-page-563"
      ]
    },
    {
      "id": "page-564",
      "number": null,
      "title": "Page 564",
      "level": 1,
      "pageStart": 564,
      "pageEnd": 564,
      "labelStart": "559",
      "labelEnd": "559",
      "words": 397,
      "summary": {
        "text": "States that no cost-effectiveness studies were found for the Genoscholar PZA-TB II assay and lists the review's principal findings. These stress that operational costs are largely unknown, that batch size and volume drive unit costs, and that budget impact depends on who is tested, resistance prevalence and current practice.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "test costs",
          "heading": false
        },
        {
          "term": "test unit",
          "heading": false
        },
        {
          "term": "operational costs",
          "heading": false
        },
        {
          "term": "test volume",
          "heading": false
        },
        {
          "term": "batch size",
          "heading": false
        },
        {
          "term": "cost-effectiveness",
          "heading": false
        },
        {
          "term": "budget impact",
          "heading": false
        },
        {
          "term": "drivers",
          "heading": false
        }
      ],
      "extract": "559 No cost-effectiveness studies were identified using the Genoscholar PZA-TB II. Extrapolation of cost- effectiveness data from other line probe assays is not advised due to differences in diagnostic accuracy, resistance prevalence, and the testing and treatment cascade of care. PRINCIPAL FINDINGS • Operational costs likely a large proportion of unit test costs and are largely unknown aside from equipment. These",
      "extractCut": true,
      "blocks": [
        "library/10665-381036/blocks/prose-page-564"
      ]
    },
    {
      "id": "page-565",
      "number": null,
      "title": "Page 565",
      "level": 1,
      "pageStart": 565,
      "pageEnd": 565,
      "labelStart": "560",
      "labelEnd": "560",
      "words": 126,
      "summary": {
        "text": "Concludes that direct economic evidence on these new TB diagnostics is very limited and that cost-effectiveness and transmission modelling across settings is needed.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "cost-effectiveness",
          "heading": false
        },
        {
          "term": "direct evidence",
          "heading": false
        },
        {
          "term": "scenarios",
          "heading": false
        },
        {
          "term": "modelling",
          "heading": false
        },
        {
          "term": "extrapolation",
          "heading": false
        }
      ],
      "extract": "560 the additional cost of treating more MDR and XDR patients in scenarios where sensitivity is improved, and more patients are initiating anti-TB treatment. Cost-effectiveness studies providing direct evidence were not identified and extrapolation is not advised. Cost-effectiveness may be impacted by changes in diagnostic accuracy, differences in standard of care across sites, diagnostic algorithm, reductions in",
      "extractCut": true,
      "blocks": [
        "library/10665-381036/blocks/prose-page-565"
      ]
    },
    {
      "id": "page-566",
      "number": null,
      "title": "Page 566",
      "level": 1,
      "pageStart": 566,
      "pageEnd": 566,
      "labelStart": "561",
      "labelEnd": "561",
      "words": 532,
      "summary": {
        "text": "The start of the economic review's reference list, citing cost-effectiveness studies of TB diagnostic strategies, including in people with HIV.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "resistant tuberculosis",
          "heading": false
        },
        {
          "term": "infectious diseases",
          "heading": false
        },
        {
          "term": "bmc infectious",
          "heading": false
        },
        {
          "term": "plos medicine",
          "heading": false
        },
        {
          "term": "antiretroviral therapy",
          "heading": false
        },
        {
          "term": "cost analysis",
          "heading": false
        },
        {
          "term": "prisma statement",
          "heading": false
        },
        {
          "term": "drug resistant",
          "heading": false
        }
      ],
      "extract": "561 REFERENCES Abimbola, T. O., Marston, B. J., Date, A. A., Blandford, J. M., Sangrujee, N., & Wiktor, S. Z. (2012). Cost- effectiveness of tuberculosis diagnostic strategies to reduce early mortality among persons with advanced HIV infection initiating antiretroviral therapy. Journal of Acquired Immune Deficiency Syndromes, 60(1), 1–7. https://doi.org/10.1097/QAI.0b013e318246538f Adelman, M. W., McFarland, D. A.,",
      "extractCut": true,
      "blocks": [
        "library/10665-381036/blocks/prose-page-566"
      ]
    },
    {
      "id": "page-567",
      "number": null,
      "title": "Page 567",
      "level": 1,
      "pageStart": 567,
      "pageEnd": 567,
      "labelStart": "562",
      "labelEnd": "562",
      "words": 92,
      "summary": {
        "text": "The end of the economic review's reference list, citing a pyrazinamide susceptibility assay study and a cost-effectiveness analysis of TB screening in people newly diagnosed with HIV.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "rice",
          "heading": false
        },
        {
          "term": "khundi",
          "heading": false
        },
        {
          "term": "whitfield",
          "heading": false
        }
      ],
      "extract": "562 https://doi.org/10.1186/1471-2334-13-352 Whitfield, M. G., Marras, S. A. E., Warren, R. M., Van Rie, A., Rice, J., Wangh, L. J., & Kreiswirth, B. N. (2020). Rapid Pyrazinamide Drug Susceptibility Testing using a Closed-Tube PCR Assay of the Entire pncA gene. Scientific Reports, 10(1). https://doi.org/10.1038/s41598-020-61286-7 Zwerling, A. A., Sahu, M., Ngwira, L. G., Khundi, M., Harawa, T., Corbett, E. L.,",
      "extractCut": true,
      "blocks": [
        "library/10665-381036/blocks/prose-page-567"
      ]
    },
    {
      "id": "page-568",
      "number": null,
      "title": "Page 568",
      "level": 1,
      "pageStart": 568,
      "pageEnd": 568,
      "labelStart": "563",
      "labelEnd": "563",
      "words": 10,
      "summary": {
        "text": "A supplement heading referring to a Cepheid flyer with costs for a 10-colour multiplexing upgrade.",
        "status": "draft"
      },
      "keywords": [],
      "extract": "563 SUPPLEMENT Cepheid 10-Colour Multiplexing technology Upgrade Flyer with costs",
      "extractCut": false,
      "blocks": [
        "library/10665-381036/blocks/prose-page-568",
        "library/10665-381036/blocks/figure-img-p568-1"
      ]
    },
    {
      "id": "page-569",
      "number": null,
      "title": "Page 569",
      "level": 1,
      "pageStart": 569,
      "pageEnd": 569,
      "labelStart": "564",
      "labelEnd": "564",
      "words": 1,
      "summary": {
        "text": "A near-blank page showing only a page number.",
        "status": "draft"
      },
      "keywords": [],
      "extract": "564",
      "extractCut": false,
      "blocks": [
        "library/10665-381036/blocks/prose-page-569",
        "library/10665-381036/blocks/figure-img-p569-1"
      ]
    },
    {
      "id": "page-570",
      "number": null,
      "title": "Page 570",
      "level": 1,
      "pageStart": 570,
      "pageEnd": 570,
      "labelStart": "565",
      "labelEnd": "565",
      "words": 175,
      "summary": {
        "text": "The title page of Web Annex B.13, a qualitative evidence synthesis of user perspectives on nucleic acid amplification tests for TB and drug resistance, listing the authors and their affiliations and noting it was prepared for a December 2020 WHO guideline meeting.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "nora engel",
          "heading": false
        },
        {
          "term": "cape town",
          "heading": false
        },
        {
          "term": "south africa",
          "heading": false
        },
        {
          "term": "africa centre",
          "heading": false
        },
        {
          "term": "medical research",
          "heading": false
        },
        {
          "term": "maastricht",
          "heading": false
        },
        {
          "term": "liverpool",
          "heading": false
        }
      ],
      "extract": "565 Web Annex B.13. User perspectives on NAATs to detect TB and resistance to anti-TB agents: results from qualitative evidence synthesis (systematic review) Nora Engel1, Eleanor A Ochodo2,3, Perpetua Wanjiku Karanja4, Bey-Marrié Schmidt5, Ricky Janssen1, Karen R Steingart6, Sandy Oliver,7,8 Affiliations: 1Department of Health, Ethics and Society, Maastricht University, Maastricht, Netherlands (Kingdom of the)",
      "extractCut": true,
      "blocks": [
        "library/10665-381036/blocks/prose-page-570"
      ]
    },
    {
      "id": "page-571",
      "number": null,
      "title": "Page 571",
      "level": 1,
      "pageStart": 571,
      "pageEnd": 571,
      "labelStart": "566",
      "labelEnd": "566",
      "words": 659,
      "summary": {
        "text": "Sets out the background to the qualitative review, noting TB's annual toll of 10 million cases and 1.5 million deaths, the threat of drug-resistant TB and the need for early diagnosis under the End TB Strategy. It explains that user perspectives on diagnostic technologies have rarely been studied and never systematically reviewed for a group of tests.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "automated naats",
          "heading": false
        },
        {
          "term": "drug-resistant forms",
          "heading": false
        },
        {
          "term": "million cases",
          "heading": false
        },
        {
          "term": "drug susceptibility",
          "heading": false
        },
        {
          "term": "susceptibility testing",
          "heading": false
        },
        {
          "term": "world health",
          "heading": false
        },
        {
          "term": "health organization",
          "heading": false
        },
        {
          "term": "bedaquiline",
          "heading": false
        }
      ],
      "extract": "566 Background Description of the topic Tuberculosis (TB) causes 10 million cases and 1.5 million deaths annually and it is estimated that 3 million cases go undiagnosed each year (World Health Organization, 2020a). Drug-resistant TB (DR-TB) is a major threat to global TB control. Ending the global TB epidemic will be achievable over the next 20 years only if there is intensive action by all countries which have",
      "extractCut": true,
      "blocks": [
        "library/10665-381036/blocks/prose-page-571"
      ]
    },
    {
      "id": "page-572",
      "number": null,
      "title": "Page 572",
      "level": 1,
      "pageStart": 572,
      "pageEnd": 572,
      "labelStart": "567",
      "labelEnd": "567",
      "words": 556,
      "summary": {
        "text": "Argues that accuracy and cost reviews do not reveal users' experiences, which are needed to understand uptake, effectiveness and equity. It explains how automated low-complexity tests might work and lists the classes of tests under review for the WHO guideline meeting.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "automated naats",
          "heading": false
        },
        {
          "term": "user perspectives",
          "heading": false
        },
        {
          "term": "nations sustainable",
          "heading": false
        },
        {
          "term": "drug resistance",
          "heading": false
        },
        {
          "term": "united nations",
          "heading": false
        },
        {
          "term": "sustainable development",
          "heading": false
        },
        {
          "term": "tuberculosis",
          "heading": false
        },
        {
          "term": "guideline development",
          "heading": false
        }
      ],
      "extract": "567 reviewed for a group of technologies. Current WHO guidance on automated NAATs of low complexity for TB diagnosis is based on systematic reviews of diagnostic accuracy and cost-effectiveness. Accuracy studies do not reveal what users think of or experience with the diagnostic in question. Yet to understand why diagnostics are utilized, how effective they are and their impact on health equity, it is essential to",
      "extractCut": true,
      "blocks": [
        "library/10665-381036/blocks/prose-page-572"
      ]
    },
    {
      "id": "page-573",
      "number": null,
      "title": "Page 573",
      "level": 1,
      "pageStart": 573,
      "pageEnd": 573,
      "labelStart": "568",
      "labelEnd": "568",
      "words": 392,
      "summary": {
        "text": "Completes the list of test classes reviewed and explains what a qualitative evidence synthesis adds for decision makers. It states the review's objective and the types of studies eligible, such as operational research and feasibility and acceptability assessments.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "automated naats",
          "heading": false
        },
        {
          "term": "qualitative methods",
          "heading": false
        },
        {
          "term": "grounded theory",
          "heading": false
        },
        {
          "term": "tuberculosis drug",
          "heading": false
        },
        {
          "term": "open-ended survey",
          "heading": false
        },
        {
          "term": "drug resistance",
          "heading": false
        },
        {
          "term": "methodological limitations",
          "heading": false
        },
        {
          "term": "complexity",
          "heading": false
        }
      ],
      "extract": "568 • Index test 2: Moderate-complexity automated NAATs for detection of TB and resistance to rifampicin and isoniazid; • Index test 3: High-complexity hybridization-based NAATs for detection of resistance to pyrazinamide. A qualitative evidence synthesis can add value by providing decision makers with additional evidence to improve understanding of intervention complexity, contextual variations, implementation, and",
      "extractCut": true,
      "blocks": [
        "library/10665-381036/blocks/prose-page-573"
      ]
    },
    {
      "id": "page-574",
      "number": null,
      "title": "Page 574",
      "level": 1,
      "pageStart": 574,
      "pageEnd": 574,
      "labelStart": "569",
      "labelEnd": "569",
      "words": 465,
      "summary": {
        "text": "Defines the users covered by the review, from patients and caregivers to laboratory staff, providers and programme officers, as well as potential users who cannot yet access or use the tests. It describes the settings included, the search and the screening of studies by two authors.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "grey literature",
          "heading": false
        },
        {
          "term": "automated naats",
          "heading": false
        },
        {
          "term": "eligible studies",
          "heading": false
        },
        {
          "term": "review authors",
          "heading": false
        },
        {
          "term": "potential users",
          "heading": false
        },
        {
          "term": "ebscohost",
          "heading": false
        },
        {
          "term": "full text",
          "heading": false
        },
        {
          "term": "information specialist",
          "heading": false
        }
      ],
      "extract": "569 This review focuses on users and potential users of automated NAATs of low complexity. Users include patients and their caregivers, laboratory technicians, healthcare providers, implementers and programme officers who are involved in diagnosing and treating tuberculosis and drug resistant forms of TB as well as ordering, operating, maintaining diagnostics and acting on diagnostic test results. Potential users",
      "extractCut": true,
      "blocks": [
        "library/10665-381036/blocks/prose-page-574"
      ]
    },
    {
      "id": "page-575",
      "number": null,
      "title": "Page 575",
      "level": 1,
      "pageStart": 575,
      "pageEnd": 575,
      "labelStart": "570",
      "labelEnd": "570",
      "words": 527,
      "summary": {
        "text": "Describes how excluded studies were recorded, that studies in any language were sought, and how eligible studies were sampled for richness and relevance. It lists the factors the authors expected to shape user experiences, such as workflow, resources, confidence in results and equity.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "rich thick",
          "heading": false
        },
        {
          "term": "thick studies",
          "heading": false
        },
        {
          "term": "thick data",
          "heading": false
        },
        {
          "term": "eligible studies",
          "heading": false
        },
        {
          "term": "six studies",
          "heading": false
        },
        {
          "term": "study findings",
          "heading": false
        },
        {
          "term": "thickness",
          "heading": false
        },
        {
          "term": "richness",
          "heading": false
        }
      ],
      "extract": "570 assessment and their reasons for exclusion in the Characteristics of excluded studies table (appendix 5). We illustrated the study selection process in a PRISMA diagram (Moher, Liberati, Tetzlaff, & Altman, 2009). Language translation We searched for primary studies irrespective of their language of publication. Sampling of studies This qualitative evidence synthesis aims to describe the experiences of those",
      "extractCut": true,
      "blocks": [
        "library/10665-381036/blocks/prose-page-575"
      ]
    },
    {
      "id": "page-576",
      "number": null,
      "title": "Page 576",
      "level": 1,
      "pageStart": 576,
      "pageEnd": 576,
      "labelStart": "571",
      "labelEnd": "571",
      "words": 560,
      "summary": {
        "text": "Describes data extraction by two authors, assessment of methodological limitations with the EPPI-Centre tool, and safeguards so that authors did not assess their own studies. It explains the thematic approach used to draw out values, feasibility and acceptability considerations.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "methodological limitations",
          "heading": false
        },
        {
          "term": "assessed methodological",
          "heading": false
        },
        {
          "term": "data presented",
          "heading": false
        },
        {
          "term": "data collection",
          "heading": false
        },
        {
          "term": "data analysis",
          "heading": false
        },
        {
          "term": "qualitative research",
          "heading": false
        },
        {
          "term": "review authors",
          "heading": false
        },
        {
          "term": "rigor",
          "heading": false
        }
      ],
      "extract": "571 Two review authors individually extracted data from the same study and resolved any conflicts in a consensus meeting. Authors of primary studies did not extract data from their own study or studies. Instead, another author extracted these data. Assessing the methodological limitations of included studies Two review authors [any pair from NE, BS, PW, EO] independently assessed methodological limitations for each",
      "extractCut": true,
      "blocks": [
        "library/10665-381036/blocks/prose-page-576"
      ]
    },
    {
      "id": "page-577",
      "number": null,
      "title": "Page 577",
      "level": 1,
      "pageStart": 577,
      "pageEnd": 577,
      "labelStart": "572",
      "labelEnd": "572",
      "words": 622,
      "summary": {
        "text": "Describes how the analysis proceeded, coding six rich studies first and then adding data from 15 studies of medium richness using NVivo. It explains how review findings were generated and begins a reflexivity statement on the authors' prior views about the tests.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "review finding",
          "heading": false
        },
        {
          "term": "rich studies",
          "heading": false
        },
        {
          "term": "qualitative findings",
          "heading": false
        },
        {
          "term": "review authors",
          "heading": false
        },
        {
          "term": "supporting review",
          "heading": false
        },
        {
          "term": "memos",
          "heading": false
        },
        {
          "term": "key findings",
          "heading": false
        },
        {
          "term": "coding scheme",
          "heading": false
        }
      ],
      "extract": "572 Based on the key findings extracted from the six rich studies, NE developed a coding scheme which was discussed with the other review authors. Using the coding scheme, NE coded the key findings of the 6 studies with rich data using NVIVO (version 12) and wrote memos on selected themes. In a second round of analysis, data from the 15 studies of medium richness was extracted by NE, EO, PW and BS; and NE coded",
      "extractCut": true,
      "blocks": [
        "library/10665-381036/blocks/prose-page-577"
      ]
    },
    {
      "id": "page-578",
      "number": null,
      "title": "Page 578",
      "level": 1,
      "pageStart": 578,
      "pageEnd": 578,
      "labelStart": "573",
      "labelEnd": "573",
      "words": 666,
      "summary": {
        "text": "Continues the reflexivity statement, describing the range of prior views among the authors and the techniques used to limit their influence on the analysis, followed by short biographies of the review team.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "she",
          "heading": false
        },
        {
          "term": "automated naats",
          "heading": false
        },
        {
          "term": "cochrane infectious",
          "heading": false
        },
        {
          "term": "review team",
          "heading": false
        },
        {
          "term": "systematic reviews",
          "heading": false
        },
        {
          "term": "review findings",
          "heading": false
        },
        {
          "term": "infectious disease",
          "heading": false
        },
        {
          "term": "health physician",
          "heading": false
        }
      ],
      "extract": "573 exist to their implementation, while others might be more hesitant about the presumed automatic benefit of introducing advanced technologies but then not investing in strengthening weak health systems, while again some might wonder about the design process of automated NAATs of low complexity and to what extent it took into account perspectives of various users. All would have been in contact with different",
      "extractCut": true,
      "blocks": [
        "library/10665-381036/blocks/prose-page-578"
      ]
    },
    {
      "id": "page-579",
      "number": null,
      "title": "Page 579",
      "level": 1,
      "pageStart": 579,
      "pageEnd": 579,
      "labelStart": "574",
      "labelEnd": "574",
      "words": 706,
      "summary": {
        "text": "Opens the results of a qualitative evidence synthesis, prepared for the WHO Global TB Programme, on user perspectives of low-complexity automated nucleic acid amplification tests (NAATs) for TB. It reports that 27 studies met the inclusion criteria, of which 21 published between 2012 and 2020 were sampled, all from high-TB-burden countries such as South Africa, India and Viet Nam. It describes the studies as mostly qualitative and descriptive, with few using a theoretical framework, and focused on views of providers, managers and patients.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "sampled studies",
          "heading": false
        },
        {
          "term": "mcdowell pai",
          "heading": false
        },
        {
          "term": "studies focused",
          "heading": false
        },
        {
          "term": "studies reported",
          "heading": false
        },
        {
          "term": "household contacts",
          "heading": false
        },
        {
          "term": "private facilities",
          "heading": false
        },
        {
          "term": "low-complexity automated",
          "heading": false
        },
        {
          "term": "royce",
          "heading": false
        }
      ],
      "extract": "574 Results Results of the search We found 27 studies that met our inclusion criteria. We sampled 21 of these studies for inclusion in the analysis (see Figure 1: Flow chart Appendix 4). All of the sampled studies were published between 2012 and 2020. Six studies remain to be reviewed which were not sampled as we assessed them as particularly thin (see section sampling). They do not address participants not already",
      "extractCut": true,
      "blocks": [
        "library/10665-381036/blocks/prose-page-579"
      ]
    },
    {
      "id": "page-580",
      "number": null,
      "title": "Page 580",
      "level": 1,
      "pageStart": 580,
      "pageEnd": 580,
      "labelStart": "575",
      "labelEnd": "575",
      "words": 628,
      "summary": {
        "text": "Describes the two broad groups of included studies, those exploring perspectives on NAAT use and implementation challenges and those examining the process of using diagnostics, and judges their methodological quality as generally good. It then presents the first finding, that patients value an accurate diagnosis and closure, avoiding delays and low costs. A quote from a parent illustrates the distress caused by late detection of a child's TB.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "feel guilty",
          "heading": false
        },
        {
          "term": "patients feel",
          "heading": false
        },
        {
          "term": "diagnostic delays",
          "heading": false
        },
        {
          "term": "methodological limitations",
          "heading": false
        },
        {
          "term": "diagnostic closure",
          "heading": false
        },
        {
          "term": "infecting others",
          "heading": false
        },
        {
          "term": "moderate confidence",
          "heading": false
        },
        {
          "term": "towards methodological",
          "heading": false
        }
      ],
      "extract": "and low-complexity automated NAATs use and challenges to their implementation (Cattamanchi, et al., 2020; Creswell, et al., 2014; Jaroslawski & Pai, 2012; Joshi, et al., 2018; McDowell, et al., 2018; Mwaura, et al., 2020; Naidoo, et al., 2015; Newtonraj, et al., 2019; Phyo, et al., 2019; R. de Camargo, R. Guedes, Caetano, Menezes, & Trajman, 2015; Rendell, et al., 2017; Royce, et al., 2014; Shewade, et al., 2018). A",
      "extractCut": true,
      "blocks": [
        "library/10665-381036/blocks/prose-page-580"
      ]
    },
    {
      "id": "page-581",
      "number": null,
      "title": "Page 581",
      "level": 1,
      "pageStart": 581,
      "pageEnd": 581,
      "labelStart": "576",
      "labelEnd": "576",
      "words": 719,
      "summary": {
        "text": "Continues the patient perspective with examples from South Africa, where patients preferred public clinics to private ones, and Brazil, where delays and costs were not a burden. It reports that health professionals value the speed, accuracy, range of sample types and drug-resistance detection of automated NAATs compared with sputum microscopy. It adds that clinicians value the confidence that NAAT results give them in starting treatment and reassuring patients.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "low-complexity automated",
          "heading": false
        },
        {
          "term": "mcdowell pai",
          "heading": false
        },
        {
          "term": "automated naats",
          "heading": false
        },
        {
          "term": "detect drug",
          "heading": false
        },
        {
          "term": "drug resistance",
          "heading": false
        },
        {
          "term": "camargo",
          "heading": false
        },
        {
          "term": "healthcare professionals",
          "heading": false
        },
        {
          "term": "hospital stays",
          "heading": false
        }
      ],
      "extract": "576 patients would recommend family and friends to avoid private sector services and instead immediately go to the public primary care facilities despite perceptions of long waiting times, lack of privacy and poor staff attitudes associated with public facilities (Naidoo 2015). In a study from Brazil, patients did not struggle with delays or cost, because they either lived close by testing facilities and those who",
      "extractCut": true,
      "blocks": [
        "library/10665-381036/blocks/prose-page-581"
      ]
    },
    {
      "id": "page-582",
      "number": null,
      "title": "Page 582",
      "level": 1,
      "pageStart": 582,
      "pageEnd": 582,
      "labelStart": "577",
      "labelEnd": "577",
      "words": 630,
      "summary": {
        "text": "Explains that confidence in NAAT results helps clinicians justify decisions and has increased private paediatricians' trust in public laboratories in India. It reports that laboratory technicians value easier, safer and more ergonomic work than with microscopy. It then turns to patient barriers to testing, such as stigma, fear of side effects, inability to produce sputum, distance, cost and inconvenient clinic hours.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "automated naat",
          "heading": false
        },
        {
          "term": "low-complexity automated",
          "heading": false
        },
        {
          "term": "interrupted treatment",
          "heading": false
        },
        {
          "term": "symbolic meaning",
          "heading": false
        },
        {
          "term": "sputum microscopy",
          "heading": false
        },
        {
          "term": "prevent patients",
          "heading": false
        },
        {
          "term": "healthcare workers",
          "heading": false
        },
        {
          "term": "recognize symptoms",
          "heading": false
        }
      ],
      "extract": "577 to start treatment, reassure and motivate family and patients (to begin and adhere to treatment) and justify actions towards other doctors who do not question low-complexity automated NAAT result. Experience with successful treatment following a positive NAAT result increases that confidence among clinicians and pediatricians (McDowell, et al., 2018; Oliwa, et al., 2020). Availability of low-complexity automated",
      "extractCut": true,
      "blocks": [
        "library/10665-381036/blocks/prose-page-582"
      ]
    },
    {
      "id": "page-583",
      "number": null,
      "title": "Page 583",
      "level": 1,
      "pageStart": 583,
      "pageEnd": 583,
      "labelStart": "578",
      "labelEnd": "578",
      "words": 761,
      "summary": {
        "text": "Reports that health workers may be reluctant to test for TB or drug-resistant TB because of stigma, fear of infection, fear of supervisors and concerns about side effects in children, illustrated by a Kenyan paediatrician linking TB stigma to HIV. It describes how delays accumulate along the testing pathway through non-adherence to algorithms, late testing and empirical treatment. It also cites slow sample transport and result reporting, inconsistent recording and weak referral follow-up.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "patient-related delays",
          "heading": false
        },
        {
          "term": "recalling patients",
          "heading": false
        },
        {
          "term": "diagnostic delays",
          "heading": false
        },
        {
          "term": "turn-around time",
          "heading": false
        },
        {
          "term": "mcdowell pai",
          "heading": false
        },
        {
          "term": "testing algorithms",
          "heading": false
        },
        {
          "term": "automated naats",
          "heading": false
        },
        {
          "term": "empirical treatment",
          "heading": false
        }
      ],
      "extract": "578 Finding 8: Health workers can be reluctant to test for TB or MDR-TB because of TB associated stigma and consequences for their patients, fears of acquiring TB, fear from supervisors when reclassifying patients already on TB treatment who turn out to be misclassified, fear of side effects of drugs in children, and community awareness of disease manifestations in children. (high confidence:(Oliwa, et al., 2020;",
      "extractCut": true,
      "blocks": [
        "library/10665-381036/blocks/prose-page-583"
      ]
    },
    {
      "id": "page-584",
      "number": null,
      "title": "Page 584",
      "level": 1,
      "pageStart": 584,
      "pageEnd": 584,
      "labelStart": "579",
      "labelEnd": "579",
      "words": 698,
      "summary": {
        "text": "Gives examples of treatment delays, such as weekly consensus meetings for drug-resistant TB in Moldova and longer delays in South Africa for patients first treated on clinical grounds. It notes that private practitioners in India try several antibiotics before considering TB and that providers' coping strategies can lengthen turnaround. It also describes resource problems such as cartridge stock-outs that delayed diagnoses and discouraged future test orders.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "mcdowell pai",
          "heading": false
        },
        {
          "term": "sample transport",
          "heading": false
        },
        {
          "term": "automated naat",
          "heading": false
        },
        {
          "term": "low-complexity automated",
          "heading": false
        },
        {
          "term": "unreliable logistics",
          "heading": false
        },
        {
          "term": "rendell",
          "heading": false
        },
        {
          "term": "hoang",
          "heading": false
        },
        {
          "term": "sample collection",
          "heading": false
        }
      ],
      "extract": "579 initiating MDR-TB treatment because of the procedural requirement to determine the MDR-TB treatment plan at a weekly consensus meeting (Rendell, et al., 2017). In South Africa, “delays overall were longer for patients in whom initial tests were negative with 1st-line TB treatment started on clinical or chest x-ray findings.”(p9) (Naidoo, et al., 2015). Strategies by providers to deal with associated delays",
      "extractCut": true,
      "blocks": [
        "library/10665-381036/blocks/prose-page-584"
      ]
    },
    {
      "id": "page-585",
      "number": null,
      "title": "Page 585",
      "level": 1,
      "pageStart": 585,
      "pageEnd": 585,
      "labelStart": "580",
      "labelEnd": "580",
      "words": 718,
      "summary": {
        "text": "Describes infrastructure problems affecting NAAT testing, including power cuts, heat, dust, lack of space and internet, which contribute to test failures and indeterminate results. It covers difficulties in hub-and-spoke sample transport, such as a lack of containers and couriers. It also lists organizational weaknesses like non-standardized systems, poor filing, unclear follow-up, weak public–private links and limited laboratory staff hours.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "low-complexity automated",
          "heading": false
        },
        {
          "term": "automated naat",
          "heading": false
        },
        {
          "term": "camargo",
          "heading": false
        },
        {
          "term": "lab technician",
          "heading": false
        },
        {
          "term": "laboratory technicians",
          "heading": false
        },
        {
          "term": "stime",
          "heading": false
        },
        {
          "term": "rendell",
          "heading": false
        },
        {
          "term": "sputum sample",
          "heading": false
        }
      ],
      "extract": "580 Poor laboratory infrastructure, including frequent power cuts, lack of air conditioners and/or dusty environment and lack of adequate rooms or proper furniture, can challenge proper testing (Creswell, et al., 2014; Joshi, et al., 2018; Nalugwa, et al., 2020) and explain high test failure rates and indeterminate results (Joshi, et al., 2018). Yet, differences between types of failed tests are unclear and",
      "extractCut": true,
      "blocks": [
        "library/10665-381036/blocks/prose-page-585"
      ]
    },
    {
      "id": "page-586",
      "number": null,
      "title": "Page 586",
      "level": 1,
      "pageStart": 586,
      "pageEnd": 586,
      "labelStart": "581",
      "labelEnd": "581",
      "words": 711,
      "summary": {
        "text": "Notes that NAAT use changes patient flows, requiring only one sputum sample but sometimes confusing movement between departments. It reports a finding that excessive trust in NAAT accuracy can lead clinicians to accept negative results without using clinical judgement and patients to trust machine results. It also covers training gaps, staff turnover and weak change management, with South African testing algorithms, forms and registers updated only after implementation.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "low-complexity automated",
          "heading": false
        },
        {
          "term": "automated naat",
          "heading": false
        },
        {
          "term": "naat accuracy",
          "heading": false
        },
        {
          "term": "newtonraj",
          "heading": false
        },
        {
          "term": "colvin",
          "heading": false
        },
        {
          "term": "clinical impressions",
          "heading": false
        },
        {
          "term": "joshi",
          "heading": false
        },
        {
          "term": "roll out",
          "heading": false
        }
      ],
      "extract": "581 Low-complexity automated NAAT use also has implications for patient flows who only have to submit one sputum sample (Phyo, et al., 2019) but might find it difficult to find their way through different sites and departments (Stime, et al., 2018; Vijayageetha, et al., 2019) or where they need to (Oliwa, et al., 2020; Stime, et al., 2018). Finding 14: Too much confidence in low-complexity automated NAAT's accuracy",
      "extractCut": true,
      "blocks": [
        "library/10665-381036/blocks/prose-page-586"
      ]
    },
    {
      "id": "page-587",
      "number": null,
      "title": "Page 587",
      "level": 1,
      "pageStart": 587,
      "pageEnd": 587,
      "labelStart": "582",
      "labelEnd": "582",
      "words": 627,
      "summary": {
        "text": "Stresses involving relevant stakeholders and national consensus processes when introducing new diagnostics, citing South Africa where the fast-paced, externally driven Xpert roll-out sidelined national and provincial TB actors. It describes how this lack of inclusion affected implementation. It then states the high-confidence finding that delays, underuse of NAATs and lack of lower-level facilities hamper access, especially for vulnerable groups.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "automated naats",
          "heading": false
        },
        {
          "term": "voiced concerns",
          "heading": false
        },
        {
          "term": "low-complexity automated",
          "heading": false
        },
        {
          "term": "colvin",
          "heading": false
        },
        {
          "term": "camargo",
          "heading": false
        },
        {
          "term": "lpa",
          "heading": false
        },
        {
          "term": "provincial",
          "heading": false
        },
        {
          "term": "pace",
          "heading": false
        }
      ],
      "extract": "582 When introducing new diagnostics, it is also important to include relevant stakeholders in decision-making processes and in planning regarding implementation and allow a national policy consensus process. This could involve national and provincial programme managers and health officers, clinicians, and laboratory staff. In South Africa, Xpert had high visibility but its introduction was not inclusive, focused",
      "extractCut": true,
      "blocks": [
        "library/10665-381036/blocks/prose-page-587"
      ]
    },
    {
      "id": "page-588",
      "number": null,
      "title": "Page 588",
      "level": 1,
      "pageStart": 588,
      "pageEnd": 588,
      "labelStart": "583",
      "labelEnd": "583",
      "words": 652,
      "summary": {
        "text": "Explains that diagnostic delays and underuse of NAATs hit hardest for children, people with drug-resistant TB and those unable to pay fees or transport costs, with private providers sometimes treating rather than testing. It summarizes how health system challenges compound delays and affect access and equity. It warns that these challenges risk undoing the benefits users see in NAATs and may reduce their acceptability.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "low-complexity automated",
          "heading": false
        },
        {
          "term": "automated naat",
          "heading": false
        },
        {
          "term": "mcdowell pai",
          "heading": false
        },
        {
          "term": "diagnostic delays",
          "heading": false
        },
        {
          "term": "risk undoing",
          "heading": false
        },
        {
          "term": "review finding",
          "heading": false
        },
        {
          "term": "underutilization",
          "heading": false
        },
        {
          "term": "diagnostic process",
          "heading": false
        }
      ],
      "extract": "583 Several studies showed how lengthy diagnostic delays, underutilization of low-complexity automated NAAT and lack of TB diagnostic facilities at lower levels where many presumptive patients present, hamper access to prompt and accurate treatment for those that are eligible for testing (Nalugwa, et al., 2020) with vulnerable groups and patients with difficult disease patterns (including children (Joshi, et al.,",
      "extractCut": true,
      "blocks": [
        "library/10665-381036/blocks/prose-page-588"
      ]
    },
    {
      "id": "page-589",
      "number": null,
      "title": "Page 589",
      "level": 1,
      "pageStart": 589,
      "pageEnd": 589,
      "labelStart": "584",
      "labelEnd": "584",
      "words": 18,
      "summary": {
        "text": "A near-blank page carrying a distribution notice for the WHO Global TB Programme and a figure label.",
        "status": "draft"
      },
      "keywords": [],
      "extract": "This report has been prepared for the WHO Global TB Programme. Do not distribute further. Figure 1 266",
      "extractCut": false,
      "blocks": [
        "library/10665-381036/blocks/prose-page-589",
        "library/10665-381036/blocks/figure-img-p589-1"
      ]
    },
    {
      "id": "page-590",
      "number": null,
      "title": "Page 590",
      "level": 1,
      "pageStart": 590,
      "pageEnd": 590,
      "labelStart": "585",
      "labelEnd": "585",
      "words": 638,
      "summary": {
        "text": "Summarizes the review's discussion, grouping its 18 findings into what users value, the challenges to achieving those values and the implications for access and equity. It recaps that patients value accurate, timely, affordable and accessible diagnosis, health professionals value accuracy, speed and drug-resistance information, and laboratory staff value improved working conditions. It calls for better implementation processes, including early inclusive stakeholder engagement, health system strengthening, better ground-level data and management of conflicts of interest.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "low-complexity automated",
          "heading": false
        },
        {
          "term": "automated naat",
          "heading": false
        },
        {
          "term": "complexity automated",
          "heading": false
        },
        {
          "term": "diagnostic delays",
          "heading": false
        },
        {
          "term": "healthcare professionals",
          "heading": false
        },
        {
          "term": "laboratory infrastructure",
          "heading": false
        },
        {
          "term": "keeping cost",
          "heading": false
        },
        {
          "term": "author team",
          "heading": false
        }
      ],
      "extract": "Discussion and conclusion This review synthesized qualitative research on user perspectives and experiences with automated NAATs of low complexity for detection of tuberculosis and tuberculosis drug resistance. We organized the 18 individual review findings into the following three overarching categories: 1) critical aspects users value: Patients value reaching diagnostic closure with an accurate diagnosis, avoiding",
      "extractCut": true,
      "blocks": [
        "library/10665-381036/blocks/prose-page-590"
      ]
    },
    {
      "id": "page-591",
      "number": null,
      "title": "Page 591",
      "level": 1,
      "pageStart": 591,
      "pageEnd": 591,
      "labelStart": "586",
      "labelEnd": "586",
      "words": 524,
      "summary": {
        "text": "Warns that ignoring implementation processes can limit uptake and impact of diagnostics, then proposes evidence for GRADE evidence-to-decision tables. It summarizes patient values and preferences and equity concerns, followed by the values of clinicians and laboratory staff, each with a confidence rating.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "low-complexity automated",
          "heading": false
        },
        {
          "term": "automated naat",
          "heading": false
        },
        {
          "term": "index test",
          "heading": false
        },
        {
          "term": "sputum microscopy",
          "heading": false
        },
        {
          "term": "hamper access",
          "heading": false
        },
        {
          "term": "mdr-tb because",
          "heading": false
        },
        {
          "term": "side effects",
          "heading": false
        },
        {
          "term": "concerns related",
          "heading": false
        }
      ],
      "extract": "of resources. Implementation processes that do not pay attention to these aspects can hamper feasibility, as well as further uptake and impact of diagnostics. Proposed evidence for ‘Evidence to Decision’ tables in GRADE Patient values and preferences: Patients in high-burden settings value reaching diagnostic closure (finally knowing what is wrong with me) comprising of a diagnosis that is accurate, a diagnosis that",
      "extractCut": true,
      "blocks": [
        "library/10665-381036/blocks/prose-page-591"
      ]
    },
    {
      "id": "page-592",
      "number": null,
      "title": "Page 592",
      "level": 1,
      "pageStart": 592,
      "pageEnd": 592,
      "labelStart": "587",
      "labelEnd": "587",
      "words": 548,
      "summary": {
        "text": "Continues the proposed evidence-to-decision content, stating that feasibility problems and accumulated delays risk undoing NAAT benefits and leading to underuse, mainly due to health system factors. It reports feedback from guideline group members, who valued the varied perspectives and recommended better diagnostics training for nurses and clinicians.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "low-complexity automated",
          "heading": false
        },
        {
          "term": "automated naat",
          "heading": false
        },
        {
          "term": "moderate confidence",
          "heading": false
        },
        {
          "term": "laboratory staff",
          "heading": false
        },
        {
          "term": "index test",
          "heading": false
        },
        {
          "term": "underutilization",
          "heading": false
        },
        {
          "term": "sample transport",
          "heading": false
        },
        {
          "term": "qualitative evidence",
          "heading": false
        }
      ],
      "extract": "satisfaction and has a symbolic meaning of progress within the TB world. (Low confidence, applicable to index test 1) The identified feasibility challenges with low-complexity automated NAAT utilization and accumulated delays at every step risk undoing the added value/benefits as identified by the users (avoiding delays, keeping cost lost, accurate results, drug resistant information, easing laboratory work),",
      "extractCut": true,
      "blocks": [
        "library/10665-381036/blocks/prose-page-592"
      ]
    },
    {
      "id": "page-593",
      "number": null,
      "title": "Page 593",
      "level": 1,
      "pageStart": 593,
      "pageEnd": 593,
      "labelStart": "588",
      "labelEnd": "588",
      "words": 60,
      "summary": {
        "text": "Ends the review with suggestions to include qualitative methods routinely in diagnostic studies and to collaborate with costing studies, followed by acknowledgements.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "helping",
          "heading": false
        },
        {
          "term": "grateful",
          "heading": false
        },
        {
          "term": "lutje",
          "heading": false
        }
      ],
      "extract": "• They suggested adding qualitative methods routinely and from the beginning to diagnostic evaluation and clinical studies. • One member suggested exploring collaborations with costing studies. Acknowledgements We are grateful to Vittoria Lutje, Cochrane Infectious Diseases' Information Specialist, for helping us with the search strategy. We are grateful to Darrel Ronald for helping us with the design of the figure.",
      "extractCut": false,
      "blocks": [
        "library/10665-381036/blocks/prose-page-593"
      ]
    },
    {
      "id": "page-594",
      "number": null,
      "title": "Page 594",
      "level": 1,
      "pageStart": 594,
      "pageEnd": 594,
      "labelStart": "589",
      "labelEnd": "589",
      "words": 464,
      "summary": {
        "text": "The first page of the reference list for the qualitative review on automated NAATs for TB, citing studies on Xpert MTB/RIF roll-out, diagnostic technologies and TB diagnosis in various countries.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "respiratory journal",
          "heading": false
        },
        {
          "term": "xpert mtb",
          "heading": false
        },
        {
          "term": "mtb rif",
          "heading": false
        },
        {
          "term": "european respiratory",
          "heading": false
        },
        {
          "term": "pai",
          "heading": false
        },
        {
          "term": "south africa",
          "heading": false
        },
        {
          "term": "boehme",
          "heading": false
        },
        {
          "term": "tuberculosis",
          "heading": false
        }
      ],
      "extract": "References Albert, H., Nathavitharana, R. R., Isaacs, C., Pai, M., Denkinger, C. M., & Boehme, C. C. (2016). Development, roll-out and impact of Xpert MTB/RIF for tuberculosis: what lessons have we learnt and how can we do better? [10.1183/13993003.00543-2016]. European Respiratory Journal, 48, 516-525. Bainomugisa, A., Gilpin, C., Coulter, C., & Marais, B. J. (2020). New Xpert MTB/XDR: added value and future in the",
      "extractCut": true,
      "blocks": [
        "library/10665-381036/blocks/prose-page-594"
      ]
    },
    {
      "id": "page-595",
      "number": null,
      "title": "Page 595",
      "level": 1,
      "pageStart": 595,
      "pageEnd": 595,
      "labelStart": "590",
      "labelEnd": "590",
      "words": 521,
      "summary": {
        "text": "Continues the reference list, citing qualitative and mixed-methods studies on TB diagnosis and drug-resistant TB in countries such as Viet Nam, India, Nepal and Kenya.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "xpert mtb",
          "heading": false
        },
        {
          "term": "bmc health",
          "heading": false
        },
        {
          "term": "qualitative evidence",
          "heading": false
        },
        {
          "term": "resistant tuberculosis",
          "heading": false
        },
        {
          "term": "multidrug resistant",
          "heading": false
        },
        {
          "term": "mtb rif",
          "heading": false
        },
        {
          "term": "plos",
          "heading": false
        },
        {
          "term": "services research",
          "heading": false
        }
      ],
      "extract": "Hoang, T., Nguyen, N., Dinh, S., Nguyen, H., Cobelens, F., Thwaites, G., et al. (2015). Challenges in detection and treatment of multidrug resistant tuberculosis patients in Vietnam. BMC Public Health, 15(1), 980. Jaroslawski, S., & Pai, M. (2012). Why are inaccurate tuberculosis serological tests widely used in the Indian private healthcare sector? A root-cause analysis. Journal of Epidemiology and Global Health,",
      "extractCut": true,
      "blocks": [
        "library/10665-381036/blocks/prose-page-595"
      ]
    },
    {
      "id": "page-596",
      "number": null,
      "title": "Page 596",
      "level": 1,
      "pageStart": 596,
      "pageEnd": 596,
      "labelStart": "591",
      "labelEnd": "591",
      "words": 484,
      "summary": {
        "text": "Concludes the reference list with studies from Myanmar, southern Africa and Brazil and WHO's 2020 global TB report and consolidated TB guidelines.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "tuberculosis patients",
          "heading": false
        },
        {
          "term": "world health",
          "heading": false
        },
        {
          "term": "health organization",
          "heading": false
        },
        {
          "term": "qualitative study",
          "heading": false
        },
        {
          "term": "bmc health",
          "heading": false
        },
        {
          "term": "lung disease",
          "heading": false
        },
        {
          "term": "global health",
          "heading": false
        },
        {
          "term": "infectious disease",
          "heading": false
        }
      ],
      "extract": "Pai, M., Schumacher, S. G., & Abimbola, S. (2018). Surrogate endpoints in global health research: still searching for killer apps and silver bullets? BMJ Global Health, 3(2). Phyo, A. M., Kumar, A. M. V., Soe, K. T., Kyaw, K. W. Y., Thu, A. S., Wai, P. P., et al. (2019). Contact Investigation of Multidrug-Resistant Tuberculosis Patients: A Mixed-Methods Study from Myanmar. Tropical medicine and infectious disease,",
      "extractCut": true,
      "blocks": [
        "library/10665-381036/blocks/prose-page-596"
      ]
    },
    {
      "id": "page-597",
      "number": null,
      "title": "Page 597",
      "level": 1,
      "pageStart": 597,
      "pageEnd": 597,
      "labelStart": "592",
      "labelEnd": "592",
      "words": 279,
      "summary": {
        "text": "Appendix 1, giving the Ovid MEDLINE search strategy used for the review, combining terms for TB and drug-resistant TB, automated NAAT products such as Xpert and Truenat, and qualitative or mixed methods, limited to 2007 onwards.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "mixed methods",
          "heading": false
        },
        {
          "term": "cartridge",
          "heading": false
        },
        {
          "term": "search strategy",
          "heading": false
        },
        {
          "term": "mixed-methods",
          "heading": false
        },
        {
          "term": "tuberculosis",
          "heading": false
        },
        {
          "term": "attitude",
          "heading": false
        },
        {
          "term": "health care",
          "heading": false
        }
      ],
      "extract": "Appendices Appendix 1: Search strategy Database: Ovid MEDLINE(R) and Epub Ahead of Print, In-Process & Other Non-Indexed Citations, Daily and Versions(R) <1946 to September 05, 2020> Search Strategy: -------------------------------------------------------------------------------- 1 Extensively Drug-Resistant Tuberculosis/ or Tuberculosis/ or tuberculosis.mp. or Tuberculosis, Multidrug-Resistant/ or Tuberculosis,",
      "extractCut": true,
      "blocks": [
        "library/10665-381036/blocks/prose-page-597"
      ]
    },
    {
      "id": "page-598",
      "number": null,
      "title": "Page 598",
      "level": 1,
      "pageStart": 598,
      "pageEnd": 598,
      "labelStart": "593",
      "labelEnd": "593",
      "words": 290,
      "summary": {
        "text": "Continues the search strategy appendix with the Embase search terms for TB, automated NAAT and diagnostic tests, user experience and qualitative methods, limited to 2007 onwards.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "resistant tuberculosis",
          "heading": false
        },
        {
          "term": "multidrug resistant",
          "heading": false
        },
        {
          "term": "drug resistant",
          "heading": false
        },
        {
          "term": "mycobacterium tuberculosis",
          "heading": false
        },
        {
          "term": "patient satisfaction",
          "heading": false
        },
        {
          "term": "patient preference",
          "heading": false
        },
        {
          "term": "attitude",
          "heading": false
        }
      ],
      "extract": "Database: Embase <1996 to 2020 Week 36> Search Strategy: -------------------------------------------------------------------------------- 1 tuberculosis/ or tuberculosis.mp. 2 drug resistant tuberculosis.mp. or drug resistant tuberculosis/ 3 multidrug resistant tuberculosis.mp. or multidrug resistant tuberculosis/ 4 MDR-TB.mp. 5 XDR-TB.mp. 6 extensively drug resistant tuberculosis/ 7 mycobacterium tuberculosis.mp.",
      "extractCut": true,
      "blocks": [
        "library/10665-381036/blocks/prose-page-598"
      ]
    },
    {
      "id": "page-599",
      "number": null,
      "title": "Page 599",
      "level": 1,
      "pageStart": 599,
      "pageEnd": 599,
      "labelStart": "594",
      "labelEnd": "594",
      "words": 249,
      "summary": {
        "text": "Lists the final Embase limit and the CINAHL and PsycInfo search strategies for the review, combining TB, NAAT and qualitative or patient experience terms for 2007–2020.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "resistant tuberculosis",
          "heading": false
        },
        {
          "term": "query",
          "heading": false
        },
        {
          "term": "published date",
          "heading": false
        },
        {
          "term": "cartridge",
          "heading": false
        },
        {
          "term": "ebscohost",
          "heading": false
        }
      ],
      "extract": "49 limit 48 to yr=\"2007 -Current\" Cinahl (EBSCOHost) Limiters - Published Date: 20070101-20201231 # Query S22 S8 AND S20 S21 S8 AND S20 S20 TX systematic review or meta-analysis S19 S14 OR S18 S18 S8 AND S17 S17 S15 OR S16 S16 TX focus group* S15 TX interview* OR TX ( survey* or questionnaire* ) OR TX ( qualitative research or qualitative study or qualitative methods or mixed methods ) S14 S8 AND S12 S13 S8 AND S12",
      "extractCut": true,
      "blocks": [
        "library/10665-381036/blocks/prose-page-599"
      ]
    },
    {
      "id": "page-600",
      "number": null,
      "title": "Page 600",
      "level": 1,
      "pageStart": 600,
      "pageEnd": 600,
      "labelStart": "595",
      "labelEnd": "595",
      "words": 161,
      "summary": {
        "text": "Completes the PsycInfo search strategy for the review, with terms for qualitative methods, patient experience, barriers and automated NAAT products.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "resistant tuberculosis",
          "heading": false
        },
        {
          "term": "cartridge",
          "heading": false
        },
        {
          "term": "qualitative",
          "heading": false
        },
        {
          "term": "mdr-tb",
          "heading": false
        }
      ],
      "extract": "S15 TX interview* OR TX ( survey* or questionnaire* ) OR TX ( qualitative research or qualitative study or qualitative methods or mixed methods ) S14 S8 AND S12 S13 S8 AND S12 S12 S9 OR S10 OR S11 S11 TX ( barriers or challenges ) OR TX critical pathway OR TX facilitator* S10 TX patient preference* OR TX ( patient satisfaction or patients experiences or patients perceptions or patients attitudes ) S9 TX acceptance",
      "extractCut": true,
      "blocks": [
        "library/10665-381036/blocks/prose-page-600"
      ]
    },
    {
      "id": "page-601",
      "number": null,
      "title": "Page 601",
      "level": 1,
      "pageStart": 601,
      "pageEnd": 601,
      "labelStart": "596",
      "labelEnd": "596",
      "words": 787,
      "summary": {
        "text": "Appendix 2, a table assessing the methodological limitations of each included study, rating rigour in sampling, data collection and analysis, how well findings are grounded in the data, and breadth and depth. Several studies are rated as making fairly thorough efforts, while others, such as Cattamanchi 2020, are rated as not reporting or unclear on most criteria. The page carries a notice that the report was prepared for the WHO Global TB Programme and is not for further distribution.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "thorough attempt",
          "heading": false
        },
        {
          "term": "few steps",
          "heading": false
        },
        {
          "term": "yes",
          "heading": false
        },
        {
          "term": "tell",
          "heading": false
        },
        {
          "term": "increase rigour",
          "heading": false
        },
        {
          "term": "state",
          "heading": false
        },
        {
          "term": "mcdowell",
          "heading": false
        },
        {
          "term": "findings",
          "heading": false
        }
      ],
      "extract": "This report has been prepared for the WHO Global TB Programme. Do not distribute further. 596 Appendix 2: Assessment of Methodological Limitations Study ID Were steps taken to increase rigour in the sampling? Were steps taken to increase rigour in the data collected? Were steps taken to increase rigour in the analysis of the data? Were the findings of the study grounded in/ supported by the data? Please rate the",
      "extractCut": true,
      "blocks": [
        "library/10665-381036/blocks/prose-page-601"
      ]
    },
    {
      "id": "page-602",
      "number": null,
      "title": "Page 602",
      "level": 1,
      "pageStart": 602,
      "pageEnd": 602,
      "labelStart": "597",
      "labelEnd": "597",
      "words": 857,
      "summary": {
        "text": "Appendix 3, the CERQual summary-of-findings table, starting with what users value, such as patients' wish for accurate, timely, accessible and affordable diagnosis. For each finding it rates methodological limitations, coherence, relevance and adequacy and gives an overall confidence level with an explanation. It lists the studies contributing to each finding.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "minor concerns",
          "heading": false
        },
        {
          "term": "finding minor",
          "heading": false
        },
        {
          "term": "rich studies",
          "heading": false
        },
        {
          "term": "concerns synthesis",
          "heading": false
        },
        {
          "term": "concerns across",
          "heading": false
        },
        {
          "term": "automated naat",
          "heading": false
        },
        {
          "term": "methodological quality",
          "heading": false
        },
        {
          "term": "took few",
          "heading": false
        }
      ],
      "extract": "This report has been prepared for the WHO Global TB Programme. Do not distribute further. 597 Appendix 3: CERQual summary of findings Finding # Review finding Methodological limitations Coherence Relevance Adequacy CERQual assessment of confidence in the evidence Explanation of CERQual assessment Studies contributing to review finding Critical aspects users value 1 Patients in high‐TB burden countries value 1)",
      "extractCut": true,
      "blocks": [
        "library/10665-381036/blocks/prose-page-602"
      ]
    },
    {
      "id": "page-603",
      "number": null,
      "title": "Page 603",
      "level": 1,
      "pageStart": 603,
      "pageEnd": 603,
      "labelStart": "598",
      "labelEnd": "598",
      "words": 134,
      "summary": {
        "text": "Continues the CERQual table with the finding that laboratory managers find NAAT eases monitoring, training and staff retention, rated low confidence because it rests on a single study.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "moderate concerns",
          "heading": false
        },
        {
          "term": "naat",
          "heading": false
        },
        {
          "term": "serious",
          "heading": false
        },
        {
          "term": "eases",
          "heading": false
        }
      ],
      "extract": "This report has been prepared for the WHO Global TB Programme. Do not distribute further. 598 6 Laboratory managers appreciate that monitoring of laboratory work and training is easier than with sputum microscopy and that low-complexity automated NAAT eases staff retention, as it increases staff satisfaction and has a symbolic meaning of progress within the TB world.. no/very minor concerns no concerns ‐ good fit of",
      "extractCut": true,
      "blocks": [
        "library/10665-381036/blocks/prose-page-603"
      ]
    },
    {
      "id": "page-604",
      "number": null,
      "title": "Page 604",
      "level": 1,
      "pageStart": 604,
      "pageEnd": 604,
      "labelStart": "599",
      "labelEnd": "599",
      "words": 896,
      "summary": {
        "text": "Continues the CERQual table with findings on challenges, starting with patients' reluctance to test because of stigma, fear of side effects, sputum problems and travel costs, which is rated high confidence. It also assesses findings on health worker reluctance to test, delays accumulating through health system factors, and poor sample quality and transport causing errors and underuse. Each entry gives ratings for limitations, coherence, relevance and adequacy and lists the contributing studies.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "minor concerns",
          "heading": false
        },
        {
          "term": "countries minor",
          "heading": false
        },
        {
          "term": "concerns descriptive",
          "heading": false
        },
        {
          "term": "rich studies",
          "heading": false
        },
        {
          "term": "half took",
          "heading": false
        },
        {
          "term": "concerns across",
          "heading": false
        },
        {
          "term": "towards richness",
          "heading": false
        },
        {
          "term": "rich study",
          "heading": false
        }
      ],
      "extract": "This report has been prepared for the WHO Global TB Programme. Do not distribute further. 599 Finding # Review finding Methodological limitations Coherence Relevance Adequacy CERQual assessment of confidence in the evidence Explanation of CERQual assessment Studies contributing to review finding Challenges to realizing these values 7 Patients can be reluctant to test for TB/MDR‐TB because of stigma related to MDR‐TB",
      "extractCut": true,
      "blocks": [
        "library/10665-381036/blocks/prose-page-604"
      ]
    },
    {
      "id": "page-605",
      "number": null,
      "title": "Page 605",
      "level": 1,
      "pageStart": 605,
      "pageEnd": 605,
      "labelStart": "600",
      "labelEnd": "600",
      "words": 695,
      "summary": {
        "text": "Continues the CERQual table with findings on laboratory workload, where NAAT can save staff time but may add work if layered on existing tests without staffing changes. It also rates findings on how workflows and patient flows affect use, over-reliance on NAAT results, and implementation weaknesses such as missing guidelines, training and inclusive national decision-making. Most are rated high or moderate confidence, with the contributing studies listed.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "minor concerns",
          "heading": false
        },
        {
          "term": "concerns captures",
          "heading": false
        },
        {
          "term": "took few",
          "heading": false
        },
        {
          "term": "towards richness",
          "heading": false
        },
        {
          "term": "moderate concerns",
          "heading": false
        },
        {
          "term": "studies took",
          "heading": false
        },
        {
          "term": "automated naat",
          "heading": false
        },
        {
          "term": "naat because",
          "heading": false
        }
      ],
      "extract": "This report has been prepared for the WHO Global TB Programme. Do not distribute further. 600 Finding # Review finding Methodological limitations Coherence Relevance Adequacy CERQual assessment of confidence in the evidence Eplanation of CERQual assessment Studies contributing to review finding 12 Low-complexity automated NAAT seems to decrease workload by freeing up time for laboratory staff, but in most settings",
      "extractCut": true,
      "blocks": [
        "library/10665-381036/blocks/prose-page-605"
      ]
    },
    {
      "id": "page-606",
      "number": null,
      "title": "Page 606",
      "level": 1,
      "pageStart": 606,
      "pageEnd": 606,
      "labelStart": "601",
      "labelEnd": "601",
      "words": 505,
      "summary": {
        "text": "Part of a summary-of-findings table from a qualitative review of TB NAATs, marked as prepared for the WHO Global TB Programme and not for further distribution. It gives GRADE-CERQual assessments for findings on access and equity, such as staff concerns about sustainable funding, maintenance, donor conflicts of interest and equitable use of resources for low-complexity automated NAATs, with contributing studies.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "minor concerns",
          "heading": false
        },
        {
          "term": "concerns captures",
          "heading": false
        },
        {
          "term": "concerns rich",
          "heading": false
        },
        {
          "term": "concerns because",
          "heading": false
        },
        {
          "term": "concerns out",
          "heading": false
        },
        {
          "term": "rich studies",
          "heading": false
        },
        {
          "term": "rural urban",
          "heading": false
        },
        {
          "term": "review finding",
          "heading": false
        }
      ],
      "extract": "This report has been prepared for the WHO Global TB Programme. Do not distribute further. 601 Finding # Review finding Methodological limitations Coherence Relevance Adequacy CERQual assessment of confidence in the evidence Explanation of CERQual assessment Studies contributing to review finding Concerns for access/equity 16 Staff and managers voiced concerns regarding sustainability of funding and maintenance,",
      "extractCut": true,
      "blocks": [
        "library/10665-381036/blocks/prose-page-606"
      ]
    },
    {
      "id": "page-607",
      "number": null,
      "title": "Page 607",
      "level": 1,
      "pageStart": 607,
      "pageEnd": 607,
      "labelStart": "602",
      "labelEnd": "602",
      "words": 139,
      "summary": {
        "text": "A PRISMA flow chart for the qualitative review whose extracted text is badly garbled, with letters and most study counts missing; only the screening stages and 1308 records after de-duplication are legible.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "quali",
          "heading": false
        },
        {
          "term": "lud",
          "heading": false
        },
        {
          "term": "records identified",
          "heading": false
        }
      ],
      "extract": "Appendix 4: Figure 1: PRISMA flow chart 284 Records identified through da abas s a hing (n = ) Additional records identified hrough ot sourc s (n = ) ds af dupli a s d (n = 1308 ) ds s d (n = ) ds x lud d (n = ) Full- x a i l s x lud i h asons (n = ) Da a not anal d using quali a i anal is hods Did not add ss ph nom non of int s ot a quali a i s ud sign vi a i l Full- x a i l s ass ss d f ligibili (n = ) S udi s",
      "extractCut": true,
      "blocks": [
        "library/10665-381036/blocks/prose-page-607"
      ]
    },
    {
      "id": "page-608",
      "number": null,
      "title": "Page 608",
      "level": 1,
      "pageStart": 608,
      "pageEnd": 608,
      "labelStart": "603",
      "labelEnd": "603",
      "words": 658,
      "summary": {
        "text": "Begins a table of characteristics of studies included in the qualitative review of TB NAATs, giving country and income level, setting, diagnostic technology, target population, participants, objectives and data collection methods. Entries include a Kenya and Eswatini study on Xpert Ultra and studies such as one on TB screening of pregnant women in India.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "officer interns",
          "heading": false
        },
        {
          "term": "middle income",
          "heading": false
        },
        {
          "term": "xpert mtb",
          "heading": false
        },
        {
          "term": "testing hubs",
          "heading": false
        },
        {
          "term": "nursing officers",
          "heading": false
        },
        {
          "term": "informant interviews",
          "heading": false
        },
        {
          "term": "mtb rif",
          "heading": false
        },
        {
          "term": "lower middle",
          "heading": false
        }
      ],
      "extract": "This report has been prepared for the WHO Global TB Programme. Do not distribute further. 603 Appendix 5: Study characteristics table First author Year of publication Country (income classification) Geographical setting Type of health facility public/private Background prevalence Diagnostic technology Programmatic features of the intervention (Where and how) Target population Total number of participants and types",
      "extractCut": true,
      "blocks": [
        "library/10665-381036/blocks/prose-page-608"
      ]
    },
    {
      "id": "page-609",
      "number": null,
      "title": "Page 609",
      "level": 1,
      "pageStart": 609,
      "pageEnd": 609,
      "labelStart": "604",
      "labelEnd": "604",
      "words": 892,
      "summary": {
        "text": "Continues the study characteristics table with Xpert MTB/RIF studies, including NGO-led household contact investigation for MDR-TB in Myanmar. Other entries describe programme features, participants and methods. The page ends with a mixed-methods time-and-motion study of clinic flow with point-of-care testing in Durban, South Africa.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "xpert mtb",
          "heading": false
        },
        {
          "term": "middle icome",
          "heading": false
        },
        {
          "term": "mtb rif",
          "heading": false
        },
        {
          "term": "middle income",
          "heading": false
        },
        {
          "term": "microscopy centres",
          "heading": false
        },
        {
          "term": "district hospitals",
          "heading": false
        },
        {
          "term": "chest radiography",
          "heading": false
        },
        {
          "term": "urban low-complexity",
          "heading": false
        }
      ],
      "extract": "This report has been prepared for the WHO Global TB Programme. Do not distribute further. 604 First author Year of publication Country (income classification) Geographical setting Type of health facility public/private Background prevalence Diagnostic technology Programmatic features of the intervention (Where and how) Target population Total number of participants and tpes of Research questions/ objectives Data",
      "extractCut": true,
      "blocks": [
        "library/10665-381036/blocks/prose-page-609"
      ]
    },
    {
      "id": "page-610",
      "number": null,
      "title": "Page 610",
      "level": 1,
      "pageStart": 610,
      "pageEnd": 610,
      "labelStart": "605",
      "labelEnd": "605",
      "words": 770,
      "summary": {
        "text": "Continues the study characteristics table with further Xpert MTB/RIF studies, including implementation across laboratory and clinic levels in Mongolia. It ends with a mixed-methods study of challenges in the steps from diagnosis to MDR-TB treatment, using focus groups, interviews and document review with 80 health staff.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "middle income",
          "heading": false
        },
        {
          "term": "xpert mtb",
          "heading": false
        },
        {
          "term": "mtb rif",
          "heading": false
        },
        {
          "term": "upper middle",
          "heading": false
        },
        {
          "term": "rif unclear",
          "heading": false
        },
        {
          "term": "district hospitals",
          "heading": false
        },
        {
          "term": "patients diagnosed",
          "heading": false
        },
        {
          "term": "lower middle",
          "heading": false
        }
      ],
      "extract": "This report has been prepared for the WHO Global TB Programme. Do not distribute further. 605 First author Year of publication Country (income classification) Geographical setting Type of health facility public/private Background prevalence Diagnostic technology Programmatic features of the intervention (Where and how) Target population Total number of participants and types of settings Research questions/",
      "extractCut": true,
      "blocks": [
        "library/10665-381036/blocks/prose-page-610"
      ]
    },
    {
      "id": "page-611",
      "number": null,
      "title": "Page 611",
      "level": 1,
      "pageStart": 611,
      "pageEnd": 611,
      "labelStart": "606",
      "labelEnd": "606",
      "words": 629,
      "summary": {
        "text": "Continues the study characteristics table, including a South African study of the policy transfer of Xpert and line probe assays with informants from global to district level. It ends with an interview study on why serological TB tests are popular in the private sector.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "middle income",
          "heading": false
        },
        {
          "term": "lower middle",
          "heading": false
        },
        {
          "term": "genotype lpa",
          "heading": false
        },
        {
          "term": "regional laboratories",
          "heading": false
        },
        {
          "term": "xpert mtb",
          "heading": false
        },
        {
          "term": "district hospitals",
          "heading": false
        },
        {
          "term": "mtb rif",
          "heading": false
        },
        {
          "term": "sub district",
          "heading": false
        }
      ],
      "extract": "This report has been prepared for the WHO Global TB Programme. Do not distribute further. 606 First author Year of publication Country (income classification) Geographical setting Type of health facility public/private Background prevalence Diagnostic technology Programmatic features of the intervention (Where and how) Target population Total number of participants and types of settings Research questions/",
      "extractCut": true,
      "blocks": [
        "library/10665-381036/blocks/prose-page-611"
      ]
    },
    {
      "id": "page-612",
      "number": null,
      "title": "Page 612",
      "level": 1,
      "pageStart": 612,
      "pageEnd": 612,
      "labelStart": "607",
      "labelEnd": "607",
      "words": 577,
      "summary": {
        "text": "Opens Web Annex B.14, a 2020 interview study by Maastricht University researchers on user perspectives of NAATs for TB and drug-resistant TB, prepared for a WHO guideline meeting. It argues that user views on value, feasibility and acceptability matter alongside accuracy and that qualitative research can capture them. It describes the study's interviews with clinicians, laboratory staff, programme officers and patient advocates in Moldova, India and South Africa and the participant coding system.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "nora engel",
          "heading": false
        },
        {
          "term": "acid amplification",
          "heading": false
        },
        {
          "term": "nucleic acid",
          "heading": false
        },
        {
          "term": "user perspectives",
          "heading": false
        },
        {
          "term": "amplification tests",
          "heading": false
        },
        {
          "term": "qualitative research",
          "heading": false
        },
        {
          "term": "programme officers",
          "heading": false
        },
        {
          "term": "drug-resistant tuberculosis",
          "heading": false
        }
      ],
      "extract": "Web Annex B.14. User perspectives on nucleic acid amplification tests for tuberculosis and tuberculosis drug resistance: (interviews study) Authors: Ricky Janssen, Muthoni Mwaura & Nora Engel Department of Health, Ethics and Society, Care and Public Health Research Institute (CAPHRI), Maastricht University, Maastricht, Netherlands (Kingdom of the) Produced in preparation for the WHO guideline group meeting on",
      "extractCut": true,
      "blocks": [
        "library/10665-381036/blocks/prose-page-612"
      ]
    },
    {
      "id": "page-613",
      "number": null,
      "title": "Page 613",
      "level": 1,
      "pageStart": 613,
      "pageEnd": 613,
      "labelStart": "608",
      "labelEnd": "608",
      "words": 486,
      "summary": {
        "text": "Lists the interview topics, from current diagnostic approaches to feasibility, equity and policy, and notes limitations such as small numbers and remote interviews that prevented triangulation. It outlines the report's structure and introduces the first index test, low-complexity automated NAATs.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "index tests",
          "heading": false
        },
        {
          "term": "skype",
          "heading": false
        },
        {
          "term": "health equity",
          "heading": false
        },
        {
          "term": "interviews",
          "heading": false
        },
        {
          "term": "zoom",
          "heading": false
        },
        {
          "term": "laboratory staff",
          "heading": false
        },
        {
          "term": "south africa",
          "heading": false
        },
        {
          "term": "clinicians",
          "heading": false
        }
      ],
      "extract": "Interviews were conducted over Zoom, Skype and phone. Topics discussed included: 1. current approach to diagnosing TB, MDR-TB, and XDR-TB including specific challenges; 2. experiences with using molecular TB diagnostics and the index tests specifically, including details on steps taken in the diagnostic process; 3. determining eligibility and treatment initiation as well as challenges and benefits of using the index",
      "extractCut": true,
      "blocks": [
        "library/10665-381036/blocks/prose-page-613"
      ]
    },
    {
      "id": "page-614",
      "number": null,
      "title": "Page 614",
      "level": 1,
      "pageStart": 614,
      "pageEnd": 614,
      "labelStart": "609",
      "labelEnd": "609",
      "words": 596,
      "summary": {
        "text": "Describes the Xpert MTB/XDR cartridge, which detects resistance to isoniazid, fluoroquinolones, second-line injectables and ethionamide, and notes that few participants had used it. Participants anticipated benefits such as faster drug susceptibility results, earlier detection of isoniazid monoresistance and earlier information to guide treatment regimens.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "xdr cartridge",
          "heading": false
        },
        {
          "term": "inh resistance",
          "heading": false
        },
        {
          "term": "mtb xdr",
          "heading": false
        },
        {
          "term": "xpert mtb",
          "heading": false
        },
        {
          "term": "mtb rif",
          "heading": false
        },
        {
          "term": "laboratory personnel",
          "heading": false
        },
        {
          "term": "laboratory network",
          "heading": false
        },
        {
          "term": "months just",
          "heading": false
        }
      ],
      "extract": "The first class of technologies to be evaluated at the WHO 2020 guideline meeting are low-complexity automated NAATs for the detection of resistance to isoniazid (INH) and second-line anti-TB medicines. One such test that we investigated in this study is the Xpert MTB/XDR cartridge by Cepheid. This particular cartridge detects mutations associated with resistance towards INH, fluoroquinolones (FLQ), second-line",
      "extractCut": true,
      "blocks": [
        "library/10665-381036/blocks/prose-page-614"
      ]
    },
    {
      "id": "page-615",
      "number": null,
      "title": "Page 615",
      "level": 1,
      "pageStart": 615,
      "pageEnd": 615,
      "labelStart": "610",
      "labelEnd": "610",
      "words": 577,
      "summary": {
        "text": "Continues on Xpert MTB/XDR, quoting a laboratory scientist on near-universal resistance prediction within hours. It reports challenges, chiefly cost and the need for a 10-colour GeneXpert module that may require replacing existing platforms, alongside the broad acceptability of the test.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "xdr cartridge",
          "heading": false
        },
        {
          "term": "mtb xdr",
          "heading": false
        },
        {
          "term": "xpert mtb",
          "heading": false
        },
        {
          "term": "mtb rif",
          "heading": false
        },
        {
          "term": "low-complexity automated",
          "heading": false
        },
        {
          "term": "user steps",
          "heading": false
        },
        {
          "term": "quicker",
          "heading": false
        },
        {
          "term": "reflex",
          "heading": false
        }
      ],
      "extract": "was also important in giving clinicians necessary information to develop appropriate treatment regimens as soon as possible (SM-1, IM-2). A laboratory scientist (SL-2) summarized the value of Xpert MTB/XDR as: “you would get almost universal resistance prediction for a resistant patient, within 6 hours. Because you would have RIF, you would have INH, you would have fluoroquinolones, you would have aminoglycosides,",
      "extractCut": true,
      "blocks": [
        "library/10665-381036/blocks/prose-page-615"
      ]
    },
    {
      "id": "page-616",
      "number": null,
      "title": "Page 616",
      "level": 1,
      "pageStart": 616,
      "pageEnd": 616,
      "labelStart": "611",
      "labelEnd": "611",
      "words": 680,
      "summary": {
        "text": "Concludes that Xpert MTB/XDR is acceptable and needs little training but may suit district or intermediate laboratories rather than primary care because of cost. It then introduces medium-complexity automated NAATs for TB, rifampicin and isoniazid resistance, describing their high-throughput automation and benefits such as freeing low-complexity platforms for other areas.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "medium-complexity automated",
          "heading": false
        },
        {
          "term": "automated naats",
          "heading": false
        },
        {
          "term": "laboratory technician",
          "heading": false
        },
        {
          "term": "laboratory staff",
          "heading": false
        },
        {
          "term": "dna extraction",
          "heading": false
        },
        {
          "term": "laboratory setting",
          "heading": false
        },
        {
          "term": "max",
          "heading": false
        },
        {
          "term": "level resistance",
          "heading": false
        }
      ],
      "extract": "staff and clinicians based on its simple user steps, and due to the amount of important information it provides. The new cartridge requires less user training compared to other DST methods (such as LPA and culture), making it more feasible to implement. However, the cost of the 10-colour system for this cartridge, and the value of diagnosing MTB over DR TB at primary care, makes it less feasible as a baseline test,",
      "extractCut": true,
      "blocks": [
        "library/10665-381036/blocks/prose-page-616"
      ]
    },
    {
      "id": "page-617",
      "number": null,
      "title": "Page 617",
      "level": 1,
      "pageStart": 617,
      "pageEnd": 617,
      "labelStart": "612",
      "labelEnd": "612",
      "words": 716,
      "summary": {
        "text": "Describes challenges of medium-complexity NAATs, including machine costs, sample quality and the physical size of platforms such as Fluorotype, illustrated by a laboratory scientist's quotation. It introduces the third index test, a line probe assay for pyrazinamide resistance (PZA LPA), using the Genoscholar PZA-TB II assay as an example.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "medium-complexity automated",
          "heading": false
        },
        {
          "term": "automated naats",
          "heading": false
        },
        {
          "term": "pza lpa",
          "heading": false
        },
        {
          "term": "high-complexity hybridization-based",
          "heading": false
        },
        {
          "term": "machine worth",
          "heading": false
        },
        {
          "term": "laboratory space",
          "heading": false
        },
        {
          "term": "worth running",
          "heading": false
        },
        {
          "term": "doors",
          "heading": false
        }
      ],
      "extract": "Potential challenges around medium-complexity automated NAATs include the cost of acquiring the machines and provision of good quality samples (ML-1, IL-1, IL-2). Furthermore, the chosen platform has to align with the physical laboratory space. For example, although the Fluorotype platform was valued for its automation, a participant mentioned concerns regarding the size of the platform. “So you just can’t place it",
      "extractCut": true,
      "blocks": [
        "library/10665-381036/blocks/prose-page-617"
      ]
    },
    {
      "id": "page-618",
      "number": null,
      "title": "Page 618",
      "level": 1,
      "pageStart": 618,
      "pageEnd": 618,
      "labelStart": "613",
      "labelEnd": "613",
      "words": 789,
      "summary": {
        "text": "Reports that few participants had used the PZA line probe assay but that laboratory staff saw potential benefits, such as lower cost and easier interpretation than genome sequencing and faster results than culture. It then discusses challenges, beginning with the need for skilled sample collection, transport and handling to avoid contamination.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "pza lpa",
          "heading": false
        },
        {
          "term": "pza resistance",
          "heading": false
        },
        {
          "term": "line probe",
          "heading": false
        },
        {
          "term": "probe assay",
          "heading": false
        },
        {
          "term": "culture dst",
          "heading": false
        },
        {
          "term": "genome sequencing",
          "heading": false
        },
        {
          "term": "drug resistance",
          "heading": false
        },
        {
          "term": "requires significant",
          "heading": false
        }
      ],
      "extract": "Benefits of PZA LPA Only one participant (SL-2) had experience using the NIPRO test, and this was within a research context in South Africa. However, laboratory participants did have experience doing line probe assays for first and second line DST, and were therefore able to comment on potential benefits and challenges of PZA LPA. Potential benefits of PZA LPA identified include lower cost compared to whole genome",
      "extractCut": true,
      "blocks": [
        "library/10665-381036/blocks/prose-page-618"
      ]
    },
    {
      "id": "page-619",
      "number": null,
      "title": "Page 619",
      "level": 1,
      "pageStart": 619,
      "pageEnd": 619,
      "labelStart": "614",
      "labelEnd": "614",
      "words": 816,
      "summary": {
        "text": "Continues on PZA LPA challenges, explaining that accurate results depend on careful handling, controls and a sufficient DNA load, so it is often run only on smear-positive or cultured samples. It describes difficulties in interpreting the test strips and an interpretation app of unclear status.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "pza lpa",
          "heading": false
        },
        {
          "term": "hain lpa",
          "heading": false
        },
        {
          "term": "direct lpa",
          "heading": false
        },
        {
          "term": "nipro",
          "heading": false
        },
        {
          "term": "drug susceptibility",
          "heading": false
        },
        {
          "term": "smear negatives",
          "heading": false
        },
        {
          "term": "ridiculous",
          "heading": false
        },
        {
          "term": "contamination",
          "heading": false
        }
      ],
      "extract": "results (IP-2, IL-2) (also see Finding 10 in report by Engel et al., 2020). Proper sample handling, as well as proper temperature maintenance, and use of correct volumes of liquid are crucial in order to obtain accurate results (IL-2). LPAs also require that part of the sample is dedicated to controls, and that there is sufficient sample volume to make it worth running controls from a cost perspective (IL-1). The",
      "extractCut": true,
      "blocks": [
        "library/10665-381036/blocks/prose-page-619"
      ]
    },
    {
      "id": "page-620",
      "number": null,
      "title": "Page 620",
      "level": 1,
      "pageStart": 620,
      "pageEnd": 620,
      "labelStart": "615",
      "labelEnd": "615",
      "words": 823,
      "summary": {
        "text": "Reports that PZA resistance testing is used mainly for surveillance and research rather than routine care in South Africa, for reasons including cost and doubts about results, while relevance varied between countries. It summarizes concerns about the acceptability of PZA LPA, such as performance on smear-negative samples.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "pza lpa",
          "heading": false
        },
        {
          "term": "pza dst",
          "heading": false
        },
        {
          "term": "pza resistance",
          "heading": false
        },
        {
          "term": "regarding pza",
          "heading": false
        },
        {
          "term": "culture dst",
          "heading": false
        },
        {
          "term": "resistance testing",
          "heading": false
        },
        {
          "term": "participant mentioned",
          "heading": false
        },
        {
          "term": "testing algorithm",
          "heading": false
        }
      ],
      "extract": "The relevance of PZA resistance testing in general seemed to vary between countries. In South Africa, participants often mentioned that PZA resistance testing is only done for surveillance and research, but is not routinely utilized for clinical settings (SL-2, SM-1, SP-1). “nationally we do it as a reference lab for research projects particularly and also for surveillance activities but generally in the routine",
      "extractCut": true,
      "blocks": [
        "library/10665-381036/blocks/prose-page-620"
      ]
    },
    {
      "id": "page-621",
      "number": null,
      "title": "Page 621",
      "level": 1,
      "pageStart": 621,
      "pageEnd": 621,
      "labelStart": "616",
      "labelEnd": "616",
      "words": 819,
      "summary": {
        "text": "Continues concerns about PZA LPA, including whether it detects the relevant mutations, why it is prioritized, and the training, infrastructure and automated interpretation it would need. It then turns to findings applicable to all three tests, covering sample types, collection and transport, especially in rural settings and in Moldova's donor-funded transport system.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "sample collection",
          "heading": false
        },
        {
          "term": "perform bronchoscopies",
          "heading": false
        },
        {
          "term": "phenotypic dst",
          "heading": false
        },
        {
          "term": "molecular test",
          "heading": false
        },
        {
          "term": "treatment initiation",
          "heading": false
        },
        {
          "term": "clinician",
          "heading": false
        },
        {
          "term": "infection control",
          "heading": false
        },
        {
          "term": "covid",
          "heading": false
        }
      ],
      "extract": "actually detects mutations specific to PZA resistance; and clarification in some settings as to why this specific DST drug test is being prioritized, as it is not currently part of routine DST. In regards to feasibility, participant concerns centered around the significant training and laboratory infrastructure required to implement PZA LPA, including proper sample handling (please also see section IV.). Feasibility",
      "extractCut": true,
      "blocks": [
        "library/10665-381036/blocks/prose-page-621"
      ]
    },
    {
      "id": "page-622",
      "number": null,
      "title": "Page 622",
      "level": 1,
      "pageStart": 622,
      "pageEnd": 622,
      "labelStart": "617",
      "labelEnd": "617",
      "words": 711,
      "summary": {
        "text": "Raises concerns about donor-dependent sample transport and argues for sustainable funding of supporting systems. It discusses how sample handling affects the reliability of LPAs and sequencing and how clinicians interpret complex molecular results, calling for guidelines and algorithms that support communication between clinicians and laboratories.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "laboratory staff",
          "heading": false
        },
        {
          "term": "clinician",
          "heading": false
        },
        {
          "term": "low-level",
          "heading": false
        },
        {
          "term": "diagnostics",
          "heading": false
        },
        {
          "term": "discrepant",
          "heading": false
        },
        {
          "term": "diagnostic methods",
          "heading": false
        },
        {
          "term": "hesitant",
          "heading": false
        },
        {
          "term": "south africa",
          "heading": false
        }
      ],
      "extract": "on donor funding for various TB program activities, including sample transport. This raises concern about the sustainability of TB program funding and resources, a finding echoed by other qualitative research (Colvin 2015, deCamargo 2015, Cresswell 2014). As more diagnostics are adopted by programmes, funding towards systems that support these diagnostics (e.g. sample transportation) needs to be sustainable in order",
      "extractCut": true,
      "blocks": [
        "library/10665-381036/blocks/prose-page-622"
      ]
    },
    {
      "id": "page-623",
      "number": null,
      "title": "Page 623",
      "level": 1,
      "pageStart": 623,
      "pageEnd": 623,
      "labelStart": "618",
      "labelEnd": "618",
      "words": 760,
      "summary": {
        "text": "Discusses how clinicians and laboratories reconcile discordant results with patient progress and urges policy-makers to consider clinical knowledge. It describes social barriers to diagnosis and stresses that access to new diagnostics must accompany access to new treatments.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "mdr xdr",
          "heading": false
        },
        {
          "term": "survivor",
          "heading": false
        },
        {
          "term": "patient progress",
          "heading": false
        },
        {
          "term": "improve access",
          "heading": false
        },
        {
          "term": "molecular test",
          "heading": false
        },
        {
          "term": "social issues",
          "heading": false
        },
        {
          "term": "vital component",
          "heading": false
        },
        {
          "term": "diagnostics",
          "heading": false
        }
      ],
      "extract": "such that they can discuss discordant results, and interpret laboratory results in the context of drug availability and patient history. Clinicians and laboratory staff also use patient progress to contextualize diagnostic results when there is uncertainty and use this to make treatment decisions (ML-2), but sometimes a patient is switched to another regimen based on test results despite clinical progress (SM-1). We",
      "extractCut": true,
      "blocks": [
        "library/10665-381036/blocks/prose-page-623"
      ]
    },
    {
      "id": "page-624",
      "number": null,
      "title": "Page 624",
      "level": 1,
      "pageStart": 624,
      "pageEnd": 624,
      "labelStart": "619",
      "labelEnd": "619",
      "words": 422,
      "summary": {
        "text": "Notes that WHO guidelines change faster than many countries can implement them, creating unequal access between and within countries. It concludes that new molecular diagnostics have great potential but their value depends on fit within health systems, and begins a summary of challenges such as sample transport, contamination and clinician–laboratory communication.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "pza lpa",
          "heading": false
        },
        {
          "term": "sample contamination",
          "heading": false
        },
        {
          "term": "molecular diagnostics",
          "heading": false
        },
        {
          "term": "automated naats",
          "heading": false
        },
        {
          "term": "sample transport",
          "heading": false
        },
        {
          "term": "laboratory infrastructure",
          "heading": false
        },
        {
          "term": "index test",
          "heading": false
        },
        {
          "term": "run",
          "heading": false
        }
      ],
      "extract": "Finally, the speed at which WHO guidelines are changing does not match the speed at which many country programmes are able to implement the guidelines. This translates into differential access to new TB diagnostics and treatment at an inter-country level (i.e. between countries that can and cannot quickly keep up with the rapidly changing TB diagnostic environment MR-1) as well at an intra-country level (i.e.",
      "extractCut": true,
      "blocks": [
        "library/10665-381036/blocks/prose-page-624"
      ]
    },
    {
      "id": "page-625",
      "number": null,
      "title": "Page 625",
      "level": 1,
      "pageStart": 625,
      "pageEnd": 625,
      "labelStart": "620",
      "labelEnd": "620",
      "words": 405,
      "summary": {
        "text": "Continues the summary of challenges, including clinicians' hesitancy over MDR and XDR-TB decisions, information overload at decentralized sites and equity barriers at programme and patient levels. It notes the COVID-19 context and begins recommendations, such as gathering data on the burden of pyrazinamide resistance.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "pza lpa",
          "heading": false
        },
        {
          "term": "pza resistance",
          "heading": false
        },
        {
          "term": "confer resistance",
          "heading": false
        },
        {
          "term": "automated naats",
          "heading": false
        },
        {
          "term": "sample load",
          "heading": false
        },
        {
          "term": "xdr",
          "heading": false
        },
        {
          "term": "interpret",
          "heading": false
        },
        {
          "term": "placement",
          "heading": false
        }
      ],
      "extract": "• Hesitancy of clinicians to make decisions on MDR and XDR TB on their own • Capacity of decentralized facilities to interpret and disseminate increased volumes of complex information produced by the tests 6. Equity • Barriers at program level: cost to acquire new expensive diagnostics as well as difficulties keeping up with WHO guidelines and subsequent training for clinicians and laboratory personnel • Barriers at",
      "extractCut": true,
      "blocks": [
        "library/10665-381036/blocks/prose-page-625"
      ]
    },
    {
      "id": "page-626",
      "number": null,
      "title": "Page 626",
      "level": 1,
      "pageStart": 626,
      "pageEnd": 626,
      "labelStart": "621",
      "labelEnd": "621",
      "words": 416,
      "summary": {
        "text": "Gives recommendations for all three index tests on streamlining sample collection and ensuring sufficient sample volumes in diagnostic algorithms. It also suggests content for GRADE evidence-to-decision tables and stresses patients' access to clear information on diagnostics as an equity issue.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "mtb xdr",
          "heading": false
        },
        {
          "term": "future research",
          "heading": false
        },
        {
          "term": "diagnostic tests",
          "heading": false
        },
        {
          "term": "decision-making processes",
          "heading": false
        },
        {
          "term": "pza",
          "heading": false
        },
        {
          "term": "information systems",
          "heading": false
        },
        {
          "term": "sample",
          "heading": false
        },
        {
          "term": "lpa",
          "heading": false
        }
      ],
      "extract": "PZA LPA (and PZA DST in general). This information should be monitored and taken into consideration for future guideline development. All three index tests: 4. Sample: • Algorithms may need to consider how many samples are required from the patient, where they will be collected, and at which point in the patient journey the sample will be collected. This process should be streamlined where possible. Not doing so,",
      "extractCut": true,
      "blocks": [
        "library/10665-381036/blocks/prose-page-626"
      ]
    },
    {
      "id": "page-627",
      "number": null,
      "title": "Page 627",
      "level": 1,
      "pageStart": 627,
      "pageEnd": 627,
      "labelStart": "622",
      "labelEnd": "622",
      "words": 666,
      "summary": {
        "text": "Summarizes the study's points for GRADE evidence-to-decision tables, including matching diagnostics to new treatments and unequal access caused by the speed of guideline change. It covers acceptability factors such as infrastructure, sample quality and clinician–laboratory communication.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "pza lpa",
          "heading": false
        },
        {
          "term": "pza resistance",
          "heading": false
        },
        {
          "term": "xdr cartridge",
          "heading": false
        },
        {
          "term": "laboratory staff",
          "heading": false
        },
        {
          "term": "culture dst",
          "heading": false
        },
        {
          "term": "mtb xdr",
          "heading": false
        },
        {
          "term": "quicker",
          "heading": false
        },
        {
          "term": "xpert mtb",
          "heading": false
        }
      ],
      "extract": "New treatment options need to be matched with new diagnostics: it is important to improve access to treatment based on new diagnostics, it is equally important to improve access to diagnostics for new treatment options. The speed at which WHO guidelines are changing does not match the speed at which many country programmes are able to implement the guidelines. This translates into differential access to new TB",
      "extractCut": true,
      "blocks": [
        "library/10665-381036/blocks/prose-page-627"
      ]
    },
    {
      "id": "page-628",
      "number": null,
      "title": "Page 628",
      "level": 1,
      "pageStart": 628,
      "pageEnd": 628,
      "labelStart": "623",
      "labelEnd": "623",
      "words": 466,
      "summary": {
        "text": "Summarizes the feasibility of each index test: Xpert MTB/XDR limited by the cost of the 10-colour system but needing little training, and medium-complexity platforms limited by laboratory space. It ends with references, including qualitative studies and Stop TB Partnership data.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "xdr cartridge",
          "heading": false
        },
        {
          "term": "mtb xdr",
          "heading": false
        },
        {
          "term": "medium-complexity automated",
          "heading": false
        },
        {
          "term": "xpert mtb",
          "heading": false
        },
        {
          "term": "mtb rif",
          "heading": false
        },
        {
          "term": "automated naats",
          "heading": false
        },
        {
          "term": "dlamini",
          "heading": false
        },
        {
          "term": "challenged",
          "heading": false
        }
      ],
      "extract": "and interpret laboratory results in the context of drug availability, patient history, and patient progress on a current drug regimen. Feasibility for the Xpert MTB/XDR Cartridge (Low-complexity automated NAAT) is challenged by the cost of the 10-colour system for this cartridge, and the value of diagnosing MTB over DR TB at primary care, makes it less feasible as a baseline test, though it would fit at a district",
      "extractCut": true,
      "blocks": [
        "library/10665-381036/blocks/prose-page-628"
      ]
    },
    {
      "id": "page-629",
      "number": null,
      "title": "Page 629",
      "level": 1,
      "pageStart": 629,
      "pageEnd": 629,
      "labelStart": "624",
      "labelEnd": "624",
      "words": 12,
      "summary": {
        "text": "The final reference on the page, citing the WHO Global Tuberculosis Report 2020.",
        "status": "draft"
      },
      "keywords": [],
      "extract": "World Health Organization. (2020). Global Tuberculosis Report 2020. Geneva: World Health Organization.",
      "extractCut": false,
      "blocks": [
        "library/10665-381036/blocks/prose-page-629"
      ]
    },
    {
      "id": "page-630",
      "number": null,
      "title": "Page 630",
      "level": 1,
      "pageStart": 630,
      "pageEnd": 630,
      "labelStart": "625",
      "labelEnd": "625",
      "words": 108,
      "summary": {
        "text": "The title page of Web Annex 4.15, a systematic review of the diagnostic accuracy of low-complexity automated NAATs for detecting resistance to isoniazid and second-line TB drugs, listing authors from Stellenbosch University, the Liverpool School of Tropical Medicine and FIND.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "liverpool school",
          "heading": false
        },
        {
          "term": "grant theron",
          "heading": false
        },
        {
          "term": "tropical medicine",
          "heading": false
        },
        {
          "term": "clinical sciences",
          "heading": false
        },
        {
          "term": "margaretha",
          "heading": false
        }
      ],
      "extract": "Web Annex 4.15. Low complexity automated NAATs: Diagnostic accuracy for detection of resistance to isoniazid and second-line anti- TB agents. A systematic review Samantha Pillay1, Geraint R Davies2, Marty Chaplin3, Margaretha De Vos4, Rob Warren1, Karen R Steingart5, Grant Theron1 1DSI-NRF Centre of Excellence for Biomedical Tuberculosis Research, SAMRC Centre for Tuberculosis Research, Division of Molecular Biology",
      "extractCut": true,
      "blocks": [
        "library/10665-381036/blocks/prose-page-630"
      ]
    },
    {
      "id": "page-631",
      "number": null,
      "title": "Page 631",
      "level": 1,
      "pageStart": 631,
      "pageEnd": 631,
      "labelStart": "626",
      "labelEnd": "626",
      "words": 561,
      "summary": {
        "text": "The executive summary of a systematic review of the Xpert MTB/XDR cartridge test, which detects tuberculosis and mutations linked to resistance to isoniazid, fluoroquinolones, ethionamide and second-line injectable drugs. It describes the test's proposed role as an initial test for resistance after TB is confirmed, and reports a pooled sensitivity of 94.2% and specificity of 98.0% for isoniazid resistance.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "mtb xdr",
          "heading": false
        },
        {
          "term": "isoniazid resistance",
          "heading": false
        },
        {
          "term": "xpert mtb",
          "heading": false
        },
        {
          "term": "second-line injectable",
          "heading": false
        },
        {
          "term": "rifampicin resistance",
          "heading": false
        },
        {
          "term": "injectable drugs",
          "heading": false
        },
        {
          "term": "amikacin",
          "heading": false
        },
        {
          "term": "pdst",
          "heading": false
        }
      ],
      "extract": "EXECUTIVE SUMMARY Xpert® MTB/XDR Assay (Xpert MTB/XDR, Cepheid, Sunnyvale, USA) detects MTBC (Mycobacterium tuberculosis complex) DNA and genomic mutations associated with resistance to isoniazid, fluoroquinolones, ethionamide, and second-line injectable drugs (amikacin, kanamycin, capreomycin) in a single cartridge. Xpert MTB/XDR is intended for use as a reflex test in clinical specimens (unprocessed sputum or",
      "extractCut": true,
      "blocks": [
        "library/10665-381036/blocks/prose-page-631"
      ]
    },
    {
      "id": "page-632",
      "number": null,
      "title": "Page 632",
      "level": 1,
      "pageStart": 632,
      "pageEnd": 632,
      "labelStart": "627",
      "labelEnd": "627",
      "words": 440,
      "summary": {
        "text": "Illustrates what the isoniazid results would mean per 1000 people tested and gives pooled accuracy for fluoroquinolone, ethionamide and amikacin resistance. It notes that results were similar whether or not people had rifampicin resistance and that sensitivity analyses changed little.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "mtb xdr-negative",
          "heading": false
        },
        {
          "term": "mtb xdr-positive",
          "heading": false
        },
        {
          "term": "ethionamide resistance",
          "heading": false
        },
        {
          "term": "mtb xdr",
          "heading": false
        },
        {
          "term": "fluoroquinolone resistance",
          "heading": false
        },
        {
          "term": "amikacin resistance",
          "heading": false
        },
        {
          "term": "xpert mtb",
          "heading": false
        },
        {
          "term": "rifampicin resistance",
          "heading": false
        }
      ],
      "extract": "Results of these studies indicate that in theory, of 1000 people where 50 have isoniazid resistance, 66 would be Xpert MTB/XDR-positive: of these, 19 (29%) would not have isoniazid resistance (false- positives) and 934 would be Xpert MTB/XDR-negative: of these, 3 (0%) would have isoniazid resistance (false-negatives). Xpert MTB/XDR for fluoroquinolone resistance in people with microbiologically confirmed pulmonary",
      "extractCut": true,
      "blocks": [
        "library/10665-381036/blocks/prose-page-632"
      ]
    },
    {
      "id": "page-633",
      "number": null,
      "title": "Page 633",
      "level": 1,
      "pageStart": 633,
      "pageEnd": 633,
      "labelStart": "628",
      "labelEnd": "628",
      "words": 218,
      "summary": {
        "text": "Lists the authors' conclusions on Xpert MTB/XDR sensitivity for each drug, with specificity above 97% in nearly all analyses, and calls for further studies in children, people with HIV, other settings and specimen types.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "mtb xdr",
          "heading": false
        },
        {
          "term": "xdr sensitivity",
          "heading": false
        },
        {
          "term": "xpert mtb",
          "heading": false
        },
        {
          "term": "rifampicin resistance",
          "heading": false
        },
        {
          "term": "people irrespective",
          "heading": false
        },
        {
          "term": "against reference",
          "heading": false
        },
        {
          "term": "reference standard",
          "heading": false
        }
      ],
      "extract": "• For resistance to isoniazid, in people irrespective of rifampicin resistance, Xpert MTB/XDR sensitivity was 94.2% against a reference standard of pDST. • For resistance to fluoroquinolones, in people irrespective of rifampicin resistance, Xpert MTB/XDR sensitivity was 93.1% against a reference standard of pDST. • For resistance to ethionamide, in people irrespective of rifampicin resistance, Xpert MTB/XDR",
      "extractCut": true,
      "blocks": [
        "library/10665-381036/blocks/prose-page-633"
      ]
    },
    {
      "id": "page-634",
      "number": null,
      "title": "Page 634",
      "level": 1,
      "pageStart": 634,
      "pageEnd": 634,
      "labelStart": "629",
      "labelEnd": "629",
      "words": 611,
      "summary": {
        "text": "Gives background on the need for early detection of drug-resistant tuberculosis as new all-oral regimens emerge, noting the importance of fluoroquinolones and the gaps in culture-based drug susceptibility testing.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "isoniazid resistance",
          "heading": false
        },
        {
          "term": "rifampicin resistance",
          "heading": false
        },
        {
          "term": "isoniazid susceptibility",
          "heading": false
        },
        {
          "term": "drug resistance",
          "heading": false
        },
        {
          "term": "susceptibility testing",
          "heading": false
        },
        {
          "term": "tuberculosis cases",
          "heading": false
        },
        {
          "term": "tuberculosis report",
          "heading": false
        },
        {
          "term": "global tuberculosis",
          "heading": false
        }
      ],
      "extract": "BACKGROUND Early recognition and improved characterisation of tuberculosis drug resistance is a prerequisite for the rapid delivery of novel regimens to those who could benefit from them. For MDR/rifampicin- resistant-tuberculosis, the arrival of novel or repurposed drugs such as bedaquiline, clofazimine, and linezolid has revolutionized the efficacy of longer regimens, dispensing with the need for injectable drugs,",
      "extractCut": true,
      "blocks": [
        "library/10665-381036/blocks/prose-page-634"
      ]
    },
    {
      "id": "page-635",
      "number": null,
      "title": "Page 635",
      "level": 1,
      "pageStart": 635,
      "pageEnd": 635,
      "labelStart": "630",
      "labelEnd": "630",
      "words": 501,
      "summary": {
        "text": "Notes that fewer than half of estimated drug-resistant TB cases are detected and explains WHO's support for rapid initial tests and the potential of multiplexed molecular assays. It describes the Xpert MTB/XDR assay and its claimed advantages, such as results in under 90 minutes on existing GeneXpert platforms.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "mtb xdr",
          "heading": false
        },
        {
          "term": "second-line injectable",
          "heading": false
        },
        {
          "term": "injectable drugs",
          "heading": false
        },
        {
          "term": "xpert mtb",
          "heading": false
        },
        {
          "term": "molecular dst",
          "heading": false
        },
        {
          "term": "meltpro",
          "heading": false
        },
        {
          "term": "index test",
          "heading": false
        },
        {
          "term": "cartridge-based",
          "heading": false
        }
      ],
      "extract": "annually, only 44% were detected and notified (WHO Global tuberculosis report 2020). The WHO recommends that rapid techniques be used as the initial diagnostic tests to detect tuberculosis and rifampicin resistance in order to minimize delays in starting appropriate treatment (WHO Consolidated Guidelines (Module 3) 2020). The multiplexed nature of these new technologies theoretically permits susceptibility to be",
      "extractCut": true,
      "blocks": [
        "library/10665-381036/blocks/prose-page-635"
      ]
    },
    {
      "id": "page-636",
      "number": null,
      "title": "Page 636",
      "level": 1,
      "pageStart": 636,
      "pageEnd": 636,
      "labelStart": "631",
      "labelEnd": "631",
      "words": 496,
      "summary": {
        "text": "Compares the detection limit of Xpert MTB/XDR with other Xpert assays and explains how the test reports TB detection and resistance results for each drug.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "intergenic region",
          "heading": false
        },
        {
          "term": "inha promoter",
          "heading": false
        },
        {
          "term": "mtb xdr",
          "heading": false
        },
        {
          "term": "oxyr-ahpc intergenic",
          "heading": false
        },
        {
          "term": "xdr bases",
          "heading": false
        },
        {
          "term": "xpert mtb",
          "heading": false
        },
        {
          "term": "mtb genome",
          "heading": false
        },
        {
          "term": "xdr assay",
          "heading": false
        }
      ],
      "extract": "The limit of detection for Mycobacterium tuberculosis by Xpert MTB/XDR (136 CFU/mL in unprocessed sputum) (Cepheid package insert 2020) is similar to that of Xpert MTB/RIF (112.6 CFU/mL), but higher than that of Xpert Ultra (15.6 CFU/mL) (Chakravorty 2017). The manufacturer states that “Specimens with “MTB Trace DETECTED” results when tested with the Xpert MTB/RIF Ultra Assay are expected to be below the limit of",
      "extractCut": true,
      "blocks": [
        "library/10665-381036/blocks/prose-page-636"
      ]
    },
    {
      "id": "page-637",
      "number": null,
      "title": "Page 637",
      "level": 1,
      "pageStart": 637,
      "pageEnd": 637,
      "labelStart": "632",
      "labelEnd": "632",
      "words": 322,
      "summary": {
        "text": "Sets out the clinical pathway for Xpert MTB/XDR as a replacement for culture-based susceptibility testing and describes the consequences of true and false positive and negative results. A footnote explains that the reviewed studies used the test as a reflex test on TB-positive sputum.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "mtb xdr",
          "heading": false
        },
        {
          "term": "rifampicin resistance",
          "heading": false
        },
        {
          "term": "pulmonary tuberculosis",
          "heading": false
        },
        {
          "term": "xpert mtb",
          "heading": false
        },
        {
          "term": "unnecessary treatment",
          "heading": false
        },
        {
          "term": "diagnostic accuracy",
          "heading": false
        },
        {
          "term": "objective",
          "heading": false
        },
        {
          "term": "people",
          "heading": false
        }
      ],
      "extract": "A clinical pathway presents a framework for developing recommendations about the use of a test and may assist in assessing the effect of a new test on management decisions and patient-important outcomes (Gopalakrishna 2016). We considered several clinical scenarios in Appendix 3, In this systematic review, the intended use of Xpert MTB/XDR is for diagnosis of drug resistance. The role of the test would be a",
      "extractCut": true,
      "blocks": [
        "library/10665-381036/blocks/prose-page-637"
      ]
    },
    {
      "id": "page-638",
      "number": null,
      "title": "Page 638",
      "level": 1,
      "pageStart": 638,
      "pageEnd": 638,
      "labelStart": "633",
      "labelEnd": "633",
      "words": 354,
      "summary": {
        "text": "Describes the types of studies included, excluding two-gate case-control designs, along with participants, index test, target conditions and the phenotypic, genotypic and composite reference standards.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "rifampicin resistance",
          "heading": false
        },
        {
          "term": "index test",
          "heading": false
        },
        {
          "term": "reference standard",
          "heading": false
        },
        {
          "term": "composite reference",
          "heading": false
        },
        {
          "term": "microbiological reference",
          "heading": false
        },
        {
          "term": "meltpro",
          "heading": false
        },
        {
          "term": "diagnostic accuracy",
          "heading": false
        },
        {
          "term": "target conditions",
          "heading": false
        }
      ],
      "extract": "METHODS Types of studies We included cross-sectional studies and cohort studies that assessed the diagnostic accuracy of the index test. We included diagnostic accuracy studies in which cases and controls were sampled from a single source population (referred to as a single gate design). We excluded case-control studies where cases and controls were sampled from different populations (referred to as a two-gate",
      "extractCut": true,
      "blocks": [
        "library/10665-381036/blocks/prose-page-638"
      ]
    },
    {
      "id": "page-639",
      "number": null,
      "title": "Page 639",
      "level": 1,
      "pageStart": 639,
      "pageEnd": 639,
      "labelStart": "634",
      "labelEnd": "634",
      "words": 498,
      "summary": {
        "text": "Lists the review outcomes, noting that no studies reported cure, mortality or time to diagnosis or treatment, and describes the database searches, data extraction, quality assessment and meta-analysis methods.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "resolved disagreements",
          "heading": false
        },
        {
          "term": "bivariate random",
          "heading": false
        },
        {
          "term": "review author",
          "heading": false
        },
        {
          "term": "random effects",
          "heading": false
        },
        {
          "term": "reported data",
          "heading": false
        },
        {
          "term": "isoniazid resistance",
          "heading": false
        },
        {
          "term": "search terms",
          "heading": false
        },
        {
          "term": "effects model",
          "heading": false
        }
      ],
      "extract": "Sensitivity, specificity, positive predictive value (PPV), and negative predictive value (NPV). Cure - we did not identify any studies that reported data for this outcome. Mortality - we did not identify any studies that reported data for this outcome. Time to diagnosis - we did not identify any studies that reported data for this outcome. Time to start treatment - we did not identify any studies that reported data",
      "extractCut": true,
      "blocks": [
        "library/10665-381036/blocks/prose-page-639"
      ]
    },
    {
      "id": "page-640",
      "number": null,
      "title": "Page 640",
      "level": 1,
      "pageStart": 640,
      "pageEnd": 640,
      "labelStart": "635",
      "labelEnd": "635",
      "words": 371,
      "summary": {
        "text": "Explains centre-level meta-analysis for multicentre studies and defines the two kinds of inconclusive Xpert MTB/XDR results, non-determinate and indeterminate, with an explanatory figure.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "mtb xdr",
          "heading": false
        },
        {
          "term": "non-determinate xpert",
          "heading": false
        },
        {
          "term": "xdr test",
          "heading": false
        },
        {
          "term": "indeterminate xpert",
          "heading": false
        },
        {
          "term": "inconclusive index",
          "heading": false
        },
        {
          "term": "package insert",
          "heading": false
        },
        {
          "term": "cepheid package",
          "heading": false
        },
        {
          "term": "detected",
          "heading": false
        }
      ],
      "extract": "For multicentre studies, we anticipated that there would be variability in terms of how laboratory practices were carried out between different centres. For this reason, when data were available, we performed meta-analyses at the centre level (i.e. treating each centre as a separate study). We excluded MTBC-negative and inconclusive test results from analyses of diagnostic test accuracy. Inconclusive index test",
      "extractCut": true,
      "blocks": [
        "library/10665-381036/blocks/prose-page-640",
        "library/10665-381036/blocks/figure-img-p640-1",
        "library/10665-381036/blocks/figure-vfig-p640"
      ]
    },
    {
      "id": "page-641",
      "number": null,
      "title": "Page 641",
      "level": 1,
      "pageStart": 641,
      "pageEnd": 641,
      "labelStart": "636",
      "labelEnd": "636",
      "words": 481,
      "summary": {
        "text": "Describes how missed, non-determinate and indeterminate results were analysed and how the certainty of evidence was assessed with GRADE, including imprecision and publication bias.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "mtb xdr",
          "heading": false
        },
        {
          "term": "xdr indeterminate",
          "heading": false
        },
        {
          "term": "xpert mtb",
          "heading": false
        },
        {
          "term": "publication bias",
          "heading": false
        },
        {
          "term": "further determined",
          "heading": false
        },
        {
          "term": "downgraded",
          "heading": false
        },
        {
          "term": "schünemann",
          "heading": false
        },
        {
          "term": "among specimens",
          "heading": false
        }
      ],
      "extract": "MTB NOT DETECTED, we further determined the percentage that were resistant or susceptible according to pDST. Xpert MTB/XDR NON-DETERMINATE Among the specimens initially tested, we determined the percentage of Xpert MTB/XDR NON- DETERMINATE results and, of these, the number of ERROR, INVALID, and NO RESULT results. We also determined the percentage of non-determinate results remaining following retesting. Xpert",
      "extractCut": true,
      "blocks": [
        "library/10665-381036/blocks/prose-page-641"
      ]
    },
    {
      "id": "page-642",
      "number": null,
      "title": "Page 642",
      "level": 1,
      "pageStart": 642,
      "pageEnd": 642,
      "labelStart": "637",
      "labelEnd": "637",
      "words": 365,
      "summary": {
        "text": "Reports search results, with three unpublished studies included out of 1,649 records screened, and summarizes the quality assessment and the countries where the studies were done.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "bias because",
          "heading": false
        },
        {
          "term": "unpublished studies",
          "heading": false
        },
        {
          "term": "standard domain",
          "heading": false
        },
        {
          "term": "regarding applicability",
          "heading": false
        },
        {
          "term": "patient selection",
          "heading": false
        },
        {
          "term": "reference standard",
          "heading": false
        },
        {
          "term": "diama",
          "heading": false
        },
        {
          "term": "gdst",
          "heading": false
        }
      ],
      "extract": "identified several unpublished studies, but no publications. We graded publication bias as undetected. RESULTS Results of the search We identified and screened a total of 1,649 records. Of these, we excluded 1620 for relevance to the topic. We retrieved 29 full text articles, including unpublished reports, and excluded 26 mainly because they were not rapid, low-complexity cartridge-based tests. We identified three",
      "extractCut": true,
      "blocks": [
        "library/10665-381036/blocks/prose-page-642"
      ]
    },
    {
      "id": "page-643",
      "number": null,
      "title": "Page 643",
      "level": 1,
      "pageStart": 643,
      "pageEnd": 643,
      "labelStart": "638",
      "labelEnd": "638",
      "words": 77,
      "summary": {
        "text": "Lists the review questions on using Xpert MTB/XDR to detect isoniazid and fluoroquinolone resistance, with captions for the forest plots and risk-of-bias figures.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "mtb xdr",
          "heading": false
        },
        {
          "term": "xdr assay",
          "heading": false
        },
        {
          "term": "isoniazid resistance",
          "heading": false
        }
      ],
      "extract": "PICO questions Should MTB/XDR assay on sputum be used to diagnose isoniazid resistance in patients with microbiologically confirmed pulmonary TB? Figure 3. Forest plots of Xpert MTB/XDR sensitivity and specificity for detection of isoniazid resistance, by population and reference standard. Direct refers to testing directly on sputum. Figure 4. Xpert MTB/XDR, isoniazid resistance, risk of bias and applicability",
      "extractCut": true,
      "blocks": [
        "library/10665-381036/blocks/prose-page-643",
        "library/10665-381036/blocks/figure-img-p643-1",
        "library/10665-381036/blocks/figure-img-p643-2"
      ]
    },
    {
      "id": "page-644",
      "number": null,
      "title": "Page 644",
      "level": 1,
      "pageStart": 644,
      "pageEnd": 644,
      "labelStart": "639",
      "labelEnd": "639",
      "words": 57,
      "summary": {
        "text": "Captions for figures on fluoroquinolone resistance accuracy and the review question on ethionamide resistance.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "mtb xdr",
          "heading": false
        },
        {
          "term": "resistance",
          "heading": false
        },
        {
          "term": "sputum",
          "heading": false
        }
      ],
      "extract": "Figure 5. Forest plots of MTB/XDR sensitivity and specificity for detection of resistance to fluoroquinolones by population and reference standard. Direct refers to testing directly on sputum. Figure 6. Xpert MTB/XDR, fluoroquinolone resistance, risk of bias and applicability concerns. Should MTB/XDR assay on sputum be used to diagnose ethionamide resistance in patients with microbiologically confirmed pulmonary TB?",
      "extractCut": false,
      "blocks": [
        "library/10665-381036/blocks/prose-page-644",
        "library/10665-381036/blocks/figure-img-p644-1"
      ]
    },
    {
      "id": "page-645",
      "number": null,
      "title": "Page 645",
      "level": 1,
      "pageStart": 645,
      "pageEnd": 645,
      "labelStart": "640",
      "labelEnd": "640",
      "words": 57,
      "summary": {
        "text": "Captions for figures on ethionamide resistance accuracy and the review question on amikacin resistance.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "mtb xdr",
          "heading": false
        },
        {
          "term": "ethionamide",
          "heading": false
        },
        {
          "term": "resistance",
          "heading": false
        }
      ],
      "extract": "Figure 7. Forest plots of MTB/XDR sensitivity and specificity for detection of resistance to ethionamide by population and reference standard. Direct refers to testing directly on sputum. Figure 8. Xpert MTB/XDR, ethionamide resistance, risk of bias and applicability concerns. Should MTB/XDR assay on sputum be used to diagnose amikacin resistance in patients with microbiologically confirmed pulmonary TB?",
      "extractCut": false,
      "blocks": [
        "library/10665-381036/blocks/prose-page-645",
        "library/10665-381036/blocks/figure-img-p645-1",
        "library/10665-381036/blocks/figure-img-p645-2"
      ]
    },
    {
      "id": "page-646",
      "number": null,
      "title": "Page 646",
      "level": 1,
      "pageStart": 646,
      "pageEnd": 646,
      "labelStart": "641",
      "labelEnd": "641",
      "words": 88,
      "summary": {
        "text": "Captions for figures on amikacin resistance accuracy and the heading of a table summarizing Xpert MTB/XDR performance for each drug.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "mtb xdr",
          "heading": false
        },
        {
          "term": "xpert mtb",
          "heading": false
        },
        {
          "term": "predictive value",
          "heading": false
        }
      ],
      "extract": "Figure 9. Forest plots of MTB/XDR sensitivity and specificity for detection of resistance to amikacin by population and reference standard. Direct refers to testing directly on sputum. Figure 10. Xpert MTB/XDR, amikacin resistance, risk of bias and applicability concerns. Table 2. Performance of Xpert MTB/XDR for resistance to isoniazid, fluoroquinolones, ethionamide, and amikacin Drug Reference standard No. studies",
      "extractCut": true,
      "blocks": [
        "library/10665-381036/blocks/prose-page-646",
        "library/10665-381036/blocks/figure-img-p646-2"
      ]
    },
    {
      "id": "page-647",
      "number": null,
      "title": "Page 647",
      "level": 1,
      "pageStart": 647,
      "pageEnd": 647,
      "labelStart": "642",
      "labelEnd": "642",
      "words": 626,
      "summary": {
        "text": "A table of pooled sensitivity, specificity and predictive values of Xpert MTB/XDR for isoniazid, fluoroquinolone, ethionamide and amikacin resistance, by population and reference standard. Footnotes explain the abbreviations and the prevalence assumptions used for predictive values.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "amk gdst",
          "heading": false
        },
        {
          "term": "eto gdst",
          "heading": false
        },
        {
          "term": "amk pdst",
          "heading": false
        },
        {
          "term": "inh gdst",
          "heading": false
        },
        {
          "term": "detected rifampicin",
          "heading": false
        },
        {
          "term": "rifampicin resistance",
          "heading": false
        }
      ],
      "extract": "Irrespective of rifampicin resistance INH pDST 3 (1605) 994 (61.9) 94.2 (89.3 to 97.0) 98.0 (95.2 to 99.2) 71.3 (50.1 to 86.0) 99.7 (99.4 to 99.8) INH gDST 2 (999) 682 (68.3) 97.3 (92.8 to 99.0) 98.4 (95.9 to 99.3) 75.6 (55.4 to 88.6) 99.9 (99.6 to 100.0) INH Composite 2 (1055) 768 (72.8) 93.6 (86.5 to 97.1) 99.7 (96.6 to 100.0) 94.2 (58.6 to 99.5) 99.7 (99.3 to 99.8) With detected rifampicin resistance INH pDST 2",
      "extractCut": true,
      "blocks": [
        "library/10665-381036/blocks/prose-page-647"
      ]
    },
    {
      "id": "page-648",
      "number": null,
      "title": "Page 648",
      "level": 1,
      "pageStart": 648,
      "pageEnd": 648,
      "labelStart": "643",
      "labelEnd": "643",
      "words": 500,
      "summary": {
        "text": "Notes that accuracy was similar regardless of rifampicin resistance and lists the 18 review questions by drug, population and reference standard.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "xdr assay",
          "heading": false
        },
        {
          "term": "mtb xdr",
          "heading": false
        },
        {
          "term": "eto resistance",
          "heading": false
        },
        {
          "term": "diagnose eto",
          "heading": false
        },
        {
          "term": "amk resistance",
          "heading": false
        },
        {
          "term": "detected resistance",
          "heading": false
        },
        {
          "term": "confirmed pulmonary",
          "heading": false
        },
        {
          "term": "inh resistance",
          "heading": false
        }
      ],
      "extract": "As seen in Table 2, for each drug, Xpert MTB/XDR pooled sensitivity and specificity estimates were similar in people irrespective of rifampicin resistance and people with detected rifampicin resistance. However, owing to enrolment criteria in the studies, we note that most participants were rifampicin resistant in all analyses. PICO questions 1. Should MTB/XDR assay on sputum be used to diagnose INH resistance in",
      "extractCut": true,
      "blocks": [
        "library/10665-381036/blocks/prose-page-648"
      ]
    },
    {
      "id": "page-649",
      "number": null,
      "title": "Page 649",
      "level": 1,
      "pageStart": 649,
      "pageEnd": 649,
      "labelStart": "644",
      "labelEnd": "644",
      "words": 320,
      "summary": {
        "text": "A GRADE table showing the certainty of evidence for Xpert MTB/XDR sensitivity and specificity for each drug and reference standard, with reasons for downgrading.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "irrespective rifampicin",
          "heading": false
        },
        {
          "term": "rifampicin resistance",
          "heading": false
        },
        {
          "term": "resistance pdst",
          "heading": false
        },
        {
          "term": "detected rifampicin",
          "heading": false
        },
        {
          "term": "downgraded",
          "heading": false
        },
        {
          "term": "eto",
          "heading": false
        },
        {
          "term": "inh",
          "heading": false
        },
        {
          "term": "crs",
          "heading": false
        }
      ],
      "extract": "Table 3. GRADE Certainty of Evidence See Supplement C. GRADE evidence profiles. PICO Drug Population Reference standard No. studies (participants) Pooled sensitivity % (95% CI) Pooled specificity % (95% CI) Certainty Evidence Sens Certainty Evidence Spec Explanations 1 INH Irrespective rifampicin resistance pDST 3 (1605) 94.2 (89.3, 97.0) 98.0 (95.2, 99.2) Moderate Moderate Downgraded one level for indirectness for",
      "extractCut": true,
      "blocks": [
        "library/10665-381036/blocks/prose-page-649"
      ]
    },
    {
      "id": "page-650",
      "number": null,
      "title": "Page 650",
      "level": 1,
      "pageStart": 650,
      "pageEnd": 650,
      "labelStart": "645",
      "labelEnd": "645",
      "words": 244,
      "summary": {
        "text": "Continuation of the GRADE certainty table for ethionamide and amikacin resistance, with abbreviations.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "detected rifampicin",
          "heading": false
        },
        {
          "term": "resistance pdst",
          "heading": false
        },
        {
          "term": "irrespective rifampicin",
          "heading": false
        },
        {
          "term": "amk",
          "heading": false
        },
        {
          "term": "downgraded",
          "heading": false
        },
        {
          "term": "eto",
          "heading": false
        },
        {
          "term": "imprecision",
          "heading": false
        }
      ],
      "extract": "level for risk of bias (specificity) 12 ETO With detected rifampicin resistance pDST 1 (492) 51.7 (33.1, 69.8) 94.8 (84.8, 98.3) Very Low Moderate Downgraded one level for risk of bias, one level for inconsistency, one level for imprecision (sensitivity); downgraded one level for risk of bias (specificity) 13 ETO With detected rifampicin resistance gDST 1 (434) 98.0 (74.2, 99.9) 99.7 (83.5, 100.0) Very Low Very Low",
      "extractCut": true,
      "blocks": [
        "library/10665-381036/blocks/prose-page-650"
      ]
    },
    {
      "id": "page-651",
      "number": null,
      "title": "Page 651",
      "level": 1,
      "pageStart": 651,
      "pageEnd": 651,
      "labelStart": "646",
      "labelEnd": "646",
      "words": 364,
      "summary": {
        "text": "Reports how many specimens were missed as TB not detected by Xpert MTB/XDR and how many were resistant by phenotypic testing, as well as rates of non-determinate results before and after retesting.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "non-determinate rate",
          "heading": false
        },
        {
          "term": "mtb xdr",
          "heading": false
        },
        {
          "term": "specimens tested",
          "heading": false
        },
        {
          "term": "pdst reference",
          "heading": false
        },
        {
          "term": "xpert mtb",
          "heading": false
        },
        {
          "term": "following retesting",
          "heading": false
        },
        {
          "term": "gave valid",
          "heading": false
        },
        {
          "term": "initial testing",
          "heading": false
        }
      ],
      "extract": "Xpert MTB/XDR MTB NOT DETECTED and inconclusive test results Xpert MTB/XDR MTB NOT DETECTED Here we summarize results for Xpert MTB/XDR MTB NOT DETECTED and resistant cases therefore missed. Cepheid 2020 was the only study that reported this information. Isoniazid Of 530 specimens tested, 512 had pDST results available. Of these 512 specimens with pDST results available, 32 (6.3%) were Xpert MTB/XDR MTB NOT",
      "extractCut": true,
      "blocks": [
        "library/10665-381036/blocks/prose-page-651"
      ]
    },
    {
      "id": "page-652",
      "number": null,
      "title": "Page 652",
      "level": 1,
      "pageStart": 652,
      "pageEnd": 652,
      "labelStart": "647",
      "labelEnd": "647",
      "words": 329,
      "summary": {
        "text": "Summarizes indeterminate Xpert MTB/XDR results for each drug in two studies, with their phenotypic resistance status where known.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "mtb xdr",
          "heading": false
        },
        {
          "term": "specimens tested",
          "heading": false
        },
        {
          "term": "mtb detected",
          "heading": false
        },
        {
          "term": "xpert mtb",
          "heading": false
        },
        {
          "term": "indeterminate",
          "heading": false
        },
        {
          "term": "pdst reference",
          "heading": false
        },
        {
          "term": "retesting",
          "heading": false
        },
        {
          "term": "cepheid",
          "heading": false
        }
      ],
      "extract": "647 Indeterminate test results Here we provide a summary of indeterminate results and their pDST status. Isoniazid Cepheid 2020 Of 530 specimens tested, 498 specimens had an Xpert MTB/XDR MTB DETECTED result. Of these 498 specimens, two (0.4%) had indeterminate results for detection of resistance. By the pDST reference standard, of these two specimens, two (100%) were resistant and zero (0%) were susceptible. FIND",
      "extractCut": true,
      "blocks": [
        "library/10665-381036/blocks/prose-page-652"
      ]
    },
    {
      "id": "page-653",
      "number": null,
      "title": "Page 653",
      "level": 1,
      "pageStart": 653,
      "pageEnd": 653,
      "labelStart": "648",
      "labelEnd": "648",
      "words": 224,
      "summary": {
        "text": "Presents sensitivity analyses excluding the manufacturer's study, showing that removing it made little difference to the accuracy estimates.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "cepheid pdst",
          "heading": false
        },
        {
          "term": "sensitivity analyses",
          "heading": false
        },
        {
          "term": "row",
          "heading": false
        },
        {
          "term": "ethionamide",
          "heading": false
        }
      ],
      "extract": "648 Sensitivity analyses Table 4 presents the findings from sensitivity analyses that excluded data from the manufacturer. There are two rows of results presented for each drug. The first row presents the results of the meta- analysis including Cepheid 2020, and the subsequent row, the results of the sensitivity analysis excluding Cepheid 2020 (in bold). These sensitivity analyses made little difference to any of",
      "extractCut": true,
      "blocks": [
        "library/10665-381036/blocks/prose-page-653"
      ]
    },
    {
      "id": "page-654",
      "number": null,
      "title": "Page 654",
      "level": 1,
      "pageStart": 654,
      "pageEnd": 654,
      "labelStart": "649",
      "labelEnd": "649",
      "words": 438,
      "summary": {
        "text": "Begins the discussion by summarizing the main results for each drug and what they would mean per 1000 people tested.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "ethionamide resistance",
          "heading": false
        },
        {
          "term": "mtb xdr-negative",
          "heading": false
        },
        {
          "term": "mtb xdr-positive",
          "heading": false
        },
        {
          "term": "mtb xdr",
          "heading": false
        },
        {
          "term": "fluoroquinolone resistance",
          "heading": false
        },
        {
          "term": "xpert mtb",
          "heading": false
        },
        {
          "term": "isoniazid resistance",
          "heading": false
        },
        {
          "term": "xdr pooled",
          "heading": false
        }
      ],
      "extract": "649 DISCUSSION Summary of main results This systematic review summarizes the current literature and included three unpublished studies on the accuracy of Xpert MTB/XDR for detection of resistance to isoniazid, fluoroquinolones, ethionamide, and amikacin. Xpert MTB/XDR for isoniazid resistance in people with microbiologically confirmed pulmonary tuberculosis irrespective of rifampicin resistance, pDST Xpert MTB/XDR",
      "extractCut": true,
      "blocks": [
        "library/10665-381036/blocks/prose-page-654"
      ]
    },
    {
      "id": "page-655",
      "number": null,
      "title": "Page 655",
      "level": 1,
      "pageStart": 655,
      "pageEnd": 655,
      "labelStart": "650",
      "labelEnd": "650",
      "words": 517,
      "summary": {
        "text": "Completes the summary of amikacin results and sets out the authors' conclusions and research recommendations, such as using comprehensive genotypic reference standards and studying different patient groups.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "mtb xdr",
          "heading": false
        },
        {
          "term": "xdr sensitivity",
          "heading": false
        },
        {
          "term": "amikacin resistance",
          "heading": false
        },
        {
          "term": "xpert mtb",
          "heading": false
        },
        {
          "term": "rifampicin resistance",
          "heading": false
        },
        {
          "term": "people irrespective",
          "heading": false
        },
        {
          "term": "against reference",
          "heading": false
        },
        {
          "term": "smear-negative specimens",
          "heading": false
        }
      ],
      "extract": "650 Xpert MTB/XDR pooled sensitivity and specificity were 89.1% (80.9. to 94.1) and 99.5% (96.9 to 99.9) (2 studies, 1008 participants, 15.0% with amikacin resistance; high-certainty evidence for sensitivity and specificity). Results of these studies indicate that in theory, of 1000 people where 50 have amikacin resistance, 50 would be Xpert MTB/XDR-positive: of these, 5 (10%) would not have amikacin resistance",
      "extractCut": true,
      "blocks": [
        "library/10665-381036/blocks/prose-page-655"
      ]
    },
    {
      "id": "page-656",
      "number": null,
      "title": "Page 656",
      "level": 1,
      "pageStart": 656,
      "pageEnd": 656,
      "labelStart": "651",
      "labelEnd": "651",
      "words": 539,
      "summary": {
        "text": "Ends the research recommendations and gives the acknowledgements, declarations of interest and the start of the reference list.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "mtb xdr",
          "heading": false
        },
        {
          "term": "xpert mtb",
          "heading": false
        },
        {
          "term": "mtb rif",
          "heading": false
        },
        {
          "term": "received funding",
          "heading": false
        },
        {
          "term": "rif ultra",
          "heading": false
        },
        {
          "term": "mycobacterium tuberculosis",
          "heading": false
        },
        {
          "term": "global tuberculosis",
          "heading": false
        },
        {
          "term": "tuberculosis programme",
          "heading": false
        }
      ],
      "extract": "651 diagnostic accuracy of Xpert MTB/XDR for pulmonary tuberculosis in adults, children, and people living with HIV and in people who are smear negative. Acknowledgements We are grateful to Vittoria Lutje, Cochrane Infectious Diseases' Information Specialist, for help with the search strategy. We are grateful to people at Cepheid and FIND and to all members of the DIAMA consortium for providing data and answering",
      "extractCut": true,
      "blocks": [
        "library/10665-381036/blocks/prose-page-656"
      ]
    },
    {
      "id": "page-657",
      "number": null,
      "title": "Page 657",
      "level": 1,
      "pageStart": 657,
      "pageEnd": 657,
      "labelStart": "652",
      "labelEnd": "652",
      "words": 562,
      "summary": {
        "text": "Continuation of the reference list, citing methodological sources and WHO tuberculosis guidance and reports.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "schünemann",
          "heading": false
        },
        {
          "term": "diagnostic accuracy",
          "heading": false
        },
        {
          "term": "grade guidelines",
          "heading": false
        },
        {
          "term": "clinical epidemiology",
          "heading": false
        },
        {
          "term": "test accuracy",
          "heading": false
        },
        {
          "term": "rutjes",
          "heading": false
        },
        {
          "term": "accessed october",
          "heading": false
        },
        {
          "term": "deeks",
          "heading": false
        }
      ],
      "extract": "652 GRADEpro GDT [Computer program]. Version accessed 29 October 2016. Hamilton (ON): McMaster University (developed by Evidence Prime), 2015. Available at gradepro.org. Gopalakrishna 2016 Gopalakrishna G, Langendam MW, Scholten RJ, Bossuyt PM, Leeflang MM. Defining the clinical pathway in Cochrane diagnostic test accuracy reviews. BMC Med Res Methodol. 2016;16(1):153. Heyckendorf 2017 Heyckendorf J, Andres S, Köser",
      "extractCut": true,
      "blocks": [
        "library/10665-381036/blocks/prose-page-657"
      ]
    },
    {
      "id": "page-658",
      "number": null,
      "title": "Page 658",
      "level": 1,
      "pageStart": 658,
      "pageEnd": 658,
      "labelStart": "653",
      "labelEnd": "653",
      "words": 66,
      "summary": {
        "text": "The final references, citing WHO technical reports on critical concentrations and on tuberculosis definitions and reporting.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "critical concentrations",
          "heading": false
        },
        {
          "term": "drug susceptibility",
          "heading": false
        },
        {
          "term": "technical report",
          "heading": false
        }
      ],
      "extract": "653 WHO Critical concentrations 2018 World Health Organization. Technical Report on critical concentrations for drug susceptibility testing of medicines used in the treatment of drug-resistant tuberculosis. (WHO/CDS/TB/2018.5). License: CC BY-NC- SA 3.0 IGO. who.int/tb/publications/2018/WHO_technical_report_concentrations_TB_drug_susceptibility/en/ (accessed 16 July 2020). WHO Definitions and reporting 2020 World",
      "extractCut": true,
      "blocks": [
        "library/10665-381036/blocks/prose-page-658"
      ]
    },
    {
      "id": "page-659",
      "number": null,
      "title": "Page 659",
      "level": 1,
      "pageStart": 659,
      "pageEnd": 659,
      "labelStart": "654",
      "labelEnd": "654",
      "words": 364,
      "summary": {
        "text": "The start of a glossary of terms used in the Xpert MTB/XDR review, defining terms such as amplification, codon, critical concentration and gene targets of the assay.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "detect mutations",
          "heading": false
        },
        {
          "term": "confer resistance",
          "heading": false
        },
        {
          "term": "dna sequencing",
          "heading": false
        },
        {
          "term": "mtb xdr",
          "heading": false
        },
        {
          "term": "gene target",
          "heading": false
        },
        {
          "term": "culture isolate",
          "heading": false
        },
        {
          "term": "tuberculosis cells",
          "heading": false
        },
        {
          "term": "xdr test",
          "heading": false
        }
      ],
      "extract": "654 APPENDICES Appendix 1. Glossary of terms Amplification Amplification is replication of a DNA fragment to generate copies. Both the original and the newly synthesized copies can be described as the amplicons. Codon A codon is a sequence of three DNA or RNA bases that corresponds to a specific amino acid or a signal to start or stop transcription or translation. The DNA in coding regions of the genome is read in",
      "extractCut": true,
      "blocks": [
        "library/10665-381036/blocks/prose-page-659"
      ]
    },
    {
      "id": "page-660",
      "number": null,
      "title": "Page 660",
      "level": 1,
      "pageStart": 660,
      "pageEnd": 660,
      "labelStart": "655",
      "labelEnd": "655",
      "words": 406,
      "summary": {
        "text": "Continuation of the glossary, defining heteroresistance, indeterminate results, the inhA promoter and other gene targets, presumptive tuberculosis and resistance-determining regions.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "intergenic region",
          "heading": false
        },
        {
          "term": "promoter region",
          "heading": false
        },
        {
          "term": "dna sequence",
          "heading": false
        },
        {
          "term": "mtb xdr",
          "heading": false
        },
        {
          "term": "inha promoter",
          "heading": false
        },
        {
          "term": "confer resistance",
          "heading": false
        },
        {
          "term": "xdr test",
          "heading": false
        },
        {
          "term": "xpert mtb",
          "heading": false
        }
      ],
      "extract": "655 Heteroresistance is defined as resistance to certain antibiotics in a subset of a larger microbial population that is generally considered to be susceptible to these antibiotics according to traditional phenotypic drug susceptibility testing. Indeterminate test result An indeterminate Xpert MTB/XDR test result is one that indicates that resistance to a given drug could not definitively be detected based on the",
      "extractCut": true,
      "blocks": [
        "library/10665-381036/blocks/prose-page-660"
      ]
    },
    {
      "id": "page-661",
      "number": null,
      "title": "Page 661",
      "level": 1,
      "pageStart": 661,
      "pageEnd": 661,
      "labelStart": "656",
      "labelEnd": "656",
      "words": 116,
      "summary": {
        "text": "The end of the glossary, defining the rrs gene target, Sanger sequencing, targeted gene sequencing and whole genome sequencing.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "genome",
          "heading": false
        },
        {
          "term": "dna",
          "heading": false
        },
        {
          "term": "sequencing",
          "heading": false
        },
        {
          "term": "gene",
          "heading": false
        }
      ],
      "extract": "656 Gene target included in the Xpert MTB/XDR test to detect mutations that confer resistance to second line injectable drugs, amikacin, kanamycin, and capreomycin. Sanger sequencing Technique for DNA sequencing based upon the selective incorporation of chain-terminating dideoxynucleotides by DNA polymerase during in vitro DNA replication, also known as ‘the chain termination method’. Targeted gene sequencing The",
      "extractCut": true,
      "blocks": [
        "library/10665-381036/blocks/prose-page-661"
      ]
    },
    {
      "id": "page-662",
      "number": null,
      "title": "Page 662",
      "level": 1,
      "pageStart": 662,
      "pageEnd": 662,
      "labelStart": "657",
      "labelEnd": "657",
      "words": 67,
      "summary": {
        "text": "An appendix outlining the possible results for each target of the Xpert MTB/XDR assay, reproduced with permission from the manufacturer.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "mtb detected",
          "heading": false
        },
        {
          "term": "mtb xdr",
          "heading": false
        },
        {
          "term": "xpert mtb",
          "heading": false
        }
      ],
      "extract": "657 Appendix 2. Possible test results for each target in the Xpert MTB/XDR assay Positive results for the Xpert MTB/XDR assay can be MTB DETECTED and all resistance targets are NOT DETECTED, or MTB DETECTED and one or more of the resistance targets is DETECTED, or MTB DETECTED and/or one or more of the following resistance targets is INDETERMINATE. Copyright © [2020] [Cepheid Inc]: reproduced with permission.",
      "extractCut": false,
      "blocks": [
        "library/10665-381036/blocks/prose-page-662",
        "library/10665-381036/blocks/figure-img-p662-1"
      ]
    },
    {
      "id": "page-663",
      "number": null,
      "title": "Page 663",
      "level": 1,
      "pageStart": 663,
      "pageEnd": 663,
      "labelStart": "658",
      "labelEnd": "658",
      "words": 370,
      "summary": {
        "text": "An appendix describing the clinical pathway scenarios in which Xpert MTB/XDR could be used and how results would inform treatment regimens.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "rifampicin susceptibility",
          "heading": false
        },
        {
          "term": "rifampicin resistance",
          "heading": false
        },
        {
          "term": "mtb xdr",
          "heading": false
        },
        {
          "term": "index test",
          "heading": false
        },
        {
          "term": "culture-based dst",
          "heading": false
        },
        {
          "term": "xpert mtb",
          "heading": false
        },
        {
          "term": "ultra rifampicin",
          "heading": false
        },
        {
          "term": "drug resistance",
          "heading": false
        }
      ],
      "extract": "658 Appendix 3. Figure. Clinical pathway The index test may be used in the following scenarios. A. Index test used to diagnose tuberculosis and detect drug resistance. B. Index test used to detect drug resistance in patients newly diagnosed with tuberculosis by another test where rifampicin susceptibility is unknown. Proposed role of Xpert MTB/XDR would be an initial test for resistance to isoniazid and second-line",
      "extractCut": true,
      "blocks": [
        "library/10665-381036/blocks/prose-page-663",
        "library/10665-381036/blocks/figure-img-p663-1"
      ]
    },
    {
      "id": "page-664",
      "number": null,
      "title": "Page 664",
      "level": 1,
      "pageStart": 664,
      "pageEnd": 664,
      "labelStart": "659",
      "labelEnd": "659",
      "words": 164,
      "summary": {
        "text": "The MEDLINE search strategy used for the Xpert MTB/XDR review, combining terms for drug-resistant tuberculosis and cartridge-based tests from 2015 onward.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "slid adj",
          "heading": false
        },
        {
          "term": "fluoroquinolone adj",
          "heading": false
        },
        {
          "term": "adj resistant",
          "heading": false
        },
        {
          "term": "tuberculosis adj",
          "heading": false
        },
        {
          "term": "adj resistance",
          "heading": false
        }
      ],
      "extract": "659 Database: Ovid MEDLINE(R) and Epub Ahead of Print, In-Process & Other Non-Indexed Citations, Daily and Versions(R) <1946 to present> -------------------------------------------------------------------------------- 1 Extensively Drug-Resistant Tuberculosis/ or Tuberculosis, Multidrug-Resistant/ or Tuberculosis, Pulmonary/ 2 (tuberculosis adj3 (lung or pulmonary)).mp. 3 (tuberculosis adj3 respiratory).mp. 4",
      "extractCut": true,
      "blocks": [
        "library/10665-381036/blocks/prose-page-664"
      ]
    },
    {
      "id": "page-665",
      "number": null,
      "title": "Page 665",
      "level": 1,
      "pageStart": 665,
      "pageEnd": 665,
      "labelStart": "660",
      "labelEnd": "660",
      "words": 680,
      "summary": {
        "text": "Sets out how the QUADAS-2 tool was applied for patient selection, explaining how each signalling question was answered and how applicability concerns were judged.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "answered unclear",
          "heading": false
        },
        {
          "term": "answered yes",
          "heading": false
        },
        {
          "term": "signalling question",
          "heading": false
        },
        {
          "term": "unclear concern",
          "heading": false
        },
        {
          "term": "patients enrolled",
          "heading": false
        },
        {
          "term": "enrolled tuberculosis",
          "heading": false
        },
        {
          "term": "cannot tell",
          "heading": false
        },
        {
          "term": "study enrolled",
          "heading": false
        }
      ],
      "extract": "660 Appendix 5. QUADAS-2 Domain 1: Patient selection Detection of tuberculosis Risk of bias: Could the selection of patients have introduced bias? Signalling question 1: Was a consecutive or random sample of patients enrolled? We answered yes if the study enrolled a consecutive or random sample of eligible patients; no if the study selected patients by convenience; and unclear if the study did not report the manner",
      "extractCut": true,
      "blocks": [
        "library/10665-381036/blocks/prose-page-665"
      ]
    },
    {
      "id": "page-666",
      "number": null,
      "title": "Page 666",
      "level": 1,
      "pageStart": 666,
      "pageEnd": 666,
      "labelStart": "661",
      "labelEnd": "661",
      "words": 681,
      "summary": {
        "text": "Continues the QUADAS-2 criteria for the index test and reference standard domains, explaining how blinding and the type of culture were judged.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "answered yes",
          "heading": false
        },
        {
          "term": "answered unclear",
          "heading": false
        },
        {
          "term": "signalling question",
          "heading": false
        },
        {
          "term": "unclear concern",
          "heading": false
        },
        {
          "term": "reference standard",
          "heading": false
        },
        {
          "term": "user interpretation",
          "heading": false
        },
        {
          "term": "printable test",
          "heading": false
        },
        {
          "term": "index test",
          "heading": false
        }
      ],
      "extract": "661 Risk of bias: could the conduct or interpretation of the index test have introduced bias? Signalling question 1: were the index test results interpreted without knowledge of the results of the reference standard? We answered this question yes for all studies where results are automatically generated and the user is provided with printable test results. Thus, there is no room for subjective interpretation of test",
      "extractCut": true,
      "blocks": [
        "library/10665-381036/blocks/prose-page-666"
      ]
    },
    {
      "id": "page-667",
      "number": null,
      "title": "Page 667",
      "level": 1,
      "pageStart": 667,
      "pageEnd": 667,
      "labelStart": "662",
      "labelEnd": "662",
      "words": 526,
      "summary": {
        "text": "Explains how the reliability of each reference standard was judged for detecting resistance to each drug, with a table of required gene loci, and introduces the question of testing on the same material.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "few loci",
          "heading": false
        },
        {
          "term": "loci required",
          "heading": false
        },
        {
          "term": "relevant loci",
          "heading": false
        },
        {
          "term": "inha promoter",
          "heading": false
        },
        {
          "term": "answered yes",
          "heading": false
        },
        {
          "term": "eis promoter",
          "heading": false
        },
        {
          "term": "oxyr ahpc",
          "heading": false
        },
        {
          "term": "ahpc intergenic",
          "heading": false
        }
      ],
      "extract": "662 Detection of drug resistance Risk of bias: could the reference standard, its conduct or its interpretation have introduced bias? Signalling question 1: is the reference standard likely to correctly classify the target condition? We answered these questions for each target condition separately by reference standard as follows. Drug pDST gDST, targeted sequencing Composite (pDST and gDST, targeted sequencing)",
      "extractCut": true,
      "blocks": [
        "library/10665-381036/blocks/prose-page-667"
      ]
    },
    {
      "id": "page-668",
      "number": null,
      "title": "Page 668",
      "level": 1,
      "pageStart": 668,
      "pageEnd": 668,
      "labelStart": "663",
      "labelEnd": "663",
      "words": 745,
      "summary": {
        "text": "Explains how bias from testing different material types and heteroresistance was assessed and gives a table of critical concentrations and breakpoints for drugs used against drug-resistant tuberculosis.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "answered unclear",
          "heading": false
        },
        {
          "term": "answered yes",
          "heading": false
        },
        {
          "term": "signalling question",
          "heading": false
        },
        {
          "term": "domain unclear",
          "heading": false
        },
        {
          "term": "culture isolate",
          "heading": false
        },
        {
          "term": "reference standard",
          "heading": false
        },
        {
          "term": "judged risk",
          "heading": false
        },
        {
          "term": "bias judgement",
          "heading": false
        }
      ],
      "extract": "663 resistant strains present in the original specimen (which would have been used for the index test if direct testing was done) and cause discrepant results. We think this is an important question as it addresses heteroresistance, which often explains discordance between genotypic and phenotypic results. For direct testing of a clinical specimen by the index test: we answered yes if the reference test was done",
      "extractCut": true,
      "blocks": [
        "library/10665-381036/blocks/prose-page-668"
      ]
    },
    {
      "id": "page-669",
      "number": null,
      "title": "Page 669",
      "level": 1,
      "pageStart": 669,
      "pageEnd": 669,
      "labelStart": "664",
      "labelEnd": "664",
      "words": 25,
      "summary": {
        "text": "The end of the table of critical concentrations, covering gatifloxacin, amikacin and ethionamide.",
        "status": "draft"
      },
      "keywords": [],
      "extract": "664 Gatifloxacin 0.5 - - 0.25 Second-line Amikacin 30.0 2.0 - 1.0 Other Ethionamide 40.0 5.0 10.0 5.0 Abbreviations: CB: critical breakpoint; CC: critical concentration",
      "extractCut": false,
      "blocks": [
        "library/10665-381036/blocks/prose-page-669"
      ]
    },
    {
      "id": "page-670",
      "number": null,
      "title": "Page 670",
      "level": 1,
      "pageStart": 670,
      "pageEnd": 670,
      "labelStart": "665",
      "labelEnd": "665",
      "words": 9,
      "summary": {
        "text": "A heading for the appendix on the flow of studies through the review.",
        "status": "draft"
      },
      "keywords": [],
      "extract": "665 Appendix 6. Flow of studies in the review",
      "extractCut": false,
      "blocks": [
        "library/10665-381036/blocks/prose-page-670",
        "library/10665-381036/blocks/figure-img-p670-1"
      ]
    },
    {
      "id": "page-671",
      "number": null,
      "title": "Page 671",
      "level": 1,
      "pageStart": 671,
      "pageEnd": 671,
      "labelStart": "666",
      "labelEnd": "666",
      "words": 672,
      "summary": {
        "text": "Lists the studies included in the review of the Xpert MTB/XDR assay, such as Cepheid, DIAMA and FIND evaluations, then begins a list of excluded studies with the reason for each exclusion. The exclusions include studies that did not test a cartridge-based assay for isoniazid or second-line drug resistance and studies that were not diagnostic accuracy studies. Entries give full bibliographic details.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "cartridge-based test",
          "heading": false
        },
        {
          "term": "melting curve",
          "heading": false
        },
        {
          "term": "second-line drug",
          "heading": false
        },
        {
          "term": "mycobacterium tuberculosis",
          "heading": false
        },
        {
          "term": "drug resistance",
          "heading": false
        },
        {
          "term": "clinical microbiology",
          "heading": false
        },
        {
          "term": "resistant mycobacterium",
          "heading": false
        },
        {
          "term": "xpert mtb",
          "heading": false
        }
      ],
      "extract": "666 Appendix 7. List of studies Included studies Cepheid 2020 Clinical evaluation of the Xpert® MTBXDR assay Report R244C2 Xpert MTB/XDR Rev 1.0 Sponsor: Cepheid, Sunnyvale, USA DIAMA 2020 DIAgnostics for Multidrug Resistant Tuberculosis in Africa ClinicalTrials.gov Identifier: NCT03303963 Sponsor: Dissou Affolabi, Kigali, Rwanda FIND 2020 Analytical Performance and Clinical Diagnostic Accuracy of the Xpert MTB/XDR",
      "extractCut": true,
      "blocks": [
        "library/10665-381036/blocks/prose-page-671"
      ]
    },
    {
      "id": "page-672",
      "number": null,
      "title": "Page 672",
      "level": 1,
      "pageStart": 672,
      "pageEnd": 672,
      "labelStart": "667",
      "labelEnd": "667",
      "words": 578,
      "summary": {
        "text": "Continues the list of excluded studies for the Xpert MTB/XDR review, giving each citation and its reason for exclusion, such as being a prototype test or a different assay.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "cartridge-based test",
          "heading": false
        },
        {
          "term": "second-line drug",
          "heading": false
        },
        {
          "term": "max mdr-tb",
          "heading": false
        },
        {
          "term": "quantamatrix multiplexed",
          "heading": false
        },
        {
          "term": "mycobacterium tuberculosis",
          "heading": false
        },
        {
          "term": "drug resistance",
          "heading": false
        },
        {
          "term": "multiplexed assay",
          "heading": false
        },
        {
          "term": "drug-resistant tuberculosis",
          "heading": false
        }
      ],
      "extract": "667 Tuberculosis and Respiratory Diseases. 2015;38(9):680-5. (Not a cartridge-based test for isoniazid or second-line drug resistance) 14. Kim S, Kim Y, Chang Y, Hirgo WK, Chang CL, Shim T-S, et al. Comparison of Quantamatrix multiplexed assay platform and GenoType MTBDR assay using smear-positive sputum specimens from patients with multidrug- resistant/extensively drug-resistant tuberculosis in South Korea.",
      "extractCut": true,
      "blocks": [
        "library/10665-381036/blocks/prose-page-672"
      ]
    },
    {
      "id": "page-673",
      "number": null,
      "title": "Page 673",
      "level": 1,
      "pageStart": 673,
      "pageEnd": 673,
      "labelStart": "668",
      "labelEnd": "668",
      "words": 168,
      "summary": {
        "text": "A table of characteristics of the studies included in the Xpert MTB/XDR review, giving countries, design, number of patients, age, HIV status and the reference standards and gene loci used.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "eis promoter",
          "heading": false
        },
        {
          "term": "oxyr ahpc",
          "heading": false
        },
        {
          "term": "inha promoter",
          "heading": false
        },
        {
          "term": "ahpc intergenic",
          "heading": false
        },
        {
          "term": "pdst gdst",
          "heading": false
        },
        {
          "term": "cross sectional",
          "heading": false
        }
      ],
      "extract": "668 Appendix 8. Table. Characteristics of included studies Study year Countries/centres (High MDR Burden) Study design Number of patients (% detected RR) Age of enrolment PLHIV Reference standard for drug resistance Loci included in gDST reference standard Cepheid 2020 China (yes) South Africa (yes) cross- sectional, retrospective1 530 (47.9%) ≥ 15 years2 NR pDST gDST composite katG, inhA promoter, oxyR- ahpC",
      "extractCut": true,
      "blocks": [
        "library/10665-381036/blocks/prose-page-673"
      ]
    },
    {
      "id": "page-674",
      "number": null,
      "title": "Page 674",
      "level": 1,
      "pageStart": 674,
      "pageEnd": 674,
      "labelStart": "669",
      "labelEnd": "669",
      "words": 392,
      "summary": {
        "text": "Introduces a supplement on MeltPro XDR-TB, a low-complexity test for TB drug resistance evaluated in a Chinese clinical study reported to the reviewers by WHO, and describes the study's setting and participants.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "meltpro xdr-tb",
          "heading": false
        },
        {
          "term": "xdr-tb bases",
          "heading": false
        },
        {
          "term": "xiamen zeesan",
          "heading": false
        },
        {
          "term": "promoter region",
          "heading": false
        },
        {
          "term": "bases detection",
          "heading": false
        },
        {
          "term": "drug resistance",
          "heading": false
        },
        {
          "term": "study authors",
          "heading": false
        },
        {
          "term": "clinical study",
          "heading": false
        }
      ],
      "extract": "669 SUPPLEMENTARY INFORMATION Supplement A. MeltPro® XDR-TB Background On 30 October 2020, we were notified by the WHO Global Tuberculosis Programme about a clinical study conducted in China evaluating MeltPro® XDR-TB (Xiamen Zeesan Biotech Co., Ltd., China), a low complexity test for resistance to anti-tuberculosis drugs. The WHO provided us with a report summarizing the clinical study. We corresponded with study",
      "extractCut": true,
      "blocks": [
        "library/10665-381036/blocks/prose-page-674",
        "library/10665-381036/blocks/figure-img-p674-1"
      ]
    },
    {
      "id": "page-675",
      "number": null,
      "title": "Page 675",
      "level": 1,
      "pageStart": 675,
      "pageEnd": 675,
      "labelStart": "670",
      "labelEnd": "670",
      "words": 415,
      "summary": {
        "text": "Describes how sputum samples were selected for the MeltPro XDR-TB study and how discordant results with phenotypic testing were investigated by sequencing, starting with isoniazid.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "meltpro xdr-tb",
          "heading": false
        },
        {
          "term": "meltpro sensitivity",
          "heading": false
        },
        {
          "term": "rifampicin susceptibility",
          "heading": false
        },
        {
          "term": "rifampicin resistance",
          "heading": false
        },
        {
          "term": "isoniazid resistant",
          "heading": false
        },
        {
          "term": "whose dst",
          "heading": false
        },
        {
          "term": "resolve discordant",
          "heading": false
        },
        {
          "term": "samples whose",
          "heading": false
        }
      ],
      "extract": "670 Sputum samples were selected from patients who had submitted specimens for culture and subsequent drug-susceptibility testing during the routine work of the clinical laboratory of the hospital. All selected samples were first tested by the MeltPro®MTB Test Kit (Xiamen Zeesan Biotech Co., Ltd.) and if found to be TB positive, the sample was eligible for inclusion. The authors stated, “In other words, samples",
      "extractCut": true,
      "blocks": [
        "library/10665-381036/blocks/prose-page-675"
      ]
    },
    {
      "id": "page-676",
      "number": null,
      "title": "Page 676",
      "level": 1,
      "pageStart": 676,
      "pageEnd": 676,
      "labelStart": "671",
      "labelEnd": "671",
      "words": 182,
      "summary": {
        "text": "Reports sequencing findings for MeltPro XDR-TB results that disagreed with phenotypic testing for isoniazid and fluoroquinolones, with forest plots of sensitivity and specificity by rifampicin resistance status.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "meltpro xdr-tb",
          "heading": false
        },
        {
          "term": "amikacin sensitive",
          "heading": false
        },
        {
          "term": "amikacin resistant",
          "heading": false
        },
        {
          "term": "fluoroquinolone sensitive",
          "heading": false
        },
        {
          "term": "whose dst",
          "heading": false
        },
        {
          "term": "samples whose",
          "heading": false
        }
      ],
      "extract": "671 isoniazid sensitive by MeltPro XDR-TB. Sequencing results showed that none of them showed any mutation in the coverage area of the probes. Fluoroquinolones: There were 20 samples whose DST was fluoroquinolone sensitive but detected as fluoroquinolone resistant by MeltPro XDR-TB. Sequencing results showed that all of them had mutations in gyrA. There were 10 samples whose DST was fluoroquinolone resistant but",
      "extractCut": true,
      "blocks": [
        "library/10665-381036/blocks/prose-page-676",
        "library/10665-381036/blocks/figure-img-p676-1"
      ]
    },
    {
      "id": "page-677",
      "number": null,
      "title": "Page 677",
      "level": 1,
      "pageStart": 677,
      "pageEnd": 677,
      "labelStart": "672",
      "labelEnd": "672",
      "words": 49,
      "summary": {
        "text": "A supplement showing forest plots of Xpert MTB/XDR accuracy for diagnosing pulmonary TB by population against culture.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "mtb xdr",
          "heading": false
        },
        {
          "term": "xpert mtb",
          "heading": false
        },
        {
          "term": "sputum",
          "heading": false
        }
      ],
      "extract": "672 Supplement B. Should Xpert MTB/XDR assay on sputum be used to diagnose PTB in people with signs and symptoms of TB? Figure. Forest plots of Xpert MTB/XDR sensitivity and specificity for the diagnosis of pulmonary tuberculosis by population, culture reference standard. Direct refers to testing directly on sputum",
      "extractCut": false,
      "blocks": [
        "library/10665-381036/blocks/prose-page-677",
        "library/10665-381036/blocks/figure-img-p677-1"
      ]
    },
    {
      "id": "page-678",
      "number": null,
      "title": "Page 678",
      "level": 1,
      "pageStart": 678,
      "pageEnd": 678,
      "labelStart": "673",
      "labelEnd": "673",
      "words": 470,
      "summary": {
        "text": "A GRADE evidence profile for Xpert MTB/XDR detection of isoniazid resistance against phenotypic testing, with pooled sensitivity of 0.94 and specificity of 0.98, effects per 1000 patients at different prevalences, and certainty judgements.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "seriou none",
          "heading": false
        },
        {
          "term": "mdr strains",
          "heading": false
        },
        {
          "term": "isoniazid resistance",
          "heading": false
        },
        {
          "term": "studie",
          "heading": false
        },
        {
          "term": "inh",
          "heading": false
        },
        {
          "term": "mtb xdr",
          "heading": false
        },
        {
          "term": "ity",
          "heading": false
        },
        {
          "term": "cross section",
          "heading": false
        }
      ],
      "extract": "673 Supplement C. GRADE evidence profiles 1. Question: Should MTB/XDR assay on sputum be used to diagnose INH resistance in patients with microbiologically confirmed pulmonary TB, irrespective of resistance to RIF, pDST? Sensitivity 0.94 (95% CI: 0.89 to 0.97) Specificity 0.98 (95% CI: 0.95 to 0.99) Outco m e № of studie s (№ of patien t s) Study design Factors that may decrease certainty of evidence Effect per",
      "extractCut": true,
      "blocks": [
        "library/10665-381036/blocks/prose-page-678"
      ]
    },
    {
      "id": "page-679",
      "number": null,
      "title": "Page 679",
      "level": 1,
      "pageStart": 679,
      "pageEnd": 679,
      "labelStart": "674",
      "labelEnd": "674",
      "words": 173,
      "summary": {
        "text": "Begins Web Annex B.15, a table of fluoroquinolone drug concentrations used in culture-based susceptibility testing in studies of second-line line probe assays, compared with WHO-recommended critical concentrations.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "ofloxacin",
          "heading": false
        },
        {
          "term": "agar proportion",
          "heading": false
        },
        {
          "term": "drug concentrations",
          "heading": false
        },
        {
          "term": "culture-based drug",
          "heading": false
        },
        {
          "term": "moxifloxacin",
          "heading": false
        },
        {
          "term": "drug susceptibility",
          "heading": false
        }
      ],
      "extract": "This report has been prepared for the WHO Global TB Programme. Please do not distribute further. 674 Web Annex B.15. Drug concentrations used in culture-based drug susceptibility testing for included studies on second-line line probe assays diagnostic accuracy7 Table 1. Ofloxacin, levofloxacin, and moxifloxacin, drug concentrations used in culture-based drug susceptibility testing in relation to the WHO- recommended",
      "extractCut": true,
      "blocks": [
        "library/10665-381036/blocks/prose-page-679"
      ]
    },
    {
      "id": "page-680",
      "number": null,
      "title": "Page 680",
      "level": 1,
      "pageStart": 680,
      "pageEnd": 680,
      "labelStart": "675",
      "labelEnd": "675",
      "words": 238,
      "summary": {
        "text": "Continues the table of ofloxacin, levofloxacin and moxifloxacin concentrations used by each study, by culture medium, and whether they matched WHO critical concentrations.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "bact alert",
          "heading": false
        },
        {
          "term": "ofloxacin",
          "heading": false
        },
        {
          "term": "mgit",
          "heading": false
        },
        {
          "term": "recommended concentration",
          "heading": false
        },
        {
          "term": "concentration specified",
          "heading": false
        },
        {
          "term": "middlebrook",
          "heading": false
        }
      ],
      "extract": "This report has been prepared for the WHO Global TB Programme. Please do not distribute further. 675 Hillemann 2009 MGIT 960 and LJ Ofloxacin: 2.0 for both media Yes for MGIT; no for LJ Huang 2011 MGIT 960 and Middlebrook 7H11 Ofloxacin: 2.0 Yes for both media Ignatyeva 2012 MGIT 960 Ofloxacin: 2.0 Yes Jin 2013 LJ and BacT/ALERT 3D Ofloxacin: 5.0 (LJ); 50 (BacT/ALERT 3D) No for LJ; Not applicable BacT/ALERT 3D No",
      "extractCut": true,
      "blocks": [
        "library/10665-381036/blocks/prose-page-680"
      ]
    },
    {
      "id": "page-681",
      "number": null,
      "title": "Page 681",
      "level": 1,
      "pageStart": 681,
      "pageEnd": 681,
      "labelStart": "676",
      "labelEnd": "676",
      "words": 194,
      "summary": {
        "text": "Completes the fluoroquinolone concentration table and begins a table of amikacin, kanamycin and capreomycin concentrations used in included studies.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "agar proportion",
          "heading": false
        },
        {
          "term": "concentration specified",
          "heading": false
        },
        {
          "term": "recommended concentration",
          "heading": false
        },
        {
          "term": "kanamycin",
          "heading": false
        },
        {
          "term": "critical concentrations",
          "heading": false
        },
        {
          "term": "mgit",
          "heading": false
        }
      ],
      "extract": "This report has been prepared for the WHO Global TB Programme. Please do not distribute further. 676 Tomasicchio 2016 MGIT 960 Ofloxacin: 2.0 Yes Tukvadze 2014 LJ (proportion method) Ofloxacin: 2.0 No van Ingen 2010 Middlebrook 7H10 (agar proportion) Moxifloxacin: 1.0 No Zivanovic 2012 MGIT 960 and LJ agar proportion Ofloxacin: 2.0 for both media Yes for MGIT; no for LJ LJ-Löwenstein-Jensen; MGIT –Mycobacterial",
      "extractCut": true,
      "blocks": [
        "library/10665-381036/blocks/prose-page-681"
      ]
    },
    {
      "id": "page-682",
      "number": null,
      "title": "Page 682",
      "level": 1,
      "pageStart": 682,
      "pageEnd": 682,
      "labelStart": "677",
      "labelEnd": "677",
      "words": 206,
      "summary": {
        "text": "Continues the table of second-line injectable drug concentrations used in culture-based susceptibility testing, by study and medium, with agreement with WHO recommendations.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "mgit",
          "heading": false
        },
        {
          "term": "capreomycin",
          "heading": false
        },
        {
          "term": "kanamycin",
          "heading": false
        },
        {
          "term": "bact alert",
          "heading": false
        },
        {
          "term": "amikacin",
          "heading": false
        },
        {
          "term": "agar proportion",
          "heading": false
        }
      ],
      "extract": "This report has been prepared for the WHO Global TB Programme. Please do not distribute further. 677 Capreomycin: unknown Not applicable Fan 2011 MGIT 960 Amikacin: 1.0 Yes Ferro 2013 Middlebrook 7H10 (agar proportion) Amikacin: 5.0 No Kanamycin: 5.0 Yes FIND 2016 MGIT 960 Amikacin: 1.0 Yes Kanamycin: 2.5 Yes Capreomycin: 2.5 Yes Hillemann 2009 MGIT 960 and LJ (agar proportion) Amikacin: 1.0 for MGIT and 40.0 for LJ",
      "extractCut": true,
      "blocks": [
        "library/10665-381036/blocks/prose-page-682"
      ]
    },
    {
      "id": "page-683",
      "number": null,
      "title": "Page 683",
      "level": 1,
      "pageStart": 683,
      "pageEnd": 683,
      "labelStart": "678",
      "labelEnd": "678",
      "words": 193,
      "summary": {
        "text": "Further rows of the amikacin, kanamycin and capreomycin concentration table for included studies.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "agar proportion",
          "heading": false
        },
        {
          "term": "mgit",
          "heading": false
        },
        {
          "term": "capreomycin",
          "heading": false
        },
        {
          "term": "middlebrook",
          "heading": false
        },
        {
          "term": "kanamycin",
          "heading": false
        }
      ],
      "extract": "This report has been prepared for the WHO Global TB Programme. Please do not distribute further. 678 Miotto 2012 MGIT 960 Amikacin: 1.0 Yes Kanamycin: 5.0 No Capreomycin: 2.5 Yes NICD 2015 MGIT 960 Amikacin: 1.0 Yes Kanamycin: 2.5 Yes Capreomycin: 2.5 Yes Said 2012 Middlebrook 7H11 Kanamycin: 5.0 No Capreomycin: 10.0 No Simons 2015 MGIT 960 and Middlebrook 7H10 (agar dilution) Amikacin: 1.0 for MGIT and 5.0 for",
      "extractCut": true,
      "blocks": [
        "library/10665-381036/blocks/prose-page-683"
      ]
    },
    {
      "id": "page-684",
      "number": null,
      "title": "Page 684",
      "level": 1,
      "pageStart": 684,
      "pageEnd": 684,
      "labelStart": "679",
      "labelEnd": "679",
      "words": 53,
      "summary": {
        "text": "The end of the injectable drug concentration table, with abbreviations and a reference to WHO's 2012 interim critical concentrations.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "mgit",
          "heading": false
        },
        {
          "term": "lj-lo",
          "heading": false
        },
        {
          "term": "wenstein-jensen",
          "heading": false
        }
      ],
      "extract": "This report has been prepared for the WHO Global TB Programme. Please do not distribute further. 679 Capreomycin: 2.5 for MGIT and 40.0 for LJ Yes for both types of media LJ-Löwenstein-Jensen; MGIT –Mycobacterial growth indicator tube Reference: WHO, Updated interim critical concentrations for first-line and second-line DST (as of May 2012)",
      "extractCut": true,
      "blocks": [
        "library/10665-381036/blocks/prose-page-684"
      ]
    },
    {
      "id": "page-685",
      "number": null,
      "title": "Page 685",
      "level": 1,
      "pageStart": 685,
      "pageEnd": 685,
      "labelStart": "680",
      "labelEnd": "680",
      "words": 17,
      "summary": {
        "text": "A near-empty page carrying only the distribution notice and a page number.",
        "status": "draft"
      },
      "keywords": [],
      "extract": "This report has been prepared for the WHO Global TB Programme. Please do not distribute further. 680",
      "extractCut": false,
      "blocks": [
        "library/10665-381036/blocks/prose-page-685"
      ]
    },
    {
      "id": "page-686",
      "number": null,
      "title": "Page 686",
      "level": 1,
      "pageStart": 686,
      "pageEnd": 686,
      "labelStart": "681",
      "labelEnd": "681",
      "words": 79,
      "summary": {
        "text": "The title page of Web Annex D.17, a systematic review of the accuracy of high-complexity hybridisation-based NAATs for detecting pyrazinamide resistance, with authors and affiliations.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "michael whitfield",
          "heading": false
        },
        {
          "term": "college london",
          "heading": false
        },
        {
          "term": "informatics research",
          "heading": false
        },
        {
          "term": "united kingdom",
          "heading": false
        }
      ],
      "extract": "Web Annex D.17. High complexity hybridization-based NAATs: Diagnostic accuracy for detection of resistance to pyrazinamide. A systematic review Dr. Michael G Whitfield1,2 and Prof. Dr. Annelies van Rie1 1Family Medicine and Population Health (FAMPOP), Faculty of Medicine and Health Sciences, University of Antwerp, Antwerp, Belgium; 2Institute of Health Informatics Research, University College London, London, United",
      "extractCut": true,
      "blocks": [
        "library/10665-381036/blocks/prose-page-686"
      ]
    },
    {
      "id": "page-687",
      "number": null,
      "title": "Page 687",
      "level": 1,
      "pageStart": 687,
      "pageEnd": 687,
      "labelStart": "682",
      "labelEnd": "682",
      "words": 455,
      "summary": {
        "text": "Gives background on the TB and MDR/RR-TB burden in 2019 and on the need to detect pyrazinamide resistance, and explains that the GenoScholar PZA-TB line probe assay lacks specific mutant probes because resistance mutations are spread across the pncA gene.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "pza resistance",
          "heading": false
        },
        {
          "term": "pnca gene",
          "heading": false
        },
        {
          "term": "mdr rr-tb",
          "heading": false
        },
        {
          "term": "genoscholar pza-tb",
          "heading": false
        },
        {
          "term": "mtb rif",
          "heading": false
        },
        {
          "term": "hybridization-based technology",
          "heading": false
        },
        {
          "term": "million cases",
          "heading": false
        },
        {
          "term": "mutations",
          "heading": false
        }
      ],
      "extract": "BACKGROUND Mycobacterium tuberculosis (MTB) remains in the top 10 of causes for death globally, with an estimated 10 million cases and 1.2 million deaths globally in 2019.1 Of the 10 million cases, an estimated 465,000 were incident cases of multidrug resistant (MDR)/ rifampicin resistant (RR) tuberculosis, a marker for MDR-tuberculosis (TB).1 There have been great improvements in the detection of MTB and resistance",
      "extractCut": true,
      "blocks": [
        "library/10665-381036/blocks/prose-page-687"
      ]
    },
    {
      "id": "page-688",
      "number": null,
      "title": "Page 688",
      "level": 1,
      "pageStart": 688,
      "pageEnd": 688,
      "labelStart": "683",
      "labelEnd": "683",
      "words": 439,
      "summary": {
        "text": "Describes how the GenoScholar PZA-TB assay amplifies and hybridises the pncA gene region, and sets out the review's eligibility criteria requiring comparison with phenotypic or sequencing-based reference standards.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "pza lpa",
          "heading": false
        },
        {
          "term": "pza-tb lpa",
          "heading": false
        },
        {
          "term": "pza resistance",
          "heading": false
        },
        {
          "term": "genoscholar pza-tb",
          "heading": false
        },
        {
          "term": "lpa assay",
          "heading": false
        },
        {
          "term": "pnca gene",
          "heading": false
        },
        {
          "term": "rifampicin resistance",
          "heading": false
        },
        {
          "term": "probes",
          "heading": false
        }
      ],
      "extract": "GenoScholar PZA-TB assay targets a 700bp fragment that covers the entire pncA gene and promoter region up to nucleotide -18 of the wild type H37Rv reference strain. DNA extracted from clinical specimens or cultures is amplified with primers by the polymerase chain reaction (PCR). Amplified DNA than hybridize to complementary oligonucleotides probes that are bound on a membrane-based strip. After allowing for",
      "extractCut": true,
      "blocks": [
        "library/10665-381036/blocks/prose-page-688"
      ]
    },
    {
      "id": "page-689",
      "number": null,
      "title": "Page 689",
      "level": 1,
      "pageStart": 689,
      "pageEnd": 689,
      "labelStart": "684",
      "labelEnd": "684",
      "words": 291,
      "summary": {
        "text": "Continues the inclusion criteria, limited to M. tuberculosis data from sputum or cultures, and describes the literature search and contact with the manufacturer for unpublished data.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "pnca wild",
          "heading": false
        },
        {
          "term": "wild type",
          "heading": false
        },
        {
          "term": "microbiological reference",
          "heading": false
        },
        {
          "term": "reference standard",
          "heading": false
        },
        {
          "term": "predictive value",
          "heading": false
        },
        {
          "term": "index test",
          "heading": false
        },
        {
          "term": "rifampicin resistance",
          "heading": false
        },
        {
          "term": "considered resistant",
          "heading": false
        }
      ],
      "extract": "684 for inclusion is they reported data comparing the index test to an acceptable reference standard (defined below) from which we could extract true positive (TP), true negative (TN), false negative (FN) and false positive (FP) values. We only included data on Mycobacterium tuberculosis and excluded any data on nontuberculous mycobacteria. We included results obtained from sputum samples or MTB cultures retrieved",
      "extractCut": true,
      "blocks": [
        "library/10665-381036/blocks/prose-page-689"
      ]
    },
    {
      "id": "page-690",
      "number": null,
      "title": "Page 690",
      "level": 1,
      "pageStart": 690,
      "pageEnd": 690,
      "labelStart": "685",
      "labelEnd": "685",
      "words": 407,
      "summary": {
        "text": "Describes study selection and data extraction by two reviewers, quality assessment and the approach to GRADE certainty, including projected test results at given resistance prevalences.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "resolved disagreements",
          "heading": false
        },
        {
          "term": "reviewer authors",
          "heading": false
        },
        {
          "term": "review authors",
          "heading": false
        },
        {
          "term": "quadas tool",
          "heading": false
        },
        {
          "term": "methodological quality",
          "heading": false
        },
        {
          "term": "standardized form",
          "heading": false
        },
        {
          "term": "gdt",
          "heading": false
        },
        {
          "term": "pooling",
          "heading": false
        }
      ],
      "extract": "685 Two review authors independently assessed studies for eligibility. We resolved disagreements by discussion between the two reviewer authors. We illustrate the study selection process in a PRISMA diagram. Data extraction Two review authors independently extracted data from the included studies using a standardized form. Data was extracted using a standardized form and included first author name; publication year,",
      "extractCut": true,
      "blocks": [
        "library/10665-381036/blocks/prose-page-690"
      ]
    },
    {
      "id": "page-691",
      "number": null,
      "title": "Page 691",
      "level": 1,
      "pageStart": 691,
      "pageEnd": 691,
      "labelStart": "686",
      "labelEnd": "686",
      "words": 179,
      "summary": {
        "text": "Gives the pyrazinamide resistance prevalences used for GRADE judgements and the rating of publication bias, then summarises the search results with a PRISMA diagram and exclusion reasons.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "pza lpa",
          "heading": false
        },
        {
          "term": "publication bias",
          "heading": false
        },
        {
          "term": "exclusion",
          "heading": false
        },
        {
          "term": "diagram",
          "heading": false
        },
        {
          "term": "reasons",
          "heading": false
        },
        {
          "term": "prisma",
          "heading": false
        }
      ],
      "extract": "686 judgements on imprecision from these calculations. Prevalence’s were selected based on published prevalence’s of PZA resistance, which are mainly determined by the MTB drug resistance profile: 8% prevalence PZA-R for any person with TB; 50% for MDR/RR-TB and 90% for extensively drug resistant (XDR)-TB.8-10, 22-24 Publication bias: we rated publication bias as undetected (not serious) because of the",
      "extractCut": true,
      "blocks": [
        "library/10665-381036/blocks/prose-page-691",
        "library/10665-381036/blocks/figure-img-p691-1"
      ]
    },
    {
      "id": "page-692",
      "number": null,
      "title": "Page 692",
      "level": 1,
      "pageStart": 692,
      "pageEnd": 692,
      "labelStart": "687",
      "labelEnd": "687",
      "words": 399,
      "summary": {
        "text": "Presents the QUADAS-2 quality assessment of included studies, noting that many had high risk of bias in patient selection because isolates were chosen by resistance status, with a per-study table.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "selection domain",
          "heading": false
        },
        {
          "term": "patient selection",
          "heading": false
        },
        {
          "term": "index test",
          "heading": false
        },
        {
          "term": "reference standard",
          "heading": false
        },
        {
          "term": "pza resistance",
          "heading": false
        },
        {
          "term": "judged",
          "heading": false
        },
        {
          "term": "reference methods",
          "heading": false
        },
        {
          "term": "bias",
          "heading": false
        }
      ],
      "extract": "687 RISK OF BIAS APPLICABILITY CONCERNS Review article 20 General article about TB (DR-TB) 9 Article studying NTMs 3 Commentary or editorials 3 Total 89 Quality assessment of studies The results of the assessment of methodical quality using the QUADAS-2 tool is shown in Table 1 and Figure 2. For the patient selection domain, we judge 44% of studies to have high risk of bias because they selected specific isolates",
      "extractCut": true,
      "blocks": [
        "library/10665-381036/blocks/prose-page-692",
        "library/10665-381036/blocks/figure-vfig-p692"
      ]
    },
    {
      "id": "page-693",
      "number": null,
      "title": "Page 693",
      "level": 1,
      "pageStart": 693,
      "pageEnd": 693,
      "labelStart": "688",
      "labelEnd": "688",
      "words": 192,
      "summary": {
        "text": "A chart of QUADAS-2 risk of bias and applicability results, followed by the PICO and GRADE questions on using the PZA line probe assay on sputum.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "pza lpa",
          "heading": false
        },
        {
          "term": "pza resistance",
          "heading": false
        },
        {
          "term": "lpa assay",
          "heading": false
        },
        {
          "term": "quadas domain",
          "heading": false
        },
        {
          "term": "perform stratified",
          "heading": false
        },
        {
          "term": "stratified analysis",
          "heading": false
        }
      ],
      "extract": "688 + Low - High ? Unclear Figure 2: Overview of QUADAS-2 assessment results. Patient Selection Index Test Reference Standard Flow & Timing Low High Unclear 0% 20% 40% 60% 80% 100% Proportion of studies with high, low or unclear RISK of BIAS Patient Selection Index Test Reference Standard Low High Unclear 0% 20% 40% 60% 80% 100% Proportion of studies with high, low or unclear CONCERNS regarding APPLICABILITY PICO",
      "extractCut": true,
      "blocks": [
        "library/10665-381036/blocks/prose-page-693"
      ]
    },
    {
      "id": "page-694",
      "number": null,
      "title": "Page 694",
      "level": 1,
      "pageStart": 694,
      "pageEnd": 694,
      "labelStart": "689",
      "labelEnd": "689",
      "words": 11,
      "summary": {
        "text": "A one-line note that no pooled estimates were possible because too few studies were available.",
        "status": "draft"
      },
      "keywords": [],
      "extract": "No pooled estimates – too few studies to inform on certainty.",
      "extractCut": false,
      "blocks": [
        "library/10665-381036/blocks/prose-page-694"
      ]
    },
    {
      "id": "page-695",
      "number": null,
      "title": "Page 695",
      "level": 1,
      "pageStart": 695,
      "pageEnd": 695,
      "labelStart": "690",
      "labelEnd": "690",
      "words": 271,
      "summary": {
        "text": "Forest plots of Nipro PZA line probe assay accuracy against phenotypic testing, with further PICO questions on sputum testing against other reference standards.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "pza lpa",
          "heading": false
        },
        {
          "term": "pza resistance",
          "heading": false
        },
        {
          "term": "pza assay",
          "heading": false
        },
        {
          "term": "nipro pza",
          "heading": false
        },
        {
          "term": "diagnose pza",
          "heading": false
        },
        {
          "term": "susceptibility pza",
          "heading": false
        },
        {
          "term": "lpa sensitivity",
          "heading": false
        },
        {
          "term": "confirmed ptb",
          "heading": false
        }
      ],
      "extract": "690 Figure 3: Forest plots of Nipro PZA LPA sensitivity and specificity for detection of PZA resistance against a reference standard of phenotypic drug susceptibility PZA assay (microbiological reference standard). The squares represent the sensitivity and specificity of one study, the black line its confidence interval. TP: true-positive; FP: false-positive; FN: false-negative; TN: true-negative. 43) Should PZA LPA",
      "extractCut": true,
      "blocks": [
        "library/10665-381036/blocks/prose-page-695",
        "library/10665-381036/blocks/figure-img-p695-1",
        "library/10665-381036/blocks/figure-img-p695-2"
      ]
    },
    {
      "id": "page-696",
      "number": null,
      "title": "Page 696",
      "level": 1,
      "pageStart": 696,
      "pageEnd": 696,
      "labelStart": "691",
      "labelEnd": "691",
      "words": 264,
      "summary": {
        "text": "States that no studies were available for some questions and presents summary and GRADE tables for PZA line probe assay accuracy on sputum, mostly with no data.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "estimable",
          "heading": false
        },
        {
          "term": "resistance gdst",
          "heading": false
        },
        {
          "term": "resistance pdst",
          "heading": false
        },
        {
          "term": "rifampicin resistance",
          "heading": false
        },
        {
          "term": "detected rifampicin",
          "heading": false
        },
        {
          "term": "pico sub",
          "heading": false
        },
        {
          "term": "crs",
          "heading": false
        }
      ],
      "extract": "691 No studies available to inform on decision. Table 2: PICO 1 summary: diagnostic accuracy of PZA LPA for detection of PZA resistance in sputum from pulmonary TB patients with and without RR-TB. Abbreviations: CI: confidence interval; pDST: phenotypic drug susceptibility test; gDST: genomic drug susceptibility test; CRS: composite reference standard; NA: not applicable. Table 3: GRADE certainty of evidence for sub",
      "extractCut": true,
      "blocks": [
        "library/10665-381036/blocks/prose-page-696"
      ]
    },
    {
      "id": "page-697",
      "number": null,
      "title": "Page 697",
      "level": 1,
      "pageStart": 697,
      "pageEnd": 697,
      "labelStart": "692",
      "labelEnd": "692",
      "words": 209,
      "summary": {
        "text": "Reports PZA line probe assay accuracy on culture isolates, with pooled sensitivity of 81.2% against phenotypic testing and 96.4% sensitivity with 100% specificity against genomic testing.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "pza lpa",
          "heading": false
        },
        {
          "term": "pza resistance",
          "heading": false
        },
        {
          "term": "diagnose pza",
          "heading": false
        },
        {
          "term": "lpa assay",
          "heading": false
        },
        {
          "term": "lpa pooled",
          "heading": false
        },
        {
          "term": "certainty evidence",
          "heading": false
        },
        {
          "term": "drug susceptibility",
          "heading": false
        }
      ],
      "extract": "692 Abbreviations: CI: confidence interval; pDST: phenotypic drug susceptibility test; gDST: genomic drug susceptibility test; CRS: composite reference standard; NA: not applicable. 48) Should PZA LPA assay on isolates be used to diagnose PZA resistance in patients with microbiologically confirmed PTB, irrespective of resistance to RIF, pDST? PZA LPA pooled sensitivity (95% CI) was 81.2% (75.4 to 85.8) and",
      "extractCut": true,
      "blocks": [
        "library/10665-381036/blocks/prose-page-697",
        "library/10665-381036/blocks/figure-img-p697-1",
        "library/10665-381036/blocks/figure-img-p697-2"
      ]
    },
    {
      "id": "page-698",
      "number": null,
      "title": "Page 698",
      "level": 1,
      "pageStart": 698,
      "pageEnd": 698,
      "labelStart": "693",
      "labelEnd": "693",
      "words": 156,
      "summary": {
        "text": "Forest plots and risk of bias charts for the PZA line probe assay on isolates against genomic and composite reference standards.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "pza lpa",
          "heading": false
        },
        {
          "term": "nipro pza",
          "heading": false
        },
        {
          "term": "pza resistance",
          "heading": false
        },
        {
          "term": "lpa sensitivity",
          "heading": false
        },
        {
          "term": "forest plots",
          "heading": false
        }
      ],
      "extract": "693 Figure 7: Forest plots of Nipro PZA LPA sensitivity and specificity for detection of PZA resistance against a reference standard of genomic drug susceptibility PZA assay (microbiological reference standard). The squares represent the sensitivity and specificity of one study, the black line its confidence interval. TP: true-positive; FP: false-positive; FN: false-negative; TN: true-negative. Figure 8. Risk of",
      "extractCut": true,
      "blocks": [
        "library/10665-381036/blocks/prose-page-698",
        "library/10665-381036/blocks/figure-img-p698-1",
        "library/10665-381036/blocks/figure-img-p698-2",
        "library/10665-381036/blocks/figure-img-p698-3"
      ]
    },
    {
      "id": "page-699",
      "number": null,
      "title": "Page 699",
      "level": 1,
      "pageStart": 699,
      "pageEnd": 699,
      "labelStart": "694",
      "labelEnd": "694",
      "words": 133,
      "summary": {
        "text": "Completes the figure captions and notes that no studies were available for isolates from people with rifampicin resistance.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "pza lpa",
          "heading": false
        },
        {
          "term": "pza resistance",
          "heading": false
        },
        {
          "term": "diagnose pza",
          "heading": false
        },
        {
          "term": "lpa assay",
          "heading": false
        },
        {
          "term": "detected resistance",
          "heading": false
        }
      ],
      "extract": "694 represent the sensitivity and specificity of one study, the black line its confidence interval. TP: true- positive; FP: false-positive; FN: false-negative; TN: true-negative. Figure 10. Risk of bias and applicability concerns for CRS as reference standard. 51) Should PZA LPA assay on isolates be used to diagnose PZA resistance in patients with microbiologically confirmed PTB, with detected resistance to RIF,",
      "extractCut": true,
      "blocks": [
        "library/10665-381036/blocks/prose-page-699",
        "library/10665-381036/blocks/figure-img-p699-1"
      ]
    },
    {
      "id": "page-700",
      "number": null,
      "title": "Page 700",
      "level": 1,
      "pageStart": 700,
      "pageEnd": 700,
      "labelStart": "695",
      "labelEnd": "695",
      "words": 320,
      "summary": {
        "text": "Summary and GRADE certainty tables for PZA line probe assay accuracy on isolates by reference standard, including composite standard results of 95.7% sensitivity and 98.6% specificity.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "rifampici resistanc",
          "heading": false
        },
        {
          "term": "pico sub",
          "heading": false
        },
        {
          "term": "resistance pdst",
          "heading": false
        },
        {
          "term": "ive",
          "heading": false
        },
        {
          "term": "gdst",
          "heading": false
        },
        {
          "term": "downgraded",
          "heading": false
        },
        {
          "term": "rifampicin resistance",
          "heading": false
        },
        {
          "term": "inconsistency",
          "heading": false
        }
      ],
      "extract": "695 Table 4: PICO 2 summary: diagnostic accuracy of PZA LPA for detection of PZA resistance in isolates from pulmonary TB patients with and without RIF resistant TB. Abbreviations: CI: confidence interval; pDST: phenotypic drug susceptibility test; gDST: genomic drug susceptibility test; CRS: composite reference standard; NA: not applicable. Table 5: GRADE certainty of evidence for sub PICO questions. PICO sub",
      "extractCut": true,
      "blocks": [
        "library/10665-381036/blocks/prose-page-700"
      ]
    },
    {
      "id": "page-701",
      "number": null,
      "title": "Page 701",
      "level": 1,
      "pageStart": 701,
      "pageEnd": 701,
      "labelStart": "696",
      "labelEnd": "696",
      "words": 77,
      "summary": {
        "text": "A fragment of a GRADE table noting downgrading for risk of bias and inconsistency, with empty rows for rifampicin-resistant subgroups.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "rifampici resistanc",
          "heading": false
        },
        {
          "term": "detected rifampici",
          "heading": false
        },
        {
          "term": "drug susceptibility",
          "heading": false
        }
      ],
      "extract": "696 Downgraded one level for risk of bias and one level for inconsistency(speci ficity) 45 With detected rifampici n resistanc e pDST 0 (0) NA NA NA NA 46 With detected rifampici n resistanc e gDST 0 (0) NA NA NA NA 47 With detected rifampici n resistanc e CRS 0 (0) NA NA NA NA Abbreviations: CI: confidence interval; pDST: phenotypic drug susceptibility test; gDST: genomic drug susceptibility test; CRS: composite",
      "extractCut": true,
      "blocks": [
        "library/10665-381036/blocks/prose-page-701"
      ]
    },
    {
      "id": "page-702",
      "number": null,
      "title": "Page 702",
      "level": 1,
      "pageStart": 702,
      "pageEnd": 702,
      "labelStart": "697",
      "labelEnd": "697",
      "words": 441,
      "summary": {
        "text": "Summarises the main results question by question, stating that most sputum-based questions could not be answered owing to too few studies, with estimates given only for isolates.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "pza lpa",
          "heading": false
        },
        {
          "term": "pza resistance",
          "heading": false
        },
        {
          "term": "diagnose pza",
          "heading": false
        },
        {
          "term": "lpa assay",
          "heading": false
        },
        {
          "term": "confirmed ptb",
          "heading": false
        },
        {
          "term": "detected resistance",
          "heading": false
        },
        {
          "term": "too few",
          "heading": false
        },
        {
          "term": "few studies",
          "heading": false
        }
      ],
      "extract": "697 SUMMARY OF MAIN RESULTS 1) Should PZA LPA assay on sputum be used to diagnose PZA resistance in patients with microbiologically confirmed PTB, irrespective of resistance to RIF, pDST? Too few studies to address this question. 2) Should PZA LPA assay on sputum be used to diagnose PZA resistance in patients with microbiologically confirmed PTB, irrespective of resistance to RIF, gDST? Too few studies to address",
      "extractCut": true,
      "blocks": [
        "library/10665-381036/blocks/prose-page-702"
      ]
    },
    {
      "id": "page-703",
      "number": null,
      "title": "Page 703",
      "level": 1,
      "pageStart": 703,
      "pageEnd": 703,
      "labelStart": "698",
      "labelEnd": "698",
      "words": 276,
      "summary": {
        "text": "Concludes that the Nipro GenoScholar PZA-TB assay appears accurate in detecting diverse pncA variants but evidence is mostly from stored isolates, and suggests using it as a reflex test after rifampicin resistance is detected.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "pnca variants",
          "heading": false
        },
        {
          "term": "genoscholar pza",
          "heading": false
        },
        {
          "term": "nipro genoscholar",
          "heading": false
        },
        {
          "term": "different pnca",
          "heading": false
        },
        {
          "term": "culture isolates",
          "heading": false
        },
        {
          "term": "routine settings",
          "heading": false
        },
        {
          "term": "stored culture",
          "heading": false
        },
        {
          "term": "studies conducted",
          "heading": false
        }
      ],
      "extract": "698 AUTHORS CONCLUSIONS The Nipro Genoscholar PZA TB assay appears to perform accurately to detect the presence of a wide range of different pncA variants. Majority of the studies conducted the assay using stored culture isolates; thus, we are unable to reach any conclusions regarding the use of the assay in clinical specimens. None of the studies stratified the results by resistance status, smear status or",
      "extractCut": true,
      "blocks": [
        "library/10665-381036/blocks/prose-page-703"
      ]
    },
    {
      "id": "page-704",
      "number": null,
      "title": "Page 704",
      "level": 1,
      "pageStart": 704,
      "pageEnd": 704,
      "labelStart": "699",
      "labelEnd": "699",
      "words": 101,
      "summary": {
        "text": "Acknowledgements, author contributions and declarations of interest for the pyrazinamide review, noting WHO Global TB Programme funding.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "received funding",
          "heading": false
        },
        {
          "term": "thank",
          "heading": false
        },
        {
          "term": "sharing data",
          "heading": false
        },
        {
          "term": "global tuberculosis",
          "heading": false
        }
      ],
      "extract": "699 ACKNOWLEDGEMENTS The authors would like to thank all members of the international TORCH consortium for their valuable comments. We thank Erlina Burhan from Persahabatan Hospital in Indonesia for sharing data from the ongoing trial. We thank Leen Rigouts and Bouke de Jong from Institute of Tropical Medicine (ITM) in Antwerp, Belgium for sharing data from their finalized trial. CONTRIBUTIONS OF AUTHORS Both MGW",
      "extractCut": true,
      "blocks": [
        "library/10665-381036/blocks/prose-page-704"
      ]
    },
    {
      "id": "page-705",
      "number": null,
      "title": "Page 705",
      "level": 1,
      "pageStart": 705,
      "pageEnd": 705,
      "labelStart": "700",
      "labelEnd": "700",
      "words": 414,
      "summary": {
        "text": "The first part of the reference list for the pyrazinamide resistance review, citing WHO TB reports and studies on pncA and pyrazinamide testing.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "tuberculosis pnca",
          "heading": false
        },
        {
          "term": "pnca mutations",
          "heading": false
        },
        {
          "term": "pyrazinamide susceptibility",
          "heading": false
        },
        {
          "term": "pyrazinamide resistance",
          "heading": false
        },
        {
          "term": "mycobacterium tuberculosis",
          "heading": false
        },
        {
          "term": "clin microbiol",
          "heading": false
        },
        {
          "term": "antimicrob agents",
          "heading": false
        },
        {
          "term": "mtb rif",
          "heading": false
        }
      ],
      "extract": "700 REFERENCES 1. World Health Organization. Global Tuberculosis Report 2020. https://apps.who.int/iris/bitstream/handle/10665/336069/9789240013131-eng.pdf?ua=1. 2. World Health Organization. Xpert MTB/RIF implementation manual Technical and operational ‘how-to’: practical considerations 2014. http://apps.who.int/iris/bitstream/handle/10665/112469/9789241506700_eng.pdf?sequence=1 . 3. World Health Organization.",
      "extractCut": true,
      "blocks": [
        "library/10665-381036/blocks/prose-page-705"
      ]
    },
    {
      "id": "page-706",
      "number": null,
      "title": "Page 706",
      "level": 1,
      "pageStart": 706,
      "pageEnd": 706,
      "labelStart": "701",
      "labelEnd": "701",
      "words": 458,
      "summary": {
        "text": "Continues the reference list for the pyrazinamide review, citing GRADE methodology papers, PZA line probe assay studies and the PRISMA statement.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "clin epidemiol",
          "heading": false
        },
        {
          "term": "pyrazinamide resistance",
          "heading": false
        },
        {
          "term": "mycobacterium species",
          "heading": false
        },
        {
          "term": "mycobacterium tuberculosis",
          "heading": false
        },
        {
          "term": "probe assay",
          "heading": false
        },
        {
          "term": "clin microbiol",
          "heading": false
        },
        {
          "term": "line probe",
          "heading": false
        },
        {
          "term": "assay kit",
          "heading": false
        }
      ],
      "extract": "701 18. Schünemann HJ, Mustafa R, Brozek J et al. GRADE Guidelines: 16. GRADE evidence to decision frameworks for tests in clinical practice and public health. J Clin Epidemiol 2016; 76: 89-98. 19. Schünemann HJ, Oxman AD, Brozek J et al. Grading quality of evidence and strength of recommendations for diagnostic tests and strategies. BMJ 2008; 336: 1106-10. 20. Schünemann HJ, Mustafa RA, Brozek J et al. GRADE",
      "extractCut": true,
      "blocks": [
        "library/10665-381036/blocks/prose-page-706"
      ]
    },
    {
      "id": "page-707",
      "number": null,
      "title": "Page 707",
      "level": 1,
      "pageStart": 707,
      "pageEnd": 707,
      "labelStart": "702",
      "labelEnd": "702",
      "words": 314,
      "summary": {
        "text": "An appendix setting out the QUADAS-2 signalling questions and how they were answered for patient selection and index test domains in the pyrazinamide review.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "signalling question",
          "heading": false
        },
        {
          "term": "pza lpa",
          "heading": false
        },
        {
          "term": "inappropriate exclusions",
          "heading": false
        },
        {
          "term": "judged applicability",
          "heading": false
        },
        {
          "term": "blinded manner",
          "heading": false
        },
        {
          "term": "introduced bias",
          "heading": false
        },
        {
          "term": "case-control design",
          "heading": false
        },
        {
          "term": "patient selection",
          "heading": false
        }
      ],
      "extract": "702 APPENDICES Appendix 1. QUADAS-2 tool Domain 1: Patient Selection Risk of Bias: Could the selection of patients/specimens have introduced bias? Signalling question 1: Was a consecutive or random sample of patients or specimens enrolled? ‘yes’ when the study enrolled a consecutive or random sample; ‘no’ for all other studies; ‘unclear’ when the study did not report on patient selection. Signalling question 2: Was",
      "extractCut": true,
      "blocks": [
        "library/10665-381036/blocks/prose-page-707"
      ]
    },
    {
      "id": "page-708",
      "number": null,
      "title": "Page 708",
      "level": 1,
      "pageStart": 708,
      "pageEnd": 708,
      "labelStart": "703",
      "labelEnd": "703",
      "words": 382,
      "summary": {
        "text": "Continues the QUADAS-2 guidance on applicability, reference standard and flow and timing as applied in the review.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "signalling question",
          "heading": false
        },
        {
          "term": "reference standard",
          "heading": false
        },
        {
          "term": "index test",
          "heading": false
        },
        {
          "term": "review question",
          "heading": false
        },
        {
          "term": "introduced bias",
          "heading": false
        },
        {
          "term": "answered",
          "heading": false
        },
        {
          "term": "target condition",
          "heading": false
        },
        {
          "term": "applicability",
          "heading": false
        }
      ],
      "extract": "703 Applicability: Are there concerns that the index test, its conduct, or its interpretation differ from the review question? There are a limited number of articles available for this review question, and the index test comes from a single manufacturer. If the study used multiple or blinded readers for the interpretation of the PZA LPA we deemed the applicability as ‘low concern’. Where a study used a single,",
      "extractCut": true,
      "blocks": [
        "library/10665-381036/blocks/prose-page-708"
      ]
    },
    {
      "id": "page-709",
      "number": null,
      "title": "Page 709",
      "level": 1,
      "pageStart": 709,
      "pageEnd": 709,
      "labelStart": "704",
      "labelEnd": "704",
      "words": 53,
      "summary": {
        "text": "Final QUADAS-2 signalling questions on use of the same reference standard and inclusion of all patients in analysis.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "patients isolates",
          "heading": false
        },
        {
          "term": "signaling",
          "heading": false
        },
        {
          "term": "unclear",
          "heading": false
        }
      ],
      "extract": "704 ‘yes’ when the same reference standard was used; ‘no’ when the samples were processed in different laboratories; ‘unclear’ not applicable. Signaling question 3: Were all patients included in the analysis? ‘yes’ when all patients/isolates were included in the analysis; ‘no’ when not all patients/isolates were included in the analysis; ‘unclear’ not applicable.",
      "extractCut": false,
      "blocks": [
        "library/10665-381036/blocks/prose-page-709"
      ]
    },
    {
      "id": "page-710",
      "number": null,
      "title": "Page 710",
      "level": 1,
      "pageStart": 710,
      "pageEnd": 710,
      "labelStart": "705",
      "labelEnd": "705",
      "words": 68,
      "summary": {
        "text": "The title page of Web Annex B.16, a review of targeted next-generation sequencing for detecting TB drug resistance, with authors and affiliations.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "timothy walker",
          "heading": false
        },
        {
          "term": "oxford",
          "heading": false
        },
        {
          "term": "harriss",
          "heading": false
        }
      ],
      "extract": "Web Annex B.16. Review of the diagnostic accuracy of targeted next-generation sequencing technologies for detection of drug resistance among people diagnosed with TB Phu Phan Trieu1, Eli Harriss2, Timothy M Walker1,3 1 Oxford University Clinical Research Unit, Ho Chi Minh City, Vietnam 2 Bodleian Health Care Libraries, University of Oxford, Oxford, UK 3 Nuffield Department of Medicine, University of Oxford, Oxford,",
      "extractCut": true,
      "blocks": [
        "library/10665-381036/blocks/prose-page-710"
      ]
    },
    {
      "id": "page-711",
      "number": null,
      "title": "Page 711",
      "level": 1,
      "pageStart": 711,
      "pageEnd": 711,
      "labelStart": "706",
      "labelEnd": "706",
      "words": 186,
      "summary": {
        "text": "Acknowledgements for the targeted sequencing review, thanking advisers and data contributors and listing funders such as WHO, FIND, the Gates Foundation and Wellcome.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "melinda gates",
          "heading": false
        },
        {
          "term": "gates foundation",
          "heading": false
        },
        {
          "term": "employed through",
          "heading": false
        },
        {
          "term": "wellcome",
          "heading": false
        },
        {
          "term": "oxford",
          "heading": false
        },
        {
          "term": "bill",
          "heading": false
        },
        {
          "term": "university",
          "heading": false
        }
      ],
      "extract": "Acknowledgements We would like to thanks the following for support and advice in the generation of this document: Cecily Miller, Nazir Ismail, Mathieu Bastard, Matteo Zignol, Mikashmi Kohli, Samuel Schumacher, Tamara Kredo and Karen Steingart. We would also like to thank all the contributors of data, all of whom we corresponded with regularly to ensure data accuracy. In no particular order: Mohammad Khaja Mafij",
      "extractCut": true,
      "blocks": [
        "library/10665-381036/blocks/prose-page-711"
      ]
    },
    {
      "id": "page-712",
      "number": null,
      "title": "Page 712",
      "level": 1,
      "pageStart": 712,
      "pageEnd": 712,
      "labelStart": "707",
      "labelEnd": "707",
      "words": 673,
      "summary": {
        "text": "The opening of the executive summary on targeted next-generation sequencing for TB drug susceptibility testing, explaining that current rapid tests detect resistance to few drugs. It describes the review's objective and the use of individual-level data from several studies. It outlines the modelling approach, including covariables such as Xpert semi-quantitative results and rifampicin resistance.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "deeplex myc-tb",
          "heading": false
        },
        {
          "term": "rpob inha",
          "heading": false
        },
        {
          "term": "shengting biotech",
          "heading": false
        },
        {
          "term": "whole-genome sequencing",
          "heading": false
        },
        {
          "term": "xpert ultra",
          "heading": false
        },
        {
          "term": "rif xpert",
          "heading": false
        },
        {
          "term": "drug resistance",
          "heading": false
        },
        {
          "term": "drug susceptibility",
          "heading": false
        }
      ],
      "extract": "Executive summary Molecular diagnostic tests for drug susceptibility testing (DST) of Mycobacterium tuberculosis strains are now widely understood to be the best hope for attaining the W O’s goal of universal access to drug susceptibility testing. WHO recommended rapid diagnostic (WRD) tests detect resistance to only a few select drugs due to the limited number of mutations that can be probed. Some national TB",
      "extractCut": true,
      "blocks": [
        "library/10665-381036/blocks/prose-page-712"
      ]
    },
    {
      "id": "page-713",
      "number": null,
      "title": "Page 713",
      "level": 1,
      "pageStart": 713,
      "pageEnd": 713,
      "labelStart": "708",
      "labelEnd": "708",
      "words": 601,
      "summary": {
        "text": "Continues the description of methods, including the use of HIV data from FIND and how study sites were handled, and reports rifampicin resistance results. It notes that phenotypic testing misses borderline resistance, so a composite reference standard is preferred for rifampicin.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "rifampicin resistance",
          "heading": false
        },
        {
          "term": "rifampicin resistant",
          "heading": false
        },
        {
          "term": "tngs",
          "heading": false
        },
        {
          "term": "composite reference",
          "heading": false
        },
        {
          "term": "indeterminate rate",
          "heading": false
        },
        {
          "term": "pico",
          "heading": false
        },
        {
          "term": "reference standard",
          "heading": false
        },
        {
          "term": "pooled sensitivity",
          "heading": false
        }
      ],
      "extract": "resistance result; whether a sample had been sequenced on one or on two tNGS platform (all the samples from FIND were sequenced using both Deeplex® Myc-TB and NanoTB®). Data on HIV test results were available only from FIND, where they were generated as part of the study, and were only included in models addressing the specific sub-analysis looking at diagnostic accuracy in people living with HIV infection. Study",
      "extractCut": true,
      "blocks": [
        "library/10665-381036/blocks/prose-page-713"
      ]
    },
    {
      "id": "page-714",
      "number": null,
      "title": "Page 714",
      "level": 1,
      "pageStart": 714,
      "pageEnd": 714,
      "labelStart": "709",
      "labelEnd": "709",
      "words": 587,
      "summary": {
        "text": "Reports pooled accuracy of targeted sequencing for isoniazid resistance, at 96% sensitivity and 97% specificity, and for levofloxacin, moxifloxacin and pyrazinamide. Each result gives the number of studies, indeterminate rates, certainty of evidence and expected results per 1000 patients.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "pyrazinamide resistance",
          "heading": false
        },
        {
          "term": "pyrazinamide resistant",
          "heading": false
        },
        {
          "term": "levofloxacin resistance",
          "heading": false
        },
        {
          "term": "moxifloxacin resistance",
          "heading": false
        },
        {
          "term": "isoniazid resistance",
          "heading": false
        },
        {
          "term": "indeterminate rate",
          "heading": false
        },
        {
          "term": "tngs",
          "heading": false
        },
        {
          "term": "pooled sensitivity",
          "heading": false
        }
      ],
      "extract": "Isoniazid – pDST as reference standard. Pooled sensitivity and specificity (95% confidence interval) were 96% (93-99) and 97% (95-99) respectively, based on up to 12 studies and up to 1440 samples and a 74% prevalence of isoniazid resistance. The indeterminate rate was 15%. Quality of evidence was judged to be moderate for both sensitivity and specificity. Results indicate that, in theory, of 1000 patients among",
      "extractCut": true,
      "blocks": [
        "library/10665-381036/blocks/prose-page-714"
      ]
    },
    {
      "id": "page-715",
      "number": null,
      "title": "Page 715",
      "level": 1,
      "pageStart": 715,
      "pageEnd": 715,
      "labelStart": "710",
      "labelEnd": "710",
      "words": 572,
      "summary": {
        "text": "Reports pooled targeted sequencing accuracy for ethambutol against composite and phenotypic standards, and repeats results for isoniazid and fluoroquinolones. Each result gives the certainty of evidence and the expected true and false results per 1000 patients.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "ethambutol resistance",
          "heading": false
        },
        {
          "term": "ethambutol resistant",
          "heading": false
        },
        {
          "term": "levofloxacin resistance",
          "heading": false
        },
        {
          "term": "moxifloxacin resistance",
          "heading": false
        },
        {
          "term": "isoniazid resistance",
          "heading": false
        },
        {
          "term": "indeterminate rate",
          "heading": false
        },
        {
          "term": "tngs",
          "heading": false
        },
        {
          "term": "pooled sensitivity",
          "heading": false
        }
      ],
      "extract": "Ethambutol – composite as reference standard. Pooled sensitivity and specificity (95% confidence interval) were 96% (94-99) and 99% (98-100) respectively, based on up to 4 studies and up to 432 samples and a 62% prevalence of ethambutol resistance. The indeterminate rate was 16%. Quality of evidence was judged to be low for both sensitivity and specificity. Results indicate that, in theory, of 1000 patients among",
      "extractCut": true,
      "blocks": [
        "library/10665-381036/blocks/prose-page-715"
      ]
    },
    {
      "id": "page-716",
      "number": null,
      "title": "Page 716",
      "level": 1,
      "pageStart": 716,
      "pageEnd": 716,
      "labelStart": "711",
      "labelEnd": "711",
      "words": 594,
      "summary": {
        "text": "Reports targeted sequencing accuracy for pyrazinamide, with 90% sensitivity and 99% specificity against a composite standard. It then covers bedaquiline, linezolid and clofazimine against phenotypic testing, giving expected results per 1000 patients.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "pyrazinamide resistance",
          "heading": false
        },
        {
          "term": "pyrazinamide resistant",
          "heading": false
        },
        {
          "term": "bedaquiline resistance",
          "heading": false
        },
        {
          "term": "clofazimine resistance",
          "heading": false
        },
        {
          "term": "linezolid resistance",
          "heading": false
        },
        {
          "term": "indeterminate rate",
          "heading": false
        },
        {
          "term": "tngs",
          "heading": false
        },
        {
          "term": "pooled sensitivity",
          "heading": false
        }
      ],
      "extract": "would be reported as moxifloxacin resistant by tNGS (false positive). Pyrazinamide – composite as reference standard. Pooled sensitivity and specificity (95% confidence interval) were 90% (87-93) and 99% (97-100) respectively, based on 3 studies and up to 346 samples and a 56% prevalence of pyrazinamide resistance. The indeterminate rate was 18%. Quality of evidence was judged to be high for both sensitivity and",
      "extractCut": true,
      "blocks": [
        "library/10665-381036/blocks/prose-page-716"
      ]
    },
    {
      "id": "page-717",
      "number": null,
      "title": "Page 717",
      "level": 1,
      "pageStart": 717,
      "pageEnd": 717,
      "labelStart": "712",
      "labelEnd": "712",
      "words": 555,
      "summary": {
        "text": "Reports targeted sequencing accuracy for amikacin, ethambutol and streptomycin, and summarises that indeterminate rates were mostly around 10-20%. It leads into the authors' conclusions.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "ethambutol resistance",
          "heading": false
        },
        {
          "term": "ethambutol resistant",
          "heading": false
        },
        {
          "term": "streptomycin resistance",
          "heading": false
        },
        {
          "term": "amikacin resistance",
          "heading": false
        },
        {
          "term": "indeterminate rate",
          "heading": false
        },
        {
          "term": "tngs",
          "heading": false
        },
        {
          "term": "pooled sensitivity",
          "heading": false
        },
        {
          "term": "confidence interval",
          "heading": false
        }
      ],
      "extract": "Amikacin – pDST as reference standard. Pooled sensitivity and specificity (95% confidence interval) were 87% (75-100) and 99% (98-100) respectively, based on up to 8 studies and up to 1003 samples and a 10% prevalence of amikacin resistance. The indeterminate rate was 18%. Quality of evidence was judged to be very low for sensitivity and moderate for specificity. Results indicate that, in theory, of 1000 patients",
      "extractCut": true,
      "blocks": [
        "library/10665-381036/blocks/prose-page-717"
      ]
    },
    {
      "id": "page-718",
      "number": null,
      "title": "Page 718",
      "level": 1,
      "pageStart": 718,
      "pageEnd": 718,
      "labelStart": "713",
      "labelEnd": "713",
      "words": 194,
      "summary": {
        "text": "Concludes that the impact of targeted sequencing depends on where it is placed, with stronger evidence for reflex testing after rifampicin resistance is found than as an initial test, and calls for studies on extrapulmonary specimens.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "rifampicin resistance",
          "heading": false
        },
        {
          "term": "drug resistance",
          "heading": false
        },
        {
          "term": "initial test",
          "heading": false
        },
        {
          "term": "future studies",
          "heading": false
        },
        {
          "term": "tngs",
          "heading": false
        },
        {
          "term": "placed",
          "heading": false
        }
      ],
      "extract": "The impact of tNGS platforms will depend on where they are placed. In this review the quality of evidence supporting their use as an initial test of drug resistance is lower than that supporting their use as a reflex test for patients already diagnosed with rifampicin resistance. This is largely because the datasets were strongly enriched for rifampicin resistance. Although the prevalence of resistance should not",
      "extractCut": true,
      "blocks": [
        "library/10665-381036/blocks/prose-page-718"
      ]
    },
    {
      "id": "page-719",
      "number": null,
      "title": "Page 719",
      "level": 1,
      "pageStart": 719,
      "pageEnd": 719,
      "labelStart": "714",
      "labelEnd": "714",
      "words": 614,
      "summary": {
        "text": "Sets out the background to a WHO-commissioned review of targeted next-generation sequencing (tNGS) for detecting drug resistance in tuberculosis, explaining that empirical treatment risks failure and amplified resistance where resistance is common. It notes that phenotypic drug susceptibility testing remains out of reach for most patients and that molecular tests such as Xpert MTB/RIF, line-probe assays and Xpert XDR cover only some drugs. It argues that new regimens such as BPaLM have outpaced companion diagnostics and that sequencing directly from samples could help protect these drugs.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "re-purposed drugs",
          "heading": false
        },
        {
          "term": "mycobacterial culture",
          "heading": false
        },
        {
          "term": "tngs platforms",
          "heading": false
        },
        {
          "term": "treatment regimens",
          "heading": false
        },
        {
          "term": "rifampicin resistant",
          "heading": false
        },
        {
          "term": "drug resistance",
          "heading": false
        },
        {
          "term": "resistant strains",
          "heading": false
        },
        {
          "term": "predictions",
          "heading": false
        }
      ],
      "extract": "Background Rapid, accurate detection of drug resistance for patients with tuberculosis is an important component within the process of ensuring optimal treatment outcomes both at an individual patient and population level. While empirical treatment with first line anti-tuberculosis drugs (isoniazid, rifampicin, ethambutol and pyrazinamide) would still result in successful outcomes for most patients in the world,",
      "extractCut": true,
      "blocks": [
        "library/10665-381036/blocks/prose-page-719"
      ]
    },
    {
      "id": "page-720",
      "number": null,
      "title": "Page 720",
      "level": 1,
      "pageStart": 720,
      "pageEnd": 720,
      "labelStart": "715",
      "labelEnd": "715",
      "words": 633,
      "summary": {
        "text": "Describes the clinical pathway assessed, first testing tNGS for first-line drugs and fluoroquinolones in all TB patients and then for other drugs in rifampicin-resistant patients, with sub-analyses by Xpert bacterial load and HIV status. It explains the four possible test outcomes, true and false positives and negatives, and their consequences for patient treatment. It also notes that Deeplex Myc-TB can report uncharacterized mutations, which the review counts with failures as indeterminate results; some quoted terms on the page have missing letters in the extracted text.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "uncharacterized mutation",
          "heading": false
        },
        {
          "term": "resistance mutation",
          "heading": false
        },
        {
          "term": "pli ication",
          "heading": false
        },
        {
          "term": "deeplex myc-tb",
          "heading": false
        },
        {
          "term": "aile target",
          "heading": false
        },
        {
          "term": "predicts resistance",
          "heading": false
        },
        {
          "term": "assay reports",
          "heading": false
        },
        {
          "term": "further resistance",
          "heading": false
        }
      ],
      "extract": "Clinical pathway The analyses presented here first assess the diagnostic accuracy of tNGS assays for DST for isoniazid, rifampicin, ethambutol, pyrazinamide and fluoroquinolones (levofloxacin and moxifloxacin) among all patients diagnosed with TB and then assess the diagnostic accuracy for all covered drugs (except rifampicin) for patients whose strains have already been identified as resistant to rifampicin by",
      "extractCut": true,
      "blocks": [
        "library/10665-381036/blocks/prose-page-720"
      ]
    },
    {
      "id": "page-721",
      "number": null,
      "title": "Page 721",
      "level": 1,
      "pageStart": 721,
      "pageEnd": 721,
      "labelStart": "716",
      "labelEnd": "716",
      "words": 372,
      "summary": {
        "text": "Sets out the review's two questions: whether tNGS should be the first test for drug resistance in bacteriologically confirmed pulmonary TB, and whether it should be used for patients with rifampicin-resistant TB, listing the drugs and reference standards for each. It states the review objective and notes sub-analyses for people with HIV and low bacterial load as a proxy for children.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "reference standard",
          "heading": false
        },
        {
          "term": "composite reference",
          "heading": false
        },
        {
          "term": "pdst",
          "heading": false
        },
        {
          "term": "confirmed rifampicin-resistant",
          "heading": false
        },
        {
          "term": "rifampicin-resistant pulmonary",
          "heading": false
        },
        {
          "term": "wgs",
          "heading": false
        },
        {
          "term": "xpert ultra",
          "heading": false
        },
        {
          "term": "diagnose drug",
          "heading": false
        }
      ],
      "extract": "PICOs Generically stated, this review explored two PICOs. Each is applied to a specific list of drugs: 1. Should tNGS as the initial test be used to diagnose drug resistance in patients with bacteriologically confirmed pulmonary TB disease? Applies to • Rifampicin, using a composite reference standard of pDST and WGS and MTB/RIF Xpert® or Xpert Ultra® • Rifampicin, using pDST as the reference standard • Isoniazid,",
      "extractCut": true,
      "blocks": [
        "library/10665-381036/blocks/prose-page-721"
      ]
    },
    {
      "id": "page-722",
      "number": null,
      "title": "Page 722",
      "level": 1,
      "pageStart": 722,
      "pageEnd": 722,
      "labelStart": "717",
      "labelEnd": "717",
      "words": 409,
      "summary": {
        "text": "Describes the methods, including prospective clinical studies testing tNGS directly on samples, phenotypic DST as the reference and composite references with whole genome sequencing for rifampicin, ethambutol and pyrazinamide. It lists the drugs assessed and gives the database search strategy, run in 2022 and repeated in 2023, with independent screening by two reviewers.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "pdst wgs",
          "heading": false
        },
        {
          "term": "text word",
          "heading": false
        },
        {
          "term": "xpert ultra",
          "heading": false
        },
        {
          "term": "rif xpert",
          "heading": false
        },
        {
          "term": "mtb rif",
          "heading": false
        },
        {
          "term": "search terms",
          "heading": false
        },
        {
          "term": "consi",
          "heading": false
        },
        {
          "term": "tngs",
          "heading": false
        }
      ],
      "extract": "Methods Types of studies and participants Data were included from both published and unpublished, prospective, observational clinical studies of tNGS platform diagnostic accuracy. We included all studies where tNGS had been performed directly from clinical samples and excluded studies where tNGS had been performed exclusively on cultured isolates. We included all samples as long as data on tNGS result and reference",
      "extractCut": true,
      "blocks": [
        "library/10665-381036/blocks/prose-page-722"
      ]
    },
    {
      "id": "page-723",
      "number": null,
      "title": "Page 723",
      "level": 1,
      "pageStart": 723,
      "pageEnd": 723,
      "labelStart": "718",
      "labelEnd": "718",
      "words": 461,
      "summary": {
        "text": "Lists inclusion criteria, such as specific tNGS platforms, bacteriologically confirmed TB, an accepted reference standard and available individual patient data, and explains the decision to run only an individual patient data meta-analysis. It then begins describing the QUADAS-2 quality assessment, starting with patient selection.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "signalling question",
          "heading": false
        },
        {
          "term": "sco",
          "heading": false
        },
        {
          "term": "picin resistance",
          "heading": false
        },
        {
          "term": "stu",
          "heading": false
        },
        {
          "term": "data extraction",
          "heading": false
        },
        {
          "term": "patient data",
          "heading": false
        },
        {
          "term": "patient selection",
          "heading": false
        },
        {
          "term": "individual patient",
          "heading": false
        }
      ],
      "extract": "they have, or know of, unpublished data that could be contributed. Inclusion criteria were set as follows, and all needed to be met: - Studies using ‘ esi n loc e ’ and ‘ a et ea y’ tNGS platforms - Studies assessing samples from patients diagnosed with bacteriologically confirmed tuberculosis disease by culture, WHO recommended molecular assay or lateral flow lipoarabinomannan (LF-LAM) - Studies using a gold",
      "extractCut": true,
      "blocks": [
        "library/10665-381036/blocks/prose-page-723"
      ]
    },
    {
      "id": "page-724",
      "number": null,
      "title": "Page 724",
      "level": 1,
      "pageStart": 724,
      "pageEnd": 724,
      "labelStart": "719",
      "labelEnd": "719",
      "words": 546,
      "summary": {
        "text": "Continues the QUADAS-2 assessment for the index test, reference standard and flow and timing, noting that some operators misread Deeplex Myc-TB's uncharacterized variant calls. It then introduces GRADE grading of the certainty of evidence.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "signalling question",
          "heading": false
        },
        {
          "term": "scored",
          "heading": false
        },
        {
          "term": "index test",
          "heading": false
        },
        {
          "term": "introduced bias",
          "heading": false
        },
        {
          "term": "reference standard",
          "heading": false
        },
        {
          "term": "sco",
          "heading": false
        },
        {
          "term": "uncharacterized",
          "heading": false
        },
        {
          "term": "operator",
          "heading": false
        }
      ],
      "extract": "A. Risk of bias: could the conduct or interpretation of the index test have introduced bias? i. Signalling question 1: was the index test result interpreted without knowledge of the reference test result? We scored ‘ i is ’ if the operator of the index test was unblinded to the result of the reference. Although the output of the index test is automated, there is still some room for interpretation by the operator,",
      "extractCut": true,
      "blocks": [
        "library/10665-381036/blocks/prose-page-724"
      ]
    },
    {
      "id": "page-725",
      "number": null,
      "title": "Page 725",
      "level": 1,
      "pageStart": 725,
      "pageEnd": 725,
      "labelStart": "720",
      "labelEnd": "720",
      "words": 514,
      "summary": {
        "text": "Explains the GRADE rules applied, such as downgrading for indirectness when studies were enriched for rifampicin resistance and for imprecision when confidence intervals were wide. It describes the statistical analysis, including minimum sample numbers per platform and drug and rules for excluding weaker platforms to support a class-based recommendation.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "percentage points",
          "heading": false
        },
        {
          "term": "resistant samples",
          "heading": false
        },
        {
          "term": "class recommendation",
          "heading": false
        },
        {
          "term": "points worse",
          "heading": false
        },
        {
          "term": "outlier",
          "heading": false
        },
        {
          "term": "downgraded",
          "heading": false
        },
        {
          "term": "aile",
          "heading": false
        },
        {
          "term": "mutation",
          "heading": false
        }
      ],
      "extract": "- Low (downgraded 2 levels) - Very low (downgraded by >2 levels) based on - Risk of bias - Indirectness - Inconsistency - Imprecision - Publication bias We did not downgrade the risk of bias where QUADAS-2 scored ‘ i is ’ for PICO 1 because of studies enriching for rifampicin resistant samples. Instead, we downgraded one for indirectness where this was the case. We did not downgrade for risk of bias because the",
      "extractCut": true,
      "blocks": [
        "library/10665-381036/blocks/prose-page-725"
      ]
    },
    {
      "id": "page-726",
      "number": null,
      "title": "Page 726",
      "level": 1,
      "pageStart": 726,
      "pageEnd": 726,
      "labelStart": "721",
      "labelEnd": "721",
      "words": 492,
      "summary": {
        "text": "Explains why an individual patient data meta-analysis was used, citing small studies, the ability to include covariates and repeated testing of the same samples on several platforms. It describes building mixed-effects models for sensitivity, specificity and predictive values with covariates such as Xpert rifampicin result, bacterial load and HIV status.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "margins command",
          "heading": false
        },
        {
          "term": "dependent variable",
          "heading": false
        },
        {
          "term": "rif xpert",
          "heading": false
        },
        {
          "term": "xpert ultra",
          "heading": false
        },
        {
          "term": "classical meta-analysis",
          "heading": false
        },
        {
          "term": "mtb rif",
          "heading": false
        },
        {
          "term": "random effect",
          "heading": false
        },
        {
          "term": "co-variable",
          "heading": false
        }
      ],
      "extract": "setting minimal performance characteristics which individual platforms within class will have to meet in the future. We performed and individual patient data (IPD) meta-analysis instead of a classical meta-analysis. There were a number of reasons for this: - The studies identified in the literature were generally too small to contribute to a classical meta-analysis - An IPD meta-analysis allowed for co-variables to",
      "extractCut": true,
      "blocks": [
        "library/10665-381036/blocks/prose-page-726"
      ]
    },
    {
      "id": "page-727",
      "number": null,
      "title": "Page 727",
      "level": 1,
      "pageStart": 727,
      "pageEnd": 727,
      "labelStart": "722",
      "labelEnd": "722",
      "words": 147,
      "summary": {
        "text": "Explains that, for FIND data, the repeat Xpert result informed the reference standard while the screening result was used as a model covariate, reflecting the likely real-world use of tNGS as a follow-on test after Xpert.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "xpert ultra",
          "heading": false
        },
        {
          "term": "rif xpert",
          "heading": false
        },
        {
          "term": "mtb rif",
          "heading": false
        },
        {
          "term": "screening test",
          "heading": false
        }
      ],
      "extract": "single result, the FIND data included results on two MTB/RIF Xpert® or Xpert Ultra® results. The first was from the screening test for entry into the study and the second was repeated as part of the study on the same sample that was also processed for the index test. We used the repeat test results from FIND to inform the composite reference standard for rifampicin, and the semi-quantitative results. However, we",
      "extractCut": true,
      "blocks": [
        "library/10665-381036/blocks/prose-page-727"
      ]
    },
    {
      "id": "page-728",
      "number": null,
      "title": "Page 728",
      "level": 1,
      "pageStart": 728,
      "pageEnd": 728,
      "labelStart": "723",
      "labelEnd": "723",
      "words": 452,
      "summary": {
        "text": "Reports the search results, with 876 articles screened and four published studies included from Germany, India and France, describing their settings and sample processing. It introduces unpublished data, the largest being a FIND head-to-head study of Deeplex Myc-TB and NanoTB in South Africa, India and Georgia.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "sputum samples",
          "heading": false
        },
        {
          "term": "deeplex myc-tb",
          "heading": false
        },
        {
          "term": "consecutive samples",
          "heading": false
        },
        {
          "term": "study operated",
          "heading": false
        },
        {
          "term": "drug resistant",
          "heading": false
        },
        {
          "term": "naoh",
          "heading": false
        },
        {
          "term": "mycobacterium tuberculosis",
          "heading": false
        },
        {
          "term": "rifampicin resistance",
          "heading": false
        }
      ],
      "extract": "Results Results of the literature search and call for data We identified 876 articles from the literature review. Nine full texts were reviewed after 867 articles were excluded on the basis of title alone. Three met inclusion criteria. An additional published article was identified after contacting experts in the field. Sources of published data: The four papers identified from the published literature were: 1.",
      "extractCut": true,
      "blocks": [
        "library/10665-381036/blocks/prose-page-728"
      ]
    },
    {
      "id": "page-729",
      "number": null,
      "title": "Page 729",
      "level": 1,
      "pageStart": 729,
      "pageEnd": 729,
      "labelStart": "724",
      "labelEnd": "724",
      "words": 323,
      "summary": {
        "text": "Describes further unpublished data sources, including the DIAMA study in six African countries, studies in Bangladesh, South Africa and Italy, and notes which sources provided Xpert rifampicin and semi-quantitative results.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "deeplex myc-tb",
          "heading": false
        },
        {
          "term": "shengting biotech",
          "heading": false
        },
        {
          "term": "rif xpert",
          "heading": false
        },
        {
          "term": "xpert mtb",
          "heading": false
        },
        {
          "term": "xpert ultra",
          "heading": false
        },
        {
          "term": "beijing chest",
          "heading": false
        },
        {
          "term": "sputum samples",
          "heading": false
        },
        {
          "term": "rifampicin resistance",
          "heading": false
        }
      ],
      "extract": "frozen until a sufficient number of samples for a tNGS sequencing run had been collected. The “ A nostics for Multidrug Resistant Tuberculosis in A ica” (DIAMA) study is on-going and set in Rwanda, Cameroon, Ethiopia, Guinea, Mali, and Benin. It is has enriched for patients with rifampicin resistance, aiming to recruit approximately an equal number of patients with and without rifampicin resistance. It is assessing",
      "extractCut": true,
      "blocks": [
        "library/10665-381036/blocks/prose-page-729"
      ]
    },
    {
      "id": "page-730",
      "number": null,
      "title": "Page 730",
      "level": 1,
      "pageStart": 730,
      "pageEnd": 730,
      "labelStart": "725",
      "labelEnd": "725",
      "words": 155,
      "summary": {
        "text": "Presents the flow chart of studies and explains that no drugs were dropped, while up to two platforms per drug were excluded for too few samples or performance well below the best platform, as shown in Table 1.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "susceptible samples",
          "heading": false
        },
        {
          "term": "dropped",
          "heading": false
        },
        {
          "term": "overall number",
          "heading": false
        },
        {
          "term": "platforms",
          "heading": false
        }
      ],
      "extract": "Flow chart 1: Flow of studies in the review Identifying which drugs and platforms to include in the class-based assessment There were sufficient samples among the pooled data to address each PICO. No drugs were therefore dropped from the analysis. For each drug, between 0 and 2 platforms were dropped from the analysis based on either the overall number of resistant or susceptible samples available for that platform",
      "extractCut": true,
      "blocks": [
        "library/10665-381036/blocks/prose-page-730",
        "library/10665-381036/blocks/figure-img-p730-1"
      ]
    },
    {
      "id": "page-731",
      "number": null,
      "title": "Page 731",
      "level": 1,
      "pageStart": 731,
      "pageEnd": 731,
      "labelStart": "726",
      "labelEnd": "726",
      "words": 264,
      "summary": {
        "text": "Presents Table 1, giving resistant and susceptible sample numbers and raw sensitivity and specificity of the Deeplex, NanoTB and TBSeq platforms for each drug. It shows high sensitivity for most drugs but low values for some platforms with bedaquiline, clofazimine and linezolid.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "nanotb",
          "heading": false
        },
        {
          "term": "ethambutol composite",
          "heading": false
        },
        {
          "term": "pyrazinamide composite",
          "heading": false
        },
        {
          "term": "deeplex",
          "heading": false
        },
        {
          "term": "tbseq",
          "heading": false
        },
        {
          "term": "rifampicin composite",
          "heading": false
        }
      ],
      "extract": "Table 1: Results of selection process of platforms for meta-analysis =” esistant” y e e ence stan a ”; S=”Suscepti le y e e ence stan a ” Sensiti ity an speci icity indicate a percentage. Platform Drug R S Sensitivity Specificity Deeplex Isoniazid 1056 498 97.0 95.6 NanoTB Isoniazid 505 144 95.4 98.6 TBSeq Isoniazid 229 221 90.4 79.6 Deeplex Rifampicin 1083 548 99.1 89.1 NanoTB Rifampicin 497 152 97.4 82.2 TBSeq",
      "extractCut": true,
      "blocks": [
        "library/10665-381036/blocks/prose-page-731"
      ]
    },
    {
      "id": "page-732",
      "number": null,
      "title": "Page 732",
      "level": 1,
      "pageStart": 732,
      "pageEnd": 732,
      "labelStart": "727",
      "labelEnd": "727",
      "words": 117,
      "summary": {
        "text": "Lists, in Table 2, the number of samples from each platform included in the meta-analysis for each drug, with a figure on data sources.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "ipd meta-analysis",
          "heading": false
        },
        {
          "term": "platforms",
          "heading": false
        },
        {
          "term": "ethambutol",
          "heading": false
        }
      ],
      "extract": "After exclusion of the platforms highlighted in red in table 1, data were available for the following drugs from the following platforms (table 2) for inclusion in the IPD meta-analysis. The colours in table 2 are to differentiate the platforms and have no other significance. The number of samples per study are plotted in figure 1. Table 2: Platforms and drugs included in the IPD meta-analysis Figure 1: Sources of",
      "extractCut": true,
      "blocks": [
        "library/10665-381036/blocks/prose-page-732",
        "library/10665-381036/blocks/figure-vfig-p732"
      ]
    },
    {
      "id": "page-733",
      "number": null,
      "title": "Page 733",
      "level": 1,
      "pageStart": 733,
      "pageEnd": 733,
      "labelStart": "728",
      "labelEnd": "728",
      "words": 524,
      "summary": {
        "text": "Summarises the meta-analysis results, with sensitivity above 85% for all drugs except bedaquiline, linezolid and clofazimine (around 68–70%) and specificity above 90% except for streptomycin and for rifampicin against phenotypic DST alone. Table 3 gives pooled sensitivity, specificity and predictive values for each drug under both review questions.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "ethambutol composite",
          "heading": false
        },
        {
          "term": "pyrazinamide composite",
          "heading": false
        },
        {
          "term": "ipd meta-analysis",
          "heading": false
        },
        {
          "term": "predictive value",
          "heading": false
        },
        {
          "term": "bedaquiline",
          "heading": false
        }
      ],
      "extract": "The results of the IPD meta-analysis showed a sensitivity was over 85% for all drugs with the exception of Bedaquiline, Linezolid and Clofazimine for which sensitivity was 68%, 69%, and 70%, respectively. Specificity was over 90% for all drugs with the exception of Streptomycin (75%) and RIF (81%) where only the pDST was used as the reference standard (table 3). Table 3: Summary of the results from the IPD",
      "extractCut": true,
      "blocks": [
        "library/10665-381036/blocks/prose-page-733"
      ]
    },
    {
      "id": "page-734",
      "number": null,
      "title": "Page 734",
      "level": 1,
      "pageStart": 734,
      "pageEnd": 734,
      "labelStart": "729",
      "labelEnd": "729",
      "words": 490,
      "summary": {
        "text": "Presents Table 4 with sub-analysis results by Xpert bacterial load and HIV status for isoniazid, rifampicin, ethambutol and pyrazinamide, showing true and false results, sensitivity, specificity and indeterminate rates. Indeterminate results were much more common in low-load and HIV-positive samples.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "composite semi-quantitative",
          "heading": false
        },
        {
          "term": "semi-quantitative xpert",
          "heading": false
        },
        {
          "term": "ethambutol composite",
          "heading": false
        },
        {
          "term": "pyrazinamide composite",
          "heading": false
        },
        {
          "term": "rifampicin composite",
          "heading": false
        },
        {
          "term": "composite hiv",
          "heading": false
        },
        {
          "term": "hiv test",
          "heading": false
        },
        {
          "term": "medium",
          "heading": false
        }
      ],
      "extract": "This report has been prepared for the WHO Global TB Programme. 729 Table 4: Results of sub-analyses on semi-quantitative results and for patients living with HIV Drug Sub-group TP FN Sensitivity TN FP Specificity Indeterminate (%) Isoniazid Semi-quantitative Xpert result: medium or high 1239 47 96 (93 - 99) 437 10 98 (96 - 99) 147 (8%) Isoniazid Semi-quantitative Xpert result: low or very low 149 6 97 (94 - 100) 66",
      "extractCut": true,
      "blocks": [
        "library/10665-381036/blocks/prose-page-734"
      ]
    },
    {
      "id": "page-735",
      "number": null,
      "title": "Page 735",
      "level": 1,
      "pageStart": 735,
      "pageEnd": 735,
      "labelStart": "730",
      "labelEnd": "730",
      "words": 624,
      "summary": {
        "text": "Continues Table 4 for pyrazinamide, levofloxacin, moxifloxacin, amikacin, streptomycin and the newer drugs, showing accuracy by bacterial load and HIV status and higher indeterminate rates in low-load samples. Footnotes flag where models could not control for certain covariates. For linezolid, very few resistant samples were available in the sub-groups.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "semi-quantitative xpert",
          "heading": false
        },
        {
          "term": "rif xpert",
          "heading": false
        },
        {
          "term": "hiv test",
          "heading": false
        },
        {
          "term": "medium",
          "heading": false
        },
        {
          "term": "bedaquiline",
          "heading": false
        },
        {
          "term": "streptomycin",
          "heading": false
        },
        {
          "term": "clofazimine",
          "heading": false
        },
        {
          "term": "linezolid",
          "heading": false
        }
      ],
      "extract": "This report has been prepared for the WHO Global TB Programme. 730 Pyrazinamide Semi-quantitative Xpert result: medium or high 337 55 86 (80 - 91) 329 19 94 (92 - 97) 47 (6%) Pyrazinamide Semi-quantitative Xpert result: low or very low 27 6 82 (69 - 95) 30 5 89 (79 - 99) 71 (51%) Pyrazinamide HIV test result: Positive 21 3 89 (77 - 100) 47 2 97 (93 - 100) 25 (26%) Pyrazinamide HIV test result: Negative 224 26 89 (86",
      "extractCut": true,
      "blocks": [
        "library/10665-381036/blocks/prose-page-735"
      ]
    },
    {
      "id": "page-736",
      "number": null,
      "title": "Page 736",
      "level": 1,
      "pageStart": 736,
      "pageEnd": 736,
      "labelStart": "731",
      "labelEnd": "731",
      "words": 424,
      "summary": {
        "text": "Explains how the detailed results for each question are presented and reports that, for rifampicin against a composite reference, nine studies gave pooled sensitivity of 93% and specificity of 96%. Evidence was rated moderate for sensitivity and low for specificity after downgrading for indirectness and imprecision.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "confidence interval",
          "heading": false
        },
        {
          "term": "unclea",
          "heading": false
        },
        {
          "term": "drug resistance",
          "heading": false
        },
        {
          "term": "predictive value",
          "heading": false
        },
        {
          "term": "pico",
          "heading": false
        },
        {
          "term": "samples",
          "heading": false
        },
        {
          "term": "downgraded",
          "heading": false
        },
        {
          "term": "specificity",
          "heading": false
        }
      ],
      "extract": "Detailed results addressing each PICO in turn are reported below. For each PICO, the number of TP, FP, TN and FN samples are shown that were included in the model, separated by study. Accompanying forest plots are depicted. For each PICO there are also bar charts showing the proportion of studies, and proportion of samples across all studies, t at e e assesse to e at ‘lo is ’ ‘unclea is ’ o ‘ i is ’ o ias o any o t",
      "extractCut": true,
      "blocks": [
        "library/10665-381036/blocks/prose-page-736"
      ]
    },
    {
      "id": "page-737",
      "number": null,
      "title": "Page 737",
      "level": 1,
      "pageStart": 737,
      "pageEnd": 737,
      "labelStart": "732",
      "labelEnd": "732",
      "words": 91,
      "summary": {
        "text": "Introduces the analysis of tNGS for rifampicin resistance against phenotypic DST as the reference, with sample numbers, resistance prevalence and an indeterminate rate of about 10%.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "pdst",
          "heading": false
        },
        {
          "term": "samples",
          "heading": false
        },
        {
          "term": "thirteen",
          "heading": false
        }
      ],
      "extract": "QUADAS-2 assessment: GRADE assessment: PICO 1.2: Should tNGS as the initial test be used to diagnose drug resistance to rifampin (RIF) (pDST) in patients with bacteriologically confirmed pulmonary TB disease? Thirteen studies with 961 samples were included in the model for sensitivity, and 12 studies with 425 samples for specificity. Prevalence of resistance to rifampicin (pDST) among samples included in the model",
      "extractCut": true,
      "blocks": [
        "library/10665-381036/blocks/prose-page-737"
      ]
    },
    {
      "id": "page-738",
      "number": null,
      "title": "Page 738",
      "level": 1,
      "pageStart": 738,
      "pageEnd": 738,
      "labelStart": "733",
      "labelEnd": "733",
      "words": 147,
      "summary": {
        "text": "Reports pooled sensitivity of 99% and specificity of 81% for rifampicin against phenotypic DST, with certainty rated moderate for sensitivity and very low for specificity.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "confidence interval",
          "heading": false
        },
        {
          "term": "predictive value",
          "heading": false
        },
        {
          "term": "specificity",
          "heading": false
        },
        {
          "term": "downgraded",
          "heading": false
        }
      ],
      "extract": "Results from multivariable, mixed-effects model: Pooled sensitivity was 99% (95% confidence interval (CI) 97%-100%) Pooled specificity was 81% (95% confidence interval (CI) 69%-93%) Negative predictive value was 98% (95% confidence interval (CI) 96%-99%) Positive predictive value was 94% (95% confidence interval (CI) 92%-96%) GRADE assessment: We downgraded one for indirectness for both sensitivity and specificity",
      "extractCut": true,
      "blocks": [
        "library/10665-381036/blocks/prose-page-738"
      ]
    },
    {
      "id": "page-739",
      "number": null,
      "title": "Page 739",
      "level": 1,
      "pageStart": 739,
      "pageEnd": 739,
      "labelStart": "734",
      "labelEnd": "734",
      "words": 194,
      "summary": {
        "text": "Reports that tNGS as the initial test for isoniazid resistance had pooled sensitivity of 96% and specificity of 97%, based on twelve studies. Certainty was rated moderate for both after downgrading for indirectness.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "confidence interval",
          "heading": false
        },
        {
          "term": "predictive value",
          "heading": false
        },
        {
          "term": "both sensitivity",
          "heading": false
        },
        {
          "term": "specificity",
          "heading": false
        },
        {
          "term": "samples",
          "heading": false
        }
      ],
      "extract": "GRADE table: PICO 1.3: Should tNGS as the initial test be used to diagnose drug resistance to isoniazid (INH) (pDST) in patients with bacteriologically confirmed pulmonary TB disease? Twelve studies with 1440 samples were included in the model for sensitivity, and 12 studies with 517 samples for specificity. Prevalence of resistance to isoniazid among samples included in the model was 74% (95% CI 72-76%). The",
      "extractCut": true,
      "blocks": [
        "library/10665-381036/blocks/prose-page-739"
      ]
    },
    {
      "id": "page-740",
      "number": null,
      "title": "Page 740",
      "level": 1,
      "pageStart": 740,
      "pageEnd": 740,
      "labelStart": "735",
      "labelEnd": "735",
      "words": 89,
      "summary": {
        "text": "Introduces the analysis of tNGS for levofloxacin resistance as the initial test, with sample numbers, a 42% resistance prevalence and an indeterminate rate of about 9%.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "levofloxacin",
          "heading": false
        },
        {
          "term": "samples",
          "heading": false
        },
        {
          "term": "tngs",
          "heading": false
        }
      ],
      "extract": "QUADAS-2 assessment: GRADE table: PICO 1.4: Should tNGS as the initial test be used to diagnose drug resistance to levofloxacin (LFX) (pDST) in patients with bacteriologically confirmed pulmonary TB disease? Six studies with 654 samples were included in the model for sensitivity, and 7 studies with 913 samples for specificity. Prevalence of resistance to levofloxacin among samples included in the model was 42% (95%",
      "extractCut": true,
      "blocks": [
        "library/10665-381036/blocks/prose-page-740"
      ]
    },
    {
      "id": "page-741",
      "number": null,
      "title": "Page 741",
      "level": 1,
      "pageStart": 741,
      "pageEnd": 741,
      "labelStart": "736",
      "labelEnd": "736",
      "words": 131,
      "summary": {
        "text": "Reports pooled sensitivity of 94% and specificity of 96% for levofloxacin, with certainty rated low for sensitivity and moderate for specificity.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "confidence interval",
          "heading": false
        },
        {
          "term": "predictive value",
          "heading": false
        },
        {
          "term": "downgraded",
          "heading": false
        },
        {
          "term": "sensitivity",
          "heading": false
        }
      ],
      "extract": "Results from multivariable, mixed-effects model: Pooled sensitivity was 94% (95% confidence interval (CI) 88%-100%) Pooled specificity was 96% (95% confidence interval (CI) 93%-99%) Negative predictive value was 97% (95% confidence interval (CI) 96%-98%) Positive predictive value was 93% (95% confidence interval (CI) 88%-98%) GRADE assessment: We downgraded one for indirectness for both sensitivity and specificity",
      "extractCut": true,
      "blocks": [
        "library/10665-381036/blocks/prose-page-741"
      ]
    },
    {
      "id": "page-742",
      "number": null,
      "title": "Page 742",
      "level": 1,
      "pageStart": 742,
      "pageEnd": 742,
      "labelStart": "737",
      "labelEnd": "737",
      "words": 192,
      "summary": {
        "text": "Reports that tNGS as the initial test for moxifloxacin resistance had pooled sensitivity of 96% and specificity of 96%, with certainty rated moderate for both.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "confidence interval",
          "heading": false
        },
        {
          "term": "predictive value",
          "heading": false
        },
        {
          "term": "moxifloxacin",
          "heading": false
        },
        {
          "term": "specificity",
          "heading": false
        },
        {
          "term": "samples",
          "heading": false
        }
      ],
      "extract": "PICO 1.5: Should tNGS as the initial test be used to diagnose drug resistance to moxifloxacin (MFX) (pDST) in patients with bacteriologically confirmed pulmonary TB disease? Six studies with 652 samples were included in the model for sensitivity, and 8 studies with 921 samples for specificity. Prevalence of resistance to moxifloxacin among samples included in the model was 41% (95% CI 39-44%). The proportion of",
      "extractCut": true,
      "blocks": [
        "library/10665-381036/blocks/prose-page-742"
      ]
    },
    {
      "id": "page-743",
      "number": null,
      "title": "Page 743",
      "level": 1,
      "pageStart": 743,
      "pageEnd": 743,
      "labelStart": "738",
      "labelEnd": "738",
      "words": 105,
      "summary": {
        "text": "Introduces the analysis of tNGS for pyrazinamide resistance against a composite reference, reporting pooled sensitivity of 88%.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "pyrazinamide",
          "heading": false
        },
        {
          "term": "samples",
          "heading": false
        },
        {
          "term": "composite",
          "heading": false
        }
      ],
      "extract": "QUADAS-2 assessment: GRADE table: PICO 1.6: Should tNGS as the initial test be used to diagnose drug resistance to pyrazinamide (PZA) (composite) in patients with bacteriologically confirmed pulmonary TB disease? Three studies with 346 samples were included in the model for sensitivity, and 3 studies with 269 samples for specificity. Prevalence of resistance to pyrazinamide (composite) among samples included in the",
      "extractCut": true,
      "blocks": [
        "library/10665-381036/blocks/prose-page-743"
      ]
    },
    {
      "id": "page-744",
      "number": null,
      "title": "Page 744",
      "level": 1,
      "pageStart": 744,
      "pageEnd": 744,
      "labelStart": "739",
      "labelEnd": "739",
      "words": 97,
      "summary": {
        "text": "Reports pooled specificity of 99% for pyrazinamide against the composite reference, with certainty rated moderate for both sensitivity and specificity.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "confidence interval",
          "heading": false
        },
        {
          "term": "predictive value",
          "heading": false
        },
        {
          "term": "specificity",
          "heading": false
        }
      ],
      "extract": "Pooled specificity was 99% (95% confidence interval (CI) 97%-100%) Negative predictive value was 88% (95% confidence interval (CI) 81%-95%) Positive predictive value was 99% (95% confidence interval (CI) 98%-100%) GRADE assessment: We downgraded one for indirectness for both sensitivity and specificity as all studies were enriched for rifampicin resistance, leading to applicability concerns, but not for risk of bias",
      "extractCut": true,
      "blocks": [
        "library/10665-381036/blocks/prose-page-744"
      ]
    },
    {
      "id": "page-745",
      "number": null,
      "title": "Page 745",
      "level": 1,
      "pageStart": 745,
      "pageEnd": 745,
      "labelStart": "740",
      "labelEnd": "740",
      "words": 216,
      "summary": {
        "text": "Reports that tNGS for pyrazinamide resistance against phenotypic DST had pooled sensitivity of 85% and specificity of 94%. Certainty was rated low for sensitivity, because a Bangladesh study was an outlier, and moderate for specificity.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "confidence interval",
          "heading": false
        },
        {
          "term": "predictive value",
          "heading": false
        },
        {
          "term": "sensitivity",
          "heading": false
        },
        {
          "term": "pyrazinamide",
          "heading": false
        },
        {
          "term": "specificity",
          "heading": false
        },
        {
          "term": "pdst",
          "heading": false
        }
      ],
      "extract": "PICO 1.7: Should tNGS as the initial test be used to diagnose drug resistance to pyrazinamide (PZA) (pDST) in patients with bacteriologically confirmed pulmonary TB disease? Six studies with 425 samples were included in the model for sensitivity, and 6 studies with 379 samples for specificity. Prevalence of resistance to pyrazinamide (pDST) among samples included in the model was 52% (95% CI 49-56%). The proportion",
      "extractCut": true,
      "blocks": [
        "library/10665-381036/blocks/prose-page-745"
      ]
    },
    {
      "id": "page-746",
      "number": null,
      "title": "Page 746",
      "level": 1,
      "pageStart": 746,
      "pageEnd": 746,
      "labelStart": "741",
      "labelEnd": "741",
      "words": 166,
      "summary": {
        "text": "Reports that tNGS for ethambutol resistance against a composite reference had pooled sensitivity of 96% and very high specificity and positive predictive value. It notes the model could not control for rifampicin resistance because of collinearity.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "confidence interval",
          "heading": false
        },
        {
          "term": "rifampicin resistance",
          "heading": false
        },
        {
          "term": "predictive value",
          "heading": false
        },
        {
          "term": "mtb rif",
          "heading": false
        },
        {
          "term": "rif xpert",
          "heading": false
        }
      ],
      "extract": "GRADE table: PICO 1.8: Should tNGS as the initial test be used to diagnose drug resistance to ethambutol (EMB) (composite) in patients with bacteriologically confirmed pulmonary TB disease? Four studies with 432 samples were included in the model for sensitivity, and 4 studies with 268 samples for specificity. Prevalence of resistance to ethambutol (composite) among samples included in the model was 62% (95% CI",
      "extractCut": true,
      "blocks": [
        "library/10665-381036/blocks/prose-page-746"
      ]
    },
    {
      "id": "page-747",
      "number": null,
      "title": "Page 747",
      "level": 1,
      "pageStart": 747,
      "pageEnd": 747,
      "labelStart": "742",
      "labelEnd": "742",
      "words": 122,
      "summary": {
        "text": "Explains the GRADE judgement for ethambutol against the composite reference, rated low for both sensitivity and specificity because different samples were used for index and reference tests and studies were enriched for rifampicin resistance.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "rifampicin resistance",
          "heading": false
        },
        {
          "term": "both sensitivity",
          "heading": false
        },
        {
          "term": "downgraded",
          "heading": false
        },
        {
          "term": "specificity",
          "heading": false
        }
      ],
      "extract": "The model for specificity did not control for rifampicin resistance as this variable was collinear in the original model. The quality assessment of the evidence was not downgraded as a result. We downgraded one for risk of bias for both sensitivity and specificity as difference samples were used for the index (tNGS) and reference tests. We also downgraded one for indirectness for both sensitivity and specificity as",
      "extractCut": true,
      "blocks": [
        "library/10665-381036/blocks/prose-page-747"
      ]
    },
    {
      "id": "page-748",
      "number": null,
      "title": "Page 748",
      "level": 1,
      "pageStart": 748,
      "pageEnd": 748,
      "labelStart": "743",
      "labelEnd": "743",
      "words": 330,
      "summary": {
        "text": "Reports that tNGS for ethambutol resistance against phenotypic DST, based on a single study, had pooled sensitivity of 88%. Certainty was rated very low for both sensitivity and specificity because of risk of bias, enrichment and reliance on one study.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "rifampicin resistance",
          "heading": false
        },
        {
          "term": "confidence interval",
          "heading": false
        },
        {
          "term": "collinear",
          "heading": false
        },
        {
          "term": "mtb rif",
          "heading": false
        },
        {
          "term": "rif xpert",
          "heading": false
        },
        {
          "term": "both sensitivity",
          "heading": false
        },
        {
          "term": "variable",
          "heading": false
        },
        {
          "term": "predictive value",
          "heading": false
        }
      ],
      "extract": "PICO 1.9: Should tNGS as the initial test be used to diagnose drug resistance to ethambutol (EMB) (pDST) in patients with bacteriologically confirmed pulmonary TB disease? One study with 100 samples was included in the model for sensitivity, and one study with 334 samples for specificity. Prevalence of resistance to ethambutol (pDST) among samples included in the model was 23% (95% CI 19-27%). The proportion of",
      "extractCut": true,
      "blocks": [
        "library/10665-381036/blocks/prose-page-748"
      ]
    },
    {
      "id": "page-749",
      "number": null,
      "title": "Page 749",
      "level": 1,
      "pageStart": 749,
      "pageEnd": 749,
      "labelStart": "744",
      "labelEnd": "744",
      "words": 88,
      "summary": {
        "text": "Introduces the second review question on tNGS for drug resistance in rifampicin-resistant TB, beginning with isoniazid in twelve studies.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "drug resistance",
          "heading": false
        },
        {
          "term": "inh",
          "heading": false
        },
        {
          "term": "rif-resistant",
          "heading": false
        }
      ],
      "extract": "Data by study: QUADAS-2 assessment: GRADE table: PICO 2 - TNGS as test for drug resistance in patients with bac- confirmed rif-resistant TB (RR-TB) for INH, LFX, MFX, PZA, BDQ, LZD, CFZ, AMK, EMB, ETO, PTO, STR PICO 2.1: Should tNGS be used to diagnose drug resistance to isoniazid (INH) (pDST) in patients with bacteriologically confirmed rifampicin- resistant pulmonary TB disease? Twelve studies with 1440 samples",
      "extractCut": true,
      "blocks": [
        "library/10665-381036/blocks/prose-page-749"
      ]
    },
    {
      "id": "page-750",
      "number": null,
      "title": "Page 750",
      "level": 1,
      "pageStart": 750,
      "pageEnd": 750,
      "labelStart": "745",
      "labelEnd": "745",
      "words": 105,
      "summary": {
        "text": "Reports pooled sensitivity and specificity of 96% for isoniazid in rifampicin-resistant TB, with high certainty for both.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "confidence interval",
          "heading": false
        },
        {
          "term": "predictive value",
          "heading": false
        },
        {
          "term": "epo",
          "heading": false
        }
      ],
      "extract": "included in the model was 74% (95% CI 72-76%). The proportion of samples with no tNGS esult epo te (t e ‘in ete inate ate’) as 14 6% (95% C 13 0-16.2). Results from multivariable, mixed-effects model: Pooled sensitivity was 96% (95% confidence interval (CI) 94%-99%) Pooled specificity was 96% (95% confidence interval (CI) 92%-100%) Negative predictive value was 76% (95% confidence interval (CI) 67%-84%) Positive",
      "extractCut": true,
      "blocks": [
        "library/10665-381036/blocks/prose-page-750"
      ]
    },
    {
      "id": "page-751",
      "number": null,
      "title": "Page 751",
      "level": 1,
      "pageStart": 751,
      "pageEnd": 751,
      "labelStart": "746",
      "labelEnd": "746",
      "words": 168,
      "summary": {
        "text": "Reports that tNGS for levofloxacin resistance in rifampicin-resistant TB had high pooled sensitivity and specificity. Certainty was rated moderate for sensitivity, because one FIND study was an outlier, and high for specificity.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "confidence interval",
          "heading": false
        },
        {
          "term": "predictive value",
          "heading": false
        },
        {
          "term": "levofloxacin",
          "heading": false
        },
        {
          "term": "samples",
          "heading": false
        },
        {
          "term": "outlier",
          "heading": false
        }
      ],
      "extract": "PICO 2.2: Should tNGS be used to diagnose drug resistance to levofloxacin (LFX) (pDST) in patients with bacteriologically confirmed rifampicin- resistant pulmonary TB disease? Six studies with 654 samples were included in the model for sensitivity, and 7 studies with 913 samples for specificity. Prevalence of resistance to levofloxacin among samples included in the model was 42% (95% CI 39-44%). The proportion of",
      "extractCut": true,
      "blocks": [
        "library/10665-381036/blocks/prose-page-751"
      ]
    },
    {
      "id": "page-752",
      "number": null,
      "title": "Page 752",
      "level": 1,
      "pageStart": 752,
      "pageEnd": 752,
      "labelStart": "747",
      "labelEnd": "747",
      "words": 85,
      "summary": {
        "text": "Introduces the analysis of tNGS for moxifloxacin resistance in rifampicin-resistant TB, with sample numbers, resistance prevalence and indeterminate rate.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "moxifloxacin",
          "heading": false
        },
        {
          "term": "samples",
          "heading": false
        },
        {
          "term": "tngs",
          "heading": false
        }
      ],
      "extract": "GRADE table: PICO 2.3: Should tNGS be used to diagnose drug resistance to moxifloxacin (MFX) (pDST) in patients with bacteriologically confirmed rifampicin- resistant pulmonary TB disease? Six studies with 652 samples were included in the model for sensitivity, and 8 studies with 921 samples for specificity. Prevalence of resistance to moxifloxacin among samples included in the model was 41% (95% CI 39-44%). The",
      "extractCut": true,
      "blocks": [
        "library/10665-381036/blocks/prose-page-752"
      ]
    },
    {
      "id": "page-753",
      "number": null,
      "title": "Page 753",
      "level": 1,
      "pageStart": 753,
      "pageEnd": 753,
      "labelStart": "748",
      "labelEnd": "748",
      "words": 73,
      "summary": {
        "text": "Reports pooled sensitivity of 97% and specificity of 95% for moxifloxacin in rifampicin-resistant TB, with high certainty for both.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "confidence interval",
          "heading": false
        },
        {
          "term": "predictive value",
          "heading": false
        },
        {
          "term": "downgrade",
          "heading": false
        }
      ],
      "extract": "Results from multivariable, mixed-effects model: Pooled sensitivity was 97% (95% confidence interval (CI) 94%-100%) Pooled specificity was 95% (95% confidence interval (CI) 91%-99%) Negative predictive value was 97% (95% confidence interval (CI) 96%-99%) Positive predictive value was 95% (95% confidence interval (CI) 91%-99%) GRADE assessment: We did not downgrade for any categories. Quality of evidence was thereby",
      "extractCut": true,
      "blocks": [
        "library/10665-381036/blocks/prose-page-753"
      ]
    },
    {
      "id": "page-754",
      "number": null,
      "title": "Page 754",
      "level": 1,
      "pageStart": 754,
      "pageEnd": 754,
      "labelStart": "749",
      "labelEnd": "749",
      "words": 156,
      "summary": {
        "text": "Reports that tNGS for pyrazinamide resistance against a composite reference in rifampicin-resistant TB had high accuracy, with specificity of 99% and high certainty for both measures.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "confidence interval",
          "heading": false
        },
        {
          "term": "predictive value",
          "heading": false
        },
        {
          "term": "pyrazinamide",
          "heading": false
        },
        {
          "term": "samples",
          "heading": false
        }
      ],
      "extract": "PICO 2.4: Should tNGS be used to diagnose drug resistance to pyrazinamide (PZA) (composite) in patients with bacteriologically confirmed rifampicin- resistant pulmonary TB disease? Three studies with 346 samples were included in the model for sensitivity, and 3 studies with 269 samples for specificity. Prevalence of resistance to pyrazinamide (composite) among samples included in the model was 56% (95% CI 52-60%).",
      "extractCut": true,
      "blocks": [
        "library/10665-381036/blocks/prose-page-754"
      ]
    },
    {
      "id": "page-755",
      "number": null,
      "title": "Page 755",
      "level": 1,
      "pageStart": 755,
      "pageEnd": 755,
      "labelStart": "750",
      "labelEnd": "750",
      "words": 132,
      "summary": {
        "text": "Reports that tNGS for pyrazinamide resistance against phenotypic DST in rifampicin-resistant TB had pooled sensitivity and specificity of 90% each.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "confidence interval",
          "heading": false
        },
        {
          "term": "predictive value",
          "heading": false
        },
        {
          "term": "pyrazinamide",
          "heading": false
        },
        {
          "term": "pdst",
          "heading": false
        }
      ],
      "extract": "GRADE table: PICO 2.5: Should tNGS be used to diagnose drug resistance to pyrazinamide (PZA) (pDST) in patients with bacteriologically confirmed rifampicin- resistant pulmonary TB disease? Six studies with 425 samples were included in the model for sensitivity, and 6 studies with 379 samples for specificity. Prevalence of resistance to pyrazinamide (pDST) among samples included in the model was 53% (95% CI 49-56%).",
      "extractCut": true,
      "blocks": [
        "library/10665-381036/blocks/prose-page-755"
      ]
    },
    {
      "id": "page-756",
      "number": null,
      "title": "Page 756",
      "level": 1,
      "pageStart": 756,
      "pageEnd": 756,
      "labelStart": "751",
      "labelEnd": "751",
      "words": 65,
      "summary": {
        "text": "Rates the pyrazinamide evidence moderate for sensitivity and high for specificity, and introduces the bedaquiline analysis for rifampicin-resistant TB.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "bdq",
          "heading": false
        },
        {
          "term": "outlier",
          "heading": false
        },
        {
          "term": "bedaquiline",
          "heading": false
        }
      ],
      "extract": "We downgraded on for inconsistency for sensitivity as the study from Bangladesh was an outlier (see forest plot below). Quality of evidence was thereby assessed to be moderate for sensitivity and high for specificity. Data by study: QUADAS-2 assessment: GRADE table: PICO 2.6: Should tNGS be used to diagnose drug resistance to bedaquiline (BDQ) (pDST) in patients with bacteriologically confirmed rifampicin- resistant",
      "extractCut": true,
      "blocks": [
        "library/10665-381036/blocks/prose-page-756"
      ]
    },
    {
      "id": "page-757",
      "number": null,
      "title": "Page 757",
      "level": 1,
      "pageStart": 757,
      "pageEnd": 757,
      "labelStart": "752",
      "labelEnd": "752",
      "words": 307,
      "summary": {
        "text": "Reports that tNGS for bedaquiline resistance, based on only 31 resistant samples, had pooled sensitivity of 68% and specificity of 97%. Certainty was rated low for sensitivity, because of few resistant samples and very wide confidence intervals, and high for specificity.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "mtb rif",
          "heading": false
        },
        {
          "term": "rif xpert",
          "heading": false
        },
        {
          "term": "confidence interval",
          "heading": false
        },
        {
          "term": "resistant samples",
          "heading": false
        },
        {
          "term": "original model",
          "heading": false
        },
        {
          "term": "collinear",
          "heading": false
        },
        {
          "term": "semi-quantitative",
          "heading": false
        },
        {
          "term": "rifampicin resistance",
          "heading": false
        }
      ],
      "extract": "Three studies with 31 samples were included in the model for sensitivity, and 4 studies with 519 samples for specificity. Prevalence of resistance to bedaquiline among samples included in the model was 6% (95% CI 4-8%). The proportion of samples with no tNGS esult epo te (t e ‘in ete inate ate’) as 16 7% (95% C 13 7-20.1). Results from multivariable, mixed-effects model: Pooled sensitivity was 68% (95% confidence",
      "extractCut": true,
      "blocks": [
        "library/10665-381036/blocks/prose-page-757"
      ]
    },
    {
      "id": "page-758",
      "number": null,
      "title": "Page 758",
      "level": 1,
      "pageStart": 758,
      "pageEnd": 758,
      "labelStart": "753",
      "labelEnd": "753",
      "words": 165,
      "summary": {
        "text": "Reports that tNGS for linezolid resistance, with only 31 resistant samples and 3% resistance prevalence, had pooled sensitivity of 69% and specificity of 100%. It notes model restrictions due to collinear variables.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "model restricted",
          "heading": false
        },
        {
          "term": "original model",
          "heading": false
        },
        {
          "term": "confidence interval",
          "heading": false
        },
        {
          "term": "mtb rif",
          "heading": false
        },
        {
          "term": "rif xpert",
          "heading": false
        }
      ],
      "extract": "GRADE table: PICO 2.7: Should tNGS be used to diagnose drug resistance to linezolid (LZD) (pDST) in patients with bacteriologically confirmed rifampicin-resistant pulmonary TB disease? Four studies with 31 samples were included in the model for sensitivity, and 6 studies with 1093 samples for specificity. Prevalence of resistance to linezolid among samples included in the model was 3% (95% CI 2-4%). The proportion",
      "extractCut": true,
      "blocks": [
        "library/10665-381036/blocks/prose-page-758"
      ]
    },
    {
      "id": "page-759",
      "number": null,
      "title": "Page 759",
      "level": 1,
      "pageStart": 759,
      "pageEnd": 759,
      "labelStart": "754",
      "labelEnd": "754",
      "words": 209,
      "summary": {
        "text": "Gives the positive predictive value and GRADE judgement for linezolid, rated low for sensitivity because of imprecision and high for specificity.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "collinear",
          "heading": false
        },
        {
          "term": "original model",
          "heading": false
        },
        {
          "term": "rif xpert",
          "heading": false
        },
        {
          "term": "mtb rif",
          "heading": false
        },
        {
          "term": "semi-quantitative",
          "heading": false
        },
        {
          "term": "resistant",
          "heading": false
        }
      ],
      "extract": "Positive predictive value was 93% (95% confidence interval (CI) 84%-100%) Model not controlled for semi-quantitative result from MTB/RIF Xpert as this variable was collinear, and only includes samples that were resistant to rifampicin by MTB/RIF Xpert as this variable was also collinear in the original model. GRADE assessment The model for specificity was restricted to isolates that were resistant to rifampicin by",
      "extractCut": true,
      "blocks": [
        "library/10665-381036/blocks/prose-page-759"
      ]
    },
    {
      "id": "page-760",
      "number": null,
      "title": "Page 760",
      "level": 1,
      "pageStart": 760,
      "pageEnd": 760,
      "labelStart": "755",
      "labelEnd": "755",
      "words": 239,
      "summary": {
        "text": "Reports that tNGS for clofazimine resistance had pooled sensitivity of 70% and specificity of 96%, based on very few resistant samples. Certainty was rated low for sensitivity because of outlying studies and wide confidence intervals, and high for specificity.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "confidence interval",
          "heading": false
        },
        {
          "term": "original model",
          "heading": false
        },
        {
          "term": "collinear",
          "heading": false
        },
        {
          "term": "semi-quantitative",
          "heading": false
        },
        {
          "term": "rif xpert",
          "heading": false
        },
        {
          "term": "predictive value",
          "heading": false
        },
        {
          "term": "mtb rif",
          "heading": false
        }
      ],
      "extract": "PICO 2.8: Should tNGS be used to diagnose drug resistance to clofazimine (CFZ) (pDST) in patients with bacteriologically confirmed rifampicin- resistant pulmonary TB disease? Four studies with 36 samples were included in the model for sensitivity, and 6 studies with 789 samples for specificity. Prevalence of resistance to clofazimine among samples included in the model was 3% (95% CI 2-4%). The proportion of samples",
      "extractCut": true,
      "blocks": [
        "library/10665-381036/blocks/prose-page-760"
      ]
    },
    {
      "id": "page-761",
      "number": null,
      "title": "Page 761",
      "level": 1,
      "pageStart": 761,
      "pageEnd": 761,
      "labelStart": "756",
      "labelEnd": "756",
      "words": 92,
      "summary": {
        "text": "Introduces the analysis of tNGS for amikacin resistance in rifampicin-resistant TB, with sample numbers, a 10% resistance prevalence and an indeterminate rate of about 18%.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "amikacin",
          "heading": false
        },
        {
          "term": "samples",
          "heading": false
        },
        {
          "term": "tngs",
          "heading": false
        }
      ],
      "extract": "QUADAS-2 assessment: Grade table: PICO 2.9: Should tNGS be used to diagnose drug resistance to amikacin (AMK) (pDST) in patients with bacteriologically confirmed rifampicin- resistant pulmonary TB disease? Five studies with 115 samples were included in the model for sensitivity, and 8 studies with 1003 samples for specificity. Prevalence of resistance to amikacin among samples included in the model was 10% (95% CI",
      "extractCut": true,
      "blocks": [
        "library/10665-381036/blocks/prose-page-761"
      ]
    },
    {
      "id": "page-762",
      "number": null,
      "title": "Page 762",
      "level": 1,
      "pageStart": 762,
      "pageEnd": 762,
      "labelStart": "757",
      "labelEnd": "757",
      "words": 271,
      "summary": {
        "text": "Reports pooled sensitivity of 87% and specificity of 99% for amikacin. Certainty was rated very low for sensitivity and moderate for specificity after downgrading for bias, inconsistency and imprecision.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "model restricted",
          "heading": false
        },
        {
          "term": "rif xpert",
          "heading": false
        },
        {
          "term": "original model",
          "heading": false
        },
        {
          "term": "tested resistant",
          "heading": false
        },
        {
          "term": "confidence interval",
          "heading": false
        },
        {
          "term": "mtb rif",
          "heading": false
        },
        {
          "term": "collinear",
          "heading": false
        },
        {
          "term": "rifampicin resistance",
          "heading": false
        }
      ],
      "extract": "Pooled sensitivity was 87% (95% confidence interval (CI) 75%-100%) Model restricted to samples that tested resistant to rifampicin by MTB/RIF Xpert as this variable was collinear in the original model. Pooled specificity was 99% (95% confidence interval (CI) 98%-100%) Model restricted to samples that tested resistant to rifampicin by MTB/RIF Xpert as this variable was collinear in the original model. Negative",
      "extractCut": true,
      "blocks": [
        "library/10665-381036/blocks/prose-page-762"
      ]
    },
    {
      "id": "page-763",
      "number": null,
      "title": "Page 763",
      "level": 1,
      "pageStart": 763,
      "pageEnd": 763,
      "labelStart": "758",
      "labelEnd": "758",
      "words": 159,
      "summary": {
        "text": "Introduces the analysis of tNGS for ethambutol resistance against a composite reference in rifampicin-resistant TB and reports specificity of 98% and high predictive values.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "confidence interval",
          "heading": false
        },
        {
          "term": "predictive value",
          "heading": false
        },
        {
          "term": "ethambutol",
          "heading": false
        },
        {
          "term": "model",
          "heading": false
        },
        {
          "term": "samples",
          "heading": false
        }
      ],
      "extract": "GRADE table: PICO 2.10: Should tNGS be used to diagnose drug resistance to ethambutol (EMB) (composite) in patients with bacteriologically confirmed rifampicin- resistant pulmonary TB disease? Four studies with 431 samples were included in the model for sensitivity, and 4 studies with 123 samples for specificity. Prevalence of resistance to ethambutol (composite) among samples included in the model was 78% (95% CI",
      "extractCut": true,
      "blocks": [
        "library/10665-381036/blocks/prose-page-763"
      ]
    },
    {
      "id": "page-764",
      "number": null,
      "title": "Page 764",
      "level": 1,
      "pageStart": 764,
      "pageEnd": 764,
      "labelStart": "759",
      "labelEnd": "759",
      "words": 118,
      "summary": {
        "text": "Gives the GRADE judgement for ethambutol against the composite reference in rifampicin-resistant TB, rated moderate for both measures because different samples were used for index and reference tests.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "rif xpert",
          "heading": false
        },
        {
          "term": "mtb rif",
          "heading": false
        },
        {
          "term": "collinear",
          "heading": false
        },
        {
          "term": "model",
          "heading": false
        }
      ],
      "extract": "Model not controlled for rifampicin resistance as determined by MTB/RIF Xpert as this variable was collinear. Model therefore run only on isolates that tested resistant to rifampicin by Xpert. GRADE assessment: The model for specificity was restricted to samples that were resistant to rifampicin by MTB/RIF Xpert as this variable was collinear in the original model. The model does control for semi-quantitative Xpert",
      "extractCut": true,
      "blocks": [
        "library/10665-381036/blocks/prose-page-764"
      ]
    },
    {
      "id": "page-765",
      "number": null,
      "title": "Page 765",
      "level": 1,
      "pageStart": 765,
      "pageEnd": 765,
      "labelStart": "760",
      "labelEnd": "760",
      "words": 359,
      "summary": {
        "text": "Reports that tNGS for ethambutol resistance against phenotypic DST in rifampicin-resistant TB, from a single study, had pooled sensitivity of 91% and specificity of 92%. Certainty was rated low for both because of risk of bias and data from only one country.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "rifampicin resistance",
          "heading": false
        },
        {
          "term": "tested resistant",
          "heading": false
        },
        {
          "term": "rif xpert",
          "heading": false
        },
        {
          "term": "mtb rif",
          "heading": false
        },
        {
          "term": "confidence interval",
          "heading": false
        },
        {
          "term": "collinear",
          "heading": false
        },
        {
          "term": "both sensitivity",
          "heading": false
        },
        {
          "term": "variable",
          "heading": false
        }
      ],
      "extract": "PICO 2.11: Should tNGS be used to diagnose drug resistance to ethambutol (EMB) (pDST) in patients with bacteriologically confirmed rifampicin- resistant pulmonary TB disease? One study with 89 samples was included in the model for sensitivity, and 1 study with 213 samples for specificity. Prevalence of resistance to ethambutol (pDST) among samples included in the model was 29% (95% CI 24-35%). The proportion of",
      "extractCut": true,
      "blocks": [
        "library/10665-381036/blocks/prose-page-765"
      ]
    },
    {
      "id": "page-766",
      "number": null,
      "title": "Page 766",
      "level": 1,
      "pageStart": 766,
      "pageEnd": 766,
      "labelStart": "761",
      "labelEnd": "761",
      "words": 170,
      "summary": {
        "text": "Reports that tNGS for streptomycin resistance in rifampicin-resistant TB had pooled sensitivity of 98% and specificity of 75%. Specificity was downgraded for an outlying study and wide confidence intervals.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "confidence interval",
          "heading": false
        },
        {
          "term": "predictive value",
          "heading": false
        },
        {
          "term": "streptomycin",
          "heading": false
        },
        {
          "term": "samples",
          "heading": false
        },
        {
          "term": "downgraded",
          "heading": false
        }
      ],
      "extract": "GRADE table: PICO 2.12: Should tNGS be used to diagnose drug resistance to streptomycin (STR) (pDST) in patients with bacteriologically confirmed rifampicin-resistant pulmonary TB disease? Five studies with 493 samples were included in the model for sensitivity, and 5 studies with 250 samples for specificity. Prevalence of resistance to streptomycin among samples included in the model was 66% (95% CI 63-70%). The",
      "extractCut": true,
      "blocks": [
        "library/10665-381036/blocks/prose-page-766"
      ]
    },
    {
      "id": "page-767",
      "number": null,
      "title": "Page 767",
      "level": 1,
      "pageStart": 767,
      "pageEnd": 767,
      "labelStart": "762",
      "labelEnd": "762",
      "words": 107,
      "summary": {
        "text": "Begins the authors' conclusions, noting that, as an initial test, tNGS sensitivity for first-line drugs was 88–96% and for fluoroquinolones 94–96%, comparable to whole genome sequencing from culture.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "wgs",
          "heading": false
        },
        {
          "term": "flouroquinolones",
          "heading": false
        },
        {
          "term": "tngs",
          "heading": false
        },
        {
          "term": "alleles",
          "heading": false
        }
      ],
      "extract": "was thereby assessed to be high for sensitivity but low for specificity. Data by study: QUADAS-2 assessment: GRADE table: Author’s conclusions Regarding positioning tNGS as the first test for drug resistance for patients (PICO 1): Pooled sensitivity to first line drugs was 88%-96%, with the highest estimate for isoniazid and the lowest for pyrazinamide. This is similar to the results obtained from WGS sequencing",
      "extractCut": true,
      "blocks": [
        "library/10665-381036/blocks/prose-page-767"
      ]
    },
    {
      "id": "page-768",
      "number": null,
      "title": "Page 768",
      "level": 1,
      "pageStart": 768,
      "pageEnd": 768,
      "labelStart": "763",
      "labelEnd": "763",
      "words": 346,
      "summary": {
        "text": "Continues the conclusions, reporting specificity of 96–99% for first-line drugs and 96% for fluoroquinolones and noting that positioning tNGS first would need head-to-head comparisons, cost and operational data. For rifampicin-resistant TB, sensitivity was around 68–70% for bedaquiline, clofazimine and linezolid, which the authors see as encouraging given the lack of other molecular tests, but they flag indeterminate rates of 10–20% as a concern.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "pooled specificity",
          "heading": false
        },
        {
          "term": "drug resistance",
          "heading": false
        },
        {
          "term": "bedaquiline",
          "heading": false
        },
        {
          "term": "clofazimine",
          "heading": false
        },
        {
          "term": "linezolid",
          "heading": false
        },
        {
          "term": "pico",
          "heading": false
        },
        {
          "term": "tngs",
          "heading": false
        },
        {
          "term": "detected",
          "heading": false
        }
      ],
      "extract": "Pooled specificity to first line drugs was 96%-99%, with the highest estimate for ethambutol and the lowest for rifampicin. This is again comparable to the results obtained from WGS sequencing from culture. Specificity for the flouroquinolones was 96%, indicating minimal loss in specificity for any gain in sensitivity through the detection of low frequency resistance alleles. Any recommendation to position tNGS as",
      "extractCut": true,
      "blocks": [
        "library/10665-381036/blocks/prose-page-768"
      ]
    },
    {
      "id": "page-769",
      "number": null,
      "title": "Page 769",
      "level": 1,
      "pageStart": 769,
      "pageEnd": 769,
      "labelStart": "764",
      "labelEnd": "764",
      "words": 337,
      "summary": {
        "text": "The reference list for the tNGS accuracy review, citing WHO TB reports, strategies and guidelines and studies on resistance amplification and genomic sequencing for TB.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "accessed april",
          "heading": false
        },
        {
          "term": "health organization",
          "heading": false
        },
        {
          "term": "world health",
          "heading": false
        },
        {
          "term": "oct",
          "heading": false
        },
        {
          "term": "nov",
          "heading": false
        },
        {
          "term": "pipeline",
          "heading": false
        },
        {
          "term": "tuberculosis",
          "heading": false
        },
        {
          "term": "igo",
          "heading": false
        }
      ],
      "extract": "References 1. Global Tuberculosis Report 2022. Geneva: World Health Organization; Licence: CC BY-NC-SA 3.0 IGO 2. Karmakar M, Ragonnet R, Ascher DB, Trauer JM, Denholm JT. Estimating tuberculosis drug resistance amplification rates in high-burden settings. BMC Infect Dis. 2022 Jan 24;22(1):82. 3. The End TB Strategy. Geneva: World Health Organization; WHO/HTM/TB/2015.19. Available from:",
      "extractCut": true,
      "blocks": [
        "library/10665-381036/blocks/prose-page-769"
      ]
    },
    {
      "id": "page-770",
      "number": null,
      "title": "Page 770",
      "level": 1,
      "pageStart": 770,
      "pageEnd": 770,
      "labelStart": "765",
      "labelEnd": "765",
      "words": 48,
      "summary": {
        "text": "Ends the reference list with a study on minor alleles and fluoroquinolone resistance and WHO's catalogue of TB resistance mutations.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "mycobacterium tuberculosis",
          "heading": false
        },
        {
          "term": "jac",
          "heading": false
        },
        {
          "term": "fowler",
          "heading": false
        }
      ],
      "extract": "14. Brankin AE, Fowler PW. Inclusion of minor alleles improves catalogue-based prediction of fluoroquinolone resistance in Mycobacterium tuberculosis. JAC Antimicrob Resist 2023 Apr 4;5(2) 15. Catalogue of mutations in Mycobacterium tuberculosis complex and their association with drug resistance. Geneva: World Health Organization; 2021. Licence: CC BY-NC-SA 3.0 IGO",
      "extractCut": false,
      "blocks": [
        "library/10665-381036/blocks/prose-page-770"
      ]
    },
    {
      "id": "page-771",
      "number": null,
      "title": "Page 771",
      "level": 1,
      "pageStart": 771,
      "pageEnd": 771,
      "labelStart": "766",
      "labelEnd": "766",
      "words": 73,
      "summary": {
        "text": "The title page of Web Annex B.17, a systematic and scoping review of the economic evidence on targeted next-generation sequencing for diagnosing drug-resistant TB, prepared for the WHO Global TB Programme by authors from the universities of Toronto and Ottawa.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "alice zwerling",
          "heading": false
        },
        {
          "term": "toronto",
          "heading": false
        },
        {
          "term": "ottawa",
          "heading": false
        }
      ],
      "extract": "Web Annex B.17. A Systematic and Scoping Review of the Economic Evidence around Targeted Next Generation Sequencing (tNGS) for the Diagnosis of Drug-Resistant Tuberculosis (DR-TB) Prepared for WHO Global TB Programme, Guideline Development Group Patrick Galange1, Suvesh Shrestha2, Israa Zareef2, Alice Zwerling2 1 Dalla Lana School of Public Health, University of Toronto, Toronto, Canada 2 School of Epidemiology &",
      "extractCut": true,
      "blocks": [
        "library/10665-381036/blocks/prose-page-771"
      ]
    },
    {
      "id": "page-772",
      "number": null,
      "title": "Page 772",
      "level": 1,
      "pageStart": 772,
      "pageEnd": 772,
      "labelStart": "767",
      "labelEnd": "767",
      "words": 384,
      "summary": {
        "text": "Summarises the economic review, which searched three databases in 2022 and included ten studies on tNGS and whole genome sequencing for drug-resistant TB, finding tNGS costs of about US$70 per sample and wider ranges for whole genome sequencing. It identifies sequencing as the costliest step, reagents and consumables as the main cost components and drivers such as sequencer choice, coverage depth and batching, and calls for more cost-effectiveness research.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "illumina miseq",
          "heading": false
        },
        {
          "term": "nanopore minion",
          "heading": false
        },
        {
          "term": "cost drivers",
          "heading": false
        },
        {
          "term": "greatest cost",
          "heading": false
        },
        {
          "term": "scoping review",
          "heading": false
        },
        {
          "term": "drivers identified",
          "heading": false
        },
        {
          "term": "wgs",
          "heading": false
        },
        {
          "term": "tngs",
          "heading": false
        }
      ],
      "extract": "Background: Tuberculosis (TB) remains one of the leading causes of morbidity and mortality globally. Our review aims to summarize the current economic evidence around using targeted Next Generation Sequencing (tNGS) for the diagnosis of DR-TB. Methods: We conducted a systematic review on the economic evaluation of using either tNGS or WGS to diagnose DR-TB. The following three databases were used: PubMed, EMBASE and",
      "extractCut": true,
      "blocks": [
        "library/10665-381036/blocks/prose-page-772"
      ]
    },
    {
      "id": "page-773",
      "number": null,
      "title": "Page 773",
      "level": 1,
      "pageStart": 773,
      "pageEnd": 773,
      "labelStart": "768",
      "labelEnd": "768",
      "words": 688,
      "summary": {
        "text": "Introduces the economic review, citing WHO estimates of 10.6 million TB cases and 1.6 million deaths in 2021 and defining forms of drug-resistant TB from rifampicin-resistant to extensively drug-resistant. It notes that resistance is concentrated in some high-burden countries and regions. It then explains that conventional phenotypic testing is slow and needs high-level biosafety laboratories and skilled staff.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "drug resistance",
          "heading": false
        },
        {
          "term": "dr-tb",
          "heading": false
        },
        {
          "term": "mwrds",
          "heading": false
        },
        {
          "term": "mycobacterium tuberculosis",
          "heading": false
        },
        {
          "term": "rr-tb",
          "heading": false
        },
        {
          "term": "rifampicin",
          "heading": false
        },
        {
          "term": "mdr-tb",
          "heading": false
        },
        {
          "term": "fluoroquinolone",
          "heading": false
        }
      ],
      "extract": "1. INTRODUCTION Tuberculosis remains one of the leading causes of morbidity and mortality globally (1). In 2021, the World Health Organization (WHO) estimated approximately 10.6 million new cases of TB occurred, and over 1.6 million deaths, the latter being an increase in mortality compared to trends seen between 2005 and 2019 (2, 3). DR-TB was first recognized in the late 1940s and has become an increasing public",
      "extractCut": true,
      "blocks": [
        "library/10665-381036/blocks/prose-page-773"
      ]
    },
    {
      "id": "page-774",
      "number": null,
      "title": "Page 774",
      "level": 1,
      "pageStart": 774,
      "pageEnd": 774,
      "labelStart": "769",
      "labelEnd": "769",
      "words": 579,
      "summary": {
        "text": "Describes line-probe assays as faster molecular alternatives with limits for pre-XDR, XDR and extrapulmonary TB, and explains next-generation sequencing approaches, including whole genome sequencing, tNGS and metagenomics, and their workflow steps. It then begins the methods, noting the review followed PRISMA guidelines with a librarian-supported search strategy.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "lpas",
          "heading": false
        },
        {
          "term": "isoniazid resistance",
          "heading": false
        },
        {
          "term": "conventional pdst",
          "heading": false
        },
        {
          "term": "tngs",
          "heading": false
        },
        {
          "term": "hepatitis virus",
          "heading": false
        },
        {
          "term": "systematic reviews",
          "heading": false
        },
        {
          "term": "dr-tb",
          "heading": false
        },
        {
          "term": "sequencing",
          "heading": false
        }
      ],
      "extract": "delays in diagnosis and treatment, negatively impacting patient outcomes (17, 18). Alternative second-line diagnostic approaches for DR include Line Probe Assays (LPAs), which avoid many of the steps in conventional pDST (19). This is another type of probe-based molecular test. In 2008, the WHO approved the use of LPAs for the diagnosis of MDR-TB, and there are currently ten different types commercially available",
      "extractCut": true,
      "blocks": [
        "library/10665-381036/blocks/prose-page-774"
      ]
    },
    {
      "id": "page-775",
      "number": null,
      "title": "Page 775",
      "level": 1,
      "pageStart": 775,
      "pageEnd": 775,
      "labelStart": "770",
      "labelEnd": "770",
      "words": 555,
      "summary": {
        "text": "Describes the search and eligibility methods of systematic and scoping reviews on the costs of targeted next-generation sequencing (tNGS) and whole-genome sequencing (WGS) for diagnosing drug-resistant TB. It lists the databases searched in October 2022, the inclusion of studies on confirmed or suspected DR-TB, and the cost outcomes of interest such as cost per sample, component costs, costs per step and ICERs.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "sequencing coverage",
          "heading": false
        },
        {
          "term": "cost associated",
          "heading": false
        },
        {
          "term": "data extraction",
          "heading": false
        },
        {
          "term": "wgs",
          "heading": false
        },
        {
          "term": "coverage refers",
          "heading": false
        },
        {
          "term": "tngs",
          "heading": false
        },
        {
          "term": "systematic review",
          "heading": false
        },
        {
          "term": "study characteristics",
          "heading": false
        }
      ],
      "extract": "DR-TB); concept 2 (economic data, such as cost or cost-effectiveness); and concept 3 (sequencing technologies, such as tNGS). We used the following three electronic databases to perform the search as of October 30, 2022: PubMed, EMBASE, and SCOPUS for new studies, not restricted by year of publication or language. Additionally, we screened the reference list of review articles and key identified articles for",
      "extractCut": true,
      "blocks": [
        "library/10665-381036/blocks/prose-page-775"
      ]
    },
    {
      "id": "page-776",
      "number": null,
      "title": "Page 776",
      "level": 1,
      "pageStart": 776,
      "pageEnd": 776,
      "labelStart": "771",
      "labelEnd": "771",
      "words": 511,
      "summary": {
        "text": "Explains that heterogeneity ruled out meta-analysis, so a narrative synthesis was done with costs converted to 2021 US dollars, and that study quality was rated with a modified CHEERS checklist. It then describes which cost measures the included tNGS and WGS studies reported and notes that few costed the phenotypic comparator.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "enrichment multiplex",
          "heading": false
        },
        {
          "term": "explored costs",
          "heading": false
        },
        {
          "term": "multiplex pcr",
          "heading": false
        },
        {
          "term": "either tngs",
          "heading": false
        },
        {
          "term": "dna extraction",
          "heading": false
        },
        {
          "term": "target enrichment",
          "heading": false
        },
        {
          "term": "component costs",
          "heading": false
        },
        {
          "term": "wgs",
          "heading": false
        }
      ],
      "extract": "2.4. Statistical Analysis Due to the limited number of studies available and the high degree of methodological heterogeneity between studies, a meta-analysis was deemed not appropriate. Instead, a narrative summary review was performed. All cost data was inflated to 2021 in local currency and converted to 2021 USD using the relevant International Monetary Fund (IMF) exchange rates and inflation index (36). We",
      "extractCut": true,
      "blocks": [
        "library/10665-381036/blocks/prose-page-776"
      ]
    },
    {
      "id": "page-777",
      "number": null,
      "title": "Page 777",
      "level": 1,
      "pageStart": 777,
      "pageEnd": 777,
      "labelStart": "772",
      "labelEnd": "772",
      "words": 535,
      "summary": {
        "text": "Summarizes six studies reporting tNGS costs for drug-resistant TB, their settings and whether testing was on site or centralized. It reports the limited data on cost per sample and the wide range in sequencer prices, from about $1 000 for a Nanopore MinION to over $200 000 for an Illumina NextSeq.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "illumina miseq",
          "heading": false
        },
        {
          "term": "nanopore minion",
          "heading": false
        },
        {
          "term": "overhead costs",
          "heading": false
        },
        {
          "term": "consumables costs",
          "heading": false
        },
        {
          "term": "component costs",
          "heading": false
        },
        {
          "term": "top-down costing",
          "heading": false
        },
        {
          "term": "fold coverage",
          "heading": false
        },
        {
          "term": "diagnostic cost",
          "heading": false
        }
      ],
      "extract": "3.1.1. Economic Evidence Around tNGS 3.1.1.1. Summary of Findings Six studies reported on costs for tNGS approaches (Table 1). Three of the studies were performed in the US, one collected specimen from both Ethiopia and Hong Kong, one in the UK, and one in Moldova with year of cost valuation ranging from 2018-2021 (Table 1). Of the tNGS studies, two used on-site testing, and four required sample transport to a",
      "extractCut": true,
      "blocks": [
        "library/10665-381036/blocks/prose-page-777"
      ]
    },
    {
      "id": "page-778",
      "number": null,
      "title": "Page 778",
      "level": 1,
      "pageStart": 778,
      "pageEnd": 778,
      "labelStart": "773",
      "labelEnd": "773",
      "words": 612,
      "summary": {
        "text": "Reports per-sample reagent and consumable costs for different tNGS platforms, which varied widely by manufacturer and workflow. It then presents a five-year budget impact analysis comparing tNGS, WGS and phenotypic testing scenarios, with start-up costs in the first year driven by equipment.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "wgs scenarios",
          "heading": false
        },
        {
          "term": "reagents consumables",
          "heading": false
        },
        {
          "term": "pdst scenario",
          "heading": false
        },
        {
          "term": "nanopore minion",
          "heading": false
        },
        {
          "term": "costs ranged",
          "heading": false
        },
        {
          "term": "plus pdst",
          "heading": false
        },
        {
          "term": "years costs",
          "heading": false
        },
        {
          "term": "total cost",
          "heading": false
        }
      ],
      "extract": "MinION. The cost of reagents and consumables also varied by identity of sequencing manufacturer, with the lowest being Illumina MiSeq100, and the highest Nanopore MinION. However, this was based on limited data (n=1). The per sample cost for reagents and consumables was found to be as low as $6.20 for MiSeq and $15.32 for iSeq100 (Table 7B). For this determination, samples had 15,000-fold coverage, which account for",
      "extractCut": true,
      "blocks": [
        "library/10665-381036/blocks/prose-page-778"
      ]
    },
    {
      "id": "page-779",
      "number": null,
      "title": "Page 779",
      "level": 1,
      "pageStart": 779,
      "pageEnd": 779,
      "labelStart": "774",
      "labelEnd": "774",
      "words": 512,
      "summary": {
        "text": "Notes the extra first-year start-up costs in the budget scenarios and points to an appendix for WGS results. It reports modified CHEERS quality scores for the tNGS and WGS studies, then begins the scoping review of sequencing costs for other diseases, giving cost per sample ranges and reagent costs.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "tables a-b",
          "heading": false
        },
        {
          "term": "supplementary tables",
          "heading": false
        },
        {
          "term": "component costs",
          "heading": false
        },
        {
          "term": "manuscripts assessed",
          "heading": false
        },
        {
          "term": "economic studies",
          "heading": false
        },
        {
          "term": "scores varied",
          "heading": false
        },
        {
          "term": "quality scores",
          "heading": false
        },
        {
          "term": "alleweldt",
          "heading": false
        }
      ],
      "extract": "$74,507.00) scenarios had additional projected start-up costs in year 1 due to capital expenditures and equipment costs (39). The results of the economic evidence of diagnosing DR-TB with WGS are summarized in Appendix 8.1. 3.1.3. Quality of Health Economic Studies Our quality of health economic studies extraction form was used to evaluate the quality of included tNGS (Supplementary Tables 1A and 1B) and WGS",
      "extractCut": true,
      "blocks": [
        "library/10665-381036/blocks/prose-page-779"
      ]
    },
    {
      "id": "page-780",
      "number": null,
      "title": "Page 780",
      "level": 1,
      "pageStart": 780,
      "pageEnd": 780,
      "labelStart": "775",
      "labelEnd": "775",
      "words": 606,
      "summary": {
        "text": "Continues the scoping review findings on sequencing costs for diseases such as HIV, covering component costs, sequencer capital costs and costs per step. It lists factors that influence costs, such as laboratory efficiency, staff, technology and volume discounts, and begins the quality assessment.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "avian influenza",
          "heading": false
        },
        {
          "term": "food-borne pathogens",
          "heading": false
        },
        {
          "term": "lowest costs",
          "heading": false
        },
        {
          "term": "component costs",
          "heading": false
        },
        {
          "term": "considered costs",
          "heading": false
        },
        {
          "term": "capital costs",
          "heading": false
        },
        {
          "term": "cost-effectiveness ratios",
          "heading": false
        },
        {
          "term": "gachogo",
          "heading": false
        }
      ],
      "extract": "$104.61, both for HIV. The remaining studies were between $33.49 to $62.72 for reagent and consumables. Only the manuscript by Gachogo et al. (2020) assessed component costs per sample for other components in addition to reagents and consumables (50). These ranged from $2.44 for maintenance per sample, to $105.56 for equipment per sample. The paper by Merel et al. (2001) was the only one that assessed total capital",
      "extractCut": true,
      "blocks": [
        "library/10665-381036/blocks/prose-page-780"
      ]
    },
    {
      "id": "page-781",
      "number": null,
      "title": "Page 781",
      "level": 1,
      "pageStart": 781,
      "pageEnd": 781,
      "labelStart": "776",
      "labelEnd": "776",
      "words": 640,
      "summary": {
        "text": "Gives quality scores for the scoping review studies and opens the discussion, describing the systematic review as the first on tNGS economics for drug-resistant TB and noting the scarcity of data. It discusses why per-sample costs vary, including platform choice, coverage depth and early-run inefficiencies reported in one study.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "nanopore minion",
          "heading": false
        },
        {
          "term": "illumina miseq",
          "heading": false
        },
        {
          "term": "instrument costs",
          "heading": false
        },
        {
          "term": "component costs",
          "heading": false
        },
        {
          "term": "sample runs",
          "heading": false
        },
        {
          "term": "training inefficiencies",
          "heading": false
        },
        {
          "term": "diagnostic costs",
          "heading": false
        },
        {
          "term": "total costs",
          "heading": false
        }
      ],
      "extract": "from a modified CHEERS, as described earlier. Quality scores varied from 9/21 to 19/21 with an average quality score of 12/21 among. The summary of this assessment is displayed graphically on Figure 4. 4. DISCUSSION 4.1. Interpretation of Systematic Review Findings To the best of our knowledge, this systematic review is the first of its kind to look at the economic evidence around using tNGS for the diagnosis of",
      "extractCut": true,
      "blocks": [
        "library/10665-381036/blocks/prose-page-781"
      ]
    },
    {
      "id": "page-782",
      "number": null,
      "title": "Page 782",
      "level": 1,
      "pageStart": 782,
      "pageEnd": 782,
      "labelStart": "777",
      "labelEnd": "777",
      "words": 614,
      "summary": {
        "text": "Adds that low sample volumes and limited batching raise per-sample sequencing costs. It then interprets the scoping review, highlighting a modelling study in which molecular testing plus WGS was the most cost-effective TB diagnostic strategy owing to greater sensitivity and faster diagnosis.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "scoping review",
          "heading": false
        },
        {
          "term": "cost effectiveness",
          "heading": false
        },
        {
          "term": "component costs",
          "heading": false
        },
        {
          "term": "wgs",
          "heading": false
        },
        {
          "term": "systematic review",
          "heading": false
        },
        {
          "term": "review findings",
          "heading": false
        },
        {
          "term": "molecular testing",
          "heading": false
        },
        {
          "term": "batching",
          "heading": false
        }
      ],
      "extract": "Lastly, lower sample volumes and less batching per run are likely to be associated with a greater costs per sample. This includes batching across TB samples or multiplexing with different organisms. While not explicitly mentioned in any of the papers, this could likely impact costs by spreading out certain overhead (e.g., labor costs) or equipment costs (e.g., sequencer flow cell) among more samples. This latter",
      "extractCut": true,
      "blocks": [
        "library/10665-381036/blocks/prose-page-782"
      ]
    },
    {
      "id": "page-783",
      "number": null,
      "title": "Page 783",
      "level": 1,
      "pageStart": 783,
      "pageEnd": 783,
      "labelStart": "778",
      "labelEnd": "778",
      "words": 202,
      "summary": {
        "text": "Concludes that more research is needed on cost-effectiveness, cost drivers such as batching and multiplexing, and full costing including overheads before tNGS and WGS economics for drug-resistant TB are well understood. It introduces the PRISMA flow diagram for the systematic review.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "economic markers",
          "heading": false
        },
        {
          "term": "lab equipment",
          "heading": false
        },
        {
          "term": "additional economic",
          "heading": false
        },
        {
          "term": "impact cost",
          "heading": false
        },
        {
          "term": "total lab",
          "heading": false
        },
        {
          "term": "icers",
          "heading": false
        }
      ],
      "extract": "5. CONCLUSION Given the growing interest in tNGS as a diagnostic modality, there are a number of additional data points that would be helpful to characterize. First, further studies are needed to determine additional economic markers, such as cost-effectiveness analyses or ICERs. Second, it will be prudent to develop a better understanding of the various factors that may impact cost, such as the impact of batching",
      "extractCut": true,
      "blocks": [
        "library/10665-381036/blocks/prose-page-783",
        "library/10665-381036/blocks/figure-img-p783-1"
      ]
    },
    {
      "id": "page-784",
      "number": null,
      "title": "Page 784",
      "level": 1,
      "pageStart": 784,
      "pageEnd": 784,
      "labelStart": "779",
      "labelEnd": "779",
      "words": 9,
      "summary": {
        "text": "A figure caption for the PRISMA flow diagram of the scoping review.",
        "status": "draft"
      },
      "keywords": [],
      "extract": "Figure 2. PRISMA Flow Diagram for the Scoping Review",
      "extractCut": false,
      "blocks": [
        "library/10665-381036/blocks/prose-page-784",
        "library/10665-381036/blocks/figure-img-p784-1"
      ]
    },
    {
      "id": "page-785",
      "number": null,
      "title": "Page 785",
      "level": 1,
      "pageStart": 785,
      "pageEnd": 785,
      "labelStart": "780",
      "labelEnd": "780",
      "words": 5,
      "summary": {
        "text": "A blank page with no extracted text.",
        "status": "draft"
      },
      "keywords": [],
      "extract": "_(no text on this page)_",
      "extractCut": false,
      "blocks": [
        "library/10665-381036/blocks/prose-page-785"
      ]
    },
    {
      "id": "page-786",
      "number": null,
      "title": "Page 786",
      "level": 1,
      "pageStart": 786,
      "pageEnd": 786,
      "labelStart": "781",
      "labelEnd": "781",
      "words": 288,
      "summary": {
        "text": "A table describing the included tNGS studies in the systematic review, giving country, cost year, currency, population, sequencing strategy, comparator, perspective, type of evaluation and cost sources.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "isolates tngs",
          "heading": false
        },
        {
          "term": "some cost",
          "heading": false
        },
        {
          "term": "miseq",
          "heading": false
        },
        {
          "term": "cost data",
          "heading": false
        },
        {
          "term": "sequencing instruments",
          "heading": false
        },
        {
          "term": "costing data",
          "heading": false
        },
        {
          "term": "pdst",
          "heading": false
        },
        {
          "term": "wgs",
          "heading": false
        }
      ],
      "extract": "781 Table 1. Characteristics of Included tNGS Studies for the Systematic Review Manuscript Country setting Year of Cost Valuation Currency Study Population Diagnostic Strategies (tNGS or WGS) Reference Diagnostic Strategies (pDST or mWRDs) Analysis Perspective (Healthcare or Societal) Type of Economic Evaluation Primary Outcome Secondary Outcome(s) Source of Costing Colman RE et al (2019) USA 2018 USD TB isolates",
      "extractCut": true,
      "blocks": [
        "library/10665-381036/blocks/prose-page-786"
      ]
    },
    {
      "id": "page-787",
      "number": null,
      "title": "Page 787",
      "level": 1,
      "pageStart": 787,
      "pageEnd": 787,
      "labelStart": "782",
      "labelEnd": "782",
      "words": 321,
      "summary": {
        "text": "Tables describing the included WGS studies in the systematic review, with their settings, cost years, populations, comparators, perspectives, outcomes and costing sources.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "wgs pdst",
          "heading": false
        },
        {
          "term": "mdr rr-tb",
          "heading": false
        },
        {
          "term": "wgs studies",
          "heading": false
        },
        {
          "term": "confirmed mdr",
          "heading": false
        },
        {
          "term": "rr-tb cases",
          "heading": false
        },
        {
          "term": "some cost",
          "heading": false
        },
        {
          "term": "cost data",
          "heading": false
        },
        {
          "term": "sequencing instruments",
          "heading": false
        }
      ],
      "extract": "782 Table 2A. Characteristics of Included WGS Studies for the Systematic Review Manuscript Country Setting Year of Cost Valuation Currency Study Population Diagnostic Strategies (tNGS or WGS) Reference Diagnostic Strategies (pDST or mWRDs) Cirillo DM et al (2016) Italy 2016 EUR Confirmed MDR/RR-TB cases in general population WGS Standard testing Pankhurst LJ et al (2016) Europe (UK, Ireland, Germany and France) and",
      "extractCut": true,
      "blocks": [
        "library/10665-381036/blocks/prose-page-787"
      ]
    },
    {
      "id": "page-788",
      "number": null,
      "title": "Page 788",
      "level": 1,
      "pageStart": 788,
      "pageEnd": 788,
      "labelStart": "783",
      "labelEnd": "783",
      "words": 312,
      "summary": {
        "text": "A table describing the studies in the scoping review on sequencing costs for other diseases such as influenza, food-borne pathogens, HIV and malaria, with settings, laboratory levels, strategies and outcomes.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "some cost",
          "heading": false
        },
        {
          "term": "breakeven analysis",
          "heading": false
        },
        {
          "term": "cost data",
          "heading": false
        },
        {
          "term": "tngs",
          "heading": false
        },
        {
          "term": "usd",
          "heading": false
        },
        {
          "term": "illumina",
          "heading": false
        },
        {
          "term": "component costs",
          "heading": false
        },
        {
          "term": "miseq",
          "heading": false
        }
      ],
      "extract": "783 Table 3A. Characteristics of Included Studies for the Scoping Review Manuscript Communicable disease Country setting Laboratory classification (peripheral, intermediate or central) Year of cost valuation Currency Study population Diagnostic strategies (tNGS or WGS) Reference diagnostic strategies Analysis perspective (healthcare or societal) Type of economic evaluation Type of model if applicable WTP threshold",
      "extractCut": true,
      "blocks": [
        "library/10665-381036/blocks/prose-page-788"
      ]
    },
    {
      "id": "page-789",
      "number": null,
      "title": "Page 789",
      "level": 1,
      "pageStart": 789,
      "pageEnd": 789,
      "labelStart": "784",
      "labelEnd": "784",
      "words": 311,
      "summary": {
        "text": "Continues the table of scoping review studies, covering HIV and hepatitis sequencing studies including a cost-effectiveness model of genotypic resistance testing.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "sanger sequencing",
          "heading": false
        },
        {
          "term": "reagent costs",
          "heading": false
        },
        {
          "term": "some cost",
          "heading": false
        },
        {
          "term": "cost data",
          "heading": false
        },
        {
          "term": "cost effectiveness",
          "heading": false
        },
        {
          "term": "wgs",
          "heading": false
        },
        {
          "term": "life expectancy",
          "heading": false
        },
        {
          "term": "tngs",
          "heading": false
        }
      ],
      "extract": "784 Table 3B. Characteristics of Included Studies for the Scoping Review Manuscript Communicable disease Country setting Laboratory classification (peripheral, intermediate or central) Year of cost valuation Currency Study population Diagnostic strategies (tNGS or WGS) Reference diagnostic strategies Analysis perspective (health care or societal) Type of economic evaluation Type of model if applicable WTP threshold",
      "extractCut": true,
      "blocks": [
        "library/10665-381036/blocks/prose-page-789"
      ]
    },
    {
      "id": "page-790",
      "number": null,
      "title": "Page 790",
      "level": 1,
      "pageStart": 790,
      "pageEnd": 790,
      "labelStart": "785",
      "labelEnd": "785",
      "words": 300,
      "summary": {
        "text": "Tables of methods used in the included tNGS and WGS studies, showing whether costing considered depth, coverage, sample numbers, scenarios and sensitivity analyses, plus turnaround times.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "miseq hours",
          "heading": false
        },
        {
          "term": "minion hours",
          "heading": false
        },
        {
          "term": "nextseq hours",
          "heading": false
        },
        {
          "term": "scenarios modelled",
          "heading": false
        },
        {
          "term": "scenarios variables",
          "heading": false
        },
        {
          "term": "key scenarios",
          "heading": false
        },
        {
          "term": "different scenarios",
          "heading": false
        }
      ],
      "extract": "785 Table 4. Methodologies of Included tNGS Studies for the Systematic Review Manuscript Depth for costing Coverage for costing Varying Sample Numbers for Costing Different Scenarios Modelled for Costing Key Scenarios/Variables Explored in Sensitivity Analyses (PSA, One Way, or Two Way) Time to Completion Colman RE et al (2019) Yes No Yes No No MiSeq 24 hours; iSeq100 17.5 hours for sequencing Chan WS et al (2020)",
      "extractCut": true,
      "blocks": [
        "library/10665-381036/blocks/prose-page-790"
      ]
    },
    {
      "id": "page-791",
      "number": null,
      "title": "Page 791",
      "level": 1,
      "pageStart": 791,
      "pageEnd": 791,
      "labelStart": "786",
      "labelEnd": "786",
      "words": 259,
      "summary": {
        "text": "A table of methods used in the scoping review studies, showing whether costing considered depth, coverage, sample numbers, scenarios, sensitivity analyses and feedback, along with turnaround times.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "yes",
          "heading": false
        },
        {
          "term": "costing",
          "heading": false
        },
        {
          "term": "hours",
          "heading": false
        },
        {
          "term": "opengene",
          "heading": false
        },
        {
          "term": "scenarios",
          "heading": false
        }
      ],
      "extract": "786 1. The paper by Rowlinson MC and Musser KA (2020) is a report Table 6. Methodologies of Included Studies for the Scoping Review Manuscript Depth for costing Coverage for costing Varying sample numbers for costing Different scenarios modelled for costing Key scenarios/variables explored in sensitivity analyses (PSA, one way, or two way) Did authors include information on feedback and/or knowledge translation?",
      "extractCut": true,
      "blocks": [
        "library/10665-381036/blocks/prose-page-791"
      ]
    },
    {
      "id": "page-792",
      "number": null,
      "title": "Page 792",
      "level": 1,
      "pageStart": 792,
      "pageEnd": 792,
      "labelStart": "787",
      "labelEnd": "787",
      "words": 245,
      "summary": {
        "text": "Tables of tNGS outputs from the systematic review, giving diagnostic cost per sample for MiSeq and MinION and component costs for instruments and reagents, with notes on how costs were estimated.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "illumina miseq",
          "heading": false
        },
        {
          "term": "barcoding kit",
          "heading": false
        },
        {
          "term": "mix buffer",
          "heading": false
        },
        {
          "term": "ligation sequencing",
          "heading": false
        },
        {
          "term": "tngs studies",
          "heading": false
        },
        {
          "term": "usd unless",
          "heading": false
        },
        {
          "term": "minion",
          "heading": false
        },
        {
          "term": "otherwise specified",
          "heading": false
        }
      ],
      "extract": "787 Table 7A. Output from Included tNGS Studies for the Systematic Review: Diagnostic Cost per Sample Manuscript Diagnostic Cost per Sample1,2,3 Diagnostic Intervention (tNGS) Illumina MiSeq (15,000x coverage) Nanopore MinION Tafess K et al (2020) $69.64 $73.47 1. Values are written in USD 2021 unless otherwise specified 2. Value looks at Illumina MiSeq and for lower and upper values, respectively, both at 15,000x",
      "extractCut": true,
      "blocks": [
        "library/10665-381036/blocks/prose-page-792",
        "library/10665-381036/blocks/table-023",
        "library/10665-381036/blocks/table-024"
      ]
    },
    {
      "id": "page-793",
      "number": null,
      "title": "Page 793",
      "level": 1,
      "pageStart": 793,
      "pageEnd": 793,
      "labelStart": "788",
      "labelEnd": "788",
      "words": 330,
      "summary": {
        "text": "Tables of tNGS costs per step, such as library preparation and sequencing, and of component costs per sample from one study comparing sequencing strategies with phenotypic testing.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "tngs illumina",
          "heading": false
        },
        {
          "term": "illumina iseq",
          "heading": false
        },
        {
          "term": "illumina miseq",
          "heading": false
        },
        {
          "term": "multiplying proportions",
          "heading": false
        },
        {
          "term": "nanopore minion",
          "heading": false
        },
        {
          "term": "usd unless",
          "heading": false
        },
        {
          "term": "multiplex pcr",
          "heading": false
        },
        {
          "term": "otherwise specified",
          "heading": false
        }
      ],
      "extract": "788 Table 7C. Output from Included tNGS Studies for the Systematic Review: Costs per step Manuscript Costs per step1,3 Diagnostic Intervention (tNGS Illumina MiSeq) Diagnostic Intervention (Nanopore MinION) Target Enrichment Multiplex PCR Library Prep Quality Control Sequencing DNA Extraction Target Enrichment Multiplex PCR Library Prep Quality Control Sequencing DNA Extraction Tafess K et al (2020)2 $4.15 $28.56",
      "extractCut": true,
      "blocks": [
        "library/10665-381036/blocks/prose-page-793",
        "library/10665-381036/blocks/table-025",
        "library/10665-381036/blocks/table-026",
        "library/10665-381036/blocks/table-027"
      ]
    },
    {
      "id": "page-794",
      "number": null,
      "title": "Page 794",
      "level": 1,
      "pageStart": 794,
      "pageEnd": 794,
      "labelStart": "789",
      "labelEnd": "789",
      "words": 333,
      "summary": {
        "text": "Tables of costing data and five-year budget impact estimates from one study comparing tNGS, WGS and phenotypic drug susceptibility testing scenarios for culture-positive samples.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "culture excluding",
          "heading": false
        },
        {
          "term": "multiplying proportions",
          "heading": false
        },
        {
          "term": "cates",
          "heading": false
        },
        {
          "term": "excluding xpert",
          "heading": false
        },
        {
          "term": "usd unless",
          "heading": false
        },
        {
          "term": "plus pdst",
          "heading": false
        },
        {
          "term": "wgs studies",
          "heading": false
        },
        {
          "term": "otherwise specified",
          "heading": false
        }
      ],
      "extract": "789 Table 8C. Output from Included tNGS and WGS Studies for the Systematic Review: Costing Data, Cates et al. (2022) Manuscript Diagnostic cost per sample1,2 Diagnostic Intervention (tNGS Illumina iSeq100) Diagnostic Intervention (WGS Illumina MiSeq) All culture+ excluding Xpert/RIF-, plus pDST All culture+ All culture+ excluding Xpert/RIF- Labor Equipment Reagents & Consumables Training Maintenance Total Labor",
      "extractCut": true,
      "blocks": [
        "library/10665-381036/blocks/prose-page-794",
        "library/10665-381036/blocks/table-028",
        "library/10665-381036/blocks/table-029",
        "library/10665-381036/blocks/table-030"
      ]
    },
    {
      "id": "page-795",
      "number": null,
      "title": "Page 795",
      "level": 1,
      "pageStart": 795,
      "pageEnd": 795,
      "labelStart": "790",
      "labelEnd": "790",
      "words": 338,
      "summary": {
        "text": "Further budget impact tables from the same study, giving yearly and five-year totals for tNGS and WGS testing scenarios in 2021 US dollars.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "estimates tngs",
          "heading": false
        },
        {
          "term": "wgs studies",
          "heading": false
        },
        {
          "term": "excluding xpert",
          "heading": false
        },
        {
          "term": "start-up",
          "heading": false
        },
        {
          "term": "plus pdst",
          "heading": false
        },
        {
          "term": "total budget",
          "heading": false
        },
        {
          "term": "year",
          "heading": false
        },
        {
          "term": "cates",
          "heading": false
        }
      ],
      "extract": "790 Table 9B. Output from Included tNGS and WGS Studies for the Systematic Review: BIA, Cates et al. (2022) Manuscript Total Budget Impact Estimates1 tNGS for all SSM+ or Xpert+ tNGS for all SSM+ or Xpert+, excluding Xpert/RIF- tNGS for all SSM+ or Xpert+, plus pDST Year 1 (start-up) Year 2 Year 3 Year 4 Year 5 Total Year 1 (start-up) Year 2 Year 3 Year 4 Year 5 Total Year 1 (start- up) Year 2 Year 3 Year 4 Year 5",
      "extractCut": true,
      "blocks": [
        "library/10665-381036/blocks/prose-page-795",
        "library/10665-381036/blocks/table-031",
        "library/10665-381036/blocks/table-032",
        "library/10665-381036/blocks/table-033"
      ]
    },
    {
      "id": "page-796",
      "number": null,
      "title": "Page 796",
      "level": 1,
      "pageStart": 796,
      "pageEnd": 796,
      "labelStart": "791",
      "labelEnd": "791",
      "words": 290,
      "summary": {
        "text": "Tables of WGS outputs from the systematic review, giving diagnostic cost per sample by platform compared with phenotypic testing, and component costs, with explanatory notes.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "illumina miseq",
          "heading": false
        },
        {
          "term": "wgs studies",
          "heading": false
        },
        {
          "term": "component costs",
          "heading": false
        },
        {
          "term": "diagnostic comparator",
          "heading": false
        },
        {
          "term": "usd unless",
          "heading": false
        },
        {
          "term": "sample basis",
          "heading": false
        },
        {
          "term": "otherwise specified",
          "heading": false
        },
        {
          "term": "diagnostic intervention",
          "heading": false
        }
      ],
      "extract": "791 Table 10A. Output from Included WGS Studies for the Systematic Review: Diagnostic Cost per Sample Manuscript Diagnostic cost per sample1,7 Diagnostic Intervention (WGS) Diagnostic Comparator Illumina NextSeq Illumina MiSeq Nanopore MinION pDST Cirillo DM et al (2016)10 $185.77 Pankhurst LJ et al (2016)5 $110.87 ($109.67-112.38)4 $49.00 ($48.60-49.47)4 He G et al (2020) $71.61 $45.47-102.303 Vogel M et al (2021)",
      "extractCut": true,
      "blocks": [
        "library/10665-381036/blocks/prose-page-796",
        "library/10665-381036/blocks/table-034",
        "library/10665-381036/blocks/table-035"
      ]
    },
    {
      "id": "page-797",
      "number": null,
      "title": "Page 797",
      "level": 1,
      "pageStart": 797,
      "pageEnd": 797,
      "labelStart": "792",
      "labelEnd": "792",
      "words": 90,
      "summary": {
        "text": "A table of WGS costs per step from one study, from DNA extraction to sequencing.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "wgs",
          "heading": false
        },
        {
          "term": "cycles",
          "heading": false
        },
        {
          "term": "enrichment",
          "heading": false
        }
      ],
      "extract": "792 Table 10C. Output from Included WGS Studies for the Systematic Review: Costs per step Manuscript Costs per step1,3 Diagnostic Intervention (WGS) DNA Extraction Target Enrichment Multiplex PCR Library Prep Quality Control Sequencing Vogel M et al (2021)2 $4.05 $1.31 - $2.88 $59.61 - $91.25 $3.83 - $14.70 $64.53 - $156.32 1. Values are written in 2021 USD unless otherwise specified. 2. Range based on first 174",
      "extractCut": true,
      "blocks": [
        "library/10665-381036/blocks/prose-page-797",
        "library/10665-381036/blocks/table-036"
      ]
    },
    {
      "id": "page-798",
      "number": null,
      "title": "Page 798",
      "level": 1,
      "pageStart": 798,
      "pageEnd": 798,
      "labelStart": "793",
      "labelEnd": "793",
      "words": 199,
      "summary": {
        "text": "A table of key outcomes and per-sample component costs from scoping review studies on HIV, malaria and hepatitis sequencing, comparing platforms and methods.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "illumina sequencing",
          "heading": false
        },
        {
          "term": "reagent cost",
          "heading": false
        },
        {
          "term": "component costs",
          "heading": false
        },
        {
          "term": "nanopore",
          "heading": false
        },
        {
          "term": "key outcome",
          "heading": false
        },
        {
          "term": "sample",
          "heading": false
        }
      ],
      "extract": "793 Table 11A. Output from Included Studies for the Scoping Review: Key Outcome(s) and Component Costs Manuscript Key outcome(s) Component costs per sample1,5 Diagnostic Intervention Equipment Maintenance Staffing Overhead Reagents and consumables Quality Assurance Gachogo et al (2020) To establish detailed cost profile for HIVDR testing and to identify cost drivers $105.56 $2.44 $48.25 $15.14 $104.61 $4.12 Kunasol",
      "extractCut": true,
      "blocks": [
        "library/10665-381036/blocks/prose-page-798",
        "library/10665-381036/blocks/table-037"
      ]
    },
    {
      "id": "page-799",
      "number": null,
      "title": "Page 799",
      "level": 1,
      "pageStart": 799,
      "pageEnd": 799,
      "labelStart": "794",
      "labelEnd": "794",
      "words": 75,
      "summary": {
        "text": "A table of costs per step from three scoping review studies, from sample collection to sequencing analysis.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "electrophoresis",
          "heading": false
        },
        {
          "term": "sequencing",
          "heading": false
        },
        {
          "term": "gachogo",
          "heading": false
        }
      ],
      "extract": "794 Table 11B. Output from Included Studies for the Scoping Review: Costs per step Manuscript Costs per step1,2 Diagnostic Intervention Sample collection Target Enrichment Multiplex PCR Sequencing DNA or RNA Extraction Gel electrophoresis Sequencing analysis Dimitrov et al (2017) $55.29 $56.40 $5.53 Gachogo et al (2020) $2.48 $57.86 $165.88 $23.49 $10.66 $19.75 Taylor et al (2013) $1.99 $1093.49 $1.99 1. All costs",
      "extractCut": true,
      "blocks": [
        "library/10665-381036/blocks/prose-page-799",
        "library/10665-381036/blocks/table-038"
      ]
    },
    {
      "id": "page-800",
      "number": null,
      "title": "Page 800",
      "level": 1,
      "pageStart": 800,
      "pageEnd": 800,
      "labelStart": "795",
      "labelEnd": "795",
      "words": 215,
      "summary": {
        "text": "A table of ICERs, cost per sample and equipment costs from scoping review studies, including cost per QALY from an HIV resistance testing model, with notes on assumptions.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "cer sens",
          "heading": false
        },
        {
          "term": "qalys sens",
          "heading": false
        },
        {
          "term": "sens analysis",
          "heading": false
        },
        {
          "term": "diagnostic comparator",
          "heading": false
        },
        {
          "term": "haart",
          "heading": false
        },
        {
          "term": "component costs",
          "heading": false
        }
      ],
      "extract": "795 Table 11C. Output from Included Studies for the Scoping Review: ICERs, Cost per Sample and Component Costs Total Manuscript1,7 ICERs Cost per Sample Component costs total Diagnostic Intervention Diagnostic intervention Diagnostic Comparator Diagnostic intervention Diagnostic Comparator QALYs (months) QALYs sens analysis - effectiveness of HAART (months) Added QALYs sens analysis - maximum duration of HAART",
      "extractCut": true,
      "blocks": [
        "library/10665-381036/blocks/prose-page-800",
        "library/10665-381036/blocks/table-039"
      ]
    },
    {
      "id": "page-801",
      "number": null,
      "title": "Page 801",
      "level": 1,
      "pageStart": 801,
      "pageEnd": 801,
      "labelStart": "796",
      "labelEnd": "796",
      "words": 411,
      "summary": {
        "text": "Tables of WGS and conventional method costs per sample and consumable costs for avian influenza, influenza and food-borne pathogen laboratories from one multi-country study, converted to 2021 US dollars.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "food-borne pathogens",
          "heading": false
        },
        {
          "term": "influenza fli",
          "heading": false
        },
        {
          "term": "avian influenza",
          "heading": false
        },
        {
          "term": "influenza apha",
          "heading": false
        },
        {
          "term": "alleweldt",
          "heading": false
        },
        {
          "term": "emc",
          "heading": false
        },
        {
          "term": "mdh",
          "heading": false
        },
        {
          "term": "phac",
          "heading": false
        }
      ],
      "extract": "796 Table 12A. Output from Included Studies for the Scoping Review: Cost per Sample, Alleweldt et al. (2021) Manuscript Cost per sample WGS Conventional Avian influenza (APHA) Avian influenza (FLI) Influenza A+B (EMC) Food-borne Pathogens (IZSLER) Food-borne Pathogens (INEI-ANLIS) Food-borne Pathogens (MDH) Food-borne Pathogens (PHAC) Food-borne Pathogens (PHE) Avian influenza (APHA) Avian influenza (FLI) Influenza",
      "extractCut": true,
      "blocks": [
        "library/10665-381036/blocks/prose-page-801",
        "library/10665-381036/blocks/table-040",
        "library/10665-381036/blocks/table-041",
        "library/10665-381036/blocks/table-042"
      ]
    },
    {
      "id": "page-802",
      "number": null,
      "title": "Page 802",
      "level": 1,
      "pageStart": 802,
      "pageEnd": 802,
      "labelStart": "797",
      "labelEnd": "797",
      "words": 341,
      "summary": {
        "text": "Continues the component cost tables for WGS and conventional methods from the same multi-country study, covering staff and other costs by laboratory.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "food-borne pathogens",
          "heading": false
        },
        {
          "term": "avian influenza",
          "heading": false
        },
        {
          "term": "influenza fli",
          "heading": false
        },
        {
          "term": "influenza apha",
          "heading": false
        },
        {
          "term": "prof",
          "heading": false
        },
        {
          "term": "tech",
          "heading": false
        },
        {
          "term": "component costs",
          "heading": false
        },
        {
          "term": "alleweldt",
          "heading": false
        }
      ],
      "extract": "797 Table 12D. Output from Included Studies for the Scoping Review: Cost per Sample, Alleweldt et al. (2021) Manuscript Component Costs WGS Conventional Method Staff (prof and tech): Avian influenza APHA Staff (prof and tech): Avian influenza FLI Staff (prof and tech): Influenza A+B EMC Staff (prof and tech): Food-borne pathogens IZSLER Staff (prof and tech): Food-borne pathogens ARG Staff (prof and tech):",
      "extractCut": true,
      "blocks": [
        "library/10665-381036/blocks/prose-page-802",
        "library/10665-381036/blocks/table-043",
        "library/10665-381036/blocks/table-044"
      ]
    },
    {
      "id": "page-803",
      "number": null,
      "title": "Page 803",
      "level": 1,
      "pageStart": 803,
      "pageEnd": 803,
      "labelStart": "798",
      "labelEnd": "798",
      "words": 97,
      "summary": {
        "text": "Bar charts showing modified CHEERS quality ratings for the studies in the systematic review.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "modified cheers",
          "heading": false
        },
        {
          "term": "wgs",
          "heading": false
        },
        {
          "term": "tngs",
          "heading": false
        }
      ],
      "extract": "798 Figure 3. Quality of Evidence for Systematic Review: Modified CHEERS Figure 4. Quality of Evidence for Scoping Review: Modified CHEERS 0 2 4 6 8 10 12 14 16 18 Chan W.S. et al (2020) Tafess K. et al (2020) Gliddon HD et al. (2021) Colman R.E. et al (2019) Cates L. et al (2022) Rowlinson MC and Musser KA (2022) Cirillo D.M. et al (2016) Pankhurst LJ et al (2016) He G. et al (2020) Vogel M. et al (2021) Number of",
      "extractCut": true,
      "blocks": [
        "library/10665-381036/blocks/prose-page-803",
        "library/10665-381036/blocks/figure-vfig-p803"
      ]
    },
    {
      "id": "page-804",
      "number": null,
      "title": "Page 804",
      "level": 1,
      "pageStart": 804,
      "pageEnd": 804,
      "labelStart": "799",
      "labelEnd": "799",
      "words": 74,
      "summary": {
        "text": "A bar chart showing modified CHEERS quality ratings for the studies in the scoping review.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "alleweldt",
          "heading": false
        },
        {
          "term": "chaturbhuj",
          "heading": false
        },
        {
          "term": "ekici",
          "heading": false
        }
      ],
      "extract": "799 0 5 10 15 20 25 Chaturbhuj et al (2014) Dimitrov et al (2017) Dudley et al (2012) Ekici et al (2014) Gachogo et al (2020) Kunasol et al (2022) Merel et al (2001) Taylor et al (2013) Weinstein et al (2001) Alleweldt et al (2021) Patel et al (2016) Riaz et al (2021) Wales et al (2017) Number of criteria with \"yes (blue)\" vs \"no (grey)\" vs \"N/A (orange)\" response tNGS WGS",
      "extractCut": false,
      "blocks": [
        "library/10665-381036/blocks/prose-page-804"
      ]
    },
    {
      "id": "page-805",
      "number": null,
      "title": "Page 805",
      "level": 1,
      "pageStart": 805,
      "pageEnd": 805,
      "labelStart": "800",
      "labelEnd": "800",
      "words": 496,
      "summary": {
        "text": "The start of the reference list for the review of sequencing costs for drug-resistant TB, citing work on TB diagnostics, epidemiology and WHO reports.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "drug-resistant tuberculosis",
          "heading": false
        },
        {
          "term": "infect dis",
          "heading": false
        },
        {
          "term": "pmid",
          "heading": false
        },
        {
          "term": "truenat trial",
          "heading": false
        },
        {
          "term": "trial consortium",
          "heading": false
        },
        {
          "term": "doi",
          "heading": false
        },
        {
          "term": "epub",
          "heading": false
        },
        {
          "term": "health organization",
          "heading": false
        }
      ],
      "extract": "7. REFERENCES 1) Koh WJ, Ko Y, Kim CK, Park KS, and Lee NY. Rapid diagnosis of tuberculosis and multidrug resistance using a MGIT 960 system. Ann Lab Med. 2012;32:264–9. 2) Zaheen A, and Bloom BR. Tuberculosis in 2020 - New Approaches to a Continuing Global Health Crisis. N Engl J Med. 2020 Apr 2;382(14):e26. doi: 10.1056/NEJMp2000325. PMID: 32242354. 3) Barbier M, Wirth T. The Evolutionary History, Demography, and",
      "extractCut": true,
      "blocks": [
        "library/10665-381036/blocks/prose-page-805"
      ]
    },
    {
      "id": "page-806",
      "number": null,
      "title": "Page 806",
      "level": 1,
      "pageStart": 806,
      "pageEnd": 806,
      "labelStart": "801",
      "labelEnd": "801",
      "words": 517,
      "summary": {
        "text": "A continuation of the reference list, citing sources on phenotypic and molecular drug susceptibility testing, line probe assays and sequencing in clinical microbiology.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "next-generation sequencing",
          "heading": false
        },
        {
          "term": "clin microbiol",
          "heading": false
        },
        {
          "term": "probe assays",
          "heading": false
        },
        {
          "term": "mycobacterium tuberculosis",
          "heading": false
        },
        {
          "term": "pmid",
          "heading": false
        },
        {
          "term": "drug-resistant tuberculosis",
          "heading": false
        },
        {
          "term": "line probe",
          "heading": false
        },
        {
          "term": "pmcid",
          "heading": false
        }
      ],
      "extract": "16) Cirillo DM, Miotto P, and Tortoli E. Evolution of Phenotypic and Molecular Drug Susceptibility Testing. Adv Exp Med Biol. 2017;1019:221-246. doi: 10.1007/978-3-319- 64371-7_12. PMID: 29116638. 17) Hepple, et al. Implementation of liquid culture for tuberculosis diagnosis in a remote setting: lessons learned. Int J Tuberc Lung Dis. 2011;15(3):405–407. 18) World Health Organization. Molecular line probe assays for",
      "extractCut": true,
      "blocks": [
        "library/10665-381036/blocks/prose-page-806"
      ]
    },
    {
      "id": "page-807",
      "number": null,
      "title": "Page 807",
      "level": 1,
      "pageStart": 807,
      "pageEnd": 807,
      "labelStart": "802",
      "labelEnd": "802",
      "words": 490,
      "summary": {
        "text": "A continuation of the reference list, citing sources on HIV epidemiology, TB–HIV co-infection, costing methods and the included sequencing studies.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "epub nov",
          "heading": false
        },
        {
          "term": "resistance profiling",
          "heading": false
        },
        {
          "term": "ispor health",
          "heading": false
        },
        {
          "term": "mycobacterium tuberculosis",
          "heading": false
        },
        {
          "term": "infect dis",
          "heading": false
        },
        {
          "term": "pmid",
          "heading": false
        },
        {
          "term": "lancet infect",
          "heading": false
        },
        {
          "term": "doi",
          "heading": false
        }
      ],
      "extract": "31) Hemelaar J, Elangovan R, Yun J, Dickson-Tetteh L, Fleminger I, Kirtley S, Williams B, Gouws-Williams E, Ghys PD; WHO–UNAIDS Network for HIV Isolation Characterisation. Global and regional molecular epidemiology of HIV-1, 1990-2015: a systematic review, global survey, and trend analysis. Lancet Infect Dis. 2019 Feb;19(2):143-155. doi: 10.1016/S1473-3099(18)30647-9. Epub 2018 Nov 30. Erratum in: Lancet Infect Dis.",
      "extractCut": true,
      "blocks": [
        "library/10665-381036/blocks/prose-page-807"
      ]
    },
    {
      "id": "page-808",
      "number": null,
      "title": "Page 808",
      "level": 1,
      "pageStart": 808,
      "pageEnd": 808,
      "labelStart": "803",
      "labelEnd": "803",
      "words": 591,
      "summary": {
        "text": "A continuation of the reference list, citing the included tNGS, WGS and HIV genotyping cost studies.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "genome sequencing",
          "heading": false
        },
        {
          "term": "whole-genome sequencing",
          "heading": false
        },
        {
          "term": "pmcid",
          "heading": false
        },
        {
          "term": "pmc",
          "heading": false
        },
        {
          "term": "pmid",
          "heading": false
        },
        {
          "term": "whole genome",
          "heading": false
        },
        {
          "term": "resistance genotyping",
          "heading": false
        },
        {
          "term": "doi",
          "heading": false
        }
      ],
      "extract": "BMC Res Notes. 2020 Sep 18;13(1):444. doi: 10.1186/s13104-020-05287-9. PMID: 32948225; PMCID: PMC7501614. 43) Gliddon HD, Frampton D, Munsamy V, Heaney J, Pataillot-Meakin T, Nastouli E, Pym AS, Steyn AJC, Pillay D, and McKendry RA. A Rapid Drug Resistance Genotyping Workflow for Mycobacterium tuberculosis, Using Targeted Isothermal Amplification and Nanopore Sequencing. Microbiol Spectr. 2021 Dec 22;9(3):e0061021.",
      "extractCut": true,
      "blocks": [
        "library/10665-381036/blocks/prose-page-808"
      ]
    },
    {
      "id": "page-809",
      "number": null,
      "title": "Page 809",
      "level": 1,
      "pageStart": 809,
      "pageEnd": 809,
      "labelStart": "804",
      "labelEnd": "804",
      "words": 280,
      "summary": {
        "text": "The end of the reference list, citing HIV, malaria and hepatitis C sequencing studies and a cost-effectiveness analysis of WGS for TB.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "sanger sequencing",
          "heading": false
        },
        {
          "term": "plasmodium falciparum",
          "heading": false
        },
        {
          "term": "pmcid",
          "heading": false
        },
        {
          "term": "pmid",
          "heading": false
        },
        {
          "term": "pmc",
          "heading": false
        },
        {
          "term": "doi",
          "heading": false
        },
        {
          "term": "dec",
          "heading": false
        },
        {
          "term": "epub",
          "heading": false
        }
      ],
      "extract": "2014 Feb 12;9(2):e87441. doi: 10.1371/journal.pone.0087441. PMID: 24533056; PMCID: PMC3922725. 54) Dudley DM, Chin EN, Bimber BN, Sanabani SS, Tarosso LF, Costa PR, Sauer MM, Kallas EG, O'Connor DH. Low-cost ultra-wide genotyping using Roche/454 pyrosequencing for surveillance of HIV drug resistance. PLoS One. 2012;7(5):e36494. doi: 10.1371/journal.pone.0036494. Epub 2012 May 4. PMID: 22574170; PMCID: PMC3344889.",
      "extractCut": true,
      "blocks": [
        "library/10665-381036/blocks/prose-page-809"
      ]
    },
    {
      "id": "page-810",
      "number": null,
      "title": "Page 810",
      "level": 1,
      "pageStart": 810,
      "pageEnd": 810,
      "labelStart": "805",
      "labelEnd": "805",
      "words": 472,
      "summary": {
        "text": "An appendix summarizing economic evidence on WGS for diagnosing drug-resistant TB from seven studies, covering settings, cost years and cost measures. It then begins the systematic review search strategy, listing PubMed terms for drug-resistant TB.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "resistant tuberculos",
          "heading": false
        },
        {
          "term": "tables a-b",
          "heading": false
        },
        {
          "term": "illumina miseq",
          "heading": false
        },
        {
          "term": "miseq platform",
          "heading": false
        },
        {
          "term": "sample cost",
          "heading": false
        },
        {
          "term": "sample volumes",
          "heading": false
        },
        {
          "term": "drug resistant",
          "heading": false
        },
        {
          "term": "wgs",
          "heading": false
        }
      ],
      "extract": "8. APPENDIX 8.1 Results of Economic Evidence around using WGS for the Diagnosis of DR- TB Seven manuscripts looked at cost data for WGS (Tables 2A-B). Two manuscripts were from the US, one in countries across Europe (UK, Ireland, Germany and France) as well as Canada, one in Italy, one in the Kyrgyz Republic, and one in China (Tables 2A-B). The year of cost valuation ranged from 2014-2021 across studies (Tables",
      "extractCut": true,
      "blocks": [
        "library/10665-381036/blocks/prose-page-810"
      ]
    },
    {
      "id": "page-811",
      "number": null,
      "title": "Page 811",
      "level": 1,
      "pageStart": 811,
      "pageEnd": 811,
      "labelStart": "806",
      "labelEnd": "806",
      "words": 148,
      "summary": {
        "text": "Continues the systematic review search strategy with PubMed cost and sequencing terms and the start of the Embase search.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "resistant tuberculos",
          "heading": false
        },
        {
          "term": "pulmonary tuberculos",
          "heading": false
        },
        {
          "term": "sequence analys",
          "heading": false
        },
        {
          "term": "multi-drug resistant",
          "heading": false
        },
        {
          "term": "multidrug resistant",
          "heading": false
        }
      ],
      "extract": "TB\"[tw] OR \"resistant pulmonary tuberculos*\"[tw] OR \"resistant TB\"[tw] OR \"resistant tuberculos*\"[tw] Concept #2 \"Costs and Cost Analysis\"[mesh] OR \"Costs and Cost Analys*\"[tw] OR \"Cost Analys*\"[tw] OR \"Cost Benefit Analys*\"[tw] OR \"Cost Effectiveness\"[tw] OR \"economic*\"[tw] OR \"cost allocation\"[tw] OR \"cost efficiency analys*\"[tw] Concept #3 \"Sequence Analysis\"[mesh] OR \"Sequence Analys*\"[tw] OR \"Sequence",
      "extractCut": true,
      "blocks": [
        "library/10665-381036/blocks/prose-page-811"
      ]
    },
    {
      "id": "page-812",
      "number": null,
      "title": "Page 812",
      "level": 1,
      "pageStart": 812,
      "pageEnd": 812,
      "labelStart": "807",
      "labelEnd": "807",
      "words": 164,
      "summary": {
        "text": "Continues the search strategy with Embase cost and sequencing terms and the Scopus search terms for drug-resistant TB and costs.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "resistant tuberculos",
          "heading": false
        },
        {
          "term": "cost analys",
          "heading": false
        },
        {
          "term": "efficiency analys",
          "heading": false
        },
        {
          "term": "multidrug resistant",
          "heading": false
        },
        {
          "term": "drug resistant",
          "heading": false
        },
        {
          "term": "resistant tuberculosis",
          "heading": false
        }
      ],
      "extract": "'cost'/exp OR 'cost effectiveness analysis'/exp OR 'cost benefit analysis'/exp OR ('cost analys*' OR 'cost benefit' OR 'cost-benefit analys*' OR 'cost effectiveness' OR 'cost efficiency analys*' OR 'cost allocation'):ab,ti,kw Concept #3 'sequence analysis'/exp OR 'high throughput sequencing'/exp OR ('high through-put sequencing' OR 'Sequence Analys*' OR 'Sequence Determination*' OR 'next-generation sequencing' OR '",
      "extractCut": true,
      "blocks": [
        "library/10665-381036/blocks/prose-page-812"
      ]
    },
    {
      "id": "page-813",
      "number": null,
      "title": "Page 813",
      "level": 1,
      "pageStart": 813,
      "pageEnd": 813,
      "labelStart": "808",
      "labelEnd": "808",
      "words": 108,
      "summary": {
        "text": "Ends the systematic review search strategy and begins the scoping review PubMed search, with terms for hepatitis, HIV, malaria and influenza.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "syndrome virus",
          "heading": false
        },
        {
          "term": "mesh",
          "heading": false
        },
        {
          "term": "concept",
          "heading": false
        },
        {
          "term": "malarial",
          "heading": false
        }
      ],
      "extract": "\"sequence analys* \" OR \"high throughput sequencing\" OR \"Sequence Determination*\" OR \"next-generation sequencing\" OR \"genetic sequencing\" OR \"genomic sequencing\" #1 AND #2 AND #3 – 56 records 8.3. Scoping Review Search Strategy PubMed search Concept #1A \"Hepatitis\"[Mesh:NoExp] OR \"Hepatitis, Viral, Human\"[Mesh] OR \"hepatitis\"[tiab] Concept #1B \"HIV\"[mesh] OR \"HIV\"[tw] OR \"Human Immunodeficiency Virus*\"[tw] OR \"AIDS",
      "extractCut": true,
      "blocks": [
        "library/10665-381036/blocks/prose-page-813"
      ]
    },
    {
      "id": "page-814",
      "number": null,
      "title": "Page 814",
      "level": 1,
      "pageStart": 814,
      "pageEnd": 814,
      "labelStart": "809",
      "labelEnd": "809",
      "words": 128,
      "summary": {
        "text": "Continues the scoping review search strategy with PubMed cost and sequencing terms, record counts and the start of the Embase search.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "sequence analys",
          "heading": false
        },
        {
          "term": "immunodeficiency virus",
          "heading": false
        },
        {
          "term": "syndrome virus",
          "heading": false
        },
        {
          "term": "viral hepatitis",
          "heading": false
        }
      ],
      "extract": "\"Costs and Cost Analysis\"[mesh] OR \"Costs and Cost Analys*\"[tw] OR \"Cost Analys*\"[tw] OR \"Cost Benefit Analys*\"[tw] OR \"Cost Effectiveness\"[tw] OR \"economic*\"[tw] OR \"cost allocation\"[tw] OR \"cost efficiency analys*\"[tw] Concept #3 \"Sequence Analysis\"[mesh] OR \"Sequence Analys*\"[tw] OR \"Sequence Determination*\"[tw] OR \"next-generation sequencing\"[tw] OR \" next-gen sequence analys*\"[tw] OR \"next-gen sequencing\"[tw]",
      "extractCut": true,
      "blocks": [
        "library/10665-381036/blocks/prose-page-814"
      ]
    },
    {
      "id": "page-815",
      "number": null,
      "title": "Page 815",
      "level": 1,
      "pageStart": 815,
      "pageEnd": 815,
      "labelStart": "810",
      "labelEnd": "810",
      "words": 145,
      "summary": {
        "text": "Continues the scoping review search strategy with Embase terms and record counts, then begins the Scopus search.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "analysis exp",
          "heading": false
        },
        {
          "term": "analys",
          "heading": false
        },
        {
          "term": "cost benefit",
          "heading": false
        },
        {
          "term": "cost effectiveness",
          "heading": false
        },
        {
          "term": "marsh",
          "heading": false
        }
      ],
      "extract": "'Malaria'/exp OR ('Malaria' OR 'Plasmodium Infection*' OR 'Remittent Fever' OR 'Marsh Fever' OR 'malarial fever' OR 'malarial infection*' OR 'marsh fever' OR 'paludism' OR 'Plasmodia infection*' OR 'plasmodial infection*' OR 'plasmodiosis'):ab,ti,kw Concept #1D 'influenza'/exp OR ('Influenza*' OR 'Human Flu' OR 'Grippe'):ab,ti,kw Concept #2 'cost'/exp OR 'cost effectiveness analysis'/exp OR 'cost benefit",
      "extractCut": true,
      "blocks": [
        "library/10665-381036/blocks/prose-page-815"
      ]
    },
    {
      "id": "page-816",
      "number": null,
      "title": "Page 816",
      "level": 1,
      "pageStart": 816,
      "pageEnd": 816,
      "labelStart": "811",
      "labelEnd": "811",
      "words": 141,
      "summary": {
        "text": "Completes the scoping review Scopus search strategy, with record counts for each disease.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "marsh fever",
          "heading": false
        },
        {
          "term": "analys",
          "heading": false
        },
        {
          "term": "syndrome virus",
          "heading": false
        },
        {
          "term": "cost benefit",
          "heading": false
        }
      ],
      "extract": "\"Human immunodeficiency virus* \" OR \"HIV\" OR \"AIDS Virus* \" OR \"Acquired Immune Deficiency Syndrome Virus\" OR \"Acquired Immunodeficiency Syndrome Virus\" Concept #1C \"Malaria\" OR \"Plasmodium Infection*\" OR \"Remittent Fever\" OR \"Marsh Fever\" OR \"malarial fever\" OR \"malarial infection*\" OR \"marsh fever\" OR \"paludism \" OR \"Plasmodia infection*\" OR \"plasmodial infection*\" OR \"plasmodiosis\" Concept #1D Influenza OR \"Human",
      "extractCut": true,
      "blocks": [
        "library/10665-381036/blocks/prose-page-816"
      ]
    },
    {
      "id": "page-817",
      "number": null,
      "title": "Page 817",
      "level": 1,
      "pageStart": 817,
      "pageEnd": 817,
      "labelStart": "812",
      "labelEnd": "812",
      "words": 5,
      "summary": {
        "text": "A blank page with no extracted text.",
        "status": "draft"
      },
      "keywords": [],
      "extract": "_(no text on this page)_",
      "extractCut": false,
      "blocks": [
        "library/10665-381036/blocks/prose-page-817"
      ]
    },
    {
      "id": "page-818",
      "number": null,
      "title": "Page 818",
      "level": 1,
      "pageStart": 818,
      "pageEnd": 818,
      "labelStart": "813",
      "labelEnd": "813",
      "words": 357,
      "summary": {
        "text": "A supplementary table giving yes/no answers on each quality criterion for the included tNGS studies, using the health economic study quality instrument.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "yes",
          "heading": false
        },
        {
          "term": "studies instrument",
          "heading": false
        },
        {
          "term": "tngs studies",
          "heading": false
        },
        {
          "term": "physical units",
          "heading": false
        },
        {
          "term": "instrument assessment",
          "heading": false
        },
        {
          "term": "supplementary table",
          "heading": false
        },
        {
          "term": "economic studies",
          "heading": false
        },
        {
          "term": "gliddon",
          "heading": false
        }
      ],
      "extract": "813 Supplementary Table 1A. Quality of Health Economic Studies Instrument Assessment of Included tNGS Studies for the Systematic Review Manuscript Was the study population clearly described? Were competing alternatives clearly described? Was a well-defined research question posed in answerable form? Was the actual perspective chosen appropriate? Were all important and relevant costs for each alternative identified?",
      "extractCut": true,
      "blocks": [
        "library/10665-381036/blocks/prose-page-818"
      ]
    },
    {
      "id": "page-819",
      "number": null,
      "title": "Page 819",
      "level": 1,
      "pageStart": 819,
      "pageEnd": 819,
      "labelStart": "814",
      "labelEnd": "814",
      "words": 385,
      "summary": {
        "text": "A supplementary table of quality criteria answers for the included WGS studies.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "yes",
          "heading": false
        },
        {
          "term": "musser",
          "heading": false
        },
        {
          "term": "rowlinson",
          "heading": false
        },
        {
          "term": "wgs studies",
          "heading": false
        },
        {
          "term": "studies instrument",
          "heading": false
        },
        {
          "term": "physical units",
          "heading": false
        },
        {
          "term": "instrument assessment",
          "heading": false
        },
        {
          "term": "supplementary table",
          "heading": false
        }
      ],
      "extract": "814 Rowlinson MC and Musser KA (2022)1 No Yes No Yes No No Yes No Yes 1. The paper by Rowlinson MC and Musser KA (2020) is a report. Supplementary Table 2A. Quality of Health Economic Studies Instrument Assessment of Included WGS Studies for the Systematic Review Manuscript Was the study population clearly described? Were competing alternatives clearly described? Was a well-defined research question posed in",
      "extractCut": true,
      "blocks": [
        "library/10665-381036/blocks/prose-page-819"
      ]
    },
    {
      "id": "page-820",
      "number": null,
      "title": "Page 820",
      "level": 1,
      "pageStart": 820,
      "pageEnd": 820,
      "labelStart": "815",
      "labelEnd": "815",
      "words": 319,
      "summary": {
        "text": "A supplementary table of quality criteria answers for the studies in the scoping review.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "yes",
          "heading": false
        },
        {
          "term": "physical units",
          "heading": false
        },
        {
          "term": "musser",
          "heading": false
        },
        {
          "term": "rowlinson",
          "heading": false
        },
        {
          "term": "costs",
          "heading": false
        },
        {
          "term": "measured",
          "heading": false
        },
        {
          "term": "reported",
          "heading": false
        },
        {
          "term": "studies",
          "heading": false
        }
      ],
      "extract": "815 Rowlinson MC and Musser KA (2022)1 No Yes No Yes No No Yes No Yes 1. The paper by Rowlinson MC and Musser KA (2020) is a report Supplementary Table 3A. Quality of Health Economic Studies Instrument Assessment of Included Studies for the Scoping Review Manuscript Was the study population clearly described? Were competing alternatives clearly described? Was a well- defined research question posed in answerable",
      "extractCut": true,
      "blocks": [
        "library/10665-381036/blocks/prose-page-820"
      ]
    },
    {
      "id": "page-821",
      "number": null,
      "title": "Page 821",
      "level": 1,
      "pageStart": 821,
      "pageEnd": 821,
      "labelStart": "816",
      "labelEnd": "816",
      "words": 326,
      "summary": {
        "text": "Supplementary Table 3B rates the included studies of a scoping review against a quality instrument for health economic studies, covering items such as cost sources, currency conversion, time horizon, comparators and discounting. Most studies met only some criteria, with one meeting all.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "yes",
          "heading": false
        },
        {
          "term": "time horizon",
          "heading": false
        },
        {
          "term": "costs",
          "heading": false
        },
        {
          "term": "stated",
          "heading": false
        },
        {
          "term": "appropriate",
          "heading": false
        },
        {
          "term": "authors",
          "heading": false
        },
        {
          "term": "economic",
          "heading": false
        },
        {
          "term": "study",
          "heading": false
        }
      ],
      "extract": "816 Supplementary Table 3B. Quality of Health Economic Studies Instrument Assessment of Included Studies for the Scoping Review Manuscript Were the sources of all costing included? Did the authors describe methods for converting costs into a common currency base and the exchange rate? Did the authors state the time horizon(s) over which costs were being evaluated and say why appropriate? Did the study discuss the",
      "extractCut": true,
      "blocks": [
        "library/10665-381036/blocks/prose-page-821"
      ]
    },
    {
      "id": "page-822",
      "number": null,
      "title": "Page 822",
      "level": 1,
      "pageStart": 822,
      "pageEnd": 822,
      "labelStart": "817",
      "labelEnd": "817",
      "words": 123,
      "summary": {
        "text": "Acknowledges the people who helped with the review on targeted next-generation sequencing costs, including an information specialist at Johns Hopkins, FIND staff and authors of included studies.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "thank",
          "heading": false
        },
        {
          "term": "donna",
          "heading": false
        },
        {
          "term": "altogether",
          "heading": false
        },
        {
          "term": "public health",
          "heading": false
        }
      ],
      "extract": "9. ACKNOWLEDGEMENTS There are a number of individuals whom we wish to thank for their support in completing this work. Firstly, we would like to thank Donna Hesson for her help with designing our search strategy and for being an altogether great resource. Donna is one of the Public Health Informationists at Johns Hopkins University, Bloomberg School of Public Health. Secondly, we want to thank several members of",
      "extractCut": true,
      "blocks": [
        "library/10665-381036/blocks/prose-page-822"
      ]
    },
    {
      "id": "page-823",
      "number": null,
      "title": "Page 823",
      "level": 1,
      "pageStart": 823,
      "pageEnd": 823,
      "labelStart": "818",
      "labelEnd": "818",
      "words": 51,
      "summary": {
        "text": "The title page of Web Annex B.18, a 2023 report on stakeholder experiences of using targeted next-generation sequencing (tNGS) to diagnose MDR-TB, naming the author and the WHO unit it was prepared for.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "pci",
          "heading": false
        },
        {
          "term": "natalieheleneleon",
          "heading": false
        },
        {
          "term": "draft",
          "heading": false
        }
      ],
      "extract": "Web Annex B.18. Stakeholder experiences and perspectives of using Targeted next generation sequencing for diagnosing MDR- TB: interviews results (Draft 1, 15 December 2022. Final draft 17 April 2023) Author: Dr Natalie Leon Independent public health research consultant natalieheleneleon@gmail.com A project for: Unit: TB Prevention, Diagnosis, Treatment, Care & Innovation (PCI)",
      "extractCut": false,
      "blocks": [
        "library/10665-381036/blocks/prose-page-823"
      ]
    },
    {
      "id": "page-824",
      "number": null,
      "title": "Page 824",
      "level": 1,
      "pageStart": 824,
      "pageEnd": 824,
      "labelStart": "819",
      "labelEnd": "819",
      "words": 611,
      "summary": {
        "text": "The abstract explains that tNGS on sputum can diagnose drug-resistant TB within days instead of weeks, but faces implementation barriers. It states that interviews with implementers aimed to inform a new WHO guideline by exploring acceptability, feasibility, values, preferences and equity. It begins reporting that implementers saw the technology as a major advance but found platforms complex, with few chances to catch errors early.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "tngs technology",
          "heading": false
        },
        {
          "term": "tngs platforms",
          "heading": false
        },
        {
          "term": "rapid diagnostics",
          "heading": false
        },
        {
          "term": "potential utility",
          "heading": false
        },
        {
          "term": "sputum sample",
          "heading": false
        },
        {
          "term": "mdr-tb",
          "heading": false
        },
        {
          "term": "deeplex",
          "heading": false
        },
        {
          "term": "sentiment",
          "heading": false
        }
      ],
      "extract": "Abstract BACKGROUND Timely drug resistance detection is essential to global tuberculosis management. Novel molecular testing tools are being developed to rapidly detect multi-drug resistant Tuberculosis (MDR-TB) which is needed for more effective and timely treatment of MDR-TB. Targeted next generation sequencing (tNGS), is new molecular-based rapid diagnostic technology (used on a sputum sample), that can provide",
      "extractCut": true,
      "blocks": [
        "library/10665-381036/blocks/prose-page-824"
      ]
    },
    {
      "id": "page-825",
      "number": null,
      "title": "Page 825",
      "level": 1,
      "pageStart": 825,
      "pageEnd": 825,
      "labelStart": "820",
      "labelEnd": "820",
      "words": 648,
      "summary": {
        "text": "Continues the abstract's findings on tNGS feasibility, including specialized laboratories and staff found only in central facilities and needs for stable power, internet, computing, clean water and temperature control. It also notes supply chain delays and data management concerns. Turning to values and equity, participants worried about the cost of equipment, reagents and maintenance and called for comprehensive costing.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "tngs technology",
          "heading": false
        },
        {
          "term": "tngs platforms",
          "heading": false
        },
        {
          "term": "specialized laboratory",
          "heading": false
        },
        {
          "term": "specialised laboratory",
          "heading": false
        },
        {
          "term": "storage requirements",
          "heading": false
        },
        {
          "term": "reference library",
          "heading": false
        },
        {
          "term": "specialist supplies",
          "heading": false
        },
        {
          "term": "lmic settings",
          "heading": false
        }
      ],
      "extract": "3. Specialized laboratory infrastructure and human resources are required which are potentially challenging: As tNGS is a molecular-based testing platform, the platform requires highly specialised laboratory infrastructure that includes multiple rooms to prevent contamination and specialized cold storage facilities. Highly specialized molecular/medical scientists are needed to perform the tests. In these LMIC",
      "extractCut": true,
      "blocks": [
        "library/10665-381036/blocks/prose-page-825"
      ]
    },
    {
      "id": "page-826",
      "number": null,
      "title": "Page 826",
      "level": 1,
      "pageStart": 826,
      "pageEnd": 826,
      "labelStart": "821",
      "labelEnd": "821",
      "words": 474,
      "summary": {
        "text": "Finishes the abstract's findings, calling for full cost-effectiveness analysis, synergies within diagnostic algorithms and stronger laboratory and health systems, including clinician training. It concludes that adoption in low- and middle-income countries should weigh ease of use, organizational context and stakeholder values as well as effectiveness.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "tngs technology",
          "heading": false
        },
        {
          "term": "feasibility challenges",
          "heading": false
        },
        {
          "term": "synergies",
          "heading": false
        },
        {
          "term": "implementation considerations",
          "heading": false
        },
        {
          "term": "diagnostic algorithms",
          "heading": false
        },
        {
          "term": "gains",
          "heading": false
        },
        {
          "term": "consumables",
          "heading": false
        },
        {
          "term": "mdr-tb",
          "heading": false
        }
      ],
      "extract": "consumables, extra general laboratory consumables, and the additional infrastructure needs (such as the extra space, temperature control, and internet connectivity needs). Cost- effectiveness calculations should also be comprehensive, and should include assessment of the impact of the use of tNGS testing on improving TB outcomes. 3. Synergies should be found to optimize the use of tNGS in diagnostic algorithms:",
      "extractCut": true,
      "blocks": [
        "library/10665-381036/blocks/prose-page-826"
      ]
    },
    {
      "id": "page-827",
      "number": null,
      "title": "Page 827",
      "level": 1,
      "pageStart": 827,
      "pageEnd": 827,
      "labelStart": "822",
      "labelEnd": "822",
      "words": 757,
      "summary": {
        "text": "Gives background on MDR-TB, noting that only about two in three cases are diagnosed and most patients are not cured, partly because of diagnostic and treatment delays. It explains that culture-based drug susceptibility testing takes weeks and that the End TB Strategy calls for universal testing. It then describes the tNGS workflow, stressing the precise library preparation needed before sequencing.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "tngs platforms",
          "heading": false
        },
        {
          "term": "tngs technology",
          "heading": false
        },
        {
          "term": "dna extraction",
          "heading": false
        },
        {
          "term": "drug resistance",
          "heading": false
        },
        {
          "term": "whole genome",
          "heading": false
        },
        {
          "term": "drug susceptibility",
          "heading": false
        },
        {
          "term": "library preparation",
          "heading": false
        },
        {
          "term": "susceptibility testing",
          "heading": false
        }
      ],
      "extract": "Background Tuberculosis (TB) remains a major global public health threat. One of the most challenging forms of the disease is multidrug resistant TB (MDR-TB), due to higher morbidity and mortality, complexity of treatment and higher cost (1). WHO estimated that in 2016, close to half a million people were diagnosed with MDR-TB (2). It is estimated that only two out of every three patients with MDR-TB are diagnosed,",
      "extractCut": true,
      "blocks": [
        "library/10665-381036/blocks/prose-page-827"
      ]
    },
    {
      "id": "page-828",
      "number": null,
      "title": "Page 828",
      "level": 1,
      "pageStart": 828,
      "pageEnd": 828,
      "labelStart": "823",
      "labelEnd": "823",
      "words": 583,
      "summary": {
        "text": "Completes the description of the tNGS workflow and notes known barriers to rapid diagnostics, such as cost, workflow integration, training and interpreting sequence data. It explains why health worker perspectives on implementability matter. It restates the study's objective of informing WHO guidance on tNGS.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "tngs technology",
          "heading": false
        },
        {
          "term": "tngs platforms",
          "heading": false
        },
        {
          "term": "frontline implementers",
          "heading": false
        },
        {
          "term": "shaping implementation",
          "heading": false
        },
        {
          "term": "find trial",
          "heading": false
        },
        {
          "term": "perceptions",
          "heading": false
        },
        {
          "term": "generate primary",
          "heading": false
        },
        {
          "term": "implementation considerations",
          "heading": false
        }
      ],
      "extract": "different commercially available models. Computational resources are needed for data analysis, report generation and data storage (5). Figure 1: tNGS workflow Targeted tNGS therefore hold the potential, especially in high-burden TB settings, for effective treatment and control of the spread of MDR-TB, but there are obstacles to the uptake of novel, rapid technologies. Obstacles to similar rapid diagnostics have been",
      "extractCut": true,
      "blocks": [
        "library/10665-381036/blocks/prose-page-828",
        "library/10665-381036/blocks/figure-img-p828-1"
      ]
    },
    {
      "id": "page-829",
      "number": null,
      "title": "Page 829",
      "level": 1,
      "pageStart": 829,
      "pageEnd": 829,
      "labelStart": "824",
      "labelEnd": "824",
      "words": 608,
      "summary": {
        "text": "Describes the qualitative methods, using semi-structured interviews with implementers of the FIND trial in reference laboratories in Georgia, India and South Africa, plus coordinators and other global sites. It explains purposive selection of staff with hands-on experience. It also describes recording, verbatim quotes and interview summaries as the main data source.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "tngs solutions",
          "heading": false
        },
        {
          "term": "interview schedule",
          "heading": false
        },
        {
          "term": "tngs technology",
          "heading": false
        },
        {
          "term": "find trial",
          "heading": false
        },
        {
          "term": "interview summary",
          "heading": false
        },
        {
          "term": "convenience sampling",
          "heading": false
        },
        {
          "term": "purposive",
          "heading": false
        },
        {
          "term": "implementation considerations",
          "heading": false
        }
      ],
      "extract": "Methods Study design This was a cross-sectional observational qualitative study using semi-structured interviews. Setting The main stakeholders were implementers of the FIND trial in the main reference laboratories that implemented the tNGS trial, located in Georgia, India, and South Africa. Participants We were interested to learn about how the experiences and perceptions of the stakeholders who were involved with",
      "extractCut": true,
      "blocks": [
        "library/10665-381036/blocks/prose-page-829"
      ]
    },
    {
      "id": "page-830",
      "number": null,
      "title": "Page 830",
      "level": 1,
      "pageStart": 830,
      "pageEnd": 830,
      "labelStart": "825",
      "labelEnd": "825",
      "words": 485,
      "summary": {
        "text": "Explains that participants checked interview summaries, which were analysed thematically under acceptability, feasibility, and values, preferences and equity. It notes confidentiality agreements, so countries are anonymized as A, B and C. Findings begin with strong acceptability because tNGS is comprehensive, uses sputum and is fast.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "trial implementers",
          "heading": false
        },
        {
          "term": "tngs technology",
          "heading": false
        },
        {
          "term": "find trial",
          "heading": false
        },
        {
          "term": "ethical approval",
          "heading": false
        },
        {
          "term": "trial research",
          "heading": false
        },
        {
          "term": "global experts",
          "heading": false
        },
        {
          "term": "consent form",
          "heading": false
        },
        {
          "term": "erc",
          "heading": false
        }
      ],
      "extract": "check it for accuracy. Most welcomed this opportunity and provided minor edits to improve the summary. The edited versions were used as the final version of the interview summary. The interviewer read and reread the summaries, to become familiar with the overall data set. Using a thematic analysis approach, key issues were identified within and across interview data sets, and this was synthesized into themes and",
      "extractCut": true,
      "blocks": [
        "library/10665-381036/blocks/prose-page-830"
      ]
    },
    {
      "id": "page-831",
      "number": null,
      "title": "Page 831",
      "level": 1,
      "pageStart": 831,
      "pageEnd": 831,
      "labelStart": "826",
      "labelEnd": "826",
      "words": 786,
      "summary": {
        "text": "Reports that all participants saw tNGS as a major advance, with results in 3–5 days rather than 4–6 weeks and testing for more drugs, including new and repurposed ones. Quotes describe it as revolutionary while noting it is still evolving. Participants felt now is the time to build expertise before resistance to newer drugs rises.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "tngs technology",
          "heading": false
        },
        {
          "term": "phenotypic testing",
          "heading": false
        },
        {
          "term": "get everything",
          "heading": false
        },
        {
          "term": "drug resistance",
          "heading": false
        },
        {
          "term": "technology represents",
          "heading": false
        },
        {
          "term": "major advancement",
          "heading": false
        },
        {
          "term": "drug susceptibility",
          "heading": false
        },
        {
          "term": "treatment regime",
          "heading": false
        }
      ],
      "extract": "to culture samples), and the rapidness (quick results compared to phenotypic testing times; 3-5 days as compared to 4-6 weeks). There was also the sense that the technology is arriving at the right time given that resistance to newer TB drugs is likely to increase as use if these drugs become routine. The tNGS technology represents major advancement in TB diagnostics. The view from all participants was that tNGS",
      "extractCut": true,
      "blocks": [
        "library/10665-381036/blocks/prose-page-831"
      ]
    },
    {
      "id": "page-832",
      "number": null,
      "title": "Page 832",
      "level": 1,
      "pageStart": 832,
      "pageEnd": 832,
      "labelStart": "827",
      "labelEnd": "827",
      "words": 662,
      "summary": {
        "text": "Reports the overall view that tNGS needs further development before routine use. It lists challenges such as start-up problems, specialized staff and laboratories, supply chains, complex library preparation, data management and security, and the need to keep the WHO mutation catalogue updated. It begins describing how skilled molecular scientists were available only at central laboratories.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "tngs technology",
          "heading": false
        },
        {
          "term": "tngs platform",
          "heading": false
        },
        {
          "term": "specialised human",
          "heading": false
        },
        {
          "term": "african consortium",
          "heading": false
        },
        {
          "term": "consortium countries",
          "heading": false
        },
        {
          "term": "laboratory infrastructure",
          "heading": false
        },
        {
          "term": "local vendors",
          "heading": false
        },
        {
          "term": "reference library",
          "heading": false
        }
      ],
      "extract": "the test because the resistance is low. But in another 4-5 years we still need this technology. So, it’s time to build on this technology, now, so that we are experts at it when it happens, when resistances start coming.” (Country C, participant 1). Feasibility considerations of tNGS technology The overall sentiment was that the tNGS technology needs to be further developed before it can be considered fully ready",
      "extractCut": true,
      "blocks": [
        "library/10665-381036/blocks/prose-page-832"
      ]
    },
    {
      "id": "page-833",
      "number": null,
      "title": "Page 833",
      "level": 1,
      "pageStart": 833,
      "pageEnd": 833,
      "labelStart": "828",
      "labelEnd": "828",
      "words": 734,
      "summary": {
        "text": "Explains that tNGS required highly trained molecular scientists found only in reference laboratories, so it could not be decentralized. Quotes say routine technicians could not run the test in its current form and that automation would help. It also describes requirements for high-capacity computers and internet access for data analysis.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "central laboratories",
          "heading": false
        },
        {
          "term": "specialist staff",
          "heading": false
        },
        {
          "term": "tngs platforms",
          "heading": false
        },
        {
          "term": "specialist personnel",
          "heading": false
        },
        {
          "term": "tngs technology",
          "heading": false
        },
        {
          "term": "regional laboratories",
          "heading": false
        },
        {
          "term": "degrees storage",
          "heading": false
        },
        {
          "term": "cold storage",
          "heading": false
        }
      ],
      "extract": "included laboratory technicians. The scientists had experience in molecular diagnostics, were highly trained (some had PHDs), and some had advance experience in testing other rapid molecular TB diagnostics. Molecular scientists were only available at reference/central laboratories, and not at regional laboratories, which means that in these settings this test could not be decentralized to lower- level laboratories.",
      "extractCut": true,
      "blocks": [
        "library/10665-381036/blocks/prose-page-833"
      ]
    },
    {
      "id": "page-834",
      "number": null,
      "title": "Page 834",
      "level": 1,
      "pageStart": 834,
      "pageEnd": 834,
      "labelStart": "829",
      "labelEnd": "829",
      "words": 712,
      "summary": {
        "text": "Describes the reliance of tNGS platforms on stable, high-capacity internet for uploading large data files. It reports supply chain disruptions, with specialist kits ordered from overseas causing delays. It also describes the demanding precision of sample and library preparation and the need to avoid cross-contamination.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "specialist supplies",
          "heading": false
        },
        {
          "term": "chain blockages",
          "heading": false
        },
        {
          "term": "tngs platform",
          "heading": false
        },
        {
          "term": "specialist kits",
          "heading": false
        },
        {
          "term": "caused delays",
          "heading": false
        },
        {
          "term": "laboratory consumables",
          "heading": false
        },
        {
          "term": "procurement challenges",
          "heading": false
        },
        {
          "term": "tngs technology",
          "heading": false
        }
      ],
      "extract": "platforms generate large data files which rely on high capacity, stable internet connectivity. “To implement this technology, computing power, storage infrastructure and internet connectivity are extremely critical…The two platforms we tested are reliant on internet connectivity. And we’re talking about uploading massive sizes of files of a server for analysis. If a country doesn’t have the infrastructure to support",
      "extractCut": true,
      "blocks": [
        "library/10665-381036/blocks/prose-page-834"
      ]
    },
    {
      "id": "page-835",
      "number": null,
      "title": "Page 835",
      "level": 1,
      "pageStart": 835,
      "pageEnd": 835,
      "labelStart": "830",
      "labelEnd": "830",
      "words": 818,
      "summary": {
        "text": "Describes problems implementers faced, such as contaminated controls, data upload and software problems, temperature sensitivity and failed runs eventually traced to water quality. Participants called for simplifying the many library preparation steps so that less specialized staff could perform them. It notes that the trial stopped at producing reports, so clinicians' use of results was not evaluated.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "raw data",
          "heading": false
        },
        {
          "term": "preparation steps",
          "heading": false
        },
        {
          "term": "data files",
          "heading": false
        },
        {
          "term": "analysis tool",
          "heading": false
        },
        {
          "term": "web-based analysis",
          "heading": false
        },
        {
          "term": "analysis software",
          "heading": false
        },
        {
          "term": "uploading",
          "heading": false
        },
        {
          "term": "storage space",
          "heading": false
        }
      ],
      "extract": "the correct volume is added”, which is “demanding of precision” and requires “the utmost concentration”, and with” no room for error” (Country A, participant 1). Some of the problems implementers experiences were contamination of control samples, recognition, struggles with uploading data from the sequencer to a web-based data analysis tool, problems with data analysis software, problem with computer storage",
      "extractCut": true,
      "blocks": [
        "library/10665-381036/blocks/prose-page-835"
      ]
    },
    {
      "id": "page-836",
      "number": null,
      "title": "Page 836",
      "level": 1,
      "pageStart": 836,
      "pageEnd": 836,
      "labelStart": "831",
      "labelEnd": "831",
      "words": 802,
      "summary": {
        "text": "Describes tNGS reports, which give resistance or susceptibility for each drug with a confidence level based on the WHO mutation catalogue, plus lineage data useful for surveillance. Participants noted uncertainty about resistance to newer drugs such as bedaquiline. They called the WHO catalogue essential and wanted automatic links between tNGS software and laboratory information systems.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "mutations catalogue",
          "heading": false
        },
        {
          "term": "tngs platforms",
          "heading": false
        },
        {
          "term": "data security",
          "heading": false
        },
        {
          "term": "secure data",
          "heading": false
        },
        {
          "term": "lab info",
          "heading": false
        },
        {
          "term": "repurposed drugs",
          "heading": false
        },
        {
          "term": "data ownership",
          "heading": false
        },
        {
          "term": "info system",
          "heading": false
        }
      ],
      "extract": "the utility of the tNGS reports for clinical decision-making. The process of producing a diagnostic report with test results is automated for all the three platforms. Reports differed in the level of detail they provided, and reports were presented in a format that could be used for clinical decision-making. For each drug, information on resistance is expressed in terms of whether there is resistance or",
      "extractCut": true,
      "blocks": [
        "library/10665-381036/blocks/prose-page-836"
      ]
    },
    {
      "id": "page-837",
      "number": null,
      "title": "Page 837",
      "level": 1,
      "pageStart": 837,
      "pageEnd": 837,
      "labelStart": "832",
      "labelEnd": "832",
      "words": 712,
      "summary": {
        "text": "Compares feasibility views across platforms, with library preparation seen as more complex for Deeplex than for Oxford Nanopore. Both were thought to lack early error detection, risking wasted runs. Quotes describe the products as immature and not yet market-ready.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "deeplex platform",
          "heading": false
        },
        {
          "term": "tngs platform",
          "heading": false
        },
        {
          "term": "tngs technology",
          "heading": false
        },
        {
          "term": "onp",
          "heading": false
        },
        {
          "term": "end-to-end solution",
          "heading": false
        },
        {
          "term": "feasibility challenges",
          "heading": false
        },
        {
          "term": "overall sentiment",
          "heading": false
        },
        {
          "term": "equity considerations",
          "heading": false
        }
      ],
      "extract": "Differences on feasibility views across different tNGS platforms The overall sentiment that is that all three the tNGS platforms need to be further developed before it is fully ready for operational use. However, there were differences in the sentiments about feasibility challenges, with some being regarded as having more substantial challenges. The high level of technical complexity of the sample preparation stages",
      "extractCut": true,
      "blocks": [
        "library/10665-381036/blocks/prose-page-837"
      ]
    },
    {
      "id": "page-838",
      "number": null,
      "title": "Page 838",
      "level": 1,
      "pageStart": 838,
      "pageEnd": 838,
      "labelStart": "833",
      "labelEnd": "833",
      "words": 705,
      "summary": {
        "text": "Lists areas for future tNGS development, such as reducing complexity, automating links to data analysis, securing supplies and local technical support. Participants wanted a lower-complexity platform, for example with robotic liquid handling, so testing could be decentralized. Some hoped for point-of-care tests close to patients.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "tngs technology",
          "heading": false
        },
        {
          "term": "tngs platform",
          "heading": false
        },
        {
          "term": "implement tngs",
          "heading": false
        },
        {
          "term": "lower complexity",
          "heading": false
        },
        {
          "term": "laboratory infrastructure",
          "heading": false
        },
        {
          "term": "resistance status",
          "heading": false
        },
        {
          "term": "human error",
          "heading": false
        },
        {
          "term": "laboratories",
          "heading": false
        }
      ],
      "extract": "Areas of concern that would need to be addressed in future development of the tNGS platform include the need to reduce the level of complexity of the sequencing procedures and develop more automated interlinkage with the data analysis processes. Mechanisms would need to be in place to ensure a continuous supply of specialist products, especially the reagents. Local vendors are needed for the maintenance of equipment",
      "extractCut": true,
      "blocks": [
        "library/10665-381036/blocks/prose-page-838"
      ]
    },
    {
      "id": "page-839",
      "number": null,
      "title": "Page 839",
      "level": 1,
      "pageStart": 839,
      "pageEnd": 839,
      "labelStart": "834",
      "labelEnd": "834",
      "words": 721,
      "summary": {
        "text": "Discusses equitable access, noting that placing tNGS only in reference laboratories may disadvantage some regions and that batching in low-caseload settings causes delays. A participant called for 'plug and play' single-sample testing at affordable cost. It begins listing the costs that comprehensive costing should include, such as computing and storage.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "tngs technology",
          "heading": false
        },
        {
          "term": "cost down",
          "heading": false
        },
        {
          "term": "equitable access",
          "heading": false
        },
        {
          "term": "participant",
          "heading": false
        },
        {
          "term": "plug",
          "heading": false
        },
        {
          "term": "caseloads",
          "heading": false
        },
        {
          "term": "affordability",
          "heading": false
        },
        {
          "term": "centralized",
          "heading": false
        }
      ],
      "extract": "“If the technology can become like a ‘plug and play’, it can be placed closer to the point of care” (Country C, participant 1). Equitable access Centralized, reference laboratory placement requires tradeoffs in terms of equitable access: Stakeholders agreed given the complexity of tNGS technology (and the specialist laboratory and HR requirements), it is only suitable for placement at centralized, reference",
      "extractCut": true,
      "blocks": [
        "library/10665-381036/blocks/prose-page-839"
      ]
    },
    {
      "id": "page-840",
      "number": null,
      "title": "Page 840",
      "level": 1,
      "pageStart": 840,
      "pageEnd": 840,
      "labelStart": "835",
      "labelEnd": "835",
      "words": 745,
      "summary": {
        "text": "Adds that costing should include maintenance, internet capacity and links to laboratory information systems. Participants argued cost-effectiveness should reflect accuracy, indeterminate results and impact on treatment outcomes, accepting short delays for reliable results. A participant hoped tNGS would replace rather than add to existing tests.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "culture sample",
          "heading": false
        },
        {
          "term": "successful test",
          "heading": false
        },
        {
          "term": "tngs",
          "heading": false
        },
        {
          "term": "real value",
          "heading": false
        },
        {
          "term": "cost effectiveness",
          "heading": false
        },
        {
          "term": "rationalize",
          "heading": false
        },
        {
          "term": "sputum",
          "heading": false
        },
        {
          "term": "look",
          "heading": false
        }
      ],
      "extract": "should also include equipment maintenance and servicing costs. There may also additional costs associated with securing high internet capacity and interlinking the tNGS information platform and the laboratory’s own information system. Cost effectiveness should include test effectiveness and impact on TB treatment outcomes: While there is appreciation for dramatic improvements in scope and turnaround time of",
      "extractCut": true,
      "blocks": [
        "library/10665-381036/blocks/prose-page-840"
      ]
    },
    {
      "id": "page-841",
      "number": null,
      "title": "Page 841",
      "level": 1,
      "pageStart": 841,
      "pageEnd": 841,
      "labelStart": "836",
      "labelEnd": "836",
      "words": 739,
      "summary": {
        "text": "Discusses how tNGS fits a shift from phenotypic to genotypic testing and the cost of needing both. A participant called for a simple molecular technology to manage most patients quickly, leaving complex cases for further testing. Others stressed that rapid diagnostics only pay off if laboratories and health systems become more efficient.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "tngs technology",
          "heading": false
        },
        {
          "term": "mono resistance",
          "heading": false
        },
        {
          "term": "phenotypic testing",
          "heading": false
        },
        {
          "term": "gains",
          "heading": false
        },
        {
          "term": "participant",
          "heading": false
        },
        {
          "term": "sequencer",
          "heading": false
        },
        {
          "term": "looking",
          "heading": false
        },
        {
          "term": "synergies",
          "heading": false
        }
      ],
      "extract": "Rational adoption of new rapid tests such as tNGS should also include considerations for if and how it would fit with a transition from phenotypic testing towards genotypic testing; how phenotypic testing may still be needed in future scenarios. And costing of the use of tNGS should include the costs of the scenario where both genotypic and phenotypic testing for MDR TB would still be required. A similar point was",
      "extractCut": true,
      "blocks": [
        "library/10665-381036/blocks/prose-page-841"
      ]
    },
    {
      "id": "page-842",
      "number": null,
      "title": "Page 842",
      "level": 1,
      "pageStart": 842,
      "pageEnd": 842,
      "labelStart": "837",
      "labelEnd": "837",
      "words": 677,
      "summary": {
        "text": "Quotes a global expert who argued that time gained in the laboratory is lost if the health system cannot find and treat patients. It calls for better sample referral, communication between clinicians and laboratories and clinician training on using results. A summary table of findings begins with acceptability.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "tngs technology",
          "heading": false
        },
        {
          "term": "qualitative evidence",
          "heading": false
        },
        {
          "term": "clinicians",
          "heading": false
        },
        {
          "term": "global expert",
          "heading": false
        },
        {
          "term": "mdr",
          "heading": false
        },
        {
          "term": "health care",
          "heading": false
        },
        {
          "term": "doctors",
          "heading": false
        },
        {
          "term": "care system",
          "heading": false
        }
      ],
      "extract": "from rapid diagnostics, one participant explained the importance of “reengineering” improvements in the laboratory and the broader health care system: “A colleague of mine who was involved with the LPA evaluation said that we have to reengineer the lab to do these tests. But if we don’t reengineer the health care system, the value of the time that’s gained in the lab is lost in the health care system. I think that’s",
      "extractCut": true,
      "blocks": [
        "library/10665-381036/blocks/prose-page-842"
      ]
    },
    {
      "id": "page-843",
      "number": null,
      "title": "Page 843",
      "level": 1,
      "pageStart": 843,
      "pageEnd": 843,
      "labelStart": "838",
      "labelEnd": "838",
      "words": 510,
      "summary": {
        "text": "Continues the summary of findings, listing feasibility challenges and values, preferences and equity considerations such as placement, affordability, algorithm synergies and health system strengthening. It begins the discussion, noting the positive views alongside concerns about centralization, cost and equitable access.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "tngs technology",
          "heading": false
        },
        {
          "term": "tngs platforms",
          "heading": false
        },
        {
          "term": "specialist requirements",
          "heading": false
        },
        {
          "term": "overall sentiment",
          "heading": false
        },
        {
          "term": "major advance",
          "heading": false
        },
        {
          "term": "laboratory infrastructure",
          "heading": false
        },
        {
          "term": "lmic settings",
          "heading": false
        },
        {
          "term": "equitable access",
          "heading": false
        }
      ],
      "extract": "rapidness, as well as the timeliness of the test. Feasibility The overall sentiment was that the tNGS technology needs to be further developed before it can be considered fully ready for operational use. 1. Setting up the new technology 2. High technical complexity of the test 3. Specialized laboratory infrastructure and human resources 4. Specialist requirements for operating the test 5. Supply chain challenges 6.",
      "extractCut": true,
      "blocks": [
        "library/10665-381036/blocks/prose-page-843"
      ]
    },
    {
      "id": "page-844",
      "number": null,
      "title": "Page 844",
      "level": 1,
      "pageStart": 844,
      "pageEnd": 844,
      "labelStart": "839",
      "labelEnd": "839",
      "words": 685,
      "summary": {
        "text": "Discusses participants' wish for affordable, automated point-of-care MDR-TB diagnostics and caution about integrating new tests. It notes that some feasibility challenges, such as supply chains and support, may persist and that the findings echo the 2018 WHO guidance on tNGS. It calls for evaluations of impact on treatment outcomes and mixed-methods research including providers and patients.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "rapid diagnostics",
          "heading": false
        },
        {
          "term": "tngs technology",
          "heading": false
        },
        {
          "term": "rapid mdr-tb",
          "heading": false
        },
        {
          "term": "cochrane review",
          "heading": false
        },
        {
          "term": "primary study",
          "heading": false
        },
        {
          "term": "broader health",
          "heading": false
        },
        {
          "term": "technical complexity",
          "heading": false
        },
        {
          "term": "low-complexity",
          "heading": false
        }
      ],
      "extract": "rapid MDR-TB diagnostics. The wish is for affordable, point of care rapid MDR-TB diagnostics, that is more automated and simplified (‘plug and play’), to allow for decentralized laboratory use, closer to the point of diagnosing patients. There was a sense of caution about the need to rationalize and integrate new rapid diagnostics. There is also the concern that diagnostic gains from rapid tNGS technology, can only",
      "extractCut": true,
      "blocks": [
        "library/10665-381036/blocks/prose-page-844"
      ]
    },
    {
      "id": "page-845",
      "number": null,
      "title": "Page 845",
      "level": 1,
      "pageStart": 845,
      "pageEnd": 845,
      "labelStart": "840",
      "labelEnd": "840",
      "words": 681,
      "summary": {
        "text": "Closes the discussion of a primary qualitative study on implementing targeted next-generation sequencing (tNGS) for MDR-TB diagnosis, calling for policy support to strengthen laboratory and health system functions. It sets out strengths, such as being the first study of tNGS implementers and interviewing them soon after the FIND trial, and limitations, such as limited depth across several groups and uncertainty over which problems stem from the technology being new. It concludes that tNGS is seen as a major advance but needs further development, and introduces considerations for manufacturers and decision-makers.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "tngs technology",
          "heading": false
        },
        {
          "term": "find trial",
          "heading": false
        },
        {
          "term": "qualitative research",
          "heading": false
        },
        {
          "term": "laboratory science",
          "heading": false
        },
        {
          "term": "primary qualitative",
          "heading": false
        },
        {
          "term": "implementation considerations",
          "heading": false
        },
        {
          "term": "implementers",
          "heading": false
        },
        {
          "term": "enquiry",
          "heading": false
        }
      ],
      "extract": "comprehensive view of how to optimise diagnostic gains from tNGS. Policy and practice initiatives may be required to strengthen laboratory and health system support functions, to allow for rational, integrated, and equitable use of tNGS technology. Strength and limitations The primary qualitative study responds to the gap in qualitative research on tNGS technology. To our knowledge, this is the first study on the",
      "extractCut": true,
      "blocks": [
        "library/10665-381036/blocks/prose-page-845"
      ]
    },
    {
      "id": "page-846",
      "number": null,
      "title": "Page 846",
      "level": 1,
      "pageStart": 846,
      "pageEnd": 846,
      "labelStart": "841",
      "labelEnd": "841",
      "words": 480,
      "summary": {
        "text": "Lists considerations for implementing tNGS in low- and middle-income countries, including advance planning for equipment procurement and customs clearance, hands-on training, troubleshooting and consumables checklists and local vendor support. It also calls for specialist molecular staff and for platforms to be made field-ready with simpler sample preparation.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "tngs platforms",
          "heading": false
        },
        {
          "term": "tngs technology",
          "heading": false
        },
        {
          "term": "specialist consumables",
          "heading": false
        },
        {
          "term": "custom clearances",
          "heading": false
        },
        {
          "term": "implement tngs",
          "heading": false
        },
        {
          "term": "specialist laboratory",
          "heading": false
        },
        {
          "term": "laboratory infrastructure",
          "heading": false
        },
        {
          "term": "local vendors",
          "heading": false
        }
      ],
      "extract": "1. Planning, preparation, and implementation support will be needed to implement tNGS in LMIC settings. a. Ensure the procurement of equipment is in place, including the required in country custom clearances. b. Training programmes should allow sufficient opportunity for local staff to do multiple sequencing runs by themselves, under supervision of the trainers. c. Include a checklist of challenges and errors to",
      "extractCut": true,
      "blocks": [
        "library/10665-381036/blocks/prose-page-846"
      ]
    },
    {
      "id": "page-847",
      "number": null,
      "title": "Page 847",
      "level": 1,
      "pageStart": 847,
      "pageEnd": 847,
      "labelStart": "842",
      "labelEnd": "842",
      "words": 488,
      "summary": {
        "text": "Continues the considerations, calling for more automation, seamless links between sequencing and data analysis, data storage, ownership and security arrangements and interoperability with laboratory information systems. It also stresses affordability, sustainable funding and full costing, and concludes that guidelines should consider ease of use, organizational context and stakeholder values as well as effectiveness.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "tngs technology",
          "heading": false
        },
        {
          "term": "tngs platform",
          "heading": false
        },
        {
          "term": "rapid diagnostics",
          "heading": false
        },
        {
          "term": "laboratory system",
          "heading": false
        },
        {
          "term": "cost effectiveness",
          "heading": false
        },
        {
          "term": "interlinking",
          "heading": false
        },
        {
          "term": "security considerations",
          "heading": false
        },
        {
          "term": "information system",
          "heading": false
        }
      ],
      "extract": "automation and standardization to increase efficiency and effectiveness of implementation. c. There needs to be more of a seamless linkage between the sequencing technology and the data analysis technology of the tNGS platform. d. Data analysis and data storage requirements need to be fully supported, including systems for backing up data. e. Data ownership and data security considerations will need to be put in",
      "extractCut": true,
      "blocks": [
        "library/10665-381036/blocks/prose-page-847"
      ]
    },
    {
      "id": "page-848",
      "number": null,
      "title": "Page 848",
      "level": 1,
      "pageStart": 848,
      "pageEnd": 848,
      "labelStart": "843",
      "labelEnd": "843",
      "words": 519,
      "summary": {
        "text": "Credits the study's lead author, thanks interview participants, experts and WHO staff, and states no conflicts of interest, before beginning the reference list. The references include work on drug-resistant TB and on health workers and policy implementation in South Africa.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "natalie leon",
          "heading": false
        },
        {
          "term": "thanked",
          "heading": false
        },
        {
          "term": "mycobacterium tuberculosis",
          "heading": false
        },
        {
          "term": "health organization",
          "heading": false
        },
        {
          "term": "world health",
          "heading": false
        },
        {
          "term": "tuberculosis report",
          "heading": false
        },
        {
          "term": "gilson",
          "heading": false
        },
        {
          "term": "health policy",
          "heading": false
        }
      ],
      "extract": "technology in diagnosing MDR-TB, but also the influences such as the ease of use of the technology, as organizational contexts and needs, and the values, preferences, and aspirations of stakeholders. Contributions of authors Dr Natalie Leon is the lead author of the protocol and the guarantor of the review. Acknowledgements The following individuals and groups are acknowledged for their contribution and support of",
      "extractCut": true,
      "blocks": [
        "library/10665-381036/blocks/prose-page-848"
      ]
    },
    {
      "id": "page-849",
      "number": null,
      "title": "Page 849",
      "level": 1,
      "pageStart": 849,
      "pageEnd": 849,
      "labelStart": "844",
      "labelEnd": "844",
      "words": 506,
      "summary": {
        "text": "Ends the reference list and presents the interview guide for laboratory staff and managers at trial sites, with questions on their roles, experience with molecular and sequencing technologies and preparatory work for tNGS. It then moves on to their experiences across sample and library preparation.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "tngs technology",
          "heading": false
        },
        {
          "term": "tngs rapid",
          "heading": false
        },
        {
          "term": "sequencing technologies",
          "heading": false
        },
        {
          "term": "experience comprise",
          "heading": false
        },
        {
          "term": "trial study",
          "heading": false
        },
        {
          "term": "laboratory setting",
          "heading": false
        },
        {
          "term": "interview guide",
          "heading": false
        },
        {
          "term": "prior experience",
          "heading": false
        }
      ],
      "extract": "14. Erasmus E, Gilson L. How to start thinking about investigating power in the organizational settings of policy implementation. Health policy and planning. 2008;23: 361-68. 15. Youssef A, Chaudhary ZK, Wiljer D, Mylopoulos M, Sockalingam S. Mapping Evidence of Patients' Experiences in Integrated Care: A Scoping Review. Gen Hosp Psychiatry. 2019;61:1-9. Appendix 1: Interview guide for primary qualitative study",
      "extractCut": true,
      "blocks": [
        "library/10665-381036/blocks/prose-page-849"
      ]
    },
    {
      "id": "page-850",
      "number": null,
      "title": "Page 850",
      "level": 1,
      "pageStart": 850,
      "pageEnd": 850,
      "labelStart": "845",
      "labelEnd": "845",
      "words": 393,
      "summary": {
        "text": "Continues the interview guide with questions on what worked well or poorly in sequencing and data analysis, how tNGS compares with other drug-resistance tests and what enabling factors would help it improve TB care. It closes with contact details for the researcher.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "tngs rapid",
          "heading": false
        },
        {
          "term": "tngs solutions",
          "heading": false
        },
        {
          "term": "experience compare",
          "heading": false
        },
        {
          "term": "rapid diagnostics",
          "heading": false
        },
        {
          "term": "country context",
          "heading": false
        },
        {
          "term": "diagnostic technology",
          "heading": false
        },
        {
          "term": "worked",
          "heading": false
        },
        {
          "term": "service setting",
          "heading": false
        }
      ],
      "extract": "2) sequencing 3) data analysis and reporting, what has the experience been like for you? a) What has worked well? And why? b) What has not worked well? And why? 9. For each of the tNGS solutions? What was the experience like for you? a. What has worked well? And why? b. What has not worked well? And why? 10. How would you summarise what the requirements were for implementing each of the tNGS solutions? a. What the",
      "extractCut": true,
      "blocks": [
        "library/10665-381036/blocks/prose-page-850"
      ]
    },
    {
      "id": "page-851",
      "number": null,
      "title": "Page 851",
      "level": 1,
      "pageStart": 851,
      "pageEnd": 851,
      "labelStart": "846",
      "labelEnd": "846",
      "words": 436,
      "summary": {
        "text": "Presents the information and consent form for the interview study on tNGS for detecting TB drug resistance, explaining its purpose of informing WHO guidance by exploring acceptability, feasibility, equity, values and preferences at FIND trial sites and elsewhere. It describes the independent researcher, procedures, confidentiality and the absence of expected benefits or harms.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "consent form",
          "heading": false
        },
        {
          "term": "tngs",
          "heading": false
        },
        {
          "term": "generation sequencing",
          "heading": false
        },
        {
          "term": "interview",
          "heading": false
        },
        {
          "term": "drug resistance",
          "heading": false
        },
        {
          "term": "implementation considerations",
          "heading": false
        },
        {
          "term": "perceptions",
          "heading": false
        },
        {
          "term": "approached",
          "heading": false
        }
      ],
      "extract": "Appendix 2: Information and consent form EXPERIENCES AND PERCEPTIONS OF TARGETTED NEXT GENERATION SEQUENCING (tNGS) RAPID DIAGNOSTICS FOR DETECTING TB DRUG RESISTANCE: AN INTERVIEW STUDY TO INFORM THE WHO tNGS GUIDELINE Information and consent form (V3, 2022) Study background and rationale Targeted New Generation Sequencing (tNGS) is a novel, rapid molecular diagnostic test that provide an end-to-end solution for",
      "extractCut": true,
      "blocks": [
        "library/10665-381036/blocks/prose-page-851"
      ]
    },
    {
      "id": "page-852",
      "number": null,
      "title": "Page 852",
      "level": 1,
      "pageStart": 852,
      "pageEnd": 852,
      "labelStart": "847",
      "labelEnd": "847",
      "words": 52,
      "summary": {
        "text": "The signature section of the consent form, where participants agree to recording and give consent to be interviewed.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "signature",
          "heading": false
        },
        {
          "term": "email",
          "heading": false
        },
        {
          "term": "surname",
          "heading": false
        }
      ],
      "extract": "I agree for this interview to be recorded: Please pick one: YES or NO I (name and surname) ………………………………………………., give my consent to participate in this interview. Signature ……………………………………. Date: / / 2022 Paste signature/write initials, then save as PDF and email or print, sign and email scanned printed document to natalieheleneleon@gmail.com",
      "extractCut": false,
      "blocks": [
        "library/10665-381036/blocks/prose-page-852"
      ]
    },
    {
      "id": "page-853",
      "number": null,
      "title": "Page 853",
      "level": 1,
      "pageStart": 853,
      "pageEnd": 853,
      "labelStart": "848",
      "labelEnd": "848",
      "words": 55,
      "summary": {
        "text": "The title page of Web Annex B.19, a qualitative evidence synthesis by Natalie Leon on stakeholder experiences of using tNGS to diagnose MDR-TB, dated 2022–2023 and prepared for WHO's TB unit.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "pci",
          "heading": false
        },
        {
          "term": "natalieheleneleon",
          "heading": false
        },
        {
          "term": "draft",
          "heading": false
        }
      ],
      "extract": "Web Annex B.19. Stakeholder experiences and perspectives of using Targeted next generation sequencing (tNGS) for diagnosing multi-drug resistant Tuberculosis (MDR-TB): a qualitative evidence synthesis (Draft, 15 December 2022, Final draft 17 April 2023) Author: Dr Natalie Leon Independent public health research consultant natalieheleneleon@gmail.com A project for: Unit: TB Prevention, Diagnosis, Treatment, Care &",
      "extractCut": true,
      "blocks": [
        "library/10665-381036/blocks/prose-page-853"
      ]
    },
    {
      "id": "page-854",
      "number": null,
      "title": "Page 854",
      "level": 1,
      "pageStart": 854,
      "pageEnd": 854,
      "labelStart": "849",
      "labelEnd": "849",
      "words": 677,
      "summary": {
        "text": "The abstract of the qualitative evidence synthesis, explaining that tNGS can give comprehensive drug-resistance results within days but faces technical, organizational and economic barriers. It describes a rapid review that searched Medline and other sources in 2022, with single-reviewer screening and planned thematic synthesis and CERQual assessment. It reports that no eligible studies were found and points to the companion primary study and a 2022 Cochrane review of other rapid TB tests as indirect evidence.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "mdr-tb diagnostics",
          "heading": false
        },
        {
          "term": "tngs technology",
          "heading": false
        },
        {
          "term": "rapid diagnostics",
          "heading": false
        },
        {
          "term": "full-text review",
          "heading": false
        },
        {
          "term": "synthesize qualitative",
          "heading": false
        },
        {
          "term": "qualitative evidence",
          "heading": false
        },
        {
          "term": "single author",
          "heading": false
        },
        {
          "term": "direct evidence",
          "heading": false
        }
      ],
      "extract": "Abstract BACKGROUND Timely drug resistance detection is essential to global tuberculosis management. Novel molecular testing tools are being developed to rapidly detect multi-drug resistant Tuberculosis (MDR-TB) which is needed for more effective and timely treatment of MDR-TB. Targeted next generation sequencing (tNGS), is new molecular-based rapid diagnostic technology (used on a sputum sample), that can provide",
      "extractCut": true,
      "blocks": [
        "library/10665-381036/blocks/prose-page-854"
      ]
    },
    {
      "id": "page-855",
      "number": null,
      "title": "Page 855",
      "level": 1,
      "pageStart": 855,
      "pageEnd": 855,
      "labelStart": "850",
      "labelEnd": "850",
      "words": 746,
      "summary": {
        "text": "Concludes the abstract by noting the Cochrane review's attention to patient obstacles and calling for more qualitative research alongside tNGS trials and roll-out. The background describes TB and drug resistance as major threats and explains how tNGS works on sputum samples to report resistance to multiple drugs. It notes that some platforms also report lineage information useful for tracking resistant strains.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "tngs technology",
          "heading": false
        },
        {
          "term": "mdr-tb diagnostics",
          "heading": false
        },
        {
          "term": "rapid diagnostics",
          "heading": false
        },
        {
          "term": "drug resistance",
          "heading": false
        },
        {
          "term": "whole genome",
          "heading": false
        },
        {
          "term": "drug susceptibility",
          "heading": false
        },
        {
          "term": "susceptibility testing",
          "heading": false
        },
        {
          "term": "comprehensive diagnosis",
          "heading": false
        }
      ],
      "extract": "inform the new WHO guideline on tNGS technology. Of interest, is that the Cochrane review also reports on obstacles to effective utilization of rapid TB diagnostics from the perspective of patients as recipients of rapid diagnostics, and they recommend programmes to support patient health literacy. Patient recipients’ experiences and perspectives of rapid TB diagnostics is an understudied area that deserves more",
      "extractCut": true,
      "blocks": [
        "library/10665-381036/blocks/prose-page-855"
      ]
    },
    {
      "id": "page-856",
      "number": null,
      "title": "Page 856",
      "level": 1,
      "pageStart": 856,
      "pageEnd": 856,
      "labelStart": "851",
      "labelEnd": "851",
      "words": 695,
      "summary": {
        "text": "Describes the general tNGS workflow from sample preparation and DNA extraction under biosafety level 3 to library preparation, sequencing and data analysis, stressing its complexity. It notes the lack of evidence on implementation experiences. It explains that a separate primary qualitative study was carried out alongside the FIND trial in India, Georgia and South Africa.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "tngs workflow",
          "heading": false
        },
        {
          "term": "tngs technology",
          "heading": false
        },
        {
          "term": "dna extraction",
          "heading": false
        },
        {
          "term": "workflow diagram",
          "heading": false
        },
        {
          "term": "library preparation",
          "heading": false
        },
        {
          "term": "qualitative evidence",
          "heading": false
        },
        {
          "term": "laboratory workflows",
          "heading": false
        },
        {
          "term": "frontline implementers",
          "heading": false
        }
      ],
      "extract": "resistance TB. tNGS diagnostic test results would enable timely clinical decisions on appropriate treatment for MDR-TB, which can improve TB treatment outcomes and stop the transmission of resistant strains of TB (5). Different tNGS platforms have different laboratory workflows, but the general tNGS workflow includes: preparation of the TB sputum sample, DNA extraction from the sputum sample and DNA purification,",
      "extractCut": true,
      "blocks": [
        "library/10665-381036/blocks/prose-page-856"
      ]
    },
    {
      "id": "page-857",
      "number": null,
      "title": "Page 857",
      "level": 1,
      "pageStart": 857,
      "pageEnd": 857,
      "labelStart": "852",
      "labelEnd": "852",
      "words": 536,
      "summary": {
        "text": "States the review objective of synthesising qualitative evidence on acceptability, feasibility, values, preferences and equity of tNGS from health workers' perspectives. It describes the rapid review design and the inclusion and exclusion criteria, focusing on implementers but open to other stakeholders.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "tngs technology",
          "heading": false
        },
        {
          "term": "mdr-tb diagnostics",
          "heading": false
        },
        {
          "term": "qualitative methods",
          "heading": false
        },
        {
          "term": "reference laboratories",
          "heading": false
        },
        {
          "term": "qualitative evidence",
          "heading": false
        },
        {
          "term": "primary focus",
          "heading": false
        },
        {
          "term": "rapid review",
          "heading": false
        },
        {
          "term": "wgs",
          "heading": false
        }
      ],
      "extract": "Objective This study seeks to provide evidence to inform the new WHO guideline for use of tNGS technology for MDR-TB diagnostics. The objective is to identify and synthesize qualitative evidence on implementation considerations of tNGS technology for MDR-TB, related to acceptability, feasibility, values and preferences and equity, from the perspectives of health workers as implementers. Methods Overall study design",
      "extractCut": true,
      "blocks": [
        "library/10665-381036/blocks/prose-page-857"
      ]
    },
    {
      "id": "page-858",
      "number": null,
      "title": "Page 858",
      "level": 1,
      "pageStart": 858,
      "pageEnd": 858,
      "labelStart": "853",
      "labelEnd": "853",
      "words": 409,
      "summary": {
        "text": "Describes the search methods, combining a Medline search run in August and October 2022 with open searching, hand searching and contacting experts, and single-author screening with WHO consultation. It reports that no eligible studies were found, mostly because papers were quantitative, discussion pieces or based on hypothetical views.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "search strategy",
          "heading": false
        },
        {
          "term": "discussion papers",
          "heading": false
        },
        {
          "term": "open searching",
          "heading": false
        },
        {
          "term": "eligible studies",
          "heading": false
        },
        {
          "term": "full-text review",
          "heading": false
        },
        {
          "term": "single author",
          "heading": false
        },
        {
          "term": "hypothetical views",
          "heading": false
        },
        {
          "term": "main reason",
          "heading": false
        }
      ],
      "extract": "Search methods for identification of studies Electronic searches We used a combination of a systematic search strategy and an open searching approach. The search strategy used a set of search terms associated with NGS technology as an intervention, with MDR-TB and qualitative research (and associated names). We searched Medline with no year or language limits. We designed a search strategy and ran on Aug 19, 2022,",
      "extractCut": true,
      "blocks": [
        "library/10665-381036/blocks/prose-page-858",
        "library/10665-381036/blocks/figure-img-p858-1"
      ]
    },
    {
      "id": "page-859",
      "number": null,
      "title": "Page 859",
      "level": 1,
      "pageStart": 859,
      "pageEnd": 859,
      "labelStart": "854",
      "labelEnd": "854",
      "words": 673,
      "summary": {
        "text": "Discusses the empty review, noting that tNGS is not yet widely operational and that future effectiveness studies offer chances to study implementers' experiences. It recommends including qualitative process evaluations and draws on a Cochrane review of other rapid TB diagnostics that highlights implementation factors. It also notes that patients' experiences of rapid TB diagnostics are understudied.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "tngs technology",
          "heading": false
        },
        {
          "term": "mdr-tb diagnostics",
          "heading": false
        },
        {
          "term": "rapid molecular",
          "heading": false
        },
        {
          "term": "cochrane review",
          "heading": false
        },
        {
          "term": "qualitative evidence",
          "heading": false
        },
        {
          "term": "molecular tests",
          "heading": false
        },
        {
          "term": "perception studies",
          "heading": false
        },
        {
          "term": "direct evidence",
          "heading": false
        }
      ],
      "extract": "Discussion and recommendations The aim of this study was to identify and synthesize qualitative evidence on implementation considerations of the new tNGS technology for diagnosing multi-drug resistance TB, to inform the new WHO guideline on rapid TB diagnostics. This review did not yield any direct evidence from primary qualitative perception studies on tNGS technology as no studies could be found. Research and",
      "extractCut": true,
      "blocks": [
        "library/10665-381036/blocks/prose-page-859"
      ]
    },
    {
      "id": "page-860",
      "number": null,
      "title": "Page 860",
      "level": 1,
      "pageStart": 860,
      "pageEnd": 860,
      "labelStart": "855",
      "labelEnd": "855",
      "words": 474,
      "summary": {
        "text": "Discusses strengths and limitations, noting that the empty result confirms a research gap and that the review used multiple search methods but rapid-review shortcuts such as single-reviewer screening. It closes with acknowledgements and a statement of no conflicts of interest.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "tngs technology",
          "heading": false
        },
        {
          "term": "natalie leon",
          "heading": false
        },
        {
          "term": "thanked",
          "heading": false
        },
        {
          "term": "qualitative studies",
          "heading": false
        },
        {
          "term": "rapid review",
          "heading": false
        },
        {
          "term": "primary qualitative",
          "heading": false
        },
        {
          "term": "newness",
          "heading": false
        },
        {
          "term": "reviewer",
          "heading": false
        }
      ],
      "extract": "Strength and limitations The QES found no eligible studies most likely due the newness of the tNGS technology. We anticipated finding very little information, and a pilot search prior to embarking on the review may have confirmed the lack of information. The value of having conducted the review and coming up empty, it that it confirms there is gap in qualitative studies on implementation of TNGS for MDR-TB. This",
      "extractCut": true,
      "blocks": [
        "library/10665-381036/blocks/prose-page-860"
      ]
    },
    {
      "id": "page-861",
      "number": null,
      "title": "Page 861",
      "level": 1,
      "pageStart": 861,
      "pageEnd": 861,
      "labelStart": "856",
      "labelEnd": "856",
      "words": 461,
      "summary": {
        "text": "The reference list for the qualitative evidence synthesis, citing WHO TB reports and guidelines, a WHO technical guide on next-generation sequencing for TB, studies on resistance genetics and guidance on rapid reviews.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "health organization",
          "heading": false
        },
        {
          "term": "world health",
          "heading": false
        },
        {
          "term": "health policy",
          "heading": false
        },
        {
          "term": "gilson",
          "heading": false
        },
        {
          "term": "mycobacterium tuberculosis",
          "heading": false
        },
        {
          "term": "policy plan",
          "heading": false
        },
        {
          "term": "tuberculosis report",
          "heading": false
        },
        {
          "term": "erasmus",
          "heading": false
        }
      ],
      "extract": "References 1. Tiberi S, Utjesanovic N, Galvin J, et. al. Drug resistant TB – latest developments in epidemiology, diagnostics and management. International Journal of Infectious Diseases. 2022. 2. World Health Organization. Global Tuberculosis Report 2022. Geneva: World Health Organization; 2022. 3. Farhat M, Fresch L, Calderon R, Loerger T, Snyder M, Meehan C, et al. GWAS for quantitative resistance phenotypes in",
      "extractCut": true,
      "blocks": [
        "library/10665-381036/blocks/prose-page-861"
      ]
    },
    {
      "id": "page-862",
      "number": null,
      "title": "Page 862",
      "level": 1,
      "pageStart": 862,
      "pageEnd": 862,
      "labelStart": "857",
      "labelEnd": "857",
      "words": 182,
      "summary": {
        "text": "Gives the Medline search strategy used for the qualitative evidence synthesis, combining terms for targeted sequencing, qualitative and survey methods and tuberculosis, which yielded three records.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "heading word",
          "heading": false
        },
        {
          "term": "concept word",
          "heading": false
        },
        {
          "term": "supplementary concept",
          "heading": false
        },
        {
          "term": "mixed methods",
          "heading": false
        },
        {
          "term": "search strategy",
          "heading": false
        }
      ],
      "extract": "Appendix 1: Search strategy for QES Database: Ovid MEDLINE(R) ALL <1946 to August 19, 2022> Search Strategy: -------------------------------------------------------------------------------- 1 \"targeted next generation sequencing\".mp. (2890) 2 \"targeted NGS\".mp. (782) 3 1 or 2 (3284) 4 Interviews as Topic/ or interview*.mp. or Interview/ (458448) 5 survey*.mp. or Health Surveys/ or Health Care Surveys/ or \"Surveys",
      "extractCut": true,
      "blocks": [
        "library/10665-381036/blocks/prose-page-862"
      ]
    },
    {
      "id": "page-863",
      "number": null,
      "title": "Page 863",
      "level": 1,
      "pageStart": 863,
      "pageEnd": 863,
      "labelStart": null,
      "labelEnd": null,
      "words": 155,
      "summary": {
        "text": "The title page of Web Annex B.20, a systematic review and meta-analysis of the accuracy of Mycobacterium tuberculosis antigen-based skin tests, listing the review team and advisers and noting it was prepared for a February 2022 WHO guideline meeting.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "university college",
          "heading": false
        },
        {
          "term": "college london",
          "heading": false
        },
        {
          "term": "russian federation",
          "heading": false
        },
        {
          "term": "ting",
          "heading": false
        },
        {
          "term": "germany",
          "heading": false
        },
        {
          "term": "institute",
          "heading": false
        }
      ],
      "extract": "Web Annex B20. Accuracy of Mycobacterium tuberculosis antigen- based skin tests: a systematic review and meta-analysis Review team: Yohhei Hamada1, Elena Surkova2, Irina Kontsevaya3, Ting Ting Wang1, Victoria Liu4, Liliya Eugenevna Ziganshina5,6, Molebogeng X Rangaka1,7 1. Institute for Global Health, University College London, UK 2. Royal Brompton Hospital. Part of Guy's and St Thomas' NHS Foundation Trust London,",
      "extractCut": true,
      "blocks": [
        "library/10665-381036/blocks/prose-page-863"
      ]
    },
    {
      "id": "page-864",
      "number": null,
      "title": "Page 864",
      "level": 1,
      "pageStart": 864,
      "pageEnd": 864,
      "labelStart": null,
      "labelEnd": null,
      "words": 576,
      "summary": {
        "text": "The executive summary of the skin test review, explaining that new TB antigen-based skin tests could improve access to TB infection testing if as accurate as IGRA and the tuberculin skin test. It describes updating an earlier review with searches of English, Russian and Chinese databases to July 2021, random-effects meta-analyses, a post-hoc pooled analysis requested by WHO for a class-based recommendation, and notes that no longitudinal studies were found.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "skin-based tests",
          "heading": false
        },
        {
          "term": "comparator tests",
          "heading": false
        },
        {
          "term": "skin tests",
          "heading": false
        },
        {
          "term": "published until",
          "heading": false
        },
        {
          "term": "different tbst",
          "heading": false
        },
        {
          "term": "pre-defined reference",
          "heading": false
        },
        {
          "term": "dppd",
          "heading": false
        },
        {
          "term": "study designs",
          "heading": false
        }
      ],
      "extract": "Executive summary Background Diagnosis and treatment of TB infection (TBI) is a pillar of the WHO End TB strategy to achieve a global reduction in TB incidence by 2035. Accurate diagnostic tests are needed to better identify individuals who would benefit from preventive treatment. If found to have at least equivalent diagnostic accuracy compared to existing screening tests, the interferon gamma release assays (IGRA)",
      "extractCut": true,
      "blocks": [
        "library/10665-381036/blocks/prose-page-864"
      ]
    },
    {
      "id": "page-865",
      "number": null,
      "title": "Page 865",
      "level": 1,
      "pageStart": 865,
      "pageEnd": 865,
      "labelStart": null,
      "labelEnd": null,
      "words": 568,
      "summary": {
        "text": "Reports that C-Tb studies came from South Africa, Spain and the UK, Diaskintest studies almost all from Russia and C-TST studies from China, and that Diaskintest studies had high risk of bias. It summarises sensitivity results showing Diaskintest, the tuberculin skin test and IGRAs performed similarly in adults with active TB, C-Tb had similar sensitivity to comparators, and agreement with IGRA was generally higher than with the skin test.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "three-way head-to-head",
          "heading": false
        },
        {
          "term": "pooled sensitivity",
          "heading": false
        },
        {
          "term": "pooled agreement",
          "heading": false
        },
        {
          "term": "head-to-head comparison",
          "heading": false
        },
        {
          "term": "pooled difference",
          "heading": false
        },
        {
          "term": "c-tst",
          "heading": false
        },
        {
          "term": "c-tb",
          "heading": false
        },
        {
          "term": "diaskintest",
          "heading": false
        }
      ],
      "extract": "Three C-Tb studies were conducted in South Africa, while two were in Spain and UK, respectively. 33/34 studies for Diaskintest were done in Russian Federation and the remaining one in Ukraine. All C-TST studies were done in China. Study quality varied, with low concerns about applicability for all studies but high risk of bias in Diaskintest studies, largely due to the study design (using data collected under",
      "extractCut": true,
      "blocks": [
        "library/10665-381036/blocks/prose-page-865"
      ]
    },
    {
      "id": "page-866",
      "number": null,
      "title": "Page 866",
      "level": 1,
      "pageStart": 866,
      "pageEnd": 866,
      "labelStart": null,
      "labelEnd": null,
      "words": 539,
      "summary": {
        "text": "Reports further agreement results, such as about 95% agreement of Diaskintest with IGRA and highly variable agreement with the tuberculin skin test in children, and agreement of C-Tb with IGRA and the skin test in various groups. It notes limitations such as few responses from authors, and concludes that the new skin tests perform broadly like IGRA.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "pooled agreement",
          "heading": false
        },
        {
          "term": "test performance",
          "heading": false
        },
        {
          "term": "c-tb",
          "heading": false
        },
        {
          "term": "novel skin",
          "heading": false
        },
        {
          "term": "diaskintest",
          "heading": false
        },
        {
          "term": "literature search",
          "heading": false
        },
        {
          "term": "igra",
          "heading": false
        },
        {
          "term": "tst",
          "heading": false
        }
      ],
      "extract": "Diaskintest with IGRA was 94.62% (95% CI 90.49–97.02; I² = 56.2%) in five studies in participants with any tuberculosis status. By contrast, the agreement between Diaskintest and TST5 mm showed considerable heterogeneity; the pooled agreement was estimated in children with active tuberculosis (97.39% [96.39– 98.12]) and children without TB (17.62% [6.79-38.60]). Considering all studies without restricting to 3-way",
      "extractCut": true,
      "blocks": [
        "library/10665-381036/blocks/prose-page-866"
      ]
    },
    {
      "id": "page-867",
      "number": null,
      "title": "Page 867",
      "level": 1,
      "pageStart": 867,
      "pageEnd": 867,
      "labelStart": null,
      "labelEnd": null,
      "words": 661,
      "summary": {
        "text": "Completes the conclusion, noting variable Diaskintest results likely due to observational designs and BCG vaccination and better data for C-Tb and C-TST, with more research needed. The background explains that about a quarter of the world's population has TB infection with a 5–10% lifetime risk of disease. It argues that current infection tests are imperfect and that new skin tests may perform well in children and people with HIV.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "bcg vaccination",
          "heading": false
        },
        {
          "term": "enzyme-linked immunosorbent",
          "heading": false
        },
        {
          "term": "mycobacterium tuberculosis",
          "heading": false
        },
        {
          "term": "skin test",
          "heading": false
        },
        {
          "term": "diagnostic tests",
          "heading": false
        },
        {
          "term": "active disease",
          "heading": false
        },
        {
          "term": "dppd",
          "heading": false
        },
        {
          "term": "igras",
          "heading": false
        }
      ],
      "extract": "was seen in Diaskintest performance probably because of the observational nature of the studies affecting the quality of studies and the impact of BCG vaccination. Data quality was higher for C-Tb and C-TST studies. Although the review suggests TBST may enable precise and accessible TBI testing, more research is needed to address fully diagnostic accuracy and predictive performance in different at-risk populations",
      "extractCut": true,
      "blocks": [
        "library/10665-381036/blocks/prose-page-867"
      ]
    },
    {
      "id": "page-868",
      "number": null,
      "title": "Page 868",
      "level": 1,
      "pageStart": 868,
      "pageEnd": 868,
      "labelStart": null,
      "labelEnd": null,
      "words": 301,
      "summary": {
        "text": "Notes that the earlier review found new skin tests performed similarly to the tuberculin skin test and IGRA, and explains the hierarchy of reference standards used because no gold standard exists for TB infection. It sets out the review aim and begins a table of populations, tests, comparators and outcomes.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "vitro igra",
          "heading": false
        },
        {
          "term": "igra tests",
          "heading": false
        },
        {
          "term": "diagnostic performance",
          "heading": false
        },
        {
          "term": "reference standards",
          "heading": false
        },
        {
          "term": "diagnostic accuracy",
          "heading": false
        },
        {
          "term": "hierarchy",
          "heading": false
        },
        {
          "term": "tst",
          "heading": false
        },
        {
          "term": "at-risk",
          "heading": false
        }
      ],
      "extract": "We previously conducted a systematic review to synthesise current evidence on the diagnostic performance of TBST compared to that of currently available in vitro IGRA tests and TST.17 The review suggested that those tests perform similarly to TST or IGRA. We have updated the review to inform the development of WHO guidelines. Hierarchy of reference standards The study of the diagnostic performance of tests for TB",
      "extractCut": true,
      "blocks": [
        "library/10665-381036/blocks/prose-page-868",
        "library/10665-381036/blocks/figure-img-p868-1",
        "library/10665-381036/blocks/figure-vfig-p868"
      ]
    },
    {
      "id": "page-869",
      "number": null,
      "title": "Page 869",
      "level": 1,
      "pageStart": 869,
      "pageEnd": 869,
      "labelStart": null,
      "labelEnd": null,
      "words": 304,
      "summary": {
        "text": "Completes the table of review questions, covering at-risk populations, BCG status and outcomes such as concordance with other tests and proportion started on preventive treatment. It begins the methods, setting out inclusion and exclusion criteria for study designs.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "inclusion criteria",
          "heading": false
        },
        {
          "term": "comparator tests",
          "heading": false
        },
        {
          "term": "studies evaluating",
          "heading": false
        },
        {
          "term": "index tests",
          "heading": false
        },
        {
          "term": "concordance",
          "heading": false
        },
        {
          "term": "t-spot",
          "heading": false
        },
        {
          "term": "tst",
          "heading": false
        },
        {
          "term": "exposure",
          "heading": false
        }
      ],
      "extract": "mellitus, steroid use, smoker); o High risk of prior TB exposure (prisoners, health workers, immigrants from high TB burden countries, individuals with CXR abnormalities; homeless people and people who use drugs, inhabitants of high TB burden settings)1 − BCG vaccinated vs non-vaccinated (in identified groups at risk of TB infection- stratified or in combination, as appropriate) 3. Correlation with exposure",
      "extractCut": true,
      "blocks": [
        "library/10665-381036/blocks/prose-page-869"
      ]
    },
    {
      "id": "page-870",
      "number": null,
      "title": "Page 870",
      "level": 1,
      "pageStart": 870,
      "pageEnd": 870,
      "labelStart": null,
      "labelEnd": null,
      "words": 529,
      "summary": {
        "text": "Tabulates inclusion criteria by objective, such as longitudinal studies of incident TB, contact studies by proximity, and studies of confirmed TB or low-risk groups for sensitivity and specificity. It describes the search, including Russian, Ukrainian and Chinese sources screened by native speakers or translation.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "full-text articles",
          "heading": false
        },
        {
          "term": "index test",
          "heading": false
        },
        {
          "term": "language studies",
          "heading": false
        },
        {
          "term": "studies reporting",
          "heading": false
        },
        {
          "term": "comparator test",
          "heading": false
        },
        {
          "term": "report index",
          "heading": false
        },
        {
          "term": "search strategy",
          "heading": false
        },
        {
          "term": "longitudinal studies",
          "heading": false
        }
      ],
      "extract": "1 Longitudinal studies that report index test result in the population eligible for LTBI testing, preventive therapy given and cases of incident TB during the study period Must be free of active disease at baseline; Must report method of TB diagnosis (microbiological or clinical) 2 Longitudinal studies reporting development of incident TB in the population tested with index test during the study period Must be free",
      "extractCut": true,
      "blocks": [
        "library/10665-381036/blocks/prose-page-870"
      ]
    },
    {
      "id": "page-871",
      "number": null,
      "title": "Page 871",
      "level": 1,
      "pageStart": 871,
      "pageEnd": 871,
      "labelStart": null,
      "labelEnd": null,
      "words": 401,
      "summary": {
        "text": "Describes resolving screening disagreements, using Rayyan and Excel for data management, and case definitions for incident, prevalent and active TB. It explains quality assessment with QUADAS-2, with an added domain on manufacturer involvement.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "extraction sheet",
          "heading": false
        },
        {
          "term": "data extraction",
          "heading": false
        },
        {
          "term": "study design",
          "heading": false
        },
        {
          "term": "reviewers",
          "heading": false
        },
        {
          "term": "index test",
          "heading": false
        },
        {
          "term": "quality assessment",
          "heading": false
        },
        {
          "term": "cut-off",
          "heading": false
        },
        {
          "term": "accuracy studies",
          "heading": false
        }
      ],
      "extract": "reviewers independently. Discrepancies in inclusion/exclusion between the 2 reviewers were resolved by discussion between the 2 reviewers or if needed with additional reviewers. We used the systematic review management platform Rayyan20 for study screening and tracking of exclusion reasons. Data extraction was carried out using specific data extraction sheet in Microsoft Excel. Case definitions: Incident TB disease:",
      "extractCut": true,
      "blocks": [
        "library/10665-381036/blocks/prose-page-871"
      ]
    },
    {
      "id": "page-872",
      "number": null,
      "title": "Page 872",
      "level": 1,
      "pageStart": 872,
      "pageEnd": 872,
      "labelStart": null,
      "labelEnd": null,
      "words": 559,
      "summary": {
        "text": "Explains use of GRADE and the analysis plan, including sensitivity in confirmed TB, specificity in low-risk groups in low-burden countries, test agreement with exact confidence intervals and meta-analysis where two or more studies existed. It sets out less restrictive proxy measures of specificity, restricted to presumed healthy people.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "three-way head-to-head",
          "heading": false
        },
        {
          "term": "head-to-head comparisons",
          "heading": false
        },
        {
          "term": "sensitivity analyses",
          "heading": false
        },
        {
          "term": "specificity estimates",
          "heading": false
        },
        {
          "term": "less restrictive",
          "heading": false
        },
        {
          "term": "restrictive criteria",
          "heading": false
        },
        {
          "term": "skin test",
          "heading": false
        },
        {
          "term": "index tests",
          "heading": false
        }
      ],
      "extract": "The GRADE framework22 was used to systematically assess the quality of evidence and strength of recommendations regarding the use of novel TBST. Data Analysis: Where possible, outcome measures were stratified by: type of test and population. Outcome and effect measures of interest were evaluated separately as described in Table 4. Sensitivity in those with microbiologically-confirmed active TB and specificity in",
      "extractCut": true,
      "blocks": [
        "library/10665-381036/blocks/prose-page-872"
      ]
    },
    {
      "id": "page-873",
      "number": null,
      "title": "Page 873",
      "level": 1,
      "pageStart": 873,
      "pageEnd": 873,
      "labelStart": null,
      "labelEnd": null,
      "words": 171,
      "summary": {
        "text": "Explains that proxy specificity also included people with other diseases and that publication bias was not tested because of too few studies. It notes that, at WHO's request, data across different skin tests were pooled post hoc despite heterogeneity and high risk of bias in Diaskintest studies.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "study designs",
          "heading": false
        },
        {
          "term": "different tbst",
          "heading": false
        },
        {
          "term": "ignored",
          "heading": false
        },
        {
          "term": "heterogeneity",
          "heading": false
        },
        {
          "term": "pool",
          "heading": false
        }
      ],
      "extract": "• Other diseases without TB symptoms and not suspected of having active TB and no reported history of contacts (this was assumed unless specified otherwise) The term specificity (proxy) is used when describing the estimates above. We did not conduct a test for publication bias because none of the quantitative syntheses included sufficient numbers of studies (≥ 10 studies). Our primary analysis did not pool different",
      "extractCut": true,
      "blocks": [
        "library/10665-381036/blocks/prose-page-873"
      ]
    },
    {
      "id": "page-874",
      "number": null,
      "title": "Page 874",
      "level": 1,
      "pageStart": 874,
      "pageEnd": 874,
      "labelStart": null,
      "labelEnd": null,
      "words": 275,
      "summary": {
        "text": "Presents Table 4, listing the effect measures for each review objective, such as incidence rate ratios and predictive values for progression, odds ratios by contact proximity, sensitivity and specificity, concordance and the proportion starting preventive treatment.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "skin test",
          "heading": false
        },
        {
          "term": "comparator test",
          "heading": false
        },
        {
          "term": "index test",
          "heading": false
        },
        {
          "term": "test among",
          "heading": false
        },
        {
          "term": "discordance",
          "heading": false
        },
        {
          "term": "disease progression",
          "heading": false
        },
        {
          "term": "concordance",
          "heading": false
        },
        {
          "term": "rate ratios",
          "heading": false
        }
      ],
      "extract": "Table 4: Effect measures according to objective Outcome Effect measure 1. Efficacy of preventive therapy based on the test result Incidence rates for disease progression stratified by test result Incidence Rate Ratios Negative and Positive Predictive Values for disease progression 2. Predictive value of novel recombinant skin tests for incident TB among risk- stratified populations Incidence rates for disease",
      "extractCut": true,
      "blocks": [
        "library/10665-381036/blocks/prose-page-874"
      ]
    },
    {
      "id": "page-875",
      "number": null,
      "title": "Page 875",
      "level": 1,
      "pageStart": 875,
      "pageEnd": 875,
      "labelStart": null,
      "labelEnd": null,
      "words": 158,
      "summary": {
        "text": "Reports the study selection, with the earlier review's 37 studies and new reports bringing totals to five C-Tb, 34 Diaskintest, four C-TST and one DPPD study, noting that DPPD data are shown but not pooled.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "dppd test",
          "heading": false
        },
        {
          "term": "c-tst",
          "heading": false
        },
        {
          "term": "until",
          "heading": false
        },
        {
          "term": "diaskintest",
          "heading": false
        }
      ],
      "extract": "Results 5.1 Systematic literature review Figure 2 presents the selection process. Our previous review identified 37 studies reporting TBST: 29 Diaskintest, five C-Tb, two C-TST, one DPPD, that were published from inception until 20 October 2020.17 Our updated search covering the period until 30 July 2021 identified four reports (three in Russian23-25 on Diaskintest and one in English on C-TST26) via the database",
      "extractCut": true,
      "blocks": [
        "library/10665-381036/blocks/prose-page-875"
      ]
    },
    {
      "id": "page-876",
      "number": null,
      "title": "Page 876",
      "level": 1,
      "pageStart": 876,
      "pageEnd": 876,
      "labelStart": null,
      "labelEnd": null,
      "words": 4,
      "summary": {
        "text": "A page carrying only the caption of Figure 2 on study selection.",
        "status": "draft"
      },
      "keywords": [],
      "extract": "Figure 2 Study selection",
      "extractCut": false,
      "blocks": [
        "library/10665-381036/blocks/prose-page-876",
        "library/10665-381036/blocks/figure-img-p876-1"
      ]
    },
    {
      "id": "page-877",
      "number": null,
      "title": "Page 877",
      "level": 1,
      "pageStart": 877,
      "pageEnd": 877,
      "labelStart": null,
      "labelEnd": null,
      "words": 628,
      "summary": {
        "text": "Describes the included studies, noting that nearly all Diaskintest studies were routine-care cross-sectional studies in Russia, with few head-to-head comparisons and small numbers of people with HIV. It reports high BCG coverage where recorded and varied positivity thresholds. It also outlines the C-Tb, C-TST and DPPD studies, including a Brazilian DPPD study in BCG-vaccinated people.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "five studies",
          "heading": false
        },
        {
          "term": "four studies",
          "heading": false
        },
        {
          "term": "head-to-head comparisons",
          "heading": false
        },
        {
          "term": "tst5mm",
          "heading": false
        },
        {
          "term": "induration",
          "heading": false
        },
        {
          "term": "c-tst",
          "heading": false
        },
        {
          "term": "diaskintest",
          "heading": false
        },
        {
          "term": "tst",
          "heading": false
        }
      ],
      "extract": "5.2 Characteristics of included studies All but one Diaskintest study was conducted in Russia (Table 5). All were cross-sectional assessments performed as a part of a routine care provision, and cohorts were recruited prospectively or constructed retrospectively. None of the studies randomised different tests into different groups or arms. Four studies43 44 57 60 were head-to-head comparisons of Diaskintest with TST",
      "extractCut": true,
      "blocks": [
        "library/10665-381036/blocks/prose-page-877"
      ]
    },
    {
      "id": "page-878",
      "number": null,
      "title": "Page 878",
      "level": 1,
      "pageStart": 878,
      "pageEnd": 878,
      "labelStart": null,
      "labelEnd": null,
      "words": 68,
      "summary": {
        "text": "Notes that no studies assessed incident TB, effectiveness of preventive treatment or uptake of treatment, and that manufacturers' test cut-offs were not always followed.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "preventive treatment",
          "heading": false
        },
        {
          "term": "cut-off",
          "heading": false
        },
        {
          "term": "summarises",
          "heading": false
        }
      ],
      "extract": "of preventive treatment, or the proportion of participants with positive results starting TB preventive treatment. Table S3 in supplement summarises studies available for assessment of each review objective Table 7 shows the cut-off defined for each test by test manufacturers. It should be noted, however, that they were not always followed, and the cut-off used in each study is indicated in the text and presented in",
      "extractCut": true,
      "blocks": [
        "library/10665-381036/blocks/prose-page-878"
      ]
    },
    {
      "id": "page-879",
      "number": null,
      "title": "Page 879",
      "level": 1,
      "pageStart": 879,
      "pageEnd": 879,
      "labelStart": null,
      "labelEnd": null,
      "words": 189,
      "summary": {
        "text": "Presents Table 5, listing Diaskintest studies by country, threshold, comparator, age, sample size, population and review objectives addressed. Most studies were in Russia, with children and medical students among the populations.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "diaskintestai",
          "heading": false
        },
        {
          "term": "russia",
          "heading": false
        },
        {
          "term": "tst5mm",
          "heading": false
        },
        {
          "term": "diaskintest5mm",
          "heading": false
        },
        {
          "term": "borodulina",
          "heading": false
        },
        {
          "term": "medical students",
          "heading": false
        }
      ],
      "extract": "Table 5 Characteristics of Diaskintest studies Study Country Index Test Comparators Age, years (a) Sample size (in review) Study population (b) Review Objective Addressed Test concordance Sensitivity Specificity (c ) Dose-response association (d) Aksenova 2011 Russia DiaskintestAI TST5mm NS 1551(63) Children; TB Screening X X Baryshnikova 2017 Russia DiaskintestAI TST5mm NS 811(163) Children; active PTB X",
      "extractCut": true,
      "blocks": [
        "library/10665-381036/blocks/prose-page-879"
      ]
    },
    {
      "id": "page-880",
      "number": null,
      "title": "Page 880",
      "level": 1,
      "pageStart": 880,
      "pageEnd": 880,
      "labelStart": null,
      "labelEnd": null,
      "words": 225,
      "summary": {
        "text": "Continues a table of study characteristics for Diaskintest evaluations, almost all from Russia, listing comparator tests, participant ages, sample sizes and populations. Most studies involve children or adults under investigation for tuberculosis, with some in people with HIV.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "qft-tb git",
          "heading": false
        },
        {
          "term": "diaskintestai",
          "heading": false
        },
        {
          "term": "russia",
          "heading": false
        },
        {
          "term": "tst5mm",
          "heading": false
        },
        {
          "term": "active ptb",
          "heading": false
        },
        {
          "term": "slogotskaya",
          "heading": false
        }
      ],
      "extract": "Losovskaya 2014* Russia DiaskintestAI TST5mm, IGRA (QFT-TB GIT) 0.5-15 50 (46) Children; TB investigations X Losovskaya 2016* Russia DiaskintestAI TST5mm, IGRA (QFT-TB GIT) 3-6 63 (63) Children; TB investigation X Mishin 2016 Russia DiaskintestAI None NS 529 (103) HIV- Adults; PTB; Healthy control; X Nakonechnaya 2020 Russia DiaskintestAI IGRA (QFT-TB GIT) 1-17 62 (62) Children with TB and other pulmonary conditions",
      "extractCut": true,
      "blocks": [
        "library/10665-381036/blocks/prose-page-880"
      ]
    },
    {
      "id": "page-881",
      "number": null,
      "title": "Page 881",
      "level": 1,
      "pageStart": 881,
      "pageEnd": 881,
      "labelStart": null,
      "labelEnd": null,
      "words": 255,
      "summary": {
        "text": "Completes the Diaskintest study characteristics table with further Russian studies, including some in health workers and people with suspected tuberculosis. Footnotes flag studies used in the three-way comparison with IGRA and TST and explain the abbreviations.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "qft-tb git",
          "heading": false
        },
        {
          "term": "russia",
          "heading": false
        },
        {
          "term": "tst5mm",
          "heading": false
        },
        {
          "term": "diaskintestai",
          "heading": false
        },
        {
          "term": "diaskintest5mm",
          "heading": false
        },
        {
          "term": "starshinova",
          "heading": false
        },
        {
          "term": "stogova",
          "heading": false
        },
        {
          "term": "pulmonary conditions",
          "heading": false
        }
      ],
      "extract": "Starshinova 2018* Russia Diaskintest5mm TST5mm, IGRA (T.SPOT- TB, QFT-TB GIT) Children 8.1, Adults: 37 860 (860) HIV- ; BCG-vaccinated; TB Screening; Children; Adults X Starshinova 2019a* Russia Diaskintest5mm TST5mm , IGRA (QFT-TB GIT, T-SPOT.TB) 18-65 187 (135) Adults, Culture+ TB; TB unexposed; IGRA+/Diaskintest+ X Starshinova 2019b Russia DiaskintestAI None TB hospital: 42 (0.23), General hospital: 43 (0.27) 154",
      "extractCut": true,
      "blocks": [
        "library/10665-381036/blocks/prose-page-881"
      ]
    },
    {
      "id": "page-882",
      "number": null,
      "title": "Page 882",
      "level": 1,
      "pageStart": 882,
      "pageEnd": 882,
      "labelStart": null,
      "labelEnd": null,
      "words": 364,
      "summary": {
        "text": "Table 6 lists characteristics of studies on the C-Tb, C-TST and DPPD skin tests, from countries such as the United Kingdom, South Africa, Spain and China. It gives comparators, ages, sample sizes, populations and which review objectives each study addressed, such as concordance, sensitivity and specificity.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "multiple thresholds",
          "heading": false
        },
        {
          "term": "tst5mm",
          "heading": false
        },
        {
          "term": "hiv adults",
          "heading": false
        },
        {
          "term": "dose-response association",
          "heading": false
        },
        {
          "term": "c-tb",
          "heading": false
        },
        {
          "term": "c-tst",
          "heading": false
        },
        {
          "term": "qft",
          "heading": false
        },
        {
          "term": "south africa",
          "heading": false
        }
      ],
      "extract": "Table 6 Characteristics of C-Tb, C-TST, and DPPD studies Study Country Index Test Comparators Age, years (a) Sample size (in review) Study population (b) Review Objective Addressed Test concordance Sensitivity Specificity Dose-response association (c) Aggerbeck 2013 United Kingdom C-Tb TST (multiple thresholds), QFT Cases: 33, 18-60, Controls:34, 18-65 189 (189) Active Tb (3 participants selected on the basis of",
      "extractCut": true,
      "blocks": [
        "library/10665-381036/blocks/prose-page-882"
      ]
    },
    {
      "id": "page-883",
      "number": null,
      "title": "Page 883",
      "level": 1,
      "pageStart": 883,
      "pageEnd": 883,
      "labelStart": null,
      "labelEnd": null,
      "words": 140,
      "summary": {
        "text": "Table 7 sets out the positivity cut-offs for the Diaskintest, C-Tb, C-TST and DPPD skin tests as defined by manufacturers or the latest studies.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "package insert",
          "heading": false
        },
        {
          "term": "yet commercialized",
          "heading": false
        },
        {
          "term": "cut off",
          "heading": false
        },
        {
          "term": "induration",
          "heading": false
        }
      ],
      "extract": "Table 7 Cut off of TBST defined by their manufacturers Test Source Cut off Diaskintest Package insert Negative response: The absence of infiltration and hyperaemia or the presence of ‘prick response’ up to 2 mm Ambiguous response: The presence of hyperaemia without infiltrate. Positive response: The presence of infiltrate (papule) of any size C-Tb The most recent study by Aggereck et al. (The test is not yet",
      "extractCut": true,
      "blocks": [
        "library/10665-381036/blocks/prose-page-883"
      ]
    },
    {
      "id": "page-884",
      "number": null,
      "title": "Page 884",
      "level": 1,
      "pageStart": 884,
      "pageEnd": 884,
      "labelStart": null,
      "labelEnd": null,
      "words": 589,
      "summary": {
        "text": "Describes risk of bias in the included studies, noting that poor reporting left many quality criteria unclear and that many Diaskintest studies lacked blinding to culture or comparator results. It then reports pooled results for Diaskintest, including sensitivity in people without HIV of 66% at any induration and 88% at a 5 mm cut-off.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "test assessors",
          "heading": false
        },
        {
          "term": "pooled agreement",
          "heading": false
        },
        {
          "term": "evaluating diaskintest",
          "heading": false
        },
        {
          "term": "diaskintestai",
          "heading": false
        },
        {
          "term": "studies evaluating",
          "heading": false
        },
        {
          "term": "criterion because",
          "heading": false
        },
        {
          "term": "patient selection",
          "heading": false
        },
        {
          "term": "index test",
          "heading": false
        }
      ],
      "extract": "5.3 Risk of bias in individual studies The quality of studies evaluating Diaskintest performance was difficult to assess due to inconsistencies and incomplete reporting of study methods and sample recruitment. This resulted in several “unknown” assessments against the quality criteria. Of the 16 studies evaluating the sensitivity of Diaskintest, risk of bias was high in 5 (31.3%) studies where test assessors were",
      "extractCut": true,
      "blocks": [
        "library/10665-381036/blocks/prose-page-884"
      ]
    },
    {
      "id": "page-885",
      "number": null,
      "title": "Page 885",
      "level": 1,
      "pageStart": 885,
      "pageEnd": 885,
      "labelStart": "22",
      "labelEnd": "22",
      "words": 41,
      "summary": {
        "text": "Captions for figures on test sensitivity and agreement in studies comparing Diaskintest, IGRA and TST directly against each other.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "studies comparing",
          "heading": false
        },
        {
          "term": "head-to-head",
          "heading": false
        },
        {
          "term": "microbiologically-confirmed",
          "heading": false
        }
      ],
      "extract": "22 Figure 3. Test sensitivity in three-way head-to-head studies comparing Diaskintest, IGRA and TST TP = True positive FN = False negative Includes HIV-uninfected adults with microbiologically-confirmed active TB. Figure 4 Test agreement in head-to-head Diaskintest studies comparing all three tests",
      "extractCut": false,
      "blocks": [
        "library/10665-381036/blocks/prose-page-885",
        "library/10665-381036/blocks/figure-img-p885-1"
      ]
    },
    {
      "id": "page-886",
      "number": null,
      "title": "Page 886",
      "level": 1,
      "pageStart": 886,
      "pageEnd": 886,
      "labelStart": "23",
      "labelEnd": "23",
      "words": 368,
      "summary": {
        "text": "Reports that varied methods and populations prevented meta-analysis for most Diaskintest risk groups, with sensitivity ranging from 40–71% in adults with HIV to 92–100% in children without HIV. It notes specificity could not be estimated for Diaskintest, then turns to C-Tb, where pooled specificity in low-burden settings was similar to IGRA and higher than TST at 15 mm.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "hiv-uninfected children",
          "heading": false
        },
        {
          "term": "c-tb",
          "heading": false
        },
        {
          "term": "concordant",
          "heading": false
        },
        {
          "term": "diaskintest5mm",
          "heading": false
        },
        {
          "term": "tst5mm",
          "heading": false
        },
        {
          "term": "igra",
          "heading": false
        },
        {
          "term": "diaskintest",
          "heading": false
        },
        {
          "term": "ranged",
          "heading": false
        }
      ],
      "extract": "23 Includes HIV-uninfected children under investigation for TB and those with active TB (clinical and confirmed). AI = Any induration ; Conc = Concordant; N = Total, concordant + discordant; % Agreement: represents agreement with IGRA as the comparator Highly variable methods and sub-populations precluded meaningful meta-analysis for most risk groups; sensitivity estimates from individual studies ranged from 40%-71%",
      "extractCut": true,
      "blocks": [
        "library/10665-381036/blocks/prose-page-886",
        "library/10665-381036/blocks/figure-img-p886-1"
      ]
    },
    {
      "id": "page-887",
      "number": null,
      "title": "Page 887",
      "level": 1,
      "pageStart": 887,
      "pageEnd": 887,
      "labelStart": "24",
      "labelEnd": "24",
      "words": 279,
      "summary": {
        "text": "Reports pooled agreement between C-Tb, IGRA and TST in head-to-head studies, all around 75–80%, and similar agreement in two-test comparisons. It also gives agreement among people without tuberculosis and how often C-Tb was negative among IGRA-negative participants.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "c-tb",
          "heading": false
        },
        {
          "term": "test agreement",
          "heading": false
        },
        {
          "term": "tst5mm",
          "heading": false
        },
        {
          "term": "igra",
          "heading": false
        },
        {
          "term": "tst",
          "heading": false
        },
        {
          "term": "pooled",
          "heading": false
        }
      ],
      "extract": "24 95% CI 90-95%); the analysis was not possible for TST5mm due to insufficient data. Three studies provided suitable head-to-head data for agreement comparisons between C-Tb, IGRA, and TST. Pooled test agreement between C-Tb and IGRA was 79.80% (95% CI 76.10–83.07), similar to that between IGRA and TST5 mm/15 mm (74.67% [64.01–83.01]) and C-Tb and TST5 mm/15 mm (78·92% [74·65–82·63]; figure 7).16 29 30 C-Tb results",
      "extractCut": true,
      "blocks": [
        "library/10665-381036/blocks/prose-page-887"
      ]
    },
    {
      "id": "page-888",
      "number": null,
      "title": "Page 888",
      "level": 1,
      "pageStart": 888,
      "pageEnd": 888,
      "labelStart": "25",
      "labelEnd": "25",
      "words": 28,
      "summary": {
        "text": "Caption for a figure on the sensitivity of C-Tb, IGRA and TST compared directly in people with microbiologically confirmed tuberculosis.",
        "status": "draft"
      },
      "keywords": [],
      "extract": "25 Figure 5. Test sensitivity in head-to-head studies comparing C-Tb, IGRA and TST TP = True positive; FN = False negative. Results include individuals with microbiologically-confirmed active TB.",
      "extractCut": false,
      "blocks": [
        "library/10665-381036/blocks/prose-page-888",
        "library/10665-381036/blocks/figure-img-p888-1"
      ]
    },
    {
      "id": "page-889",
      "number": null,
      "title": "Page 889",
      "level": 1,
      "pageStart": 889,
      "pageEnd": 889,
      "labelStart": "26",
      "labelEnd": "26",
      "words": 32,
      "summary": {
        "text": "Caption for a figure on the specificity of C-Tb, IGRA and TST compared directly in people without active tuberculosis in low-incidence settings.",
        "status": "draft"
      },
      "keywords": [],
      "extract": "26 Figure 6. Test specificity in head-to-head studies comparing C-Tb, IGRA and TST Individuals without active TB in studies conducted in TB low-incidence settings. TN = True negative FP = False positive",
      "extractCut": false,
      "blocks": [
        "library/10665-381036/blocks/prose-page-889",
        "library/10665-381036/blocks/figure-img-p889-1"
      ]
    },
    {
      "id": "page-890",
      "number": null,
      "title": "Page 890",
      "level": 1,
      "pageStart": 890,
      "pageEnd": 890,
      "labelStart": "27",
      "labelEnd": "27",
      "words": 57,
      "summary": {
        "text": "Caption for a figure on agreement among C-Tb, IGRA and TST in direct comparison studies, with notes on which studies lacked suitable data.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "concordant",
          "heading": false
        },
        {
          "term": "agreement",
          "heading": false
        },
        {
          "term": "bacteriologically-confirmed",
          "heading": false
        }
      ],
      "extract": "27 Figure 7 Test agreement in head-to-head C-Tb studies comparing all three tests Includes individuals with bacteriologically-confirmed active TB. Ruhwald 2017 and Aggerbeck 2013, although did three- test comparisons, did not report data suitable for estimation of %TST-IGRA agreement. Conc = Concordant; N = Total, concordant + discordant; % Agreement: represents agreement with IGRA as the comparator",
      "extractCut": false,
      "blocks": [
        "library/10665-381036/blocks/prose-page-890",
        "library/10665-381036/blocks/figure-img-p890-1"
      ]
    },
    {
      "id": "page-891",
      "number": null,
      "title": "Page 891",
      "level": 1,
      "pageStart": 891,
      "pageEnd": 891,
      "labelStart": "28",
      "labelEnd": "28",
      "words": 457,
      "summary": {
        "text": "Reports C-TST results, with a pooled sensitivity of 86% at a 5 mm cut-off and higher agreement with IGRA than with TST, largely due to BCG vaccination effects. A post-hoc meta-analysis combining all novel skin tests then gives pooled sensitivity of 76% in people with HIV-negative or unknown status and lower estimates in people with HIV.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "c-tst",
          "heading": false
        },
        {
          "term": "test agreement",
          "heading": false
        },
        {
          "term": "sensitivity analyses",
          "heading": false
        },
        {
          "term": "sensitivity objectives",
          "heading": false
        },
        {
          "term": "tst",
          "heading": false
        },
        {
          "term": "dppd",
          "heading": false
        },
        {
          "term": "tspot",
          "heading": false
        },
        {
          "term": "bcg vaccination",
          "heading": false
        }
      ],
      "extract": "28 5.6 C-TST Three studies evaluated sensitivity of the C-TST.26 61 62 Sensitivity at the ≥5mm induration threshold ranged from 77% to 90%, with a pooled estimate of 86% (95%CI: 83-89%) (Table S34). In one study, the sensitivity of C-TST (90% [73-98%]) was similar to that of TPOT.TB (89% [78-95%] and TST 10 mm (87% [76-94%] and slightly higher than TST 10 mm (82% [69-90%].26 In two studies including healthy",
      "extractCut": true,
      "blocks": [
        "library/10665-381036/blocks/prose-page-891"
      ]
    },
    {
      "id": "page-892",
      "number": null,
      "title": "Page 892",
      "level": 1,
      "pageStart": 892,
      "pageEnd": 892,
      "labelStart": "29",
      "labelEnd": "29",
      "words": 561,
      "summary": {
        "text": "Continues the combined analysis, finding little difference in specificity between the novel skin tests and IGRA but a much larger difference with TST, most likely due to BCG. Pooled agreement with IGRA was high, while agreement with TST was lower in people without tuberculosis, and the discussion begins on study quality concerns.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "c-tb studies",
          "heading": false
        },
        {
          "term": "diaskintest studies",
          "heading": false
        },
        {
          "term": "bcg vaccination",
          "heading": false
        },
        {
          "term": "tbst",
          "heading": false
        },
        {
          "term": "different studies",
          "heading": false
        },
        {
          "term": "confidence interval",
          "heading": false
        },
        {
          "term": "igra",
          "heading": false
        },
        {
          "term": "tst",
          "heading": false
        }
      ],
      "extract": "29 73%, 5 studies) in HIV-positive individuals. While this may be seen as the lower sensitivity in HIV-positive individuals, these estimates are based on different studies, and thus not conclusive. When combining all TBST, the pooled difference in specificity between TBST and IGRA was 2.29% (95%CI: -1.60-6.18%, 6 studies on Diaskintest, C-Tb and C-TST) and that between TBST and TST was 33.47% (95%CI: 18.16-48.78%,",
      "extractCut": true,
      "blocks": [
        "library/10665-381036/blocks/prose-page-892"
      ]
    },
    {
      "id": "page-893",
      "number": null,
      "title": "Page 893",
      "level": 1,
      "pageStart": 893,
      "pageEnd": 893,
      "labelStart": "30",
      "labelEnd": "30",
      "words": 367,
      "summary": {
        "text": "Discusses limitations, including inconsistent procedures, poor reporting, reliance on clinical diagnosis, varied Diaskintest cut-offs, incorporation bias and possible conflicts of interest from industry funding. It concludes that the novel skin tests appear comparable to existing tests and could allow accessible screening without laboratories or blood draws.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "diaskintest positivity",
          "heading": false
        },
        {
          "term": "novel skin",
          "heading": false
        },
        {
          "term": "predictive performance",
          "heading": false
        },
        {
          "term": "skin tests",
          "heading": false
        },
        {
          "term": "although russian",
          "heading": false
        },
        {
          "term": "russian national",
          "heading": false
        },
        {
          "term": "concordance",
          "heading": false
        },
        {
          "term": "cut-off",
          "heading": false
        }
      ],
      "extract": "30 often insufficient. Ascertainment of TB was inadequate; the diagnosis often pragmatically made on clinical and/or radiological findings rather than microbiologically-confirmed. Although Russian national TB guidelines define Diaskintest positivity as induration of any size, more than a third of studies used the 5mm cut-off, making comparison between studies and products difficult. Incorporation bias is a risk in",
      "extractCut": true,
      "blocks": [
        "library/10665-381036/blocks/prose-page-893"
      ]
    },
    {
      "id": "page-894",
      "number": null,
      "title": "Page 894",
      "level": 1,
      "pageStart": 894,
      "pageEnd": 894,
      "labelStart": "31",
      "labelEnd": "31",
      "words": 400,
      "summary": {
        "text": "The start of the reference list for the systematic review on novel tuberculosis skin tests, citing global burden studies and early work on Diaskintest.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "published online",
          "heading": false
        },
        {
          "term": "mycobacterium tuberculosis",
          "heading": false
        },
        {
          "term": "tuberculosis infection",
          "heading": false
        },
        {
          "term": "doi",
          "heading": false
        },
        {
          "term": "lung disease",
          "heading": false
        },
        {
          "term": "skin test",
          "heading": false
        },
        {
          "term": "journal",
          "heading": false
        },
        {
          "term": "global burden",
          "heading": false
        }
      ],
      "extract": "31 References 1. Hay SI, Abajobir AA, Abate KH, et al. Global, regional, and national disability-adjusted life-years (DALYs) for 333 diseases and injuries and healthy life expectancy (HALE) for 195 countries and territories, 1990&#x2013;2016: a systematic analysis for the Global Burden of Disease Study 2016. The Lancet 2017;390(10100):1260-344. doi: 10.1016/S0140-6736(17)32130-X 2. Houben RMGJ, Dodd PJ. The Global",
      "extractCut": true,
      "blocks": [
        "library/10665-381036/blocks/prose-page-894"
      ]
    },
    {
      "id": "page-895",
      "number": null,
      "title": "Page 895",
      "level": 1,
      "pageStart": 895,
      "pageEnd": 895,
      "labelStart": "32",
      "labelEnd": "32",
      "words": 458,
      "summary": {
        "text": "Continues the reference list, citing trials of C-Tb, a meta-analysis of novel skin tests and several Russian and Ukrainian studies.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "tuberculin skin",
          "heading": false
        },
        {
          "term": "tuberculosis infection",
          "heading": false
        },
        {
          "term": "tuberculosis antigen",
          "heading": false
        },
        {
          "term": "skin tests",
          "heading": false
        },
        {
          "term": "mycobacterium tuberculosis",
          "heading": false
        },
        {
          "term": "respiratory journal",
          "heading": false
        },
        {
          "term": "infectious diseases",
          "heading": false
        },
        {
          "term": "release assays",
          "heading": false
        }
      ],
      "extract": "32 15. Ruhwald M, Aggerbeck H, Gallardo RV, et al. Safety and efficacy of the C-Tb skin test to diagnose Mycobacterium tuberculosis infection, compared with an interferon gamma release assay and the tuberculin skin test: a phase 3, double-blind, randomised, controlled trial. The Lancet Respiratory Medicine 2017;5(4):259-68. 16. Hoff ST, Peter JG, Theron G, et al. Sensitivity of C-Tb: a novel RD-1-specific skin test",
      "extractCut": true,
      "blocks": [
        "library/10665-381036/blocks/prose-page-895"
      ]
    },
    {
      "id": "page-896",
      "number": null,
      "title": "Page 896",
      "level": 1,
      "pageStart": 896,
      "pageEnd": 896,
      "labelStart": "33",
      "labelEnd": "33",
      "words": 457,
      "summary": {
        "text": "Continues the reference list with C-Tb trials and Russian studies of Diaskintest in children and adolescents.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "tuberk bolezn",
          "heading": false
        },
        {
          "term": "tuberculosis recombinant",
          "heading": false
        },
        {
          "term": "differential diagnostics",
          "heading": false
        },
        {
          "term": "immunological tests",
          "heading": false
        },
        {
          "term": "tuberculosis infection",
          "heading": false
        },
        {
          "term": "pulmonary tuberculosis",
          "heading": false
        },
        {
          "term": "mantoux test",
          "heading": false
        },
        {
          "term": "comparative evaluation",
          "heading": false
        }
      ],
      "extract": "33 TUBERCULOSIS MEDICAL CENTERS (Ukrainian). Ukrainian Journal of Occupational Health 2015;1(42) 29. Aggerbeck H, Ruhwald M, Hoff ST, et al. C-Tb skin test to diagnose Mycobacterium tuberculosis infection in children and HIV-infected adults: A phase 3 trial. PLoS ONE [Electronic Resource] 2018;13(9):e0204554. 30. Aggerbeck H, Ruhwald M, Hoff ST, et al. Interaction between C-Tb and PPD given concomitantly in a",
      "extractCut": true,
      "blocks": [
        "library/10665-381036/blocks/prose-page-896"
      ]
    },
    {
      "id": "page-897",
      "number": null,
      "title": "Page 897",
      "level": 1,
      "pageStart": 897,
      "pageEnd": 897,
      "labelStart": "34",
      "labelEnd": "34",
      "words": 462,
      "summary": {
        "text": "Continues the reference list, including a Russian health ministry order and further Russian comparative studies of Diaskintest.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "bolezn lëgkih",
          "heading": false
        },
        {
          "term": "tuberk bolezn",
          "heading": false
        },
        {
          "term": "recombinant allergen",
          "heading": false
        },
        {
          "term": "recombinant protein",
          "heading": false
        },
        {
          "term": "infect dis",
          "heading": false
        },
        {
          "term": "pulmonary tuberculosis",
          "heading": false
        },
        {
          "term": "detect tuberculosis",
          "heading": false
        },
        {
          "term": "slogotskaya",
          "heading": false
        }
      ],
      "extract": "34 44. Lozovskaya ME, Belushkov VV, Gurina OP, Vasilyeva YB, Klochkova LV. Comparative evaluation of innovative diagnostic tests for latent and active TВ infection in children. Pediatr 2014; 5: 46– 50. 45. Ministry of Health, and Social Development of the Russian Federation. Order of the Ministry of Health and Social Development of the Russian Federation of October 29, 2009 N 855 ‘On Amendments to Appendix N 4 to",
      "extractCut": true,
      "blocks": [
        "library/10665-381036/blocks/prose-page-897"
      ]
    },
    {
      "id": "page-898",
      "number": null,
      "title": "Page 898",
      "level": 1,
      "pageStart": 898,
      "pageEnd": 898,
      "labelStart": "35",
      "labelEnd": "35",
      "words": 346,
      "summary": {
        "text": "Ends the reference list with studies on Diaskintest in health workers, Chinese trials of the ESAT6-CFP10 skin test and the Cochrane handbook.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "recombinant tuberculosis",
          "heading": false
        },
        {
          "term": "recombinant fusion",
          "heading": false
        },
        {
          "term": "tuberculosis allergen",
          "heading": false
        },
        {
          "term": "higgins jpt",
          "heading": false
        },
        {
          "term": "tuberculosis infection",
          "heading": false
        },
        {
          "term": "latent tuberculosis",
          "heading": false
        },
        {
          "term": "immunologic tests",
          "heading": false
        },
        {
          "term": "intradermal test",
          "heading": false
        }
      ],
      "extract": "35 58. Starshinova AA, Zinchenko YS, Istomina E V., et al. Diagnosis of Latent Tuberculosis Infection in Personnel of Various Institutions and Determination of the Risk Group for Tuberculosis. Bioprep Prev Diagnosis, Treat 2019; 19: 178–84. 59. Vaganova US, Russkih OE. Ways of rising detectability of Tuberculosis among health workers. J Pharm Qual Assur 2015; 2: 61–7. 60. A S. A comparison of intradermal test with",
      "extractCut": true,
      "blocks": [
        "library/10665-381036/blocks/prose-page-898"
      ]
    },
    {
      "id": "page-899",
      "number": null,
      "title": "Page 899",
      "level": 1,
      "pageStart": 899,
      "pageEnd": 899,
      "labelStart": "36",
      "labelEnd": "36",
      "words": 22,
      "summary": {
        "text": "The heading of Annex 1 with pooled review results and the caption of a figure on sensitivity of novel skin tests in head-to-head studies, with stray citation codes.",
        "status": "draft"
      },
      "keywords": [],
      "extract": "36 Annex 1: Pooled results of the systematic review. Figure 1. Sensitivity of TBST in head-to-head studies. {Ruhwald, 2017 #2778}{Ruhwald, 2017 #2778}",
      "extractCut": false,
      "blocks": [
        "library/10665-381036/blocks/prose-page-899"
      ]
    },
    {
      "id": "page-900",
      "number": null,
      "title": "Page 900",
      "level": 1,
      "pageStart": 900,
      "pageEnd": 900,
      "labelStart": "37",
      "labelEnd": "37",
      "words": 69,
      "summary": {
        "text": "Footnotes for the head-to-head sensitivity figure, stating which studies tested Diaskintest or C-Tb and which TST cut-offs were used.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "tst cut-off",
          "heading": false
        },
        {
          "term": "starshinova",
          "heading": false
        },
        {
          "term": "aggerbeck",
          "heading": false
        }
      ],
      "extract": "37 Starshinova 2018 (a) and Starshinova 2019 (a) studied DST5mm. The rest studied C-Tb. TST cut-off was 5mm for HIV+ and 15 mm for HIV- in Aggerbeck, 2018, Aggerbeck 2019, Hoff 2016, and Ruhwald 2017. TST cut-off was 5mm in Starshinova 2018 (a) and Starshinova 2019 (a). TBST: novel skin tests for TB infection; TST: tuberculin skin test: QFT: quantiferon; CT: confidence interval; TP: true positive; FN: false negative.",
      "extractCut": false,
      "blocks": [
        "library/10665-381036/blocks/prose-page-900",
        "library/10665-381036/blocks/figure-img-p900-1"
      ]
    },
    {
      "id": "page-901",
      "number": null,
      "title": "Page 901",
      "level": 1,
      "pageStart": 901,
      "pageEnd": 901,
      "labelStart": "38",
      "labelEnd": "38",
      "words": 51,
      "summary": {
        "text": "Caption for a figure on sensitivity of novel skin tests in people with HIV-negative or unknown status, giving a pooled sensitivity of about 74% when Diaskintest at 5 mm is excluded.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "tbst",
          "heading": false
        },
        {
          "term": "dst5mm",
          "heading": false
        },
        {
          "term": "skin",
          "heading": false
        }
      ],
      "extract": "38 Figure 2. Sensitivity of TBST in all studies in individuals with HIV-negative or unknown status The pooled sensitivity when DST5mm was excluded: 74.21% [95%CI 68.30; 79.36] TBST: novel skin tests for TB infection; DST: Diaskintest; TST: tuberculin skin test: QFT: quantiferon; CI: confidence interval; TP: true positive; FN: false negative.",
      "extractCut": false,
      "blocks": [
        "library/10665-381036/blocks/prose-page-901",
        "library/10665-381036/blocks/figure-img-p901-1"
      ]
    },
    {
      "id": "page-902",
      "number": null,
      "title": "Page 902",
      "level": 1,
      "pageStart": 902,
      "pageEnd": 902,
      "labelStart": "39",
      "labelEnd": "39",
      "words": 105,
      "summary": {
        "text": "Captions for figures on sensitivity of novel skin tests in people with HIV, pooled at about 61%, and in children, noting one study excluded because few cases were confirmed.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "novel skin",
          "heading": false
        },
        {
          "term": "confidence interval",
          "heading": false
        },
        {
          "term": "skin tests",
          "heading": false
        }
      ],
      "extract": "39 Figure 3. Sensitivity of TBST in HIV-positive individuals s 0.6131 [0.4790; 0.7 319] Pooled sensitivity when DST5mm was excluded: 61.31% [47.90; 73.19] TBST: novel skin tests for TB infection; DST: Diaskintest; TST: tuberculin skin test: QFT: quantiferon; CI: confidence interval; TP: true positive; FN: false negative. Figure 4 Sensitivity of TBST in children ss ss TBST: novel skin tests for TB infection; DST:",
      "extractCut": true,
      "blocks": [
        "library/10665-381036/blocks/prose-page-902",
        "library/10665-381036/blocks/figure-img-p902-1",
        "library/10665-381036/blocks/figure-img-p902-2",
        "library/10665-381036/blocks/figure-vfig-p902"
      ]
    },
    {
      "id": "page-903",
      "number": null,
      "title": "Page 903",
      "level": 1,
      "pageStart": 903,
      "pageEnd": 903,
      "labelStart": "40",
      "labelEnd": "40",
      "words": 66,
      "summary": {
        "text": "Caption for a figure on agreement between novel skin tests and IGRA in people without active tuberculosis, with a pooled value of about 89%.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "ntb",
          "heading": false
        },
        {
          "term": "dst",
          "heading": false
        },
        {
          "term": "tbst",
          "heading": false
        }
      ],
      "extract": "40 Figure 5 Agreement of TBST vs IGRA in all studies including participants without active TB Pooled agreement when only DSTAI was used for DST: 89.28 [95%CI 84.13; 92.90] TBST novel skin tests for TB infection QFT quantiferon DST Diaskintest CI confidence interval AI any induration size ntb non-TB US Under surveillance for TB PTB/TBI study sample includes individuals with pulmonary TB or latent TB infection",
      "extractCut": false,
      "blocks": [
        "library/10665-381036/blocks/prose-page-903",
        "library/10665-381036/blocks/figure-img-p903-1"
      ]
    },
    {
      "id": "page-904",
      "number": null,
      "title": "Page 904",
      "level": 1,
      "pageStart": 904,
      "pageEnd": 904,
      "labelStart": "41",
      "labelEnd": "41",
      "words": 45,
      "summary": {
        "text": "Caption for a figure on agreement between novel skin tests and IGRA in people with active tuberculosis, pooled at about 82% with Diaskintest at 5 mm excluded.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "dst",
          "heading": false
        },
        {
          "term": "tbst",
          "heading": false
        },
        {
          "term": "agreement",
          "heading": false
        }
      ],
      "extract": "41 Figure 6. Agreement of TBST vs IGRA in all studies including people with active TB Pooled agreement when DST 5mm was excluded: 81.83 [95%CI 77.56; 85.45] TBST novel skin tests for TB infection QFT quantiferon DST Diaskintest CI confidence interval AI any induration size",
      "extractCut": false,
      "blocks": [
        "library/10665-381036/blocks/prose-page-904",
        "library/10665-381036/blocks/figure-img-p904-1"
      ]
    },
    {
      "id": "page-905",
      "number": null,
      "title": "Page 905",
      "level": 1,
      "pageStart": 905,
      "pageEnd": 905,
      "labelStart": "42",
      "labelEnd": "42",
      "words": 65,
      "summary": {
        "text": "Caption for a figure on agreement between novel skin tests and TST in people without active tuberculosis, pooled at about 63%, with abbreviation notes and stray characters.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "ttt",
          "heading": false
        },
        {
          "term": "investigation",
          "heading": false
        },
        {
          "term": "ntb",
          "heading": false
        }
      ],
      "extract": "42 Figure 7 Agreement of TBST vs TST in all studies including participants without active TB Tsss Pooled agreement when DST5mm was excluded: 63.20% [95%CI: 47.38; 76.62] UI under investigation for TB CI confidence interval nTB non-TB TST tuberculin skin test G general population UT active TB or under investigation for TB, results not reported separately DST Diaskintest PE potentially exposed (health care workers) Ttt",
      "extractCut": false,
      "blocks": [
        "library/10665-381036/blocks/prose-page-905",
        "library/10665-381036/blocks/figure-img-p905-1"
      ]
    },
    {
      "id": "page-906",
      "number": null,
      "title": "Page 906",
      "level": 1,
      "pageStart": 906,
      "pageEnd": 906,
      "labelStart": "43",
      "labelEnd": "43",
      "words": 60,
      "summary": {
        "text": "Caption for a figure on agreement between novel skin tests and TST in people with active tuberculosis, pooled at about 87%, with abbreviations.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "clm",
          "heading": false
        },
        {
          "term": "actnr",
          "heading": false
        },
        {
          "term": "ccs",
          "heading": false
        }
      ],
      "extract": "43 Figure 8 Agreement of TBST vs TST in all studies including people with active TB Pooled agreement when DST5mm was excluded: 86.98% [80.76-91.41%] actNR active TB, diagnostic method not reported TST tuberculin skin test CI confidence interval CC culture-confirmed TB CCPCR culture or PCR confirmed CLM clinically or microbiologically confirmed TB CCS culture or smear confirmed TB DST Diaskintest",
      "extractCut": false,
      "blocks": [
        "library/10665-381036/blocks/prose-page-906",
        "library/10665-381036/blocks/figure-img-p906-1"
      ]
    },
    {
      "id": "page-907",
      "number": null,
      "title": "Page 907",
      "level": 1,
      "pageStart": 907,
      "pageEnd": 907,
      "labelStart": "44",
      "labelEnd": "44",
      "words": 60,
      "summary": {
        "text": "Caption for a figure on agreement between novel skin tests and IGRA in children without active tuberculosis, pooled at about 54% with wide uncertainty.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "ntb",
          "heading": false
        },
        {
          "term": "tbst",
          "heading": false
        },
        {
          "term": "dst5mm",
          "heading": false
        }
      ],
      "extract": "44 Tttt Figure 9 Agreement of TBST vs IGRA in children without active TB Pooled agreement when DST5mm was excluded: 54.02 [26.46; 79.31] TBST novel skin tests for TB infection QFT quantiferon DST Diaskintest CI confidence interval AI any induration size ntb non-TB US Under surveillance for TB PTB/TBI study sample includes individuals with pulmonary TB or latent TB infection",
      "extractCut": false,
      "blocks": [
        "library/10665-381036/blocks/prose-page-907",
        "library/10665-381036/blocks/figure-img-p907-1"
      ]
    },
    {
      "id": "page-908",
      "number": null,
      "title": "Page 908",
      "level": 1,
      "pageStart": 908,
      "pageEnd": 908,
      "labelStart": "45",
      "labelEnd": "45",
      "words": 94,
      "summary": {
        "text": "Captions for figures on agreement between novel skin tests and TST in children without and with active tuberculosis, with abbreviation notes.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "tst tuberculin",
          "heading": false
        },
        {
          "term": "tuberculin skin",
          "heading": false
        },
        {
          "term": "figure agreement",
          "heading": false
        }
      ],
      "extract": "45 Figure 10 Agreement of TBST vs TST in children without active TB Pooled agreement when DST5mm was excluded 89.81 [83.30; 93.96] TsssUI under investigation for TB CI confidence interval nTB non-TB TST tuberculin skin test G general population UT active TB or under investigation for TB, results not reported separately DST Diaskintest NegC Negative control CL Close contacts Figure 11 Agreement of TBST vs TST in",
      "extractCut": true,
      "blocks": [
        "library/10665-381036/blocks/prose-page-908",
        "library/10665-381036/blocks/figure-img-p908-1",
        "library/10665-381036/blocks/figure-img-p908-2"
      ]
    },
    {
      "id": "page-909",
      "number": null,
      "title": "Page 909",
      "level": 1,
      "pageStart": 909,
      "pageEnd": 909,
      "labelStart": "46",
      "labelEnd": "46",
      "words": 9,
      "summary": {
        "text": "A near-empty page holding only two leftover abbreviations from a figure legend.",
        "status": "draft"
      },
      "keywords": [],
      "extract": "46 CCS culture or smear confirmed TB DST Diaskintest",
      "extractCut": false,
      "blocks": [
        "library/10665-381036/blocks/prose-page-909"
      ]
    },
    {
      "id": "page-910",
      "number": null,
      "title": "Page 910",
      "level": 1,
      "pageStart": 910,
      "pageEnd": 910,
      "labelStart": "47",
      "labelEnd": "47",
      "words": 54,
      "summary": {
        "text": "Captions for figures on agreement of novel skin tests with TST in children under five without active tuberculosis and with QuantiFERON in BCG-vaccinated people without active tuberculosis.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "dst diaskintest",
          "heading": false
        },
        {
          "term": "confidence interval",
          "heading": false
        },
        {
          "term": "figure agreement",
          "heading": false
        }
      ],
      "extract": "47 Figure 12 Agreement of TBST vs TST in children aged < 5 years without active TB CI confidence interval TST tuberculin skin test G general population CL Close contacts DST Diaskintest Figure 13 Agreement of TBST vs QFT in BCG-vaccinated individuals without active TB CI confidence interval QFT quantiferon ntb non-TB DST Diaskintest",
      "extractCut": false,
      "blocks": [
        "library/10665-381036/blocks/prose-page-910",
        "library/10665-381036/blocks/figure-img-p910-1",
        "library/10665-381036/blocks/figure-img-p910-2"
      ]
    },
    {
      "id": "page-911",
      "number": null,
      "title": "Page 911",
      "level": 1,
      "pageStart": 911,
      "pageEnd": 911,
      "labelStart": "48",
      "labelEnd": "48",
      "words": 52,
      "summary": {
        "text": "Captions for figures on agreement of novel skin tests with QuantiFERON and with TST in BCG-vaccinated people with and without active tuberculosis.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "ntb non-tb",
          "heading": false
        },
        {
          "term": "bcg-vaccinated individuals",
          "heading": false
        },
        {
          "term": "dst diaskintest",
          "heading": false
        }
      ],
      "extract": "48 Figure 14 Agreement of TBST vs QFT in BCG-vaccinated individuals with active TB CI confidence interval QFT quantiferon ntb non-TB DST Diaskintest Figure 15 Agreement of TBST vs TST in BCG-vaccinated individuals without active TB CI confidence interval TST tuberculin skin test ntb non-TB UI under investigation for TB DST Diaskintest",
      "extractCut": false,
      "blocks": [
        "library/10665-381036/blocks/prose-page-911",
        "library/10665-381036/blocks/figure-img-p911-1",
        "library/10665-381036/blocks/figure-img-p911-2"
      ]
    },
    {
      "id": "page-912",
      "number": null,
      "title": "Page 912",
      "level": 1,
      "pageStart": 912,
      "pageEnd": 912,
      "labelStart": "49",
      "labelEnd": "49",
      "words": 107,
      "summary": {
        "text": "Caption for a figure on the difference in specificity between novel skin tests and IGRA, explaining that overlapping cohorts from one study meant only the Diaskintest–QuantiFERON comparison was pooled here.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "dst",
          "heading": false
        },
        {
          "term": "qft",
          "heading": false
        },
        {
          "term": "tspot",
          "heading": false
        },
        {
          "term": "starshinova",
          "heading": false
        }
      ],
      "extract": "49 Figure 16 Difference in specificity -TBST vs IGRA (using data on DST vs QFT from Starshinova 2018) CI confidence interval QFT quantiferon DST Diaskintest Note: Starshinova 2018a and Starshinova 2018b presented data on DST 5mm vs QFT and DST 5mm and TSPOT.TB using the same cohort of participants. Because of the overlap in the cohort, both DST 5mm vs QFT and DST 5mm and TSPOT.TB cannot be pooled together. Hence,",
      "extractCut": true,
      "blocks": [
        "library/10665-381036/blocks/prose-page-912",
        "library/10665-381036/blocks/figure-img-p912-1"
      ]
    },
    {
      "id": "page-913",
      "number": null,
      "title": "Page 913",
      "level": 1,
      "pageStart": 913,
      "pageEnd": 913,
      "labelStart": "50",
      "labelEnd": "50",
      "words": 135,
      "summary": {
        "text": "Captions for figures on specificity differences between novel skin tests and IGRA, using the Diaskintest–T-SPOT.TB data, and between novel skin tests and TST, with a pooled difference of about 22 percentage points when Diaskintest at 5 mm is excluded.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "dst diaskintest",
          "heading": false
        },
        {
          "term": "tspot",
          "heading": false
        },
        {
          "term": "figure difference",
          "heading": false
        },
        {
          "term": "starshinova",
          "heading": false
        }
      ],
      "extract": "50 Figure 17 Difference in specificity - TBST vs IGRA (using data on DST vs TSPOT.TB from Starshinova 2018) CI confidence interval QFT quantiferon DST Diaskintest Note: Starshinova 2018a and Starshinova 2018b presented data on DST 5mm vs QFT and DST 5mm and TSPOT.TB using the same cohort of participants. Because of the overlap in the cohort, both DST 5mm vs QFT and DST 5mm and TSPOT.TB cannot be pooled together.",
      "extractCut": true,
      "blocks": [
        "library/10665-381036/blocks/prose-page-913",
        "library/10665-381036/blocks/figure-img-p913-1",
        "library/10665-381036/blocks/figure-img-p913-2"
      ]
    },
    {
      "id": "page-914",
      "number": null,
      "title": "Page 914",
      "level": 1,
      "pageStart": 914,
      "pageEnd": 914,
      "labelStart": "51",
      "labelEnd": "51",
      "words": 19,
      "summary": {
        "text": "A footnote explaining that an alternative specificity measure estimates the difference in the proportion testing negative in healthy populations.",
        "status": "draft"
      },
      "keywords": [],
      "extract": "51 *Alternate specificity measure. Estimates difference in proportion negative in healthy populations (see the method section for the definition).",
      "extractCut": false,
      "blocks": [
        "library/10665-381036/blocks/prose-page-914"
      ]
    },
    {
      "id": "page-915",
      "number": null,
      "title": "Page 915",
      "level": 1,
      "pageStart": 915,
      "pageEnd": 915,
      "labelStart": "52",
      "labelEnd": "52",
      "words": 85,
      "summary": {
        "text": "Captions for figures on specificity differences between novel skin tests and IGRA, and between novel skin tests and TST, in children, with a pooled difference versus TST of about 20 points.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "alternate specificity",
          "heading": false
        },
        {
          "term": "diaskintest alternate",
          "heading": false
        },
        {
          "term": "estimates difference",
          "heading": false
        }
      ],
      "extract": "52 Figure 19 Difference in specificity - TBST vs IGRA in children CI confidence interval QFT quantiferon DST Diaskintest *Alternate specificity measure. Estimates difference in proportion negative in healthy populations (see the method section for the definition). Figure 20 Difference in specificity - TBST vs TST in children Pooled difference when DST5mm was excluded: 20.17 [95%CI 4.93; 35.42] CI confidence interval",
      "extractCut": true,
      "blocks": [
        "library/10665-381036/blocks/prose-page-915",
        "library/10665-381036/blocks/figure-img-p915-1",
        "library/10665-381036/blocks/figure-img-p915-2"
      ]
    },
    {
      "id": "page-916",
      "number": null,
      "title": "Page 916",
      "level": 1,
      "pageStart": 916,
      "pageEnd": 916,
      "labelStart": "53",
      "labelEnd": "53",
      "words": 86,
      "summary": {
        "text": "Captions for figures on specificity differences between novel skin tests and IGRA or TST in BCG-vaccinated people, with explanatory footnotes.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "alternate specificity",
          "heading": false
        },
        {
          "term": "diaskintest alternate",
          "heading": false
        },
        {
          "term": "estimates difference",
          "heading": false
        }
      ],
      "extract": "53 Figure 21 Difference in specificity - TBST vs IGRA in BCG-vaccinated individuals CI confidence interval QFT quantiferon DST Diaskintest *Alternate specificity measure. Estimates difference in proportion negative in healthy populations (see the method section for the definition). Figure 22 Difference in specificity- TBST vs TST in BCG-vaccinated individuals Pooled difference when DST5mm was excluded: 20.17 [95%CI",
      "extractCut": true,
      "blocks": [
        "library/10665-381036/blocks/prose-page-916",
        "library/10665-381036/blocks/figure-img-p916-1",
        "library/10665-381036/blocks/figure-img-p916-2"
      ]
    },
    {
      "id": "page-917",
      "number": null,
      "title": "Page 917",
      "level": 1,
      "pageStart": 917,
      "pageEnd": 917,
      "labelStart": "54",
      "labelEnd": "54",
      "words": 87,
      "summary": {
        "text": "Captions for figures on specificity of novel skin tests in healthy adults, children and BCG-vaccinated people with negative IGRA results, with pooled estimates near 98–99%.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "qft quantiferon",
          "heading": false
        },
        {
          "term": "dst diaskintest",
          "heading": false
        },
        {
          "term": "dst5mm",
          "heading": false
        }
      ],
      "extract": "54 Figure 23 Specificity in healthy individuals with negative IGRA results Pooled estimated when DST5mm vs TSPOT.TB was used instead of DST5mm vs QFT: 98.46 [95%CI 94.36; 99.60] CI confidence interval TST tuberculin skin test DST Diaskintest Figure 24 Specificity in healthy children with negative IGRA results CI confidence interval QFT quantiferon DST Diaskintest Figure 25 Specificity in BCG-vaccinated individuals",
      "extractCut": true,
      "blocks": [
        "library/10665-381036/blocks/prose-page-917",
        "library/10665-381036/blocks/figure-img-p917-1",
        "library/10665-381036/blocks/figure-img-p917-2",
        "library/10665-381036/blocks/figure-img-p917-3"
      ]
    },
    {
      "id": "page-918",
      "number": null,
      "title": "Page 918",
      "level": 1,
      "pageStart": 918,
      "pageEnd": 918,
      "labelStart": "55",
      "labelEnd": "55",
      "words": 157,
      "summary": {
        "text": "The title page of Web Annex B21, a systematic review and meta-analysis on the safety of tuberculosis antigen-based skin tests, naming the review team and advisers and noting it was prepared for a WHO guideline meeting in February 2022.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "university college",
          "heading": false
        },
        {
          "term": "college london",
          "heading": false
        },
        {
          "term": "ting",
          "heading": false
        },
        {
          "term": "federation",
          "heading": false
        },
        {
          "term": "germany",
          "heading": false
        },
        {
          "term": "russian",
          "heading": false
        }
      ],
      "extract": "55 Web Annex B 21. Safety of Mycobacterium tuberculosis antigen- based skin tests: a systematic review and meta-analysis Review team: Yohhei Hamada1, Irina Kontsevaya2, Elena Surkova3, Ting Ting Wang1, Victoria Liu4, Liliya Eugenevna Ziganshina5,6, Molebogeng X Rangaka1,7 8. Institute for Global Health, University College London, UK 9. Research Center Borstel, Germany 10. Royal Brompton Hospital. Part of Guy's and",
      "extractCut": true,
      "blocks": [
        "library/10665-381036/blocks/prose-page-918"
      ]
    },
    {
      "id": "page-919",
      "number": null,
      "title": "Page 919",
      "level": 1,
      "pageStart": 919,
      "pageEnd": 919,
      "labelStart": "56",
      "labelEnd": "56",
      "words": 72,
      "summary": {
        "text": "The list of abbreviations used in the safety review of novel tuberculosis skin tests.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "confidence interval",
          "heading": false
        },
        {
          "term": "daids",
          "heading": false
        },
        {
          "term": "tbst",
          "heading": false
        },
        {
          "term": "isr",
          "heading": false
        }
      ],
      "extract": "56 Abbreviations AE adverse events BCG bacille Calmette-Guérin CI confidence interval CI confidence interval DAIDS division of AIDS DST diaskintest GDG guideline development group IGRA interferon gamma release assay ISR injection site reaction MTB mycobacterium tuberculosis PICO population, intervention, comparison, outcome PPD purified protein derivative QFT quantiferon RR risk ratio TB tuberculosis TBST novel",
      "extractCut": true,
      "blocks": [
        "library/10665-381036/blocks/prose-page-919"
      ]
    },
    {
      "id": "page-920",
      "number": null,
      "title": "Page 920",
      "level": 1,
      "pageStart": 920,
      "pageEnd": 920,
      "labelStart": "57",
      "labelEnd": "57",
      "words": 508,
      "summary": {
        "text": "The executive summary of the safety review explains that the tuberculin skin test is known to be safe but that newer antigen-based skin tests had not been systematically assessed. It describes searches of English, Russian and Chinese databases up to July 2021, plus manufacturer data and a WHO call for data. It notes that some studies were at high risk of bias owing to lack of blinding or passive collection of adverse events.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "adverse events",
          "heading": false
        },
        {
          "term": "site reactions",
          "heading": false
        },
        {
          "term": "five studies",
          "heading": false
        },
        {
          "term": "systemic adverse",
          "heading": false
        },
        {
          "term": "injection site",
          "heading": false
        },
        {
          "term": "seven studies",
          "heading": false
        },
        {
          "term": "studies reporting",
          "heading": false
        },
        {
          "term": "comparable data",
          "heading": false
        }
      ],
      "extract": "57 Executive summary Background The diagnostic tests in current use for identification of TB infection are the tuberculin skin test (TST) and interferon-gamma release assay (IGRA). The safety of TST, an in-vivo test, is well established and associated with only uncommon adverse reactions. Over the last decade, novel skin-based tests for TB infection using TB specific antigens (TBST) have been developed. Evidence on",
      "extractCut": true,
      "blocks": [
        "library/10665-381036/blocks/prose-page-920"
      ]
    },
    {
      "id": "page-921",
      "number": null,
      "title": "Page 921",
      "level": 1,
      "pageStart": 921,
      "pageEnd": 921,
      "labelStart": "58",
      "labelEnd": "58",
      "words": 423,
      "summary": {
        "text": "Summarises key findings: injection site reactions with C-Tb were no more common than with TST and were mostly mild or moderate, while one Chinese report found more reactions with C-TST. Diaskintest safety data were too inconsistent to pool, and overall no safety signal was seen that would affect the choice between the novel tests and TST. The background notes that about a quarter of the world's population has tuberculosis infection.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "site reactions",
          "heading": false
        },
        {
          "term": "systemic adverse",
          "heading": false
        },
        {
          "term": "injection site",
          "heading": false
        },
        {
          "term": "isr",
          "heading": false
        },
        {
          "term": "adverse events",
          "heading": false
        },
        {
          "term": "studies reported",
          "heading": false
        },
        {
          "term": "safety data",
          "heading": false
        },
        {
          "term": "tst",
          "heading": false
        }
      ],
      "extract": "58 The pooled risk of any injection site reaction (ISR) due to C-Tb (N= 2931, 5 studies) was not significantly different from TST (RR 1.05; 95%CI 0.70-1.58). Over 95% of ISR were reported as mild or moderate; common ISR included pain, itching and rash. In one study that allowed, 49/153 (37.6%) of participants given C-Tb developed any systemic adverse events (e.g. fever and headache) in comparison with 37.6% (56/149)",
      "extractCut": true,
      "blocks": [
        "library/10665-381036/blocks/prose-page-921"
      ]
    },
    {
      "id": "page-922",
      "number": null,
      "title": "Page 922",
      "level": 1,
      "pageStart": 922,
      "pageEnd": 922,
      "labelStart": "59",
      "labelEnd": "59",
      "words": 421,
      "summary": {
        "text": "Explains why better tests for tuberculosis infection are needed, describing the drawbacks of TST, such as false positives after BCG vaccination, low sensitivity in people with HIV and the need for two visits. It notes that the safety of the novel skin tests had not previously been reviewed and states the review's objective.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "skin test",
          "heading": false
        },
        {
          "term": "adverse events",
          "heading": false
        },
        {
          "term": "diagnostic tests",
          "heading": false
        },
        {
          "term": "dppd",
          "heading": false
        },
        {
          "term": "tst",
          "heading": false
        },
        {
          "term": "reactions",
          "heading": false
        },
        {
          "term": "krutikov",
          "heading": false
        },
        {
          "term": "c-tb",
          "heading": false
        }
      ],
      "extract": "59 such as people living with HIV and those who are known to be recently infected (i.e. household contacts of people with TB) are important targets for treatment of TB infection, also known as TB preventive treatment.4 Currently, available tests for LTBI are imperfect, as they cannot accurately distinguish between active TB disease and TB infection, nor are they useful predictors of progression to active disease.5",
      "extractCut": true,
      "blocks": [
        "library/10665-381036/blocks/prose-page-922"
      ]
    },
    {
      "id": "page-923",
      "number": null,
      "title": "Page 923",
      "level": 1,
      "pageStart": 923,
      "pageEnd": 923,
      "labelStart": "60",
      "labelEnd": "60",
      "words": 164,
      "summary": {
        "text": "Sets out the review's aim and PICO question on whether novel skin tests cause more adverse reactions than TST or IGRA, the outcomes sought, and inclusion criteria naming the index tests, such as C-Tb, Diaskintest and C-TST, and comparators.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "adverse reactions",
          "heading": false
        },
        {
          "term": "vitro igra",
          "heading": false
        },
        {
          "term": "comparator tests",
          "heading": false
        },
        {
          "term": "adverse events",
          "heading": false
        },
        {
          "term": "index tests",
          "heading": false
        },
        {
          "term": "tst",
          "heading": false
        }
      ],
      "extract": "60 currently available in vitro IGRA tests and TST to inform the development of WHO guidelines. Aims and Objectives Aim To evaluate the safety of novel TBST for detection of TB infection compared to currently available in vitro IGRA tests or TST. PICO Do TBST cause more adverse reactions compared to TST or IGRA? Outcomes: - Relative risks of both local and systemic reactions adverse reactions, where possible, graded",
      "extractCut": true,
      "blocks": [
        "library/10665-381036/blocks/prose-page-923"
      ]
    },
    {
      "id": "page-924",
      "number": null,
      "title": "Page 924",
      "level": 1,
      "pageStart": 924,
      "pageEnd": 924,
      "labelStart": "61",
      "labelEnd": "61",
      "words": 333,
      "summary": {
        "text": "Explains how adverse reactions were defined, noting that induration is the intended response and counting only exaggerated reactions as adverse where trials did so. Severity was graded with the DAIDS scale and serious events defined in standard terms, followed by exclusion criteria and the search strategy.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "adverse reactions",
          "heading": false
        },
        {
          "term": "adverse events",
          "heading": false
        },
        {
          "term": "language studies",
          "heading": false
        },
        {
          "term": "search strategy",
          "heading": false
        },
        {
          "term": "study authors",
          "heading": false
        },
        {
          "term": "chinese",
          "heading": false
        },
        {
          "term": "e-library",
          "heading": false
        },
        {
          "term": "skin tests",
          "heading": false
        }
      ],
      "extract": "61 Based on published literature, we expected the most frequent adverse reactions to be injection site reactions, although systemic reactions like headache, fever and even lymphadenitis have also been reported.11 12 Induration/swelling/inflammation are the intent of the skin tests and may not necessarily be “adverse” reactions in all instances, however some clinical trials consider these as adverse reactions if",
      "extractCut": true,
      "blocks": [
        "library/10665-381036/blocks/prose-page-924"
      ]
    },
    {
      "id": "page-925",
      "number": null,
      "title": "Page 925",
      "level": 1,
      "pageStart": 925,
      "pageEnd": 925,
      "labelStart": "62",
      "labelEnd": "62",
      "words": 406,
      "summary": {
        "text": "Describes how studies in English, Russian and Chinese were screened and data extracted by pairs of independent reviewers, with disagreements resolved by discussion. It explains how risk of bias was judged for randomised and non-randomised studies.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "independent reviewers",
          "heading": false
        },
        {
          "term": "full-text articles",
          "heading": false
        },
        {
          "term": "data extraction",
          "heading": false
        },
        {
          "term": "extracted data",
          "heading": false
        },
        {
          "term": "study screening",
          "heading": false
        },
        {
          "term": "relevant studies",
          "heading": false
        },
        {
          "term": "titles",
          "heading": false
        },
        {
          "term": "abstracts",
          "heading": false
        }
      ],
      "extract": "62 Study Screening and Data Collection Process: In support of data synthesis for the GDG, we developed a broad search strategy for English papers to allow title and abstract screening informing multiple systematic reviews addressing other objectives. The initial list of English titles and abstracts were reviewed by two independent reviewers (YH and LEZ) to identify studies reporting any new skin tests regardless of",
      "extractCut": true,
      "blocks": [
        "library/10665-381036/blocks/prose-page-925"
      ]
    },
    {
      "id": "page-926",
      "number": null,
      "title": "Page 926",
      "level": 1,
      "pageStart": 926,
      "pageEnd": 926,
      "labelStart": "63",
      "labelEnd": "63",
      "words": 315,
      "summary": {
        "text": "Describes the use of GRADE and the statistical methods, including random-effects meta-analysis of risk ratios and pooled proportions and combining trial and observational data where appropriate. It begins describing the included studies, which covered several recombinant antigen preparations.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "studies reported",
          "heading": false
        },
        {
          "term": "dichotomous",
          "heading": false
        },
        {
          "term": "estimator",
          "heading": false
        },
        {
          "term": "homogenous",
          "heading": false
        },
        {
          "term": "adjustment",
          "heading": false
        },
        {
          "term": "esat",
          "heading": false
        },
        {
          "term": "heterogeneity",
          "heading": false
        },
        {
          "term": "recombinant",
          "heading": false
        }
      ],
      "extract": "63 randomized participants into different doses of TBST, this was not considered randomized studies. We used the GRADE framework19 to systematically assess the quality of evidence regarding the use of novel skin tests. Data Analysis: The summary measures for dichotomous outcomes were relative risks for dichotomous data or proportions in the absence of a control group, with 95% confidence intervals. We conducted a",
      "extractCut": true,
      "blocks": [
        "library/10665-381036/blocks/prose-page-926"
      ]
    },
    {
      "id": "page-927",
      "number": null,
      "title": "Page 927",
      "level": 1,
      "pageStart": 927,
      "pageEnd": 927,
      "labelStart": "64",
      "labelEnd": "64",
      "words": 319,
      "summary": {
        "text": "Notes that no safety data were found for DPPD and that the report focuses on C-Tb, C-TST and Diaskintest. It describes the seven C-Tb studies, five of which were double-blind comparisons with TST at low risk of bias, though systemic events could not be attributed to one test when both were given.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "c-tb",
          "heading": false
        },
        {
          "term": "five studies",
          "heading": false
        },
        {
          "term": "systemic adverse",
          "heading": false
        },
        {
          "term": "isr",
          "heading": false
        },
        {
          "term": "participants received",
          "heading": false
        },
        {
          "term": "tst",
          "heading": false
        },
        {
          "term": "adverse events",
          "heading": false
        },
        {
          "term": "south africa",
          "heading": false
        }
      ],
      "extract": "64 in C-Tb.42 43 One study reported on ESAT-6 developed in-house.44 These studies are summarized in Tables 2 and 3. We did not find studies that reported safety data on DPPD. Hereafter, this report focuses on C-Tb, C-TST, and Diaskintest since the other tests or antigens are different from those translated into the final products or have not reached the late stage of the product development. Characteristics of",
      "extractCut": true,
      "blocks": [
        "library/10665-381036/blocks/prose-page-927"
      ]
    },
    {
      "id": "page-928",
      "number": null,
      "title": "Page 928",
      "level": 1,
      "pageStart": 928,
      "pageEnd": 928,
      "labelStart": "65",
      "labelEnd": "65",
      "words": 354,
      "summary": {
        "text": "Describes the C-TST studies, all in HIV-negative adults in China, which were non-blinded and at serious risk of bias for outcome measurement. It notes that most Diaskintest studies collected adverse events passively and poorly defined them, placing them at high risk of bias.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "systemic adverse",
          "heading": false
        },
        {
          "term": "isr",
          "heading": false
        },
        {
          "term": "adverse events",
          "heading": false
        },
        {
          "term": "participants received",
          "heading": false
        },
        {
          "term": "c-tst",
          "heading": false
        },
        {
          "term": "received both",
          "heading": false
        },
        {
          "term": "serious risk",
          "heading": false
        },
        {
          "term": "diaskintest",
          "heading": false
        }
      ],
      "extract": "65 Out of the five studies that evaluated C-TST, participants received both C-TST and TST in three studies (Table 2).25 27 Tests were administered to either of the arms; allocation was non-blinded and the choice was determined a priori without randomization. In one of the remaining two studies, a sub-set of the participants received C-TST in one arm and placebo in the other arm26 and, in the other study,25",
      "extractCut": true,
      "blocks": [
        "library/10665-381036/blocks/prose-page-928"
      ]
    },
    {
      "id": "page-929",
      "number": null,
      "title": "Page 929",
      "level": 1,
      "pageStart": 929,
      "pageEnd": 929,
      "labelStart": "66",
      "labelEnd": "66",
      "words": 346,
      "summary": {
        "text": "Reports that injection site reactions with C-Tb occurred in about a quarter to half of recipients, mostly mild or moderate, with no significant pooled difference from TST despite high heterogeneity. It notes more frequent haematoma at the C-Tb site in European studies and gives limited C-TST comparison data.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "c-tb injection",
          "heading": false
        },
        {
          "term": "isr",
          "heading": false
        },
        {
          "term": "injection site",
          "heading": false
        },
        {
          "term": "local reactions",
          "heading": false
        },
        {
          "term": "mild",
          "heading": false
        },
        {
          "term": "pruritus",
          "heading": false
        },
        {
          "term": "tst",
          "heading": false
        },
        {
          "term": "itching",
          "heading": false
        }
      ],
      "extract": "66 Injection site reactions For C-Tb, the frequency of any ISR reactions ranged from 23.7% to 53.1% (Table 4). Most (>95%) ISR were reported as mild to moderate by the investigators (mild: easily tolerated; moderate: sufficient to interfere with daily activities; severe: sufficient to prevent normal activity). Common ISR included itching, pain, and rash. One study reported only mild reactions and in four studies,",
      "extractCut": true,
      "blocks": [
        "library/10665-381036/blocks/prose-page-929"
      ]
    },
    {
      "id": "page-930",
      "number": null,
      "title": "Page 930",
      "level": 1,
      "pageStart": 930,
      "pageEnd": 930,
      "labelStart": "67",
      "labelEnd": "67",
      "words": 380,
      "summary": {
        "text": "Reports that Diaskintest safety data were poorly standardised, with two small studies noting more hyperallergic reactions with Diaskintest than TST in people with tuberculosis and in health workers. It begins reporting systemic adverse events in C-Tb studies, where only a small share were linked to the skin tests.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "systemic adverse",
          "heading": false
        },
        {
          "term": "hyperallergic reactions",
          "heading": false
        },
        {
          "term": "adverse events",
          "heading": false
        },
        {
          "term": "diaskintest injection",
          "heading": false
        },
        {
          "term": "both c-tb",
          "heading": false
        },
        {
          "term": "injection site",
          "heading": false
        },
        {
          "term": "studies reported",
          "heading": false
        },
        {
          "term": "tst",
          "heading": false
        }
      ],
      "extract": "67 Safety data on the Diaskintest were poorly reported lacking standardization of types of adverse events and assessment of severity based on a priori criteria thus precluding pooling of data (Table 6). Two studies reported the frequency of ISR in participants given Diaskintest and TST at the same time in different arms; one included adults with active TB (n=53) and the other TB care health workers (n=25).34 In the",
      "extractCut": true,
      "blocks": [
        "library/10665-381036/blocks/prose-page-930"
      ]
    },
    {
      "id": "page-931",
      "number": null,
      "title": "Page 931",
      "level": 1,
      "pageStart": 931,
      "pageEnd": 931,
      "labelStart": "68",
      "labelEnd": "68",
      "words": 326,
      "summary": {
        "text": "Gives systemic adverse event data for C-Tb, C-TST and Diaskintest, including a pooled fever frequency of about 2.6% for Diaskintest. It reports no test-related serious adverse events among nearly 3000 C-Tb recipients and describes findings in people with HIV.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "systemic adverse",
          "heading": false
        },
        {
          "term": "adverse events",
          "heading": false
        },
        {
          "term": "serious adverse",
          "heading": false
        },
        {
          "term": "received diaskintest",
          "heading": false
        },
        {
          "term": "hiv participants",
          "heading": false
        },
        {
          "term": "event related",
          "heading": false
        },
        {
          "term": "c-tb",
          "heading": false
        },
        {
          "term": "four studies",
          "heading": false
        }
      ],
      "extract": "68 related to either agent separately, they were ascribed to C-Tb.” In two studies, the frequency of systemic adverse events deemed at least possibly related to C-Tb among participants were 5% (7/151)21 and 14% (36/253).24 Four studies on C-TST reported data on systemic adverse events (Table 8). In two studies, participants received both C-TST and TST.26 27 In the phase 2a study (n=144),25 nine systemic adverse",
      "extractCut": true,
      "blocks": [
        "library/10665-381036/blocks/prose-page-931"
      ]
    },
    {
      "id": "page-932",
      "number": null,
      "title": "Page 932",
      "level": 1,
      "pageStart": 932,
      "pageEnd": 932,
      "labelStart": "69",
      "labelEnd": "69",
      "words": 406,
      "summary": {
        "text": "Notes that adverse events in children given Diaskintest were not systematically recorded and that one Russian study in pregnant women with tuberculosis reported no embryo toxicity. It rates evidence as high quality for injection site reactions and concludes that no safety signal affects the choice between the novel tests and TST.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "systemic reactions",
          "heading": false
        },
        {
          "term": "systemic adverse",
          "heading": false
        },
        {
          "term": "pregnant women",
          "heading": false
        },
        {
          "term": "adverse events",
          "heading": false
        },
        {
          "term": "site reactions",
          "heading": false
        },
        {
          "term": "injection site",
          "heading": false
        },
        {
          "term": "diaskintest",
          "heading": false
        },
        {
          "term": "tbst",
          "heading": false
        }
      ],
      "extract": "69 Children Five studies reported adverse events in children who received Diaskintest.28-30 36 37 As mentioned above, adverse events were not systematically ascertained (Table 6). Pregnant women Only one study included pregnant women.31 The study by Borisova et al used Diaskintest in 267 pregnant women with TB.31 In 124 patients (46.4%) Diaskintest was performed in the first half of pregnancy (but after 12 weeks),",
      "extractCut": true,
      "blocks": [
        "library/10665-381036/blocks/prose-page-932"
      ]
    },
    {
      "id": "page-933",
      "number": null,
      "title": "Page 933",
      "level": 1,
      "pageStart": 933,
      "pageEnd": 933,
      "labelStart": "70",
      "labelEnd": "70",
      "words": 412,
      "summary": {
        "text": "The start of the reference list for the safety review, citing global burden estimates, WHO preventive treatment guidance and studies on IGRAs.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "tuberculin skin",
          "heading": false
        },
        {
          "term": "c-tb skin",
          "heading": false
        },
        {
          "term": "mycobacterium tuberculosis",
          "heading": false
        },
        {
          "term": "tuberculosis infection",
          "heading": false
        },
        {
          "term": "published online",
          "heading": false
        },
        {
          "term": "skin test",
          "heading": false
        },
        {
          "term": "release assays",
          "heading": false
        },
        {
          "term": "infectious diseases",
          "heading": false
        }
      ],
      "extract": "70 References 1. Hay SI, Abajobir AA, Abate KH, et al. Global, regional, and national disability-adjusted life-years (DALYs) for 333 diseases and injuries and healthy life expectancy (HALE) for 195 countries and territories, 1990&#x2013;2016: a systematic analysis for the Global Burden of Disease Study 2016. The Lancet 2017;390(10100):1260-344. doi: 10.1016/S0140-6736(17)32130-X 2. Houben RMGJ, Dodd PJ. The Global",
      "extractCut": true,
      "blocks": [
        "library/10665-381036/blocks/prose-page-933"
      ]
    },
    {
      "id": "page-934",
      "number": null,
      "title": "Page 934",
      "level": 1,
      "pageStart": 934,
      "pageEnd": 934,
      "labelStart": "71",
      "labelEnd": "71",
      "words": 424,
      "summary": {
        "text": "Continues the safety review reference list with methods sources such as DAIDS grading, risk-of-bias tools and GRADE, and trials of C-Tb and the ESAT6-CFP10 skin test.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "test reagent",
          "heading": false
        },
        {
          "term": "recombinant fusion",
          "heading": false
        },
        {
          "term": "randomised controlled",
          "heading": false
        },
        {
          "term": "skin test",
          "heading": false
        },
        {
          "term": "clinical trial",
          "heading": false
        },
        {
          "term": "tuberculosis infection",
          "heading": false
        },
        {
          "term": "tuberculosis diagnosis",
          "heading": false
        },
        {
          "term": "esat6-cfp",
          "heading": false
        }
      ],
      "extract": "71 https://rsc.niaid.nih.gov/sites/default/files/daidsgradingcorrectedv21.pdf Accessed 11 September 2020. 14. Europen Medial Agency. Serious adverse reaction. https://www.ema.europa.eu/en/glossary/serious-adverse-reaction accessed 3 December 2021. 15. Ouzzani M, Hammady H, Fedorowicz Z, et al. Rayyan—a web and mobile app for systematic reviews. Systematic Reviews 2016;5(1):210. doi: 10.1186/s13643-016-0384-4 16.",
      "extractCut": true,
      "blocks": [
        "library/10665-381036/blocks/prose-page-934"
      ]
    },
    {
      "id": "page-935",
      "number": null,
      "title": "Page 935",
      "level": 1,
      "pageStart": 935,
      "pageEnd": 935,
      "labelStart": "72",
      "labelEnd": "72",
      "words": 390,
      "summary": {
        "text": "Continues the reference list with Russian and Ukrainian studies of Diaskintest, including in children, pregnant women and people with HIV, and Chinese studies of ESAT-6.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "tuberculosis recombinant",
          "heading": false
        },
        {
          "term": "allergen tuberculosis",
          "heading": false
        },
        {
          "term": "mycobacterium tuberculosis",
          "heading": false
        },
        {
          "term": "skin test",
          "heading": false
        },
        {
          "term": "adverse reactions",
          "heading": false
        },
        {
          "term": "russian",
          "heading": false
        },
        {
          "term": "litvinov",
          "heading": false
        },
        {
          "term": "diaskintest",
          "heading": false
        }
      ],
      "extract": "72 28. Aksenova VA, Klevno NI, Baryshnikova LA, et al. Diaskintest for tuberculosis in children and adolescents. [Russian]. Problemy tuberkuleza i boleznei legkikh 2009(10):13-16. 29. Belushkov V.V. LME, Novik G.A., Gurina O.P., Shibakova N.D. IMPORTANCE OF DIASKINTEST AND QUANTIFERON TEST IN THE DIAGNOSTICS OF TUBERCULOSIS IN CHILDREN (in Russian) FUNDAMENTAL RESEARCH 2012;7:34-39. 30. Bаrminа N, Bаryshnikovа L.",
      "extractCut": true,
      "blocks": [
        "library/10665-381036/blocks/prose-page-935"
      ]
    },
    {
      "id": "page-936",
      "number": null,
      "title": "Page 936",
      "level": 1,
      "pageStart": 936,
      "pageEnd": 936,
      "labelStart": "73",
      "labelEnd": "73",
      "words": 126,
      "summary": {
        "text": "Ends the reference list with early trials of recombinant ESAT-6 skin test reagents.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "mycobacterium tuberculosis",
          "heading": false
        },
        {
          "term": "test reagent",
          "heading": false
        },
        {
          "term": "tuberculosis infection",
          "heading": false
        },
        {
          "term": "skin test",
          "heading": false
        }
      ],
      "extract": "73 41. Sun QF, Xu M, Wu JG, et al. Efficacy and safety of recombinant Mycobacterium tuberculosis ESAT-6 protein for diagnosis of pulmonary tuberculosis: a phase II trial. Medical Science Monitor 2013;19:969-77. 42. Arend SM, Franken WP, Aggerbeck H, et al. Double-blind randomized Phase I study comparing rdESAT-6 to tuberculin as skin test reagent in the diagnosis of tuberculosis infection. Tuberculosis",
      "extractCut": true,
      "blocks": [
        "library/10665-381036/blocks/prose-page-936"
      ]
    },
    {
      "id": "page-937",
      "number": null,
      "title": "Page 937",
      "level": 1,
      "pageStart": 937,
      "pageEnd": 937,
      "labelStart": "74",
      "labelEnd": "74",
      "words": 54,
      "summary": {
        "text": "Table 1 lists the variables extracted, covering study design, population characteristics, index and comparator tests, and the type, severity and seriousness of adverse events.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "study design",
          "heading": false
        },
        {
          "term": "seriousness",
          "heading": false
        },
        {
          "term": "variables",
          "heading": false
        }
      ],
      "extract": "74 Table 1: Variables of interest Category Variables Study design Study design, country, setting, period of recruitment, sample size Population summary measures Age, gender, history of immunosuppression, HIV status, pregnancy and lactating status, co-morbidities Index test Recombinant antigen skin test used Comparator Types of tests used Outcome Type, severity, and seriousness of adverse events.",
      "extractCut": false,
      "blocks": [
        "library/10665-381036/blocks/prose-page-937"
      ]
    },
    {
      "id": "page-938",
      "number": null,
      "title": "Page 938",
      "level": 1,
      "pageStart": 938,
      "pageEnd": 938,
      "labelStart": "75",
      "labelEnd": "75",
      "words": 336,
      "summary": {
        "text": "Table 2 summarises the C-Tb, C-TST and other recombinant antigen studies, giving design, control, country, population, age and proportion female.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "open-label split",
          "heading": false
        },
        {
          "term": "split body",
          "heading": false
        },
        {
          "term": "double-blind split",
          "heading": false
        },
        {
          "term": "body rct",
          "heading": false
        },
        {
          "term": "body trial",
          "heading": false
        },
        {
          "term": "healthy adults",
          "heading": false
        },
        {
          "term": "healthy volunteers",
          "heading": false
        }
      ],
      "extract": "Table 2. Summary of C-Tb, C-TST, and other studies. Test Study design Control Country Study population Age %Female C-Tb Dose-finding trial No control UK Adults with TB Mean: 33 n/d C-Tb Double-blind split body RCT TST UK BCG vaccinated healthy adults Mean: 34 60.9% C-Tb Double-blind split body RCT TST South Africa Individuals suspected of TB, active TB, contact and children. Children < 5rs (20%) Children 5-17 yrs",
      "extractCut": true,
      "blocks": [
        "library/10665-381036/blocks/prose-page-938"
      ]
    },
    {
      "id": "page-939",
      "number": null,
      "title": "Page 939",
      "level": 1,
      "pageStart": 939,
      "pageEnd": 939,
      "labelStart": "76",
      "labelEnd": "76",
      "words": 198,
      "summary": {
        "text": "Table 3 summarises the Diaskintest safety studies, mostly cross-sectional studies from Russia in children, adults with tuberculosis or HIV, pregnant women and health workers.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "russia",
          "heading": false
        },
        {
          "term": "cross-sectional",
          "heading": false
        },
        {
          "term": "dst group",
          "heading": false
        },
        {
          "term": "adverse events",
          "heading": false
        },
        {
          "term": "slogotskaya",
          "heading": false
        },
        {
          "term": "case series",
          "heading": false
        },
        {
          "term": "mean",
          "heading": false
        }
      ],
      "extract": "Table 3. Summary of Diaskintest studies Study design Control Country Study population Age Aksenova, 2009 Cross-sectional n/d** Russia Children and adolescents with TB 2-17 Slogotskaya, 2011a Cross-sectional n/d** Russia TB/HIV coinfected adults mean: 32 Slogotskaya 2011b Cross-sectional n/d** Russia People with TB including people living with HIV n/d Streltsova, 2011 Cross-sectional TST Russia Adults with TB mean:",
      "extractCut": true,
      "blocks": [
        "library/10665-381036/blocks/prose-page-939"
      ]
    },
    {
      "id": "page-940",
      "number": null,
      "title": "Page 940",
      "level": 1,
      "pageStart": 940,
      "pageEnd": 940,
      "labelStart": "77",
      "labelEnd": "77",
      "words": 333,
      "summary": {
        "text": "Table 4 gives the frequency of injection site reactions such as itching, pain, rash and swelling in C-Tb and TST arms of each study, plus aggregated C-TST data with an unclear denominator.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "c-tb",
          "heading": false
        },
        {
          "term": "injection site",
          "heading": false
        },
        {
          "term": "site reactions",
          "heading": false
        },
        {
          "term": "aggerbeck",
          "heading": false
        }
      ],
      "extract": "Table 4. The frequencies of local injection site reactions in studies on C-Tb Study Test N Any ISR Itching Pain Rash Erythema Swelling Vesicle induration Aggerbeck, 2013a C-Tb 26 - 16 (61.5%) 6 (23.1%) 1 (3.8%) - 1 (3.8%) - - TST - - - - - - - - - Aggerbeck, 2013b C-Tb 151 48 (31.8%) - - - - - - - TST 151 31 (20.5%) - - - - - - - Aggerbeck, 2018 C-Tb 1188 282 (23.7%) 210 (17.7%) 90 (7.6%) 58 (4.9%) 3 (0.3%) 5 (0.4%)",
      "extractCut": true,
      "blocks": [
        "library/10665-381036/blocks/prose-page-940"
      ]
    },
    {
      "id": "page-941",
      "number": null,
      "title": "Page 941",
      "level": 1,
      "pageStart": 941,
      "pageEnd": 941,
      "labelStart": "78",
      "labelEnd": "78",
      "words": 5,
      "summary": {
        "text": "A blank page with no text.",
        "status": "draft"
      },
      "keywords": [],
      "extract": "_(no text on this page)_",
      "extractCut": false,
      "blocks": [
        "library/10665-381036/blocks/prose-page-941"
      ]
    },
    {
      "id": "page-942",
      "number": null,
      "title": "Page 942",
      "level": 1,
      "pageStart": 942,
      "pageEnd": 942,
      "labelStart": "79",
      "labelEnd": "79",
      "words": 273,
      "summary": {
        "text": "Table 6 lists adverse events reported in studies of Diaskintest in children, adults, pregnant women and people with TB or HIV, and Table 7 begins listing fever, headache and dizziness in participants given C-Tb or the tuberculin skin test. Most reactions shown are described as mild to moderate.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "allergic reacti",
          "heading": false
        },
        {
          "term": "hyper allergic",
          "heading": false
        },
        {
          "term": "adverse events",
          "heading": false
        },
        {
          "term": "tst site",
          "heading": false
        },
        {
          "term": "dst site",
          "heading": false
        },
        {
          "term": "hyperallergic",
          "heading": false
        },
        {
          "term": "lymphangitis",
          "heading": false
        }
      ],
      "extract": "Table 6. Frequencies of adverse events in studies on Diaskintest Study Population Diaskintest vs TST Fever Others Aksenova, 2009# Children and adolescents with TB NA 2/63 (3.2%) Barmina, 2018# Child and adolescent household contact NA NA Any adverse events: Belushkov, 2012 Children suspected of TB NA 4/88 (4.5%) Hyper allergic reacti Borisova, 2017 Pregnant women with TB NA NA Any adverse events: Dotsenko 2015 TB",
      "extractCut": true,
      "blocks": [
        "library/10665-381036/blocks/prose-page-942"
      ]
    },
    {
      "id": "page-943",
      "number": null,
      "title": "Page 943",
      "level": 1,
      "pageStart": 943,
      "pageEnd": 943,
      "labelStart": "80",
      "labelEnd": "80",
      "words": 14,
      "summary": {
        "text": "The end of Table 7, giving the share of mild systemic reactions by HIV status in one study and figures from Ruhwald 2017.",
        "status": "draft"
      },
      "keywords": [],
      "extract": "HIV- and 76.6% in HIV+ group Ruhwald, 2017 NA 137/979 (14%) NA Mild-moderate: 100%",
      "extractCut": false,
      "blocks": [
        "library/10665-381036/blocks/prose-page-943"
      ]
    },
    {
      "id": "page-944",
      "number": null,
      "title": "Page 944",
      "level": 1,
      "pageStart": 944,
      "pageEnd": 944,
      "labelStart": "81",
      "labelEnd": "81",
      "words": 68,
      "summary": {
        "text": "Table 8 lists systemic adverse events reported in studies of the C-TST skin test, such as fever, raised blood pressure and phlebitis.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "systemic reactions",
          "heading": false
        },
        {
          "term": "adverse events",
          "heading": false
        },
        {
          "term": "vasculitis",
          "heading": false
        }
      ],
      "extract": "Table 8. Systemic adverse events in studies on C-TST Study Systemic reactions Li 2016a No systemic reactions in 6 participants Li 2016b 9 adverse events in 144 patients. Abnormal percentage of eosinophil (n=1); Increased blood pressure (n=2); fever (n=1); phlebitis (n=2); vasculitis (n=3) Xu 2021* Fever (7.1%); nausea (0.3%); headache (0.7%); allergy (0.2%); muscle pain (0.8%) *This paper reported two control trials",
      "extractCut": true,
      "blocks": [
        "library/10665-381036/blocks/prose-page-944"
      ]
    },
    {
      "id": "page-945",
      "number": null,
      "title": "Page 945",
      "level": 1,
      "pageStart": 945,
      "pageEnd": 945,
      "labelStart": "82",
      "labelEnd": "82",
      "words": 204,
      "summary": {
        "text": "Table 9, a GRADE evidence profile asking whether TB antigen-based skin tests cause more adverse reactions than tuberculin skin tests, finding similar rates of injection site reactions (high certainty) and systemic reactions (moderate certainty).",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "reactions randomise",
          "heading": false
        },
        {
          "term": "randomise trials",
          "heading": false
        },
        {
          "term": "seriou",
          "heading": false
        },
        {
          "term": "aggerbeck",
          "heading": false
        },
        {
          "term": "nrs",
          "heading": false
        }
      ],
      "extract": "Table 9 Question: Do TBST cause more adverse reactions compared to tuberculin skin tests? Setting: Global Bibliography: Aggerbeck 2013; Aggerbeck 2018; Aggerbeck 2019; Hoff 2016, Ruhwald 2017; Streltsova 2011 Certainty assessment № of patients Effect Certainty Importanc e № of studie s Study design Risk of bias Inconsistenc y Indirectnes s Imprecisio n Other consideration s TBST tuberculi n skin tests Relativ e (95%",
      "extractCut": true,
      "blocks": [
        "library/10665-381036/blocks/prose-page-945"
      ]
    },
    {
      "id": "page-946",
      "number": null,
      "title": "Page 946",
      "level": 1,
      "pageStart": 946,
      "pageEnd": 946,
      "labelStart": "83",
      "labelEnd": "83",
      "words": 5,
      "summary": {
        "text": "A heading page for the figures, introducing Figure 1 on study selection.",
        "status": "draft"
      },
      "keywords": [],
      "extract": "Figures Figure 1. Study selection",
      "extractCut": false,
      "blocks": [
        "library/10665-381036/blocks/prose-page-946",
        "library/10665-381036/blocks/figure-img-p946-1"
      ]
    },
    {
      "id": "page-947",
      "number": null,
      "title": "Page 947",
      "level": 1,
      "pageStart": 947,
      "pageEnd": 947,
      "labelStart": "84",
      "labelEnd": "84",
      "words": 66,
      "summary": {
        "text": "Figure 2 shows injection site reactions in skin test studies, with notes on the share of participants living with HIV, children and people with TB in each study.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "years old",
          "heading": false
        },
        {
          "term": "aggerbeck",
          "heading": false
        },
        {
          "term": "children years",
          "heading": false
        }
      ],
      "extract": "Figure 2. Any injection site reactions Proportion of HIV+: Aggerbeck 2018 (25%), Aggerbeck 2019 (20%); Hoff 2016 (39.5%). Other studies included HIV-negative individuals. Aggerbeck 2018 included children < 5 years old (20%) and 5-17 years old (31%); Ruhwald included children < 5 years old (3.5%) and 5-17 years old (8.8%); Other studies included adults. Hoff 2016, Aggerbeck 2019, and Streltsova, 2011 included people",
      "extractCut": true,
      "blocks": [
        "library/10665-381036/blocks/prose-page-947",
        "library/10665-381036/blocks/figure-img-p947-1"
      ]
    },
    {
      "id": "page-948",
      "number": null,
      "title": "Page 948",
      "level": 1,
      "pageStart": 948,
      "pageEnd": 948,
      "labelStart": "85",
      "labelEnd": "85",
      "words": 62,
      "summary": {
        "text": "Figure 3 shows itching or pruritus after skin testing, with notes on the HIV, age and TB status of study populations.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "years old",
          "heading": false
        },
        {
          "term": "aggerbeck",
          "heading": false
        },
        {
          "term": "children years",
          "heading": false
        }
      ],
      "extract": "Figure 3. Itching/ Pruritus Proportion of HIV+: Aggerbeck 2018 (25%), Aggerbeck 2019 (20%); Hoff 2016 (39.5%). Other studies included HIV-negative individuals. Aggerbeck 2018 included children < 5 years old (20%) and 5-17 years old (31%); Ruhwald included children < 5 years old (3.5%) and 5-17 years old (8.8%); Other studies included adults. Hoff 2016 and Aggerbeck 2019 included people with TB only.",
      "extractCut": false,
      "blocks": [
        "library/10665-381036/blocks/prose-page-948",
        "library/10665-381036/blocks/figure-img-p948-1",
        "library/10665-381036/blocks/figure-img-p948-2"
      ]
    },
    {
      "id": "page-949",
      "number": null,
      "title": "Page 949",
      "level": 1,
      "pageStart": 949,
      "pageEnd": 949,
      "labelStart": "86",
      "labelEnd": "86",
      "words": 66,
      "summary": {
        "text": "Figure 4 shows pain at the injection site, with notes on study populations, and introduces Figure 5 on rash.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "years old",
          "heading": false
        },
        {
          "term": "aggerbeck",
          "heading": false
        },
        {
          "term": "children years",
          "heading": false
        }
      ],
      "extract": "Figure 4. Pain Proportion of HIV+: Aggerbeck 2018 (25%), Aggerbeck 2019 (20%); Hoff 2016 (39.5%). Other studies included HIV-negative individuals. Aggerbeck 2018 included children < 5 years old (20%) and 5-17 years old (31%); Ruhwald included children < 5 years old (3.5%) and 5-17 years old (8.8%); Other studies included adults. Hoff 2016, Aggerbeck 2019, and Streltsova, 2011 included people with TB only. Figure 5.",
      "extractCut": true,
      "blocks": [
        "library/10665-381036/blocks/prose-page-949",
        "library/10665-381036/blocks/figure-img-p949-1"
      ]
    },
    {
      "id": "page-950",
      "number": null,
      "title": "Page 950",
      "level": 1,
      "pageStart": 950,
      "pageEnd": 950,
      "labelStart": "87",
      "labelEnd": "87",
      "words": 123,
      "summary": {
        "text": "Notes on the study populations accompanying the skin test adverse event figures on rash and the following figure, giving shares of participants with HIV, children and people with TB.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "years old",
          "heading": false
        },
        {
          "term": "aggerbeck",
          "heading": false
        },
        {
          "term": "children years",
          "heading": false
        },
        {
          "term": "hoff",
          "heading": false
        }
      ],
      "extract": "Proportion of HIV+: Aggerbeck 2018 (25%), Aggerbeck 2019 (20%); Hoff 2016 (39.5%). Other studies included HIV-negative individuals. Aggerbeck 2018 included children < 5 years old (20%) and 5-17 years old (31%); Ruhwald included children < 5 years old (3.5%) and 5-17 years old (8.8%); Other studies included adults. Hoff 2016, Aggerbeck 2019, and Streltsova, 2011 included people with TB only. Figure 6. Erythema",
      "extractCut": true,
      "blocks": [
        "library/10665-381036/blocks/prose-page-950",
        "library/10665-381036/blocks/figure-img-p950-1"
      ]
    },
    {
      "id": "page-951",
      "number": null,
      "title": "Page 951",
      "level": 1,
      "pageStart": 951,
      "pageEnd": 951,
      "labelStart": "88",
      "labelEnd": "88",
      "words": 72,
      "summary": {
        "text": "Figure 7 shows swelling or oedema after skin testing, with notes on the HIV, age and TB status of study populations.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "years old",
          "heading": false
        },
        {
          "term": "aggerbeck",
          "heading": false
        },
        {
          "term": "hoff",
          "heading": false
        }
      ],
      "extract": "Figure 7. Swelling/Oedema Proportion of HIV+: Aggerbeck 2018 (25%); Hoff 2016 (39.5%). Other studies included HIV-negative individuals. Aggerbeck 2018 included children < 5 years old (20%) and 5-17 years old (31%); Ruhwald included children < 5 years old (3.5%) and 5-17 years old (8.8%); Other studies included adults. Hoff 2016 included people with TB only. Proportion of HIV+: Aggerbeck 2018 (25%), Aggerbeck 2019",
      "extractCut": true,
      "blocks": [
        "library/10665-381036/blocks/prose-page-951",
        "library/10665-381036/blocks/figure-img-p951-1",
        "library/10665-381036/blocks/figure-img-p951-2"
      ]
    },
    {
      "id": "page-952",
      "number": null,
      "title": "Page 952",
      "level": 1,
      "pageStart": 952,
      "pageEnd": 952,
      "labelStart": "89",
      "labelEnd": "89",
      "words": 102,
      "summary": {
        "text": "Population notes for Figures 8 and 9 on vesicles and induration after skin testing.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "years old",
          "heading": false
        },
        {
          "term": "aggerbeck",
          "heading": false
        },
        {
          "term": "children years",
          "heading": false
        }
      ],
      "extract": "Aggerbeck 2018 included children < 5 years old (20%) and 5-17 years old (31%); Ruhwald included children < 5 years old (3.5%) and 5-17 years old (8.8%); Other studies included adults. Aggerbeck 2019 and Hoff 2016 included people with TB only. Figure 8. Vesicle Figure 9. Induration Proportion of HIV+: Aggerbeck 2018 (25%), Aggerbeck 2019 (20%); Hoff 2016 (39.5%). Other studies included HIV-negative individuals.",
      "extractCut": true,
      "blocks": [
        "library/10665-381036/blocks/prose-page-952",
        "library/10665-381036/blocks/figure-img-p952-1"
      ]
    },
    {
      "id": "page-953",
      "number": null,
      "title": "Page 953",
      "level": 1,
      "pageStart": 953,
      "pageEnd": 953,
      "labelStart": "90",
      "labelEnd": "90",
      "words": 13,
      "summary": {
        "text": "The caption of Figure 10, pooled estimates of the risk of any and individual injection site reactions.",
        "status": "draft"
      },
      "keywords": [],
      "extract": "Figure 10. Pooled estimates of the risk for any ISR and individual ISR.",
      "extractCut": false,
      "blocks": [
        "library/10665-381036/blocks/prose-page-953",
        "library/10665-381036/blocks/figure-img-p953-1",
        "library/10665-381036/blocks/figure-img-p953-2"
      ]
    },
    {
      "id": "page-954",
      "number": null,
      "title": "Page 954",
      "level": 1,
      "pageStart": 954,
      "pageEnd": 954,
      "labelStart": "91",
      "labelEnd": "91",
      "words": 88,
      "summary": {
        "text": "Figures 11 and 12 show frequencies of any systemic adverse events and of fever in skin test studies, with population notes.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "years old",
          "heading": false
        },
        {
          "term": "aggerbeck",
          "heading": false
        },
        {
          "term": "hoff",
          "heading": false
        }
      ],
      "extract": "Figure 11. Frequencies of any systemic adverse events Proportion of HIV+: Aggerbeck 2018 (25%), Aggerbeck 2019 (20%); Hoff 2016 (39.5%). Other studies included HIV-negative individuals. Aggerbeck 2018 included children < 5 years old (20%) and 5-17 years old (31%); Ruhwald included children < 5 years old (3.5%) and 5-17 years old (8.8%); Other studies included adults. Aggerbeck 2019 and Hoff 2016 included people with",
      "extractCut": true,
      "blocks": [
        "library/10665-381036/blocks/prose-page-954",
        "library/10665-381036/blocks/figure-img-p954-1"
      ]
    },
    {
      "id": "page-955",
      "number": null,
      "title": "Page 955",
      "level": 1,
      "pageStart": 955,
      "pageEnd": 955,
      "labelStart": "92",
      "labelEnd": "92",
      "words": 115,
      "summary": {
        "text": "Population notes for the systemic adverse event figures, including studies limited to children or people with active TB, and the caption for Figure 13 on headache.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "years old",
          "heading": false
        },
        {
          "term": "children years",
          "heading": false
        },
        {
          "term": "aggerbeck",
          "heading": false
        }
      ],
      "extract": "Aggerbeck 2018 included children < 5 years old (20%) and 5-17 years old (31%); Ruhwald included children < 5 years old (3.5%) and 5-17 years old (8.8%). Aksenova 2009, Belushkov 2018, Rutkovsky 2020, and Yarovaya, 2019 included only children and adolescents <18 years old. Aksenova 2009, Slogotskaya, and Streltsova included people with active TB only. Figure 13. Frequencies of headache Proportion of HIV+: Aggerbeck",
      "extractCut": true,
      "blocks": [
        "library/10665-381036/blocks/prose-page-955",
        "library/10665-381036/blocks/figure-img-p955-1"
      ]
    },
    {
      "id": "page-956",
      "number": null,
      "title": "Page 956",
      "level": 1,
      "pageStart": 956,
      "pageEnd": 956,
      "labelStart": "93",
      "labelEnd": "93",
      "words": 126,
      "summary": {
        "text": "The title page of Web Annex B.22, a systematic review by a team mainly from University College London on the cost-effectiveness of Mycobacterium tuberculosis antigen-based skin tests, prepared for a February 2022 WHO guideline meeting.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "college london",
          "heading": false
        },
        {
          "term": "imperial college",
          "heading": false
        },
        {
          "term": "university college",
          "heading": false
        },
        {
          "term": "peter white",
          "heading": false
        },
        {
          "term": "ting",
          "heading": false
        }
      ],
      "extract": "Web Annex B.22. Cost–effectiveness of Mycobacterium tuberculosis antigen-based skin tests: a systematic review Review team: Lara Goscé1, Finna Parkinson1, Kasim Allel,1,2 Elena Surkova3, Irina Kontsevaya4, Ting Ting Wang1, Victoria Liu2, Yohhei Hamada1, Peter White5, Molebogeng X Rangaka1 1Institute for Global Health, University College London, UK 2London School of Hygiene and Tropical Medicine, UK 3Royal Brompton",
      "extractCut": true,
      "blocks": [
        "library/10665-381036/blocks/prose-page-956"
      ]
    },
    {
      "id": "page-957",
      "number": null,
      "title": "Page 957",
      "level": 1,
      "pageStart": 957,
      "pageEnd": 957,
      "labelStart": "94",
      "labelEnd": "94",
      "words": 92,
      "summary": {
        "text": "A list of abbreviations used in the cost-effectiveness review, such as BCG, ICER, IGRA, TBST, TPT and TST.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "skin tests",
          "heading": false
        },
        {
          "term": "cba",
          "heading": false
        },
        {
          "term": "tuberculosis",
          "heading": false
        },
        {
          "term": "hics",
          "heading": false
        },
        {
          "term": "bacillus",
          "heading": false
        }
      ],
      "extract": "Abbreviations BCG: Bacillus Calmette-Guérin CBA: Cost-benefit analysis CUA: Cost-utility analysis CEA: Cost-effective analysis DOT: Directly observed therapy HICs: High-income countries HIV: Human immunodeficiency virus ICER: incremental cost-effectiveness ratios IGRA: interferon-gamma release assays LMICs: Low- and middle-income countries PPD: purified protein derivative PRISMA – Preferred Reporting Items for",
      "extractCut": true,
      "blocks": [
        "library/10665-381036/blocks/prose-page-957"
      ]
    },
    {
      "id": "page-958",
      "number": null,
      "title": "Page 958",
      "level": 1,
      "pageStart": 958,
      "pageEnd": 958,
      "labelStart": "95",
      "labelEnd": "95",
      "words": 467,
      "summary": {
        "text": "Gives the background to the review, noting about 1.7 billion people with TB infection and WHO's recommendation of preventive treatment guided by testing where possible. It contrasts the tuberculin skin test, which needs two visits and is less specific after BCG vaccination, with blood-based IGRA tests, and introduces newer specific skin tests.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "ppd-tst",
          "heading": false
        },
        {
          "term": "igra",
          "heading": false
        },
        {
          "term": "higher specificity",
          "heading": false
        },
        {
          "term": "risk factors",
          "heading": false
        },
        {
          "term": "tbi",
          "heading": false
        },
        {
          "term": "tpt",
          "heading": false
        },
        {
          "term": "tests",
          "heading": false
        },
        {
          "term": "tbst",
          "heading": false
        }
      ],
      "extract": "BACKGROUND With an estimated 1.7 billion people infected with tuberculosis infection (TBI), progression of infection to active TB disease poses a large public health risk1. Prominent risk factors of this transition include clinical risk factors such as human immunodeficiency virus (HIV), diabetes, undernutrition, and contextual or societal risk factors in the most vulnerable and disadvantaged populations including,",
      "extractCut": true,
      "blocks": [
        "library/10665-381036/blocks/prose-page-958"
      ]
    },
    {
      "id": "page-959",
      "number": null,
      "title": "Page 959",
      "level": 1,
      "pageStart": 959,
      "pageEnd": 959,
      "labelStart": "96",
      "labelEnd": "96",
      "words": 375,
      "summary": {
        "text": "Explains that accuracy alone does not justify recommending the new skin tests, so their cost-effectiveness must be examined. It states the research question and four objectives: two systematic reviews of costs and cost-effectiveness of the new and current tests, and modelling of cost-effectiveness across settings.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "novel tbst",
          "heading": false
        },
        {
          "term": "tbst compared",
          "heading": false
        },
        {
          "term": "markov-chain model",
          "heading": false
        },
        {
          "term": "index tests",
          "heading": false
        },
        {
          "term": "tbi testing",
          "heading": false
        },
        {
          "term": "unit costs",
          "heading": false
        },
        {
          "term": "ppd-tst",
          "heading": false
        },
        {
          "term": "cost-effectiveness",
          "heading": false
        }
      ],
      "extract": "sensitivity for TBI, especially in resource-constrained settings and contexts where BCG vaccination is implemented routinely. 8,9. The diagnostic accuracy of the tests alone, however, is not sufficient evidence for the recommendation of their use in TBI testing guidelines. To provide sufficient evidence for the intervention, cost-effectiveness must also be considered to ensure that the tests are affordable and",
      "extractCut": true,
      "blocks": [
        "library/10665-381036/blocks/prose-page-959"
      ]
    },
    {
      "id": "page-960",
      "number": null,
      "title": "Page 960",
      "level": 1,
      "pageStart": 960,
      "pageEnd": 960,
      "labelStart": "97",
      "labelEnd": "97",
      "words": 42,
      "summary": {
        "text": "Explains that the report has two parts, with this document containing Section A on the systematic reviews and Section B on the modelling provided separately.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "abstract",
          "heading": false
        },
        {
          "term": "section",
          "heading": false
        },
        {
          "term": "attachment",
          "heading": false
        }
      ],
      "extract": "LAYOUT OF THE REPORT The report is presented in two parts. Section A: Abstract, methods and results for Objectives 1-2 Section B: Abstract, methods and result for Objectives 3-4. This document contains Section A. Section B is submitted as a separate attachment.",
      "extractCut": false,
      "blocks": [
        "library/10665-381036/blocks/prose-page-960"
      ]
    },
    {
      "id": "page-961",
      "number": null,
      "title": "Page 961",
      "level": 1,
      "pageStart": 961,
      "pageEnd": 961,
      "labelStart": "98",
      "labelEnd": "98",
      "words": 415,
      "summary": {
        "text": "The abstract of the systematic reviews, explaining that novel TB-specific skin tests may offer accurate, scalable alternatives to the tuberculin skin test and IGRA. It reports finding only eight economic studies of the new tests, seven on Diaskintest in Russia and one in Brazil, with low unit costs but generally poor study quality, and calls for more high-quality studies.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "drummond scores",
          "heading": false
        },
        {
          "term": "novel tbst",
          "heading": false
        },
        {
          "term": "drummond checklist",
          "heading": false
        },
        {
          "term": "economic evaluations",
          "heading": false
        },
        {
          "term": "economic evidence",
          "heading": false
        },
        {
          "term": "cost effectiveness",
          "heading": false
        },
        {
          "term": "c-tst",
          "heading": false
        },
        {
          "term": "dppd",
          "heading": false
        }
      ],
      "extract": "Systematic literature reviews Abstract Background: The tuberculin skin test (TST) and interferon-gamma release assays (IGRA) are the currently used tests for identifying individuals with TB infection that should be offered TB preventive treatment, however challenges around access and implementation have limited their use. Novel Mycobacterium tuberculosis specific skin tests (TBST) such as the DiaskinTest,",
      "extractCut": true,
      "blocks": [
        "library/10665-381036/blocks/prose-page-961"
      ]
    },
    {
      "id": "page-962",
      "number": null,
      "title": "Page 962",
      "level": 1,
      "pageStart": 962,
      "pageEnd": 962,
      "labelStart": "99",
      "labelEnd": "99",
      "words": 357,
      "summary": {
        "text": "Describes the methods of two registered literature reviews, one on costs and cost-effectiveness of the new skin tests and a secondary one on the tuberculin skin test and IGRA. It lists the English, Chinese and Russian databases searched, the three concept groups of search terms, and the use of manufacturer data and a WHO public call for data.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "secondary review",
          "heading": false
        },
        {
          "term": "systematic review",
          "heading": false
        },
        {
          "term": "tbst compared",
          "heading": false
        },
        {
          "term": "ppd-tst",
          "heading": false
        },
        {
          "term": "primary review",
          "heading": false
        },
        {
          "term": "search strategy",
          "heading": false
        },
        {
          "term": "unit costs",
          "heading": false
        },
        {
          "term": "cost-effectiveness",
          "heading": false
        }
      ],
      "extract": "Methods We performed two different literature reviews. (a) a primary review looking at the costs and cost-effectiveness of the novel skin tests (registered on PROSPERO: CRD42021275585) (b) a secondary review for the cost-effectiveness of PPD-TST and IGRAs tests (registered on PROSPERO: CRD42021275684) Firstly, we reviewed the literature on the cost and cost-effectiveness of the novel tests. Due to the anticipated",
      "extractCut": true,
      "blocks": [
        "library/10665-381036/blocks/prose-page-962"
      ]
    },
    {
      "id": "page-963",
      "number": null,
      "title": "Page 963",
      "level": 1,
      "pageStart": 963,
      "pageEnd": 963,
      "labelStart": "100",
      "labelEnd": "100",
      "words": 397,
      "summary": {
        "text": "Sets out inclusion criteria requiring full economic evaluations from a health care perspective, published in English, Chinese or Russian, and the test products covered. It describes how reviewers screened papers in each language, extracted data, converted costs to 2021 US dollars and assessed quality with the Drummond checklist.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "screened abstracts",
          "heading": false
        },
        {
          "term": "economic evaluations",
          "heading": false
        },
        {
          "term": "novel skin",
          "heading": false
        },
        {
          "term": "full text",
          "heading": false
        },
        {
          "term": "skin tests",
          "heading": false
        },
        {
          "term": "study selection",
          "heading": false
        },
        {
          "term": "secondary review",
          "heading": false
        },
        {
          "term": "articles",
          "heading": false
        }
      ],
      "extract": "We did not have an exclusion criterion for specific populations, and all articles had to be published in English, Chinese or Russian and relate to TBI in humans. Papers had to be full original economic evaluations, meaning having clear measures of costs, outcomes, and sufficient incremental analysis using the healthcare perspective. No time restriction was imposed for the primary review on novel skin tests, whereas",
      "extractCut": true,
      "blocks": [
        "library/10665-381036/blocks/prose-page-963"
      ]
    },
    {
      "id": "page-964",
      "number": null,
      "title": "Page 964",
      "level": 1,
      "pageStart": 964,
      "pageEnd": 964,
      "labelStart": "101",
      "labelEnd": "101",
      "words": 96,
      "summary": {
        "text": "Reports the search results, with 8 relevant studies on the new skin tests (mostly in Russian) and 29 studies on the tuberculin skin test and IGRA selected for analysis.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "prisma flow",
          "heading": false
        },
        {
          "term": "russian",
          "heading": false
        },
        {
          "term": "written",
          "heading": false
        }
      ],
      "extract": "Results Identification, screening, eligibility, and inclusion For the primary search (systematic review 1) on cost-effectiveness of novel skin tests, 367 records were identified for full text screening (103 written in English/Chinese, and 264 in Russian) of which only 8 were relevant to the research question (only one of those written in English and 7 in Russian) (See PRISMA flow in Figure 1). For the secondary",
      "extractCut": true,
      "blocks": [
        "library/10665-381036/blocks/prose-page-964"
      ]
    },
    {
      "id": "page-965",
      "number": null,
      "title": "Page 965",
      "level": 1,
      "pageStart": 965,
      "pageEnd": 965,
      "labelStart": "102",
      "labelEnd": "102",
      "words": 115,
      "summary": {
        "text": "Figure 1, a PRISMA flowchart for the primary review of novel skin tests, showing searches in English, Chinese and Russian databases leading to the included studies, with a note that no eligible study came from manufacturers or the WHO call for data.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "records",
          "heading": false
        },
        {
          "term": "e-library",
          "heading": false
        },
        {
          "term": "flowchart",
          "heading": false
        },
        {
          "term": "duplicates",
          "heading": false
        }
      ],
      "extract": "Figure 1. PRISMA flowchart for primary systematic review (Novel tests) Note: no eligible study was identified among papers shared by test manufacturers and those identified though a WHO public call for data. English and Chinese languages searches Russian language search 405 records in e-library 141 records deemed not relevant 264 records for full text review 257 records do not report health economics analysis 7",
      "extractCut": true,
      "blocks": [
        "library/10665-381036/blocks/prose-page-965",
        "library/10665-381036/blocks/figure-vfig-p965"
      ]
    },
    {
      "id": "page-966",
      "number": null,
      "title": "Page 966",
      "level": 1,
      "pageStart": 966,
      "pageEnd": 966,
      "labelStart": "103",
      "labelEnd": "103",
      "words": 243,
      "summary": {
        "text": "Figure 2, a PRISMA flowchart for the secondary review of the tuberculin skin test and IGRA, followed by a description of the eight studies on the new tests, mostly Russian studies in children comparing Diaskintest with the tuberculin skin test. It singles out a Brazilian Markov model study in people living with HIV as the only one meeting most quality criteria.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "ppd-tst",
          "heading": false
        },
        {
          "term": "russia",
          "heading": false
        },
        {
          "term": "diaskintest",
          "heading": false
        },
        {
          "term": "records",
          "heading": false
        },
        {
          "term": "articles",
          "heading": false
        },
        {
          "term": "icer",
          "heading": false
        },
        {
          "term": "cost-effectiveness",
          "heading": false
        },
        {
          "term": "tbst",
          "heading": false
        }
      ],
      "extract": "Figure 2. PRISMA flowchart for the secondary systematic review (PPD-TST and IGRA) Description of the articles found in the primary review (specific TBST) Eight economic evaluations were conducted from middle-income countries (Russia and Brazil), these mostly compared DiaskinTest against PPD-TST (Table A2, supplementary). One study met most of the Drummond’s checklist factors and reported all the required",
      "extractCut": true,
      "blocks": [
        "library/10665-381036/blocks/prose-page-966",
        "library/10665-381036/blocks/figure-vfig-p966"
      ]
    },
    {
      "id": "page-967",
      "number": null,
      "title": "Page 967",
      "level": 1,
      "pageStart": 967,
      "pageEnd": 967,
      "labelStart": "104",
      "labelEnd": "104",
      "words": 457,
      "summary": {
        "text": "Notes that most studies of the new skin tests lacked sensitivity analyses and clear model details, so their quality was concerning. It then describes the 29 studies on the tuberculin skin test and IGRA, mostly from high-income countries, which used various models and were generally of high quality.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "probabilistic sensitivity",
          "heading": false
        },
        {
          "term": "supplementary material",
          "heading": false
        },
        {
          "term": "drummond checklist",
          "heading": false
        },
        {
          "term": "sensitivity analysis",
          "heading": false
        },
        {
          "term": "economic evaluations",
          "heading": false
        },
        {
          "term": "language searches",
          "heading": false
        },
        {
          "term": "c-tst",
          "heading": false
        },
        {
          "term": "diaskintest",
          "heading": false
        }
      ],
      "extract": "We evaluated study quality using the Drummond’s checklist for health economic evaluations (supplementary material, Table A7). On average, we identified that most studies did not present any sensitivity analysis, and that the information on relevant parameters such as time horizon, type of model used, year of the evaluation, and discounting rate were unclear, or not stated. Overall, study quality was concerning.",
      "extractCut": true,
      "blocks": [
        "library/10665-381036/blocks/prose-page-967"
      ]
    },
    {
      "id": "page-968",
      "number": null,
      "title": "Page 968",
      "level": 1,
      "pageStart": 968,
      "pageEnd": 968,
      "labelStart": "105",
      "labelEnd": "105",
      "words": 312,
      "summary": {
        "text": "Summarizes findings that Diaskintest kits cost about $1.29–3.49 and that almost all studies judged it cost-effective compared with the tuberculin skin test, with results sensitive to unit costs. Table 1 gives unit costs of Diaskintest and C-TST from the primary review in 2021 US dollars.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "unit costs",
          "heading": false
        },
        {
          "term": "diaskintest",
          "heading": false
        },
        {
          "term": "solodun",
          "heading": false
        },
        {
          "term": "russia",
          "heading": false
        },
        {
          "term": "yagudina",
          "heading": false
        },
        {
          "term": "icer",
          "heading": false
        },
        {
          "term": "steffen",
          "heading": false
        },
        {
          "term": "ppd-tst",
          "heading": false
        }
      ],
      "extract": "compared strategies to DiaskinTest only. The dominance of DiaskinTest was very sensitive to unit costs of DiaskinTest which is highly uncertain due to using market value and hence varies widely by health system and country. The rest of the articles found that the cost of the DiaskinTest kit ranged from $1.29 to $3.49 and that it was not very sensitive to unit costs after employing univariate sensitivity analyses (if",
      "extractCut": true,
      "blocks": [
        "library/10665-381036/blocks/prose-page-968"
      ]
    },
    {
      "id": "page-969",
      "number": null,
      "title": "Page 969",
      "level": 1,
      "pageStart": 969,
      "pageEnd": 969,
      "labelStart": "106",
      "labelEnd": "106",
      "words": 540,
      "summary": {
        "text": "Summarizes the secondary review, noting that most studies were in low-burden, high-income countries and that testing was more likely to be cost-effective in high-risk groups or high-burden settings, without consensus on which test to use. It reports that studies in people living with HIV generally found IGRA more cost-effective, with one finding Diaskintest most cost-effective, and describes reasons for variation in unit costs.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "utilise ppd-tst",
          "heading": false
        },
        {
          "term": "found igra",
          "heading": false
        },
        {
          "term": "cost-effective strategy",
          "heading": false
        },
        {
          "term": "either igra",
          "heading": false
        },
        {
          "term": "unit costs",
          "heading": false
        },
        {
          "term": "studies analysing",
          "heading": false
        },
        {
          "term": "high-income countries",
          "heading": false
        },
        {
          "term": "combined sequential",
          "heading": false
        }
      ],
      "extract": "Most studies evaluated the costs and cost-effectiveness of PPD-TST and IGRA with wide-ranging study populations including PLHIV, immunocompromised people other than PLHIV, immigrants/migrants, healthcare workers and different methods were used, especially time horizons. 22 studies were set in low TB burden countries (UK, USA, Canada, Norway, Oman, Spain), 4 in lower moderate (Brazil, Japan, Singapore), 1 in upper-",
      "extractCut": true,
      "blocks": [
        "library/10665-381036/blocks/prose-page-969"
      ]
    },
    {
      "id": "page-970",
      "number": null,
      "title": "Page 970",
      "level": 1,
      "pageStart": 970,
      "pageEnd": 970,
      "labelStart": "107",
      "labelEnd": "107",
      "words": 166,
      "summary": {
        "text": "Table 2 lists unit costs of the tuberculin skin test from studies in different countries, broken down into kit, staff time, consumables and other components, in 2021 US dollars.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "usa",
          "heading": false
        },
        {
          "term": "unit costs",
          "heading": false
        },
        {
          "term": "ppd-tst",
          "heading": false
        },
        {
          "term": "canada",
          "heading": false
        }
      ],
      "extract": "Table 2: Unit costs of PPD-TST (2021 USD) PPD-TST COSTS Study ID Country Test Kit Staff Time Consu mable Overh eads Labora tory Disposa bles Unit Costs Linas (2011) 22 USA $2.88 $23.92 $26.81 del Campo, (2012) 25 Spain ✓ ✓ ✓ $60.35 Eralp, (2012) a 26 UK $31.12 Mandalakas, (2013) 27 South Africa ✓ ✓ ✓ $21.92̶ 99.13 Kim (2018) 28 South Africa $1.75 $1.70 $0.08 $4.40 Pareek (2013) b 29 UK $68.34 Steffen (2013) 7 USA",
      "extractCut": true,
      "blocks": [
        "library/10665-381036/blocks/prose-page-970"
      ]
    },
    {
      "id": "page-971",
      "number": null,
      "title": "Page 971",
      "level": 1,
      "pageStart": 971,
      "pageEnd": 971,
      "labelStart": "108",
      "labelEnd": "108",
      "words": 337,
      "summary": {
        "text": "Notes explaining Table 2, followed by part of a table giving unit costs of IGRA tests such as QuantiFERON and T-SPOT from studies in several countries.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "unit costs",
          "heading": false
        },
        {
          "term": "nice",
          "heading": false
        },
        {
          "term": "clinical diagnosis",
          "heading": false
        },
        {
          "term": "qft",
          "heading": false
        },
        {
          "term": "pareek",
          "heading": false
        },
        {
          "term": "tick",
          "heading": false
        },
        {
          "term": "usa",
          "heading": false
        },
        {
          "term": "steffen",
          "heading": false
        }
      ],
      "extract": "Notes: A tick mark (✓) stands for those articles that mention they included certain cost components but did not explicitly state the figures and only included the total costs per test diagnostic. There were no further details provided but only the overall costs of the test If no tick (✓) is observed. a Calculated from the National Institute for Health and Clinical Excellence. Clinical diagnosis and management of",
      "extractCut": true,
      "blocks": [
        "library/10665-381036/blocks/prose-page-971"
      ]
    },
    {
      "id": "page-972",
      "number": null,
      "title": "Page 972",
      "level": 1,
      "pageStart": 972,
      "pageEnd": 972,
      "labelStart": "109",
      "labelEnd": "109",
      "words": 318,
      "summary": {
        "text": "Notes to the cost tables and the rest of the IGRA unit cost table, covering studies from Canada, Brazil, Singapore and the USA.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "clinical diagnosis",
          "heading": false
        },
        {
          "term": "nice",
          "heading": false
        },
        {
          "term": "tick",
          "heading": false
        },
        {
          "term": "qft-git",
          "heading": false
        },
        {
          "term": "t-spot",
          "heading": false
        },
        {
          "term": "screening strategies",
          "heading": false
        },
        {
          "term": "canada",
          "heading": false
        },
        {
          "term": "calculated",
          "heading": false
        }
      ],
      "extract": "Notes A tick mark (✓) stands for those articles that mention they included certain cost components but did not explicitly state the figures and only included the total costs per diagnostic test. There were no further details provided but only the overall costs of the test If no tick (✓) is observed. a Calculated from the National Institute for Health and Clinical Excellence. Clinical diagnosis and management of",
      "extractCut": true,
      "blocks": [
        "library/10665-381036/blocks/prose-page-972"
      ]
    },
    {
      "id": "page-973",
      "number": null,
      "title": "Page 973",
      "level": 1,
      "pageStart": 973,
      "pageEnd": 973,
      "labelStart": "110",
      "labelEnd": "110",
      "words": 266,
      "summary": {
        "text": "Interprets the findings, noting that novel skin tests cost far less than IGRA or the tuberculin skin test but that low costs alone, from few and generally poor-quality studies in Russia and Brazil, do not show likely economic impact. It states that a modelling study was undertaken with results in Part B.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "average cost",
          "heading": false
        },
        {
          "term": "cost effectiveness",
          "heading": false
        },
        {
          "term": "skin tests",
          "heading": false
        },
        {
          "term": "diaskintest",
          "heading": false
        },
        {
          "term": "tst",
          "heading": false
        },
        {
          "term": "igra",
          "heading": false
        },
        {
          "term": "novel",
          "heading": false
        },
        {
          "term": "cost-effectiveness",
          "heading": false
        }
      ],
      "extract": "Interpretation Considering the same factors (ingredients) for economic costing, costs of novel skin tests (DiaskinTest=$5.07, C- TST=$9.9912) were substantially lower than those of IGRA (average cost was $89.33; ranging from $22.1712 to $247.1227) and the TST (average cost=$37.84, ranging from $4.4028 to $181.6324). However, in isolation, observed low costs of DiaskinTest and C-TST compared to TST and IGRA are not",
      "extractCut": true,
      "blocks": [
        "library/10665-381036/blocks/prose-page-973"
      ]
    },
    {
      "id": "page-974",
      "number": null,
      "title": "Page 974",
      "level": 1,
      "pageStart": 974,
      "pageEnd": 974,
      "labelStart": "111",
      "labelEnd": "111",
      "words": 437,
      "summary": {
        "text": "The start of the reference list for the cost-effectiveness review, citing work on the burden of TB infection, WHO reports and economic studies, including some in Russian.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "interferon-γ release",
          "heading": false
        },
        {
          "term": "latent tuberculosis",
          "heading": false
        },
        {
          "term": "tuberculosis infection",
          "heading": false
        },
        {
          "term": "tuberculin skin",
          "heading": false
        },
        {
          "term": "mycobacterium tuberculosis",
          "heading": false
        },
        {
          "term": "детей подростков",
          "heading": false
        },
        {
          "term": "release assays",
          "heading": false
        },
        {
          "term": "туберкулезной инфекции",
          "heading": false
        }
      ],
      "extract": "References 1. Houben RM, Dodd PJ. The global burden of latent tuberculosis infection: a re-estimation using mathematical modelling. PLoS medicine 2016; 13(10): e1002152. 2. World Health Organization. Global tuberculosis report 2020: World Health Organization; 2020. 3. Farhat M, Greenaway C, Pai M, Menzies D. False-positive tuberculin skin tests: what is the absolute effect of BCG and non-tuberculous mycobacteria?",
      "extractCut": true,
      "blocks": [
        "library/10665-381036/blocks/prose-page-974"
      ]
    },
    {
      "id": "page-975",
      "number": null,
      "title": "Page 975",
      "level": 1,
      "pageStart": 975,
      "pageEnd": 975,
      "labelStart": "112",
      "labelEnd": "112",
      "words": 490,
      "summary": {
        "text": "Part of the reference list, citing Russian-language economic studies of Diaskintest and English-language studies on IGRA and tuberculin skin test screening of migrants and other groups.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "latent tuberculosis",
          "heading": false
        },
        {
          "term": "tuberculosis infection",
          "heading": false
        },
        {
          "term": "american journal",
          "heading": false
        },
        {
          "term": "детей подростков",
          "heading": false
        },
        {
          "term": "release assays",
          "heading": false
        },
        {
          "term": "cost effectiveness",
          "heading": false
        },
        {
          "term": "horsburgh",
          "heading": false
        },
        {
          "term": "linas",
          "heading": false
        }
      ],
      "extract": "16. Солодун ИЮ, Эва ХМ, Башлакова ЕЕ, Ермолаева ТН, Давыдовская МВ, Евдошенко ЕП. Клинико- экономический анализ применения метода диагностики туберкулезной инфекции у детей и подростков с использованием аллергена туберкулезного рекомбинантного. Проблемы стандартизации в здравоохранении 2017; (3-4). 17. Чугаев Ю, Камаева Н, Цветков А, Кудлай Д, Черняев И. ИННОВАЦИОННЫЕ РЕКОМБИНАНТНЫЕ ТЕХНОЛОГИИ ВЫЯВЛЕНИЯ И",
      "extractCut": true,
      "blocks": [
        "library/10665-381036/blocks/prose-page-975"
      ]
    },
    {
      "id": "page-976",
      "number": null,
      "title": "Page 976",
      "level": 1,
      "pageStart": 976,
      "pageEnd": 976,
      "labelStart": "113",
      "labelEnd": "113",
      "words": 485,
      "summary": {
        "text": "The end of the reference list, citing cost-effectiveness studies of TB infection screening in long-term care, refugees, migrants and other populations.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "latent tuberculosis",
          "heading": false
        },
        {
          "term": "tuberculosis screening",
          "heading": false
        },
        {
          "term": "cost-effectiveness analysis",
          "heading": false
        },
        {
          "term": "gold in-tube",
          "heading": false
        },
        {
          "term": "quantiferon-tb gold",
          "heading": false
        },
        {
          "term": "infection screening",
          "heading": false
        },
        {
          "term": "bmc infectious",
          "heading": false
        },
        {
          "term": "inflammatory bowel",
          "heading": false
        }
      ],
      "extract": "30. Verma G, Chuck A, Jacobs P. Tuberculosis screening for long-term care: a cost-effectiveness analysis. The International journal of tuberculosis and lung disease 2013; 17(9): 1170-7. 31. La’Marcus TW, Coleman MS, de la Motte Hurst C, et al. A cost-benefit analysis of a proposed overseas refugee latent tuberculosis infection screening and treatment program. BMC public health 2015; 15(1): 1-14. 32. Nijhawan AE,",
      "extractCut": true,
      "blocks": [
        "library/10665-381036/blocks/prose-page-976"
      ]
    },
    {
      "id": "page-977",
      "number": null,
      "title": "Page 977",
      "level": 1,
      "pageStart": 977,
      "pageEnd": 977,
      "labelStart": "114",
      "labelEnd": "114",
      "words": 297,
      "summary": {
        "text": "The start of the supplementary documentation, describing the search period for the primary review and showing the search strategy terms for TB, diagnostic tests and cost-effectiveness.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "interferon gamma",
          "heading": false
        },
        {
          "term": "exp tuberculosis",
          "heading": false
        },
        {
          "term": "gamma release",
          "heading": false
        },
        {
          "term": "tuberculin skin",
          "heading": false
        },
        {
          "term": "exp mycobacterium",
          "heading": false
        },
        {
          "term": "term exp",
          "heading": false
        },
        {
          "term": "systematic literature",
          "heading": false
        },
        {
          "term": "tuberculin test",
          "heading": false
        }
      ],
      "extract": "SUPPLEMENTARY DOCUMENTATION Section A: Systematic literature reviews I. Literature review For the primary systematic literature review (new skin tests), the search included papers from inception until 30 July 2021. Since the previous review included papers published until 20 October 2020, our updated search excluded studies published before October 2020. Table A1.1. Search strategy for the primary systematic",
      "extractCut": true,
      "blocks": [
        "library/10665-381036/blocks/prose-page-977",
        "library/10665-381036/blocks/table-045"
      ]
    },
    {
      "id": "page-978",
      "number": null,
      "title": "Page 978",
      "level": 1,
      "pageStart": 978,
      "pageEnd": 978,
      "labelStart": "115",
      "labelEnd": "115",
      "words": 193,
      "summary": {
        "text": "Table A2 extracts data from Russian economic studies of Diaskintest in children and adolescents, giving cost year, currency, strategies compared and unit costs.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "tst diaskintest",
          "heading": false
        },
        {
          "term": "rub",
          "heading": false
        },
        {
          "term": "rubles",
          "heading": false
        },
        {
          "term": "unit costs",
          "heading": false
        },
        {
          "term": "decision tree",
          "heading": false
        },
        {
          "term": "stated",
          "heading": false
        },
        {
          "term": "russia",
          "heading": false
        }
      ],
      "extract": "Study Characteristics Kulikov 2009 14 Aksenova 2011 13 Yagudina 2013 15 Country Setting Russia Russia Russia Year of Cost Valuation Not Stated 2010 (Assumption) Not stated. Currency Rubles Rubles Rubles Study Population Children and Adolescents Children Children and Adolescents Index Diagnostic Test Strategies DiaskinTest DiaskinTest DiaskinTest TST + DiaskinTest Alternative Provided TST TST TST Type of economic",
      "extractCut": true,
      "blocks": [
        "library/10665-381036/blocks/prose-page-978"
      ]
    },
    {
      "id": "page-979",
      "number": null,
      "title": "Page 979",
      "level": 1,
      "pageStart": 979,
      "pageEnd": 979,
      "labelStart": "116",
      "labelEnd": "116",
      "words": 200,
      "summary": {
        "text": "A continuation of Table A2 with data from further Russian Diaskintest studies, including one in people living with HIV.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "tst diaskintest",
          "heading": false
        },
        {
          "term": "rub case",
          "heading": false
        },
        {
          "term": "rubles",
          "heading": false
        },
        {
          "term": "stated",
          "heading": false
        },
        {
          "term": "none carried",
          "heading": false
        },
        {
          "term": "russia",
          "heading": false
        },
        {
          "term": "carried out",
          "heading": false
        },
        {
          "term": "sensitivity analysis",
          "heading": false
        }
      ],
      "extract": "Continuation of Table A2 Study Characteristics Moiseeva 2014 Solodun 2017 16 Sinitsyn 2018 Country Setting Russia Russia Russia Year of Cost Valuation 2013 Not stated. 2015 Currency Rubles Rubles Rubles Study Population Children Children and Adolescents People living with HIV Index Diagnostic Test Strategies DiaskinTest 1. TST+ DiaskinTest 1) DiaskinTest 2) TST + DiaskinTest DiaskinTest Alternative Provided TST TST",
      "extractCut": true,
      "blocks": [
        "library/10665-381036/blocks/prose-page-979"
      ]
    },
    {
      "id": "page-980",
      "number": null,
      "title": "Page 980",
      "level": 1,
      "pageStart": 980,
      "pageEnd": 980,
      "labelStart": "117",
      "labelEnd": "117",
      "words": 131,
      "summary": {
        "text": "A continuation of Table A2 with data from a Russian study in children and a Brazilian cost-utility study in adults living with HIV.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "sensitivity analysis",
          "heading": false
        },
        {
          "term": "diaskintest",
          "heading": false
        },
        {
          "term": "tst",
          "heading": false
        },
        {
          "term": "chugaev",
          "heading": false
        },
        {
          "term": "rubles",
          "heading": false
        }
      ],
      "extract": "Continuation of Table A2 Study Characteristics Chugaev 2020 17 Steffen (2020) 12 Country Setting Russia Brazil Year of Cost Valuation 2013 for TST 2020 2019 for DiaskinTest Currency Rubles USD Study Population Children Adults living with HIV Index Diagnostic Test Strategies DiaskinTest 1. TST, 2. QFT-GIT, e. EC test Alternative Provided TST DiaskinTest Type of economic evaluation Cost analysis CUA Source of costing",
      "extractCut": true,
      "blocks": [
        "library/10665-381036/blocks/prose-page-980"
      ]
    },
    {
      "id": "page-981",
      "number": null,
      "title": "Page 981",
      "level": 1,
      "pageStart": 981,
      "pageEnd": 981,
      "labelStart": "118",
      "labelEnd": "118",
      "words": 189,
      "summary": {
        "text": "Table A3 begins extracting data from the secondary review, covering studies from the USA, UK and Spain on tuberculin skin test and IGRA strategies in migrants, immunocompromised people and health workers.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "one-way deterministic",
          "heading": false
        },
        {
          "term": "qft sensitivity",
          "heading": false
        },
        {
          "term": "decision tree",
          "heading": false
        },
        {
          "term": "case averted",
          "heading": false
        },
        {
          "term": "empirical data",
          "heading": false
        },
        {
          "term": "sensitivity analysis",
          "heading": false
        },
        {
          "term": "tst",
          "heading": false
        }
      ],
      "extract": "Table A3: Data extraction results for all the entries from the secondary systematic review Study Characteristics Linas (2011) 22 Pareek (2011)38 del Campo (2012) 25 Country Setting USA UK Spain Year of Cost Valuation 2011 2010 2012 Currency USD GBP Euros Study Population 1) Immigrant/Migrants 2) Immunocompromised 3) Vulnerable Recently arrived immigrants (<16y.o. and 16- 35y.o.) Healthcare workers. Index Diagnostic",
      "extractCut": true,
      "blocks": [
        "library/10665-381036/blocks/prose-page-981",
        "library/10665-381036/blocks/table-046"
      ]
    },
    {
      "id": "page-982",
      "number": null,
      "title": "Page 982",
      "level": 1,
      "pageStart": 982,
      "pageEnd": 982,
      "labelStart": "119",
      "labelEnd": "119",
      "words": 193,
      "summary": {
        "text": "A continuation of Table A3 with data from UK, US and South African studies of TB infection testing in health workers, clinic attendees and child contacts.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "tst qft",
          "heading": false
        },
        {
          "term": "tst t-spot",
          "heading": false
        },
        {
          "term": "qft sensitivity",
          "heading": false
        },
        {
          "term": "ltbi prevalence",
          "heading": false
        },
        {
          "term": "one-way deterministic",
          "heading": false
        },
        {
          "term": "cea",
          "heading": false
        },
        {
          "term": "sensitivity analysis",
          "heading": false
        }
      ],
      "extract": "Continuation of Table A3 Study Characteristics Eralp. (2012) 26 Shah (2012) 39 Mandalakas (2013) 27 Country Setting UK USA South Africa Year of Cost Valuation 2011 2012 2009 Currency GBP USD USD Study Population Healthcare Workers Individuals at primary health clinic with positive TST. Children (0-2 and 3- 5y.o.) contacts. Index Diagnostic Test Strategies 1. QFT 2. TST TST + QFT-GIT 1) TST 2) TST+QFT. 3) TST-QFT. 4)",
      "extractCut": true,
      "blocks": [
        "library/10665-381036/blocks/prose-page-982"
      ]
    },
    {
      "id": "page-983",
      "number": null,
      "title": "Page 983",
      "level": 1,
      "pageStart": 983,
      "pageEnd": 983,
      "labelStart": "120",
      "labelEnd": "120",
      "words": 181,
      "summary": {
        "text": "A continuation of Table A3 with data from UK and US studies on immigrants, close contacts and immunosuppressed patients.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "tst qft",
          "heading": false
        },
        {
          "term": "qft sensitivity",
          "heading": false
        },
        {
          "term": "one-way deterministic",
          "heading": false
        },
        {
          "term": "decision tree",
          "heading": false
        },
        {
          "term": "ltbi prevalence",
          "heading": false
        },
        {
          "term": "published literature",
          "heading": false
        },
        {
          "term": "case averted",
          "heading": false
        }
      ],
      "extract": "Continuation of Table A3 Study Characteristics Pareek (2013) 29 Steffen (2013) 7 Swaminath (2013) 40 Country Setting UK USA USA Year of Cost Valuation 2011 2012 Not stated. Currency GBP USD USD Study Population Recently arrived immigrants (≤35 y.o.). 35y.o. close contacts. Immunosuppressed with IBD Index Diagnostic Test Strategies 1. T-SPOT 2. QFT 3. TST + T-SPOT 4. TST + QFT 1. QFT 2. TST + QFT QFT Alternative",
      "extractCut": true,
      "blocks": [
        "library/10665-381036/blocks/prose-page-983"
      ]
    },
    {
      "id": "page-984",
      "number": null,
      "title": "Page 984",
      "level": 1,
      "pageStart": 984,
      "pageEnd": 984,
      "labelStart": "121",
      "labelEnd": "121",
      "words": 184,
      "summary": {
        "text": "A continuation of Table A3 with data from studies in Canada, the UK and the USA on older people in long-term care, adults with HIV and refugees.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "qft sensitivity",
          "heading": false
        },
        {
          "term": "one-way deterministic",
          "heading": false
        },
        {
          "term": "ltbi prevalence",
          "heading": false
        },
        {
          "term": "published literature",
          "heading": false
        },
        {
          "term": "case averted",
          "heading": false
        },
        {
          "term": "markov",
          "heading": false
        },
        {
          "term": "euro",
          "heading": false
        }
      ],
      "extract": "Continuation of Table A3 Study Characteristics Verma (2013) 30 Capocci, (2015) 21 Wingate (2015) 31 Country Setting Canada UK USA Year of Cost Valuation 2012 2012 2012 Currency Canadian Dollars Euro USD Study Population >65y.o. in long term care Adults living with HIV Pre arrival refugees to USA. Index Diagnostic Test Strategies TST 1. QFT + TST 2. QFT (for higher risk) 3. QFT (for all) TST Alternative Provided No",
      "extractCut": true,
      "blocks": [
        "library/10665-381036/blocks/prose-page-984"
      ]
    },
    {
      "id": "page-985",
      "number": null,
      "title": "Page 985",
      "level": 1,
      "pageStart": 985,
      "pageEnd": 985,
      "labelStart": "122",
      "labelEnd": "122",
      "words": 195,
      "summary": {
        "text": "A continuation of Table A3 with data from UK, US and Canadian studies covering children, immunocompromised people, immigrants, prisoners and refugees.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "tst igra",
          "heading": false
        },
        {
          "term": "qft sensitivity",
          "heading": false
        },
        {
          "term": "event simulation",
          "heading": false
        },
        {
          "term": "discrete event",
          "heading": false
        },
        {
          "term": "decision tree",
          "heading": false
        },
        {
          "term": "ltbi prevalence",
          "heading": false
        },
        {
          "term": "sensitivity analysis",
          "heading": false
        },
        {
          "term": "published literature",
          "heading": false
        }
      ],
      "extract": "Continuation of Table A3 Study Characteristics Auguste. (2016)19 Nijhawan (2016) 32 Campbell (2017) 41 Country Setting UK USA Canada Year of Cost Valuation 2012 2013 2016 Currency Euro USD Canadian Dollars Study Population 1) Children 2) Immunocompromised 3) Recently Arrived Immigrants 4) General Population. Adults entering jail. Pre-arrival refugees to USA. Index Diagnostic Test Strategies 1. IGRA 2. TST + IGRA 3.",
      "extractCut": true,
      "blocks": [
        "library/10665-381036/blocks/prose-page-985"
      ]
    },
    {
      "id": "page-986",
      "number": null,
      "title": "Page 986",
      "level": 1,
      "pageStart": 986,
      "pageEnd": 986,
      "labelStart": "123",
      "labelEnd": "123",
      "words": 198,
      "summary": {
        "text": "A continuation of Table A3 with data from Norwegian, Canadian and US studies on immigrants, health workers and people with comorbidities.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "qft sensitivity",
          "heading": false
        },
        {
          "term": "igra tst",
          "heading": false
        },
        {
          "term": "decision tree",
          "heading": false
        },
        {
          "term": "published literature",
          "heading": false
        },
        {
          "term": "ltbi prevalence",
          "heading": false
        },
        {
          "term": "one-way",
          "heading": false
        },
        {
          "term": "sensitivity analysis",
          "heading": false
        }
      ],
      "extract": "Continuation of Table A3 Study Characteristics Haukaas (2017) 33 Mullie (2017) 34 Tasillo, (2017) 18 Country Setting Norway Canada USA Year of Cost Valuation 2013 2015 2015 Currency Euro Canadian Dollars USD Study Population Recently arrived immigrants <35y.o. HCW with negative TST at time of employment. US-born or migrants living with or without comorbidities. Index Diagnostic Test Strategies 1. QFT (for those with",
      "extractCut": true,
      "blocks": [
        "library/10665-381036/blocks/prose-page-986"
      ]
    },
    {
      "id": "page-987",
      "number": null,
      "title": "Page 987",
      "level": 1,
      "pageStart": 987,
      "pageEnd": 987,
      "labelStart": "124",
      "labelEnd": "124",
      "words": 182,
      "summary": {
        "text": "A continuation of Table A3 with data from studies in the UK, Hong Kong and Japan on immigrants, contacts, older people in care homes and adolescents.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "decision tree",
          "heading": false
        },
        {
          "term": "qft",
          "heading": false
        },
        {
          "term": "psa",
          "heading": false
        },
        {
          "term": "tst",
          "heading": false
        },
        {
          "term": "published literature",
          "heading": false
        },
        {
          "term": "sensitivity analysis",
          "heading": false
        },
        {
          "term": "icer",
          "heading": false
        }
      ],
      "extract": "Continuation of Table A3 Study Characteristics Abubakar (2018) 24 Li (2018) 42 Sohn (2018) 35 Country Setting UK Hong Kong Japan Year of Cost Valuation Not Stated. Not stated. 2015 Currency GBP USD USD Study Population 1. Recent immigrants. 2. Contacts Elderly (>65y.o.) at admission to residential care home. Adolescents (13- 18y.o.) contacts. Index Diagnostic Test Strategies 1. T-SPOT.TB 2. QFT-GIT 3. TST (varying",
      "extractCut": true,
      "blocks": [
        "library/10665-381036/blocks/prose-page-987"
      ]
    },
    {
      "id": "page-988",
      "number": null,
      "title": "Page 988",
      "level": 1,
      "pageStart": 988,
      "pageEnd": 988,
      "labelStart": "125",
      "labelEnd": "125",
      "words": 212,
      "summary": {
        "text": "A continuation of Table A3 with data from Canadian and Brazilian studies on immigrants, migrants with kidney disease and health workers.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "qft sensitivity",
          "heading": false
        },
        {
          "term": "canadian dollars",
          "heading": false
        },
        {
          "term": "british columbia",
          "heading": false
        },
        {
          "term": "reactivation rate",
          "heading": false
        },
        {
          "term": "tst",
          "heading": false
        },
        {
          "term": "qft-git",
          "heading": false
        },
        {
          "term": "expert opinion",
          "heading": false
        },
        {
          "term": "sensitivity analysis",
          "heading": false
        }
      ],
      "extract": "Continuation of Table A3 Study Characteristics Campbell (2019a) 36 Campbell (2019b) 23 Loureiro (2019) 37 Country Setting Canada Canada Brazil Year of Cost Valuation 2016 2016 2016 Currency Canadian Dollars Canadian Dollars USD Study Population Pre-arrival immigrants. Migrants with either late-stage CKD or beginning dialysis. Primary HCW. Index Diagnostic Test Strategies 1. QFT-GIT 2. TST + QFT-GIT 3. TST (>10mm) 1.",
      "extractCut": true,
      "blocks": [
        "library/10665-381036/blocks/prose-page-988"
      ]
    },
    {
      "id": "page-989",
      "number": null,
      "title": "Page 989",
      "level": 1,
      "pageStart": 989,
      "pageEnd": 989,
      "labelStart": "126",
      "labelEnd": "126",
      "words": 215,
      "summary": {
        "text": "A continuation of Table A3 with data from studies in Singapore, Oman and the USA on health workers, immigrants and various high-risk groups.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "qft sensitivity",
          "heading": false
        },
        {
          "term": "reactivation rate",
          "heading": false
        },
        {
          "term": "incidence rate",
          "heading": false
        },
        {
          "term": "psa",
          "heading": false
        },
        {
          "term": "cua",
          "heading": false
        },
        {
          "term": "sensitivity analysis",
          "heading": false
        },
        {
          "term": "icer",
          "heading": false
        },
        {
          "term": "stated",
          "heading": false
        }
      ],
      "extract": "Continuation of Table A3 Study Characteristics Png (2019) 43 Al Abri (2020) 44 Jo (2020) 20 Country Setting Singapore Oman USA Year of Cost Valuation 2016 2020 2018 Currency USD USD USD Study Population HCW. 20-year-old recent immigrants. (1) non–US-born, (2) living with diabetes, (3) HIV-positive, (4) experiencing recent homelessness, (5) incarcerated Index Diagnostic Test Strategies QFT-GIT either annually or",
      "extractCut": true,
      "blocks": [
        "library/10665-381036/blocks/prose-page-989"
      ]
    },
    {
      "id": "page-990",
      "number": null,
      "title": "Page 990",
      "level": 1,
      "pageStart": 990,
      "pageEnd": 990,
      "labelStart": "127",
      "labelEnd": "127",
      "words": 137,
      "summary": {
        "text": "A continuation of Table A3 with data from studies in Brazil on adults with HIV and in South Africa on pregnant women with HIV.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "sensitivity analysis",
          "heading": false
        },
        {
          "term": "qft-git",
          "heading": false
        },
        {
          "term": "psa",
          "heading": false
        },
        {
          "term": "two-way",
          "heading": false
        },
        {
          "term": "tst",
          "heading": false
        },
        {
          "term": "one-way",
          "heading": false
        }
      ],
      "extract": "Continuation of Table A3 Study Characteristics Steffen (2020) 12 Kim (2018) 28 Country Setting Brazil South Africa Year of Cost Valuation 2020 2016 Currency USD USD Study Population Adults living with HIV HIV+ pregnant women Index Diagnostic Test Strategies 1. TST 2. QFT-GIT 3. EC Test 1. TST Alternative Provided (Baseline for Incremental Analysis) DiaskinTest QFT-GIT Type of economic evaluation CUA CEA Source of",
      "extractCut": true,
      "blocks": [
        "library/10665-381036/blocks/prose-page-990"
      ]
    },
    {
      "id": "page-991",
      "number": null,
      "title": "Page 991",
      "level": 1,
      "pageStart": 991,
      "pageEnd": 991,
      "labelStart": "128",
      "labelEnd": "128",
      "words": 158,
      "summary": {
        "text": "Table A7 begins applying the Drummond quality checklist to economic studies of novel skin tests, here for three Russian Diaskintest studies.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "drummond checklist",
          "heading": false
        },
        {
          "term": "yes",
          "heading": false
        },
        {
          "term": "alternatives",
          "heading": false
        },
        {
          "term": "yagudina",
          "heading": false
        },
        {
          "term": "kulikov",
          "heading": false
        }
      ],
      "extract": "128 Table A7. Drummond checklist for studies quality: Cost/Cost-effectiveness analyses for Novel skin tests for diagnosing TBI Drummond Checklist Questions Kulikov 2009 Aksenova 2011 Yagudina 2013 1. Was a well-defined question posed in answerable form? 1.1. Did the study examine both costs and effects of the service(s) or programme(s)? Yes No, only presents costs Yes 1.2. Did the study involve a comparison of",
      "extractCut": true,
      "blocks": [
        "library/10665-381036/blocks/prose-page-991",
        "library/10665-381036/blocks/table-047"
      ]
    },
    {
      "id": "page-992",
      "number": null,
      "title": "Page 992",
      "level": 1,
      "pageStart": 992,
      "pageEnd": 992,
      "labelStart": "129",
      "labelEnd": "129",
      "words": 135,
      "summary": {
        "text": "A continuation of the Drummond checklist table for novel skin test studies, covering how effectiveness was established and which costs were identified.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "yes",
          "heading": false
        },
        {
          "term": "observational data",
          "heading": false
        },
        {
          "term": "ppd-l",
          "heading": false
        },
        {
          "term": "clinical studies",
          "heading": false
        }
      ],
      "extract": "129 3.2. Was effectiveness established through an overview of clinical studies? Yes. Sensitivity and specificity of tests values from number of clinical studies. No, cost analysis, no CE Yes 3.3. Were observational data or assumptions used to establish effectiveness? If so, what are the potential biases in results? Yes. Observational data, no time horizon/discounting provided. N/A Assumption on the proportion of",
      "extractCut": true,
      "blocks": [
        "library/10665-381036/blocks/prose-page-992"
      ]
    },
    {
      "id": "page-993",
      "number": null,
      "title": "Page 993",
      "level": 1,
      "pageStart": 993,
      "pageEnd": 993,
      "labelStart": "130",
      "labelEnd": "130",
      "words": 210,
      "summary": {
        "text": "A continuation of the Drummond checklist for novel skin test studies, covering cost components, measurement and valuation.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "market values",
          "heading": false
        },
        {
          "term": "operating costs",
          "heading": false
        },
        {
          "term": "outcome costs",
          "heading": false
        },
        {
          "term": "yes",
          "heading": false
        },
        {
          "term": "unclear",
          "heading": false
        },
        {
          "term": "stated",
          "heading": false
        }
      ],
      "extract": "130 4.3. Were the capital costs, as well as operating costs, included? Test and treatment costs included, the rest is unclear Only research costs, sample analyses costs, preventive treatment, consultation and Xrays Yes, it included treatment, diagnostic, drugs and chemoteraphy costs, registering and operating costs, among others 5. Were costs and consequences measured accurately in appropriate physical units? 5.1.",
      "extractCut": true,
      "blocks": [
        "library/10665-381036/blocks/prose-page-993"
      ]
    },
    {
      "id": "page-994",
      "number": null,
      "title": "Page 994",
      "level": 1,
      "pageStart": 994,
      "pageEnd": 994,
      "labelStart": "131",
      "labelEnd": "131",
      "words": 194,
      "summary": {
        "text": "A continuation of the Drummond checklist for novel skin test studies, covering discounting, incremental analysis and sensitivity analysis.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "yes",
          "heading": false
        },
        {
          "term": "consequences",
          "heading": false
        },
        {
          "term": "costs",
          "heading": false
        },
        {
          "term": "stated",
          "heading": false
        },
        {
          "term": "parameters",
          "heading": false
        }
      ],
      "extract": "131 6.4. Was the valuation of consequences appropriate for the question posed? Yes N/A Yes 7. Were costs and consequences adjusted for differential timing? 7.1. Were costs and consequences that occur in the future ‘discounted’ to their present values? No N/A Not stated 7.2. Was there any justification given for the discount rate used? Discounting rate No stated N/A N/A 8. Was an incremental analysis of costs and",
      "extractCut": true,
      "blocks": [
        "library/10665-381036/blocks/prose-page-994"
      ]
    },
    {
      "id": "page-995",
      "number": null,
      "title": "Page 995",
      "level": 1,
      "pageStart": 995,
      "pageEnd": 995,
      "labelStart": "132",
      "labelEnd": "132",
      "words": 147,
      "summary": {
        "text": "A continuation of the Drummond checklist for novel skin test studies, covering how results and conclusions were presented and discussed.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "yes",
          "heading": false
        },
        {
          "term": "rubles",
          "heading": false
        },
        {
          "term": "ratio",
          "heading": false
        },
        {
          "term": "allude",
          "heading": false
        }
      ],
      "extract": "132 to changes in key parameters with the cost of a second clinical visit being the most influential to the cost-effectiveness ratios 10. Did the presentation and discussion of study results include all issues of concern to users? 10.1. Were the conclusions of the analysis based on some overall index or ratio of costs to consequences (e.g. cost-effectiveness ratio)? Yes (2.28 rubles compared to 3.42) Yes 10.2. Were",
      "extractCut": true,
      "blocks": [
        "library/10665-381036/blocks/prose-page-995"
      ]
    },
    {
      "id": "page-996",
      "number": null,
      "title": "Page 996",
      "level": 1,
      "pageStart": 996,
      "pageEnd": 996,
      "labelStart": "133",
      "labelEnd": "133",
      "words": 39,
      "summary": {
        "text": "The final checklist item for the first three novel skin test studies, on whether implementation feasibility was discussed.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "redeployed",
          "heading": false
        },
        {
          "term": "yes",
          "heading": false
        },
        {
          "term": "freed",
          "heading": false
        }
      ],
      "extract": "133 10.5. Did the study discuss issues of implementation, such as the feasibility of adopting the ‘preferred’ programme given existing financial or other constraints, and whether any freed resources could be redeployed to other worthwhile programmes? Yes Yes No",
      "extractCut": false,
      "blocks": [
        "library/10665-381036/blocks/prose-page-996"
      ]
    },
    {
      "id": "page-997",
      "number": null,
      "title": "Page 997",
      "level": 1,
      "pageStart": 997,
      "pageEnd": 997,
      "labelStart": "134",
      "labelEnd": "134",
      "words": 163,
      "summary": {
        "text": "A continuation of Table A7 applying the Drummond checklist to four more Diaskintest studies, covering study questions, alternatives and effectiveness.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "yes",
          "heading": false
        },
        {
          "term": "alternatives",
          "heading": false
        },
        {
          "term": "chugaev",
          "heading": false
        },
        {
          "term": "moiseeva",
          "heading": false
        },
        {
          "term": "sinitsyn",
          "heading": false
        }
      ],
      "extract": "134 Continuation of Table A7 Drummond Checklist Questions Moiseeva 2014 Solodun 2017 Sinitsyn 2018 Chugaev 2020 1. Was a well-defined question posed in answerable form? 1.1. Did the study examine both costs and effects of the service(s) or programme(s)? Yes Yes Yes Yes 1.2. Did the study involve a comparison of alternatives? Yes Yes Yes Yes 1.3. Was a viewpoint for the analysis stated and was the study placed in any",
      "extractCut": true,
      "blocks": [
        "library/10665-381036/blocks/prose-page-997"
      ]
    },
    {
      "id": "page-998",
      "number": null,
      "title": "Page 998",
      "level": 1,
      "pageStart": 998,
      "pageEnd": 998,
      "labelStart": "135",
      "labelEnd": "135",
      "words": 140,
      "summary": {
        "text": "A continuation of the Drummond checklist for further novel skin test studies, covering effectiveness evidence and cost components.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "yes",
          "heading": false
        },
        {
          "term": "operating costs",
          "heading": false
        },
        {
          "term": "observational data",
          "heading": false
        },
        {
          "term": "do-nothing",
          "heading": false
        },
        {
          "term": "computed",
          "heading": false
        }
      ],
      "extract": "135 3.2. Was effectiveness established through an overview of clinical studies? Yes Yes Yes, CB analysis Yes 3.3. Were observational data or assumptions used to establish effectiveness? If so, what are the potential biases in results? Not clear CE method used Yes, it uses observational data from specific settings Yes, ICER is not computed and no other interventions were employed rather than do-nothing and",
      "extractCut": true,
      "blocks": [
        "library/10665-381036/blocks/prose-page-998"
      ]
    },
    {
      "id": "page-999",
      "number": null,
      "title": "Page 999",
      "level": 1,
      "pageStart": 999,
      "pageEnd": 999,
      "labelStart": "136",
      "labelEnd": "136",
      "words": 195,
      "summary": {
        "text": "A continuation of the Drummond checklist for further novel skin test studies, covering measurement, valuation and discounting.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "market values",
          "heading": false
        },
        {
          "term": "yes",
          "heading": false
        },
        {
          "term": "consequences",
          "heading": false
        },
        {
          "term": "treasure",
          "heading": false
        },
        {
          "term": "stated",
          "heading": false
        }
      ],
      "extract": "136 5.1. Were any of the identified items omitted from measurement? If so, does this mean that they carried no weight in the subsequent analysis? No No No No 5.2. Were there any special circumstances (e.g., joint use of resources) that made measurement difficult? Were these circumstances handled appropriately? No No No No 6. Were the cost and consequences valued credibly? 6.1. Were the sources of all values clearly",
      "extractCut": true,
      "blocks": [
        "library/10665-381036/blocks/prose-page-999"
      ]
    },
    {
      "id": "page-1000",
      "number": null,
      "title": "Page 1000",
      "level": 1,
      "pageStart": 1000,
      "pageEnd": 1000,
      "labelStart": "137",
      "labelEnd": "137",
      "words": 178,
      "summary": {
        "text": "A continuation of the Drummond checklist for further novel skin test studies, covering incremental and sensitivity analyses and the basis of conclusions.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "analyses employed",
          "heading": false
        },
        {
          "term": "non sensitivity",
          "heading": false
        },
        {
          "term": "yes",
          "heading": false
        },
        {
          "term": "consequences",
          "heading": false
        },
        {
          "term": "costs",
          "heading": false
        }
      ],
      "extract": "137 8. Was an incremental analysis of costs and consequences of alternatives performed? 8.1. Were the additional (incremental) costs generated by one alternative over another compared to the additional effects, benefits, or utilities generated? Yes Yes Non ICER computed, comparison between two alternatives Yes Diaskin over TST, costs saved 9. Was allowance made for uncertainty in the estimates of costs and",
      "extractCut": true,
      "blocks": [
        "library/10665-381036/blocks/prose-page-1000"
      ]
    },
    {
      "id": "page-1001",
      "number": null,
      "title": "Page 1001",
      "level": 1,
      "pageStart": 1001,
      "pageEnd": 1001,
      "labelStart": "138",
      "labelEnd": "138",
      "words": 124,
      "summary": {
        "text": "The last Drummond checklist items for further novel skin test studies, on comparison with other work, generalisability and implementation.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "study discuss",
          "heading": false
        },
        {
          "term": "allude",
          "heading": false
        },
        {
          "term": "redeployed",
          "heading": false
        }
      ],
      "extract": "138 10.2. Were the results compared with those of others who have investigated the same question? If so, were allowances made for potential differences in study methodology? No No No No 10.3. Did the study discuss the generalisability of the results to other settings and patient/client groups? No No No Yes 10.4. Did the study allude to, or take account of, other important factors in the choice or decision under",
      "extractCut": true,
      "blocks": [
        "library/10665-381036/blocks/prose-page-1001"
      ]
    },
    {
      "id": "page-1002",
      "number": null,
      "title": "Page 1002",
      "level": 1,
      "pageStart": 1002,
      "pageEnd": 1002,
      "labelStart": "139",
      "labelEnd": "139",
      "words": 201,
      "summary": {
        "text": "Table A8 begins applying the Drummond checklist to economic studies of the tuberculin skin test and IGRA, for five studies from 2011–2012.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "yes",
          "heading": false
        },
        {
          "term": "drummond checklist",
          "heading": false
        },
        {
          "term": "nothing",
          "heading": false
        },
        {
          "term": "healthcare workers",
          "heading": false
        },
        {
          "term": "alternatives",
          "heading": false
        },
        {
          "term": "usa",
          "heading": false
        }
      ],
      "extract": "139 Table A8. Drummond Checklist for studies quality: Cost/Cost-effectiveness analyses for TST or IGRA for diagnosing TBI Drummond Checklist Questions Linas (2011) Pareek (2011) del Campo (2012) Eralp (2012) Shah (2012) 1. Was a well-defined question posed in answerable form? 1.1. Did the study examine both costs and effects of the service(s) or programme(s)? Yes Yes Yes Yes Yes 1.2. Did the study involve a",
      "extractCut": true,
      "blocks": [
        "library/10665-381036/blocks/prose-page-1002",
        "library/10665-381036/blocks/table-048"
      ]
    },
    {
      "id": "page-1003",
      "number": null,
      "title": "Page 1003",
      "level": 1,
      "pageStart": 1003,
      "pageEnd": 1003,
      "labelStart": "140",
      "labelEnd": "140",
      "words": 236,
      "summary": {
        "text": "A continuation of Table A8, covering effectiveness evidence and the range of costs and consequences for the first five tuberculin skin test and IGRA studies.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "references reasoned",
          "heading": false
        },
        {
          "term": "assumptions references",
          "heading": false
        },
        {
          "term": "effectiveness assumptions",
          "heading": false
        },
        {
          "term": "yes",
          "heading": false
        },
        {
          "term": "tests values",
          "heading": false
        },
        {
          "term": "clinical studies",
          "heading": false
        },
        {
          "term": "key assumption",
          "heading": false
        },
        {
          "term": "ltbi",
          "heading": false
        }
      ],
      "extract": "140 controlled clinical trial? If so, did the trial protocol reflect what would happen in regular practice? 3.2. Was effectiveness established through an overview of clinical studies? Yes. Sensitivity and specificity of tests values from number of clinical studies. Yes. Sensitivity and specificity of tests values from number of clinical studies. Yes. Sensitivity and specificity of tests values from number of",
      "extractCut": true,
      "blocks": [
        "library/10665-381036/blocks/prose-page-1003"
      ]
    },
    {
      "id": "page-1004",
      "number": null,
      "title": "Page 1004",
      "level": 1,
      "pageStart": 1004,
      "pageEnd": 1004,
      "labelStart": "141",
      "labelEnd": "141",
      "words": 161,
      "summary": {
        "text": "A continuation of Table A8, covering which cost components were included and how costs were valued.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "yes",
          "heading": false
        },
        {
          "term": "operating costs",
          "heading": false
        },
        {
          "term": "rent",
          "heading": false
        },
        {
          "term": "overheads",
          "heading": false
        },
        {
          "term": "measurement",
          "heading": false
        }
      ],
      "extract": "141 4.3. Were the capital costs, as well as operating costs, included? No. State only direct medical costs included. No. No. Yes, stated overheads included but no description provided. Yes, operating costs such as quality assurance, specimen transport, supply delivery, and estimates for rent and utilities included. 5. Were costs and consequences measured accurately in appropriate physical units? 5.1. Were any of the",
      "extractCut": true,
      "blocks": [
        "library/10665-381036/blocks/prose-page-1004"
      ]
    },
    {
      "id": "page-1005",
      "number": null,
      "title": "Page 1005",
      "level": 1,
      "pageStart": 1005,
      "pageEnd": 1005,
      "labelStart": "142",
      "labelEnd": "142",
      "words": 166,
      "summary": {
        "text": "A continuation of Table A8, covering valuation of consequences, discounting and incremental analysis.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "discount rate",
          "heading": false
        },
        {
          "term": "market values",
          "heading": false
        },
        {
          "term": "yes",
          "heading": false
        },
        {
          "term": "consequences",
          "heading": false
        },
        {
          "term": "costs",
          "heading": false
        }
      ],
      "extract": "142 6.3. Where market values were absent (e.g. volunteer labour), or market values did not reflect actual values (such as clinic space donated at a reduced rate), were adjustments made to approximate market values? N/A N/A N/A N/A N/A 6.4. Was the valuation of consequences appropriate for the question posed? Yes Yes Yes Yes Yes 7. Were costs and consequences adjusted for differential timing? 7.1. Were costs and",
      "extractCut": true,
      "blocks": [
        "library/10665-381036/blocks/prose-page-1005"
      ]
    },
    {
      "id": "page-1006",
      "number": null,
      "title": "Page 1006",
      "level": 1,
      "pageStart": 1006,
      "pageEnd": 1006,
      "labelStart": "143",
      "labelEnd": "143",
      "words": 131,
      "summary": {
        "text": "A continuation of Table A8, covering allowance for uncertainty and the basis of study conclusions.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "yes",
          "heading": false
        },
        {
          "term": "consequences",
          "heading": false
        },
        {
          "term": "parameters",
          "heading": false
        },
        {
          "term": "conclusions",
          "heading": false
        }
      ],
      "extract": "143 9. Was allowance made for uncertainty in the estimates of costs and consequences? 9.1. If data on costs and consequences were stochastic (randomly determined sequence of observations), were appropriate statistical analyses performed? Yes Yes Yes Yes Yes 9.2. If sensitivity analysis was employed, was justification provided for the range of values (or for key study parameters)? Yes Yes Yes Yes Yes 9.3. Were the",
      "extractCut": true,
      "blocks": [
        "library/10665-381036/blocks/prose-page-1006"
      ]
    },
    {
      "id": "page-1007",
      "number": null,
      "title": "Page 1007",
      "level": 1,
      "pageStart": 1007,
      "pageEnd": 1007,
      "labelStart": "144",
      "labelEnd": "144",
      "words": 128,
      "summary": {
        "text": "A continuation of Table A8, covering comparison with other studies, generalisability and implementation issues.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "yes",
          "heading": false
        },
        {
          "term": "study discuss",
          "heading": false
        },
        {
          "term": "allude",
          "heading": false
        },
        {
          "term": "redeployed",
          "heading": false
        }
      ],
      "extract": "144 10.2. Were the results compared with those of others who have investigated the same question? If so, were allowances made for potential differences in study methodology? No Yes Yes No No 10.3. Did the study discuss the generalisability of the results to other settings and patient/client groups? No Yes No No Yes 10.4. Did the study allude to, or take account of, other important factors in the choice or decision",
      "extractCut": true,
      "blocks": [
        "library/10665-381036/blocks/prose-page-1007"
      ]
    },
    {
      "id": "page-1008",
      "number": null,
      "title": "Page 1008",
      "level": 1,
      "pageStart": 1008,
      "pageEnd": 1008,
      "labelStart": "145",
      "labelEnd": "145",
      "words": 201,
      "summary": {
        "text": "A continuation of Table A8 for five studies from 2013, covering study questions, alternatives and effectiveness.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "yes",
          "heading": false
        },
        {
          "term": "nothing",
          "heading": false
        },
        {
          "term": "alternatives",
          "heading": false
        },
        {
          "term": "ibd",
          "heading": false
        },
        {
          "term": "swaminath",
          "heading": false
        }
      ],
      "extract": "145 Continuation of Table A8 Drummond Checklist Questions Mandalakas (2013) Pareek (2013) Steffen (2013) Swaminath (2013) Verma (2013) 1. Was a well-defined question posed in answerable form? 1.1. Did the study examine both costs and effects of the service(s) or programme(s)? Yes Yes Yes Yes Yes 1.2. Did the study involve a comparison of alternatives? Yes Yes Yes Yes Yes 1.3. Was a viewpoint for the analysis stated",
      "extractCut": true,
      "blocks": [
        "library/10665-381036/blocks/prose-page-1008"
      ]
    },
    {
      "id": "page-1009",
      "number": null,
      "title": "Page 1009",
      "level": 1,
      "pageStart": 1009,
      "pageEnd": 1009,
      "labelStart": "146",
      "labelEnd": "146",
      "words": 217,
      "summary": {
        "text": "A continuation of the Drummond checklist for the 2013 studies, covering effectiveness evidence and the range of costs and consequences.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "yes",
          "heading": false
        },
        {
          "term": "references reasoning",
          "heading": false
        },
        {
          "term": "tests values",
          "heading": false
        },
        {
          "term": "clinical studies",
          "heading": false
        },
        {
          "term": "assumptions",
          "heading": false
        },
        {
          "term": "effectiveness",
          "heading": false
        },
        {
          "term": "specificity",
          "heading": false
        }
      ],
      "extract": "146 happen in regular practice? 3.2. Was effectiveness established through an overview of clinical studies? Yes. Sensitivity and specificity of tests values from number of clinical studies. Yes. Sensitivity and specificity of tests values from number of clinical studies. Yes. Sensitivity and specificity of tests values from number of clinical studies. Yes. Sensitivity and specificity of tests values from number of",
      "extractCut": true,
      "blocks": [
        "library/10665-381036/blocks/prose-page-1009"
      ]
    },
    {
      "id": "page-1010",
      "number": null,
      "title": "Page 1010",
      "level": 1,
      "pageStart": 1010,
      "pageEnd": 1010,
      "labelStart": "147",
      "labelEnd": "147",
      "words": 189,
      "summary": {
        "text": "A continuation of the Drummond checklist for the 2013 studies, covering cost components and the sources of values.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "hospitalisation costs",
          "heading": false
        },
        {
          "term": "operating costs",
          "heading": false
        },
        {
          "term": "yes",
          "heading": false
        },
        {
          "term": "breakdown",
          "heading": false
        },
        {
          "term": "assumed",
          "heading": false
        },
        {
          "term": "state",
          "heading": false
        }
      ],
      "extract": "147 4.3. Were the capital costs, as well as operating costs, included? Unclear. Outpatient hospitalisation costs included but no description provided. No, state only direct medical costs included and clearly state breakdown of hospitalisation costs. No. No, authors use Linas 2011 hospitalisation costs. No. Hospitalisation costs breakdown do not state any overheads/operating costs. 5. Were costs and consequences",
      "extractCut": true,
      "blocks": [
        "library/10665-381036/blocks/prose-page-1010"
      ]
    },
    {
      "id": "page-1011",
      "number": null,
      "title": "Page 1011",
      "level": 1,
      "pageStart": 1011,
      "pageEnd": 1011,
      "labelStart": "148",
      "labelEnd": "148",
      "words": 140,
      "summary": {
        "text": "A continuation of the Drummond checklist for the 2013 studies, covering market values, discounting and the discount rate used.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "market values",
          "heading": false
        },
        {
          "term": "yes",
          "heading": false
        },
        {
          "term": "consequences",
          "heading": false
        },
        {
          "term": "rate",
          "heading": false
        }
      ],
      "extract": "148 6.2. Were market values employed for changes involving resources gained or depleted? Yes Yes Yes Yes Yes 6.3. Where market values were absent (e.g. volunteer labour), or market values did not reflect actual values (such as clinic space donated at a reduced rate), were adjustments made to approximate market values? N/A N/A N/A N/A N/A 6.4. Was the valuation of consequences appropriate for the question posed? Yes",
      "extractCut": true,
      "blocks": [
        "library/10665-381036/blocks/prose-page-1011"
      ]
    },
    {
      "id": "page-1012",
      "number": null,
      "title": "Page 1012",
      "level": 1,
      "pageStart": 1012,
      "pageEnd": 1012,
      "labelStart": "149",
      "labelEnd": "149",
      "words": 147,
      "summary": {
        "text": "A continuation of the Drummond checklist for the 2013 studies, covering incremental analysis and sensitivity of results to key parameters.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "yes",
          "heading": false
        },
        {
          "term": "sensitive",
          "heading": false
        },
        {
          "term": "costs",
          "heading": false
        },
        {
          "term": "stochastic",
          "heading": false
        },
        {
          "term": "generated",
          "heading": false
        }
      ],
      "extract": "149 8.1. Were the additional (incremental) costs generated by one alternative over another compared to the additional effects, benefits, or utilities generated? Yes Yes Yes Yes Yes 9. Was allowance made for uncertainty in the estimates of costs and consequences? 9.1. If data on costs and consequences were stochastic (randomly determined sequence of observations), were appropriate statistical analyses performed? Yes",
      "extractCut": true,
      "blocks": [
        "library/10665-381036/blocks/prose-page-1012"
      ]
    },
    {
      "id": "page-1013",
      "number": null,
      "title": "Page 1013",
      "level": 1,
      "pageStart": 1013,
      "pageEnd": 1013,
      "labelStart": "150",
      "labelEnd": "150",
      "words": 130,
      "summary": {
        "text": "A continuation of the Drummond checklist for the 2013 studies, covering how conclusions were reached and other factors considered.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "yes",
          "heading": false
        },
        {
          "term": "ratio",
          "heading": false
        },
        {
          "term": "conclusions",
          "heading": false
        },
        {
          "term": "allude",
          "heading": false
        }
      ],
      "extract": "150 10.1. Were the conclusions of the analysis based on some overall index or ratio of costs to consequences (e.g. cost- effectiveness ratio)? Yes Yes Yes No No cost-effectiveness ratio was used. Conclusions were based on “highest benefits” and “lowest cost” strategy. Yes 10.2. Were the results compared with those of others who have investigated the same question? If so, were allowances made for potential",
      "extractCut": true,
      "blocks": [
        "library/10665-381036/blocks/prose-page-1013"
      ]
    },
    {
      "id": "page-1014",
      "number": null,
      "title": "Page 1014",
      "level": 1,
      "pageStart": 1014,
      "pageEnd": 1014,
      "labelStart": "151",
      "labelEnd": "151",
      "words": 41,
      "summary": {
        "text": "The final Drummond checklist item for the 2013 studies, on discussion of implementation feasibility.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "yes",
          "heading": false
        },
        {
          "term": "redeployed",
          "heading": false
        },
        {
          "term": "freed",
          "heading": false
        }
      ],
      "extract": "151 10.5. Did the study discuss issues of implementation, such as the feasibility of adopting the ‘preferred’ programme given existing financial or other constraints, and whether any freed resources could be redeployed to other worthwhile programmes? Yes Yes Yes No No",
      "extractCut": false,
      "blocks": [
        "library/10665-381036/blocks/prose-page-1014"
      ]
    },
    {
      "id": "page-1015",
      "number": null,
      "title": "Page 1015",
      "level": 1,
      "pageStart": 1015,
      "pageEnd": 1015,
      "labelStart": "152",
      "labelEnd": "152",
      "words": 5,
      "summary": {
        "text": "A near-blank page carrying only a page number and the heading for a continuation of Table A8.",
        "status": "draft"
      },
      "keywords": [],
      "extract": "152 Continuation of Table A8",
      "extractCut": false,
      "blocks": [
        "library/10665-381036/blocks/prose-page-1015"
      ]
    },
    {
      "id": "page-1016",
      "number": null,
      "title": "Page 1016",
      "level": 1,
      "pageStart": 1016,
      "pageEnd": 1016,
      "labelStart": "153",
      "labelEnd": "153",
      "words": 174,
      "summary": {
        "text": "Begins a table applying the Drummond checklist for economic evaluations to five cost-effectiveness studies of tuberculosis infection testing published in 2015–2017. All five compared costs and effects of alternatives for groups such as people with HIV, refugees, immigrants and people entering jail, and most included a do-nothing option.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "yes",
          "heading": false
        },
        {
          "term": "nothing",
          "heading": false
        },
        {
          "term": "refugees",
          "heading": false
        },
        {
          "term": "alternatives",
          "heading": false
        },
        {
          "term": "wingate",
          "heading": false
        }
      ],
      "extract": "153 Drummond Checklist Questions Capocci, (2015) Wingate (2015) Auguste. (2016) Nijhawan (2016) Campbell (2017) 2. Was a well-defined question posed in answerable form? 1.1. Did the study examine both costs and effects of the service(s) or programme(s)? Yes Yes Yes Yes Yes 1.2. Did the study involve a comparison of alternatives? Yes Yes Yes Yes Yes 1.3. Was a viewpoint for the analysis stated and was the study",
      "extractCut": true,
      "blocks": [
        "library/10665-381036/blocks/prose-page-1016"
      ]
    },
    {
      "id": "page-1017",
      "number": null,
      "title": "Page 1017",
      "level": 1,
      "pageStart": 1017,
      "pageEnd": 1017,
      "labelStart": "154",
      "labelEnd": "154",
      "words": 190,
      "summary": {
        "text": "Continues the Drummond checklist table for the same five studies, on how effectiveness was established. None used randomized trials; most drew test sensitivity and specificity from clinical studies or reviews, and the table notes how well their assumptions were referenced.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "references reasoning",
          "heading": false
        },
        {
          "term": "yes",
          "heading": false
        },
        {
          "term": "clinical studies",
          "heading": false
        },
        {
          "term": "adequate references",
          "heading": false
        },
        {
          "term": "assumptions",
          "heading": false
        },
        {
          "term": "clinical study",
          "heading": false
        }
      ],
      "extract": "154 3.1. Was this done through a randomised, controlled clinical trial? If so, did the trial protocol reflect what would happen in regular practice? No No No No No 3.2. Was effectiveness established through an overview of clinical studies? Somewhat. Sensitivity of IGRA used from one clinical study. Yes Sensitivity and specificity of TST values from number of clinical studies Yes Systematic review carried out to",
      "extractCut": true,
      "blocks": [
        "library/10665-381036/blocks/prose-page-1017"
      ]
    },
    {
      "id": "page-1018",
      "number": null,
      "title": "Page 1018",
      "level": 1,
      "pageStart": 1018,
      "pageEnd": 1018,
      "labelStart": "155",
      "labelEnd": "155",
      "words": 168,
      "summary": {
        "text": "Continues the checklist table on whether the studies identified and measured all relevant costs and consequences. It records gaps such as unclear cost breakdowns, missing capital costs and one study omitting treatment and outcome costs.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "yes",
          "heading": false
        },
        {
          "term": "capital costs",
          "heading": false
        },
        {
          "term": "qft-git",
          "heading": false
        },
        {
          "term": "breakdown",
          "heading": false
        },
        {
          "term": "overheads",
          "heading": false
        }
      ],
      "extract": "155 4.1. Was the range wide enough for the research question at hand? Yes Yes Yes Yes Yes 4.2. Did it cover all relevant viewpoints? Yes Yes Yes Yes Yes 4.3. Were the capital costs, as well as operating costs, included? Unclear breakdown of costs provided. No. Includes labour but no indication of other operating/capital costs. No. Clear breakdown provided and capital/overheads not included. Yes. For QFT-GIT",
      "extractCut": true,
      "blocks": [
        "library/10665-381036/blocks/prose-page-1018"
      ]
    },
    {
      "id": "page-1019",
      "number": null,
      "title": "Page 1019",
      "level": 1,
      "pageStart": 1019,
      "pageEnd": 1019,
      "labelStart": "156",
      "labelEnd": "156",
      "words": 154,
      "summary": {
        "text": "Continues the checklist on valuation and discounting, noting that future costs were mostly discounted at 1.5–3.5% with rates justified by national guidance, while one study did not discount.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "market values",
          "heading": false
        },
        {
          "term": "yes",
          "heading": false
        },
        {
          "term": "reference nice",
          "heading": false
        },
        {
          "term": "nice recommendations",
          "heading": false
        },
        {
          "term": "consequences",
          "heading": false
        }
      ],
      "extract": "156 6.2. Were market values employed for changes involving resources gained or depleted? Yes Yes Yes Yes Yes 6.3. Where market values were absent (e.g. volunteer labour), or market values did not reflect actual values (such as clinic space donated at a reduced rate), were adjustments made to approximate market values? N/A N/A N/A N/A N/A 6.4. Was the valuation of consequences appropriate for the question posed? Yes",
      "extractCut": true,
      "blocks": [
        "library/10665-381036/blocks/prose-page-1019"
      ]
    },
    {
      "id": "page-1020",
      "number": null,
      "title": "Page 1020",
      "level": 1,
      "pageStart": 1020,
      "pageEnd": 1020,
      "labelStart": "157",
      "labelEnd": "157",
      "words": 124,
      "summary": {
        "text": "Records that all five studies did incremental analyses and allowed for uncertainty, with only one finding its results sensitive to the treatments received.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "yes",
          "heading": false
        },
        {
          "term": "stochastic",
          "heading": false
        },
        {
          "term": "generated",
          "heading": false
        },
        {
          "term": "consequences",
          "heading": false
        }
      ],
      "extract": "157 8.1. Were the additional (incremental) costs generated by one alternative over another compared to the additional effects, benefits, or utilities generated? Yes Yes Yes Yes Yes 9. Was allowance made for uncertainty in the estimates of costs and consequences? 9.1. If data on costs and consequences were stochastic (randomly determined sequence of observations), were appropriate statistical analyses performed? Yes",
      "extractCut": true,
      "blocks": [
        "library/10665-381036/blocks/prose-page-1020"
      ]
    },
    {
      "id": "page-1021",
      "number": null,
      "title": "Page 1021",
      "level": 1,
      "pageStart": 1021,
      "pageEnd": 1021,
      "labelStart": "158",
      "labelEnd": "158",
      "words": 115,
      "summary": {
        "text": "Records whether each study reported cost-effectiveness ratios, compared results with other work, and discussed generalizability and other decision factors.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "yes",
          "heading": false
        },
        {
          "term": "ratio",
          "heading": false
        },
        {
          "term": "allude",
          "heading": false
        },
        {
          "term": "consequences",
          "heading": false
        }
      ],
      "extract": "158 10.1. Were the conclusions of the analysis based on some overall index or ratio of costs to consequences (e.g. cost- effectiveness ratio)? Yes Yes Yes No Yes 10.2. Were the results compared with those of others who have investigated the same question? If so, were allowances made for potential differences in study methodology? No Yes Yes Yes Yes 10.3. Did the study discuss the generalisability of the results to",
      "extractCut": true,
      "blocks": [
        "library/10665-381036/blocks/prose-page-1021"
      ]
    },
    {
      "id": "page-1022",
      "number": null,
      "title": "Page 1022",
      "level": 1,
      "pageStart": 1022,
      "pageEnd": 1022,
      "labelStart": "159",
      "labelEnd": "159",
      "words": 41,
      "summary": {
        "text": "Records whether each study discussed implementation issues such as feasibility and redeployment of freed resources.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "yes",
          "heading": false
        },
        {
          "term": "redeployed",
          "heading": false
        },
        {
          "term": "freed",
          "heading": false
        }
      ],
      "extract": "159 10.5. Did the study discuss issues of implementation, such as the feasibility of adopting the ‘preferred’ programme given existing financial or other constraints, and whether any freed resources could be redeployed to other worthwhile programmes? Yes No Yes Yes Yes",
      "extractCut": false,
      "blocks": [
        "library/10665-381036/blocks/prose-page-1022"
      ]
    },
    {
      "id": "page-1023",
      "number": null,
      "title": "Page 1023",
      "level": 1,
      "pageStart": 1023,
      "pageEnd": 1023,
      "labelStart": "160",
      "labelEnd": "160",
      "words": 5,
      "summary": {
        "text": "A page marking the continuation of Table A8.",
        "status": "draft"
      },
      "keywords": [],
      "extract": "160 Continuation of Table A8",
      "extractCut": false,
      "blocks": [
        "library/10665-381036/blocks/prose-page-1023"
      ]
    },
    {
      "id": "page-1024",
      "number": null,
      "title": "Page 1024",
      "level": 1,
      "pageStart": 1024,
      "pageEnd": 1024,
      "labelStart": "161",
      "labelEnd": "161",
      "words": 211,
      "summary": {
        "text": "Applies the Drummond checklist to a second set of five cost-effectiveness studies of tuberculosis infection testing from 2017–2018. Their target groups include young immigrants to Norway, health workers, US-born people and migrants, recent UK immigrants and elderly care home residents in Hong Kong.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "yes",
          "heading": false
        },
        {
          "term": "nothing",
          "heading": false
        },
        {
          "term": "alternatives",
          "heading": false
        },
        {
          "term": "haukaas",
          "heading": false
        },
        {
          "term": "mullie",
          "heading": false
        }
      ],
      "extract": "161 Drummond Checklist Questions Haukaas (2017) Mullie (2017) Tasillo, (2017) Abubakar (2018) Li (2018) 1. Was a well-defined question posed in answerable form? 1.1. Did the study examine both costs and effects of the service(s) or programme(s)? Yes Yes Yes Yes Yes 1.2. Did the study involve a comparison of alternatives? Yes Yes Yes Yes Yes 1.3. Was a viewpoint for the analysis stated and was the study placed in any",
      "extractCut": true,
      "blocks": [
        "library/10665-381036/blocks/prose-page-1024"
      ]
    },
    {
      "id": "page-1025",
      "number": null,
      "title": "Page 1025",
      "level": 1,
      "pageStart": 1025,
      "pageEnd": 1025,
      "labelStart": "162",
      "labelEnd": "162",
      "words": 205,
      "summary": {
        "text": "Shows how the second set of studies established effectiveness, mainly from clinical studies of test accuracy, and notes key assumptions such as no quality-of-life loss from uncomplicated treatment. It also records that all covered a wide enough range of costs and viewpoints.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "references reasoning",
          "heading": false
        },
        {
          "term": "yes",
          "heading": false
        },
        {
          "term": "key assumption",
          "heading": false
        },
        {
          "term": "tests values",
          "heading": false
        },
        {
          "term": "clinical studies",
          "heading": false
        },
        {
          "term": "ltbi",
          "heading": false
        },
        {
          "term": "specificity",
          "heading": false
        }
      ],
      "extract": "162 3.2. Was effectiveness established through an overview of clinical studies? Somewhat. Sensitivity and specificity of TST values from only one study. Yes Sensitivity and specificity of tests values from number of clinical studies. Yes Sensitivity and specificity of tests values from number of clinical studies. No Yes Sensitivity and specificity of tests values from number of clinical studies. 3.3. Were",
      "extractCut": true,
      "blocks": [
        "library/10665-381036/blocks/prose-page-1025"
      ]
    },
    {
      "id": "page-1026",
      "number": null,
      "title": "Page 1026",
      "level": 1,
      "pageStart": 1026,
      "pageEnd": 1026,
      "labelStart": "163",
      "labelEnd": "163",
      "words": 189,
      "summary": {
        "text": "Records for the second set of studies whether capital and operating costs were included and whether any items were left out of measurement. Notes include unclear hospital cost breakdowns and omitted costs that may underestimate totals.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "clear breakdown",
          "heading": false
        },
        {
          "term": "hospitalisation costs",
          "heading": false
        },
        {
          "term": "yes",
          "heading": false
        },
        {
          "term": "valuation",
          "heading": false
        },
        {
          "term": "unclear",
          "heading": false
        },
        {
          "term": "capital",
          "heading": false
        }
      ],
      "extract": "163 4.3. Were the capital costs, as well as operating costs, included? Unclear. Hospitalisation costs included but no breakdown provided. Unclear. Hospitalisation costs included but no breakdown provided. Unclear. Treatment costs included but no breakdown provided. No. Clear breakdown provided and capital/overheads not included No. Clear breakdown provided and capital/overhea ds not included 5. Were costs and",
      "extractCut": true,
      "blocks": [
        "library/10665-381036/blocks/prose-page-1026"
      ]
    },
    {
      "id": "page-1027",
      "number": null,
      "title": "Page 1027",
      "level": 1,
      "pageStart": 1027,
      "pageEnd": 1027,
      "labelStart": "164",
      "labelEnd": "164",
      "words": 184,
      "summary": {
        "text": "Records discount rates of 3–5% and their justification for the second set of studies, all of which performed incremental analyses.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "yes",
          "heading": false
        },
        {
          "term": "market values",
          "heading": false
        },
        {
          "term": "current recommendations",
          "heading": false
        },
        {
          "term": "consequences",
          "heading": false
        },
        {
          "term": "state current",
          "heading": false
        },
        {
          "term": "discounted",
          "heading": false
        }
      ],
      "extract": "164 6.3. Where market values were absent (e.g. volunteer labour), or market values did not reflect actual values (such as clinic space donated at a reduced rate), were adjustments made to approximate market values? N/A N/A N/A N/A N/A 6.4. Was the valuation of consequences appropriate for the question posed? Yes Yes Yes Yes Yes 7. Were costs and consequences adjusted for differential timing? 7.1. Were costs and",
      "extractCut": true,
      "blocks": [
        "library/10665-381036/blocks/prose-page-1027"
      ]
    },
    {
      "id": "page-1028",
      "number": null,
      "title": "Page 1028",
      "level": 1,
      "pageStart": 1028,
      "pageEnd": 1028,
      "labelStart": "165",
      "labelEnd": "165",
      "words": 149,
      "summary": {
        "text": "Records statistical and sensitivity analyses for the second set of studies, noting results sensitive to IGRA cost, infection rate and TST sensitivity, and whether results were compared with other studies.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "yes",
          "heading": false
        },
        {
          "term": "sensitive",
          "heading": false
        },
        {
          "term": "ratio",
          "heading": false
        },
        {
          "term": "stochastic",
          "heading": false
        },
        {
          "term": "consequences",
          "heading": false
        }
      ],
      "extract": "165 9.1. If data on costs and consequences were stochastic (randomly determined sequence of observations), were appropriate statistical analyses performed? Yes Yes Yes Yes Yes 9.2. If sensitivity analysis was employed, was justification provided for the range of values (or for key study parameters)? No Yes Yes Yes Yes 9.3. Were the study results sensitive to changes in the values? Yes. Sensitive to IGRA cost. No Yes",
      "extractCut": true,
      "blocks": [
        "library/10665-381036/blocks/prose-page-1028"
      ]
    },
    {
      "id": "page-1029",
      "number": null,
      "title": "Page 1029",
      "level": 1,
      "pageStart": 1029,
      "pageEnd": 1029,
      "labelStart": "166",
      "labelEnd": "166",
      "words": 97,
      "summary": {
        "text": "Records whether the second set of studies discussed generalizability, other decision factors and implementation.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "yes",
          "heading": false
        },
        {
          "term": "study discuss",
          "heading": false
        },
        {
          "term": "allude",
          "heading": false
        }
      ],
      "extract": "166 10.3. Did the study discuss the generalisability of the results to other settings and patient/client groups? No Yes No Yes Yes 10.4. Did the study allude to, or take account of, other important factors in the choice or decision under consideration (e.g. distribution of costs and consequences, or relevant ethical issues)? Yes Yes Yes Yes Yes 10.5. Did the study discuss issues of implementation, such as the",
      "extractCut": true,
      "blocks": [
        "library/10665-381036/blocks/prose-page-1029"
      ]
    },
    {
      "id": "page-1030",
      "number": null,
      "title": "Page 1030",
      "level": 1,
      "pageStart": 1030,
      "pageEnd": 1030,
      "labelStart": "167",
      "labelEnd": "167",
      "words": 5,
      "summary": {
        "text": "A page marking the continuation of Table A8.",
        "status": "draft"
      },
      "keywords": [],
      "extract": "167 Continuation of Table A8",
      "extractCut": false,
      "blocks": [
        "library/10665-381036/blocks/prose-page-1030"
      ]
    },
    {
      "id": "page-1031",
      "number": null,
      "title": "Page 1031",
      "level": 1,
      "pageStart": 1031,
      "pageEnd": 1031,
      "labelStart": "168",
      "labelEnd": "168",
      "words": 186,
      "summary": {
        "text": "Applies the Drummond checklist to a third set of five studies from 2018–2019, covering adolescent contacts in Japan, immigrants to Canada, migrants with kidney disease, and health workers in Brazil and Singapore. All compared costs and effects of alternatives, and none used randomized trials.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "yes",
          "heading": false
        },
        {
          "term": "nothing",
          "heading": false
        },
        {
          "term": "hcw",
          "heading": false
        },
        {
          "term": "alternatives",
          "heading": false
        },
        {
          "term": "campbell",
          "heading": false
        }
      ],
      "extract": "168 Drummond Checklist Questions Sohn (2018). Campbell (2019a). Campbell (2019b). Loureiro (2019). Png (2019). 1. Was a well-defined question posed in answerable form? 1.1. Did the study examine both costs and effects of the service(s) or programme(s)? Yes Yes Yes Yes Yes 1.2. Did the study involve a comparison of alternatives? Yes Yes Yes Yes Yes 1.3. Was a viewpoint for the analysis stated and was the study placed",
      "extractCut": true,
      "blocks": [
        "library/10665-381036/blocks/prose-page-1031"
      ]
    },
    {
      "id": "page-1032",
      "number": null,
      "title": "Page 1032",
      "level": 1,
      "pageStart": 1032,
      "pageEnd": 1032,
      "labelStart": "169",
      "labelEnd": "169",
      "words": 214,
      "summary": {
        "text": "Shows how the third set of studies established effectiveness from clinical studies and reviews and comments on their key assumptions. One study assumed perfect test accuracy, while another gave no references for its assumptions.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "references reasoning",
          "heading": false
        },
        {
          "term": "yes",
          "heading": false
        },
        {
          "term": "adequate references",
          "heading": false
        },
        {
          "term": "assumptions",
          "heading": false
        },
        {
          "term": "tests values",
          "heading": false
        },
        {
          "term": "key assumption",
          "heading": false
        },
        {
          "term": "clinical studies",
          "heading": false
        }
      ],
      "extract": "169 3.2. Was effectiveness established through an overview of clinical studies? Yes Sensitivity and specificity of tests values from number of clinical studies and systematic reviews. Yes Sensitivity and specificity of tests values from number of clinical studies. Yes Sensitivity and specificity of tests values from number of clinical studies. Yes Sensitivity and specificity of tests values from number of clinical",
      "extractCut": true,
      "blocks": [
        "library/10665-381036/blocks/prose-page-1032"
      ]
    },
    {
      "id": "page-1033",
      "number": null,
      "title": "Page 1033",
      "level": 1,
      "pageStart": 1033,
      "pageEnd": 1033,
      "labelStart": "170",
      "labelEnd": "170",
      "words": 178,
      "summary": {
        "text": "Records cost coverage for the third set of studies, such as whether overheads and equipment were included. It also notes omitted items judged to have minimal impact and whether value sources were stated.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "hospitalisation costs",
          "heading": false
        },
        {
          "term": "capital costs",
          "heading": false
        },
        {
          "term": "yes",
          "heading": false
        },
        {
          "term": "minimal impact",
          "heading": false
        },
        {
          "term": "breakdown",
          "heading": false
        },
        {
          "term": "assumed",
          "heading": false
        }
      ],
      "extract": "170 4.3. Were the capital costs, as well as operating costs, included? Yes. Includes overheads and vehicle operations. Unclear. Hospitalisation costs included but no breakdown provided. Unclear. Hospitalisation costs included but no breakdown provided. Yes. No capital costs stated but equipment use costs clearly included. Yes. State that hospitalisation and testing costs include labour and overhead costs. 5. Were",
      "extractCut": true,
      "blocks": [
        "library/10665-381036/blocks/prose-page-1033"
      ]
    },
    {
      "id": "page-1034",
      "number": null,
      "title": "Page 1034",
      "level": 1,
      "pageStart": 1034,
      "pageEnd": 1034,
      "labelStart": "171",
      "labelEnd": "171",
      "words": 172,
      "summary": {
        "text": "Records discounting choices for the third set of studies, with some not discounting because of short time horizons, and confirms that all did incremental analyses.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "market values",
          "heading": false
        },
        {
          "term": "yes",
          "heading": false
        },
        {
          "term": "short horizon",
          "heading": false
        },
        {
          "term": "state due",
          "heading": false
        },
        {
          "term": "consequences",
          "heading": false
        }
      ],
      "extract": "171 6.3. Where market values were absent (e.g. volunteer labour), or market values did not reflect actual values (such as clinic space donated at a reduced rate), were adjustments made to approximate market values? N/A N/A N/A N/A N/A 6.4. Was the valuation of consequences appropriate for the question posed? Yes Yes Yes Yes Yes 7. Were costs and consequences adjusted for differential timing? 7.1. Were costs and",
      "extractCut": true,
      "blocks": [
        "library/10665-381036/blocks/prose-page-1034"
      ]
    },
    {
      "id": "page-1035",
      "number": null,
      "title": "Page 1035",
      "level": 1,
      "pageStart": 1035,
      "pageEnd": 1035,
      "labelStart": "172",
      "labelEnd": "172",
      "words": 139,
      "summary": {
        "text": "Records sensitivity analyses for the third set of studies, including sensitivity to QFT-GIT cost and to migrants' origin, and whether conclusions used cost-effectiveness ratios.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "yes",
          "heading": false
        },
        {
          "term": "sensitivity analysis",
          "heading": false
        },
        {
          "term": "consequences",
          "heading": false
        },
        {
          "term": "ratio",
          "heading": false
        },
        {
          "term": "stochastic",
          "heading": false
        }
      ],
      "extract": "172 9. Was allowance made for uncertainty in the estimates of costs and consequences? 9.1. If data on costs and consequences were stochastic (randomly determined sequence of observations), were appropriate statistical analyses performed? Yes Yes Yes Yes Yes 9.2. If sensitivity analysis was employed, was justification provided for the range of values (or for key study parameters)? Yes Yes Yes Yes Yes 9.3. Were the",
      "extractCut": true,
      "blocks": [
        "library/10665-381036/blocks/prose-page-1035"
      ]
    },
    {
      "id": "page-1036",
      "number": null,
      "title": "Page 1036",
      "level": 1,
      "pageStart": 1036,
      "pageEnd": 1036,
      "labelStart": "173",
      "labelEnd": "173",
      "words": 128,
      "summary": {
        "text": "Records whether the third set of studies compared results with others and discussed generalizability, decision factors and implementation.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "yes",
          "heading": false
        },
        {
          "term": "study discuss",
          "heading": false
        },
        {
          "term": "allude",
          "heading": false
        },
        {
          "term": "redeployed",
          "heading": false
        }
      ],
      "extract": "173 10.2. Were the results compared with those of others who have investigated the same question? If so, were allowances made for potential differences in study methodology? Yes Yes Yes Yes Yes 10.3. Did the study discuss the generalisability of the results to other settings and patient/client groups? Yes Yes Yes No Yes 10.4. Did the study allude to, or take account of, other important factors in the choice or",
      "extractCut": true,
      "blocks": [
        "library/10665-381036/blocks/prose-page-1036"
      ]
    },
    {
      "id": "page-1037",
      "number": null,
      "title": "Page 1037",
      "level": 1,
      "pageStart": 1037,
      "pageEnd": 1037,
      "labelStart": "174",
      "labelEnd": "174",
      "words": 1,
      "summary": {
        "text": "A page containing only a page number.",
        "status": "draft"
      },
      "keywords": [],
      "extract": "174",
      "extractCut": false,
      "blocks": [
        "library/10665-381036/blocks/prose-page-1037"
      ]
    },
    {
      "id": "page-1038",
      "number": null,
      "title": "Page 1038",
      "level": 1,
      "pageStart": 1038,
      "pageEnd": 1038,
      "labelStart": "175",
      "labelEnd": "175",
      "words": 5,
      "summary": {
        "text": "A page marking the continuation of Table A8.",
        "status": "draft"
      },
      "keywords": [],
      "extract": "175 Continuation of Table A8",
      "extractCut": false,
      "blocks": [
        "library/10665-381036/blocks/prose-page-1038"
      ]
    },
    {
      "id": "page-1039",
      "number": null,
      "title": "Page 1039",
      "level": 1,
      "pageStart": 1039,
      "pageEnd": 1039,
      "labelStart": "176",
      "labelEnd": "176",
      "words": 224,
      "summary": {
        "text": "Applies the Drummond checklist to a final four studies from 2018–2020, covering recent immigrants in Oman, a general population, adults with HIV in Brazil and pregnant women with HIV. None included a do-nothing option or used trials, and all drew test accuracy from reviews or clinical studies.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "yes",
          "heading": false
        },
        {
          "term": "tests values",
          "heading": false
        },
        {
          "term": "systematic reviews",
          "heading": false
        },
        {
          "term": "alternatives",
          "heading": false
        },
        {
          "term": "clinical studies",
          "heading": false
        },
        {
          "term": "sensitivity",
          "heading": false
        },
        {
          "term": "specificity",
          "heading": false
        }
      ],
      "extract": "176 Drummond Checklist Questions Al Abri (2020). Jo (2020). Steffen (2020) Kim (2018) 1.Was a well-defined question posed in answerable form? 1.1. Did the study examine both costs and effects of the service(s) or programme(s)? Yes Yes Yes Yes 1.2. Did the study involve a comparison of alternatives? Yes Yes Yes Yes 1.3. Was a viewpoint for the analysis stated and was the study placed in any decision-making context?",
      "extractCut": true,
      "blocks": [
        "library/10665-381036/blocks/prose-page-1039"
      ]
    },
    {
      "id": "page-1040",
      "number": null,
      "title": "Page 1040",
      "level": 1,
      "pageStart": 1040,
      "pageEnd": 1040,
      "labelStart": "177",
      "labelEnd": "177",
      "words": 200,
      "summary": {
        "text": "Records the effectiveness assumptions of the final four studies, noting one that imputed rates from Omani data without clear assumptions. It also records how fully each covered costs, including overheads and equipment.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "references reasoning",
          "heading": false
        },
        {
          "term": "capital costs",
          "heading": false
        },
        {
          "term": "unclear breakdown",
          "heading": false
        },
        {
          "term": "yes",
          "heading": false
        },
        {
          "term": "adequate references",
          "heading": false
        },
        {
          "term": "assumptions",
          "heading": false
        }
      ],
      "extract": "177 3.3. Were observational data or assumptions used to establish effectiveness? If so, what are the potential biases in results? Yes No clear assumptions stated. TB incidence and the LTBI rate, BCG vaccination rate, (MDR- TB) rate, TB mortality, and rate of adherence to treatment were imputed from Omani data. Yes Most assumptions for effectiveness all have adequate references/reasoning. Yes All assumptions for",
      "extractCut": true,
      "blocks": [
        "library/10665-381036/blocks/prose-page-1040"
      ]
    },
    {
      "id": "page-1041",
      "number": null,
      "title": "Page 1041",
      "level": 1,
      "pageStart": 1041,
      "pageEnd": 1041,
      "labelStart": "178",
      "labelEnd": "178",
      "words": 219,
      "summary": {
        "text": "Records how credibly the final four studies valued costs and how they discounted, with one study lacking clear value sources, market values and discounting. All performed incremental analyses.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "market values",
          "heading": false
        },
        {
          "term": "yes",
          "heading": false
        },
        {
          "term": "consequences",
          "heading": false
        },
        {
          "term": "costs",
          "heading": false
        },
        {
          "term": "incremental",
          "heading": false
        },
        {
          "term": "generated",
          "heading": false
        }
      ],
      "extract": "178 5.2. Were there any special circumstances (e.g., joint use of resources) that made measurement difficult? Were these circumstances handled appropriately? No No No No 6. Were the cost and consequences valued credibly? 6.1. Were the sources of all values clearly identified? No Yes Yes Yes 6.2. Were market values employed for changes involving resources gained or depleted? No Yes Yes Yes 6.3. Where market values",
      "extractCut": true,
      "blocks": [
        "library/10665-381036/blocks/prose-page-1041"
      ]
    },
    {
      "id": "page-1042",
      "number": null,
      "title": "Page 1042",
      "level": 1,
      "pageStart": 1042,
      "pageEnd": 1042,
      "labelStart": "179",
      "labelEnd": "179",
      "words": 207,
      "summary": {
        "text": "Records sensitivity results for the final four studies, such as sensitivity to QFT-GIT specificity, DiaskinTest cost and TB risk, and whether they discussed generalizability and other factors.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "yes",
          "heading": false
        },
        {
          "term": "consequences",
          "heading": false
        },
        {
          "term": "sensitive",
          "heading": false
        },
        {
          "term": "study",
          "heading": false
        },
        {
          "term": "ratio",
          "heading": false
        },
        {
          "term": "costs",
          "heading": false
        }
      ],
      "extract": "179 9.1. If data on costs and consequences were stochastic (randomly determined sequence of observations), were appropriate statistical analyses performed? Yes Yes Yes Yes 9.2. If sensitivity analysis was employed, was justification provided for the range of values (or for key study parameters)? No Yes Yes Yes 9.3. Were the study results sensitive to changes in the values? Yes Sensitive to treatments received. Yes",
      "extractCut": true,
      "blocks": [
        "library/10665-381036/blocks/prose-page-1042"
      ]
    },
    {
      "id": "page-1043",
      "number": null,
      "title": "Page 1043",
      "level": 1,
      "pageStart": 1043,
      "pageEnd": 1043,
      "labelStart": "180",
      "labelEnd": "180",
      "words": 40,
      "summary": {
        "text": "Records whether the final four studies discussed implementation issues.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "yes",
          "heading": false
        },
        {
          "term": "redeployed",
          "heading": false
        },
        {
          "term": "freed",
          "heading": false
        }
      ],
      "extract": "180 10.5. Did the study discuss issues of implementation, such as the feasibility of adopting the ‘preferred’ programme given existing financial or other constraints, and whether any freed resources could be redeployed to other worthwhile programmes? No Yes Yes Yes",
      "extractCut": false,
      "blocks": [
        "library/10665-381036/blocks/prose-page-1043"
      ]
    },
    {
      "id": "page-1044",
      "number": null,
      "title": "Page 1044",
      "level": 1,
      "pageStart": 1044,
      "pageEnd": 1044,
      "labelStart": "181",
      "labelEnd": "181",
      "words": 15,
      "summary": {
        "text": "The title of Table A9, summarizing the proportion of articles meeting each Drummond criterion.",
        "status": "draft"
      },
      "keywords": [],
      "extract": "181 Table A9. Summary of the proportion of articles accomplishing each of the Drummond’s criteria",
      "extractCut": false,
      "blocks": [
        "library/10665-381036/blocks/prose-page-1044",
        "library/10665-381036/blocks/table-049"
      ]
    },
    {
      "id": "page-1045",
      "number": null,
      "title": "Page 1045",
      "level": 1,
      "pageStart": 1045,
      "pageEnd": 1045,
      "labelStart": "182",
      "labelEnd": "182",
      "words": 403,
      "summary": {
        "text": "Table A9 gives the share of all reviewed economic studies, DiaskinTest studies and TST or IGRA studies meeting each Drummond criterion. Almost all compared alternatives and drew effectiveness from clinical studies, none used randomized trials, and few included capital costs, while 60% discounted future costs.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "market values",
          "heading": false
        },
        {
          "term": "question posed",
          "heading": false
        },
        {
          "term": "consequences",
          "heading": false
        },
        {
          "term": "costs",
          "heading": false
        },
        {
          "term": "alternatives",
          "heading": false
        },
        {
          "term": "omitted",
          "heading": false
        },
        {
          "term": "measurement",
          "heading": false
        },
        {
          "term": "effectiveness",
          "heading": false
        }
      ],
      "extract": "182 Drummond Checklist Questions % Of papers accomplishing each criterion All articles DiaskinTest- related TST or IGRA 1. Was a well-defined question posed in answerable form? 1.1. Did the study examine both costs and effects of the service(s) or programme(s)? 97.1% 87.5% 100.0% 1.2. Did the study involve a comparison of alternatives? 100.0% 100.0% 100.0% 1.3. Was a viewpoint for the analysis stated and was the",
      "extractCut": true,
      "blocks": [
        "library/10665-381036/blocks/prose-page-1045"
      ]
    },
    {
      "id": "page-1046",
      "number": null,
      "title": "Page 1046",
      "level": 1,
      "pageStart": 1046,
      "pageEnd": 1046,
      "labelStart": "183",
      "labelEnd": "183",
      "words": 281,
      "summary": {
        "text": "Continues Table A9 with the share of reviewed studies meeting the remaining Drummond criteria, from discount rate justification to discussion of implementation. DiaskinTest-related studies met many criteria less often than TST or IGRA studies, for example in sensitivity analysis and comparison with other work.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "study discuss",
          "heading": false
        },
        {
          "term": "consequences",
          "heading": false
        },
        {
          "term": "costs",
          "heading": false
        },
        {
          "term": "justification",
          "heading": false
        },
        {
          "term": "incremental",
          "heading": false
        },
        {
          "term": "ratio",
          "heading": false
        },
        {
          "term": "generated",
          "heading": false
        }
      ],
      "extract": "183 7.2. Was there any justification given for the discount rate used? 60.0% 12.5% 75.0% 8. Was an incremental analysis of costs and consequences of alternatives performed? 8.1. Were the additional (incremental) costs generated by one alternative over another compared to the additional effects, benefits, or utilities generated? 94.3% 75.0% 100.0% 9. Was allowance made for uncertainty in the estimates of costs and",
      "extractCut": true,
      "blocks": [
        "library/10665-381036/blocks/prose-page-1046"
      ]
    },
    {
      "id": "page-1047",
      "number": null,
      "title": "Page 1047",
      "level": 1,
      "pageStart": 1047,
      "pageEnd": 1047,
      "labelStart": "184",
      "labelEnd": "184",
      "words": 5,
      "summary": {
        "text": "A blank page with no extracted text.",
        "status": "draft"
      },
      "keywords": [],
      "extract": "_(no text on this page)_",
      "extractCut": false,
      "blocks": [
        "library/10665-381036/blocks/prose-page-1047"
      ]
    },
    {
      "id": "page-1048",
      "number": null,
      "title": "Page 1048",
      "level": 1,
      "pageStart": 1048,
      "pageEnd": 1048,
      "labelStart": "185",
      "labelEnd": "185",
      "words": 110,
      "summary": {
        "text": "The title page of Web Annex B.23, a modelling study of the economic evidence for tuberculosis antigen-based skin tests, naming the review team and stating it was prepared for a February 2022 WHO guideline meeting.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "ting",
          "heading": false
        },
        {
          "term": "london",
          "heading": false
        },
        {
          "term": "allel",
          "heading": false
        },
        {
          "term": "finna",
          "heading": false
        }
      ],
      "extract": "Web Annex B.23. Modelling for economic evidence for the use of Mycobacterium tuberculosis antigen-based skin tests Review team: Lara Goscé1, Finna Parkinson1, Kasim Allel,1,2 Elena Surkova3, Irina Kontsevaya4, Ting Ting Wang1, Victoria Liu2, Yohhei Hamada1, Peter J White5, Molebogeng X Rangaka1 1Institute for Global Health, University College London, UK 2London School of Hygiene and Tropical Medicine, UK 3Royal",
      "extractCut": true,
      "blocks": [
        "library/10665-381036/blocks/prose-page-1048"
      ]
    },
    {
      "id": "page-1049",
      "number": null,
      "title": "Page 1049",
      "level": 1,
      "pageStart": 1049,
      "pageEnd": 1049,
      "labelStart": "186",
      "labelEnd": "186",
      "words": 92,
      "summary": {
        "text": "A list of abbreviations used in the economic modelling annex on tuberculosis skin tests.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "skin tests",
          "heading": false
        },
        {
          "term": "cba",
          "heading": false
        },
        {
          "term": "tuberculosis",
          "heading": false
        },
        {
          "term": "hics",
          "heading": false
        },
        {
          "term": "bacillus",
          "heading": false
        }
      ],
      "extract": "Abbreviations BCG: Bacillus Calmette-Guérin CBA: Cost-benefit analysis CUA: Cost-utility analysis CEA: Cost-effective analysis DOT: Directly observed therapy HICs: High-income countries HIV: Human immunodeficiency virus ICER: incremental cost-effectiveness ratios IGRA: interferon-gamma release assays LMICs: Low- and middle-income countries PPD: purified protein derivative PRISMA – Preferred Reporting Items for",
      "extractCut": true,
      "blocks": [
        "library/10665-381036/blocks/prose-page-1049"
      ]
    },
    {
      "id": "page-1050",
      "number": null,
      "title": "Page 1050",
      "level": 1,
      "pageStart": 1050,
      "pageEnd": 1050,
      "labelStart": "187",
      "labelEnd": "187",
      "words": 437,
      "summary": {
        "text": "The extended summary explains that a Markov model was built to compare the cost-effectiveness of new antigen-based skin tests with the PPD tuberculin skin test and IGRA in Brazil, South Africa and the UK, focusing on DiaskinTest because only its maker supplied costs. Costs are from a health system perspective, and sensitivity analyses explore test prices and uncertainty in clinical and utility parameters.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "unit costs",
          "heading": false
        },
        {
          "term": "tbst",
          "heading": false
        },
        {
          "term": "economic impact",
          "heading": false
        },
        {
          "term": "modelling study",
          "heading": false
        },
        {
          "term": "tuberculosis infection",
          "heading": false
        },
        {
          "term": "diaskintest",
          "heading": false
        },
        {
          "term": "impact report",
          "heading": false
        },
        {
          "term": "systematic review",
          "heading": false
        }
      ],
      "extract": "Extended Summary Background: Our systematic review on the economic impact of novel Mycobacterium tuberculosis specific skin tests for tuberculosis infection (TBST) conducted for this WHO meeting (Section A, Economic impact report) shows that studies are few and limited by study quality. However, our report does provide the most updated evidence on the cost-effectiveness of the use of TBST compared to currently used",
      "extractCut": true,
      "blocks": [
        "library/10665-381036/blocks/prose-page-1050"
      ]
    },
    {
      "id": "page-1051",
      "number": null,
      "title": "Page 1051",
      "level": 1,
      "pageStart": 1051,
      "pageEnd": 1051,
      "labelStart": "188",
      "labelEnd": "188",
      "words": 529,
      "summary": {
        "text": "Reports that DiaskinTest was cost saving with small QALY gains against both comparators in Brazil and South Africa, and against the skin test but not IGRA in the UK, where it remained cost-effective, and sets out how far test prices could rise and stay cost saving. The interpretation stresses that results depend on country-specific costing and limited evidence and that other new skin tests could not be modelled for lack of cost data.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "cost saving",
          "heading": false
        },
        {
          "term": "saving compared",
          "heading": false
        },
        {
          "term": "incremental gain",
          "heading": false
        },
        {
          "term": "ppd-tst",
          "heading": false
        },
        {
          "term": "unit costs",
          "heading": false
        },
        {
          "term": "south africa",
          "heading": false
        },
        {
          "term": "qalys",
          "heading": false
        },
        {
          "term": "igra",
          "heading": false
        }
      ],
      "extract": "Results: In Brazil, strategy 1 is cost saving compared to strategy 2 and 3. Compared to PPD-TST, DiaskinTest is cost-saving at $5.6 with an incremental gain of 0.024 QALYs per patient. Compared to IGRA, DiaskinTest is cost saving at $8.4 with an incremental gain of 0.01 QALYs. In South Africa, DST is more cost saving than IGRA and PPD-TST. Compared to PPD-TST, DiaskinTest is cost-saving at $4.39 with an incremental",
      "extractCut": true,
      "blocks": [
        "library/10665-381036/blocks/prose-page-1051"
      ]
    },
    {
      "id": "page-1052",
      "number": null,
      "title": "Page 1052",
      "level": 1,
      "pageStart": 1052,
      "pageEnd": 1052,
      "labelStart": "189",
      "labelEnd": "189",
      "words": 40,
      "summary": {
        "text": "Concludes that since accuracy appears similar across new skin tests, unit cost will mainly drive cost-effectiveness, which may vary by country.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "unit costs",
          "heading": false
        },
        {
          "term": "cost-effective",
          "heading": false
        },
        {
          "term": "saving",
          "heading": false
        }
      ],
      "extract": "factor likely to influence cost-effectiveness will be unit costs. Our sensitivity analysis suggests, regardless of type, TBST could be both cost saving and cost-effective or simply cost-effective depending on the specific country context despite some variations of the unit costs.",
      "extractCut": false,
      "blocks": [
        "library/10665-381036/blocks/prose-page-1052"
      ]
    },
    {
      "id": "page-1053",
      "number": null,
      "title": "Page 1053",
      "level": 1,
      "pageStart": 1053,
      "pageEnd": 1053,
      "labelStart": "190",
      "labelEnd": "190",
      "words": 154,
      "summary": {
        "text": "States the research question and objectives of the modelling: comparing antigen-based skin tests with IGRA and PPD skin tests in Brazil, South Africa and the UK using a Markov model and sensitivity analyses. The outcomes are cost-effectiveness ratios or net benefit per QALY and test costs per patient.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "index tests",
          "heading": false
        },
        {
          "term": "unit costs",
          "heading": false
        },
        {
          "term": "cost-effectiveness",
          "heading": false
        },
        {
          "term": "tbst",
          "heading": false
        },
        {
          "term": "incremental",
          "heading": false
        },
        {
          "term": "igra",
          "heading": false
        }
      ],
      "extract": "Research Question Are Mycobacterium tuberculosis specific antigen-based skin tests for the detection of tuberculosis infection (TBST) cost-effective compared to currently available in vitro IGRA or the PPD-TST tests in reducing TB in Brazil, South Africa, and the UK? Objectives 5) To model the possible cost-effectiveness of index tests vs current tests by using unit costs of index tests and their accuracy",
      "extractCut": true,
      "blocks": [
        "library/10665-381036/blocks/prose-page-1053"
      ]
    },
    {
      "id": "page-1054",
      "number": null,
      "title": "Page 1054",
      "level": 1,
      "pageStart": 1054,
      "pageEnd": 1054,
      "labelStart": "191",
      "labelEnd": "191",
      "words": 45,
      "summary": {
        "text": "Explains that the economic report has two parts and that this document is Section B, with Section A submitted separately.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "abstract",
          "heading": false
        },
        {
          "term": "section",
          "heading": false
        },
        {
          "term": "attachment",
          "heading": false
        }
      ],
      "extract": "PRESENTATION OF THE ECONOMIC IMPACT REPORT The final report is presented in two parts. Section A: Abstract, methods and results for Objectives 1-2 Section B: Abstract, methods and result for Objectives 3-4. This document contains Section B. Section A is submitted as a separate attachment.",
      "extractCut": false,
      "blocks": [
        "library/10665-381036/blocks/prose-page-1054"
      ]
    },
    {
      "id": "page-1055",
      "number": null,
      "title": "Page 1055",
      "level": 1,
      "pageStart": 1055,
      "pageEnd": 1055,
      "labelStart": "192",
      "labelEnd": "192",
      "words": 240,
      "summary": {
        "text": "Describes the Markov model, which follows a cohort without active TB through testing for infection, treatment, completion or interruption, active TB, recovery or death, across eleven states. It is parametrized for the UK, Brazil and South Africa, and the modelling objectives are restated.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "model simulating",
          "heading": false
        },
        {
          "term": "simulating cohort",
          "heading": false
        },
        {
          "term": "markov model",
          "heading": false
        },
        {
          "term": "tuberculosis infection",
          "heading": false
        },
        {
          "term": "model scheme",
          "heading": false
        },
        {
          "term": "index tests",
          "heading": false
        },
        {
          "term": "unit costs",
          "heading": false
        },
        {
          "term": "treatment started",
          "heading": false
        }
      ],
      "extract": "Economic evaluation of the interventions and cost-effectiveness analysis Model scheme and characteristics We created a Markov model simulating a cohort of individuals transitioning among different states, the cohort being comprised at baseline of individuals without active TB. Following the cascade of care, these individuals are tested for TB infection (TBI), if positive, they may initiate and eventually complete or",
      "extractCut": true,
      "blocks": [
        "library/10665-381036/blocks/prose-page-1055"
      ]
    },
    {
      "id": "page-1056",
      "number": null,
      "title": "Page 1056",
      "level": 1,
      "pageStart": 1056,
      "pageEnd": 1056,
      "labelStart": "193",
      "labelEnd": "193",
      "words": 246,
      "summary": {
        "text": "Describes the model diagram and parameters, starting with 100,000 people tested and followed over 20 annual cycles. Test accuracy comes from the authors' systematic review, the skin test's specificity is assumed equal to IGRA's, and the model covers the general population without separating by HIV status.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "tuberculosis infection",
          "heading": false
        },
        {
          "term": "treatment started",
          "heading": false
        },
        {
          "term": "probabilities",
          "heading": false
        },
        {
          "term": "model",
          "heading": false
        },
        {
          "term": "interrupted",
          "heading": false
        },
        {
          "term": "untreated",
          "heading": false
        },
        {
          "term": "assumed",
          "heading": false
        }
      ],
      "extract": "Figure 1. Model diagram. The model describes the following states and steps in the TB infection care cascade: (1) no tuberculosis infection, tested; (2) tuberculosis infection, tested; (3) no tuberculosis infection, treated; (4) no tuberculosis infection, untreated; (5) no tuberculosis infection, treatment started but interrupted; (6) tuberculosis infection, treated; (7) tuberculosis infection, untreated; (8)",
      "extractCut": true,
      "blocks": [
        "library/10665-381036/blocks/prose-page-1056",
        "library/10665-381036/blocks/figure-img-p1056-1"
      ]
    },
    {
      "id": "page-1057",
      "number": null,
      "title": "Page 1057",
      "level": 1,
      "pageStart": 1057,
      "pageEnd": 1057,
      "labelStart": "194",
      "labelEnd": "194",
      "words": 173,
      "summary": {
        "text": "Table 1 lists model parameters by country, including the prevalence of TB infection, treatment initiation, completion and interruption, progression to active TB, treatment efficacy, TB treatment coverage and recovery rates.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "south africa",
          "heading": false
        },
        {
          "term": "brazil",
          "heading": false
        },
        {
          "term": "tbi",
          "heading": false
        },
        {
          "term": "nhs",
          "heading": false
        },
        {
          "term": "percentage",
          "heading": false
        }
      ],
      "extract": "Table 1. Model parameters Parameter Value Source Prevalence of TB infection in TB-negative individuals, percentage Brazil= 13.27% [95%CI= 9.4 – 18.1] UK= 1.76% [95%CI= 1.3 – 2.7] South Africa= 31.53% [95%CI= 28.8 – 36.1] Literature 1 (see Table A1 supplementary) People completing treatment after initiation following a positive TBI result, percentage Brazil= 33.96% UK= 44.2% South Africa= 12.06% Brazil 2 UK, NHS 3",
      "extractCut": true,
      "blocks": [
        "library/10665-381036/blocks/prose-page-1057"
      ]
    },
    {
      "id": "page-1058",
      "number": null,
      "title": "Page 1058",
      "level": 1,
      "pageStart": 1058,
      "pageEnd": 1058,
      "labelStart": "195",
      "labelEnd": "195",
      "words": 399,
      "summary": {
        "text": "Continues the parameters with TB death rates and the sensitivity and specificity of the skin tests and IGRA. It explains that DiaskinTest unit costs combine the manufacturer's price with standard skin test costs, and that the largest observed country costs were chosen as a conservative assumption.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "unit costs",
          "heading": false
        },
        {
          "term": "igra test",
          "heading": false
        },
        {
          "term": "c-tb test",
          "heading": false
        },
        {
          "term": "laboratory costs",
          "heading": false
        },
        {
          "term": "utility scores",
          "heading": false
        },
        {
          "term": "tbst systematic",
          "heading": false
        },
        {
          "term": "systematic review",
          "heading": false
        },
        {
          "term": "disposable",
          "heading": false
        }
      ],
      "extract": "Death from Active TB (treated+untreated) Brazil = 11.1% [95%CI= 9.1–12.7] UK = 14.1% [95%CI= 10.3–16.4] South Africa = 9.4% [95%CI= 8.0–10.6] 9,10 Probability of a true positive test result if the patient has TB infection (sensitivity) TST: 88.24 (78.20–94.01) Diaskintest: 91·18 (81.72–95.98) IGRA test (QFT): 89.66 (78.83–95.28) IGRA test (T-spot): 90.91 (79.95–96.16) C-TB test (skin): 86·06 (82.39–89.07) TBST",
      "extractCut": true,
      "blocks": [
        "library/10665-381036/blocks/prose-page-1058"
      ]
    },
    {
      "id": "page-1059",
      "number": null,
      "title": "Page 1059",
      "level": 1,
      "pageStart": 1059,
      "pageEnd": 1059,
      "labelStart": "196",
      "labelEnd": "196",
      "words": 539,
      "summary": {
        "text": "Describes how testing and treatment costs were drawn from published studies for each country, and explains the QALY assumptions, 20-year horizon and country discount rates. It lists the sensitivity and scenario analyses, including a worst case in which one vial is used for a single patient.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "unit costs",
          "heading": false
        },
        {
          "term": "tbi treatment",
          "heading": false
        },
        {
          "term": "treating tbi",
          "heading": false
        },
        {
          "term": "clinic visits",
          "heading": false
        },
        {
          "term": "side effects",
          "heading": false
        },
        {
          "term": "averts",
          "heading": false
        },
        {
          "term": "south africa",
          "heading": false
        },
        {
          "term": "sensitivity analysis",
          "heading": false
        }
      ],
      "extract": "account for the full cost of each visit and follow-up. The study assumes that test strategies involving TST require two clinic visits, whereas those involving only IGRAs (T-SPOT.TB or QFT-GIT or both) only require one clinic visit. The TST visits represent the day of PPD placement and a further visit for assessment of results any skin induration. The IGRA visit represents the phlebotomy visit. Testing strategies in",
      "extractCut": true,
      "blocks": [
        "library/10665-381036/blocks/prose-page-1059"
      ]
    },
    {
      "id": "page-1060",
      "number": null,
      "title": "Page 1060",
      "level": 1,
      "pageStart": 1060,
      "pageEnd": 1060,
      "labelStart": "197",
      "labelEnd": "197",
      "words": 243,
      "summary": {
        "text": "Gives the extra cost of the single-use vial scenario and describes the three testing strategies compared, with results reported as cost-effectiveness ratios or net benefit against country thresholds. Table 2 lists unit costs of each test by country and utility values.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "utility loss",
          "heading": false
        },
        {
          "term": "united kingdom",
          "heading": false
        },
        {
          "term": "unit costs",
          "heading": false
        },
        {
          "term": "south africa",
          "heading": false
        },
        {
          "term": "loss associated",
          "heading": false
        },
        {
          "term": "inb",
          "heading": false
        },
        {
          "term": "diaskintest",
          "heading": false
        },
        {
          "term": "icers",
          "heading": false
        }
      ],
      "extract": "approximatively $18.55, meaning an additional $16.93 (16.88 –16.98) on the DiaskinTest unit cost in the three countries analysed. Strategies Three testing strategies were considered in this analysis: (i) DiaskinTest; (ii) PPD-TST test; (iii) IGRA, QuantiFERON-TB test (either Gold In-Tube or Gold-Plus). The model was parametrised for each of the three selected countries and ran considering these three testing",
      "extractCut": true,
      "blocks": [
        "library/10665-381036/blocks/prose-page-1060"
      ]
    },
    {
      "id": "page-1061",
      "number": null,
      "title": "Page 1061",
      "level": 1,
      "pageStart": 1061,
      "pageEnd": 1061,
      "labelStart": "198",
      "labelEnd": "198",
      "words": 329,
      "summary": {
        "text": "Completes the utility values and notes on test costs, then gives Table 3 on the cost of TB infection treatment regimens by country. Costs are shown as drug and staff costs in 2021 US dollars.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "chest radiograph",
          "heading": false
        },
        {
          "term": "clinic visits",
          "heading": false
        },
        {
          "term": "tbi treatment",
          "heading": false
        },
        {
          "term": "laboratory technicians",
          "heading": false
        },
        {
          "term": "utility loss",
          "heading": false
        },
        {
          "term": "usds",
          "heading": false
        },
        {
          "term": "disposables",
          "heading": false
        },
        {
          "term": "inflated",
          "heading": false
        }
      ],
      "extract": "Utility loss due to active TB treatment adverse effects Utility loss due to TBI treatment 0.17 0.2 Notes: Costs provided in 2021 USDs ($). aUnit cost calculated by summing DiaskinTest costs as provided by the manufacturer (Tables B4−5) and PPD-TST associated costs (excluding test cost) from literature review 12,14,17. bThese costs represent the whole screening strategy including the costs of the tests (disposables,",
      "extractCut": true,
      "blocks": [
        "library/10665-381036/blocks/prose-page-1061"
      ]
    },
    {
      "id": "page-1062",
      "number": null,
      "title": "Page 1062",
      "level": 1,
      "pageStart": 1062,
      "pageEnd": 1062,
      "labelStart": "199",
      "labelEnd": "199",
      "words": 336,
      "summary": {
        "text": "Table 4 gives the costs of treating drug-sensitive active TB under directly observed therapy in each country, with notes on visit and test costs. The results section begins with Brazil, where DiaskinTest was cost saving compared with both other tests.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "liver function",
          "heading": false
        },
        {
          "term": "chest x-ray",
          "heading": false
        },
        {
          "term": "months treatment",
          "heading": false
        },
        {
          "term": "single cost",
          "heading": false
        },
        {
          "term": "function test",
          "heading": false
        },
        {
          "term": "follow-up check",
          "heading": false
        },
        {
          "term": "culture test",
          "heading": false
        },
        {
          "term": "medical consultation",
          "heading": false
        }
      ],
      "extract": "(supplementary material). Table 4 Costs per active DOT TB treatment (drug-sensitive), by country (inflated, expressed in 2021 USDs) Costs per active TB treatment (6 months treatment) Drug costs Staff costs (medical and nurse follow- up consultations) a Chest X-ray, culture tests, and liver function tests costs h Total cost per case Brazil 2 months RHZE $16.7 20 $332.3 b $41.93 e 4 months RH $19.09 20 $410.52 6",
      "extractCut": true,
      "blocks": [
        "library/10665-381036/blocks/prose-page-1062"
      ]
    },
    {
      "id": "page-1063",
      "number": null,
      "title": "Page 1063",
      "level": 1,
      "pageStart": 1063,
      "pageEnd": 1063,
      "labelStart": "200",
      "labelEnd": "200",
      "words": 173,
      "summary": {
        "text": "Completes the Brazil results, showing that any antigen skin test would stay cost saving against the PPD skin test up to about three times DiaskinTest's price. In the worst-case vial scenario it would no longer save costs but would remain cost-effective.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "cost saving",
          "heading": false
        },
        {
          "term": "diaskintest vial",
          "heading": false
        },
        {
          "term": "unit cost",
          "heading": false
        },
        {
          "term": "tbst unit",
          "heading": false
        },
        {
          "term": "expected cost",
          "heading": false
        }
      ],
      "extract": "saving at $8.4 with an incremental gain of 0.01 QALYs. As the intervention was cost saving, we calculated incremental net benefit (INB) rather than incremental cost-effective ratio (Table 5). Sensitivity analysis on unit costs of TBST shows that, assuming same sensitivity and specificity values as DiaskinTest, a testing strategy using any TBST would remain cost saving compared to PPD-TST for an increase in TBST unit",
      "extractCut": true,
      "blocks": [
        "library/10665-381036/blocks/prose-page-1063",
        "library/10665-381036/blocks/figure-img-p1063-1",
        "library/10665-381036/blocks/figure-img-p1063-2"
      ]
    },
    {
      "id": "page-1064",
      "number": null,
      "title": "Page 1064",
      "level": 1,
      "pageStart": 1064,
      "pageEnd": 1064,
      "labelStart": "201",
      "labelEnd": "201",
      "words": 263,
      "summary": {
        "text": "Presents cost-effectiveness planes and results for South Africa, where DiaskinTest was cost saving against both comparators and would remain so up to a modestly higher price. In the worst-case vial scenario it would remain cost-effective, and the UK results begin.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "cost saving",
          "heading": false
        },
        {
          "term": "saving compared",
          "heading": false
        },
        {
          "term": "diaskintest versus",
          "heading": false
        },
        {
          "term": "incremental gain",
          "heading": false
        },
        {
          "term": "unit cost",
          "heading": false
        },
        {
          "term": "expected cost",
          "heading": false
        },
        {
          "term": "ppd-tst",
          "heading": false
        },
        {
          "term": "south africa",
          "heading": false
        }
      ],
      "extract": "Figure 2. Incremental cost-effectiveness planes of DiaskinTest versus PPD-TST (blue), and DiaskinTest versus IGRA (green), in Brazil, South Africa and UK. These figures show scatter plots of 1,000 Monte Carlo simulations for the mean incremental costs and incremental effectiveness in quality-adjusted life years. South Africa Strategy 1 was cost saving compared to both strategy 2 and 3 (Figure 2). Compared to",
      "extractCut": true,
      "blocks": [
        "library/10665-381036/blocks/prose-page-1064",
        "library/10665-381036/blocks/figure-img-p1064-1"
      ]
    },
    {
      "id": "page-1065",
      "number": null,
      "title": "Page 1065",
      "level": 1,
      "pageStart": 1065,
      "pageEnd": 1065,
      "labelStart": "202",
      "labelEnd": "202",
      "words": 289,
      "summary": {
        "text": "Reports UK results, where DiaskinTest was cost saving compared with the skin test and cost-effective compared with IGRA, staying cost-effective at prices up to about 2.35 times its own cost. Table 5 sets out modelled costs, QALYs and incremental net benefit for each strategy in the three countries.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "willingness-to-pay threshold",
          "heading": false
        },
        {
          "term": "unit cost",
          "heading": false
        },
        {
          "term": "incremental gain",
          "heading": false
        },
        {
          "term": "cost saving",
          "heading": false
        },
        {
          "term": "expected cost",
          "heading": false
        },
        {
          "term": "diaskintest",
          "heading": false
        },
        {
          "term": "test unit",
          "heading": false
        }
      ],
      "extract": "DiaskinTest was cost saving at $73.33 with an incremental gain of 0.0351 QALYs. Compared to IGRA, DiaskinTest showed an incremental gain of $15.80 and an incremental gain of 0.0266 QALYs, or $521.45 (95% CI 500.94 ̶ 545.07) per QALY, below the willingness-to-pay threshold of $20.223 per QALY16. Sensitivity analyses on cost of the test show that, with same sensitivity and specificity values as DiaskinTest, a TBST",
      "extractCut": true,
      "blocks": [
        "library/10665-381036/blocks/prose-page-1065"
      ]
    },
    {
      "id": "page-1066",
      "number": null,
      "title": "Page 1066",
      "level": 1,
      "pageStart": 1066,
      "pageEnd": 1066,
      "labelStart": "203",
      "labelEnd": "203",
      "words": 447,
      "summary": {
        "text": "Interprets the results, noting that DiaskinTest dominated the other tests in Brazil and South Africa but cost more than IGRA in the UK. It discusses limits such as manufacturer costs that vary with order size, wasted doses from opened vials, the provider-only perspective and differences between study and real-world costing.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "incremental costs",
          "heading": false
        },
        {
          "term": "costs indicate",
          "heading": false
        },
        {
          "term": "larger orders",
          "heading": false
        },
        {
          "term": "orders come",
          "heading": false
        },
        {
          "term": "wasted doses",
          "heading": false
        },
        {
          "term": "ppd-tst",
          "heading": false
        },
        {
          "term": "diaskintest",
          "heading": false
        },
        {
          "term": "igra",
          "heading": false
        }
      ],
      "extract": "IGRA 624.91 12.8044 ̶ 15.80 ̶ 0.0303 ̶ 628.56 Note. Positive incremental costs indicate the amount of money saved on average, when using DiaskinTest instead of PPD- TST or IGRA. Vice versa, negative incremental costs indicate the amount of money lost when using DiaskinTest. Similarly, negative incremental QALYs indicate that strategies using PPD-TST or IGRA comport a loss in QALYs compared to DiaskinTest strategy. a",
      "extractCut": true,
      "blocks": [
        "library/10665-381036/blocks/prose-page-1066"
      ]
    },
    {
      "id": "page-1067",
      "number": null,
      "title": "Page 1067",
      "level": 1,
      "pageStart": 1067,
      "pageEnd": 1067,
      "labelStart": "204",
      "labelEnd": "204",
      "words": 418,
      "summary": {
        "text": "Explains that unit costs vary widely between countries because of different costing methods and assumptions about clinic visits, and that other new skin tests could not be modelled because they are not yet marketed. It suggests future work on at-risk groups such as people with HIV, children, contacts and migrants.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "unit costs",
          "heading": false
        },
        {
          "term": "both ppd-tst",
          "heading": false
        },
        {
          "term": "tbst",
          "heading": false
        },
        {
          "term": "south africa",
          "heading": false
        },
        {
          "term": "cost-effective",
          "heading": false
        },
        {
          "term": "igra",
          "heading": false
        },
        {
          "term": "diaskintest",
          "heading": false
        },
        {
          "term": "scenario",
          "heading": false
        }
      ],
      "extract": "effects. For this reason, unit costs and, consequently, final expected costs, can vary vastly according to the specific activities chosen to define the service. The unit costs used in our analysis (Table 2) show large differences between countries because of this. UK’s unit costs are based on NHS tariffs which do not differentiate between activities but between staff members involved, thus UK costs are heavily",
      "extractCut": true,
      "blocks": [
        "library/10665-381036/blocks/prose-page-1067"
      ]
    },
    {
      "id": "page-1068",
      "number": null,
      "title": "Page 1068",
      "level": 1,
      "pageStart": 1068,
      "pageEnd": 1068,
      "labelStart": "205",
      "labelEnd": "205",
      "words": 455,
      "summary": {
        "text": "The first part of the reference list for the economic modelling annex, citing studies on latent TB burden, cascades of care, test accuracy and cost-effectiveness.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "latent tuberculosis",
          "heading": false
        },
        {
          "term": "tuberculosis infection",
          "heading": false
        },
        {
          "term": "quantiferon-tb gold",
          "heading": false
        },
        {
          "term": "release assays",
          "heading": false
        },
        {
          "term": "tuberculin skin",
          "heading": false
        },
        {
          "term": "lancet infectious",
          "heading": false
        },
        {
          "term": "qiagen",
          "heading": false
        },
        {
          "term": "infectious diseases",
          "heading": false
        }
      ],
      "extract": "References 1. Houben RM, Dodd PJ. The global burden of latent tuberculosis infection: a re-estimation using mathematical modelling. PLoS medicine 2016; 13(10): e1002152. 2. Wysocki AD, Villa TCS, Arakawa T, et al. Latent tuberculosis infection diagnostic and treatment cascade among contacts in primary health care in a city of Sao Paulo State, Brazil: cross-sectional study. PloS one 2016; 11(6): e0155348. 3. National",
      "extractCut": true,
      "blocks": [
        "library/10665-381036/blocks/prose-page-1068"
      ]
    },
    {
      "id": "page-1069",
      "number": null,
      "title": "Page 1069",
      "level": 1,
      "pageStart": 1069,
      "pageEnd": 1069,
      "labelStart": "206",
      "labelEnd": "206",
      "words": 233,
      "summary": {
        "text": "Completes the reference list, citing cost-effectiveness and treatment cost studies from Brazil, South Africa and the UK and WHO TB treatment guidance.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "latent tuberculosis",
          "heading": false
        },
        {
          "term": "tuberculosis infection",
          "heading": false
        },
        {
          "term": "tuberculin skin",
          "heading": false
        },
        {
          "term": "dowdy",
          "heading": false
        },
        {
          "term": "skin testing",
          "heading": false
        },
        {
          "term": "south africa",
          "heading": false
        },
        {
          "term": "cost-effectiveness",
          "heading": false
        }
      ],
      "extract": "17. Steffen RE, Caetano R, Pinto M, et al. Cost-effectiveness of Quantiferon®-TB Gold-in-Tube versus tuberculin skin testing for contact screening and treatment of latent tuberculosis infection in Brazil. PloS one 2013; 8(4): e59546. 18. Kim H, Hanrahan C, Martinson N, Golub J, Dowdy D. Cost-effectiveness of universal isoniazid preventive therapy among HIV-infected pregnant women in South Africa. The International",
      "extractCut": true,
      "blocks": [
        "library/10665-381036/blocks/prose-page-1069"
      ]
    },
    {
      "id": "page-1070",
      "number": null,
      "title": "Page 1070",
      "level": 1,
      "pageStart": 1070,
      "pageEnd": 1070,
      "labelStart": "207",
      "labelEnd": "207",
      "words": 141,
      "summary": {
        "text": "Supplementary tables give the calculated prevalence of TB infection in Brazil, the UK and South Africa and estimated rates of progression from infection to active TB.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "population estimates",
          "heading": false
        },
        {
          "term": "ltbi",
          "heading": false
        },
        {
          "term": "tbi",
          "heading": false
        },
        {
          "term": "progression",
          "heading": false
        }
      ],
      "extract": "SUPPLEMENTARY DOCUMENTATION Economic evaluation of the interventions and cost-effectiveness analysis Model parameters additional information Table B1. Calculation of the TBI progression ISO code LTBI estimates 2014 1 Population estimates 2014 9 LTBI/population (%) BRA 26,900,000 [19,100,000 - 36,700,000] 202,763,744 13.27 [9.4 – 18.1] GBR 1,150,000 [ 867,000 - 1,790,000] 65,423,048 1.76 [1.3 – 2.7] ZAF 17,200,000",
      "extractCut": true,
      "blocks": [
        "library/10665-381036/blocks/prose-page-1070",
        "library/10665-381036/blocks/table-050",
        "library/10665-381036/blocks/table-051"
      ]
    },
    {
      "id": "page-1071",
      "number": null,
      "title": "Page 1071",
      "level": 1,
      "pageStart": 1071,
      "pageEnd": 1071,
      "labelStart": "208",
      "labelEnd": "208",
      "words": 211,
      "summary": {
        "text": "Gives progression rates for people with HIV and explains that the model could be adapted for such groups. Table B3 shows uninflated TB infection treatment costs by regimen and country.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "single cost",
          "heading": false
        },
        {
          "term": "follow-up check",
          "heading": false
        },
        {
          "term": "tbi treatment",
          "heading": false
        },
        {
          "term": "medical consultation",
          "heading": false
        },
        {
          "term": "isoniazid",
          "heading": false
        },
        {
          "term": "model",
          "heading": false
        }
      ],
      "extract": "Proportion of TST or IGRA positive, untreated, HIV positive individuals progressing to active TB (post‐ exposure TB) over 20 years 0.40 (0.20‐0.80) 22,24 Notes: All individuals in the model are assumed to belong to the general population with recent TBI infection. Differentiation between HIV status or duration of infection are not included in the model but these values are reported in this table to show how the",
      "extractCut": true,
      "blocks": [
        "library/10665-381036/blocks/prose-page-1071",
        "library/10665-381036/blocks/table-052"
      ]
    },
    {
      "id": "page-1072",
      "number": null,
      "title": "Page 1072",
      "level": 1,
      "pageStart": 1072,
      "pageEnd": 1072,
      "labelStart": "209",
      "labelEnd": "209",
      "words": 320,
      "summary": {
        "text": "Explains how treatment staff costs were calculated, then Tables B4 and B5 give DiaskinTest vial prices by order volume and delivery costs by country. They work these out as a cost per patient, using manufacturer data.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "africa pack",
          "heading": false
        },
        {
          "term": "costs delivery",
          "heading": false
        },
        {
          "term": "full costs",
          "heading": false
        },
        {
          "term": "diaskin test",
          "heading": false
        },
        {
          "term": "shelf life",
          "heading": false
        },
        {
          "term": "vial",
          "heading": false
        },
        {
          "term": "test manufacturer",
          "heading": false
        },
        {
          "term": "price",
          "heading": false
        }
      ],
      "extract": "treatment with isoniazid, 12= 12 months treatment with isoniazid, 2. a Calculated considering one medical check plus the number of follow-up checks administered by nurses depending upon the regimen, it is as follows: 3H: 2 nurse consultations; 6H: 5; 9H: 8; 12H: 11. *Drug costs were obtained from the NHS drug tariff (2014) (for H and R) and British National Formulary (2013) (for Pz); quantities of drugs used for",
      "extractCut": true,
      "blocks": [
        "library/10665-381036/blocks/prose-page-1072",
        "library/10665-381036/blocks/table-053",
        "library/10665-381036/blocks/table-054"
      ]
    },
    {
      "id": "page-1073",
      "number": null,
      "title": "Page 1073",
      "level": 1,
      "pageStart": 1073,
      "pageEnd": 1073,
      "labelStart": "210",
      "labelEnd": "210",
      "words": 219,
      "summary": {
        "text": "Applies the Drummond checklist to the authors' own modelling study, which compared alternatives and drew test accuracy from clinical studies and reviews.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "drummond checklist",
          "heading": false
        },
        {
          "term": "yes",
          "heading": false
        },
        {
          "term": "alternatives",
          "heading": false
        },
        {
          "term": "clinical studies",
          "heading": false
        },
        {
          "term": "assumptions",
          "heading": false
        },
        {
          "term": "effectiveness",
          "heading": false
        }
      ],
      "extract": "210 Table B6: Drummond checklist for the quality of our study: Cost-effectiveness analyses for Novel skin tests for diagnosing TBI Drummond Checklist Questions Our study 1.Was a well-defined question posed in answerable form? 1.1. Did the study examine both costs and effects of the service(s) or programme(s)? Yes 1.2. Did the study involve a comparison of alternatives? Yes 1.3. Was a viewpoint for the analysis",
      "extractCut": true,
      "blocks": [
        "library/10665-381036/blocks/prose-page-1073",
        "library/10665-381036/blocks/table-055"
      ]
    },
    {
      "id": "page-1074",
      "number": null,
      "title": "Page 1074",
      "level": 1,
      "pageStart": 1074,
      "pageEnd": 1074,
      "labelStart": "211",
      "labelEnd": "211",
      "words": 247,
      "summary": {
        "text": "Continues the self-assessment, noting that diagnostic, treatment, staff and laboratory costs were included and that costs were discounted with justification.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "market values",
          "heading": false
        },
        {
          "term": "operating costs",
          "heading": false
        },
        {
          "term": "consequences",
          "heading": false
        },
        {
          "term": "yes",
          "heading": false
        },
        {
          "term": "incremental",
          "heading": false
        },
        {
          "term": "measurement",
          "heading": false
        },
        {
          "term": "generated",
          "heading": false
        }
      ],
      "extract": "211 4.2. Did it cover all relevant viewpoints? Yes 4.3. Were the capital costs, as well as operating costs, included? Diagnostic, treatment, staff, laboratory, material, and operating costs included 5. Were costs and consequences measured accurately in appropriate physical units? 5.1. Were any of the identified items omitted from measurement? No If so, does this mean that they carried no weight in the subsequent",
      "extractCut": true,
      "blocks": [
        "library/10665-381036/blocks/prose-page-1074"
      ]
    },
    {
      "id": "page-1075",
      "number": null,
      "title": "Page 1075",
      "level": 1,
      "pageStart": 1075,
      "pageEnd": 1075,
      "labelStart": "212",
      "labelEnd": "212",
      "words": 206,
      "summary": {
        "text": "Completes the self-assessment, reporting appropriate statistical and sensitivity analyses and discussion of generalizability and implementation.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "study discuss",
          "heading": false
        },
        {
          "term": "yes",
          "heading": false
        },
        {
          "term": "consequences",
          "heading": false
        },
        {
          "term": "ratio",
          "heading": false
        },
        {
          "term": "costs",
          "heading": false
        },
        {
          "term": "sensitive",
          "heading": false
        }
      ],
      "extract": "212 9.1. If data on costs and consequences were stochastic (randomly determined sequence of observations), were appropriate statistical analyses performed? Yes 9.2. If sensitivity analysis was employed, was justification provided for the range of values (or for key study parameters)? Yes 9.3. Were the study results sensitive to changes in the values? Yes Sensitive to treatments received. 10. Did the presentation and",
      "extractCut": true,
      "blocks": [
        "library/10665-381036/blocks/prose-page-1075"
      ]
    },
    {
      "id": "page-1076",
      "number": null,
      "title": "Page 1076",
      "level": 1,
      "pageStart": 1076,
      "pageEnd": 1076,
      "labelStart": null,
      "labelEnd": null,
      "words": 127,
      "summary": {
        "text": "The title page of Web Annex F, a review of qualitative evidence on tuberculosis antigen-based skin tests, naming the review team prepared for the February 2022 WHO guideline meeting.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "united kingdom",
          "heading": false
        },
        {
          "term": "sheffield",
          "heading": false
        },
        {
          "term": "ting",
          "heading": false
        },
        {
          "term": "auckland",
          "heading": false
        },
        {
          "term": "amy",
          "heading": false
        }
      ],
      "extract": "Web Annex F Qualitative evidence for the use of Mycobacterium tuberculosis antigen-based skin tests Review team: Amy Hai Yan Chan1,2 , Kate Loveys1, Matthew Quaife3, Amy Clarke2, Liliya Eugenevna Ziganshina4, Irina Kontsevaya5, Chloe Tuck6, Elena Surkova7, Ting Ting Wang2, Liu (Victoria) Wan-Hsin3, Yohhei Hamada2, Molebogeng X Rangaka2 1. The University of Auckland, Auckland, New Zealand 2. University College",
      "extractCut": true,
      "blocks": [
        "library/10665-381036/blocks/prose-page-1076"
      ]
    },
    {
      "id": "page-1077",
      "number": null,
      "title": "Page 1077",
      "level": 1,
      "pageStart": 1077,
      "pageEnd": 1077,
      "labelStart": null,
      "labelEnd": null,
      "words": 1,
      "summary": {
        "text": "A page containing only a stray character.",
        "status": "draft"
      },
      "keywords": [],
      "extract": "0",
      "extractCut": false,
      "blocks": [
        "library/10665-381036/blocks/prose-page-1077"
      ]
    },
    {
      "id": "page-1078",
      "number": null,
      "title": "Page 1078",
      "level": 1,
      "pageStart": 1078,
      "pageEnd": 1078,
      "labelStart": "1",
      "labelEnd": "1",
      "words": 529,
      "summary": {
        "text": "Lists abbreviations and opens the executive summary, explaining that end-user values, acceptability, feasibility and equity effects of new TB skin tests are unknown. It describes three work packages: systematic reviews of qualitative evidence, 20 interviews with providers and people with TB infection, and an online discrete choice experiment. Confidence in evidence was rated with GRADE-CERQual.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "choice experiment",
          "heading": false
        },
        {
          "term": "work package",
          "heading": false
        },
        {
          "term": "discrete choice",
          "heading": false
        },
        {
          "term": "antigen-based skin",
          "heading": false
        },
        {
          "term": "end-user values",
          "heading": false
        },
        {
          "term": "systematic reviews",
          "heading": false
        },
        {
          "term": "skin tests",
          "heading": false
        },
        {
          "term": "tbst",
          "heading": false
        }
      ],
      "extract": "1 Abbreviations BCG – Bacillus Clamette-Guérin DCE – Discrete Choice Experiment GRADE-CERQual – Confidence in the Evidence from Reviews of Qualitative Research HIC – High Income Country HIV – Human Immunodeficiency Virus IGRA – Interferon gamma release assays LMIC – Low-Middle Income Country PPD-TST – Purified protein derivative tuberculin skin tests PRISMA – Preferred Reporting Items for Systematic Reviews and",
      "extractCut": true,
      "blocks": [
        "library/10665-381036/blocks/prose-page-1078"
      ]
    },
    {
      "id": "page-1079",
      "number": null,
      "title": "Page 1079",
      "level": 1,
      "pageStart": 1079,
      "pageEnd": 1079,
      "labelStart": "2",
      "labelEnd": "2",
      "words": 689,
      "summary": {
        "text": "Reports that the reviews found only four relevant studies, of low to moderate confidence, while the interviews covered 20 people and the choice experiment 234 respondents, mainly from India, the United States and South Africa. Providers and consumers valued accuracy, convenience, a positive experience, low cost and low resource needs. They preferred tests that avoid follow-up visits and specialist staff and use existing infrastructure.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "end-user interviews",
          "heading": false
        },
        {
          "term": "tbi tests",
          "heading": false
        },
        {
          "term": "end-user values",
          "heading": false
        },
        {
          "term": "consumer experience",
          "heading": false
        },
        {
          "term": "healthcare providers",
          "heading": false
        },
        {
          "term": "dce",
          "heading": false
        },
        {
          "term": "skin tests",
          "heading": false
        },
        {
          "term": "tbsts",
          "heading": false
        }
      ],
      "extract": "2 were developed for consumers and providers to represent the different potential determinants of choice to either, and a minimum sample size of 45 was deemed sufficient to draw statistical inference in both designs. Choice data were analysed using multinomial logistic regression models, and willingness-to-accept analyses used to compare results within and across designs. Results: Characteristics of data included in",
      "extractCut": true,
      "blocks": [
        "library/10665-381036/blocks/prose-page-1079"
      ]
    },
    {
      "id": "page-1080",
      "number": null,
      "title": "Page 1080",
      "level": 1,
      "pageStart": 1080,
      "pageEnd": 1080,
      "labelStart": "3",
      "labelEnd": "3",
      "words": 699,
      "summary": {
        "text": "Reports that new skin tests were seen as more accurate than the tuberculin skin test but sharing its drawbacks compared with IGRA, which remained preferred where already in use. They appear feasible and low-cost where the tuberculin skin test is already used and are unlikely to create new equity problems. The conclusion finds them more acceptable than and as feasible as the tuberculin skin test, with likely equity benefits.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "dce found",
          "heading": false
        },
        {
          "term": "end-user interviews",
          "heading": false
        },
        {
          "term": "healthcare settings",
          "heading": false
        },
        {
          "term": "skin tests",
          "heading": false
        },
        {
          "term": "healthcare providers",
          "heading": false
        },
        {
          "term": "tbst",
          "heading": false
        },
        {
          "term": "settings compared",
          "heading": false
        },
        {
          "term": "test option",
          "heading": false
        }
      ],
      "extract": "3 Acceptability Qualitative data from systematic reviews and end-user interviews suggests TBST were perceived to have greater specificity and sensitivity than the TST. Having greater test accuracy was deemed desirable to avoid the negative consequences of false positives or negatives. However, the TBST was expected to have many of the same limitations as skin tests in terms of patient experience (e.g., a return",
      "extractCut": true,
      "blocks": [
        "library/10665-381036/blocks/prose-page-1080"
      ]
    },
    {
      "id": "page-1081",
      "number": null,
      "title": "Page 1081",
      "level": 1,
      "pageStart": 1081,
      "pageEnd": 1081,
      "labelStart": "4",
      "labelEnd": "4",
      "words": 672,
      "summary": {
        "text": "Sets out the background to a study of end-user values and preferences on tests for TB infection, comparing the tuberculin skin test (TST) and interferon-gamma release assays (IGRA). It notes that IGRAs are preferred in high-income settings partly because they need only one visit. It then explains that IGRAs cost more and need laboratories, phlebotomy and trained technicians, and are often run in batches.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "tbi testing",
          "heading": false
        },
        {
          "term": "immunosuppressive conditions",
          "heading": false
        },
        {
          "term": "igra",
          "heading": false
        },
        {
          "term": "tst",
          "heading": false
        },
        {
          "term": "active disease",
          "heading": false
        },
        {
          "term": "quarter",
          "heading": false
        },
        {
          "term": "global population",
          "heading": false
        },
        {
          "term": "ppd",
          "heading": false
        }
      ],
      "extract": "4 preferrable for use in more resource-limited settings compared to the TST due to the higher accuracy whilst retaining portability and ability to administer in a community / primary care setting. Test preferences were influenced by end-user values such as test accuracy, convenience, cost, positive patient experience, and resource requirements. IGRA remain the preferred test option in high-income countries with",
      "extractCut": true,
      "blocks": [
        "library/10665-381036/blocks/prose-page-1081"
      ]
    },
    {
      "id": "page-1082",
      "number": null,
      "title": "Page 1082",
      "level": 1,
      "pageStart": 1082,
      "pageEnd": 1082,
      "labelStart": "5",
      "labelEnd": "5",
      "words": 528,
      "summary": {
        "text": "Describes the drawbacks of IGRAs and introduces newer TB antigen-based skin tests (TBST) such as C-Tb, Diaskintest and the ESAT6-CFP10 test, which may match IGRA accuracy at lower cost. It then states the project's aim of exploring end-user preferences and trade-offs through a systematic review, interviews and a discrete choice experiment.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "antigen-based skin",
          "heading": false
        },
        {
          "term": "in-depth interviews",
          "heading": false
        },
        {
          "term": "skin tests",
          "heading": false
        },
        {
          "term": "end-user values",
          "heading": false
        },
        {
          "term": "systematic reviews",
          "heading": false
        },
        {
          "term": "test attributes",
          "heading": false
        },
        {
          "term": "health equity",
          "heading": false
        },
        {
          "term": "choice experiment",
          "heading": false
        }
      ],
      "extract": "5 system costs; thus, it is not necessarily true that results would be immediate. IGRA are also more invasive, requiring venepuncture, which may impair acceptability. Over the past decade, Mycobacterium tuberculosis specific antigen-based skin tests (TBST) have been developed with the aim of improving diagnostic performance while using the same platform as the PPD-TST. These antigen-based skin tests include the C-Tb",
      "extractCut": true,
      "blocks": [
        "library/10665-381036/blocks/prose-page-1082"
      ]
    },
    {
      "id": "page-1083",
      "number": null,
      "title": "Page 1083",
      "level": 1,
      "pageStart": 1083,
      "pageEnd": 1083,
      "labelStart": "6",
      "labelEnd": "6",
      "words": 52,
      "summary": {
        "text": "Lists the three work packages of the TB skin test preference study (qualitative evidence review, end-user interviews and a discrete choice experiment) and notes the role of a multidisciplinary expert advisory panel.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "dce",
          "heading": false
        },
        {
          "term": "comprised",
          "heading": false
        },
        {
          "term": "experiment",
          "heading": false
        }
      ],
      "extract": "6 the relevant section describing each of the following work packages: A. Systematic review of qualitative evidence B. End-user interviews C. Discrete choice experiment (DCE) An expert technical advisory panel comprised of multidisciplinary experts with skills in global health, infectious diseases and behavioural medicine contributed to the design of all three studies.",
      "extractCut": false,
      "blocks": [
        "library/10665-381036/blocks/prose-page-1083"
      ]
    },
    {
      "id": "page-1084",
      "number": null,
      "title": "Page 1084",
      "level": 1,
      "pageStart": 1084,
      "pageEnd": 1084,
      "labelStart": "7",
      "labelEnd": "7",
      "words": 486,
      "summary": {
        "text": "Introduces the first work package, two systematic reviews of qualitative evidence on end-user views of antigen-based skin tests compared with IGRA and TST, and their possible equity effects. It describes the databases searched, including Russian and Chinese sources, plus manual searches and a WHO public call for data.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "systematic reviews",
          "heading": false
        },
        {
          "term": "search terms",
          "heading": false
        },
        {
          "term": "search strategy",
          "heading": false
        },
        {
          "term": "manual searches",
          "heading": false
        },
        {
          "term": "antigen-based skin",
          "heading": false
        },
        {
          "term": "tbst",
          "heading": false
        },
        {
          "term": "skin tests",
          "heading": false
        },
        {
          "term": "end-user values",
          "heading": false
        }
      ],
      "extract": "7 3.1 Work Package A-Systematic review This activity intends to answer the following objectives: Objective A: To conduct a systematic review that summarizes the evidence on end-user values and preferences regarding the acceptability and feasibility of antigen-based skin tests for TB infection, compared to current tests of infection (IGRA, TST). Objective C: To evaluate any potential impacts of TBST on health equity",
      "extractCut": true,
      "blocks": [
        "library/10665-381036/blocks/prose-page-1084"
      ]
    },
    {
      "id": "page-1085",
      "number": null,
      "title": "Page 1085",
      "level": 1,
      "pageStart": 1085,
      "pageEnd": 1085,
      "labelStart": "8",
      "labelEnd": "8",
      "words": 403,
      "summary": {
        "text": "Sets out the eligibility criteria for the qualitative reviews, which included studies using qualitative data collection and analysis and excluded those analysing qualitative data quantitatively. It also covers the populations, tests and settings considered and how two reviewers screened the results in several languages.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "qualitative methods",
          "heading": false
        },
        {
          "term": "grey literature",
          "heading": false
        },
        {
          "term": "study designs",
          "heading": false
        },
        {
          "term": "data collection",
          "heading": false
        },
        {
          "term": "potential users",
          "heading": false
        },
        {
          "term": "open-ended",
          "heading": false
        },
        {
          "term": "studies",
          "heading": false
        },
        {
          "term": "proceedings",
          "heading": false
        }
      ],
      "extract": "8 antigens). Grey literature Grey literature was not searched as part of the review. 3.1.2 Eligibility criteria Study design Included studies were primary research studies that used qualitative methodologies or study designs. Studies were required to use qualitative methods for data collection (e.g., interviews, focus groups, open-ended survey questions) and analysis (e.g., thematic analysis, grounded theory). Mixed",
      "extractCut": true,
      "blocks": [
        "library/10665-381036/blocks/prose-page-1085"
      ]
    },
    {
      "id": "page-1086",
      "number": null,
      "title": "Page 1086",
      "level": 1,
      "pageStart": 1086,
      "pageEnd": 1086,
      "labelStart": "9",
      "labelEnd": "9",
      "words": 356,
      "summary": {
        "text": "Describes how qualitative data on acceptability, feasibility and equity, plus study characteristics, were extracted in duplicate. It explains the thematic synthesis approach and the use of GRADE-CERQual to judge confidence in each review finding.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "raters",
          "heading": false
        },
        {
          "term": "review finding",
          "heading": false
        },
        {
          "term": "coding scheme",
          "heading": false
        },
        {
          "term": "systematic reviews",
          "heading": false
        },
        {
          "term": "research team",
          "heading": false
        },
        {
          "term": "duplicate",
          "heading": false
        },
        {
          "term": "health equity",
          "heading": false
        },
        {
          "term": "grade-cerqual",
          "heading": false
        }
      ],
      "extract": "9 Qualitative data pertaining to test acceptability, feasibility, and health equity were extracted from the included papers independently in duplicate by two raters (AC, KL) using Covidence software. Data were also extracted on study characteristics, including publication language, country, type of facility (including public/private, rural/urban), study objectives, methods of data collection and analysis, study",
      "extractCut": true,
      "blocks": [
        "library/10665-381036/blocks/prose-page-1086"
      ]
    },
    {
      "id": "page-1087",
      "number": null,
      "title": "Page 1087",
      "level": 1,
      "pageStart": 1087,
      "pageEnd": 1087,
      "labelStart": "10",
      "labelEnd": "10",
      "words": 162,
      "summary": {
        "text": "Reports that four studies met inclusion criteria: one on the Diaskintest from a WHO call for data and three on IGRA and TST, published between 2014 and 2021, with PRISMA flow charts.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "tst compared",
          "heading": false
        },
        {
          "term": "tbst compared",
          "heading": false
        },
        {
          "term": "flow charts",
          "heading": false
        },
        {
          "term": "papers",
          "heading": false
        },
        {
          "term": "inclusion criteria",
          "heading": false
        }
      ],
      "extract": "10 3.1.4 Results from Systematic Review A and B 3.1.4.1 Results of the Search Four studies were identified that met the inclusion criteria (see Figure A1 for Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) flow charts). Review A included papers focused on specific TBST compared to the IGRA and/or the TST, while Review B focused on papers on the IGRA and TST compared to each other or",
      "extractCut": true,
      "blocks": [
        "library/10665-381036/blocks/prose-page-1087",
        "library/10665-381036/blocks/figure-img-p1087-1",
        "library/10665-381036/blocks/figure-img-p1087-2"
      ]
    },
    {
      "id": "page-1088",
      "number": null,
      "title": "Page 1088",
      "level": 1,
      "pageStart": 1088,
      "pageEnd": 1088,
      "labelStart": "11",
      "labelEnd": "11",
      "words": 662,
      "summary": {
        "text": "Describes the four included studies, from a mass child screening programme in Russia's Penza region to HIV clinic services and immigrant screening in the Netherlands. It summarises their methodological limitations, such as missing participant quotes and unreported ethics. It begins the GRADE-CERQual assessment of confidence in the findings.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "studies reported",
          "heading": false
        },
        {
          "term": "upper-middle income",
          "heading": false
        },
        {
          "term": "review findings",
          "heading": false
        },
        {
          "term": "russian federation",
          "heading": false
        },
        {
          "term": "public call",
          "heading": false
        },
        {
          "term": "conceptual framework",
          "heading": false
        },
        {
          "term": "income country",
          "heading": false
        },
        {
          "term": "data analysis",
          "heading": false
        }
      ],
      "extract": "11 3.1.4.2 Description of the Studies A table summarizing the Characteristics of the included studies identified from Review A and B are presented in Table A1. Test From Review A, only one study reported on a TBST which was the Diaskintest18, which was from the WHO public call for data. The Diaskintest was evaluated as part of a large-scale screening program for children and adolescents in the Penza region of the",
      "extractCut": true,
      "blocks": [
        "library/10665-381036/blocks/prose-page-1088"
      ]
    },
    {
      "id": "page-1089",
      "number": null,
      "title": "Page 1089",
      "level": 1,
      "pageStart": 1089,
      "pageEnd": 1089,
      "labelStart": "12",
      "labelEnd": "12",
      "words": 144,
      "summary": {
        "text": "Reports moderate confidence in the review findings on values, acceptability and feasibility and low confidence for health equity, citing small numbers of studies, thin data and focus on narrow subgroups.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "health equity",
          "heading": false
        },
        {
          "term": "findings",
          "heading": false
        },
        {
          "term": "richness",
          "heading": false
        },
        {
          "term": "confidence",
          "heading": false
        }
      ],
      "extract": "12 health equity), 3 findings (end user values and preferences, acceptability, feasibility) were rated with moderate confidence based on the findings from Review A and B. Health equity received a low confidence rating. Appendix B provides a detailed summary table of the GRADE-CERQual analysis. There were serious concerns about data adequacy for the feasibility and health equity findings due to the small number of",
      "extractCut": true,
      "blocks": [
        "library/10665-381036/blocks/prose-page-1089"
      ]
    },
    {
      "id": "page-1090",
      "number": null,
      "title": "Page 1090",
      "level": 1,
      "pageStart": 1090,
      "pageEnd": 1090,
      "labelStart": null,
      "labelEnd": null,
      "words": 453,
      "summary": {
        "text": "A table of characteristics of the four studies included in the qualitative reviews, covering test type, country, setting, participants, data collection, analysis, frameworks and conflicts of interest.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "semi structured",
          "heading": false
        },
        {
          "term": "structured guide",
          "heading": false
        },
        {
          "term": "reviewed article",
          "heading": false
        },
        {
          "term": "peer reviewed",
          "heading": false
        },
        {
          "term": "demographic data",
          "heading": false
        },
        {
          "term": "individual interviews",
          "heading": false
        },
        {
          "term": "conceptual framework",
          "heading": false
        },
        {
          "term": "quantifer",
          "heading": false
        }
      ],
      "extract": "0 Table A1: Systematic Reviews A and B- Characteristics of Included Studies Study ID Publication type TBI Tests Country Facility Type Public/ Private Rural/ Urban Participants Programmatic features Comparato rs Data collection Study duration Method of data analysis Conceptual framework Conflicts of Interest Review A findings on TBST Aksenova 2021 (Review A) Report (WHO call for data) Diaskintest Russian Federation",
      "extractCut": true,
      "blocks": [
        "library/10665-381036/blocks/prose-page-1090",
        "library/10665-381036/blocks/table-056"
      ]
    },
    {
      "id": "page-1091",
      "number": null,
      "title": "Page 1091",
      "level": 1,
      "pageStart": 1091,
      "pageEnd": 1091,
      "labelStart": null,
      "labelEnd": null,
      "words": 481,
      "summary": {
        "text": "Introduces the combined qualitative findings on test values, acceptability, feasibility and equity, noting how limited the data were. It reports that accuracy shaped preferences, with IGRA often favoured over TST for being less subjective, although some clinic staff doubted IGRA accuracy in people with HIV.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "values preferences",
          "heading": false
        },
        {
          "term": "user preferences",
          "heading": false
        },
        {
          "term": "end-user values",
          "heading": false
        },
        {
          "term": "tbi tests",
          "heading": false
        },
        {
          "term": "review findings",
          "heading": false
        },
        {
          "term": "solid grey",
          "heading": false
        },
        {
          "term": "contextual factors",
          "heading": false
        },
        {
          "term": "grey refers",
          "heading": false
        }
      ],
      "extract": "0 3.1.4.5 Review Findings Our qualitative evidence synthesis from Work Package A draws on the findings from both Systematic Reviews A and B. Overall, there were limited data available hence the decision to combine findings from both Reviews, with Review A on TBST retrieving only one relevant data report, and Review B on TST and IGRA retrieving only three papers. The findings identified factors contributing to",
      "extractCut": true,
      "blocks": [
        "library/10665-381036/blocks/prose-page-1091",
        "library/10665-381036/blocks/figure-img-p1091-1",
        "library/10665-381036/blocks/figure-img-p1091-2"
      ]
    },
    {
      "id": "page-1092",
      "number": null,
      "title": "Page 1092",
      "level": 1,
      "pageStart": 1092,
      "pageEnd": 1092,
      "labelStart": "1",
      "labelEnd": "1",
      "words": 632,
      "summary": {
        "text": "Reports how convenience factors such as clinic waits, transport and crowding affected preferences for IGRA and TST, while the Diaskintest was seen as convenient for mass screening. It then discusses people-related factors in test acceptability, including discomfort from the TST, illustrated with quotes from South Africa.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "south africa",
          "heading": false
        },
        {
          "term": "tbi tests",
          "heading": false
        },
        {
          "term": "consumer experience",
          "heading": false
        },
        {
          "term": "test preferences",
          "heading": false
        },
        {
          "term": "providers reported",
          "heading": false
        },
        {
          "term": "trained staff",
          "heading": false
        },
        {
          "term": "tst",
          "heading": false
        },
        {
          "term": "irritating",
          "heading": false
        }
      ],
      "extract": "1 that there was a high frequency of indeterminate results from the IGRA, although this was not supported in the clinic data where only 1% of indeterminate results were received20. “Sometimes we’re not sure if they measure it correctly, or if the TST was done correctly, did they take enough, was it inserted sub-dermally? There can come human errors as well. With blood, I think the result is the result.” (South",
      "extractCut": true,
      "blocks": [
        "library/10665-381036/blocks/prose-page-1092"
      ]
    },
    {
      "id": "page-1093",
      "number": null,
      "title": "Page 1093",
      "level": 1,
      "pageStart": 1093,
      "pageEnd": 1093,
      "labelStart": "2",
      "labelEnd": "2",
      "words": 647,
      "summary": {
        "text": "Describes test-related factors affecting acceptability, with TBST and IGRA seen as more specific than TST and the Diaskintest's specificity encouraging parents to test their children. It notes no contextual factors affected acceptability. It then opens the feasibility findings, which came only from IGRA and TST studies and were rated with moderate confidence.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "blood draw",
          "heading": false
        },
        {
          "term": "blood test",
          "heading": false
        },
        {
          "term": "less acceptable",
          "heading": false
        },
        {
          "term": "igra",
          "heading": false
        },
        {
          "term": "contextual factors",
          "heading": false
        },
        {
          "term": "tbi tests",
          "heading": false
        },
        {
          "term": "south africa",
          "heading": false
        },
        {
          "term": "tst",
          "heading": false
        }
      ],
      "extract": "2 Test Factors Acceptability was affected by test-related factors, including the accuracy of the test, the certainty of results, and the suitability of the test for use in particular subgroups (e.g., children and adolescents, persons with HIV, needle-phobic individuals). TBST and IGRA were perceived as having greater specificity than the TST18,21. The TST was described as having a high rate of false positives; thus",
      "extractCut": true,
      "blocks": [
        "library/10665-381036/blocks/prose-page-1093"
      ]
    },
    {
      "id": "page-1094",
      "number": null,
      "title": "Page 1094",
      "level": 1,
      "pageStart": 1094,
      "pageEnd": 1094,
      "labelStart": "3",
      "labelEnd": "3",
      "words": 698,
      "summary": {
        "text": "Explains that the need for a second clinic visit to read the TST was a key feasibility concern, especially where travel and waiting times are long, while IGRA needs only one visit. It reports provider views from South Africa that using routine blood draws could ease follow-up problems, along with a patient's worry about delays.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "clinic staff",
          "heading": false
        },
        {
          "term": "south africa",
          "heading": false
        },
        {
          "term": "blood draws",
          "heading": false
        },
        {
          "term": "north west",
          "heading": false
        },
        {
          "term": "healthcare providers",
          "heading": false
        },
        {
          "term": "spruijt",
          "heading": false
        },
        {
          "term": "phs",
          "heading": false
        },
        {
          "term": "igra",
          "heading": false
        }
      ],
      "extract": "3 Aspects of the individual experience were found to affect the feasibility of the IGRA and TST. A common feasibility concern for the TST, based on findings from Review B, were that consumers were required to visit the clinic a second time within 72 hours to read the test result19,20,21. Kerrigan et al. described how in the North West Province of South Africa, many consumers experienced difficulties with visiting a",
      "extractCut": true,
      "blocks": [
        "library/10665-381036/blocks/prose-page-1094"
      ]
    },
    {
      "id": "page-1095",
      "number": null,
      "title": "Page 1095",
      "level": 1,
      "pageStart": 1095,
      "pageEnd": 1095,
      "labelStart": "4",
      "labelEnd": "4",
      "words": 713,
      "summary": {
        "text": "Continues the feasibility findings with concerns about infrequent blood draws delaying detection, and notes that public funding and supply of the TST helped feasibility in South Africa. It then summarises health equity issues, including access and transport barriers, staffing, scalability for mass screening and suitability for children, people with HIV and needle-phobic people.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "tst read",
          "heading": false
        },
        {
          "term": "blood draw",
          "heading": false
        },
        {
          "term": "trained staff",
          "heading": false
        },
        {
          "term": "south africa",
          "heading": false
        },
        {
          "term": "tbi tests",
          "heading": false
        },
        {
          "term": "equity impacts",
          "heading": false
        },
        {
          "term": "having access",
          "heading": false
        },
        {
          "term": "health equity",
          "heading": false
        }
      ],
      "extract": "4 the low frequency with which they would typically have a blood draw: “While there was general consensus on this issue, one patient did relay a concern about timing, as many patients may only have a CD4 blood draw 1–2 times a year. So while this patient thought screening the CD4 blood draw for TB was a good idea, he wouldn’t want that to delay finding out he had TB, as he would want to know that information as soon",
      "extractCut": true,
      "blocks": [
        "library/10665-381036/blocks/prose-page-1095"
      ]
    },
    {
      "id": "page-1096",
      "number": null,
      "title": "Page 1096",
      "level": 1,
      "pageStart": 1096,
      "pageEnd": 1096,
      "labelStart": "5",
      "labelEnd": "5",
      "words": 282,
      "summary": {
        "text": "Expands on equity issues, highlighting the return visit for TST reading as a barrier and shortages of trained staff for TST and IGRA. It notes the Diaskintest was reported as suitable for mass screening of children, while some US clinicians doubted IGRA results in people with HIV.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "russian federation",
          "heading": false
        },
        {
          "term": "united states",
          "heading": false
        },
        {
          "term": "quote",
          "heading": false
        },
        {
          "term": "igra",
          "heading": false
        },
        {
          "term": "mass",
          "heading": false
        },
        {
          "term": "tst",
          "heading": false
        },
        {
          "term": "diaskintest",
          "heading": false
        },
        {
          "term": "accessibility",
          "heading": false
        }
      ],
      "extract": "5 In terms of access and transport issues, the return visit required to read the TST result was focused on as a major accessibility issue in 3 studies19,20,21. This included at-risk groups in both middle- and high-income countries (South Africa, United States). Kerrigan et al., which focused on an HIV clinic in a middle-income country, documented how many consumers experienced challenges with transportation and wait",
      "extractCut": true,
      "blocks": [
        "library/10665-381036/blocks/prose-page-1096"
      ]
    },
    {
      "id": "page-1097",
      "number": null,
      "title": "Page 1097",
      "level": 1,
      "pageStart": 1097,
      "pageEnd": 1097,
      "labelStart": "6",
      "labelEnd": "6",
      "words": 191,
      "summary": {
        "text": "Summarises the systematic review findings: data on antigen-based skin tests were scarce and setting-specific, and key values included accuracy, convenience, patient experience, cost and resources. It explains how these findings shaped the interview guide and discrete choice experiment.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "contextual factors",
          "heading": false
        },
        {
          "term": "work package",
          "heading": false
        },
        {
          "term": "limited data",
          "heading": false
        },
        {
          "term": "health equity",
          "heading": false
        },
        {
          "term": "data available",
          "heading": false
        },
        {
          "term": "relating",
          "heading": false
        }
      ],
      "extract": "6 3.1.5 Summary of Work Package A findings from the Systematic Reviews Overall, there were limited data from the reviews on TBSTs, with only 4 studies identified. Importantly, these studies were conducted in very specific healthcare settings and populations, limiting our confidence in the data quality and the generalisability of these findings. Most of the data available related to TST and IGRA. Despite the limited",
      "extractCut": true,
      "blocks": [
        "library/10665-381036/blocks/prose-page-1097"
      ]
    },
    {
      "id": "page-1098",
      "number": null,
      "title": "Page 1098",
      "level": 1,
      "pageStart": 1098,
      "pageEnd": 1098,
      "labelStart": "7",
      "labelEnd": "7",
      "words": 476,
      "summary": {
        "text": "Introduces the second work package, qualitative interviews with 20 people with TB and providers recruited through global networks and organisations such as TB civil society groups and the Stop TB Partnership. It describes the email invitation and the interview topics, tailored to consumers and providers.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "interview topics",
          "heading": false
        },
        {
          "term": "tbi tests",
          "heading": false
        },
        {
          "term": "individuals living",
          "heading": false
        },
        {
          "term": "healthcare provider",
          "heading": false
        },
        {
          "term": "tbst",
          "heading": false
        },
        {
          "term": "zoom",
          "heading": false
        },
        {
          "term": "work package",
          "heading": false
        },
        {
          "term": "systematic review",
          "heading": false
        }
      ],
      "extract": "7 Work Package B-Qualitative user interviews This activity intends to answer following objectives: A qualitative interview study was conducted with 20 participants who were individuals living with TB or providers involved in TB testing and /or care of individuals living with TB. Participants were recruited from the research team’s global networks across high and low-middle income countries, with support from WHO.",
      "extractCut": true,
      "blocks": [
        "library/10665-381036/blocks/prose-page-1098"
      ]
    },
    {
      "id": "page-1099",
      "number": null,
      "title": "Page 1099",
      "level": 1,
      "pageStart": 1099,
      "pageEnd": 1099,
      "labelStart": "8",
      "labelEnd": "8",
      "words": 391,
      "summary": {
        "text": "Lists the interview topics, from current skin test use to preferences, feasibility, acceptability and equity, and explains that interviews were transcribed and coded in NVivo. A table and figure describe the 13 providers and 7 consumers from high- and low/middle-income countries.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "participant characteristics",
          "heading": false
        },
        {
          "term": "interview data",
          "heading": false
        },
        {
          "term": "ethics committee",
          "heading": false
        },
        {
          "term": "skin-based tests",
          "heading": false
        },
        {
          "term": "middle-income country",
          "heading": false
        },
        {
          "term": "high-income country",
          "heading": false
        },
        {
          "term": "field notes",
          "heading": false
        },
        {
          "term": "healthcare providers",
          "heading": false
        }
      ],
      "extract": "8 1. Current approach to using skin tests as part of the TB diagnostic process; 2. End-user values and preferences with regard to TB testing, from their previous experience with skin-based tests – focusing on ease of use and process for TBST, IGRA, and TST; 3. End-user values and preferences considering the challenges and benefits of skin-based tests, particularly TBST, which test(s) they would prefer and reasons",
      "extractCut": true,
      "blocks": [
        "library/10665-381036/blocks/prose-page-1099"
      ]
    },
    {
      "id": "page-1100",
      "number": null,
      "title": "Page 1100",
      "level": 1,
      "pageStart": 1100,
      "pageEnd": 1100,
      "labelStart": "9",
      "labelEnd": "9",
      "words": 269,
      "summary": {
        "text": "Explains that the interview analysis reused the people, test and contextual factor framework from the review. It reports that participants valued accuracy and saw TBST and IGRA as more accurate than TST, with downstream benefits such as avoiding unnecessary treatment and stress.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "end-user values",
          "heading": false
        },
        {
          "term": "subthemes",
          "heading": false
        },
        {
          "term": "grey refers",
          "heading": false
        },
        {
          "term": "contextual factors",
          "heading": false
        },
        {
          "term": "healthcare consumers",
          "heading": false
        },
        {
          "term": "coding framework",
          "heading": false
        },
        {
          "term": "test accuracy",
          "heading": false
        },
        {
          "term": "preferences",
          "heading": false
        }
      ],
      "extract": "9 1.2.3 Key Findings The findings from Work Package A were used to inform the coding framework and analyses undertaken in Work Package B – as such, the same subthemes of people, test, and contextual factors were used to explore acceptability and feasibility of the tests, with health equity and end-user values and preferences as separate subthemes. The full coding framework used can be found in Appendix E. As before,",
      "extractCut": true,
      "blocks": [
        "library/10665-381036/blocks/prose-page-1100",
        "library/10665-381036/blocks/figure-img-p1100-1"
      ]
    },
    {
      "id": "page-1101",
      "number": null,
      "title": "Page 1101",
      "level": 1,
      "pageStart": 1101,
      "pageEnd": 1101,
      "labelStart": "10",
      "labelEnd": "10",
      "words": 684,
      "summary": {
        "text": "Reports interviewees' concerns that false-positive TST results cause costly and stressful follow-up. It describes how IGRA was seen as more convenient because it needs one visit. It also notes that IGRAs demand more resources, such as laboratories, phlebotomy and trained staff, than skin tests.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "tbi tests",
          "heading": false
        },
        {
          "term": "tsts",
          "heading": false
        },
        {
          "term": "tbsts",
          "heading": false
        },
        {
          "term": "false positives",
          "heading": false
        },
        {
          "term": "end users",
          "heading": false
        },
        {
          "term": "skin tests",
          "heading": false
        },
        {
          "term": "igras",
          "heading": false
        },
        {
          "term": "resource-limited settings",
          "heading": false
        }
      ],
      "extract": "10 perceived to have lower accuracy and were associated with downstream challenges by end-users. These included greater expense and psychological stress. “The big issue I think is the false positives with the current tests that we use and that then leads to a whole chain of events which I think is very expensive and stressful for people because if you’re told you might have TB or you probably have got TB and then",
      "extractCut": true,
      "blocks": [
        "library/10665-381036/blocks/prose-page-1101"
      ]
    },
    {
      "id": "page-1102",
      "number": null,
      "title": "Page 1102",
      "level": 1,
      "pageStart": 1102,
      "pageEnd": 1102,
      "labelStart": "11",
      "labelEnd": "11",
      "words": 392,
      "summary": {
        "text": "Notes a provider's view that TBSTs need little laboratory infrastructure. It then presents people-related factors in acceptability, such as consumer experience and perceptions of skin tests, with mixed views on whether new tests would cause anxiety.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "intradermal injection",
          "heading": false
        },
        {
          "term": "painful test",
          "heading": false
        },
        {
          "term": "consumer experience",
          "heading": false
        },
        {
          "term": "tbi tests",
          "heading": false
        },
        {
          "term": "psychological consequences",
          "heading": false
        },
        {
          "term": "physical consequences",
          "heading": false
        },
        {
          "term": "people-related factors",
          "heading": false
        },
        {
          "term": "skin tests",
          "heading": false
        }
      ],
      "extract": "11 test equipment are still required, and clinics and patient transport are needed in some instances. “I feel like the good thing about [the TBSTs] is you don’t need much lab infrastructure, I feel like the need to draw blood is a barrier for IGRAs.” (ID017, HIC, Provider) 3.2.3.2. Acceptability People-related factors There were 7 subthemes relating to people factors for acceptability of TBI tests (Figure B3). These",
      "extractCut": true,
      "blocks": [
        "library/10665-381036/blocks/prose-page-1102",
        "library/10665-381036/blocks/figure-img-p1102-1"
      ]
    },
    {
      "id": "page-1103",
      "number": null,
      "title": "Page 1103",
      "level": 1,
      "pageStart": 1103,
      "pageEnd": 1103,
      "labelStart": "12",
      "labelEnd": "12",
      "words": 680,
      "summary": {
        "text": "Presents interview quotes on fears about skin test injections and live readings, and on blood draws as a barrier to IGRA, including cultural beliefs about blood. It shows that initial worries about injections often eased with experience. It also contrasts the invasiveness of skin and blood tests.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "draw blood",
          "heading": false
        },
        {
          "term": "blood test",
          "heading": false
        },
        {
          "term": "skin test",
          "heading": false
        },
        {
          "term": "little bit",
          "heading": false
        },
        {
          "term": "worry",
          "heading": false
        },
        {
          "term": "indistinct",
          "heading": false
        },
        {
          "term": "hic",
          "heading": false
        },
        {
          "term": "going",
          "heading": false
        }
      ],
      "extract": "12 ‘live’ reading that took place in front of them, an experience that is avoided with the IGRA. “We also found perspective from the patient that maybe people at the beginning, they worry that it’s painful and they scared of injection, but once they (indistinct), they like it very much because you can see physically the test result on your arm… at the beginning, many people worry about it, they worry that it would",
      "extractCut": true,
      "blocks": [
        "library/10665-381036/blocks/prose-page-1103"
      ]
    },
    {
      "id": "page-1104",
      "number": null,
      "title": "Page 1104",
      "level": 1,
      "pageStart": 1104,
      "pageEnd": 1104,
      "labelStart": "13",
      "labelEnd": "13",
      "words": 654,
      "summary": {
        "text": "Reports that the complexity of skin test procedures may reduce acceptability among people with low health literacy. It discusses demographic concerns about using IGRA and TBST in some groups. It also includes providers' hopes for less invasive formats and one view that skin testing should be abandoned altogether.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "darker skin",
          "heading": false
        },
        {
          "term": "skin tones",
          "heading": false
        },
        {
          "term": "skin tests",
          "heading": false
        },
        {
          "term": "skin types",
          "heading": false
        },
        {
          "term": "different skin",
          "heading": false
        },
        {
          "term": "blood tests",
          "heading": false
        },
        {
          "term": "blood draw",
          "heading": false
        },
        {
          "term": "hic",
          "heading": false
        }
      ],
      "extract": "13 Lastly, the complicated process involved with skin tests was perceived to reduce acceptability in consumers with low health literacy. “First of all the test is a very complex thing, though to the provider it might be easy but from the patient’s perspective it is difficult. Like as of my understanding, patient should not have, should not rub on the injected areas and all those certain precautions need to be taken",
      "extractCut": true,
      "blocks": [
        "library/10665-381036/blocks/prose-page-1104"
      ]
    },
    {
      "id": "page-1105",
      "number": null,
      "title": "Page 1105",
      "level": 1,
      "pageStart": 1105,
      "pageEnd": 1105,
      "labelStart": "14",
      "labelEnd": "14",
      "words": 605,
      "summary": {
        "text": "Continues with participants' views that skin tests are outdated technology and that most knew little about TBST, calling for public awareness and evidence. It reports that clear explanation and endorsement by providers and WHO were expected to improve acceptability.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "skin test",
          "heading": false
        },
        {
          "term": "lmic",
          "heading": false
        },
        {
          "term": "tbst",
          "heading": false
        },
        {
          "term": "consumer",
          "heading": false
        },
        {
          "term": "leaves",
          "heading": false
        },
        {
          "term": "perception",
          "heading": false
        },
        {
          "term": "lot",
          "heading": false
        },
        {
          "term": "provider",
          "heading": false
        }
      ],
      "extract": "14 something that makes much more sense… This whole conversation is surreal to me, why people are doing this with a 100 year old technology… If it’s better than the TB skin test then the issue is replacing that test with this test, that’s, I totally understand that and that’s a perfectly reasonable thing. We are trying to get away from skin testing period.” (ID014, HIC, Provider) Knowledge Most participants",
      "extractCut": true,
      "blocks": [
        "library/10665-381036/blocks/prose-page-1105"
      ]
    },
    {
      "id": "page-1106",
      "number": null,
      "title": "Page 1106",
      "level": 1,
      "pageStart": 1106,
      "pageEnd": 1106,
      "labelStart": "15",
      "labelEnd": "15",
      "words": 446,
      "summary": {
        "text": "Reports that some consumers doubted the usefulness of TBST without evidence that it beats existing tests, or questioned what care follows a positive result. Providers expected the new skin tests to match IGRA specificity in skin-test form and would prefer them over the TST.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "novel skin",
          "heading": false
        },
        {
          "term": "skin test",
          "heading": false
        },
        {
          "term": "test acceptability",
          "heading": false
        },
        {
          "term": "test factors",
          "heading": false
        },
        {
          "term": "subthemes",
          "heading": false
        },
        {
          "term": "tbi tests",
          "heading": false
        },
        {
          "term": "consumer",
          "heading": false
        },
        {
          "term": "healthcare provider",
          "heading": false
        }
      ],
      "extract": "15 that it’s a good one, it’s worth carrying on with.” (ID001, HIC, Consumer) Usefulness A couple of consumers questioned how useful the TBST would be. Interestingly, this did not come up as a finding from any healthcare provider participant. One consumer reported needing evidence that the TBST are better than the TST and IGRA to think that they are useful. Another consumer felt that how useful the TBI tests are in",
      "extractCut": true,
      "blocks": [
        "library/10665-381036/blocks/prose-page-1106",
        "library/10665-381036/blocks/figure-img-p1106-1"
      ]
    },
    {
      "id": "page-1107",
      "number": null,
      "title": "Page 1107",
      "level": 1,
      "pageStart": 1107,
      "pageEnd": 1107,
      "labelStart": "16",
      "labelEnd": "16",
      "words": 661,
      "summary": {
        "text": "Presents provider criticism of how subjective TST readings are and lists perceived benefits of TBST's greater accuracy, including use in people who inject drugs. It also notes that none of the tests can distinguish latent from active TB.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "less suited",
          "heading": false
        },
        {
          "term": "igra test",
          "heading": false
        },
        {
          "term": "little bit",
          "heading": false
        },
        {
          "term": "psychological stress",
          "heading": false
        },
        {
          "term": "participants discussed",
          "heading": false
        },
        {
          "term": "tbst",
          "heading": false
        },
        {
          "term": "tst",
          "heading": false
        },
        {
          "term": "tbi tests",
          "heading": false
        }
      ],
      "extract": "16 specificity really.” (ID019, HIC, Provider) “The measurement involves a ballpoint pen with free flowing ink and you sort of make the mark on the person’s arm until you start to feel a little bit of resistance and then you stop and then you do that on the other side and you stop, and then you measure the distance between those two stops and that’s probably the most accurate way to interpret the induration. But as",
      "extractCut": true,
      "blocks": [
        "library/10665-381036/blocks/prose-page-1107"
      ]
    },
    {
      "id": "page-1108",
      "number": null,
      "title": "Page 1108",
      "level": 1,
      "pageStart": 1108,
      "pageEnd": 1108,
      "labelStart": "17",
      "labelEnd": "17",
      "words": 524,
      "summary": {
        "text": "Reports views on the difficulty of developing a biomarker that separates latent from active TB. It describes contextual factors in acceptability, such as provider perceptions and follow-up infrastructure, including consequences like deportation after positive tests in travellers. It notes that hospital settings caused anxiety for some consumers.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "test acceptability",
          "heading": false
        },
        {
          "term": "tbi test",
          "heading": false
        },
        {
          "term": "providers felt",
          "heading": false
        },
        {
          "term": "provider perceptions",
          "heading": false
        },
        {
          "term": "test follow-up",
          "heading": false
        },
        {
          "term": "test environment",
          "heading": false
        },
        {
          "term": "contextual factors",
          "heading": false
        },
        {
          "term": "consumer",
          "heading": false
        }
      ],
      "extract": "17 developing a test to achieve that aim: “No the challenges were that it was not really possible to differentiate by the results of the PPD test who is really infected and who really needs preventive treatment… currently all researchers in the field all over the world are looking for some biomarker that could help differentiate latent TB infection from the active TB infection right, yes, but it is very difficult to",
      "extractCut": true,
      "blocks": [
        "library/10665-381036/blocks/prose-page-1108",
        "library/10665-381036/blocks/figure-img-p1108-1"
      ]
    },
    {
      "id": "page-1109",
      "number": null,
      "title": "Page 1109",
      "level": 1,
      "pageStart": 1109,
      "pageEnd": 1109,
      "labelStart": "18",
      "labelEnd": "18",
      "words": 438,
      "summary": {
        "text": "Opens the interview findings on feasibility, noting that consumer experience was the only people factor raised. It reports that IGRA's single-visit requirement was seen as a clear advantage that lets providers focus follow-up on positive cases.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "consumer experience",
          "heading": false
        },
        {
          "term": "tbi tests",
          "heading": false
        },
        {
          "term": "people factors",
          "heading": false
        },
        {
          "term": "subtheme",
          "heading": false
        },
        {
          "term": "appointment",
          "heading": false
        },
        {
          "term": "skin tests",
          "heading": false
        },
        {
          "term": "healthcare providers",
          "heading": false
        },
        {
          "term": "feasibility",
          "heading": false
        }
      ],
      "extract": "18 an earlier section (see Acceptability > Consumer experience). This issue could be applicable to all 3 TBI tests, although a hospital appointment is most often involved when receiving the IGRA compared to the skin tests. 3.2.3.3 Feasibility People Factors Only one subtheme described a people factor that impacted feasibility, which was consumer experience. This subtheme was discussed by both healthcare providers",
      "extractCut": true,
      "blocks": [
        "library/10665-381036/blocks/prose-page-1109",
        "library/10665-381036/blocks/figure-img-p1109-1"
      ]
    },
    {
      "id": "page-1110",
      "number": null,
      "title": "Page 1110",
      "level": 1,
      "pageStart": 1110,
      "pageEnd": 1110,
      "labelStart": "19",
      "labelEnd": "19",
      "words": 506,
      "summary": {
        "text": "Presents quotes on the single-visit benefit of IGRA versus repeat TST visits and on transport burdens, especially in lower-income countries. It introduces four test factors affecting feasibility: cost, time to result, portability and ease of administration, starting with the lower cost of skin tests.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "consumer experience",
          "heading": false
        },
        {
          "term": "test feasibility",
          "heading": false
        },
        {
          "term": "four subthemes",
          "heading": false
        },
        {
          "term": "test factors",
          "heading": false
        },
        {
          "term": "healthcare providers",
          "heading": false
        },
        {
          "term": "igra",
          "heading": false
        },
        {
          "term": "waiting",
          "heading": false
        },
        {
          "term": "hic",
          "heading": false
        }
      ],
      "extract": "19 “The good thing about the T-SPOT or the IGRA is that they, once they’ve had the blood test done that’s it and actually if they’re not sort of then we can put effort knowing that it’s positive or negative. If it’s positive then obviously we will be following up and putting more effort into trying to find somebody whereas often with a Mantoux, if they don’t come back within the timeframe then it has to be",
      "extractCut": true,
      "blocks": [
        "library/10665-381036/blocks/prose-page-1110",
        "library/10665-381036/blocks/figure-img-p1110-1"
      ]
    },
    {
      "id": "page-1111",
      "number": null,
      "title": "Page 1111",
      "level": 1,
      "pageStart": 1111,
      "pageEnd": 1111,
      "labelStart": "20",
      "labelEnd": "20",
      "words": 700,
      "summary": {
        "text": "Reports providers' views that the lower cost of TBST could save money and make government funding more likely, including for testing children. It discusses time to result and the portability of skin tests for community outreach. It notes that the TST was considered fairly easy to administer with trained staff.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "novel skin",
          "heading": false
        },
        {
          "term": "skin tests",
          "heading": false
        },
        {
          "term": "providers discussed",
          "heading": false
        },
        {
          "term": "healthcare setting",
          "heading": false
        },
        {
          "term": "portability",
          "heading": false
        },
        {
          "term": "gonna",
          "heading": false
        },
        {
          "term": "cheaper",
          "heading": false
        },
        {
          "term": "lmic",
          "heading": false
        }
      ],
      "extract": "20 costs in their current practice with TBST, while others acknowledged that the low cost may increase the willingness of governments to fund the TBST. A couple of providers discussed how the low cost affected their usage intentions towards the TBST. Quotes from providers discussing these aspects are presented below: “I think in my current practice, since we are now dealing with TB patients as well, it will be an",
      "extractCut": true,
      "blocks": [
        "library/10665-381036/blocks/prose-page-1111"
      ]
    },
    {
      "id": "page-1112",
      "number": null,
      "title": "Page 1112",
      "level": 1,
      "pageStart": 1112,
      "pageEnd": 1112,
      "labelStart": "21",
      "labelEnd": "21",
      "words": 561,
      "summary": {
        "text": "Presents quotes on the TST technique being fiddly at first but manageable with training, and on the need for frequent retraining in community settings. It also includes a wish for simpler tests such as fingerprick assays. It then introduces contextual factors in feasibility: resource needs, the COVID-19 pandemic and the health system setting.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "don think",
          "heading": false
        },
        {
          "term": "novel skin",
          "heading": false
        },
        {
          "term": "skin test",
          "heading": false
        },
        {
          "term": "contextual factors",
          "heading": false
        },
        {
          "term": "hic",
          "heading": false
        },
        {
          "term": "technique",
          "heading": false
        },
        {
          "term": "provider",
          "heading": false
        },
        {
          "term": "mantoux",
          "heading": false
        }
      ],
      "extract": "21 tricky at first, but ease of use came with practice and appropriate training: “I mean, they’re fairly easy to use. I mean they’re a bit fiddly but they’re not, once you get used to it it’s just getting the technique… But it’s yeah, it’s not difficult, once you get the hang of it.” (ID012, HIC, Provider) “We found that we have to retrain our staff at least every six months of the year… with the result sometimes",
      "extractCut": true,
      "blocks": [
        "library/10665-381036/blocks/prose-page-1112",
        "library/10665-381036/blocks/figure-img-p1112-1"
      ]
    },
    {
      "id": "page-1113",
      "number": null,
      "title": "Page 1113",
      "level": 1,
      "pageStart": 1113,
      "pageEnd": 1113,
      "labelStart": "22",
      "labelEnd": "22",
      "words": 610,
      "summary": {
        "text": "Describes contextual factors affecting the feasibility of tests for TB infection, noting that skin tests (TBST and TST) and IGRA all need trained staff and equipment, while IGRA also needs a laboratory, a blood draw and travel to a facility. It introduces equity factors, with tests needing less infrastructure seen as more accessible in resource-limited settings.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "blood draw",
          "heading": false
        },
        {
          "term": "blood test",
          "heading": false
        },
        {
          "term": "test feasibility",
          "heading": false
        },
        {
          "term": "tbi tests",
          "heading": false
        },
        {
          "term": "feel like",
          "heading": false
        },
        {
          "term": "don know",
          "heading": false
        },
        {
          "term": "five subthemes",
          "heading": false
        },
        {
          "term": "resource-limited settings",
          "heading": false
        }
      ],
      "extract": "22 Figure describing the contextual factors influencing test feasibility Resource Requirements The TBST, TST, and IGRA all require access to specific test equipment and trained staff – as such, the availability of a trained workforce was considered key for test feasibility. However, the IGRA also requires access to a laboratory for test analysis and a hospital or clinic for the blood draw. As a result, there is also",
      "extractCut": true,
      "blocks": [
        "library/10665-381036/blocks/prose-page-1113"
      ]
    },
    {
      "id": "page-1114",
      "number": null,
      "title": "Page 1114",
      "level": 1,
      "pageStart": 1114,
      "pageEnd": 1114,
      "labelStart": "23",
      "labelEnd": "23",
      "words": 505,
      "summary": {
        "text": "Discusses how tests for TB infection affect health equity, explaining that skin tests are more portable and may not need a facility visit, which helps people living far from clinics. It notes that IGRA was seen as less suited to low-income settings because of its cost and resource needs.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "low-resource settings",
          "heading": false
        },
        {
          "term": "tbi tests",
          "heading": false
        },
        {
          "term": "low-income country",
          "heading": false
        },
        {
          "term": "long journey",
          "heading": false
        },
        {
          "term": "skin tests",
          "heading": false
        },
        {
          "term": "settings due",
          "heading": false
        },
        {
          "term": "healthcare facility",
          "heading": false
        },
        {
          "term": "infrastructure required",
          "heading": false
        }
      ],
      "extract": "23 Figure describing the factors influencing test health equity Access and Transport Issues The IGRA typically requires a visit to a healthcare facility for test administration, whereas the TBST and the TST are more portable with less resource requirements, thus a visit to a healthcare facility might not always be required. This is a distinct advantage of the skin tests in low-resource settings, as the tests can be",
      "extractCut": true,
      "blocks": [
        "library/10665-381036/blocks/prose-page-1114",
        "library/10665-381036/blocks/figure-img-p1114-1"
      ]
    },
    {
      "id": "page-1115",
      "number": null,
      "title": "Page 1115",
      "level": 1,
      "pageStart": 1115,
      "pageEnd": 1115,
      "labelStart": "24",
      "labelEnd": "24",
      "words": 531,
      "summary": {
        "text": "Presents interview quotes on affordability and the value of simple skin tests where phlebotomy is unavailable, and notes that skin tests may suit groups in whom finding veins is hard. It concludes that equity effects of these tests may differ by population.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "skin tones",
          "heading": false
        },
        {
          "term": "darker skin",
          "heading": false
        },
        {
          "term": "finding veins",
          "heading": false
        },
        {
          "term": "intradermal injection",
          "heading": false
        },
        {
          "term": "tbi tests",
          "heading": false
        },
        {
          "term": "blood draw",
          "heading": false
        },
        {
          "term": "bcg vaccination",
          "heading": false
        },
        {
          "term": "phlebotomy",
          "heading": false
        }
      ],
      "extract": "24 required for implementation compared to the TST and the TBST. “I guess the issue of making it more affordable, its bringing the potential of a different technology in a more affordable way to people who have a high burden of the problem.” (ID014, HIC, Provider) “We’ve got access to phlebotomy and can get the IGRA done and it’s quite easy, it sort of feels to me like well what would be the benefit changing. But I",
      "extractCut": true,
      "blocks": [
        "library/10665-381036/blocks/prose-page-1115"
      ]
    },
    {
      "id": "page-1116",
      "number": null,
      "title": "Page 1116",
      "level": 1,
      "pageStart": 1116,
      "pageEnd": 1116,
      "labelStart": "25",
      "labelEnd": "25",
      "words": 711,
      "summary": {
        "text": "Summarizes the user interview findings: providers and consumers valued accuracy, convenience, a good patient experience, low cost and low resource needs. The new antigen-based skin tests were seen as matching IGRA accuracy at lower cost and resource needs, and as more accurate than the TST at similar cost. Interviewees cautioned that in low-income settings the TBST alone would not fix wider access barriers such as stock, staff training and equipment.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "skin tests",
          "heading": false
        },
        {
          "term": "low-resource settings",
          "heading": false
        },
        {
          "term": "tbsts",
          "heading": false
        },
        {
          "term": "test option",
          "heading": false
        },
        {
          "term": "resource-limited settings",
          "heading": false
        },
        {
          "term": "equity impacts",
          "heading": false
        },
        {
          "term": "user interviews",
          "heading": false
        },
        {
          "term": "return visit",
          "heading": false
        }
      ],
      "extract": "25 3.2.4 Summary of Work Package B findings from User Interviews End user values and preferences Healthcare providers and consumers were found to value TBI test accuracy, convenience, a positive patient experience, low cost and resource requirements, and these factors affected their preferences for TBI tests. The novel antigen-based skin tests (TBSTs) were discussed as having comparable accuracy to the IGRA, however",
      "extractCut": true,
      "blocks": [
        "library/10665-381036/blocks/prose-page-1116"
      ]
    },
    {
      "id": "page-1117",
      "number": null,
      "title": "Page 1117",
      "level": 1,
      "pageStart": 1117,
      "pageEnd": 1117,
      "labelStart": "26",
      "labelEnd": "26",
      "words": 109,
      "summary": {
        "text": "Concludes that antigen-based skin tests were judged more acceptable than and as feasible as the TST, with equity benefits, and possibly preferable in resource-limited settings, while IGRA remains favoured in high-income countries; these findings shaped the discrete choice experiment.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "tbst",
          "heading": false
        },
        {
          "term": "conclusion",
          "heading": false
        },
        {
          "term": "igra",
          "heading": false
        },
        {
          "term": "tst",
          "heading": false
        }
      ],
      "extract": "26 Conclusion In conclusion, TBST were deemed to be more acceptable and equally feasible to the TST, with greater benefits for health equity driven by higher sensitivity and specificity. TBST may be more preferable for use in more resource-limited settings compared to the TST. IGRA appears the preferred test option in high-income countries with the infrastructure to support their use; it is unlikely that widespread",
      "extractCut": true,
      "blocks": [
        "library/10665-381036/blocks/prose-page-1117"
      ]
    },
    {
      "id": "page-1118",
      "number": null,
      "title": "Page 1118",
      "level": 1,
      "pageStart": 1118,
      "pageEnd": 1118,
      "labelStart": "27",
      "labelEnd": "27",
      "words": 545,
      "summary": {
        "text": "Introduces Work Package C, a discrete choice experiment to measure the trade-offs consumers and providers are willing to make between attributes of TB infection tests. It explains how attributes were drawn from the reviews and interviews, covering acceptability, accuracy, feasibility and health equity.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "test attributes",
          "heading": false
        },
        {
          "term": "choice experiment",
          "heading": false
        },
        {
          "term": "discrete choice",
          "heading": false
        },
        {
          "term": "dce",
          "heading": false
        },
        {
          "term": "user interviews",
          "heading": false
        },
        {
          "term": "explore end-user",
          "heading": false
        },
        {
          "term": "hensher",
          "heading": false
        },
        {
          "term": "team discussed",
          "heading": false
        }
      ],
      "extract": "27 Work Package C - Discrete choice experiment (DCE) This activity intends to answer following objective: Objective D: To explore end-user values and preferences for TB testing by investigating the trade- offs end users are willing to make between test attributes derived from systematic reviews and in- depth user interviews, and determine the order of preference of different test attributes using a discrete choice",
      "extractCut": true,
      "blocks": [
        "library/10665-381036/blocks/prose-page-1118"
      ]
    },
    {
      "id": "page-1119",
      "number": null,
      "title": "Page 1119",
      "level": 1,
      "pageStart": 1119,
      "pageEnd": 1119,
      "labelStart": "28",
      "labelEnd": "28",
      "words": 214,
      "summary": {
        "text": "Explains how the choice tasks were built, each offering two hypothetical tests plus an opt-out, with separate versions for providers and consumers, and how a pilot informed the final design hosted online.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "pairwise choice",
          "heading": false
        },
        {
          "term": "choice tasks",
          "heading": false
        },
        {
          "term": "priors",
          "heading": false
        },
        {
          "term": "dce",
          "heading": false
        },
        {
          "term": "attributes",
          "heading": false
        },
        {
          "term": "respondents",
          "heading": false
        }
      ],
      "extract": "28 A choice task is where a participant is given a choice between different scenarios based on different attribute and level combinations. We constructed a DCE with choice tasks that included two options of hypothetical TBI test alternatives and an opt-out alternative of choosing neither, which was included to estimate preferences more relevant to real-world choices. Separate DCE choice tasks were created for",
      "extractCut": true,
      "blocks": [
        "library/10665-381036/blocks/prose-page-1119"
      ]
    },
    {
      "id": "page-1120",
      "number": null,
      "title": "Page 1120",
      "level": 1,
      "pageStart": 1120,
      "pageEnd": 1120,
      "labelStart": null,
      "labelEnd": null,
      "words": 343,
      "summary": {
        "text": "Tabulates the attributes and levels used in the provider and consumer choice experiments, such as cost, time to results, need for follow-up visits, false positive and negative rates, testing location and how the test is done.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "get treatment",
          "heading": false
        },
        {
          "term": "get test",
          "heading": false
        },
        {
          "term": "chance",
          "heading": false
        },
        {
          "term": "follow-up appointment",
          "heading": false
        },
        {
          "term": "consumer dces",
          "heading": false
        },
        {
          "term": "appointment required",
          "heading": false
        },
        {
          "term": "skin prick",
          "heading": false
        },
        {
          "term": "in-person follow-up",
          "heading": false
        }
      ],
      "extract": "1 Table C1: List of attributes and levels included in both provider and consumer DCEs Provider DCE Consumer DCE Attribute Levels Description Levels Cost to healthcare practice USD 100 Time required for test results to come back 1 day USD 50 3 days USD 25 7 days If a follow-up appointment is needed to get test results In-person follow-up appointment needed If a follow-up appointment is needed to get test results",
      "extractCut": true,
      "blocks": [
        "library/10665-381036/blocks/prose-page-1120",
        "library/10665-381036/blocks/table-057"
      ]
    },
    {
      "id": "page-1121",
      "number": null,
      "title": "Page 1121",
      "level": 1,
      "pageStart": 1121,
      "pageEnd": 1121,
      "labelStart": null,
      "labelEnd": null,
      "words": 532,
      "summary": {
        "text": "Describes recruitment of choice experiment participants through TB networks and WHO groups, the online consent process and analysis methods. It summarizes respondents, most of whom were based in India, the United States, South Africa, Pakistan and Zimbabwe.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "test attributes",
          "heading": false
        },
        {
          "term": "dce",
          "heading": false
        },
        {
          "term": "sample size",
          "heading": false
        },
        {
          "term": "participant number",
          "heading": false
        },
        {
          "term": "respondents",
          "heading": false
        },
        {
          "term": "information sheet",
          "heading": false
        },
        {
          "term": "non-provider",
          "heading": false
        },
        {
          "term": "dces",
          "heading": false
        }
      ],
      "extract": "0 3.3.2.3 Recruitment Participants for the DCE were recruited from the same research networks used to recruit the users for the interviews for Work Package B e.g. from a clinical, research and community setting: • TB Treatment Action Group • TB Civil Societies • Members of the WHO Guideline Development Group for TBST • Global Coalition of TB Activists (GCTA) • Stop TB Partnership • WHO TBI Task Force Potential",
      "extractCut": true,
      "blocks": [
        "library/10665-381036/blocks/prose-page-1121"
      ]
    },
    {
      "id": "page-1122",
      "number": null,
      "title": "Page 1122",
      "level": 1,
      "pageStart": 1122,
      "pageEnd": 1122,
      "labelStart": "1",
      "labelEnd": "1",
      "words": 321,
      "summary": {
        "text": "Tabulates characteristics of the 186 provider and 48 consumer respondents and begins the choice analysis, noting that consumers strongly preferred any test over no test.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "coefficients",
          "heading": false
        },
        {
          "term": "across models",
          "heading": false
        },
        {
          "term": "compared across",
          "heading": false
        },
        {
          "term": "attribute",
          "heading": false
        },
        {
          "term": "consumers",
          "heading": false
        },
        {
          "term": "whilst",
          "heading": false
        },
        {
          "term": "dce",
          "heading": false
        },
        {
          "term": "choice",
          "heading": false
        }
      ],
      "extract": "1 Provider (n=186) Consumer (n=48) Gender Female 112 (60%) 26 (54%) Male 73 (39%) 22 (46%) Other 1 (1%) Age Category 18-35 32 (17%) 13 (27%) 36-55 106 (57%) 24 (50%) 56-75 44 (24%) 11 (23%) 75+ 4 (2%) 0 (0%) Figure C1: Location of DCE respondents 3.3.3.2 Choice analysis Table 4 shows choice model results, analysing DCE data for providers and consumers using multinomial logistic regression models. Where coefficients",
      "extractCut": true,
      "blocks": [
        "library/10665-381036/blocks/prose-page-1122",
        "library/10665-381036/blocks/figure-img-p1122-1"
      ]
    },
    {
      "id": "page-1123",
      "number": null,
      "title": "Page 1123",
      "level": 1,
      "pageStart": 1123,
      "pageEnd": 1123,
      "labelStart": "2",
      "labelEnd": "2",
      "words": 501,
      "summary": {
        "text": "Reports that for providers, after accuracy, the most influential attributes were avoiding an in-person follow-up visit and not needing specialist staff or equipment, with cost least important. It presents the model results and notes that providers valued avoiding follow-up far more than consumers did.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "false positivity",
          "heading": false
        },
        {
          "term": "positivity rate",
          "heading": false
        },
        {
          "term": "attribute",
          "heading": false
        },
        {
          "term": "greater false",
          "heading": false
        },
        {
          "term": "in-person follow-up",
          "heading": false
        },
        {
          "term": "percentage point",
          "heading": false
        },
        {
          "term": "skin prick",
          "heading": false
        },
        {
          "term": "follow-up appointment",
          "heading": false
        }
      ],
      "extract": "2 Among providers, after test accuracy the next most influential attribute was not requiring an in- person follow-up appointment (β=0.151, p=0.02), followed by not requiring specialist staff or equipment to administer or interpret the test (β=0.144, p=0.01). There was weak evidence that providers preferred more expensive tests, though test cost was the least important determinant of choice (β=0.133, p=0.05). Cost",
      "extractCut": true,
      "blocks": [
        "library/10665-381036/blocks/prose-page-1123"
      ]
    },
    {
      "id": "page-1124",
      "number": null,
      "title": "Page 1124",
      "level": 1,
      "pageStart": 1124,
      "pageEnd": 1124,
      "labelStart": "3",
      "labelEnd": "3",
      "words": 303,
      "summary": {
        "text": "Shows how much higher false-positive rate consumers and providers would accept in exchange for other test attributes, such as avoiding a seven-day wait for results.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "false positivity",
          "heading": false
        },
        {
          "term": "dce attributes",
          "heading": false
        },
        {
          "term": "positivity rate",
          "heading": false
        },
        {
          "term": "accept change",
          "heading": false
        },
        {
          "term": "day wait",
          "heading": false
        },
        {
          "term": "follow-up appointment",
          "heading": false
        },
        {
          "term": "percentage point",
          "heading": false
        },
        {
          "term": "person follow-up",
          "heading": false
        }
      ],
      "extract": "3 slightly more negatively than the same increase in likelihood of a false positive; the opposite was true among providers. Figure C2: Willingness to accept change in false positivity rate for DCE attributes. Panel A shows results for consumers, and panel B results for providers. A positive value indicates that respondents are willing to accept a lower likelihood of a false-positive result for that attribute. Panel",
      "extractCut": true,
      "blocks": [
        "library/10665-381036/blocks/prose-page-1124"
      ]
    },
    {
      "id": "page-1125",
      "number": null,
      "title": "Page 1125",
      "level": 1,
      "pageStart": 1125,
      "pageEnd": 1125,
      "labelStart": "4",
      "labelEnd": "4",
      "words": 363,
      "summary": {
        "text": "Summarizes the choice experiment: consumers most preferred testing in primary care rather than hospitals, and both groups would accept lower accuracy to get faster results and avoid follow-up visits. It notes that too few responses were collected to compare preferences across regions.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "real-world choices",
          "heading": false
        },
        {
          "term": "sample size",
          "heading": false
        },
        {
          "term": "in-person follow-up",
          "heading": false
        },
        {
          "term": "geographic diversity",
          "heading": false
        },
        {
          "term": "percentage points",
          "heading": false
        },
        {
          "term": "target sample",
          "heading": false
        },
        {
          "term": "reasonable geographic",
          "heading": false
        },
        {
          "term": "respondents",
          "heading": false
        }
      ],
      "extract": "4 consumers’ strongest preferences were for the location of testing, with testing in primary care strongly preferred to hospital locations. For providers, the next most important attribute was the lack of requiring an in-person follow-up appointment, followed by not needing specialist staff or equipment to interpret or administer the test. Willingness-to-accept analyses indicated that both consumers and providers",
      "extractCut": true,
      "blocks": [
        "library/10665-381036/blocks/prose-page-1125"
      ]
    },
    {
      "id": "page-1126",
      "number": null,
      "title": "Page 1126",
      "level": 1,
      "pageStart": 1126,
      "pageEnd": 1126,
      "labelStart": "5",
      "labelEnd": "5",
      "words": 689,
      "summary": {
        "text": "Introduces the report on user perspectives on TB infection testing, describing TB's global burden and that about a quarter to a third of people are estimated to have TB infection, which can progress to disease. It describes current tests (TST and IGRA) and the newer antigen-based skin tests, which are portable and expected to be low cost but need two clinic visits.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "tbi testing",
          "heading": false
        },
        {
          "term": "antigen-based skin",
          "heading": false
        },
        {
          "term": "skin tests",
          "heading": false
        },
        {
          "term": "immunosuppressive conditions",
          "heading": false
        },
        {
          "term": "tst",
          "heading": false
        },
        {
          "term": "clinic visits",
          "heading": false
        },
        {
          "term": "mycobacterium tuberculosis",
          "heading": false
        },
        {
          "term": "igra",
          "heading": false
        }
      ],
      "extract": "5 Introduction Tuberculosis (TB) is an airborne transmissible infectious disease caused by Mycobacterium tuberculosis. TB is a major cause of health loss (i.e., healthy life years lost to death, illness, or disability), affecting approximately one quarter of the global population and ranking as one of the top ten causes of death1. Approximately one quarter to one-third of the global population is estimated to have",
      "extractCut": true,
      "blocks": [
        "library/10665-381036/blocks/prose-page-1126"
      ]
    },
    {
      "id": "page-1127",
      "number": null,
      "title": "Page 1127",
      "level": 1,
      "pageStart": 1127,
      "pageEnd": 1127,
      "labelStart": "6",
      "labelEnd": "6",
      "words": 438,
      "summary": {
        "text": "Explains that WHO commissioned reviews of user perspectives on the new skin tests because their acceptability, feasibility and equity effects were unknown. It outlines the three work packages, a systematic review, user interviews and a discrete choice experiment, guided by an expert advisory panel.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "in-depth interviews",
          "heading": false
        },
        {
          "term": "antigen-based skin",
          "heading": false
        },
        {
          "term": "end-user values",
          "heading": false
        },
        {
          "term": "choice experiment",
          "heading": false
        },
        {
          "term": "discrete choice",
          "heading": false
        },
        {
          "term": "systematic reviews",
          "heading": false
        },
        {
          "term": "health equity",
          "heading": false
        },
        {
          "term": "skin tests",
          "heading": false
        }
      ],
      "extract": "6 acceptable or feasible for use in routine practice for end users (e.g., individuals and healthcare providers), and whether use of these tests would impact health equity. To address this knowledge gap, World Health Organization (WHO) commissioned systematic reviews into the perspectives, preferences, and experiences of users of TBST and explore health equity. The reviews aim to qualitatively explore what the end",
      "extractCut": true,
      "blocks": [
        "library/10665-381036/blocks/prose-page-1127"
      ]
    },
    {
      "id": "page-1128",
      "number": null,
      "title": "Page 1128",
      "level": 1,
      "pageStart": 1128,
      "pageEnd": 1128,
      "labelStart": "7",
      "labelEnd": "7",
      "words": 485,
      "summary": {
        "text": "Introduces Work Package A, two systematic reviews of qualitative evidence on end users' views of antigen-based skin tests compared with IGRA and TST, and on their equity effects. It describes the database searches, including Russian and Chinese databases and a WHO public call for data.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "systematic reviews",
          "heading": false
        },
        {
          "term": "search terms",
          "heading": false
        },
        {
          "term": "search strategy",
          "heading": false
        },
        {
          "term": "manual searches",
          "heading": false
        },
        {
          "term": "antigen-based skin",
          "heading": false
        },
        {
          "term": "tbst",
          "heading": false
        },
        {
          "term": "skin tests",
          "heading": false
        },
        {
          "term": "end-user values",
          "heading": false
        }
      ],
      "extract": "7 Work Package A-Systematic review This activity intends to answer the following objectives: Objective A: To conduct a systematic review that summarizes the evidence on end-user values and preferences regarding the acceptability and feasibility of antigen-based skin tests for TB infection, compared to current tests of infection (IGRA, TST). Objective C: To evaluate any potential impacts of TBST on health equity Two",
      "extractCut": true,
      "blocks": [
        "library/10665-381036/blocks/prose-page-1128"
      ]
    },
    {
      "id": "page-1129",
      "number": null,
      "title": "Page 1129",
      "level": 1,
      "pageStart": 1129,
      "pageEnd": 1129,
      "labelStart": "8",
      "labelEnd": "8",
      "words": 403,
      "summary": {
        "text": "Sets out the review eligibility criteria, which required qualitative data collection and analysis, and describes screening in duplicate, including by native speakers for Russian and Chinese database results.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "qualitative methods",
          "heading": false
        },
        {
          "term": "grey literature",
          "heading": false
        },
        {
          "term": "study designs",
          "heading": false
        },
        {
          "term": "data collection",
          "heading": false
        },
        {
          "term": "potential users",
          "heading": false
        },
        {
          "term": "open-ended",
          "heading": false
        },
        {
          "term": "studies",
          "heading": false
        },
        {
          "term": "proceedings",
          "heading": false
        }
      ],
      "extract": "8 antigens). Grey literature Grey literature was not searched as part of the review. 3.1.2 Eligibility criteria Study design Included studies were primary research studies that used qualitative methodologies or study designs. Studies were required to use qualitative methods for data collection (e.g., interviews, focus groups, open-ended survey questions) and analysis (e.g., thematic analysis, grounded theory). Mixed",
      "extractCut": true,
      "blocks": [
        "library/10665-381036/blocks/prose-page-1129"
      ]
    },
    {
      "id": "page-1130",
      "number": null,
      "title": "Page 1130",
      "level": 1,
      "pageStart": 1130,
      "pageEnd": 1130,
      "labelStart": "9",
      "labelEnd": "9",
      "words": 356,
      "summary": {
        "text": "Describes data extraction in duplicate using Covidence, the study characteristics recorded, and the use of GRADE-CERQual to rate confidence in each review finding.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "raters",
          "heading": false
        },
        {
          "term": "review finding",
          "heading": false
        },
        {
          "term": "coding scheme",
          "heading": false
        },
        {
          "term": "systematic reviews",
          "heading": false
        },
        {
          "term": "research team",
          "heading": false
        },
        {
          "term": "duplicate",
          "heading": false
        },
        {
          "term": "health equity",
          "heading": false
        },
        {
          "term": "grade-cerqual",
          "heading": false
        }
      ],
      "extract": "9 Qualitative data pertaining to test acceptability, feasibility, and health equity were extracted from the included papers independently in duplicate by two raters (AC, KL) using Covidence software. Data were also extracted on study characteristics, including publication language, country, type of facility (including public/private, rural/urban), study objectives, methods of data collection and analysis, study",
      "extractCut": true,
      "blocks": [
        "library/10665-381036/blocks/prose-page-1130"
      ]
    },
    {
      "id": "page-1131",
      "number": null,
      "title": "Page 1131",
      "level": 1,
      "pageStart": 1131,
      "pageEnd": 1131,
      "labelStart": "10",
      "labelEnd": "10",
      "words": 162,
      "summary": {
        "text": "Reports that four studies met the inclusion criteria: one on a skin test from WHO's call for data and three on IGRA and TST, published between 2014 and 2021, with PRISMA flow charts.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "tst compared",
          "heading": false
        },
        {
          "term": "tbst compared",
          "heading": false
        },
        {
          "term": "flow charts",
          "heading": false
        },
        {
          "term": "papers",
          "heading": false
        },
        {
          "term": "inclusion criteria",
          "heading": false
        }
      ],
      "extract": "10 3.1.4 Results from Systematic Review A and B 3.1.4.1 Results of the Search Four studies were identified that met the inclusion criteria (see Figure A1 for Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) flow charts). Review A included papers focused on specific TBST compared to the IGRA and/or the TST, while Review B focused on papers on the IGRA and TST compared to each other or",
      "extractCut": true,
      "blocks": [
        "library/10665-381036/blocks/prose-page-1131"
      ]
    },
    {
      "id": "page-1132",
      "number": null,
      "title": "Page 1132",
      "level": 1,
      "pageStart": 1132,
      "pageEnd": 1132,
      "labelStart": "11",
      "labelEnd": "11",
      "words": 662,
      "summary": {
        "text": "Describes the included studies, including the only skin test study on Diaskintest in a mass screening programme for children in the Russian Federation, and three studies on IGRA and TST. It begins describing the confidence ratings for the review findings.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "studies reported",
          "heading": false
        },
        {
          "term": "upper-middle income",
          "heading": false
        },
        {
          "term": "review findings",
          "heading": false
        },
        {
          "term": "russian federation",
          "heading": false
        },
        {
          "term": "public call",
          "heading": false
        },
        {
          "term": "conceptual framework",
          "heading": false
        },
        {
          "term": "income country",
          "heading": false
        },
        {
          "term": "data analysis",
          "heading": false
        }
      ],
      "extract": "11 3.1.4.2 Description of the Studies A table summarizing the Characteristics of the included studies identified from Review A and B are presented in Table A1. Test From Review A, only one study reported on a TBST which was the Diaskintest18, which was from the WHO public call for data. The Diaskintest was evaluated as part of a large-scale screening program for children and adolescents in the Penza region of the",
      "extractCut": true,
      "blocks": [
        "library/10665-381036/blocks/prose-page-1132"
      ]
    },
    {
      "id": "page-1133",
      "number": null,
      "title": "Page 1133",
      "level": 1,
      "pageStart": 1133,
      "pageEnd": 1133,
      "labelStart": "12",
      "labelEnd": "12",
      "words": 144,
      "summary": {
        "text": "Reports that findings on values, acceptability and feasibility were rated moderate confidence and health equity low, owing to few studies, thin data and focus on specific subgroups.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "health equity",
          "heading": false
        },
        {
          "term": "findings",
          "heading": false
        },
        {
          "term": "richness",
          "heading": false
        },
        {
          "term": "confidence",
          "heading": false
        }
      ],
      "extract": "12 health equity), 3 findings (end user values and preferences, acceptability, feasibility) were rated with moderate confidence based on the findings from Review A and B. Health equity received a low confidence rating. Appendix B provides a detailed summary table of the GRADE-CERQual analysis. There were serious concerns about data adequacy for the feasibility and health equity findings due to the small number of",
      "extractCut": true,
      "blocks": [
        "library/10665-381036/blocks/prose-page-1133"
      ]
    },
    {
      "id": "page-1134",
      "number": null,
      "title": "Page 1134",
      "level": 1,
      "pageStart": 1134,
      "pageEnd": 1134,
      "labelStart": null,
      "labelEnd": null,
      "words": 453,
      "summary": {
        "text": "Tabulates the characteristics of the four included studies, including test, country, setting, participants, methods, conceptual framework and conflicts of interest.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "semi structured",
          "heading": false
        },
        {
          "term": "structured guide",
          "heading": false
        },
        {
          "term": "reviewed article",
          "heading": false
        },
        {
          "term": "peer reviewed",
          "heading": false
        },
        {
          "term": "demographic data",
          "heading": false
        },
        {
          "term": "individual interviews",
          "heading": false
        },
        {
          "term": "conceptual framework",
          "heading": false
        },
        {
          "term": "quantifer",
          "heading": false
        }
      ],
      "extract": "0 Table A1: Systematic Reviews A and B- Characteristics of Included Studies Study ID Publication type TBI Tests Country Facility Type Public/ Private Rural/ Urban Participants Programmatic features Comparato rs Data collection Study duration Method of data analysis Conceptual framework Conflicts of Interest Review A findings on TBST Aksenova 2021 (Review A) Report (WHO call for data) Diaskintest Russian Federation",
      "extractCut": true,
      "blocks": [
        "library/10665-381036/blocks/prose-page-1134"
      ]
    },
    {
      "id": "page-1135",
      "number": null,
      "title": "Page 1135",
      "level": 1,
      "pageStart": 1135,
      "pageEnd": 1135,
      "labelStart": null,
      "labelEnd": null,
      "words": 481,
      "summary": {
        "text": "Presents review findings on end-user values and acceptability, combining both reviews because data were scarce. It notes the perceived accuracy of the tests and that clinic staff had concerns about IGRA accuracy in adults with HIV.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "values preferences",
          "heading": false
        },
        {
          "term": "user preferences",
          "heading": false
        },
        {
          "term": "end-user values",
          "heading": false
        },
        {
          "term": "tbi tests",
          "heading": false
        },
        {
          "term": "review findings",
          "heading": false
        },
        {
          "term": "solid grey",
          "heading": false
        },
        {
          "term": "contextual factors",
          "heading": false
        },
        {
          "term": "grey refers",
          "heading": false
        }
      ],
      "extract": "0 3.1.4.5 Review Findings Our qualitative evidence synthesis from Work Package A draws on the findings from both Systematic Reviews A and B. Overall, there were limited data available hence the decision to combine findings from both Reviews, with Review A on TBST retrieving only one relevant data report, and Review B on TST and IGRA retrieving only three papers. The findings identified factors contributing to",
      "extractCut": true,
      "blocks": [
        "library/10665-381036/blocks/prose-page-1135"
      ]
    },
    {
      "id": "page-1136",
      "number": null,
      "title": "Page 1136",
      "level": 1,
      "pageStart": 1136,
      "pageEnd": 1136,
      "labelStart": "1",
      "labelEnd": "1",
      "words": 632,
      "summary": {
        "text": "Continues the findings on acceptability, noting that perceived IGRA indeterminate results were not borne out by clinic data, and that convenience shaped test preferences in all four studies. Quotes illustrate views on human error in skin tests and discomfort from the TST.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "south africa",
          "heading": false
        },
        {
          "term": "tbi tests",
          "heading": false
        },
        {
          "term": "consumer experience",
          "heading": false
        },
        {
          "term": "test preferences",
          "heading": false
        },
        {
          "term": "providers reported",
          "heading": false
        },
        {
          "term": "trained staff",
          "heading": false
        },
        {
          "term": "tst",
          "heading": false
        },
        {
          "term": "irritating",
          "heading": false
        }
      ],
      "extract": "1 that there was a high frequency of indeterminate results from the IGRA, although this was not supported in the clinic data where only 1% of indeterminate results were received20. “Sometimes we’re not sure if they measure it correctly, or if the TST was done correctly, did they take enough, was it inserted sub-dermally? There can come human errors as well. With blood, I think the result is the result.” (South",
      "extractCut": true,
      "blocks": [
        "library/10665-381036/blocks/prose-page-1136"
      ]
    },
    {
      "id": "page-1137",
      "number": null,
      "title": "Page 1137",
      "level": 1,
      "pageStart": 1137,
      "pageEnd": 1137,
      "labelStart": "2",
      "labelEnd": "2",
      "words": 647,
      "summary": {
        "text": "Describes test-related factors in acceptability, with skin tests and IGRA seen as more specific than the TST, which had many false positives. It notes that the skin test's specificity encouraged parents to have children tested, and that no study assessed TBST feasibility, with moderate confidence in the evidence.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "blood draw",
          "heading": false
        },
        {
          "term": "blood test",
          "heading": false
        },
        {
          "term": "less acceptable",
          "heading": false
        },
        {
          "term": "igra",
          "heading": false
        },
        {
          "term": "contextual factors",
          "heading": false
        },
        {
          "term": "tbi tests",
          "heading": false
        },
        {
          "term": "south africa",
          "heading": false
        },
        {
          "term": "tst",
          "heading": false
        }
      ],
      "extract": "2 Test Factors Acceptability was affected by test-related factors, including the accuracy of the test, the certainty of results, and the suitability of the test for use in particular subgroups (e.g., children and adolescents, persons with HIV, needle-phobic individuals). TBST and IGRA were perceived as having greater specificity than the TST18,21. The TST was described as having a high rate of false positives; thus",
      "extractCut": true,
      "blocks": [
        "library/10665-381036/blocks/prose-page-1137"
      ]
    },
    {
      "id": "page-1138",
      "number": null,
      "title": "Page 1138",
      "level": 1,
      "pageStart": 1138,
      "pageEnd": 1138,
      "labelStart": "3",
      "labelEnd": "3",
      "words": 698,
      "summary": {
        "text": "Describes individual factors in feasibility, especially the TST's need for a return visit within 72 hours, which was hard for people facing long journeys, waits and transport problems in South Africa and the United States. It reports that using routine blood draws for IGRA was seen as easing logistics.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "clinic staff",
          "heading": false
        },
        {
          "term": "south africa",
          "heading": false
        },
        {
          "term": "blood draws",
          "heading": false
        },
        {
          "term": "north west",
          "heading": false
        },
        {
          "term": "healthcare providers",
          "heading": false
        },
        {
          "term": "spruijt",
          "heading": false
        },
        {
          "term": "phs",
          "heading": false
        },
        {
          "term": "igra",
          "heading": false
        }
      ],
      "extract": "3 Aspects of the individual experience were found to affect the feasibility of the IGRA and TST. A common feasibility concern for the TST, based on findings from Review B, were that consumers were required to visit the clinic a second time within 72 hours to read the test result19,20,21. Kerrigan et al. described how in the North West Province of South Africa, many consumers experienced difficulties with visiting a",
      "extractCut": true,
      "blocks": [
        "library/10665-381036/blocks/prose-page-1138"
      ]
    },
    {
      "id": "page-1139",
      "number": null,
      "title": "Page 1139",
      "level": 1,
      "pageStart": 1139,
      "pageEnd": 1139,
      "labelStart": "4",
      "labelEnd": "4",
      "words": 713,
      "summary": {
        "text": "Reports concern that linking TB testing to infrequent CD4 blood draws might delay diagnosis, and providers' view that it could complement rather than replace other testing. It summarizes contextual feasibility factors such as transport, waiting times, scalability and suitability for subgroups.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "tst read",
          "heading": false
        },
        {
          "term": "blood draw",
          "heading": false
        },
        {
          "term": "trained staff",
          "heading": false
        },
        {
          "term": "south africa",
          "heading": false
        },
        {
          "term": "tbi tests",
          "heading": false
        },
        {
          "term": "equity impacts",
          "heading": false
        },
        {
          "term": "having access",
          "heading": false
        },
        {
          "term": "health equity",
          "heading": false
        }
      ],
      "extract": "4 the low frequency with which they would typically have a blood draw: “While there was general consensus on this issue, one patient did relay a concern about timing, as many patients may only have a CD4 blood draw 1–2 times a year. So while this patient thought screening the CD4 blood draw for TB was a good idea, he wouldn’t want that to delay finding out he had TB, as he would want to know that information as soon",
      "extractCut": true,
      "blocks": [
        "library/10665-381036/blocks/prose-page-1139"
      ]
    },
    {
      "id": "page-1140",
      "number": null,
      "title": "Page 1140",
      "level": 1,
      "pageStart": 1140,
      "pageEnd": 1140,
      "labelStart": "5",
      "labelEnd": "5",
      "words": 282,
      "summary": {
        "text": "Describes access and transport as the main equity issue, with the TST return visit a barrier in several studies, alongside shortages of trained staff. It notes reports that Diaskintest worked well for mass screening of children.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "russian federation",
          "heading": false
        },
        {
          "term": "united states",
          "heading": false
        },
        {
          "term": "quote",
          "heading": false
        },
        {
          "term": "igra",
          "heading": false
        },
        {
          "term": "mass",
          "heading": false
        },
        {
          "term": "tst",
          "heading": false
        },
        {
          "term": "diaskintest",
          "heading": false
        },
        {
          "term": "accessibility",
          "heading": false
        }
      ],
      "extract": "5 In terms of access and transport issues, the return visit required to read the TST result was focused on as a major accessibility issue in 3 studies19,20,21. This included at-risk groups in both middle- and high-income countries (South Africa, United States). Kerrigan et al., which focused on an HIV clinic in a middle-income country, documented how many consumers experienced challenges with transportation and wait",
      "extractCut": true,
      "blocks": [
        "library/10665-381036/blocks/prose-page-1140"
      ]
    },
    {
      "id": "page-1141",
      "number": null,
      "title": "Page 1141",
      "level": 1,
      "pageStart": 1141,
      "pageEnd": 1141,
      "labelStart": "6",
      "labelEnd": "6",
      "words": 191,
      "summary": {
        "text": "Summarizes Work Package A: only four studies were found, mostly on TST and IGRA in specific settings, limiting confidence, but key factors for values, acceptability, feasibility and equity were identified and used to shape the interviews and choice experiment.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "contextual factors",
          "heading": false
        },
        {
          "term": "work package",
          "heading": false
        },
        {
          "term": "limited data",
          "heading": false
        },
        {
          "term": "health equity",
          "heading": false
        },
        {
          "term": "data available",
          "heading": false
        },
        {
          "term": "relating",
          "heading": false
        }
      ],
      "extract": "6 3.1.5 Summary of Work Package A findings from the Systematic Reviews Overall, there were limited data from the reviews on TBSTs, with only 4 studies identified. Importantly, these studies were conducted in very specific healthcare settings and populations, limiting our confidence in the data quality and the generalisability of these findings. Most of the data available related to TST and IGRA. Despite the limited",
      "extractCut": true,
      "blocks": [
        "library/10665-381036/blocks/prose-page-1141"
      ]
    },
    {
      "id": "page-1142",
      "number": null,
      "title": "Page 1142",
      "level": 1,
      "pageStart": 1142,
      "pageEnd": 1142,
      "labelStart": "7",
      "labelEnd": "7",
      "words": 476,
      "summary": {
        "text": "Introduces Work Package B, a qualitative interview study with 20 people living with TB or providers involved in TB testing and care, recruited through global networks with WHO support. It lists the recruiting organizations and the objectives on views of skin tests and equity.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "interview topics",
          "heading": false
        },
        {
          "term": "tbi tests",
          "heading": false
        },
        {
          "term": "individuals living",
          "heading": false
        },
        {
          "term": "healthcare provider",
          "heading": false
        },
        {
          "term": "tbst",
          "heading": false
        },
        {
          "term": "zoom",
          "heading": false
        },
        {
          "term": "work package",
          "heading": false
        },
        {
          "term": "systematic review",
          "heading": false
        }
      ],
      "extract": "7 Work Package B-Qualitative user interviews This activity intends to answer following objectives: A qualitative interview study was conducted with 20 participants who were individuals living with TB or providers involved in TB testing and /or care of individuals living with TB. Participants were recruited from the research team’s global networks across high and low-middle income countries, with support from WHO.",
      "extractCut": true,
      "blocks": [
        "library/10665-381036/blocks/prose-page-1142"
      ]
    },
    {
      "id": "page-1143",
      "number": null,
      "title": "Page 1143",
      "level": 1,
      "pageStart": 1143,
      "pageEnd": 1143,
      "labelStart": "8",
      "labelEnd": "8",
      "words": 391,
      "summary": {
        "text": "Lists the topics covered in the interviews, from current use of skin tests to user preferences, feasibility, acceptability and equity, and summarizes participants' roles and countries.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "participant characteristics",
          "heading": false
        },
        {
          "term": "interview data",
          "heading": false
        },
        {
          "term": "ethics committee",
          "heading": false
        },
        {
          "term": "skin-based tests",
          "heading": false
        },
        {
          "term": "middle-income country",
          "heading": false
        },
        {
          "term": "high-income country",
          "heading": false
        },
        {
          "term": "field notes",
          "heading": false
        },
        {
          "term": "healthcare providers",
          "heading": false
        }
      ],
      "extract": "8 1. Current approach to using skin tests as part of the TB diagnostic process; 2. End-user values and preferences with regard to TB testing, from their previous experience with skin-based tests – focusing on ease of use and process for TBST, IGRA, and TST; 3. End-user values and preferences considering the challenges and benefits of skin-based tests, particularly TBST, which test(s) they would prefer and reasons",
      "extractCut": true,
      "blocks": [
        "library/10665-381036/blocks/prose-page-1143"
      ]
    },
    {
      "id": "page-1144",
      "number": null,
      "title": "Page 1144",
      "level": 1,
      "pageStart": 1144,
      "pageEnd": 1144,
      "labelStart": "9",
      "labelEnd": "9",
      "words": 269,
      "summary": {
        "text": "Explains that the interview analysis used the same people, test and context subthemes as the reviews, and begins reporting findings on end-user values, such as the hope that more accurate tests would reduce unnecessary treatment and stress.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "end-user values",
          "heading": false
        },
        {
          "term": "subthemes",
          "heading": false
        },
        {
          "term": "grey refers",
          "heading": false
        },
        {
          "term": "contextual factors",
          "heading": false
        },
        {
          "term": "healthcare consumers",
          "heading": false
        },
        {
          "term": "coding framework",
          "heading": false
        },
        {
          "term": "test accuracy",
          "heading": false
        },
        {
          "term": "preferences",
          "heading": false
        }
      ],
      "extract": "9 1.2.4 Key Findings The findings from Work Package A were used to inform the coding framework and analyses undertaken in Work Package B – as such, the same subthemes of people, test, and contextual factors were used to explore acceptability and feasibility of the tests, with health equity and end-user values and preferences as separate subthemes. The full coding framework used can be found in Appendix E. As before,",
      "extractCut": true,
      "blocks": [
        "library/10665-381036/blocks/prose-page-1144"
      ]
    },
    {
      "id": "page-1145",
      "number": null,
      "title": "Page 1145",
      "level": 1,
      "pageStart": 1145,
      "pageEnd": 1145,
      "labelStart": "10",
      "labelEnd": "10",
      "words": 684,
      "summary": {
        "text": "Reports that interviewees saw the TST as less accurate, leading to costly and stressful follow-up after false positives. It also describes the resources each test requires, with IGRA needing laboratories, phlebotomy and trained staff.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "tbi tests",
          "heading": false
        },
        {
          "term": "tsts",
          "heading": false
        },
        {
          "term": "tbsts",
          "heading": false
        },
        {
          "term": "false positives",
          "heading": false
        },
        {
          "term": "end users",
          "heading": false
        },
        {
          "term": "skin tests",
          "heading": false
        },
        {
          "term": "igras",
          "heading": false
        },
        {
          "term": "resource-limited settings",
          "heading": false
        }
      ],
      "extract": "10 perceived to have lower accuracy and were associated with downstream challenges by end-users. These included greater expense and psychological stress. “The big issue I think is the false positives with the current tests that we use and that then leads to a whole chain of events which I think is very expensive and stressful for people because if you’re told you might have TB or you probably have got TB and then",
      "extractCut": true,
      "blocks": [
        "library/10665-381036/blocks/prose-page-1145"
      ]
    },
    {
      "id": "page-1146",
      "number": null,
      "title": "Page 1146",
      "level": 1,
      "pageStart": 1146,
      "pageEnd": 1146,
      "labelStart": "11",
      "labelEnd": "11",
      "words": 392,
      "summary": {
        "text": "Notes that skin tests need less infrastructure than IGRA, then sets out seven people-related factors affecting acceptability, such as consumer experience, perceptions, knowledge and provider communication. It describes anxiety linked to new tests, injections and uncertain skin reactions.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "intradermal injection",
          "heading": false
        },
        {
          "term": "painful test",
          "heading": false
        },
        {
          "term": "consumer experience",
          "heading": false
        },
        {
          "term": "tbi tests",
          "heading": false
        },
        {
          "term": "psychological consequences",
          "heading": false
        },
        {
          "term": "physical consequences",
          "heading": false
        },
        {
          "term": "people-related factors",
          "heading": false
        },
        {
          "term": "skin tests",
          "heading": false
        }
      ],
      "extract": "11 test equipment are still required, and clinics and patient transport are needed in some instances. “I feel like the good thing about [the TBSTs] is you don’t need much lab infrastructure, I feel like the need to draw blood is a barrier for IGRAs.” (ID017, HIC, Provider) 3.2.3.2. Acceptability People-related factors There were 7 subthemes relating to people factors for acceptability of TBI tests (Figure B3). These",
      "extractCut": true,
      "blocks": [
        "library/10665-381036/blocks/prose-page-1146"
      ]
    },
    {
      "id": "page-1147",
      "number": null,
      "title": "Page 1147",
      "level": 1,
      "pageStart": 1147,
      "pageEnd": 1147,
      "labelStart": "12",
      "labelEnd": "12",
      "words": 680,
      "summary": {
        "text": "Presents interview findings on the patient experience of tuberculosis infection tests, with quotes on initial fear of injections and the reassurance of seeing the result on one's own arm. A provider describes how long it took to convince people that skin testing was safe. Other participants compare skin tests with blood draws, one noting local myths about taking blood.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "draw blood",
          "heading": false
        },
        {
          "term": "blood test",
          "heading": false
        },
        {
          "term": "skin test",
          "heading": false
        },
        {
          "term": "little bit",
          "heading": false
        },
        {
          "term": "worry",
          "heading": false
        },
        {
          "term": "indistinct",
          "heading": false
        },
        {
          "term": "hic",
          "heading": false
        },
        {
          "term": "going",
          "heading": false
        }
      ],
      "extract": "12 ‘live’ reading that took place in front of them, an experience that is avoided with the IGRA. “We also found perspective from the patient that maybe people at the beginning, they worry that it’s painful and they scared of injection, but once they (indistinct), they like it very much because you can see physically the test result on your arm… at the beginning, many people worry about it, they worry that it would",
      "extractCut": true,
      "blocks": [
        "library/10665-381036/blocks/prose-page-1147"
      ]
    },
    {
      "id": "page-1148",
      "number": null,
      "title": "Page 1148",
      "level": 1,
      "pageStart": 1148,
      "pageEnd": 1148,
      "labelStart": "13",
      "labelEnd": "13",
      "words": 654,
      "summary": {
        "text": "Reports that the complex steps of skin testing, such as avoiding rubbing the site and returning for a reading, may reduce acceptability for people with low health literacy. It notes concerns about using blood tests and skin tests in people with darker skin, where veins and reactions can be harder to see. Some providers questioned continuing with skin tests at all.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "darker skin",
          "heading": false
        },
        {
          "term": "skin tones",
          "heading": false
        },
        {
          "term": "skin tests",
          "heading": false
        },
        {
          "term": "skin types",
          "heading": false
        },
        {
          "term": "different skin",
          "heading": false
        },
        {
          "term": "blood tests",
          "heading": false
        },
        {
          "term": "blood draw",
          "heading": false
        },
        {
          "term": "hic",
          "heading": false
        }
      ],
      "extract": "13 Lastly, the complicated process involved with skin tests was perceived to reduce acceptability in consumers with low health literacy. “First of all the test is a very complex thing, though to the provider it might be easy but from the patient’s perspective it is difficult. Like as of my understanding, patient should not have, should not rub on the injected areas and all those certain precautions need to be taken",
      "extractCut": true,
      "blocks": [
        "library/10665-381036/blocks/prose-page-1148"
      ]
    },
    {
      "id": "page-1149",
      "number": null,
      "title": "Page 1149",
      "level": 1,
      "pageStart": 1149,
      "pageEnd": 1149,
      "labelStart": "14",
      "labelEnd": "14",
      "words": 605,
      "summary": {
        "text": "Continues with a provider's view that skin testing is outdated technology, then reports that most participants knew little about the novel skin tests and wanted evidence and public awareness. Familiarity with existing skin tests and endorsement by bodies such as WHO were expected to improve acceptance.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "skin test",
          "heading": false
        },
        {
          "term": "lmic",
          "heading": false
        },
        {
          "term": "tbst",
          "heading": false
        },
        {
          "term": "consumer",
          "heading": false
        },
        {
          "term": "leaves",
          "heading": false
        },
        {
          "term": "perception",
          "heading": false
        },
        {
          "term": "lot",
          "heading": false
        },
        {
          "term": "provider",
          "heading": false
        }
      ],
      "extract": "14 something that makes much more sense… This whole conversation is surreal to me, why people are doing this with a 100 year old technology… If it’s better than the TB skin test then the issue is replacing that test with this test, that’s, I totally understand that and that’s a perfectly reasonable thing. We are trying to get away from skin testing period.” (ID014, HIC, Provider) Knowledge Most participants",
      "extractCut": true,
      "blocks": [
        "library/10665-381036/blocks/prose-page-1149"
      ]
    },
    {
      "id": "page-1150",
      "number": null,
      "title": "Page 1150",
      "level": 1,
      "pageStart": 1150,
      "pageEnd": 1150,
      "labelStart": "15",
      "labelEnd": "15",
      "words": 446,
      "summary": {
        "text": "Reports that some consumers doubted the usefulness of the novel skin tests without proof they beat existing tests or without follow-up care after a positive result. It introduces test factors affecting acceptability, with providers favouring novel skin tests over the tuberculin skin test for better specificity.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "novel skin",
          "heading": false
        },
        {
          "term": "skin test",
          "heading": false
        },
        {
          "term": "test acceptability",
          "heading": false
        },
        {
          "term": "test factors",
          "heading": false
        },
        {
          "term": "subthemes",
          "heading": false
        },
        {
          "term": "tbi tests",
          "heading": false
        },
        {
          "term": "consumer",
          "heading": false
        },
        {
          "term": "healthcare provider",
          "heading": false
        }
      ],
      "extract": "15 that it’s a good one, it’s worth carrying on with.” (ID001, HIC, Consumer) Usefulness A couple of consumers questioned how useful the TBST would be. Interestingly, this did not come up as a finding from any healthcare provider participant. One consumer reported needing evidence that the TBST are better than the TST and IGRA to think that they are useful. Another consumer felt that how useful the TBI tests are in",
      "extractCut": true,
      "blocks": [
        "library/10665-381036/blocks/prose-page-1150"
      ]
    },
    {
      "id": "page-1151",
      "number": null,
      "title": "Page 1151",
      "level": 1,
      "pageStart": 1151,
      "pageEnd": 1151,
      "labelStart": "16",
      "labelEnd": "16",
      "words": 661,
      "summary": {
        "text": "Includes a provider's criticism of how hard it is to measure induration precisely, then lists perceived downstream benefits of more accurate novel tests, such as fewer false positives, better diagnosis and avoiding unnecessary treatment. It notes that none of the three test types can distinguish latent from active tuberculosis.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "less suited",
          "heading": false
        },
        {
          "term": "igra test",
          "heading": false
        },
        {
          "term": "little bit",
          "heading": false
        },
        {
          "term": "psychological stress",
          "heading": false
        },
        {
          "term": "participants discussed",
          "heading": false
        },
        {
          "term": "tbst",
          "heading": false
        },
        {
          "term": "tst",
          "heading": false
        },
        {
          "term": "tbi tests",
          "heading": false
        }
      ],
      "extract": "16 specificity really.” (ID019, HIC, Provider) “The measurement involves a ballpoint pen with free flowing ink and you sort of make the mark on the person’s arm until you start to feel a little bit of resistance and then you stop and then you do that on the other side and you stop, and then you measure the distance between those two stops and that’s probably the most accurate way to interpret the induration. But as",
      "extractCut": true,
      "blocks": [
        "library/10665-381036/blocks/prose-page-1151"
      ]
    },
    {
      "id": "page-1152",
      "number": null,
      "title": "Page 1152",
      "level": 1,
      "pageStart": 1152,
      "pageEnd": 1152,
      "labelStart": "17",
      "labelEnd": "17",
      "words": 524,
      "summary": {
        "text": "Quotes a provider on the difficulty of finding a biomarker to separate latent and active tuberculosis, then describes contextual factors in acceptability: provider perceptions, follow-up infrastructure and the test environment. Only consumers raised the test environment as a factor.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "test acceptability",
          "heading": false
        },
        {
          "term": "tbi test",
          "heading": false
        },
        {
          "term": "providers felt",
          "heading": false
        },
        {
          "term": "provider perceptions",
          "heading": false
        },
        {
          "term": "test follow-up",
          "heading": false
        },
        {
          "term": "test environment",
          "heading": false
        },
        {
          "term": "contextual factors",
          "heading": false
        },
        {
          "term": "consumer",
          "heading": false
        }
      ],
      "extract": "17 developing a test to achieve that aim: “No the challenges were that it was not really possible to differentiate by the results of the PPD test who is really infected and who really needs preventive treatment… currently all researchers in the field all over the world are looking for some biomarker that could help differentiate latent TB infection from the active TB infection right, yes, but it is very difficult to",
      "extractCut": true,
      "blocks": [
        "library/10665-381036/blocks/prose-page-1152"
      ]
    },
    {
      "id": "page-1153",
      "number": null,
      "title": "Page 1153",
      "level": 1,
      "pageStart": 1153,
      "pageEnd": 1153,
      "labelStart": "18",
      "labelEnd": "18",
      "words": 438,
      "summary": {
        "text": "Begins the feasibility findings, noting that consumer experience was the only people-related factor discussed and that IGRA's single visit was seen by some providers as an advantage over skin tests needing a return visit.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "consumer experience",
          "heading": false
        },
        {
          "term": "tbi tests",
          "heading": false
        },
        {
          "term": "people factors",
          "heading": false
        },
        {
          "term": "subtheme",
          "heading": false
        },
        {
          "term": "appointment",
          "heading": false
        },
        {
          "term": "skin tests",
          "heading": false
        },
        {
          "term": "healthcare providers",
          "heading": false
        },
        {
          "term": "feasibility",
          "heading": false
        }
      ],
      "extract": "18 an earlier section (see Acceptability > Consumer experience). This issue could be applicable to all 3 TBI tests, although a hospital appointment is most often involved when receiving the IGRA compared to the skin tests. 3.2.3.3 Feasibility People Factors Only one subtheme described a people factor that impacted feasibility, which was consumer experience. This subtheme was discussed by both healthcare providers",
      "extractCut": true,
      "blocks": [
        "library/10665-381036/blocks/prose-page-1153"
      ]
    },
    {
      "id": "page-1154",
      "number": null,
      "title": "Page 1154",
      "level": 1,
      "pageStart": 1154,
      "pageEnd": 1154,
      "labelStart": "19",
      "labelEnd": "19",
      "words": 506,
      "summary": {
        "text": "Quotes providers on the advantage of IGRA needing no return visit and describes the transport and parking burden of attending hospital for a blood test, likely greater in lower-income countries. It then notes that skin tests were seen as cheaper than IGRA.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "consumer experience",
          "heading": false
        },
        {
          "term": "test feasibility",
          "heading": false
        },
        {
          "term": "four subthemes",
          "heading": false
        },
        {
          "term": "test factors",
          "heading": false
        },
        {
          "term": "healthcare providers",
          "heading": false
        },
        {
          "term": "igra",
          "heading": false
        },
        {
          "term": "waiting",
          "heading": false
        },
        {
          "term": "hic",
          "heading": false
        }
      ],
      "extract": "19 “The good thing about the T-SPOT or the IGRA is that they, once they’ve had the blood test done that’s it and actually if they’re not sort of then we can put effort knowing that it’s positive or negative. If it’s positive then obviously we will be following up and putting more effort into trying to find somebody whereas often with a Mantoux, if they don’t come back within the timeframe then it has to be",
      "extractCut": true,
      "blocks": [
        "library/10665-381036/blocks/prose-page-1154"
      ]
    },
    {
      "id": "page-1155",
      "number": null,
      "title": "Page 1155",
      "level": 1,
      "pageStart": 1155,
      "pageEnd": 1155,
      "labelStart": "20",
      "labelEnd": "20",
      "words": 700,
      "summary": {
        "text": "Reports that providers saw cost savings from novel skin tests and thought low cost might make governments more willing to fund them, especially where sputum collection from children is difficult. It then discusses ease of administration, with the tuberculin skin test seen as manageable with trained staff.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "novel skin",
          "heading": false
        },
        {
          "term": "skin tests",
          "heading": false
        },
        {
          "term": "providers discussed",
          "heading": false
        },
        {
          "term": "healthcare setting",
          "heading": false
        },
        {
          "term": "portability",
          "heading": false
        },
        {
          "term": "gonna",
          "heading": false
        },
        {
          "term": "cheaper",
          "heading": false
        },
        {
          "term": "lmic",
          "heading": false
        }
      ],
      "extract": "20 costs in their current practice with TBST, while others acknowledged that the low cost may increase the willingness of governments to fund the TBST. A couple of providers discussed how the low cost affected their usage intentions towards the TBST. Quotes from providers discussing these aspects are presented below: “I think in my current practice, since we are now dealing with TB patients as well, it will be an",
      "extractCut": true,
      "blocks": [
        "library/10665-381036/blocks/prose-page-1155"
      ]
    },
    {
      "id": "page-1156",
      "number": null,
      "title": "Page 1156",
      "level": 1,
      "pageStart": 1156,
      "pageEnd": 1156,
      "labelStart": "21",
      "labelEnd": "21",
      "words": 561,
      "summary": {
        "text": "Presents provider views that the tuberculin skin test is fiddly at first but easy with practice, though staff may need frequent retraining. It notes judgements on the ease of novel skin tests and introduces contextual feasibility factors: resource needs, the COVID-19 pandemic and the health system setting.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "don think",
          "heading": false
        },
        {
          "term": "novel skin",
          "heading": false
        },
        {
          "term": "skin test",
          "heading": false
        },
        {
          "term": "contextual factors",
          "heading": false
        },
        {
          "term": "hic",
          "heading": false
        },
        {
          "term": "technique",
          "heading": false
        },
        {
          "term": "provider",
          "heading": false
        },
        {
          "term": "mantoux",
          "heading": false
        }
      ],
      "extract": "21 tricky at first, but ease of use came with practice and appropriate training: “I mean, they’re fairly easy to use. I mean they’re a bit fiddly but they’re not, once you get used to it it’s just getting the technique… But it’s yeah, it’s not difficult, once you get the hang of it.” (ID012, HIC, Provider) “We found that we have to retrain our staff at least every six months of the year… with the result sometimes",
      "extractCut": true,
      "blocks": [
        "library/10665-381036/blocks/prose-page-1156"
      ]
    },
    {
      "id": "page-1157",
      "number": null,
      "title": "Page 1157",
      "level": 1,
      "pageStart": 1157,
      "pageEnd": 1157,
      "labelStart": "22",
      "labelEnd": "22",
      "words": 610,
      "summary": {
        "text": "Explains that all three test types need equipment and trained staff, but IGRA also needs a laboratory, a blood draw and patient travel, making it less feasible in resource-limited settings. It introduces equity factors, noting tests needing less infrastructure were seen as more accessible.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "blood draw",
          "heading": false
        },
        {
          "term": "blood test",
          "heading": false
        },
        {
          "term": "test feasibility",
          "heading": false
        },
        {
          "term": "tbi tests",
          "heading": false
        },
        {
          "term": "feel like",
          "heading": false
        },
        {
          "term": "don know",
          "heading": false
        },
        {
          "term": "five subthemes",
          "heading": false
        },
        {
          "term": "resource-limited settings",
          "heading": false
        }
      ],
      "extract": "22 Figure describing the contextual factors influencing test feasibility Resource Requirements The TBST, TST, and IGRA all require access to specific test equipment and trained staff – as such, the availability of a trained workforce was considered key for test feasibility. However, the IGRA also requires access to a laboratory for test analysis and a hospital or clinic for the blood draw. As a result, there is also",
      "extractCut": true,
      "blocks": [
        "library/10665-381036/blocks/prose-page-1157"
      ]
    },
    {
      "id": "page-1158",
      "number": null,
      "title": "Page 1158",
      "level": 1,
      "pageStart": 1158,
      "pageEnd": 1158,
      "labelStart": "23",
      "labelEnd": "23",
      "words": 505,
      "summary": {
        "text": "Describes how portable skin tests can reach people far from health facilities, avoiding travel, crowded clinics and long waits, an advantage in low-resource settings. It notes IGRA was seen as less suited to low-income countries because of cost and resource needs.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "low-resource settings",
          "heading": false
        },
        {
          "term": "tbi tests",
          "heading": false
        },
        {
          "term": "low-income country",
          "heading": false
        },
        {
          "term": "long journey",
          "heading": false
        },
        {
          "term": "skin tests",
          "heading": false
        },
        {
          "term": "settings due",
          "heading": false
        },
        {
          "term": "healthcare facility",
          "heading": false
        },
        {
          "term": "infrastructure required",
          "heading": false
        }
      ],
      "extract": "23 Figure describing the factors influencing test health equity Access and Transport Issues The IGRA typically requires a visit to a healthcare facility for test administration, whereas the TBST and the TST are more portable with less resource requirements, thus a visit to a healthcare facility might not always be required. This is a distinct advantage of the skin tests in low-resource settings, as the tests can be",
      "extractCut": true,
      "blocks": [
        "library/10665-381036/blocks/prose-page-1158"
      ]
    },
    {
      "id": "page-1159",
      "number": null,
      "title": "Page 1159",
      "level": 1,
      "pageStart": 1159,
      "pageEnd": 1159,
      "labelStart": "24",
      "labelEnd": "24",
      "words": 531,
      "summary": {
        "text": "Presents quotes on making testing more affordable where tuberculosis burden is high and phlebotomy is unavailable, and on the scalability of skin tests for large screening in hard-to-reach communities. It concludes that equity impacts may vary by population group.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "skin tones",
          "heading": false
        },
        {
          "term": "darker skin",
          "heading": false
        },
        {
          "term": "finding veins",
          "heading": false
        },
        {
          "term": "intradermal injection",
          "heading": false
        },
        {
          "term": "tbi tests",
          "heading": false
        },
        {
          "term": "blood draw",
          "heading": false
        },
        {
          "term": "bcg vaccination",
          "heading": false
        },
        {
          "term": "phlebotomy",
          "heading": false
        }
      ],
      "extract": "24 required for implementation compared to the TST and the TBST. “I guess the issue of making it more affordable, its bringing the potential of a different technology in a more affordable way to people who have a high burden of the problem.” (ID014, HIC, Provider) “We’ve got access to phlebotomy and can get the IGRA done and it’s quite easy, it sort of feels to me like well what would be the benefit changing. But I",
      "extractCut": true,
      "blocks": [
        "library/10665-381036/blocks/prose-page-1159"
      ]
    },
    {
      "id": "page-1160",
      "number": null,
      "title": "Page 1160",
      "level": 1,
      "pageStart": 1160,
      "pageEnd": 1160,
      "labelStart": "25",
      "labelEnd": "25",
      "words": 711,
      "summary": {
        "text": "Summarises interview findings that providers and consumers value accuracy, convenience, good patient experience, low cost and low resource needs. Novel skin tests were seen as similar in accuracy to IGRA but cheaper and less resource-intensive, and more accurate than the tuberculin skin test, though still needing a return visit. It adds that wider access barriers in low-income settings will not be solved by introducing the new tests alone.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "skin tests",
          "heading": false
        },
        {
          "term": "low-resource settings",
          "heading": false
        },
        {
          "term": "tbsts",
          "heading": false
        },
        {
          "term": "test option",
          "heading": false
        },
        {
          "term": "resource-limited settings",
          "heading": false
        },
        {
          "term": "equity impacts",
          "heading": false
        },
        {
          "term": "user interviews",
          "heading": false
        },
        {
          "term": "return visit",
          "heading": false
        }
      ],
      "extract": "25 3.2.4 Summary of Work Package B findings from User Interviews End user values and preferences Healthcare providers and consumers were found to value TBI test accuracy, convenience, a positive patient experience, low cost and resource requirements, and these factors affected their preferences for TBI tests. The novel antigen-based skin tests (TBSTs) were discussed as having comparable accuracy to the IGRA, however",
      "extractCut": true,
      "blocks": [
        "library/10665-381036/blocks/prose-page-1160"
      ]
    },
    {
      "id": "page-1161",
      "number": null,
      "title": "Page 1161",
      "level": 1,
      "pageStart": 1161,
      "pageEnd": 1161,
      "labelStart": "26",
      "labelEnd": "26",
      "words": 109,
      "summary": {
        "text": "Concludes that novel skin tests were judged more acceptable than and as feasible as the tuberculin skin test, with greater equity benefits, while IGRA remains preferred in well-resourced high-income settings.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "tbst",
          "heading": false
        },
        {
          "term": "conclusion",
          "heading": false
        },
        {
          "term": "igra",
          "heading": false
        },
        {
          "term": "tst",
          "heading": false
        }
      ],
      "extract": "26 Conclusion In conclusion, TBST were deemed to be more acceptable and equally feasible to the TST, with greater benefits for health equity driven by higher sensitivity and specificity. TBST may be more preferable for use in more resource-limited settings compared to the TST. IGRA appears the preferred test option in high-income countries with the infrastructure to support their use; it is unlikely that widespread",
      "extractCut": true,
      "blocks": [
        "library/10665-381036/blocks/prose-page-1161"
      ]
    },
    {
      "id": "page-1162",
      "number": null,
      "title": "Page 1162",
      "level": 1,
      "pageStart": 1162,
      "pageEnd": 1162,
      "labelStart": "27",
      "labelEnd": "27",
      "words": 545,
      "summary": {
        "text": "Introduces Work Package C, a discrete choice experiment to explore how test users and providers trade off test attributes. It describes the online cross-sectional survey design and how attributes covering acceptability, accuracy, feasibility and equity were chosen.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "test attributes",
          "heading": false
        },
        {
          "term": "choice experiment",
          "heading": false
        },
        {
          "term": "discrete choice",
          "heading": false
        },
        {
          "term": "dce",
          "heading": false
        },
        {
          "term": "user interviews",
          "heading": false
        },
        {
          "term": "explore end-user",
          "heading": false
        },
        {
          "term": "hensher",
          "heading": false
        },
        {
          "term": "team discussed",
          "heading": false
        }
      ],
      "extract": "27 Work Package C - Discrete choice experiment (DCE) This activity intends to answer following objective: Objective D: To explore end-user values and preferences for TB testing by investigating the trade- offs end users are willing to make between test attributes derived from systematic reviews and in- depth user interviews, and determine the order of preference of different test attributes using a discrete choice",
      "extractCut": true,
      "blocks": [
        "library/10665-381036/blocks/prose-page-1162"
      ]
    },
    {
      "id": "page-1163",
      "number": null,
      "title": "Page 1163",
      "level": 1,
      "pageStart": 1163,
      "pageEnd": 1163,
      "labelStart": "28",
      "labelEnd": "28",
      "words": 214,
      "summary": {
        "text": "Explains how choice tasks offered two hypothetical tests plus an opt-out, with separate versions for providers and consumers, and how a 10-task efficient design was built from the many possible profiles using NGENE software after piloting.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "pairwise choice",
          "heading": false
        },
        {
          "term": "choice tasks",
          "heading": false
        },
        {
          "term": "priors",
          "heading": false
        },
        {
          "term": "dce",
          "heading": false
        },
        {
          "term": "attributes",
          "heading": false
        },
        {
          "term": "respondents",
          "heading": false
        }
      ],
      "extract": "28 A choice task is where a participant is given a choice between different scenarios based on different attribute and level combinations. We constructed a DCE with choice tasks that included two options of hypothetical TBI test alternatives and an opt-out alternative of choosing neither, which was included to estimate preferences more relevant to real-world choices. Separate DCE choice tasks were created for",
      "extractCut": true,
      "blocks": [
        "library/10665-381036/blocks/prose-page-1163"
      ]
    },
    {
      "id": "page-1164",
      "number": null,
      "title": "Page 1164",
      "level": 1,
      "pageStart": 1164,
      "pageEnd": 1164,
      "labelStart": null,
      "labelEnd": null,
      "words": 343,
      "summary": {
        "text": "Table C1 lists the attributes and levels in the provider and consumer choice experiments, such as cost, waiting time, follow-up visits, false positive and false negative rates, test location and how the test is done.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "get treatment",
          "heading": false
        },
        {
          "term": "get test",
          "heading": false
        },
        {
          "term": "chance",
          "heading": false
        },
        {
          "term": "follow-up appointment",
          "heading": false
        },
        {
          "term": "consumer dces",
          "heading": false
        },
        {
          "term": "appointment required",
          "heading": false
        },
        {
          "term": "skin prick",
          "heading": false
        },
        {
          "term": "in-person follow-up",
          "heading": false
        }
      ],
      "extract": "1 Table C1: List of attributes and levels included in both provider and consumer DCEs Provider DCE Consumer DCE Attribute Levels Description Levels Cost to healthcare practice USD 100 Time required for test results to come back 1 day USD 50 3 days USD 25 7 days If a follow-up appointment is needed to get test results In-person follow-up appointment needed If a follow-up appointment is needed to get test results",
      "extractCut": true,
      "blocks": [
        "library/10665-381036/blocks/prose-page-1164"
      ]
    },
    {
      "id": "page-1165",
      "number": null,
      "title": "Page 1165",
      "level": 1,
      "pageStart": 1165,
      "pageEnd": 1165,
      "labelStart": null,
      "labelEnd": null,
      "words": 545,
      "summary": {
        "text": "Describes recruitment of participants through tuberculosis networks and civil society groups, online consent, and analysis using multinomial logit models. It begins reporting respondent characteristics, with most respondents from India, the United States, South Africa, Pakistan and Zimbabwe.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "test attributes",
          "heading": false
        },
        {
          "term": "dce",
          "heading": false
        },
        {
          "term": "sample size",
          "heading": false
        },
        {
          "term": "participant number",
          "heading": false
        },
        {
          "term": "respondents",
          "heading": false
        },
        {
          "term": "information sheet",
          "heading": false
        },
        {
          "term": "non-provider",
          "heading": false
        },
        {
          "term": "dces",
          "heading": false
        }
      ],
      "extract": "3.3.2.3 Recruitment Participants for the DCE were recruited from the same research networks used to recruit the users for the interviews for Work Package B e.g. from a clinical, research and community setting: • TB Treatment Action Group • TB Civil Societies • Members of the WHO Guideline Development Group for TBST • Global Coalition of TB Activists (GCTA) • Stop TB Partnership • WHO TBI Task Force Potential",
      "extractCut": true,
      "blocks": [
        "library/10665-381036/blocks/prose-page-1165"
      ]
    },
    {
      "id": "page-1166",
      "number": null,
      "title": "Page 1166",
      "level": 1,
      "pageStart": 1166,
      "pageEnd": 1166,
      "labelStart": null,
      "labelEnd": null,
      "words": 396,
      "summary": {
        "text": "Gives the age breakdown and location of choice experiment respondents and explains how to read the multinomial logit results. It begins presenting the choice model results for consumers and providers.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "influential attribute",
          "heading": false
        },
        {
          "term": "coefficients",
          "heading": false
        },
        {
          "term": "choice model",
          "heading": false
        },
        {
          "term": "among providers",
          "heading": false
        },
        {
          "term": "across models",
          "heading": false
        },
        {
          "term": "test accuracy",
          "heading": false
        },
        {
          "term": "compared across",
          "heading": false
        },
        {
          "term": "follow-up appointment",
          "heading": false
        }
      ],
      "extract": "Other 1 (1%) Age Category 18-35 32 (17%) 13 (27%) 36-55 106 (57%) 24 (50%) 56-75 44 (24%) 11 (23%) 75+ 4 (2%) 0 (0%) Figure C1: Location of DCE respondents 3.3.3.2 Choice analysis Table 4 shows choice model results, analysing DCE data for providers and consumers using multinomial logistic regression models. Where coefficients are significantly greater than zero, an attribute can be interpreted as having a relatively",
      "extractCut": true,
      "blocks": [
        "library/10665-381036/blocks/prose-page-1166"
      ]
    },
    {
      "id": "page-1167",
      "number": null,
      "title": "Page 1167",
      "level": 1,
      "pageStart": 1167,
      "pageEnd": 1167,
      "labelStart": null,
      "labelEnd": null,
      "words": 440,
      "summary": {
        "text": "Presents the choice model coefficients, showing that both consumers and providers strongly disliked false positive and false negative results and that consumers preferred testing in primary care or the community over hospitals. It notes that consumers weighed false negatives slightly more than false positives, while providers did the reverse.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "false positivity",
          "heading": false
        },
        {
          "term": "positivity rate",
          "heading": false
        },
        {
          "term": "greater false",
          "heading": false
        },
        {
          "term": "percentage point",
          "heading": false
        },
        {
          "term": "skin prick",
          "heading": false
        },
        {
          "term": "attribute",
          "heading": false
        },
        {
          "term": "accept change",
          "heading": false
        },
        {
          "term": "in-person follow-up",
          "heading": false
        }
      ],
      "extract": "Chance of the test wrongly saying there is TB infection when there is not (false positive) -0.790*** (0.181) -0.189** (0.0819) Chance of the test wrongly saying there is no TB infection when there is (false negative) -0.967*** (0.184) -0.169* (0.0960) Waiting time in days for test result -0.0953* (0.0523) (not presented as an attribute) Place of the test (Reference: hospital) Primary care (e.g. family doctor, GP,",
      "extractCut": true,
      "blocks": [
        "library/10665-381036/blocks/prose-page-1167"
      ]
    },
    {
      "id": "page-1168",
      "number": null,
      "title": "Page 1168",
      "level": 1,
      "pageStart": 1168,
      "pageEnd": 1168,
      "labelStart": null,
      "labelEnd": null,
      "words": 430,
      "summary": {
        "text": "Explains how to read willingness-to-accept estimates, for example that consumers would accept a higher false positive rate to avoid a week's wait for results. It summarises that 236 respondents most valued test accuracy, followed by other attributes such as convenience.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "false positivity",
          "heading": false
        },
        {
          "term": "dce attributes",
          "heading": false
        },
        {
          "term": "positivity rate",
          "heading": false
        },
        {
          "term": "day wait",
          "heading": false
        },
        {
          "term": "percentage points",
          "heading": false
        },
        {
          "term": "accept change",
          "heading": false
        },
        {
          "term": "follow-up appointment",
          "heading": false
        },
        {
          "term": "in-person follow-up",
          "heading": false
        }
      ],
      "extract": "Panel A shows results for consumers, and panel B results for providers. A positive value indicates that respondents are willing to accept a lower likelihood of a false-positive result for that attribute. Panel A, example interpretation: Consumers would be willing to accept an 8.4 percentage point greater false positivity rate to avoid a seven-day wait for test results. Panel B, example interpretation: Providers",
      "extractCut": true,
      "blocks": [
        "library/10665-381036/blocks/prose-page-1168"
      ]
    },
    {
      "id": "page-1169",
      "number": null,
      "title": "Page 1169",
      "level": 1,
      "pageStart": 1169,
      "pageEnd": 1169,
      "labelStart": null,
      "labelEnd": null,
      "words": 201,
      "summary": {
        "text": "Sets out limitations of the choice experiment, including possible hypothetical bias, recruitment of only about a quarter of the target consumer sample, and too few responses to explore differences between geographic settings.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "real-world choices",
          "heading": false
        },
        {
          "term": "sample size",
          "heading": false
        },
        {
          "term": "target sample",
          "heading": false
        },
        {
          "term": "dces",
          "heading": false
        },
        {
          "term": "dce",
          "heading": false
        },
        {
          "term": "hypothetical",
          "heading": false
        },
        {
          "term": "respondents",
          "heading": false
        }
      ],
      "extract": "systematic review evidence to design an initial DCE task for piloting. This DCE study has several limitations. First, DCEs require choices between hypothetical alternatives which may not reflect real-world choices accurately or comprehensively. Although there is evidence that DCEs predict real-world choices reasonably well29, there remains the potential for hypothetical bias in these data if respondents chose",
      "extractCut": true,
      "blocks": [
        "library/10665-381036/blocks/prose-page-1169"
      ]
    }
  ],
  "checks": {
    "tocAlignment": {
      "listed_not_found": {
        "count": 1,
        "items": [
          "sequencing (tNGS) for diagnosing multi-drug resistant Tuberculosis (MDR-TB): a qualitative evidence synthesis"
        ]
      },
      "found_not_listed": {
        "count": 0,
        "items": []
      },
      "page_mismatch": {
        "count": 17,
        "items": [
          "detection of pulmonary TB and resistance to isoniazid/rifampicin in adults and adolescents: a systematic review of diagnostic accuracy: listed p1, found p23",
          "Web Annex B.2. Low complexity automated NAATs for pulmonary and extrapulmonary tuberculosis and rifampicin resistance in children: a systematic review of diagnostic accuracy: listed p45, found p50",
          "Web Annex B.3. Accuracy of LC-aNAATs for extrapulmonary tuberculosis and rifampicin resistance in adults and adolescents: a systematic review: listed p91, found p96",
          "Web Annex B.4. Impact of Rapid Nucleic Acid Amplification Tests for Tuberculosis on Patient Outcomes: A Systematic Review: listed p157, found p162",
          "Web Annex B.5. LC-mNAATs for detection of pulmonary and extrapulmonary tuberculosis in adults and adolescents: a systematic review of diagnostic accuracy: listed p204, found p209",
          "Web Annex B.6. LC-mNAATs for detection of pulmonary and extrapulmonary tuberculosis in children: a systematic review of diagnostic accuracy: listed p234, found p239",
          "respiratory samples and stool with or without lateral flow urine lipoarabinomannan assays to detect pulmonary tuberculosis disease in children: listed p252, found p222",
          "lateral flow urine lipoarabinomannan assay to detect tuberculosis disease in adults and adolescents with HIV: a systematic review: listed p319, found p381",
          "Web Annex B.9. Systematic Review of Economic Evidence Around Low and Moderate Complexity Nucleic Acid Amplification Tests for TB Diagnosis and Detection of Resistance: listed p375, found p380",
          "Web Annex B.10. Nucleic acid amplification tests (NAATs) for tuberculosis and tuberculosis drug resistance: A qualitative evidence synthesis of user perspectives: listed p443, found p448",
          "Web Annex B.11. Moderate complexity automated NAATs: Diagnostic accuracy for TB detection and detection of resistance to rifampicin and isoniazid. A systematic review and meta-analysis: listed p504, found p509",
          "Web Annex B.12. Systematic Literature Review of Economic Evidence for Nucleic acid amplification tests (NAATs) to detect TB and DR-TB in adults and children: listed p549, found p554",
          "Web Annex B.13. User perspectives on NAATs to detect TB and resistance to anti-TB agents: results from qualitative evidence synthesis (systematic review): listed p565, found p570",
          "Web Annex B.14. User perspectives on nucleic acid amplification tests for tuberculosis and tuberculosis drug resistance: (interviews study): listed p607, found p612",
          "Web Annex B.15. Drug concentrations used in culture-based drug susceptibility testing for included studies on second-line line probe assays diagnostic accuracy7: listed p674, found p679",
          "Web Annex B.16. Review of the diagnostic accuracy of targeted next-generation sequencing technologies for detection of drug resistance among people diagnosed with TB: listed p705, found p710",
          "Web Annex B.18. Stakeholder experiences and perspectives of using Targeted next generation sequencing for diagnosing MDR-TB: interviews results: listed p818, found p823"
        ]
      }
    },
    "figureSequenceGaps": [],
    "pageLabelConflicts": {
      "count": 0,
      "items": []
    }
  },
  "withheld": false,
  "keywords": [
    {
      "term": "tuberculosis test",
      "heading": true
    },
    {
      "term": "test xpert",
      "heading": true
    },
    {
      "term": "resistance tuberculosis",
      "heading": false
    },
    {
      "term": "test study",
      "heading": false
    },
    {
      "term": "test sensitivity",
      "heading": true
    },
    {
      "term": "tuberculosis diagnostic",
      "heading": false
    },
    {
      "term": "diagnostic studies",
      "heading": true
    },
    {
      "term": "mtb test",
      "heading": false
    },
    {
      "term": "rif studies",
      "heading": false
    },
    {
      "term": "test specificity",
      "heading": true
    },
    {
      "term": "pulmonary tuberculosis",
      "heading": true
    },
    {
      "term": "ultra studies",
      "heading": true
    }
  ],
  "pageLabels": [
    {
      "physical": 1,
      "label": null,
      "source": null,
      "confidence": 0
    },
    {
      "physical": 2,
      "label": null,
      "source": null,
      "confidence": 0
    },
    {
      "physical": 3,
      "label": "ii",
      "source": "printed",
      "confidence": 0.7
    },
    {
      "physical": 4,
      "label": "iii",
      "source": "printed",
      "confidence": 0.7
    },
    {
      "physical": 5,
      "label": "iv",
      "source": "printed",
      "confidence": 0.7
    },
    {
      "physical": 6,
      "label": "1",
      "source": "printed",
      "confidence": 0.7
    },
    {
      "physical": 7,
      "label": "2",
      "source": "printed",
      "confidence": 0.7
    },
    {
      "physical": 8,
      "label": "3",
      "source": "printed",
      "confidence": 0.7
    },
    {
      "physical": 9,
      "label": "4",
      "source": "printed",
      "confidence": 0.7
    },
    {
      "physical": 10,
      "label": "5",
      "source": "printed",
      "confidence": 0.7
    },
    {
      "physical": 11,
      "label": "6",
      "source": "printed",
      "confidence": 0.7
    },
    {
      "physical": 12,
      "label": "7",
      "source": "printed",
      "confidence": 0.7
    },
    {
      "physical": 13,
      "label": "8",
      "source": "printed",
      "confidence": 0.7
    },
    {
      "physical": 14,
      "label": "9",
      "source": "printed",
      "confidence": 0.7
    },
    {
      "physical": 15,
      "label": "10",
      "source": "printed",
      "confidence": 0.7
    },
    {
      "physical": 16,
      "label": "11",
      "source": "printed",
      "confidence": 0.7
    },
    {
      "physical": 17,
      "label": "12",
      "source": "printed",
      "confidence": 0.7
    },
    {
      "physical": 18,
      "label": "13",
      "source": "printed",
      "confidence": 0.7
    },
    {
      "physical": 19,
      "label": "14",
      "source": "printed",
      "confidence": 0.7
    },
    {
      "physical": 20,
      "label": "15",
      "source": "printed",
      "confidence": 0.7
    },
    {
      "physical": 21,
      "label": "16",
      "source": "printed",
      "confidence": 0.7
    },
    {
      "physical": 22,
      "label": "17",
      "source": "printed",
      "confidence": 0.7
    },
    {
      "physical": 23,
      "label": "18",
      "source": "printed",
      "confidence": 0.7
    },
    {
      "physical": 24,
      "label": "19",
      "source": "printed",
      "confidence": 0.7
    },
    {
      "physical": 25,
      "label": "20",
      "source": "printed",
      "confidence": 0.7
    },
    {
      "physical": 26,
      "label": "21",
      "source": "printed",
      "confidence": 0.7
    },
    {
      "physical": 27,
      "label": "22",
      "source": "printed",
      "confidence": 0.7
    },
    {
      "physical": 28,
      "label": "23",
      "source": "printed",
      "confidence": 0.7
    },
    {
      "physical": 29,
      "label": "24",
      "source": "printed",
      "confidence": 0.7
    },
    {
      "physical": 30,
      "label": "25",
      "source": "printed",
      "confidence": 0.7
    },
    {
      "physical": 31,
      "label": "26",
      "source": "printed",
      "confidence": 0.7
    },
    {
      "physical": 32,
      "label": "27",
      "source": "printed",
      "confidence": 0.7
    },
    {
      "physical": 33,
      "label": "28",
      "source": "printed",
      "confidence": 0.7
    },
    {
      "physical": 34,
      "label": "29",
      "source": "printed",
      "confidence": 0.7
    },
    {
      "physical": 35,
      "label": "30",
      "source": "printed",
      "confidence": 0.7
    },
    {
      "physical": 36,
      "label": "31",
      "source": "printed",
      "confidence": 0.7
    },
    {
      "physical": 37,
      "label": "32",
      "source": "printed",
      "confidence": 0.7
    },
    {
      "physical": 38,
      "label": "33",
      "source": "printed",
      "confidence": 0.7
    },
    {
      "physical": 39,
      "label": "34",
      "source": "interpolated",
      "confidence": 0.5
    },
    {
      "physical": 40,
      "label": "35",
      "source": "printed",
      "confidence": 0.7
    },
    {
      "physical": 41,
      "label": "36",
      "source": "printed",
      "confidence": 0.7
    },
    {
      "physical": 42,
      "label": "37",
      "source": "printed",
      "confidence": 0.7
    },
    {
      "physical": 43,
      "label": "38",
      "source": "printed",
      "confidence": 0.7
    },
    {
      "physical": 44,
      "label": "39",
      "source": "printed",
      "confidence": 0.7
    },
    {
      "physical": 45,
      "label": "40",
      "source": "printed",
      "confidence": 0.7
    },
    {
      "physical": 46,
      "label": "41",
      "source": "printed",
      "confidence": 0.7
    },
    {
      "physical": 47,
      "label": "42",
      "source": "printed",
      "confidence": 0.7
    },
    {
      "physical": 48,
      "label": "43",
      "source": "printed",
      "confidence": 0.7
    },
    {
      "physical": 49,
      "label": "44",
      "source": "printed",
      "confidence": 0.7
    },
    {
      "physical": 50,
      "label": "45",
      "source": "printed",
      "confidence": 0.7
    },
    {
      "physical": 51,
      "label": "46",
      "source": "printed",
      "confidence": 0.7
    },
    {
      "physical": 52,
      "label": "47",
      "source": "printed",
      "confidence": 0.7
    },
    {
      "physical": 53,
      "label": "48",
      "source": "printed",
      "confidence": 0.7
    },
    {
      "physical": 54,
      "label": "49",
      "source": "printed",
      "confidence": 0.7
    },
    {
      "physical": 55,
      "label": "50",
      "source": "printed",
      "confidence": 0.7
    },
    {
      "physical": 56,
      "label": "51",
      "source": "printed",
      "confidence": 0.7
    },
    {
      "physical": 57,
      "label": "52",
      "source": "printed",
      "confidence": 0.7
    },
    {
      "physical": 58,
      "label": "53",
      "source": "printed",
      "confidence": 0.7
    },
    {
      "physical": 59,
      "label": "54",
      "source": "printed",
      "confidence": 0.7
    },
    {
      "physical": 60,
      "label": "55",
      "source": "printed",
      "confidence": 0.7
    },
    {
      "physical": 61,
      "label": "56",
      "source": "printed",
      "confidence": 0.7
    },
    {
      "physical": 62,
      "label": "57",
      "source": "printed",
      "confidence": 0.7
    },
    {
      "physical": 63,
      "label": "58",
      "source": "printed",
      "confidence": 0.7
    },
    {
      "physical": 64,
      "label": "59",
      "source": "printed",
      "confidence": 0.7
    },
    {
      "physical": 65,
      "label": "60",
      "source": "printed",
      "confidence": 0.7
    },
    {
      "physical": 66,
      "label": "61",
      "source": "printed",
      "confidence": 0.7
    },
    {
      "physical": 67,
      "label": "62",
      "source": "printed",
      "confidence": 0.7
    },
    {
      "physical": 68,
      "label": "63",
      "source": "printed",
      "confidence": 0.7
    },
    {
      "physical": 69,
      "label": "64",
      "source": "printed",
      "confidence": 0.7
    },
    {
      "physical": 70,
      "label": "65",
      "source": "printed",
      "confidence": 0.7
    },
    {
      "physical": 71,
      "label": "66",
      "source": "printed",
      "confidence": 0.7
    },
    {
      "physical": 72,
      "label": "67",
      "source": "printed",
      "confidence": 0.7
    },
    {
      "physical": 73,
      "label": "68",
      "source": "printed",
      "confidence": 0.7
    },
    {
      "physical": 74,
      "label": "69",
      "source": "printed",
      "confidence": 0.7
    },
    {
      "physical": 75,
      "label": "70",
      "source": "printed",
      "confidence": 0.7
    },
    {
      "physical": 76,
      "label": "71",
      "source": "printed",
      "confidence": 0.7
    },
    {
      "physical": 77,
      "label": "72",
      "source": "printed",
      "confidence": 0.7
    },
    {
      "physical": 78,
      "label": "73",
      "source": "printed",
      "confidence": 0.7
    },
    {
      "physical": 79,
      "label": "74",
      "source": "printed",
      "confidence": 0.7
    },
    {
      "physical": 80,
      "label": "75",
      "source": "printed",
      "confidence": 0.7
    },
    {
      "physical": 81,
      "label": "76",
      "source": "printed",
      "confidence": 0.7
    },
    {
      "physical": 82,
      "label": "77",
      "source": "printed",
      "confidence": 0.7
    },
    {
      "physical": 83,
      "label": "78",
      "source": "printed",
      "confidence": 0.7
    },
    {
      "physical": 84,
      "label": "79",
      "source": "printed",
      "confidence": 0.7
    },
    {
      "physical": 85,
      "label": "80",
      "source": "printed",
      "confidence": 0.7
    },
    {
      "physical": 86,
      "label": "81",
      "source": "printed",
      "confidence": 0.7
    },
    {
      "physical": 87,
      "label": "82",
      "source": "printed",
      "confidence": 0.7
    },
    {
      "physical": 88,
      "label": "83",
      "source": "printed",
      "confidence": 0.7
    },
    {
      "physical": 89,
      "label": "84",
      "source": "printed",
      "confidence": 0.7
    },
    {
      "physical": 90,
      "label": "85",
      "source": "printed",
      "confidence": 0.7
    },
    {
      "physical": 91,
      "label": "86",
      "source": "printed",
      "confidence": 0.7
    },
    {
      "physical": 92,
      "label": "87",
      "source": "printed",
      "confidence": 0.7
    },
    {
      "physical": 93,
      "label": "88",
      "source": "printed",
      "confidence": 0.7
    },
    {
      "physical": 94,
      "label": "89",
      "source": "printed",
      "confidence": 0.7
    },
    {
      "physical": 95,
      "label": "90",
      "source": "printed",
      "confidence": 0.7
    },
    {
      "physical": 96,
      "label": "91",
      "source": "printed",
      "confidence": 0.7
    },
    {
      "physical": 97,
      "label": "92",
      "source": "printed",
      "confidence": 0.7
    },
    {
      "physical": 98,
      "label": "93",
      "source": "printed",
      "confidence": 0.7
    },
    {
      "physical": 99,
      "label": "94",
      "source": "printed",
      "confidence": 0.7
    },
    {
      "physical": 100,
      "label": "95",
      "source": "printed",
      "confidence": 0.7
    },
    {
      "physical": 101,
      "label": "96",
      "source": "printed",
      "confidence": 0.7
    },
    {
      "physical": 102,
      "label": "97",
      "source": "printed",
      "confidence": 0.7
    },
    {
      "physical": 103,
      "label": "98",
      "source": "printed",
      "confidence": 0.7
    },
    {
      "physical": 104,
      "label": "99",
      "source": "printed",
      "confidence": 0.7
    },
    {
      "physical": 105,
      "label": "100",
      "source": "printed",
      "confidence": 0.7
    },
    {
      "physical": 106,
      "label": "101",
      "source": "printed",
      "confidence": 0.7
    },
    {
      "physical": 107,
      "label": "102",
      "source": "printed",
      "confidence": 0.7
    },
    {
      "physical": 108,
      "label": "103",
      "source": "printed",
      "confidence": 0.7
    },
    {
      "physical": 109,
      "label": "104",
      "source": "printed",
      "confidence": 0.7
    },
    {
      "physical": 110,
      "label": "105",
      "source": "printed",
      "confidence": 0.7
    },
    {
      "physical": 111,
      "label": "106",
      "source": "printed",
      "confidence": 0.7
    },
    {
      "physical": 112,
      "label": "107",
      "source": "printed",
      "confidence": 0.7
    },
    {
      "physical": 113,
      "label": "108",
      "source": "printed",
      "confidence": 0.7
    },
    {
      "physical": 114,
      "label": "109",
      "source": "printed",
      "confidence": 0.7
    },
    {
      "physical": 115,
      "label": "110",
      "source": "printed",
      "confidence": 0.7
    },
    {
      "physical": 116,
      "label": "111",
      "source": "printed",
      "confidence": 0.7
    },
    {
      "physical": 117,
      "label": "112",
      "source": "printed",
      "confidence": 0.7
    },
    {
      "physical": 118,
      "label": "113",
      "source": "printed",
      "confidence": 0.7
    },
    {
      "physical": 119,
      "label": "114",
      "source": "printed",
      "confidence": 0.7
    },
    {
      "physical": 120,
      "label": "115",
      "source": "printed",
      "confidence": 0.7
    },
    {
      "physical": 121,
      "label": "116",
      "source": "printed",
      "confidence": 0.7
    },
    {
      "physical": 122,
      "label": "117",
      "source": "printed",
      "confidence": 0.7
    },
    {
      "physical": 123,
      "label": "118",
      "source": "printed",
      "confidence": 0.7
    },
    {
      "physical": 124,
      "label": "119",
      "source": "printed",
      "confidence": 0.7
    },
    {
      "physical": 125,
      "label": "120",
      "source": "printed",
      "confidence": 0.7
    },
    {
      "physical": 126,
      "label": "121",
      "source": "printed",
      "confidence": 0.7
    },
    {
      "physical": 127,
      "label": "122",
      "source": "printed",
      "confidence": 0.7
    },
    {
      "physical": 128,
      "label": "123",
      "source": "printed",
      "confidence": 0.7
    },
    {
      "physical": 129,
      "label": "124",
      "source": "printed",
      "confidence": 0.7
    },
    {
      "physical": 130,
      "label": "125",
      "source": "printed",
      "confidence": 0.7
    },
    {
      "physical": 131,
      "label": "126",
      "source": "printed",
      "confidence": 0.7
    },
    {
      "physical": 132,
      "label": "127",
      "source": "printed",
      "confidence": 0.7
    },
    {
      "physical": 133,
      "label": "128",
      "source": "printed",
      "confidence": 0.7
    },
    {
      "physical": 134,
      "label": "129",
      "source": "printed",
      "confidence": 0.7
    },
    {
      "physical": 135,
      "label": "130",
      "source": "printed",
      "confidence": 0.7
    },
    {
      "physical": 136,
      "label": "131",
      "source": "printed",
      "confidence": 0.7
    },
    {
      "physical": 137,
      "label": "132",
      "source": "printed",
      "confidence": 0.7
    },
    {
      "physical": 138,
      "label": "133",
      "source": "printed",
      "confidence": 0.7
    },
    {
      "physical": 139,
      "label": "134",
      "source": "printed",
      "confidence": 0.7
    },
    {
      "physical": 140,
      "label": "135",
      "source": "printed",
      "confidence": 0.7
    },
    {
      "physical": 141,
      "label": "136",
      "source": "printed",
      "confidence": 0.7
    },
    {
      "physical": 142,
      "label": "137",
      "source": "printed",
      "confidence": 0.7
    },
    {
      "physical": 143,
      "label": "138",
      "source": "printed",
      "confidence": 0.7
    },
    {
      "physical": 144,
      "label": "139",
      "source": "printed",
      "confidence": 0.7
    },
    {
      "physical": 145,
      "label": "140",
      "source": "printed",
      "confidence": 0.7
    },
    {
      "physical": 146,
      "label": "141",
      "source": "printed",
      "confidence": 0.7
    },
    {
      "physical": 147,
      "label": "142",
      "source": "printed",
      "confidence": 0.7
    },
    {
      "physical": 148,
      "label": "143",
      "source": "printed",
      "confidence": 0.7
    },
    {
      "physical": 149,
      "label": "144",
      "source": "printed",
      "confidence": 0.7
    },
    {
      "physical": 150,
      "label": "145",
      "source": "printed",
      "confidence": 0.7
    },
    {
      "physical": 151,
      "label": "146",
      "source": "printed",
      "confidence": 0.7
    },
    {
      "physical": 152,
      "label": "147",
      "source": "printed",
      "confidence": 0.7
    },
    {
      "physical": 153,
      "label": "148",
      "source": "printed",
      "confidence": 0.7
    },
    {
      "physical": 154,
      "label": "149",
      "source": "printed",
      "confidence": 0.7
    },
    {
      "physical": 155,
      "label": "150",
      "source": "printed",
      "confidence": 0.7
    },
    {
      "physical": 156,
      "label": "151",
      "source": "printed",
      "confidence": 0.7
    },
    {
      "physical": 157,
      "label": "152",
      "source": "printed",
      "confidence": 0.7
    },
    {
      "physical": 158,
      "label": "153",
      "source": "printed",
      "confidence": 0.7
    },
    {
      "physical": 159,
      "label": "154",
      "source": "printed",
      "confidence": 0.7
    },
    {
      "physical": 160,
      "label": "155",
      "source": "printed",
      "confidence": 0.7
    },
    {
      "physical": 161,
      "label": "156",
      "source": "printed",
      "confidence": 0.7
    },
    {
      "physical": 162,
      "label": "157",
      "source": "printed",
      "confidence": 0.7
    },
    {
      "physical": 163,
      "label": "158",
      "source": "printed",
      "confidence": 0.7
    },
    {
      "physical": 164,
      "label": "159",
      "source": "printed",
      "confidence": 0.7
    },
    {
      "physical": 165,
      "label": "160",
      "source": "printed",
      "confidence": 0.7
    },
    {
      "physical": 166,
      "label": "161",
      "source": "printed",
      "confidence": 0.7
    },
    {
      "physical": 167,
      "label": "162",
      "source": "printed",
      "confidence": 0.7
    },
    {
      "physical": 168,
      "label": "163",
      "source": "printed",
      "confidence": 0.7
    },
    {
      "physical": 169,
      "label": "164",
      "source": "printed",
      "confidence": 0.7
    },
    {
      "physical": 170,
      "label": "165",
      "source": "printed",
      "confidence": 0.7
    },
    {
      "physical": 171,
      "label": "166",
      "source": "printed",
      "confidence": 0.7
    },
    {
      "physical": 172,
      "label": "167",
      "source": "printed",
      "confidence": 0.7
    },
    {
      "physical": 173,
      "label": "168",
      "source": "printed",
      "confidence": 0.7
    },
    {
      "physical": 174,
      "label": "169",
      "source": "printed",
      "confidence": 0.7
    },
    {
      "physical": 175,
      "label": "170",
      "source": "printed",
      "confidence": 0.7
    },
    {
      "physical": 176,
      "label": "171",
      "source": "printed",
      "confidence": 0.7
    },
    {
      "physical": 177,
      "label": "172",
      "source": "printed",
      "confidence": 0.7
    },
    {
      "physical": 178,
      "label": "173",
      "source": "printed",
      "confidence": 0.7
    },
    {
      "physical": 179,
      "label": "174",
      "source": "printed",
      "confidence": 0.7
    },
    {
      "physical": 180,
      "label": "175",
      "source": "printed",
      "confidence": 0.7
    },
    {
      "physical": 181,
      "label": "176",
      "source": "printed",
      "confidence": 0.7
    },
    {
      "physical": 182,
      "label": "177",
      "source": "printed",
      "confidence": 0.7
    },
    {
      "physical": 183,
      "label": "178",
      "source": "printed",
      "confidence": 0.7
    },
    {
      "physical": 184,
      "label": "179",
      "source": "printed",
      "confidence": 0.7
    },
    {
      "physical": 185,
      "label": "180",
      "source": "printed",
      "confidence": 0.7
    },
    {
      "physical": 186,
      "label": "181",
      "source": "printed",
      "confidence": 0.7
    },
    {
      "physical": 187,
      "label": "182",
      "source": "printed",
      "confidence": 0.7
    },
    {
      "physical": 188,
      "label": "183",
      "source": "printed",
      "confidence": 0.7
    },
    {
      "physical": 189,
      "label": "184",
      "source": "printed",
      "confidence": 0.7
    },
    {
      "physical": 190,
      "label": "185",
      "source": "printed",
      "confidence": 0.7
    },
    {
      "physical": 191,
      "label": "186",
      "source": "printed",
      "confidence": 0.7
    },
    {
      "physical": 192,
      "label": "187",
      "source": "printed",
      "confidence": 0.7
    },
    {
      "physical": 193,
      "label": "188",
      "source": "printed",
      "confidence": 0.7
    },
    {
      "physical": 194,
      "label": "189",
      "source": "printed",
      "confidence": 0.7
    },
    {
      "physical": 195,
      "label": "190",
      "source": "printed",
      "confidence": 0.7
    },
    {
      "physical": 196,
      "label": "191",
      "source": "printed",
      "confidence": 0.7
    },
    {
      "physical": 197,
      "label": "192",
      "source": "printed",
      "confidence": 0.7
    },
    {
      "physical": 198,
      "label": "193",
      "source": "printed",
      "confidence": 0.7
    },
    {
      "physical": 199,
      "label": "194",
      "source": "printed",
      "confidence": 0.7
    },
    {
      "physical": 200,
      "label": "195",
      "source": "printed",
      "confidence": 0.7
    },
    {
      "physical": 201,
      "label": "196",
      "source": "printed",
      "confidence": 0.7
    },
    {
      "physical": 202,
      "label": "197",
      "source": "printed",
      "confidence": 0.7
    },
    {
      "physical": 203,
      "label": "198",
      "source": "printed",
      "confidence": 0.7
    },
    {
      "physical": 204,
      "label": "199",
      "source": "printed",
      "confidence": 0.7
    },
    {
      "physical": 205,
      "label": "200",
      "source": "printed",
      "confidence": 0.7
    },
    {
      "physical": 206,
      "label": "201",
      "source": "printed",
      "confidence": 0.7
    },
    {
      "physical": 207,
      "label": "202",
      "source": "printed",
      "confidence": 0.7
    },
    {
      "physical": 208,
      "label": "203",
      "source": "printed",
      "confidence": 0.7
    },
    {
      "physical": 209,
      "label": "204",
      "source": "printed",
      "confidence": 0.7
    },
    {
      "physical": 210,
      "label": "205",
      "source": "printed",
      "confidence": 0.7
    },
    {
      "physical": 211,
      "label": "206",
      "source": "printed",
      "confidence": 0.7
    },
    {
      "physical": 212,
      "label": "207",
      "source": "printed",
      "confidence": 0.7
    },
    {
      "physical": 213,
      "label": "208",
      "source": "printed",
      "confidence": 0.7
    },
    {
      "physical": 214,
      "label": "209",
      "source": "printed",
      "confidence": 0.7
    },
    {
      "physical": 215,
      "label": "210",
      "source": "printed",
      "confidence": 0.7
    },
    {
      "physical": 216,
      "label": "211",
      "source": "printed",
      "confidence": 0.7
    },
    {
      "physical": 217,
      "label": "212",
      "source": "printed",
      "confidence": 0.7
    },
    {
      "physical": 218,
      "label": "213",
      "source": "printed",
      "confidence": 0.7
    },
    {
      "physical": 219,
      "label": "214",
      "source": "printed",
      "confidence": 0.7
    },
    {
      "physical": 220,
      "label": "215",
      "source": "printed",
      "confidence": 0.7
    },
    {
      "physical": 221,
      "label": "216",
      "source": "printed",
      "confidence": 0.7
    },
    {
      "physical": 222,
      "label": "217",
      "source": "printed",
      "confidence": 0.7
    },
    {
      "physical": 223,
      "label": "218",
      "source": "printed",
      "confidence": 0.7
    },
    {
      "physical": 224,
      "label": "219",
      "source": "printed",
      "confidence": 0.7
    },
    {
      "physical": 225,
      "label": "220",
      "source": "printed",
      "confidence": 0.7
    },
    {
      "physical": 226,
      "label": "221",
      "source": "printed",
      "confidence": 0.7
    },
    {
      "physical": 227,
      "label": "222",
      "source": "printed",
      "confidence": 0.7
    },
    {
      "physical": 228,
      "label": "223",
      "source": "printed",
      "confidence": 0.7
    },
    {
      "physical": 229,
      "label": "224",
      "source": "printed",
      "confidence": 0.7
    },
    {
      "physical": 230,
      "label": "225",
      "source": "printed",
      "confidence": 0.7
    },
    {
      "physical": 231,
      "label": "226",
      "source": "printed",
      "confidence": 0.7
    },
    {
      "physical": 232,
      "label": "227",
      "source": "printed",
      "confidence": 0.7
    },
    {
      "physical": 233,
      "label": "228",
      "source": "printed",
      "confidence": 0.7
    },
    {
      "physical": 234,
      "label": "229",
      "source": "printed",
      "confidence": 0.7
    },
    {
      "physical": 235,
      "label": "230",
      "source": "printed",
      "confidence": 0.7
    },
    {
      "physical": 236,
      "label": "231",
      "source": "printed",
      "confidence": 0.7
    },
    {
      "physical": 237,
      "label": "232",
      "source": "printed",
      "confidence": 0.7
    },
    {
      "physical": 238,
      "label": "233",
      "source": "printed",
      "confidence": 0.7
    },
    {
      "physical": 239,
      "label": "234",
      "source": "printed",
      "confidence": 0.7
    },
    {
      "physical": 240,
      "label": "235",
      "source": "printed",
      "confidence": 0.7
    },
    {
      "physical": 241,
      "label": "236",
      "source": "printed",
      "confidence": 0.7
    },
    {
      "physical": 242,
      "label": "237",
      "source": "printed",
      "confidence": 0.7
    },
    {
      "physical": 243,
      "label": "238",
      "source": "printed",
      "confidence": 0.7
    },
    {
      "physical": 244,
      "label": "239",
      "source": "printed",
      "confidence": 0.7
    },
    {
      "physical": 245,
      "label": "240",
      "source": "printed",
      "confidence": 0.7
    },
    {
      "physical": 246,
      "label": "241",
      "source": "printed",
      "confidence": 0.7
    },
    {
      "physical": 247,
      "label": "242",
      "source": "printed",
      "confidence": 0.7
    },
    {
      "physical": 248,
      "label": "243",
      "source": "printed",
      "confidence": 0.7
    },
    {
      "physical": 249,
      "label": "244",
      "source": "printed",
      "confidence": 0.7
    },
    {
      "physical": 250,
      "label": "245",
      "source": "printed",
      "confidence": 0.7
    },
    {
      "physical": 251,
      "label": "246",
      "source": "printed",
      "confidence": 0.7
    },
    {
      "physical": 252,
      "label": "247",
      "source": "printed",
      "confidence": 0.7
    },
    {
      "physical": 253,
      "label": "248",
      "source": "printed",
      "confidence": 0.7
    },
    {
      "physical": 254,
      "label": "249",
      "source": "printed",
      "confidence": 0.7
    },
    {
      "physical": 255,
      "label": "250",
      "source": "printed",
      "confidence": 0.7
    },
    {
      "physical": 256,
      "label": "251",
      "source": "printed",
      "confidence": 0.7
    },
    {
      "physical": 257,
      "label": "252",
      "source": "printed",
      "confidence": 0.7
    },
    {
      "physical": 258,
      "label": "253",
      "source": "printed",
      "confidence": 0.7
    },
    {
      "physical": 259,
      "label": "254",
      "source": "printed",
      "confidence": 0.7
    },
    {
      "physical": 260,
      "label": "255",
      "source": "printed",
      "confidence": 0.7
    },
    {
      "physical": 261,
      "label": "256",
      "source": "printed",
      "confidence": 0.7
    },
    {
      "physical": 262,
      "label": "257",
      "source": "printed",
      "confidence": 0.7
    },
    {
      "physical": 263,
      "label": "258",
      "source": "printed",
      "confidence": 0.7
    },
    {
      "physical": 264,
      "label": "259",
      "source": "printed",
      "confidence": 0.7
    },
    {
      "physical": 265,
      "label": "260",
      "source": "printed",
      "confidence": 0.7
    },
    {
      "physical": 266,
      "label": "261",
      "source": "printed",
      "confidence": 0.7
    },
    {
      "physical": 267,
      "label": "262",
      "source": "printed",
      "confidence": 0.7
    },
    {
      "physical": 268,
      "label": "263",
      "source": "printed",
      "confidence": 0.7
    },
    {
      "physical": 269,
      "label": "264",
      "source": "printed",
      "confidence": 0.7
    },
    {
      "physical": 270,
      "label": "265",
      "source": "printed",
      "confidence": 0.7
    },
    {
      "physical": 271,
      "label": "266",
      "source": "printed",
      "confidence": 0.7
    },
    {
      "physical": 272,
      "label": "267",
      "source": "printed",
      "confidence": 0.7
    },
    {
      "physical": 273,
      "label": "268",
      "source": "printed",
      "confidence": 0.7
    },
    {
      "physical": 274,
      "label": "269",
      "source": "printed",
      "confidence": 0.7
    },
    {
      "physical": 275,
      "label": "270",
      "source": "printed",
      "confidence": 0.7
    },
    {
      "physical": 276,
      "label": "271",
      "source": "printed",
      "confidence": 0.7
    },
    {
      "physical": 277,
      "label": "272",
      "source": "printed",
      "confidence": 0.7
    },
    {
      "physical": 278,
      "label": "273",
      "source": "printed",
      "confidence": 0.7
    },
    {
      "physical": 279,
      "label": "274",
      "source": "printed",
      "confidence": 0.7
    },
    {
      "physical": 280,
      "label": "275",
      "source": "printed",
      "confidence": 0.7
    },
    {
      "physical": 281,
      "label": "276",
      "source": "printed",
      "confidence": 0.7
    },
    {
      "physical": 282,
      "label": "277",
      "source": "printed",
      "confidence": 0.7
    },
    {
      "physical": 283,
      "label": "278",
      "source": "printed",
      "confidence": 0.7
    },
    {
      "physical": 284,
      "label": "279",
      "source": "printed",
      "confidence": 0.7
    },
    {
      "physical": 285,
      "label": "280",
      "source": "printed",
      "confidence": 0.7
    },
    {
      "physical": 286,
      "label": "281",
      "source": "printed",
      "confidence": 0.7
    },
    {
      "physical": 287,
      "label": "282",
      "source": "printed",
      "confidence": 0.7
    },
    {
      "physical": 288,
      "label": "283",
      "source": "printed",
      "confidence": 0.7
    },
    {
      "physical": 289,
      "label": "284",
      "source": "printed",
      "confidence": 0.7
    },
    {
      "physical": 290,
      "label": "285",
      "source": "printed",
      "confidence": 0.7
    },
    {
      "physical": 291,
      "label": "286",
      "source": "printed",
      "confidence": 0.7
    },
    {
      "physical": 292,
      "label": "287",
      "source": "printed",
      "confidence": 0.7
    },
    {
      "physical": 293,
      "label": "288",
      "source": "printed",
      "confidence": 0.7
    },
    {
      "physical": 294,
      "label": "289",
      "source": "printed",
      "confidence": 0.7
    },
    {
      "physical": 295,
      "label": "290",
      "source": "printed",
      "confidence": 0.7
    },
    {
      "physical": 296,
      "label": "291",
      "source": "printed",
      "confidence": 0.7
    },
    {
      "physical": 297,
      "label": "292",
      "source": "printed",
      "confidence": 0.7
    },
    {
      "physical": 298,
      "label": "293",
      "source": "printed",
      "confidence": 0.7
    },
    {
      "physical": 299,
      "label": "294",
      "source": "printed",
      "confidence": 0.7
    },
    {
      "physical": 300,
      "label": "295",
      "source": "printed",
      "confidence": 0.7
    },
    {
      "physical": 301,
      "label": "296",
      "source": "printed",
      "confidence": 0.7
    },
    {
      "physical": 302,
      "label": "297",
      "source": "printed",
      "confidence": 0.7
    },
    {
      "physical": 303,
      "label": "298",
      "source": "printed",
      "confidence": 0.7
    },
    {
      "physical": 304,
      "label": "299",
      "source": "printed",
      "confidence": 0.7
    },
    {
      "physical": 305,
      "label": "300",
      "source": "printed",
      "confidence": 0.7
    },
    {
      "physical": 306,
      "label": "301",
      "source": "printed",
      "confidence": 0.7
    },
    {
      "physical": 307,
      "label": "302",
      "source": "printed",
      "confidence": 0.7
    },
    {
      "physical": 308,
      "label": "303",
      "source": "printed",
      "confidence": 0.7
    },
    {
      "physical": 309,
      "label": "304",
      "source": "printed",
      "confidence": 0.7
    },
    {
      "physical": 310,
      "label": "305",
      "source": "printed",
      "confidence": 0.7
    },
    {
      "physical": 311,
      "label": "306",
      "source": "printed",
      "confidence": 0.7
    },
    {
      "physical": 312,
      "label": "307",
      "source": "printed",
      "confidence": 0.7
    },
    {
      "physical": 313,
      "label": "308",
      "source": "printed",
      "confidence": 0.7
    },
    {
      "physical": 314,
      "label": "309",
      "source": "printed",
      "confidence": 0.7
    },
    {
      "physical": 315,
      "label": "310",
      "source": "printed",
      "confidence": 0.7
    },
    {
      "physical": 316,
      "label": "311",
      "source": "printed",
      "confidence": 0.7
    },
    {
      "physical": 317,
      "label": "312",
      "source": "printed",
      "confidence": 0.7
    },
    {
      "physical": 318,
      "label": "313",
      "source": "printed",
      "confidence": 0.7
    },
    {
      "physical": 319,
      "label": "314",
      "source": "printed",
      "confidence": 0.7
    },
    {
      "physical": 320,
      "label": "315",
      "source": "printed",
      "confidence": 0.7
    },
    {
      "physical": 321,
      "label": "316",
      "source": "printed",
      "confidence": 0.7
    },
    {
      "physical": 322,
      "label": "317",
      "source": "printed",
      "confidence": 0.7
    },
    {
      "physical": 323,
      "label": "318",
      "source": "printed",
      "confidence": 0.7
    },
    {
      "physical": 324,
      "label": "319",
      "source": "printed",
      "confidence": 0.7
    },
    {
      "physical": 325,
      "label": "320",
      "source": "printed",
      "confidence": 0.7
    },
    {
      "physical": 326,
      "label": "321",
      "source": "printed",
      "confidence": 0.7
    },
    {
      "physical": 327,
      "label": "322",
      "source": "printed",
      "confidence": 0.7
    },
    {
      "physical": 328,
      "label": "323",
      "source": "printed",
      "confidence": 0.7
    },
    {
      "physical": 329,
      "label": "324",
      "source": "printed",
      "confidence": 0.7
    },
    {
      "physical": 330,
      "label": "325",
      "source": "printed",
      "confidence": 0.7
    },
    {
      "physical": 331,
      "label": "326",
      "source": "printed",
      "confidence": 0.7
    },
    {
      "physical": 332,
      "label": "327",
      "source": "printed",
      "confidence": 0.7
    },
    {
      "physical": 333,
      "label": "328",
      "source": "printed",
      "confidence": 0.7
    },
    {
      "physical": 334,
      "label": "329",
      "source": "printed",
      "confidence": 0.7
    },
    {
      "physical": 335,
      "label": "330",
      "source": "printed",
      "confidence": 0.7
    },
    {
      "physical": 336,
      "label": "331",
      "source": "printed",
      "confidence": 0.7
    },
    {
      "physical": 337,
      "label": "332",
      "source": "printed",
      "confidence": 0.7
    },
    {
      "physical": 338,
      "label": "333",
      "source": "printed",
      "confidence": 0.7
    },
    {
      "physical": 339,
      "label": "334",
      "source": "printed",
      "confidence": 0.7
    },
    {
      "physical": 340,
      "label": "335",
      "source": "printed",
      "confidence": 0.7
    },
    {
      "physical": 341,
      "label": "336",
      "source": "printed",
      "confidence": 0.7
    },
    {
      "physical": 342,
      "label": "337",
      "source": "printed",
      "confidence": 0.7
    },
    {
      "physical": 343,
      "label": "338",
      "source": "printed",
      "confidence": 0.7
    },
    {
      "physical": 344,
      "label": "339",
      "source": "printed",
      "confidence": 0.7
    },
    {
      "physical": 345,
      "label": "340",
      "source": "printed",
      "confidence": 0.7
    },
    {
      "physical": 346,
      "label": "341",
      "source": "printed",
      "confidence": 0.7
    },
    {
      "physical": 347,
      "label": "342",
      "source": "printed",
      "confidence": 0.7
    },
    {
      "physical": 348,
      "label": "343",
      "source": "printed",
      "confidence": 0.7
    },
    {
      "physical": 349,
      "label": "344",
      "source": "printed",
      "confidence": 0.7
    },
    {
      "physical": 350,
      "label": "345",
      "source": "printed",
      "confidence": 0.7
    },
    {
      "physical": 351,
      "label": "346",
      "source": "printed",
      "confidence": 0.7
    },
    {
      "physical": 352,
      "label": "347",
      "source": "printed",
      "confidence": 0.7
    },
    {
      "physical": 353,
      "label": "348",
      "source": "printed",
      "confidence": 0.7
    },
    {
      "physical": 354,
      "label": "349",
      "source": "printed",
      "confidence": 0.7
    },
    {
      "physical": 355,
      "label": "350",
      "source": "printed",
      "confidence": 0.7
    },
    {
      "physical": 356,
      "label": "351",
      "source": "printed",
      "confidence": 0.7
    },
    {
      "physical": 357,
      "label": "352",
      "source": "printed",
      "confidence": 0.7
    },
    {
      "physical": 358,
      "label": "353",
      "source": "printed",
      "confidence": 0.7
    },
    {
      "physical": 359,
      "label": "354",
      "source": "printed",
      "confidence": 0.7
    },
    {
      "physical": 360,
      "label": "355",
      "source": "printed",
      "confidence": 0.7
    },
    {
      "physical": 361,
      "label": "356",
      "source": "printed",
      "confidence": 0.7
    },
    {
      "physical": 362,
      "label": "357",
      "source": "printed",
      "confidence": 0.7
    },
    {
      "physical": 363,
      "label": "358",
      "source": "printed",
      "confidence": 0.7
    },
    {
      "physical": 364,
      "label": "359",
      "source": "printed",
      "confidence": 0.7
    },
    {
      "physical": 365,
      "label": "360",
      "source": "printed",
      "confidence": 0.7
    },
    {
      "physical": 366,
      "label": "361",
      "source": "printed",
      "confidence": 0.7
    },
    {
      "physical": 367,
      "label": "362",
      "source": "printed",
      "confidence": 0.7
    },
    {
      "physical": 368,
      "label": "363",
      "source": "printed",
      "confidence": 0.7
    },
    {
      "physical": 369,
      "label": "364",
      "source": "printed",
      "confidence": 0.7
    },
    {
      "physical": 370,
      "label": "365",
      "source": "printed",
      "confidence": 0.7
    },
    {
      "physical": 371,
      "label": "366",
      "source": "printed",
      "confidence": 0.7
    },
    {
      "physical": 372,
      "label": "367",
      "source": "printed",
      "confidence": 0.7
    },
    {
      "physical": 373,
      "label": "368",
      "source": "printed",
      "confidence": 0.7
    },
    {
      "physical": 374,
      "label": "369",
      "source": "printed",
      "confidence": 0.7
    },
    {
      "physical": 375,
      "label": "370",
      "source": "printed",
      "confidence": 0.7
    },
    {
      "physical": 376,
      "label": "371",
      "source": "printed",
      "confidence": 0.7
    },
    {
      "physical": 377,
      "label": "372",
      "source": "printed",
      "confidence": 0.7
    },
    {
      "physical": 378,
      "label": "373",
      "source": "printed",
      "confidence": 0.7
    },
    {
      "physical": 379,
      "label": "374",
      "source": "printed",
      "confidence": 0.7
    },
    {
      "physical": 380,
      "label": "375",
      "source": "printed",
      "confidence": 0.7
    },
    {
      "physical": 381,
      "label": "376",
      "source": "printed",
      "confidence": 0.7
    },
    {
      "physical": 382,
      "label": "377",
      "source": "printed",
      "confidence": 0.7
    },
    {
      "physical": 383,
      "label": "378",
      "source": "printed",
      "confidence": 0.7
    },
    {
      "physical": 384,
      "label": "379",
      "source": "printed",
      "confidence": 0.7
    },
    {
      "physical": 385,
      "label": "380",
      "source": "printed",
      "confidence": 0.7
    },
    {
      "physical": 386,
      "label": "381",
      "source": "printed",
      "confidence": 0.7
    },
    {
      "physical": 387,
      "label": "382",
      "source": "printed",
      "confidence": 0.7
    },
    {
      "physical": 388,
      "label": "383",
      "source": "printed",
      "confidence": 0.7
    },
    {
      "physical": 389,
      "label": "384",
      "source": "printed",
      "confidence": 0.7
    },
    {
      "physical": 390,
      "label": "385",
      "source": "printed",
      "confidence": 0.7
    },
    {
      "physical": 391,
      "label": "386",
      "source": "printed",
      "confidence": 0.7
    },
    {
      "physical": 392,
      "label": "387",
      "source": "printed",
      "confidence": 0.7
    },
    {
      "physical": 393,
      "label": "388",
      "source": "printed",
      "confidence": 0.7
    },
    {
      "physical": 394,
      "label": "389",
      "source": "printed",
      "confidence": 0.7
    },
    {
      "physical": 395,
      "label": "390",
      "source": "printed",
      "confidence": 0.7
    },
    {
      "physical": 396,
      "label": "391",
      "source": "printed",
      "confidence": 0.7
    },
    {
      "physical": 397,
      "label": "392",
      "source": "printed",
      "confidence": 0.7
    },
    {
      "physical": 398,
      "label": "393",
      "source": "printed",
      "confidence": 0.7
    },
    {
      "physical": 399,
      "label": "394",
      "source": "printed",
      "confidence": 0.7
    },
    {
      "physical": 400,
      "label": "395",
      "source": "printed",
      "confidence": 0.7
    },
    {
      "physical": 401,
      "label": "396",
      "source": "printed",
      "confidence": 0.7
    },
    {
      "physical": 402,
      "label": "397",
      "source": "printed",
      "confidence": 0.7
    },
    {
      "physical": 403,
      "label": "398",
      "source": "printed",
      "confidence": 0.7
    },
    {
      "physical": 404,
      "label": "399",
      "source": "printed",
      "confidence": 0.7
    },
    {
      "physical": 405,
      "label": "400",
      "source": "printed",
      "confidence": 0.7
    },
    {
      "physical": 406,
      "label": "401",
      "source": "printed",
      "confidence": 0.7
    },
    {
      "physical": 407,
      "label": "402",
      "source": "printed",
      "confidence": 0.7
    },
    {
      "physical": 408,
      "label": "403",
      "source": "printed",
      "confidence": 0.7
    },
    {
      "physical": 409,
      "label": "404",
      "source": "printed",
      "confidence": 0.7
    },
    {
      "physical": 410,
      "label": "405",
      "source": "printed",
      "confidence": 0.7
    },
    {
      "physical": 411,
      "label": "406",
      "source": "printed",
      "confidence": 0.7
    },
    {
      "physical": 412,
      "label": "407",
      "source": "printed",
      "confidence": 0.7
    },
    {
      "physical": 413,
      "label": "408",
      "source": "printed",
      "confidence": 0.7
    },
    {
      "physical": 414,
      "label": "409",
      "source": "printed",
      "confidence": 0.7
    },
    {
      "physical": 415,
      "label": "410",
      "source": "printed",
      "confidence": 0.7
    },
    {
      "physical": 416,
      "label": "411",
      "source": "printed",
      "confidence": 0.7
    },
    {
      "physical": 417,
      "label": "412",
      "source": "printed",
      "confidence": 0.7
    },
    {
      "physical": 418,
      "label": "413",
      "source": "printed",
      "confidence": 0.7
    },
    {
      "physical": 419,
      "label": "414",
      "source": "printed",
      "confidence": 0.7
    },
    {
      "physical": 420,
      "label": "415",
      "source": "printed",
      "confidence": 0.7
    },
    {
      "physical": 421,
      "label": "416",
      "source": "printed",
      "confidence": 0.7
    },
    {
      "physical": 422,
      "label": "417",
      "source": "printed",
      "confidence": 0.7
    },
    {
      "physical": 423,
      "label": "418",
      "source": "printed",
      "confidence": 0.7
    },
    {
      "physical": 424,
      "label": "419",
      "source": "printed",
      "confidence": 0.7
    },
    {
      "physical": 425,
      "label": "420",
      "source": "printed",
      "confidence": 0.7
    },
    {
      "physical": 426,
      "label": "421",
      "source": "printed",
      "confidence": 0.7
    },
    {
      "physical": 427,
      "label": "422",
      "source": "printed",
      "confidence": 0.7
    },
    {
      "physical": 428,
      "label": "423",
      "source": "printed",
      "confidence": 0.7
    },
    {
      "physical": 429,
      "label": "424",
      "source": "printed",
      "confidence": 0.7
    },
    {
      "physical": 430,
      "label": "425",
      "source": "printed",
      "confidence": 0.7
    },
    {
      "physical": 431,
      "label": "426",
      "source": "printed",
      "confidence": 0.7
    },
    {
      "physical": 432,
      "label": "427",
      "source": "printed",
      "confidence": 0.7
    },
    {
      "physical": 433,
      "label": "428",
      "source": "printed",
      "confidence": 0.7
    },
    {
      "physical": 434,
      "label": "429",
      "source": "printed",
      "confidence": 0.7
    },
    {
      "physical": 435,
      "label": "430",
      "source": "printed",
      "confidence": 0.7
    },
    {
      "physical": 436,
      "label": "431",
      "source": "printed",
      "confidence": 0.7
    },
    {
      "physical": 437,
      "label": "432",
      "source": "printed",
      "confidence": 0.7
    },
    {
      "physical": 438,
      "label": "433",
      "source": "printed",
      "confidence": 0.7
    },
    {
      "physical": 439,
      "label": "434",
      "source": "printed",
      "confidence": 0.7
    },
    {
      "physical": 440,
      "label": "435",
      "source": "printed",
      "confidence": 0.7
    },
    {
      "physical": 441,
      "label": "436",
      "source": "printed",
      "confidence": 0.7
    },
    {
      "physical": 442,
      "label": "437",
      "source": "printed",
      "confidence": 0.7
    },
    {
      "physical": 443,
      "label": "438",
      "source": "printed",
      "confidence": 0.7
    },
    {
      "physical": 444,
      "label": "439",
      "source": "printed",
      "confidence": 0.7
    },
    {
      "physical": 445,
      "label": "440",
      "source": "printed",
      "confidence": 0.7
    },
    {
      "physical": 446,
      "label": "441",
      "source": "printed",
      "confidence": 0.7
    },
    {
      "physical": 447,
      "label": "442",
      "source": "printed",
      "confidence": 0.7
    },
    {
      "physical": 448,
      "label": "443",
      "source": "printed",
      "confidence": 0.7
    },
    {
      "physical": 449,
      "label": "444",
      "source": "printed",
      "confidence": 0.7
    },
    {
      "physical": 450,
      "label": "445",
      "source": "printed",
      "confidence": 0.7
    },
    {
      "physical": 451,
      "label": "446",
      "source": "printed",
      "confidence": 0.7
    },
    {
      "physical": 452,
      "label": "447",
      "source": "printed",
      "confidence": 0.7
    },
    {
      "physical": 453,
      "label": "448",
      "source": "printed",
      "confidence": 0.7
    },
    {
      "physical": 454,
      "label": "449",
      "source": "printed",
      "confidence": 0.7
    },
    {
      "physical": 455,
      "label": "450",
      "source": "printed",
      "confidence": 0.7
    },
    {
      "physical": 456,
      "label": "451",
      "source": "printed",
      "confidence": 0.7
    },
    {
      "physical": 457,
      "label": "452",
      "source": "printed",
      "confidence": 0.7
    },
    {
      "physical": 458,
      "label": "453",
      "source": "printed",
      "confidence": 0.7
    },
    {
      "physical": 459,
      "label": "454",
      "source": "printed",
      "confidence": 0.7
    },
    {
      "physical": 460,
      "label": "455",
      "source": "printed",
      "confidence": 0.7
    },
    {
      "physical": 461,
      "label": "456",
      "source": "printed",
      "confidence": 0.7
    },
    {
      "physical": 462,
      "label": "457",
      "source": "printed",
      "confidence": 0.7
    },
    {
      "physical": 463,
      "label": "458",
      "source": "printed",
      "confidence": 0.7
    },
    {
      "physical": 464,
      "label": "459",
      "source": "printed",
      "confidence": 0.7
    },
    {
      "physical": 465,
      "label": "460",
      "source": "printed",
      "confidence": 0.7
    },
    {
      "physical": 466,
      "label": "461",
      "source": "printed",
      "confidence": 0.7
    },
    {
      "physical": 467,
      "label": "462",
      "source": "printed",
      "confidence": 0.7
    },
    {
      "physical": 468,
      "label": "463",
      "source": "printed",
      "confidence": 0.7
    },
    {
      "physical": 469,
      "label": "464",
      "source": "printed",
      "confidence": 0.7
    },
    {
      "physical": 470,
      "label": "465",
      "source": "printed",
      "confidence": 0.7
    },
    {
      "physical": 471,
      "label": "466",
      "source": "printed",
      "confidence": 0.7
    },
    {
      "physical": 472,
      "label": "467",
      "source": "printed",
      "confidence": 0.7
    },
    {
      "physical": 473,
      "label": "468",
      "source": "printed",
      "confidence": 0.7
    },
    {
      "physical": 474,
      "label": "469",
      "source": "printed",
      "confidence": 0.7
    },
    {
      "physical": 475,
      "label": "470",
      "source": "printed",
      "confidence": 0.7
    },
    {
      "physical": 476,
      "label": "471",
      "source": "printed",
      "confidence": 0.7
    },
    {
      "physical": 477,
      "label": "472",
      "source": "printed",
      "confidence": 0.7
    },
    {
      "physical": 478,
      "label": "473",
      "source": "printed",
      "confidence": 0.7
    },
    {
      "physical": 479,
      "label": "474",
      "source": "printed",
      "confidence": 0.7
    },
    {
      "physical": 480,
      "label": "475",
      "source": "printed",
      "confidence": 0.7
    },
    {
      "physical": 481,
      "label": "476",
      "source": "printed",
      "confidence": 0.7
    },
    {
      "physical": 482,
      "label": "477",
      "source": "printed",
      "confidence": 0.7
    },
    {
      "physical": 483,
      "label": "478",
      "source": "printed",
      "confidence": 0.7
    },
    {
      "physical": 484,
      "label": "479",
      "source": "printed",
      "confidence": 0.7
    },
    {
      "physical": 485,
      "label": "480",
      "source": "printed",
      "confidence": 0.7
    },
    {
      "physical": 486,
      "label": "481",
      "source": "printed",
      "confidence": 0.7
    },
    {
      "physical": 487,
      "label": "482",
      "source": "printed",
      "confidence": 0.7
    },
    {
      "physical": 488,
      "label": "483",
      "source": "printed",
      "confidence": 0.7
    },
    {
      "physical": 489,
      "label": "484",
      "source": "printed",
      "confidence": 0.7
    },
    {
      "physical": 490,
      "label": "485",
      "source": "printed",
      "confidence": 0.7
    },
    {
      "physical": 491,
      "label": "486",
      "source": "printed",
      "confidence": 0.7
    },
    {
      "physical": 492,
      "label": "487",
      "source": "printed",
      "confidence": 0.7
    },
    {
      "physical": 493,
      "label": "488",
      "source": "printed",
      "confidence": 0.7
    },
    {
      "physical": 494,
      "label": "489",
      "source": "printed",
      "confidence": 0.7
    },
    {
      "physical": 495,
      "label": "490",
      "source": "printed",
      "confidence": 0.7
    },
    {
      "physical": 496,
      "label": "491",
      "source": "printed",
      "confidence": 0.7
    },
    {
      "physical": 497,
      "label": "492",
      "source": "printed",
      "confidence": 0.7
    },
    {
      "physical": 498,
      "label": "493",
      "source": "printed",
      "confidence": 0.7
    },
    {
      "physical": 499,
      "label": "494",
      "source": "printed",
      "confidence": 0.7
    },
    {
      "physical": 500,
      "label": "495",
      "source": "printed",
      "confidence": 0.7
    },
    {
      "physical": 501,
      "label": "496",
      "source": "printed",
      "confidence": 0.7
    },
    {
      "physical": 502,
      "label": "497",
      "source": "printed",
      "confidence": 0.7
    },
    {
      "physical": 503,
      "label": "498",
      "source": "printed",
      "confidence": 0.7
    },
    {
      "physical": 504,
      "label": "499",
      "source": "printed",
      "confidence": 0.7
    },
    {
      "physical": 505,
      "label": "500",
      "source": "printed",
      "confidence": 0.7
    },
    {
      "physical": 506,
      "label": "501",
      "source": "printed",
      "confidence": 0.7
    },
    {
      "physical": 507,
      "label": "502",
      "source": "printed",
      "confidence": 0.7
    },
    {
      "physical": 508,
      "label": "503",
      "source": "printed",
      "confidence": 0.7
    },
    {
      "physical": 509,
      "label": "504",
      "source": "printed",
      "confidence": 0.7
    },
    {
      "physical": 510,
      "label": "505",
      "source": "printed",
      "confidence": 0.7
    },
    {
      "physical": 511,
      "label": "506",
      "source": "printed",
      "confidence": 0.7
    },
    {
      "physical": 512,
      "label": "507",
      "source": "printed",
      "confidence": 0.7
    },
    {
      "physical": 513,
      "label": "508",
      "source": "printed",
      "confidence": 0.7
    },
    {
      "physical": 514,
      "label": "509",
      "source": "printed",
      "confidence": 0.7
    },
    {
      "physical": 515,
      "label": "510",
      "source": "printed",
      "confidence": 0.7
    },
    {
      "physical": 516,
      "label": "511",
      "source": "printed",
      "confidence": 0.7
    },
    {
      "physical": 517,
      "label": "512",
      "source": "printed",
      "confidence": 0.7
    },
    {
      "physical": 518,
      "label": "513",
      "source": "printed",
      "confidence": 0.7
    },
    {
      "physical": 519,
      "label": "514",
      "source": "printed",
      "confidence": 0.7
    },
    {
      "physical": 520,
      "label": "515",
      "source": "printed",
      "confidence": 0.7
    },
    {
      "physical": 521,
      "label": "516",
      "source": "printed",
      "confidence": 0.7
    },
    {
      "physical": 522,
      "label": "517",
      "source": "printed",
      "confidence": 0.7
    },
    {
      "physical": 523,
      "label": "518",
      "source": "printed",
      "confidence": 0.7
    },
    {
      "physical": 524,
      "label": "519",
      "source": "printed",
      "confidence": 0.7
    },
    {
      "physical": 525,
      "label": "520",
      "source": "printed",
      "confidence": 0.7
    },
    {
      "physical": 526,
      "label": "521",
      "source": "printed",
      "confidence": 0.7
    },
    {
      "physical": 527,
      "label": "522",
      "source": "printed",
      "confidence": 0.7
    },
    {
      "physical": 528,
      "label": "523",
      "source": "printed",
      "confidence": 0.7
    },
    {
      "physical": 529,
      "label": "524",
      "source": "printed",
      "confidence": 0.7
    },
    {
      "physical": 530,
      "label": "525",
      "source": "printed",
      "confidence": 0.7
    },
    {
      "physical": 531,
      "label": "526",
      "source": "printed",
      "confidence": 0.7
    },
    {
      "physical": 532,
      "label": "527",
      "source": "printed",
      "confidence": 0.7
    },
    {
      "physical": 533,
      "label": "528",
      "source": "printed",
      "confidence": 0.7
    },
    {
      "physical": 534,
      "label": "529",
      "source": "printed",
      "confidence": 0.7
    },
    {
      "physical": 535,
      "label": "530",
      "source": "printed",
      "confidence": 0.7
    },
    {
      "physical": 536,
      "label": "531",
      "source": "printed",
      "confidence": 0.7
    },
    {
      "physical": 537,
      "label": "532",
      "source": "printed",
      "confidence": 0.7
    },
    {
      "physical": 538,
      "label": "533",
      "source": "printed",
      "confidence": 0.7
    },
    {
      "physical": 539,
      "label": "534",
      "source": "printed",
      "confidence": 0.7
    },
    {
      "physical": 540,
      "label": "535",
      "source": "printed",
      "confidence": 0.7
    },
    {
      "physical": 541,
      "label": "536",
      "source": "printed",
      "confidence": 0.7
    },
    {
      "physical": 542,
      "label": "537",
      "source": "printed",
      "confidence": 0.7
    },
    {
      "physical": 543,
      "label": "538",
      "source": "printed",
      "confidence": 0.7
    },
    {
      "physical": 544,
      "label": "539",
      "source": "printed",
      "confidence": 0.7
    },
    {
      "physical": 545,
      "label": "540",
      "source": "printed",
      "confidence": 0.7
    },
    {
      "physical": 546,
      "label": "541",
      "source": "printed",
      "confidence": 0.7
    },
    {
      "physical": 547,
      "label": "542",
      "source": "printed",
      "confidence": 0.7
    },
    {
      "physical": 548,
      "label": "543",
      "source": "printed",
      "confidence": 0.7
    },
    {
      "physical": 549,
      "label": "544",
      "source": "printed",
      "confidence": 0.7
    },
    {
      "physical": 550,
      "label": "545",
      "source": "printed",
      "confidence": 0.7
    },
    {
      "physical": 551,
      "label": "546",
      "source": "printed",
      "confidence": 0.7
    },
    {
      "physical": 552,
      "label": "547",
      "source": "printed",
      "confidence": 0.7
    },
    {
      "physical": 553,
      "label": "548",
      "source": "printed",
      "confidence": 0.7
    },
    {
      "physical": 554,
      "label": "549",
      "source": "printed",
      "confidence": 0.7
    },
    {
      "physical": 555,
      "label": "550",
      "source": "printed",
      "confidence": 0.7
    },
    {
      "physical": 556,
      "label": "551",
      "source": "printed",
      "confidence": 0.7
    },
    {
      "physical": 557,
      "label": "552",
      "source": "printed",
      "confidence": 0.7
    },
    {
      "physical": 558,
      "label": "553",
      "source": "printed",
      "confidence": 0.7
    },
    {
      "physical": 559,
      "label": "554",
      "source": "printed",
      "confidence": 0.7
    },
    {
      "physical": 560,
      "label": "555",
      "source": "printed",
      "confidence": 0.7
    },
    {
      "physical": 561,
      "label": "556",
      "source": "printed",
      "confidence": 0.7
    },
    {
      "physical": 562,
      "label": "557",
      "source": "printed",
      "confidence": 0.7
    },
    {
      "physical": 563,
      "label": "558",
      "source": "printed",
      "confidence": 0.7
    },
    {
      "physical": 564,
      "label": "559",
      "source": "printed",
      "confidence": 0.7
    },
    {
      "physical": 565,
      "label": "560",
      "source": "printed",
      "confidence": 0.7
    },
    {
      "physical": 566,
      "label": "561",
      "source": "printed",
      "confidence": 0.7
    },
    {
      "physical": 567,
      "label": "562",
      "source": "printed",
      "confidence": 0.7
    },
    {
      "physical": 568,
      "label": "563",
      "source": "printed",
      "confidence": 0.7
    },
    {
      "physical": 569,
      "label": "564",
      "source": "printed",
      "confidence": 0.7
    },
    {
      "physical": 570,
      "label": "565",
      "source": "printed",
      "confidence": 0.7
    },
    {
      "physical": 571,
      "label": "566",
      "source": "printed",
      "confidence": 0.7
    },
    {
      "physical": 572,
      "label": "567",
      "source": "printed",
      "confidence": 0.7
    },
    {
      "physical": 573,
      "label": "568",
      "source": "printed",
      "confidence": 0.7
    },
    {
      "physical": 574,
      "label": "569",
      "source": "printed",
      "confidence": 0.7
    },
    {
      "physical": 575,
      "label": "570",
      "source": "printed",
      "confidence": 0.7
    },
    {
      "physical": 576,
      "label": "571",
      "source": "printed",
      "confidence": 0.7
    },
    {
      "physical": 577,
      "label": "572",
      "source": "printed",
      "confidence": 0.7
    },
    {
      "physical": 578,
      "label": "573",
      "source": "printed",
      "confidence": 0.7
    },
    {
      "physical": 579,
      "label": "574",
      "source": "printed",
      "confidence": 0.7
    },
    {
      "physical": 580,
      "label": "575",
      "source": "interpolated",
      "confidence": 0.5
    },
    {
      "physical": 581,
      "label": "576",
      "source": "printed",
      "confidence": 0.7
    },
    {
      "physical": 582,
      "label": "577",
      "source": "printed",
      "confidence": 0.7
    },
    {
      "physical": 583,
      "label": "578",
      "source": "printed",
      "confidence": 0.7
    },
    {
      "physical": 584,
      "label": "579",
      "source": "printed",
      "confidence": 0.7
    },
    {
      "physical": 585,
      "label": "580",
      "source": "printed",
      "confidence": 0.7
    },
    {
      "physical": 586,
      "label": "581",
      "source": "printed",
      "confidence": 0.7
    },
    {
      "physical": 587,
      "label": "582",
      "source": "printed",
      "confidence": 0.7
    },
    {
      "physical": 588,
      "label": "583",
      "source": "printed",
      "confidence": 0.7
    },
    {
      "physical": 589,
      "label": "584",
      "source": "interpolated",
      "confidence": 0.5
    },
    {
      "physical": 590,
      "label": "585",
      "source": "interpolated",
      "confidence": 0.5
    },
    {
      "physical": 591,
      "label": "586",
      "source": "printed",
      "confidence": 0.7
    },
    {
      "physical": 592,
      "label": "587",
      "source": "printed",
      "confidence": 0.7
    },
    {
      "physical": 593,
      "label": "588",
      "source": "printed",
      "confidence": 0.7
    },
    {
      "physical": 594,
      "label": "589",
      "source": "printed",
      "confidence": 0.7
    },
    {
      "physical": 595,
      "label": "590",
      "source": "printed",
      "confidence": 0.7
    },
    {
      "physical": 596,
      "label": "591",
      "source": "printed",
      "confidence": 0.7
    },
    {
      "physical": 597,
      "label": "592",
      "source": "printed",
      "confidence": 0.7
    },
    {
      "physical": 598,
      "label": "593",
      "source": "printed",
      "confidence": 0.7
    },
    {
      "physical": 599,
      "label": "594",
      "source": "printed",
      "confidence": 0.7
    },
    {
      "physical": 600,
      "label": "595",
      "source": "printed",
      "confidence": 0.7
    },
    {
      "physical": 601,
      "label": "596",
      "source": "printed",
      "confidence": 0.7
    },
    {
      "physical": 602,
      "label": "597",
      "source": "printed",
      "confidence": 0.7
    },
    {
      "physical": 603,
      "label": "598",
      "source": "printed",
      "confidence": 0.7
    },
    {
      "physical": 604,
      "label": "599",
      "source": "printed",
      "confidence": 0.7
    },
    {
      "physical": 605,
      "label": "600",
      "source": "printed",
      "confidence": 0.7
    },
    {
      "physical": 606,
      "label": "601",
      "source": "printed",
      "confidence": 0.7
    },
    {
      "physical": 607,
      "label": "602",
      "source": "printed",
      "confidence": 0.7
    },
    {
      "physical": 608,
      "label": "603",
      "source": "printed",
      "confidence": 0.7
    },
    {
      "physical": 609,
      "label": "604",
      "source": "printed",
      "confidence": 0.7
    },
    {
      "physical": 610,
      "label": "605",
      "source": "printed",
      "confidence": 0.7
    },
    {
      "physical": 611,
      "label": "606",
      "source": "printed",
      "confidence": 0.7
    },
    {
      "physical": 612,
      "label": "607",
      "source": "printed",
      "confidence": 0.7
    },
    {
      "physical": 613,
      "label": "608",
      "source": "printed",
      "confidence": 0.7
    },
    {
      "physical": 614,
      "label": "609",
      "source": "printed",
      "confidence": 0.7
    },
    {
      "physical": 615,
      "label": "610",
      "source": "printed",
      "confidence": 0.7
    },
    {
      "physical": 616,
      "label": "611",
      "source": "printed",
      "confidence": 0.7
    },
    {
      "physical": 617,
      "label": "612",
      "source": "printed",
      "confidence": 0.7
    },
    {
      "physical": 618,
      "label": "613",
      "source": "printed",
      "confidence": 0.7
    },
    {
      "physical": 619,
      "label": "614",
      "source": "printed",
      "confidence": 0.7
    },
    {
      "physical": 620,
      "label": "615",
      "source": "printed",
      "confidence": 0.7
    },
    {
      "physical": 621,
      "label": "616",
      "source": "printed",
      "confidence": 0.7
    },
    {
      "physical": 622,
      "label": "617",
      "source": "printed",
      "confidence": 0.7
    },
    {
      "physical": 623,
      "label": "618",
      "source": "printed",
      "confidence": 0.7
    },
    {
      "physical": 624,
      "label": "619",
      "source": "printed",
      "confidence": 0.7
    },
    {
      "physical": 625,
      "label": "620",
      "source": "printed",
      "confidence": 0.7
    },
    {
      "physical": 626,
      "label": "621",
      "source": "printed",
      "confidence": 0.7
    },
    {
      "physical": 627,
      "label": "622",
      "source": "printed",
      "confidence": 0.7
    },
    {
      "physical": 628,
      "label": "623",
      "source": "printed",
      "confidence": 0.7
    },
    {
      "physical": 629,
      "label": "624",
      "source": "printed",
      "confidence": 0.7
    },
    {
      "physical": 630,
      "label": "625",
      "source": "printed",
      "confidence": 0.7
    },
    {
      "physical": 631,
      "label": "626",
      "source": "printed",
      "confidence": 0.7
    },
    {
      "physical": 632,
      "label": "627",
      "source": "printed",
      "confidence": 0.7
    },
    {
      "physical": 633,
      "label": "628",
      "source": "printed",
      "confidence": 0.7
    },
    {
      "physical": 634,
      "label": "629",
      "source": "printed",
      "confidence": 0.7
    },
    {
      "physical": 635,
      "label": "630",
      "source": "printed",
      "confidence": 0.7
    },
    {
      "physical": 636,
      "label": "631",
      "source": "printed",
      "confidence": 0.7
    },
    {
      "physical": 637,
      "label": "632",
      "source": "printed",
      "confidence": 0.7
    },
    {
      "physical": 638,
      "label": "633",
      "source": "printed",
      "confidence": 0.7
    },
    {
      "physical": 639,
      "label": "634",
      "source": "printed",
      "confidence": 0.7
    },
    {
      "physical": 640,
      "label": "635",
      "source": "printed",
      "confidence": 0.7
    },
    {
      "physical": 641,
      "label": "636",
      "source": "printed",
      "confidence": 0.7
    },
    {
      "physical": 642,
      "label": "637",
      "source": "printed",
      "confidence": 0.7
    },
    {
      "physical": 643,
      "label": "638",
      "source": "printed",
      "confidence": 0.7
    },
    {
      "physical": 644,
      "label": "639",
      "source": "printed",
      "confidence": 0.7
    },
    {
      "physical": 645,
      "label": "640",
      "source": "printed",
      "confidence": 0.7
    },
    {
      "physical": 646,
      "label": "641",
      "source": "printed",
      "confidence": 0.7
    },
    {
      "physical": 647,
      "label": "642",
      "source": "printed",
      "confidence": 0.7
    },
    {
      "physical": 648,
      "label": "643",
      "source": "printed",
      "confidence": 0.7
    },
    {
      "physical": 649,
      "label": "644",
      "source": "printed",
      "confidence": 0.7
    },
    {
      "physical": 650,
      "label": "645",
      "source": "printed",
      "confidence": 0.7
    },
    {
      "physical": 651,
      "label": "646",
      "source": "printed",
      "confidence": 0.7
    },
    {
      "physical": 652,
      "label": "647",
      "source": "printed",
      "confidence": 0.7
    },
    {
      "physical": 653,
      "label": "648",
      "source": "printed",
      "confidence": 0.7
    },
    {
      "physical": 654,
      "label": "649",
      "source": "printed",
      "confidence": 0.7
    },
    {
      "physical": 655,
      "label": "650",
      "source": "printed",
      "confidence": 0.7
    },
    {
      "physical": 656,
      "label": "651",
      "source": "printed",
      "confidence": 0.7
    },
    {
      "physical": 657,
      "label": "652",
      "source": "printed",
      "confidence": 0.7
    },
    {
      "physical": 658,
      "label": "653",
      "source": "printed",
      "confidence": 0.7
    },
    {
      "physical": 659,
      "label": "654",
      "source": "printed",
      "confidence": 0.7
    },
    {
      "physical": 660,
      "label": "655",
      "source": "printed",
      "confidence": 0.7
    },
    {
      "physical": 661,
      "label": "656",
      "source": "printed",
      "confidence": 0.7
    },
    {
      "physical": 662,
      "label": "657",
      "source": "printed",
      "confidence": 0.7
    },
    {
      "physical": 663,
      "label": "658",
      "source": "printed",
      "confidence": 0.7
    },
    {
      "physical": 664,
      "label": "659",
      "source": "printed",
      "confidence": 0.7
    },
    {
      "physical": 665,
      "label": "660",
      "source": "printed",
      "confidence": 0.7
    },
    {
      "physical": 666,
      "label": "661",
      "source": "printed",
      "confidence": 0.7
    },
    {
      "physical": 667,
      "label": "662",
      "source": "printed",
      "confidence": 0.7
    },
    {
      "physical": 668,
      "label": "663",
      "source": "printed",
      "confidence": 0.7
    },
    {
      "physical": 669,
      "label": "664",
      "source": "printed",
      "confidence": 0.7
    },
    {
      "physical": 670,
      "label": "665",
      "source": "printed",
      "confidence": 0.7
    },
    {
      "physical": 671,
      "label": "666",
      "source": "printed",
      "confidence": 0.7
    },
    {
      "physical": 672,
      "label": "667",
      "source": "printed",
      "confidence": 0.7
    },
    {
      "physical": 673,
      "label": "668",
      "source": "printed",
      "confidence": 0.7
    },
    {
      "physical": 674,
      "label": "669",
      "source": "printed",
      "confidence": 0.7
    },
    {
      "physical": 675,
      "label": "670",
      "source": "printed",
      "confidence": 0.7
    },
    {
      "physical": 676,
      "label": "671",
      "source": "printed",
      "confidence": 0.7
    },
    {
      "physical": 677,
      "label": "672",
      "source": "printed",
      "confidence": 0.7
    },
    {
      "physical": 678,
      "label": "673",
      "source": "printed",
      "confidence": 0.7
    },
    {
      "physical": 679,
      "label": "674",
      "source": "printed",
      "confidence": 0.7
    },
    {
      "physical": 680,
      "label": "675",
      "source": "printed",
      "confidence": 0.7
    },
    {
      "physical": 681,
      "label": "676",
      "source": "printed",
      "confidence": 0.7
    },
    {
      "physical": 682,
      "label": "677",
      "source": "printed",
      "confidence": 0.7
    },
    {
      "physical": 683,
      "label": "678",
      "source": "printed",
      "confidence": 0.7
    },
    {
      "physical": 684,
      "label": "679",
      "source": "printed",
      "confidence": 0.7
    },
    {
      "physical": 685,
      "label": "680",
      "source": "printed",
      "confidence": 0.7
    },
    {
      "physical": 686,
      "label": "681",
      "source": "printed",
      "confidence": 0.7
    },
    {
      "physical": 687,
      "label": "682",
      "source": "printed",
      "confidence": 0.7
    },
    {
      "physical": 688,
      "label": "683",
      "source": "printed",
      "confidence": 0.7
    },
    {
      "physical": 689,
      "label": "684",
      "source": "printed",
      "confidence": 0.7
    },
    {
      "physical": 690,
      "label": "685",
      "source": "printed",
      "confidence": 0.7
    },
    {
      "physical": 691,
      "label": "686",
      "source": "printed",
      "confidence": 0.7
    },
    {
      "physical": 692,
      "label": "687",
      "source": "printed",
      "confidence": 0.7
    },
    {
      "physical": 693,
      "label": "688",
      "source": "printed",
      "confidence": 0.7
    },
    {
      "physical": 694,
      "label": "689",
      "source": "printed",
      "confidence": 0.7
    },
    {
      "physical": 695,
      "label": "690",
      "source": "printed",
      "confidence": 0.7
    },
    {
      "physical": 696,
      "label": "691",
      "source": "printed",
      "confidence": 0.7
    },
    {
      "physical": 697,
      "label": "692",
      "source": "printed",
      "confidence": 0.7
    },
    {
      "physical": 698,
      "label": "693",
      "source": "printed",
      "confidence": 0.7
    },
    {
      "physical": 699,
      "label": "694",
      "source": "printed",
      "confidence": 0.7
    },
    {
      "physical": 700,
      "label": "695",
      "source": "printed",
      "confidence": 0.7
    },
    {
      "physical": 701,
      "label": "696",
      "source": "printed",
      "confidence": 0.7
    },
    {
      "physical": 702,
      "label": "697",
      "source": "printed",
      "confidence": 0.7
    },
    {
      "physical": 703,
      "label": "698",
      "source": "printed",
      "confidence": 0.7
    },
    {
      "physical": 704,
      "label": "699",
      "source": "printed",
      "confidence": 0.7
    },
    {
      "physical": 705,
      "label": "700",
      "source": "printed",
      "confidence": 0.7
    },
    {
      "physical": 706,
      "label": "701",
      "source": "printed",
      "confidence": 0.7
    },
    {
      "physical": 707,
      "label": "702",
      "source": "printed",
      "confidence": 0.7
    },
    {
      "physical": 708,
      "label": "703",
      "source": "printed",
      "confidence": 0.7
    },
    {
      "physical": 709,
      "label": "704",
      "source": "printed",
      "confidence": 0.7
    },
    {
      "physical": 710,
      "label": "705",
      "source": "printed",
      "confidence": 0.7
    },
    {
      "physical": 711,
      "label": "706",
      "source": "printed",
      "confidence": 0.7
    },
    {
      "physical": 712,
      "label": "707",
      "source": "printed",
      "confidence": 0.7
    },
    {
      "physical": 713,
      "label": "708",
      "source": "printed",
      "confidence": 0.7
    },
    {
      "physical": 714,
      "label": "709",
      "source": "printed",
      "confidence": 0.7
    },
    {
      "physical": 715,
      "label": "710",
      "source": "printed",
      "confidence": 0.7
    },
    {
      "physical": 716,
      "label": "711",
      "source": "printed",
      "confidence": 0.7
    },
    {
      "physical": 717,
      "label": "712",
      "source": "printed",
      "confidence": 0.7
    },
    {
      "physical": 718,
      "label": "713",
      "source": "printed",
      "confidence": 0.7
    },
    {
      "physical": 719,
      "label": "714",
      "source": "printed",
      "confidence": 0.7
    },
    {
      "physical": 720,
      "label": "715",
      "source": "printed",
      "confidence": 0.7
    },
    {
      "physical": 721,
      "label": "716",
      "source": "printed",
      "confidence": 0.7
    },
    {
      "physical": 722,
      "label": "717",
      "source": "printed",
      "confidence": 0.7
    },
    {
      "physical": 723,
      "label": "718",
      "source": "printed",
      "confidence": 0.7
    },
    {
      "physical": 724,
      "label": "719",
      "source": "printed",
      "confidence": 0.7
    },
    {
      "physical": 725,
      "label": "720",
      "source": "printed",
      "confidence": 0.7
    },
    {
      "physical": 726,
      "label": "721",
      "source": "printed",
      "confidence": 0.7
    },
    {
      "physical": 727,
      "label": "722",
      "source": "printed",
      "confidence": 0.7
    },
    {
      "physical": 728,
      "label": "723",
      "source": "printed",
      "confidence": 0.7
    },
    {
      "physical": 729,
      "label": "724",
      "source": "printed",
      "confidence": 0.7
    },
    {
      "physical": 730,
      "label": "725",
      "source": "printed",
      "confidence": 0.7
    },
    {
      "physical": 731,
      "label": "726",
      "source": "printed",
      "confidence": 0.7
    },
    {
      "physical": 732,
      "label": "727",
      "source": "printed",
      "confidence": 0.7
    },
    {
      "physical": 733,
      "label": "728",
      "source": "printed",
      "confidence": 0.7
    },
    {
      "physical": 734,
      "label": "729",
      "source": "printed",
      "confidence": 0.7
    },
    {
      "physical": 735,
      "label": "730",
      "source": "printed",
      "confidence": 0.7
    },
    {
      "physical": 736,
      "label": "731",
      "source": "printed",
      "confidence": 0.7
    },
    {
      "physical": 737,
      "label": "732",
      "source": "printed",
      "confidence": 0.7
    },
    {
      "physical": 738,
      "label": "733",
      "source": "printed",
      "confidence": 0.7
    },
    {
      "physical": 739,
      "label": "734",
      "source": "printed",
      "confidence": 0.7
    },
    {
      "physical": 740,
      "label": "735",
      "source": "printed",
      "confidence": 0.7
    },
    {
      "physical": 741,
      "label": "736",
      "source": "printed",
      "confidence": 0.7
    },
    {
      "physical": 742,
      "label": "737",
      "source": "printed",
      "confidence": 0.7
    },
    {
      "physical": 743,
      "label": "738",
      "source": "printed",
      "confidence": 0.7
    },
    {
      "physical": 744,
      "label": "739",
      "source": "printed",
      "confidence": 0.7
    },
    {
      "physical": 745,
      "label": "740",
      "source": "printed",
      "confidence": 0.7
    },
    {
      "physical": 746,
      "label": "741",
      "source": "printed",
      "confidence": 0.7
    },
    {
      "physical": 747,
      "label": "742",
      "source": "printed",
      "confidence": 0.7
    },
    {
      "physical": 748,
      "label": "743",
      "source": "printed",
      "confidence": 0.7
    },
    {
      "physical": 749,
      "label": "744",
      "source": "printed",
      "confidence": 0.7
    },
    {
      "physical": 750,
      "label": "745",
      "source": "printed",
      "confidence": 0.7
    },
    {
      "physical": 751,
      "label": "746",
      "source": "printed",
      "confidence": 0.7
    },
    {
      "physical": 752,
      "label": "747",
      "source": "printed",
      "confidence": 0.7
    },
    {
      "physical": 753,
      "label": "748",
      "source": "printed",
      "confidence": 0.7
    },
    {
      "physical": 754,
      "label": "749",
      "source": "printed",
      "confidence": 0.7
    },
    {
      "physical": 755,
      "label": "750",
      "source": "printed",
      "confidence": 0.7
    },
    {
      "physical": 756,
      "label": "751",
      "source": "printed",
      "confidence": 0.7
    },
    {
      "physical": 757,
      "label": "752",
      "source": "printed",
      "confidence": 0.7
    },
    {
      "physical": 758,
      "label": "753",
      "source": "printed",
      "confidence": 0.7
    },
    {
      "physical": 759,
      "label": "754",
      "source": "printed",
      "confidence": 0.7
    },
    {
      "physical": 760,
      "label": "755",
      "source": "printed",
      "confidence": 0.7
    },
    {
      "physical": 761,
      "label": "756",
      "source": "printed",
      "confidence": 0.7
    },
    {
      "physical": 762,
      "label": "757",
      "source": "printed",
      "confidence": 0.7
    },
    {
      "physical": 763,
      "label": "758",
      "source": "printed",
      "confidence": 0.7
    },
    {
      "physical": 764,
      "label": "759",
      "source": "printed",
      "confidence": 0.7
    },
    {
      "physical": 765,
      "label": "760",
      "source": "printed",
      "confidence": 0.7
    },
    {
      "physical": 766,
      "label": "761",
      "source": "printed",
      "confidence": 0.7
    },
    {
      "physical": 767,
      "label": "762",
      "source": "printed",
      "confidence": 0.7
    },
    {
      "physical": 768,
      "label": "763",
      "source": "printed",
      "confidence": 0.7
    },
    {
      "physical": 769,
      "label": "764",
      "source": "printed",
      "confidence": 0.7
    },
    {
      "physical": 770,
      "label": "765",
      "source": "printed",
      "confidence": 0.7
    },
    {
      "physical": 771,
      "label": "766",
      "source": "printed",
      "confidence": 0.7
    },
    {
      "physical": 772,
      "label": "767",
      "source": "printed",
      "confidence": 0.7
    },
    {
      "physical": 773,
      "label": "768",
      "source": "printed",
      "confidence": 0.7
    },
    {
      "physical": 774,
      "label": "769",
      "source": "printed",
      "confidence": 0.7
    },
    {
      "physical": 775,
      "label": "770",
      "source": "printed",
      "confidence": 0.7
    },
    {
      "physical": 776,
      "label": "771",
      "source": "printed",
      "confidence": 0.7
    },
    {
      "physical": 777,
      "label": "772",
      "source": "printed",
      "confidence": 0.7
    },
    {
      "physical": 778,
      "label": "773",
      "source": "printed",
      "confidence": 0.7
    },
    {
      "physical": 779,
      "label": "774",
      "source": "printed",
      "confidence": 0.7
    },
    {
      "physical": 780,
      "label": "775",
      "source": "printed",
      "confidence": 0.7
    },
    {
      "physical": 781,
      "label": "776",
      "source": "printed",
      "confidence": 0.7
    },
    {
      "physical": 782,
      "label": "777",
      "source": "printed",
      "confidence": 0.7
    },
    {
      "physical": 783,
      "label": "778",
      "source": "printed",
      "confidence": 0.7
    },
    {
      "physical": 784,
      "label": "779",
      "source": "printed",
      "confidence": 0.7
    },
    {
      "physical": 785,
      "label": "780",
      "source": "printed",
      "confidence": 0.7
    },
    {
      "physical": 786,
      "label": "781",
      "source": "printed",
      "confidence": 0.7
    },
    {
      "physical": 787,
      "label": "782",
      "source": "printed",
      "confidence": 0.7
    },
    {
      "physical": 788,
      "label": "783",
      "source": "printed",
      "confidence": 0.7
    },
    {
      "physical": 789,
      "label": "784",
      "source": "printed",
      "confidence": 0.7
    },
    {
      "physical": 790,
      "label": "785",
      "source": "printed",
      "confidence": 0.7
    },
    {
      "physical": 791,
      "label": "786",
      "source": "printed",
      "confidence": 0.7
    },
    {
      "physical": 792,
      "label": "787",
      "source": "printed",
      "confidence": 0.7
    },
    {
      "physical": 793,
      "label": "788",
      "source": "printed",
      "confidence": 0.7
    },
    {
      "physical": 794,
      "label": "789",
      "source": "printed",
      "confidence": 0.7
    },
    {
      "physical": 795,
      "label": "790",
      "source": "printed",
      "confidence": 0.7
    },
    {
      "physical": 796,
      "label": "791",
      "source": "printed",
      "confidence": 0.7
    },
    {
      "physical": 797,
      "label": "792",
      "source": "printed",
      "confidence": 0.7
    },
    {
      "physical": 798,
      "label": "793",
      "source": "printed",
      "confidence": 0.7
    },
    {
      "physical": 799,
      "label": "794",
      "source": "printed",
      "confidence": 0.7
    },
    {
      "physical": 800,
      "label": "795",
      "source": "printed",
      "confidence": 0.7
    },
    {
      "physical": 801,
      "label": "796",
      "source": "printed",
      "confidence": 0.7
    },
    {
      "physical": 802,
      "label": "797",
      "source": "printed",
      "confidence": 0.7
    },
    {
      "physical": 803,
      "label": "798",
      "source": "printed",
      "confidence": 0.7
    },
    {
      "physical": 804,
      "label": "799",
      "source": "printed",
      "confidence": 0.7
    },
    {
      "physical": 805,
      "label": "800",
      "source": "printed",
      "confidence": 0.7
    },
    {
      "physical": 806,
      "label": "801",
      "source": "printed",
      "confidence": 0.7
    },
    {
      "physical": 807,
      "label": "802",
      "source": "printed",
      "confidence": 0.7
    },
    {
      "physical": 808,
      "label": "803",
      "source": "printed",
      "confidence": 0.7
    },
    {
      "physical": 809,
      "label": "804",
      "source": "printed",
      "confidence": 0.7
    },
    {
      "physical": 810,
      "label": "805",
      "source": "printed",
      "confidence": 0.7
    },
    {
      "physical": 811,
      "label": "806",
      "source": "printed",
      "confidence": 0.7
    },
    {
      "physical": 812,
      "label": "807",
      "source": "printed",
      "confidence": 0.7
    },
    {
      "physical": 813,
      "label": "808",
      "source": "printed",
      "confidence": 0.7
    },
    {
      "physical": 814,
      "label": "809",
      "source": "printed",
      "confidence": 0.7
    },
    {
      "physical": 815,
      "label": "810",
      "source": "printed",
      "confidence": 0.7
    },
    {
      "physical": 816,
      "label": "811",
      "source": "printed",
      "confidence": 0.7
    },
    {
      "physical": 817,
      "label": "812",
      "source": "printed",
      "confidence": 0.7
    },
    {
      "physical": 818,
      "label": "813",
      "source": "printed",
      "confidence": 0.7
    },
    {
      "physical": 819,
      "label": "814",
      "source": "printed",
      "confidence": 0.7
    },
    {
      "physical": 820,
      "label": "815",
      "source": "printed",
      "confidence": 0.7
    },
    {
      "physical": 821,
      "label": "816",
      "source": "printed",
      "confidence": 0.7
    },
    {
      "physical": 822,
      "label": "817",
      "source": "printed",
      "confidence": 0.7
    },
    {
      "physical": 823,
      "label": "818",
      "source": "printed",
      "confidence": 0.7
    },
    {
      "physical": 824,
      "label": "819",
      "source": "printed",
      "confidence": 0.7
    },
    {
      "physical": 825,
      "label": "820",
      "source": "printed",
      "confidence": 0.7
    },
    {
      "physical": 826,
      "label": "821",
      "source": "printed",
      "confidence": 0.7
    },
    {
      "physical": 827,
      "label": "822",
      "source": "printed",
      "confidence": 0.7
    },
    {
      "physical": 828,
      "label": "823",
      "source": "printed",
      "confidence": 0.7
    },
    {
      "physical": 829,
      "label": "824",
      "source": "printed",
      "confidence": 0.7
    },
    {
      "physical": 830,
      "label": "825",
      "source": "printed",
      "confidence": 0.7
    },
    {
      "physical": 831,
      "label": "826",
      "source": "printed",
      "confidence": 0.7
    },
    {
      "physical": 832,
      "label": "827",
      "source": "printed",
      "confidence": 0.7
    },
    {
      "physical": 833,
      "label": "828",
      "source": "printed",
      "confidence": 0.7
    },
    {
      "physical": 834,
      "label": "829",
      "source": "printed",
      "confidence": 0.7
    },
    {
      "physical": 835,
      "label": "830",
      "source": "printed",
      "confidence": 0.7
    },
    {
      "physical": 836,
      "label": "831",
      "source": "printed",
      "confidence": 0.7
    },
    {
      "physical": 837,
      "label": "832",
      "source": "printed",
      "confidence": 0.7
    },
    {
      "physical": 838,
      "label": "833",
      "source": "printed",
      "confidence": 0.7
    },
    {
      "physical": 839,
      "label": "834",
      "source": "printed",
      "confidence": 0.7
    },
    {
      "physical": 840,
      "label": "835",
      "source": "printed",
      "confidence": 0.7
    },
    {
      "physical": 841,
      "label": "836",
      "source": "printed",
      "confidence": 0.7
    },
    {
      "physical": 842,
      "label": "837",
      "source": "printed",
      "confidence": 0.7
    },
    {
      "physical": 843,
      "label": "838",
      "source": "printed",
      "confidence": 0.7
    },
    {
      "physical": 844,
      "label": "839",
      "source": "printed",
      "confidence": 0.7
    },
    {
      "physical": 845,
      "label": "840",
      "source": "printed",
      "confidence": 0.7
    },
    {
      "physical": 846,
      "label": "841",
      "source": "printed",
      "confidence": 0.7
    },
    {
      "physical": 847,
      "label": "842",
      "source": "printed",
      "confidence": 0.7
    },
    {
      "physical": 848,
      "label": "843",
      "source": "printed",
      "confidence": 0.7
    },
    {
      "physical": 849,
      "label": "844",
      "source": "printed",
      "confidence": 0.7
    },
    {
      "physical": 850,
      "label": "845",
      "source": "printed",
      "confidence": 0.7
    },
    {
      "physical": 851,
      "label": "846",
      "source": "printed",
      "confidence": 0.7
    },
    {
      "physical": 852,
      "label": "847",
      "source": "printed",
      "confidence": 0.7
    },
    {
      "physical": 853,
      "label": "848",
      "source": "printed",
      "confidence": 0.7
    },
    {
      "physical": 854,
      "label": "849",
      "source": "printed",
      "confidence": 0.7
    },
    {
      "physical": 855,
      "label": "850",
      "source": "printed",
      "confidence": 0.7
    },
    {
      "physical": 856,
      "label": "851",
      "source": "printed",
      "confidence": 0.7
    },
    {
      "physical": 857,
      "label": "852",
      "source": "printed",
      "confidence": 0.7
    },
    {
      "physical": 858,
      "label": "853",
      "source": "printed",
      "confidence": 0.7
    },
    {
      "physical": 859,
      "label": "854",
      "source": "printed",
      "confidence": 0.7
    },
    {
      "physical": 860,
      "label": "855",
      "source": "printed",
      "confidence": 0.7
    },
    {
      "physical": 861,
      "label": "856",
      "source": "printed",
      "confidence": 0.7
    },
    {
      "physical": 862,
      "label": "857",
      "source": "printed",
      "confidence": 0.7
    },
    {
      "physical": 863,
      "label": null,
      "source": null,
      "confidence": 0
    },
    {
      "physical": 864,
      "label": null,
      "source": null,
      "confidence": 0
    },
    {
      "physical": 865,
      "label": null,
      "source": null,
      "confidence": 0
    },
    {
      "physical": 866,
      "label": null,
      "source": null,
      "confidence": 0
    },
    {
      "physical": 867,
      "label": null,
      "source": null,
      "confidence": 0
    },
    {
      "physical": 868,
      "label": null,
      "source": null,
      "confidence": 0
    },
    {
      "physical": 869,
      "label": null,
      "source": null,
      "confidence": 0
    },
    {
      "physical": 870,
      "label": null,
      "source": null,
      "confidence": 0
    },
    {
      "physical": 871,
      "label": null,
      "source": null,
      "confidence": 0
    },
    {
      "physical": 872,
      "label": null,
      "source": null,
      "confidence": 0
    },
    {
      "physical": 873,
      "label": null,
      "source": null,
      "confidence": 0
    },
    {
      "physical": 874,
      "label": null,
      "source": null,
      "confidence": 0
    },
    {
      "physical": 875,
      "label": null,
      "source": null,
      "confidence": 0
    },
    {
      "physical": 876,
      "label": null,
      "source": null,
      "confidence": 0
    },
    {
      "physical": 877,
      "label": null,
      "source": null,
      "confidence": 0
    },
    {
      "physical": 878,
      "label": null,
      "source": null,
      "confidence": 0
    },
    {
      "physical": 879,
      "label": null,
      "source": null,
      "confidence": 0
    },
    {
      "physical": 880,
      "label": null,
      "source": null,
      "confidence": 0
    },
    {
      "physical": 881,
      "label": null,
      "source": null,
      "confidence": 0
    },
    {
      "physical": 882,
      "label": null,
      "source": null,
      "confidence": 0
    },
    {
      "physical": 883,
      "label": null,
      "source": null,
      "confidence": 0
    },
    {
      "physical": 884,
      "label": null,
      "source": null,
      "confidence": 0
    },
    {
      "physical": 885,
      "label": "22",
      "source": "printed",
      "confidence": 0.7
    },
    {
      "physical": 886,
      "label": "23",
      "source": "printed",
      "confidence": 0.7
    },
    {
      "physical": 887,
      "label": "24",
      "source": "printed",
      "confidence": 0.7
    },
    {
      "physical": 888,
      "label": "25",
      "source": "printed",
      "confidence": 0.7
    },
    {
      "physical": 889,
      "label": "26",
      "source": "printed",
      "confidence": 0.7
    },
    {
      "physical": 890,
      "label": "27",
      "source": "printed",
      "confidence": 0.7
    },
    {
      "physical": 891,
      "label": "28",
      "source": "printed",
      "confidence": 0.7
    },
    {
      "physical": 892,
      "label": "29",
      "source": "printed",
      "confidence": 0.7
    },
    {
      "physical": 893,
      "label": "30",
      "source": "printed",
      "confidence": 0.7
    },
    {
      "physical": 894,
      "label": "31",
      "source": "printed",
      "confidence": 0.7
    },
    {
      "physical": 895,
      "label": "32",
      "source": "printed",
      "confidence": 0.7
    },
    {
      "physical": 896,
      "label": "33",
      "source": "printed",
      "confidence": 0.7
    },
    {
      "physical": 897,
      "label": "34",
      "source": "printed",
      "confidence": 0.7
    },
    {
      "physical": 898,
      "label": "35",
      "source": "printed",
      "confidence": 0.7
    },
    {
      "physical": 899,
      "label": "36",
      "source": "printed",
      "confidence": 0.7
    },
    {
      "physical": 900,
      "label": "37",
      "source": "printed",
      "confidence": 0.7
    },
    {
      "physical": 901,
      "label": "38",
      "source": "printed",
      "confidence": 0.7
    },
    {
      "physical": 902,
      "label": "39",
      "source": "printed",
      "confidence": 0.7
    },
    {
      "physical": 903,
      "label": "40",
      "source": "printed",
      "confidence": 0.7
    },
    {
      "physical": 904,
      "label": "41",
      "source": "printed",
      "confidence": 0.7
    },
    {
      "physical": 905,
      "label": "42",
      "source": "printed",
      "confidence": 0.7
    },
    {
      "physical": 906,
      "label": "43",
      "source": "printed",
      "confidence": 0.7
    },
    {
      "physical": 907,
      "label": "44",
      "source": "printed",
      "confidence": 0.7
    },
    {
      "physical": 908,
      "label": "45",
      "source": "printed",
      "confidence": 0.7
    },
    {
      "physical": 909,
      "label": "46",
      "source": "printed",
      "confidence": 0.7
    },
    {
      "physical": 910,
      "label": "47",
      "source": "printed",
      "confidence": 0.7
    },
    {
      "physical": 911,
      "label": "48",
      "source": "printed",
      "confidence": 0.7
    },
    {
      "physical": 912,
      "label": "49",
      "source": "printed",
      "confidence": 0.7
    },
    {
      "physical": 913,
      "label": "50",
      "source": "printed",
      "confidence": 0.7
    },
    {
      "physical": 914,
      "label": "51",
      "source": "printed",
      "confidence": 0.7
    },
    {
      "physical": 915,
      "label": "52",
      "source": "printed",
      "confidence": 0.7
    },
    {
      "physical": 916,
      "label": "53",
      "source": "printed",
      "confidence": 0.7
    },
    {
      "physical": 917,
      "label": "54",
      "source": "printed",
      "confidence": 0.7
    },
    {
      "physical": 918,
      "label": "55",
      "source": "printed",
      "confidence": 0.7
    },
    {
      "physical": 919,
      "label": "56",
      "source": "printed",
      "confidence": 0.7
    },
    {
      "physical": 920,
      "label": "57",
      "source": "printed",
      "confidence": 0.7
    },
    {
      "physical": 921,
      "label": "58",
      "source": "printed",
      "confidence": 0.7
    },
    {
      "physical": 922,
      "label": "59",
      "source": "printed",
      "confidence": 0.7
    },
    {
      "physical": 923,
      "label": "60",
      "source": "printed",
      "confidence": 0.7
    },
    {
      "physical": 924,
      "label": "61",
      "source": "printed",
      "confidence": 0.7
    },
    {
      "physical": 925,
      "label": "62",
      "source": "printed",
      "confidence": 0.7
    },
    {
      "physical": 926,
      "label": "63",
      "source": "printed",
      "confidence": 0.7
    },
    {
      "physical": 927,
      "label": "64",
      "source": "printed",
      "confidence": 0.7
    },
    {
      "physical": 928,
      "label": "65",
      "source": "printed",
      "confidence": 0.7
    },
    {
      "physical": 929,
      "label": "66",
      "source": "printed",
      "confidence": 0.7
    },
    {
      "physical": 930,
      "label": "67",
      "source": "printed",
      "confidence": 0.7
    },
    {
      "physical": 931,
      "label": "68",
      "source": "printed",
      "confidence": 0.7
    },
    {
      "physical": 932,
      "label": "69",
      "source": "printed",
      "confidence": 0.7
    },
    {
      "physical": 933,
      "label": "70",
      "source": "printed",
      "confidence": 0.7
    },
    {
      "physical": 934,
      "label": "71",
      "source": "printed",
      "confidence": 0.7
    },
    {
      "physical": 935,
      "label": "72",
      "source": "printed",
      "confidence": 0.7
    },
    {
      "physical": 936,
      "label": "73",
      "source": "printed",
      "confidence": 0.7
    },
    {
      "physical": 937,
      "label": "74",
      "source": "printed",
      "confidence": 0.7
    },
    {
      "physical": 938,
      "label": "75",
      "source": "printed",
      "confidence": 0.7
    },
    {
      "physical": 939,
      "label": "76",
      "source": "printed",
      "confidence": 0.7
    },
    {
      "physical": 940,
      "label": "77",
      "source": "printed",
      "confidence": 0.7
    },
    {
      "physical": 941,
      "label": "78",
      "source": "printed",
      "confidence": 0.7
    },
    {
      "physical": 942,
      "label": "79",
      "source": "printed",
      "confidence": 0.7
    },
    {
      "physical": 943,
      "label": "80",
      "source": "printed",
      "confidence": 0.7
    },
    {
      "physical": 944,
      "label": "81",
      "source": "printed",
      "confidence": 0.7
    },
    {
      "physical": 945,
      "label": "82",
      "source": "printed",
      "confidence": 0.7
    },
    {
      "physical": 946,
      "label": "83",
      "source": "printed",
      "confidence": 0.7
    },
    {
      "physical": 947,
      "label": "84",
      "source": "printed",
      "confidence": 0.7
    },
    {
      "physical": 948,
      "label": "85",
      "source": "printed",
      "confidence": 0.7
    },
    {
      "physical": 949,
      "label": "86",
      "source": "printed",
      "confidence": 0.7
    },
    {
      "physical": 950,
      "label": "87",
      "source": "printed",
      "confidence": 0.7
    },
    {
      "physical": 951,
      "label": "88",
      "source": "printed",
      "confidence": 0.7
    },
    {
      "physical": 952,
      "label": "89",
      "source": "printed",
      "confidence": 0.7
    },
    {
      "physical": 953,
      "label": "90",
      "source": "printed",
      "confidence": 0.7
    },
    {
      "physical": 954,
      "label": "91",
      "source": "printed",
      "confidence": 0.7
    },
    {
      "physical": 955,
      "label": "92",
      "source": "printed",
      "confidence": 0.7
    },
    {
      "physical": 956,
      "label": "93",
      "source": "printed",
      "confidence": 0.7
    },
    {
      "physical": 957,
      "label": "94",
      "source": "printed",
      "confidence": 0.7
    },
    {
      "physical": 958,
      "label": "95",
      "source": "printed",
      "confidence": 0.7
    },
    {
      "physical": 959,
      "label": "96",
      "source": "printed",
      "confidence": 0.7
    },
    {
      "physical": 960,
      "label": "97",
      "source": "printed",
      "confidence": 0.7
    },
    {
      "physical": 961,
      "label": "98",
      "source": "printed",
      "confidence": 0.7
    },
    {
      "physical": 962,
      "label": "99",
      "source": "printed",
      "confidence": 0.7
    },
    {
      "physical": 963,
      "label": "100",
      "source": "printed",
      "confidence": 0.7
    },
    {
      "physical": 964,
      "label": "101",
      "source": "printed",
      "confidence": 0.7
    },
    {
      "physical": 965,
      "label": "102",
      "source": "printed",
      "confidence": 0.7
    },
    {
      "physical": 966,
      "label": "103",
      "source": "printed",
      "confidence": 0.7
    },
    {
      "physical": 967,
      "label": "104",
      "source": "printed",
      "confidence": 0.7
    },
    {
      "physical": 968,
      "label": "105",
      "source": "printed",
      "confidence": 0.7
    },
    {
      "physical": 969,
      "label": "106",
      "source": "printed",
      "confidence": 0.7
    },
    {
      "physical": 970,
      "label": "107",
      "source": "printed",
      "confidence": 0.7
    },
    {
      "physical": 971,
      "label": "108",
      "source": "printed",
      "confidence": 0.7
    },
    {
      "physical": 972,
      "label": "109",
      "source": "printed",
      "confidence": 0.7
    },
    {
      "physical": 973,
      "label": "110",
      "source": "printed",
      "confidence": 0.7
    },
    {
      "physical": 974,
      "label": "111",
      "source": "printed",
      "confidence": 0.7
    },
    {
      "physical": 975,
      "label": "112",
      "source": "printed",
      "confidence": 0.7
    },
    {
      "physical": 976,
      "label": "113",
      "source": "printed",
      "confidence": 0.7
    },
    {
      "physical": 977,
      "label": "114",
      "source": "printed",
      "confidence": 0.7
    },
    {
      "physical": 978,
      "label": "115",
      "source": "printed",
      "confidence": 0.7
    },
    {
      "physical": 979,
      "label": "116",
      "source": "printed",
      "confidence": 0.7
    },
    {
      "physical": 980,
      "label": "117",
      "source": "printed",
      "confidence": 0.7
    },
    {
      "physical": 981,
      "label": "118",
      "source": "printed",
      "confidence": 0.7
    },
    {
      "physical": 982,
      "label": "119",
      "source": "printed",
      "confidence": 0.7
    },
    {
      "physical": 983,
      "label": "120",
      "source": "printed",
      "confidence": 0.7
    },
    {
      "physical": 984,
      "label": "121",
      "source": "printed",
      "confidence": 0.7
    },
    {
      "physical": 985,
      "label": "122",
      "source": "printed",
      "confidence": 0.7
    },
    {
      "physical": 986,
      "label": "123",
      "source": "printed",
      "confidence": 0.7
    },
    {
      "physical": 987,
      "label": "124",
      "source": "printed",
      "confidence": 0.7
    },
    {
      "physical": 988,
      "label": "125",
      "source": "printed",
      "confidence": 0.7
    },
    {
      "physical": 989,
      "label": "126",
      "source": "printed",
      "confidence": 0.7
    },
    {
      "physical": 990,
      "label": "127",
      "source": "printed",
      "confidence": 0.7
    },
    {
      "physical": 991,
      "label": "128",
      "source": "printed",
      "confidence": 0.7
    },
    {
      "physical": 992,
      "label": "129",
      "source": "printed",
      "confidence": 0.7
    },
    {
      "physical": 993,
      "label": "130",
      "source": "printed",
      "confidence": 0.7
    },
    {
      "physical": 994,
      "label": "131",
      "source": "printed",
      "confidence": 0.7
    },
    {
      "physical": 995,
      "label": "132",
      "source": "printed",
      "confidence": 0.7
    },
    {
      "physical": 996,
      "label": "133",
      "source": "printed",
      "confidence": 0.7
    },
    {
      "physical": 997,
      "label": "134",
      "source": "printed",
      "confidence": 0.7
    },
    {
      "physical": 998,
      "label": "135",
      "source": "printed",
      "confidence": 0.7
    },
    {
      "physical": 999,
      "label": "136",
      "source": "printed",
      "confidence": 0.7
    },
    {
      "physical": 1000,
      "label": "137",
      "source": "printed",
      "confidence": 0.7
    },
    {
      "physical": 1001,
      "label": "138",
      "source": "printed",
      "confidence": 0.7
    },
    {
      "physical": 1002,
      "label": "139",
      "source": "printed",
      "confidence": 0.7
    },
    {
      "physical": 1003,
      "label": "140",
      "source": "printed",
      "confidence": 0.7
    },
    {
      "physical": 1004,
      "label": "141",
      "source": "printed",
      "confidence": 0.7
    },
    {
      "physical": 1005,
      "label": "142",
      "source": "printed",
      "confidence": 0.7
    },
    {
      "physical": 1006,
      "label": "143",
      "source": "printed",
      "confidence": 0.7
    },
    {
      "physical": 1007,
      "label": "144",
      "source": "printed",
      "confidence": 0.7
    },
    {
      "physical": 1008,
      "label": "145",
      "source": "printed",
      "confidence": 0.7
    },
    {
      "physical": 1009,
      "label": "146",
      "source": "printed",
      "confidence": 0.7
    },
    {
      "physical": 1010,
      "label": "147",
      "source": "printed",
      "confidence": 0.7
    },
    {
      "physical": 1011,
      "label": "148",
      "source": "printed",
      "confidence": 0.7
    },
    {
      "physical": 1012,
      "label": "149",
      "source": "printed",
      "confidence": 0.7
    },
    {
      "physical": 1013,
      "label": "150",
      "source": "printed",
      "confidence": 0.7
    },
    {
      "physical": 1014,
      "label": "151",
      "source": "printed",
      "confidence": 0.7
    },
    {
      "physical": 1015,
      "label": "152",
      "source": "printed",
      "confidence": 0.7
    },
    {
      "physical": 1016,
      "label": "153",
      "source": "printed",
      "confidence": 0.7
    },
    {
      "physical": 1017,
      "label": "154",
      "source": "printed",
      "confidence": 0.7
    },
    {
      "physical": 1018,
      "label": "155",
      "source": "printed",
      "confidence": 0.7
    },
    {
      "physical": 1019,
      "label": "156",
      "source": "printed",
      "confidence": 0.7
    },
    {
      "physical": 1020,
      "label": "157",
      "source": "printed",
      "confidence": 0.7
    },
    {
      "physical": 1021,
      "label": "158",
      "source": "printed",
      "confidence": 0.7
    },
    {
      "physical": 1022,
      "label": "159",
      "source": "printed",
      "confidence": 0.7
    },
    {
      "physical": 1023,
      "label": "160",
      "source": "printed",
      "confidence": 0.7
    },
    {
      "physical": 1024,
      "label": "161",
      "source": "printed",
      "confidence": 0.7
    },
    {
      "physical": 1025,
      "label": "162",
      "source": "printed",
      "confidence": 0.7
    },
    {
      "physical": 1026,
      "label": "163",
      "source": "printed",
      "confidence": 0.7
    },
    {
      "physical": 1027,
      "label": "164",
      "source": "printed",
      "confidence": 0.7
    },
    {
      "physical": 1028,
      "label": "165",
      "source": "printed",
      "confidence": 0.7
    },
    {
      "physical": 1029,
      "label": "166",
      "source": "printed",
      "confidence": 0.7
    },
    {
      "physical": 1030,
      "label": "167",
      "source": "printed",
      "confidence": 0.7
    },
    {
      "physical": 1031,
      "label": "168",
      "source": "printed",
      "confidence": 0.7
    },
    {
      "physical": 1032,
      "label": "169",
      "source": "printed",
      "confidence": 0.7
    },
    {
      "physical": 1033,
      "label": "170",
      "source": "printed",
      "confidence": 0.7
    },
    {
      "physical": 1034,
      "label": "171",
      "source": "printed",
      "confidence": 0.7
    },
    {
      "physical": 1035,
      "label": "172",
      "source": "printed",
      "confidence": 0.7
    },
    {
      "physical": 1036,
      "label": "173",
      "source": "printed",
      "confidence": 0.7
    },
    {
      "physical": 1037,
      "label": "174",
      "source": "printed",
      "confidence": 0.7
    },
    {
      "physical": 1038,
      "label": "175",
      "source": "printed",
      "confidence": 0.7
    },
    {
      "physical": 1039,
      "label": "176",
      "source": "printed",
      "confidence": 0.7
    },
    {
      "physical": 1040,
      "label": "177",
      "source": "printed",
      "confidence": 0.7
    },
    {
      "physical": 1041,
      "label": "178",
      "source": "printed",
      "confidence": 0.7
    },
    {
      "physical": 1042,
      "label": "179",
      "source": "printed",
      "confidence": 0.7
    },
    {
      "physical": 1043,
      "label": "180",
      "source": "printed",
      "confidence": 0.7
    },
    {
      "physical": 1044,
      "label": "181",
      "source": "printed",
      "confidence": 0.7
    },
    {
      "physical": 1045,
      "label": "182",
      "source": "printed",
      "confidence": 0.7
    },
    {
      "physical": 1046,
      "label": "183",
      "source": "printed",
      "confidence": 0.7
    },
    {
      "physical": 1047,
      "label": "184",
      "source": "interpolated",
      "confidence": 0.5
    },
    {
      "physical": 1048,
      "label": "185",
      "source": "printed",
      "confidence": 0.7
    },
    {
      "physical": 1049,
      "label": "186",
      "source": "printed",
      "confidence": 0.7
    },
    {
      "physical": 1050,
      "label": "187",
      "source": "printed",
      "confidence": 0.7
    },
    {
      "physical": 1051,
      "label": "188",
      "source": "printed",
      "confidence": 0.7
    },
    {
      "physical": 1052,
      "label": "189",
      "source": "printed",
      "confidence": 0.7
    },
    {
      "physical": 1053,
      "label": "190",
      "source": "printed",
      "confidence": 0.7
    },
    {
      "physical": 1054,
      "label": "191",
      "source": "printed",
      "confidence": 0.7
    },
    {
      "physical": 1055,
      "label": "192",
      "source": "printed",
      "confidence": 0.7
    },
    {
      "physical": 1056,
      "label": "193",
      "source": "printed",
      "confidence": 0.7
    },
    {
      "physical": 1057,
      "label": "194",
      "source": "printed",
      "confidence": 0.7
    },
    {
      "physical": 1058,
      "label": "195",
      "source": "printed",
      "confidence": 0.7
    },
    {
      "physical": 1059,
      "label": "196",
      "source": "printed",
      "confidence": 0.7
    },
    {
      "physical": 1060,
      "label": "197",
      "source": "printed",
      "confidence": 0.7
    },
    {
      "physical": 1061,
      "label": "198",
      "source": "printed",
      "confidence": 0.7
    },
    {
      "physical": 1062,
      "label": "199",
      "source": "printed",
      "confidence": 0.7
    },
    {
      "physical": 1063,
      "label": "200",
      "source": "printed",
      "confidence": 0.7
    },
    {
      "physical": 1064,
      "label": "201",
      "source": "printed",
      "confidence": 0.7
    },
    {
      "physical": 1065,
      "label": "202",
      "source": "printed",
      "confidence": 0.7
    },
    {
      "physical": 1066,
      "label": "203",
      "source": "printed",
      "confidence": 0.7
    },
    {
      "physical": 1067,
      "label": "204",
      "source": "printed",
      "confidence": 0.7
    },
    {
      "physical": 1068,
      "label": "205",
      "source": "printed",
      "confidence": 0.7
    },
    {
      "physical": 1069,
      "label": "206",
      "source": "printed",
      "confidence": 0.7
    },
    {
      "physical": 1070,
      "label": "207",
      "source": "printed",
      "confidence": 0.7
    },
    {
      "physical": 1071,
      "label": "208",
      "source": "printed",
      "confidence": 0.7
    },
    {
      "physical": 1072,
      "label": "209",
      "source": "printed",
      "confidence": 0.7
    },
    {
      "physical": 1073,
      "label": "210",
      "source": "printed",
      "confidence": 0.7
    },
    {
      "physical": 1074,
      "label": "211",
      "source": "printed",
      "confidence": 0.7
    },
    {
      "physical": 1075,
      "label": "212",
      "source": "printed",
      "confidence": 0.7
    },
    {
      "physical": 1076,
      "label": null,
      "source": null,
      "confidence": 0
    },
    {
      "physical": 1077,
      "label": null,
      "source": null,
      "confidence": 0
    },
    {
      "physical": 1078,
      "label": "1",
      "source": "printed",
      "confidence": 0.7
    },
    {
      "physical": 1079,
      "label": "2",
      "source": "printed",
      "confidence": 0.7
    },
    {
      "physical": 1080,
      "label": "3",
      "source": "printed",
      "confidence": 0.7
    },
    {
      "physical": 1081,
      "label": "4",
      "source": "printed",
      "confidence": 0.7
    },
    {
      "physical": 1082,
      "label": "5",
      "source": "printed",
      "confidence": 0.7
    },
    {
      "physical": 1083,
      "label": "6",
      "source": "printed",
      "confidence": 0.7
    },
    {
      "physical": 1084,
      "label": "7",
      "source": "printed",
      "confidence": 0.7
    },
    {
      "physical": 1085,
      "label": "8",
      "source": "printed",
      "confidence": 0.7
    },
    {
      "physical": 1086,
      "label": "9",
      "source": "printed",
      "confidence": 0.7
    },
    {
      "physical": 1087,
      "label": "10",
      "source": "printed",
      "confidence": 0.7
    },
    {
      "physical": 1088,
      "label": "11",
      "source": "printed",
      "confidence": 0.7
    },
    {
      "physical": 1089,
      "label": "12",
      "source": "printed",
      "confidence": 0.7
    },
    {
      "physical": 1090,
      "label": null,
      "source": null,
      "confidence": 0
    },
    {
      "physical": 1091,
      "label": null,
      "source": null,
      "confidence": 0
    },
    {
      "physical": 1092,
      "label": "1",
      "source": "printed",
      "confidence": 0.7
    },
    {
      "physical": 1093,
      "label": "2",
      "source": "printed",
      "confidence": 0.7
    },
    {
      "physical": 1094,
      "label": "3",
      "source": "printed",
      "confidence": 0.7
    },
    {
      "physical": 1095,
      "label": "4",
      "source": "printed",
      "confidence": 0.7
    },
    {
      "physical": 1096,
      "label": "5",
      "source": "printed",
      "confidence": 0.7
    },
    {
      "physical": 1097,
      "label": "6",
      "source": "printed",
      "confidence": 0.7
    },
    {
      "physical": 1098,
      "label": "7",
      "source": "printed",
      "confidence": 0.7
    },
    {
      "physical": 1099,
      "label": "8",
      "source": "printed",
      "confidence": 0.7
    },
    {
      "physical": 1100,
      "label": "9",
      "source": "printed",
      "confidence": 0.7
    },
    {
      "physical": 1101,
      "label": "10",
      "source": "printed",
      "confidence": 0.7
    },
    {
      "physical": 1102,
      "label": "11",
      "source": "printed",
      "confidence": 0.7
    },
    {
      "physical": 1103,
      "label": "12",
      "source": "printed",
      "confidence": 0.7
    },
    {
      "physical": 1104,
      "label": "13",
      "source": "printed",
      "confidence": 0.7
    },
    {
      "physical": 1105,
      "label": "14",
      "source": "printed",
      "confidence": 0.7
    },
    {
      "physical": 1106,
      "label": "15",
      "source": "printed",
      "confidence": 0.7
    },
    {
      "physical": 1107,
      "label": "16",
      "source": "printed",
      "confidence": 0.7
    },
    {
      "physical": 1108,
      "label": "17",
      "source": "printed",
      "confidence": 0.7
    },
    {
      "physical": 1109,
      "label": "18",
      "source": "printed",
      "confidence": 0.7
    },
    {
      "physical": 1110,
      "label": "19",
      "source": "printed",
      "confidence": 0.7
    },
    {
      "physical": 1111,
      "label": "20",
      "source": "printed",
      "confidence": 0.7
    },
    {
      "physical": 1112,
      "label": "21",
      "source": "printed",
      "confidence": 0.7
    },
    {
      "physical": 1113,
      "label": "22",
      "source": "printed",
      "confidence": 0.7
    },
    {
      "physical": 1114,
      "label": "23",
      "source": "printed",
      "confidence": 0.7
    },
    {
      "physical": 1115,
      "label": "24",
      "source": "printed",
      "confidence": 0.7
    },
    {
      "physical": 1116,
      "label": "25",
      "source": "printed",
      "confidence": 0.7
    },
    {
      "physical": 1117,
      "label": "26",
      "source": "printed",
      "confidence": 0.7
    },
    {
      "physical": 1118,
      "label": "27",
      "source": "printed",
      "confidence": 0.7
    },
    {
      "physical": 1119,
      "label": "28",
      "source": "printed",
      "confidence": 0.7
    },
    {
      "physical": 1120,
      "label": null,
      "source": null,
      "confidence": 0
    },
    {
      "physical": 1121,
      "label": null,
      "source": null,
      "confidence": 0
    },
    {
      "physical": 1122,
      "label": "1",
      "source": "printed",
      "confidence": 0.7
    },
    {
      "physical": 1123,
      "label": "2",
      "source": "printed",
      "confidence": 0.7
    },
    {
      "physical": 1124,
      "label": "3",
      "source": "printed",
      "confidence": 0.7
    },
    {
      "physical": 1125,
      "label": "4",
      "source": "printed",
      "confidence": 0.7
    },
    {
      "physical": 1126,
      "label": "5",
      "source": "printed",
      "confidence": 0.7
    },
    {
      "physical": 1127,
      "label": "6",
      "source": "printed",
      "confidence": 0.7
    },
    {
      "physical": 1128,
      "label": "7",
      "source": "printed",
      "confidence": 0.7
    },
    {
      "physical": 1129,
      "label": "8",
      "source": "printed",
      "confidence": 0.7
    },
    {
      "physical": 1130,
      "label": "9",
      "source": "printed",
      "confidence": 0.7
    },
    {
      "physical": 1131,
      "label": "10",
      "source": "printed",
      "confidence": 0.7
    },
    {
      "physical": 1132,
      "label": "11",
      "source": "printed",
      "confidence": 0.7
    },
    {
      "physical": 1133,
      "label": "12",
      "source": "printed",
      "confidence": 0.7
    },
    {
      "physical": 1134,
      "label": null,
      "source": null,
      "confidence": 0
    },
    {
      "physical": 1135,
      "label": null,
      "source": null,
      "confidence": 0
    },
    {
      "physical": 1136,
      "label": "1",
      "source": "printed",
      "confidence": 0.7
    },
    {
      "physical": 1137,
      "label": "2",
      "source": "printed",
      "confidence": 0.7
    },
    {
      "physical": 1138,
      "label": "3",
      "source": "printed",
      "confidence": 0.7
    },
    {
      "physical": 1139,
      "label": "4",
      "source": "printed",
      "confidence": 0.7
    },
    {
      "physical": 1140,
      "label": "5",
      "source": "printed",
      "confidence": 0.7
    },
    {
      "physical": 1141,
      "label": "6",
      "source": "printed",
      "confidence": 0.7
    },
    {
      "physical": 1142,
      "label": "7",
      "source": "printed",
      "confidence": 0.7
    },
    {
      "physical": 1143,
      "label": "8",
      "source": "printed",
      "confidence": 0.7
    },
    {
      "physical": 1144,
      "label": "9",
      "source": "printed",
      "confidence": 0.7
    },
    {
      "physical": 1145,
      "label": "10",
      "source": "printed",
      "confidence": 0.7
    },
    {
      "physical": 1146,
      "label": "11",
      "source": "printed",
      "confidence": 0.7
    },
    {
      "physical": 1147,
      "label": "12",
      "source": "printed",
      "confidence": 0.7
    },
    {
      "physical": 1148,
      "label": "13",
      "source": "printed",
      "confidence": 0.7
    },
    {
      "physical": 1149,
      "label": "14",
      "source": "printed",
      "confidence": 0.7
    },
    {
      "physical": 1150,
      "label": "15",
      "source": "printed",
      "confidence": 0.7
    },
    {
      "physical": 1151,
      "label": "16",
      "source": "printed",
      "confidence": 0.7
    },
    {
      "physical": 1152,
      "label": "17",
      "source": "printed",
      "confidence": 0.7
    },
    {
      "physical": 1153,
      "label": "18",
      "source": "printed",
      "confidence": 0.7
    },
    {
      "physical": 1154,
      "label": "19",
      "source": "printed",
      "confidence": 0.7
    },
    {
      "physical": 1155,
      "label": "20",
      "source": "printed",
      "confidence": 0.7
    },
    {
      "physical": 1156,
      "label": "21",
      "source": "printed",
      "confidence": 0.7
    },
    {
      "physical": 1157,
      "label": "22",
      "source": "printed",
      "confidence": 0.7
    },
    {
      "physical": 1158,
      "label": "23",
      "source": "printed",
      "confidence": 0.7
    },
    {
      "physical": 1159,
      "label": "24",
      "source": "printed",
      "confidence": 0.7
    },
    {
      "physical": 1160,
      "label": "25",
      "source": "printed",
      "confidence": 0.7
    },
    {
      "physical": 1161,
      "label": "26",
      "source": "printed",
      "confidence": 0.7
    },
    {
      "physical": 1162,
      "label": "27",
      "source": "printed",
      "confidence": 0.7
    },
    {
      "physical": 1163,
      "label": "28",
      "source": "printed",
      "confidence": 0.7
    },
    {
      "physical": 1164,
      "label": null,
      "source": null,
      "confidence": 0
    },
    {
      "physical": 1165,
      "label": null,
      "source": null,
      "confidence": 0
    },
    {
      "physical": 1166,
      "label": null,
      "source": null,
      "confidence": 0
    },
    {
      "physical": 1167,
      "label": null,
      "source": null,
      "confidence": 0
    },
    {
      "physical": 1168,
      "label": null,
      "source": null,
      "confidence": 0
    },
    {
      "physical": 1169,
      "label": null,
      "source": null,
      "confidence": 0
    }
  ],
  "figures": [
    {
      "kind": "figure",
      "number": "1",
      "title": "Study flow diagram for Xpert Ultra",
      "page": 13,
      "pageLabel": "8",
      "confidence": 0.9,
      "evidence": [
        "referenced",
        "in-sequence",
        "graphic"
      ]
    },
    {
      "kind": "figure",
      "number": "2",
      "title": "Study flow diagram for Truenat assays",
      "page": 14,
      "pageLabel": "9",
      "confidence": 0.9,
      "evidence": [
        "referenced",
        "in-sequence",
        "graphic"
      ]
    },
    {
      "kind": "figure",
      "number": "3",
      "title": "Study flow diagram for STANDARD M10 and other new LC-aNAATs",
      "page": 15,
      "pageLabel": "10",
      "confidence": 0.9,
      "evidence": [
        "referenced",
        "in-sequence",
        "graphic"
      ]
    },
    {
      "kind": "table",
      "number": "1",
      "title": "Xpert Ultra: Characteristics of included studies",
      "page": 17,
      "pageLabel": "12",
      "confidence": 0.8,
      "evidence": [
        "referenced",
        "in-sequence"
      ]
    },
    {
      "kind": "table",
      "number": "2",
      "title": "Truenat assays: Characteristics of included studies",
      "page": 20,
      "pageLabel": "15",
      "confidence": 0.8,
      "evidence": [
        "referenced",
        "in-sequence"
      ]
    },
    {
      "kind": "figure",
      "number": "4",
      "title": "Risk of bias and applicability concern for each study: respiratory specimens and microbiological reference standard",
      "page": 21,
      "pageLabel": "16",
      "confidence": 0.9,
      "evidence": [
        "referenced",
        "in-sequence",
        "graphic"
      ]
    },
    {
      "kind": "figure",
      "number": "5",
      "title": "Risk of bias and applicability summary: respiratory specimens and microbiological reference",
      "page": 22,
      "pageLabel": "17",
      "confidence": 0.9,
      "evidence": [
        "referenced",
        "in-sequence",
        "graphic"
      ]
    },
    {
      "kind": "table",
      "number": "3",
      "title": "Diagnostic accuracy of LC-aNAATs for pulmonary TB and rifampicin resistance in adults and adolescents",
      "page": 23,
      "pageLabel": "18",
      "confidence": 0.8,
      "evidence": [
        "referenced",
        "in-sequence"
      ]
    },
    {
      "kind": "figure",
      "number": "6",
      "title": "Forest plot of LC-aNAAT sensitivity and specificity for detection of pulmonary TB using a microbiological reference standard",
      "page": 26,
      "pageLabel": "21",
      "confidence": 0.9,
      "evidence": [
        "referenced",
        "in-sequence",
        "graphic"
      ]
    },
    {
      "kind": "figure",
      "number": "7",
      "title": "Risk of bias and applicability for each study: respiratory specimens and composite reference standard",
      "page": 28,
      "pageLabel": "23",
      "confidence": 0.9,
      "evidence": [
        "referenced",
        "in-sequence",
        "graphic"
      ]
    },
    {
      "kind": "table",
      "number": "4",
      "title": "CRS Definitions",
      "page": 28,
      "pageLabel": "23",
      "confidence": 0.8,
      "evidence": [
        "referenced",
        "in-sequence"
      ]
    },
    {
      "kind": "figure",
      "number": "8",
      "title": "Forest plot of LC-aNAATs for detection of pulmonary TB using a composite reference standard. Index test in all studies is Xpert Ultra",
      "page": 29,
      "pageLabel": "24",
      "confidence": 0.9,
      "evidence": [
        "referenced",
        "in-sequence",
        "graphic"
      ]
    },
    {
      "kind": "figure",
      "number": "9",
      "title": "Risk of bias and applicability concern for each study: respiratory specimens and microbiological reference standard in PLHIV",
      "page": 30,
      "pageLabel": "25",
      "confidence": 0.9,
      "evidence": [
        "referenced",
        "in-sequence",
        "graphic"
      ]
    },
    {
      "kind": "figure",
      "number": "10",
      "title": "Forest plot of LC-aNAAT sensitivity and specificity for detection of pulmonary TB in PLHIV using a microbiological reference standard",
      "page": 30,
      "pageLabel": "25",
      "confidence": 0.9,
      "evidence": [
        "referenced",
        "in-sequence",
        "graphic"
      ]
    },
    {
      "kind": "figure",
      "number": "11",
      "title": "Risk of bias and applicability concern for each study: sputum specimen and microbiological reference standard in HIV negative adults and adolescents",
      "page": 31,
      "pageLabel": "26",
      "confidence": 0.9,
      "evidence": [
        "referenced",
        "in-sequence",
        "graphic"
      ]
    },
    {
      "kind": "figure",
      "number": "12",
      "title": "Forest plot of LC-aNAAT sensitivity and specificity for detection of pulmonary TB in HIV negative adults and adolescents using a microbiological reference standard",
      "page": 31,
      "pageLabel": "26",
      "confidence": 0.9,
      "evidence": [
        "referenced",
        "in-sequence",
        "graphic"
      ]
    },
    {
      "kind": "figure",
      "number": "13",
      "title": "Risk of bias and applicability concern for each study for detection of rifampicin resistance: respiratory specimens",
      "page": 32,
      "pageLabel": "27",
      "confidence": 0.9,
      "evidence": [
        "referenced",
        "in-sequence",
        "graphic"
      ]
    },
    {
      "kind": "figure",
      "number": "14",
      "title": "Forest plot of LC-aNAATs for detection of rifampicin resistance: respiratory specimens",
      "page": 33,
      "pageLabel": "28",
      "confidence": 0.9,
      "evidence": [
        "referenced",
        "in-sequence",
        "graphic"
      ]
    },
    {
      "kind": "figure",
      "number": "15",
      "title": "Xpert Ultra for pulmonary tuberculosis using nasopharyngeal aspirate and a microbiological reference standard. FN: false negative; FP: false positive; TN: true negative; TP: true positive",
      "page": 67,
      "pageLabel": "62",
      "confidence": 0.9,
      "evidence": [
        "referenced",
        "in-sequence",
        "graphic"
      ]
    },
    {
      "kind": "figure",
      "number": "16",
      "title": "Risk of bias and applicability summary for pulmonary tuberculosis: nasopharyngeal aspirate and composite reference standard",
      "page": 68,
      "pageLabel": "63",
      "confidence": 0.9,
      "evidence": [
        "referenced",
        "in-sequence",
        "graphic"
      ]
    },
    {
      "kind": "figure",
      "number": "17",
      "title": "Xpert Ultra for pulmonary tuberculosis using nasopharyngeal aspirate and a composite reference standard. FN: false negative; FP: false positive; TN: true negative; TP: true positive",
      "page": 68,
      "pageLabel": "63",
      "confidence": 0.9,
      "evidence": [
        "referenced",
        "in-sequence",
        "graphic"
      ]
    },
    {
      "kind": "figure",
      "number": "18",
      "title": "Risk of bias and applicability summary for pulmonary tuberculosis: stool and microbiological reference standard Ten studies (2885 participants) evaluating stool against a MRS of culture or Xpert Ultra on sputum or gastric aspirate were included with sensitivities between 26% and 100% and specificiti",
      "page": 69,
      "pageLabel": "64",
      "confidence": 0.9,
      "evidence": [
        "referenced",
        "in-sequence",
        "graphic"
      ]
    },
    {
      "kind": "figure",
      "number": "19",
      "title": "Xpert Ultra for pulmonary tuberculosis using stool and a microbiological reference standard. The studies are sorted on the plot by decreasing sensitivity. FN: false negative; FP: false positive; TN: true negative; TP: true positive",
      "page": 70,
      "pageLabel": "65",
      "confidence": 0.9,
      "evidence": [
        "referenced",
        "in-sequence",
        "graphic"
      ]
    },
    {
      "kind": "figure",
      "number": "20",
      "title": "Risk of bias and applicability summary for pulmonary tuberculosis: stool and composite reference standard Six studies (1778 participants) evaluating stool against a CRS were included with sensitivities of 9% to 58% and specificities of 97% and 100% (Figure 21). All six studies were included in the m",
      "page": 70,
      "pageLabel": "65",
      "confidence": 0.9,
      "evidence": [
        "referenced",
        "in-sequence",
        "graphic"
      ]
    },
    {
      "kind": "figure",
      "number": "21",
      "title": "Xpert Ultra for pulmonary tuberculosis using stool and a composite reference standard. The studies are sorted on the plot by decreasing sensitivity. FN: false negative; FP: false positive; TN: true negative; TP: true positive",
      "page": 71,
      "pageLabel": "66",
      "confidence": 0.9,
      "evidence": [
        "referenced",
        "in-sequence",
        "graphic"
      ]
    },
    {
      "kind": "figure",
      "number": "22",
      "title": "Risk of bias and applicability summary for detection of rifampicin resistance from sputum specimens Three studies (76 participants) using sputum were included. Only one study had two cases in total",
      "page": 71,
      "pageLabel": "66",
      "confidence": 0.9,
      "evidence": [
        "referenced",
        "in-sequence",
        "graphic"
      ]
    },
    {
      "kind": "figure",
      "number": "23",
      "title": "Xpert Ultra for detection of rifampicin resistance. FN: false negative; FP: false positive; TN: true negative; TP: true positive",
      "page": 72,
      "pageLabel": "67",
      "confidence": 0.9,
      "evidence": [
        "referenced",
        "in-sequence",
        "graphic"
      ]
    },
    {
      "kind": "figure",
      "number": "24",
      "title": "Risk of bias and applicability summary for extrapulmonary tuberculosis using CSF and a microbiological reference standard Three studies (215 participants) were included with sensitivities of 67% to 100% and specificities of 91% to 100% (Figure 25). Meta-analysis was not performed due to the small nu",
      "page": 72,
      "pageLabel": "67",
      "confidence": 0.9,
      "evidence": [
        "referenced",
        "in-sequence",
        "graphic"
      ]
    },
    {
      "kind": "figure",
      "number": "25",
      "title": "Xpert Ultra for extrapulmonary tuberculosis using CSF and a microbiological reference standard. FN: false negative; FP: false positive; TN: true negative; TP: true positive",
      "page": 72,
      "pageLabel": "67",
      "confidence": 0.9,
      "evidence": [
        "referenced",
        "in-sequence",
        "graphic"
      ]
    },
    {
      "kind": "figure",
      "number": "26",
      "title": "Risk of bias and applicability summary for extrapulmonary tuberculosis using CSF and a composite reference standard Two studies (67 participants) were included with sensitivities of 12% to 19% and all had a specificity of 100% (Figure 27). Meta-analysis was not performed due to the small number of s",
      "page": 73,
      "pageLabel": "68",
      "confidence": 0.7,
      "evidence": [
        "in-sequence",
        "graphic"
      ]
    },
    {
      "kind": "figure",
      "number": "27",
      "title": "LC-aNAATs for extrapulmonary tuberculosis using CSF and a composite reference standard. FN: false negative; FP: false positive; TN: true negative; TP: true positive",
      "page": 73,
      "pageLabel": "68",
      "confidence": 0.9,
      "evidence": [
        "referenced",
        "in-sequence",
        "graphic"
      ]
    },
    {
      "kind": "figure",
      "number": "28",
      "title": "Risk of bias and applicability summary for extrapulmonary tuberculosis using lymph node tissue or aspirates and a microbiological reference standard Two studies (58 participants) were included all with a sensitivity of 100% and specificities between 33% and 82% (Figure 29). Meta-analysis was not per",
      "page": 74,
      "pageLabel": "69",
      "confidence": 0.7,
      "evidence": [
        "in-sequence",
        "graphic"
      ]
    },
    {
      "kind": "figure",
      "number": "29",
      "title": "Xpert Ultra for extrapulmonary tuberculosis using lymph node and a microbiological reference standard. FN: false negative; FP: false positive; TN: true negative; TP: true positive",
      "page": 74,
      "pageLabel": "69",
      "confidence": 0.9,
      "evidence": [
        "referenced",
        "in-sequence",
        "graphic"
      ]
    },
    {
      "kind": "figure",
      "number": "30",
      "title": "Risk of bias and applicability summary for extrapulmonary tuberculosis using lymph node tissue and aspirates and a composite reference standard Two studies (58 participants) were included with sensitivities of 50% to 805 and a sensitivity of 100% (Figure 31). Meta-analysis was not performed due to t",
      "page": 75,
      "pageLabel": "70",
      "confidence": 0.7,
      "evidence": [
        "in-sequence",
        "graphic"
      ]
    },
    {
      "kind": "figure",
      "number": "31",
      "title": "LC-aNAATs for extrapulmonary tuberculosis using LN and a composite reference standard. FN: false negative; FP: false positive; TN: true negative; TP: true positive",
      "page": 75,
      "pageLabel": "70",
      "confidence": 0.9,
      "evidence": [
        "referenced",
        "in-sequence",
        "graphic"
      ]
    },
    {
      "kind": "figure",
      "number": "32",
      "title": "LC-aNAATs for extrapulmonary tuberculosis using a microbiological reference standard. EPTB: extrapulmonary tuberculosis; FN: false negative; FP: false positive; TN: true negative; TP: true positive",
      "page": 76,
      "pageLabel": "71",
      "confidence": 0.9,
      "evidence": [
        "referenced",
        "in-sequence",
        "graphic"
      ]
    },
    {
      "kind": "box",
      "number": "1",
      "title": "Criteria for the inclusion of individual test technologies in a NAAT class",
      "page": 100,
      "pageLabel": "95",
      "confidence": 0.8,
      "evidence": [
        "referenced",
        "in-sequence"
      ]
    },
    {
      "kind": "figure",
      "number": "2a",
      "title": "Of the 36 studies, 30 studies (83.3%) took place in high tuberculosis burden and 22 (59.4%) in high tuberculosis/HIV burden countries. We judged risk of bias to be low in the patient selection, index test, and flow and timing domains and high or unclear in the reference standard domain because many",
      "page": 104,
      "pageLabel": "99",
      "confidence": 0.8,
      "evidence": [
        "referenced",
        "graphic"
      ]
    },
    {
      "kind": "figure",
      "number": "2b",
      "title": "Summary of risk of bias and applicability assessment for each Truenat MTB plus study",
      "page": 105,
      "pageLabel": "100",
      "confidence": 0.8,
      "evidence": [
        "referenced",
        "graphic"
      ]
    },
    {
      "kind": "table",
      "number": "5",
      "title": "Starting volumes and concentration for pleural fluid and diagnostic accuracy",
      "page": 121,
      "pageLabel": "116",
      "confidence": 0.8,
      "evidence": [
        "referenced",
        "in-sequence"
      ]
    },
    {
      "kind": "table",
      "number": "6",
      "title": "Diagnostic accuracy of LC-aNAATs for detection of rifampicin resistance in adults and adolescents",
      "page": 122,
      "pageLabel": "117",
      "confidence": 0.8,
      "evidence": [
        "referenced",
        "in-sequence"
      ]
    },
    {
      "kind": "table",
      "number": "7",
      "title": "Subgroup comparisons of interest for assessing heterogeneity Variable",
      "page": 272,
      "pageLabel": "267",
      "confidence": 0.8,
      "evidence": [
        "referenced",
        "in-sequence"
      ]
    },
    {
      "kind": "table",
      "number": "8",
      "title": "Eligible comparisons Comparison #",
      "page": 334,
      "pageLabel": "329",
      "confidence": 0.8,
      "evidence": [
        "referenced",
        "in-sequence"
      ]
    },
    {
      "kind": "table",
      "number": "9",
      "title": "Summary accuracy by presence of symptoms. Pooled test accuracy along with summary difference between the parallel use (LC-aNAAT and LF-LAM) versus LC-aNAAT alone for detection of tuberculosis using a microbiological reference standard",
      "page": 354,
      "pageLabel": "349",
      "confidence": 0.8,
      "evidence": [
        "referenced",
        "in-sequence"
      ]
    },
    {
      "kind": "table",
      "number": "10",
      "title": "Summary accuracy by CD4. Pooled test accuracy along with difference between the parallel use (LC-aNAAT and LF-LAM) versus LC-aNAAT alone for detection of tuberculosis using a microbiological reference standard",
      "page": 355,
      "pageLabel": "350",
      "confidence": 0.8,
      "evidence": [
        "referenced",
        "in-sequence"
      ]
    },
    {
      "kind": "table",
      "number": "11",
      "title": "Summary accuracy by clinical setting. Pooled test accuracy along with difference between the parallel use (LC-aNAAT and LF-LAM) versus LC-aNAAT alone for detection of tuberculosis using a microbiological reference standard",
      "page": 355,
      "pageLabel": "350",
      "confidence": 0.8,
      "evidence": [
        "referenced",
        "in-sequence"
      ]
    },
    {
      "kind": "table",
      "number": "12",
      "title": "Summary accuracy for screening positive. Pooled test accuracy along with difference between the parallel use (LC-aNAAT and LF-LAM) versus LC-aNAAT alone for detection of tuberculosis using a microbiological reference standard",
      "page": 356,
      "pageLabel": "351",
      "confidence": 0.8,
      "evidence": [
        "referenced",
        "in-sequence"
      ]
    },
    {
      "kind": "table",
      "number": "13",
      "title": "Summary accuracy for advanced HIV. Summary accuracy by test with the difference between the parallel use (LC-aNAAT and LF-LAM) versus LC-aNAAT alone for detection of tuberculosis against a microbiological reference standard",
      "page": 356,
      "pageLabel": "351",
      "confidence": 0.8,
      "evidence": [
        "referenced",
        "in-sequence"
      ]
    },
    {
      "kind": "table",
      "number": "14",
      "title": "Summary accuracy for seriously ill",
      "page": 356,
      "pageLabel": "351",
      "confidence": 0.8,
      "evidence": [
        "referenced",
        "in-sequence"
      ]
    },
    {
      "kind": "table",
      "number": "15",
      "title": "Summary accuracy for Xpert Ultra only. Summary accuracy by test with the difference between the parallel use (Xpert Ultra and LF-LAM) versus Xpert Ultra alone for detection of tuberculosis against a microbiological reference standard",
      "page": 357,
      "pageLabel": "352",
      "confidence": 0.8,
      "evidence": [
        "referenced",
        "in-sequence"
      ]
    },
    {
      "kind": "table",
      "number": "16",
      "title": "Within study comparison of Xpert vs Ultra",
      "page": 357,
      "pageLabel": "352",
      "confidence": 0.8,
      "evidence": [
        "referenced",
        "in-sequence"
      ]
    },
    {
      "kind": "table",
      "number": "17",
      "title": "When excluding participants with at least one unavailable or non-determinate index test result (1.966 participants), pooled difference in sensitivity decreased to 4.4% (95% CrI 2.8 to 6.5) while pooled difference in specificity was -6.9% (95% CrI -9.1 to -4.5) (27 studies, 10,685 participants)",
      "page": 358,
      "pageLabel": "353",
      "confidence": 0.8,
      "evidence": [
        "referenced",
        "in-sequence"
      ]
    },
    {
      "kind": "table",
      "number": "18",
      "title": "Comparison of mortality in randomized trials evaluating interventions that included respiratory LC-aNAATs and urine LF-LAM in adult inpatients with HIV",
      "page": 361,
      "pageLabel": "356",
      "confidence": 0.8,
      "evidence": [
        "referenced",
        "in-sequence"
      ]
    },
    {
      "kind": "table",
      "number": "2a",
      "title": "Diagnostic accuracy of each index test- TB detection Parameter",
      "page": 530,
      "pageLabel": "525",
      "confidence": 0.7,
      "evidence": [
        "referenced"
      ]
    },
    {
      "kind": "table",
      "number": "2b",
      "title": "Diagnostic accuracy for TB detection by smear status",
      "page": 530,
      "pageLabel": "525",
      "confidence": 0.7,
      "evidence": [
        "referenced"
      ]
    },
    {
      "kind": "table",
      "number": "3a",
      "title": "Diagnostic accuracy of each index test - resistance detection with phenotypic DST as reference standard",
      "page": 532,
      "pageLabel": "527",
      "confidence": 0.7,
      "evidence": [
        "referenced"
      ]
    },
    {
      "kind": "table",
      "number": "3b",
      "title": "Diagnostic accuracy of each index test - resistance detection with composite reference standard",
      "page": 533,
      "pageLabel": "528",
      "confidence": 0.7,
      "evidence": [
        "referenced"
      ]
    },
    {
      "kind": "figure",
      "number": "S1",
      "title": "Sanity 2.0",
      "page": 674,
      "pageLabel": "669",
      "confidence": 0.6,
      "evidence": [
        "graphic"
      ]
    },
    {
      "kind": "figure",
      "number": "S2",
      "title": "Forest plots of MeltPro XDR-TB sensitivity and specificity for detection of resistance to isoniazid, fluoroquinolones (levofloxacin), and amikacin by rifampicin resistance status",
      "page": 676,
      "pageLabel": "671",
      "confidence": 0.8,
      "evidence": [
        "referenced",
        "graphic"
      ]
    },
    {
      "kind": "table",
      "number": "7A",
      "title": "Output from Included tNGS Studies for the Systematic Review: Diagnostic Cost per Sample",
      "page": 792,
      "pageLabel": "787",
      "confidence": 0.7,
      "evidence": [
        "referenced"
      ]
    },
    {
      "kind": "table",
      "number": "7B",
      "title": "Output from Included tNGS Studies for the Systematic Review: Component Costs",
      "page": 792,
      "pageLabel": "787",
      "confidence": 0.7,
      "evidence": [
        "referenced"
      ]
    },
    {
      "kind": "table",
      "number": "7C",
      "title": "Output from Included tNGS Studies for the Systematic Review: Costs per step",
      "page": 793,
      "pageLabel": "788",
      "confidence": 0.7,
      "evidence": [
        "referenced"
      ]
    },
    {
      "kind": "table",
      "number": "8A",
      "title": "Output from Included tNGS and WGS Studies for the Systematic Review: Costing Data, Cates et al. (2022)",
      "page": 793,
      "pageLabel": "788",
      "confidence": 0.7,
      "evidence": [
        "referenced"
      ]
    },
    {
      "kind": "table",
      "number": "8B",
      "title": "Output from Included tNGS and WGS Studies for the Systematic Review: Costing Data, Cates et al. (2022)",
      "page": 793,
      "pageLabel": "788",
      "confidence": 0.5,
      "evidence": []
    },
    {
      "kind": "table",
      "number": "8C",
      "title": "Output from Included tNGS and WGS Studies for the Systematic Review: Costing Data, Cates et al. (2022)",
      "page": 794,
      "pageLabel": "789",
      "confidence": 0.5,
      "evidence": []
    },
    {
      "kind": "table",
      "number": "8D",
      "title": "Output from Included tNGS and WGS Studies for the Systematic Review: Costing Data, Cates et al. (2022)",
      "page": 794,
      "pageLabel": "789",
      "confidence": 0.5,
      "evidence": []
    },
    {
      "kind": "table",
      "number": "9A",
      "title": "Output from Included tNGS and WGS Studies for the Systematic Review: BIA, Cates et al. (2022)",
      "page": 794,
      "pageLabel": "789",
      "confidence": 0.7,
      "evidence": [
        "referenced"
      ]
    },
    {
      "kind": "table",
      "number": "9B",
      "title": "Output from Included tNGS and WGS Studies for the Systematic Review: BIA, Cates et al. (2022)",
      "page": 795,
      "pageLabel": "790",
      "confidence": 0.5,
      "evidence": []
    },
    {
      "kind": "table",
      "number": "9C",
      "title": "Output from Included tNGS and WGS Studies for the Systematic Review: BIA, Cates et al. (2022)",
      "page": 795,
      "pageLabel": "790",
      "confidence": 0.5,
      "evidence": []
    },
    {
      "kind": "table",
      "number": "9D",
      "title": "Output from Included tNGS and WGS Studies for the Systematic Review: BIA, Cates et al. (2022)",
      "page": 795,
      "pageLabel": "790",
      "confidence": 0.5,
      "evidence": []
    },
    {
      "kind": "table",
      "number": "10A",
      "title": "Output from Included WGS Studies for the Systematic Review: Diagnostic Cost per Sample",
      "page": 796,
      "pageLabel": "791",
      "confidence": 0.7,
      "evidence": [
        "referenced"
      ]
    },
    {
      "kind": "table",
      "number": "10B",
      "title": "Output from Included WGS Studies for the Systematic Review: Component Costs",
      "page": 796,
      "pageLabel": "791",
      "confidence": 0.5,
      "evidence": []
    },
    {
      "kind": "table",
      "number": "10C",
      "title": "Output from Included WGS Studies for the Systematic Review: Costs per step",
      "page": 797,
      "pageLabel": "792",
      "confidence": 0.5,
      "evidence": []
    },
    {
      "kind": "table",
      "number": "11A",
      "title": "Output from Included Studies for the Scoping Review: Key Outcome(s) and Component Costs",
      "page": 798,
      "pageLabel": "793",
      "confidence": 0.7,
      "evidence": [
        "referenced"
      ]
    },
    {
      "kind": "table",
      "number": "11B",
      "title": "Output from Included Studies for the Scoping Review: Costs per step",
      "page": 799,
      "pageLabel": "794",
      "confidence": 0.7,
      "evidence": [
        "referenced"
      ]
    },
    {
      "kind": "table",
      "number": "11C",
      "title": "Output from Included Studies for the Scoping Review: ICERs, Cost per Sample and Component Costs Total",
      "page": 800,
      "pageLabel": "795",
      "confidence": 0.7,
      "evidence": [
        "referenced"
      ]
    },
    {
      "kind": "table",
      "number": "12A",
      "title": "Output from Included Studies for the Scoping Review: Cost per Sample, Alleweldt et al. (2021)",
      "page": 801,
      "pageLabel": "796",
      "confidence": 0.7,
      "evidence": [
        "referenced"
      ]
    },
    {
      "kind": "table",
      "number": "12B",
      "title": "Output from Included Studies for the Scoping Review: Component Costs, Alleweldt et al. (2021)",
      "page": 801,
      "pageLabel": "796",
      "confidence": 0.5,
      "evidence": []
    },
    {
      "kind": "table",
      "number": "12C",
      "title": "Output from Included Studies for the Scoping Review: Cost per Sample, Alleweldt et al. (2021)",
      "page": 801,
      "pageLabel": "796",
      "confidence": 0.5,
      "evidence": []
    },
    {
      "kind": "table",
      "number": "12D",
      "title": "Output from Included Studies for the Scoping Review: Cost per Sample, Alleweldt et al. (2021)",
      "page": 802,
      "pageLabel": "797",
      "confidence": 0.5,
      "evidence": []
    },
    {
      "kind": "table",
      "number": "12E",
      "title": "Output from Included Studies for the Scoping Review: Cost per Sample, Alleweldt et al. (2021)",
      "page": 802,
      "pageLabel": "797",
      "confidence": 0.5,
      "evidence": []
    },
    {
      "kind": "table",
      "number": "A1.1",
      "title": "Search strategy for the primary systematic literature review (nov",
      "page": 977,
      "pageLabel": "114",
      "confidence": 0.8,
      "evidence": [
        "referenced",
        "in-sequence"
      ]
    },
    {
      "kind": "table",
      "number": "A3",
      "title": "Data extraction results for all the entries from the secondary systematic review",
      "page": 981,
      "pageLabel": "118",
      "confidence": 0.7,
      "evidence": [
        "referenced"
      ]
    },
    {
      "kind": "table",
      "number": "A7",
      "title": "Drummond checklist for studies quality: Cost/Cost-effectiveness analyses for Novel skin tests for diagnosing TBI",
      "page": 991,
      "pageLabel": "128",
      "confidence": 0.7,
      "evidence": [
        "referenced"
      ]
    },
    {
      "kind": "table",
      "number": "A8",
      "title": "Drummond Checklist for studies quality: Cost/Cost-effectiveness analyses for TST or IGRA for diagnosing TBI",
      "page": 1002,
      "pageLabel": "139",
      "confidence": 0.7,
      "evidence": [
        "referenced"
      ]
    },
    {
      "kind": "table",
      "number": "A9",
      "title": "Summary of the proportion of articles accomplishing each of the Drummond’s criteria",
      "page": 1044,
      "pageLabel": "181",
      "confidence": 0.5,
      "evidence": []
    },
    {
      "kind": "table",
      "number": "B1",
      "title": "Calculation of the TBI progression",
      "page": 1070,
      "pageLabel": "207",
      "confidence": 0.7,
      "evidence": [
        "referenced"
      ]
    },
    {
      "kind": "table",
      "number": "B2",
      "title": "Progression from LTBI to active TB: population estimates",
      "page": 1070,
      "pageLabel": "207",
      "confidence": 0.7,
      "evidence": [
        "referenced"
      ]
    },
    {
      "kind": "table",
      "number": "B3",
      "title": "Costs per TBI treatment, by country (not inflated, different currencies) Cost per TBI treatment regime, by country",
      "page": 1071,
      "pageLabel": "208",
      "confidence": 0.7,
      "evidence": [
        "referenced"
      ]
    },
    {
      "kind": "table",
      "number": "B4",
      "title": "Cost of the Diaskin Test per vial for different delivery volumes and considering that 1 vial is used for 15 patients",
      "page": 1072,
      "pageLabel": "209",
      "confidence": 0.7,
      "evidence": [
        "referenced"
      ]
    },
    {
      "kind": "table",
      "number": "B5",
      "title": "Full costs including delivery, and cost per patient by country",
      "page": 1072,
      "pageLabel": "209",
      "confidence": 0.5,
      "evidence": []
    },
    {
      "kind": "table",
      "number": "B6",
      "title": "Drummond checklist for the quality of our study: Cost-effectiveness analyses for Novel skin tests for diagnosing TBI",
      "page": 1073,
      "pageLabel": "210",
      "confidence": 0.7,
      "evidence": [
        "referenced"
      ]
    },
    {
      "kind": "figure",
      "number": "A1",
      "title": "PRISMA Flow Charts Review A: Papers on TBST compared to the IGRA and/or the TST",
      "page": 1087,
      "pageLabel": "10",
      "confidence": 0.8,
      "evidence": [
        "referenced",
        "graphic"
      ]
    },
    {
      "kind": "table",
      "number": "A1",
      "title": "Systematic Reviews A and B- Characteristics of Included Studies",
      "page": 1090,
      "pageLabel": null,
      "confidence": 0.7,
      "evidence": [
        "referenced"
      ]
    },
    {
      "kind": "figure",
      "number": "A2",
      "title": "Themes and subthemes identified from Systematic Review A and B",
      "page": 1091,
      "pageLabel": null,
      "confidence": 0.8,
      "evidence": [
        "referenced",
        "graphic"
      ]
    },
    {
      "kind": "figure",
      "number": "B1",
      "title": "Participant country distribution (n=20)",
      "page": 1099,
      "pageLabel": "8",
      "confidence": 0.8,
      "evidence": [
        "referenced",
        "graphic"
      ]
    },
    {
      "kind": "figure",
      "number": "B2",
      "title": "End-user values and preferences",
      "page": 1100,
      "pageLabel": "9",
      "confidence": 0.8,
      "evidence": [
        "referenced",
        "graphic"
      ]
    },
    {
      "kind": "figure",
      "number": "B3",
      "title": "Acceptability – people-related factors",
      "page": 1102,
      "pageLabel": "11",
      "confidence": 0.8,
      "evidence": [
        "referenced",
        "graphic"
      ]
    },
    {
      "kind": "figure",
      "number": "B4",
      "title": "Acceptability – Test factors",
      "page": 1106,
      "pageLabel": "15",
      "confidence": 0.8,
      "evidence": [
        "referenced",
        "graphic"
      ]
    },
    {
      "kind": "figure",
      "number": "B5",
      "title": "Acceptability – Contextual factors",
      "page": 1108,
      "pageLabel": "17",
      "confidence": 0.8,
      "evidence": [
        "referenced",
        "graphic"
      ]
    },
    {
      "kind": "figure",
      "number": "B6",
      "title": "Feasibility – People factors",
      "page": 1109,
      "pageLabel": "18",
      "confidence": 0.8,
      "evidence": [
        "referenced",
        "graphic"
      ]
    },
    {
      "kind": "figure",
      "number": "B7",
      "title": "Feasibility –Test factors",
      "page": 1110,
      "pageLabel": "19",
      "confidence": 0.8,
      "evidence": [
        "referenced",
        "graphic"
      ]
    },
    {
      "kind": "figure",
      "number": "B8",
      "title": "Feasibility – Contextual factors",
      "page": 1112,
      "pageLabel": "21",
      "confidence": 0.8,
      "evidence": [
        "referenced",
        "graphic"
      ]
    },
    {
      "kind": "figure",
      "number": "B9",
      "title": "Equity factors",
      "page": 1113,
      "pageLabel": "22",
      "confidence": 0.8,
      "evidence": [
        "referenced",
        "graphic"
      ]
    },
    {
      "kind": "table",
      "number": "C1",
      "title": "List of attributes and levels included in both provider and consumer DCEs",
      "page": 1120,
      "pageLabel": null,
      "confidence": 0.7,
      "evidence": [
        "referenced"
      ]
    },
    {
      "kind": "figure",
      "number": "C1",
      "title": "Location of DCE respondents",
      "page": 1122,
      "pageLabel": "1",
      "confidence": 0.8,
      "evidence": [
        "referenced",
        "graphic"
      ]
    },
    {
      "kind": "figure",
      "number": "C2",
      "title": "Willingness to accept change in false positivity rate for DCE attributes",
      "page": 1124,
      "pageLabel": "3",
      "confidence": 0.8,
      "evidence": [
        "referenced",
        "graphic"
      ]
    }
  ],
  "images": [
    {
      "id": "img-p013-1",
      "file": "images/img-p013-1.webp",
      "page": 13,
      "narratives": {
        "en": "PRISMA flow diagram of study selection for Xpert Ultra. From 1267 database records (746 duplicates removed), 521 were screened, 110 reports were assessed for eligibility and 79 were excluded with reasons listed; 8 further records came from a WHO public call. 33 studies were included in the review.",
        "ar": "مخطط تدفق PRISMA لاختيار الدراسات الخاصة باختبار Xpert Ultra. من بين 1267 سجلاً من قواعد البيانات (حُذف 746 سجلاً مكرراً)، فُحص 521 سجلاً، وقُيّم 110 تقارير من حيث الأهلية واستُبعد 79 منها مع ذكر الأسباب؛ وجاءت 8 سجلات إضافية من دعوة عامة أطلقتها المنظمة. وأُدرجت 33 دراسة في الاستعراض.",
        "zh": "Xpert Ultra研究筛选的PRISMA流程图。从1267条数据库记录（删除746条重复记录）中筛选了521条，评估了110份报告的合格性，排除79份并列出原因；另有8条记录来自世卫组织公开征集。最终纳入33项研究。",
        "es": "Diagrama de flujo PRISMA de la selección de estudios sobre Xpert Ultra. De 1267 registros de bases de datos (se eliminaron 746 duplicados), se cribaron 521, se evaluó la elegibilidad de 110 informes y se excluyeron 79, con los motivos indicados; otros 8 registros procedieron de una convocatoria pública de la OMS. Se incluyeron 33 estudios en la revisión.",
        "fr": "Diagramme de flux PRISMA de la sélection des études sur Xpert Ultra. Sur 1267 enregistrements issus des bases de données (746 doublons supprimés), 521 ont été examinés, l'éligibilité de 110 rapports a été évaluée et 79 ont été exclus, avec les motifs indiqués ; 8 autres enregistrements provenaient d'un appel public de l'OMS. 33 études ont été incluses dans la revue.",
        "ru": "Блок-схема PRISMA отбора исследований по Xpert Ultra. Из 1267 записей баз данных (удалено 746 дубликатов) проверено 521, на соответствие критериям оценено 110 отчётов, 79 исключено с указанием причин; ещё 8 записей получено в ответ на открытый призыв ВОЗ. В обзор включено 33 исследования."
      },
      "state": "draft"
    },
    {
      "id": "img-p014-1",
      "file": "images/img-p014-1.webp",
      "page": 14,
      "narratives": {
        "en": "PRISMA flow diagram of study selection for Truenat assays. From 1175 database records (524 duplicates removed), 651 were screened and 34 reports were assessed for eligibility; 4 further reports came from citation searching and a WHO call for data. Five studies were included in the review (four for pulmonary TB and two for rifampicin resistance).",
        "ar": "مخطط تدفق PRISMA لاختيار الدراسات الخاصة باختبارات Truenat. من بين 1175 سجلاً من قواعد البيانات (حُذف 524 سجلاً مكرراً)، فُحص 651 سجلاً وقُيّم 34 تقريراً من حيث الأهلية؛ وجاءت 4 تقارير إضافية من البحث في الاستشهادات ومن دعوة المنظمة لتقديم البيانات. وأُدرجت خمس دراسات في الاستعراض (أربع للسل الرئوي واثنتان لمقاومة الريفامبيسين).",
        "zh": "Truenat检测研究筛选的PRISMA流程图。从1175条数据库记录（删除524条重复记录）中筛选了651条，评估了34份报告的合格性；另有4份报告来自引文检索和世卫组织数据征集。最终纳入5项研究（4项涉及肺结核，2项涉及利福平耐药）。",
        "es": "Diagrama de flujo PRISMA de la selección de estudios sobre las pruebas Truenat. De 1175 registros de bases de datos (se eliminaron 524 duplicados), se cribaron 651 y se evaluó la elegibilidad de 34 informes; otros 4 informes procedieron de la búsqueda de citas y de una convocatoria de datos de la OMS. Se incluyeron cinco estudios (cuatro sobre TB pulmonar y dos sobre resistencia a la rifampicina).",
        "fr": "Diagramme de flux PRISMA de la sélection des études sur les tests Truenat. Sur 1175 enregistrements issus des bases de données (524 doublons supprimés), 651 ont été examinés et l'éligibilité de 34 rapports a été évaluée ; 4 autres rapports provenaient de la recherche de citations et d'un appel à données de l'OMS. Cinq études ont été incluses (quatre sur la tuberculose pulmonaire et deux sur la résistance à la rifampicine).",
        "ru": "Блок-схема PRISMA отбора исследований по тестам Truenat. Из 1175 записей баз данных (удалено 524 дубликата) проверена 651, на соответствие критериям оценено 34 отчёта; ещё 4 отчёта получено из поиска по цитированию и в ответ на запрос данных ВОЗ. Включено пять исследований (четыре по туберкулёзу лёгких и два по устойчивости к рифампицину)."
      },
      "state": "draft"
    },
    {
      "id": "img-p015-1",
      "file": "images/img-p015-1.webp",
      "page": 15,
      "narratives": {
        "en": "PRISMA flow diagram of study selection for STANDARD M10 and other new LC-aNAATs. From 37 database records (3 duplicates removed), 34 were screened, 32 excluded and 2 reports assessed for eligibility; both were excluded (an ongoing trial and a conference abstract/case-control study). No studies were included.",
        "ar": "مخطط تدفق PRISMA لاختيار الدراسات الخاصة باختبار STANDARD M10 وغيره من اختبارات LC-aNAAT الجديدة. من بين 37 سجلاً من قواعد البيانات (حُذفت 3 سجلات مكررة)، فُحص 34 سجلاً واستُبعد 32 منها وقُيّم تقريران من حيث الأهلية؛ واستُبعد كلاهما (تجربة جارية وملخص مؤتمر/دراسة حالات وشواهد). ولم تُدرج أي دراسة.",
        "zh": "STANDARD M10及其他新型LC-aNAATs研究筛选的PRISMA流程图。从37条数据库记录（删除3条重复记录）中筛选了34条，排除32条，评估了2份报告的合格性；两份均被排除（一项正在进行的试验和一份会议摘要/病例对照研究）。未纳入任何研究。",
        "es": "Diagrama de flujo PRISMA de la selección de estudios sobre STANDARD M10 y otras LC-aNAAT nuevas. De 37 registros de bases de datos (se eliminaron 3 duplicados), se cribaron 34, se excluyeron 32 y se evaluó la elegibilidad de 2 informes; ambos se excluyeron (un ensayo en curso y un resumen de congreso/estudio de casos y controles). No se incluyó ningún estudio.",
        "fr": "Diagramme de flux PRISMA de la sélection des études sur STANDARD M10 et d'autres nouveaux LC-aNAAT. Sur 37 enregistrements issus des bases de données (3 doublons supprimés), 34 ont été examinés, 32 exclus et l'éligibilité de 2 rapports évaluée ; les deux ont été exclus (un essai en cours et un résumé de congrès/étude cas-témoins). Aucune étude n'a été incluse.",
        "ru": "Блок-схема PRISMA отбора исследований по STANDARD M10 и другим новым LC-aNAAT. Из 37 записей баз данных (удалено 3 дубликата) проверено 34, исключено 32, на соответствие критериям оценено 2 отчёта; оба исключены (текущее испытание и тезисы конференции/исследование «случай-контроль»). Ни одно исследование не включено."
      },
      "state": "draft"
    },
    {
      "id": "img-p022-1",
      "file": "images/img-p022-1.webp",
      "page": 22,
      "narratives": {
        "en": "Risk-of-bias and applicability-concerns chart for 36 studies of LC-aNAATs on respiratory specimens with a microbiological reference standard. Each study is rated high (red), unclear (yellow) or low (green) for patient selection, index test (LC-aNAATs), reference standard and flow and timing; most ratings are low. High or unclear ratings occur mainly for patient selection.",
        "ar": "مخطط لخطر التحيز والمخاوف بشأن قابلية التطبيق لعدد 36 دراسة لاختبارات LC-aNAAT على العينات التنفسية مع معيار مرجعي ميكروبيولوجي. تُصنَّف كل دراسة على أنها مرتفعة (بالأحمر) أو غير واضحة (بالأصفر) أو منخفضة (بالأخضر) من حيث اختيار المرضى والاختبار المؤشر (LC-aNAATs) والمعيار المرجعي والتدفق والتوقيت؛ ومعظم التقييمات منخفضة. وتظهر التقييمات المرتفعة أو غير الواضحة أساساً في اختيار المرضى.",
        "zh": "36项研究的偏倚风险和适用性问题图（呼吸道标本、微生物学参考标准下的LC-aNAATs）。每项研究在患者选择、指标试验（LC-aNAATs）、参考标准以及流程和时间方面被评为高（红色）、不明确（黄色）或低（绿色）；大多数评级为低。高或不明确的评级主要出现在患者选择方面。",
        "es": "Gráfico del riesgo de sesgo y los problemas de aplicabilidad de 36 estudios de LC-aNAAT en muestras respiratorias con un patrón de referencia microbiológico. Cada estudio se califica como alto (rojo), incierto (amarillo) o bajo (verde) en selección de pacientes, prueba índice (LC-aNAAT), patrón de referencia y flujo y cronología; la mayoría de las calificaciones son bajas. Las calificaciones altas o inciertas se concentran sobre todo en la selección de pacientes.",
        "fr": "Graphique du risque de biais et des préoccupations quant à l'applicabilité pour 36 études de LC-aNAAT sur des échantillons respiratoires avec une norme de référence microbiologique. Chaque étude est jugée élevée (rouge), incertaine (jaune) ou faible (vert) pour la sélection des patients, le test index (LC-aNAAT), la norme de référence et le flux et la chronologie ; la plupart des évaluations sont faibles. Les évaluations élevées ou incertaines concernent surtout la sélection des patients.",
        "ru": "Диаграмма риска систематической ошибки и вопросов применимости для 36 исследований LC-aNAAT на респираторных образцах с микробиологическим эталонным стандартом. Каждое исследование оценивается как высокий (красный), неясный (жёлтый) или низкий (зелёный) риск по отбору пациентов, индексному тесту (LC-aNAAT), эталонному стандарту, а также потоку и срокам; большинство оценок низкие. Высокие или неясные оценки встречаются в основном в отборе пациентов."
      },
      "state": "draft"
    },
    {
      "id": "img-p023-1",
      "file": "images/img-p023-1.webp",
      "page": 23,
      "narratives": {
        "en": "Stacked horizontal bar chart summarizing risk of bias and applicability concerns across 36 studies, as percentages of studies rated high (red), unclear (yellow) or low (green). For risk of bias, patient selection was 3 high, 5 unclear and 28 low; index test 1 unclear and 35 low; reference standard 1 high, 4 unclear and 31 low; flow and timing 2 unclear and 34 low. For applicability, patient selection was 8 high, 4 unclear and 24 low; index test 1 unclear and 35 low; reference standard 1 high, 6 unclear and 29 low.",
        "ar": "مخطط شريطي أفقي مكدّس يلخص خطر التحيز والمخاوف بشأن قابلية التطبيق في 36 دراسة، كنسب مئوية من الدراسات المصنفة مرتفعة (بالأحمر) أو غير واضحة (بالأصفر) أو منخفضة (بالأخضر). بالنسبة لخطر التحيز: اختيار المرضى 3 مرتفعة و5 غير واضحة و28 منخفضة؛ الاختبار المؤشر 1 غير واضحة و35 منخفضة؛ المعيار المرجعي 1 مرتفعة و4 غير واضحة و31 منخفضة؛ التدفق والتوقيت 2 غير واضحة و34 منخفضة. وبالنسبة لقابلية التطبيق: اختيار المرضى 8 مرتفعة و4 غير واضحة و24 منخفضة؛ الاختبار المؤشر 1 غير واضحة و35 منخفضة؛ المعيار المرجعي 1 مرتفعة و6 غير واضحة و29 منخفضة.",
        "zh": "堆积水平条形图，汇总36项研究的偏倚风险和适用性问题，以评为高（红色）、不明确（黄色）或低（绿色）的研究百分比表示。偏倚风险：患者选择3项高、5项不明确、28项低；指标试验1项不明确、35项低；参考标准1项高、4项不明确、31项低；流程和时间2项不明确、34项低。适用性：患者选择8项高、4项不明确、24项低；指标试验1项不明确、35项低；参考标准1项高、6项不明确、29项低。",
        "es": "Gráfico de barras horizontales apiladas que resume el riesgo de sesgo y los problemas de aplicabilidad en 36 estudios, como porcentaje de estudios calificados como alto (rojo), incierto (amarillo) o bajo (verde). En riesgo de sesgo: selección de pacientes, 3 alto, 5 incierto y 28 bajo; prueba índice, 1 incierto y 35 bajo; patrón de referencia, 1 alto, 4 incierto y 31 bajo; flujo y cronología, 2 incierto y 34 bajo. En aplicabilidad: selección de pacientes, 8 alto, 4 incierto y 24 bajo; prueba índice, 1 incierto y 35 bajo; patrón de referencia, 1 alto, 6 incierto y 29 bajo.",
        "fr": "Diagramme en barres horizontales empilées résumant le risque de biais et les préoccupations quant à l'applicabilité pour 36 études, en pourcentage d'études jugées élevées (rouge), incertaines (jaune) ou faibles (vert). Risque de biais : sélection des patients, 3 élevé, 5 incertain et 28 faible ; test index, 1 incertain et 35 faible ; norme de référence, 1 élevé, 4 incertain et 31 faible ; flux et chronologie, 2 incertain et 34 faible. Applicabilité : sélection des patients, 8 élevé, 4 incertain et 24 faible ; test index, 1 incertain et 35 faible ; norme de référence, 1 élevé, 6 incertain et 29 faible.",
        "ru": "Горизонтальная столбчатая диаграмма с накоплением, обобщающая риск систематической ошибки и вопросы применимости по 36 исследованиям в процентах исследований с высокой (красный), неясной (жёлтый) или низкой (зелёный) оценкой. Риск ошибки: отбор пациентов — 3 высокий, 5 неясный, 28 низкий; индексный тест — 1 неясный, 35 низкий; эталонный стандарт — 1 высокий, 4 неясный, 31 низкий; поток и сроки — 2 неясный, 34 низкий. Применимость: отбор пациентов — 8 высокий, 4 неясный, 24 низкий; индексный тест — 1 неясный, 35 низкий; эталонный стандарт — 1 высокий, 6 неясный, 29 низкий."
      },
      "state": "draft"
    },
    {
      "id": "img-p026-1",
      "file": "images/img-p026-1.webp",
      "page": 26,
      "narratives": {
        "en": "Forest plot of sensitivity and specificity with 95% confidence intervals for 36 studies of LC-aNAATs for pulmonary TB, listing true and false positives and negatives and the brand (4 Truenat MTB Plus, 32 Xpert Ultra). Most sensitivities lie between about 0.8 and 1.0 (lowest 0.54, Mukoka 2023) and most specificities above 0.9; one study (Zar 2019) has sensitivity not estimable.",
        "ar": "مخطط غابي للحساسية والنوعية مع فترات ثقة 95% لـ36 دراسة لاختبارات LC-aNAAT للكشف عن السل الرئوي، يبين الإيجابيات والسلبيات الحقيقية والكاذبة والعلامة التجارية (4 Truenat MTB Plus و32 Xpert Ultra). تتراوح معظم قيم الحساسية بين نحو 0.8 و1.0 (أدناها 0.54، Mukoka 2023) ومعظم قيم النوعية أعلى من 0.9؛ والحساسية غير قابلة للتقدير في دراسة واحدة (Zar 2019).",
        "zh": "36项LC-aNAATs检测肺结核研究的灵敏度和特异度森林图（含95%置信区间），列出真阳性、假阳性、假阴性、真阴性及品牌（4项Truenat MTB Plus，32项Xpert Ultra）。大多数灵敏度约在0.8至1.0之间（最低为0.54，Mukoka 2023），大多数特异度高于0.9；一项研究（Zar 2019）的灵敏度无法估计。",
        "es": "Diagrama de bosque (forest plot) de la sensibilidad y la especificidad con intervalos de confianza del 95% de 36 estudios de LC-aNAAT para la TB pulmonar, con verdaderos y falsos positivos y negativos y la marca (4 Truenat MTB Plus, 32 Xpert Ultra). La mayoría de las sensibilidades se sitúan entre 0,8 y 1,0 aproximadamente (la más baja, 0,54, Mukoka 2023) y la mayoría de las especificidades superan 0,9; en un estudio (Zar 2019) la sensibilidad no es estimable.",
        "fr": "Graphique en forêt (forest plot) de la sensibilité et de la spécificité avec intervalles de confiance à 95 % pour 36 études de LC-aNAAT pour la tuberculose pulmonaire, indiquant les vrais et faux positifs et négatifs et la marque (4 Truenat MTB Plus, 32 Xpert Ultra). La plupart des sensibilités se situent entre environ 0,8 et 1,0 (la plus faible : 0,54, Mukoka 2023) et la plupart des spécificités dépassent 0,9 ; pour une étude (Zar 2019), la sensibilité n'est pas estimable.",
        "ru": "Лесовидный график чувствительности и специфичности с 95% доверительными интервалами для 36 исследований LC-aNAAT при туберкулёзе лёгких с указанием истинно и ложноположительных и отрицательных результатов и марки теста (4 Truenat MTB Plus, 32 Xpert Ultra). Большинство значений чувствительности примерно от 0,8 до 1,0 (минимальное 0,54, Mukoka 2023), специфичности — в основном выше 0,9; в одном исследовании (Zar 2019) чувствительность не поддаётся оценке."
      },
      "state": "draft"
    },
    {
      "id": "img-p029-1",
      "file": "images/img-p029-1.webp",
      "page": 29,
      "narratives": {
        "en": "Risk-of-bias and applicability-concerns chart for 10 studies of LC-aNAATs on respiratory specimens with a composite reference standard. Each study is rated high (red), unclear (yellow) or low (green) for patient selection, index test (LC-aNAATs), reference standard and flow and timing; most ratings are low.",
        "ar": "مخطط لخطر التحيز والمخاوف بشأن قابلية التطبيق لعدد 10 دراسة لاختبارات LC-aNAAT على العينات التنفسية مع معيار مرجعي مركّب. تُصنَّف كل دراسة على أنها مرتفعة (بالأحمر) أو غير واضحة (بالأصفر) أو منخفضة (بالأخضر) من حيث اختيار المرضى والاختبار المؤشر (LC-aNAATs) والمعيار المرجعي والتدفق والتوقيت؛ ومعظم التقييمات منخفضة.",
        "zh": "10项研究的偏倚风险和适用性问题图（呼吸道标本、复合参考标准下的LC-aNAATs）。每项研究在患者选择、指标试验（LC-aNAATs）、参考标准以及流程和时间方面被评为高（红色）、不明确（黄色）或低（绿色）；大多数评级为低。",
        "es": "Gráfico del riesgo de sesgo y los problemas de aplicabilidad de 10 estudios de LC-aNAAT en muestras respiratorias con un patrón de referencia compuesto. Cada estudio se califica como alto (rojo), incierto (amarillo) o bajo (verde) en selección de pacientes, prueba índice (LC-aNAAT), patrón de referencia y flujo y cronología; la mayoría de las calificaciones son bajas.",
        "fr": "Graphique du risque de biais et des préoccupations quant à l'applicabilité pour 10 études de LC-aNAAT sur des échantillons respiratoires avec une norme de référence composite. Chaque étude est jugée élevée (rouge), incertaine (jaune) ou faible (vert) pour la sélection des patients, le test index (LC-aNAAT), la norme de référence et le flux et la chronologie ; la plupart des évaluations sont faibles.",
        "ru": "Диаграмма риска систематической ошибки и вопросов применимости для 10 исследований LC-aNAAT на респираторных образцах с комбинированным эталонным стандартом. Каждое исследование оценивается как высокий (красный), неясный (жёлтый) или низкий (зелёный) риск по отбору пациентов, индексному тесту (LC-aNAAT), эталонному стандарту, а также потоку и срокам; большинство оценок низкие."
      },
      "state": "draft"
    },
    {
      "id": "img-p029-2",
      "file": "images/img-p029-2.webp",
      "page": 29,
      "narratives": {
        "en": "Forest plot of sensitivity and specificity with 95% confidence intervals for 10 studies of LC-aNAATs for pulmonary TB against a composite reference standard. Sensitivity varies widely, from 0.00 (Zar 2019) to 0.96 (Opota 2019), while specificity is 0.96–1.00 in all studies.",
        "ar": "مخطط غابي للحساسية والنوعية مع فترات ثقة 95% لـ10 دراسات لاختبارات LC-aNAAT للكشف عن السل الرئوي مقارنةً بمعيار مرجعي مركّب. تتفاوت الحساسية تفاوتاً كبيراً من 0.00 (Zar 2019) إلى 0.96 (Opota 2019)، في حين تتراوح النوعية بين 0.96 و1.00 في جميع الدراسات.",
        "zh": "10项LC-aNAATs检测肺结核研究（以复合参考标准为对照）的灵敏度和特异度森林图（含95%置信区间）。灵敏度差异很大，从0.00（Zar 2019）到0.96（Opota 2019），而所有研究的特异度均为0.96–1.00。",
        "es": "Diagrama de bosque de la sensibilidad y la especificidad con intervalos de confianza del 95% de 10 estudios de LC-aNAAT para la TB pulmonar frente a un patrón de referencia compuesto. La sensibilidad varía mucho, de 0,00 (Zar 2019) a 0,96 (Opota 2019), mientras que la especificidad es de 0,96–1,00 en todos los estudios.",
        "fr": "Graphique en forêt de la sensibilité et de la spécificité avec intervalles de confiance à 95 % pour 10 études de LC-aNAAT pour la tuberculose pulmonaire par rapport à une norme de référence composite. La sensibilité varie fortement, de 0,00 (Zar 2019) à 0,96 (Opota 2019), tandis que la spécificité est de 0,96–1,00 dans toutes les études.",
        "ru": "Лесовидный график чувствительности и специфичности с 95% доверительными интервалами для 10 исследований LC-aNAAT при туберкулёзе лёгких относительно комбинированного эталонного стандарта. Чувствительность сильно варьирует — от 0,00 (Zar 2019) до 0,96 (Opota 2019), тогда как специфичность во всех исследованиях составляет 0,96–1,00."
      },
      "state": "draft"
    },
    {
      "id": "img-p030-1",
      "file": "images/img-p030-1.webp",
      "page": 30,
      "narratives": {
        "en": "Risk-of-bias and applicability-concerns chart for 12 studies of LC-aNAATs in people living with HIV. Each study is rated high (red), unclear (yellow) or low (green) for patient selection, index test (LC-aNAATs), reference standard and flow and timing; most ratings are low.",
        "ar": "مخطط لخطر التحيز والمخاوف بشأن قابلية التطبيق لعدد 12 دراسة لاختبارات LC-aNAAT لدى المتعايشين مع فيروس العوز المناعي البشري. تُصنَّف كل دراسة على أنها مرتفعة (بالأحمر) أو غير واضحة (بالأصفر) أو منخفضة (بالأخضر) من حيث اختيار المرضى والاختبار المؤشر (LC-aNAATs) والمعيار المرجعي والتدفق والتوقيت؛ ومعظم التقييمات منخفضة.",
        "zh": "12项研究的偏倚风险和适用性问题图（艾滋病毒感染者中的LC-aNAATs）。每项研究在患者选择、指标试验（LC-aNAATs）、参考标准以及流程和时间方面被评为高（红色）、不明确（黄色）或低（绿色）；大多数评级为低。",
        "es": "Gráfico del riesgo de sesgo y los problemas de aplicabilidad de 12 estudios de LC-aNAAT en personas con el VIH. Cada estudio se califica como alto (rojo), incierto (amarillo) o bajo (verde) en selección de pacientes, prueba índice (LC-aNAAT), patrón de referencia y flujo y cronología; la mayoría de las calificaciones son bajas.",
        "fr": "Graphique du risque de biais et des préoccupations quant à l'applicabilité pour 12 études de LC-aNAAT chez les personnes vivant avec le VIH. Chaque étude est jugée élevée (rouge), incertaine (jaune) ou faible (vert) pour la sélection des patients, le test index (LC-aNAAT), la norme de référence et le flux et la chronologie ; la plupart des évaluations sont faibles.",
        "ru": "Диаграмма риска систематической ошибки и вопросов применимости для 12 исследований LC-aNAAT у людей, живущих с ВИЧ. Каждое исследование оценивается как высокий (красный), неясный (жёлтый) или низкий (зелёный) риск по отбору пациентов, индексному тесту (LC-aNAAT), эталонному стандарту, а также потоку и срокам; большинство оценок низкие."
      },
      "state": "draft"
    },
    {
      "id": "img-p030-2",
      "file": "images/img-p030-2.webp",
      "page": 30,
      "narratives": {
        "en": "Forest plot of sensitivity and specificity with 95% confidence intervals for 12 studies of LC-aNAATs for pulmonary TB in people living with HIV (2 Truenat MTB Plus, 10 Xpert Ultra). Sensitivity ranges from 0.54 (Mukoka 2023) to 1.00 and specificity from 0.78 to 1.00.",
        "ar": "مخطط غابي للحساسية والنوعية مع فترات ثقة 95% لـ12 دراسة لاختبارات LC-aNAAT للكشف عن السل الرئوي لدى المتعايشين مع فيروس العوز المناعي البشري (2 Truenat MTB Plus و10 Xpert Ultra). تتراوح الحساسية بين 0.54 (Mukoka 2023) و1.00 والنوعية بين 0.78 و1.00.",
        "zh": "12项LC-aNAATs在艾滋病毒感染者中检测肺结核研究的灵敏度和特异度森林图（含95%置信区间）（2项Truenat MTB Plus，10项Xpert Ultra）。灵敏度范围为0.54（Mukoka 2023）至1.00，特异度为0.78至1.00。",
        "es": "Diagrama de bosque de la sensibilidad y la especificidad con intervalos de confianza del 95% de 12 estudios de LC-aNAAT para la TB pulmonar en personas con el VIH (2 Truenat MTB Plus, 10 Xpert Ultra). La sensibilidad oscila entre 0,54 (Mukoka 2023) y 1,00 y la especificidad entre 0,78 y 1,00.",
        "fr": "Graphique en forêt de la sensibilité et de la spécificité avec intervalles de confiance à 95 % pour 12 études de LC-aNAAT pour la tuberculose pulmonaire chez les personnes vivant avec le VIH (2 Truenat MTB Plus, 10 Xpert Ultra). La sensibilité va de 0,54 (Mukoka 2023) à 1,00 et la spécificité de 0,78 à 1,00.",
        "ru": "Лесовидный график чувствительности и специфичности с 95% доверительными интервалами для 12 исследований LC-aNAAT при туберкулёзе лёгких у ЛЖВ (2 Truenat MTB Plus, 10 Xpert Ultra). Чувствительность — от 0,54 (Mukoka 2023) до 1,00, специфичность — от 0,78 до 1,00."
      },
      "state": "draft"
    },
    {
      "id": "img-p031-1",
      "file": "images/img-p031-1.webp",
      "page": 31,
      "narratives": {
        "en": "Risk-of-bias and applicability-concerns chart for 6 studies of LC-aNAATs on sputum in HIV-negative people. Each study is rated high (red), unclear (yellow) or low (green) for patient selection, index test (LC-aNAATs), reference standard and flow and timing; most ratings are low. The only high rating is applicability of patient selection for Park 2019.",
        "ar": "مخطط لخطر التحيز والمخاوف بشأن قابلية التطبيق لعدد 6 دراسة لاختبارات LC-aNAAT على البلغم لدى غير المصابين بفيروس العوز المناعي البشري. تُصنَّف كل دراسة على أنها مرتفعة (بالأحمر) أو غير واضحة (بالأصفر) أو منخفضة (بالأخضر) من حيث اختيار المرضى والاختبار المؤشر (LC-aNAATs) والمعيار المرجعي والتدفق والتوقيت؛ ومعظم التقييمات منخفضة. والتقييم المرتفع الوحيد هو قابلية تطبيق اختيار المرضى في دراسة Park 2019.",
        "zh": "6项研究的偏倚风险和适用性问题图（艾滋病毒阴性者痰标本中的LC-aNAATs）。每项研究在患者选择、指标试验（LC-aNAATs）、参考标准以及流程和时间方面被评为高（红色）、不明确（黄色）或低（绿色）；大多数评级为低。唯一的高评级是Park 2019的患者选择适用性。",
        "es": "Gráfico del riesgo de sesgo y los problemas de aplicabilidad de 6 estudios de LC-aNAAT en esputo de personas VIH-negativas. Cada estudio se califica como alto (rojo), incierto (amarillo) o bajo (verde) en selección de pacientes, prueba índice (LC-aNAAT), patrón de referencia y flujo y cronología; la mayoría de las calificaciones son bajas. La única calificación alta es la aplicabilidad de la selección de pacientes en Park 2019.",
        "fr": "Graphique du risque de biais et des préoccupations quant à l'applicabilité pour 6 études de LC-aNAAT sur des expectorations de personnes séronégatives pour le VIH. Chaque étude est jugée élevée (rouge), incertaine (jaune) ou faible (vert) pour la sélection des patients, le test index (LC-aNAAT), la norme de référence et le flux et la chronologie ; la plupart des évaluations sont faibles. La seule évaluation élevée concerne l'applicabilité de la sélection des patients pour Park 2019.",
        "ru": "Диаграмма риска систематической ошибки и вопросов применимости для 6 исследований LC-aNAAT на мокроте у ВИЧ-отрицательных лиц. Каждое исследование оценивается как высокий (красный), неясный (жёлтый) или низкий (зелёный) риск по отбору пациентов, индексному тесту (LC-aNAAT), эталонному стандарту, а также потоку и срокам; большинство оценок низкие. Единственная высокая оценка — применимость отбора пациентов в Park 2019."
      },
      "state": "draft"
    },
    {
      "id": "img-p031-2",
      "file": "images/img-p031-2.webp",
      "page": 31,
      "narratives": {
        "en": "Forest plot of sensitivity and specificity with 95% confidence intervals for 6 studies of LC-aNAATs for pulmonary TB in HIV-negative people (2 Truenat MTB Plus, 4 Xpert Ultra). Sensitivities range from 0.88 to 0.97 and specificities from 0.91 to 0.99.",
        "ar": "مخطط غابي للحساسية والنوعية مع فترات ثقة 95% لـ6 دراسات لاختبارات LC-aNAAT للكشف عن السل الرئوي لدى غير المصابين بفيروس العوز المناعي البشري (2 Truenat MTB Plus و4 Xpert Ultra). تتراوح الحساسية بين 0.88 و0.97 والنوعية بين 0.91 و0.99.",
        "zh": "6项LC-aNAATs在艾滋病毒阴性者中检测肺结核研究的灵敏度和特异度森林图（含95%置信区间）（2项Truenat MTB Plus，4项Xpert Ultra）。灵敏度范围为0.88至0.97，特异度为0.91至0.99。",
        "es": "Diagrama de bosque de la sensibilidad y la especificidad con intervalos de confianza del 95% de 6 estudios de LC-aNAAT para la TB pulmonar en personas VIH-negativas (2 Truenat MTB Plus, 4 Xpert Ultra). Las sensibilidades van de 0,88 a 0,97 y las especificidades de 0,91 a 0,99.",
        "fr": "Graphique en forêt de la sensibilité et de la spécificité avec intervalles de confiance à 95 % pour 6 études de LC-aNAAT pour la tuberculose pulmonaire chez des personnes séronégatives pour le VIH (2 Truenat MTB Plus, 4 Xpert Ultra). Les sensibilités vont de 0,88 à 0,97 et les spécificités de 0,91 à 0,99.",
        "ru": "Лесовидный график чувствительности и специфичности с 95% доверительными интервалами для 6 исследований LC-aNAAT при туберкулёзе лёгких у ВИЧ-отрицательных лиц (2 Truenat MTB Plus, 4 Xpert Ultra). Чувствительность — от 0,88 до 0,97, специфичность — от 0,91 до 0,99."
      },
      "state": "draft"
    },
    {
      "id": "img-p032-1",
      "file": "images/img-p032-1.webp",
      "page": 32,
      "narratives": {
        "en": "Risk-of-bias and applicability-concerns chart for 13 studies of LC-aNAATs for detection of rifampicin resistance. Each study is rated high (red), unclear (yellow) or low (green) for patient selection, index test (LC-aNAATs), reference standard and flow and timing; most ratings are low.",
        "ar": "مخطط لخطر التحيز والمخاوف بشأن قابلية التطبيق لعدد 13 دراسة لاختبارات LC-aNAAT للكشف عن مقاومة الريفامبيسين. تُصنَّف كل دراسة على أنها مرتفعة (بالأحمر) أو غير واضحة (بالأصفر) أو منخفضة (بالأخضر) من حيث اختيار المرضى والاختبار المؤشر (LC-aNAATs) والمعيار المرجعي والتدفق والتوقيت؛ ومعظم التقييمات منخفضة.",
        "zh": "13项研究的偏倚风险和适用性问题图（LC-aNAATs检测利福平耐药）。每项研究在患者选择、指标试验（LC-aNAATs）、参考标准以及流程和时间方面被评为高（红色）、不明确（黄色）或低（绿色）；大多数评级为低。",
        "es": "Gráfico del riesgo de sesgo y los problemas de aplicabilidad de 13 estudios de LC-aNAAT para la detección de la resistencia a la rifampicina. Cada estudio se califica como alto (rojo), incierto (amarillo) o bajo (verde) en selección de pacientes, prueba índice (LC-aNAAT), patrón de referencia y flujo y cronología; la mayoría de las calificaciones son bajas.",
        "fr": "Graphique du risque de biais et des préoccupations quant à l'applicabilité pour 13 études de LC-aNAAT pour la détection de la résistance à la rifampicine. Chaque étude est jugée élevée (rouge), incertaine (jaune) ou faible (vert) pour la sélection des patients, le test index (LC-aNAAT), la norme de référence et le flux et la chronologie ; la plupart des évaluations sont faibles.",
        "ru": "Диаграмма риска систематической ошибки и вопросов применимости для 13 исследований LC-aNAAT для выявления устойчивости к рифампицину. Каждое исследование оценивается как высокий (красный), неясный (жёлтый) или низкий (зелёный) риск по отбору пациентов, индексному тесту (LC-aNAAT), эталонному стандарту, а также потоку и срокам; большинство оценок низкие."
      },
      "state": "draft"
    },
    {
      "id": "img-p033-1",
      "file": "images/img-p033-1.webp",
      "page": 33,
      "narratives": {
        "en": "Risk-of-bias and applicability-concerns chart for 13 studies of LC-aNAATs for detection of rifampicin resistance. Each study is rated high (red), unclear (yellow) or low (green) for patient selection, index test (LC-aNAATs), reference standard and flow and timing; most ratings are low. It is nearly identical to the chart on the previous page.",
        "ar": "مخطط لخطر التحيز والمخاوف بشأن قابلية التطبيق لعدد 13 دراسة لاختبارات LC-aNAAT للكشف عن مقاومة الريفامبيسين. تُصنَّف كل دراسة على أنها مرتفعة (بالأحمر) أو غير واضحة (بالأصفر) أو منخفضة (بالأخضر) من حيث اختيار المرضى والاختبار المؤشر (LC-aNAATs) والمعيار المرجعي والتدفق والتوقيت؛ ومعظم التقييمات منخفضة. وهو مطابق تقريباً للمخطط الوارد في الصفحة السابقة.",
        "zh": "13项研究的偏倚风险和适用性问题图（LC-aNAATs检测利福平耐药）。每项研究在患者选择、指标试验（LC-aNAATs）、参考标准以及流程和时间方面被评为高（红色）、不明确（黄色）或低（绿色）；大多数评级为低。该图与上一页的图几乎相同。",
        "es": "Gráfico del riesgo de sesgo y los problemas de aplicabilidad de 13 estudios de LC-aNAAT para la detección de la resistencia a la rifampicina. Cada estudio se califica como alto (rojo), incierto (amarillo) o bajo (verde) en selección de pacientes, prueba índice (LC-aNAAT), patrón de referencia y flujo y cronología; la mayoría de las calificaciones son bajas. Es casi idéntico al gráfico de la página anterior.",
        "fr": "Graphique du risque de biais et des préoccupations quant à l'applicabilité pour 13 études de LC-aNAAT pour la détection de la résistance à la rifampicine. Chaque étude est jugée élevée (rouge), incertaine (jaune) ou faible (vert) pour la sélection des patients, le test index (LC-aNAAT), la norme de référence et le flux et la chronologie ; la plupart des évaluations sont faibles. Il est presque identique au graphique de la page précédente.",
        "ru": "Диаграмма риска систематической ошибки и вопросов применимости для 13 исследований LC-aNAAT для выявления устойчивости к рифампицину. Каждое исследование оценивается как высокий (красный), неясный (жёлтый) или низкий (зелёный) риск по отбору пациентов, индексному тесту (LC-aNAAT), эталонному стандарту, а также потоку и срокам; большинство оценок низкие. Она почти идентична диаграмме на предыдущей странице."
      },
      "state": "draft"
    },
    {
      "id": "img-p033-2",
      "file": "images/img-p033-2.webp",
      "page": 33,
      "narratives": {
        "en": "Forest plot of sensitivity and specificity with 95% confidence intervals for detection of rifampicin resistance in 13 studies (2 Truenat MTB-RIF Dx, 11 Xpert Ultra). Truenat MTB-RIF Dx sensitivities are 0.53 and 0.85; Xpert Ultra sensitivities are 0.93–1.00 where estimable, and specificities are 0.97–1.00 across studies.",
        "ar": "مخطط غابي للحساسية والنوعية مع فترات ثقة 95% للكشف عن مقاومة الريفامبيسين في 13 دراسة (2 Truenat MTB-RIF Dx و11 Xpert Ultra). قيمتا الحساسية لاختبار Truenat MTB-RIF Dx هما 0.53 و0.85؛ وتتراوح حساسية Xpert Ultra بين 0.93 و1.00 حيثما أمكن تقديرها، والنوعية بين 0.97 و1.00 في جميع الدراسات.",
        "zh": "13项研究检测利福平耐药的灵敏度和特异度森林图（含95%置信区间）（2项Truenat MTB-RIF Dx，11项Xpert Ultra）。Truenat MTB-RIF Dx的灵敏度为0.53和0.85；Xpert Ultra在可估计时的灵敏度为0.93–1.00，各研究特异度为0.97–1.00。",
        "es": "Diagrama de bosque de la sensibilidad y la especificidad con intervalos de confianza del 95% para la detección de la resistencia a la rifampicina en 13 estudios (2 Truenat MTB-RIF Dx, 11 Xpert Ultra). Las sensibilidades de Truenat MTB-RIF Dx son 0,53 y 0,85; las de Xpert Ultra son de 0,93–1,00 cuando son estimables, y las especificidades son de 0,97–1,00.",
        "fr": "Graphique en forêt de la sensibilité et de la spécificité avec intervalles de confiance à 95 % pour la détection de la résistance à la rifampicine dans 13 études (2 Truenat MTB-RIF Dx, 11 Xpert Ultra). Les sensibilités de Truenat MTB-RIF Dx sont de 0,53 et 0,85 ; celles de Xpert Ultra sont de 0,93–1,00 lorsqu'elles sont estimables, et les spécificités de 0,97–1,00.",
        "ru": "Лесовидный график чувствительности и специфичности с 95% доверительными интервалами для выявления устойчивости к рифампицину в 13 исследованиях (2 Truenat MTB-RIF Dx, 11 Xpert Ultra). Чувствительность Truenat MTB-RIF Dx — 0,53 и 0,85; Xpert Ultra — 0,93–1,00 там, где её можно оценить; специфичность — 0,97–1,00."
      },
      "state": "draft"
    },
    {
      "id": "img-p044-1",
      "file": "images/img-p044-1.webp",
      "page": 44,
      "narratives": {
        "en": "Forest plot of sensitivity and specificity with 95% confidence intervals, grouped by brand, for pulmonary TB on sputum with a microbiological reference standard (MRS): 32 Xpert Ultra studies sorted by sensitivity (0.54 to 1.00) and 4 Truenat MTB Plus studies (0.85 to 0.96). Most specificities are above 0.9.",
        "ar": "مخطط غابي للحساسية والنوعية مع فترات ثقة 95%، مجمّع حسب العلامة التجارية، للكشف عن السل الرئوي في البلغم مع معيار مرجعي ميكروبيولوجي (MRS): 32 دراسة لاختبار Xpert Ultra مرتبة حسب الحساسية (من 0.54 إلى 1.00) و4 دراسات لاختبار Truenat MTB Plus (من 0.85 إلى 0.96). ومعظم قيم النوعية أعلى من 0.9.",
        "zh": "灵敏度和特异度森林图（含95%置信区间），按品牌分组，用于以微生物学参考标准（MRS）检测痰标本中的肺结核：32项Xpert Ultra研究按灵敏度排序（0.54至1.00），4项Truenat MTB Plus研究（0.85至0.96）。大多数特异度高于0.9。",
        "es": "Diagrama de bosque de la sensibilidad y la especificidad con intervalos de confianza del 95%, agrupado por marca, para la TB pulmonar en esputo con un patrón de referencia microbiológico (MRS): 32 estudios de Xpert Ultra ordenados por sensibilidad (0,54 a 1,00) y 4 estudios de Truenat MTB Plus (0,85 a 0,96). La mayoría de las especificidades superan 0,9.",
        "fr": "Graphique en forêt de la sensibilité et de la spécificité avec intervalles de confiance à 95 %, regroupé par marque, pour la tuberculose pulmonaire sur expectorations avec une norme de référence microbiologique (MRS) : 32 études Xpert Ultra classées par sensibilité (0,54 à 1,00) et 4 études Truenat MTB Plus (0,85 à 0,96). La plupart des spécificités dépassent 0,9.",
        "ru": "Лесовидный график чувствительности и специфичности с 95% доверительными интервалами, по маркам тестов, для туберкулёза лёгких по мокроте с микробиологическим эталонным стандартом (MRS): 32 исследования Xpert Ultra, упорядоченные по чувствительности (от 0,54 до 1,00), и 4 исследования Truenat MTB Plus (от 0,85 до 0,96). Специфичность в большинстве случаев выше 0,9."
      },
      "state": "draft"
    },
    {
      "id": "img-p045-1",
      "file": "images/img-p045-1.webp",
      "page": 45,
      "narratives": {
        "en": "Forest plot of sensitivity and specificity with 95% confidence intervals, grouped by brand, for pulmonary TB in people living with HIV against a microbiological reference standard: 11 Xpert Ultra studies (sensitivity 0.54 to 1.00) and 2 Truenat MTB Plus studies (0.92 and 0.86).",
        "ar": "مخطط غابي للحساسية والنوعية مع فترات ثقة 95%، مجمّع حسب العلامة التجارية، للكشف عن السل الرئوي لدى المتعايشين مع فيروس العوز المناعي البشري مقارنةً بمعيار مرجعي ميكروبيولوجي: 11 دراسة لاختبار Xpert Ultra (الحساسية من 0.54 إلى 1.00) ودراستان لاختبار Truenat MTB Plus (0.92 و0.86).",
        "zh": "灵敏度和特异度森林图（含95%置信区间），按品牌分组，以微生物学参考标准检测艾滋病毒感染者中的肺结核：11项Xpert Ultra研究（灵敏度0.54至1.00）和2项Truenat MTB Plus研究（0.92和0.86）。",
        "es": "Diagrama de bosque de la sensibilidad y la especificidad con intervalos de confianza del 95%, agrupado por marca, para la TB pulmonar en personas con el VIH frente a un patrón de referencia microbiológico: 11 estudios de Xpert Ultra (sensibilidad de 0,54 a 1,00) y 2 de Truenat MTB Plus (0,92 y 0,86).",
        "fr": "Graphique en forêt de la sensibilité et de la spécificité avec intervalles de confiance à 95 %, regroupé par marque, pour la tuberculose pulmonaire chez les personnes vivant avec le VIH par rapport à une norme de référence microbiologique : 11 études Xpert Ultra (sensibilité de 0,54 à 1,00) et 2 études Truenat MTB Plus (0,92 et 0,86).",
        "ru": "Лесовидный график чувствительности и специфичности с 95% доверительными интервалами, по маркам тестов, для туберкулёза лёгких у ЛЖВ относительно микробиологического эталонного стандарта: 11 исследований Xpert Ultra (чувствительность от 0,54 до 1,00) и 2 исследования Truenat MTB Plus (0,92 и 0,86)."
      },
      "state": "draft"
    },
    {
      "id": "img-p045-2",
      "file": "images/img-p045-2.webp",
      "page": 45,
      "narratives": {
        "en": "Forest plot of sensitivity and specificity with 95% confidence intervals, grouped by brand, for pulmonary TB in HIV-negative people against a microbiological reference standard: 4 Xpert Ultra studies (sensitivity 0.88 to 0.91) and 2 Truenat MTB Plus studies (0.97 and 0.88).",
        "ar": "مخطط غابي للحساسية والنوعية مع فترات ثقة 95%، مجمّع حسب العلامة التجارية، للكشف عن السل الرئوي لدى غير المصابين بفيروس العوز المناعي البشري مقارنةً بمعيار مرجعي ميكروبيولوجي: 4 دراسات لاختبار Xpert Ultra (الحساسية من 0.88 إلى 0.91) ودراستان لاختبار Truenat MTB Plus (0.97 و0.88).",
        "zh": "灵敏度和特异度森林图（含95%置信区间），按品牌分组，以微生物学参考标准检测艾滋病毒阴性者中的肺结核：4项Xpert Ultra研究（灵敏度0.88至0.91）和2项Truenat MTB Plus研究（0.97和0.88）。",
        "es": "Diagrama de bosque de la sensibilidad y la especificidad con intervalos de confianza del 95%, agrupado por marca, para la TB pulmonar en personas VIH-negativas frente a un patrón de referencia microbiológico: 4 estudios de Xpert Ultra (sensibilidad de 0,88 a 0,91) y 2 de Truenat MTB Plus (0,97 y 0,88).",
        "fr": "Graphique en forêt de la sensibilité et de la spécificité avec intervalles de confiance à 95 %, regroupé par marque, pour la tuberculose pulmonaire chez des personnes séronégatives pour le VIH par rapport à une norme de référence microbiologique : 4 études Xpert Ultra (sensibilité de 0,88 à 0,91) et 2 études Truenat MTB Plus (0,97 et 0,88).",
        "ru": "Лесовидный график чувствительности и специфичности с 95% доверительными интервалами, по маркам тестов, для туберкулёза лёгких у ВИЧ-отрицательных лиц относительно микробиологического эталонного стандарта: 4 исследования Xpert Ultra (чувствительность от 0,88 до 0,91) и 2 исследования Truenat MTB Plus (0,97 и 0,88)."
      },
      "state": "draft"
    },
    {
      "id": "img-p046-1",
      "file": "images/img-p046-1.webp",
      "page": 46,
      "narratives": {
        "en": "Forest plot of sensitivity and specificity with 95% confidence intervals, grouped by brand, for smear-positive pulmonary TB against a microbiological reference standard: 16 Xpert Ultra and 3 Truenat MTB Plus studies. Sensitivities are 0.96–1.00, while specificities are often not estimable or have very wide intervals because of few true negatives.",
        "ar": "مخطط غابي للحساسية والنوعية مع فترات ثقة 95%، مجمّع حسب العلامة التجارية، للسل الرئوي إيجابي اللطاخة مقارنةً بمعيار مرجعي ميكروبيولوجي: 16 دراسة لاختبار Xpert Ultra و3 دراسات لاختبار Truenat MTB Plus. تتراوح الحساسية بين 0.96 و1.00، بينما تكون النوعية في الغالب غير قابلة للتقدير أو ذات فترات واسعة جداً بسبب قلة السلبيات الحقيقية.",
        "zh": "灵敏度和特异度森林图（含95%置信区间），按品牌分组，以微生物学参考标准检测涂片阳性肺结核：16项Xpert Ultra研究和3项Truenat MTB Plus研究。灵敏度为0.96–1.00，而由于真阴性很少，特异度常无法估计或置信区间很宽。",
        "es": "Diagrama de bosque de la sensibilidad y la especificidad con intervalos de confianza del 95%, agrupado por marca, para la TB pulmonar con baciloscopia positiva frente a un patrón de referencia microbiológico: 16 estudios de Xpert Ultra y 3 de Truenat MTB Plus. Las sensibilidades son de 0,96–1,00, mientras que las especificidades a menudo no son estimables o tienen intervalos muy amplios por los pocos verdaderos negativos.",
        "fr": "Graphique en forêt de la sensibilité et de la spécificité avec intervalles de confiance à 95 %, regroupé par marque, pour la tuberculose pulmonaire à frottis positif par rapport à une norme de référence microbiologique : 16 études Xpert Ultra et 3 études Truenat MTB Plus. Les sensibilités sont de 0,96–1,00, tandis que les spécificités sont souvent non estimables ou ont des intervalles très larges en raison du faible nombre de vrais négatifs.",
        "ru": "Лесовидный график чувствительности и специфичности с 95% доверительными интервалами, по маркам тестов, для туберкулёза лёгких с положительным мазком относительно микробиологического эталонного стандарта: 16 исследований Xpert Ultra и 3 исследования Truenat MTB Plus. Чувствительность 0,96–1,00, а специфичность часто не поддаётся оценке или имеет очень широкие интервалы из-за малого числа истинно отрицательных результатов."
      },
      "state": "draft"
    },
    {
      "id": "img-p046-2",
      "file": "images/img-p046-2.webp",
      "page": 46,
      "narratives": {
        "en": "Forest plot of sensitivity and specificity with 95% confidence intervals, grouped by brand, for smear-negative pulmonary TB against a microbiological reference standard: 17 Xpert Ultra studies (sensitivity 0.00 in Sabi 2018, otherwise 0.60 to 0.93) and 3 Truenat MTB Plus studies (0.72 to 0.81). Specificities are mostly 0.89–0.99.",
        "ar": "مخطط غابي للحساسية والنوعية مع فترات ثقة 95%، مجمّع حسب العلامة التجارية، للسل الرئوي سلبي اللطاخة مقارنةً بمعيار مرجعي ميكروبيولوجي: 17 دراسة لاختبار Xpert Ultra (الحساسية 0.00 في Sabi 2018، وفي غيرها من 0.60 إلى 0.93) و3 دراسات لاختبار Truenat MTB Plus (من 0.72 إلى 0.81). ومعظم قيم النوعية بين 0.89 و0.99.",
        "zh": "灵敏度和特异度森林图（含95%置信区间），按品牌分组，以微生物学参考标准检测涂片阴性肺结核：17项Xpert Ultra研究（Sabi 2018灵敏度为0.00，其余为0.60至0.93）和3项Truenat MTB Plus研究（0.72至0.81）。特异度大多为0.89–0.99。",
        "es": "Diagrama de bosque de la sensibilidad y la especificidad con intervalos de confianza del 95%, agrupado por marca, para la TB pulmonar con baciloscopia negativa frente a un patrón de referencia microbiológico: 17 estudios de Xpert Ultra (sensibilidad de 0,00 en Sabi 2018 y de 0,60 a 0,93 en los demás) y 3 de Truenat MTB Plus (0,72 a 0,81). Las especificidades son mayoritariamente de 0,89–0,99.",
        "fr": "Graphique en forêt de la sensibilité et de la spécificité avec intervalles de confiance à 95 %, regroupé par marque, pour la tuberculose pulmonaire à frottis négatif par rapport à une norme de référence microbiologique : 17 études Xpert Ultra (sensibilité de 0,00 pour Sabi 2018, sinon de 0,60 à 0,93) et 3 études Truenat MTB Plus (0,72 à 0,81). Les spécificités sont pour la plupart de 0,89–0,99.",
        "ru": "Лесовидный график чувствительности и специфичности с 95% доверительными интервалами, по маркам тестов, для туберкулёза лёгких с отрицательным мазком относительно микробиологического эталонного стандарта: 17 исследований Xpert Ultra (чувствительность 0,00 в Sabi 2018, в остальных — от 0,60 до 0,93) и 3 исследования Truenat MTB Plus (от 0,72 до 0,81). Специфичность в основном 0,89–0,99."
      },
      "state": "draft"
    },
    {
      "id": "img-p047-1",
      "file": "images/img-p047-1.webp",
      "page": 47,
      "narratives": {
        "en": "Forest plot of sensitivity and specificity with 95% confidence intervals, grouped by brand, for pulmonary TB in people with a history of TB against a microbiological reference standard: 11 Xpert Ultra studies with wide confidence intervals and 1 Truenat MTB Plus study (Ngangue 2022, sensitivity 0.96, specificity 0.93).",
        "ar": "مخطط غابي للحساسية والنوعية مع فترات ثقة 95%، مجمّع حسب العلامة التجارية، للكشف عن السل الرئوي لدى أشخاص لديهم سوابق إصابة بالسل مقارنةً بمعيار مرجعي ميكروبيولوجي: 11 دراسة لاختبار Xpert Ultra ذات فترات ثقة واسعة ودراسة واحدة لاختبار Truenat MTB Plus (Ngangue 2022، الحساسية 0.96 والنوعية 0.93).",
        "zh": "灵敏度和特异度森林图（含95%置信区间），按品牌分组，以微生物学参考标准检测有结核病史者中的肺结核：11项Xpert Ultra研究，置信区间较宽；1项Truenat MTB Plus研究（Ngangue 2022，灵敏度0.96，特异度0.93）。",
        "es": "Diagrama de bosque de la sensibilidad y la especificidad con intervalos de confianza del 95%, agrupado por marca, para la TB pulmonar en personas con antecedentes de TB frente a un patrón de referencia microbiológico: 11 estudios de Xpert Ultra con intervalos de confianza amplios y 1 de Truenat MTB Plus (Ngangue 2022, sensibilidad 0,96, especificidad 0,93).",
        "fr": "Graphique en forêt de la sensibilité et de la spécificité avec intervalles de confiance à 95 %, regroupé par marque, pour la tuberculose pulmonaire chez des personnes ayant des antécédents de tuberculose par rapport à une norme de référence microbiologique : 11 études Xpert Ultra avec de larges intervalles de confiance et 1 étude Truenat MTB Plus (Ngangue 2022, sensibilité 0,96, spécificité 0,93).",
        "ru": "Лесовидный график чувствительности и специфичности с 95% доверительными интервалами, по маркам тестов, для туберкулёза лёгких у лиц с туберкулёзом в анамнезе относительно микробиологического эталонного стандарта: 11 исследований Xpert Ultra с широкими доверительными интервалами и 1 исследование Truenat MTB Plus (Ngangue 2022, чувствительность 0,96, специфичность 0,93)."
      },
      "state": "draft"
    },
    {
      "id": "img-p047-2",
      "file": "images/img-p047-2.webp",
      "page": 47,
      "narratives": {
        "en": "Forest plot of sensitivity and specificity with 95% confidence intervals, grouped by brand, for pulmonary TB in people with no history of TB against a microbiological reference standard: 9 Xpert Ultra studies (sensitivity 0.89 to 1.00, specificity 0.85 to 1.00) and 1 Truenat MTB Plus study (Ngangue 2022, 0.96 and 0.95).",
        "ar": "مخطط غابي للحساسية والنوعية مع فترات ثقة 95%، مجمّع حسب العلامة التجارية، للكشف عن السل الرئوي لدى أشخاص ليست لديهم سوابق إصابة بالسل مقارنةً بمعيار مرجعي ميكروبيولوجي: 9 دراسات لاختبار Xpert Ultra (الحساسية من 0.89 إلى 1.00 والنوعية من 0.85 إلى 1.00) ودراسة واحدة لاختبار Truenat MTB Plus (Ngangue 2022، 0.96 و0.95).",
        "zh": "灵敏度和特异度森林图（含95%置信区间），按品牌分组，以微生物学参考标准检测无结核病史者中的肺结核：9项Xpert Ultra研究（灵敏度0.89至1.00，特异度0.85至1.00）和1项Truenat MTB Plus研究（Ngangue 2022，0.96和0.95）。",
        "es": "Diagrama de bosque de la sensibilidad y la especificidad con intervalos de confianza del 95%, agrupado por marca, para la TB pulmonar en personas sin antecedentes de TB frente a un patrón de referencia microbiológico: 9 estudios de Xpert Ultra (sensibilidad de 0,89 a 1,00, especificidad de 0,85 a 1,00) y 1 de Truenat MTB Plus (Ngangue 2022, 0,96 y 0,95).",
        "fr": "Graphique en forêt de la sensibilité et de la spécificité avec intervalles de confiance à 95 %, regroupé par marque, pour la tuberculose pulmonaire chez des personnes sans antécédents de tuberculose par rapport à une norme de référence microbiologique : 9 études Xpert Ultra (sensibilité de 0,89 à 1,00, spécificité de 0,85 à 1,00) et 1 étude Truenat MTB Plus (Ngangue 2022, 0,96 et 0,95).",
        "ru": "Лесовидный график чувствительности и специфичности с 95% доверительными интервалами, по маркам тестов, для туберкулёза лёгких у лиц без туберкулёза в анамнезе относительно микробиологического эталонного стандарта: 9 исследований Xpert Ultra (чувствительность от 0,89 до 1,00, специфичность от 0,85 до 1,00) и 1 исследование Truenat MTB Plus (Ngangue 2022, 0,96 и 0,95)."
      },
      "state": "draft"
    },
    {
      "id": "img-p048-1",
      "file": "images/img-p048-1.webp",
      "page": 48,
      "narratives": {
        "en": "Forest plot of sensitivity and specificity with 95% confidence intervals, grouped by brand, for detection of rifampicin resistance: 13 Xpert Ultra studies (sensitivity 0.93–1.00 where estimable) and 2 Truenat MTB-RIF Dx studies (0.53 and 0.85). Specificities are 0.97–1.00.",
        "ar": "مخطط غابي للحساسية والنوعية مع فترات ثقة 95%، مجمّع حسب العلامة التجارية، للكشف عن مقاومة الريفامبيسين: 13 دراسة لاختبار Xpert Ultra (الحساسية من 0.93 إلى 1.00 حيثما أمكن تقديرها) ودراستان لاختبار Truenat MTB-RIF Dx (0.53 و0.85). وتتراوح النوعية بين 0.97 و1.00.",
        "zh": "灵敏度和特异度森林图（含95%置信区间），按品牌分组，用于检测利福平耐药：13项Xpert Ultra研究（可估计时灵敏度为0.93–1.00）和2项Truenat MTB-RIF Dx研究（0.53和0.85）。特异度为0.97–1.00。",
        "es": "Diagrama de bosque de la sensibilidad y la especificidad con intervalos de confianza del 95%, agrupado por marca, para la detección de la resistencia a la rifampicina: 13 estudios de Xpert Ultra (sensibilidad de 0,93–1,00 cuando es estimable) y 2 de Truenat MTB-RIF Dx (0,53 y 0,85). Las especificidades son de 0,97–1,00.",
        "fr": "Graphique en forêt de la sensibilité et de la spécificité avec intervalles de confiance à 95 %, regroupé par marque, pour la détection de la résistance à la rifampicine : 13 études Xpert Ultra (sensibilité de 0,93–1,00 lorsqu'elle est estimable) et 2 études Truenat MTB-RIF Dx (0,53 et 0,85). Les spécificités sont de 0,97–1,00.",
        "ru": "Лесовидный график чувствительности и специфичности с 95% доверительными интервалами, по маркам тестов, для выявления устойчивости к рифампицину: 13 исследований Xpert Ultra (чувствительность 0,93–1,00 там, где её можно оценить) и 2 исследования Truenat MTB-RIF Dx (0,53 и 0,85). Специфичность 0,97–1,00."
      },
      "state": "draft"
    },
    {
      "id": "img-p048-2",
      "file": "images/img-p048-2.webp",
      "page": 48,
      "narratives": {
        "en": "Forest plot of sensitivity and specificity with 95% confidence intervals, for 8 studies of Xpert Ultra (adolescents only, per the caption). Sensitivities range from 0.67 to 1.00 with wide intervals (one not estimable) and specificities from 0.80 to 1.00.",
        "ar": "مخطط غابي للحساسية والنوعية مع فترات ثقة 95%، لـ8 دراسات لاختبار Xpert Ultra (لدى المراهقين فقط، وفقاً للتعليق). تتراوح الحساسية بين 0.67 و1.00 بفترات واسعة (وقيمة واحدة غير قابلة للتقدير) والنوعية بين 0.80 و1.00.",
        "zh": "灵敏度和特异度森林图（含95%置信区间），8项Xpert Ultra研究（据图题，仅限青少年）。灵敏度为0.67至1.00，置信区间较宽（一项无法估计），特异度为0.80至1.00。",
        "es": "Diagrama de bosque de la sensibilidad y la especificidad con intervalos de confianza del 95%, de 8 estudios de Xpert Ultra (solo adolescentes, según el título). Las sensibilidades van de 0,67 a 1,00 con intervalos amplios (una no estimable) y las especificidades de 0,80 a 1,00.",
        "fr": "Graphique en forêt de la sensibilité et de la spécificité avec intervalles de confiance à 95 %, pour 8 études Xpert Ultra (adolescents uniquement, selon la légende). Les sensibilités vont de 0,67 à 1,00 avec de larges intervalles (une non estimable) et les spécificités de 0,80 à 1,00.",
        "ru": "Лесовидный график чувствительности и специфичности с 95% доверительными интервалами, для 8 исследований Xpert Ultra (согласно подписи, только подростки). Чувствительность от 0,67 до 1,00 с широкими интервалами (одна не поддаётся оценке), специфичность от 0,80 до 1,00."
      },
      "state": "draft"
    },
    {
      "id": "img-p049-1",
      "file": "images/img-p049-1.webp",
      "page": 49,
      "narratives": {
        "en": "Forest plot of sensitivity and specificity with 95% confidence intervals, grouped by brand, for pulmonary TB against a microbiological reference standard (adults only, per the caption): 22 Xpert Ultra studies (sensitivity 0.54 to 1.00) and 3 Truenat MTB Plus studies (0.85 to 0.96).",
        "ar": "مخطط غابي للحساسية والنوعية مع فترات ثقة 95%، مجمّع حسب العلامة التجارية، للكشف عن السل الرئوي مقارنةً بمعيار مرجعي ميكروبيولوجي (لدى البالغين فقط، وفقاً للتعليق): 22 دراسة لاختبار Xpert Ultra (الحساسية من 0.54 إلى 1.00) و3 دراسات لاختبار Truenat MTB Plus (من 0.85 إلى 0.96).",
        "zh": "灵敏度和特异度森林图（含95%置信区间），按品牌分组，以微生物学参考标准检测肺结核（据图题，仅限成人）：22项Xpert Ultra研究（灵敏度0.54至1.00）和3项Truenat MTB Plus研究（0.85至0.96）。",
        "es": "Diagrama de bosque de la sensibilidad y la especificidad con intervalos de confianza del 95%, agrupado por marca, para la TB pulmonar frente a un patrón de referencia microbiológico (solo adultos, según el título): 22 estudios de Xpert Ultra (sensibilidad de 0,54 a 1,00) y 3 de Truenat MTB Plus (0,85 a 0,96).",
        "fr": "Graphique en forêt de la sensibilité et de la spécificité avec intervalles de confiance à 95 %, regroupé par marque, pour la tuberculose pulmonaire par rapport à une norme de référence microbiologique (adultes uniquement, selon la légende) : 22 études Xpert Ultra (sensibilité de 0,54 à 1,00) et 3 études Truenat MTB Plus (0,85 à 0,96).",
        "ru": "Лесовидный график чувствительности и специфичности с 95% доверительными интервалами, по маркам тестов, для туберкулёза лёгких относительно микробиологического эталонного стандарта (согласно подписи, только взрослые): 22 исследования Xpert Ultra (чувствительность от 0,54 до 1,00) и 3 исследования Truenat MTB Plus (от 0,85 до 0,96)."
      },
      "state": "draft"
    },
    {
      "id": "img-p049-2",
      "file": "images/img-p049-2.webp",
      "page": 49,
      "narratives": {
        "en": "Forest plot of sensitivity and specificity with 95% confidence intervals, for detection of rifampicin resistance by LC-aNAATs, in two panels: smear positive and smear negative, each with 6 studies (1 Truenat MTB-RIF Dx, 5 Xpert Ultra). Truenat MTB-RIF Dx (Gomathi 2020) has the lowest sensitivity in both panels (0.57 and 0.17).",
        "ar": "مخطط غابي للحساسية والنوعية مع فترات ثقة 95%، للكشف عن مقاومة الريفامبيسين باختبارات LC-aNAAT، في لوحتين: إيجابي اللطاخة وسلبي اللطاخة، تضم كل منهما 6 دراسات (دراسة واحدة لاختبار Truenat MTB-RIF Dx و5 لاختبار Xpert Ultra). ولاختبار Truenat MTB-RIF Dx (Gomathi 2020) أدنى حساسية في اللوحتين (0.57 و0.17).",
        "zh": "灵敏度和特异度森林图（含95%置信区间），LC-aNAATs检测利福平耐药，分为两个图组：涂片阳性和涂片阴性，各含6项研究（1项Truenat MTB-RIF Dx，5项Xpert Ultra）。Truenat MTB-RIF Dx（Gomathi 2020）在两个图组中灵敏度均最低（0.57和0.17）。",
        "es": "Diagrama de bosque de la sensibilidad y la especificidad con intervalos de confianza del 95%, para la detección de la resistencia a la rifampicina con LC-aNAAT, en dos paneles: baciloscopia positiva y baciloscopia negativa, cada uno con 6 estudios (1 de Truenat MTB-RIF Dx y 5 de Xpert Ultra). Truenat MTB-RIF Dx (Gomathi 2020) tiene la sensibilidad más baja en ambos paneles (0,57 y 0,17).",
        "fr": "Graphique en forêt de la sensibilité et de la spécificité avec intervalles de confiance à 95 %, pour la détection de la résistance à la rifampicine par les LC-aNAAT, en deux panneaux : frottis positif et frottis négatif, chacun avec 6 études (1 Truenat MTB-RIF Dx, 5 Xpert Ultra). Truenat MTB-RIF Dx (Gomathi 2020) a la sensibilité la plus faible dans les deux panneaux (0,57 et 0,17).",
        "ru": "Лесовидный график чувствительности и специфичности с 95% доверительными интервалами, для выявления устойчивости к рифампицину с помощью LC-aNAAT, в двух панелях: положительный и отрицательный мазок, по 6 исследований в каждой (1 Truenat MTB-RIF Dx, 5 Xpert Ultra). У Truenat MTB-RIF Dx (Gomathi 2020) самая низкая чувствительность в обеих панелях (0,57 и 0,17)."
      },
      "state": "draft"
    },
    {
      "id": "img-p054-1",
      "file": "images/img-p054-1.webp",
      "page": 54,
      "narratives": {
        "en": "PRISMA flow diagram for the review update in children. 14 studies came from the previous review; of 431 new database records (234 duplicates removed), 197 were screened, 63 reports assessed and 54 excluded with reasons listed, and 2 records came from organizations. Nine new studies were included, giving 23 studies in total.",
        "ar": "مخطط تدفق PRISMA لتحديث الاستعراض لدى الأطفال. جاءت 14 دراسة من الاستعراض السابق؛ ومن بين 431 سجلاً جديداً من قواعد البيانات (حُذف 234 سجلاً مكرراً) فُحص 197 سجلاً، وقُيّم 63 تقريراً واستُبعد 54 منها مع ذكر الأسباب، وجاء سجلان من منظمات. وأُدرجت تسع دراسات جديدة، ليصبح المجموع 23 دراسة.",
        "zh": "儿童综述更新的PRISMA流程图。14项研究来自上一版综述；在431条新的数据库记录（删除234条重复记录）中筛选了197条，评估了63份报告并排除54份（列出原因），另有2条记录来自组织。新纳入9项研究，共计23项研究。",
        "es": "Diagrama de flujo PRISMA de la actualización de la revisión en niños. 14 estudios procedían de la revisión anterior; de 431 registros nuevos de bases de datos (se eliminaron 234 duplicados), se cribaron 197, se evaluaron 63 informes y se excluyeron 54 con los motivos indicados, y 2 registros procedieron de organizaciones. Se incluyeron nueve estudios nuevos, con un total de 23 estudios.",
        "fr": "Diagramme de flux PRISMA de la mise à jour de la revue chez l'enfant. 14 études provenaient de la version précédente ; sur 431 nouveaux enregistrements issus des bases de données (234 doublons supprimés), 197 ont été examinés, 63 rapports évalués et 54 exclus avec les motifs indiqués, et 2 enregistrements provenaient d'organisations. Neuf nouvelles études ont été incluses, soit 23 études au total.",
        "ru": "Блок-схема PRISMA обновления обзора по детям. 14 исследований взято из предыдущей версии обзора; из 431 новой записи баз данных (удалено 234 дубликата) проверено 197, оценено 63 отчёта, 54 исключено с указанием причин, ещё 2 записи получены от организаций. Включено девять новых исследований, всего 23 исследования."
      },
      "state": "draft"
    },
    {
      "id": "img-p059-1",
      "file": "images/img-p059-1.webp",
      "page": 59,
      "narratives": {
        "en": "Risk-of-bias and applicability chart for 15 studies in children: sputum with a microbiological reference standard. Each study is rated high (red), unclear (yellow) or low (green) for patient selection, index test, reference test and flow and timing, and for applicability.",
        "ar": "مخطط لخطر التحيز وقابلية التطبيق لعدد 15 دراسة لدى الأطفال: البلغم مع معيار مرجعي ميكروبيولوجي. تُصنَّف كل دراسة على أنها مرتفعة (بالأحمر) أو غير واضحة (بالأصفر) أو منخفضة (بالأخضر) من حيث اختيار المرضى والاختبار المؤشر والاختبار المرجعي والتدفق والتوقيت، ومن حيث قابلية التطبيق.",
        "zh": "儿童15项研究的偏倚风险和适用性图：痰标本、微生物学参考标准。每项研究在患者选择、指标试验、参考试验以及流程和时间方面，以及适用性方面被评为高（红色）、不明确（黄色）或低（绿色）。",
        "es": "Gráfico del riesgo de sesgo y la aplicabilidad de 15 estudios en niños: esputo con un patrón de referencia microbiológico. Cada estudio se califica como alto (rojo), incierto (amarillo) o bajo (verde) en selección de pacientes, prueba índice, prueba de referencia y flujo y cronología, así como en aplicabilidad.",
        "fr": "Graphique du risque de biais et de l'applicabilité pour 15 études chez l'enfant : expectorations avec une norme de référence microbiologique. Chaque étude est jugée élevée (rouge), incertaine (jaune) ou faible (vert) pour la sélection des patients, le test index, le test de référence et le flux et la chronologie, ainsi que pour l'applicabilité.",
        "ru": "Диаграмма риска систематической ошибки и применимости для 15 исследований у детей: мокрота с микробиологическим эталонным стандартом. Каждое исследование оценивается как высокий (красный), неясный (жёлтый) или низкий (зелёный) риск по отбору пациентов, индексному тесту, эталонному тесту, потоку и срокам, а также по применимости."
      },
      "state": "draft"
    },
    {
      "id": "img-p060-1",
      "file": "images/img-p060-1.webp",
      "page": 60,
      "narratives": {
        "en": "Forest plot of sensitivity and specificity with 95% confidence intervals for 15 studies in children: sputum with a microbiological reference standard. Sensitivity ranges from 0.57 to 0.91 where estimable and specificity from 0.82 to 1.00.",
        "ar": "مخطط غابي للحساسية والنوعية مع فترات ثقة 95% لـ15 دراسة لدى الأطفال: البلغم مع معيار مرجعي ميكروبيولوجي. تتراوح الحساسية بين 0.57 و0.91 حيثما أمكن تقديرها والنوعية بين 0.82 و1.00.",
        "zh": "儿童15项研究的灵敏度和特异度森林图（含95%置信区间）：痰标本、微生物学参考标准。可估计的灵敏度范围为0.57至0.91，特异度为0.82至1.00。",
        "es": "Diagrama de bosque de la sensibilidad y la especificidad con intervalos de confianza del 95% de 15 estudios en niños: esputo con un patrón de referencia microbiológico. La sensibilidad va de 0,57 a 0,91 cuando es estimable y la especificidad de 0,82 a 1,00.",
        "fr": "Graphique en forêt de la sensibilité et de la spécificité avec intervalles de confiance à 95 % pour 15 études chez l'enfant : expectorations avec une norme de référence microbiologique. La sensibilité va de 0,57 à 0,91 lorsqu'elle est estimable et la spécificité de 0,82 à 1,00.",
        "ru": "Лесовидный график чувствительности и специфичности с 95% доверительными интервалами для 15 исследований у детей: мокрота с микробиологическим эталонным стандартом. Чувствительность — от 0,57 до 0,91 там, где её можно оценить, специфичность — от 0,82 до 1,00."
      },
      "state": "draft"
    },
    {
      "id": "img-p061-1",
      "file": "images/img-p061-1.webp",
      "page": 61,
      "narratives": {
        "en": "Risk-of-bias and applicability chart for 11 studies in children: sputum with a composite reference standard. Each study is rated high (red), unclear (yellow) or low (green) for patient selection, index test, reference test and flow and timing, and for applicability.",
        "ar": "مخطط لخطر التحيز وقابلية التطبيق لعدد 11 دراسة لدى الأطفال: البلغم مع معيار مرجعي مركّب. تُصنَّف كل دراسة على أنها مرتفعة (بالأحمر) أو غير واضحة (بالأصفر) أو منخفضة (بالأخضر) من حيث اختيار المرضى والاختبار المؤشر والاختبار المرجعي والتدفق والتوقيت، ومن حيث قابلية التطبيق.",
        "zh": "儿童11项研究的偏倚风险和适用性图：痰标本、复合参考标准。每项研究在患者选择、指标试验、参考试验以及流程和时间方面，以及适用性方面被评为高（红色）、不明确（黄色）或低（绿色）。",
        "es": "Gráfico del riesgo de sesgo y la aplicabilidad de 11 estudios en niños: esputo con un patrón de referencia compuesto. Cada estudio se califica como alto (rojo), incierto (amarillo) o bajo (verde) en selección de pacientes, prueba índice, prueba de referencia y flujo y cronología, así como en aplicabilidad.",
        "fr": "Graphique du risque de biais et de l'applicabilité pour 11 études chez l'enfant : expectorations avec une norme de référence composite. Chaque étude est jugée élevée (rouge), incertaine (jaune) ou faible (vert) pour la sélection des patients, le test index, le test de référence et le flux et la chronologie, ainsi que pour l'applicabilité.",
        "ru": "Диаграмма риска систематической ошибки и применимости для 11 исследований у детей: мокрота с комбинированным эталонным стандартом. Каждое исследование оценивается как высокий (красный), неясный (жёлтый) или низкий (зелёный) риск по отбору пациентов, индексному тесту, эталонному тесту, потоку и срокам, а также по применимости."
      },
      "state": "draft"
    },
    {
      "id": "img-p061-2",
      "file": "images/img-p061-2.webp",
      "page": 61,
      "narratives": {
        "en": "Forest plot of sensitivity and specificity with 95% confidence intervals for 11 studies in children: sputum with a composite reference standard. Sensitivity is low, mostly 0.17–0.27 (highest 0.63, Yenew 2023), while specificity is 1.00 in all studies.",
        "ar": "مخطط غابي للحساسية والنوعية مع فترات ثقة 95% لـ11 دراسة لدى الأطفال: البلغم مع معيار مرجعي مركّب. الحساسية منخفضة، وتتراوح في الغالب بين 0.17 و0.27 (أعلاها 0.63، Yenew 2023)، في حين تبلغ النوعية 1.00 في جميع الدراسات.",
        "zh": "儿童11项研究的灵敏度和特异度森林图（含95%置信区间）：痰标本、复合参考标准。灵敏度较低，大多为0.17–0.27（最高0.63，Yenew 2023），而所有研究的特异度均为1.00。",
        "es": "Diagrama de bosque de la sensibilidad y la especificidad con intervalos de confianza del 95% de 11 estudios en niños: esputo con un patrón de referencia compuesto. La sensibilidad es baja, mayoritariamente de 0,17–0,27 (la más alta, 0,63, Yenew 2023), mientras que la especificidad es de 1,00 en todos los estudios.",
        "fr": "Graphique en forêt de la sensibilité et de la spécificité avec intervalles de confiance à 95 % pour 11 études chez l'enfant : expectorations avec une norme de référence composite. La sensibilité est faible, le plus souvent de 0,17–0,27 (la plus élevée : 0,63, Yenew 2023), tandis que la spécificité est de 1,00 dans toutes les études.",
        "ru": "Лесовидный график чувствительности и специфичности с 95% доверительными интервалами для 11 исследований у детей: мокрота с комбинированным эталонным стандартом. Чувствительность низкая, в основном 0,17–0,27 (максимум 0,63, Yenew 2023), тогда как специфичность во всех исследованиях равна 1,00."
      },
      "state": "draft"
    },
    {
      "id": "img-p062-1",
      "file": "images/img-p062-1.webp",
      "page": 62,
      "narratives": {
        "en": "Risk-of-bias and applicability chart for 11 studies in children: sputum in children living with HIV, microbiological reference standard. Each study is rated high (red), unclear (yellow) or low (green) for patient selection, index test, reference test and flow and timing, and for applicability.",
        "ar": "مخطط لخطر التحيز وقابلية التطبيق لعدد 11 دراسة لدى الأطفال: البلغم لدى الأطفال المتعايشين مع فيروس العوز المناعي البشري، معيار مرجعي ميكروبيولوجي. تُصنَّف كل دراسة على أنها مرتفعة (بالأحمر) أو غير واضحة (بالأصفر) أو منخفضة (بالأخضر) من حيث اختيار المرضى والاختبار المؤشر والاختبار المرجعي والتدفق والتوقيت، ومن حيث قابلية التطبيق.",
        "zh": "儿童11项研究的偏倚风险和适用性图：艾滋病毒感染儿童痰标本、微生物学参考标准。每项研究在患者选择、指标试验、参考试验以及流程和时间方面，以及适用性方面被评为高（红色）、不明确（黄色）或低（绿色）。",
        "es": "Gráfico del riesgo de sesgo y la aplicabilidad de 11 estudios en niños: esputo en niños con el VIH, patrón de referencia microbiológico. Cada estudio se califica como alto (rojo), incierto (amarillo) o bajo (verde) en selección de pacientes, prueba índice, prueba de referencia y flujo y cronología, así como en aplicabilidad.",
        "fr": "Graphique du risque de biais et de l'applicabilité pour 11 études chez l'enfant : expectorations chez les enfants vivant avec le VIH, norme de référence microbiologique. Chaque étude est jugée élevée (rouge), incertaine (jaune) ou faible (vert) pour la sélection des patients, le test index, le test de référence et le flux et la chronologie, ainsi que pour l'applicabilité.",
        "ru": "Диаграмма риска систематической ошибки и применимости для 11 исследований у детей: мокрота у детей, живущих с ВИЧ, микробиологический эталонный стандарт. Каждое исследование оценивается как высокий (красный), неясный (жёлтый) или низкий (зелёный) риск по отбору пациентов, индексному тесту, эталонному тесту, потоку и срокам, а также по применимости."
      },
      "state": "draft"
    },
    {
      "id": "img-p063-1",
      "file": "images/img-p063-1.webp",
      "page": 63,
      "narratives": {
        "en": "Forest plot of sensitivity and specificity with 95% confidence intervals for 11 studies in children: sputum in children living with HIV, microbiological reference standard. Sensitivity ranges from 0.40 to 1.00 where estimable and specificity from 0.77 to 1.00.",
        "ar": "مخطط غابي للحساسية والنوعية مع فترات ثقة 95% لـ11 دراسة لدى الأطفال: البلغم لدى الأطفال المتعايشين مع فيروس العوز المناعي البشري، معيار مرجعي ميكروبيولوجي. تتراوح الحساسية بين 0.40 و1.00 حيثما أمكن تقديرها والنوعية بين 0.77 و1.00.",
        "zh": "儿童11项研究的灵敏度和特异度森林图（含95%置信区间）：艾滋病毒感染儿童痰标本、微生物学参考标准。可估计的灵敏度范围为0.40至1.00，特异度为0.77至1.00。",
        "es": "Diagrama de bosque de la sensibilidad y la especificidad con intervalos de confianza del 95% de 11 estudios en niños: esputo en niños con el VIH, patrón de referencia microbiológico. La sensibilidad va de 0,40 a 1,00 cuando es estimable y la especificidad de 0,77 a 1,00.",
        "fr": "Graphique en forêt de la sensibilité et de la spécificité avec intervalles de confiance à 95 % pour 11 études chez l'enfant : expectorations chez les enfants vivant avec le VIH, norme de référence microbiologique. La sensibilité va de 0,40 à 1,00 lorsqu'elle est estimable et la spécificité de 0,77 à 1,00.",
        "ru": "Лесовидный график чувствительности и специфичности с 95% доверительными интервалами для 11 исследований у детей: мокрота у детей, живущих с ВИЧ, микробиологический эталонный стандарт. Чувствительность — от 0,40 до 1,00 там, где её можно оценить, специфичность — от 0,77 до 1,00."
      },
      "state": "draft"
    },
    {
      "id": "img-p063-2",
      "file": "images/img-p063-2.webp",
      "page": 63,
      "narratives": {
        "en": "Risk-of-bias and applicability chart for 7 studies in children: sputum in children living with HIV, composite reference standard. Each study is rated high (red), unclear (yellow) or low (green) for patient selection, index test, reference test and flow and timing, and for applicability.",
        "ar": "مخطط لخطر التحيز وقابلية التطبيق لعدد 7 دراسة لدى الأطفال: البلغم لدى الأطفال المتعايشين مع فيروس العوز المناعي البشري، معيار مرجعي مركّب. تُصنَّف كل دراسة على أنها مرتفعة (بالأحمر) أو غير واضحة (بالأصفر) أو منخفضة (بالأخضر) من حيث اختيار المرضى والاختبار المؤشر والاختبار المرجعي والتدفق والتوقيت، ومن حيث قابلية التطبيق.",
        "zh": "儿童7项研究的偏倚风险和适用性图：艾滋病毒感染儿童痰标本、复合参考标准。每项研究在患者选择、指标试验、参考试验以及流程和时间方面，以及适用性方面被评为高（红色）、不明确（黄色）或低（绿色）。",
        "es": "Gráfico del riesgo de sesgo y la aplicabilidad de 7 estudios en niños: esputo en niños con el VIH, patrón de referencia compuesto. Cada estudio se califica como alto (rojo), incierto (amarillo) o bajo (verde) en selección de pacientes, prueba índice, prueba de referencia y flujo y cronología, así como en aplicabilidad.",
        "fr": "Graphique du risque de biais et de l'applicabilité pour 7 études chez l'enfant : expectorations chez les enfants vivant avec le VIH, norme de référence composite. Chaque étude est jugée élevée (rouge), incertaine (jaune) ou faible (vert) pour la sélection des patients, le test index, le test de référence et le flux et la chronologie, ainsi que pour l'applicabilité.",
        "ru": "Диаграмма риска систематической ошибки и применимости для 7 исследований у детей: мокрота у детей, живущих с ВИЧ, комбинированный эталонный стандарт. Каждое исследование оценивается как высокий (красный), неясный (жёлтый) или низкий (зелёный) риск по отбору пациентов, индексному тесту, эталонному тесту, потоку и срокам, а также по применимости."
      },
      "state": "draft"
    },
    {
      "id": "img-p064-1",
      "file": "images/img-p064-1.webp",
      "page": 64,
      "narratives": {
        "en": "Forest plot of sensitivity and specificity with 95% confidence intervals for 7 studies in children: sputum in children living with HIV, composite reference standard. Sensitivity ranges from 0.00 to 0.25, while specificity is 1.00 in all studies.",
        "ar": "مخطط غابي للحساسية والنوعية مع فترات ثقة 95% لـ7 دراسة لدى الأطفال: البلغم لدى الأطفال المتعايشين مع فيروس العوز المناعي البشري، معيار مرجعي مركّب. تتراوح الحساسية بين 0.00 و0.25، في حين تبلغ النوعية 1.00 في جميع الدراسات.",
        "zh": "儿童7项研究的灵敏度和特异度森林图（含95%置信区间）：艾滋病毒感染儿童痰标本、复合参考标准。灵敏度范围为0.00至0.25，而所有研究的特异度均为1.00。",
        "es": "Diagrama de bosque de la sensibilidad y la especificidad con intervalos de confianza del 95% de 7 estudios en niños: esputo en niños con el VIH, patrón de referencia compuesto. La sensibilidad va de 0,00 a 0,25, mientras que la especificidad es de 1,00 en todos los estudios.",
        "fr": "Graphique en forêt de la sensibilité et de la spécificité avec intervalles de confiance à 95 % pour 7 études chez l'enfant : expectorations chez les enfants vivant avec le VIH, norme de référence composite. La sensibilité va de 0,00 à 0,25, tandis que la spécificité est de 1,00 dans toutes les études.",
        "ru": "Лесовидный график чувствительности и специфичности с 95% доверительными интервалами для 7 исследований у детей: мокрота у детей, живущих с ВИЧ, комбинированный эталонный стандарт. Чувствительность — от 0,00 до 0,25, тогда как специфичность во всех исследованиях равна 1,00."
      },
      "state": "draft"
    },
    {
      "id": "img-p064-2",
      "file": "images/img-p064-2.webp",
      "page": 64,
      "narratives": {
        "en": "Risk-of-bias and applicability chart for 12 studies in children: gastric aspirate with a microbiological reference standard. Each study is rated high (red), unclear (yellow) or low (green) for patient selection, index test, reference test and flow and timing, and for applicability.",
        "ar": "مخطط لخطر التحيز وقابلية التطبيق لعدد 12 دراسة لدى الأطفال: الرشافة المعدية مع معيار مرجعي ميكروبيولوجي. تُصنَّف كل دراسة على أنها مرتفعة (بالأحمر) أو غير واضحة (بالأصفر) أو منخفضة (بالأخضر) من حيث اختيار المرضى والاختبار المؤشر والاختبار المرجعي والتدفق والتوقيت، ومن حيث قابلية التطبيق.",
        "zh": "儿童12项研究的偏倚风险和适用性图：胃抽吸物、微生物学参考标准。每项研究在患者选择、指标试验、参考试验以及流程和时间方面，以及适用性方面被评为高（红色）、不明确（黄色）或低（绿色）。",
        "es": "Gráfico del riesgo de sesgo y la aplicabilidad de 12 estudios en niños: aspirado gástrico con un patrón de referencia microbiológico. Cada estudio se califica como alto (rojo), incierto (amarillo) o bajo (verde) en selección de pacientes, prueba índice, prueba de referencia y flujo y cronología, así como en aplicabilidad.",
        "fr": "Graphique du risque de biais et de l'applicabilité pour 12 études chez l'enfant : aspiration gastrique avec une norme de référence microbiologique. Chaque étude est jugée élevée (rouge), incertaine (jaune) ou faible (vert) pour la sélection des patients, le test index, le test de référence et le flux et la chronologie, ainsi que pour l'applicabilité.",
        "ru": "Диаграмма риска систематической ошибки и применимости для 12 исследований у детей: желудочный аспират с микробиологическим эталонным стандартом. Каждое исследование оценивается как высокий (красный), неясный (жёлтый) или низкий (зелёный) риск по отбору пациентов, индексному тесту, эталонному тесту, потоку и срокам, а также по применимости."
      },
      "state": "draft"
    },
    {
      "id": "img-p065-1",
      "file": "images/img-p065-1.webp",
      "page": 65,
      "narratives": {
        "en": "Forest plot of sensitivity and specificity with 95% confidence intervals for 12 studies in children: gastric aspirate with a microbiological reference standard. Sensitivity ranges from 0.00 to 1.00 where estimable and specificity from 0.67 to 1.00.",
        "ar": "مخطط غابي للحساسية والنوعية مع فترات ثقة 95% لـ12 دراسة لدى الأطفال: الرشافة المعدية مع معيار مرجعي ميكروبيولوجي. تتراوح الحساسية بين 0.00 و1.00 حيثما أمكن تقديرها والنوعية بين 0.67 و1.00.",
        "zh": "儿童12项研究的灵敏度和特异度森林图（含95%置信区间）：胃抽吸物、微生物学参考标准。可估计的灵敏度范围为0.00至1.00，特异度为0.67至1.00。",
        "es": "Diagrama de bosque de la sensibilidad y la especificidad con intervalos de confianza del 95% de 12 estudios en niños: aspirado gástrico con un patrón de referencia microbiológico. La sensibilidad va de 0,00 a 1,00 cuando es estimable y la especificidad de 0,67 a 1,00.",
        "fr": "Graphique en forêt de la sensibilité et de la spécificité avec intervalles de confiance à 95 % pour 12 études chez l'enfant : aspiration gastrique avec une norme de référence microbiologique. La sensibilité va de 0,00 à 1,00 lorsqu'elle est estimable et la spécificité de 0,67 à 1,00.",
        "ru": "Лесовидный график чувствительности и специфичности с 95% доверительными интервалами для 12 исследований у детей: желудочный аспират с микробиологическим эталонным стандартом. Чувствительность — от 0,00 до 1,00 там, где её можно оценить, специфичность — от 0,67 до 1,00."
      },
      "state": "draft"
    },
    {
      "id": "img-p066-1",
      "file": "images/img-p066-1.webp",
      "page": 66,
      "narratives": {
        "en": "Risk-of-bias and applicability chart for 7 studies in children: gastric aspirate with a composite reference standard. Each study is rated high (red), unclear (yellow) or low (green) for patient selection, index test, reference test and flow and timing, and for applicability.",
        "ar": "مخطط لخطر التحيز وقابلية التطبيق لعدد 7 دراسة لدى الأطفال: الرشافة المعدية مع معيار مرجعي مركّب. تُصنَّف كل دراسة على أنها مرتفعة (بالأحمر) أو غير واضحة (بالأصفر) أو منخفضة (بالأخضر) من حيث اختيار المرضى والاختبار المؤشر والاختبار المرجعي والتدفق والتوقيت، ومن حيث قابلية التطبيق.",
        "zh": "儿童7项研究的偏倚风险和适用性图：胃抽吸物、复合参考标准。每项研究在患者选择、指标试验、参考试验以及流程和时间方面，以及适用性方面被评为高（红色）、不明确（黄色）或低（绿色）。",
        "es": "Gráfico del riesgo de sesgo y la aplicabilidad de 7 estudios en niños: aspirado gástrico con un patrón de referencia compuesto. Cada estudio se califica como alto (rojo), incierto (amarillo) o bajo (verde) en selección de pacientes, prueba índice, prueba de referencia y flujo y cronología, así como en aplicabilidad.",
        "fr": "Graphique du risque de biais et de l'applicabilité pour 7 études chez l'enfant : aspiration gastrique avec une norme de référence composite. Chaque étude est jugée élevée (rouge), incertaine (jaune) ou faible (vert) pour la sélection des patients, le test index, le test de référence et le flux et la chronologie, ainsi que pour l'applicabilité.",
        "ru": "Диаграмма риска систематической ошибки и применимости для 7 исследований у детей: желудочный аспират с комбинированным эталонным стандартом. Каждое исследование оценивается как высокий (красный), неясный (жёлтый) или низкий (зелёный) риск по отбору пациентов, индексному тесту, эталонному тесту, потоку и срокам, а также по применимости."
      },
      "state": "draft"
    },
    {
      "id": "img-p066-2",
      "file": "images/img-p066-2.webp",
      "page": 66,
      "narratives": {
        "en": "Forest plot of sensitivity and specificity with 95% confidence intervals for 7 studies in children: gastric aspirate with a composite reference standard. Sensitivity ranges from 0.19 to 0.83 where estimable and specificity from 0.91 to 1.00.",
        "ar": "مخطط غابي للحساسية والنوعية مع فترات ثقة 95% لـ7 دراسة لدى الأطفال: الرشافة المعدية مع معيار مرجعي مركّب. تتراوح الحساسية بين 0.19 و0.83 حيثما أمكن تقديرها والنوعية بين 0.91 و1.00.",
        "zh": "儿童7项研究的灵敏度和特异度森林图（含95%置信区间）：胃抽吸物、复合参考标准。可估计的灵敏度范围为0.19至0.83，特异度为0.91至1.00。",
        "es": "Diagrama de bosque de la sensibilidad y la especificidad con intervalos de confianza del 95% de 7 estudios en niños: aspirado gástrico con un patrón de referencia compuesto. La sensibilidad va de 0,19 a 0,83 cuando es estimable y la especificidad de 0,91 a 1,00.",
        "fr": "Graphique en forêt de la sensibilité et de la spécificité avec intervalles de confiance à 95 % pour 7 études chez l'enfant : aspiration gastrique avec une norme de référence composite. La sensibilité va de 0,19 à 0,83 lorsqu'elle est estimable et la spécificité de 0,91 à 1,00.",
        "ru": "Лесовидный график чувствительности и специфичности с 95% доверительными интервалами для 7 исследований у детей: желудочный аспират с комбинированным эталонным стандартом. Чувствительность — от 0,19 до 0,83 там, где её можно оценить, специфичность — от 0,91 до 1,00."
      },
      "state": "draft"
    },
    {
      "id": "img-p067-1",
      "file": "images/img-p067-1.webp",
      "page": 67,
      "narratives": {
        "en": "Risk-of-bias and applicability chart for 7 studies in children: nasopharyngeal aspirate with a microbiological reference standard. Each study is rated high (red), unclear (yellow) or low (green) for patient selection, index test, reference test and flow and timing, and for applicability.",
        "ar": "مخطط لخطر التحيز وقابلية التطبيق لعدد 7 دراسة لدى الأطفال: الرشافة الأنفية البلعومية مع معيار مرجعي ميكروبيولوجي. تُصنَّف كل دراسة على أنها مرتفعة (بالأحمر) أو غير واضحة (بالأصفر) أو منخفضة (بالأخضر) من حيث اختيار المرضى والاختبار المؤشر والاختبار المرجعي والتدفق والتوقيت، ومن حيث قابلية التطبيق.",
        "zh": "儿童7项研究的偏倚风险和适用性图：鼻咽抽吸物、微生物学参考标准。每项研究在患者选择、指标试验、参考试验以及流程和时间方面，以及适用性方面被评为高（红色）、不明确（黄色）或低（绿色）。",
        "es": "Gráfico del riesgo de sesgo y la aplicabilidad de 7 estudios en niños: aspirado nasofaríngeo con un patrón de referencia microbiológico. Cada estudio se califica como alto (rojo), incierto (amarillo) o bajo (verde) en selección de pacientes, prueba índice, prueba de referencia y flujo y cronología, así como en aplicabilidad.",
        "fr": "Graphique du risque de biais et de l'applicabilité pour 7 études chez l'enfant : aspiration nasopharyngée avec une norme de référence microbiologique. Chaque étude est jugée élevée (rouge), incertaine (jaune) ou faible (vert) pour la sélection des patients, le test index, le test de référence et le flux et la chronologie, ainsi que pour l'applicabilité.",
        "ru": "Диаграмма риска систематической ошибки и применимости для 7 исследований у детей: носоглоточный аспират с микробиологическим эталонным стандартом. Каждое исследование оценивается как высокий (красный), неясный (жёлтый) или низкий (зелёный) риск по отбору пациентов, индексному тесту, эталонному тесту, потоку и срокам, а также по применимости."
      },
      "state": "draft"
    },
    {
      "id": "img-p067-2",
      "file": "images/img-p067-2.webp",
      "page": 67,
      "narratives": {
        "en": "Forest plot of sensitivity and specificity with 95% confidence intervals for 7 studies in children: nasopharyngeal aspirate with a microbiological reference standard. Sensitivity ranges from 0.33 to 0.67 where estimable and specificity from 0.50 to 0.99.",
        "ar": "مخطط غابي للحساسية والنوعية مع فترات ثقة 95% لـ7 دراسة لدى الأطفال: الرشافة الأنفية البلعومية مع معيار مرجعي ميكروبيولوجي. تتراوح الحساسية بين 0.33 و0.67 حيثما أمكن تقديرها والنوعية بين 0.50 و0.99.",
        "zh": "儿童7项研究的灵敏度和特异度森林图（含95%置信区间）：鼻咽抽吸物、微生物学参考标准。可估计的灵敏度范围为0.33至0.67，特异度为0.50至0.99。",
        "es": "Diagrama de bosque de la sensibilidad y la especificidad con intervalos de confianza del 95% de 7 estudios en niños: aspirado nasofaríngeo con un patrón de referencia microbiológico. La sensibilidad va de 0,33 a 0,67 cuando es estimable y la especificidad de 0,50 a 0,99.",
        "fr": "Graphique en forêt de la sensibilité et de la spécificité avec intervalles de confiance à 95 % pour 7 études chez l'enfant : aspiration nasopharyngée avec une norme de référence microbiologique. La sensibilité va de 0,33 à 0,67 lorsqu'elle est estimable et la spécificité de 0,50 à 0,99.",
        "ru": "Лесовидный график чувствительности и специфичности с 95% доверительными интервалами для 7 исследований у детей: носоглоточный аспират с микробиологическим эталонным стандартом. Чувствительность — от 0,33 до 0,67 там, где её можно оценить, специфичность — от 0,50 до 0,99."
      },
      "state": "draft"
    },
    {
      "id": "img-p068-1",
      "file": "images/img-p068-1.webp",
      "page": 68,
      "narratives": {
        "en": "Risk-of-bias and applicability chart for 4 studies in children: nasopharyngeal aspirate with a composite reference standard. Each study is rated high (red), unclear (yellow) or low (green) for patient selection, index test, reference test and flow and timing, and for applicability.",
        "ar": "مخطط لخطر التحيز وقابلية التطبيق لعدد 4 دراسة لدى الأطفال: الرشافة الأنفية البلعومية مع معيار مرجعي مركّب. تُصنَّف كل دراسة على أنها مرتفعة (بالأحمر) أو غير واضحة (بالأصفر) أو منخفضة (بالأخضر) من حيث اختيار المرضى والاختبار المؤشر والاختبار المرجعي والتدفق والتوقيت، ومن حيث قابلية التطبيق.",
        "zh": "儿童4项研究的偏倚风险和适用性图：鼻咽抽吸物、复合参考标准。每项研究在患者选择、指标试验、参考试验以及流程和时间方面，以及适用性方面被评为高（红色）、不明确（黄色）或低（绿色）。",
        "es": "Gráfico del riesgo de sesgo y la aplicabilidad de 4 estudios en niños: aspirado nasofaríngeo con un patrón de referencia compuesto. Cada estudio se califica como alto (rojo), incierto (amarillo) o bajo (verde) en selección de pacientes, prueba índice, prueba de referencia y flujo y cronología, así como en aplicabilidad.",
        "fr": "Graphique du risque de biais et de l'applicabilité pour 4 études chez l'enfant : aspiration nasopharyngée avec une norme de référence composite. Chaque étude est jugée élevée (rouge), incertaine (jaune) ou faible (vert) pour la sélection des patients, le test index, le test de référence et le flux et la chronologie, ainsi que pour l'applicabilité.",
        "ru": "Диаграмма риска систематической ошибки и применимости для 4 исследований у детей: носоглоточный аспират с комбинированным эталонным стандартом. Каждое исследование оценивается как высокий (красный), неясный (жёлтый) или низкий (зелёный) риск по отбору пациентов, индексному тесту, эталонному тесту, потоку и срокам, а также по применимости."
      },
      "state": "draft"
    },
    {
      "id": "img-p068-2",
      "file": "images/img-p068-2.webp",
      "page": 68,
      "narratives": {
        "en": "Forest plot of sensitivity and specificity with 95% confidence intervals for 4 studies in children: nasopharyngeal aspirate with a composite reference standard. Sensitivity ranges from 0.09 to 0.36, while specificity is 1.00 in all studies.",
        "ar": "مخطط غابي للحساسية والنوعية مع فترات ثقة 95% لـ4 دراسة لدى الأطفال: الرشافة الأنفية البلعومية مع معيار مرجعي مركّب. تتراوح الحساسية بين 0.09 و0.36، في حين تبلغ النوعية 1.00 في جميع الدراسات.",
        "zh": "儿童4项研究的灵敏度和特异度森林图（含95%置信区间）：鼻咽抽吸物、复合参考标准。灵敏度范围为0.09至0.36，而所有研究的特异度均为1.00。",
        "es": "Diagrama de bosque de la sensibilidad y la especificidad con intervalos de confianza del 95% de 4 estudios en niños: aspirado nasofaríngeo con un patrón de referencia compuesto. La sensibilidad va de 0,09 a 0,36, mientras que la especificidad es de 1,00 en todos los estudios.",
        "fr": "Graphique en forêt de la sensibilité et de la spécificité avec intervalles de confiance à 95 % pour 4 études chez l'enfant : aspiration nasopharyngée avec une norme de référence composite. La sensibilité va de 0,09 à 0,36, tandis que la spécificité est de 1,00 dans toutes les études.",
        "ru": "Лесовидный график чувствительности и специфичности с 95% доверительными интервалами для 4 исследований у детей: носоглоточный аспират с комбинированным эталонным стандартом. Чувствительность — от 0,09 до 0,36, тогда как специфичность во всех исследованиях равна 1,00."
      },
      "state": "draft"
    },
    {
      "id": "img-p069-1",
      "file": "images/img-p069-1.webp",
      "page": 69,
      "narratives": {
        "en": "Risk-of-bias and applicability chart for 10 studies in children: stool with a microbiological reference standard. Each study is rated high (red), unclear (yellow) or low (green) for patient selection, index test, reference test and flow and timing, and for applicability. The column headings are printed upside down in the image.",
        "ar": "مخطط لخطر التحيز وقابلية التطبيق لعدد 10 دراسة لدى الأطفال: البراز مع معيار مرجعي ميكروبيولوجي. تُصنَّف كل دراسة على أنها مرتفعة (بالأحمر) أو غير واضحة (بالأصفر) أو منخفضة (بالأخضر) من حيث اختيار المرضى والاختبار المؤشر والاختبار المرجعي والتدفق والتوقيت، ومن حيث قابلية التطبيق. وتظهر عناوين الأعمدة مقلوبة في الصورة.",
        "zh": "儿童10项研究的偏倚风险和适用性图：粪便标本、微生物学参考标准。每项研究在患者选择、指标试验、参考试验以及流程和时间方面，以及适用性方面被评为高（红色）、不明确（黄色）或低（绿色）。图中各列标题为上下颠倒印刷。",
        "es": "Gráfico del riesgo de sesgo y la aplicabilidad de 10 estudios en niños: heces con un patrón de referencia microbiológico. Cada estudio se califica como alto (rojo), incierto (amarillo) o bajo (verde) en selección de pacientes, prueba índice, prueba de referencia y flujo y cronología, así como en aplicabilidad. Los encabezados de las columnas aparecen invertidos en la imagen.",
        "fr": "Graphique du risque de biais et de l'applicabilité pour 10 études chez l'enfant : selles avec une norme de référence microbiologique. Chaque étude est jugée élevée (rouge), incertaine (jaune) ou faible (vert) pour la sélection des patients, le test index, le test de référence et le flux et la chronologie, ainsi que pour l'applicabilité. Les en-têtes de colonnes sont imprimés à l'envers dans l'image.",
        "ru": "Диаграмма риска систематической ошибки и применимости для 10 исследований у детей: кал с микробиологическим эталонным стандартом. Каждое исследование оценивается как высокий (красный), неясный (жёлтый) или низкий (зелёный) риск по отбору пациентов, индексному тесту, эталонному тесту, потоку и срокам, а также по применимости. Заголовки столбцов на изображении перевёрнуты."
      },
      "state": "draft"
    },
    {
      "id": "img-p070-1",
      "file": "images/img-p070-1.webp",
      "page": 70,
      "narratives": {
        "en": "Forest plot of sensitivity and specificity with 95% confidence intervals for 10 studies in children: stool with a microbiological reference standard. Sensitivity ranges from 0.26 to 1.00 where estimable and specificity from 0.89 to 1.00.",
        "ar": "مخطط غابي للحساسية والنوعية مع فترات ثقة 95% لـ10 دراسة لدى الأطفال: البراز مع معيار مرجعي ميكروبيولوجي. تتراوح الحساسية بين 0.26 و1.00 حيثما أمكن تقديرها والنوعية بين 0.89 و1.00.",
        "zh": "儿童10项研究的灵敏度和特异度森林图（含95%置信区间）：粪便标本、微生物学参考标准。可估计的灵敏度范围为0.26至1.00，特异度为0.89至1.00。",
        "es": "Diagrama de bosque de la sensibilidad y la especificidad con intervalos de confianza del 95% de 10 estudios en niños: heces con un patrón de referencia microbiológico. La sensibilidad va de 0,26 a 1,00 cuando es estimable y la especificidad de 0,89 a 1,00.",
        "fr": "Graphique en forêt de la sensibilité et de la spécificité avec intervalles de confiance à 95 % pour 10 études chez l'enfant : selles avec une norme de référence microbiologique. La sensibilité va de 0,26 à 1,00 lorsqu'elle est estimable et la spécificité de 0,89 à 1,00.",
        "ru": "Лесовидный график чувствительности и специфичности с 95% доверительными интервалами для 10 исследований у детей: кал с микробиологическим эталонным стандартом. Чувствительность — от 0,26 до 1,00 там, где её можно оценить, специфичность — от 0,89 до 1,00."
      },
      "state": "draft"
    },
    {
      "id": "img-p070-2",
      "file": "images/img-p070-2.webp",
      "page": 70,
      "narratives": {
        "en": "Risk-of-bias and applicability chart for 6 studies in children: stool with a composite reference standard. Each study is rated high (red), unclear (yellow) or low (green) for patient selection, index test, reference test and flow and timing, and for applicability.",
        "ar": "مخطط لخطر التحيز وقابلية التطبيق لعدد 6 دراسة لدى الأطفال: البراز مع معيار مرجعي مركّب. تُصنَّف كل دراسة على أنها مرتفعة (بالأحمر) أو غير واضحة (بالأصفر) أو منخفضة (بالأخضر) من حيث اختيار المرضى والاختبار المؤشر والاختبار المرجعي والتدفق والتوقيت، ومن حيث قابلية التطبيق.",
        "zh": "儿童6项研究的偏倚风险和适用性图：粪便标本、复合参考标准。每项研究在患者选择、指标试验、参考试验以及流程和时间方面，以及适用性方面被评为高（红色）、不明确（黄色）或低（绿色）。",
        "es": "Gráfico del riesgo de sesgo y la aplicabilidad de 6 estudios en niños: heces con un patrón de referencia compuesto. Cada estudio se califica como alto (rojo), incierto (amarillo) o bajo (verde) en selección de pacientes, prueba índice, prueba de referencia y flujo y cronología, así como en aplicabilidad.",
        "fr": "Graphique du risque de biais et de l'applicabilité pour 6 études chez l'enfant : selles avec une norme de référence composite. Chaque étude est jugée élevée (rouge), incertaine (jaune) ou faible (vert) pour la sélection des patients, le test index, le test de référence et le flux et la chronologie, ainsi que pour l'applicabilité.",
        "ru": "Диаграмма риска систематической ошибки и применимости для 6 исследований у детей: кал с комбинированным эталонным стандартом. Каждое исследование оценивается как высокий (красный), неясный (жёлтый) или низкий (зелёный) риск по отбору пациентов, индексному тесту, эталонному тесту, потоку и срокам, а также по применимости."
      },
      "state": "draft"
    },
    {
      "id": "img-p071-1",
      "file": "images/img-p071-1.webp",
      "page": 71,
      "narratives": {
        "en": "Forest plot of sensitivity and specificity with 95% confidence intervals for 6 studies in children: stool with a composite reference standard. Sensitivity ranges from 0.09 to 0.58 where estimable and specificity from 0.97 to 1.00.",
        "ar": "مخطط غابي للحساسية والنوعية مع فترات ثقة 95% لـ6 دراسة لدى الأطفال: البراز مع معيار مرجعي مركّب. تتراوح الحساسية بين 0.09 و0.58 حيثما أمكن تقديرها والنوعية بين 0.97 و1.00.",
        "zh": "儿童6项研究的灵敏度和特异度森林图（含95%置信区间）：粪便标本、复合参考标准。可估计的灵敏度范围为0.09至0.58，特异度为0.97至1.00。",
        "es": "Diagrama de bosque de la sensibilidad y la especificidad con intervalos de confianza del 95% de 6 estudios en niños: heces con un patrón de referencia compuesto. La sensibilidad va de 0,09 a 0,58 cuando es estimable y la especificidad de 0,97 a 1,00.",
        "fr": "Graphique en forêt de la sensibilité et de la spécificité avec intervalles de confiance à 95 % pour 6 études chez l'enfant : selles avec une norme de référence composite. La sensibilité va de 0,09 à 0,58 lorsqu'elle est estimable et la spécificité de 0,97 à 1,00.",
        "ru": "Лесовидный график чувствительности и специфичности с 95% доверительными интервалами для 6 исследований у детей: кал с комбинированным эталонным стандартом. Чувствительность — от 0,09 до 0,58 там, где её можно оценить, специфичность — от 0,97 до 1,00."
      },
      "state": "draft"
    },
    {
      "id": "img-p071-2",
      "file": "images/img-p071-2.webp",
      "page": 71,
      "narratives": {
        "en": "Risk-of-bias and applicability chart for 3 studies in children: detection of rifampicin resistance. Each study is rated high (red), unclear (yellow) or low (green) for patient selection, index test, reference test and flow and timing, and for applicability.",
        "ar": "مخطط لخطر التحيز وقابلية التطبيق لعدد 3 دراسة لدى الأطفال: الكشف عن مقاومة الريفامبيسين. تُصنَّف كل دراسة على أنها مرتفعة (بالأحمر) أو غير واضحة (بالأصفر) أو منخفضة (بالأخضر) من حيث اختيار المرضى والاختبار المؤشر والاختبار المرجعي والتدفق والتوقيت، ومن حيث قابلية التطبيق.",
        "zh": "儿童3项研究的偏倚风险和适用性图：利福平耐药检测。每项研究在患者选择、指标试验、参考试验以及流程和时间方面，以及适用性方面被评为高（红色）、不明确（黄色）或低（绿色）。",
        "es": "Gráfico del riesgo de sesgo y la aplicabilidad de 3 estudios en niños: detección de la resistencia a la rifampicina. Cada estudio se califica como alto (rojo), incierto (amarillo) o bajo (verde) en selección de pacientes, prueba índice, prueba de referencia y flujo y cronología, así como en aplicabilidad.",
        "fr": "Graphique du risque de biais et de l'applicabilité pour 3 études chez l'enfant : détection de la résistance à la rifampicine. Chaque étude est jugée élevée (rouge), incertaine (jaune) ou faible (vert) pour la sélection des patients, le test index, le test de référence et le flux et la chronologie, ainsi que pour l'applicabilité.",
        "ru": "Диаграмма риска систематической ошибки и применимости для 3 исследований у детей: выявление устойчивости к рифампицину. Каждое исследование оценивается как высокий (красный), неясный (жёлтый) или низкий (зелёный) риск по отбору пациентов, индексному тесту, эталонному тесту, потоку и срокам, а также по применимости."
      },
      "state": "draft"
    },
    {
      "id": "img-p072-1",
      "file": "images/img-p072-1.webp",
      "page": 72,
      "narratives": {
        "en": "Forest plot of sensitivity and specificity with 95% confidence intervals for 3 studies in children: detection of rifampicin resistance. Sensitivity is not estimable in two studies and 1.00 [0.16, 1.00] in Zar 2018-2023; specificity is 1.00 in all three.",
        "ar": "مخطط غابي للحساسية والنوعية مع فترات ثقة 95% لـ3 دراسة لدى الأطفال: الكشف عن مقاومة الريفامبيسين. الحساسية غير قابلة للتقدير في دراستين وتبلغ 1.00 [0.16، 1.00] في Zar 2018-2023؛ والنوعية 1.00 في الدراسات الثلاث.",
        "zh": "儿童3项研究的灵敏度和特异度森林图（含95%置信区间）：利福平耐药检测。两项研究的灵敏度无法估计，Zar 2018-2023为1.00 [0.16, 1.00]；三项研究特异度均为1.00。",
        "es": "Diagrama de bosque de la sensibilidad y la especificidad con intervalos de confianza del 95% de 3 estudios en niños: detección de la resistencia a la rifampicina. La sensibilidad no es estimable en dos estudios y es de 1,00 [0,16; 1,00] en Zar 2018-2023; la especificidad es de 1,00 en los tres.",
        "fr": "Graphique en forêt de la sensibilité et de la spécificité avec intervalles de confiance à 95 % pour 3 études chez l'enfant : détection de la résistance à la rifampicine. La sensibilité n'est pas estimable dans deux études et est de 1,00 [0,16 ; 1,00] dans Zar 2018-2023 ; la spécificité est de 1,00 dans les trois.",
        "ru": "Лесовидный график чувствительности и специфичности с 95% доверительными интервалами для 3 исследований у детей: выявление устойчивости к рифампицину. Чувствительность не поддаётся оценке в двух исследованиях и составляет 1,00 [0,16; 1,00] в Zar 2018-2023; специфичность во всех трёх равна 1,00."
      },
      "state": "draft"
    },
    {
      "id": "img-p072-2",
      "file": "images/img-p072-2.webp",
      "page": 72,
      "narratives": {
        "en": "Risk-of-bias and applicability chart for 3 studies in children: cerebrospinal fluid (CSF) with a microbiological reference standard. Each study is rated high (red), unclear (yellow) or low (green) for patient selection, index test, reference test and flow and timing, and for applicability.",
        "ar": "مخطط لخطر التحيز وقابلية التطبيق لعدد 3 دراسة لدى الأطفال: السائل الدماغي الشوكي مع معيار مرجعي ميكروبيولوجي. تُصنَّف كل دراسة على أنها مرتفعة (بالأحمر) أو غير واضحة (بالأصفر) أو منخفضة (بالأخضر) من حيث اختيار المرضى والاختبار المؤشر والاختبار المرجعي والتدفق والتوقيت، ومن حيث قابلية التطبيق.",
        "zh": "儿童3项研究的偏倚风险和适用性图：脑脊液、微生物学参考标准。每项研究在患者选择、指标试验、参考试验以及流程和时间方面，以及适用性方面被评为高（红色）、不明确（黄色）或低（绿色）。",
        "es": "Gráfico del riesgo de sesgo y la aplicabilidad de 3 estudios en niños: líquido cefalorraquídeo con un patrón de referencia microbiológico. Cada estudio se califica como alto (rojo), incierto (amarillo) o bajo (verde) en selección de pacientes, prueba índice, prueba de referencia y flujo y cronología, así como en aplicabilidad.",
        "fr": "Graphique du risque de biais et de l'applicabilité pour 3 études chez l'enfant : liquide céphalorachidien avec une norme de référence microbiologique. Chaque étude est jugée élevée (rouge), incertaine (jaune) ou faible (vert) pour la sélection des patients, le test index, le test de référence et le flux et la chronologie, ainsi que pour l'applicabilité.",
        "ru": "Диаграмма риска систематической ошибки и применимости для 3 исследований у детей: спинномозговая жидкость с микробиологическим эталонным стандартом. Каждое исследование оценивается как высокий (красный), неясный (жёлтый) или низкий (зелёный) риск по отбору пациентов, индексному тесту, эталонному тесту, потоку и срокам, а также по применимости."
      },
      "state": "draft"
    },
    {
      "id": "img-p072-3",
      "file": "images/img-p072-3.webp",
      "page": 72,
      "narratives": {
        "en": "Forest plot of sensitivity and specificity with 95% confidence intervals for 3 studies in children: cerebrospinal fluid (CSF) with a microbiological reference standard. Sensitivity ranges from 0.67 to 1.00 where estimable and specificity from 0.91 to 1.00.",
        "ar": "مخطط غابي للحساسية والنوعية مع فترات ثقة 95% لـ3 دراسة لدى الأطفال: السائل الدماغي الشوكي مع معيار مرجعي ميكروبيولوجي. تتراوح الحساسية بين 0.67 و1.00 حيثما أمكن تقديرها والنوعية بين 0.91 و1.00.",
        "zh": "儿童3项研究的灵敏度和特异度森林图（含95%置信区间）：脑脊液、微生物学参考标准。可估计的灵敏度范围为0.67至1.00，特异度为0.91至1.00。",
        "es": "Diagrama de bosque de la sensibilidad y la especificidad con intervalos de confianza del 95% de 3 estudios en niños: líquido cefalorraquídeo con un patrón de referencia microbiológico. La sensibilidad va de 0,67 a 1,00 cuando es estimable y la especificidad de 0,91 a 1,00.",
        "fr": "Graphique en forêt de la sensibilité et de la spécificité avec intervalles de confiance à 95 % pour 3 études chez l'enfant : liquide céphalorachidien avec une norme de référence microbiologique. La sensibilité va de 0,67 à 1,00 lorsqu'elle est estimable et la spécificité de 0,91 à 1,00.",
        "ru": "Лесовидный график чувствительности и специфичности с 95% доверительными интервалами для 3 исследований у детей: спинномозговая жидкость с микробиологическим эталонным стандартом. Чувствительность — от 0,67 до 1,00 там, где её можно оценить, специфичность — от 0,91 до 1,00."
      },
      "state": "draft"
    },
    {
      "id": "img-p073-1",
      "file": "images/img-p073-1.webp",
      "page": 73,
      "narratives": {
        "en": "Risk-of-bias and applicability chart for 2 studies in children: cerebrospinal fluid (CSF) with a composite reference standard. Each study is rated high (red), unclear (yellow) or low (green) for patient selection, index test, reference test and flow and timing, and for applicability.",
        "ar": "مخطط لخطر التحيز وقابلية التطبيق لعدد 2 دراسة لدى الأطفال: السائل الدماغي الشوكي مع معيار مرجعي مركّب. تُصنَّف كل دراسة على أنها مرتفعة (بالأحمر) أو غير واضحة (بالأصفر) أو منخفضة (بالأخضر) من حيث اختيار المرضى والاختبار المؤشر والاختبار المرجعي والتدفق والتوقيت، ومن حيث قابلية التطبيق.",
        "zh": "儿童2项研究的偏倚风险和适用性图：脑脊液、复合参考标准。每项研究在患者选择、指标试验、参考试验以及流程和时间方面，以及适用性方面被评为高（红色）、不明确（黄色）或低（绿色）。",
        "es": "Gráfico del riesgo de sesgo y la aplicabilidad de 2 estudios en niños: líquido cefalorraquídeo con un patrón de referencia compuesto. Cada estudio se califica como alto (rojo), incierto (amarillo) o bajo (verde) en selección de pacientes, prueba índice, prueba de referencia y flujo y cronología, así como en aplicabilidad.",
        "fr": "Graphique du risque de biais et de l'applicabilité pour 2 études chez l'enfant : liquide céphalorachidien avec une norme de référence composite. Chaque étude est jugée élevée (rouge), incertaine (jaune) ou faible (vert) pour la sélection des patients, le test index, le test de référence et le flux et la chronologie, ainsi que pour l'applicabilité.",
        "ru": "Диаграмма риска систематической ошибки и применимости для 2 исследований у детей: спинномозговая жидкость с комбинированным эталонным стандартом. Каждое исследование оценивается как высокий (красный), неясный (жёлтый) или низкий (зелёный) риск по отбору пациентов, индексному тесту, эталонному тесту, потоку и срокам, а также по применимости."
      },
      "state": "draft"
    },
    {
      "id": "img-p073-2",
      "file": "images/img-p073-2.webp",
      "page": 73,
      "narratives": {
        "en": "Forest plot of sensitivity and specificity with 95% confidence intervals for 2 studies in children: cerebrospinal fluid (CSF) with a composite reference standard. Sensitivity ranges from 0.12 to 0.19, while specificity is 1.00 in all studies.",
        "ar": "مخطط غابي للحساسية والنوعية مع فترات ثقة 95% لـ2 دراسة لدى الأطفال: السائل الدماغي الشوكي مع معيار مرجعي مركّب. تتراوح الحساسية بين 0.12 و0.19، في حين تبلغ النوعية 1.00 في جميع الدراسات.",
        "zh": "儿童2项研究的灵敏度和特异度森林图（含95%置信区间）：脑脊液、复合参考标准。灵敏度范围为0.12至0.19，而所有研究的特异度均为1.00。",
        "es": "Diagrama de bosque de la sensibilidad y la especificidad con intervalos de confianza del 95% de 2 estudios en niños: líquido cefalorraquídeo con un patrón de referencia compuesto. La sensibilidad va de 0,12 a 0,19, mientras que la especificidad es de 1,00 en todos los estudios.",
        "fr": "Graphique en forêt de la sensibilité et de la spécificité avec intervalles de confiance à 95 % pour 2 études chez l'enfant : liquide céphalorachidien avec une norme de référence composite. La sensibilité va de 0,12 à 0,19, tandis que la spécificité est de 1,00 dans toutes les études.",
        "ru": "Лесовидный график чувствительности и специфичности с 95% доверительными интервалами для 2 исследований у детей: спинномозговая жидкость с комбинированным эталонным стандартом. Чувствительность — от 0,12 до 0,19, тогда как специфичность во всех исследованиях равна 1,00."
      },
      "state": "draft"
    },
    {
      "id": "img-p074-1",
      "file": "images/img-p074-1.webp",
      "page": 74,
      "narratives": {
        "en": "Risk-of-bias and applicability chart for 2 studies in children: lymph node specimens with a microbiological reference standard. Each study is rated high (red), unclear (yellow) or low (green) for patient selection, index test, reference test and flow and timing, and for applicability.",
        "ar": "مخطط لخطر التحيز وقابلية التطبيق لعدد 2 دراسة لدى الأطفال: عينات العقد اللمفية مع معيار مرجعي ميكروبيولوجي. تُصنَّف كل دراسة على أنها مرتفعة (بالأحمر) أو غير واضحة (بالأصفر) أو منخفضة (بالأخضر) من حيث اختيار المرضى والاختبار المؤشر والاختبار المرجعي والتدفق والتوقيت، ومن حيث قابلية التطبيق.",
        "zh": "儿童2项研究的偏倚风险和适用性图：淋巴结标本、微生物学参考标准。每项研究在患者选择、指标试验、参考试验以及流程和时间方面，以及适用性方面被评为高（红色）、不明确（黄色）或低（绿色）。",
        "es": "Gráfico del riesgo de sesgo y la aplicabilidad de 2 estudios en niños: muestras de ganglio linfático con un patrón de referencia microbiológico. Cada estudio se califica como alto (rojo), incierto (amarillo) o bajo (verde) en selección de pacientes, prueba índice, prueba de referencia y flujo y cronología, así como en aplicabilidad.",
        "fr": "Graphique du risque de biais et de l'applicabilité pour 2 études chez l'enfant : prélèvements ganglionnaires avec une norme de référence microbiologique. Chaque étude est jugée élevée (rouge), incertaine (jaune) ou faible (vert) pour la sélection des patients, le test index, le test de référence et le flux et la chronologie, ainsi que pour l'applicabilité.",
        "ru": "Диаграмма риска систематической ошибки и применимости для 2 исследований у детей: образцы лимфатических узлов с микробиологическим эталонным стандартом. Каждое исследование оценивается как высокий (красный), неясный (жёлтый) или низкий (зелёный) риск по отбору пациентов, индексному тесту, эталонному тесту, потоку и срокам, а также по применимости."
      },
      "state": "draft"
    },
    {
      "id": "img-p074-2",
      "file": "images/img-p074-2.webp",
      "page": 74,
      "narratives": {
        "en": "Forest plot of sensitivity and specificity with 95% confidence intervals for 2 studies in children: lymph node specimens with a microbiological reference standard. Both studies show sensitivity 1.00; specificity is 0.82 (Zar 2018-2023) and 0.33 (Aurilio 2022).",
        "ar": "مخطط غابي للحساسية والنوعية مع فترات ثقة 95% لـ2 دراسة لدى الأطفال: عينات العقد اللمفية مع معيار مرجعي ميكروبيولوجي. تُظهر الدراستان حساسية 1.00؛ وتبلغ النوعية 0.82 (Zar 2018-2023) و0.33 (Aurilio 2022).",
        "zh": "儿童2项研究的灵敏度和特异度森林图（含95%置信区间）：淋巴结标本、微生物学参考标准。两项研究灵敏度均为1.00；特异度分别为0.82（Zar 2018-2023）和0.33（Aurilio 2022）。",
        "es": "Diagrama de bosque de la sensibilidad y la especificidad con intervalos de confianza del 95% de 2 estudios en niños: muestras de ganglio linfático con un patrón de referencia microbiológico. Ambos estudios muestran una sensibilidad de 1,00; la especificidad es de 0,82 (Zar 2018-2023) y 0,33 (Aurilio 2022).",
        "fr": "Graphique en forêt de la sensibilité et de la spécificité avec intervalles de confiance à 95 % pour 2 études chez l'enfant : prélèvements ganglionnaires avec une norme de référence microbiologique. Les deux études montrent une sensibilité de 1,00 ; la spécificité est de 0,82 (Zar 2018-2023) et de 0,33 (Aurilio 2022).",
        "ru": "Лесовидный график чувствительности и специфичности с 95% доверительными интервалами для 2 исследований у детей: образцы лимфатических узлов с микробиологическим эталонным стандартом. В обоих исследованиях чувствительность 1,00; специфичность 0,82 (Zar 2018-2023) и 0,33 (Aurilio 2022)."
      },
      "state": "draft"
    },
    {
      "id": "img-p075-2",
      "file": "images/img-p075-2.webp",
      "page": 75,
      "narratives": {
        "en": "Forest plot of sensitivity and specificity with 95% confidence intervals for 2 studies in children: lymph node specimens with a composite reference standard. Sensitivity is 0.80 (Aurilio 2022) and 0.50 (Zar 2018-2023); specificity is not estimable in one and 1.00 in the other.",
        "ar": "مخطط غابي للحساسية والنوعية مع فترات ثقة 95% لـ2 دراسة لدى الأطفال: عينات العقد اللمفية مع معيار مرجعي مركّب. تبلغ الحساسية 0.80 (Aurilio 2022) و0.50 (Zar 2018-2023)؛ والنوعية غير قابلة للتقدير في إحداهما و1.00 في الأخرى.",
        "zh": "儿童2项研究的灵敏度和特异度森林图（含95%置信区间）：淋巴结标本、复合参考标准。灵敏度为0.80（Aurilio 2022）和0.50（Zar 2018-2023）；特异度一项无法估计，另一项为1.00。",
        "es": "Diagrama de bosque de la sensibilidad y la especificidad con intervalos de confianza del 95% de 2 estudios en niños: muestras de ganglio linfático con un patrón de referencia compuesto. La sensibilidad es de 0,80 (Aurilio 2022) y 0,50 (Zar 2018-2023); la especificidad no es estimable en uno y es de 1,00 en el otro.",
        "fr": "Graphique en forêt de la sensibilité et de la spécificité avec intervalles de confiance à 95 % pour 2 études chez l'enfant : prélèvements ganglionnaires avec une norme de référence composite. La sensibilité est de 0,80 (Aurilio 2022) et de 0,50 (Zar 2018-2023) ; la spécificité n'est pas estimable dans l'une et est de 1,00 dans l'autre.",
        "ru": "Лесовидный график чувствительности и специфичности с 95% доверительными интервалами для 2 исследований у детей: образцы лимфатических узлов с комбинированным эталонным стандартом. Чувствительность 0,80 (Aurilio 2022) и 0,50 (Zar 2018-2023); специфичность в одном не поддаётся оценке, в другом равна 1,00."
      },
      "state": "draft"
    },
    {
      "id": "img-p076-1",
      "file": "images/img-p076-1.webp",
      "page": 76,
      "narratives": {
        "en": "Forest plot of sensitivity and specificity with 95% confidence intervals for Xpert Ultra for extrapulmonary TB in children aged 0–9 years against culture, in four panels: pleural (3 studies), bone and joint (3), urine (1) and tissue/biopsy (1). Few cases are present and most estimates are not estimable or have very wide intervals.",
        "ar": "مخطط غابي للحساسية والنوعية مع فترات ثقة 95% لاختبار Xpert Ultra للكشف عن السل خارج الرئة لدى الأطفال من سن 0 إلى 9 سنوات مقارنةً بالمزرعة، في أربع لوحات: الجنبة (3 دراسات)، والعظام والمفاصل (3)، والبول (1)، والنسيج/الخزعة (1). الحالات قليلة ومعظم التقديرات غير قابلة للتقدير أو ذات فترات واسعة جداً.",
        "zh": "Xpert Ultra检测0–9岁儿童肺外结核（以培养为参考）的灵敏度和特异度森林图（含95%置信区间），分为四个图组：胸膜（3项研究）、骨与关节（3项）、尿液（1项）和组织/活检（1项）。病例很少，大多数估计值无法估计或置信区间很宽。",
        "es": "Diagrama de bosque de la sensibilidad y la especificidad con intervalos de confianza del 95% de Xpert Ultra para la TB extrapulmonar en niños de 0 a 9 años frente al cultivo, en cuatro paneles: pleural (3 estudios), hueso y articulación (3), orina (1) y tejido/biopsia (1). Hay pocos casos y la mayoría de las estimaciones no son estimables o tienen intervalos muy amplios.",
        "fr": "Graphique en forêt de la sensibilité et de la spécificité avec intervalles de confiance à 95 % de Xpert Ultra pour la tuberculose extrapulmonaire chez l'enfant de 0 à 9 ans par rapport à la culture, en quatre panneaux : plèvre (3 études), os et articulations (3), urine (1) et tissu/biopsie (1). Les cas sont peu nombreux et la plupart des estimations ne sont pas estimables ou ont des intervalles très larges.",
        "ru": "Лесовидный график чувствительности и специфичности с 95% доверительными интервалами для Xpert Ultra при внелёгочном туберкулёзе у детей 0–9 лет относительно посева, в четырёх панелях: плевра (3 исследования), кости и суставы (3), моча (1) и ткань/биопсия (1). Случаев мало, большинство показателей не поддаются оценке или имеют очень широкие интервалы."
      },
      "state": "draft"
    },
    {
      "id": "img-p091-1",
      "file": "images/img-p091-1.webp",
      "page": 91,
      "narratives": {
        "en": "PRISMA flow diagram of study selection for Truenat assays (Appendix 2A). From 1175 database records (524 duplicates removed), 651 were screened and 34 reports assessed, all excluded (including 8 for wrong age group); 4 further reports from other methods were also excluded. No studies were included.",
        "ar": "مخطط تدفق PRISMA لاختيار الدراسات الخاصة باختبارات Truenat (التذييل 2A). من بين 1175 سجلاً من قواعد البيانات (حُذف 524 سجلاً مكرراً)، فُحص 651 سجلاً وقُيّم 34 تقريراً استُبعدت جميعها (منها 8 بسبب الفئة العمرية غير المناسبة)؛ واستُبعدت أيضاً 4 تقارير إضافية من طرق أخرى. ولم تُدرج أي دراسة.",
        "zh": "Truenat检测研究筛选的PRISMA流程图（附录2A）。从1175条数据库记录（删除524条重复记录）中筛选了651条，评估了34份报告，全部被排除（其中8份因年龄组不符）；另有4份来自其他方法的报告也被排除。未纳入任何研究。",
        "es": "Diagrama de flujo PRISMA de la selección de estudios sobre las pruebas Truenat (apéndice 2A). De 1175 registros de bases de datos (se eliminaron 524 duplicados), se cribaron 651 y se evaluaron 34 informes, todos excluidos (8 de ellos por grupo de edad incorrecto); también se excluyeron 4 informes obtenidos por otros métodos. No se incluyó ningún estudio.",
        "fr": "Diagramme de flux PRISMA de la sélection des études sur les tests Truenat (appendice 2A). Sur 1175 enregistrements issus des bases de données (524 doublons supprimés), 651 ont été examinés et 34 rapports évalués, tous exclus (dont 8 pour tranche d'âge inadaptée) ; 4 rapports issus d'autres méthodes ont également été exclus. Aucune étude n'a été incluse.",
        "ru": "Блок-схема PRISMA отбора исследований по тестам Truenat (приложение 2A). Из 1175 записей баз данных (удалено 524 дубликата) проверена 651, оценено 34 отчёта, все исключены (8 — из-за несоответствующей возрастной группы); ещё 4 отчёта, полученные другими методами, также исключены. Ни одно исследование не включено."
      },
      "state": "draft"
    },
    {
      "id": "img-p092-1",
      "file": "images/img-p092-1.webp",
      "page": 92,
      "narratives": {
        "en": "PRISMA flow diagram of study selection for STANDARD M10 and IRON-qPCR (Appendix 2B). From 37 database records (3 duplicates removed), 34 were screened, 32 excluded and 2 reports assessed; both were excluded (an ongoing trial and a conference abstract/case-control study). No studies were included.",
        "ar": "مخطط تدفق PRISMA لاختيار الدراسات الخاصة باختباري STANDARD M10 وIRON-qPCR (التذييل 2B). من بين 37 سجلاً من قواعد البيانات (حُذفت 3 سجلات مكررة)، فُحص 34 سجلاً واستُبعد 32 منها وقُيّم تقريران استُبعد كلاهما (تجربة جارية وملخص مؤتمر/دراسة حالات وشواهد). ولم تُدرج أي دراسة.",
        "zh": "STANDARD M10和IRON-qPCR研究筛选的PRISMA流程图（附录2B）。从37条数据库记录（删除3条重复记录）中筛选了34条，排除32条，评估了2份报告，两份均被排除（一项正在进行的试验和一份会议摘要/病例对照研究）。未纳入任何研究。",
        "es": "Diagrama de flujo PRISMA de la selección de estudios sobre STANDARD M10 e IRON-qPCR (apéndice 2B). De 37 registros de bases de datos (se eliminaron 3 duplicados), se cribaron 34, se excluyeron 32 y se evaluaron 2 informes, ambos excluidos (un ensayo en curso y un resumen de congreso/estudio de casos y controles). No se incluyó ningún estudio.",
        "fr": "Diagramme de flux PRISMA de la sélection des études sur STANDARD M10 et IRON-qPCR (appendice 2B). Sur 37 enregistrements issus des bases de données (3 doublons supprimés), 34 ont été examinés, 32 exclus et 2 rapports évalués, tous deux exclus (un essai en cours et un résumé de congrès/étude cas-témoins). Aucune étude n'a été incluse.",
        "ru": "Блок-схема PRISMA отбора исследований по STANDARD M10 и IRON-qPCR (приложение 2B). Из 37 записей баз данных (удалено 3 дубликата) проверено 34, исключено 32, оценено 2 отчёта, оба исключены (текущее испытание и тезисы конференции/исследование «случай-контроль»). Ни одно исследование не включено."
      },
      "state": "draft"
    },
    {
      "id": "img-p104-1",
      "file": "images/img-p104-1.webp",
      "page": 104,
      "narratives": {
        "en": "Stacked horizontal bar chart summarizing risk of bias and applicability concerns for 36 Xpert Ultra studies (high red, unclear yellow, low green). Risk of bias: patient selection 1 high, 5 unclear, 30 low; index test 36 low; reference standard 9 unclear, 27 low; flow and timing 36 low. Applicability: patient selection 4 high, 21 unclear, 11 low; index test 3 high, 1 unclear, 32 low; reference standard 5 unclear, 31 low.",
        "ar": "مخطط شريطي أفقي مكدّس يلخص خطر التحيز والمخاوف بشأن قابلية التطبيق لـ36 دراسة لاختبار Xpert Ultra (مرتفع بالأحمر، غير واضح بالأصفر، منخفض بالأخضر). خطر التحيز: اختيار المرضى 1 مرتفع و5 غير واضح و30 منخفض؛ الاختبار المؤشر 36 منخفض؛ المعيار المرجعي 9 غير واضح و27 منخفض؛ التدفق والتوقيت 36 منخفض. قابلية التطبيق: اختيار المرضى 4 مرتفع و21 غير واضح و11 منخفض؛ الاختبار المؤشر 3 مرتفع و1 غير واضح و32 منخفض؛ المعيار المرجعي 5 غير واضح و31 منخفض.",
        "zh": "堆积水平条形图，汇总36项Xpert Ultra研究的偏倚风险和适用性问题（高为红色，不明确为黄色，低为绿色）。偏倚风险：患者选择1项高、5项不明确、30项低；指标试验36项低；参考标准9项不明确、27项低；流程和时间36项低。适用性：患者选择4项高、21项不明确、11项低；指标试验3项高、1项不明确、32项低；参考标准5项不明确、31项低。",
        "es": "Gráfico de barras horizontales apiladas que resume el riesgo de sesgo y los problemas de aplicabilidad de 36 estudios de Xpert Ultra (alto en rojo, incierto en amarillo, bajo en verde). Riesgo de sesgo: selección de pacientes, 1 alto, 5 incierto, 30 bajo; prueba índice, 36 bajo; patrón de referencia, 9 incierto, 27 bajo; flujo y cronología, 36 bajo. Aplicabilidad: selección de pacientes, 4 alto, 21 incierto, 11 bajo; prueba índice, 3 alto, 1 incierto, 32 bajo; patrón de referencia, 5 incierto, 31 bajo.",
        "fr": "Diagramme en barres horizontales empilées résumant le risque de biais et les préoccupations quant à l'applicabilité pour 36 études Xpert Ultra (élevé en rouge, incertain en jaune, faible en vert). Risque de biais : sélection des patients, 1 élevé, 5 incertain, 30 faible ; test index, 36 faible ; norme de référence, 9 incertain, 27 faible ; flux et chronologie, 36 faible. Applicabilité : sélection des patients, 4 élevé, 21 incertain, 11 faible ; test index, 3 élevé, 1 incertain, 32 faible ; norme de référence, 5 incertain, 31 faible.",
        "ru": "Горизонтальная столбчатая диаграмма с накоплением, обобщающая риск систематической ошибки и вопросы применимости для 36 исследований Xpert Ultra (высокий — красный, неясный — жёлтый, низкий — зелёный). Риск ошибки: отбор пациентов — 1 высокий, 5 неясный, 30 низкий; индексный тест — 36 низкий; эталонный стандарт — 9 неясный, 27 низкий; поток и сроки — 36 низкий. Применимость: отбор пациентов — 4 высокий, 21 неясный, 11 низкий; индексный тест — 3 высокий, 1 неясный, 32 низкий; эталонный стандарт — 5 неясный, 31 низкий."
      },
      "state": "draft"
    },
    {
      "id": "img-p105-1",
      "file": "images/img-p105-1.webp",
      "page": 105,
      "narratives": {
        "en": "Risk-of-bias and applicability chart for three Truenat MTB Plus studies (Jose 2024, Sharma 2021, Sharma 2023). Jose 2024 is rated high risk for the reference standard; both Sharma studies are unclear for the reference standard in both risk of bias and applicability; all other domains are low.",
        "ar": "مخطط لخطر التحيز وقابلية التطبيق لثلاث دراسات لاختبار Truenat MTB Plus (Jose 2024 وSharma 2021 وSharma 2023). صُنّفت دراسة Jose 2024 مرتفعة الخطر من حيث المعيار المرجعي؛ وصُنّفت دراستا Sharma غير واضحتين من حيث المعيار المرجعي في خطر التحيز وقابلية التطبيق؛ وجميع المجالات الأخرى منخفضة.",
        "zh": "3项Truenat MTB Plus研究（Jose 2024、Sharma 2021、Sharma 2023）的偏倚风险和适用性图。Jose 2024在参考标准方面被评为高风险；两项Sharma研究的参考标准在偏倚风险和适用性方面均为不明确；其他所有领域均为低。",
        "es": "Gráfico del riesgo de sesgo y la aplicabilidad de tres estudios de Truenat MTB Plus (Jose 2024, Sharma 2021, Sharma 2023). Jose 2024 se califica de riesgo alto en el patrón de referencia; ambos estudios de Sharma son inciertos en el patrón de referencia tanto en riesgo de sesgo como en aplicabilidad; todos los demás dominios son bajos.",
        "fr": "Graphique du risque de biais et de l'applicabilité pour trois études Truenat MTB Plus (Jose 2024, Sharma 2021, Sharma 2023). Jose 2024 est jugée à risque élevé pour la norme de référence ; les deux études Sharma sont incertaines pour la norme de référence, tant pour le risque de biais que pour l'applicabilité ; tous les autres domaines sont faibles.",
        "ru": "Диаграмма риска систематической ошибки и применимости для трёх исследований Truenat MTB Plus (Jose 2024, Sharma 2021, Sharma 2023). Jose 2024 оценено как высокий риск по эталонному стандарту; оба исследования Sharma — неясный по эталонному стандарту как по риску ошибки, так и по применимости; все остальные домены — низкий риск."
      },
      "state": "draft"
    },
    {
      "id": "img-p107-1",
      "file": "images/img-p107-1.webp",
      "page": 107,
      "narratives": {
        "en": "Risk of bias and applicability chart for tuberculous meningitis in cerebrospinal fluid, with one row per study (18 studies). Each study is rated for risk of bias (patient selection, index test, reference standard, flow and timing) and applicability (patient selection, index test, reference standard) using green (low), yellow (unclear) and red (high) circles. Most ratings are low; high ratings are given for Perez-Risco 2018 (risk of bias, patient selection); Mekkaoui 2021, Slail 2023 (applicability, patient selection); Chin 2019, Shao 2020 (applicability, index test).",
        "ar": "مخطط خطر التحيز وقابلية التطبيق بشأن التهاب السحايا السلي في السائل الدماغي الشوكي، بصف واحد لكل دراسة (عدد الدراسات: 18). تُقيَّم كل دراسة من حيث خطر التحيز (اختيار المرضى، والاختبار المؤشر، والمعيار المرجعي، والتدفق والتوقيت) وقابلية التطبيق (اختيار المرضى، والاختبار المؤشر، والمعيار المرجعي) باستخدام دوائر خضراء (منخفض) وصفراء (غير واضح) وحمراء (مرتفع). معظم التقييمات منخفضة؛ والتقييمات المرتفعة هي: Perez-Risco 2018 (خطر التحيز، اختيار المرضى)؛ Mekkaoui 2021, Slail 2023 (قابلية التطبيق، اختيار المرضى)؛ Chin 2019, Shao 2020 (قابلية التطبيق، الاختبار المؤشر).",
        "zh": "脑脊液检测结核性脑膜炎的偏倚风险和适用性图，每项研究一行（18项研究）。每项研究按偏倚风险（患者选择、待评价试验、参考标准、流程和时间）和适用性（患者选择、待评价试验、参考标准）评级，以绿色（低）、黄色（不明确）和红色（高）圆圈表示。 大多数评级为低；评为高的有：Perez-Risco 2018 (偏倚风险，患者选择)；Mekkaoui 2021, Slail 2023 (适用性，患者选择)；Chin 2019, Shao 2020 (适用性，待评价试验)。",
        "es": "Gráfico de riesgo de sesgo y aplicabilidad para la meningitis tuberculosa en líquido cefalorraquídeo, con una fila por estudio (18 estudios). Cada estudio se califica en cuanto a riesgo de sesgo (selección de pacientes, prueba índice, estándar de referencia, flujo y cronología) y aplicabilidad (selección de pacientes, prueba índice, estándar de referencia) con círculos verdes (bajo), amarillos (incierto) y rojos (alto). La mayoría de las calificaciones son bajas; las calificaciones altas corresponden a Perez-Risco 2018 (riesgo de sesgo, selección de pacientes); Mekkaoui 2021, Slail 2023 (aplicabilidad, selección de pacientes); Chin 2019, Shao 2020 (aplicabilidad, prueba índice).",
        "fr": "Graphique du risque de biais et de l'applicabilité pour la méningite tuberculeuse dans le liquide céphalorachidien, avec une ligne par étude (18 études). Chaque étude est évaluée pour le risque de biais (sélection des patients, test index, norme de référence, flux et calendrier) et l'applicabilité (sélection des patients, test index, norme de référence) au moyen de cercles verts (faible), jaunes (incertain) et rouges (élevé). La plupart des évaluations sont faibles ; les évaluations élevées concernent Perez-Risco 2018 (risque de biais, sélection des patients) ; Mekkaoui 2021, Slail 2023 (applicabilité, sélection des patients) ; Chin 2019, Shao 2020 (applicabilité, test index).",
        "ru": "Диаграмма риска систематической ошибки и применимости: туберкулезный менингит, спинномозговая жидкость; одна строка на исследование (исследований: 18). Каждое исследование оценено по риску систематической ошибки (отбор пациентов, индексный тест, эталонный стандарт, поток и сроки) и применимости (отбор пациентов, индексный тест, эталонный стандарт) с помощью зеленых (низкий), желтых (неясный) и красных (высокий) кружков. Большинство оценок низкие; высокие оценки: Perez-Risco 2018 (риск систематической ошибки, отбор пациентов); Mekkaoui 2021, Slail 2023 (применимость, отбор пациентов); Chin 2019, Shao 2020 (применимость, индексный тест)."
      },
      "state": "draft"
    },
    {
      "id": "img-p108-1",
      "file": "images/img-p108-1.webp",
      "page": 108,
      "narratives": {
        "en": "Paired forest plots of sensitivity and specificity. Test: Xpert Ultra; specimen: cerebrospinal fluid; reference standard: culture; 18 studies. For each study the table lists TP, FP, FN and TN counts with sensitivity and specificity (95% CI), plotted as squares with confidence-interval lines on scales from 0 to 1. Sensitivity ranges from 0.50 to 1.00. Sensitivity is not estimable for Mekkaoui 2021, Osei 2019. Specificity ranges from 0.50 to 1.00.",
        "ar": "مخططا غابة متقابلان للحساسية والنوعية. الاختبار: Xpert Ultra؛ العينة: السائل الدماغي الشوكي؛ المعيار المرجعي: الزرع؛ عدد الدراسات: 18. يُدرج الجدول لكل دراسة أعداد الإيجابيات الحقيقية (TP) والإيجابيات الكاذبة (FP) والسلبيات الكاذبة (FN) والسلبيات الحقيقية (TN) مع الحساسية والنوعية (فاصل الثقة 95%)، وتُعرض كمربعات مع خطوط فواصل الثقة على مقياس من 0 إلى 1. تتراوح الحساسية بين 0.50 و1.00. الحساسية غير قابلة للتقدير في Mekkaoui 2021, Osei 2019. تتراوح النوعية بين 0.50 و1.00.",
        "zh": "敏感度和特异度的配对森林图。检测：Xpert Ultra；标本：脑脊液；参考标准：培养；18项研究。 表中列出每项研究的真阳性（TP）、假阳性（FP）、假阴性（FN）和真阴性（TN）数以及敏感度和特异度（95% CI），并以方块和置信区间线绘于0至1的刻度上。 敏感度范围为0.50至1.00。 Mekkaoui 2021, Osei 2019的敏感度无法估计。 特异度范围为0.50至1.00。",
        "es": "Diagramas de bosque emparejados de sensibilidad y especificidad. Prueba: Xpert Ultra; muestra: líquido cefalorraquídeo; estándar de referencia: cultivo; 18 estudios. Para cada estudio, la tabla indica los recuentos TP, FP, FN y TN (verdaderos positivos, falsos positivos, falsos negativos y verdaderos negativos) con la sensibilidad y la especificidad (IC del 95%), representadas como cuadrados con líneas de intervalo de confianza en escalas de 0 a 1. La sensibilidad varía entre 0,50 y 1,00. La sensibilidad no es estimable en Mekkaoui 2021, Osei 2019. La especificidad varía entre 0,50 y 1,00.",
        "fr": "Graphiques en forêt appariés de la sensibilité et de la spécificité. Test : Xpert Ultra ; échantillon : liquide céphalorachidien ; norme de référence : culture ; 18 études. Pour chaque étude, le tableau indique les nombres TP, FP, FN et TN (vrais positifs, faux positifs, faux négatifs et vrais négatifs) ainsi que la sensibilité et la spécificité (IC à 95 %), représentées par des carrés avec des lignes d'intervalle de confiance sur des échelles de 0 à 1. La sensibilité varie de 0,50 à 1,00. La sensibilité n'est pas estimable pour Mekkaoui 2021, Osei 2019. La spécificité varie de 0,50 à 1,00.",
        "ru": "Парные лесовидные диаграммы чувствительности и специфичности. Тест: Xpert Ultra; образец: спинномозговая жидкость; эталонный стандарт: посев; исследований: 18. Для каждого исследования в таблице приведены числа TP, FP, FN и TN (истинно положительные, ложноположительные, ложноотрицательные и истинно отрицательные результаты), а также чувствительность и специфичность (95% ДИ), показанные квадратами с линиями доверительных интервалов на шкалах от 0 до 1. Чувствительность колеблется от 0,50 до 1,00. Чувствительность не поддается оценке для Mekkaoui 2021, Osei 2019. Специфичность колеблется от 0,50 до 1,00."
      },
      "state": "draft"
    },
    {
      "id": "img-p108-2",
      "file": "images/img-p108-2.webp",
      "page": 108,
      "narratives": {
        "en": "Paired forest plots of sensitivity and specificity. Test: Xpert Ultra; specimen: cerebrospinal fluid; reference standard: composite reference standard; 10 studies. For each study the table lists TP, FP, FN and TN counts with sensitivity and specificity (95% CI), plotted as squares with confidence-interval lines on scales from 0 to 1. Sensitivity ranges from 0.18 to 0.76. Specificity ranges from 0.95 to 1.00.",
        "ar": "مخططا غابة متقابلان للحساسية والنوعية. الاختبار: Xpert Ultra؛ العينة: السائل الدماغي الشوكي؛ المعيار المرجعي: المعيار المرجعي المركب؛ عدد الدراسات: 10. يُدرج الجدول لكل دراسة أعداد الإيجابيات الحقيقية (TP) والإيجابيات الكاذبة (FP) والسلبيات الكاذبة (FN) والسلبيات الحقيقية (TN) مع الحساسية والنوعية (فاصل الثقة 95%)، وتُعرض كمربعات مع خطوط فواصل الثقة على مقياس من 0 إلى 1. تتراوح الحساسية بين 0.18 و0.76. تتراوح النوعية بين 0.95 و1.00.",
        "zh": "敏感度和特异度的配对森林图。检测：Xpert Ultra；标本：脑脊液；参考标准：复合参考标准；10项研究。 表中列出每项研究的真阳性（TP）、假阳性（FP）、假阴性（FN）和真阴性（TN）数以及敏感度和特异度（95% CI），并以方块和置信区间线绘于0至1的刻度上。 敏感度范围为0.18至0.76。 特异度范围为0.95至1.00。",
        "es": "Diagramas de bosque emparejados de sensibilidad y especificidad. Prueba: Xpert Ultra; muestra: líquido cefalorraquídeo; estándar de referencia: estándar de referencia compuesto; 10 estudios. Para cada estudio, la tabla indica los recuentos TP, FP, FN y TN (verdaderos positivos, falsos positivos, falsos negativos y verdaderos negativos) con la sensibilidad y la especificidad (IC del 95%), representadas como cuadrados con líneas de intervalo de confianza en escalas de 0 a 1. La sensibilidad varía entre 0,18 y 0,76. La especificidad varía entre 0,95 y 1,00.",
        "fr": "Graphiques en forêt appariés de la sensibilité et de la spécificité. Test : Xpert Ultra ; échantillon : liquide céphalorachidien ; norme de référence : norme de référence composite ; 10 études. Pour chaque étude, le tableau indique les nombres TP, FP, FN et TN (vrais positifs, faux positifs, faux négatifs et vrais négatifs) ainsi que la sensibilité et la spécificité (IC à 95 %), représentées par des carrés avec des lignes d'intervalle de confiance sur des échelles de 0 à 1. La sensibilité varie de 0,18 à 0,76. La spécificité varie de 0,95 à 1,00.",
        "ru": "Парные лесовидные диаграммы чувствительности и специфичности. Тест: Xpert Ultra; образец: спинномозговая жидкость; эталонный стандарт: комбинированный эталонный стандарт; исследований: 10. Для каждого исследования в таблице приведены числа TP, FP, FN и TN (истинно положительные, ложноположительные, ложноотрицательные и истинно отрицательные результаты), а также чувствительность и специфичность (95% ДИ), показанные квадратами с линиями доверительных интервалов на шкалах от 0 до 1. Чувствительность колеблется от 0,18 до 0,76. Специфичность колеблется от 0,95 до 1,00."
      },
      "state": "draft"
    },
    {
      "id": "img-p108-3",
      "file": "images/img-p108-3.webp",
      "page": 108,
      "narratives": {
        "en": "Paired forest plots of sensitivity and specificity. Test: Truenat MTB plus; specimen: cerebrospinal fluid; reference standard: culture; 2 studies (Jose 2024, Sharma 2021). For each study the table lists TP, FP, FN and TN counts with sensitivity and specificity (95% CI), plotted as squares with confidence-interval lines on scales from 0 to 1. Sensitivity ranges from 0.95 to 1.00. Specificity ranges from 0.55 to 1.00.",
        "ar": "مخططا غابة متقابلان للحساسية والنوعية. الاختبار: Truenat MTB plus؛ العينة: السائل الدماغي الشوكي؛ المعيار المرجعي: الزرع؛ عدد الدراسات: 2 (Jose 2024, Sharma 2021). يُدرج الجدول لكل دراسة أعداد الإيجابيات الحقيقية (TP) والإيجابيات الكاذبة (FP) والسلبيات الكاذبة (FN) والسلبيات الحقيقية (TN) مع الحساسية والنوعية (فاصل الثقة 95%)، وتُعرض كمربعات مع خطوط فواصل الثقة على مقياس من 0 إلى 1. تتراوح الحساسية بين 0.95 و1.00. تتراوح النوعية بين 0.55 و1.00.",
        "zh": "敏感度和特异度的配对森林图。检测：Truenat MTB plus；标本：脑脊液；参考标准：培养；2项研究 (Jose 2024, Sharma 2021)。 表中列出每项研究的真阳性（TP）、假阳性（FP）、假阴性（FN）和真阴性（TN）数以及敏感度和特异度（95% CI），并以方块和置信区间线绘于0至1的刻度上。 敏感度范围为0.95至1.00。 特异度范围为0.55至1.00。",
        "es": "Diagramas de bosque emparejados de sensibilidad y especificidad. Prueba: Truenat MTB plus; muestra: líquido cefalorraquídeo; estándar de referencia: cultivo; 2 estudios (Jose 2024, Sharma 2021). Para cada estudio, la tabla indica los recuentos TP, FP, FN y TN (verdaderos positivos, falsos positivos, falsos negativos y verdaderos negativos) con la sensibilidad y la especificidad (IC del 95%), representadas como cuadrados con líneas de intervalo de confianza en escalas de 0 a 1. La sensibilidad varía entre 0,95 y 1,00. La especificidad varía entre 0,55 y 1,00.",
        "fr": "Graphiques en forêt appariés de la sensibilité et de la spécificité. Test : Truenat MTB plus ; échantillon : liquide céphalorachidien ; norme de référence : culture ; 2 études (Jose 2024, Sharma 2021). Pour chaque étude, le tableau indique les nombres TP, FP, FN et TN (vrais positifs, faux positifs, faux négatifs et vrais négatifs) ainsi que la sensibilité et la spécificité (IC à 95 %), représentées par des carrés avec des lignes d'intervalle de confiance sur des échelles de 0 à 1. La sensibilité varie de 0,95 à 1,00. La spécificité varie de 0,55 à 1,00.",
        "ru": "Парные лесовидные диаграммы чувствительности и специфичности. Тест: Truenat MTB plus; образец: спинномозговая жидкость; эталонный стандарт: посев; исследований: 2 (Jose 2024, Sharma 2021). Для каждого исследования в таблице приведены числа TP, FP, FN и TN (истинно положительные, ложноположительные, ложноотрицательные и истинно отрицательные результаты), а также чувствительность и специфичность (95% ДИ), показанные квадратами с линиями доверительных интервалов на шкалах от 0 до 1. Чувствительность колеблется от 0,95 до 1,00. Специфичность колеблется от 0,55 до 1,00."
      },
      "state": "draft"
    },
    {
      "id": "img-p108-4",
      "file": "images/img-p108-4.webp",
      "page": 108,
      "narratives": {
        "en": "Paired forest plots of sensitivity and specificity. Test: Truenat MTB plus; specimen: cerebrospinal fluid; reference standard: composite reference standard; 1 study (Sharma 2021). For each study the table lists TP, FP, FN and TN counts with sensitivity and specificity (95% CI), plotted as squares with confidence-interval lines on scales from 0 to 1. Sensitivity is 0.79 (95% CI 0.70–0.86). Specificity is 1.00 (95% CI 0.91–1.00).",
        "ar": "مخططا غابة متقابلان للحساسية والنوعية. الاختبار: Truenat MTB plus؛ العينة: السائل الدماغي الشوكي؛ المعيار المرجعي: المعيار المرجعي المركب؛ عدد الدراسات: 1 (Sharma 2021). يُدرج الجدول لكل دراسة أعداد الإيجابيات الحقيقية (TP) والإيجابيات الكاذبة (FP) والسلبيات الكاذبة (FN) والسلبيات الحقيقية (TN) مع الحساسية والنوعية (فاصل الثقة 95%)، وتُعرض كمربعات مع خطوط فواصل الثقة على مقياس من 0 إلى 1. الحساسية 0.79 (فاصل الثقة 95%: 0.70–0.86). النوعية 1.00 (فاصل الثقة 95%: 0.91–1.00).",
        "zh": "敏感度和特异度的配对森林图。检测：Truenat MTB plus；标本：脑脊液；参考标准：复合参考标准；1项研究 (Sharma 2021)。 表中列出每项研究的真阳性（TP）、假阳性（FP）、假阴性（FN）和真阴性（TN）数以及敏感度和特异度（95% CI），并以方块和置信区间线绘于0至1的刻度上。 敏感度为0.79（95% CI 0.70–0.86）。 特异度为1.00（95% CI 0.91–1.00）。",
        "es": "Diagramas de bosque emparejados de sensibilidad y especificidad. Prueba: Truenat MTB plus; muestra: líquido cefalorraquídeo; estándar de referencia: estándar de referencia compuesto; 1 estudio (Sharma 2021). Para cada estudio, la tabla indica los recuentos TP, FP, FN y TN (verdaderos positivos, falsos positivos, falsos negativos y verdaderos negativos) con la sensibilidad y la especificidad (IC del 95%), representadas como cuadrados con líneas de intervalo de confianza en escalas de 0 a 1. La sensibilidad es de 0,79 (IC del 95%: 0,70–0,86). La especificidad es de 1,00 (IC del 95%: 0,91–1,00).",
        "fr": "Graphiques en forêt appariés de la sensibilité et de la spécificité. Test : Truenat MTB plus ; échantillon : liquide céphalorachidien ; norme de référence : norme de référence composite ; 1 étude (Sharma 2021). Pour chaque étude, le tableau indique les nombres TP, FP, FN et TN (vrais positifs, faux positifs, faux négatifs et vrais négatifs) ainsi que la sensibilité et la spécificité (IC à 95 %), représentées par des carrés avec des lignes d'intervalle de confiance sur des échelles de 0 à 1. La sensibilité est de 0,79 (IC à 95 % : 0,70–0,86). La spécificité est de 1,00 (IC à 95 % : 0,91–1,00).",
        "ru": "Парные лесовидные диаграммы чувствительности и специфичности. Тест: Truenat MTB plus; образец: спинномозговая жидкость; эталонный стандарт: комбинированный эталонный стандарт; исследований: 1 (Sharma 2021). Для каждого исследования в таблице приведены числа TP, FP, FN и TN (истинно положительные, ложноположительные, ложноотрицательные и истинно отрицательные результаты), а также чувствительность и специфичность (95% ДИ), показанные квадратами с линиями доверительных интервалов на шкалах от 0 до 1. Чувствительность составляет 0,79 (95% ДИ: 0,70–0,86). Специфичность составляет 1,00 (95% ДИ: 0,91–1,00)."
      },
      "state": "draft"
    },
    {
      "id": "img-p109-1",
      "file": "images/img-p109-1.webp",
      "page": 109,
      "narratives": {
        "en": "Risk of bias and applicability chart for lymph node tuberculosis in lymph node aspirate, with one row per study (9 studies). Each study is rated for risk of bias (patient selection, index test, reference standard, flow and timing) and applicability (patient selection, index test, reference standard) using green (low), yellow (unclear) and red (high) circles. Most ratings are low; high ratings are given for Hoel 2020, Hoel 2020a, Slail 2023 (applicability, patient selection).",
        "ar": "مخطط خطر التحيز وقابلية التطبيق بشأن سل العقد اللمفية في رشافة العقدة اللمفية، بصف واحد لكل دراسة (عدد الدراسات: 9). تُقيَّم كل دراسة من حيث خطر التحيز (اختيار المرضى، والاختبار المؤشر، والمعيار المرجعي، والتدفق والتوقيت) وقابلية التطبيق (اختيار المرضى، والاختبار المؤشر، والمعيار المرجعي) باستخدام دوائر خضراء (منخفض) وصفراء (غير واضح) وحمراء (مرتفع). معظم التقييمات منخفضة؛ والتقييمات المرتفعة هي: Hoel 2020, Hoel 2020a, Slail 2023 (قابلية التطبيق، اختيار المرضى).",
        "zh": "淋巴结抽吸物检测淋巴结结核的偏倚风险和适用性图，每项研究一行（9项研究）。每项研究按偏倚风险（患者选择、待评价试验、参考标准、流程和时间）和适用性（患者选择、待评价试验、参考标准）评级，以绿色（低）、黄色（不明确）和红色（高）圆圈表示。 大多数评级为低；评为高的有：Hoel 2020, Hoel 2020a, Slail 2023 (适用性，患者选择)。",
        "es": "Gráfico de riesgo de sesgo y aplicabilidad para la tuberculosis ganglionar en aspirado de ganglio linfático, con una fila por estudio (9 estudios). Cada estudio se califica en cuanto a riesgo de sesgo (selección de pacientes, prueba índice, estándar de referencia, flujo y cronología) y aplicabilidad (selección de pacientes, prueba índice, estándar de referencia) con círculos verdes (bajo), amarillos (incierto) y rojos (alto). La mayoría de las calificaciones son bajas; las calificaciones altas corresponden a Hoel 2020, Hoel 2020a, Slail 2023 (aplicabilidad, selección de pacientes).",
        "fr": "Graphique du risque de biais et de l'applicabilité pour la tuberculose ganglionnaire dans l'aspirat de ganglion lymphatique, avec une ligne par étude (9 études). Chaque étude est évaluée pour le risque de biais (sélection des patients, test index, norme de référence, flux et calendrier) et l'applicabilité (sélection des patients, test index, norme de référence) au moyen de cercles verts (faible), jaunes (incertain) et rouges (élevé). La plupart des évaluations sont faibles ; les évaluations élevées concernent Hoel 2020, Hoel 2020a, Slail 2023 (applicabilité, sélection des patients).",
        "ru": "Диаграмма риска систематической ошибки и применимости: туберкулез лимфатических узлов, аспират лимфатического узла; одна строка на исследование (исследований: 9). Каждое исследование оценено по риску систематической ошибки (отбор пациентов, индексный тест, эталонный стандарт, поток и сроки) и применимости (отбор пациентов, индексный тест, эталонный стандарт) с помощью зеленых (низкий), желтых (неясный) и красных (высокий) кружков. Большинство оценок низкие; высокие оценки: Hoel 2020, Hoel 2020a, Slail 2023 (применимость, отбор пациентов)."
      },
      "state": "draft"
    },
    {
      "id": "img-p110-1",
      "file": "images/img-p110-1.webp",
      "page": 110,
      "narratives": {
        "en": "Paired forest plots of sensitivity and specificity. Test: Xpert Ultra; specimen: lymph node aspirate; reference standard: culture; 9 studies. For each study the table lists TP, FP, FN and TN counts with sensitivity and specificity (95% CI), plotted as squares with confidence-interval lines on scales from 0 to 1. Sensitivity ranges from 0.50 to 1.00. Specificity ranges from 0.33 to 1.00.",
        "ar": "مخططا غابة متقابلان للحساسية والنوعية. الاختبار: Xpert Ultra؛ العينة: رشافة العقدة اللمفية؛ المعيار المرجعي: الزرع؛ عدد الدراسات: 9. يُدرج الجدول لكل دراسة أعداد الإيجابيات الحقيقية (TP) والإيجابيات الكاذبة (FP) والسلبيات الكاذبة (FN) والسلبيات الحقيقية (TN) مع الحساسية والنوعية (فاصل الثقة 95%)، وتُعرض كمربعات مع خطوط فواصل الثقة على مقياس من 0 إلى 1. تتراوح الحساسية بين 0.50 و1.00. تتراوح النوعية بين 0.33 و1.00.",
        "zh": "敏感度和特异度的配对森林图。检测：Xpert Ultra；标本：淋巴结抽吸物；参考标准：培养；9项研究。 表中列出每项研究的真阳性（TP）、假阳性（FP）、假阴性（FN）和真阴性（TN）数以及敏感度和特异度（95% CI），并以方块和置信区间线绘于0至1的刻度上。 敏感度范围为0.50至1.00。 特异度范围为0.33至1.00。",
        "es": "Diagramas de bosque emparejados de sensibilidad y especificidad. Prueba: Xpert Ultra; muestra: aspirado de ganglio linfático; estándar de referencia: cultivo; 9 estudios. Para cada estudio, la tabla indica los recuentos TP, FP, FN y TN (verdaderos positivos, falsos positivos, falsos negativos y verdaderos negativos) con la sensibilidad y la especificidad (IC del 95%), representadas como cuadrados con líneas de intervalo de confianza en escalas de 0 a 1. La sensibilidad varía entre 0,50 y 1,00. La especificidad varía entre 0,33 y 1,00.",
        "fr": "Graphiques en forêt appariés de la sensibilité et de la spécificité. Test : Xpert Ultra ; échantillon : aspirat de ganglion lymphatique ; norme de référence : culture ; 9 études. Pour chaque étude, le tableau indique les nombres TP, FP, FN et TN (vrais positifs, faux positifs, faux négatifs et vrais négatifs) ainsi que la sensibilité et la spécificité (IC à 95 %), représentées par des carrés avec des lignes d'intervalle de confiance sur des échelles de 0 à 1. La sensibilité varie de 0,50 à 1,00. La spécificité varie de 0,33 à 1,00.",
        "ru": "Парные лесовидные диаграммы чувствительности и специфичности. Тест: Xpert Ultra; образец: аспират лимфатического узла; эталонный стандарт: посев; исследований: 9. Для каждого исследования в таблице приведены числа TP, FP, FN и TN (истинно положительные, ложноположительные, ложноотрицательные и истинно отрицательные результаты), а также чувствительность и специфичность (95% ДИ), показанные квадратами с линиями доверительных интервалов на шкалах от 0 до 1. Чувствительность колеблется от 0,50 до 1,00. Специфичность колеблется от 0,33 до 1,00."
      },
      "state": "draft"
    },
    {
      "id": "img-p110-2",
      "file": "images/img-p110-2.webp",
      "page": 110,
      "narratives": {
        "en": "Paired forest plots of sensitivity and specificity. Test: Xpert Ultra; specimen: lymph node aspirate; reference standard: composite reference standard; 6 studies. For each study the table lists TP, FP, FN and TN counts with sensitivity and specificity (95% CI), plotted as squares with confidence-interval lines on scales from 0 to 1. Sensitivity ranges from 0.60 to 0.81. Specificity ranges from 0.71 to 1.00.",
        "ar": "مخططا غابة متقابلان للحساسية والنوعية. الاختبار: Xpert Ultra؛ العينة: رشافة العقدة اللمفية؛ المعيار المرجعي: المعيار المرجعي المركب؛ عدد الدراسات: 6. يُدرج الجدول لكل دراسة أعداد الإيجابيات الحقيقية (TP) والإيجابيات الكاذبة (FP) والسلبيات الكاذبة (FN) والسلبيات الحقيقية (TN) مع الحساسية والنوعية (فاصل الثقة 95%)، وتُعرض كمربعات مع خطوط فواصل الثقة على مقياس من 0 إلى 1. تتراوح الحساسية بين 0.60 و0.81. تتراوح النوعية بين 0.71 و1.00.",
        "zh": "敏感度和特异度的配对森林图。检测：Xpert Ultra；标本：淋巴结抽吸物；参考标准：复合参考标准；6项研究。 表中列出每项研究的真阳性（TP）、假阳性（FP）、假阴性（FN）和真阴性（TN）数以及敏感度和特异度（95% CI），并以方块和置信区间线绘于0至1的刻度上。 敏感度范围为0.60至0.81。 特异度范围为0.71至1.00。",
        "es": "Diagramas de bosque emparejados de sensibilidad y especificidad. Prueba: Xpert Ultra; muestra: aspirado de ganglio linfático; estándar de referencia: estándar de referencia compuesto; 6 estudios. Para cada estudio, la tabla indica los recuentos TP, FP, FN y TN (verdaderos positivos, falsos positivos, falsos negativos y verdaderos negativos) con la sensibilidad y la especificidad (IC del 95%), representadas como cuadrados con líneas de intervalo de confianza en escalas de 0 a 1. La sensibilidad varía entre 0,60 y 0,81. La especificidad varía entre 0,71 y 1,00.",
        "fr": "Graphiques en forêt appariés de la sensibilité et de la spécificité. Test : Xpert Ultra ; échantillon : aspirat de ganglion lymphatique ; norme de référence : norme de référence composite ; 6 études. Pour chaque étude, le tableau indique les nombres TP, FP, FN et TN (vrais positifs, faux positifs, faux négatifs et vrais négatifs) ainsi que la sensibilité et la spécificité (IC à 95 %), représentées par des carrés avec des lignes d'intervalle de confiance sur des échelles de 0 à 1. La sensibilité varie de 0,60 à 0,81. La spécificité varie de 0,71 à 1,00.",
        "ru": "Парные лесовидные диаграммы чувствительности и специфичности. Тест: Xpert Ultra; образец: аспират лимфатического узла; эталонный стандарт: комбинированный эталонный стандарт; исследований: 6. Для каждого исследования в таблице приведены числа TP, FP, FN и TN (истинно положительные, ложноположительные, ложноотрицательные и истинно отрицательные результаты), а также чувствительность и специфичность (95% ДИ), показанные квадратами с линиями доверительных интервалов на шкалах от 0 до 1. Чувствительность колеблется от 0,60 до 0,81. Специфичность колеблется от 0,71 до 1,00."
      },
      "state": "draft"
    },
    {
      "id": "img-p110-3",
      "file": "images/img-p110-3.webp",
      "page": 110,
      "narratives": {
        "en": "Paired forest plots of sensitivity and specificity. Test: Truenat MTB plus; specimen: lymph node aspirate; reference standard: composite reference standard (upper panel) and culture (lower panel); 1 study (Sharma 2023). For each study the table lists TP, FP, FN and TN counts with sensitivity and specificity (95% CI), plotted as squares with confidence-interval lines on scales from 0 to 1. Against the composite reference standard, sensitivity is 0.77 and specificity 1.00; against culture, sensitivity is 1.00 and specificity 0.56.",
        "ar": "مخططا غابة متقابلان للحساسية والنوعية. الاختبار: Truenat MTB plus؛ العينة: رشافة العقدة اللمفية؛ المعيار المرجعي: المعيار المرجعي المركب (اللوحة العليا) والزرع (اللوحة السفلى)؛ عدد الدراسات: 1 (Sharma 2023). يُدرج الجدول لكل دراسة أعداد الإيجابيات الحقيقية (TP) والإيجابيات الكاذبة (FP) والسلبيات الكاذبة (FN) والسلبيات الحقيقية (TN) مع الحساسية والنوعية (فاصل الثقة 95%)، وتُعرض كمربعات مع خطوط فواصل الثقة على مقياس من 0 إلى 1. مقابل المعيار المرجعي المركب تبلغ الحساسية 0.77 والنوعية 1.00؛ ومقابل الزرع تبلغ الحساسية 1.00 والنوعية 0.56.",
        "zh": "敏感度和特异度的配对森林图。检测：Truenat MTB plus；标本：淋巴结抽吸物；参考标准：复合参考标准（上图）和培养（下图）；1项研究 (Sharma 2023)。 表中列出每项研究的真阳性（TP）、假阳性（FP）、假阴性（FN）和真阴性（TN）数以及敏感度和特异度（95% CI），并以方块和置信区间线绘于0至1的刻度上。 以复合参考标准为参照，敏感度为0.77，特异度为1.00；以培养为参照，敏感度为1.00，特异度为0.56。",
        "es": "Diagramas de bosque emparejados de sensibilidad y especificidad. Prueba: Truenat MTB plus; muestra: aspirado de ganglio linfático; estándar de referencia: estándar de referencia compuesto (panel superior) y cultivo (panel inferior); 1 estudio (Sharma 2023). Para cada estudio, la tabla indica los recuentos TP, FP, FN y TN (verdaderos positivos, falsos positivos, falsos negativos y verdaderos negativos) con la sensibilidad y la especificidad (IC del 95%), representadas como cuadrados con líneas de intervalo de confianza en escalas de 0 a 1. Frente al estándar de referencia compuesto, la sensibilidad es de 0,77 y la especificidad de 1,00; frente al cultivo, la sensibilidad es de 1,00 y la especificidad de 0,56.",
        "fr": "Graphiques en forêt appariés de la sensibilité et de la spécificité. Test : Truenat MTB plus ; échantillon : aspirat de ganglion lymphatique ; norme de référence : norme de référence composite (panneau supérieur) et culture (panneau inférieur) ; 1 étude (Sharma 2023). Pour chaque étude, le tableau indique les nombres TP, FP, FN et TN (vrais positifs, faux positifs, faux négatifs et vrais négatifs) ainsi que la sensibilité et la spécificité (IC à 95 %), représentées par des carrés avec des lignes d'intervalle de confiance sur des échelles de 0 à 1. Par rapport à la norme de référence composite, la sensibilité est de 0,77 et la spécificité de 1,00 ; par rapport à la culture, la sensibilité est de 1,00 et la spécificité de 0,56.",
        "ru": "Парные лесовидные диаграммы чувствительности и специфичности. Тест: Truenat MTB plus; образец: аспират лимфатического узла; эталонный стандарт: комбинированный эталонный стандарт (верхняя панель) и посев (нижняя панель); исследований: 1 (Sharma 2023). Для каждого исследования в таблице приведены числа TP, FP, FN и TN (истинно положительные, ложноположительные, ложноотрицательные и истинно отрицательные результаты), а также чувствительность и специфичность (95% ДИ), показанные квадратами с линиями доверительных интервалов на шкалах от 0 до 1. По сравнению с комбинированным эталонным стандартом чувствительность составляет 0,77, а специфичность 1,00; по сравнению с посевом чувствительность составляет 1,00, а специфичность 0,56."
      },
      "state": "draft"
    },
    {
      "id": "img-p111-1",
      "file": "images/img-p111-1.webp",
      "page": 111,
      "narratives": {
        "en": "Risk of bias and applicability chart for lymph node tuberculosis in lymph node tissue, with one row per study (9 studies). Each study is rated for risk of bias (patient selection, index test, reference standard, flow and timing) and applicability (patient selection, index test, reference standard) using green (low), yellow (unclear) and red (high) circles. Most ratings are low; high ratings are given for Hoel 2020, Hoel 2020a, Mekkaoui 2021, Slail 2023 (applicability, patient selection); Wu 2019 (applicability, index test).",
        "ar": "مخطط خطر التحيز وقابلية التطبيق بشأن سل العقد اللمفية في نسيج العقدة اللمفية، بصف واحد لكل دراسة (عدد الدراسات: 9). تُقيَّم كل دراسة من حيث خطر التحيز (اختيار المرضى، والاختبار المؤشر، والمعيار المرجعي، والتدفق والتوقيت) وقابلية التطبيق (اختيار المرضى، والاختبار المؤشر، والمعيار المرجعي) باستخدام دوائر خضراء (منخفض) وصفراء (غير واضح) وحمراء (مرتفع). معظم التقييمات منخفضة؛ والتقييمات المرتفعة هي: Hoel 2020, Hoel 2020a, Mekkaoui 2021, Slail 2023 (قابلية التطبيق، اختيار المرضى)؛ Wu 2019 (قابلية التطبيق، الاختبار المؤشر).",
        "zh": "淋巴结组织检测淋巴结结核的偏倚风险和适用性图，每项研究一行（9项研究）。每项研究按偏倚风险（患者选择、待评价试验、参考标准、流程和时间）和适用性（患者选择、待评价试验、参考标准）评级，以绿色（低）、黄色（不明确）和红色（高）圆圈表示。 大多数评级为低；评为高的有：Hoel 2020, Hoel 2020a, Mekkaoui 2021, Slail 2023 (适用性，患者选择)；Wu 2019 (适用性，待评价试验)。",
        "es": "Gráfico de riesgo de sesgo y aplicabilidad para la tuberculosis ganglionar en tejido de ganglio linfático, con una fila por estudio (9 estudios). Cada estudio se califica en cuanto a riesgo de sesgo (selección de pacientes, prueba índice, estándar de referencia, flujo y cronología) y aplicabilidad (selección de pacientes, prueba índice, estándar de referencia) con círculos verdes (bajo), amarillos (incierto) y rojos (alto). La mayoría de las calificaciones son bajas; las calificaciones altas corresponden a Hoel 2020, Hoel 2020a, Mekkaoui 2021, Slail 2023 (aplicabilidad, selección de pacientes); Wu 2019 (aplicabilidad, prueba índice).",
        "fr": "Graphique du risque de biais et de l'applicabilité pour la tuberculose ganglionnaire dans le tissu ganglionnaire, avec une ligne par étude (9 études). Chaque étude est évaluée pour le risque de biais (sélection des patients, test index, norme de référence, flux et calendrier) et l'applicabilité (sélection des patients, test index, norme de référence) au moyen de cercles verts (faible), jaunes (incertain) et rouges (élevé). La plupart des évaluations sont faibles ; les évaluations élevées concernent Hoel 2020, Hoel 2020a, Mekkaoui 2021, Slail 2023 (applicabilité, sélection des patients) ; Wu 2019 (applicabilité, test index).",
        "ru": "Диаграмма риска систематической ошибки и применимости: туберкулез лимфатических узлов, ткань лимфатического узла; одна строка на исследование (исследований: 9). Каждое исследование оценено по риску систематической ошибки (отбор пациентов, индексный тест, эталонный стандарт, поток и сроки) и применимости (отбор пациентов, индексный тест, эталонный стандарт) с помощью зеленых (низкий), желтых (неясный) и красных (высокий) кружков. Большинство оценок низкие; высокие оценки: Hoel 2020, Hoel 2020a, Mekkaoui 2021, Slail 2023 (применимость, отбор пациентов); Wu 2019 (применимость, индексный тест)."
      },
      "state": "draft"
    },
    {
      "id": "img-p112-1",
      "file": "images/img-p112-1.webp",
      "page": 112,
      "narratives": {
        "en": "Paired forest plots of sensitivity and specificity. Test: Xpert Ultra; specimen: lymph node biopsy; reference standard: culture; 9 studies. For each study the table lists TP, FP, FN and TN counts with sensitivity and specificity (95% CI), plotted as squares with confidence-interval lines on scales from 0 to 1. Sensitivity ranges from 0.88 to 1.00. Sensitivity is not estimable for Hoel 2020. Specificity ranges from 0.38 to 1.00.",
        "ar": "مخططا غابة متقابلان للحساسية والنوعية. الاختبار: Xpert Ultra؛ العينة: خزعة العقدة اللمفية؛ المعيار المرجعي: الزرع؛ عدد الدراسات: 9. يُدرج الجدول لكل دراسة أعداد الإيجابيات الحقيقية (TP) والإيجابيات الكاذبة (FP) والسلبيات الكاذبة (FN) والسلبيات الحقيقية (TN) مع الحساسية والنوعية (فاصل الثقة 95%)، وتُعرض كمربعات مع خطوط فواصل الثقة على مقياس من 0 إلى 1. تتراوح الحساسية بين 0.88 و1.00. الحساسية غير قابلة للتقدير في Hoel 2020. تتراوح النوعية بين 0.38 و1.00.",
        "zh": "敏感度和特异度的配对森林图。检测：Xpert Ultra；标本：淋巴结活检；参考标准：培养；9项研究。 表中列出每项研究的真阳性（TP）、假阳性（FP）、假阴性（FN）和真阴性（TN）数以及敏感度和特异度（95% CI），并以方块和置信区间线绘于0至1的刻度上。 敏感度范围为0.88至1.00。 Hoel 2020的敏感度无法估计。 特异度范围为0.38至1.00。",
        "es": "Diagramas de bosque emparejados de sensibilidad y especificidad. Prueba: Xpert Ultra; muestra: biopsia de ganglio linfático; estándar de referencia: cultivo; 9 estudios. Para cada estudio, la tabla indica los recuentos TP, FP, FN y TN (verdaderos positivos, falsos positivos, falsos negativos y verdaderos negativos) con la sensibilidad y la especificidad (IC del 95%), representadas como cuadrados con líneas de intervalo de confianza en escalas de 0 a 1. La sensibilidad varía entre 0,88 y 1,00. La sensibilidad no es estimable en Hoel 2020. La especificidad varía entre 0,38 y 1,00.",
        "fr": "Graphiques en forêt appariés de la sensibilité et de la spécificité. Test : Xpert Ultra ; échantillon : biopsie de ganglion lymphatique ; norme de référence : culture ; 9 études. Pour chaque étude, le tableau indique les nombres TP, FP, FN et TN (vrais positifs, faux positifs, faux négatifs et vrais négatifs) ainsi que la sensibilité et la spécificité (IC à 95 %), représentées par des carrés avec des lignes d'intervalle de confiance sur des échelles de 0 à 1. La sensibilité varie de 0,88 à 1,00. La sensibilité n'est pas estimable pour Hoel 2020. La spécificité varie de 0,38 à 1,00.",
        "ru": "Парные лесовидные диаграммы чувствительности и специфичности. Тест: Xpert Ultra; образец: биоптат лимфатического узла; эталонный стандарт: посев; исследований: 9. Для каждого исследования в таблице приведены числа TP, FP, FN и TN (истинно положительные, ложноположительные, ложноотрицательные и истинно отрицательные результаты), а также чувствительность и специфичность (95% ДИ), показанные квадратами с линиями доверительных интервалов на шкалах от 0 до 1. Чувствительность колеблется от 0,88 до 1,00. Чувствительность не поддается оценке для Hoel 2020. Специфичность колеблется от 0,38 до 1,00."
      },
      "state": "draft"
    },
    {
      "id": "img-p112-2",
      "file": "images/img-p112-2.webp",
      "page": 112,
      "narratives": {
        "en": "Paired forest plots of sensitivity and specificity. Test: Xpert Ultra; specimen: lymph node biopsy; reference standard: composite reference standard; 4 studies. For each study the table lists TP, FP, FN and TN counts with sensitivity and specificity (95% CI), plotted as squares with confidence-interval lines on scales from 0 to 1. Sensitivity ranges from 0.47 to 0.73. Sensitivity is not estimable for Hoel 2020. Specificity ranges from 0.96 to 1.00.",
        "ar": "مخططا غابة متقابلان للحساسية والنوعية. الاختبار: Xpert Ultra؛ العينة: خزعة العقدة اللمفية؛ المعيار المرجعي: المعيار المرجعي المركب؛ عدد الدراسات: 4. يُدرج الجدول لكل دراسة أعداد الإيجابيات الحقيقية (TP) والإيجابيات الكاذبة (FP) والسلبيات الكاذبة (FN) والسلبيات الحقيقية (TN) مع الحساسية والنوعية (فاصل الثقة 95%)، وتُعرض كمربعات مع خطوط فواصل الثقة على مقياس من 0 إلى 1. تتراوح الحساسية بين 0.47 و0.73. الحساسية غير قابلة للتقدير في Hoel 2020. تتراوح النوعية بين 0.96 و1.00.",
        "zh": "敏感度和特异度的配对森林图。检测：Xpert Ultra；标本：淋巴结活检；参考标准：复合参考标准；4项研究。 表中列出每项研究的真阳性（TP）、假阳性（FP）、假阴性（FN）和真阴性（TN）数以及敏感度和特异度（95% CI），并以方块和置信区间线绘于0至1的刻度上。 敏感度范围为0.47至0.73。 Hoel 2020的敏感度无法估计。 特异度范围为0.96至1.00。",
        "es": "Diagramas de bosque emparejados de sensibilidad y especificidad. Prueba: Xpert Ultra; muestra: biopsia de ganglio linfático; estándar de referencia: estándar de referencia compuesto; 4 estudios. Para cada estudio, la tabla indica los recuentos TP, FP, FN y TN (verdaderos positivos, falsos positivos, falsos negativos y verdaderos negativos) con la sensibilidad y la especificidad (IC del 95%), representadas como cuadrados con líneas de intervalo de confianza en escalas de 0 a 1. La sensibilidad varía entre 0,47 y 0,73. La sensibilidad no es estimable en Hoel 2020. La especificidad varía entre 0,96 y 1,00.",
        "fr": "Graphiques en forêt appariés de la sensibilité et de la spécificité. Test : Xpert Ultra ; échantillon : biopsie de ganglion lymphatique ; norme de référence : norme de référence composite ; 4 études. Pour chaque étude, le tableau indique les nombres TP, FP, FN et TN (vrais positifs, faux positifs, faux négatifs et vrais négatifs) ainsi que la sensibilité et la spécificité (IC à 95 %), représentées par des carrés avec des lignes d'intervalle de confiance sur des échelles de 0 à 1. La sensibilité varie de 0,47 à 0,73. La sensibilité n'est pas estimable pour Hoel 2020. La spécificité varie de 0,96 à 1,00.",
        "ru": "Парные лесовидные диаграммы чувствительности и специфичности. Тест: Xpert Ultra; образец: биоптат лимфатического узла; эталонный стандарт: комбинированный эталонный стандарт; исследований: 4. Для каждого исследования в таблице приведены числа TP, FP, FN и TN (истинно положительные, ложноположительные, ложноотрицательные и истинно отрицательные результаты), а также чувствительность и специфичность (95% ДИ), показанные квадратами с линиями доверительных интервалов на шкалах от 0 до 1. Чувствительность колеблется от 0,47 до 0,73. Чувствительность не поддается оценке для Hoel 2020. Специфичность колеблется от 0,96 до 1,00."
      },
      "state": "draft"
    },
    {
      "id": "img-p112-3",
      "file": "images/img-p112-3.webp",
      "page": 112,
      "narratives": {
        "en": "Paired forest plots of sensitivity and specificity. Test: Truenat MTB plus; specimen: lymph node biopsy; reference standard: culture; 1 study (Jose 2024). For each study the table lists TP, FP, FN and TN counts with sensitivity and specificity (95% CI), plotted as squares with confidence-interval lines on scales from 0 to 1. Sensitivity is 0.86 (95% CI 0.42–1.00). Specificity is 0.98 (95% CI 0.91–1.00).",
        "ar": "مخططا غابة متقابلان للحساسية والنوعية. الاختبار: Truenat MTB plus؛ العينة: خزعة العقدة اللمفية؛ المعيار المرجعي: الزرع؛ عدد الدراسات: 1 (Jose 2024). يُدرج الجدول لكل دراسة أعداد الإيجابيات الحقيقية (TP) والإيجابيات الكاذبة (FP) والسلبيات الكاذبة (FN) والسلبيات الحقيقية (TN) مع الحساسية والنوعية (فاصل الثقة 95%)، وتُعرض كمربعات مع خطوط فواصل الثقة على مقياس من 0 إلى 1. الحساسية 0.86 (فاصل الثقة 95%: 0.42–1.00). النوعية 0.98 (فاصل الثقة 95%: 0.91–1.00).",
        "zh": "敏感度和特异度的配对森林图。检测：Truenat MTB plus；标本：淋巴结活检；参考标准：培养；1项研究 (Jose 2024)。 表中列出每项研究的真阳性（TP）、假阳性（FP）、假阴性（FN）和真阴性（TN）数以及敏感度和特异度（95% CI），并以方块和置信区间线绘于0至1的刻度上。 敏感度为0.86（95% CI 0.42–1.00）。 特异度为0.98（95% CI 0.91–1.00）。",
        "es": "Diagramas de bosque emparejados de sensibilidad y especificidad. Prueba: Truenat MTB plus; muestra: biopsia de ganglio linfático; estándar de referencia: cultivo; 1 estudio (Jose 2024). Para cada estudio, la tabla indica los recuentos TP, FP, FN y TN (verdaderos positivos, falsos positivos, falsos negativos y verdaderos negativos) con la sensibilidad y la especificidad (IC del 95%), representadas como cuadrados con líneas de intervalo de confianza en escalas de 0 a 1. La sensibilidad es de 0,86 (IC del 95%: 0,42–1,00). La especificidad es de 0,98 (IC del 95%: 0,91–1,00).",
        "fr": "Graphiques en forêt appariés de la sensibilité et de la spécificité. Test : Truenat MTB plus ; échantillon : biopsie de ganglion lymphatique ; norme de référence : culture ; 1 étude (Jose 2024). Pour chaque étude, le tableau indique les nombres TP, FP, FN et TN (vrais positifs, faux positifs, faux négatifs et vrais négatifs) ainsi que la sensibilité et la spécificité (IC à 95 %), représentées par des carrés avec des lignes d'intervalle de confiance sur des échelles de 0 à 1. La sensibilité est de 0,86 (IC à 95 % : 0,42–1,00). La spécificité est de 0,98 (IC à 95 % : 0,91–1,00).",
        "ru": "Парные лесовидные диаграммы чувствительности и специфичности. Тест: Truenat MTB plus; образец: биоптат лимфатического узла; эталонный стандарт: посев; исследований: 1 (Jose 2024). Для каждого исследования в таблице приведены числа TP, FP, FN и TN (истинно положительные, ложноположительные, ложноотрицательные и истинно отрицательные результаты), а также чувствительность и специфичность (95% ДИ), показанные квадратами с линиями доверительных интервалов на шкалах от 0 до 1. Чувствительность составляет 0,86 (95% ДИ: 0,42–1,00). Специфичность составляет 0,98 (95% ДИ: 0,91–1,00)."
      },
      "state": "draft"
    },
    {
      "id": "img-p112-4",
      "file": "images/img-p112-4.webp",
      "page": 112,
      "narratives": {
        "en": "Risk of bias and applicability chart for pleural tuberculosis in pleural fluid, with one row per study (14 studies). Each study is rated for risk of bias (patient selection, index test, reference standard, flow and timing) and applicability (patient selection, index test, reference standard) using green (low), yellow (unclear) and red (high) circles. Most ratings are low; high ratings are given for Perez-Risco 2018 (risk of bias, patient selection); Hoel 2020, Mekkaoui 2021, Slail 2023 (applicability, patient selection); Wu 2019 (applicability, index test).",
        "ar": "مخطط خطر التحيز وقابلية التطبيق بشأن السل الجنبي في السائل الجنبي، بصف واحد لكل دراسة (عدد الدراسات: 14). تُقيَّم كل دراسة من حيث خطر التحيز (اختيار المرضى، والاختبار المؤشر، والمعيار المرجعي، والتدفق والتوقيت) وقابلية التطبيق (اختيار المرضى، والاختبار المؤشر، والمعيار المرجعي) باستخدام دوائر خضراء (منخفض) وصفراء (غير واضح) وحمراء (مرتفع). معظم التقييمات منخفضة؛ والتقييمات المرتفعة هي: Perez-Risco 2018 (خطر التحيز، اختيار المرضى)؛ Hoel 2020, Mekkaoui 2021, Slail 2023 (قابلية التطبيق، اختيار المرضى)؛ Wu 2019 (قابلية التطبيق، الاختبار المؤشر).",
        "zh": "胸腔积液检测胸膜结核的偏倚风险和适用性图，每项研究一行（14项研究）。每项研究按偏倚风险（患者选择、待评价试验、参考标准、流程和时间）和适用性（患者选择、待评价试验、参考标准）评级，以绿色（低）、黄色（不明确）和红色（高）圆圈表示。 大多数评级为低；评为高的有：Perez-Risco 2018 (偏倚风险，患者选择)；Hoel 2020, Mekkaoui 2021, Slail 2023 (适用性，患者选择)；Wu 2019 (适用性，待评价试验)。",
        "es": "Gráfico de riesgo de sesgo y aplicabilidad para la tuberculosis pleural en líquido pleural, con una fila por estudio (14 estudios). Cada estudio se califica en cuanto a riesgo de sesgo (selección de pacientes, prueba índice, estándar de referencia, flujo y cronología) y aplicabilidad (selección de pacientes, prueba índice, estándar de referencia) con círculos verdes (bajo), amarillos (incierto) y rojos (alto). La mayoría de las calificaciones son bajas; las calificaciones altas corresponden a Perez-Risco 2018 (riesgo de sesgo, selección de pacientes); Hoel 2020, Mekkaoui 2021, Slail 2023 (aplicabilidad, selección de pacientes); Wu 2019 (aplicabilidad, prueba índice).",
        "fr": "Graphique du risque de biais et de l'applicabilité pour la tuberculose pleurale dans le liquide pleural, avec une ligne par étude (14 études). Chaque étude est évaluée pour le risque de biais (sélection des patients, test index, norme de référence, flux et calendrier) et l'applicabilité (sélection des patients, test index, norme de référence) au moyen de cercles verts (faible), jaunes (incertain) et rouges (élevé). La plupart des évaluations sont faibles ; les évaluations élevées concernent Perez-Risco 2018 (risque de biais, sélection des patients) ; Hoel 2020, Mekkaoui 2021, Slail 2023 (applicabilité, sélection des patients) ; Wu 2019 (applicabilité, test index).",
        "ru": "Диаграмма риска систематической ошибки и применимости: плевральный туберкулез, плевральная жидкость; одна строка на исследование (исследований: 14). Каждое исследование оценено по риску систематической ошибки (отбор пациентов, индексный тест, эталонный стандарт, поток и сроки) и применимости (отбор пациентов, индексный тест, эталонный стандарт) с помощью зеленых (низкий), желтых (неясный) и красных (высокий) кружков. Большинство оценок низкие; высокие оценки: Perez-Risco 2018 (риск систематической ошибки, отбор пациентов); Hoel 2020, Mekkaoui 2021, Slail 2023 (применимость, отбор пациентов); Wu 2019 (применимость, индексный тест)."
      },
      "state": "draft"
    },
    {
      "id": "img-p113-1",
      "file": "images/img-p113-1.webp",
      "page": 113,
      "narratives": {
        "en": "Paired forest plots of sensitivity and specificity by study (13 studies), part of Figure 10 (LC-aNAATs for pleural tuberculosis in pleural fluid); the panel heading naming the test and reference standard is not included in the image. For each study the table lists TP, FP, FN and TN counts with sensitivity and specificity (95% CI), plotted as squares with confidence-interval lines on scales from 0 to 1. Sensitivity ranges from 0.00 to 1.00. Specificity ranges from 0.57 to 1.00.",
        "ar": "مخططا غابة متقابلان للحساسية والنوعية حسب الدراسة (عدد الدراسات: 13)، وهما جزء من الشكل 10 (اختبارات LC-aNAAT للسل الجنبي في السائل الجنبي)؛ ولا تتضمن الصورة عنوان اللوحة الذي يحدد الاختبار والمعيار المرجعي. يُدرج الجدول لكل دراسة أعداد الإيجابيات الحقيقية (TP) والإيجابيات الكاذبة (FP) والسلبيات الكاذبة (FN) والسلبيات الحقيقية (TN) مع الحساسية والنوعية (فاصل الثقة 95%)، وتُعرض كمربعات مع خطوط فواصل الثقة على مقياس من 0 إلى 1. تتراوح الحساسية بين 0.00 و1.00. تتراوح النوعية بين 0.57 و1.00.",
        "zh": "按研究列出的敏感度和特异度配对森林图（13项研究），属于图10（LC-aNAAT用于胸腔积液检测胸膜结核）的一部分；图像中未包含标明检测和参考标准的分图标题。 表中列出每项研究的真阳性（TP）、假阳性（FP）、假阴性（FN）和真阴性（TN）数以及敏感度和特异度（95% CI），并以方块和置信区间线绘于0至1的刻度上。 敏感度范围为0.00至1.00。 特异度范围为0.57至1.00。",
        "es": "Diagramas de bosque emparejados de sensibilidad y especificidad por estudio (13 estudios), parte de la figura 10 (LC-aNAAT para la tuberculosis pleural en líquido pleural); el encabezado del panel que indica la prueba y el estándar de referencia no aparece en la imagen. Para cada estudio, la tabla indica los recuentos TP, FP, FN y TN (verdaderos positivos, falsos positivos, falsos negativos y verdaderos negativos) con la sensibilidad y la especificidad (IC del 95%), representadas como cuadrados con líneas de intervalo de confianza en escalas de 0 a 1. La sensibilidad varía entre 0,00 y 1,00. La especificidad varía entre 0,57 y 1,00.",
        "fr": "Graphiques en forêt appariés de la sensibilité et de la spécificité par étude (13 études), faisant partie de la figure 10 (LC-aNAAT pour la tuberculose pleurale dans le liquide pleural) ; l'en-tête du panneau indiquant le test et la norme de référence ne figure pas dans l'image. Pour chaque étude, le tableau indique les nombres TP, FP, FN et TN (vrais positifs, faux positifs, faux négatifs et vrais négatifs) ainsi que la sensibilité et la spécificité (IC à 95 %), représentées par des carrés avec des lignes d'intervalle de confiance sur des échelles de 0 à 1. La sensibilité varie de 0,00 à 1,00. La spécificité varie de 0,57 à 1,00.",
        "ru": "Парные лесовидные диаграммы чувствительности и специфичности по исследованиям (исследований: 13), часть рисунка 10 (LC-aNAAT для диагностики плеврального туберкулеза в плевральной жидкости); заголовок панели с указанием теста и эталонного стандарта на изображении отсутствует. Для каждого исследования в таблице приведены числа TP, FP, FN и TN (истинно положительные, ложноположительные, ложноотрицательные и истинно отрицательные результаты), а также чувствительность и специфичность (95% ДИ), показанные квадратами с линиями доверительных интервалов на шкалах от 0 до 1. Чувствительность колеблется от 0,00 до 1,00. Специфичность колеблется от 0,57 до 1,00."
      },
      "state": "draft"
    },
    {
      "id": "img-p113-2",
      "file": "images/img-p113-2.webp",
      "page": 113,
      "narratives": {
        "en": "Paired forest plots of sensitivity and specificity. Test: Xpert Ultra; specimen: pleural fluid; reference standard: composite reference standard; 7 studies. For each study the table lists TP, FP, FN and TN counts with sensitivity and specificity (95% CI), plotted as squares with confidence-interval lines on scales from 0 to 1. Sensitivity ranges from 0.00 to 0.61. Specificity ranges from 0.94 to 1.00.",
        "ar": "مخططا غابة متقابلان للحساسية والنوعية. الاختبار: Xpert Ultra؛ العينة: السائل الجنبي؛ المعيار المرجعي: المعيار المرجعي المركب؛ عدد الدراسات: 7. يُدرج الجدول لكل دراسة أعداد الإيجابيات الحقيقية (TP) والإيجابيات الكاذبة (FP) والسلبيات الكاذبة (FN) والسلبيات الحقيقية (TN) مع الحساسية والنوعية (فاصل الثقة 95%)، وتُعرض كمربعات مع خطوط فواصل الثقة على مقياس من 0 إلى 1. تتراوح الحساسية بين 0.00 و0.61. تتراوح النوعية بين 0.94 و1.00.",
        "zh": "敏感度和特异度的配对森林图。检测：Xpert Ultra；标本：胸腔积液；参考标准：复合参考标准；7项研究。 表中列出每项研究的真阳性（TP）、假阳性（FP）、假阴性（FN）和真阴性（TN）数以及敏感度和特异度（95% CI），并以方块和置信区间线绘于0至1的刻度上。 敏感度范围为0.00至0.61。 特异度范围为0.94至1.00。",
        "es": "Diagramas de bosque emparejados de sensibilidad y especificidad. Prueba: Xpert Ultra; muestra: líquido pleural; estándar de referencia: estándar de referencia compuesto; 7 estudios. Para cada estudio, la tabla indica los recuentos TP, FP, FN y TN (verdaderos positivos, falsos positivos, falsos negativos y verdaderos negativos) con la sensibilidad y la especificidad (IC del 95%), representadas como cuadrados con líneas de intervalo de confianza en escalas de 0 a 1. La sensibilidad varía entre 0,00 y 0,61. La especificidad varía entre 0,94 y 1,00.",
        "fr": "Graphiques en forêt appariés de la sensibilité et de la spécificité. Test : Xpert Ultra ; échantillon : liquide pleural ; norme de référence : norme de référence composite ; 7 études. Pour chaque étude, le tableau indique les nombres TP, FP, FN et TN (vrais positifs, faux positifs, faux négatifs et vrais négatifs) ainsi que la sensibilité et la spécificité (IC à 95 %), représentées par des carrés avec des lignes d'intervalle de confiance sur des échelles de 0 à 1. La sensibilité varie de 0,00 à 0,61. La spécificité varie de 0,94 à 1,00.",
        "ru": "Парные лесовидные диаграммы чувствительности и специфичности. Тест: Xpert Ultra; образец: плевральная жидкость; эталонный стандарт: комбинированный эталонный стандарт; исследований: 7. Для каждого исследования в таблице приведены числа TP, FP, FN и TN (истинно положительные, ложноположительные, ложноотрицательные и истинно отрицательные результаты), а также чувствительность и специфичность (95% ДИ), показанные квадратами с линиями доверительных интервалов на шкалах от 0 до 1. Чувствительность колеблется от 0,00 до 0,61. Специфичность колеблется от 0,94 до 1,00."
      },
      "state": "draft"
    },
    {
      "id": "img-p113-3",
      "file": "images/img-p113-3.webp",
      "page": 113,
      "narratives": {
        "en": "Paired forest plots of sensitivity and specificity. Test: Truenat MTB plus; specimen: pleural fluid; reference standard: culture; 1 study (Jose 2024). For each study the table lists TP, FP, FN and TN counts with sensitivity and specificity (95% CI), plotted as squares with confidence-interval lines on scales from 0 to 1. Sensitivity is 1.00 (95% CI 0.03–1.00). Specificity is 1.00 (95% CI 0.95–1.00).",
        "ar": "مخططا غابة متقابلان للحساسية والنوعية. الاختبار: Truenat MTB plus؛ العينة: السائل الجنبي؛ المعيار المرجعي: الزرع؛ عدد الدراسات: 1 (Jose 2024). يُدرج الجدول لكل دراسة أعداد الإيجابيات الحقيقية (TP) والإيجابيات الكاذبة (FP) والسلبيات الكاذبة (FN) والسلبيات الحقيقية (TN) مع الحساسية والنوعية (فاصل الثقة 95%)، وتُعرض كمربعات مع خطوط فواصل الثقة على مقياس من 0 إلى 1. الحساسية 1.00 (فاصل الثقة 95%: 0.03–1.00). النوعية 1.00 (فاصل الثقة 95%: 0.95–1.00).",
        "zh": "敏感度和特异度的配对森林图。检测：Truenat MTB plus；标本：胸腔积液；参考标准：培养；1项研究 (Jose 2024)。 表中列出每项研究的真阳性（TP）、假阳性（FP）、假阴性（FN）和真阴性（TN）数以及敏感度和特异度（95% CI），并以方块和置信区间线绘于0至1的刻度上。 敏感度为1.00（95% CI 0.03–1.00）。 特异度为1.00（95% CI 0.95–1.00）。",
        "es": "Diagramas de bosque emparejados de sensibilidad y especificidad. Prueba: Truenat MTB plus; muestra: líquido pleural; estándar de referencia: cultivo; 1 estudio (Jose 2024). Para cada estudio, la tabla indica los recuentos TP, FP, FN y TN (verdaderos positivos, falsos positivos, falsos negativos y verdaderos negativos) con la sensibilidad y la especificidad (IC del 95%), representadas como cuadrados con líneas de intervalo de confianza en escalas de 0 a 1. La sensibilidad es de 1,00 (IC del 95%: 0,03–1,00). La especificidad es de 1,00 (IC del 95%: 0,95–1,00).",
        "fr": "Graphiques en forêt appariés de la sensibilité et de la spécificité. Test : Truenat MTB plus ; échantillon : liquide pleural ; norme de référence : culture ; 1 étude (Jose 2024). Pour chaque étude, le tableau indique les nombres TP, FP, FN et TN (vrais positifs, faux positifs, faux négatifs et vrais négatifs) ainsi que la sensibilité et la spécificité (IC à 95 %), représentées par des carrés avec des lignes d'intervalle de confiance sur des échelles de 0 à 1. La sensibilité est de 1,00 (IC à 95 % : 0,03–1,00). La spécificité est de 1,00 (IC à 95 % : 0,95–1,00).",
        "ru": "Парные лесовидные диаграммы чувствительности и специфичности. Тест: Truenat MTB plus; образец: плевральная жидкость; эталонный стандарт: посев; исследований: 1 (Jose 2024). Для каждого исследования в таблице приведены числа TP, FP, FN и TN (истинно положительные, ложноположительные, ложноотрицательные и истинно отрицательные результаты), а также чувствительность и специфичность (95% ДИ), показанные квадратами с линиями доверительных интервалов на шкалах от 0 до 1. Чувствительность составляет 1,00 (95% ДИ: 0,03–1,00). Специфичность составляет 1,00 (95% ДИ: 0,95–1,00)."
      },
      "state": "draft"
    },
    {
      "id": "img-p114-1",
      "file": "images/img-p114-1.webp",
      "page": 114,
      "narratives": {
        "en": "Risk of bias and applicability chart for pleural tuberculosis in pleural tissue, with one row per study (2 studies (Christopher 2021, Gao 2021)). Each study is rated for risk of bias (patient selection, index test, reference standard, flow and timing) and applicability (patient selection, index test, reference standard) using green (low), yellow (unclear) and red (high) circles. No study is rated high; both are rated unclear for applicability of patient selection, and Gao 2021 is also unclear for the reference standard.",
        "ar": "مخطط خطر التحيز وقابلية التطبيق بشأن السل الجنبي في النسيج الجنبي، بصف واحد لكل دراسة (عدد الدراسات: 2 (Christopher 2021, Gao 2021)). تُقيَّم كل دراسة من حيث خطر التحيز (اختيار المرضى، والاختبار المؤشر، والمعيار المرجعي، والتدفق والتوقيت) وقابلية التطبيق (اختيار المرضى، والاختبار المؤشر، والمعيار المرجعي) باستخدام دوائر خضراء (منخفض) وصفراء (غير واضح) وحمراء (مرتفع). لم تُقيَّم أي دراسة بخطر مرتفع؛ وكلتاهما مقيَّمتان بغير واضح في قابلية التطبيق لاختيار المرضى، كما أن Gao 2021 غير واضحة أيضاً في المعيار المرجعي.",
        "zh": "胸膜组织检测胸膜结核的偏倚风险和适用性图，每项研究一行（2项研究 (Christopher 2021, Gao 2021)）。每项研究按偏倚风险（患者选择、待评价试验、参考标准、流程和时间）和适用性（患者选择、待评价试验、参考标准）评级，以绿色（低）、黄色（不明确）和红色（高）圆圈表示。 没有研究被评为高；两项研究在患者选择的适用性方面均为不明确，Gao 2021在参考标准方面也为不明确。",
        "es": "Gráfico de riesgo de sesgo y aplicabilidad para la tuberculosis pleural en tejido pleural, con una fila por estudio (2 estudios (Christopher 2021, Gao 2021)). Cada estudio se califica en cuanto a riesgo de sesgo (selección de pacientes, prueba índice, estándar de referencia, flujo y cronología) y aplicabilidad (selección de pacientes, prueba índice, estándar de referencia) con círculos verdes (bajo), amarillos (incierto) y rojos (alto). Ningún estudio se califica como alto; ambos son inciertos en la aplicabilidad de la selección de pacientes, y Gao 2021 también es incierto en el estándar de referencia.",
        "fr": "Graphique du risque de biais et de l'applicabilité pour la tuberculose pleurale dans le tissu pleural, avec une ligne par étude (2 études (Christopher 2021, Gao 2021)). Chaque étude est évaluée pour le risque de biais (sélection des patients, test index, norme de référence, flux et calendrier) et l'applicabilité (sélection des patients, test index, norme de référence) au moyen de cercles verts (faible), jaunes (incertain) et rouges (élevé). Aucune étude n'est évaluée comme élevée ; les deux sont incertaines pour l'applicabilité de la sélection des patients, et Gao 2021 l'est aussi pour la norme de référence.",
        "ru": "Диаграмма риска систематической ошибки и применимости: плевральный туберкулез, ткань плевры; одна строка на исследование (исследований: 2 (Christopher 2021, Gao 2021)). Каждое исследование оценено по риску систематической ошибки (отбор пациентов, индексный тест, эталонный стандарт, поток и сроки) и применимости (отбор пациентов, индексный тест, эталонный стандарт) с помощью зеленых (низкий), желтых (неясный) и красных (высокий) кружков. Ни одно исследование не получило высокой оценки; оба оценены как неясные по применимости отбора пациентов, а Gao 2021 — также по эталонному стандарту."
      },
      "state": "draft"
    },
    {
      "id": "img-p114-2",
      "file": "images/img-p114-2.webp",
      "page": 114,
      "narratives": {
        "en": "Paired forest plots of sensitivity and specificity. Test: Xpert Ultra; specimen: pleural tissue; reference standard: culture; 2 studies (Gao 2021, Christopher 2021). For each study the table lists TP, FP, FN and TN counts with sensitivity and specificity (95% CI), plotted as squares with confidence-interval lines on scales from 0 to 1. Sensitivity ranges from 0.80 to 1.00. Specificity ranges from 0.75 to 0.86.",
        "ar": "مخططا غابة متقابلان للحساسية والنوعية. الاختبار: Xpert Ultra؛ العينة: النسيج الجنبي؛ المعيار المرجعي: الزرع؛ عدد الدراسات: 2 (Gao 2021, Christopher 2021). يُدرج الجدول لكل دراسة أعداد الإيجابيات الحقيقية (TP) والإيجابيات الكاذبة (FP) والسلبيات الكاذبة (FN) والسلبيات الحقيقية (TN) مع الحساسية والنوعية (فاصل الثقة 95%)، وتُعرض كمربعات مع خطوط فواصل الثقة على مقياس من 0 إلى 1. تتراوح الحساسية بين 0.80 و1.00. تتراوح النوعية بين 0.75 و0.86.",
        "zh": "敏感度和特异度的配对森林图。检测：Xpert Ultra；标本：胸膜组织；参考标准：培养；2项研究 (Gao 2021, Christopher 2021)。 表中列出每项研究的真阳性（TP）、假阳性（FP）、假阴性（FN）和真阴性（TN）数以及敏感度和特异度（95% CI），并以方块和置信区间线绘于0至1的刻度上。 敏感度范围为0.80至1.00。 特异度范围为0.75至0.86。",
        "es": "Diagramas de bosque emparejados de sensibilidad y especificidad. Prueba: Xpert Ultra; muestra: tejido pleural; estándar de referencia: cultivo; 2 estudios (Gao 2021, Christopher 2021). Para cada estudio, la tabla indica los recuentos TP, FP, FN y TN (verdaderos positivos, falsos positivos, falsos negativos y verdaderos negativos) con la sensibilidad y la especificidad (IC del 95%), representadas como cuadrados con líneas de intervalo de confianza en escalas de 0 a 1. La sensibilidad varía entre 0,80 y 1,00. La especificidad varía entre 0,75 y 0,86.",
        "fr": "Graphiques en forêt appariés de la sensibilité et de la spécificité. Test : Xpert Ultra ; échantillon : tissu pleural ; norme de référence : culture ; 2 études (Gao 2021, Christopher 2021). Pour chaque étude, le tableau indique les nombres TP, FP, FN et TN (vrais positifs, faux positifs, faux négatifs et vrais négatifs) ainsi que la sensibilité et la spécificité (IC à 95 %), représentées par des carrés avec des lignes d'intervalle de confiance sur des échelles de 0 à 1. La sensibilité varie de 0,80 à 1,00. La spécificité varie de 0,75 à 0,86.",
        "ru": "Парные лесовидные диаграммы чувствительности и специфичности. Тест: Xpert Ultra; образец: ткань плевры; эталонный стандарт: посев; исследований: 2 (Gao 2021, Christopher 2021). Для каждого исследования в таблице приведены числа TP, FP, FN и TN (истинно положительные, ложноположительные, ложноотрицательные и истинно отрицательные результаты), а также чувствительность и специфичность (95% ДИ), показанные квадратами с линиями доверительных интервалов на шкалах от 0 до 1. Чувствительность колеблется от 0,80 до 1,00. Специфичность колеблется от 0,75 до 0,86."
      },
      "state": "draft"
    },
    {
      "id": "img-p114-3",
      "file": "images/img-p114-3.webp",
      "page": 114,
      "narratives": {
        "en": "Paired forest plots of sensitivity and specificity. Test: Xpert Ultra; specimen: pleural tissue; reference standard: composite reference standard; 2 studies (Gao 2021, Christopher 2021). For each study the table lists TP, FP, FN and TN counts with sensitivity and specificity (95% CI), plotted as squares with confidence-interval lines on scales from 0 to 1. Sensitivity ranges from 0.54 to 0.81. Specificity ranges from 0.94 to 0.97.",
        "ar": "مخططا غابة متقابلان للحساسية والنوعية. الاختبار: Xpert Ultra؛ العينة: النسيج الجنبي؛ المعيار المرجعي: المعيار المرجعي المركب؛ عدد الدراسات: 2 (Gao 2021, Christopher 2021). يُدرج الجدول لكل دراسة أعداد الإيجابيات الحقيقية (TP) والإيجابيات الكاذبة (FP) والسلبيات الكاذبة (FN) والسلبيات الحقيقية (TN) مع الحساسية والنوعية (فاصل الثقة 95%)، وتُعرض كمربعات مع خطوط فواصل الثقة على مقياس من 0 إلى 1. تتراوح الحساسية بين 0.54 و0.81. تتراوح النوعية بين 0.94 و0.97.",
        "zh": "敏感度和特异度的配对森林图。检测：Xpert Ultra；标本：胸膜组织；参考标准：复合参考标准；2项研究 (Gao 2021, Christopher 2021)。 表中列出每项研究的真阳性（TP）、假阳性（FP）、假阴性（FN）和真阴性（TN）数以及敏感度和特异度（95% CI），并以方块和置信区间线绘于0至1的刻度上。 敏感度范围为0.54至0.81。 特异度范围为0.94至0.97。",
        "es": "Diagramas de bosque emparejados de sensibilidad y especificidad. Prueba: Xpert Ultra; muestra: tejido pleural; estándar de referencia: estándar de referencia compuesto; 2 estudios (Gao 2021, Christopher 2021). Para cada estudio, la tabla indica los recuentos TP, FP, FN y TN (verdaderos positivos, falsos positivos, falsos negativos y verdaderos negativos) con la sensibilidad y la especificidad (IC del 95%), representadas como cuadrados con líneas de intervalo de confianza en escalas de 0 a 1. La sensibilidad varía entre 0,54 y 0,81. La especificidad varía entre 0,94 y 0,97.",
        "fr": "Graphiques en forêt appariés de la sensibilité et de la spécificité. Test : Xpert Ultra ; échantillon : tissu pleural ; norme de référence : norme de référence composite ; 2 études (Gao 2021, Christopher 2021). Pour chaque étude, le tableau indique les nombres TP, FP, FN et TN (vrais positifs, faux positifs, faux négatifs et vrais négatifs) ainsi que la sensibilité et la spécificité (IC à 95 %), représentées par des carrés avec des lignes d'intervalle de confiance sur des échelles de 0 à 1. La sensibilité varie de 0,54 à 0,81. La spécificité varie de 0,94 à 0,97.",
        "ru": "Парные лесовидные диаграммы чувствительности и специфичности. Тест: Xpert Ultra; образец: ткань плевры; эталонный стандарт: комбинированный эталонный стандарт; исследований: 2 (Gao 2021, Christopher 2021). Для каждого исследования в таблице приведены числа TP, FP, FN и TN (истинно положительные, ложноположительные, ложноотрицательные и истинно отрицательные результаты), а также чувствительность и специфичность (95% ДИ), показанные квадратами с линиями доверительных интервалов на шкалах от 0 до 1. Чувствительность колеблется от 0,54 до 0,81. Специфичность колеблется от 0,94 до 0,97."
      },
      "state": "draft"
    },
    {
      "id": "img-p115-1",
      "file": "images/img-p115-1.webp",
      "page": 115,
      "narratives": {
        "en": "Risk of bias and applicability chart for genitourinary tuberculosis in urine, with one row per study (6 studies). Each study is rated for risk of bias (patient selection, index test, reference standard, flow and timing) and applicability (patient selection, index test, reference standard) using green (low), yellow (unclear) and red (high) circles. Most ratings are low; high ratings are given for Perez-Risco 2018 (risk of bias, patient selection); Mekkaoui 2021 (applicability, patient selection). The final study row and the legend continue in a separate image.",
        "ar": "مخطط خطر التحيز وقابلية التطبيق بشأن السل البولي التناسلي في البول، بصف واحد لكل دراسة (عدد الدراسات: 6). تُقيَّم كل دراسة من حيث خطر التحيز (اختيار المرضى، والاختبار المؤشر، والمعيار المرجعي، والتدفق والتوقيت) وقابلية التطبيق (اختيار المرضى، والاختبار المؤشر، والمعيار المرجعي) باستخدام دوائر خضراء (منخفض) وصفراء (غير واضح) وحمراء (مرتفع). معظم التقييمات منخفضة؛ والتقييمات المرتفعة هي: Perez-Risco 2018 (خطر التحيز، اختيار المرضى)؛ Mekkaoui 2021 (قابلية التطبيق، اختيار المرضى). يرد صف الدراسة الأخير ومفتاح الرموز في صورة منفصلة.",
        "zh": "尿液检测泌尿生殖系统结核的偏倚风险和适用性图，每项研究一行（6项研究）。每项研究按偏倚风险（患者选择、待评价试验、参考标准、流程和时间）和适用性（患者选择、待评价试验、参考标准）评级，以绿色（低）、黄色（不明确）和红色（高）圆圈表示。 大多数评级为低；评为高的有：Perez-Risco 2018 (偏倚风险，患者选择)；Mekkaoui 2021 (适用性，患者选择)。 最后一行研究和图例见另一幅图像。",
        "es": "Gráfico de riesgo de sesgo y aplicabilidad para la tuberculosis genitourinaria en orina, con una fila por estudio (6 estudios). Cada estudio se califica en cuanto a riesgo de sesgo (selección de pacientes, prueba índice, estándar de referencia, flujo y cronología) y aplicabilidad (selección de pacientes, prueba índice, estándar de referencia) con círculos verdes (bajo), amarillos (incierto) y rojos (alto). La mayoría de las calificaciones son bajas; las calificaciones altas corresponden a Perez-Risco 2018 (riesgo de sesgo, selección de pacientes); Mekkaoui 2021 (aplicabilidad, selección de pacientes). La última fila de estudio y la leyenda continúan en una imagen aparte.",
        "fr": "Graphique du risque de biais et de l'applicabilité pour la tuberculose génito-urinaire dans l'urine, avec une ligne par étude (6 études). Chaque étude est évaluée pour le risque de biais (sélection des patients, test index, norme de référence, flux et calendrier) et l'applicabilité (sélection des patients, test index, norme de référence) au moyen de cercles verts (faible), jaunes (incertain) et rouges (élevé). La plupart des évaluations sont faibles ; les évaluations élevées concernent Perez-Risco 2018 (risque de biais, sélection des patients) ; Mekkaoui 2021 (applicabilité, sélection des patients). La dernière ligne d'étude et la légende se trouvent dans une image distincte.",
        "ru": "Диаграмма риска систематической ошибки и применимости: мочеполовой туберкулез, моча; одна строка на исследование (исследований: 6). Каждое исследование оценено по риску систематической ошибки (отбор пациентов, индексный тест, эталонный стандарт, поток и сроки) и применимости (отбор пациентов, индексный тест, эталонный стандарт) с помощью зеленых (низкий), желтых (неясный) и красных (высокий) кружков. Большинство оценок низкие; высокие оценки: Perez-Risco 2018 (риск систематической ошибки, отбор пациентов); Mekkaoui 2021 (применимость, отбор пациентов). Последняя строка исследования и легенда приведены на отдельном изображении."
      },
      "state": "draft"
    },
    {
      "id": "img-p115-2",
      "file": "images/img-p115-2.webp",
      "page": 115,
      "narratives": {
        "en": "Final row of the risk of bias and applicability chart for genitourinary tuberculosis in urine (Figure 13): Spener-Gomes 2021 is rated low on all four risk-of-bias domains, unclear on applicability of patient selection and index test, and low on applicability of the reference standard. Below it is the legend: red (high), green (low), yellow (unclear).",
        "ar": "الصف الأخير من مخطط خطر التحيز وقابلية التطبيق بشأن السل البولي التناسلي في البول (الشكل 13): قُيِّمت دراسة Spener-Gomes 2021 بخطر منخفض في جميع مجالات خطر التحيز الأربعة، وبغير واضح في قابلية التطبيق لاختيار المرضى والاختبار المؤشر، وبمنخفض في قابلية التطبيق للمعيار المرجعي. ويليه مفتاح الرموز: أحمر (مرتفع)، أخضر (منخفض)، أصفر (غير واضح).",
        "zh": "尿液检测泌尿生殖系统结核的偏倚风险和适用性图（图13）的最后一行：Spener-Gomes 2021在全部四个偏倚风险领域均为低，在患者选择和待评价试验的适用性方面为不明确，在参考标准的适用性方面为低。下方为图例：红色（高）、绿色（低）、黄色（不明确）。",
        "es": "Última fila del gráfico de riesgo de sesgo y aplicabilidad para la tuberculosis genitourinaria en orina (figura 13): Spener-Gomes 2021 se califica como bajo en los cuatro dominios de riesgo de sesgo, incierto en la aplicabilidad de la selección de pacientes y de la prueba índice, y bajo en la aplicabilidad del estándar de referencia. Debajo figura la leyenda: rojo (alto), verde (bajo), amarillo (incierto).",
        "fr": "Dernière ligne du graphique du risque de biais et de l'applicabilité pour la tuberculose génito-urinaire dans l'urine (figure 13) : Spener-Gomes 2021 est évaluée faible dans les quatre domaines de risque de biais, incertaine pour l'applicabilité de la sélection des patients et du test index, et faible pour l'applicabilité de la norme de référence. En dessous figure la légende : rouge (élevé), vert (faible), jaune (incertain).",
        "ru": "Последняя строка диаграммы риска систематической ошибки и применимости для мочеполового туберкулеза в моче (рисунок 13): исследование Spener-Gomes 2021 оценено как низкий риск во всех четырех доменах риска систематической ошибки, как неясное по применимости отбора пациентов и индексного теста и как низкое по применимости эталонного стандарта. Ниже приведена легенда: красный (высокий), зеленый (низкий), желтый (неясный)."
      },
      "state": "draft"
    },
    {
      "id": "img-p115-3",
      "file": "images/img-p115-3.webp",
      "page": 115,
      "narratives": {
        "en": "Paired forest plots of sensitivity and specificity. Test: Xpert Ultra; specimen: urine; reference standard: culture; 7 studies. For each study the table lists TP, FP, FN and TN counts with sensitivity and specificity (95% CI), plotted as squares with confidence-interval lines on scales from 0 to 1. Sensitivity ranges from 0.25 to 1.00. Sensitivity is not estimable for Huerga 2023, Mekkaoui 2021, Osei 2019. Specificity ranges from 0.28 to 1.00.",
        "ar": "مخططا غابة متقابلان للحساسية والنوعية. الاختبار: Xpert Ultra؛ العينة: البول؛ المعيار المرجعي: الزرع؛ عدد الدراسات: 7. يُدرج الجدول لكل دراسة أعداد الإيجابيات الحقيقية (TP) والإيجابيات الكاذبة (FP) والسلبيات الكاذبة (FN) والسلبيات الحقيقية (TN) مع الحساسية والنوعية (فاصل الثقة 95%)، وتُعرض كمربعات مع خطوط فواصل الثقة على مقياس من 0 إلى 1. تتراوح الحساسية بين 0.25 و1.00. الحساسية غير قابلة للتقدير في Huerga 2023, Mekkaoui 2021, Osei 2019. تتراوح النوعية بين 0.28 و1.00.",
        "zh": "敏感度和特异度的配对森林图。检测：Xpert Ultra；标本：尿液；参考标准：培养；7项研究。 表中列出每项研究的真阳性（TP）、假阳性（FP）、假阴性（FN）和真阴性（TN）数以及敏感度和特异度（95% CI），并以方块和置信区间线绘于0至1的刻度上。 敏感度范围为0.25至1.00。 Huerga 2023, Mekkaoui 2021, Osei 2019的敏感度无法估计。 特异度范围为0.28至1.00。",
        "es": "Diagramas de bosque emparejados de sensibilidad y especificidad. Prueba: Xpert Ultra; muestra: orina; estándar de referencia: cultivo; 7 estudios. Para cada estudio, la tabla indica los recuentos TP, FP, FN y TN (verdaderos positivos, falsos positivos, falsos negativos y verdaderos negativos) con la sensibilidad y la especificidad (IC del 95%), representadas como cuadrados con líneas de intervalo de confianza en escalas de 0 a 1. La sensibilidad varía entre 0,25 y 1,00. La sensibilidad no es estimable en Huerga 2023, Mekkaoui 2021, Osei 2019. La especificidad varía entre 0,28 y 1,00.",
        "fr": "Graphiques en forêt appariés de la sensibilité et de la spécificité. Test : Xpert Ultra ; échantillon : urine ; norme de référence : culture ; 7 études. Pour chaque étude, le tableau indique les nombres TP, FP, FN et TN (vrais positifs, faux positifs, faux négatifs et vrais négatifs) ainsi que la sensibilité et la spécificité (IC à 95 %), représentées par des carrés avec des lignes d'intervalle de confiance sur des échelles de 0 à 1. La sensibilité varie de 0,25 à 1,00. La sensibilité n'est pas estimable pour Huerga 2023, Mekkaoui 2021, Osei 2019. La spécificité varie de 0,28 à 1,00.",
        "ru": "Парные лесовидные диаграммы чувствительности и специфичности. Тест: Xpert Ultra; образец: моча; эталонный стандарт: посев; исследований: 7. Для каждого исследования в таблице приведены числа TP, FP, FN и TN (истинно положительные, ложноположительные, ложноотрицательные и истинно отрицательные результаты), а также чувствительность и специфичность (95% ДИ), показанные квадратами с линиями доверительных интервалов на шкалах от 0 до 1. Чувствительность колеблется от 0,25 до 1,00. Чувствительность не поддается оценке для Huerga 2023, Mekkaoui 2021, Osei 2019. Специфичность колеблется от 0,28 до 1,00."
      },
      "state": "draft"
    },
    {
      "id": "img-p115-4",
      "file": "images/img-p115-4.webp",
      "page": 115,
      "narratives": {
        "en": "Paired forest plots of sensitivity and specificity. Test: Xpert Ultra; specimen: urine; reference standard: composite reference standard; 3 studies (Minnies 2021, Huerga 2023, Cresswell 2020a). For each study the table lists TP, FP, FN and TN counts with sensitivity and specificity (95% CI), plotted as squares with confidence-interval lines on scales from 0 to 1. Sensitivity ranges from 0.13 to 0.34. Specificity ranges from 0.95 to 1.00.",
        "ar": "مخططا غابة متقابلان للحساسية والنوعية. الاختبار: Xpert Ultra؛ العينة: البول؛ المعيار المرجعي: المعيار المرجعي المركب؛ عدد الدراسات: 3 (Minnies 2021, Huerga 2023, Cresswell 2020a). يُدرج الجدول لكل دراسة أعداد الإيجابيات الحقيقية (TP) والإيجابيات الكاذبة (FP) والسلبيات الكاذبة (FN) والسلبيات الحقيقية (TN) مع الحساسية والنوعية (فاصل الثقة 95%)، وتُعرض كمربعات مع خطوط فواصل الثقة على مقياس من 0 إلى 1. تتراوح الحساسية بين 0.13 و0.34. تتراوح النوعية بين 0.95 و1.00.",
        "zh": "敏感度和特异度的配对森林图。检测：Xpert Ultra；标本：尿液；参考标准：复合参考标准；3项研究 (Minnies 2021, Huerga 2023, Cresswell 2020a)。 表中列出每项研究的真阳性（TP）、假阳性（FP）、假阴性（FN）和真阴性（TN）数以及敏感度和特异度（95% CI），并以方块和置信区间线绘于0至1的刻度上。 敏感度范围为0.13至0.34。 特异度范围为0.95至1.00。",
        "es": "Diagramas de bosque emparejados de sensibilidad y especificidad. Prueba: Xpert Ultra; muestra: orina; estándar de referencia: estándar de referencia compuesto; 3 estudios (Minnies 2021, Huerga 2023, Cresswell 2020a). Para cada estudio, la tabla indica los recuentos TP, FP, FN y TN (verdaderos positivos, falsos positivos, falsos negativos y verdaderos negativos) con la sensibilidad y la especificidad (IC del 95%), representadas como cuadrados con líneas de intervalo de confianza en escalas de 0 a 1. La sensibilidad varía entre 0,13 y 0,34. La especificidad varía entre 0,95 y 1,00.",
        "fr": "Graphiques en forêt appariés de la sensibilité et de la spécificité. Test : Xpert Ultra ; échantillon : urine ; norme de référence : norme de référence composite ; 3 études (Minnies 2021, Huerga 2023, Cresswell 2020a). Pour chaque étude, le tableau indique les nombres TP, FP, FN et TN (vrais positifs, faux positifs, faux négatifs et vrais négatifs) ainsi que la sensibilité et la spécificité (IC à 95 %), représentées par des carrés avec des lignes d'intervalle de confiance sur des échelles de 0 à 1. La sensibilité varie de 0,13 à 0,34. La spécificité varie de 0,95 à 1,00.",
        "ru": "Парные лесовидные диаграммы чувствительности и специфичности. Тест: Xpert Ultra; образец: моча; эталонный стандарт: комбинированный эталонный стандарт; исследований: 3 (Minnies 2021, Huerga 2023, Cresswell 2020a). Для каждого исследования в таблице приведены числа TP, FP, FN и TN (истинно положительные, ложноположительные, ложноотрицательные и истинно отрицательные результаты), а также чувствительность и специфичность (95% ДИ), показанные квадратами с линиями доверительных интервалов на шкалах от 0 до 1. Чувствительность колеблется от 0,13 до 0,34. Специфичность колеблется от 0,95 до 1,00."
      },
      "state": "draft"
    },
    {
      "id": "img-p115-5",
      "file": "images/img-p115-5.webp",
      "page": 115,
      "narratives": {
        "en": "Paired forest plots of sensitivity and specificity. Test: Truenat MTB plus; specimen: urine; reference standard: culture; 1 study (Jose 2024). For each study the table lists TP, FP, FN and TN counts with sensitivity and specificity (95% CI), plotted as squares with confidence-interval lines on scales from 0 to 1. Sensitivity is not estimable for Jose 2024. Specificity is 0.90 (95% CI 0.55–1.00).",
        "ar": "مخططا غابة متقابلان للحساسية والنوعية. الاختبار: Truenat MTB plus؛ العينة: البول؛ المعيار المرجعي: الزرع؛ عدد الدراسات: 1 (Jose 2024). يُدرج الجدول لكل دراسة أعداد الإيجابيات الحقيقية (TP) والإيجابيات الكاذبة (FP) والسلبيات الكاذبة (FN) والسلبيات الحقيقية (TN) مع الحساسية والنوعية (فاصل الثقة 95%)، وتُعرض كمربعات مع خطوط فواصل الثقة على مقياس من 0 إلى 1. الحساسية غير قابلة للتقدير في Jose 2024. النوعية 0.90 (فاصل الثقة 95%: 0.55–1.00).",
        "zh": "敏感度和特异度的配对森林图。检测：Truenat MTB plus；标本：尿液；参考标准：培养；1项研究 (Jose 2024)。 表中列出每项研究的真阳性（TP）、假阳性（FP）、假阴性（FN）和真阴性（TN）数以及敏感度和特异度（95% CI），并以方块和置信区间线绘于0至1的刻度上。 Jose 2024的敏感度无法估计。 特异度为0.90（95% CI 0.55–1.00）。",
        "es": "Diagramas de bosque emparejados de sensibilidad y especificidad. Prueba: Truenat MTB plus; muestra: orina; estándar de referencia: cultivo; 1 estudio (Jose 2024). Para cada estudio, la tabla indica los recuentos TP, FP, FN y TN (verdaderos positivos, falsos positivos, falsos negativos y verdaderos negativos) con la sensibilidad y la especificidad (IC del 95%), representadas como cuadrados con líneas de intervalo de confianza en escalas de 0 a 1. La sensibilidad no es estimable en Jose 2024. La especificidad es de 0,90 (IC del 95%: 0,55–1,00).",
        "fr": "Graphiques en forêt appariés de la sensibilité et de la spécificité. Test : Truenat MTB plus ; échantillon : urine ; norme de référence : culture ; 1 étude (Jose 2024). Pour chaque étude, le tableau indique les nombres TP, FP, FN et TN (vrais positifs, faux positifs, faux négatifs et vrais négatifs) ainsi que la sensibilité et la spécificité (IC à 95 %), représentées par des carrés avec des lignes d'intervalle de confiance sur des échelles de 0 à 1. La sensibilité n'est pas estimable pour Jose 2024. La spécificité est de 0,90 (IC à 95 % : 0,55–1,00).",
        "ru": "Парные лесовидные диаграммы чувствительности и специфичности. Тест: Truenat MTB plus; образец: моча; эталонный стандарт: посев; исследований: 1 (Jose 2024). Для каждого исследования в таблице приведены числа TP, FP, FN и TN (истинно положительные, ложноположительные, ложноотрицательные и истинно отрицательные результаты), а также чувствительность и специфичность (95% ДИ), показанные квадратами с линиями доверительных интервалов на шкалах от 0 до 1. Чувствительность не поддается оценке для Jose 2024. Специфичность составляет 0,90 (95% ДИ: 0,55–1,00)."
      },
      "state": "draft"
    },
    {
      "id": "img-p116-1",
      "file": "images/img-p116-1.webp",
      "page": 116,
      "narratives": {
        "en": "Risk of bias and applicability chart for bone or joint tuberculosis in bone or joint fluid, with one row per study (5 studies). Each study is rated for risk of bias (patient selection, index test, reference standard, flow and timing) and applicability (patient selection, index test, reference standard) using green (low), yellow (unclear) and red (high) circles. Most ratings are low; high ratings are given for Perez-Risco 2018 (risk of bias, patient selection); Mekkaoui 2021, Slail 2023 (applicability, patient selection).",
        "ar": "مخطط خطر التحيز وقابلية التطبيق بشأن سل العظام أو المفاصل في سائل العظم أو المفصل، بصف واحد لكل دراسة (عدد الدراسات: 5). تُقيَّم كل دراسة من حيث خطر التحيز (اختيار المرضى، والاختبار المؤشر، والمعيار المرجعي، والتدفق والتوقيت) وقابلية التطبيق (اختيار المرضى، والاختبار المؤشر، والمعيار المرجعي) باستخدام دوائر خضراء (منخفض) وصفراء (غير واضح) وحمراء (مرتفع). معظم التقييمات منخفضة؛ والتقييمات المرتفعة هي: Perez-Risco 2018 (خطر التحيز، اختيار المرضى)؛ Mekkaoui 2021, Slail 2023 (قابلية التطبيق، اختيار المرضى).",
        "zh": "骨或关节液检测骨关节结核的偏倚风险和适用性图，每项研究一行（5项研究）。每项研究按偏倚风险（患者选择、待评价试验、参考标准、流程和时间）和适用性（患者选择、待评价试验、参考标准）评级，以绿色（低）、黄色（不明确）和红色（高）圆圈表示。 大多数评级为低；评为高的有：Perez-Risco 2018 (偏倚风险，患者选择)；Mekkaoui 2021, Slail 2023 (适用性，患者选择)。",
        "es": "Gráfico de riesgo de sesgo y aplicabilidad para la tuberculosis osteoarticular en líquido óseo o articular, con una fila por estudio (5 estudios). Cada estudio se califica en cuanto a riesgo de sesgo (selección de pacientes, prueba índice, estándar de referencia, flujo y cronología) y aplicabilidad (selección de pacientes, prueba índice, estándar de referencia) con círculos verdes (bajo), amarillos (incierto) y rojos (alto). La mayoría de las calificaciones son bajas; las calificaciones altas corresponden a Perez-Risco 2018 (riesgo de sesgo, selección de pacientes); Mekkaoui 2021, Slail 2023 (aplicabilidad, selección de pacientes).",
        "fr": "Graphique du risque de biais et de l'applicabilité pour la tuberculose ostéo-articulaire dans le liquide osseux ou articulaire, avec une ligne par étude (5 études). Chaque étude est évaluée pour le risque de biais (sélection des patients, test index, norme de référence, flux et calendrier) et l'applicabilité (sélection des patients, test index, norme de référence) au moyen de cercles verts (faible), jaunes (incertain) et rouges (élevé). La plupart des évaluations sont faibles ; les évaluations élevées concernent Perez-Risco 2018 (risque de biais, sélection des patients) ; Mekkaoui 2021, Slail 2023 (applicabilité, sélection des patients).",
        "ru": "Диаграмма риска систематической ошибки и применимости: туберкулез костей или суставов, костная или суставная жидкость; одна строка на исследование (исследований: 5). Каждое исследование оценено по риску систематической ошибки (отбор пациентов, индексный тест, эталонный стандарт, поток и сроки) и применимости (отбор пациентов, индексный тест, эталонный стандарт) с помощью зеленых (низкий), желтых (неясный) и красных (высокий) кружков. Большинство оценок низкие; высокие оценки: Perez-Risco 2018 (риск систематической ошибки, отбор пациентов); Mekkaoui 2021, Slail 2023 (применимость, отбор пациентов)."
      },
      "state": "draft"
    },
    {
      "id": "img-p117-1",
      "file": "images/img-p117-1.webp",
      "page": 117,
      "narratives": {
        "en": "Paired forest plots of sensitivity and specificity. Test: Xpert Ultra; specimen: bone or joint aspirate; reference standard: culture; 5 studies. For each study the table lists TP, FP, FN and TN counts with sensitivity and specificity (95% CI), plotted as squares with confidence-interval lines on scales from 0 to 1. Sensitivity ranges from 0.88 to 1.00. Sensitivity is not estimable for Peñata 2021. Specificity ranges from 0.80 to 1.00. Specificity is not estimable for Perez-Risco 2018.",
        "ar": "مخططا غابة متقابلان للحساسية والنوعية. الاختبار: Xpert Ultra؛ العينة: رشافة العظم أو المفصل؛ المعيار المرجعي: الزرع؛ عدد الدراسات: 5. يُدرج الجدول لكل دراسة أعداد الإيجابيات الحقيقية (TP) والإيجابيات الكاذبة (FP) والسلبيات الكاذبة (FN) والسلبيات الحقيقية (TN) مع الحساسية والنوعية (فاصل الثقة 95%)، وتُعرض كمربعات مع خطوط فواصل الثقة على مقياس من 0 إلى 1. تتراوح الحساسية بين 0.88 و1.00. الحساسية غير قابلة للتقدير في Peñata 2021. تتراوح النوعية بين 0.80 و1.00. النوعية غير قابلة للتقدير في Perez-Risco 2018.",
        "zh": "敏感度和特异度的配对森林图。检测：Xpert Ultra；标本：骨或关节抽吸物；参考标准：培养；5项研究。 表中列出每项研究的真阳性（TP）、假阳性（FP）、假阴性（FN）和真阴性（TN）数以及敏感度和特异度（95% CI），并以方块和置信区间线绘于0至1的刻度上。 敏感度范围为0.88至1.00。 Peñata 2021的敏感度无法估计。 特异度范围为0.80至1.00。 Perez-Risco 2018的特异度无法估计。",
        "es": "Diagramas de bosque emparejados de sensibilidad y especificidad. Prueba: Xpert Ultra; muestra: aspirado óseo o articular; estándar de referencia: cultivo; 5 estudios. Para cada estudio, la tabla indica los recuentos TP, FP, FN y TN (verdaderos positivos, falsos positivos, falsos negativos y verdaderos negativos) con la sensibilidad y la especificidad (IC del 95%), representadas como cuadrados con líneas de intervalo de confianza en escalas de 0 a 1. La sensibilidad varía entre 0,88 y 1,00. La sensibilidad no es estimable en Peñata 2021. La especificidad varía entre 0,80 y 1,00. La especificidad no es estimable en Perez-Risco 2018.",
        "fr": "Graphiques en forêt appariés de la sensibilité et de la spécificité. Test : Xpert Ultra ; échantillon : aspirat osseux ou articulaire ; norme de référence : culture ; 5 études. Pour chaque étude, le tableau indique les nombres TP, FP, FN et TN (vrais positifs, faux positifs, faux négatifs et vrais négatifs) ainsi que la sensibilité et la spécificité (IC à 95 %), représentées par des carrés avec des lignes d'intervalle de confiance sur des échelles de 0 à 1. La sensibilité varie de 0,88 à 1,00. La sensibilité n'est pas estimable pour Peñata 2021. La spécificité varie de 0,80 à 1,00. La spécificité n'est pas estimable pour Perez-Risco 2018.",
        "ru": "Парные лесовидные диаграммы чувствительности и специфичности. Тест: Xpert Ultra; образец: аспират кости или сустава; эталонный стандарт: посев; исследований: 5. Для каждого исследования в таблице приведены числа TP, FP, FN и TN (истинно положительные, ложноположительные, ложноотрицательные и истинно отрицательные результаты), а также чувствительность и специфичность (95% ДИ), показанные квадратами с линиями доверительных интервалов на шкалах от 0 до 1. Чувствительность колеблется от 0,88 до 1,00. Чувствительность не поддается оценке для Peñata 2021. Специфичность колеблется от 0,80 до 1,00. Специфичность не поддается оценке для Perez-Risco 2018."
      },
      "state": "draft"
    },
    {
      "id": "img-p117-2",
      "file": "images/img-p117-2.webp",
      "page": 117,
      "narratives": {
        "en": "Paired forest plots of sensitivity and specificity. Test: Xpert Ultra; specimen: bone or joint aspirate; reference standard: composite reference standard; 1 study (Sun 2019). For each study the table lists TP, FP, FN and TN counts with sensitivity and specificity (95% CI), plotted as squares with confidence-interval lines on scales from 0 to 1. Sensitivity is 0.96 (95% CI 0.91–0.99). Specificity is 0.97 (95% CI 0.85–1.00).",
        "ar": "مخططا غابة متقابلان للحساسية والنوعية. الاختبار: Xpert Ultra؛ العينة: رشافة العظم أو المفصل؛ المعيار المرجعي: المعيار المرجعي المركب؛ عدد الدراسات: 1 (Sun 2019). يُدرج الجدول لكل دراسة أعداد الإيجابيات الحقيقية (TP) والإيجابيات الكاذبة (FP) والسلبيات الكاذبة (FN) والسلبيات الحقيقية (TN) مع الحساسية والنوعية (فاصل الثقة 95%)، وتُعرض كمربعات مع خطوط فواصل الثقة على مقياس من 0 إلى 1. الحساسية 0.96 (فاصل الثقة 95%: 0.91–0.99). النوعية 0.97 (فاصل الثقة 95%: 0.85–1.00).",
        "zh": "敏感度和特异度的配对森林图。检测：Xpert Ultra；标本：骨或关节抽吸物；参考标准：复合参考标准；1项研究 (Sun 2019)。 表中列出每项研究的真阳性（TP）、假阳性（FP）、假阴性（FN）和真阴性（TN）数以及敏感度和特异度（95% CI），并以方块和置信区间线绘于0至1的刻度上。 敏感度为0.96（95% CI 0.91–0.99）。 特异度为0.97（95% CI 0.85–1.00）。",
        "es": "Diagramas de bosque emparejados de sensibilidad y especificidad. Prueba: Xpert Ultra; muestra: aspirado óseo o articular; estándar de referencia: estándar de referencia compuesto; 1 estudio (Sun 2019). Para cada estudio, la tabla indica los recuentos TP, FP, FN y TN (verdaderos positivos, falsos positivos, falsos negativos y verdaderos negativos) con la sensibilidad y la especificidad (IC del 95%), representadas como cuadrados con líneas de intervalo de confianza en escalas de 0 a 1. La sensibilidad es de 0,96 (IC del 95%: 0,91–0,99). La especificidad es de 0,97 (IC del 95%: 0,85–1,00).",
        "fr": "Graphiques en forêt appariés de la sensibilité et de la spécificité. Test : Xpert Ultra ; échantillon : aspirat osseux ou articulaire ; norme de référence : norme de référence composite ; 1 étude (Sun 2019). Pour chaque étude, le tableau indique les nombres TP, FP, FN et TN (vrais positifs, faux positifs, faux négatifs et vrais négatifs) ainsi que la sensibilité et la spécificité (IC à 95 %), représentées par des carrés avec des lignes d'intervalle de confiance sur des échelles de 0 à 1. La sensibilité est de 0,96 (IC à 95 % : 0,91–0,99). La spécificité est de 0,97 (IC à 95 % : 0,85–1,00).",
        "ru": "Парные лесовидные диаграммы чувствительности и специфичности. Тест: Xpert Ultra; образец: аспират кости или сустава; эталонный стандарт: комбинированный эталонный стандарт; исследований: 1 (Sun 2019). Для каждого исследования в таблице приведены числа TP, FP, FN и TN (истинно положительные, ложноположительные, ложноотрицательные и истинно отрицательные результаты), а также чувствительность и специфичность (95% ДИ), показанные квадратами с линиями доверительных интервалов на шкалах от 0 до 1. Чувствительность составляет 0,96 (95% ДИ: 0,91–0,99). Специфичность составляет 0,97 (95% ДИ: 0,85–1,00)."
      },
      "state": "draft"
    },
    {
      "id": "img-p117-3",
      "file": "images/img-p117-3.webp",
      "page": 117,
      "narratives": {
        "en": "Paired forest plots of sensitivity and specificity. Test: Truenat MTB plus; specimen: synovial fluid (upper panel) and synovial/bone tissue (lower panel); reference standard: culture; 1 study (Jose 2024). For each study the table lists TP, FP, FN and TN counts with sensitivity and specificity (95% CI), plotted as squares with confidence-interval lines on scales from 0 to 1. In synovial fluid, sensitivity is not estimable and specificity is 1.00 (95% CI 0.59–1.00); in synovial/bone tissue, sensitivity is 1.00 (0.29–1.00) and specificity 1.00 (0.88–1.00).",
        "ar": "مخططا غابة متقابلان للحساسية والنوعية. الاختبار: Truenat MTB plus؛ العينة: السائل الزليلي (اللوحة العليا) والنسيج الزليلي/العظمي (اللوحة السفلى)؛ المعيار المرجعي: الزرع؛ عدد الدراسات: 1 (Jose 2024). يُدرج الجدول لكل دراسة أعداد الإيجابيات الحقيقية (TP) والإيجابيات الكاذبة (FP) والسلبيات الكاذبة (FN) والسلبيات الحقيقية (TN) مع الحساسية والنوعية (فاصل الثقة 95%)، وتُعرض كمربعات مع خطوط فواصل الثقة على مقياس من 0 إلى 1. في السائل الزليلي، الحساسية غير قابلة للتقدير والنوعية 1.00 (فاصل الثقة 95%: 0.59–1.00)؛ وفي النسيج الزليلي/العظمي، الحساسية 1.00 (0.29–1.00) والنوعية 1.00 (0.88–1.00).",
        "zh": "敏感度和特异度的配对森林图。检测：Truenat MTB plus；标本：滑液（上图）和滑膜/骨组织（下图）；参考标准：培养；1项研究 (Jose 2024)。 表中列出每项研究的真阳性（TP）、假阳性（FP）、假阴性（FN）和真阴性（TN）数以及敏感度和特异度（95% CI），并以方块和置信区间线绘于0至1的刻度上。 在滑液中，敏感度无法估计，特异度为1.00（95% CI 0.59–1.00）；在滑膜/骨组织中，敏感度为1.00（0.29–1.00），特异度为1.00（0.88–1.00）。",
        "es": "Diagramas de bosque emparejados de sensibilidad y especificidad. Prueba: Truenat MTB plus; muestra: líquido sinovial (panel superior) y tejido sinovial u óseo (panel inferior); estándar de referencia: cultivo; 1 estudio (Jose 2024). Para cada estudio, la tabla indica los recuentos TP, FP, FN y TN (verdaderos positivos, falsos positivos, falsos negativos y verdaderos negativos) con la sensibilidad y la especificidad (IC del 95%), representadas como cuadrados con líneas de intervalo de confianza en escalas de 0 a 1. En líquido sinovial, la sensibilidad no es estimable y la especificidad es de 1,00 (IC del 95%: 0,59–1,00); en tejido sinovial u óseo, la sensibilidad es de 1,00 (0,29–1,00) y la especificidad de 1,00 (0,88–1,00).",
        "fr": "Graphiques en forêt appariés de la sensibilité et de la spécificité. Test : Truenat MTB plus ; échantillon : liquide synovial (panneau supérieur) et tissu synovial ou osseux (panneau inférieur) ; norme de référence : culture ; 1 étude (Jose 2024). Pour chaque étude, le tableau indique les nombres TP, FP, FN et TN (vrais positifs, faux positifs, faux négatifs et vrais négatifs) ainsi que la sensibilité et la spécificité (IC à 95 %), représentées par des carrés avec des lignes d'intervalle de confiance sur des échelles de 0 à 1. Dans le liquide synovial, la sensibilité n'est pas estimable et la spécificité est de 1,00 (IC à 95 % : 0,59–1,00) ; dans le tissu synovial ou osseux, la sensibilité est de 1,00 (0,29–1,00) et la spécificité de 1,00 (0,88–1,00).",
        "ru": "Парные лесовидные диаграммы чувствительности и специфичности. Тест: Truenat MTB plus; образец: синовиальная жидкость (верхняя панель) и синовиальная/костная ткань (нижняя панель); эталонный стандарт: посев; исследований: 1 (Jose 2024). Для каждого исследования в таблице приведены числа TP, FP, FN и TN (истинно положительные, ложноположительные, ложноотрицательные и истинно отрицательные результаты), а также чувствительность и специфичность (95% ДИ), показанные квадратами с линиями доверительных интервалов на шкалах от 0 до 1. В синовиальной жидкости чувствительность не поддается оценке, а специфичность составляет 1,00 (95% ДИ: 0,59–1,00); в синовиальной/костной ткани чувствительность составляет 1,00 (0,29–1,00), а специфичность 1,00 (0,88–1,00)."
      },
      "state": "draft"
    },
    {
      "id": "img-p117-4",
      "file": "images/img-p117-4.webp",
      "page": 117,
      "narratives": {
        "en": "Risk of bias and applicability chart for pericardial tuberculosis in pericardial fluid, with one row per study (5 studies). Each study is rated for risk of bias (patient selection, index test, reference standard, flow and timing) and applicability (patient selection, index test, reference standard) using green (low), yellow (unclear) and red (high) circles. Most ratings are low; high ratings are given for Mekkaoui 2021, Slail 2023 (applicability, patient selection).",
        "ar": "مخطط خطر التحيز وقابلية التطبيق بشأن السل التاموري في السائل التاموري، بصف واحد لكل دراسة (عدد الدراسات: 5). تُقيَّم كل دراسة من حيث خطر التحيز (اختيار المرضى، والاختبار المؤشر، والمعيار المرجعي، والتدفق والتوقيت) وقابلية التطبيق (اختيار المرضى، والاختبار المؤشر، والمعيار المرجعي) باستخدام دوائر خضراء (منخفض) وصفراء (غير واضح) وحمراء (مرتفع). معظم التقييمات منخفضة؛ والتقييمات المرتفعة هي: Mekkaoui 2021, Slail 2023 (قابلية التطبيق، اختيار المرضى).",
        "zh": "心包积液检测心包结核的偏倚风险和适用性图，每项研究一行（5项研究）。每项研究按偏倚风险（患者选择、待评价试验、参考标准、流程和时间）和适用性（患者选择、待评价试验、参考标准）评级，以绿色（低）、黄色（不明确）和红色（高）圆圈表示。 大多数评级为低；评为高的有：Mekkaoui 2021, Slail 2023 (适用性，患者选择)。",
        "es": "Gráfico de riesgo de sesgo y aplicabilidad para la tuberculosis pericárdica en líquido pericárdico, con una fila por estudio (5 estudios). Cada estudio se califica en cuanto a riesgo de sesgo (selección de pacientes, prueba índice, estándar de referencia, flujo y cronología) y aplicabilidad (selección de pacientes, prueba índice, estándar de referencia) con círculos verdes (bajo), amarillos (incierto) y rojos (alto). La mayoría de las calificaciones son bajas; las calificaciones altas corresponden a Mekkaoui 2021, Slail 2023 (aplicabilidad, selección de pacientes).",
        "fr": "Graphique du risque de biais et de l'applicabilité pour la tuberculose péricardique dans le liquide péricardique, avec une ligne par étude (5 études). Chaque étude est évaluée pour le risque de biais (sélection des patients, test index, norme de référence, flux et calendrier) et l'applicabilité (sélection des patients, test index, norme de référence) au moyen de cercles verts (faible), jaunes (incertain) et rouges (élevé). La plupart des évaluations sont faibles ; les évaluations élevées concernent Mekkaoui 2021, Slail 2023 (applicabilité, sélection des patients).",
        "ru": "Диаграмма риска систематической ошибки и применимости: перикардиальный туберкулез, перикардиальная жидкость; одна строка на исследование (исследований: 5). Каждое исследование оценено по риску систематической ошибки (отбор пациентов, индексный тест, эталонный стандарт, поток и сроки) и применимости (отбор пациентов, индексный тест, эталонный стандарт) с помощью зеленых (низкий), желтых (неясный) и красных (высокий) кружков. Большинство оценок низкие; высокие оценки: Mekkaoui 2021, Slail 2023 (применимость, отбор пациентов)."
      },
      "state": "draft"
    },
    {
      "id": "img-p118-1",
      "file": "images/img-p118-1.webp",
      "page": 118,
      "narratives": {
        "en": "Paired forest plots of sensitivity and specificity. Test: Xpert Ultra; specimen: pericardial fluid; reference standard: culture; 5 studies. For each study the table lists TP, FP, FN and TN counts with sensitivity and specificity (95% CI), plotted as squares with confidence-interval lines on scales from 0 to 1. Sensitivity ranges from 0.67 to 0.86. Sensitivity is not estimable for Mekkaoui 2021, Peñata 2021. Specificity ranges from 0.83 to 1.00.",
        "ar": "مخططا غابة متقابلان للحساسية والنوعية. الاختبار: Xpert Ultra؛ العينة: السائل التاموري؛ المعيار المرجعي: الزرع؛ عدد الدراسات: 5. يُدرج الجدول لكل دراسة أعداد الإيجابيات الحقيقية (TP) والإيجابيات الكاذبة (FP) والسلبيات الكاذبة (FN) والسلبيات الحقيقية (TN) مع الحساسية والنوعية (فاصل الثقة 95%)، وتُعرض كمربعات مع خطوط فواصل الثقة على مقياس من 0 إلى 1. تتراوح الحساسية بين 0.67 و0.86. الحساسية غير قابلة للتقدير في Mekkaoui 2021, Peñata 2021. تتراوح النوعية بين 0.83 و1.00.",
        "zh": "敏感度和特异度的配对森林图。检测：Xpert Ultra；标本：心包积液；参考标准：培养；5项研究。 表中列出每项研究的真阳性（TP）、假阳性（FP）、假阴性（FN）和真阴性（TN）数以及敏感度和特异度（95% CI），并以方块和置信区间线绘于0至1的刻度上。 敏感度范围为0.67至0.86。 Mekkaoui 2021, Peñata 2021的敏感度无法估计。 特异度范围为0.83至1.00。",
        "es": "Diagramas de bosque emparejados de sensibilidad y especificidad. Prueba: Xpert Ultra; muestra: líquido pericárdico; estándar de referencia: cultivo; 5 estudios. Para cada estudio, la tabla indica los recuentos TP, FP, FN y TN (verdaderos positivos, falsos positivos, falsos negativos y verdaderos negativos) con la sensibilidad y la especificidad (IC del 95%), representadas como cuadrados con líneas de intervalo de confianza en escalas de 0 a 1. La sensibilidad varía entre 0,67 y 0,86. La sensibilidad no es estimable en Mekkaoui 2021, Peñata 2021. La especificidad varía entre 0,83 y 1,00.",
        "fr": "Graphiques en forêt appariés de la sensibilité et de la spécificité. Test : Xpert Ultra ; échantillon : liquide péricardique ; norme de référence : culture ; 5 études. Pour chaque étude, le tableau indique les nombres TP, FP, FN et TN (vrais positifs, faux positifs, faux négatifs et vrais négatifs) ainsi que la sensibilité et la spécificité (IC à 95 %), représentées par des carrés avec des lignes d'intervalle de confiance sur des échelles de 0 à 1. La sensibilité varie de 0,67 à 0,86. La sensibilité n'est pas estimable pour Mekkaoui 2021, Peñata 2021. La spécificité varie de 0,83 à 1,00.",
        "ru": "Парные лесовидные диаграммы чувствительности и специфичности. Тест: Xpert Ultra; образец: перикардиальная жидкость; эталонный стандарт: посев; исследований: 5. Для каждого исследования в таблице приведены числа TP, FP, FN и TN (истинно положительные, ложноположительные, ложноотрицательные и истинно отрицательные результаты), а также чувствительность и специфичность (95% ДИ), показанные квадратами с линиями доверительных интервалов на шкалах от 0 до 1. Чувствительность колеблется от 0,67 до 0,86. Чувствительность не поддается оценке для Mekkaoui 2021, Peñata 2021. Специфичность колеблется от 0,83 до 1,00."
      },
      "state": "draft"
    },
    {
      "id": "img-p118-2",
      "file": "images/img-p118-2.webp",
      "page": 118,
      "narratives": {
        "en": "Paired forest plots of sensitivity and specificity. Test: Xpert Ultra; specimen: peritoneal fluid; reference standard: culture; 3 studies (Peñata 2021, Slail 2023, Perez-Risco 2018). For each study the table lists TP, FP, FN and TN counts with sensitivity and specificity (95% CI), plotted as squares with confidence-interval lines on scales from 0 to 1. Sensitivity ranges from 0.33 to 0.67. Specificity ranges from 0.94 to 1.00. Specificity is not estimable for Perez-Risco 2018.",
        "ar": "مخططا غابة متقابلان للحساسية والنوعية. الاختبار: Xpert Ultra؛ العينة: السائل البريتوني؛ المعيار المرجعي: الزرع؛ عدد الدراسات: 3 (Peñata 2021, Slail 2023, Perez-Risco 2018). يُدرج الجدول لكل دراسة أعداد الإيجابيات الحقيقية (TP) والإيجابيات الكاذبة (FP) والسلبيات الكاذبة (FN) والسلبيات الحقيقية (TN) مع الحساسية والنوعية (فاصل الثقة 95%)، وتُعرض كمربعات مع خطوط فواصل الثقة على مقياس من 0 إلى 1. تتراوح الحساسية بين 0.33 و0.67. تتراوح النوعية بين 0.94 و1.00. النوعية غير قابلة للتقدير في Perez-Risco 2018.",
        "zh": "敏感度和特异度的配对森林图。检测：Xpert Ultra；标本：腹腔积液；参考标准：培养；3项研究 (Peñata 2021, Slail 2023, Perez-Risco 2018)。 表中列出每项研究的真阳性（TP）、假阳性（FP）、假阴性（FN）和真阴性（TN）数以及敏感度和特异度（95% CI），并以方块和置信区间线绘于0至1的刻度上。 敏感度范围为0.33至0.67。 特异度范围为0.94至1.00。 Perez-Risco 2018的特异度无法估计。",
        "es": "Diagramas de bosque emparejados de sensibilidad y especificidad. Prueba: Xpert Ultra; muestra: líquido peritoneal; estándar de referencia: cultivo; 3 estudios (Peñata 2021, Slail 2023, Perez-Risco 2018). Para cada estudio, la tabla indica los recuentos TP, FP, FN y TN (verdaderos positivos, falsos positivos, falsos negativos y verdaderos negativos) con la sensibilidad y la especificidad (IC del 95%), representadas como cuadrados con líneas de intervalo de confianza en escalas de 0 a 1. La sensibilidad varía entre 0,33 y 0,67. La especificidad varía entre 0,94 y 1,00. La especificidad no es estimable en Perez-Risco 2018.",
        "fr": "Graphiques en forêt appariés de la sensibilité et de la spécificité. Test : Xpert Ultra ; échantillon : liquide péritonéal ; norme de référence : culture ; 3 études (Peñata 2021, Slail 2023, Perez-Risco 2018). Pour chaque étude, le tableau indique les nombres TP, FP, FN et TN (vrais positifs, faux positifs, faux négatifs et vrais négatifs) ainsi que la sensibilité et la spécificité (IC à 95 %), représentées par des carrés avec des lignes d'intervalle de confiance sur des échelles de 0 à 1. La sensibilité varie de 0,33 à 0,67. La spécificité varie de 0,94 à 1,00. La spécificité n'est pas estimable pour Perez-Risco 2018.",
        "ru": "Парные лесовидные диаграммы чувствительности и специфичности. Тест: Xpert Ultra; образец: перитонеальная жидкость; эталонный стандарт: посев; исследований: 3 (Peñata 2021, Slail 2023, Perez-Risco 2018). Для каждого исследования в таблице приведены числа TP, FP, FN и TN (истинно положительные, ложноположительные, ложноотрицательные и истинно отрицательные результаты), а также чувствительность и специфичность (95% ДИ), показанные квадратами с линиями доверительных интервалов на шкалах от 0 до 1. Чувствительность колеблется от 0,33 до 0,67. Специфичность колеблется от 0,94 до 1,00. Специфичность не поддается оценке для Perez-Risco 2018."
      },
      "state": "draft"
    },
    {
      "id": "img-p118-3",
      "file": "images/img-p118-3.webp",
      "page": 118,
      "narratives": {
        "en": "Paired forest plots of sensitivity and specificity. Test: Truenat MTB plus; specimen: peritoneal fluid; reference standard: culture; 1 study (Jose 2024). For each study the table lists TP, FP, FN and TN counts with sensitivity and specificity (95% CI), plotted as squares with confidence-interval lines on scales from 0 to 1. Sensitivity is 0.00 (95% CI 0.00–0.97). Specificity is 0.93 (95% CI 0.68–1.00).",
        "ar": "مخططا غابة متقابلان للحساسية والنوعية. الاختبار: Truenat MTB plus؛ العينة: السائل البريتوني؛ المعيار المرجعي: الزرع؛ عدد الدراسات: 1 (Jose 2024). يُدرج الجدول لكل دراسة أعداد الإيجابيات الحقيقية (TP) والإيجابيات الكاذبة (FP) والسلبيات الكاذبة (FN) والسلبيات الحقيقية (TN) مع الحساسية والنوعية (فاصل الثقة 95%)، وتُعرض كمربعات مع خطوط فواصل الثقة على مقياس من 0 إلى 1. الحساسية 0.00 (فاصل الثقة 95%: 0.00–0.97). النوعية 0.93 (فاصل الثقة 95%: 0.68–1.00).",
        "zh": "敏感度和特异度的配对森林图。检测：Truenat MTB plus；标本：腹腔积液；参考标准：培养；1项研究 (Jose 2024)。 表中列出每项研究的真阳性（TP）、假阳性（FP）、假阴性（FN）和真阴性（TN）数以及敏感度和特异度（95% CI），并以方块和置信区间线绘于0至1的刻度上。 敏感度为0.00（95% CI 0.00–0.97）。 特异度为0.93（95% CI 0.68–1.00）。",
        "es": "Diagramas de bosque emparejados de sensibilidad y especificidad. Prueba: Truenat MTB plus; muestra: líquido peritoneal; estándar de referencia: cultivo; 1 estudio (Jose 2024). Para cada estudio, la tabla indica los recuentos TP, FP, FN y TN (verdaderos positivos, falsos positivos, falsos negativos y verdaderos negativos) con la sensibilidad y la especificidad (IC del 95%), representadas como cuadrados con líneas de intervalo de confianza en escalas de 0 a 1. La sensibilidad es de 0,00 (IC del 95%: 0,00–0,97). La especificidad es de 0,93 (IC del 95%: 0,68–1,00).",
        "fr": "Graphiques en forêt appariés de la sensibilité et de la spécificité. Test : Truenat MTB plus ; échantillon : liquide péritonéal ; norme de référence : culture ; 1 étude (Jose 2024). Pour chaque étude, le tableau indique les nombres TP, FP, FN et TN (vrais positifs, faux positifs, faux négatifs et vrais négatifs) ainsi que la sensibilité et la spécificité (IC à 95 %), représentées par des carrés avec des lignes d'intervalle de confiance sur des échelles de 0 à 1. La sensibilité est de 0,00 (IC à 95 % : 0,00–0,97). La spécificité est de 0,93 (IC à 95 % : 0,68–1,00).",
        "ru": "Парные лесовидные диаграммы чувствительности и специфичности. Тест: Truenat MTB plus; образец: перитонеальная жидкость; эталонный стандарт: посев; исследований: 1 (Jose 2024). Для каждого исследования в таблице приведены числа TP, FP, FN и TN (истинно положительные, ложноположительные, ложноотрицательные и истинно отрицательные результаты), а также чувствительность и специфичность (95% ДИ), показанные квадратами с линиями доверительных интервалов на шкалах от 0 до 1. Чувствительность составляет 0,00 (95% ДИ: 0,00–0,97). Специфичность составляет 0,93 (95% ДИ: 0,68–1,00)."
      },
      "state": "draft"
    },
    {
      "id": "img-p118-4",
      "file": "images/img-p118-4.webp",
      "page": 118,
      "narratives": {
        "en": "Paired forest plots of sensitivity and specificity. Test: Xpert Ultra; specimen: blood; reference standard: culture; 1 study (Boloko 2022). For each study the table lists TP, FP, FN and TN counts with sensitivity and specificity (95% CI), plotted as squares with confidence-interval lines on scales from 0 to 1. Sensitivity is 0.38 (95% CI 0.33–0.43). Specificity is 0.98 (95% CI 0.94–1.00).",
        "ar": "مخططا غابة متقابلان للحساسية والنوعية. الاختبار: Xpert Ultra؛ العينة: الدم؛ المعيار المرجعي: الزرع؛ عدد الدراسات: 1 (Boloko 2022). يُدرج الجدول لكل دراسة أعداد الإيجابيات الحقيقية (TP) والإيجابيات الكاذبة (FP) والسلبيات الكاذبة (FN) والسلبيات الحقيقية (TN) مع الحساسية والنوعية (فاصل الثقة 95%)، وتُعرض كمربعات مع خطوط فواصل الثقة على مقياس من 0 إلى 1. الحساسية 0.38 (فاصل الثقة 95%: 0.33–0.43). النوعية 0.98 (فاصل الثقة 95%: 0.94–1.00).",
        "zh": "敏感度和特异度的配对森林图。检测：Xpert Ultra；标本：血液；参考标准：培养；1项研究 (Boloko 2022)。 表中列出每项研究的真阳性（TP）、假阳性（FP）、假阴性（FN）和真阴性（TN）数以及敏感度和特异度（95% CI），并以方块和置信区间线绘于0至1的刻度上。 敏感度为0.38（95% CI 0.33–0.43）。 特异度为0.98（95% CI 0.94–1.00）。",
        "es": "Diagramas de bosque emparejados de sensibilidad y especificidad. Prueba: Xpert Ultra; muestra: sangre; estándar de referencia: cultivo; 1 estudio (Boloko 2022). Para cada estudio, la tabla indica los recuentos TP, FP, FN y TN (verdaderos positivos, falsos positivos, falsos negativos y verdaderos negativos) con la sensibilidad y la especificidad (IC del 95%), representadas como cuadrados con líneas de intervalo de confianza en escalas de 0 a 1. La sensibilidad es de 0,38 (IC del 95%: 0,33–0,43). La especificidad es de 0,98 (IC del 95%: 0,94–1,00).",
        "fr": "Graphiques en forêt appariés de la sensibilité et de la spécificité. Test : Xpert Ultra ; échantillon : sang ; norme de référence : culture ; 1 étude (Boloko 2022). Pour chaque étude, le tableau indique les nombres TP, FP, FN et TN (vrais positifs, faux positifs, faux négatifs et vrais négatifs) ainsi que la sensibilité et la spécificité (IC à 95 %), représentées par des carrés avec des lignes d'intervalle de confiance sur des échelles de 0 à 1. La sensibilité est de 0,38 (IC à 95 % : 0,33–0,43). La spécificité est de 0,98 (IC à 95 % : 0,94–1,00).",
        "ru": "Парные лесовидные диаграммы чувствительности и специфичности. Тест: Xpert Ultra; образец: кровь; эталонный стандарт: посев; исследований: 1 (Boloko 2022). Для каждого исследования в таблице приведены числа TP, FP, FN и TN (истинно положительные, ложноположительные, ложноотрицательные и истинно отрицательные результаты), а также чувствительность и специфичность (95% ДИ), показанные квадратами с линиями доверительных интервалов на шкалах от 0 до 1. Чувствительность составляет 0,38 (95% ДИ: 0,33–0,43). Специфичность составляет 0,98 (95% ДИ: 0,94–1,00)."
      },
      "state": "draft"
    },
    {
      "id": "img-p118-5",
      "file": "images/img-p118-5.webp",
      "page": 118,
      "narratives": {
        "en": "Risk of bias and applicability chart for peritoneal tuberculosis in peritoneal fluid, with one row per study (3 studies (Penata 2021, Slail 2023, Perez-Risco 2018)). Each study is rated for risk of bias (patient selection, index test, reference standard, flow and timing) and applicability (patient selection, index test, reference standard) using green (low), yellow (unclear) and red (high) circles. Most ratings are low; high ratings are given for Perez-Risco 2018 (risk of bias, patient selection); Slail 2023 (applicability, patient selection).",
        "ar": "مخطط خطر التحيز وقابلية التطبيق بشأن السل البريتوني في السائل البريتوني، بصف واحد لكل دراسة (عدد الدراسات: 3 (Penata 2021, Slail 2023, Perez-Risco 2018)). تُقيَّم كل دراسة من حيث خطر التحيز (اختيار المرضى، والاختبار المؤشر، والمعيار المرجعي، والتدفق والتوقيت) وقابلية التطبيق (اختيار المرضى، والاختبار المؤشر، والمعيار المرجعي) باستخدام دوائر خضراء (منخفض) وصفراء (غير واضح) وحمراء (مرتفع). معظم التقييمات منخفضة؛ والتقييمات المرتفعة هي: Perez-Risco 2018 (خطر التحيز، اختيار المرضى)؛ Slail 2023 (قابلية التطبيق، اختيار المرضى).",
        "zh": "腹腔积液检测腹膜结核的偏倚风险和适用性图，每项研究一行（3项研究 (Penata 2021, Slail 2023, Perez-Risco 2018)）。每项研究按偏倚风险（患者选择、待评价试验、参考标准、流程和时间）和适用性（患者选择、待评价试验、参考标准）评级，以绿色（低）、黄色（不明确）和红色（高）圆圈表示。 大多数评级为低；评为高的有：Perez-Risco 2018 (偏倚风险，患者选择)；Slail 2023 (适用性，患者选择)。",
        "es": "Gráfico de riesgo de sesgo y aplicabilidad para la tuberculosis peritoneal en líquido peritoneal, con una fila por estudio (3 estudios (Penata 2021, Slail 2023, Perez-Risco 2018)). Cada estudio se califica en cuanto a riesgo de sesgo (selección de pacientes, prueba índice, estándar de referencia, flujo y cronología) y aplicabilidad (selección de pacientes, prueba índice, estándar de referencia) con círculos verdes (bajo), amarillos (incierto) y rojos (alto). La mayoría de las calificaciones son bajas; las calificaciones altas corresponden a Perez-Risco 2018 (riesgo de sesgo, selección de pacientes); Slail 2023 (aplicabilidad, selección de pacientes).",
        "fr": "Graphique du risque de biais et de l'applicabilité pour la tuberculose péritonéale dans le liquide péritonéal, avec une ligne par étude (3 études (Penata 2021, Slail 2023, Perez-Risco 2018)). Chaque étude est évaluée pour le risque de biais (sélection des patients, test index, norme de référence, flux et calendrier) et l'applicabilité (sélection des patients, test index, norme de référence) au moyen de cercles verts (faible), jaunes (incertain) et rouges (élevé). La plupart des évaluations sont faibles ; les évaluations élevées concernent Perez-Risco 2018 (risque de biais, sélection des patients) ; Slail 2023 (applicabilité, sélection des patients).",
        "ru": "Диаграмма риска систематической ошибки и применимости: перитонеальный туберкулез, перитонеальная жидкость; одна строка на исследование (исследований: 3 (Penata 2021, Slail 2023, Perez-Risco 2018)). Каждое исследование оценено по риску систематической ошибки (отбор пациентов, индексный тест, эталонный стандарт, поток и сроки) и применимости (отбор пациентов, индексный тест, эталонный стандарт) с помощью зеленых (низкий), желтых (неясный) и красных (высокий) кружков. Большинство оценок низкие; высокие оценки: Perez-Risco 2018 (риск систематической ошибки, отбор пациентов); Slail 2023 (применимость, отбор пациентов)."
      },
      "state": "draft"
    },
    {
      "id": "img-p119-1",
      "file": "images/img-p119-1.webp",
      "page": 119,
      "narratives": {
        "en": "Risk of bias and applicability chart for disseminated tuberculosis in blood, with one row per study (1 study (Boloko 2022)). Each study is rated for risk of bias (patient selection, index test, reference standard, flow and timing) and applicability (patient selection, index test, reference standard) using green (low), yellow (unclear) and red (high) circles. Boloko 2022 is rated low on all four risk-of-bias domains and on applicability of the index test, and unclear on applicability of patient selection and reference standard.",
        "ar": "مخطط خطر التحيز وقابلية التطبيق بشأن السل المنتشر في الدم، بصف واحد لكل دراسة (عدد الدراسات: 1 (Boloko 2022)). تُقيَّم كل دراسة من حيث خطر التحيز (اختيار المرضى، والاختبار المؤشر، والمعيار المرجعي، والتدفق والتوقيت) وقابلية التطبيق (اختيار المرضى، والاختبار المؤشر، والمعيار المرجعي) باستخدام دوائر خضراء (منخفض) وصفراء (غير واضح) وحمراء (مرتفع). قُيِّمت دراسة Boloko 2022 بخطر منخفض في جميع مجالات خطر التحيز الأربعة وفي قابلية التطبيق للاختبار المؤشر، وبغير واضح في قابلية التطبيق لاختيار المرضى والمعيار المرجعي.",
        "zh": "血液检测播散性结核的偏倚风险和适用性图，每项研究一行（1项研究 (Boloko 2022)）。每项研究按偏倚风险（患者选择、待评价试验、参考标准、流程和时间）和适用性（患者选择、待评价试验、参考标准）评级，以绿色（低）、黄色（不明确）和红色（高）圆圈表示。 Boloko 2022在全部四个偏倚风险领域及待评价试验的适用性方面均为低，在患者选择和参考标准的适用性方面为不明确。",
        "es": "Gráfico de riesgo de sesgo y aplicabilidad para la tuberculosis diseminada en sangre, con una fila por estudio (1 estudio (Boloko 2022)). Cada estudio se califica en cuanto a riesgo de sesgo (selección de pacientes, prueba índice, estándar de referencia, flujo y cronología) y aplicabilidad (selección de pacientes, prueba índice, estándar de referencia) con círculos verdes (bajo), amarillos (incierto) y rojos (alto). Boloko 2022 se califica como bajo en los cuatro dominios de riesgo de sesgo y en la aplicabilidad de la prueba índice, e incierto en la aplicabilidad de la selección de pacientes y del estándar de referencia.",
        "fr": "Graphique du risque de biais et de l'applicabilité pour la tuberculose disséminée dans le sang, avec une ligne par étude (1 étude (Boloko 2022)). Chaque étude est évaluée pour le risque de biais (sélection des patients, test index, norme de référence, flux et calendrier) et l'applicabilité (sélection des patients, test index, norme de référence) au moyen de cercles verts (faible), jaunes (incertain) et rouges (élevé). Boloko 2022 est évaluée faible dans les quatre domaines de risque de biais et pour l'applicabilité du test index, et incertaine pour l'applicabilité de la sélection des patients et de la norme de référence.",
        "ru": "Диаграмма риска систематической ошибки и применимости: диссеминированный туберкулез, кровь; одна строка на исследование (исследований: 1 (Boloko 2022)). Каждое исследование оценено по риску систематической ошибки (отбор пациентов, индексный тест, эталонный стандарт, поток и сроки) и применимости (отбор пациентов, индексный тест, эталонный стандарт) с помощью зеленых (низкий), желтых (неясный) и красных (высокий) кружков. Исследование Boloko 2022 оценено как низкий риск во всех четырех доменах риска систематической ошибки и по применимости индексного теста и как неясное по применимости отбора пациентов и эталонного стандарта."
      },
      "state": "draft"
    },
    {
      "id": "img-p119-2",
      "file": "images/img-p119-2.webp",
      "page": 119,
      "narratives": {
        "en": "Paired forest plots of sensitivity and specificity for 3 studies (Bahr 2017, Cresswell 2020, Quinn 2021), part of Figure 21 (LC-aNAAT for TB meningitis in HIV-positive adults and adolescents); the panel heading is not included in the image. For each study the table lists TP, FP, FN and TN counts with sensitivity and specificity (95% CI), plotted as squares with confidence-interval lines on scales from 0 to 1. Sensitivity ranges from 0.87 to 0.90. Specificity ranges from 0.88 to 0.92.",
        "ar": "مخططا غابة متقابلان للحساسية والنوعية لثلاث دراسات (Bahr 2017 وCresswell 2020 وQuinn 2021)، وهما جزء من الشكل 21 (اختبار LC-aNAAT لالتهاب السحايا السلي لدى البالغين والمراهقين المصابين بفيروس العوز المناعي البشري)؛ ولا تتضمن الصورة عنوان اللوحة. يُدرج الجدول لكل دراسة أعداد الإيجابيات الحقيقية (TP) والإيجابيات الكاذبة (FP) والسلبيات الكاذبة (FN) والسلبيات الحقيقية (TN) مع الحساسية والنوعية (فاصل الثقة 95%)، وتُعرض كمربعات مع خطوط فواصل الثقة على مقياس من 0 إلى 1. تتراوح الحساسية بين 0.87 و0.90. تتراوح النوعية بين 0.88 و0.92.",
        "zh": "3项研究（Bahr 2017、Cresswell 2020、Quinn 2021）的敏感度和特异度配对森林图，属于图21（LC-aNAAT用于艾滋病毒阳性成人和青少年结核性脑膜炎）的一部分；图像中未包含分图标题。 表中列出每项研究的真阳性（TP）、假阳性（FP）、假阴性（FN）和真阴性（TN）数以及敏感度和特异度（95% CI），并以方块和置信区间线绘于0至1的刻度上。 敏感度范围为0.87至0.90。 特异度范围为0.88至0.92。",
        "es": "Diagramas de bosque emparejados de sensibilidad y especificidad para 3 estudios (Bahr 2017, Cresswell 2020, Quinn 2021), parte de la figura 21 (LC-aNAAT para la meningitis tuberculosa en adultos y adolescentes con VIH); el encabezado del panel no aparece en la imagen. Para cada estudio, la tabla indica los recuentos TP, FP, FN y TN (verdaderos positivos, falsos positivos, falsos negativos y verdaderos negativos) con la sensibilidad y la especificidad (IC del 95%), representadas como cuadrados con líneas de intervalo de confianza en escalas de 0 a 1. La sensibilidad varía entre 0,87 y 0,90. La especificidad varía entre 0,88 y 0,92.",
        "fr": "Graphiques en forêt appariés de la sensibilité et de la spécificité pour 3 études (Bahr 2017, Cresswell 2020, Quinn 2021), faisant partie de la figure 21 (LC-aNAAT pour la méningite tuberculeuse chez les adultes et adolescents séropositifs pour le VIH) ; l'en-tête du panneau ne figure pas dans l'image. Pour chaque étude, le tableau indique les nombres TP, FP, FN et TN (vrais positifs, faux positifs, faux négatifs et vrais négatifs) ainsi que la sensibilité et la spécificité (IC à 95 %), représentées par des carrés avec des lignes d'intervalle de confiance sur des échelles de 0 à 1. La sensibilité varie de 0,87 à 0,90. La spécificité varie de 0,88 à 0,92.",
        "ru": "Парные лесовидные диаграммы чувствительности и специфичности для 3 исследований (Bahr 2017, Cresswell 2020, Quinn 2021), часть рисунка 21 (LC-aNAAT для диагностики туберкулезного менингита у ВИЧ-положительных взрослых и подростков); заголовок панели на изображении отсутствует. Для каждого исследования в таблице приведены числа TP, FP, FN и TN (истинно положительные, ложноположительные, ложноотрицательные и истинно отрицательные результаты), а также чувствительность и специфичность (95% ДИ), показанные квадратами с линиями доверительных интервалов на шкалах от 0 до 1. Чувствительность колеблется от 0,87 до 0,90. Специфичность колеблется от 0,88 до 0,92."
      },
      "state": "draft"
    },
    {
      "id": "img-p122-1",
      "file": "images/img-p122-1.webp",
      "page": 122,
      "narratives": {
        "en": "Risk of bias and applicability chart for rifampicin resistance, with one row per study (16 studies). Each study is rated for risk of bias (patient selection, index test, reference standard, flow and timing) and applicability (patient selection, index test, reference standard) using green (low), yellow (unclear) and red (high) circles. Most ratings are low; high ratings are given for Hoel 2020a, Mekkaoui 2021, Slail 2023 (applicability, patient selection); Chin 2019, Wu 2019 (applicability, index test).",
        "ar": "مخطط خطر التحيز وقابلية التطبيق بشأن مقاومة الريفامبيسين، بصف واحد لكل دراسة (عدد الدراسات: 16). تُقيَّم كل دراسة من حيث خطر التحيز (اختيار المرضى، والاختبار المؤشر، والمعيار المرجعي، والتدفق والتوقيت) وقابلية التطبيق (اختيار المرضى، والاختبار المؤشر، والمعيار المرجعي) باستخدام دوائر خضراء (منخفض) وصفراء (غير واضح) وحمراء (مرتفع). معظم التقييمات منخفضة؛ والتقييمات المرتفعة هي: Hoel 2020a, Mekkaoui 2021, Slail 2023 (قابلية التطبيق، اختيار المرضى)؛ Chin 2019, Wu 2019 (قابلية التطبيق، الاختبار المؤشر).",
        "zh": "利福平耐药的偏倚风险和适用性图，每项研究一行（16项研究）。每项研究按偏倚风险（患者选择、待评价试验、参考标准、流程和时间）和适用性（患者选择、待评价试验、参考标准）评级，以绿色（低）、黄色（不明确）和红色（高）圆圈表示。 大多数评级为低；评为高的有：Hoel 2020a, Mekkaoui 2021, Slail 2023 (适用性，患者选择)；Chin 2019, Wu 2019 (适用性，待评价试验)。",
        "es": "Gráfico de riesgo de sesgo y aplicabilidad para la resistencia a la rifampicina, con una fila por estudio (16 estudios). Cada estudio se califica en cuanto a riesgo de sesgo (selección de pacientes, prueba índice, estándar de referencia, flujo y cronología) y aplicabilidad (selección de pacientes, prueba índice, estándar de referencia) con círculos verdes (bajo), amarillos (incierto) y rojos (alto). La mayoría de las calificaciones son bajas; las calificaciones altas corresponden a Hoel 2020a, Mekkaoui 2021, Slail 2023 (aplicabilidad, selección de pacientes); Chin 2019, Wu 2019 (aplicabilidad, prueba índice).",
        "fr": "Graphique du risque de biais et de l'applicabilité pour la résistance à la rifampicine, avec une ligne par étude (16 études). Chaque étude est évaluée pour le risque de biais (sélection des patients, test index, norme de référence, flux et calendrier) et l'applicabilité (sélection des patients, test index, norme de référence) au moyen de cercles verts (faible), jaunes (incertain) et rouges (élevé). La plupart des évaluations sont faibles ; les évaluations élevées concernent Hoel 2020a, Mekkaoui 2021, Slail 2023 (applicabilité, sélection des patients) ; Chin 2019, Wu 2019 (applicabilité, test index).",
        "ru": "Диаграмма риска систематической ошибки и применимости: устойчивость к рифампицину; одна строка на исследование (исследований: 16). Каждое исследование оценено по риску систематической ошибки (отбор пациентов, индексный тест, эталонный стандарт, поток и сроки) и применимости (отбор пациентов, индексный тест, эталонный стандарт) с помощью зеленых (низкий), желтых (неясный) и красных (высокий) кружков. Большинство оценок низкие; высокие оценки: Hoel 2020a, Mekkaoui 2021, Slail 2023 (применимость, отбор пациентов); Chin 2019, Wu 2019 (применимость, индексный тест)."
      },
      "state": "draft"
    },
    {
      "id": "img-p123-1",
      "file": "images/img-p123-1.webp",
      "page": 123,
      "narratives": {
        "en": "Paired forest plots of sensitivity and specificity for detection of rifampicin resistance by LC-aNAATs (Figure 23); 16 studies. For each study the table lists TP, FP, FN and TN counts with sensitivity and specificity (95% CI), plotted as squares with confidence-interval lines on scales from 0 to 1. Sensitivity is 1.00 in every study where it is estimable, with lower confidence limits ranging from 0.03 to 0.72. Sensitivity is not estimable for Chin 2019, Mekkaoui 2021, Spener-Gomes 2021. Specificity ranges from 0.98 to 1.00.",
        "ar": "مخططا غابة متقابلان للحساسية والنوعية للكشف عن مقاومة الريفامبيسين باختبارات LC-aNAAT (الشكل 23)؛ عدد الدراسات: 16. يُدرج الجدول لكل دراسة أعداد الإيجابيات الحقيقية (TP) والإيجابيات الكاذبة (FP) والسلبيات الكاذبة (FN) والسلبيات الحقيقية (TN) مع الحساسية والنوعية (فاصل الثقة 95%)، وتُعرض كمربعات مع خطوط فواصل الثقة على مقياس من 0 إلى 1. تبلغ الحساسية 1.00 في كل دراسة أمكن فيها تقديرها، مع حدود ثقة دنيا تتراوح بين 0.03 و0.72. الحساسية غير قابلة للتقدير في Chin 2019, Mekkaoui 2021, Spener-Gomes 2021. تتراوح النوعية بين 0.98 و1.00.",
        "zh": "LC-aNAAT检测利福平耐药的敏感度和特异度配对森林图（图23）；16项研究。 表中列出每项研究的真阳性（TP）、假阳性（FP）、假阴性（FN）和真阴性（TN）数以及敏感度和特异度（95% CI），并以方块和置信区间线绘于0至1的刻度上。 在可估计的每项研究中敏感度均为1.00，置信区间下限从0.03到0.72不等。 Chin 2019, Mekkaoui 2021, Spener-Gomes 2021的敏感度无法估计。 特异度范围为0.98至1.00。",
        "es": "Diagramas de bosque emparejados de sensibilidad y especificidad para la detección de la resistencia a la rifampicina mediante LC-aNAAT (figura 23); 16 estudios. Para cada estudio, la tabla indica los recuentos TP, FP, FN y TN (verdaderos positivos, falsos positivos, falsos negativos y verdaderos negativos) con la sensibilidad y la especificidad (IC del 95%), representadas como cuadrados con líneas de intervalo de confianza en escalas de 0 a 1. La sensibilidad es de 1,00 en todos los estudios en que es estimable, con límites inferiores de confianza entre 0,03 y 0,72. La sensibilidad no es estimable en Chin 2019, Mekkaoui 2021, Spener-Gomes 2021. La especificidad varía entre 0,98 y 1,00.",
        "fr": "Graphiques en forêt appariés de la sensibilité et de la spécificité pour la détection de la résistance à la rifampicine par les LC-aNAAT (figure 23) ; 16 études. Pour chaque étude, le tableau indique les nombres TP, FP, FN et TN (vrais positifs, faux positifs, faux négatifs et vrais négatifs) ainsi que la sensibilité et la spécificité (IC à 95 %), représentées par des carrés avec des lignes d'intervalle de confiance sur des échelles de 0 à 1. La sensibilité est de 1,00 dans toutes les études où elle est estimable, avec des limites inférieures de confiance allant de 0,03 à 0,72. La sensibilité n'est pas estimable pour Chin 2019, Mekkaoui 2021, Spener-Gomes 2021. La spécificité varie de 0,98 à 1,00.",
        "ru": "Парные лесовидные диаграммы чувствительности и специфичности для выявления устойчивости к рифампицину с помощью LC-aNAAT (рисунок 23); исследований: 16. Для каждого исследования в таблице приведены числа TP, FP, FN и TN (истинно положительные, ложноположительные, ложноотрицательные и истинно отрицательные результаты), а также чувствительность и специфичность (95% ДИ), показанные квадратами с линиями доверительных интервалов на шкалах от 0 до 1. Чувствительность составляет 1,00 во всех исследованиях, где она поддается оценке, при нижних границах доверительного интервала от 0,03 до 0,72. Чувствительность не поддается оценке для Chin 2019, Mekkaoui 2021, Spener-Gomes 2021. Специфичность колеблется от 0,98 до 1,00."
      },
      "state": "draft"
    },
    {
      "id": "img-p182-1",
      "file": "images/img-p182-1.webp",
      "page": 182,
      "narratives": {
        "en": "Risk of bias summary for an individually randomized trial (Figure 2): Esmail 2023, Xpert Ultra versus smear microscopy, outcome time to treatment, weight 596. All domains D1–D5 (randomisation process, deviations from the intended interventions, missing outcome data, measurement of the outcome, selection of the reported result) and the overall judgement are rated low risk (green).",
        "ar": "ملخص خطر التحيز لتجربة معشاة على المستوى الفردي (الشكل 2): Esmail 2023، اختبار Xpert Ultra مقابل الفحص المجهري للُطاخة، والحصيلة هي الوقت حتى العلاج، والوزن 596. قُيِّمت جميع المجالات D1–D5 (عملية التعشية، والانحرافات عن التدخلات المقصودة، والبيانات الناقصة عن الحصائل، وقياس الحصيلة، واختيار النتيجة المُبلَّغ عنها) والحكم الإجمالي بخطر منخفض (أخضر).",
        "zh": "个体随机试验的偏倚风险汇总（图2）：Esmail 2023，Xpert Ultra对比痰涂片显微镜检查，结局为至治疗时间，权重596。D1–D5所有领域（随机化过程、偏离既定干预、结局数据缺失、结局测量、报告结果的选择）及总体判断均为低风险（绿色）。",
        "es": "Resumen del riesgo de sesgo de un ensayo con aleatorización individual (figura 2): Esmail 2023, Xpert Ultra frente a baciloscopia, resultado tiempo hasta el tratamiento, peso 596. Todos los dominios D1–D5 (proceso de aleatorización, desviaciones de las intervenciones previstas, datos de resultado faltantes, medición del resultado, selección del resultado notificado) y el juicio global se califican como riesgo bajo (verde).",
        "fr": "Synthèse du risque de biais d'un essai randomisé individuel (figure 2) : Esmail 2023, Xpert Ultra contre microscopie de frottis, critère délai avant le traitement, poids 596. Tous les domaines D1–D5 (processus de randomisation, écarts par rapport aux interventions prévues, données de résultat manquantes, mesure du résultat, sélection du résultat rapporté) et le jugement global sont évalués à risque faible (vert).",
        "ru": "Сводка риска систематической ошибки для индивидуально рандомизированного исследования (рисунок 2): Esmail 2023, Xpert Ultra в сравнении с микроскопией мазка, исход — время до начала лечения, вес 596. Все домены D1–D5 (процесс рандомизации, отклонения от запланированных вмешательств, отсутствующие данные об исходах, измерение исхода, выбор представляемого результата) и общая оценка отмечены как низкий риск (зеленый)."
      },
      "state": "draft"
    },
    {
      "id": "img-p182-2",
      "file": "images/img-p182-2.webp",
      "page": 182,
      "narratives": {
        "en": "Risk of bias summary for a cluster-randomized trial (Figure 3): Cattamanchi 2021, Xpert Ultra versus smear microscopy, outcomes time to diagnosis and time to treatment, weight 10644. For both outcomes, D1a (randomisation process) and D3 (missing outcome data) are low risk, while D1b (timing of identification or recruitment of participants), D2 (deviations from the intended interventions), D4 (measurement of the outcome), D5 (selection of the reported result) and the overall judgement show some concerns (yellow).",
        "ar": "ملخص خطر التحيز لتجربة معشاة عنقودية (الشكل 3): Cattamanchi 2021، اختبار Xpert Ultra مقابل الفحص المجهري للُطاخة، والحصيلتان هما الوقت حتى التشخيص والوقت حتى العلاج، والوزن 10644. بالنسبة للحصيلتين، المجالان D1a (عملية التعشية) وD3 (البيانات الناقصة عن الحصائل) منخفضا الخطر، في حين تُظهر المجالات D1b (توقيت تحديد المشاركين أو تجنيدهم) وD2 (الانحرافات عن التدخلات المقصودة) وD4 (قياس الحصيلة) وD5 (اختيار النتيجة المُبلَّغ عنها) والحكم الإجمالي بعض المخاوف (أصفر).",
        "zh": "整群随机试验的偏倚风险汇总（图3）：Cattamanchi 2021，Xpert Ultra对比痰涂片显微镜检查，结局为至诊断时间和至治疗时间，权重10644。两项结局中，D1a（随机化过程）和D3（结局数据缺失）为低风险，而D1b（参与者识别或招募的时间）、D2（偏离既定干预）、D4（结局测量）、D5（报告结果的选择）及总体判断为存在一些担忧（黄色）。",
        "es": "Resumen del riesgo de sesgo de un ensayo aleatorizado por conglomerados (figura 3): Cattamanchi 2021, Xpert Ultra frente a baciloscopia, resultados tiempo hasta el diagnóstico y tiempo hasta el tratamiento, peso 10644. Para ambos resultados, D1a (proceso de aleatorización) y D3 (datos de resultado faltantes) tienen riesgo bajo, mientras que D1b (momento de identificación o reclutamiento de los participantes), D2 (desviaciones de las intervenciones previstas), D4 (medición del resultado), D5 (selección del resultado notificado) y el juicio global presentan algunas dudas (amarillo).",
        "fr": "Synthèse du risque de biais d'un essai randomisé en grappes (figure 3) : Cattamanchi 2021, Xpert Ultra contre microscopie de frottis, critères délai avant le diagnostic et délai avant le traitement, poids 10644. Pour les deux critères, D1a (processus de randomisation) et D3 (données de résultat manquantes) sont à risque faible, tandis que D1b (moment de l'identification ou du recrutement des participants), D2 (écarts par rapport aux interventions prévues), D4 (mesure du résultat), D5 (sélection du résultat rapporté) et le jugement global suscitent certaines préoccupations (jaune).",
        "ru": "Сводка риска систематической ошибки для кластерного рандомизированного исследования (рисунок 3): Cattamanchi 2021, Xpert Ultra в сравнении с микроскопией мазка, исходы — время до постановки диагноза и время до начала лечения, вес 10644. Для обоих исходов домены D1a (процесс рандомизации) и D3 (отсутствующие данные об исходах) отмечены как низкий риск, а D1b (сроки выявления или набора участников), D2 (отклонения от запланированных вмешательств), D4 (измерение исхода), D5 (выбор представляемого результата) и общая оценка — как вызывающие некоторые опасения (желтый)."
      },
      "state": "draft"
    },
    {
      "id": "img-p217-1",
      "file": "images/img-p217-1.webp",
      "page": 217,
      "narratives": {
        "en": "Risk of bias and applicability summary grid for 27 studies on pulmonary TB, from Bojang 2016 to Yadav 2021. Rows list the studies; columns show four risk-of-bias domains (patient selection, index test, reference standard, flow and timing) and three applicability domains (patient selection, index test, reference standard), each rated high (red), unclear (yellow) or low (green). Most cells are green; a few are yellow, and red (high) ratings appear for Getahun 2017 (patient selection bias) and for applicability of patient selection in Mitarai 2011, Promsena 2022 and Xin 2023.",
        "ar": "شبكة ملخّص لمخاطر التحيّز وقابلية التطبيق تشمل 27 دراسات بشأن السل الرئوي، من Bojang 2016 إلى Yadav 2021. تسرد الصفوف الدراسات، وتعرض الأعمدة أربعة مجالات لمخاطر التحيّز (اختيار المرضى، والاختبار المؤشّر، والمعيار المرجعي، والتدفّق والتوقيت) وثلاثة مجالات لقابلية التطبيق (اختيار المرضى، والاختبار المؤشّر، والمعيار المرجعي)، ويُصنَّف كل منها مرتفعاً (أحمر) أو غير واضح (أصفر) أو منخفضاً (أخضر). معظم الخلايا خضراء؛ وبعضها أصفر، وتظهر تقييمات حمراء (مرتفعة) لدراسة Getahun 2017 (تحيّز اختيار المرضى) ولقابلية تطبيق اختيار المرضى في Mitarai 2011 وPromsena 2022 وXin 2023.",
        "zh": "肺结核相关的（从Bojang 2016到Yadav 2021）27项研究的偏倚风险和适用性汇总网格。行列出各项研究；列显示四个偏倚风险领域（患者选择、待评价试验、参考标准、流程和时间）和三个适用性领域（患者选择、待评价试验、参考标准），每项评为高（红色）、不清楚（黄色）或低（绿色）。大多数单元格为绿色；少数为黄色，红色（高）评级出现在Getahun 2017（患者选择偏倚）以及Mitarai 2011、Promsena 2022和Xin 2023的患者选择适用性上。",
        "es": "Cuadrícula resumen del riesgo de sesgo y la aplicabilidad de 27 estudios sobre la TB pulmonar, de Bojang 2016 a Yadav 2021. Las filas enumeran los estudios; las columnas muestran cuatro dominios de riesgo de sesgo (selección de pacientes, prueba índice, patrón de referencia, flujo y cronología) y tres dominios de aplicabilidad (selección de pacientes, prueba índice, patrón de referencia), cada uno calificado como alto (rojo), incierto (amarillo) o bajo (verde). La mayoría de las celdas son verdes; algunas son amarillas, y hay calificaciones rojas (altas) para Getahun 2017 (sesgo de selección de pacientes) y para la aplicabilidad de la selección de pacientes en Mitarai 2011, Promsena 2022 y Xin 2023.",
        "fr": "Grille récapitulative du risque de biais et de l’applicabilité pour 27 études sur la TB pulmonaire, de Bojang 2016 à Yadav 2021. Les lignes listent les études ; les colonnes présentent quatre domaines de risque de biais (sélection des patients, test index, test de référence, flux et chronologie) et trois domaines d’applicabilité (sélection des patients, test index, test de référence), chacun jugé élevé (rouge), incertain (jaune) ou faible (vert). La plupart des cases sont vertes ; quelques-unes sont jaunes, et des jugements rouges (élevés) apparaissent pour Getahun 2017 (biais de sélection des patients) et pour l’applicabilité de la sélection des patients dans Mitarai 2011, Promsena 2022 et Xin 2023.",
        "ru": "Сводная таблица риска систематической ошибки и применимости для 27 исследований по туберкулёзу лёгких, от Bojang 2016 до Yadav 2021. В строках перечислены исследования; в столбцах — четыре домена риска систематической ошибки (отбор пациентов, индексный тест, эталонный стандарт, ход и сроки исследования) и три домена применимости (отбор пациентов, индексный тест, эталонный стандарт), каждый оценён как высокий (красный), неясный (жёлтый) или низкий (зелёный). Большинство ячеек зелёные; несколько жёлтых, а красные (высокие) оценки есть у Getahun 2017 (систематическая ошибка отбора пациентов) и по применимости отбора пациентов у Mitarai 2011, Promsena 2022 и Xin 2023."
      },
      "state": "draft"
    },
    {
      "id": "img-p218-1",
      "file": "images/img-p218-1.webp",
      "page": 218,
      "narratives": {
        "en": "Stacked horizontal bar charts showing the percentage of studies judged high (red), unclear (yellow) or low (green) for each domain, with study counts on the bars. Risk of bias: patient selection 1 high, 1 unclear, 25 low; index test 27 low; reference standard 6 unclear, 21 low; flow and timing 1 unclear, 26 low. Applicability concerns: patient selection 3 high, 2 unclear, 22 low; index test 3 unclear, 24 low; reference standard 1 unclear, 26 low.",
        "ar": "مخططات شريطية أفقية مكدّسة تبيّن النسبة المئوية للدراسات المصنّفة مرتفعة (أحمر) أو غير واضحة (أصفر) أو منخفضة (أخضر) في كل مجال، مع أعداد الدراسات على الأشرطة. مخاطر التحيّز: اختيار المرضى 1 مرتفع و1 غير واضح و25 منخفض؛ الاختبار المؤشّر 27 منخفض؛ المعيار المرجعي 6 غير واضح و21 منخفض؛ التدفّق والتوقيت 1 غير واضح و26 منخفض. شواغل قابلية التطبيق: اختيار المرضى 3 مرتفع و2 غير واضح و22 منخفض؛ الاختبار المؤشّر 3 غير واضح و24 منخفض؛ المعيار المرجعي 1 غير واضح و26 منخفض.",
        "zh": "堆积水平条形图，显示每个领域中被评为高（红色）、不清楚（黄色）或低（绿色）的研究百分比，条上标有研究数量。偏倚风险：患者选择1项高、1项不清楚、25项低；待评价试验27项低；参考标准6项不清楚、21项低；流程和时间1项不清楚、26项低。适用性问题：患者选择3项高、2项不清楚、22项低；待评价试验3项不清楚、24项低；参考标准1项不清楚、26项低。",
        "es": "Gráficos de barras horizontales apiladas que muestran el porcentaje de estudios calificados como alto (rojo), incierto (amarillo) o bajo (verde) en cada dominio, con el número de estudios en las barras. Riesgo de sesgo: selección de pacientes 1 alto, 1 incierto, 25 bajo; prueba índice 27 bajo; patrón de referencia 6 incierto, 21 bajo; flujo y cronología 1 incierto, 26 bajo. Problemas de aplicabilidad: selección de pacientes 3 alto, 2 incierto, 22 bajo; prueba índice 3 incierto, 24 bajo; patrón de referencia 1 incierto, 26 bajo.",
        "fr": "Diagrammes à barres horizontales empilées montrant le pourcentage d’études jugées à risque élevé (rouge), incertain (jaune) ou faible (vert) pour chaque domaine, avec le nombre d’études sur les barres. Risque de biais : sélection des patients 1 élevé, 1 incertain, 25 faible ; test index 27 faible ; test de référence 6 incertain, 21 faible ; flux et chronologie 1 incertain, 26 faible. Préoccupations d’applicabilité : sélection des patients 3 élevé, 2 incertain, 22 faible ; test index 3 incertain, 24 faible ; test de référence 1 incertain, 26 faible.",
        "ru": "Горизонтальные столбчатые диаграммы с накоплением, показывающие долю исследований с высокой (красный), неясной (жёлтый) или низкой (зелёный) оценкой по каждому домену; на столбцах указано число исследований. Риск систематической ошибки: отбор пациентов — 1 высокий, 1 неясный, 25 низких; индексный тест — 27 низких; эталонный стандарт — 6 неясных, 21 низкий; ход и сроки — 1 неясный, 26 низких. Применимость: отбор пациентов — 3 высоких, 2 неясных, 22 низких; индексный тест — 3 неясных, 24 низких; эталонный стандарт — 1 неясный, 26 низких."
      },
      "state": "draft"
    },
    {
      "id": "img-p220-1",
      "file": "images/img-p220-1.webp",
      "page": 220,
      "narratives": {
        "en": "Forest plot of sensitivity and specificity of LC-mNAATs for pulmonary TB in respiratory samples across 26 studies, from Nakiyingi 2018 to Yadav 2017. Each row gives TP, FP, FN and TN counts with sensitivity and specificity (95% CI), plotted as blue squares with confidence-interval lines on 0–1 scales. Sensitivity ranges from 0.55 to 1.00 and specificity from 0.70 to 1.00, with most specificities near 1.",
        "ar": "مخطط غابي لحساسية ونوعية اختبارات LC-mNAAT للكشف عن السل الرئوي في العيّنات التنفّسية عبر 26 دراسة، من Nakiyingi 2018 إلى Yadav 2017. يعرض كل صف أعداد الإيجابيات الحقيقية والإيجابيات الكاذبة والسلبيات الكاذبة والسلبيات الحقيقية مع الحساسية والنوعية (فاصل ثقة 95%)، مرسومة كمربعات زرقاء مع خطوط فواصل الثقة على مقياس من 0 إلى 1. تتراوح الحساسية بين 0.55 و1.00 والنوعية بين 0.70 و1.00، ومعظم قيم النوعية قريبة من 1.",
        "zh": "LC-mNAAT检测呼吸道样本中肺结核的灵敏度和特异度森林图，涵盖26项研究（从Nakiyingi 2018到Yadav 2017）。每行列出真阳性、假阳性、假阴性和真阴性数及灵敏度和特异度（95%置信区间），以蓝色方块和置信区间线绘于0–1刻度上。灵敏度介于0.55至1.00，特异度介于0.70至1.00，大多数特异度接近1。",
        "es": "Diagrama de bosque de la sensibilidad y la especificidad de las LC-mNAAT para la TB pulmonar en muestras respiratorias en 26 estudios, de Nakiyingi 2018 a Yadav 2017. Cada fila presenta los recuentos de VP, FP, FN y VN con la sensibilidad y la especificidad (IC del 95%), representadas como cuadrados azules con líneas de intervalo de confianza en escalas de 0 a 1. La sensibilidad varía de 0,55 a 1,00 y la especificidad de 0,70 a 1,00, con la mayoría de las especificidades cercanas a 1.",
        "fr": "Graphique en forêt de la sensibilité et de la spécificité des LC-mNAAT pour la TB pulmonaire sur échantillons respiratoires dans 26 études, de Nakiyingi 2018 à Yadav 2017. Chaque ligne indique les nombres de VP, FP, FN et VN avec la sensibilité et la spécificité (IC à 95 %), représentées par des carrés bleus avec des lignes d’intervalle de confiance sur des échelles de 0 à 1. La sensibilité va de 0,55 à 1,00 et la spécificité de 0,70 à 1,00, la plupart des spécificités étant proches de 1.",
        "ru": "Лесовидный график чувствительности и специфичности LC-mNAAT при туберкулёзе лёгких в респираторных образцах по 26 исследованиям, от Nakiyingi 2018 до Yadav 2017. В каждой строке приведены числа ИП, ЛП, ЛО и ИО с чувствительностью и специфичностью (95% ДИ), изображёнными синими квадратами с линиями доверительных интервалов на шкалах от 0 до 1. Чувствительность варьирует от 0,55 до 1,00, специфичность — от 0,70 до 1,00, причём большинство значений специфичности близки к 1."
      },
      "state": "draft"
    },
    {
      "id": "img-p221-1",
      "file": "images/img-p221-1.webp",
      "page": 221,
      "narratives": {
        "en": "Risk of bias and applicability summary grid for 8 studies on pulmonary TB detection in people living with HIV. Rows list the studies; columns show four risk-of-bias domains (patient selection, index test, reference standard, flow and timing) and three applicability domains (patient selection, index test, reference standard), each rated high (red), unclear (yellow) or low (green). All ratings are low except unclear ratings for patient selection in N'Guessan 2016 and reference standard in Nakiyingi 2018.",
        "ar": "شبكة ملخّص لمخاطر التحيّز وقابلية التطبيق تشمل 8 دراسات بشأن الكشف عن السل الرئوي لدى المتعايشين مع فيروس العوز المناعي البشري. تسرد الصفوف الدراسات، وتعرض الأعمدة أربعة مجالات لمخاطر التحيّز (اختيار المرضى، والاختبار المؤشّر، والمعيار المرجعي، والتدفّق والتوقيت) وثلاثة مجالات لقابلية التطبيق (اختيار المرضى، والاختبار المؤشّر، والمعيار المرجعي)، ويُصنَّف كل منها مرتفعاً (أحمر) أو غير واضح (أصفر) أو منخفضاً (أخضر). جميع التقييمات منخفضة باستثناء تقييمين غير واضحين: اختيار المرضى في N'Guessan 2016 والمعيار المرجعي في Nakiyingi 2018.",
        "zh": "在艾滋病毒感染者中检测肺结核的8项研究的偏倚风险和适用性汇总网格。行列出各项研究；列显示四个偏倚风险领域（患者选择、待评价试验、参考标准、流程和时间）和三个适用性领域（患者选择、待评价试验、参考标准），每项评为高（红色）、不清楚（黄色）或低（绿色）。除N'Guessan 2016的患者选择和Nakiyingi 2018的参考标准评为不清楚外，其余均为低。",
        "es": "Cuadrícula resumen del riesgo de sesgo y la aplicabilidad de 8 estudios sobre la detección de la TB pulmonar en personas con el VIH. Las filas enumeran los estudios; las columnas muestran cuatro dominios de riesgo de sesgo (selección de pacientes, prueba índice, patrón de referencia, flujo y cronología) y tres dominios de aplicabilidad (selección de pacientes, prueba índice, patrón de referencia), cada uno calificado como alto (rojo), incierto (amarillo) o bajo (verde). Todas las calificaciones son bajas, salvo las inciertas de selección de pacientes en N'Guessan 2016 y del patrón de referencia en Nakiyingi 2018.",
        "fr": "Grille récapitulative du risque de biais et de l’applicabilité pour 8 études sur la détection de la TB pulmonaire chez les personnes vivant avec le VIH. Les lignes listent les études ; les colonnes présentent quatre domaines de risque de biais (sélection des patients, test index, test de référence, flux et chronologie) et trois domaines d’applicabilité (sélection des patients, test index, test de référence), chacun jugé élevé (rouge), incertain (jaune) ou faible (vert). Tous les jugements sont faibles, sauf ceux incertains pour la sélection des patients dans N'Guessan 2016 et le test de référence dans Nakiyingi 2018.",
        "ru": "Сводная таблица риска систематической ошибки и применимости для 8 исследований по выявлению туберкулёза лёгких у людей, живущих с ВИЧ. В строках перечислены исследования; в столбцах — четыре домена риска систематической ошибки (отбор пациентов, индексный тест, эталонный стандарт, ход и сроки исследования) и три домена применимости (отбор пациентов, индексный тест, эталонный стандарт), каждый оценён как высокий (красный), неясный (жёлтый) или низкий (зелёный). Все оценки низкие, кроме неясных по отбору пациентов в N'Guessan 2016 и по эталонному стандарту в Nakiyingi 2018."
      },
      "state": "draft"
    },
    {
      "id": "img-p221-2",
      "file": "images/img-p221-2.webp",
      "page": 221,
      "narratives": {
        "en": "Forest plot of LC-mNAAT sensitivity and specificity for pulmonary TB in people living with HIV, 8 studies from Nakiyingi 2018 to Danfack 2018. Each row gives TP, FP, FN and TN counts with sensitivity and specificity (95% CI), plotted as blue squares with confidence-interval lines on 0–1 scales. Sensitivity ranges from 0.52 to 1.00; specificity is mostly 0.88–1.00, with one outlier of 0.27 (N'Guessan 2016).",
        "ar": "مخطط غابي لحساسية ونوعية اختبارات LC-mNAAT للسل الرئوي لدى المتعايشين مع فيروس العوز المناعي البشري، يشمل 8 دراسات من Nakiyingi 2018 إلى Danfack 2018. يعرض كل صف أعداد الإيجابيات الحقيقية والإيجابيات الكاذبة والسلبيات الكاذبة والسلبيات الحقيقية مع الحساسية والنوعية (فاصل ثقة 95%)، مرسومة كمربعات زرقاء مع خطوط فواصل الثقة على مقياس من 0 إلى 1. تتراوح الحساسية بين 0.52 و1.00؛ والنوعية في الغالب بين 0.88 و1.00، مع قيمة شاذة واحدة هي 0.27 (N'Guessan 2016).",
        "zh": "艾滋病毒感染者中LC-mNAAT检测肺结核的灵敏度和特异度森林图，共8项研究（从Nakiyingi 2018到Danfack 2018）。每行列出真阳性、假阳性、假阴性和真阴性数及灵敏度和特异度（95%置信区间），以蓝色方块和置信区间线绘于0–1刻度上。灵敏度介于0.52至1.00；特异度多为0.88–1.00，另有一个离群值0.27（N'Guessan 2016）。",
        "es": "Diagrama de bosque de la sensibilidad y la especificidad de las LC-mNAAT para la TB pulmonar en personas con el VIH, 8 estudios de Nakiyingi 2018 a Danfack 2018. Cada fila presenta los recuentos de VP, FP, FN y VN con la sensibilidad y la especificidad (IC del 95%), representadas como cuadrados azules con líneas de intervalo de confianza en escalas de 0 a 1. La sensibilidad varía de 0,52 a 1,00; la especificidad es mayoritariamente de 0,88 a 1,00, con un valor atípico de 0,27 (N'Guessan 2016).",
        "fr": "Graphique en forêt de la sensibilité et de la spécificité des LC-mNAAT pour la TB pulmonaire chez les personnes vivant avec le VIH, 8 études de Nakiyingi 2018 à Danfack 2018. Chaque ligne indique les nombres de VP, FP, FN et VN avec la sensibilité et la spécificité (IC à 95 %), représentées par des carrés bleus avec des lignes d’intervalle de confiance sur des échelles de 0 à 1. La sensibilité va de 0,52 à 1,00 ; la spécificité est surtout comprise entre 0,88 et 1,00, avec une valeur aberrante de 0,27 (N'Guessan 2016).",
        "ru": "Лесовидный график чувствительности и специфичности LC-mNAAT при туберкулёзе лёгких у людей, живущих с ВИЧ, 8 исследований от Nakiyingi 2018 до Danfack 2018. В каждой строке приведены числа ИП, ЛП, ЛО и ИО с чувствительностью и специфичностью (95% ДИ), изображёнными синими квадратами с линиями доверительных интервалов на шкалах от 0 до 1. Чувствительность от 0,52 до 1,00; специфичность в основном 0,88–1,00, с одним выбросом 0,27 (N'Guessan 2016)."
      },
      "state": "draft"
    },
    {
      "id": "img-p222-1",
      "file": "images/img-p222-1.webp",
      "page": 222,
      "narratives": {
        "en": "Cropped forest plot fragment for people living with HIV with CD4 count <200: one study (Spooner 2022) with TP 14, FP 8, FN 9, TN 204, sensitivity 0.61 (0.39–0.80) and specificity 0.96 (0.93–0.98). The heading of the next subgroup (CD4 count ≥200) is cut off at the bottom.",
        "ar": "جزء مقتطع من مخطط غابي للمتعايشين مع فيروس العوز المناعي البشري الذين يقل عدد خلايا CD4 لديهم عن 200: دراسة واحدة (Spooner 2022) بإيجابيات حقيقية 14 وإيجابيات كاذبة 8 وسلبيات كاذبة 9 وسلبيات حقيقية 204، وحساسية 0.61 (0.39–0.80) ونوعية 0.96 (0.93–0.98). عنوان المجموعة الفرعية التالية (CD4 ≥200) مقطوع في الأسفل.",
        "zh": "CD4计数<200的艾滋病毒感染者森林图截取片段：一项研究（Spooner 2022），真阳性14、假阳性8、假阴性9、真阴性204，灵敏度0.61（0.39–0.80），特异度0.96（0.93–0.98）。下一亚组（CD4计数≥200）的标题在底部被截断。",
        "es": "Fragmento recortado de un diagrama de bosque para personas con el VIH con recuento de CD4 <200: un estudio (Spooner 2022) con VP 14, FP 8, FN 9, VN 204, sensibilidad 0,61 (0,39–0,80) y especificidad 0,96 (0,93–0,98). El encabezado del subgrupo siguiente (CD4 ≥200) está cortado en la parte inferior.",
        "fr": "Fragment rogné d’un graphique en forêt pour les personnes vivant avec le VIH ayant un taux de CD4 <200 : une étude (Spooner 2022) avec VP 14, FP 8, FN 9, VN 204, sensibilité 0,61 (0,39–0,80) et spécificité 0,96 (0,93–0,98). L’intitulé du sous-groupe suivant (CD4 ≥200) est coupé en bas.",
        "ru": "Обрезанный фрагмент лесовидного графика для людей, живущих с ВИЧ, с числом CD4 <200: одно исследование (Spooner 2022) — ИП 14, ЛП 8, ЛО 9, ИО 204, чувствительность 0,61 (0,39–0,80), специфичность 0,96 (0,93–0,98). Заголовок следующей подгруппы (CD4 ≥200) обрезан внизу."
      },
      "state": "draft"
    },
    {
      "id": "img-p222-2",
      "file": "images/img-p222-2.webp",
      "page": 222,
      "narratives": {
        "en": "Risk of bias and applicability summary grid for 3 studies on pulmonary TB detection in HIV-negative adults and adolescents (Danfack 2023, Nliwasa 2016, Odeume 2021). Rows list the studies; columns show four risk-of-bias domains (patient selection, index test, reference standard, flow and timing) and three applicability domains (patient selection, index test, reference standard), each rated high (red), unclear (yellow) or low (green). All cells are rated low (green).",
        "ar": "شبكة ملخّص لمخاطر التحيّز وقابلية التطبيق تشمل 3 دراسات بشأن الكشف عن السل الرئوي لدى البالغين والمراهقين غير المصابين بفيروس العوز المناعي البشري (Danfack 2023 وNliwasa 2016 وOdeume 2021). تسرد الصفوف الدراسات، وتعرض الأعمدة أربعة مجالات لمخاطر التحيّز (اختيار المرضى، والاختبار المؤشّر، والمعيار المرجعي، والتدفّق والتوقيت) وثلاثة مجالات لقابلية التطبيق (اختيار المرضى، والاختبار المؤشّر، والمعيار المرجعي)، ويُصنَّف كل منها مرتفعاً (أحمر) أو غير واضح (أصفر) أو منخفضاً (أخضر). جميع الخلايا مصنّفة منخفضة (أخضر).",
        "zh": "在艾滋病毒阴性成人和青少年中检测肺结核的（Danfack 2023、Nliwasa 2016、Odeume 2021）3项研究的偏倚风险和适用性汇总网格。行列出各项研究；列显示四个偏倚风险领域（患者选择、待评价试验、参考标准、流程和时间）和三个适用性领域（患者选择、待评价试验、参考标准），每项评为高（红色）、不清楚（黄色）或低（绿色）。所有单元格均评为低（绿色）。",
        "es": "Cuadrícula resumen del riesgo de sesgo y la aplicabilidad de 3 estudios sobre la detección de la TB pulmonar en adultos y adolescentes VIH-negativos (Danfack 2023, Nliwasa 2016, Odeume 2021). Las filas enumeran los estudios; las columnas muestran cuatro dominios de riesgo de sesgo (selección de pacientes, prueba índice, patrón de referencia, flujo y cronología) y tres dominios de aplicabilidad (selección de pacientes, prueba índice, patrón de referencia), cada uno calificado como alto (rojo), incierto (amarillo) o bajo (verde). Todas las celdas se califican como bajo (verde).",
        "fr": "Grille récapitulative du risque de biais et de l’applicabilité pour 3 études sur la détection de la TB pulmonaire chez les adultes et adolescents séronégatifs pour le VIH (Danfack 2023, Nliwasa 2016, Odeume 2021). Les lignes listent les études ; les colonnes présentent quatre domaines de risque de biais (sélection des patients, test index, test de référence, flux et chronologie) et trois domaines d’applicabilité (sélection des patients, test index, test de référence), chacun jugé élevé (rouge), incertain (jaune) ou faible (vert). Toutes les cases sont jugées faibles (vert).",
        "ru": "Сводная таблица риска систематической ошибки и применимости для 3 исследований по выявлению туберкулёза лёгких у ВИЧ-отрицательных взрослых и подростков (Danfack 2023, Nliwasa 2016, Odeume 2021). В строках перечислены исследования; в столбцах — четыре домена риска систематической ошибки (отбор пациентов, индексный тест, эталонный стандарт, ход и сроки исследования) и три домена применимости (отбор пациентов, индексный тест, эталонный стандарт), каждый оценён как высокий (красный), неясный (жёлтый) или низкий (зелёный). Все ячейки оценены как низкие (зелёный)."
      },
      "state": "draft"
    },
    {
      "id": "img-p222-3",
      "file": "images/img-p222-3.webp",
      "page": 222,
      "narratives": {
        "en": "Forest plot of LC-mNAAT sensitivity and specificity for pulmonary TB in HIV-negative people, 3 studies. Each row gives TP, FP, FN and TN counts with sensitivity and specificity (95% CI), plotted as blue squares with confidence-interval lines on 0–1 scales. Sensitivity is 0.53 (Nliwasa 2016), 0.76 (Odeume 2021) and 0.89 (Danfack 2023); specificity is 0.98–1.00 in all three.",
        "ar": "مخطط غابي لحساسية ونوعية اختبارات LC-mNAAT للسل الرئوي لدى غير المصابين بفيروس العوز المناعي البشري، يشمل 3 دراسات. يعرض كل صف أعداد الإيجابيات الحقيقية والإيجابيات الكاذبة والسلبيات الكاذبة والسلبيات الحقيقية مع الحساسية والنوعية (فاصل ثقة 95%)، مرسومة كمربعات زرقاء مع خطوط فواصل الثقة على مقياس من 0 إلى 1. الحساسية 0.53 (Nliwasa 2016) و0.76 (Odeume 2021) و0.89 (Danfack 2023)؛ والنوعية بين 0.98 و1.00 في الدراسات الثلاث.",
        "zh": "艾滋病毒阴性人群中LC-mNAAT检测肺结核的灵敏度和特异度森林图，共3项研究。每行列出真阳性、假阳性、假阴性和真阴性数及灵敏度和特异度（95%置信区间），以蓝色方块和置信区间线绘于0–1刻度上。灵敏度分别为0.53（Nliwasa 2016）、0.76（Odeume 2021）和0.89（Danfack 2023）；三项研究的特异度均为0.98–1.00。",
        "es": "Diagrama de bosque de la sensibilidad y la especificidad de las LC-mNAAT para la TB pulmonar en personas VIH-negativas, 3 estudios. Cada fila presenta los recuentos de VP, FP, FN y VN con la sensibilidad y la especificidad (IC del 95%), representadas como cuadrados azules con líneas de intervalo de confianza en escalas de 0 a 1. La sensibilidad es de 0,53 (Nliwasa 2016), 0,76 (Odeume 2021) y 0,89 (Danfack 2023); la especificidad es de 0,98 a 1,00 en los tres.",
        "fr": "Graphique en forêt de la sensibilité et de la spécificité des LC-mNAAT pour la TB pulmonaire chez les personnes séronégatives pour le VIH, 3 études. Chaque ligne indique les nombres de VP, FP, FN et VN avec la sensibilité et la spécificité (IC à 95 %), représentées par des carrés bleus avec des lignes d’intervalle de confiance sur des échelles de 0 à 1. La sensibilité est de 0,53 (Nliwasa 2016), 0,76 (Odeume 2021) et 0,89 (Danfack 2023) ; la spécificité est de 0,98 à 1,00 dans les trois.",
        "ru": "Лесовидный график чувствительности и специфичности LC-mNAAT при туберкулёзе лёгких у ВИЧ-отрицательных лиц, 3 исследования. В каждой строке приведены числа ИП, ЛП, ЛО и ИО с чувствительностью и специфичностью (95% ДИ), изображёнными синими квадратами с линиями доверительных интервалов на шкалах от 0 до 1. Чувствительность 0,53 (Nliwasa 2016), 0,76 (Odeume 2021) и 0,89 (Danfack 2023); специфичность 0,98–1,00 во всех трёх."
      },
      "state": "draft"
    },
    {
      "id": "img-p223-1",
      "file": "images/img-p223-1.webp",
      "page": 223,
      "narratives": {
        "en": "Forest plot of LC-mNAAT sensitivity and specificity for pulmonary TB in smear-positive people, 22 studies from Danfack 2018 to Yadav 2021. Each row gives TP, FP, FN and TN counts with sensitivity and specificity (95% CI), plotted as blue squares with confidence-interval lines on 0–1 scales. Sensitivity is high (0.64–1.00), while specificity is widely scattered (0.00–1.00) with very wide intervals, and several studies are marked 'Not estimable'.",
        "ar": "مخطط غابي لحساسية ونوعية اختبارات LC-mNAAT للسل الرئوي لدى إيجابيي اللطاخة، يشمل 22 دراسة من Danfack 2018 إلى Yadav 2021. يعرض كل صف أعداد الإيجابيات الحقيقية والإيجابيات الكاذبة والسلبيات الكاذبة والسلبيات الحقيقية مع الحساسية والنوعية (فاصل ثقة 95%)، مرسومة كمربعات زرقاء مع خطوط فواصل الثقة على مقياس من 0 إلى 1. الحساسية مرتفعة (0.64–1.00)، بينما تتشتّت النوعية على نطاق واسع (0.00–1.00) بفواصل ثقة عريضة جداً، وعدة دراسات موسومة بأنها «غير قابلة للتقدير».",
        "zh": "涂片阳性者中LC-mNAAT检测肺结核的灵敏度和特异度森林图，共22项研究（从Danfack 2018到Yadav 2021）。每行列出真阳性、假阳性、假阴性和真阴性数及灵敏度和特异度（95%置信区间），以蓝色方块和置信区间线绘于0–1刻度上。灵敏度较高（0.64–1.00），而特异度分布很分散（0.00–1.00），置信区间很宽，数项研究标为“不可估计”。",
        "es": "Diagrama de bosque de la sensibilidad y la especificidad de las LC-mNAAT para la TB pulmonar en personas con baciloscopia positiva, 22 estudios de Danfack 2018 a Yadav 2021. Cada fila presenta los recuentos de VP, FP, FN y VN con la sensibilidad y la especificidad (IC del 95%), representadas como cuadrados azules con líneas de intervalo de confianza en escalas de 0 a 1. La sensibilidad es alta (0,64–1,00), mientras que la especificidad está muy dispersa (0,00–1,00) con intervalos muy amplios, y varios estudios figuran como «No estimable».",
        "fr": "Graphique en forêt de la sensibilité et de la spécificité des LC-mNAAT pour la TB pulmonaire chez les personnes à frottis positif, 22 études de Danfack 2018 à Yadav 2021. Chaque ligne indique les nombres de VP, FP, FN et VN avec la sensibilité et la spécificité (IC à 95 %), représentées par des carrés bleus avec des lignes d’intervalle de confiance sur des échelles de 0 à 1. La sensibilité est élevée (0,64–1,00), tandis que la spécificité est très dispersée (0,00–1,00) avec des intervalles très larges, et plusieurs études sont marquées « Non estimable ».",
        "ru": "Лесовидный график чувствительности и специфичности LC-mNAAT при туберкулёзе лёгких у мазок-положительных лиц, 22 исследования от Danfack 2018 до Yadav 2021. В каждой строке приведены числа ИП, ЛП, ЛО и ИО с чувствительностью и специфичностью (95% ДИ), изображёнными синими квадратами с линиями доверительных интервалов на шкалах от 0 до 1. Чувствительность высокая (0,64–1,00), а специфичность сильно разбросана (0,00–1,00) с очень широкими интервалами; ряд исследований помечен «Не поддаётся оценке»."
      },
      "state": "draft"
    },
    {
      "id": "img-p224-1",
      "file": "images/img-p224-1.webp",
      "page": 224,
      "narratives": {
        "en": "Forest plot of LC-mNAAT sensitivity and specificity for pulmonary TB in smear-negative people, 25 studies from Nakiyingi 2018 to Yadav 2021. Each row gives TP, FP, FN and TN counts with sensitivity and specificity (95% CI), plotted as blue squares with confidence-interval lines on 0–1 scales. Sensitivity is lower and variable (0.24–1.00), while specificity is mostly 0.94–1.00, with lower values for Ou 2016 (0.87) and Mitarai 2011 (0.74).",
        "ar": "مخطط غابي لحساسية ونوعية اختبارات LC-mNAAT للسل الرئوي لدى سلبيي اللطاخة، يشمل 25 دراسة من Nakiyingi 2018 إلى Yadav 2021. يعرض كل صف أعداد الإيجابيات الحقيقية والإيجابيات الكاذبة والسلبيات الكاذبة والسلبيات الحقيقية مع الحساسية والنوعية (فاصل ثقة 95%)، مرسومة كمربعات زرقاء مع خطوط فواصل الثقة على مقياس من 0 إلى 1. الحساسية أدنى ومتفاوتة (0.24–1.00)، بينما النوعية في الغالب بين 0.94 و1.00، مع قيم أدنى في Ou 2016 (0.87) وMitarai 2011 (0.74).",
        "zh": "涂片阴性者中LC-mNAAT检测肺结核的灵敏度和特异度森林图，共25项研究（从Nakiyingi 2018到Yadav 2021）。每行列出真阳性、假阳性、假阴性和真阴性数及灵敏度和特异度（95%置信区间），以蓝色方块和置信区间线绘于0–1刻度上。灵敏度较低且差异大（0.24–1.00），特异度多为0.94–1.00，Ou 2016（0.87）和Mitarai 2011（0.74）较低。",
        "es": "Diagrama de bosque de la sensibilidad y la especificidad de las LC-mNAAT para la TB pulmonar en personas con baciloscopia negativa, 25 estudios de Nakiyingi 2018 a Yadav 2021. Cada fila presenta los recuentos de VP, FP, FN y VN con la sensibilidad y la especificidad (IC del 95%), representadas como cuadrados azules con líneas de intervalo de confianza en escalas de 0 a 1. La sensibilidad es menor y variable (0,24–1,00), mientras que la especificidad es mayoritariamente de 0,94 a 1,00, con valores más bajos en Ou 2016 (0,87) y Mitarai 2011 (0,74).",
        "fr": "Graphique en forêt de la sensibilité et de la spécificité des LC-mNAAT pour la TB pulmonaire chez les personnes à frottis négatif, 25 études de Nakiyingi 2018 à Yadav 2021. Chaque ligne indique les nombres de VP, FP, FN et VN avec la sensibilité et la spécificité (IC à 95 %), représentées par des carrés bleus avec des lignes d’intervalle de confiance sur des échelles de 0 à 1. La sensibilité est plus faible et variable (0,24–1,00), tandis que la spécificité est surtout comprise entre 0,94 et 1,00, avec des valeurs plus basses pour Ou 2016 (0,87) et Mitarai 2011 (0,74).",
        "ru": "Лесовидный график чувствительности и специфичности LC-mNAAT при туберкулёзе лёгких у мазок-отрицательных лиц, 25 исследований от Nakiyingi 2018 до Yadav 2021. В каждой строке приведены числа ИП, ЛП, ЛО и ИО с чувствительностью и специфичностью (95% ДИ), изображёнными синими квадратами с линиями доверительных интервалов на шкалах от 0 до 1. Чувствительность ниже и вариабельна (0,24–1,00), а специфичность в основном 0,94–1,00, с более низкими значениями у Ou 2016 (0,87) и Mitarai 2011 (0,74)."
      },
      "state": "draft"
    },
    {
      "id": "img-p224-2",
      "file": "images/img-p224-2.webp",
      "page": 224,
      "narratives": {
        "en": "Risk of bias and applicability summary grid for 3 studies on extrapulmonary TB (Danfack 2024a, Promsena 2022, Singh 2021). Rows list the studies; columns show four risk-of-bias domains (patient selection, index test, reference standard, flow and timing) and three applicability domains (patient selection, index test, reference standard), each rated high (red), unclear (yellow) or low (green). All ratings are low except unclear reference-standard bias for Promsena 2022 and Singh 2021 and unclear reference-standard applicability for Singh 2021.",
        "ar": "شبكة ملخّص لمخاطر التحيّز وقابلية التطبيق تشمل 3 دراسات بشأن السل خارج الرئة (Danfack 2024a وPromsena 2022 وSingh 2021). تسرد الصفوف الدراسات، وتعرض الأعمدة أربعة مجالات لمخاطر التحيّز (اختيار المرضى، والاختبار المؤشّر، والمعيار المرجعي، والتدفّق والتوقيت) وثلاثة مجالات لقابلية التطبيق (اختيار المرضى، والاختبار المؤشّر، والمعيار المرجعي)، ويُصنَّف كل منها مرتفعاً (أحمر) أو غير واضح (أصفر) أو منخفضاً (أخضر). جميع التقييمات منخفضة باستثناء تحيّز المعيار المرجعي غير الواضح في Promsena 2022 وSingh 2021، وقابلية تطبيق المعيار المرجعي غير الواضحة في Singh 2021.",
        "zh": "肺外结核相关的（Danfack 2024a、Promsena 2022、Singh 2021）3项研究的偏倚风险和适用性汇总网格。行列出各项研究；列显示四个偏倚风险领域（患者选择、待评价试验、参考标准、流程和时间）和三个适用性领域（患者选择、待评价试验、参考标准），每项评为高（红色）、不清楚（黄色）或低（绿色）。除Promsena 2022和Singh 2021的参考标准偏倚以及Singh 2021的参考标准适用性评为不清楚外，其余均为低。",
        "es": "Cuadrícula resumen del riesgo de sesgo y la aplicabilidad de 3 estudios sobre la TB extrapulmonar (Danfack 2024a, Promsena 2022, Singh 2021). Las filas enumeran los estudios; las columnas muestran cuatro dominios de riesgo de sesgo (selección de pacientes, prueba índice, patrón de referencia, flujo y cronología) y tres dominios de aplicabilidad (selección de pacientes, prueba índice, patrón de referencia), cada uno calificado como alto (rojo), incierto (amarillo) o bajo (verde). Todas las calificaciones son bajas, salvo el sesgo incierto del patrón de referencia en Promsena 2022 y Singh 2021 y la aplicabilidad incierta del patrón de referencia en Singh 2021.",
        "fr": "Grille récapitulative du risque de biais et de l’applicabilité pour 3 études sur la TB extrapulmonaire (Danfack 2024a, Promsena 2022, Singh 2021). Les lignes listent les études ; les colonnes présentent quatre domaines de risque de biais (sélection des patients, test index, test de référence, flux et chronologie) et trois domaines d’applicabilité (sélection des patients, test index, test de référence), chacun jugé élevé (rouge), incertain (jaune) ou faible (vert). Tous les jugements sont faibles, sauf le biais incertain du test de référence pour Promsena 2022 et Singh 2021 et l’applicabilité incertaine du test de référence pour Singh 2021.",
        "ru": "Сводная таблица риска систематической ошибки и применимости для 3 исследований по внелёгочному туберкулёзу (Danfack 2024a, Promsena 2022, Singh 2021). В строках перечислены исследования; в столбцах — четыре домена риска систематической ошибки (отбор пациентов, индексный тест, эталонный стандарт, ход и сроки исследования) и три домена применимости (отбор пациентов, индексный тест, эталонный стандарт), каждый оценён как высокий (красный), неясный (жёлтый) или низкий (зелёный). Все оценки низкие, кроме неясного риска ошибки эталонного стандарта у Promsena 2022 и Singh 2021 и неясной применимости эталонного стандарта у Singh 2021."
      },
      "state": "draft"
    },
    {
      "id": "img-p225-1",
      "file": "images/img-p225-1.webp",
      "page": 225,
      "narratives": {
        "en": "Cropped forest plot of TB-LAMP for lymph node TB with partly cut-off headings. In lymph node biopsy (3 studies), sensitivity is 0.93 (Danfack 2024a), 1.00 (Promsena 2022) and 1.00 (Singh 2021), with specificity 0.88–1.00; in lymph node aspirate (Danfack 2024a), sensitivity is 0.67 and specificity 0.75. A further heading for LN pus is cut off.",
        "ar": "مخطط غابي مقتطع لاختبار TB-LAMP للسل العقدي اللمفاوي بعناوين مقطوعة جزئياً. في خزعة العقدة اللمفاوية (3 دراسات) الحساسية 0.93 (Danfack 2024a) و1.00 (Promsena 2022) و1.00 (Singh 2021)، والنوعية بين 0.88 و1.00؛ وفي رشافة العقدة اللمفاوية (Danfack 2024a) الحساسية 0.67 والنوعية 0.75. وعنوان آخر يخص قيح العقدة اللمفاوية مقطوع.",
        "zh": "TB-LAMP检测淋巴结结核的截取森林图，部分标题被截断。在淋巴结活检（3项研究）中，灵敏度分别为0.93（Danfack 2024a）、1.00（Promsena 2022）和1.00（Singh 2021），特异度为0.88–1.00；在淋巴结抽吸物（Danfack 2024a）中，灵敏度为0.67，特异度为0.75。另一个关于淋巴结脓液的标题被截断。",
        "es": "Diagrama de bosque recortado de TB-LAMP para la TB ganglionar, con encabezados parcialmente cortados. En biopsia de ganglio linfático (3 estudios), la sensibilidad es de 0,93 (Danfack 2024a), 1,00 (Promsena 2022) y 1,00 (Singh 2021), con especificidad de 0,88 a 1,00; en aspirado ganglionar (Danfack 2024a), la sensibilidad es de 0,67 y la especificidad de 0,75. Otro encabezado sobre pus ganglionar está cortado.",
        "fr": "Graphique en forêt rogné de TB-LAMP pour la TB ganglionnaire, avec des intitulés partiellement coupés. Sur biopsie ganglionnaire (3 études), la sensibilité est de 0,93 (Danfack 2024a), 1,00 (Promsena 2022) et 1,00 (Singh 2021), avec une spécificité de 0,88 à 1,00 ; sur aspiration ganglionnaire (Danfack 2024a), la sensibilité est de 0,67 et la spécificité de 0,75. Un autre intitulé concernant le pus ganglionnaire est coupé.",
        "ru": "Обрезанный лесовидный график TB-LAMP при туберкулёзе лимфатических узлов с частично обрезанными заголовками. В биоптате лимфоузла (3 исследования) чувствительность 0,93 (Danfack 2024a), 1,00 (Promsena 2022) и 1,00 (Singh 2021), специфичность 0,88–1,00; в аспирате лимфоузла (Danfack 2024a) чувствительность 0,67, специфичность 0,75. Ещё один заголовок, о гное из лимфоузла, обрезан."
      },
      "state": "draft"
    },
    {
      "id": "img-p225-2",
      "file": "images/img-p225-2.webp",
      "page": 225,
      "narratives": {
        "en": "Forest plot of LC-mNAAT sensitivity and specificity for TB meningitis in cerebrospinal fluid, 2 studies. Each row gives TP, FP, FN and TN counts with sensitivity and specificity (95% CI), plotted as blue squares with confidence-interval lines on 0–1 scales. Danfack 2024a: sensitivity 0.00 (0.00–0.84), specificity 0.97; Singh 2021: sensitivity 1.00 (0.03–1.00), specificity 1.00.",
        "ar": "مخطط غابي لحساسية ونوعية اختبارات LC-mNAAT لالتهاب السحايا السلي في السائل الدماغي الشوكي، دراستان. يعرض كل صف أعداد الإيجابيات الحقيقية والإيجابيات الكاذبة والسلبيات الكاذبة والسلبيات الحقيقية مع الحساسية والنوعية (فاصل ثقة 95%)، مرسومة كمربعات زرقاء مع خطوط فواصل الثقة على مقياس من 0 إلى 1. Danfack 2024a: الحساسية 0.00 (0.00–0.84) والنوعية 0.97؛ Singh 2021: الحساسية 1.00 (0.03–1.00) والنوعية 1.00.",
        "zh": "LC-mNAAT检测脑脊液中结核性脑膜炎（2项研究）的灵敏度和特异度森林图。每行列出真阳性、假阳性、假阴性和真阴性数及灵敏度和特异度（95%置信区间），以蓝色方块和置信区间线绘于0–1刻度上。Danfack 2024a：灵敏度0.00（0.00–0.84），特异度0.97；Singh 2021：灵敏度1.00（0.03–1.00），特异度1.00。",
        "es": "Diagrama de bosque de la sensibilidad y la especificidad de las LC-mNAAT para la meningitis tuberculosa en líquido cefalorraquídeo, 2 estudios. Cada fila presenta los recuentos de VP, FP, FN y VN con la sensibilidad y la especificidad (IC del 95%), representadas como cuadrados azules con líneas de intervalo de confianza en escalas de 0 a 1. Danfack 2024a: sensibilidad 0,00 (0,00–0,84), especificidad 0,97; Singh 2021: sensibilidad 1,00 (0,03–1,00), especificidad 1,00.",
        "fr": "Graphique en forêt de la sensibilité et de la spécificité des LC-mNAAT pour la méningite tuberculeuse dans le liquide céphalorachidien, 2 études. Chaque ligne indique les nombres de VP, FP, FN et VN avec la sensibilité et la spécificité (IC à 95 %), représentées par des carrés bleus avec des lignes d’intervalle de confiance sur des échelles de 0 à 1. Danfack 2024a : sensibilité 0,00 (0,00–0,84), spécificité 0,97 ; Singh 2021 : sensibilité 1,00 (0,03–1,00), spécificité 1,00.",
        "ru": "Лесовидный график чувствительности и специфичности LC-mNAAT при туберкулёзном менингите в спинномозговой жидкости, 2 исследования. В каждой строке приведены числа ИП, ЛП, ЛО и ИО с чувствительностью и специфичностью (95% ДИ), изображёнными синими квадратами с линиями доверительных интервалов на шкалах от 0 до 1. Danfack 2024a: чувствительность 0,00 (0,00–0,84), специфичность 0,97; Singh 2021: чувствительность 1,00 (0,03–1,00), специфичность 1,00."
      },
      "state": "draft"
    },
    {
      "id": "img-p226-1",
      "file": "images/img-p226-1.webp",
      "page": 226,
      "narratives": {
        "en": "Forest plot of LC-mNAAT sensitivity and specificity for abdominal TB in ascitic fluid, 2 studies. Each row gives TP, FP, FN and TN counts with sensitivity and specificity (95% CI), plotted as blue squares with confidence-interval lines on 0–1 scales. Danfack 2024a: sensitivity 0.17, specificity 0.95; Singh 2021: sensitivity 1.00, specificity 0.94.",
        "ar": "مخطط غابي لحساسية ونوعية اختبارات LC-mNAAT للسل البطني في سائل الاستسقاء، دراستان. يعرض كل صف أعداد الإيجابيات الحقيقية والإيجابيات الكاذبة والسلبيات الكاذبة والسلبيات الحقيقية مع الحساسية والنوعية (فاصل ثقة 95%)، مرسومة كمربعات زرقاء مع خطوط فواصل الثقة على مقياس من 0 إلى 1. Danfack 2024a: الحساسية 0.17 والنوعية 0.95؛ Singh 2021: الحساسية 1.00 والنوعية 0.94.",
        "zh": "LC-mNAAT检测腹水中腹部结核（2项研究）的灵敏度和特异度森林图。每行列出真阳性、假阳性、假阴性和真阴性数及灵敏度和特异度（95%置信区间），以蓝色方块和置信区间线绘于0–1刻度上。Danfack 2024a：灵敏度0.17，特异度0.95；Singh 2021：灵敏度1.00，特异度0.94。",
        "es": "Diagrama de bosque de la sensibilidad y la especificidad de las LC-mNAAT para la TB abdominal en líquido ascítico, 2 estudios. Cada fila presenta los recuentos de VP, FP, FN y VN con la sensibilidad y la especificidad (IC del 95%), representadas como cuadrados azules con líneas de intervalo de confianza en escalas de 0 a 1. Danfack 2024a: sensibilidad 0,17, especificidad 0,95; Singh 2021: sensibilidad 1,00, especificidad 0,94.",
        "fr": "Graphique en forêt de la sensibilité et de la spécificité des LC-mNAAT pour la TB abdominale dans le liquide d’ascite, 2 études. Chaque ligne indique les nombres de VP, FP, FN et VN avec la sensibilité et la spécificité (IC à 95 %), représentées par des carrés bleus avec des lignes d’intervalle de confiance sur des échelles de 0 à 1. Danfack 2024a : sensibilité 0,17, spécificité 0,95 ; Singh 2021 : sensibilité 1,00, spécificité 0,94.",
        "ru": "Лесовидный график чувствительности и специфичности LC-mNAAT при абдоминальном туберкулёзе в асцитической жидкости, 2 исследования. В каждой строке приведены числа ИП, ЛП, ЛО и ИО с чувствительностью и специфичностью (95% ДИ), изображёнными синими квадратами с линиями доверительных интервалов на шкалах от 0 до 1. Danfack 2024a: чувствительность 0,17, специфичность 0,95; Singh 2021: чувствительность 1,00, специфичность 0,94."
      },
      "state": "draft"
    },
    {
      "id": "img-p226-2",
      "file": "images/img-p226-2.webp",
      "page": 226,
      "narratives": {
        "en": "Cropped forest plot of TB-LAMP for pleural TB with partly cut-off labels. In pleural fluid, Danfack 2024a has sensitivity 0.48 and specificity 0.96, and Singh 2021 sensitivity 0.75 and specificity 0.89; in pleural biopsy (Danfack 2024a), sensitivity is 0.00 (0.00–0.10) and specificity 0.93. A heading for pleural pus is cut off at the bottom.",
        "ar": "مخطط غابي مقتطع لاختبار TB-LAMP للسل الجنبي بتسميات مقطوعة جزئياً. في السائل الجنبي، لدى Danfack 2024a حساسية 0.48 ونوعية 0.96، ولدى Singh 2021 حساسية 0.75 ونوعية 0.89؛ وفي خزعة الجنبة (Danfack 2024a) الحساسية 0.00 (0.00–0.10) والنوعية 0.93. وعنوان يخص القيح الجنبي مقطوع في الأسفل.",
        "zh": "TB-LAMP检测胸膜结核的截取森林图，部分标签被截断。在胸腔积液中，Danfack 2024a灵敏度0.48、特异度0.96，Singh 2021灵敏度0.75、特异度0.89；在胸膜活检（Danfack 2024a）中，灵敏度0.00（0.00–0.10），特异度0.93。底部关于胸膜脓液的标题被截断。",
        "es": "Diagrama de bosque recortado de TB-LAMP para la TB pleural, con etiquetas parcialmente cortadas. En líquido pleural, Danfack 2024a tiene sensibilidad 0,48 y especificidad 0,96, y Singh 2021 sensibilidad 0,75 y especificidad 0,89; en biopsia pleural (Danfack 2024a), la sensibilidad es de 0,00 (0,00–0,10) y la especificidad de 0,93. Un encabezado sobre pus pleural está cortado en la parte inferior.",
        "fr": "Graphique en forêt rogné de TB-LAMP pour la TB pleurale, avec des libellés partiellement coupés. Dans le liquide pleural, Danfack 2024a a une sensibilité de 0,48 et une spécificité de 0,96, et Singh 2021 une sensibilité de 0,75 et une spécificité de 0,89 ; sur biopsie pleurale (Danfack 2024a), la sensibilité est de 0,00 (0,00–0,10) et la spécificité de 0,93. Un intitulé concernant le pus pleural est coupé en bas.",
        "ru": "Обрезанный лесовидный график TB-LAMP при плевральном туберкулёзе с частично обрезанными подписями. В плевральной жидкости у Danfack 2024a чувствительность 0,48 и специфичность 0,96, у Singh 2021 — 0,75 и 0,89; в биоптате плевры (Danfack 2024a) чувствительность 0,00 (0,00–0,10), специфичность 0,93. Заголовок о плевральном гное обрезан внизу."
      },
      "state": "draft"
    },
    {
      "id": "img-p226-3",
      "file": "images/img-p226-3.webp",
      "page": 226,
      "narratives": {
        "en": "Cropped single-row forest plot with a cut-off header: Danfack 2024a with TP 1, FP 0, FN 0, TN 4, sensitivity 1.00 (0.03–1.00) and specificity 1.00 (0.40–1.00), plotted on 0–1 scales.",
        "ar": "مخطط غابي مقتطع من صف واحد بترويسة مقطوعة: Danfack 2024a بإيجابيات حقيقية 1 وإيجابيات كاذبة 0 وسلبيات كاذبة 0 وسلبيات حقيقية 4، وحساسية 1.00 (0.03–1.00) ونوعية 1.00 (0.40–1.00)، مرسومة على مقياس من 0 إلى 1.",
        "zh": "截取的单行森林图，表头被截断：Danfack 2024a，真阳性1、假阳性0、假阴性0、真阴性4，灵敏度1.00（0.03–1.00），特异度1.00（0.40–1.00），绘于0–1刻度上。",
        "es": "Diagrama de bosque recortado de una sola fila con el encabezado cortado: Danfack 2024a con VP 1, FP 0, FN 0, VN 4, sensibilidad 1,00 (0,03–1,00) y especificidad 1,00 (0,40–1,00), representadas en escalas de 0 a 1.",
        "fr": "Graphique en forêt rogné d’une seule ligne, en-tête coupé : Danfack 2024a avec VP 1, FP 0, FN 0, VN 4, sensibilité 1,00 (0,03–1,00) et spécificité 1,00 (0,40–1,00), sur des échelles de 0 à 1.",
        "ru": "Обрезанный однострочный лесовидный график с обрезанной шапкой: Danfack 2024a — ИП 1, ЛП 0, ЛО 0, ИО 4, чувствительность 1,00 (0,03–1,00), специфичность 1,00 (0,40–1,00) на шкалах от 0 до 1."
      },
      "state": "draft"
    },
    {
      "id": "img-p227-1",
      "file": "images/img-p227-1.webp",
      "page": 227,
      "narratives": {
        "en": "Forest plot of LC-mNAAT sensitivity and specificity for genitourinary TB in urine, 1 study. Each row gives TP, FP, FN and TN counts with sensitivity and specificity (95% CI), plotted as blue squares with confidence-interval lines on 0–1 scales. Danfack 2024a: TP 1, FP 0, FN 1, TN 30; sensitivity 0.50 (0.01–0.99), specificity 1.00 (0.88–1.00).",
        "ar": "مخطط غابي لحساسية ونوعية اختبارات LC-mNAAT للسل البولي التناسلي في البول، دراسة واحدة. يعرض كل صف أعداد الإيجابيات الحقيقية والإيجابيات الكاذبة والسلبيات الكاذبة والسلبيات الحقيقية مع الحساسية والنوعية (فاصل ثقة 95%)، مرسومة كمربعات زرقاء مع خطوط فواصل الثقة على مقياس من 0 إلى 1. Danfack 2024a: إيجابيات حقيقية 1، إيجابيات كاذبة 0، سلبيات كاذبة 1، سلبيات حقيقية 30؛ الحساسية 0.50 (0.01–0.99) والنوعية 1.00 (0.88–1.00).",
        "zh": "LC-mNAAT检测尿液中泌尿生殖系统结核（1项研究）的灵敏度和特异度森林图。每行列出真阳性、假阳性、假阴性和真阴性数及灵敏度和特异度（95%置信区间），以蓝色方块和置信区间线绘于0–1刻度上。Danfack 2024a：真阳性1、假阳性0、假阴性1、真阴性30；灵敏度0.50（0.01–0.99），特异度1.00（0.88–1.00）。",
        "es": "Diagrama de bosque de la sensibilidad y la especificidad de las LC-mNAAT para la TB genitourinaria en orina, 1 estudio. Cada fila presenta los recuentos de VP, FP, FN y VN con la sensibilidad y la especificidad (IC del 95%), representadas como cuadrados azules con líneas de intervalo de confianza en escalas de 0 a 1. Danfack 2024a: VP 1, FP 0, FN 1, VN 30; sensibilidad 0,50 (0,01–0,99), especificidad 1,00 (0,88–1,00).",
        "fr": "Graphique en forêt de la sensibilité et de la spécificité des LC-mNAAT pour la TB génito-urinaire dans les urines, 1 étude. Chaque ligne indique les nombres de VP, FP, FN et VN avec la sensibilité et la spécificité (IC à 95 %), représentées par des carrés bleus avec des lignes d’intervalle de confiance sur des échelles de 0 à 1. Danfack 2024a : VP 1, FP 0, FN 1, VN 30 ; sensibilité 0,50 (0,01–0,99), spécificité 1,00 (0,88–1,00).",
        "ru": "Лесовидный график чувствительности и специфичности LC-mNAAT при мочеполовом туберкулёзе в моче, 1 исследование. В каждой строке приведены числа ИП, ЛП, ЛО и ИО с чувствительностью и специфичностью (95% ДИ), изображёнными синими квадратами с линиями доверительных интервалов на шкалах от 0 до 1. Danfack 2024a: ИП 1, ЛП 0, ЛО 1, ИО 30; чувствительность 0,50 (0,01–0,99), специфичность 1,00 (0,88–1,00)."
      },
      "state": "draft"
    },
    {
      "id": "img-p233-1",
      "file": "images/img-p233-1.webp",
      "page": 233,
      "narratives": {
        "en": "Cropped forest plot of TB-LAMP for pulmonary TB in other specimen types, with partly cut-off labels. The first panel (3 studies) shows sensitivity 0.64 for Danfack 2024b, 'Not estimable' for Promsena 2022 and 1.00 for Yadav 2021, with specificity 0.94–1.00; the panel for gastric aspirate specimens shows sensitivity 0.50 (Promsena 2022) and 'Not estimable' (Yadav 2021), specificity 1.00. A heading for gastric lavage specimens is cut off.",
        "ar": "مخطط غابي مقتطع لاختبار TB-LAMP للسل الرئوي في أنواع أخرى من العيّنات بتسميات مقطوعة جزئياً. تعرض اللوحة الأولى (3 دراسات) حساسية 0.64 لـ Danfack 2024b و«غير قابلة للتقدير» لـ Promsena 2022 و1.00 لـ Yadav 2021، مع نوعية بين 0.94 و1.00؛ وتعرض لوحة عيّنات رشافة المعدة حساسية 0.50 (Promsena 2022) و«غير قابلة للتقدير» (Yadav 2021)، ونوعية 1.00. وعنوان عيّنات غسل المعدة مقطوع.",
        "zh": "TB-LAMP检测其他标本类型中肺结核的截取森林图，部分标签被截断。第一个面板（3项研究）显示Danfack 2024b灵敏度0.64、Promsena 2022“不可估计”、Yadav 2021为1.00，特异度0.94–1.00；胃抽吸物标本面板显示灵敏度0.50（Promsena 2022）和“不可估计”（Yadav 2021），特异度1.00。胃灌洗标本的标题被截断。",
        "es": "Diagrama de bosque recortado de TB-LAMP para la TB pulmonar en otros tipos de muestra, con etiquetas parcialmente cortadas. El primer panel (3 estudios) muestra una sensibilidad de 0,64 para Danfack 2024b, «No estimable» para Promsena 2022 y 1,00 para Yadav 2021, con especificidad de 0,94 a 1,00; el panel de aspirado gástrico muestra una sensibilidad de 0,50 (Promsena 2022) y «No estimable» (Yadav 2021), con especificidad de 1,00. Un encabezado sobre lavado gástrico está cortado.",
        "fr": "Graphique en forêt rogné de TB-LAMP pour la TB pulmonaire sur d’autres types d’échantillons, avec des libellés partiellement coupés. Le premier panneau (3 études) montre une sensibilité de 0,64 pour Danfack 2024b, « Non estimable » pour Promsena 2022 et 1,00 pour Yadav 2021, avec une spécificité de 0,94 à 1,00 ; le panneau des aspirations gastriques montre une sensibilité de 0,50 (Promsena 2022) et « Non estimable » (Yadav 2021), spécificité 1,00. Un intitulé sur les lavages gastriques est coupé.",
        "ru": "Обрезанный лесовидный график TB-LAMP при туберкулёзе лёгких в других типах образцов с частично обрезанными подписями. Первая панель (3 исследования): чувствительность 0,64 у Danfack 2024b, «Не поддаётся оценке» у Promsena 2022 и 1,00 у Yadav 2021, специфичность 0,94–1,00; панель аспирата желудка: чувствительность 0,50 (Promsena 2022) и «Не поддаётся оценке» (Yadav 2021), специфичность 1,00. Заголовок о промывных водах желудка обрезан."
      },
      "state": "draft"
    },
    {
      "id": "img-p233-2",
      "file": "images/img-p233-2.webp",
      "page": 233,
      "narratives": {
        "en": "Two-panel forest plot of TB-LAMP for pulmonary TB (PTB) by laboratory setting: 'peripheral lab' (7 studies, Nliwasa 2016 to Wang 2019) and 'central lab' (19 studies, Spooner 2022 to Yadav 2017). Each row gives TP, FP, FN and TN counts with sensitivity and specificity (95% CI), plotted as blue squares with confidence-interval lines on 0–1 scales. Peripheral-lab sensitivity ranges 0.65–0.89 with specificity 0.96–1.00; central-lab sensitivity ranges 0.57–1.00 with specificity mostly 0.86–1.00 and a low of 0.70 (Wahid 2020).",
        "ar": "مخطط غابي من لوحتين لاختبار TB-LAMP للسل الرئوي حسب نوع المختبر: «مختبر طرفي» (7 دراسات، من Nliwasa 2016 إلى Wang 2019) و«مختبر مركزي» (19 دراسة، من Spooner 2022 إلى Yadav 2017). يعرض كل صف أعداد الإيجابيات الحقيقية والإيجابيات الكاذبة والسلبيات الكاذبة والسلبيات الحقيقية مع الحساسية والنوعية (فاصل ثقة 95%)، مرسومة كمربعات زرقاء مع خطوط فواصل الثقة على مقياس من 0 إلى 1. تتراوح الحساسية في المختبر الطرفي بين 0.65 و0.89 والنوعية بين 0.96 و1.00؛ وفي المختبر المركزي تتراوح الحساسية بين 0.57 و1.00 والنوعية في الغالب بين 0.86 و1.00 وأدناها 0.70 (Wahid 2020).",
        "zh": "按实验室类型分列的TB-LAMP检测肺结核双面板森林图：“外周实验室”（7项研究，从Nliwasa 2016到Wang 2019）和“中心实验室”（19项研究，从Spooner 2022到Yadav 2017）。每行列出真阳性、假阳性、假阴性和真阴性数及灵敏度和特异度（95%置信区间），以蓝色方块和置信区间线绘于0–1刻度上。外周实验室灵敏度0.65–0.89，特异度0.96–1.00；中心实验室灵敏度0.57–1.00，特异度多为0.86–1.00，最低0.70（Wahid 2020）。",
        "es": "Diagrama de bosque de dos paneles de TB-LAMP para la TB pulmonar (TBP) según el tipo de laboratorio: «laboratorio periférico» (7 estudios, de Nliwasa 2016 a Wang 2019) y «laboratorio central» (19 estudios, de Spooner 2022 a Yadav 2017). Cada fila presenta los recuentos de VP, FP, FN y VN con la sensibilidad y la especificidad (IC del 95%), representadas como cuadrados azules con líneas de intervalo de confianza en escalas de 0 a 1. En el laboratorio periférico la sensibilidad va de 0,65 a 0,89 y la especificidad de 0,96 a 1,00; en el central la sensibilidad va de 0,57 a 1,00 y la especificidad es mayoritariamente de 0,86 a 1,00, con un mínimo de 0,70 (Wahid 2020).",
        "fr": "Graphique en forêt à deux panneaux de TB-LAMP pour la TB pulmonaire (TBP) selon le type de laboratoire : « laboratoire périphérique » (7 études, de Nliwasa 2016 à Wang 2019) et « laboratoire central » (19 études, de Spooner 2022 à Yadav 2017). Chaque ligne indique les nombres de VP, FP, FN et VN avec la sensibilité et la spécificité (IC à 95 %), représentées par des carrés bleus avec des lignes d’intervalle de confiance sur des échelles de 0 à 1. En laboratoire périphérique, la sensibilité va de 0,65 à 0,89 et la spécificité de 0,96 à 1,00 ; en laboratoire central, la sensibilité va de 0,57 à 1,00 et la spécificité est surtout de 0,86 à 1,00, avec un minimum de 0,70 (Wahid 2020).",
        "ru": "Двухпанельный лесовидный график TB-LAMP при туберкулёзе лёгких (ТЛ) в зависимости от уровня лаборатории: «периферическая лаборатория» (7 исследований, от Nliwasa 2016 до Wang 2019) и «центральная лаборатория» (19 исследований, от Spooner 2022 до Yadav 2017). В каждой строке приведены числа ИП, ЛП, ЛО и ИО с чувствительностью и специфичностью (95% ДИ), изображёнными синими квадратами с линиями доверительных интервалов на шкалах от 0 до 1. В периферических лабораториях чувствительность 0,65–0,89, специфичность 0,96–1,00; в центральных чувствительность 0,57–1,00, специфичность в основном 0,86–1,00, минимум 0,70 (Wahid 2020)."
      },
      "state": "draft"
    },
    {
      "id": "img-p234-1",
      "file": "images/img-p234-1.webp",
      "page": 234,
      "narratives": {
        "en": "Forest plot of TB-LAMP for pulmonary TB in high TB burden settings, 17 studies from Nakiyingi 2018 to Yadav 2017. Each row gives TP, FP, FN and TN counts with sensitivity and specificity (95% CI), plotted as blue squares with confidence-interval lines on 0–1 scales. Sensitivity ranges from 0.55 to 1.00 and specificity mostly from 0.86 to 1.00, with a low of 0.70 (Wahid 2020).",
        "ar": "مخطط غابي لاختبار TB-LAMP للسل الرئوي في البيئات المرتفعة العبء بالسل، يشمل 17 دراسة من Nakiyingi 2018 إلى Yadav 2017. يعرض كل صف أعداد الإيجابيات الحقيقية والإيجابيات الكاذبة والسلبيات الكاذبة والسلبيات الحقيقية مع الحساسية والنوعية (فاصل ثقة 95%)، مرسومة كمربعات زرقاء مع خطوط فواصل الثقة على مقياس من 0 إلى 1. تتراوح الحساسية بين 0.55 و1.00 والنوعية في الغالب بين 0.86 و1.00 وأدناها 0.70 (Wahid 2020).",
        "zh": "结核病高负担环境中TB-LAMP检测肺结核的森林图，共17项研究（从Nakiyingi 2018到Yadav 2017）。每行列出真阳性、假阳性、假阴性和真阴性数及灵敏度和特异度（95%置信区间），以蓝色方块和置信区间线绘于0–1刻度上。灵敏度介于0.55至1.00，特异度多为0.86至1.00，最低0.70（Wahid 2020）。",
        "es": "Diagrama de bosque de TB-LAMP para la TB pulmonar en entornos con alta carga de TB, 17 estudios de Nakiyingi 2018 a Yadav 2017. Cada fila presenta los recuentos de VP, FP, FN y VN con la sensibilidad y la especificidad (IC del 95%), representadas como cuadrados azules con líneas de intervalo de confianza en escalas de 0 a 1. La sensibilidad varía de 0,55 a 1,00 y la especificidad mayoritariamente de 0,86 a 1,00, con un mínimo de 0,70 (Wahid 2020).",
        "fr": "Graphique en forêt de TB-LAMP pour la TB pulmonaire dans les contextes à forte charge de TB, 17 études de Nakiyingi 2018 à Yadav 2017. Chaque ligne indique les nombres de VP, FP, FN et VN avec la sensibilité et la spécificité (IC à 95 %), représentées par des carrés bleus avec des lignes d’intervalle de confiance sur des échelles de 0 à 1. La sensibilité va de 0,55 à 1,00 et la spécificité surtout de 0,86 à 1,00, avec un minimum de 0,70 (Wahid 2020).",
        "ru": "Лесовидный график TB-LAMP при туберкулёзе лёгких в условиях высокого бремени ТБ, 17 исследований от Nakiyingi 2018 до Yadav 2017. В каждой строке приведены числа ИП, ЛП, ЛО и ИО с чувствительностью и специфичностью (95% ДИ), изображёнными синими квадратами с линиями доверительных интервалов на шкалах от 0 до 1. Чувствительность от 0,55 до 1,00, специфичность в основном от 0,86 до 1,00, минимум 0,70 (Wahid 2020)."
      },
      "state": "draft"
    },
    {
      "id": "img-p249-1",
      "file": "images/img-p249-1.webp",
      "page": 249,
      "narratives": {
        "en": "Risk of bias and applicability summary grid for 1 study on extrapulmonary TB (Promsena 2022). Rows list the studies; columns show four risk-of-bias domains (patient selection, index test, reference standard, flow and timing) and three applicability domains (patient selection, index test, reference standard), each rated high (red), unclear (yellow) or low (green). All domains are rated low except a high (red) applicability concern for patient selection.",
        "ar": "شبكة ملخّص لمخاطر التحيّز وقابلية التطبيق تشمل دراسة واحدة بشأن السل خارج الرئة (Promsena 2022). تسرد الصفوف الدراسات، وتعرض الأعمدة أربعة مجالات لمخاطر التحيّز (اختيار المرضى، والاختبار المؤشّر، والمعيار المرجعي، والتدفّق والتوقيت) وثلاثة مجالات لقابلية التطبيق (اختيار المرضى، والاختبار المؤشّر، والمعيار المرجعي)، ويُصنَّف كل منها مرتفعاً (أحمر) أو غير واضح (أصفر) أو منخفضاً (أخضر). جميع المجالات مصنّفة منخفضة باستثناء شاغل مرتفع (أحمر) بشأن قابلية تطبيق اختيار المرضى.",
        "zh": "肺外结核相关的（Promsena 2022）1项研究的偏倚风险和适用性汇总网格。行列出各项研究；列显示四个偏倚风险领域（患者选择、待评价试验、参考标准、流程和时间）和三个适用性领域（患者选择、待评价试验、参考标准），每项评为高（红色）、不清楚（黄色）或低（绿色）。除患者选择适用性评为高（红色）外，其余领域均为低。",
        "es": "Cuadrícula resumen del riesgo de sesgo y la aplicabilidad de 1 estudio sobre la TB extrapulmonar (Promsena 2022). Las filas enumeran los estudios; las columnas muestran cuatro dominios de riesgo de sesgo (selección de pacientes, prueba índice, patrón de referencia, flujo y cronología) y tres dominios de aplicabilidad (selección de pacientes, prueba índice, patrón de referencia), cada uno calificado como alto (rojo), incierto (amarillo) o bajo (verde). Todos los dominios se califican como bajo, salvo un problema alto (rojo) de aplicabilidad en la selección de pacientes.",
        "fr": "Grille récapitulative du risque de biais et de l’applicabilité pour 1 étude sur la TB extrapulmonaire (Promsena 2022). Les lignes listent les études ; les colonnes présentent quatre domaines de risque de biais (sélection des patients, test index, test de référence, flux et chronologie) et trois domaines d’applicabilité (sélection des patients, test index, test de référence), chacun jugé élevé (rouge), incertain (jaune) ou faible (vert). Tous les domaines sont jugés faibles, sauf une préoccupation élevée (rouge) d’applicabilité pour la sélection des patients.",
        "ru": "Сводная таблица риска систематической ошибки и применимости для 1 исследования по внелёгочному туберкулёзу (Promsena 2022). В строках перечислены исследования; в столбцах — четыре домена риска систематической ошибки (отбор пациентов, индексный тест, эталонный стандарт, ход и сроки исследования) и три домена применимости (отбор пациентов, индексный тест, эталонный стандарт), каждый оценён как высокий (красный), неясный (жёлтый) или низкий (зелёный). Все домены оценены как низкие, кроме высокой (красной) оценки применимости по отбору пациентов."
      },
      "state": "draft"
    },
    {
      "id": "img-p254-1",
      "file": "images/img-p254-1.webp",
      "page": 254,
      "narratives": {
        "en": "Six single-study forest plots (Danfack 2024) of TB-LAMP for pulmonary TB in children by HIV status and specimen. For children living with HIV (CLHIV), gastric aspirate, NPA and stool all show sensitivity 'Not estimable' and specificity 0.93–1.00. For HIV-negative children, sensitivity is 0.64 (gastric aspirate), 0.58 (NPA) and 1.00 (stool), with specificity 0.91–0.93.",
        "ar": "ستة مخططات غابية لدراسة واحدة (Danfack 2024) لاختبار TB-LAMP للسل الرئوي لدى الأطفال حسب حالة الإصابة بفيروس العوز المناعي البشري ونوع العيّنة. لدى الأطفال المتعايشين مع الفيروس، تُظهر رشافة المعدة ورشافة البلعوم الأنفي والبراز حساسية «غير قابلة للتقدير» ونوعية بين 0.93 و1.00. ولدى الأطفال غير المصابين، الحساسية 0.64 (رشافة المعدة) و0.58 (رشافة البلعوم الأنفي) و1.00 (البراز)، والنوعية بين 0.91 و0.93.",
        "zh": "六个单项研究（Danfack 2024）森林图，按艾滋病毒感染状况和标本类型显示TB-LAMP检测儿童肺结核的结果。对感染艾滋病毒的儿童，胃抽吸物、鼻咽抽吸物和粪便的灵敏度均为“不可估计”，特异度0.93–1.00。对艾滋病毒阴性儿童，灵敏度为0.64（胃抽吸物）、0.58（鼻咽抽吸物）和1.00（粪便），特异度0.91–0.93。",
        "es": "Seis diagramas de bosque de un solo estudio (Danfack 2024) de TB-LAMP para la TB pulmonar en niños según el estado serológico respecto del VIH y el tipo de muestra. En niños con el VIH, el aspirado gástrico, el aspirado nasofaríngeo y las heces muestran sensibilidad «No estimable» y especificidad de 0,93 a 1,00. En niños VIH-negativos, la sensibilidad es de 0,64 (aspirado gástrico), 0,58 (aspirado nasofaríngeo) y 1,00 (heces), con especificidad de 0,91 a 0,93.",
        "fr": "Six graphiques en forêt d’une seule étude (Danfack 2024) de TB-LAMP pour la TB pulmonaire chez l’enfant selon le statut VIH et le type d’échantillon. Chez les enfants vivant avec le VIH, l’aspiration gastrique, l’aspiration nasopharyngée et les selles présentent une sensibilité « Non estimable » et une spécificité de 0,93 à 1,00. Chez les enfants séronégatifs, la sensibilité est de 0,64 (aspiration gastrique), 0,58 (aspiration nasopharyngée) et 1,00 (selles), avec une spécificité de 0,91 à 0,93.",
        "ru": "Шесть лесовидных графиков по одному исследованию (Danfack 2024) для TB-LAMP при туберкулёзе лёгких у детей в зависимости от ВИЧ-статуса и типа образца. У детей, живущих с ВИЧ, для аспирата желудка, назофарингеального аспирата и кала чувствительность «Не поддаётся оценке», специфичность 0,93–1,00. У ВИЧ-отрицательных детей чувствительность 0,64 (аспират желудка), 0,58 (назофарингеальный аспират) и 1,00 (кал), специфичность 0,91–0,93."
      },
      "state": "draft"
    },
    {
      "id": "img-p262-1",
      "file": "images/img-p262-1.webp",
      "page": 262,
      "narratives": {
        "en": "Table listing TB diagnostic tests with acceptable specimen types and whether they detect rifampicin resistance. Xpert MTB/RIF accepts sputum, gastric fluid, nasopharyngeal aspirate, stool, CSF, lymph node aspirate or biopsy, pleural, peritoneal, pericardial and synovial fluid, urine and blood (yes); Xpert Ultra accepts sputum, gastric fluid, nasopharyngeal aspirate, stool, CSF and lymph node aspirate or biopsy (yes); Truenat MTB and MTB Plus accepts sputum (yes); TB-LAMP accepts sputum (no); LF-LAM accepts urine (no). Footnotes say blood is recommended for people living with HIV with disseminated TB and urine for children and adolescents living with HIV.",
        "ar": "جدول يسرد اختبارات تشخيص السل مع أنواع العيّنات المقبولة وما إذا كانت تكشف مقاومة الريفامبيسين. يقبل Xpert MTB/RIF البلغم وسائل المعدة ورشافة البلعوم الأنفي والبراز والسائل الدماغي الشوكي ورشافة العقدة اللمفاوية أو خزعتها والسوائل الجنبية والصفاقية والتأمورية والزليلية والبول والدم (نعم)؛ ويقبل Xpert Ultra البلغم وسائل المعدة ورشافة البلعوم الأنفي والبراز والسائل الدماغي الشوكي ورشافة العقدة اللمفاوية أو خزعتها (نعم)؛ ويقبل Truenat MTB وMTB Plus البلغم (نعم)؛ ويقبل TB-LAMP البلغم (لا)؛ ويقبل LF-LAM البول (لا). وتشير الحواشي إلى التوصية بعيّنة الدم للمتعايشين مع فيروس العوز المناعي البشري المصابين بالسل المنتشر، وبعيّنة البول للأطفال والمراهقين المتعايشين مع الفيروس.",
        "zh": "表格列出结核病诊断检测、可接受的标本类型及是否检测利福平耐药。Xpert MTB/RIF可用痰、胃液、鼻咽抽吸物、粪便、脑脊液、淋巴结抽吸物或活检、胸腔积液、腹腔积液、心包积液、滑膜液、尿液和血液（是）；Xpert Ultra可用痰、胃液、鼻咽抽吸物、粪便、脑脊液和淋巴结抽吸物或活检（是）；Truenat MTB和MTB Plus可用痰（是）；TB-LAMP可用痰（否）；LF-LAM可用尿液（否）。脚注说明建议对患播散性结核的艾滋病毒感染者使用血液标本，对感染艾滋病毒的儿童和青少年使用尿液。",
        "es": "Tabla que enumera pruebas diagnósticas de la TB con los tipos de muestra aceptables y si detectan resistencia a la rifampicina. Xpert MTB/RIF acepta esputo, líquido gástrico, aspirado nasofaríngeo, heces, LCR, aspirado o biopsia de ganglio linfático, líquido pleural, peritoneal, pericárdico y sinovial, orina y sangre (sí); Xpert Ultra acepta esputo, líquido gástrico, aspirado nasofaríngeo, heces, LCR y aspirado o biopsia de ganglio linfático (sí); Truenat MTB y MTB Plus acepta esputo (sí); TB-LAMP acepta esputo (no); LF-LAM acepta orina (no). Las notas indican que se recomienda la sangre en personas con el VIH con TB diseminada y la orina en niños y adolescentes con el VIH.",
        "fr": "Tableau listant des tests de diagnostic de la TB, les types d’échantillons acceptables et la détection ou non de la résistance à la rifampicine. Xpert MTB/RIF accepte expectorations, liquide gastrique, aspiration nasopharyngée, selles, LCR, aspiration ou biopsie ganglionnaire, liquides pleural, péritonéal, péricardique et synovial, urine et sang (oui) ; Xpert Ultra accepte expectorations, liquide gastrique, aspiration nasopharyngée, selles, LCR et aspiration ou biopsie ganglionnaire (oui) ; Truenat MTB et MTB Plus accepte les expectorations (oui) ; TB-LAMP accepte les expectorations (non) ; LF-LAM accepte l’urine (non). Les notes indiquent que le sang est recommandé chez les personnes vivant avec le VIH atteintes de TB disséminée et l’urine chez les enfants et adolescents vivant avec le VIH.",
        "ru": "Таблица с перечнем диагностических тестов на ТБ, допустимых типов образцов и выявления устойчивости к рифампицину. Xpert MTB/RIF: мокрота, желудочная жидкость, назофарингеальный аспират, кал, СМЖ, аспират или биоптат лимфоузла, плевральная, перитонеальная, перикардиальная и синовиальная жидкость, моча и кровь (да); Xpert Ultra: мокрота, желудочная жидкость, назофарингеальный аспират, кал, СМЖ и аспират или биоптат лимфоузла (да); Truenat MTB и MTB Plus: мокрота (да); TB-LAMP: мокрота (нет); LF-LAM: моча (нет). В сносках указано, что кровь рекомендуется для людей, живущих с ВИЧ, с диссеминированным ТБ, а моча — для детей и подростков, живущих с ВИЧ."
      },
      "state": "draft"
    },
    {
      "id": "img-p276-1",
      "file": "images/img-p276-1.webp",
      "page": 276,
      "narratives": {
        "en": "Two-panel risk of bias and applicability grid. Panel a lists 12 studies (Ainan 2021 to Wobudeya 2024) and panel b lists 7 studies (Chipinduro 2017 to Orikiriza 2021); columns cover risk-of-bias domains including patient selection, index test, reference standards (MRS/CRS or microbiological/composite) and flow and timing, plus three applicability domains. Cells are coloured low (green), high (red), unclear (yellow) or not applicable (grey); the composite reference standard column is red for most studies.",
        "ar": "شبكة من لوحتين لمخاطر التحيّز وقابلية التطبيق. تسرد اللوحة a اثنتي عشرة دراسة (من Ainan 2021 إلى Wobudeya 2024) وتسرد اللوحة b سبع دراسات (من Chipinduro 2017 إلى Orikiriza 2021)؛ وتغطي الأعمدة مجالات مخاطر التحيّز ومنها اختيار المرضى والاختبار المؤشّر والمعايير المرجعية (MRS/CRS أو الميكروبيولوجي/المركّب) والتدفّق والتوقيت، إضافة إلى ثلاثة مجالات لقابلية التطبيق. تُلوَّن الخلايا منخفضة (أخضر) أو مرتفعة (أحمر) أو غير واضحة (أصفر) أو غير منطبقة (رمادي)؛ وعمود المعيار المرجعي المركّب أحمر في معظم الدراسات.",
        "zh": "双面板偏倚风险和适用性网格。面板a列出12项研究（从Ainan 2021到Wobudeya 2024），面板b列出7项研究（从Chipinduro 2017到Orikiriza 2021）；列涵盖患者选择、待评价试验、参考标准（MRS/CRS或微生物学/复合参考标准）及流程和时间等偏倚风险领域，以及三个适用性领域。单元格以低（绿色）、高（红色）、不清楚（黄色）或不适用（灰色）着色；大多数研究的复合参考标准列为红色。",
        "es": "Cuadrícula de dos paneles de riesgo de sesgo y aplicabilidad. El panel a enumera 12 estudios (de Ainan 2021 a Wobudeya 2024) y el panel b 7 estudios (de Chipinduro 2017 a Orikiriza 2021); las columnas abarcan dominios de riesgo de sesgo como selección de pacientes, prueba índice, patrones de referencia (MRS/CRS o microbiológico/compuesto) y flujo y cronología, además de tres dominios de aplicabilidad. Las celdas se colorean como bajo (verde), alto (rojo), incierto (amarillo) o no aplicable (gris); la columna del patrón de referencia compuesto es roja en la mayoría de los estudios.",
        "fr": "Grille à deux panneaux du risque de biais et de l’applicabilité. Le panneau a liste 12 études (d’Ainan 2021 à Wobudeya 2024) et le panneau b 7 études (de Chipinduro 2017 à Orikiriza 2021) ; les colonnes couvrent des domaines de risque de biais dont la sélection des patients, le test index, les tests de référence (MRS/CRS ou microbiologique/composite) et le flux et la chronologie, ainsi que trois domaines d’applicabilité. Les cases sont colorées faible (vert), élevé (rouge), incertain (jaune) ou sans objet (gris) ; la colonne du test de référence composite est rouge pour la plupart des études.",
        "ru": "Двухпанельная таблица риска систематической ошибки и применимости. Панель a содержит 12 исследований (от Ainan 2021 до Wobudeya 2024), панель b — 7 исследований (от Chipinduro 2017 до Orikiriza 2021); столбцы охватывают домены риска ошибки, включая отбор пациентов, индексный тест, эталонные стандарты (MRS/CRS или микробиологический/комбинированный) и ход и сроки, а также три домена применимости. Ячейки окрашены как низкий (зелёный), высокий (красный), неясный (жёлтый) или неприменимо (серый); столбец комбинированного эталонного стандарта красный у большинства исследований."
      },
      "state": "draft"
    },
    {
      "id": "img-p278-1",
      "file": "images/img-p278-1.webp",
      "page": 278,
      "narratives": {
        "en": "Two-panel risk-of-bias grid with five domains: patient selection, index test, micro reference standard, comp reference standard, and flow and timing. Panel a covers 12 studies (Ainan 2021 to Wobudeya 2024) and panel b 7 studies (Chipinduro 2017 to Orikiriza 2021); cells are low (green, +), high (red, −), unclear (yellow, ?) or not applicable (grey, NA). Most cells are low, but the composite reference standard is rated high in nearly every study, with unclear ratings in Hanrahan 2018 (a) and Jaganath 2024 (b).",
        "ar": "شبكة مخاطر تحيّز من لوحتين بخمسة مجالات: اختيار المرضى، والاختبار المؤشّر، والمعيار المرجعي الميكروبيولوجي، والمعيار المرجعي المركّب، والتدفّق والتوقيت. تشمل اللوحة a اثنتي عشرة دراسة (من Ainan 2021 إلى Wobudeya 2024) واللوحة b سبع دراسات (من Chipinduro 2017 إلى Orikiriza 2021)؛ والخلايا منخفضة (أخضر، +) أو مرتفعة (أحمر، −) أو غير واضحة (أصفر، ?) أو غير منطبقة (رمادي، NA). معظم الخلايا منخفضة، لكن المعيار المرجعي المركّب مصنّف مرتفعاً في كل الدراسات تقريباً، مع تقييمين غير واضحين في Hanrahan 2018 (a) وJaganath 2024 (b).",
        "zh": "双面板偏倚风险网格，含五个领域：患者选择、待评价试验、微生物参考标准、复合参考标准、流程和时间。面板a涵盖12项研究（从Ainan 2021到Wobudeya 2024），面板b涵盖7项研究（从Chipinduro 2017到Orikiriza 2021）；单元格为低（绿色，+）、高（红色，−）、不清楚（黄色，?）或不适用（灰色，NA）。大多数单元格为低，但几乎每项研究的复合参考标准均评为高，Hanrahan 2018（a）和Jaganath 2024（b）为不清楚。",
        "es": "Cuadrícula de riesgo de sesgo de dos paneles con cinco dominios: selección de pacientes, prueba índice, patrón de referencia microbiológico, patrón de referencia compuesto y flujo y cronología. El panel a abarca 12 estudios (de Ainan 2021 a Wobudeya 2024) y el panel b 7 estudios (de Chipinduro 2017 a Orikiriza 2021); las celdas son bajo (verde, +), alto (rojo, −), incierto (amarillo, ?) o no aplicable (gris, NA). La mayoría son bajas, pero el patrón de referencia compuesto se califica como alto en casi todos los estudios, con calificaciones inciertas en Hanrahan 2018 (a) y Jaganath 2024 (b).",
        "fr": "Grille de risque de biais à deux panneaux comportant cinq domaines : sélection des patients, test index, test de référence microbiologique, test de référence composite, et flux et chronologie. Le panneau a couvre 12 études (d’Ainan 2021 à Wobudeya 2024) et le panneau b 7 études (de Chipinduro 2017 à Orikiriza 2021) ; les cases sont faible (vert, +), élevé (rouge, −), incertain (jaune, ?) ou sans objet (gris, NA). La plupart sont faibles, mais le test de référence composite est jugé élevé dans presque toutes les études, avec des jugements incertains pour Hanrahan 2018 (a) et Jaganath 2024 (b).",
        "ru": "Двухпанельная таблица риска систематической ошибки с пятью доменами: отбор пациентов, индексный тест, микробиологический эталонный стандарт, комбинированный эталонный стандарт, ход и сроки. Панель a охватывает 12 исследований (от Ainan 2021 до Wobudeya 2024), панель b — 7 исследований (от Chipinduro 2017 до Orikiriza 2021); ячейки: низкий (зелёный, +), высокий (красный, −), неясный (жёлтый, ?) или неприменимо (серый, NA). Большинство ячеек низкие, но комбинированный эталонный стандарт оценён как высокий почти во всех исследованиях, с неясными оценками у Hanrahan 2018 (a) и Jaganath 2024 (b)."
      },
      "state": "draft"
    },
    {
      "id": "img-p284-1",
      "file": "images/img-p284-1.webp",
      "page": 284,
      "narratives": {
        "en": "Forest plot, panel a, of 8 studies (Chishala 2024 to Orikiriza 2021) giving TP, FP, FN, TN, sensitivity and specificity (95% CI), with black squares and CI lines on 0–1 scales and a summary diamond. The summary estimate is sensitivity 0.80 (0.68–0.90) and specificity 0.93 (0.87–0.97).",
        "ar": "مخطط غابي، اللوحة a، لعدد 8 دراسات (من Chishala 2024 إلى Orikiriza 2021) يعرض الإيجابيات الحقيقية والإيجابيات الكاذبة والسلبيات الكاذبة والسلبيات الحقيقية والحساسية والنوعية (فاصل ثقة 95%)، بمربعات سوداء وخطوط فواصل الثقة على مقياس من 0 إلى 1 ومعيّن للتقدير الإجمالي. التقدير الإجمالي: الحساسية 0.80 (0.68–0.90) والنوعية 0.93 (0.87–0.97).",
        "zh": "森林图面板a，共8项研究（从Chishala 2024到Orikiriza 2021），列出真阳性、假阳性、假阴性、真阴性及灵敏度和特异度（95%置信区间），以黑色方块和置信区间线绘于0–1刻度上，并有汇总菱形。汇总估计：灵敏度0.80（0.68–0.90），特异度0.93（0.87–0.97）。",
        "es": "Diagrama de bosque, panel a, de 8 estudios (de Chishala 2024 a Orikiriza 2021) con VP, FP, FN, VN, sensibilidad y especificidad (IC del 95%), con cuadrados negros y líneas de IC en escalas de 0 a 1 y un rombo de estimación resumida. La estimación resumida es una sensibilidad de 0,80 (0,68–0,90) y una especificidad de 0,93 (0,87–0,97).",
        "fr": "Graphique en forêt, panneau a, de 8 études (de Chishala 2024 à Orikiriza 2021) indiquant VP, FP, FN, VN, sensibilité et spécificité (IC à 95 %), avec des carrés noirs et des lignes d’IC sur des échelles de 0 à 1 et un losange d’estimation globale. L’estimation globale est une sensibilité de 0,80 (0,68–0,90) et une spécificité de 0,93 (0,87–0,97).",
        "ru": "Лесовидный график, панель a, 8 исследований (от Chishala 2024 до Orikiriza 2021) с ИП, ЛП, ЛО, ИО, чувствительностью и специфичностью (95% ДИ), чёрными квадратами и линиями ДИ на шкалах от 0 до 1 и ромбом сводной оценки. Сводная оценка: чувствительность 0,80 (0,68–0,90), специфичность 0,93 (0,87–0,97)."
      },
      "state": "draft"
    },
    {
      "id": "img-p284-2",
      "file": "images/img-p284-2.webp",
      "page": 284,
      "narratives": {
        "en": "Forest plot, panel b, of 7 studies (Chipinduro 2017 to Orikiriza 2021) giving TP, FP, FN, TN, sensitivity and specificity (95% CI), with black squares and CI lines on 0–1 scales and a summary diamond. Hanrahan 2018 sensitivity is shown as NaN; the summary estimate is sensitivity 0.70 (0.51–0.85) and specificity 0.95 (0.92–0.98).",
        "ar": "مخطط غابي، اللوحة b، لعدد 7 دراسات (من Chipinduro 2017 إلى Orikiriza 2021) يعرض الإيجابيات الحقيقية والإيجابيات الكاذبة والسلبيات الكاذبة والسلبيات الحقيقية والحساسية والنوعية (فاصل ثقة 95%)، بمربعات سوداء وخطوط فواصل الثقة على مقياس من 0 إلى 1 ومعيّن للتقدير الإجمالي. تظهر حساسية Hanrahan 2018 بالقيمة NaN؛ والتقدير الإجمالي: الحساسية 0.70 (0.51–0.85) والنوعية 0.95 (0.92–0.98).",
        "zh": "森林图面板b，共7项研究（从Chipinduro 2017到Orikiriza 2021），列出真阳性、假阳性、假阴性、真阴性及灵敏度和特异度（95%置信区间），以黑色方块和置信区间线绘于0–1刻度上，并有汇总菱形。Hanrahan 2018的灵敏度显示为NaN；汇总估计：灵敏度0.70（0.51–0.85），特异度0.95（0.92–0.98）。",
        "es": "Diagrama de bosque, panel b, de 7 estudios (de Chipinduro 2017 a Orikiriza 2021) con VP, FP, FN, VN, sensibilidad y especificidad (IC del 95%), con cuadrados negros y líneas de IC en escalas de 0 a 1 y un rombo de estimación resumida. La sensibilidad de Hanrahan 2018 aparece como NaN; la estimación resumida es una sensibilidad de 0,70 (0,51–0,85) y una especificidad de 0,95 (0,92–0,98).",
        "fr": "Graphique en forêt, panneau b, de 7 études (de Chipinduro 2017 à Orikiriza 2021) indiquant VP, FP, FN, VN, sensibilité et spécificité (IC à 95 %), avec des carrés noirs et des lignes d’IC sur des échelles de 0 à 1 et un losange d’estimation globale. La sensibilité de Hanrahan 2018 apparaît comme NaN ; l’estimation globale est une sensibilité de 0,70 (0,51–0,85) et une spécificité de 0,95 (0,92–0,98).",
        "ru": "Лесовидный график, панель b, 7 исследований (от Chipinduro 2017 до Orikiriza 2021) с ИП, ЛП, ЛО, ИО, чувствительностью и специфичностью (95% ДИ), чёрными квадратами и линиями ДИ на шкалах от 0 до 1 и ромбом сводной оценки. Чувствительность Hanrahan 2018 указана как NaN; сводная оценка: чувствительность 0,70 (0,51–0,85), специфичность 0,95 (0,92–0,98)."
      },
      "state": "draft"
    },
    {
      "id": "img-p286-1",
      "file": "images/img-p286-1.webp",
      "page": 286,
      "narratives": {
        "en": "Forest plots of study-specific differences in sensitivity and specificity (parallel LC-aNAAT testing versus LC-aNAAT on respiratory samples alone) for 8 studies, Chishala 2024 to Orikiriza 2021, with total N and risk-of-bias ratings (P, I, R, FT) shown as coloured dots on the right. Differences in sensitivity range from 0 to 0.143 and in specificity from −0.08 to 0; the summary difference is 0.072 (95% CrI −0.0971 to 0.241) for sensitivity and −0.0162 (−0.0831 to 0.0396) for specificity.",
        "ar": "مخططات غابية للفروق الخاصة بكل دراسة في الحساسية والنوعية (الاختبار المتوازي بـ LC-aNAAT مقابل LC-aNAAT على العيّنات التنفّسية وحدها) لعدد 8 دراسات، من Chishala 2024 إلى Orikiriza 2021، مع العدد الإجمالي N وتقييمات مخاطر التحيّز (P وI وR وFT) في صورة نقاط ملوّنة على اليمين. تتراوح الفروق في الحساسية بين 0 و0.143 وفي النوعية بين −0.08 و0؛ والفرق الإجمالي 0.072 (فترة موثوقية 95%: −0.0971 إلى 0.241) للحساسية و−0.0162 (−0.0831 إلى 0.0396) للنوعية.",
        "zh": "8项研究（从Chishala 2024到Orikiriza 2021）灵敏度和特异度研究特异性差异的森林图（LC-aNAAT平行检测与仅对呼吸道样本进行LC-aNAAT相比），右侧显示总样本量N及以彩色圆点表示的偏倚风险评级（P、I、R、FT）。灵敏度差异介于0至0.143，特异度差异介于−0.08至0；汇总差异灵敏度为0.072（95%可信区间−0.0971至0.241），特异度为−0.0162（−0.0831至0.0396）。",
        "es": "Diagramas de bosque de las diferencias de sensibilidad y especificidad por estudio (pruebas LC-aNAAT en paralelo frente a LC-aNAAT solo en muestras respiratorias) en 8 estudios, de Chishala 2024 a Orikiriza 2021, con el N total y las calificaciones de riesgo de sesgo (P, I, R, FT) como puntos de colores a la derecha. Las diferencias de sensibilidad van de 0 a 0,143 y las de especificidad de −0,08 a 0; la diferencia resumida es de 0,072 (ICr del 95%: −0,0971 a 0,241) para la sensibilidad y de −0,0162 (−0,0831 a 0,0396) para la especificidad.",
        "fr": "Graphiques en forêt des différences de sensibilité et de spécificité par étude (tests LC-aNAAT en parallèle par rapport au LC-aNAAT sur échantillons respiratoires seuls) pour 8 études, de Chishala 2024 à Orikiriza 2021, avec le N total et les jugements de risque de biais (P, I, R, FT) sous forme de points colorés à droite. Les différences de sensibilité vont de 0 à 0,143 et celles de spécificité de −0,08 à 0 ; la différence globale est de 0,072 (ICr à 95 % : −0,0971 à 0,241) pour la sensibilité et de −0,0162 (−0,0831 à 0,0396) pour la spécificité.",
        "ru": "Лесовидные графики различий чувствительности и специфичности по исследованиям (параллельное тестирование LC-aNAAT по сравнению с LC-aNAAT только на респираторных образцах) для 8 исследований, от Chishala 2024 до Orikiriza 2021, с общим N и оценками риска систематической ошибки (P, I, R, FT) в виде цветных точек справа. Различия чувствительности составляют от 0 до 0,143, специфичности — от −0,08 до 0; сводное различие — 0,072 (95% ДостИ от −0,0971 до 0,241) для чувствительности и −0,0162 (от −0,0831 до 0,0396) для специфичности."
      },
      "state": "draft"
    },
    {
      "id": "img-p287-1",
      "file": "images/img-p287-1.webp",
      "page": 287,
      "narratives": {
        "en": "Forest plot of pooled sensitivity and specificity (95% CrI) for LC-aNAAT on stool, LC-aNAAT on respiratory samples and parallel testing (N 2145 with 173 TB cases by MRS; about 3579 with 1513 cases by CRS), shown separately by microbiological (MRS) and composite (CRS) reference standard, with differences (Δ parallel vs. resp, Δ parallel vs. stool). By MRS, sensitivity is 56.3% (stool), 72.6% (resp) and 79.9% (parallel), with specificity 93.4–97.5%; by CRS, sensitivity is 16.4%, 21.7% and 29.0%, with specificity 99.1–99.7%.",
        "ar": "مخطط غابي للحساسية والنوعية المجمّعتين (فترة موثوقية 95%) لاختبار LC-aNAAT على البراز وعلى العيّنات التنفّسية والاختبار المتوازي (العدد 2145 منهم 173 حالة سل وفق MRS؛ ونحو 3579 منهم 1513 حالة وفق CRS)، معروضة بشكل منفصل حسب المعيار المرجعي الميكروبيولوجي (MRS) والمركّب (CRS)، مع الفروق (Δ المتوازي مقابل التنفّسي، Δ المتوازي مقابل البراز). وفق MRS، الحساسية 56.3% (البراز) و72.6% (التنفّسي) و79.9% (المتوازي)، والنوعية بين 93.4% و97.5%؛ ووفق CRS، الحساسية 16.4% و21.7% و29.0%، والنوعية بين 99.1% و99.7%.",
        "zh": "粪便LC-aNAAT、呼吸道样本LC-aNAAT及平行检测（MRS：N=2145，结核病例173例；CRS：约3579例，病例1513例）的合并灵敏度和特异度（95%可信区间）森林图，按微生物参考标准（MRS）和复合参考标准（CRS）分别显示，并列出差异（Δ平行与呼吸道、Δ平行与粪便）。按MRS，灵敏度为56.3%（粪便）、72.6%（呼吸道）和79.9%（平行），特异度93.4%–97.5%；按CRS，灵敏度为16.4%、21.7%和29.0%，特异度99.1%–99.7%。",
        "es": "Diagrama de bosque de la sensibilidad y la especificidad agrupadas (ICr del 95%) de LC-aNAAT en heces, LC-aNAAT en muestras respiratorias y pruebas en paralelo (N 2145 con 173 casos de TB según MRS; unos 3579 con 1513 casos según CRS), por separado según el patrón de referencia microbiológico (MRS) y compuesto (CRS), con las diferencias (Δ paralelo vs. resp., Δ paralelo vs. heces). Según MRS, la sensibilidad es del 56,3% (heces), 72,6% (resp.) y 79,9% (paralelo), con especificidad del 93,4% al 97,5%; según CRS, la sensibilidad es del 16,4%, 21,7% y 29,0%, con especificidad del 99,1% al 99,7%.",
        "fr": "Graphique en forêt de la sensibilité et de la spécificité poolées (ICr à 95 %) du LC-aNAAT sur selles, du LC-aNAAT sur échantillons respiratoires et des tests en parallèle (N 2145 dont 173 cas de TB selon MRS ; environ 3579 dont 1513 cas selon CRS), présentées séparément selon le test de référence microbiologique (MRS) et composite (CRS), avec les différences (Δ parallèle vs resp., Δ parallèle vs selles). Selon MRS, la sensibilité est de 56,3 % (selles), 72,6 % (resp.) et 79,9 % (parallèle), avec une spécificité de 93,4 à 97,5 % ; selon CRS, la sensibilité est de 16,4 %, 21,7 % et 29,0 %, avec une spécificité de 99,1 à 99,7 %.",
        "ru": "Лесовидный график объединённых чувствительности и специфичности (95% ДостИ) для LC-aNAAT на кале, LC-aNAAT на респираторных образцах и параллельного тестирования (N 2145, из них 173 случая ТБ по MRS; около 3579, из них 1513 случаев по CRS), отдельно по микробиологическому (MRS) и комбинированному (CRS) эталонному стандарту, с различиями (Δ параллельное vs респ., Δ параллельное vs кал). По MRS чувствительность 56,3% (кал), 72,6% (респ.) и 79,9% (параллельное), специфичность 93,4–97,5%; по CRS чувствительность 16,4%, 21,7% и 29,0%, специфичность 99,1–99,7%."
      },
      "state": "draft"
    },
    {
      "id": "img-p287-2",
      "file": "images/img-p287-2.webp",
      "page": 287,
      "narratives": {
        "en": "Forest plot of pooled sensitivity and specificity (95% CrI) for LC-aNAAT on stool, LC-aNAAT on respiratory samples and parallel testing (N 697 with 44 TB cases by MRS; 718 with 287 cases by CRS), shown separately by microbiological (MRS) and composite (CRS) reference standard, with differences (Δ parallel vs. resp, Δ parallel vs. stool). By MRS, sensitivity is 60.8% (stool), 66.4% (resp) and 70.2% (parallel), with specificity 95.4–97.2%; by CRS, sensitivity is 12.6%, 14.6% and 16.1%, with specificity 95.5–98.3%.",
        "ar": "مخطط غابي للحساسية والنوعية المجمّعتين (فترة موثوقية 95%) لاختبار LC-aNAAT على البراز وعلى العيّنات التنفّسية والاختبار المتوازي (العدد 697 منهم 44 حالة سل وفق MRS؛ و718 منهم 287 حالة وفق CRS)، معروضة بشكل منفصل حسب المعيار المرجعي الميكروبيولوجي (MRS) والمركّب (CRS)، مع الفروق (Δ المتوازي مقابل التنفّسي، Δ المتوازي مقابل البراز). وفق MRS، الحساسية 60.8% (البراز) و66.4% (التنفّسي) و70.2% (المتوازي)، والنوعية بين 95.4% و97.2%؛ ووفق CRS، الحساسية 12.6% و14.6% و16.1%، والنوعية بين 95.5% و98.3%.",
        "zh": "粪便LC-aNAAT、呼吸道样本LC-aNAAT及平行检测（MRS：N=697，结核病例44例；CRS：718例，病例287例）的合并灵敏度和特异度（95%可信区间）森林图，按微生物参考标准（MRS）和复合参考标准（CRS）分别显示，并列出差异（Δ平行与呼吸道、Δ平行与粪便）。按MRS，灵敏度为60.8%（粪便）、66.4%（呼吸道）和70.2%（平行），特异度95.4%–97.2%；按CRS，灵敏度为12.6%、14.6%和16.1%，特异度95.5%–98.3%。",
        "es": "Diagrama de bosque de la sensibilidad y la especificidad agrupadas (ICr del 95%) de LC-aNAAT en heces, LC-aNAAT en muestras respiratorias y pruebas en paralelo (N 697 con 44 casos de TB según MRS; 718 con 287 casos según CRS), por separado según el patrón de referencia microbiológico (MRS) y compuesto (CRS), con las diferencias (Δ paralelo vs. resp., Δ paralelo vs. heces). Según MRS, la sensibilidad es del 60,8% (heces), 66,4% (resp.) y 70,2% (paralelo), con especificidad del 95,4% al 97,2%; según CRS, la sensibilidad es del 12,6%, 14,6% y 16,1%, con especificidad del 95,5% al 98,3%.",
        "fr": "Graphique en forêt de la sensibilité et de la spécificité poolées (ICr à 95 %) du LC-aNAAT sur selles, du LC-aNAAT sur échantillons respiratoires et des tests en parallèle (N 697 dont 44 cas de TB selon MRS ; 718 dont 287 cas selon CRS), présentées séparément selon le test de référence microbiologique (MRS) et composite (CRS), avec les différences (Δ parallèle vs resp., Δ parallèle vs selles). Selon MRS, la sensibilité est de 60,8 % (selles), 66,4 % (resp.) et 70,2 % (parallèle), avec une spécificité de 95,4 à 97,2 % ; selon CRS, la sensibilité est de 12,6 %, 14,6 % et 16,1 %, avec une spécificité de 95,5 à 98,3 %.",
        "ru": "Лесовидный график объединённых чувствительности и специфичности (95% ДостИ) для LC-aNAAT на кале, LC-aNAAT на респираторных образцах и параллельного тестирования (N 697, из них 44 случая ТБ по MRS; 718, из них 287 случаев по CRS), отдельно по микробиологическому (MRS) и комбинированному (CRS) эталонному стандарту, с различиями (Δ параллельное vs респ., Δ параллельное vs кал). По MRS чувствительность 60,8% (кал), 66,4% (респ.) и 70,2% (параллельное), специфичность 95,4–97,2%; по CRS чувствительность 12,6%, 14,6% и 16,1%, специфичность 95,5–98,3%."
      },
      "state": "draft"
    },
    {
      "id": "img-p289-1",
      "file": "images/img-p289-1.webp",
      "page": 289,
      "narratives": {
        "en": "Forest plots of study-specific differences in sensitivity and specificity (parallel LC-aNAAT testing versus LC-aNAAT on stool alone) for 8 studies, Chishala 2024 to Orikiriza 2021, with total N and risk-of-bias ratings (P, I, R, FT) shown as coloured dots on the right. Sensitivity gains range from 0.067 to 1 (Hanrahan 2018) and specificity differences from −0.13 to 0; the summary difference is 0.2349 (95% CrI 0.0559 to 0.403) for sensitivity and −0.0405 (−0.105 to 0.004) for specificity.",
        "ar": "مخططات غابية للفروق الخاصة بكل دراسة في الحساسية والنوعية (الاختبار المتوازي بـ LC-aNAAT مقابل LC-aNAAT على البراز وحده) لعدد 8 دراسات، من Chishala 2024 إلى Orikiriza 2021، مع العدد الإجمالي N وتقييمات مخاطر التحيّز (P وI وR وFT) في صورة نقاط ملوّنة على اليمين. تتراوح الزيادات في الحساسية بين 0.067 و1 (Hanrahan 2018) والفروق في النوعية بين −0.13 و0؛ والفرق الإجمالي 0.2349 (فترة موثوقية 95%: 0.0559 إلى 0.403) للحساسية و−0.0405 (−0.105 إلى 0.004) للنوعية.",
        "zh": "8项研究（从Chishala 2024到Orikiriza 2021）灵敏度和特异度研究特异性差异的森林图（LC-aNAAT平行检测与仅对粪便进行LC-aNAAT相比），右侧显示总样本量N及以彩色圆点表示的偏倚风险评级（P、I、R、FT）。灵敏度增益介于0.067至1（Hanrahan 2018），特异度差异介于−0.13至0；汇总差异灵敏度为0.2349（95%可信区间0.0559至0.403），特异度为−0.0405（−0.105至0.004）。",
        "es": "Diagramas de bosque de las diferencias de sensibilidad y especificidad por estudio (pruebas LC-aNAAT en paralelo frente a LC-aNAAT solo en heces) en 8 estudios, de Chishala 2024 a Orikiriza 2021, con el N total y las calificaciones de riesgo de sesgo (P, I, R, FT) como puntos de colores a la derecha. Las ganancias de sensibilidad van de 0,067 a 1 (Hanrahan 2018) y las diferencias de especificidad de −0,13 a 0; la diferencia resumida es de 0,2349 (ICr del 95%: 0,0559 a 0,403) para la sensibilidad y de −0,0405 (−0,105 a 0,004) para la especificidad.",
        "fr": "Graphiques en forêt des différences de sensibilité et de spécificité par étude (tests LC-aNAAT en parallèle par rapport au LC-aNAAT sur selles seules) pour 8 études, de Chishala 2024 à Orikiriza 2021, avec le N total et les jugements de risque de biais (P, I, R, FT) sous forme de points colorés à droite. Les gains de sensibilité vont de 0,067 à 1 (Hanrahan 2018) et les différences de spécificité de −0,13 à 0 ; la différence globale est de 0,2349 (ICr à 95 % : 0,0559 à 0,403) pour la sensibilité et de −0,0405 (−0,105 à 0,004) pour la spécificité.",
        "ru": "Лесовидные графики различий чувствительности и специфичности по исследованиям (параллельное тестирование LC-aNAAT по сравнению с LC-aNAAT только на кале) для 8 исследований, от Chishala 2024 до Orikiriza 2021, с общим N и оценками риска систематической ошибки (P, I, R, FT) в виде цветных точек справа. Прирост чувствительности составляет от 0,067 до 1 (Hanrahan 2018), различия специфичности — от −0,13 до 0; сводное различие — 0,2349 (95% ДостИ от 0,0559 до 0,403) для чувствительности и −0,0405 (от −0,105 до 0,004) для специфичности."
      },
      "state": "draft"
    },
    {
      "id": "img-p291-1",
      "file": "images/img-p291-1.webp",
      "page": 291,
      "narratives": {
        "en": "Forest plot, panel a, of 11 studies (Ainan 2021 to Wobudeya 2024) giving TP, FP, FN, TN, sensitivity and specificity (95% CI), with black squares and CI lines on 0–1 scales and a summary diamond. Sensitivity is generally low (0.05–0.88) and specificity high (0.77–1.00); the summary estimate is sensitivity 0.29 (0.17–0.45) and specificity 0.99 (0.96–1.00).",
        "ar": "مخطط غابي، اللوحة a، لعدد 11 دراسات (من Ainan 2021 إلى Wobudeya 2024) يعرض الإيجابيات الحقيقية والإيجابيات الكاذبة والسلبيات الكاذبة والسلبيات الحقيقية والحساسية والنوعية (فاصل ثقة 95%)، بمربعات سوداء وخطوط فواصل الثقة على مقياس من 0 إلى 1 ومعيّن للتقدير الإجمالي. الحساسية منخفضة عموماً (0.05–0.88) والنوعية مرتفعة (0.77–1.00)؛ والتقدير الإجمالي: الحساسية 0.29 (0.17–0.45) والنوعية 0.99 (0.96–1.00).",
        "zh": "森林图面板a，共11项研究（从Ainan 2021到Wobudeya 2024），列出真阳性、假阳性、假阴性、真阴性及灵敏度和特异度（95%置信区间），以黑色方块和置信区间线绘于0–1刻度上，并有汇总菱形。灵敏度普遍较低（0.05–0.88），特异度较高（0.77–1.00）；汇总估计：灵敏度0.29（0.17–0.45），特异度0.99（0.96–1.00）。",
        "es": "Diagrama de bosque, panel a, de 11 estudios (de Ainan 2021 a Wobudeya 2024) con VP, FP, FN, VN, sensibilidad y especificidad (IC del 95%), con cuadrados negros y líneas de IC en escalas de 0 a 1 y un rombo de estimación resumida. La sensibilidad es en general baja (0,05–0,88) y la especificidad alta (0,77–1,00); la estimación resumida es una sensibilidad de 0,29 (0,17–0,45) y una especificidad de 0,99 (0,96–1,00).",
        "fr": "Graphique en forêt, panneau a, de 11 études (de Ainan 2021 à Wobudeya 2024) indiquant VP, FP, FN, VN, sensibilité et spécificité (IC à 95 %), avec des carrés noirs et des lignes d’IC sur des échelles de 0 à 1 et un losange d’estimation globale. La sensibilité est généralement faible (0,05–0,88) et la spécificité élevée (0,77–1,00) ; l’estimation globale est une sensibilité de 0,29 (0,17–0,45) et une spécificité de 0,99 (0,96–1,00).",
        "ru": "Лесовидный график, панель a, 11 исследований (от Ainan 2021 до Wobudeya 2024) с ИП, ЛП, ЛО, ИО, чувствительностью и специфичностью (95% ДИ), чёрными квадратами и линиями ДИ на шкалах от 0 до 1 и ромбом сводной оценки. Чувствительность в целом низкая (0,05–0,88), специфичность высокая (0,77–1,00); сводная оценка: чувствительность 0,29 (0,17–0,45), специфичность 0,99 (0,96–1,00)."
      },
      "state": "draft"
    },
    {
      "id": "img-p291-2",
      "file": "images/img-p291-2.webp",
      "page": 291,
      "narratives": {
        "en": "Forest plot, panel b, of 7 studies (Chipinduro 2017 to Orikiriza 2021) giving TP, FP, FN, TN, sensitivity and specificity (95% CI), with black squares and CI lines on 0–1 scales and a summary diamond. Sensitivity ranges from 0.00 to 1.00 and specificity from 0.79 to 1.00; the summary estimate is sensitivity 0.16 (0.08–0.31) and specificity 0.95 (0.90–0.98).",
        "ar": "مخطط غابي، اللوحة b، لعدد 7 دراسات (من Chipinduro 2017 إلى Orikiriza 2021) يعرض الإيجابيات الحقيقية والإيجابيات الكاذبة والسلبيات الكاذبة والسلبيات الحقيقية والحساسية والنوعية (فاصل ثقة 95%)، بمربعات سوداء وخطوط فواصل الثقة على مقياس من 0 إلى 1 ومعيّن للتقدير الإجمالي. تتراوح الحساسية بين 0.00 و1.00 والنوعية بين 0.79 و1.00؛ والتقدير الإجمالي: الحساسية 0.16 (0.08–0.31) والنوعية 0.95 (0.90–0.98).",
        "zh": "森林图面板b，共7项研究（从Chipinduro 2017到Orikiriza 2021），列出真阳性、假阳性、假阴性、真阴性及灵敏度和特异度（95%置信区间），以黑色方块和置信区间线绘于0–1刻度上，并有汇总菱形。灵敏度介于0.00至1.00，特异度介于0.79至1.00；汇总估计：灵敏度0.16（0.08–0.31），特异度0.95（0.90–0.98）。",
        "es": "Diagrama de bosque, panel b, de 7 estudios (de Chipinduro 2017 a Orikiriza 2021) con VP, FP, FN, VN, sensibilidad y especificidad (IC del 95%), con cuadrados negros y líneas de IC en escalas de 0 a 1 y un rombo de estimación resumida. La sensibilidad varía de 0,00 a 1,00 y la especificidad de 0,79 a 1,00; la estimación resumida es una sensibilidad de 0,16 (0,08–0,31) y una especificidad de 0,95 (0,90–0,98).",
        "fr": "Graphique en forêt, panneau b, de 7 études (de Chipinduro 2017 à Orikiriza 2021) indiquant VP, FP, FN, VN, sensibilité et spécificité (IC à 95 %), avec des carrés noirs et des lignes d’IC sur des échelles de 0 à 1 et un losange d’estimation globale. La sensibilité va de 0,00 à 1,00 et la spécificité de 0,79 à 1,00 ; l’estimation globale est une sensibilité de 0,16 (0,08–0,31) et une spécificité de 0,95 (0,90–0,98).",
        "ru": "Лесовидный график, панель b, 7 исследований (от Chipinduro 2017 до Orikiriza 2021) с ИП, ЛП, ЛО, ИО, чувствительностью и специфичностью (95% ДИ), чёрными квадратами и линиями ДИ на шкалах от 0 до 1 и ромбом сводной оценки. Чувствительность от 0,00 до 1,00, специфичность от 0,79 до 1,00; сводная оценка: чувствительность 0,16 (0,08–0,31), специфичность 0,95 (0,90–0,98)."
      },
      "state": "draft"
    },
    {
      "id": "img-p293-1",
      "file": "images/img-p293-1.webp",
      "page": 293,
      "narratives": {
        "en": "Forest plots of study-specific differences in sensitivity and specificity (parallel LC-aNAAT testing versus LC-aNAAT on respiratory samples alone) for 11 studies, Ainan 2021 to Wobudeya 2024, with total N and risk-of-bias ratings (P, I, R, FT) shown as coloured dots on the right. Sensitivity differences range from 0 to 0.36 (Kabir 2021) and specificity differences from −0.06 to 0; the summary difference is 0.072 (95% CrI −0.0967 to 0.253) for sensitivity and −0.0057 (−0.0356 to 0.0121) for specificity. The reference-standard (R) column is red for most studies.",
        "ar": "مخططات غابية للفروق الخاصة بكل دراسة في الحساسية والنوعية (الاختبار المتوازي بـ LC-aNAAT مقابل LC-aNAAT على العيّنات التنفّسية وحدها) لعدد 11 دراسات، من Ainan 2021 إلى Wobudeya 2024، مع العدد الإجمالي N وتقييمات مخاطر التحيّز (P وI وR وFT) في صورة نقاط ملوّنة على اليمين. تتراوح الفروق في الحساسية بين 0 و0.36 (Kabir 2021) وفي النوعية بين −0.06 و0؛ والفرق الإجمالي 0.072 (فترة موثوقية 95%: −0.0967 إلى 0.253) للحساسية و−0.0057 (−0.0356 إلى 0.0121) للنوعية. وعمود المعيار المرجعي (R) أحمر في معظم الدراسات.",
        "zh": "11项研究（从Ainan 2021到Wobudeya 2024）灵敏度和特异度研究特异性差异的森林图（LC-aNAAT平行检测与仅对呼吸道样本进行LC-aNAAT相比），右侧显示总样本量N及以彩色圆点表示的偏倚风险评级（P、I、R、FT）。灵敏度差异介于0至0.36（Kabir 2021），特异度差异介于−0.06至0；汇总差异灵敏度为0.072（95%可信区间−0.0967至0.253），特异度为−0.0057（−0.0356至0.0121）。大多数研究的参考标准（R）列为红色。",
        "es": "Diagramas de bosque de las diferencias de sensibilidad y especificidad por estudio (pruebas LC-aNAAT en paralelo frente a LC-aNAAT solo en muestras respiratorias) en 11 estudios, de Ainan 2021 a Wobudeya 2024, con el N total y las calificaciones de riesgo de sesgo (P, I, R, FT) como puntos de colores a la derecha. Las diferencias de sensibilidad van de 0 a 0,36 (Kabir 2021) y las de especificidad de −0,06 a 0; la diferencia resumida es de 0,072 (ICr del 95%: −0,0967 a 0,253) para la sensibilidad y de −0,0057 (−0,0356 a 0,0121) para la especificidad. La columna del patrón de referencia (R) es roja en la mayoría de los estudios.",
        "fr": "Graphiques en forêt des différences de sensibilité et de spécificité par étude (tests LC-aNAAT en parallèle par rapport au LC-aNAAT sur échantillons respiratoires seuls) pour 11 études, de Ainan 2021 à Wobudeya 2024, avec le N total et les jugements de risque de biais (P, I, R, FT) sous forme de points colorés à droite. Les différences de sensibilité vont de 0 à 0,36 (Kabir 2021) et celles de spécificité de −0,06 à 0 ; la différence globale est de 0,072 (ICr à 95 % : −0,0967 à 0,253) pour la sensibilité et de −0,0057 (−0,0356 à 0,0121) pour la spécificité. La colonne du test de référence (R) est rouge pour la plupart des études.",
        "ru": "Лесовидные графики различий чувствительности и специфичности по исследованиям (параллельное тестирование LC-aNAAT по сравнению с LC-aNAAT только на респираторных образцах) для 11 исследований, от Ainan 2021 до Wobudeya 2024, с общим N и оценками риска систематической ошибки (P, I, R, FT) в виде цветных точек справа. Различия чувствительности от 0 до 0,36 (Kabir 2021), специфичности — от −0,06 до 0; сводное различие — 0,072 (95% ДостИ от −0,0967 до 0,253) для чувствительности и −0,0057 (от −0,0356 до 0,0121) для специфичности. Столбец эталонного стандарта (R) красный у большинства исследований."
      },
      "state": "draft"
    },
    {
      "id": "img-p295-1",
      "file": "images/img-p295-1.webp",
      "page": 295,
      "narratives": {
        "en": "Forest plots of study-specific differences in sensitivity and specificity (parallel LC-aNAAT testing versus LC-aNAAT on stool alone) for 11 studies, Ainan 2021 to Wobudeya 2024, with total N and risk-of-bias ratings (P, I, R, FT) shown as coloured dots on the right. Sensitivity differences range from 0.041 to 0.318 and specificity differences are mostly 0 (−0.19 for Jaganath); the summary difference is 0.1237 (95% CrI −0.046 to 0.300) for sensitivity and −0.0016 (−0.032 to 0.014) for specificity.",
        "ar": "مخططات غابية للفروق الخاصة بكل دراسة في الحساسية والنوعية (الاختبار المتوازي بـ LC-aNAAT مقابل LC-aNAAT على البراز وحده) لعدد 11 دراسات، من Ainan 2021 إلى Wobudeya 2024، مع العدد الإجمالي N وتقييمات مخاطر التحيّز (P وI وR وFT) في صورة نقاط ملوّنة على اليمين. تتراوح الفروق في الحساسية بين 0.041 و0.318 والفروق في النوعية صفر في الغالب (−0.19 في Jaganath)؛ والفرق الإجمالي 0.1237 (فترة موثوقية 95%: −0.046 إلى 0.300) للحساسية و−0.0016 (−0.032 إلى 0.014) للنوعية.",
        "zh": "11项研究（从Ainan 2021到Wobudeya 2024）灵敏度和特异度研究特异性差异的森林图（LC-aNAAT平行检测与仅对粪便进行LC-aNAAT相比），右侧显示总样本量N及以彩色圆点表示的偏倚风险评级（P、I、R、FT）。灵敏度差异介于0.041至0.318，特异度差异大多为0（Jaganath为−0.19）；汇总差异灵敏度为0.1237（95%可信区间−0.046至0.300），特异度为−0.0016（−0.032至0.014）。",
        "es": "Diagramas de bosque de las diferencias de sensibilidad y especificidad por estudio (pruebas LC-aNAAT en paralelo frente a LC-aNAAT solo en heces) en 11 estudios, de Ainan 2021 a Wobudeya 2024, con el N total y las calificaciones de riesgo de sesgo (P, I, R, FT) como puntos de colores a la derecha. Las diferencias de sensibilidad van de 0,041 a 0,318 y las de especificidad son mayoritariamente 0 (−0,19 en Jaganath); la diferencia resumida es de 0,1237 (ICr del 95%: −0,046 a 0,300) para la sensibilidad y de −0,0016 (−0,032 a 0,014) para la especificidad.",
        "fr": "Graphiques en forêt des différences de sensibilité et de spécificité par étude (tests LC-aNAAT en parallèle par rapport au LC-aNAAT sur selles seules) pour 11 études, de Ainan 2021 à Wobudeya 2024, avec le N total et les jugements de risque de biais (P, I, R, FT) sous forme de points colorés à droite. Les différences de sensibilité vont de 0,041 à 0,318 et celles de spécificité sont surtout nulles (−0,19 pour Jaganath) ; la différence globale est de 0,1237 (ICr à 95 % : −0,046 à 0,300) pour la sensibilité et de −0,0016 (−0,032 à 0,014) pour la spécificité.",
        "ru": "Лесовидные графики различий чувствительности и специфичности по исследованиям (параллельное тестирование LC-aNAAT по сравнению с LC-aNAAT только на кале) для 11 исследований, от Ainan 2021 до Wobudeya 2024, с общим N и оценками риска систематической ошибки (P, I, R, FT) в виде цветных точек справа. Различия чувствительности от 0,041 до 0,318, специфичности — в основном 0 (−0,19 у Jaganath); сводное различие — 0,1237 (95% ДостИ от −0,046 до 0,300) для чувствительности и −0,0016 (от −0,032 до 0,014) для специфичности."
      },
      "state": "draft"
    },
    {
      "id": "img-p298-1",
      "file": "images/img-p298-1.webp",
      "page": 298,
      "narratives": {
        "en": "Forest plot of 6 studies (Chipinduro 2017 to Orikiriza 2021) giving TP, FP, FN, TN, sensitivity and specificity (95% CI), with black squares and CI lines on 0–1 scales and a summary diamond. Hanrahan 2018 sensitivity is NaN; other sensitivities range 0.64–0.89 and specificities 0.63–0.92; the summary estimate is sensitivity 0.78 (0.60–0.90) and specificity 0.84 (0.74–0.90).",
        "ar": "مخطط غابي لعدد 6 دراسات (من Chipinduro 2017 إلى Orikiriza 2021) يعرض الإيجابيات الحقيقية والإيجابيات الكاذبة والسلبيات الكاذبة والسلبيات الحقيقية والحساسية والنوعية (فاصل ثقة 95%)، بمربعات سوداء وخطوط فواصل الثقة على مقياس من 0 إلى 1 ومعيّن للتقدير الإجمالي. حساسية Hanrahan 2018 هي NaN؛ وتتراوح الحساسيات الأخرى بين 0.64 و0.89 والنوعيات بين 0.63 و0.92؛ والتقدير الإجمالي: الحساسية 0.78 (0.60–0.90) والنوعية 0.84 (0.74–0.90).",
        "zh": "森林图，共6项研究（从Chipinduro 2017到Orikiriza 2021），列出真阳性、假阳性、假阴性、真阴性及灵敏度和特异度（95%置信区间），以黑色方块和置信区间线绘于0–1刻度上，并有汇总菱形。Hanrahan 2018的灵敏度为NaN；其余灵敏度介于0.64–0.89，特异度介于0.63–0.92；汇总估计：灵敏度0.78（0.60–0.90），特异度0.84（0.74–0.90）。",
        "es": "Diagrama de bosque de 6 estudios (de Chipinduro 2017 a Orikiriza 2021) con VP, FP, FN, VN, sensibilidad y especificidad (IC del 95%), con cuadrados negros y líneas de IC en escalas de 0 a 1 y un rombo de estimación resumida. La sensibilidad de Hanrahan 2018 es NaN; las demás sensibilidades van de 0,64 a 0,89 y las especificidades de 0,63 a 0,92; la estimación resumida es una sensibilidad de 0,78 (0,60–0,90) y una especificidad de 0,84 (0,74–0,90).",
        "fr": "Graphique en forêt de 6 études (de Chipinduro 2017 à Orikiriza 2021) indiquant VP, FP, FN, VN, sensibilité et spécificité (IC à 95 %), avec des carrés noirs et des lignes d’IC sur des échelles de 0 à 1 et un losange d’estimation globale. La sensibilité de Hanrahan 2018 est NaN ; les autres sensibilités vont de 0,64 à 0,89 et les spécificités de 0,63 à 0,92 ; l’estimation globale est une sensibilité de 0,78 (0,60–0,90) et une spécificité de 0,84 (0,74–0,90).",
        "ru": "Лесовидный график 6 исследований (от Chipinduro 2017 до Orikiriza 2021) с ИП, ЛП, ЛО, ИО, чувствительностью и специфичностью (95% ДИ), чёрными квадратами и линиями ДИ на шкалах от 0 до 1 и ромбом сводной оценки. Чувствительность Hanrahan 2018 — NaN; остальные значения чувствительности 0,64–0,89, специфичности 0,63–0,92; сводная оценка: чувствительность 0,78 (0,60–0,90), специфичность 0,84 (0,74–0,90)."
      },
      "state": "draft"
    },
    {
      "id": "img-p299-1",
      "file": "images/img-p299-1.webp",
      "page": 299,
      "narratives": {
        "en": "Forest plots of study-specific differences in sensitivity and specificity (parallel LC-aNAAT test plus LF-LAM versus parallel LC-aNAAT test) for 6 studies, Chipinduro 2017 to Orikiriza 2021, with total N and risk-of-bias ratings (P, I, R, FT) shown as coloured dots on the right. Sensitivity differences range from 0 to 0.5 (Hanrahan 2018 NaN) and specificity differences from −0.28 to −0.02; the summary difference is 0.0816 (95% CrI −0.1482 to 0.3123) for sensitivity and −0.1142 (−0.2172 to −0.0368) for specificity.",
        "ar": "مخططات غابية للفروق الخاصة بكل دراسة في الحساسية والنوعية (اختبار LC-aNAAT المتوازي مع LF-LAM مقابل اختبار LC-aNAAT المتوازي) لعدد 6 دراسات، من Chipinduro 2017 إلى Orikiriza 2021، مع العدد الإجمالي N وتقييمات مخاطر التحيّز (P وI وR وFT) في صورة نقاط ملوّنة على اليمين. تتراوح الفروق في الحساسية بين 0 و0.5 (Hanrahan 2018 بقيمة NaN) وفي النوعية بين −0.28 و−0.02؛ والفرق الإجمالي 0.0816 (فترة موثوقية 95%: −0.1482 إلى 0.3123) للحساسية و−0.1142 (−0.2172 إلى −0.0368) للنوعية.",
        "zh": "6项研究（从Chipinduro 2017到Orikiriza 2021）灵敏度和特异度研究特异性差异的森林图（LC-aNAAT平行检测加LF-LAM与LC-aNAAT平行检测相比），右侧显示总样本量N及以彩色圆点表示的偏倚风险评级（P、I、R、FT）。灵敏度差异介于0至0.5（Hanrahan 2018为NaN），特异度差异介于−0.28至−0.02；汇总差异灵敏度为0.0816（95%可信区间−0.1482至0.3123），特异度为−0.1142（−0.2172至−0.0368）。",
        "es": "Diagramas de bosque de las diferencias de sensibilidad y especificidad por estudio (prueba LC-aNAAT en paralelo más LF-LAM frente a prueba LC-aNAAT en paralelo) en 6 estudios, de Chipinduro 2017 a Orikiriza 2021, con el N total y las calificaciones de riesgo de sesgo (P, I, R, FT) como puntos de colores a la derecha. Las diferencias de sensibilidad van de 0 a 0,5 (Hanrahan 2018 NaN) y las de especificidad de −0,28 a −0,02; la diferencia resumida es de 0,0816 (ICr del 95%: −0,1482 a 0,3123) para la sensibilidad y de −0,1142 (−0,2172 a −0,0368) para la especificidad.",
        "fr": "Graphiques en forêt des différences de sensibilité et de spécificité par étude (test LC-aNAAT en parallèle plus LF-LAM par rapport au test LC-aNAAT en parallèle) pour 6 études, de Chipinduro 2017 à Orikiriza 2021, avec le N total et les jugements de risque de biais (P, I, R, FT) sous forme de points colorés à droite. Les différences de sensibilité vont de 0 à 0,5 (Hanrahan 2018 NaN) et celles de spécificité de −0,28 à −0,02 ; la différence globale est de 0,0816 (ICr à 95 % : −0,1482 à 0,3123) pour la sensibilité et de −0,1142 (−0,2172 à −0,0368) pour la spécificité.",
        "ru": "Лесовидные графики различий чувствительности и специфичности по исследованиям (параллельный тест LC-aNAAT плюс LF-LAM по сравнению с параллельным тестом LC-aNAAT) для 6 исследований, от Chipinduro 2017 до Orikiriza 2021, с общим N и оценками риска систематической ошибки (P, I, R, FT) в виде цветных точек справа. Различия чувствительности от 0 до 0,5 (у Hanrahan 2018 — NaN), специфичности — от −0,28 до −0,02; сводное различие — 0,0816 (95% ДостИ от −0,1482 до 0,3123) для чувствительности и −0,1142 (от −0,2172 до −0,0368) для специфичности."
      },
      "state": "draft"
    },
    {
      "id": "img-p300-1",
      "file": "images/img-p300-1.webp",
      "page": 300,
      "narratives": {
        "en": "Forest plot of pooled sensitivity and specificity (95% CrI) for LF-LAM, combined LC-aNAATs and parallel testing, by microbiological (MRS; N 653, 43 TB cases) and composite (CRS; N 674, 286 cases) reference standard, with differences for parallel testing. By MRS, sensitivity is 27.4% (LF-LAM), 69.3% (combined LC-aNAATs) and 77.6% (parallel), with specificity 88.2%, 95.4% and 83.9%; by CRS, sensitivity is 17.7%, 14.8% and 30%, with specificity 88.7%, 95.5% and 83.3%.",
        "ar": "مخطط غابي للحساسية والنوعية المجمّعتين (فترة موثوقية 95%) لاختبار LF-LAM واختبارات LC-aNAAT المجمّعة والاختبار المتوازي، حسب المعيار المرجعي الميكروبيولوجي (MRS؛ العدد 653، و43 حالة سل) والمركّب (CRS؛ العدد 674، و286 حالة)، مع فروق الاختبار المتوازي. وفق MRS، الحساسية 27.4% (LF-LAM) و69.3% (LC-aNAAT المجمّعة) و77.6% (المتوازي)، والنوعية 88.2% و95.4% و83.9%؛ ووفق CRS، الحساسية 17.7% و14.8% و30%، والنوعية 88.7% و95.5% و83.3%.",
        "zh": "LF-LAM、联合LC-aNAAT及平行检测的合并灵敏度和特异度（95%可信区间）森林图，按微生物参考标准（MRS；N=653，结核病例43例）和复合参考标准（CRS；N=674，病例286例）分列，并显示平行检测的差异。按MRS，灵敏度为27.4%（LF-LAM）、69.3%（联合LC-aNAAT）和77.6%（平行），特异度为88.2%、95.4%和83.9%；按CRS，灵敏度为17.7%、14.8%和30%，特异度为88.7%、95.5%和83.3%。",
        "es": "Diagrama de bosque de la sensibilidad y la especificidad agrupadas (ICr del 95%) de LF-LAM, LC-aNAAT combinadas y pruebas en paralelo, según el patrón de referencia microbiológico (MRS; N 653, 43 casos de TB) y compuesto (CRS; N 674, 286 casos), con las diferencias de las pruebas en paralelo. Según MRS, la sensibilidad es del 27,4% (LF-LAM), 69,3% (LC-aNAAT combinadas) y 77,6% (paralelo), con especificidad del 88,2%, 95,4% y 83,9%; según CRS, la sensibilidad es del 17,7%, 14,8% y 30%, con especificidad del 88,7%, 95,5% y 83,3%.",
        "fr": "Graphique en forêt de la sensibilité et de la spécificité poolées (ICr à 95 %) de LF-LAM, des LC-aNAAT combinés et des tests en parallèle, selon le test de référence microbiologique (MRS ; N 653, 43 cas de TB) et composite (CRS ; N 674, 286 cas), avec les différences pour les tests en parallèle. Selon MRS, la sensibilité est de 27,4 % (LF-LAM), 69,3 % (LC-aNAAT combinés) et 77,6 % (parallèle), avec une spécificité de 88,2 %, 95,4 % et 83,9 % ; selon CRS, la sensibilité est de 17,7 %, 14,8 % et 30 %, avec une spécificité de 88,7 %, 95,5 % et 83,3 %.",
        "ru": "Лесовидный график объединённых чувствительности и специфичности (95% ДостИ) для LF-LAM, комбинированных LC-aNAAT и параллельного тестирования по микробиологическому (MRS; N 653, 43 случая ТБ) и комбинированному (CRS; N 674, 286 случаев) эталонному стандарту, с различиями для параллельного тестирования. По MRS чувствительность 27,4% (LF-LAM), 69,3% (комбинированные LC-aNAAT) и 77,6% (параллельное), специфичность 88,2%, 95,4% и 83,9%; по CRS чувствительность 17,7%, 14,8% и 30%, специфичность 88,7%, 95,5% и 83,3%."
      },
      "state": "draft"
    },
    {
      "id": "img-p301-1",
      "file": "images/img-p301-1.webp",
      "page": 301,
      "narratives": {
        "en": "Forest plot of 6 studies (Chipinduro 2017 to Orikiriza 2021) giving TP, FP, FN, TN, sensitivity and specificity (95% CI), with black squares and CI lines on 0–1 scales and a summary diamond. Sensitivity ranges from 0.06 (Hanrahan 2018) to 0.88 (Chipinduro 2017) and specificity from 0.25 to 0.93; the summary estimate is sensitivity 0.30 (0.13–0.55) and specificity 0.83 (0.70–0.90).",
        "ar": "مخطط غابي لعدد 6 دراسات (من Chipinduro 2017 إلى Orikiriza 2021) يعرض الإيجابيات الحقيقية والإيجابيات الكاذبة والسلبيات الكاذبة والسلبيات الحقيقية والحساسية والنوعية (فاصل ثقة 95%)، بمربعات سوداء وخطوط فواصل الثقة على مقياس من 0 إلى 1 ومعيّن للتقدير الإجمالي. تتراوح الحساسية بين 0.06 (Hanrahan 2018) و0.88 (Chipinduro 2017) والنوعية بين 0.25 و0.93؛ والتقدير الإجمالي: الحساسية 0.30 (0.13–0.55) والنوعية 0.83 (0.70–0.90).",
        "zh": "森林图，共6项研究（从Chipinduro 2017到Orikiriza 2021），列出真阳性、假阳性、假阴性、真阴性及灵敏度和特异度（95%置信区间），以黑色方块和置信区间线绘于0–1刻度上，并有汇总菱形。灵敏度介于0.06（Hanrahan 2018）至0.88（Chipinduro 2017），特异度介于0.25至0.93；汇总估计：灵敏度0.30（0.13–0.55），特异度0.83（0.70–0.90）。",
        "es": "Diagrama de bosque de 6 estudios (de Chipinduro 2017 a Orikiriza 2021) con VP, FP, FN, VN, sensibilidad y especificidad (IC del 95%), con cuadrados negros y líneas de IC en escalas de 0 a 1 y un rombo de estimación resumida. La sensibilidad varía de 0,06 (Hanrahan 2018) a 0,88 (Chipinduro 2017) y la especificidad de 0,25 a 0,93; la estimación resumida es una sensibilidad de 0,30 (0,13–0,55) y una especificidad de 0,83 (0,70–0,90).",
        "fr": "Graphique en forêt de 6 études (de Chipinduro 2017 à Orikiriza 2021) indiquant VP, FP, FN, VN, sensibilité et spécificité (IC à 95 %), avec des carrés noirs et des lignes d’IC sur des échelles de 0 à 1 et un losange d’estimation globale. La sensibilité va de 0,06 (Hanrahan 2018) à 0,88 (Chipinduro 2017) et la spécificité de 0,25 à 0,93 ; l’estimation globale est une sensibilité de 0,30 (0,13–0,55) et une spécificité de 0,83 (0,70–0,90).",
        "ru": "Лесовидный график 6 исследований (от Chipinduro 2017 до Orikiriza 2021) с ИП, ЛП, ЛО, ИО, чувствительностью и специфичностью (95% ДИ), чёрными квадратами и линиями ДИ на шкалах от 0 до 1 и ромбом сводной оценки. Чувствительность от 0,06 (Hanrahan 2018) до 0,88 (Chipinduro 2017), специфичность от 0,25 до 0,93; сводная оценка: чувствительность 0,30 (0,13–0,55), специфичность 0,83 (0,70–0,90)."
      },
      "state": "draft"
    },
    {
      "id": "img-p303-1",
      "file": "images/img-p303-1.webp",
      "page": 303,
      "narratives": {
        "en": "Forest plots of study-specific differences in sensitivity and specificity (parallel LC-aNAAT test plus LF-LAM versus parallel LC-aNAAT test) for 6 studies, Chipinduro 2017 to Orikiriza 2021, with total N and risk-of-bias ratings (P, I, R, FT) shown as coloured dots on the right. Sensitivity differences range from 0 to 0.333 and specificity differences from −0.75 (Hanrahan 2018) to −0.05; the summary difference is 0.149 (95% CrI −0.0594 to 0.411) for sensitivity and −0.120 (−0.257 to −0.0258) for specificity.",
        "ar": "مخططات غابية للفروق الخاصة بكل دراسة في الحساسية والنوعية (اختبار LC-aNAAT المتوازي مع LF-LAM مقابل اختبار LC-aNAAT المتوازي) لعدد 6 دراسات، من Chipinduro 2017 إلى Orikiriza 2021، مع العدد الإجمالي N وتقييمات مخاطر التحيّز (P وI وR وFT) في صورة نقاط ملوّنة على اليمين. تتراوح الفروق في الحساسية بين 0 و0.333 وفي النوعية بين −0.75 (Hanrahan 2018) و−0.05؛ والفرق الإجمالي 0.149 (فترة موثوقية 95%: −0.0594 إلى 0.411) للحساسية و−0.120 (−0.257 إلى −0.0258) للنوعية.",
        "zh": "6项研究（从Chipinduro 2017到Orikiriza 2021）灵敏度和特异度研究特异性差异的森林图（LC-aNAAT平行检测加LF-LAM与LC-aNAAT平行检测相比），右侧显示总样本量N及以彩色圆点表示的偏倚风险评级（P、I、R、FT）。灵敏度差异介于0至0.333，特异度差异介于−0.75（Hanrahan 2018）至−0.05；汇总差异灵敏度为0.149（95%可信区间−0.0594至0.411），特异度为−0.120（−0.257至−0.0258）。",
        "es": "Diagramas de bosque de las diferencias de sensibilidad y especificidad por estudio (prueba LC-aNAAT en paralelo más LF-LAM frente a prueba LC-aNAAT en paralelo) en 6 estudios, de Chipinduro 2017 a Orikiriza 2021, con el N total y las calificaciones de riesgo de sesgo (P, I, R, FT) como puntos de colores a la derecha. Las diferencias de sensibilidad van de 0 a 0,333 y las de especificidad de −0,75 (Hanrahan 2018) a −0,05; la diferencia resumida es de 0,149 (ICr del 95%: −0,0594 a 0,411) para la sensibilidad y de −0,120 (−0,257 a −0,0258) para la especificidad.",
        "fr": "Graphiques en forêt des différences de sensibilité et de spécificité par étude (test LC-aNAAT en parallèle plus LF-LAM par rapport au test LC-aNAAT en parallèle) pour 6 études, de Chipinduro 2017 à Orikiriza 2021, avec le N total et les jugements de risque de biais (P, I, R, FT) sous forme de points colorés à droite. Les différences de sensibilité vont de 0 à 0,333 et celles de spécificité de −0,75 (Hanrahan 2018) à −0,05 ; la différence globale est de 0,149 (ICr à 95 % : −0,0594 à 0,411) pour la sensibilité et de −0,120 (−0,257 à −0,0258) pour la spécificité.",
        "ru": "Лесовидные графики различий чувствительности и специфичности по исследованиям (параллельный тест LC-aNAAT плюс LF-LAM по сравнению с параллельным тестом LC-aNAAT) для 6 исследований, от Chipinduro 2017 до Orikiriza 2021, с общим N и оценками риска систематической ошибки (P, I, R, FT) в виде цветных точек справа. Различия чувствительности от 0 до 0,333, специфичности — от −0,75 (Hanrahan 2018) до −0,05; сводное различие — 0,149 (95% ДостИ от −0,0594 до 0,411) для чувствительности и −0,120 (от −0,257 до −0,0258) для специфичности."
      },
      "state": "draft"
    },
    {
      "id": "img-p343-1",
      "file": "images/img-p343-1.webp",
      "page": 343,
      "narratives": {
        "en": "Flow diagram of studies in the review across identification, screening and inclusion stages. 449 studies from databases/registers (MEDLINE 385, ClinicalTrials.gov 64) and 8 references from other sources (WHO public call for data 1, citation searching 7); 15 duplicates removed. 442 studies screened (312 excluded), 130 sought for retrieval (0 not retrieved), 130 assessed for eligibility (99 excluded, with reasons listed, e.g. duplicate/subgroup analysis 23, no or insufficient accuracy data 19), and 31 studies included in the review.",
        "ar": "مخطط انسيابي للدراسات في المراجعة عبر مراحل التحديد والفرز والإدراج. 449 دراسة من قواعد البيانات/السجلات (MEDLINE 385، وClinicalTrials.gov 64) و8 مراجع من مصادر أخرى (دعوة منظمة الصحة العالمية العامة لتقديم البيانات 1، والبحث في الاستشهادات 7)؛ وحُذفت 15 نسخة مكرّرة. فُرزت 442 دراسة (استُبعدت 312)، وطُلب استرجاع 130 (لم يُسترجع 0)، وقُيّمت أهلية 130 (استُبعدت 99 مع ذكر الأسباب، مثل تحليل مكرّر/لمجموعة فرعية 23، وبيانات دقة منعدمة أو غير كافية 19)، وأُدرجت 31 دراسة في المراجعة.",
        "zh": "综述中研究的流程图，涵盖识别、筛选和纳入阶段。来自数据库/注册库的研究449项（MEDLINE 385项，ClinicalTrials.gov 64项）及其他来源的参考文献8篇（世卫组织公开征集数据1篇，引文检索7篇）；删除重复15篇。筛选442项（排除312项），寻求获取130项（未获取0项），评估合格性130项（排除99项，列出原因，如重复/亚组分析23项、无或不足的准确性数据19项），最终纳入综述31项研究。",
        "es": "Diagrama de flujo de los estudios de la revisión en las etapas de identificación, cribado e inclusión. 449 estudios de bases de datos/registros (MEDLINE 385, ClinicalTrials.gov 64) y 8 referencias de otras fuentes (convocatoria pública de datos de la OMS 1, búsqueda de citas 7); se eliminaron 15 duplicados. Se cribaron 442 estudios (312 excluidos), se solicitaron 130 (0 no recuperados), se evaluó la elegibilidad de 130 (99 excluidos, con motivos enumerados, p. ej., análisis duplicado/de subgrupo 23, datos de exactitud nulos o insuficientes 19) y se incluyeron 31 estudios en la revisión.",
        "fr": "Diagramme de flux des études de la revue selon les étapes d’identification, de sélection et d’inclusion. 449 études issues de bases de données/registres (MEDLINE 385, ClinicalTrials.gov 64) et 8 références d’autres sources (appel public à données de l’OMS 1, recherche de citations 7) ; 15 doublons supprimés. 442 études sélectionnées (312 exclues), 130 recherchées (0 non obtenue), 130 évaluées pour l’éligibilité (99 exclues, avec motifs, par ex. analyse en double/de sous-groupe 23, données d’exactitude absentes ou insuffisantes 19) et 31 études incluses dans la revue.",
        "ru": "Блок-схема исследований в обзоре по этапам идентификации, скрининга и включения. 449 исследований из баз данных/регистров (MEDLINE 385, ClinicalTrials.gov 64) и 8 ссылок из других источников (публичный запрос данных ВОЗ 1, поиск по цитированию 7); удалено 15 дубликатов. Проскринировано 442 исследования (исключено 312), запрошено 130 (не получено 0), оценено на соответствие 130 (исключено 99 с указанием причин, например дублирующий/подгрупповой анализ 23, отсутствие или недостаточность данных о точности 19), в обзор включено 31 исследование."
      },
      "state": "draft"
    },
    {
      "id": "img-p344-1",
      "file": "images/img-p344-1.webp",
      "page": 344,
      "narratives": {
        "en": "Risk of bias and applicability grid for 31 studies (Åhsberg 2023 to Yoon 2019). Columns cover risk of bias (patient selection, index test, micro reference standard, comp reference standard, flow and timing) and applicability (patient selection, index test, reference standard), coloured low (green), high (red), unclear (yellow) or not applicable (grey). Index test and applicability are mostly low, while high ratings are frequent for patient selection, the reference standards and flow and timing.",
        "ar": "شبكة مخاطر التحيّز وقابلية التطبيق لإحدى وثلاثين دراسة (من Åhsberg 2023 إلى Yoon 2019). تغطي الأعمدة مخاطر التحيّز (اختيار المرضى، والاختبار المؤشّر، والمعيار المرجعي الميكروبيولوجي، والمعيار المرجعي المركّب، والتدفّق والتوقيت) وقابلية التطبيق (اختيار المرضى، والاختبار المؤشّر، والمعيار المرجعي)، ملوّنة منخفضة (أخضر) أو مرتفعة (أحمر) أو غير واضحة (أصفر) أو غير منطبقة (رمادي). الاختبار المؤشّر وقابلية التطبيق منخفضان في الغالب، بينما تكثر التقييمات المرتفعة في اختيار المرضى والمعايير المرجعية والتدفّق والتوقيت.",
        "zh": "31项研究（从Åhsberg 2023到Yoon 2019）的偏倚风险和适用性网格。列涵盖偏倚风险（患者选择、待评价试验、微生物参考标准、复合参考标准、流程和时间）和适用性（患者选择、待评价试验、参考标准），以低（绿色）、高（红色）、不清楚（黄色）或不适用（灰色）着色。待评价试验和适用性大多为低，而患者选择、参考标准以及流程和时间常评为高。",
        "es": "Cuadrícula de riesgo de sesgo y aplicabilidad de 31 estudios (de Åhsberg 2023 a Yoon 2019). Las columnas abarcan el riesgo de sesgo (selección de pacientes, prueba índice, patrón de referencia microbiológico, patrón de referencia compuesto, flujo y cronología) y la aplicabilidad (selección de pacientes, prueba índice, patrón de referencia), coloreadas como bajo (verde), alto (rojo), incierto (amarillo) o no aplicable (gris). La prueba índice y la aplicabilidad son mayoritariamente bajas, mientras que las calificaciones altas son frecuentes en la selección de pacientes, los patrones de referencia y el flujo y la cronología.",
        "fr": "Grille du risque de biais et de l’applicabilité pour 31 études (d’Åhsberg 2023 à Yoon 2019). Les colonnes couvrent le risque de biais (sélection des patients, test index, test de référence microbiologique, test de référence composite, flux et chronologie) et l’applicabilité (sélection des patients, test index, test de référence), colorées faible (vert), élevé (rouge), incertain (jaune) ou sans objet (gris). Le test index et l’applicabilité sont surtout faibles, tandis que les jugements élevés sont fréquents pour la sélection des patients, les tests de référence et le flux et la chronologie.",
        "ru": "Таблица риска систематической ошибки и применимости для 31 исследования (от Åhsberg 2023 до Yoon 2019). Столбцы охватывают риск ошибки (отбор пациентов, индексный тест, микробиологический эталонный стандарт, комбинированный эталонный стандарт, ход и сроки) и применимость (отбор пациентов, индексный тест, эталонный стандарт), окрашенные как низкий (зелёный), высокий (красный), неясный (жёлтый) или неприменимо (серый). Индексный тест и применимость в основном низкие, тогда как высокие оценки часты для отбора пациентов, эталонных стандартов и хода и сроков."
      },
      "state": "draft"
    },
    {
      "id": "img-p347-1",
      "file": "images/img-p347-1.webp",
      "page": 347,
      "narratives": {
        "en": "Risk-of-bias grid for comparative accuracy in 31 studies (Åhsberg 2023 to Yoon 2019), with five domains: patient selection, index test, micro reference standard, comp reference standard, and flow and timing. Cells are low (green), high (red), unclear (yellow) or not applicable (grey); the composite reference standard is high or not applicable in almost every study, and high ratings are also common for patient selection and flow and timing.",
        "ar": "شبكة مخاطر التحيّز للدقة المقارنة في إحدى وثلاثين دراسة (من Åhsberg 2023 إلى Yoon 2019)، بخمسة مجالات: اختيار المرضى، والاختبار المؤشّر، والمعيار المرجعي الميكروبيولوجي، والمعيار المرجعي المركّب، والتدفّق والتوقيت. الخلايا منخفضة (أخضر) أو مرتفعة (أحمر) أو غير واضحة (أصفر) أو غير منطبقة (رمادي)؛ والمعيار المرجعي المركّب مرتفع أو غير منطبق في كل الدراسات تقريباً، كما تشيع التقييمات المرتفعة في اختيار المرضى والتدفّق والتوقيت.",
        "zh": "31项研究（从Åhsberg 2023到Yoon 2019）比较准确性的偏倚风险网格，含五个领域：患者选择、待评价试验、微生物参考标准、复合参考标准、流程和时间。单元格为低（绿色）、高（红色）、不清楚（黄色）或不适用（灰色）；几乎每项研究的复合参考标准均为高或不适用，患者选择以及流程和时间也常评为高。",
        "es": "Cuadrícula de riesgo de sesgo de la exactitud comparativa en 31 estudios (de Åhsberg 2023 a Yoon 2019), con cinco dominios: selección de pacientes, prueba índice, patrón de referencia microbiológico, patrón de referencia compuesto y flujo y cronología. Las celdas son bajo (verde), alto (rojo), incierto (amarillo) o no aplicable (gris); el patrón de referencia compuesto es alto o no aplicable en casi todos los estudios, y las calificaciones altas también son comunes en la selección de pacientes y el flujo y la cronología.",
        "fr": "Grille du risque de biais de l’exactitude comparative dans 31 études (d’Åhsberg 2023 à Yoon 2019), avec cinq domaines : sélection des patients, test index, test de référence microbiologique, test de référence composite, et flux et chronologie. Les cases sont faible (vert), élevé (rouge), incertain (jaune) ou sans objet (gris) ; le test de référence composite est élevé ou sans objet dans presque toutes les études, et les jugements élevés sont aussi fréquents pour la sélection des patients et le flux et la chronologie.",
        "ru": "Таблица риска систематической ошибки сравнительной точности в 31 исследовании (от Åhsberg 2023 до Yoon 2019) с пятью доменами: отбор пациентов, индексный тест, микробиологический эталонный стандарт, комбинированный эталонный стандарт, ход и сроки. Ячейки: низкий (зелёный), высокий (красный), неясный (жёлтый) или неприменимо (серый); комбинированный эталонный стандарт высокий или неприменим почти во всех исследованиях, высокие оценки также часты для отбора пациентов и хода и сроков."
      },
      "state": "draft"
    },
    {
      "id": "img-p349-2",
      "file": "images/img-p349-2.webp",
      "page": 349,
      "narratives": {
        "en": "Forest plot labelled 'Parallel' for 30 studies (Ahsberg 2023 to Yoon 2019), giving TP, FP, FN, TN and sensitivity and specificity (95% CI), plotted as blue squares with CI lines on 0–1 scales. Sensitivity ranges from 0.33 (Olbrich 2024) to 1.00 and specificity from 0.57 (Huerga 2019) to 1.00, with most sensitivities between about 0.6 and 0.9.",
        "ar": "مخطط غابي بعنوان «Parallel» (متوازٍ) لثلاثين دراسة (من Ahsberg 2023 إلى Yoon 2019)، يعرض الإيجابيات الحقيقية والإيجابيات الكاذبة والسلبيات الكاذبة والسلبيات الحقيقية والحساسية والنوعية (فاصل ثقة 95%)، مرسومة كمربعات زرقاء مع خطوط فواصل الثقة على مقياس من 0 إلى 1. تتراوح الحساسية بين 0.33 (Olbrich 2024) و1.00 والنوعية بين 0.57 (Huerga 2019) و1.00، ومعظم قيم الحساسية بين نحو 0.6 و0.9.",
        "zh": "标为“Parallel”（平行）的森林图，共30项研究（从Ahsberg 2023到Yoon 2019），列出真阳性、假阳性、假阴性、真阴性及灵敏度和特异度（95%置信区间），以蓝色方块和置信区间线绘于0–1刻度上。灵敏度介于0.33（Olbrich 2024）至1.00，特异度介于0.57（Huerga 2019）至1.00，大多数灵敏度约在0.6至0.9之间。",
        "es": "Diagrama de bosque titulado «Parallel» (paralelo) de 30 estudios (de Ahsberg 2023 a Yoon 2019), con VP, FP, FN, VN y sensibilidad y especificidad (IC del 95%), representadas como cuadrados azules con líneas de IC en escalas de 0 a 1. La sensibilidad varía de 0,33 (Olbrich 2024) a 1,00 y la especificidad de 0,57 (Huerga 2019) a 1,00, con la mayoría de las sensibilidades entre aproximadamente 0,6 y 0,9.",
        "fr": "Graphique en forêt intitulé « Parallel » (parallèle) de 30 études (d’Ahsberg 2023 à Yoon 2019), indiquant VP, FP, FN, VN et sensibilité et spécificité (IC à 95 %), représentées par des carrés bleus avec des lignes d’IC sur des échelles de 0 à 1. La sensibilité va de 0,33 (Olbrich 2024) à 1,00 et la spécificité de 0,57 (Huerga 2019) à 1,00, la plupart des sensibilités se situant entre environ 0,6 et 0,9.",
        "ru": "Лесовидный график с подписью «Parallel» (параллельное) для 30 исследований (от Ahsberg 2023 до Yoon 2019) с ИП, ЛП, ЛО, ИО, чувствительностью и специфичностью (95% ДИ), изображёнными синими квадратами с линиями ДИ на шкалах от 0 до 1. Чувствительность от 0,33 (Olbrich 2024) до 1,00, специфичность от 0,57 (Huerga 2019) до 1,00; большинство значений чувствительности примерно 0,6–0,9."
      },
      "state": "draft"
    },
    {
      "id": "img-p351-1",
      "file": "images/img-p351-1.webp",
      "page": 351,
      "narratives": {
        "en": "Paired forest plot (Figure 12) of 27 studies, from Ahsberg 2023 to Yoon 2019, showing the difference in sensitivity and in specificity between parallel testing (LC-aNAAT plus LF-LAM) and LC-aNAAT alone, with total N and coloured risk-of-bias ratings (P, I, R, FT) for each study. The summary difference is 0.0946 (95% CrI 0.0147 to 0.176) for sensitivity, favouring the parallel test, and -0.0731 (95% CrI -0.1102 to -0.0426) for specificity, favouring the LC-aNAAT test.",
        "ar": "مخطط شجري مزدوج (الشكل 12) لـ 27 دراسة، من Ahsberg 2023 إلى Yoon 2019، يبين الفرق في الحساسية والنوعية بين الاختبار المتوازي (LC-aNAAT مع LF-LAM) واختبار LC-aNAAT وحده، مع العدد الإجمالي وتقديرات ملونة لخطر التحيز (P وI وR وFT) لكل دراسة. ويبلغ الفرق الإجمالي 0.0946 (فاصل الموثوقية 95%: 0.0147 إلى 0.176) في الحساسية لصالح الاختبار المتوازي، و-0.0731 (فاصل الموثوقية 95%: -0.1102 إلى -0.0426) في النوعية لصالح اختبار LC-aNAAT.",
        "zh": "成对森林图（图12），涵盖从Ahsberg 2023到Yoon 2019的27项研究，显示平行检测（LC-aNAAT加LF-LAM）与单独使用LC-aNAAT之间灵敏度和特异度的差异，并列出每项研究的总人数及彩色偏倚风险评级（P、I、R、FT）。灵敏度的汇总差异为0.0946（95%可信区间0.0147至0.176），有利于平行检测；特异度的汇总差异为-0.0731（95%可信区间-0.1102至-0.0426），有利于LC-aNAAT检测。",
        "es": "Diagrama de bosque doble (figura 12) de 27 estudios, de Ahsberg 2023 a Yoon 2019, que muestra la diferencia de sensibilidad y de especificidad entre las pruebas en paralelo (LC-aNAAT más LF-LAM) y la LC-aNAAT sola, con el N total y las calificaciones de riesgo de sesgo por colores (P, I, R, FT) de cada estudio. La diferencia resumida es 0,0946 (ICr del 95%: 0,0147 a 0,176) para la sensibilidad, a favor de la prueba en paralelo, y -0,0731 (ICr del 95%: -0,1102 a -0,0426) para la especificidad, a favor de la LC-aNAAT.",
        "fr": "Graphique en forêt double (figure 12) de 27 études, d’Ahsberg 2023 à Yoon 2019, montrant la différence de sensibilité et de spécificité entre le test en parallèle (LC-aNAAT plus LF-LAM) et le LC-aNAAT seul, avec le N total et des évaluations colorées du risque de biais (P, I, R, FT) pour chaque étude. La différence globale est de 0,0946 (ICr à 95 % : 0,0147 à 0,176) pour la sensibilité, en faveur du test en parallèle, et de -0,0731 (ICr à 95 % : -0,1102 à -0,0426) pour la spécificité, en faveur du LC-aNAAT.",
        "ru": "Парный лесовидный график (рисунок 12) по 27 исследованиям, от Ahsberg 2023 до Yoon 2019, показывающий разницу в чувствительности и специфичности между параллельным тестированием (LC-aNAAT и LF-LAM) и только LC-aNAAT, с общим N и цветными оценками риска систематической ошибки (P, I, R, FT) для каждого исследования. Сводная разница составляет 0,0946 (95% ДИнт 0,0147–0,176) по чувствительности в пользу параллельного теста и -0,0731 (95% ДИнт -0,1102 – -0,0426) по специфичности в пользу LC-aNAAT."
      },
      "state": "draft"
    },
    {
      "id": "img-p352-1",
      "file": "images/img-p352-1.webp",
      "page": 352,
      "narratives": {
        "en": "Forest plot (Figure 13) of pooled sensitivity and specificity for LF-LAM, LC-aNAAT and their parallel use, against a microbiological reference standard (MRS, 12 651 participants, 18.7% with TB) and a composite reference standard (CRS, 11 109 participants, 33.5% with TB). Against MRS, sensitivity is 39.1% for LF-LAM, 68.0% for LC-aNAAT and 77.5% for parallel use (difference 6.7%), with specificity 91.9%, 96.7% and 89.4% (difference -6.8%). Against CRS, sensitivity is 38.6%, 46.8% and 67.6% (difference 16.0%) and specificity 96.3%, 99.9% and 96.2% (difference -3.5%).",
        "ar": "مخطط شجري (الشكل 13) للحساسية والنوعية المجمّعتين لاختبار LF-LAM واختبار LC-aNAAT واستخدامهما المتوازي، مقارنةً بمعيار مرجعي ميكروبيولوجي (MRS، 651 12 مشاركاً، 18.7% منهم مصابون بالسل) ومعيار مرجعي مركّب (CRS، 109 11 مشاركين، 33.5% منهم مصابون بالسل). ومقارنةً بالمعيار MRS، تبلغ الحساسية 39.1% لـ LF-LAM و68.0% لـ LC-aNAAT و77.5% للاستخدام المتوازي (الفرق 6.7%)، والنوعية 91.9% و96.7% و89.4% (الفرق -6.8%). ومقارنةً بالمعيار CRS، تبلغ الحساسية 38.6% و46.8% و67.6% (الفرق 16.0%) والنوعية 96.3% و99.9% و96.2% (الفرق -3.5%).",
        "zh": "森林图（图13），显示LF-LAM、LC-aNAAT及二者平行使用的汇总灵敏度和特异度，分别以微生物学参考标准（MRS，12 651名参与者，18.7%患结核病）和复合参考标准（CRS，11 109名参与者，33.5%患结核病）为参照。以MRS为参照时，LF-LAM、LC-aNAAT和平行使用的灵敏度分别为39.1%、68.0%和77.5%（差异6.7%），特异度分别为91.9%、96.7%和89.4%（差异-6.8%）。以CRS为参照时，灵敏度分别为38.6%、46.8%和67.6%（差异16.0%），特异度分别为96.3%、99.9%和96.2%（差异-3.5%）。",
        "es": "Diagrama de bosque (figura 13) de la sensibilidad y la especificidad agrupadas de LF-LAM, LC-aNAAT y su uso en paralelo, frente a un patrón de referencia microbiológico (MRS; 12 651 participantes, 18,7% con TB) y un patrón de referencia compuesto (CRS; 11 109 participantes, 33,5% con TB). Frente al MRS, la sensibilidad es del 39,1% para LF-LAM, del 68,0% para LC-aNAAT y del 77,5% para el uso en paralelo (diferencia del 6,7%), y la especificidad del 91,9%, 96,7% y 89,4% (diferencia del -6,8%). Frente al CRS, la sensibilidad es del 38,6%, 46,8% y 67,6% (diferencia del 16,0%) y la especificidad del 96,3%, 99,9% y 96,2% (diferencia del -3,5%).",
        "fr": "Graphique en forêt (figure 13) de la sensibilité et de la spécificité poolées du LF-LAM, du LC-aNAAT et de leur utilisation en parallèle, par rapport à une norme de référence microbiologique (MRS ; 12 651 participants, 18,7 % atteints de TB) et à une norme de référence composite (CRS ; 11 109 participants, 33,5 % atteints de TB). Par rapport à la MRS, la sensibilité est de 39,1 % pour le LF-LAM, 68,0 % pour le LC-aNAAT et 77,5 % pour l’utilisation en parallèle (différence 6,7 %), et la spécificité de 91,9 %, 96,7 % et 89,4 % (différence -6,8 %). Par rapport à la CRS, la sensibilité est de 38,6 %, 46,8 % et 67,6 % (différence 16,0 %) et la spécificité de 96,3 %, 99,9 % et 96,2 % (différence -3,5 %).",
        "ru": "Лесовидный график (рисунок 13) объединенной чувствительности и специфичности LF-LAM, LC-aNAAT и их параллельного применения по сравнению с микробиологическим эталонным стандартом (MRS; 12 651 участник, 18,7% с ТБ) и комбинированным эталонным стандартом (CRS; 11 109 участников, 33,5% с ТБ). По MRS чувствительность составляет 39,1% для LF-LAM, 68,0% для LC-aNAAT и 77,5% при параллельном применении (разница 6,7%), специфичность — 91,9%, 96,7% и 89,4% (разница -6,8%). По CRS чувствительность составляет 38,6%, 46,8% и 67,6% (разница 16,0%), специфичность — 96,3%, 99,9% и 96,2% (разница -3,5%)."
      },
      "state": "draft"
    },
    {
      "id": "img-p357-1",
      "file": "images/img-p357-1.webp",
      "page": 357,
      "narratives": {
        "en": "Table rendered as an image (Table 16) comparing, within the studies Gils 2023 and Reeve 2023, the absolute difference in sensitivity and specificity (point estimate and 95% CI) of parallel testing versus Xpert Ultra and versus Xpert MTB/RIF. P values for interaction are 0.944 and 0.719 for Gils 2023 and 0.919 and 0.411 for Reeve 2023, each noted as no evidence of a difference between Xpert Ultra and Xpert MTB/RIF. Both column groups are headed 'Absolute difference in sensitivity'.",
        "ar": "جدول معروض كصورة (الجدول 16) يقارن، ضمن دراستي Gils 2023 وReeve 2023، الفرق المطلق في الحساسية والنوعية (التقدير النقطي وفاصل الثقة 95%) للاختبار المتوازي مقابل Xpert Ultra ومقابل Xpert MTB/RIF. وتبلغ قيم P للتفاعل 0.944 و0.719 لدراسة Gils 2023، و0.919 و0.411 لدراسة Reeve 2023، مع الإشارة في كل منها إلى عدم وجود دليل على فرق بين Xpert Ultra وXpert MTB/RIF. ويحمل كلا مجموعتي الأعمدة عنوان «الفرق المطلق في الحساسية».",
        "zh": "以图像形式呈现的表格（表16），在Gils 2023和Reeve 2023两项研究内比较平行检测相对于Xpert Ultra和相对于Xpert MTB/RIF的灵敏度和特异度绝对差异（点估计值及95%置信区间）。Gils 2023的交互作用P值为0.944和0.719，Reeve 2023为0.919和0.411，均注明无证据表明Xpert Ultra与Xpert MTB/RIF之间存在差异。两组列的标题均为“灵敏度绝对差异”。",
        "es": "Tabla presentada como imagen (cuadro 16) que compara, dentro de los estudios Gils 2023 y Reeve 2023, la diferencia absoluta de sensibilidad y especificidad (estimación puntual e IC del 95%) de las pruebas en paralelo frente a Xpert Ultra y frente a Xpert MTB/RIF. Los valores de p de interacción son 0,944 y 0,719 en Gils 2023 y 0,919 y 0,411 en Reeve 2023, señalándose en cada caso que no hay evidencia de diferencia entre Xpert Ultra y Xpert MTB/RIF. Ambos grupos de columnas llevan el encabezado «Diferencia absoluta en la sensibilidad».",
        "fr": "Tableau présenté sous forme d’image (tableau 16) comparant, au sein des études Gils 2023 et Reeve 2023, la différence absolue de sensibilité et de spécificité (estimation ponctuelle et IC à 95 %) du test en parallèle par rapport au Xpert Ultra et par rapport au Xpert MTB/RIF. Les valeurs p d’interaction sont de 0,944 et 0,719 pour Gils 2023 et de 0,919 et 0,411 pour Reeve 2023, chacune accompagnée de la mention d’une absence de preuve de différence entre Xpert Ultra et Xpert MTB/RIF. Les deux groupes de colonnes portent l’intitulé « Différence absolue de sensibilité ».",
        "ru": "Таблица в виде изображения (таблица 16), сравнивающая в рамках исследований Gils 2023 и Reeve 2023 абсолютную разницу в чувствительности и специфичности (точечная оценка и 95% ДИ) параллельного тестирования по сравнению с Xpert Ultra и с Xpert MTB/RIF. Значения P для взаимодействия составляют 0,944 и 0,719 для Gils 2023 и 0,919 и 0,411 для Reeve 2023, и в каждом случае указано отсутствие данных о различии между Xpert Ultra и Xpert MTB/RIF. Обе группы столбцов озаглавлены «Абсолютная разница в чувствительности»."
      },
      "state": "draft"
    },
    {
      "id": "img-p360-1",
      "file": "images/img-p360-1.webp",
      "page": 360,
      "narratives": {
        "en": "Fragment of the risk-of-bias summary (Figure 14): two rows of seven circles, mostly green with a plus sign (low risk) and some yellow with a question mark (unclear risk). Study and domain labels are not included in this image.",
        "ar": "جزء من ملخص خطر التحيز (الشكل 14): صفان من سبع دوائر، معظمها خضراء بعلامة زائد (خطر منخفض) وبعضها صفراء بعلامة استفهام (خطر غير واضح). ولا تتضمن هذه الصورة أسماء الدراسات أو المجالات.",
        "zh": "偏倚风险汇总图（图14）的局部：两行各七个圆圈，大多为带加号的绿色圆圈（低风险），部分为带问号的黄色圆圈（风险不明）。本图像不含研究名称和领域标签。",
        "es": "Fragmento del resumen del riesgo de sesgo (figura 14): dos filas de siete círculos, en su mayoría verdes con un signo más (riesgo bajo) y algunos amarillos con un signo de interrogación (riesgo incierto). La imagen no incluye las etiquetas de estudios ni de dominios.",
        "fr": "Fragment du résumé du risque de biais (figure 14) : deux rangées de sept cercles, pour la plupart verts avec un signe plus (risque faible) et quelques-uns jaunes avec un point d’interrogation (risque incertain). Les libellés des études et des domaines ne figurent pas dans cette image.",
        "ru": "Фрагмент сводки риска систематической ошибки (рисунок 14): два ряда по семь кругов, в основном зеленых со знаком «плюс» (низкий риск) и несколько желтых со знаком вопроса (неясный риск). Названия исследований и доменов в это изображение не входят."
      },
      "state": "draft"
    },
    {
      "id": "img-p360-3",
      "file": "images/img-p360-3.webp",
      "page": 360,
      "narratives": {
        "en": "Column labels of the risk-of-bias summary (Figure 14), set vertically: random sequence generation (selection bias), allocation concealment (selection bias), blinding of participants and personnel (performance bias), blinding of outcome assessment (detection bias), incomplete outcome data (attrition bias), selective reporting (reporting bias), and other bias.",
        "ar": "عناوين أعمدة ملخص خطر التحيز (الشكل 14) مكتوبة عمودياً: توليد التسلسل العشوائي (تحيز الاختيار)، وإخفاء التخصيص (تحيز الاختيار)، وتعمية المشاركين والعاملين (تحيز الأداء)، وتعمية تقييم الحصائل (تحيز الكشف)، وبيانات الحصائل غير المكتملة (تحيز الاستنزاف)، والإبلاغ الانتقائي (تحيز الإبلاغ)، وتحيزات أخرى.",
        "zh": "偏倚风险汇总图（图14）的列标签，竖向排列：随机序列生成（选择偏倚）、分配隐藏（选择偏倚）、对受试者和研究人员施盲（实施偏倚）、对结局评估施盲（测量偏倚）、结局数据不完整（失访偏倚）、选择性报告（报告偏倚）以及其他偏倚。",
        "es": "Etiquetas de columna del resumen del riesgo de sesgo (figura 14), en vertical: generación de la secuencia aleatoria (sesgo de selección), ocultación de la asignación (sesgo de selección), cegamiento de participantes y personal (sesgo de realización), cegamiento de la evaluación de resultados (sesgo de detección), datos de resultados incompletos (sesgo de desgaste), notificación selectiva (sesgo de notificación) y otros sesgos.",
        "fr": "Libellés des colonnes du résumé du risque de biais (figure 14), disposés verticalement : génération de la séquence aléatoire (biais de sélection), dissimulation de l’allocation (biais de sélection), mise en aveugle des participants et du personnel (biais de performance), mise en aveugle de l’évaluation des résultats (biais de détection), données de résultats incomplètes (biais d’attrition), notification sélective (biais de notification) et autres biais.",
        "ru": "Вертикальные заголовки столбцов сводки риска систематической ошибки (рисунок 14): генерация случайной последовательности (ошибка отбора), сокрытие распределения (ошибка отбора), ослепление участников и персонала (ошибка проведения), ослепление оценки исходов (ошибка выявления), неполные данные об исходах (ошибка выбывания), избирательная отчетность (ошибка отчетности) и другие систематические ошибки."
      },
      "state": "draft"
    },
    {
      "id": "img-p361-1",
      "file": "images/img-p361-1.webp",
      "page": 361,
      "narratives": {
        "en": "Forest plot (Figure 15) of risk ratios (M-H, random, 95% CI) for mortality comparing parallel testing with LC-aNAAT in three trials: Ahsberg 2023 (1.28 [0.95, 1.74]), Gupta-Wright 2018 (0.86 [0.74, 1.01]) and Peter 2016 (0.79 [0.65, 0.97]). The pooled risk ratio is 0.93 [0.74, 1.17] (2258 vs 2344 participants), with heterogeneity I² = 71% and test for overall effect P = 0.53; the axis runs from 0.01 to 100, labelled 'Favours [Parallel]' and 'Favours [LC-aNAAT]'.",
        "ar": "مخطط شجري (الشكل 15) لنسب الخطر (M-H، تأثيرات عشوائية، فاصل ثقة 95%) للوفيات بمقارنة الاختبار المتوازي باختبار LC-aNAAT في ثلاث تجارب: Ahsberg 2023 (1.28 [0.95، 1.74])، وGupta-Wright 2018 (0.86 [0.74، 1.01])، وPeter 2016 (0.79 [0.65، 0.97]). وتبلغ نسبة الخطر المجمّعة 0.93 [0.74، 1.17] (2258 مقابل 2344 مشاركاً)، مع عدم تجانس I² = 71% واختبار للأثر الكلي P = 0.53؛ ويمتد المحور من 0.01 إلى 100 مع التسميتين «لصالح الاختبار المتوازي» و«لصالح LC-aNAAT».",
        "zh": "森林图（图15），显示三项试验中平行检测与LC-aNAAT比较的死亡率风险比（M-H法，随机效应，95%置信区间）：Ahsberg 2023（1.28 [0.95, 1.74]）、Gupta-Wright 2018（0.86 [0.74, 1.01]）和Peter 2016（0.79 [0.65, 0.97]）。合并风险比为0.93 [0.74, 1.17]（2258对2344名参与者），异质性I² = 71%，总体效应检验P = 0.53；横轴范围为0.01至100，两侧分别标注“有利于平行检测”和“有利于LC-aNAAT”。",
        "es": "Diagrama de bosque (figura 15) de razones de riesgo (M-H, efectos aleatorios, IC del 95%) de mortalidad que compara las pruebas en paralelo con la LC-aNAAT en tres ensayos: Ahsberg 2023 (1,28 [0,95; 1,74]), Gupta-Wright 2018 (0,86 [0,74; 1,01]) y Peter 2016 (0,79 [0,65; 0,97]). La razón de riesgo agrupada es 0,93 [0,74; 1,17] (2258 frente a 2344 participantes), con heterogeneidad I² = 71% y prueba de efecto global p = 0,53; el eje va de 0,01 a 100, con las etiquetas «A favor de [en paralelo]» y «A favor de [LC-aNAAT]».",
        "fr": "Graphique en forêt (figure 15) des risques relatifs (M-H, effets aléatoires, IC à 95 %) de mortalité comparant le test en parallèle au LC-aNAAT dans trois essais : Ahsberg 2023 (1,28 [0,95 ; 1,74]), Gupta-Wright 2018 (0,86 [0,74 ; 1,01]) et Peter 2016 (0,79 [0,65 ; 0,97]). Le risque relatif poolé est de 0,93 [0,74 ; 1,17] (2258 contre 2344 participants), avec une hétérogénéité I² = 71 % et un test de l’effet global p = 0,53 ; l’axe va de 0,01 à 100, avec les libellés « En faveur du test en parallèle » et « En faveur du LC-aNAAT ».",
        "ru": "Лесовидный график (рисунок 15) отношений рисков (M-H, случайные эффекты, 95% ДИ) смертности при сравнении параллельного тестирования с LC-aNAAT в трех исследованиях: Ahsberg 2023 (1,28 [0,95; 1,74]), Gupta-Wright 2018 (0,86 [0,74; 1,01]) и Peter 2016 (0,79 [0,65; 0,97]). Объединенное отношение рисков — 0,93 [0,74; 1,17] (2258 и 2344 участника), гетерогенность I² = 71%, проверка общего эффекта P = 0,53; ось от 0,01 до 100 с подписями «В пользу параллельного теста» и «В пользу LC-aNAAT»."
      },
      "state": "draft"
    },
    {
      "id": "img-p363-1",
      "file": "images/img-p363-1.webp",
      "page": 363,
      "narratives": {
        "en": "Forest plot (Figure 16) of risk ratios (M-H, random, 95% CI) comparing parallel testing with LC-aNAAT in two trials of the proportion of adult inpatients with HIV diagnosed with tuberculosis: Ahsberg 2023 (1.82 [1.31, 2.54]) and Gupta-Wright 2018 (1.47 [1.24, 1.73]). The pooled risk ratio is 1.56 [1.29, 1.88] (1460 vs 1533 participants), with I² = 23% and test for overall effect P < 0.00001; the axis runs from 0.01 to 100, labelled 'Favours [LC-aNAAT]' and 'Favours [Parallel]'.",
        "ar": "مخطط شجري (الشكل 16) لنسب الخطر (M-H، تأثيرات عشوائية، فاصل ثقة 95%) بمقارنة الاختبار المتوازي باختبار LC-aNAAT في تجربتين لنسبة المرضى البالغين المصابين بفيروس العوز المناعي البشري في المستشفيات الذين شُخّصوا بالسل: Ahsberg 2023 (1.82 [1.31, 2.54]) وGupta-Wright 2018 (1.47 [1.24, 1.73]). وتبلغ نسبة الخطر المجمّعة 1.56 [1.29, 1.88] (1460 مقابل 1533 مشاركاً)، مع I² = 23% واختبار للأثر الكلي P < 0.00001؛ ويمتد المحور من 0.01 إلى 100 مع التسميتين «لصالح LC-aNAAT» و«لصالح الاختبار المتوازي».",
        "zh": "森林图（图16），显示两项试验中平行检测与LC-aNAAT比较的风险比（M-H法，随机效应，95%置信区间）（结局为被诊断为结核病的成年艾滋病毒感染住院患者比例）：Ahsberg 2023（1.82 [1.31, 2.54]）和Gupta-Wright 2018（1.47 [1.24, 1.73]）。合并风险比为1.56 [1.29, 1.88]（1460对1533名参与者），I² = 23%，总体效应检验P < 0.00001；横轴范围为0.01至100，两侧分别标注“有利于LC-aNAAT”和“有利于平行检测”。",
        "es": "Diagrama de bosque (figura 16) de razones de riesgo (M-H, efectos aleatorios, IC del 95%) que compara las pruebas en paralelo con la LC-aNAAT en dos ensayos para la proporción de pacientes adultos hospitalizados con VIH diagnosticados de tuberculosis: Ahsberg 2023 (1,82 [1,31; 2,54]) y Gupta-Wright 2018 (1,47 [1,24; 1,73]). La razón de riesgo agrupada es 1,56 [1,29; 1,88] (1460 frente a 1533 participantes), con I² = 23% y prueba de efecto global P < 0,00001; el eje va de 0,01 a 100, con las etiquetas «A favor de [LC-aNAAT]» y «A favor de [en paralelo]».",
        "fr": "Graphique en forêt (figure 16) des risques relatifs (M-H, effets aléatoires, IC à 95 %) comparant le test en parallèle au LC-aNAAT dans deux essais pour la proportion de patients adultes hospitalisés vivant avec le VIH chez qui une tuberculose a été diagnostiquée : Ahsberg 2023 (1,82 [1,31; 2,54]) et Gupta-Wright 2018 (1,47 [1,24; 1,73]). Le risque relatif poolé est de 1,56 [1,29; 1,88] (1460 contre 1533 participants), avec I² = 23% et un test de l’effet global P < 0,00001 ; l’axe va de 0,01 à 100, avec les libellés « En faveur du LC-aNAAT » et « En faveur du test en parallèle ».",
        "ru": "Лесовидный график (рисунок 16) отношений рисков (M-H, случайные эффекты, 95% ДИ) при сравнении параллельного тестирования с LC-aNAAT в двух исследованиях по доле взрослых стационарных пациентов с ВИЧ, у которых диагностирован туберкулез: Ahsberg 2023 (1,82 [1,31; 2,54]) и Gupta-Wright 2018 (1,47 [1,24; 1,73]). Объединенное отношение рисков — 1,56 [1,29; 1,88] (1460 и 1533 участника), I² = 23%, проверка общего эффекта P < 0,00001; ось от 0,01 до 100 с подписями «В пользу LC-aNAAT» и «В пользу параллельного теста»."
      },
      "state": "draft"
    },
    {
      "id": "img-p363-2",
      "file": "images/img-p363-2.webp",
      "page": 363,
      "narratives": {
        "en": "Forest plot (Figure 17) of risk ratios (M-H, random, 95% CI) comparing parallel testing with LC-aNAAT in two trials of the proportion of adult inpatients with HIV with a confirmed tuberculosis diagnosis: Ahsberg 2023 (4.27 [2.46, 7.40]) and Gupta-Wright 2018 (2.47 [1.94, 3.14]). The pooled risk ratio is 3.06 [1.82, 5.16] (1460 vs 1533 participants), with I² = 68% and test for overall effect P < 0.0001; the axis runs from 0.01 to 100, labelled 'Favours [LC-aNAAT]' and 'Favours [Parallel]'.",
        "ar": "مخطط شجري (الشكل 17) لنسب الخطر (M-H، تأثيرات عشوائية، فاصل ثقة 95%) بمقارنة الاختبار المتوازي باختبار LC-aNAAT في تجربتين لنسبة المرضى البالغين المصابين بفيروس العوز المناعي البشري في المستشفيات الذين تأكد تشخيص إصابتهم بالسل: Ahsberg 2023 (4.27 [2.46, 7.40]) وGupta-Wright 2018 (2.47 [1.94, 3.14]). وتبلغ نسبة الخطر المجمّعة 3.06 [1.82, 5.16] (1460 مقابل 1533 مشاركاً)، مع I² = 68% واختبار للأثر الكلي P < 0.0001؛ ويمتد المحور من 0.01 إلى 100 مع التسميتين «لصالح LC-aNAAT» و«لصالح الاختبار المتوازي».",
        "zh": "森林图（图17），显示两项试验中平行检测与LC-aNAAT比较的风险比（M-H法，随机效应，95%置信区间）（结局为确诊结核病的成年艾滋病毒感染住院患者比例）：Ahsberg 2023（4.27 [2.46, 7.40]）和Gupta-Wright 2018（2.47 [1.94, 3.14]）。合并风险比为3.06 [1.82, 5.16]（1460对1533名参与者），I² = 68%，总体效应检验P < 0.0001；横轴范围为0.01至100，两侧分别标注“有利于LC-aNAAT”和“有利于平行检测”。",
        "es": "Diagrama de bosque (figura 17) de razones de riesgo (M-H, efectos aleatorios, IC del 95%) que compara las pruebas en paralelo con la LC-aNAAT en dos ensayos para la proporción de pacientes adultos hospitalizados con VIH con diagnóstico confirmado de tuberculosis: Ahsberg 2023 (4,27 [2,46; 7,40]) y Gupta-Wright 2018 (2,47 [1,94; 3,14]). La razón de riesgo agrupada es 3,06 [1,82; 5,16] (1460 frente a 1533 participantes), con I² = 68% y prueba de efecto global P < 0,0001; el eje va de 0,01 a 100, con las etiquetas «A favor de [LC-aNAAT]» y «A favor de [en paralelo]».",
        "fr": "Graphique en forêt (figure 17) des risques relatifs (M-H, effets aléatoires, IC à 95 %) comparant le test en parallèle au LC-aNAAT dans deux essais pour la proportion de patients adultes hospitalisés vivant avec le VIH ayant un diagnostic confirmé de tuberculose : Ahsberg 2023 (4,27 [2,46; 7,40]) et Gupta-Wright 2018 (2,47 [1,94; 3,14]). Le risque relatif poolé est de 3,06 [1,82; 5,16] (1460 contre 1533 participants), avec I² = 68% et un test de l’effet global P < 0,0001 ; l’axe va de 0,01 à 100, avec les libellés « En faveur du LC-aNAAT » et « En faveur du test en parallèle ».",
        "ru": "Лесовидный график (рисунок 17) отношений рисков (M-H, случайные эффекты, 95% ДИ) при сравнении параллельного тестирования с LC-aNAAT в двух исследованиях по доле взрослых стационарных пациентов с ВИЧ с подтвержденным диагнозом туберкулеза: Ahsberg 2023 (4,27 [2,46; 7,40]) и Gupta-Wright 2018 (2,47 [1,94; 3,14]). Объединенное отношение рисков — 3,06 [1,82; 5,16] (1460 и 1533 участника), I² = 68%, проверка общего эффекта P < 0,0001; ось от 0,01 до 100 с подписями «В пользу LC-aNAAT» и «В пользу параллельного теста»."
      },
      "state": "draft"
    },
    {
      "id": "img-p364-1",
      "file": "images/img-p364-1.webp",
      "page": 364,
      "narratives": {
        "en": "Forest plot (Figure 18) of risk ratios (M-H, random, 95% CI) comparing parallel testing with LC-aNAAT in two trials of the proportion of adult inpatients with HIV treated for tuberculosis: Ahsberg 2023 (1.47 [0.95, 2.27]) and Gupta-Wright 2018 (1.47 [1.24, 1.75]). The pooled risk ratio is 1.47 [1.25, 1.73] (1460 vs 1533 participants), with I² = 0% and test for overall effect P < 0.00001; the axis runs from 0.01 to 100, labelled 'Favours [LC-aNAAT]' and 'Favours [Parallel]'.",
        "ar": "مخطط شجري (الشكل 18) لنسب الخطر (M-H، تأثيرات عشوائية، فاصل ثقة 95%) بمقارنة الاختبار المتوازي باختبار LC-aNAAT في تجربتين لنسبة المرضى البالغين المصابين بفيروس العوز المناعي البشري في المستشفيات الذين عولجوا من السل: Ahsberg 2023 (1.47 [0.95, 2.27]) وGupta-Wright 2018 (1.47 [1.24, 1.75]). وتبلغ نسبة الخطر المجمّعة 1.47 [1.25, 1.73] (1460 مقابل 1533 مشاركاً)، مع I² = 0% واختبار للأثر الكلي P < 0.00001؛ ويمتد المحور من 0.01 إلى 100 مع التسميتين «لصالح LC-aNAAT» و«لصالح الاختبار المتوازي».",
        "zh": "森林图（图18），显示两项试验中平行检测与LC-aNAAT比较的风险比（M-H法，随机效应，95%置信区间）（结局为接受结核病治疗的成年艾滋病毒感染住院患者比例）：Ahsberg 2023（1.47 [0.95, 2.27]）和Gupta-Wright 2018（1.47 [1.24, 1.75]）。合并风险比为1.47 [1.25, 1.73]（1460对1533名参与者），I² = 0%，总体效应检验P < 0.00001；横轴范围为0.01至100，两侧分别标注“有利于LC-aNAAT”和“有利于平行检测”。",
        "es": "Diagrama de bosque (figura 18) de razones de riesgo (M-H, efectos aleatorios, IC del 95%) que compara las pruebas en paralelo con la LC-aNAAT en dos ensayos para la proporción de pacientes adultos hospitalizados con VIH tratados por tuberculosis: Ahsberg 2023 (1,47 [0,95; 2,27]) y Gupta-Wright 2018 (1,47 [1,24; 1,75]). La razón de riesgo agrupada es 1,47 [1,25; 1,73] (1460 frente a 1533 participantes), con I² = 0% y prueba de efecto global P < 0,00001; el eje va de 0,01 a 100, con las etiquetas «A favor de [LC-aNAAT]» y «A favor de [en paralelo]».",
        "fr": "Graphique en forêt (figure 18) des risques relatifs (M-H, effets aléatoires, IC à 95 %) comparant le test en parallèle au LC-aNAAT dans deux essais pour la proportion de patients adultes hospitalisés vivant avec le VIH traités pour la tuberculose : Ahsberg 2023 (1,47 [0,95; 2,27]) et Gupta-Wright 2018 (1,47 [1,24; 1,75]). Le risque relatif poolé est de 1,47 [1,25; 1,73] (1460 contre 1533 participants), avec I² = 0% et un test de l’effet global P < 0,00001 ; l’axe va de 0,01 à 100, avec les libellés « En faveur du LC-aNAAT » et « En faveur du test en parallèle ».",
        "ru": "Лесовидный график (рисунок 18) отношений рисков (M-H, случайные эффекты, 95% ДИ) при сравнении параллельного тестирования с LC-aNAAT в двух исследованиях по доле взрослых стационарных пациентов с ВИЧ, получавших лечение от туберкулеза: Ahsberg 2023 (1,47 [0,95; 2,27]) и Gupta-Wright 2018 (1,47 [1,24; 1,75]). Объединенное отношение рисков — 1,47 [1,25; 1,73] (1460 и 1533 участника), I² = 0%, проверка общего эффекта P < 0,00001; ось от 0,01 до 100 с подписями «В пользу LC-aNAAT» и «В пользу параллельного теста»."
      },
      "state": "draft"
    },
    {
      "id": "img-p428-1",
      "file": "images/img-p428-1.webp",
      "page": 428,
      "narratives": {
        "en": "PRISMA flow diagram (Figure 3) of the MC-aNAAT economic evaluation review in three stages. Identification: 123 studies from databases (Embase 60, PubMed 33, Web of Science 15, Scopus 15), with 31 references removed. Screening: 82 studies screened and 78 excluded (66 not an economic evaluation, 12 not on MC-aNAAT); 4 sought for retrieval and 4 assessed for eligibility, of which 3 were excluded because they did not evaluate cost-effectiveness of MC-aNAAT. Included: 1 study.",
        "ar": "مخطط تدفق PRISMA (الشكل 3) لمراجعة التقييمات الاقتصادية لاختبار MC-aNAAT على ثلاث مراحل. التحديد: 123 دراسة من قواعد البيانات (Embase 60، PubMed 33، Web of Science 15، Scopus 15)، مع حذف 31 مرجعاً. الفرز: فُرزت 82 دراسة واستُبعدت 78 (66 ليست تقييمات اقتصادية و12 لا تتناول MC-aNAAT)؛ وطُلب استرجاع 4 دراسات وقُيّمت أهلية 4، استُبعد منها 3 لأنها لم تقيّم مردودية MC-aNAAT. الإدراج: دراسة واحدة.",
        "zh": "PRISMA流程图（图3），分三个阶段展示MC-aNAAT经济学评价综述的研究筛选。识别：从数据库检索到123项研究（Embase 60项、PubMed 33项、Web of Science 15项、Scopus 15项），删除31条文献。筛选：筛选82项研究，排除78项（66项非经济学评价，12项与MC-aNAAT无关）；4项寻求获取全文，4项进行合格性评估，其中3项因未评价MC-aNAAT的成本效益而被排除。纳入：1项研究。",
        "es": "Diagrama de flujo PRISMA (figura 3) de la revisión de evaluaciones económicas de la MC-aNAAT en tres etapas. Identificación: 123 estudios procedentes de bases de datos (Embase 60, PubMed 33, Web of Science 15, Scopus 15), con 31 referencias eliminadas. Cribado: se cribaron 82 estudios y se excluyeron 78 (66 no eran evaluaciones económicas y 12 no trataban sobre la MC-aNAAT); se buscaron 4 para su recuperación y se evaluó la elegibilidad de 4, de los que se excluyeron 3 por no evaluar la costoeficacia de la MC-aNAAT. Incluidos: 1 estudio.",
        "fr": "Diagramme de flux PRISMA (figure 3) de la revue des évaluations économiques du MC-aNAAT en trois étapes. Identification : 123 études issues de bases de données (Embase 60, PubMed 33, Web of Science 15, Scopus 15), 31 références étant supprimées. Sélection : 82 études examinées et 78 exclues (66 n’étaient pas des évaluations économiques, 12 ne portaient pas sur le MC-aNAAT) ; 4 recherchées pour récupération et 4 évaluées pour l’éligibilité, dont 3 exclues car elles n’évaluaient pas le rapport coût-efficacité du MC-aNAAT. Incluse : 1 étude.",
        "ru": "Блок-схема PRISMA (рисунок 3) обзора экономических оценок MC-aNAAT в три этапа. Выявление: 123 исследования из баз данных (Embase 60, PubMed 33, Web of Science 15, Scopus 15), удалена 31 ссылка. Скрининг: проверено 82 исследования, исключено 78 (66 не являлись экономической оценкой, 12 не касались MC-aNAAT); 4 запрошены для получения полного текста и 4 оценены на соответствие критериям, из них 3 исключены, так как не оценивали затратоэффективность MC-aNAAT. Включено: 1 исследование."
      },
      "state": "draft"
    },
    {
      "id": "img-p520-1",
      "file": "images/img-p520-1.webp",
      "page": 520,
      "narratives": {
        "en": "Stacked horizontal bar chart (Figure 2) of QUADAS-2 judgements across 29 studies, showing the proportion rated high (red), unclear (yellow) or low (green) for risk of bias and applicability concerns by domain. For risk of bias, patient selection is 7 high, 9 unclear and 13 low; index test is 29 low; reference standard is 3 high, 6 unclear and 20 low; flow and timing is 1 high, 2 unclear and 26 low. For applicability, patient selection is 13 high, 3 unclear and 13 low, and index test and reference standard are 29 low.",
        "ar": "مخطط أعمدة أفقية مكدسة (الشكل 2) لأحكام QUADAS-2 في 29 دراسة، يبين نسبة التقديرات المرتفعة (أحمر) وغير الواضحة (أصفر) والمنخفضة (أخضر) لخطر التحيز والمخاوف المتعلقة بقابلية التطبيق حسب المجال. بالنسبة لخطر التحيز: اختيار المرضى 7 مرتفع و9 غير واضح و13 منخفض؛ والاختبار المؤشر 29 منخفض؛ والمعيار المرجعي 3 مرتفع و6 غير واضح و20 منخفض؛ والتدفق والتوقيت 1 مرتفع و2 غير واضح و26 منخفض. وبالنسبة لقابلية التطبيق: اختيار المرضى 13 مرتفع و3 غير واضح و13 منخفض، والاختبار المؤشر والمعيار المرجعي 29 منخفض.",
        "zh": "堆积水平条形图（图2），显示29项研究的QUADAS-2评价结果，按领域列出偏倚风险和适用性关注被评为高（红色）、不明（黄色）或低（绿色）的比例。偏倚风险方面：患者选择高7项、不明9项、低13项；待评价试验低29项；参考标准高3项、不明6项、低20项；流程和时间高1项、不明2项、低26项。适用性方面：患者选择高13项、不明3项、低13项，待评价试验和参考标准均为低29项。",
        "es": "Gráfico de barras horizontales apiladas (figura 2) de las valoraciones QUADAS-2 de 29 estudios, que muestra la proporción calificada como alta (rojo), incierta (amarillo) o baja (verde) en cuanto a riesgo de sesgo y problemas de aplicabilidad por dominio. En riesgo de sesgo, la selección de pacientes es alta en 7, incierta en 9 y baja en 13; la prueba índice es baja en 29; el patrón de referencia es alto en 3, incierto en 6 y bajo en 20; el flujo y la cronología son altos en 1, inciertos en 2 y bajos en 26. En aplicabilidad, la selección de pacientes es alta en 13, incierta en 3 y baja en 13, y la prueba índice y el patrón de referencia son bajos en 29.",
        "fr": "Diagramme à barres horizontales empilées (figure 2) des évaluations QUADAS-2 de 29 études, montrant la proportion jugée élevée (rouge), incertaine (jaune) ou faible (vert) pour le risque de biais et les préoccupations d’applicabilité par domaine. Pour le risque de biais, la sélection des patients est élevée pour 7, incertaine pour 9 et faible pour 13 ; le test index est faible pour 29 ; la norme de référence est élevée pour 3, incertaine pour 6 et faible pour 20 ; le flux et la chronologie sont élevés pour 1, incertains pour 2 et faibles pour 26. Pour l’applicabilité, la sélection des patients est élevée pour 13, incertaine pour 3 et faible pour 13, et le test index et la norme de référence sont faibles pour 29.",
        "ru": "Горизонтальная столбчатая диаграмма с накоплением (рисунок 2) оценок QUADAS-2 по 29 исследованиям, показывающая долю оценок «высокий» (красный), «неясный» (желтый) и «низкий» (зеленый) для риска систематической ошибки и проблем применимости по доменам. Риск систематической ошибки: отбор пациентов — высокий 7, неясный 9, низкий 13; индексный тест — низкий 29; эталонный стандарт — высокий 3, неясный 6, низкий 20; поток и сроки — высокий 1, неясный 2, низкий 26. Применимость: отбор пациентов — высокий 13, неясный 3, низкий 13; индексный тест и эталонный стандарт — низкий 29."
      },
      "state": "draft"
    },
    {
      "id": "img-p521-1",
      "file": "images/img-p521-1.webp",
      "page": 521,
      "narratives": {
        "en": "Forest plot (Figure 3) of sensitivity and specificity for TB detection for 29 studies, listing TP, FP, FN and TN counts with sensitivity and specificity (95% CI) and plots of each estimate on a 0–1 scale. Most sensitivity estimates lie between 0.79 (Berhanu 2018) and 1.00; most specificity estimates are 0.92 or higher, with lower values for Obasanya 2017 (0.60), Shaheed 2020 (0.68), Paradis 2018 (0.72) and Wang 2016 (0.84).",
        "ar": "مخطط شجري (الشكل 3) للحساسية والنوعية في الكشف عن السل لـ 29 دراسة، يورد أعداد الإيجابيات الحقيقية والإيجابيات الكاذبة والسلبيات الكاذبة والسلبيات الحقيقية (TP وFP وFN وTN) مع الحساسية والنوعية (فاصل ثقة 95%) ورسوماً لكل تقدير على مقياس من 0 إلى 1. وتتراوح معظم تقديرات الحساسية بين 0.79 (Berhanu 2018) و1.00؛ ومعظم تقديرات النوعية 0.92 أو أعلى، مع قيم أدنى لدى Obasanya 2017 (0.60) وShaheed 2020 (0.68) وParadis 2018 (0.72) وWang 2016 (0.84).",
        "zh": "森林图（图3），显示结核病检测的灵敏度和特异度，涵盖29项研究，列出真阳性、假阳性、假阴性和真阴性（TP、FP、FN、TN）数量及灵敏度和特异度（95%置信区间），并在0–1刻度上绘出各估计值。大多数灵敏度估计值介于0.79（Berhanu 2018）和1.00之间；大多数特异度估计值为0.92或以上，Obasanya 2017（0.60）、Shaheed 2020（0.68）、Paradis 2018（0.72）和Wang 2016（0.84）较低。",
        "es": "Diagrama de bosque (figura 3) de la sensibilidad y la especificidad para la detección de la TB de 29 estudios, con los recuentos de VP, FP, FN y VN (TP, FP, FN, TN), la sensibilidad y la especificidad (IC del 95%) y la representación de cada estimación en una escala de 0 a 1. La mayoría de las estimaciones de sensibilidad se sitúan entre 0,79 (Berhanu 2018) y 1,00; la mayoría de las de especificidad son de 0,92 o más, con valores inferiores en Obasanya 2017 (0,60), Shaheed 2020 (0,68), Paradis 2018 (0,72) y Wang 2016 (0,84).",
        "fr": "Graphique en forêt (figure 3) de la sensibilité et de la spécificité pour la détection de la TB pour 29 études, indiquant les effectifs VP, FP, FN et VN (TP, FP, FN, TN), la sensibilité et la spécificité (IC à 95 %) et la représentation de chaque estimation sur une échelle de 0 à 1. La plupart des estimations de sensibilité se situent entre 0,79 (Berhanu 2018) et 1,00 ; la plupart des estimations de spécificité sont de 0,92 ou plus, avec des valeurs plus faibles pour Obasanya 2017 (0,60), Shaheed 2020 (0,68), Paradis 2018 (0,72) et Wang 2016 (0,84).",
        "ru": "Лесовидный график (рисунок 3) чувствительности и специфичности для выявления ТБ по 29 исследованиям с числом ИП, ЛП, ЛО и ИО (TP, FP, FN, TN), чувствительностью и специфичностью (95% ДИ) и отображением каждой оценки на шкале от 0 до 1. Большинство оценок чувствительности находятся в диапазоне от 0,79 (Berhanu 2018) до 1,00; большинство оценок специфичности составляют 0,92 и выше, более низкие значения — у Obasanya 2017 (0,60), Shaheed 2020 (0,68), Paradis 2018 (0,72) и Wang 2016 (0,84)."
      },
      "state": "draft"
    },
    {
      "id": "img-p522-1",
      "file": "images/img-p522-1.webp",
      "page": 522,
      "narratives": {
        "en": "Forest plot (Figure 4) of sensitivity for TB detection in smear-positive specimens for 26 studies, listing TP, FP, FN and TN counts with sensitivity (95% CI) and a plot of each estimate on a 0–1 scale. Sensitivity ranges from 0.93 (Shaheed 2020) to 1.00, with most studies at 0.97 or above.",
        "ar": "مخطط شجري (الشكل 4) للحساسية في الكشف عن السل في العينات إيجابية اللطاخة لـ 26 دراسة، يورد أعداد الإيجابيات الحقيقية والإيجابيات الكاذبة والسلبيات الكاذبة والسلبيات الحقيقية (TP وFP وFN وTN) مع الحساسية (فاصل ثقة 95%) ورسماً لكل تقدير على مقياس من 0 إلى 1. وتتراوح الحساسية بين 0.93 (Shaheed 2020) و1.00، ومعظم الدراسات عند 0.97 أو أعلى.",
        "zh": "森林图（图4），显示涂片阳性标本中结核病检测的灵敏度，涵盖26项研究，列出真阳性、假阳性、假阴性和真阴性（TP、FP、FN、TN）数量及灵敏度（95%置信区间），并在0–1刻度上绘出各估计值。灵敏度范围为0.93（Shaheed 2020）至1.00，大多数研究在0.97或以上。",
        "es": "Diagrama de bosque (figura 4) de la sensibilidad para la detección de la TB en muestras con baciloscopia positiva de 26 estudios, con los recuentos de VP, FP, FN y VN (TP, FP, FN, TN), la sensibilidad (IC del 95%) y la representación de cada estimación en una escala de 0 a 1. La sensibilidad oscila entre 0,93 (Shaheed 2020) y 1,00, y la mayoría de los estudios se sitúan en 0,97 o más.",
        "fr": "Graphique en forêt (figure 4) de la sensibilité pour la détection de la TB dans les échantillons à frottis positif pour 26 études, indiquant les effectifs VP, FP, FN et VN (TP, FP, FN, TN), la sensibilité (IC à 95 %) et la représentation de chaque estimation sur une échelle de 0 à 1. La sensibilité varie de 0,93 (Shaheed 2020) à 1,00, la plupart des études se situant à 0,97 ou plus.",
        "ru": "Лесовидный график (рисунок 4) чувствительности для выявления ТБ в мазок-положительных образцах по 26 исследованиям с числом ИП, ЛП, ЛО и ИО (TP, FP, FN, TN), чувствительностью (95% ДИ) и отображением каждой оценки на шкале от 0 до 1. Чувствительность варьирует от 0,93 (Shaheed 2020) до 1,00, в большинстве исследований — 0,97 и выше."
      },
      "state": "draft"
    },
    {
      "id": "img-p522-2",
      "file": "images/img-p522-2.webp",
      "page": 522,
      "narratives": {
        "en": "Forest plot (Figure 5) of sensitivity and specificity for TB detection in smear-negative specimens for 27 studies, listing TP, FP, FN and TN counts with sensitivity and specificity (95% CI) and plots of each estimate on a 0–1 scale. Studies are ordered by an 'S- C+' column (from 65.12 to 3.14); sensitivity varies widely, from 0.22 (Howlett 2020) to 1.00, while most specificity estimates are 0.91 or higher.",
        "ar": "مخطط شجري (الشكل 5) للحساسية والنوعية في الكشف عن السل في العينات سلبية اللطاخة لـ 27 دراسة، يورد أعداد الإيجابيات الحقيقية والإيجابيات الكاذبة والسلبيات الكاذبة والسلبيات الحقيقية (TP وFP وFN وTN) مع الحساسية والنوعية (فاصل ثقة 95%) ورسوماً لكل تقدير على مقياس من 0 إلى 1. وتُرتَّب الدراسات حسب عمود «S- C+» (من 65.12 إلى 3.14)؛ وتتفاوت الحساسية تفاوتاً كبيراً من 0.22 (Howlett 2020) إلى 1.00، بينما تبلغ معظم تقديرات النوعية 0.91 أو أعلى.",
        "zh": "森林图（图5），显示涂片阴性标本中结核病检测的灵敏度和特异度，涵盖27项研究，列出真阳性、假阳性、假阴性和真阴性（TP、FP、FN、TN）数量及灵敏度和特异度（95%置信区间），并在0–1刻度上绘出各估计值。各研究按“S- C+”列排序（从65.12至3.14）；灵敏度差异很大，从0.22（Howlett 2020）到1.00，而大多数特异度估计值为0.91或以上。",
        "es": "Diagrama de bosque (figura 5) de la sensibilidad y la especificidad para la detección de la TB en muestras con baciloscopia negativa de 27 estudios, con los recuentos de VP, FP, FN y VN (TP, FP, FN, TN), la sensibilidad y la especificidad (IC del 95%) y la representación de cada estimación en una escala de 0 a 1. Los estudios se ordenan según una columna «S- C+» (de 65,12 a 3,14); la sensibilidad varía mucho, de 0,22 (Howlett 2020) a 1,00, mientras que la mayoría de las estimaciones de especificidad son de 0,91 o más.",
        "fr": "Graphique en forêt (figure 5) de la sensibilité et de la spécificité pour la détection de la TB dans les échantillons à frottis négatif pour 27 études, indiquant les effectifs VP, FP, FN et VN (TP, FP, FN, TN), la sensibilité et la spécificité (IC à 95 %) et la représentation de chaque estimation sur une échelle de 0 à 1. Les études sont classées selon une colonne « S- C+ » (de 65,12 à 3,14) ; la sensibilité varie fortement, de 0,22 (Howlett 2020) à 1,00, tandis que la plupart des estimations de spécificité sont de 0,91 ou plus.",
        "ru": "Лесовидный график (рисунок 5) чувствительности и специфичности для выявления ТБ в мазок-отрицательных образцах по 27 исследованиям с числом ИП, ЛП, ЛО и ИО (TP, FP, FN, TN), чувствительностью и специфичностью (95% ДИ) и отображением каждой оценки на шкале от 0 до 1. Исследования упорядочены по столбцу «S- C+» (от 65,12 до 3,14); чувствительность сильно варьирует — от 0,22 (Howlett 2020) до 1,00, тогда как большинство оценок специфичности составляют 0,91 и выше."
      },
      "state": "draft"
    },
    {
      "id": "img-p523-1",
      "file": "images/img-p523-1.webp",
      "page": 523,
      "narratives": {
        "en": "Paired forest plots (part of Figure 6, head-to-head comparisons) for index-test TB detection in Berhanu 2018, Scott 2017 and Wang 2016 (upper panel) and for Xpert on the same specimens (lower panel), each listing TP, FP, FN, TN and sensitivity and specificity (95% CI). Index-test sensitivity is 0.79, 0.85 and 1.00 versus 0.82, 0.92 and 0.97 for Xpert; specificity is 0.97, 0.92 and 0.84 versus 1.00, 0.98 and 0.90.",
        "ar": "مخططات شجرية مزدوجة (جزء من الشكل 6، مقارنات مباشرة) للكشف عن السل باختبار الاختبار المؤشر في Berhanu 2018, Scott 2017 and Wang 2016 (اللوحة العليا) وXpert على العينات نفسها (اللوحة السفلى)، يورد كل منها TP وFP وFN وTN والحساسية والنوعية (فاصل ثقة 95%). تبلغ حساسية الاختبار المؤشر 0.79 و0.85 و1.00 مقابل 0.82 و0.92 و0.97 لـ Xpert؛ والنوعية 0.97 و0.92 و0.84 مقابل 1.00 و0.98 و0.90.",
        "zh": "成对森林图（图6的一部分，头对头比较），上图为Berhanu 2018, Scott 2017 and Wang 2016中待评价试验的结核病检测结果，下图为同一标本上Xpert的结果，各列出TP、FP、FN、TN及灵敏度和特异度（95%置信区间）。待评价试验的灵敏度为0.79、0.85和1.00，Xpert为0.82、0.92和0.97；特异度为0.97、0.92和0.84，Xpert为1.00、0.98和0.90。",
        "es": "Diagramas de bosque emparejados (parte de la figura 6, comparaciones directas) de la detección de la TB con la prueba índice en Berhanu 2018, Scott 2017 and Wang 2016 (panel superior) y con Xpert en las mismas muestras (panel inferior), cada uno con VP, FP, FN, VN (TP, FP, FN, TN) y la sensibilidad y la especificidad (IC del 95%). La sensibilidad de la prueba índice es de 0,79, 0,85 y 1,00 frente a 0,82, 0,92 y 0,97 con Xpert; la especificidad es de 0,97, 0,92 y 0,84 frente a 1,00, 0,98 y 0,90.",
        "fr": "Graphiques en forêt appariés (partie de la figure 6, comparaisons directes) de la détection de la TB par le test index dans Berhanu 2018, Scott 2017 and Wang 2016 (panneau supérieur) et par Xpert sur les mêmes échantillons (panneau inférieur), chacun indiquant VP, FP, FN, VN (TP, FP, FN, TN) ainsi que la sensibilité et la spécificité (IC à 95 %). La sensibilité du test index est de 0,79, 0,85 et 1,00 contre 0,82, 0,92 et 0,97 pour Xpert ; la spécificité est de 0,97, 0,92 et 0,84 contre 1,00, 0,98 et 0,90.",
        "ru": "Парные лесовидные графики (часть рисунка 6, прямые сравнения) выявления ТБ с помощью индексного теста в исследованиях Berhanu 2018, Scott 2017 and Wang 2016 (верхняя панель) и с помощью Xpert на тех же образцах (нижняя панель), с указанием TP, FP, FN, TN, чувствительности и специфичности (95% ДИ). Чувствительность индексного теста — 0,79, 0,85 и 1,00 против 0,82, 0,92 и 0,97 у Xpert; специфичность — 0,97, 0,92 и 0,84 против 1,00, 0,98 и 0,90."
      },
      "state": "draft"
    },
    {
      "id": "img-p524-1",
      "file": "images/img-p524-1.webp",
      "page": 524,
      "narratives": {
        "en": "Paired forest plots (part of Figure 6, head-to-head comparisons) for index-test TB detection in Berhanu 2018 and Howlett 2020 (upper panel) and for Xpert Ultra on the same specimens (lower panel), each listing TP, FP, FN, TN and sensitivity and specificity (95% CI). Index-test sensitivity is 0.79 and 0.81 versus 0.89 and 0.93 for Ultra; specificity is 0.97 in both studies versus 0.96 and 0.97.",
        "ar": "مخططات شجرية مزدوجة (جزء من الشكل 6، مقارنات مباشرة) للكشف عن السل باختبار الاختبار المؤشر في Berhanu 2018 and Howlett 2020 (اللوحة العليا) وXpert Ultra على العينات نفسها (اللوحة السفلى)، يورد كل منها TP وFP وFN وTN والحساسية والنوعية (فاصل ثقة 95%). تبلغ حساسية الاختبار المؤشر 0.79 و0.81 مقابل 0.89 و0.93 لـ Ultra؛ والنوعية 0.97 في الدراستين مقابل 0.96 و0.97.",
        "zh": "成对森林图（图6的一部分，头对头比较），上图为Berhanu 2018 and Howlett 2020中待评价试验的结核病检测结果，下图为同一标本上Xpert Ultra的结果，各列出TP、FP、FN、TN及灵敏度和特异度（95%置信区间）。待评价试验的灵敏度为0.79和0.81，Ultra为0.89和0.93；两项研究的特异度均为0.97，Ultra为0.96和0.97。",
        "es": "Diagramas de bosque emparejados (parte de la figura 6, comparaciones directas) de la detección de la TB con la prueba índice en Berhanu 2018 and Howlett 2020 (panel superior) y con Xpert Ultra en las mismas muestras (panel inferior), cada uno con VP, FP, FN, VN (TP, FP, FN, TN) y la sensibilidad y la especificidad (IC del 95%). La sensibilidad de la prueba índice es de 0,79 y 0,81 frente a 0,89 y 0,93 con Ultra; la especificidad es de 0,97 en ambos estudios frente a 0,96 y 0,97.",
        "fr": "Graphiques en forêt appariés (partie de la figure 6, comparaisons directes) de la détection de la TB par le test index dans Berhanu 2018 and Howlett 2020 (panneau supérieur) et par Xpert Ultra sur les mêmes échantillons (panneau inférieur), chacun indiquant VP, FP, FN, VN (TP, FP, FN, TN) ainsi que la sensibilité et la spécificité (IC à 95 %). La sensibilité du test index est de 0,79 et 0,81 contre 0,89 et 0,93 pour Ultra ; la spécificité est de 0,97 dans les deux études contre 0,96 et 0,97.",
        "ru": "Парные лесовидные графики (часть рисунка 6, прямые сравнения) выявления ТБ с помощью индексного теста в исследованиях Berhanu 2018 and Howlett 2020 (верхняя панель) и с помощью Xpert Ultra на тех же образцах (нижняя панель), с указанием TP, FP, FN, TN, чувствительности и специфичности (95% ДИ). Чувствительность индексного теста — 0,79 и 0,81 против 0,89 и 0,93 у Ultra; специфичность — 0,97 в обоих исследованиях против 0,96 и 0,97."
      },
      "state": "draft"
    },
    {
      "id": "img-p524-2",
      "file": "images/img-p524-2.webp",
      "page": 524,
      "narratives": {
        "en": "Forest plot (part of Figure 6) comparing two rows from one study: Obasanya 2017 (sensitivity 0.89 [0.79, 0.95], specificity 0.60 [0.53, 0.66]) and Obasanya 2017-Xpert (sensitivity 0.79 [0.67, 0.87], specificity 0.94 [0.90, 0.97]), with TP, FP, FN and TN counts.",
        "ar": "مخطط شجري (جزء من الشكل 6) يقارن صفين من دراسة واحدة: Obasanya 2017 (الحساسية 0.89 [0.79، 0.95]، النوعية 0.60 [0.53، 0.66]) وObasanya 2017-Xpert (الحساسية 0.79 [0.67، 0.87]، النوعية 0.94 [0.90، 0.97])، مع أعداد TP وFP وFN وTN.",
        "zh": "森林图（图6的一部分），比较同一研究的两行结果：Obasanya 2017（灵敏度0.89 [0.79, 0.95]，特异度0.60 [0.53, 0.66]）和Obasanya 2017-Xpert（灵敏度0.79 [0.67, 0.87]，特异度0.94 [0.90, 0.97]），并列出TP、FP、FN和TN数量。",
        "es": "Diagrama de bosque (parte de la figura 6) que compara dos filas de un mismo estudio: Obasanya 2017 (sensibilidad 0,89 [0,79; 0,95], especificidad 0,60 [0,53; 0,66]) y Obasanya 2017-Xpert (sensibilidad 0,79 [0,67; 0,87], especificidad 0,94 [0,90; 0,97]), con los recuentos de VP, FP, FN y VN.",
        "fr": "Graphique en forêt (partie de la figure 6) comparant deux lignes d’une même étude : Obasanya 2017 (sensibilité 0,89 [0,79 ; 0,95], spécificité 0,60 [0,53 ; 0,66]) et Obasanya 2017-Xpert (sensibilité 0,79 [0,67 ; 0,87], spécificité 0,94 [0,90 ; 0,97]), avec les effectifs VP, FP, FN et VN.",
        "ru": "Лесовидный график (часть рисунка 6), сравнивающий две строки одного исследования: Obasanya 2017 (чувствительность 0,89 [0,79; 0,95], специфичность 0,60 [0,53; 0,66]) и Obasanya 2017-Xpert (чувствительность 0,79 [0,67; 0,87], специфичность 0,94 [0,90; 0,97]), с числом TP, FP, FN и TN."
      },
      "state": "draft"
    },
    {
      "id": "img-p524-4",
      "file": "images/img-p524-4.webp",
      "page": 524,
      "narratives": {
        "en": "Paired forest plots (part of Figure 6, head-to-head comparisons) for index-test TB detection in Paradis 2018 and Shah 2019 (upper panel) and for a comparator on the same specimens (lower panel), each listing TP, FP, FN, TN and sensitivity and specificity (95% CI). Index-test sensitivity is 0.95 and 0.93 and specificity 0.72 and 0.97; for the comparator, sensitivity is 0.95 and 0.90 and specificity 0.73 and 0.98.",
        "ar": "مخططات شجرية مزدوجة (جزء من الشكل 6، مقارنات مباشرة) للكشف عن السل باختبار الاختبار المؤشر في Paradis 2018 and Shah 2019 (اللوحة العليا) واختبار مقارن على العينات نفسها (اللوحة السفلى)، يورد كل منها TP وFP وFN وTN والحساسية والنوعية (فاصل ثقة 95%). تبلغ حساسية الاختبار المؤشر 0.95 و0.93 والنوعية 0.72 و0.97؛ وتبلغ حساسية الاختبار المقارن 0.95 و0.90 والنوعية 0.73 و0.98.",
        "zh": "成对森林图（图6的一部分，头对头比较），上图为Paradis 2018 and Shah 2019中待评价试验的结核病检测结果，下图为同一标本上对照试验的结果，各列出TP、FP、FN、TN及灵敏度和特异度（95%置信区间）。待评价试验的灵敏度为0.95和0.93，特异度为0.72和0.97；对照试验的灵敏度为0.95和0.90，特异度为0.73和0.98。",
        "es": "Diagramas de bosque emparejados (parte de la figura 6, comparaciones directas) de la detección de la TB con la prueba índice en Paradis 2018 and Shah 2019 (panel superior) y con un comparador en las mismas muestras (panel inferior), cada uno con VP, FP, FN, VN (TP, FP, FN, TN) y la sensibilidad y la especificidad (IC del 95%). La sensibilidad de la prueba índice es de 0,95 y 0,93 y la especificidad de 0,72 y 0,97; la del comparador es de 0,95 y 0,90 y la especificidad de 0,73 y 0,98.",
        "fr": "Graphiques en forêt appariés (partie de la figure 6, comparaisons directes) de la détection de la TB par le test index dans Paradis 2018 and Shah 2019 (panneau supérieur) et par un comparateur sur les mêmes échantillons (panneau inférieur), chacun indiquant VP, FP, FN, VN (TP, FP, FN, TN) ainsi que la sensibilité et la spécificité (IC à 95 %). La sensibilité du test index est de 0,95 et 0,93 et la spécificité de 0,72 et 0,97 ; pour le comparateur, la sensibilité est de 0,95 et 0,90 et la spécificité de 0,73 et 0,98.",
        "ru": "Парные лесовидные графики (часть рисунка 6, прямые сравнения) выявления ТБ с помощью индексного теста в исследованиях Paradis 2018 and Shah 2019 (верхняя панель) и с помощью теста сравнения на тех же образцах (нижняя панель), с указанием TP, FP, FN, TN, чувствительности и специфичности (95% ДИ). Чувствительность индексного теста — 0,95 и 0,93, специфичность — 0,72 и 0,97; у теста сравнения чувствительность — 0,95 и 0,90, специфичность — 0,73 и 0,98."
      },
      "state": "draft"
    },
    {
      "id": "img-p524-8",
      "file": "images/img-p524-8.webp",
      "page": 524,
      "narratives": {
        "en": "Paired forest plots (part of Figure 6) for one study, de Vos 2020: 'Cobas 6800/8800 Tb detection' has sensitivity 0.92 [0.88, 0.95] and specificity 0.96 [0.92, 0.98], and the comparator has sensitivity 0.90 [0.85, 0.94] and specificity 0.95 [0.90, 0.98].",
        "ar": "مخططات شجرية مزدوجة (جزء من الشكل 6) لدراسة واحدة هي de Vos 2020: يبلغ «الكشف عن السل باختبار Cobas 6800/8800» حساسية 0.92 [0.88، 0.95] ونوعية 0.96 [0.92، 0.98]، ويبلغ الاختبار المقارن حساسية 0.90 [0.85، 0.94] ونوعية 0.95 [0.90، 0.98].",
        "zh": "一项研究（de Vos 2020）的成对森林图（图6的一部分）：“Cobas 6800/8800结核病检测”的灵敏度为0.92 [0.88, 0.95]，特异度为0.96 [0.92, 0.98]；对照试验的灵敏度为0.90 [0.85, 0.94]，特异度为0.95 [0.90, 0.98]。",
        "es": "Diagramas de bosque emparejados (parte de la figura 6) de un estudio, de Vos 2020: la «detección de TB con Cobas 6800/8800» tiene una sensibilidad de 0,92 [0,88; 0,95] y una especificidad de 0,96 [0,92; 0,98], y el comparador una sensibilidad de 0,90 [0,85; 0,94] y una especificidad de 0,95 [0,90; 0,98].",
        "fr": "Graphiques en forêt appariés (partie de la figure 6) pour une étude, de Vos 2020 : la « détection de la TB par Cobas 6800/8800 » a une sensibilité de 0,92 [0,88 ; 0,95] et une spécificité de 0,96 [0,92 ; 0,98], et le comparateur une sensibilité de 0,90 [0,85 ; 0,94] et une spécificité de 0,95 [0,90 ; 0,98].",
        "ru": "Парные лесовидные графики (часть рисунка 6) для одного исследования, de Vos 2020: «выявление ТБ с помощью Cobas 6800/8800» — чувствительность 0,92 [0,88; 0,95], специфичность 0,96 [0,92; 0,98]; тест сравнения — чувствительность 0,90 [0,85; 0,94], специфичность 0,95 [0,90; 0,98]."
      },
      "state": "draft"
    },
    {
      "id": "img-p525-1",
      "file": "images/img-p525-1.webp",
      "page": 525,
      "narratives": {
        "en": "Stacked horizontal bar chart (Figure 7) of QUADAS-2 judgements across 18 studies, showing the proportion rated high (red), unclear (yellow) or low (green) for risk of bias and applicability concerns by domain. For risk of bias, patient selection is 2 high, 6 unclear and 10 low; index test is 18 low; reference standard is 1 high, 3 unclear and 14 low; flow and timing is 1 high, 1 unclear and 16 low. For applicability, patient selection is 6 high, 3 unclear and 9 low, and index test and reference standard are 18 low.",
        "ar": "مخطط أعمدة أفقية مكدسة (الشكل 7) لأحكام QUADAS-2 في 18 دراسة، يبين نسبة التقديرات المرتفعة (أحمر) وغير الواضحة (أصفر) والمنخفضة (أخضر) لخطر التحيز والمخاوف المتعلقة بقابلية التطبيق حسب المجال. بالنسبة لخطر التحيز: اختيار المرضى 2 مرتفع و6 غير واضح و10 منخفض؛ والاختبار المؤشر 18 منخفض؛ والمعيار المرجعي 1 مرتفع و3 غير واضح و14 منخفض؛ والتدفق والتوقيت 1 مرتفع و1 غير واضح و16 منخفض. وبالنسبة لقابلية التطبيق: اختيار المرضى 6 مرتفع و3 غير واضح و9 منخفض، والاختبار المؤشر والمعيار المرجعي 18 منخفض.",
        "zh": "堆积水平条形图（图7），显示18项研究的QUADAS-2评价结果，按领域列出偏倚风险和适用性关注被评为高（红色）、不明（黄色）或低（绿色）的比例。偏倚风险方面：患者选择高2项、不明6项、低10项；待评价试验低18项；参考标准高1项、不明3项、低14项；流程和时间高1项、不明1项、低16项。适用性方面：患者选择高6项、不明3项、低9项，待评价试验和参考标准均为低18项。",
        "es": "Gráfico de barras horizontales apiladas (figura 7) de las valoraciones QUADAS-2 de 18 estudios, que muestra la proporción calificada como alta (rojo), incierta (amarillo) o baja (verde) en cuanto a riesgo de sesgo y problemas de aplicabilidad por dominio. En riesgo de sesgo, la selección de pacientes es alta en 2, incierta en 6 y baja en 10; la prueba índice es baja en 18; el patrón de referencia es alto en 1, incierto en 3 y bajo en 14; el flujo y la cronología son altos en 1, inciertos en 1 y bajos en 16. En aplicabilidad, la selección de pacientes es alta en 6, incierta en 3 y baja en 9, y la prueba índice y el patrón de referencia son bajos en 18.",
        "fr": "Diagramme à barres horizontales empilées (figure 7) des évaluations QUADAS-2 de 18 études, montrant la proportion jugée élevée (rouge), incertaine (jaune) ou faible (vert) pour le risque de biais et les préoccupations d’applicabilité par domaine. Pour le risque de biais, la sélection des patients est élevée pour 2, incertaine pour 6 et faible pour 10 ; le test index est faible pour 18 ; la norme de référence est élevée pour 1, incertaine pour 3 et faible pour 14 ; le flux et la chronologie sont élevés pour 1, incertains pour 1 et faibles pour 16. Pour l’applicabilité, la sélection des patients est élevée pour 6, incertaine pour 3 et faible pour 9, et le test index et la norme de référence sont faibles pour 18.",
        "ru": "Горизонтальная столбчатая диаграмма с накоплением (рисунок 7) оценок QUADAS-2 по 18 исследованиям, показывающая долю оценок «высокий» (красный), «неясный» (желтый) и «низкий» (зеленый) для риска систематической ошибки и проблем применимости по доменам. Риск систематической ошибки: отбор пациентов — высокий 2, неясный 6, низкий 10; индексный тест — низкий 18; эталонный стандарт — высокий 1, неясный 3, низкий 14; поток и сроки — высокий 1, неясный 1, низкий 16. Применимость: отбор пациентов — высокий 6, неясный 3, низкий 9; индексный тест и эталонный стандарт — низкий 18."
      },
      "state": "draft"
    },
    {
      "id": "img-p526-1",
      "file": "images/img-p526-1.webp",
      "page": 526,
      "narratives": {
        "en": "Forest plot (Figure 8) of sensitivity and specificity for rifampicin resistance detection with phenotypic DST as reference standard for 19 studies, listing TP, FP, FN and TN counts with sensitivity and specificity (95% CI) and plots of each estimate on a 0–1 scale. Sensitivity is mostly 0.88–1.00 (not estimable for Cieslelczuk 2020 and Luukinen 2020) and specificity is 0.95–1.00.",
        "ar": "مخطط شجري (الشكل 8) للحساسية والنوعية في الكشف عن مقاومة الريفامبيسين باستخدام اختبار الحساسية للأدوية المظهري معياراً مرجعياً لـ 19 دراسة، يورد أعداد الإيجابيات الحقيقية والإيجابيات الكاذبة والسلبيات الكاذبة والسلبيات الحقيقية (TP وFP وFN وTN) مع الحساسية والنوعية (فاصل ثقة 95%) ورسوماً لكل تقدير على مقياس من 0 إلى 1. وتتراوح الحساسية في معظمها بين 0.88 و1.00 (غير قابلة للتقدير في Cieslelczuk 2020 وLuukinen 2020)، والنوعية بين 0.95 و1.00.",
        "zh": "森林图（图8），显示以表型药敏试验为参考标准的利福平耐药检测灵敏度和特异度，涵盖19项研究，列出真阳性、假阳性、假阴性和真阴性（TP、FP、FN、TN）数量及灵敏度和特异度（95%置信区间），并在0–1刻度上绘出各估计值。灵敏度大多为0.88–1.00（Cieslelczuk 2020和Luukinen 2020无法估计），特异度为0.95–1.00。",
        "es": "Diagrama de bosque (figura 8) de la sensibilidad y la especificidad para la detección de la resistencia a la rifampicina con la PSF fenotípica como patrón de referencia de 19 estudios, con los recuentos de VP, FP, FN y VN (TP, FP, FN, TN), la sensibilidad y la especificidad (IC del 95%) y la representación de cada estimación en una escala de 0 a 1. La sensibilidad se sitúa mayoritariamente entre 0,88 y 1,00 (no estimable en Cieslelczuk 2020 y Luukinen 2020) y la especificidad entre 0,95 y 1,00.",
        "fr": "Graphique en forêt (figure 8) de la sensibilité et de la spécificité pour la détection de la résistance à la rifampicine avec le TPM phénotypique comme norme de référence pour 19 études, indiquant les effectifs VP, FP, FN et VN (TP, FP, FN, TN), la sensibilité et la spécificité (IC à 95 %) et la représentation de chaque estimation sur une échelle de 0 à 1. La sensibilité se situe pour l’essentiel entre 0,88 et 1,00 (non estimable pour Cieslelczuk 2020 et Luukinen 2020) et la spécificité entre 0,95 et 1,00.",
        "ru": "Лесовидный график (рисунок 8) чувствительности и специфичности для выявления устойчивости к рифампицину с фенотипическим ТЛЧ в качестве эталонного стандарта по 19 исследованиям с числом ИП, ЛП, ЛО и ИО (TP, FP, FN, TN), чувствительностью и специфичностью (95% ДИ) и отображением каждой оценки на шкале от 0 до 1. Чувствительность в основном составляет 0,88–1,00 (не поддается оценке для Cieslelczuk 2020 и Luukinen 2020), специфичность — 0,95–1,00."
      },
      "state": "draft"
    },
    {
      "id": "img-p526-2",
      "file": "images/img-p526-2.webp",
      "page": 526,
      "narratives": {
        "en": "Forest plot (Figure 9) of sensitivity and specificity for isoniazid resistance detection with phenotypic DST as reference standard for 19 studies, listing TP, FP, FN and TN counts with sensitivity and specificity (95% CI) and plots of each estimate on a 0–1 scale. Studies are ordered by a column headed '%RIF resistant' (56.85 to 0.0); sensitivity ranges from 0.58 (Hofmann-Thiel 2020) to 1.00, while specificity is 0.94–1.00.",
        "ar": "مخطط شجري (الشكل 9) للحساسية والنوعية في الكشف عن مقاومة الإيزونيازيد باستخدام اختبار الحساسية للأدوية المظهري معياراً مرجعياً لـ 19 دراسة، يورد أعداد الإيجابيات الحقيقية والإيجابيات الكاذبة والسلبيات الكاذبة والسلبيات الحقيقية (TP وFP وFN وTN) مع الحساسية والنوعية (فاصل ثقة 95%) ورسوماً لكل تقدير على مقياس من 0 إلى 1. وتُرتَّب الدراسات حسب عمود بعنوان «%RIF resistant» (من 56.85 إلى 0.0)؛ وتتراوح الحساسية بين 0.58 (Hofmann-Thiel 2020) و1.00، والنوعية بين 0.94 و1.00.",
        "zh": "森林图（图9），显示以表型药敏试验为参考标准的异烟肼耐药检测灵敏度和特异度，涵盖19项研究，列出真阳性、假阳性、假阴性和真阴性（TP、FP、FN、TN）数量及灵敏度和特异度（95%置信区间），并在0–1刻度上绘出各估计值。各研究按标题为“%RIF resistant”的列排序（56.85至0.0）；灵敏度范围为0.58（Hofmann-Thiel 2020）至1.00，特异度为0.94–1.00。",
        "es": "Diagrama de bosque (figura 9) de la sensibilidad y la especificidad para la detección de la resistencia a la isoniazida con la PSF fenotípica como patrón de referencia de 19 estudios, con los recuentos de VP, FP, FN y VN (TP, FP, FN, TN), la sensibilidad y la especificidad (IC del 95%) y la representación de cada estimación en una escala de 0 a 1. Los estudios se ordenan según una columna titulada «%RIF resistant» (de 56,85 a 0,0); la sensibilidad oscila entre 0,58 (Hofmann-Thiel 2020) y 1,00, y la especificidad entre 0,94 y 1,00.",
        "fr": "Graphique en forêt (figure 9) de la sensibilité et de la spécificité pour la détection de la résistance à l’isoniazide avec le TPM phénotypique comme norme de référence pour 19 études, indiquant les effectifs VP, FP, FN et VN (TP, FP, FN, TN), la sensibilité et la spécificité (IC à 95 %) et la représentation de chaque estimation sur une échelle de 0 à 1. Les études sont classées selon une colonne intitulée « %RIF resistant » (de 56,85 à 0,0) ; la sensibilité varie de 0,58 (Hofmann-Thiel 2020) à 1,00 et la spécificité de 0,94 à 1,00.",
        "ru": "Лесовидный график (рисунок 9) чувствительности и специфичности для выявления устойчивости к изониазиду с фенотипическим ТЛЧ в качестве эталонного стандарта по 19 исследованиям с числом ИП, ЛП, ЛО и ИО (TP, FP, FN, TN), чувствительностью и специфичностью (95% ДИ) и отображением каждой оценки на шкале от 0 до 1. Исследования упорядочены по столбцу «%RIF resistant» (от 56,85 до 0,0); чувствительность варьирует от 0,58 (Hofmann-Thiel 2020) до 1,00, специфичность — 0,94–1,00."
      },
      "state": "draft"
    },
    {
      "id": "img-p527-1",
      "file": "images/img-p527-1.webp",
      "page": 527,
      "narratives": {
        "en": "Forest plot (Figure 10) of sensitivity and specificity for rifampicin resistance detection with a composite reference standard for 9 studies, listing TP, FP, FN and TN counts with sensitivity and specificity (95% CI) and plots of each estimate on a 0–1 scale. Sensitivity ranges from 0.92 to 1.00 and specificity from 0.95 to 1.00; de Vos 2020 has a very wide specificity interval (0.03 to 1.00).",
        "ar": "مخطط شجري (الشكل 10) للحساسية والنوعية في الكشف عن مقاومة الريفامبيسين باستخدام معيار مرجعي مركّب لـ 9 دراسة، يورد أعداد الإيجابيات الحقيقية والإيجابيات الكاذبة والسلبيات الكاذبة والسلبيات الحقيقية (TP وFP وFN وTN) مع الحساسية والنوعية (فاصل ثقة 95%) ورسوماً لكل تقدير على مقياس من 0 إلى 1. وتتراوح الحساسية بين 0.92 و1.00 والنوعية بين 0.95 و1.00؛ ولدى de Vos 2020 فاصل نوعية واسع جداً (0.03 إلى 1.00).",
        "zh": "森林图（图10），显示以复合参考标准衡量的利福平耐药检测灵敏度和特异度，涵盖9项研究，列出真阳性、假阳性、假阴性和真阴性（TP、FP、FN、TN）数量及灵敏度和特异度（95%置信区间），并在0–1刻度上绘出各估计值。灵敏度范围为0.92至1.00，特异度为0.95至1.00；de Vos 2020的特异度区间非常宽（0.03至1.00）。",
        "es": "Diagrama de bosque (figura 10) de la sensibilidad y la especificidad para la detección de la resistencia a la rifampicina con un patrón de referencia compuesto de 9 estudios, con los recuentos de VP, FP, FN y VN (TP, FP, FN, TN), la sensibilidad y la especificidad (IC del 95%) y la representación de cada estimación en una escala de 0 a 1. La sensibilidad oscila entre 0,92 y 1,00 y la especificidad entre 0,95 y 1,00; de Vos 2020 presenta un intervalo de especificidad muy amplio (0,03 a 1,00).",
        "fr": "Graphique en forêt (figure 10) de la sensibilité et de la spécificité pour la détection de la résistance à la rifampicine avec une norme de référence composite pour 9 études, indiquant les effectifs VP, FP, FN et VN (TP, FP, FN, TN), la sensibilité et la spécificité (IC à 95 %) et la représentation de chaque estimation sur une échelle de 0 à 1. La sensibilité varie de 0,92 à 1,00 et la spécificité de 0,95 à 1,00 ; de Vos 2020 présente un intervalle de spécificité très large (0,03 à 1,00).",
        "ru": "Лесовидный график (рисунок 10) чувствительности и специфичности для выявления устойчивости к рифампицину с комбинированным эталонным стандартом по 9 исследованиям с числом ИП, ЛП, ЛО и ИО (TP, FP, FN, TN), чувствительностью и специфичностью (95% ДИ) и отображением каждой оценки на шкале от 0 до 1. Чувствительность варьирует от 0,92 до 1,00, специфичность — от 0,95 до 1,00; у de Vos 2020 очень широкий интервал специфичности (0,03–1,00)."
      },
      "state": "draft"
    },
    {
      "id": "img-p527-2",
      "file": "images/img-p527-2.webp",
      "page": 527,
      "narratives": {
        "en": "Forest plot (Figure 11) of sensitivity and specificity for isoniazid resistance detection with a composite reference standard for 8 studies, listing TP, FP, FN and TN counts with sensitivity and specificity (95% CI) and plots of each estimate on a 0–1 scale. Sensitivity ranges from 0.58 (Hofmann-Thiel 2020) to 0.92 and specificity from 0.99 to 1.00.",
        "ar": "مخطط شجري (الشكل 11) للحساسية والنوعية في الكشف عن مقاومة الإيزونيازيد باستخدام معيار مرجعي مركّب لـ 8 دراسة، يورد أعداد الإيجابيات الحقيقية والإيجابيات الكاذبة والسلبيات الكاذبة والسلبيات الحقيقية (TP وFP وFN وTN) مع الحساسية والنوعية (فاصل ثقة 95%) ورسوماً لكل تقدير على مقياس من 0 إلى 1. وتتراوح الحساسية بين 0.58 (Hofmann-Thiel 2020) و0.92، والنوعية بين 0.99 و1.00.",
        "zh": "森林图（图11），显示以复合参考标准衡量的异烟肼耐药检测灵敏度和特异度，涵盖8项研究，列出真阳性、假阳性、假阴性和真阴性（TP、FP、FN、TN）数量及灵敏度和特异度（95%置信区间），并在0–1刻度上绘出各估计值。灵敏度范围为0.58（Hofmann-Thiel 2020）至0.92，特异度为0.99至1.00。",
        "es": "Diagrama de bosque (figura 11) de la sensibilidad y la especificidad para la detección de la resistencia a la isoniazida con un patrón de referencia compuesto de 8 estudios, con los recuentos de VP, FP, FN y VN (TP, FP, FN, TN), la sensibilidad y la especificidad (IC del 95%) y la representación de cada estimación en una escala de 0 a 1. La sensibilidad oscila entre 0,58 (Hofmann-Thiel 2020) y 0,92, y la especificidad entre 0,99 y 1,00.",
        "fr": "Graphique en forêt (figure 11) de la sensibilité et de la spécificité pour la détection de la résistance à l’isoniazide avec une norme de référence composite pour 8 études, indiquant les effectifs VP, FP, FN et VN (TP, FP, FN, TN), la sensibilité et la spécificité (IC à 95 %) et la représentation de chaque estimation sur une échelle de 0 à 1. La sensibilité varie de 0,58 (Hofmann-Thiel 2020) à 0,92 et la spécificité de 0,99 à 1,00.",
        "ru": "Лесовидный график (рисунок 11) чувствительности и специфичности для выявления устойчивости к изониазиду с комбинированным эталонным стандартом по 8 исследованиям с числом ИП, ЛП, ЛО и ИО (TP, FP, FN, TN), чувствительностью и специфичностью (95% ДИ) и отображением каждой оценки на шкале от 0 до 1. Чувствительность варьирует от 0,58 (Hofmann-Thiel 2020) до 0,92, специфичность — от 0,99 до 1,00."
      },
      "state": "draft"
    },
    {
      "id": "img-p540-1",
      "file": "images/img-p540-1.webp",
      "page": 540,
      "narratives": {
        "en": "Risk-of-bias and applicability summary (Figure A) for 29 studies, from Berhanu 2018 to Wang 2016, with a coloured circle per QUADAS-2 domain: red minus for high, yellow question mark for unclear and green plus for low. Index test is rated low in every study. High or unclear ratings occur mainly for patient selection, in both risk of bias and applicability.",
        "ar": "ملخص خطر التحيز وقابلية التطبيق (الشكل A) لـ 29 دراسة، من Berhanu 2018 إلى Wang 2016، مع دائرة ملونة لكل مجال من مجالات QUADAS-2: علامة ناقص حمراء للخطر المرتفع، وعلامة استفهام صفراء لغير الواضح، وعلامة زائد خضراء للمنخفض. ويُقيَّم الاختبار المؤشر منخفض الخطر في جميع الدراسات. وتتركز تقديرات الخطر المرتفع أو غير الواضح أساساً في مجال اختيار المرضى، سواء في خطر التحيز أو قابلية التطبيق.",
        "zh": "偏倚风险和适用性汇总图（图A），涵盖从Berhanu 2018到Wang 2016的29项研究，每个QUADAS-2领域用一个彩色圆圈表示：红色减号为高，黄色问号为不明，绿色加号为低。所有研究的待评价试验均评为低。高或不明评级主要出现在患者选择领域，包括偏倚风险和适用性两方面。",
        "es": "Resumen del riesgo de sesgo y de la aplicabilidad (figura A) de 29 estudios, de Berhanu 2018 a Wang 2016, con un círculo de color por dominio QUADAS-2: signo menos rojo para alto, signo de interrogación amarillo para incierto y signo más verde para bajo. La prueba índice se califica como baja en todos los estudios. Las calificaciones altas o inciertas se concentran principalmente en la selección de pacientes, tanto en riesgo de sesgo como en aplicabilidad.",
        "fr": "Résumé du risque de biais et de l’applicabilité (figure A) pour 29 études, de Berhanu 2018 à Wang 2016, avec un cercle coloré par domaine QUADAS-2 : signe moins rouge pour élevé, point d’interrogation jaune pour incertain et signe plus vert pour faible. Le test index est jugé faible dans toutes les études. Les évaluations élevées ou incertaines concernent principalement la sélection des patients, tant pour le risque de biais que pour l’applicabilité.",
        "ru": "Сводка риска систематической ошибки и применимости (рисунок A) по 29 исследованиям, от Berhanu 2018 до Wang 2016, с цветным кругом для каждого домена QUADAS-2: красный минус — высокий, желтый знак вопроса — неясный, зеленый плюс — низкий. Индексный тест во всех исследованиях оценен как низкий риск. Высокие или неясные оценки приходятся в основном на отбор пациентов — как по риску систематической ошибки, так и по применимости."
      },
      "state": "draft"
    },
    {
      "id": "img-p541-1",
      "file": "images/img-p541-1.webp",
      "page": 541,
      "narratives": {
        "en": "Risk-of-bias and applicability summary (Figure B) for 18 studies, from Berhanu 2018 to Tam 2017, with a coloured circle per QUADAS-2 domain: red minus for high, yellow question mark for unclear and green plus for low. Index test is rated low in every study. High or unclear ratings occur mainly for patient selection, in both risk of bias and applicability.",
        "ar": "ملخص خطر التحيز وقابلية التطبيق (الشكل B) لـ 18 دراسة، من Berhanu 2018 إلى Tam 2017، مع دائرة ملونة لكل مجال من مجالات QUADAS-2: علامة ناقص حمراء للخطر المرتفع، وعلامة استفهام صفراء لغير الواضح، وعلامة زائد خضراء للمنخفض. ويُقيَّم الاختبار المؤشر منخفض الخطر في جميع الدراسات. وتتركز تقديرات الخطر المرتفع أو غير الواضح أساساً في مجال اختيار المرضى، سواء في خطر التحيز أو قابلية التطبيق.",
        "zh": "偏倚风险和适用性汇总图（图B），涵盖从Berhanu 2018到Tam 2017的18项研究，每个QUADAS-2领域用一个彩色圆圈表示：红色减号为高，黄色问号为不明，绿色加号为低。所有研究的待评价试验均评为低。高或不明评级主要出现在患者选择领域，包括偏倚风险和适用性两方面。",
        "es": "Resumen del riesgo de sesgo y de la aplicabilidad (figura B) de 18 estudios, de Berhanu 2018 a Tam 2017, con un círculo de color por dominio QUADAS-2: signo menos rojo para alto, signo de interrogación amarillo para incierto y signo más verde para bajo. La prueba índice se califica como baja en todos los estudios. Las calificaciones altas o inciertas se concentran principalmente en la selección de pacientes, tanto en riesgo de sesgo como en aplicabilidad.",
        "fr": "Résumé du risque de biais et de l’applicabilité (figure B) pour 18 études, de Berhanu 2018 à Tam 2017, avec un cercle coloré par domaine QUADAS-2 : signe moins rouge pour élevé, point d’interrogation jaune pour incertain et signe plus vert pour faible. Le test index est jugé faible dans toutes les études. Les évaluations élevées ou incertaines concernent principalement la sélection des patients, tant pour le risque de biais que pour l’applicabilité.",
        "ru": "Сводка риска систематической ошибки и применимости (рисунок B) по 18 исследованиям, от Berhanu 2018 до Tam 2017, с цветным кругом для каждого домена QUADAS-2: красный минус — высокий, желтый знак вопроса — неясный, зеленый плюс — низкий. Индексный тест во всех исследованиях оценен как низкий риск. Высокие или неясные оценки приходятся в основном на отбор пациентов — как по риску систематической ошибки, так и по применимости."
      },
      "state": "draft"
    },
    {
      "id": "img-p545-1",
      "file": "images/img-p545-1.webp",
      "page": 545,
      "narratives": {
        "en": "Forest plot (Figure A) of TB detection by the Abbott RealTime MTB assay for 12 studies, listing TP, FP, FN and TN counts with sensitivity and specificity (95% CI) and plots on a 0–1 scale. Sensitivity ranges from 0.79 (Berhanu 2018) to 1.00 and specificity from 0.84 (Wang 2016) to 1.00.",
        "ar": "مخطط شجري (الشكل A) للكشف عن السل باختبار Abbott RealTime MTB assay في 12 دراسات، يورد أعداد TP وFP وFN وTN مع الحساسية والنوعية (فاصل ثقة 95%) ورسوماً على مقياس من 0 إلى 1. وتتراوح الحساسية بين 0.79 (Berhanu 2018) و1.00، والنوعية بين 0.84 (Wang 2016) و1.00.",
        "zh": "森林图（图A），显示12项研究中Abbott RealTime MTB assay的结核病检测结果，列出TP、FP、FN和TN数量及灵敏度和特异度（95%置信区间），并在0–1刻度上绘图。灵敏度范围为0.79（Berhanu 2018）至1.00，特异度为0.84（Wang 2016）至1.00。",
        "es": "Diagrama de bosque (figura A) de la detección de la TB con el Abbott RealTime MTB assay en 12 estudios, con los recuentos de VP, FP, FN y VN, la sensibilidad y la especificidad (IC del 95%) y su representación en una escala de 0 a 1. La sensibilidad oscila entre 0,79 (Berhanu 2018) y 1,00, y la especificidad entre 0,84 (Wang 2016) y 1,00.",
        "fr": "Graphique en forêt (figure A) de la détection de la TB par le Abbott RealTime MTB assay dans 12 études, indiquant les effectifs VP, FP, FN et VN, la sensibilité et la spécificité (IC à 95 %) et leur représentation sur une échelle de 0 à 1. La sensibilité varie de 0,79 (Berhanu 2018) à 1,00 et la spécificité de 0,84 (Wang 2016) à 1,00.",
        "ru": "Лесовидный график (рисунок A) выявления ТБ с помощью Abbott RealTime MTB assay в 12 исследованиях с числом TP, FP, FN и TN, чувствительностью и специфичностью (95% ДИ) и их отображением на шкале от 0 до 1. Чувствительность варьирует от 0,79 (Berhanu 2018) до 1,00, специфичность — от 0,84 (Wang 2016) до 1,00."
      },
      "state": "draft"
    },
    {
      "id": "img-p545-2",
      "file": "images/img-p545-2.webp",
      "page": 545,
      "narratives": {
        "en": "Forest plot (Figure B) of TB detection by the FluoroType MTB assay for 6 studies, listing TP, FP, FN and TN counts with sensitivity and specificity (95% CI) and plots on a 0–1 scale. Sensitivity ranges from 0.87 to 0.95; specificity is 0.94–1.00 except Obasanya 2017 (0.60).",
        "ar": "مخطط شجري (الشكل B) للكشف عن السل باختبار FluoroType MTB assay في 6 دراسات، يورد أعداد TP وFP وFN وTN مع الحساسية والنوعية (فاصل ثقة 95%) ورسوماً على مقياس من 0 إلى 1. وتتراوح الحساسية بين 0.87 و0.95؛ والنوعية بين 0.94 و1.00 باستثناء Obasanya 2017 (0.60).",
        "zh": "森林图（图B），显示6项研究中FluoroType MTB assay的结核病检测结果，列出TP、FP、FN和TN数量及灵敏度和特异度（95%置信区间），并在0–1刻度上绘图。灵敏度范围为0.87至0.95；除Obasanya 2017（0.60）外，特异度为0.94–1.00。",
        "es": "Diagrama de bosque (figura B) de la detección de la TB con el FluoroType MTB assay en 6 estudios, con los recuentos de VP, FP, FN y VN, la sensibilidad y la especificidad (IC del 95%) y su representación en una escala de 0 a 1. La sensibilidad oscila entre 0,87 y 0,95; la especificidad es de 0,94 a 1,00, salvo en Obasanya 2017 (0,60).",
        "fr": "Graphique en forêt (figure B) de la détection de la TB par le FluoroType MTB assay dans 6 études, indiquant les effectifs VP, FP, FN et VN, la sensibilité et la spécificité (IC à 95 %) et leur représentation sur une échelle de 0 à 1. La sensibilité varie de 0,87 à 0,95 ; la spécificité est de 0,94 à 1,00, sauf pour Obasanya 2017 (0,60).",
        "ru": "Лесовидный график (рисунок B) выявления ТБ с помощью FluoroType MTB assay в 6 исследованиях с числом TP, FP, FN и TN, чувствительностью и специфичностью (95% ДИ) и их отображением на шкале от 0 до 1. Чувствительность варьирует от 0,87 до 0,95; специфичность — 0,94–1,00, за исключением Obasanya 2017 (0,60)."
      },
      "state": "draft"
    },
    {
      "id": "img-p545-3",
      "file": "images/img-p545-3.webp",
      "page": 545,
      "narratives": {
        "en": "Forest plot (Figure C) of TB detection by the FluoroType MTBDR assay for 4 studies, listing TP, FP, FN and TN counts with sensitivity and specificity (95% CI) and plots on a 0–1 scale. Sensitivity ranges from 0.85 to 0.96 and specificity from 0.97 to 1.00.",
        "ar": "مخطط شجري (الشكل C) للكشف عن السل باختبار FluoroType MTBDR assay في 4 دراسات، يورد أعداد TP وFP وFN وTN مع الحساسية والنوعية (فاصل ثقة 95%) ورسوماً على مقياس من 0 إلى 1. وتتراوح الحساسية بين 0.85 و0.96، والنوعية بين 0.97 و1.00.",
        "zh": "森林图（图C），显示4项研究中FluoroType MTBDR assay的结核病检测结果，列出TP、FP、FN和TN数量及灵敏度和特异度（95%置信区间），并在0–1刻度上绘图。灵敏度范围为0.85至0.96，特异度为0.97至1.00。",
        "es": "Diagrama de bosque (figura C) de la detección de la TB con el FluoroType MTBDR assay en 4 estudios, con los recuentos de VP, FP, FN y VN, la sensibilidad y la especificidad (IC del 95%) y su representación en una escala de 0 a 1. La sensibilidad oscila entre 0,85 y 0,96, y la especificidad entre 0,97 y 1,00.",
        "fr": "Graphique en forêt (figure C) de la détection de la TB par le FluoroType MTBDR assay dans 4 études, indiquant les effectifs VP, FP, FN et VN, la sensibilité et la spécificité (IC à 95 %) et leur représentation sur une échelle de 0 à 1. La sensibilité varie de 0,85 à 0,96 et la spécificité de 0,97 à 1,00.",
        "ru": "Лесовидный график (рисунок C) выявления ТБ с помощью FluoroType MTBDR assay в 4 исследованиях с числом TP, FP, FN и TN, чувствительностью и специфичностью (95% ДИ) и их отображением на шкале от 0 до 1. Чувствительность варьирует от 0,85 до 0,96, специфичность — от 0,97 до 1,00."
      },
      "state": "draft"
    },
    {
      "id": "img-p546-1",
      "file": "images/img-p546-1.webp",
      "page": 546,
      "narratives": {
        "en": "Forest plot of TB detection by the BD Max MDR-TB assay (Figure D) in four studies: Ciesielczuk 2020, Hofmann-Thiel 2020, Shah 2019 and Shaheed 2020. Each row gives a study's TP, FP, FN and TN counts and sensitivity and specificity with 95% CI, plotted as squares with CI lines on 0–1 scales. Sensitivity ranges from 0.87 to 0.95; specificity is 0.93–1.00 except 0.68 in Shaheed 2020.",
        "ar": "مخطط غابي لكشف السل بواسطة اختبار BD Max MDR-TB (الشكل D) في أربع دراسات: Ciesielczuk 2020 وHofmann-Thiel 2020 وShah 2019 وShaheed 2020. يعرض كل صف أعداد الإيجابيات الحقيقية والإيجابيات الكاذبة والسلبيات الكاذبة والسلبيات الحقيقية لدراسة ما، والحساسية والنوعية مع فترات ثقة 95%، ممثلة بمربعات وخطوط فترات الثقة على مقياس من 0 إلى 1. تتراوح الحساسية بين 0.87 و0.95؛ وتبلغ النوعية 0.93–1.00 باستثناء 0.68 في دراسة Shaheed 2020.",
        "zh": "BD Max MDR-TB检测法检出结核病的森林图（图D），涉及四项研究：Ciesielczuk 2020、Hofmann-Thiel 2020、Shah 2019和Shaheed 2020。每行列出一项研究的真阳性、假阳性、假阴性和真阴性数，以及灵敏度和特异性（95%置信区间），以方块和置信区间线绘于0–1刻度上。灵敏度为0.87至0.95；特异性为0.93–1.00，但Shaheed 2020为0.68。",
        "es": "Diagrama de bosque (forest plot) de la detección de la TB mediante la prueba BD Max MDR-TB (figura D) en cuatro estudios: Ciesielczuk 2020, Hofmann-Thiel 2020, Shah 2019 y Shaheed 2020. Cada fila presenta los VP, FP, FN y VN de un estudio y la sensibilidad y especificidad con IC del 95 %, representadas como cuadrados con líneas de IC en escalas de 0 a 1. La sensibilidad oscila entre 0,87 y 0,95; la especificidad es de 0,93–1,00, salvo 0,68 en Shaheed 2020.",
        "fr": "Graphique en forêt (forest plot) de la détection de la TB par le test BD Max MDR-TB (figure D) dans quatre études : Ciesielczuk 2020, Hofmann-Thiel 2020, Shah 2019 et Shaheed 2020. Chaque ligne indique les VP, FP, FN et VN d'une étude ainsi que la sensibilité et la spécificité avec IC à 95 %, représentées par des carrés et des barres d'IC sur des échelles de 0 à 1. La sensibilité varie de 0,87 à 0,95 ; la spécificité est de 0,93–1,00, sauf 0,68 dans Shaheed 2020.",
        "ru": "Форест-диаграмма выявления ТБ с помощью теста BD Max MDR-TB (рисунок D) в четырех исследованиях: Ciesielczuk 2020, Hofmann-Thiel 2020, Shah 2019 и Shaheed 2020. В каждой строке приведены число ИП, ЛП, ЛО и ИО в исследовании, а также чувствительность и специфичность с 95% ДИ, показанные квадратами с линиями ДИ на шкалах от 0 до 1. Чувствительность составляет от 0,87 до 0,95; специфичность — 0,93–1,00, за исключением 0,68 в Shaheed 2020."
      },
      "state": "draft"
    },
    {
      "id": "img-p546-2",
      "file": "images/img-p546-2.webp",
      "page": 546,
      "narratives": {
        "en": "Forest plot of TB detection by the Cobas MTB assay (Figure E) in two studies, Cobas 2020 and de Vos 2020. Each row gives a study's TP, FP, FN and TN counts and sensitivity and specificity with 95% CI, plotted as squares with CI lines on 0–1 scales. Sensitivity is 0.95 and 0.92, and specificity 0.98 and 0.96.",
        "ar": "مخطط غابي لكشف السل بواسطة اختبار Cobas MTB (الشكل E) في دراستين هما Cobas 2020 وde Vos 2020. يعرض كل صف أعداد الإيجابيات الحقيقية والإيجابيات الكاذبة والسلبيات الكاذبة والسلبيات الحقيقية لدراسة ما، والحساسية والنوعية مع فترات ثقة 95%، ممثلة بمربعات وخطوط فترات الثقة على مقياس من 0 إلى 1. تبلغ الحساسية 0.95 و0.92، والنوعية 0.98 و0.96.",
        "zh": "Cobas MTB检测法检出结核病的森林图（图E），涉及两项研究：Cobas 2020和de Vos 2020。每行列出一项研究的真阳性、假阳性、假阴性和真阴性数，以及灵敏度和特异性（95%置信区间），以方块和置信区间线绘于0–1刻度上。灵敏度分别为0.95和0.92，特异性分别为0.98和0.96。",
        "es": "Diagrama de bosque (forest plot) de la detección de la TB mediante la prueba Cobas MTB (figura E) en dos estudios, Cobas 2020 y de Vos 2020. Cada fila presenta los VP, FP, FN y VN de un estudio y la sensibilidad y especificidad con IC del 95 %, representadas como cuadrados con líneas de IC en escalas de 0 a 1. La sensibilidad es de 0,95 y 0,92, y la especificidad de 0,98 y 0,96.",
        "fr": "Graphique en forêt (forest plot) de la détection de la TB par le test Cobas MTB (figure E) dans deux études, Cobas 2020 et de Vos 2020. Chaque ligne indique les VP, FP, FN et VN d'une étude ainsi que la sensibilité et la spécificité avec IC à 95 %, représentées par des carrés et des barres d'IC sur des échelles de 0 à 1. La sensibilité est de 0,95 et 0,92, et la spécificité de 0,98 et 0,96.",
        "ru": "Форест-диаграмма выявления ТБ с помощью теста Cobas MTB (рисунок E) в двух исследованиях: Cobas 2020 и de Vos 2020. В каждой строке приведены число ИП, ЛП, ЛО и ИО в исследовании, а также чувствительность и специфичность с 95% ДИ, показанные квадратами с линиями ДИ на шкалах от 0 до 1. Чувствительность составляет 0,95 и 0,92, специфичность — 0,98 и 0,96."
      },
      "state": "draft"
    },
    {
      "id": "img-p546-3",
      "file": "images/img-p546-3.webp",
      "page": 546,
      "narratives": {
        "en": "Forest plots of rifampicin (RIF) resistance detection by the Abbott RealTime RIF/INH assay, in three panels by reference standard: culture (9 studies), sequencing (3 studies) and composite reference standard (CRS, 3 studies). Each row gives a study's TP, FP, FN and TN counts and sensitivity and specificity with 95% CI, plotted as squares with CI lines on 0–1 scales. Estimable sensitivities range from 0.88 to 1.00 and specificities from 0.98 to 1.00.",
        "ar": "مخططات غابية لكشف مقاومة الريفامبيسين (RIF) بواسطة اختبار Abbott RealTime RIF/INH، في ثلاث لوحات حسب المعيار المرجعي: المزرعة (9 دراسات) والتسلسل الجيني (3 دراسات) والمعيار المرجعي المركب (CRS، 3 دراسات). يعرض كل صف أعداد الإيجابيات الحقيقية والإيجابيات الكاذبة والسلبيات الكاذبة والسلبيات الحقيقية لدراسة ما، والحساسية والنوعية مع فترات ثقة 95%، ممثلة بمربعات وخطوط فترات الثقة على مقياس من 0 إلى 1. تتراوح قيم الحساسية القابلة للتقدير بين 0.88 و1.00، والنوعية بين 0.98 و1.00.",
        "zh": "Abbott RealTime RIF/INH检测法检测利福平（RIF）耐药的森林图，按参考标准分为三组：培养（9项研究）、测序（3项研究）和复合参考标准（CRS，3项研究）。每行列出一项研究的真阳性、假阳性、假阴性和真阴性数，以及灵敏度和特异性（95%置信区间），以方块和置信区间线绘于0–1刻度上。可估计的灵敏度为0.88至1.00，特异性为0.98至1.00。",
        "es": "Diagramas de bosque (forest plots) de la detección de la resistencia a la rifampicina (RIF) mediante la prueba Abbott RealTime RIF/INH, en tres paneles según el patrón de referencia: cultivo (9 estudios), secuenciación (3 estudios) y patrón de referencia compuesto (CRS, 3 estudios). Cada fila presenta los VP, FP, FN y VN de un estudio y la sensibilidad y especificidad con IC del 95 %, representadas como cuadrados con líneas de IC en escalas de 0 a 1. Las sensibilidades estimables oscilan entre 0,88 y 1,00 y las especificidades entre 0,98 y 1,00.",
        "fr": "Graphiques en forêt (forest plots) de la détection de la résistance à la rifampicine (RIF) par le test Abbott RealTime RIF/INH, en trois panneaux selon la norme de référence : culture (9 études), séquençage (3 études) et norme de référence composite (CRS, 3 études). Chaque ligne indique les VP, FP, FN et VN d'une étude ainsi que la sensibilité et la spécificité avec IC à 95 %, représentées par des carrés et des barres d'IC sur des échelles de 0 à 1. Les sensibilités estimables vont de 0,88 à 1,00 et les spécificités de 0,98 à 1,00.",
        "ru": "Форест-диаграммы выявления устойчивости к рифампицину (RIF) с помощью теста Abbott RealTime RIF/INH в трех панелях по эталонному стандарту: посев (9 исследований), секвенирование (3 исследования) и комбинированный эталонный стандарт (CRS, 3 исследования). В каждой строке приведены число ИП, ЛП, ЛО и ИО в исследовании, а также чувствительность и специфичность с 95% ДИ, показанные квадратами с линиями ДИ на шкалах от 0 до 1. Оцениваемая чувствительность составляет от 0,88 до 1,00, специфичность — от 0,98 до 1,00."
      },
      "state": "draft"
    },
    {
      "id": "img-p547-1",
      "file": "images/img-p547-1.webp",
      "page": 547,
      "narratives": {
        "en": "Forest plots of isoniazid (INH) resistance detection by the Abbott RealTime RIF/INH assay, in three panels by reference standard: culture (9 studies), sequencing (3 studies) and CRS (3 studies). Each row gives a study's TP, FP, FN and TN counts and sensitivity and specificity with 95% CI, plotted as squares with CI lines on 0–1 scales. Sensitivities range from 0.79 to 1.00 and specificities from 0.94 to 1.00.",
        "ar": "مخططات غابية لكشف مقاومة الإيزونيازيد (INH) بواسطة اختبار Abbott RealTime RIF/INH، في ثلاث لوحات حسب المعيار المرجعي: المزرعة (9 دراسات) والتسلسل الجيني (3 دراسات) والمعيار المرجعي المركب CRS (3 دراسات). يعرض كل صف أعداد الإيجابيات الحقيقية والإيجابيات الكاذبة والسلبيات الكاذبة والسلبيات الحقيقية لدراسة ما، والحساسية والنوعية مع فترات ثقة 95%، ممثلة بمربعات وخطوط فترات الثقة على مقياس من 0 إلى 1. تتراوح الحساسية بين 0.79 و1.00، والنوعية بين 0.94 و1.00.",
        "zh": "Abbott RealTime RIF/INH检测法检测异烟肼（INH）耐药的森林图，按参考标准分为三组：培养（9项研究）、测序（3项研究）和CRS（3项研究）。每行列出一项研究的真阳性、假阳性、假阴性和真阴性数，以及灵敏度和特异性（95%置信区间），以方块和置信区间线绘于0–1刻度上。灵敏度为0.79至1.00，特异性为0.94至1.00。",
        "es": "Diagramas de bosque (forest plots) de la detección de la resistencia a la isoniazida (INH) mediante la prueba Abbott RealTime RIF/INH, en tres paneles según el patrón de referencia: cultivo (9 estudios), secuenciación (3 estudios) y CRS (3 estudios). Cada fila presenta los VP, FP, FN y VN de un estudio y la sensibilidad y especificidad con IC del 95 %, representadas como cuadrados con líneas de IC en escalas de 0 a 1. Las sensibilidades oscilan entre 0,79 y 1,00 y las especificidades entre 0,94 y 1,00.",
        "fr": "Graphiques en forêt (forest plots) de la détection de la résistance à l'isoniazide (INH) par le test Abbott RealTime RIF/INH, en trois panneaux selon la norme de référence : culture (9 études), séquençage (3 études) et CRS (3 études). Chaque ligne indique les VP, FP, FN et VN d'une étude ainsi que la sensibilité et la spécificité avec IC à 95 %, représentées par des carrés et des barres d'IC sur des échelles de 0 à 1. Les sensibilités vont de 0,79 à 1,00 et les spécificités de 0,94 à 1,00.",
        "ru": "Форест-диаграммы выявления устойчивости к изониазиду (INH) с помощью теста Abbott RealTime RIF/INH в трех панелях по эталонному стандарту: посев (9 исследований), секвенирование (3 исследования) и CRS (3 исследования). В каждой строке приведены число ИП, ЛП, ЛО и ИО в исследовании, а также чувствительность и специфичность с 95% ДИ, показанные квадратами с линиями ДИ на шкалах от 0 до 1. Чувствительность составляет от 0,79 до 1,00, специфичность — от 0,94 до 1,00."
      },
      "state": "draft"
    },
    {
      "id": "img-p547-2",
      "file": "images/img-p547-2.webp",
      "page": 547,
      "narratives": {
        "en": "Forest plot of rifampicin resistance detection by the FluoroType MTBDR assay in three studies: Haasis 2018, Hillemann 2018 and Shaheed 2020. Each row gives a study's TP, FP, FN and TN counts and sensitivity and specificity with 95% CI, plotted as squares with CI lines on 0–1 scales. Sensitivity is 0.97–1.00 and specificity 0.95–1.00.",
        "ar": "مخطط غابي لكشف مقاومة الريفامبيسين بواسطة اختبار FluoroType MTBDR في ثلاث دراسات: Haasis 2018 وHillemann 2018 وShaheed 2020. يعرض كل صف أعداد الإيجابيات الحقيقية والإيجابيات الكاذبة والسلبيات الكاذبة والسلبيات الحقيقية لدراسة ما، والحساسية والنوعية مع فترات ثقة 95%، ممثلة بمربعات وخطوط فترات الثقة على مقياس من 0 إلى 1. تبلغ الحساسية 0.97–1.00 والنوعية 0.95–1.00.",
        "zh": "FluoroType MTBDR检测法检测利福平耐药的森林图，涉及三项研究：Haasis 2018、Hillemann 2018和Shaheed 2020。每行列出一项研究的真阳性、假阳性、假阴性和真阴性数，以及灵敏度和特异性（95%置信区间），以方块和置信区间线绘于0–1刻度上。灵敏度为0.97–1.00，特异性为0.95–1.00。",
        "es": "Diagrama de bosque (forest plot) de la detección de la resistencia a la rifampicina mediante la prueba FluoroType MTBDR en tres estudios: Haasis 2018, Hillemann 2018 y Shaheed 2020. Cada fila presenta los VP, FP, FN y VN de un estudio y la sensibilidad y especificidad con IC del 95 %, representadas como cuadrados con líneas de IC en escalas de 0 a 1. La sensibilidad es de 0,97–1,00 y la especificidad de 0,95–1,00.",
        "fr": "Graphique en forêt (forest plot) de la détection de la résistance à la rifampicine par le test FluoroType MTBDR dans trois études : Haasis 2018, Hillemann 2018 et Shaheed 2020. Chaque ligne indique les VP, FP, FN et VN d'une étude ainsi que la sensibilité et la spécificité avec IC à 95 %, représentées par des carrés et des barres d'IC sur des échelles de 0 à 1. La sensibilité est de 0,97–1,00 et la spécificité de 0,95–1,00.",
        "ru": "Форест-диаграмма выявления устойчивости к рифампицину с помощью теста FluoroType MTBDR в трех исследованиях: Haasis 2018, Hillemann 2018 и Shaheed 2020. В каждой строке приведены число ИП, ЛП, ЛО и ИО в исследовании, а также чувствительность и специфичность с 95% ДИ, показанные квадратами с линиями ДИ на шкалах от 0 до 1. Чувствительность составляет 0,97–1,00, специфичность — 0,95–1,00."
      },
      "state": "draft"
    },
    {
      "id": "img-p547-3",
      "file": "images/img-p547-3.webp",
      "page": 547,
      "narratives": {
        "en": "Forest plot of isoniazid resistance detection by the FluoroType MTBDR assay in three studies: Haasis 2018, Hillemann 2018 and Shaheed 2020. Each row gives a study's TP, FP, FN and TN counts and sensitivity and specificity with 95% CI, plotted as squares with CI lines on 0–1 scales. Sensitivity is 0.70, 0.92 and 0.79, and specificity 0.99–1.00.",
        "ar": "مخطط غابي لكشف مقاومة الإيزونيازيد بواسطة اختبار FluoroType MTBDR في ثلاث دراسات: Haasis 2018 وHillemann 2018 وShaheed 2020. يعرض كل صف أعداد الإيجابيات الحقيقية والإيجابيات الكاذبة والسلبيات الكاذبة والسلبيات الحقيقية لدراسة ما، والحساسية والنوعية مع فترات ثقة 95%، ممثلة بمربعات وخطوط فترات الثقة على مقياس من 0 إلى 1. تبلغ الحساسية 0.70 و0.92 و0.79، والنوعية 0.99–1.00.",
        "zh": "FluoroType MTBDR检测法检测异烟肼耐药的森林图，涉及三项研究：Haasis 2018、Hillemann 2018和Shaheed 2020。每行列出一项研究的真阳性、假阳性、假阴性和真阴性数，以及灵敏度和特异性（95%置信区间），以方块和置信区间线绘于0–1刻度上。灵敏度分别为0.70、0.92和0.79，特异性为0.99–1.00。",
        "es": "Diagrama de bosque (forest plot) de la detección de la resistencia a la isoniazida mediante la prueba FluoroType MTBDR en tres estudios: Haasis 2018, Hillemann 2018 y Shaheed 2020. Cada fila presenta los VP, FP, FN y VN de un estudio y la sensibilidad y especificidad con IC del 95 %, representadas como cuadrados con líneas de IC en escalas de 0 a 1. La sensibilidad es de 0,70, 0,92 y 0,79, y la especificidad de 0,99–1,00.",
        "fr": "Graphique en forêt (forest plot) de la détection de la résistance à l'isoniazide par le test FluoroType MTBDR dans trois études : Haasis 2018, Hillemann 2018 et Shaheed 2020. Chaque ligne indique les VP, FP, FN et VN d'une étude ainsi que la sensibilité et la spécificité avec IC à 95 %, représentées par des carrés et des barres d'IC sur des échelles de 0 à 1. La sensibilité est de 0,70, 0,92 et 0,79, et la spécificité de 0,99–1,00.",
        "ru": "Форест-диаграмма выявления устойчивости к изониазиду с помощью теста FluoroType MTBDR в трех исследованиях: Haasis 2018, Hillemann 2018 и Shaheed 2020. В каждой строке приведены число ИП, ЛП, ЛО и ИО в исследовании, а также чувствительность и специфичность с 95% ДИ, показанные квадратами с линиями ДИ на шкалах от 0 до 1. Чувствительность составляет 0,70, 0,92 и 0,79, специфичность — 0,99–1,00."
      },
      "state": "draft"
    },
    {
      "id": "img-p548-1",
      "file": "images/img-p548-1.webp",
      "page": 548,
      "narratives": {
        "en": "Forest plots of rifampicin and isoniazid resistance detection by the BD Max MDR-TB assay, each panel with four studies (Ciesielczuk 2020, Hofmann-Thiel 2020, Shah 2019, Shaheed 2020). Each row gives a study's TP, FP, FN and TN counts and sensitivity and specificity with 95% CI, plotted as squares with CI lines on 0–1 scales. For rifampicin, estimable sensitivity is 0.90–1.00 and specificity 0.95–0.98; for isoniazid, sensitivity is 0.58–1.00 and specificity 0.99–1.00.",
        "ar": "مخططات غابية لكشف مقاومة الريفامبيسين والإيزونيازيد بواسطة اختبار BD Max MDR-TB، وتضم كل لوحة أربع دراسات (Ciesielczuk 2020 وHofmann-Thiel 2020 وShah 2019 وShaheed 2020). يعرض كل صف أعداد الإيجابيات الحقيقية والإيجابيات الكاذبة والسلبيات الكاذبة والسلبيات الحقيقية لدراسة ما، والحساسية والنوعية مع فترات ثقة 95%، ممثلة بمربعات وخطوط فترات الثقة على مقياس من 0 إلى 1. بالنسبة للريفامبيسين، تبلغ الحساسية القابلة للتقدير 0.90–1.00 والنوعية 0.95–0.98؛ وبالنسبة للإيزونيازيد، تبلغ الحساسية 0.58–1.00 والنوعية 0.99–1.00.",
        "zh": "BD Max MDR-TB检测法检测利福平和异烟肼耐药的森林图，每组含四项研究（Ciesielczuk 2020、Hofmann-Thiel 2020、Shah 2019、Shaheed 2020）。每行列出一项研究的真阳性、假阳性、假阴性和真阴性数，以及灵敏度和特异性（95%置信区间），以方块和置信区间线绘于0–1刻度上。利福平的可估计灵敏度为0.90–1.00，特异性为0.95–0.98；异烟肼的灵敏度为0.58–1.00，特异性为0.99–1.00。",
        "es": "Diagramas de bosque (forest plots) de la detección de la resistencia a la rifampicina y a la isoniazida mediante la prueba BD Max MDR-TB; cada panel incluye cuatro estudios (Ciesielczuk 2020, Hofmann-Thiel 2020, Shah 2019, Shaheed 2020). Cada fila presenta los VP, FP, FN y VN de un estudio y la sensibilidad y especificidad con IC del 95 %, representadas como cuadrados con líneas de IC en escalas de 0 a 1. Para la rifampicina, la sensibilidad estimable es de 0,90–1,00 y la especificidad de 0,95–0,98; para la isoniazida, la sensibilidad es de 0,58–1,00 y la especificidad de 0,99–1,00.",
        "fr": "Graphiques en forêt (forest plots) de la détection de la résistance à la rifampicine et à l'isoniazide par le test BD Max MDR-TB, chaque panneau comprenant quatre études (Ciesielczuk 2020, Hofmann-Thiel 2020, Shah 2019, Shaheed 2020). Chaque ligne indique les VP, FP, FN et VN d'une étude ainsi que la sensibilité et la spécificité avec IC à 95 %, représentées par des carrés et des barres d'IC sur des échelles de 0 à 1. Pour la rifampicine, la sensibilité estimable est de 0,90–1,00 et la spécificité de 0,95–0,98 ; pour l'isoniazide, la sensibilité est de 0,58–1,00 et la spécificité de 0,99–1,00.",
        "ru": "Форест-диаграммы выявления устойчивости к рифампицину и изониазиду с помощью теста BD Max MDR-TB; каждая панель включает четыре исследования (Ciesielczuk 2020, Hofmann-Thiel 2020, Shah 2019, Shaheed 2020). В каждой строке приведены число ИП, ЛП, ЛО и ИО в исследовании, а также чувствительность и специфичность с 95% ДИ, показанные квадратами с линиями ДИ на шкалах от 0 до 1. Для рифампицина оцениваемая чувствительность составляет 0,90–1,00, специфичность — 0,95–0,98; для изониазида чувствительность — 0,58–1,00, специфичность — 0,99–1,00."
      },
      "state": "draft"
    },
    {
      "id": "img-p548-2",
      "file": "images/img-p548-2.webp",
      "page": 548,
      "narratives": {
        "en": "Forest plots of rifampicin and isoniazid resistance detection by the Cobas MTB-DR assay (panels 'Cobas RIF' and 'Cobas INH'), each with two studies, de Vos 2020 and Scott 2020. Each row gives a study's TP, FP, FN and TN counts and sensitivity and specificity with 95% CI, plotted as squares with CI lines on 0–1 scales. Rifampicin sensitivity is 0.91 and 1.00, isoniazid sensitivity 0.90 and 0.80, and all specificities are 0.96–1.00.",
        "ar": "مخططات غابية لكشف مقاومة الريفامبيسين والإيزونيازيد بواسطة اختبار Cobas MTB-DR (اللوحتان 'Cobas RIF' و'Cobas INH')، تضم كل منهما دراستين هما de Vos 2020 وScott 2020. يعرض كل صف أعداد الإيجابيات الحقيقية والإيجابيات الكاذبة والسلبيات الكاذبة والسلبيات الحقيقية لدراسة ما، والحساسية والنوعية مع فترات ثقة 95%، ممثلة بمربعات وخطوط فترات الثقة على مقياس من 0 إلى 1. تبلغ حساسية الريفامبيسين 0.91 و1.00، وحساسية الإيزونيازيد 0.90 و0.80، وتتراوح جميع قيم النوعية بين 0.96 و1.00.",
        "zh": "Cobas MTB-DR检测法检测利福平和异烟肼耐药的森林图（“Cobas RIF”和“Cobas INH”两组），每组含两项研究：de Vos 2020和Scott 2020。每行列出一项研究的真阳性、假阳性、假阴性和真阴性数，以及灵敏度和特异性（95%置信区间），以方块和置信区间线绘于0–1刻度上。利福平灵敏度为0.91和1.00，异烟肼灵敏度为0.90和0.80，所有特异性均为0.96–1.00。",
        "es": "Diagramas de bosque (forest plots) de la detección de la resistencia a la rifampicina y a la isoniazida mediante la prueba Cobas MTB-DR (paneles «Cobas RIF» y «Cobas INH»), cada uno con dos estudios, de Vos 2020 y Scott 2020. Cada fila presenta los VP, FP, FN y VN de un estudio y la sensibilidad y especificidad con IC del 95 %, representadas como cuadrados con líneas de IC en escalas de 0 a 1. La sensibilidad para la rifampicina es de 0,91 y 1,00, para la isoniazida de 0,90 y 0,80, y todas las especificidades son de 0,96–1,00.",
        "fr": "Graphiques en forêt (forest plots) de la détection de la résistance à la rifampicine et à l'isoniazide par le test Cobas MTB-DR (panneaux « Cobas RIF » et « Cobas INH »), chacun avec deux études, de Vos 2020 et Scott 2020. Chaque ligne indique les VP, FP, FN et VN d'une étude ainsi que la sensibilité et la spécificité avec IC à 95 %, représentées par des carrés et des barres d'IC sur des échelles de 0 à 1. La sensibilité pour la rifampicine est de 0,91 et 1,00, pour l'isoniazide de 0,90 et 0,80, et toutes les spécificités sont de 0,96–1,00.",
        "ru": "Форест-диаграммы выявления устойчивости к рифампицину и изониазиду с помощью теста Cobas MTB-DR (панели «Cobas RIF» и «Cobas INH»), каждая с двумя исследованиями: de Vos 2020 и Scott 2020. В каждой строке приведены число ИП, ЛП, ЛО и ИО в исследовании, а также чувствительность и специфичность с 95% ДИ, показанные квадратами с линиями ДИ на шкалах от 0 до 1. Чувствительность для рифампицина составляет 0,91 и 1,00, для изониазида — 0,90 и 0,80; вся специфичность — 0,96–1,00."
      },
      "state": "draft"
    },
    {
      "id": "img-p558-1",
      "file": "images/img-p558-1.webp",
      "page": 558,
      "narratives": {
        "en": "Stacked bar chart 'Per-test cost (BD)' (Figure 2A) showing per-test cost in 2019 USD for the primary estimate (PE), low and high scenarios of the sensitivity analysis, split into overhead, building, staff, equipment and test kits. Totals are roughly $18 (PE), $14 (low) and $41 (high); test kits are the largest component in the PE and low bars, while equipment makes up a large share of the high bar.",
        "ar": "مخطط أعمدة مكدسة بعنوان 'Per-test cost (BD)' (الشكل 2A) يبين تكلفة الاختبار الواحد بدولارات الولايات المتحدة لعام 2019 للتقدير الأولي (PE) والسيناريوهين المنخفض والمرتفع لتحليل الحساسية، موزعة على التكاليف العامة والمبنى والموظفين والمعدات ومجموعات الاختبار. يبلغ المجموع نحو 18 دولارًا (PE) و14 دولارًا (منخفض) و41 دولارًا (مرتفع)؛ وتمثل مجموعات الاختبار المكون الأكبر في عمودي PE والمنخفض، بينما تشكل المعدات حصة كبيرة من العمود المرتفع.",
        "zh": "堆积条形图“Per-test cost (BD)”（图2A），显示敏感性分析中主要估计值（PE）、低值和高值情景下每次检测的成本（2019年美元），分为间接费用、房屋、人员、设备和检测试剂盒。总额约为18美元（PE）、14美元（低）和41美元（高）；在PE和低值条形中试剂盒是最大组成部分，而在高值条形中设备占很大比例。",
        "es": "Gráfico de barras apiladas «Per-test cost (BD)» (figura 2A) que muestra el costo por prueba en USD de 2019 para la estimación principal (PE) y los escenarios bajo y alto del análisis de sensibilidad, desglosado en gastos generales, edificio, personal, equipo y kits de prueba. Los totales son de aproximadamente 18 USD (PE), 14 USD (bajo) y 41 USD (alto); los kits de prueba son el mayor componente en las barras PE y baja, mientras que el equipo representa una gran parte de la barra alta.",
        "fr": "Graphique à barres empilées « Per-test cost (BD) » (figure 2A) montrant le coût par test en USD de 2019 pour l'estimation principale (PE) et les scénarios bas et haut de l'analyse de sensibilité, ventilé en frais généraux, bâtiment, personnel, équipement et kits de test. Les totaux sont d'environ 18 USD (PE), 14 USD (bas) et 41 USD (haut) ; les kits de test constituent la composante la plus importante des barres PE et basse, tandis que l'équipement représente une large part de la barre haute.",
        "ru": "Столбчатая диаграмма с накоплением «Per-test cost (BD)» (рисунок 2A), показывающая стоимость одного теста в долларах США 2019 г. для основной оценки (PE), низкого и высокого сценариев анализа чувствительности с разбивкой на накладные расходы, здание, персонал, оборудование и тест-наборы. Итоговые значения — около 18 долл. (PE), 14 долл. (низкий) и 41 долл. (высокий); тест-наборы — крупнейший компонент в столбцах PE и низкого сценария, а в высоком сценарии большую долю составляет оборудование."
      },
      "state": "draft"
    },
    {
      "id": "img-p558-2",
      "file": "images/img-p558-2.webp",
      "page": 558,
      "narratives": {
        "en": "Stacked bar chart 'Per-test cost (Hain)' (Figure 2B) showing per-test cost in 2019 USD for the primary estimate (PE), low and high scenarios, split into overhead, building, staff, equipment and test kits. Totals are roughly $15 (PE), $10 (low) and $37 (high); test kits dominate the PE and low bars, and equipment is the largest component of the high bar.",
        "ar": "مخطط أعمدة مكدسة بعنوان 'Per-test cost (Hain)' (الشكل 2B) يبين تكلفة الاختبار الواحد بدولارات الولايات المتحدة لعام 2019 للتقدير الأولي (PE) والسيناريوهين المنخفض والمرتفع، موزعة على التكاليف العامة والمبنى والموظفين والمعدات ومجموعات الاختبار. يبلغ المجموع نحو 15 دولارًا (PE) و10 دولارات (منخفض) و37 دولارًا (مرتفع)؛ وتهيمن مجموعات الاختبار على عمودي PE والمنخفض، والمعدات هي المكون الأكبر في العمود المرتفع.",
        "zh": "堆积条形图“Per-test cost (Hain)”（图2B），显示主要估计值（PE）、低值和高值情景下每次检测的成本（2019年美元），分为间接费用、房屋、人员、设备和检测试剂盒。总额约为15美元（PE）、10美元（低）和37美元（高）；PE和低值条形以试剂盒为主，高值条形中设备是最大组成部分。",
        "es": "Gráfico de barras apiladas «Per-test cost (Hain)» (figura 2B) que muestra el costo por prueba en USD de 2019 para la estimación principal (PE) y los escenarios bajo y alto, desglosado en gastos generales, edificio, personal, equipo y kits de prueba. Los totales son de aproximadamente 15 USD (PE), 10 USD (bajo) y 37 USD (alto); los kits de prueba predominan en las barras PE y baja, y el equipo es el mayor componente de la barra alta.",
        "fr": "Graphique à barres empilées « Per-test cost (Hain) » (figure 2B) montrant le coût par test en USD de 2019 pour l'estimation principale (PE) et les scénarios bas et haut, ventilé en frais généraux, bâtiment, personnel, équipement et kits de test. Les totaux sont d'environ 15 USD (PE), 10 USD (bas) et 37 USD (haut) ; les kits de test dominent les barres PE et basse, et l'équipement est la composante la plus importante de la barre haute.",
        "ru": "Столбчатая диаграмма с накоплением «Per-test cost (Hain)» (рисунок 2B), показывающая стоимость одного теста в долларах США 2019 г. для основной оценки (PE), низкого и высокого сценариев с разбивкой на накладные расходы, здание, персонал, оборудование и тест-наборы. Итоговые значения — около 15 долл. (PE), 10 долл. (низкий) и 37 долл. (высокий); в столбцах PE и низкого сценария преобладают тест-наборы, а в высоком сценарии крупнейший компонент — оборудование."
      },
      "state": "draft"
    },
    {
      "id": "img-p559-1",
      "file": "images/img-p559-1.webp",
      "page": 559,
      "narratives": {
        "en": "Line chart 'Per-test cost by annual testing volume (BD vs. Hain)' (Figure 3), plotting per-test cost (2019 USD) against annual testing volume from 0 to 25,000 tests, with background bands shaded red below 5,000, yellow from 5,000 to 10,000 and green above 10,000. Both lines fall steeply at low volumes and flatten above about 5,000 tests; the Hain line levels off at roughly $12–13 and the BD line ends near 6,000 tests at about $18.",
        "ar": "مخطط خطي بعنوان 'Per-test cost by annual testing volume (BD vs. Hain)' (الشكل 3) يبين تكلفة الاختبار الواحد (بدولارات 2019) مقابل حجم الاختبارات السنوي من 0 إلى 25000 اختبار، مع خلفية مظللة بالأحمر دون 5000، وبالأصفر من 5000 إلى 10000، وبالأخضر فوق 10000. ينخفض الخطان بشدة عند الأحجام المنخفضة ويستويان فوق نحو 5000 اختبار؛ ويستقر خط Hain عند نحو 12–13 دولارًا، بينما ينتهي خط BD قرب 6000 اختبار عند نحو 18 دولارًا.",
        "zh": "折线图“Per-test cost by annual testing volume (BD vs. Hain)”（图3），绘制每次检测成本（2019年美元）与年检测量（0至25,000次）的关系，背景在5,000以下为红色、5,000至10,000为黄色、10,000以上为绿色。两条线在低检测量时急剧下降，在约5,000次以上趋于平稳；Hain线稳定在约12–13美元，BD线在约6,000次处结束，约为18美元。",
        "es": "Gráfico de líneas «Per-test cost by annual testing volume (BD vs. Hain)» (figura 3) que representa el costo por prueba (USD de 2019) frente al volumen anual de pruebas, de 0 a 25 000, con franjas de fondo en rojo por debajo de 5000, en amarillo de 5000 a 10 000 y en verde por encima de 10 000. Ambas líneas descienden bruscamente con volúmenes bajos y se estabilizan a partir de unas 5000 pruebas; la línea de Hain se estabiliza en torno a 12–13 USD y la de BD termina cerca de 6000 pruebas, en unos 18 USD.",
        "fr": "Graphique linéaire « Per-test cost by annual testing volume (BD vs. Hain) » (figure 3) représentant le coût par test (USD de 2019) en fonction du volume annuel de tests, de 0 à 25 000, avec des bandes de fond rouges en dessous de 5000, jaunes de 5000 à 10 000 et vertes au-delà de 10 000. Les deux courbes chutent fortement aux faibles volumes et s'aplanissent au-delà d'environ 5000 tests ; la courbe Hain se stabilise vers 12–13 USD et la courbe BD s'arrête vers 6000 tests, à environ 18 USD.",
        "ru": "Линейный график «Per-test cost by annual testing volume (BD vs. Hain)» (рисунок 3), отражающий стоимость одного теста (долл. США 2019 г.) в зависимости от годового объема тестирования от 0 до 25 000, с фоновыми полосами: красной ниже 5000, желтой от 5000 до 10 000 и зеленой выше 10 000. Обе линии резко снижаются при малых объемах и выравниваются выше примерно 5000 тестов; линия Hain стабилизируется на уровне около 12–13 долл., а линия BD заканчивается около 6000 тестов на уровне около 18 долл."
      },
      "state": "draft"
    },
    {
      "id": "img-p568-1",
      "file": "images/img-p568-1.webp",
      "page": 568,
      "narratives": {
        "en": "Manufacturer flyer titled '10-Color Multiplexing Technology: GeneXpert System Upgrade Options for HBDC Customers', with product photos above three numbered options: 1) convert current GeneXpert modules from 6-color to 10-color; 2) daisy-chain a 10-color satellite instrument to the current GeneXpert System; 3) order a new GeneXpert System with 10-color technology. Each option lists what must be ordered separately and computer requirements.",
        "ar": "نشرة صادرة عن الجهة المصنعة بعنوان '10-Color Multiplexing Technology: GeneXpert System Upgrade Options for HBDC Customers'، تتضمن صورًا للمنتجات فوق ثلاثة خيارات مرقمة: 1) تحويل وحدات GeneXpert الحالية من 6 ألوان إلى 10 ألوان؛ 2) ربط جهاز تابع بعشرة ألوان بنظام GeneXpert الحالي؛ 3) طلب نظام GeneXpert جديد بتقنية العشرة ألوان. ويذكر كل خيار ما يجب طلبه بشكل منفصل ومتطلبات الحاسوب.",
        "zh": "制造商宣传单，标题为“10-Color Multiplexing Technology: GeneXpert System Upgrade Options for HBDC Customers”，产品照片下方列出三个编号选项：1）将现有GeneXpert模块从6色转换为10色；2）将10色卫星仪器串联到现有GeneXpert系统；3）订购采用10色技术的新GeneXpert系统。每个选项均列出需单独订购的项目和计算机要求。",
        "es": "Folleto del fabricante titulado «10-Color Multiplexing Technology: GeneXpert System Upgrade Options for HBDC Customers», con fotos de productos sobre tres opciones numeradas: 1) convertir los módulos GeneXpert actuales de 6 colores a 10 colores; 2) conectar en cadena un instrumento satélite de 10 colores al sistema GeneXpert actual; 3) pedir un nuevo sistema GeneXpert con tecnología de 10 colores. Cada opción indica lo que debe pedirse por separado y los requisitos informáticos.",
        "fr": "Dépliant du fabricant intitulé « 10-Color Multiplexing Technology: GeneXpert System Upgrade Options for HBDC Customers », avec des photos de produits au-dessus de trois options numérotées : 1) convertir les modules GeneXpert actuels de 6 couleurs en 10 couleurs ; 2) connecter en chaîne un instrument satellite à 10 couleurs au système GeneXpert actuel ; 3) commander un nouveau système GeneXpert doté de la technologie à 10 couleurs. Chaque option précise ce qui doit être commandé séparément et la configuration informatique requise.",
        "ru": "Рекламная листовка производителя под названием «10-Color Multiplexing Technology: GeneXpert System Upgrade Options for HBDC Customers» с фотографиями продукции над тремя пронумерованными вариантами: 1) перевести имеющиеся модули GeneXpert с 6 цветов на 10; 2) последовательно подключить 10-цветный сателлитный прибор к имеющейся системе GeneXpert; 3) заказать новую систему GeneXpert с 10-цветной технологией. Для каждого варианта указано, что заказывается отдельно, и требования к компьютеру."
      },
      "state": "draft"
    },
    {
      "id": "img-p569-1",
      "file": "images/img-p569-1.webp",
      "page": 569,
      "narratives": {
        "en": "Ordering information table from the manufacturer flyer listing catalogue numbers, descriptions and prices (US dollars) for GeneXpert 10-color products, grouped as New Systems with Desktop, New Systems with Laptop, Satellite Instruments + DAISYKIT required, New Module and Accessories. Systems range from 1-module to 16-module configurations; the small print is only partly legible.",
        "ar": "جدول معلومات الطلب من نشرة الجهة المصنعة يسرد أرقام الكتالوج والأوصاف والأسعار (بدولارات الولايات المتحدة) لمنتجات GeneXpert بعشرة ألوان، مجمعة تحت: New Systems with Desktop وNew Systems with Laptop وSatellite Instruments + DAISYKIT required وNew Module وAccessories. تتراوح الأنظمة من تكوينات بوحدة واحدة إلى 16 وحدة؛ والخط الصغير مقروء جزئيًا فقط.",
        "zh": "制造商宣传单中的订购信息表，列出GeneXpert 10色产品的目录号、说明和价格（美元），分为New Systems with Desktop、New Systems with Laptop、Satellite Instruments + DAISYKIT required、New Module和Accessories。系统配置从1模块到16模块不等；小字仅部分可辨。",
        "es": "Tabla de información para pedidos del folleto del fabricante que enumera números de catálogo, descripciones y precios (en dólares de los Estados Unidos) de los productos GeneXpert de 10 colores, agrupados en New Systems with Desktop, New Systems with Laptop, Satellite Instruments + DAISYKIT required, New Module y Accessories. Los sistemas van de configuraciones de 1 a 16 módulos; la letra pequeña solo es parcialmente legible.",
        "fr": "Tableau d'informations de commande tiré du dépliant du fabricant, indiquant les numéros de catalogue, les descriptions et les prix (en dollars des États-Unis) des produits GeneXpert à 10 couleurs, regroupés en New Systems with Desktop, New Systems with Laptop, Satellite Instruments + DAISYKIT required, New Module et Accessories. Les systèmes vont de configurations à 1 module à 16 modules ; les petits caractères ne sont que partiellement lisibles.",
        "ru": "Таблица с информацией для заказа из листовки производителя с каталожными номерами, описаниями и ценами (в долларах США) на 10-цветную продукцию GeneXpert, сгруппированными как New Systems with Desktop, New Systems with Laptop, Satellite Instruments + DAISYKIT required, New Module и Accessories. Конфигурации систем — от 1 до 16 модулей; мелкий шрифт читается лишь частично."
      },
      "state": "draft"
    },
    {
      "id": "img-p589-1",
      "file": "images/img-p589-1.webp",
      "page": 589,
      "narratives": {
        "en": "Diagram (Figure 1) with 'Critical Aspects Users Value' at the top, listed for patients, health workers, lab technicians and lab managers (e.g. avoid delays, keep cost low, accuracy, biosafety), above a chevron sequence of care steps: Seek Care, Order Test(s), Produce and Transport Sample, Test Runs, Results Reported and Treatment Initiated. Below, 'Challenges to Realizing Those Values' lists barriers at each step, such as stigma and cost concerns, eligibility restrictions, poor sample quality and transport, lack of resources, poor result communication and delays in recalling patients, under the banner 'Compounding Delay & Under Utilization – Undoes User Added Value; Challenges to Access & Equity'.",
        "ar": "مخطط (الشكل 1) يعرض في أعلاه 'Critical Aspects Users Value' للمرضى والعاملين الصحيين وفنيي المختبرات ومديري المختبرات (مثل تجنب التأخير، وإبقاء التكلفة منخفضة، والدقة، والسلامة البيولوجية)، فوق تسلسل من خطوات الرعاية: التماس الرعاية، وطلب الاختبار، وإنتاج العينة ونقلها، وإجراء الاختبار، والإبلاغ عن النتائج، وبدء العلاج. وفي الأسفل تسرد 'Challenges to Realizing Those Values' العوائق في كل خطوة، مثل الوصم ومخاوف التكلفة، وقيود الأهلية، وسوء جودة العينات ونقلها، ونقص الموارد، وضعف إبلاغ النتائج، والتأخر في استدعاء المرضى، تحت عنوان 'Compounding Delay & Under Utilization – Undoes User Added Value; Challenges to Access & Equity'.",
        "zh": "示意图（图1），顶部为“Critical Aspects Users Value”，分别列出患者、卫生工作者、实验室技术人员和实验室管理人员重视的方面（如避免延误、降低成本、准确性、生物安全），其下为一系列箭头形诊疗步骤：寻求医疗、开具检测、采集和运送样本、运行检测、报告结果和开始治疗。下方“Challenges to Realizing Those Values”列出各步骤的障碍，例如污名和费用顾虑、资格限制、样本质量和运送不佳、资源缺乏、结果传达不畅以及召回患者延误，标题为“Compounding Delay & Under Utilization – Undoes User Added Value; Challenges to Access & Equity”。",
        "es": "Diagrama (figura 1) con «Critical Aspects Users Value» en la parte superior, enumerados para pacientes, trabajadores de la salud, técnicos de laboratorio y gestores de laboratorio (p. ej., evitar retrasos, mantener bajo el costo, exactitud, bioseguridad), sobre una secuencia de etapas de la atención: búsqueda de atención, solicitud de pruebas, obtención y transporte de la muestra, realización de la prueba, notificación de resultados e inicio del tratamiento. Debajo, «Challenges to Realizing Those Values» enumera los obstáculos de cada etapa, como el estigma y la preocupación por el costo, las restricciones de elegibilidad, la mala calidad y el transporte de las muestras, la falta de recursos, la mala comunicación de resultados y los retrasos en volver a citar a los pacientes, bajo el lema «Compounding Delay & Under Utilization – Undoes User Added Value; Challenges to Access & Equity».",
        "fr": "Schéma (figure 1) présentant en haut les « Critical Aspects Users Value » pour les patients, les agents de santé, les techniciens de laboratoire et les responsables de laboratoire (par ex. éviter les retards, maintenir un faible coût, exactitude, biosécurité), au-dessus d'une séquence d'étapes de soins : recours aux soins, prescription du test, prélèvement et transport de l'échantillon, réalisation du test, communication des résultats et début du traitement. En dessous, « Challenges to Realizing Those Values » énumère les obstacles à chaque étape, tels que la stigmatisation et les préoccupations liées au coût, les restrictions d'éligibilité, la mauvaise qualité et le transport des échantillons, le manque de ressources, la mauvaise communication des résultats et les retards pour rappeler les patients, sous le bandeau « Compounding Delay & Under Utilization – Undoes User Added Value; Challenges to Access & Equity ».",
        "ru": "Схема (рисунок 1): вверху — «Critical Aspects Users Value» для пациентов, медицинских работников, лаборантов и руководителей лабораторий (например, избегать задержек, низкая стоимость, точность, биобезопасность), ниже — последовательность этапов: обращение за помощью, назначение теста, получение и транспортировка образца, выполнение теста, сообщение результатов и начало лечения. Внизу в разделе «Challenges to Realizing Those Values» перечислены препятствия на каждом этапе, например стигма и опасения по поводу затрат, ограничения по критериям, низкое качество и транспортировка образцов, нехватка ресурсов, плохая передача результатов и задержки с повторным вызовом пациентов, под заголовком «Compounding Delay & Under Utilization – Undoes User Added Value; Challenges to Access & Equity»."
      },
      "state": "draft"
    },
    {
      "id": "img-p640-1",
      "file": "images/img-p640-1.webp",
      "page": 640,
      "narratives": {
        "en": "Fragment of a colour-coded table with columns 'Drug Class' and 'Result Call': for drug class N/A, the rows read INVALID/ERROR/NO RESULT (white), MTB DETECTED (red) and MTB NOT DETECTED (green). It illustrates how non-determinate Xpert MTB/XDR results relate to MTB DETECTED and MTB NOT DETECTED.",
        "ar": "جزء من جدول مرمز بالألوان بعمودين 'Drug Class' و'Result Call': بالنسبة لفئة الدواء N/A، تقرأ الصفوف INVALID/ERROR/NO RESULT (أبيض) وMTB DETECTED (أحمر) وMTB NOT DETECTED (أخضر). ويوضح كيف ترتبط نتائج Xpert MTB/XDR غير المحددة بنتيجتي MTB DETECTED وMTB NOT DETECTED.",
        "zh": "带颜色编码的表格片段，列为“Drug Class”和“Result Call”：药物类别为N/A时，各行依次为INVALID/ERROR/NO RESULT（白色）、MTB DETECTED（红色）和MTB NOT DETECTED（绿色）。它说明了Xpert MTB/XDR不确定结果与MTB DETECTED和MTB NOT DETECTED的关系。",
        "es": "Fragmento de una tabla codificada por colores con las columnas «Drug Class» y «Result Call»: para la clase de fármaco N/A, las filas indican INVALID/ERROR/NO RESULT (blanco), MTB DETECTED (rojo) y MTB NOT DETECTED (verde). Ilustra la relación de los resultados no determinados de Xpert MTB/XDR con MTB DETECTED y MTB NOT DETECTED.",
        "fr": "Fragment d'un tableau à code couleur avec les colonnes « Drug Class » et « Result Call » : pour la classe de médicament N/A, les lignes indiquent INVALID/ERROR/NO RESULT (blanc), MTB DETECTED (rouge) et MTB NOT DETECTED (vert). Il illustre le lien entre les résultats non déterminés de Xpert MTB/XDR et MTB DETECTED et MTB NOT DETECTED.",
        "ru": "Фрагмент таблицы с цветовой кодировкой и столбцами «Drug Class» и «Result Call»: для класса препаратов N/A строки гласят INVALID/ERROR/NO RESULT (белый), MTB DETECTED (красный) и MTB NOT DETECTED (зеленый). Показано, как неопределенные результаты Xpert MTB/XDR соотносятся с MTB DETECTED и MTB NOT DETECTED."
      },
      "state": "draft"
    },
    {
      "id": "img-p643-1",
      "file": "images/img-p643-1.webp",
      "page": 643,
      "narratives": {
        "en": "Forest plots of Xpert MTB/XDR sensitivity and specificity for detecting isoniazid resistance on sputum (Figure 3), in six panels: irrespective of rifampicin resistance and with detected rifampicin resistance, each against pDST, gDST and a composite reference standard. Studies are from Cepheid, DIAMA and FIND sites (e.g. China, South Africa, Benin, Cameroon, Rwanda, Moldova, Mumbai, New Delhi). Each row gives a study's TP, FP, FN and TN counts and sensitivity and specificity with 95% CI, plotted as squares with CI lines on 0–1 scales. Most sensitivities are 0.80–1.00 and most specificities 0.93–1.00, with wider intervals in the rifampicin-resistant panels.",
        "ar": "مخططات غابية لحساسية ونوعية اختبار Xpert MTB/XDR في كشف مقاومة الإيزونيازيد على البلغم (الشكل 3)، في ست لوحات: بغض النظر عن مقاومة الريفامبيسين ومع وجود مقاومة للريفامبيسين، مقابل كل من pDST وgDST والمعيار المرجعي المركب. الدراسات من مواقع Cepheid وDIAMA وFIND (مثل الصين وجنوب أفريقيا وبنن والكاميرون ورواندا ومولدوفا ومومباي ونيودلهي). يعرض كل صف أعداد الإيجابيات الحقيقية والإيجابيات الكاذبة والسلبيات الكاذبة والسلبيات الحقيقية لدراسة ما، والحساسية والنوعية مع فترات ثقة 95%، ممثلة بمربعات وخطوط فترات الثقة على مقياس من 0 إلى 1. تتراوح معظم قيم الحساسية بين 0.80 و1.00 ومعظم قيم النوعية بين 0.93 و1.00، مع فترات أوسع في لوحات المقاومة للريفامبيسين.",
        "zh": "Xpert MTB/XDR对痰标本检测异烟肼耐药的灵敏度和特异性森林图（图3），分为六组：不论利福平耐药状况及已检出利福平耐药，分别以pDST、gDST和复合参考标准为参照。研究来自Cepheid、DIAMA和FIND各研究点（如中国、南非、贝宁、喀麦隆、卢旺达、摩尔多瓦、孟买、新德里）。每行列出一项研究的真阳性、假阳性、假阴性和真阴性数，以及灵敏度和特异性（95%置信区间），以方块和置信区间线绘于0–1刻度上。大多数灵敏度为0.80–1.00，大多数特异性为0.93–1.00，利福平耐药组的置信区间较宽。",
        "es": "Diagramas de bosque (forest plots) de la sensibilidad y especificidad de Xpert MTB/XDR para detectar la resistencia a la isoniazida en esputo (figura 3), en seis paneles: con independencia de la resistencia a la rifampicina y con resistencia a la rifampicina detectada, frente a pDST, gDST y un patrón de referencia compuesto. Los estudios proceden de centros de Cepheid, DIAMA y FIND (p. ej., China, Sudáfrica, Benin, Camerún, Rwanda, Moldova, Mumbai, Nueva Delhi). Cada fila presenta los VP, FP, FN y VN de un estudio y la sensibilidad y especificidad con IC del 95 %, representadas como cuadrados con líneas de IC en escalas de 0 a 1. La mayoría de las sensibilidades son de 0,80–1,00 y la mayoría de las especificidades de 0,93–1,00, con intervalos más amplios en los paneles de resistencia a la rifampicina.",
        "fr": "Graphiques en forêt (forest plots) de la sensibilité et de la spécificité de Xpert MTB/XDR pour la détection de la résistance à l'isoniazide sur expectorations (figure 3), en six panneaux : indépendamment de la résistance à la rifampicine et avec résistance à la rifampicine détectée, par rapport au pDST, au gDST et à une norme de référence composite. Les études proviennent de sites Cepheid, DIAMA et FIND (par ex. Chine, Afrique du Sud, Bénin, Cameroun, Rwanda, Moldova, Mumbai, New Delhi). Chaque ligne indique les VP, FP, FN et VN d'une étude ainsi que la sensibilité et la spécificité avec IC à 95 %, représentées par des carrés et des barres d'IC sur des échelles de 0 à 1. La plupart des sensibilités sont de 0,80–1,00 et la plupart des spécificités de 0,93–1,00, avec des intervalles plus larges dans les panneaux de résistance à la rifampicine.",
        "ru": "Форест-диаграммы чувствительности и специфичности Xpert MTB/XDR при выявлении устойчивости к изониазиду в мокроте (рисунок 3) в шести панелях: независимо от устойчивости к рифампицину и при выявленной устойчивости к рифампицину, в сравнении с pDST, gDST и комбинированным эталонным стандартом. Исследования проведены на площадках Cepheid, DIAMA и FIND (например, Китай, Южная Африка, Бенин, Камерун, Руанда, Молдова, Мумбаи, Нью-Дели). В каждой строке приведены число ИП, ЛП, ЛО и ИО в исследовании, а также чувствительность и специфичность с 95% ДИ, показанные квадратами с линиями ДИ на шкалах от 0 до 1. Большинство значений чувствительности — 0,80–1,00, специфичности — 0,93–1,00; в панелях с устойчивостью к рифампицину интервалы шире."
      },
      "state": "draft"
    },
    {
      "id": "img-p643-2",
      "file": "images/img-p643-2.webp",
      "page": 643,
      "narratives": {
        "en": "Risk of bias and applicability concerns chart (QUADAS-2) for Xpert MTB/XDR isoniazid-resistance studies (Figure 4), rating Cepheid 2020, DIAMA 2020 and FIND 2020 across patient selection, index test, reference standard and flow and timing. Nearly all ratings are low; Cepheid 2020 is unclear for patient selection and DIAMA 2020 is high for flow and timing. Key: red = high, yellow '?' = unclear, green = low.",
        "ar": "مخطط خطر التحيز والمخاوف المتعلقة بقابلية التطبيق (QUADAS-2) لدراسات مقاومة الإيزونيازيد باختبار Xpert MTB/XDR (الشكل 4)، يقيّم Cepheid 2020 وDIAMA 2020 وFIND 2020 في مجالات اختيار المرضى والاختبار المؤشر والمعيار المرجعي والتدفق والتوقيت. جميع التقييمات تقريبًا منخفضة؛ Cepheid 2020 غير واضح في اختيار المرضى وDIAMA 2020 مرتفع في التدفق والتوقيت. المفتاح: الأحمر = مرتفع، الأصفر '?' = غير واضح، الأخضر = منخفض.",
        "zh": "Xpert MTB/XDR异烟肼耐药研究的偏倚风险和适用性问题图（QUADAS-2）（图4），对Cepheid 2020、DIAMA 2020和FIND 2020在患者选择、待评价试验、参考标准以及流程和时间方面进行评级。几乎所有评级均为低；Cepheid 2020在患者选择方面不明确，DIAMA 2020在流程和时间方面为高。图例：红色=高，黄色“?”=不明确，绿色=低。",
        "es": "Gráfico de riesgo de sesgo y problemas de aplicabilidad (QUADAS-2) de los estudios de resistencia a la isoniazida con Xpert MTB/XDR (figura 4), que califica Cepheid 2020, DIAMA 2020 y FIND 2020 en selección de pacientes, prueba índice, patrón de referencia y flujo y cronología. Casi todas las calificaciones son bajas; Cepheid 2020 es incierto en selección de pacientes y DIAMA 2020 es alto en flujo y cronología. Leyenda: rojo = alto, amarillo «?» = incierto, verde = bajo.",
        "fr": "Graphique du risque de biais et des problèmes d'applicabilité (QUADAS-2) des études sur la résistance à l'isoniazide avec Xpert MTB/XDR (figure 4), évaluant Cepheid 2020, DIAMA 2020 et FIND 2020 pour la sélection des patients, le test index, la norme de référence et le flux et la chronologie. Presque toutes les évaluations sont faibles ; Cepheid 2020 est incertain pour la sélection des patients et DIAMA 2020 est élevé pour le flux et la chronologie. Légende : rouge = élevé, jaune « ? » = incertain, vert = faible.",
        "ru": "Диаграмма риска систематической ошибки и проблем применимости (QUADAS-2) для исследований устойчивости к изониазиду с Xpert MTB/XDR (рисунок 4), оценивающая Cepheid 2020, DIAMA 2020 и FIND 2020 по отбору пациентов, индексному тесту, эталонному стандарту, а также последовательности и срокам. Почти все оценки низкие; у Cepheid 2020 неясный риск при отборе пациентов, у DIAMA 2020 высокий риск по последовательности и срокам. Обозначения: красный — высокий, желтый «?» — неясный, зеленый — низкий."
      },
      "state": "draft"
    },
    {
      "id": "img-p644-1",
      "file": "images/img-p644-1.webp",
      "page": 644,
      "narratives": {
        "en": "Forest plots of Xpert MTB/XDR sensitivity and specificity for detecting fluoroquinolone resistance on sputum (Figure 5), in six panels: irrespective of rifampicin resistance and with detected rifampicin resistance, each against pDST, gDST and a composite reference standard. Studies are from Cepheid, DIAMA and FIND sites (e.g. China, South Africa, Benin, Cameroon, Rwanda, Moldova, Mumbai, New Delhi). Each row gives a study's TP, FP, FN and TN counts and sensitivity and specificity with 95% CI, plotted as squares with CI lines on 0–1 scales. Estimable sensitivities are mostly 0.83–1.00; specificities are mostly 0.96–1.00, lower for FIND Mumbai (0.84 and 0.71) and FIND New Delhi.",
        "ar": "مخططات غابية لحساسية ونوعية اختبار Xpert MTB/XDR في كشف مقاومة الفلوروكينولونات على البلغم (الشكل 5)، في ست لوحات: بغض النظر عن مقاومة الريفامبيسين ومع وجود مقاومة للريفامبيسين، مقابل كل من pDST وgDST والمعيار المرجعي المركب. الدراسات من مواقع Cepheid وDIAMA وFIND (مثل الصين وجنوب أفريقيا وبنن والكاميرون ورواندا ومولدوفا ومومباي ونيودلهي). يعرض كل صف أعداد الإيجابيات الحقيقية والإيجابيات الكاذبة والسلبيات الكاذبة والسلبيات الحقيقية لدراسة ما، والحساسية والنوعية مع فترات ثقة 95%، ممثلة بمربعات وخطوط فترات الثقة على مقياس من 0 إلى 1. تتراوح معظم قيم الحساسية القابلة للتقدير بين 0.83 و1.00؛ ومعظم قيم النوعية بين 0.96 و1.00، وهي أقل في FIND Mumbai (0.84 و0.71) وFIND New Delhi.",
        "zh": "Xpert MTB/XDR对痰标本检测氟喹诺酮类药物耐药的灵敏度和特异性森林图（图5），分为六组：不论利福平耐药状况及已检出利福平耐药，分别以pDST、gDST和复合参考标准为参照。研究来自Cepheid、DIAMA和FIND各研究点（如中国、南非、贝宁、喀麦隆、卢旺达、摩尔多瓦、孟买、新德里）。每行列出一项研究的真阳性、假阳性、假阴性和真阴性数，以及灵敏度和特异性（95%置信区间），以方块和置信区间线绘于0–1刻度上。可估计的灵敏度大多为0.83–1.00；特异性大多为0.96–1.00，FIND Mumbai（0.84和0.71）和FIND New Delhi较低。",
        "es": "Diagramas de bosque (forest plots) de la sensibilidad y especificidad de Xpert MTB/XDR para detectar la resistencia a las fluoroquinolonas en esputo (figura 5), en seis paneles: con independencia de la resistencia a la rifampicina y con resistencia a la rifampicina detectada, frente a pDST, gDST y un patrón de referencia compuesto. Los estudios proceden de centros de Cepheid, DIAMA y FIND (p. ej., China, Sudáfrica, Benin, Camerún, Rwanda, Moldova, Mumbai, Nueva Delhi). Cada fila presenta los VP, FP, FN y VN de un estudio y la sensibilidad y especificidad con IC del 95 %, representadas como cuadrados con líneas de IC en escalas de 0 a 1. Las sensibilidades estimables son en su mayoría de 0,83–1,00; las especificidades, en su mayoría de 0,96–1,00, son menores en FIND Mumbai (0,84 y 0,71) y FIND New Delhi.",
        "fr": "Graphiques en forêt (forest plots) de la sensibilité et de la spécificité de Xpert MTB/XDR pour la détection de la résistance aux fluoroquinolones sur expectorations (figure 5), en six panneaux : indépendamment de la résistance à la rifampicine et avec résistance à la rifampicine détectée, par rapport au pDST, au gDST et à une norme de référence composite. Les études proviennent de sites Cepheid, DIAMA et FIND (par ex. Chine, Afrique du Sud, Bénin, Cameroun, Rwanda, Moldova, Mumbai, New Delhi). Chaque ligne indique les VP, FP, FN et VN d'une étude ainsi que la sensibilité et la spécificité avec IC à 95 %, représentées par des carrés et des barres d'IC sur des échelles de 0 à 1. Les sensibilités estimables sont pour la plupart de 0,83–1,00 ; les spécificités, pour la plupart de 0,96–1,00, sont plus faibles pour FIND Mumbai (0,84 et 0,71) et FIND New Delhi.",
        "ru": "Форест-диаграммы чувствительности и специфичности Xpert MTB/XDR при выявлении устойчивости к фторхинолонам в мокроте (рисунок 5) в шести панелях: независимо от устойчивости к рифампицину и при выявленной устойчивости к рифампицину, в сравнении с pDST, gDST и комбинированным эталонным стандартом. Исследования проведены на площадках Cepheid, DIAMA и FIND (например, Китай, Южная Африка, Бенин, Камерун, Руанда, Молдова, Мумбаи, Нью-Дели). В каждой строке приведены число ИП, ЛП, ЛО и ИО в исследовании, а также чувствительность и специфичность с 95% ДИ, показанные квадратами с линиями ДИ на шкалах от 0 до 1. Оцениваемая чувствительность в основном 0,83–1,00; специфичность в основном 0,96–1,00, ниже для FIND Mumbai (0,84 и 0,71) и FIND New Delhi."
      },
      "state": "draft"
    },
    {
      "id": "img-p645-1",
      "file": "images/img-p645-1.webp",
      "page": 645,
      "narratives": {
        "en": "Forest plots of Xpert MTB/XDR sensitivity and specificity for detecting ethionamide resistance on sputum (Figure 7), in six panels: irrespective of rifampicin resistance and with detected rifampicin resistance, each against pDST, gDST and a composite reference standard. Studies are from Cepheid, DIAMA and FIND sites (e.g. China, South Africa, Benin, Cameroon, Rwanda, Moldova, Mumbai, New Delhi). Each row gives a study's TP, FP, FN and TN counts and sensitivity and specificity with 95% CI, plotted as squares with CI lines on 0–1 scales. Sensitivity against pDST and the composite standard is low to moderate (about 0.31–0.80), but higher against gDST (0.78–1.00); specificities are 0.86–1.00.",
        "ar": "مخططات غابية لحساسية ونوعية اختبار Xpert MTB/XDR في كشف مقاومة الإيثيوناميد على البلغم (الشكل 7)، في ست لوحات: بغض النظر عن مقاومة الريفامبيسين ومع وجود مقاومة للريفامبيسين، مقابل كل من pDST وgDST والمعيار المرجعي المركب. الدراسات من مواقع Cepheid وDIAMA وFIND (مثل الصين وجنوب أفريقيا وبنن والكاميرون ورواندا ومولدوفا ومومباي ونيودلهي). يعرض كل صف أعداد الإيجابيات الحقيقية والإيجابيات الكاذبة والسلبيات الكاذبة والسلبيات الحقيقية لدراسة ما، والحساسية والنوعية مع فترات ثقة 95%، ممثلة بمربعات وخطوط فترات الثقة على مقياس من 0 إلى 1. الحساسية مقابل pDST والمعيار المركب منخفضة إلى متوسطة (نحو 0.31–0.80)، لكنها أعلى مقابل gDST (0.78–1.00)؛ وتتراوح النوعية بين 0.86 و1.00.",
        "zh": "Xpert MTB/XDR对痰标本检测乙硫异烟胺耐药的灵敏度和特异性森林图（图7），分为六组：不论利福平耐药状况及已检出利福平耐药，分别以pDST、gDST和复合参考标准为参照。研究来自Cepheid、DIAMA和FIND各研究点（如中国、南非、贝宁、喀麦隆、卢旺达、摩尔多瓦、孟买、新德里）。每行列出一项研究的真阳性、假阳性、假阴性和真阴性数，以及灵敏度和特异性（95%置信区间），以方块和置信区间线绘于0–1刻度上。以pDST和复合标准为参照的灵敏度为低至中等（约0.31–0.80），以gDST为参照时较高（0.78–1.00）；特异性为0.86–1.00。",
        "es": "Diagramas de bosque (forest plots) de la sensibilidad y especificidad de Xpert MTB/XDR para detectar la resistencia a la etionamida en esputo (figura 7), en seis paneles: con independencia de la resistencia a la rifampicina y con resistencia a la rifampicina detectada, frente a pDST, gDST y un patrón de referencia compuesto. Los estudios proceden de centros de Cepheid, DIAMA y FIND (p. ej., China, Sudáfrica, Benin, Camerún, Rwanda, Moldova, Mumbai, Nueva Delhi). Cada fila presenta los VP, FP, FN y VN de un estudio y la sensibilidad y especificidad con IC del 95 %, representadas como cuadrados con líneas de IC en escalas de 0 a 1. La sensibilidad frente a pDST y al patrón compuesto es baja o moderada (aproximadamente 0,31–0,80), pero mayor frente a gDST (0,78–1,00); las especificidades son de 0,86–1,00.",
        "fr": "Graphiques en forêt (forest plots) de la sensibilité et de la spécificité de Xpert MTB/XDR pour la détection de la résistance à l'éthionamide sur expectorations (figure 7), en six panneaux : indépendamment de la résistance à la rifampicine et avec résistance à la rifampicine détectée, par rapport au pDST, au gDST et à une norme de référence composite. Les études proviennent de sites Cepheid, DIAMA et FIND (par ex. Chine, Afrique du Sud, Bénin, Cameroun, Rwanda, Moldova, Mumbai, New Delhi). Chaque ligne indique les VP, FP, FN et VN d'une étude ainsi que la sensibilité et la spécificité avec IC à 95 %, représentées par des carrés et des barres d'IC sur des échelles de 0 à 1. La sensibilité par rapport au pDST et à la norme composite est faible à modérée (environ 0,31–0,80), mais plus élevée par rapport au gDST (0,78–1,00) ; les spécificités sont de 0,86–1,00.",
        "ru": "Форест-диаграммы чувствительности и специфичности Xpert MTB/XDR при выявлении устойчивости к этионамиду в мокроте (рисунок 7) в шести панелях: независимо от устойчивости к рифампицину и при выявленной устойчивости к рифампицину, в сравнении с pDST, gDST и комбинированным эталонным стандартом. Исследования проведены на площадках Cepheid, DIAMA и FIND (например, Китай, Южная Африка, Бенин, Камерун, Руанда, Молдова, Мумбаи, Нью-Дели). В каждой строке приведены число ИП, ЛП, ЛО и ИО в исследовании, а также чувствительность и специфичность с 95% ДИ, показанные квадратами с линиями ДИ на шкалах от 0 до 1. Чувствительность по сравнению с pDST и комбинированным стандартом низкая или умеренная (около 0,31–0,80), но выше по сравнению с gDST (0,78–1,00); специфичность — 0,86–1,00."
      },
      "state": "draft"
    },
    {
      "id": "img-p645-2",
      "file": "images/img-p645-2.webp",
      "page": 645,
      "narratives": {
        "en": "Risk of bias and applicability concerns chart (QUADAS-2) for Xpert MTB/XDR ethionamide-resistance studies (Figure 8), rating Cepheid 2020 and FIND 2020. FIND 2020 is low in all domains; Cepheid 2020 is unclear for patient selection and high for reference standard and flow and timing, with low applicability concerns. Key: red = high, yellow '?' = unclear, green = low.",
        "ar": "مخطط خطر التحيز والمخاوف المتعلقة بقابلية التطبيق (QUADAS-2) لدراسات مقاومة الإيثيوناميد باختبار Xpert MTB/XDR (الشكل 8)، يقيّم Cepheid 2020 وFIND 2020. دراسة FIND 2020 منخفضة في جميع المجالات؛ وCepheid 2020 غير واضحة في اختيار المرضى ومرتفعة في المعيار المرجعي والتدفق والتوقيت، مع مخاوف منخفضة بشأن قابلية التطبيق. المفتاح: الأحمر = مرتفع، الأصفر '?' = غير واضح، الأخضر = منخفض.",
        "zh": "Xpert MTB/XDR乙硫异烟胺耐药研究的偏倚风险和适用性问题图（QUADAS-2）（图8），对Cepheid 2020和FIND 2020进行评级。FIND 2020所有领域均为低；Cepheid 2020在患者选择方面不明确，在参考标准以及流程和时间方面为高，适用性问题为低。图例：红色=高，黄色“?”=不明确，绿色=低。",
        "es": "Gráfico de riesgo de sesgo y problemas de aplicabilidad (QUADAS-2) de los estudios de resistencia a la etionamida con Xpert MTB/XDR (figura 8), que califica Cepheid 2020 y FIND 2020. FIND 2020 es bajo en todos los dominios; Cepheid 2020 es incierto en selección de pacientes y alto en patrón de referencia y en flujo y cronología, con problemas de aplicabilidad bajos. Leyenda: rojo = alto, amarillo «?» = incierto, verde = bajo.",
        "fr": "Graphique du risque de biais et des problèmes d'applicabilité (QUADAS-2) des études sur la résistance à l'éthionamide avec Xpert MTB/XDR (figure 8), évaluant Cepheid 2020 et FIND 2020. FIND 2020 est faible dans tous les domaines ; Cepheid 2020 est incertain pour la sélection des patients et élevé pour la norme de référence et pour le flux et la chronologie, avec de faibles problèmes d'applicabilité. Légende : rouge = élevé, jaune « ? » = incertain, vert = faible.",
        "ru": "Диаграмма риска систематической ошибки и проблем применимости (QUADAS-2) для исследований устойчивости к этионамиду с Xpert MTB/XDR (рисунок 8), оценивающая Cepheid 2020 и FIND 2020. У FIND 2020 риск низкий во всех доменах; у Cepheid 2020 неясный риск при отборе пациентов и высокий — по эталонному стандарту, а также последовательности и срокам; проблемы применимости низкие. Обозначения: красный — высокий, желтый «?» — неясный, зеленый — низкий."
      },
      "state": "draft"
    },
    {
      "id": "img-p646-2",
      "file": "images/img-p646-2.webp",
      "page": 646,
      "narratives": {
        "en": "Forest plots of Xpert MTB/XDR sensitivity and specificity for detecting amikacin resistance on sputum (Figure 9), in six panels: irrespective of rifampicin resistance and with detected rifampicin resistance, each against pDST, gDST and a composite reference standard. Studies are from Cepheid, DIAMA and FIND sites (e.g. China, South Africa, Benin, Cameroon, Rwanda, Moldova, Mumbai, New Delhi). Each row gives a study's TP, FP, FN and TN counts and sensitivity and specificity with 95% CI, plotted as squares with CI lines on 0–1 scales. Sensitivity varies from 0.29 to 1.00, lowest at FIND New Delhi, and some DIAMA estimates are not estimable; specificities are 0.96–1.00.",
        "ar": "مخططات غابية لحساسية ونوعية اختبار Xpert MTB/XDR في كشف مقاومة الأميكاسين على البلغم (الشكل 9)، في ست لوحات: بغض النظر عن مقاومة الريفامبيسين ومع وجود مقاومة للريفامبيسين، مقابل كل من pDST وgDST والمعيار المرجعي المركب. الدراسات من مواقع Cepheid وDIAMA وFIND (مثل الصين وجنوب أفريقيا وبنن والكاميرون ورواندا ومولدوفا ومومباي ونيودلهي). يعرض كل صف أعداد الإيجابيات الحقيقية والإيجابيات الكاذبة والسلبيات الكاذبة والسلبيات الحقيقية لدراسة ما، والحساسية والنوعية مع فترات ثقة 95%، ممثلة بمربعات وخطوط فترات الثقة على مقياس من 0 إلى 1. تتفاوت الحساسية بين 0.29 و1.00، وأدناها في FIND New Delhi، وبعض تقديرات DIAMA غير قابلة للتقدير؛ وتتراوح النوعية بين 0.96 و1.00.",
        "zh": "Xpert MTB/XDR对痰标本检测阿米卡星耐药的灵敏度和特异性森林图（图9），分为六组：不论利福平耐药状况及已检出利福平耐药，分别以pDST、gDST和复合参考标准为参照。研究来自Cepheid、DIAMA和FIND各研究点（如中国、南非、贝宁、喀麦隆、卢旺达、摩尔多瓦、孟买、新德里）。每行列出一项研究的真阳性、假阳性、假阴性和真阴性数，以及灵敏度和特异性（95%置信区间），以方块和置信区间线绘于0–1刻度上。灵敏度在0.29至1.00之间，FIND New Delhi最低，部分DIAMA估计值不可估计；特异性为0.96–1.00。",
        "es": "Diagramas de bosque (forest plots) de la sensibilidad y especificidad de Xpert MTB/XDR para detectar la resistencia a la amikacina en esputo (figura 9), en seis paneles: con independencia de la resistencia a la rifampicina y con resistencia a la rifampicina detectada, frente a pDST, gDST y un patrón de referencia compuesto. Los estudios proceden de centros de Cepheid, DIAMA y FIND (p. ej., China, Sudáfrica, Benin, Camerún, Rwanda, Moldova, Mumbai, Nueva Delhi). Cada fila presenta los VP, FP, FN y VN de un estudio y la sensibilidad y especificidad con IC del 95 %, representadas como cuadrados con líneas de IC en escalas de 0 a 1. La sensibilidad varía de 0,29 a 1,00, con el valor más bajo en FIND New Delhi, y algunas estimaciones de DIAMA no son estimables; las especificidades son de 0,96–1,00.",
        "fr": "Graphiques en forêt (forest plots) de la sensibilité et de la spécificité de Xpert MTB/XDR pour la détection de la résistance à l'amikacine sur expectorations (figure 9), en six panneaux : indépendamment de la résistance à la rifampicine et avec résistance à la rifampicine détectée, par rapport au pDST, au gDST et à une norme de référence composite. Les études proviennent de sites Cepheid, DIAMA et FIND (par ex. Chine, Afrique du Sud, Bénin, Cameroun, Rwanda, Moldova, Mumbai, New Delhi). Chaque ligne indique les VP, FP, FN et VN d'une étude ainsi que la sensibilité et la spécificité avec IC à 95 %, représentées par des carrés et des barres d'IC sur des échelles de 0 à 1. La sensibilité varie de 0,29 à 1,00, la plus faible à FIND New Delhi, et certaines estimations DIAMA ne sont pas estimables ; les spécificités sont de 0,96–1,00.",
        "ru": "Форест-диаграммы чувствительности и специфичности Xpert MTB/XDR при выявлении устойчивости к амикацину в мокроте (рисунок 9) в шести панелях: независимо от устойчивости к рифампицину и при выявленной устойчивости к рифампицину, в сравнении с pDST, gDST и комбинированным эталонным стандартом. Исследования проведены на площадках Cepheid, DIAMA и FIND (например, Китай, Южная Африка, Бенин, Камерун, Руанда, Молдова, Мумбаи, Нью-Дели). В каждой строке приведены число ИП, ЛП, ЛО и ИО в исследовании, а также чувствительность и специфичность с 95% ДИ, показанные квадратами с линиями ДИ на шкалах от 0 до 1. Чувствительность варьирует от 0,29 до 1,00, минимальная — в FIND New Delhi; часть оценок DIAMA не поддается оценке; специфичность — 0,96–1,00."
      },
      "state": "draft"
    },
    {
      "id": "img-p662-1",
      "file": "images/img-p662-1.webp",
      "page": 662,
      "narratives": {
        "en": "Photo of an Xpert MTB/XDR cartridge beside a colour-coded table of possible result calls by drug class (N/A, isoniazid, fluoroquinolone, amikacin, kanamycin, capreomycin, ethionamide). Results such as 'Resistance DETECTED' and 'Low Resistance DETECTED' are shaded red, 'NOT DETECTED' green and 'INDETERMINATE' yellow.",
        "ar": "صورة لخرطوشة Xpert MTB/XDR بجانب جدول مرمز بالألوان لنتائج الاختبار المحتملة حسب فئة الدواء (N/A، الإيزونيازيد، الفلوروكينولون، الأميكاسين، الكاناميسين، الكابريومايسين، الإيثيوناميد). النتائج مثل 'Resistance DETECTED' و'Low Resistance DETECTED' مظللة بالأحمر، و'NOT DETECTED' بالأخضر، و'INDETERMINATE' بالأصفر.",
        "zh": "Xpert MTB/XDR检测盒照片，旁边是按药物类别（N/A、异烟肼、氟喹诺酮、阿米卡星、卡那霉素、卷曲霉素、乙硫异烟胺）列出可能结果的颜色编码表。“Resistance DETECTED”和“Low Resistance DETECTED”等结果为红色，“NOT DETECTED”为绿色，“INDETERMINATE”为黄色。",
        "es": "Foto de un cartucho Xpert MTB/XDR junto a una tabla codificada por colores de los posibles resultados por clase de fármaco (N/A, isoniazida, fluoroquinolona, amikacina, kanamicina, capreomicina, etionamida). Los resultados como «Resistance DETECTED» y «Low Resistance DETECTED» aparecen en rojo, «NOT DETECTED» en verde e «INDETERMINATE» en amarillo.",
        "fr": "Photo d'une cartouche Xpert MTB/XDR à côté d'un tableau à code couleur des résultats possibles par classe de médicament (N/A, isoniazide, fluoroquinolone, amikacine, kanamycine, capréomycine, éthionamide). Les résultats tels que « Resistance DETECTED » et « Low Resistance DETECTED » sont en rouge, « NOT DETECTED » en vert et « INDETERMINATE » en jaune.",
        "ru": "Фотография картриджа Xpert MTB/XDR рядом с таблицей возможных результатов по классам препаратов с цветовой кодировкой (N/A, изониазид, фторхинолон, амикацин, канамицин, капреомицин, этионамид). Результаты вида «Resistance DETECTED» и «Low Resistance DETECTED» выделены красным, «NOT DETECTED» — зеленым, «INDETERMINATE» — желтым."
      },
      "state": "draft"
    },
    {
      "id": "img-p663-1",
      "file": "images/img-p663-1.webp",
      "page": 663,
      "narratives": {
        "en": "Clinical pathway diagram with four flowcharts, Scenarios A to D, under an arrow labelled 'Increasing likelihood of resistance'. A: index test to diagnose TB and do DST; B: DST in patients newly diagnosed with TB by another test; C: DST in newly diagnosed patients whose RIF susceptibility is already known; D: DST in patients on treatment. Each branches from the index test into TB-negative/TB-positive, no resistance or resistance to at least one drug, and ends in treatment.",
        "ar": "مخطط المسار السريري يتضمن أربعة مخططات انسيابية، السيناريوهات من A إلى D، أسفل سهم بعنوان 'Increasing likelihood of resistance'. A: الاختبار المؤشر لتشخيص السل وإجراء اختبار الحساسية للأدوية؛ B: اختبار الحساسية لدى المرضى المشخصين حديثًا بالسل باختبار آخر؛ C: اختبار الحساسية لدى المرضى المشخصين حديثًا ممن تُعرف حساسيتهم للريفامبيسين؛ D: اختبار الحساسية لدى المرضى قيد العلاج. يتفرع كل منها من الاختبار المؤشر إلى سلبي/إيجابي للسل، وعدم وجود مقاومة أو مقاومة لدواء واحد على الأقل، وينتهي بالعلاج.",
        "zh": "临床路径图，包含四个流程图（情景A至D），上方箭头标注“Increasing likelihood of resistance”。A：用待评价试验诊断结核病并进行药敏试验；B：对经其他检测新诊断结核病的患者进行药敏试验；C：对已知利福平敏感性的新诊断患者进行药敏试验；D：对正在治疗的患者进行药敏试验。每个流程从待评价试验分为结核阴性/阳性、无耐药或至少对一种药物耐药，最终进入治疗。",
        "es": "Diagrama de la vía clínica con cuatro diagramas de flujo, escenarios A a D, bajo una flecha titulada «Increasing likelihood of resistance». A: prueba índice para diagnosticar la TB y realizar la PSF; B: PSF en pacientes recién diagnosticados de TB mediante otra prueba; C: PSF en pacientes recién diagnosticados cuya sensibilidad a la RIF ya se conoce; D: PSF en pacientes en tratamiento. Cada uno se ramifica desde la prueba índice en TB negativa/positiva, sin resistencia o resistencia a al menos un fármaco, y termina en el tratamiento.",
        "fr": "Schéma du parcours clinique avec quatre logigrammes, scénarios A à D, sous une flèche intitulée « Increasing likelihood of resistance ». A : test index pour diagnostiquer la TB et réaliser le TPM ; B : TPM chez les patients nouvellement diagnostiqués avec la TB par un autre test ; C : TPM chez les patients nouvellement diagnostiqués dont la sensibilité à la RIF est déjà connue ; D : TPM chez les patients sous traitement. Chacun se ramifie à partir du test index en TB négative/positive, absence de résistance ou résistance à au moins un médicament, et aboutit au traitement.",
        "ru": "Схема клинического маршрута из четырех блок-схем, сценарии A–D, под стрелкой «Increasing likelihood of resistance». A: индексный тест для диагностики ТБ и ТЛЧ; B: ТЛЧ у пациентов с ТБ, впервые диагностированным другим тестом; C: ТЛЧ у впервые диагностированных пациентов с известной чувствительностью к RIF; D: ТЛЧ у пациентов, получающих лечение. Каждая схема ветвится от индексного теста на ТБ-отрицательных/положительных, отсутствие устойчивости или устойчивость как минимум к одному препарату и завершается лечением."
      },
      "state": "draft"
    },
    {
      "id": "img-p670-1",
      "file": "images/img-p670-1.webp",
      "page": 670,
      "narratives": {
        "en": "Flow diagram of studies in the review: 1647 records from database searching and 3 from other sources; 1649 after duplicates removed and screened; 1620 excluded; 29 full-text articles (datasets) assessed for eligibility, of which 26 were excluded (not a cartridge-based test for isoniazid or second-line drug resistance 17, index test is BD MAX 3, prototype test 2, not a diagnostic accuracy study 2, extrapulmonary specimen 1, not commercially available 1). Three studies were included in both qualitative and quantitative synthesis (meta-analysis).",
        "ar": "مخطط انسيابي للدراسات في المراجعة: 1647 سجلًا من البحث في قواعد البيانات و3 من مصادر أخرى؛ 1649 بعد إزالة التكرارات وتم فرزها؛ استُبعد 1620؛ وقُيّمت 29 مقالة كاملة النص (مجموعات بيانات) للأهلية، استُبعدت منها 26 (ليس اختبارًا قائمًا على الخرطوشة لمقاومة الإيزونيازيد أو أدوية الخط الثاني 17، الاختبار المؤشر هو BD MAX 3، اختبار نموذجي أولي 2، ليست دراسة دقة تشخيصية 2، عينة خارج الرئة 1، غير متاح تجاريًا 1). أُدرجت ثلاث دراسات في كل من التوليف النوعي والكمي (التحليل التلوي).",
        "zh": "综述中研究的流程图：数据库检索得到1647条记录，其他来源3条；去重后1649条并进行筛选；排除1620条；评估29篇全文文章（数据集）的合格性，其中排除26篇（非基于检测盒的异烟肼或二线药物耐药检测17篇，待评价试验为BD MAX 3篇，原型检测2篇，非诊断准确性研究2篇，肺外标本1篇，未上市1篇）。三项研究纳入定性综合和定量综合（荟萃分析）。",
        "es": "Diagrama de flujo de los estudios de la revisión: 1647 registros de búsquedas en bases de datos y 3 de otras fuentes; 1649 tras eliminar duplicados y cribados; 1620 excluidos; 29 artículos a texto completo (conjuntos de datos) evaluados para determinar su elegibilidad, de los cuales se excluyeron 26 (no es una prueba basada en cartuchos para la resistencia a la isoniazida o a fármacos de segunda línea 17, la prueba índice es BD MAX 3, prueba prototipo 2, no es un estudio de exactitud diagnóstica 2, muestra extrapulmonar 1, no disponible comercialmente 1). Se incluyeron tres estudios en la síntesis cualitativa y en la cuantitativa (metanálisis).",
        "fr": "Diagramme de flux des études de la revue : 1647 enregistrements issus de la recherche dans les bases de données et 3 d'autres sources ; 1649 après suppression des doublons et sélectionnés ; 1620 exclus ; 29 articles en texte intégral (jeux de données) évalués pour l'éligibilité, dont 26 exclus (pas un test sur cartouche pour la résistance à l'isoniazide ou aux médicaments de deuxième intention 17, test index BD MAX 3, test prototype 2, pas une étude d'exactitude diagnostique 2, échantillon extrapulmonaire 1, non commercialisé 1). Trois études ont été incluses dans les synthèses qualitative et quantitative (méta-analyse).",
        "ru": "Блок-схема отбора исследований для обзора: 1647 записей из поиска по базам данных и 3 из других источников; 1649 после удаления дубликатов и прошли скрининг; 1620 исключены; 29 полнотекстовых статей (наборов данных) оценены на соответствие критериям, из них 26 исключены (не картриджный тест на устойчивость к изониазиду или препаратам второго ряда — 17, индексный тест BD MAX — 3, прототип теста — 2, не исследование диагностической точности — 2, внелегочный образец — 1, нет в продаже — 1). Три исследования включены в качественный и количественный синтез (метаанализ)."
      },
      "state": "draft"
    },
    {
      "id": "img-p674-1",
      "file": "images/img-p674-1.webp",
      "page": 674,
      "narratives": {
        "en": "Product photo of the Sanity 2.0 all-in-one benchtop instrument used for MeltPro XDR-TB testing (Figure S1): a white cabinet with a touchscreen at the top and a front opening, bearing the Zeesan name.",
        "ar": "صورة منتج لجهاز Sanity 2.0 المتكامل المكتبي المستخدم في اختبار MeltPro XDR-TB (الشكل S1): خزانة بيضاء بشاشة لمس في الأعلى وفتحة أمامية، وتحمل اسم Zeesan.",
        "zh": "用于MeltPro XDR-TB检测的Sanity 2.0一体化台式仪器产品照片（图S1）：白色机身，顶部有触摸屏，前部有开口，带有Zeesan字样。",
        "es": "Foto del instrumento de sobremesa todo en uno Sanity 2.0 utilizado para la prueba MeltPro XDR-TB (figura S1): una unidad blanca con pantalla táctil en la parte superior y una abertura frontal, con el nombre Zeesan.",
        "fr": "Photo du produit Sanity 2.0, instrument de paillasse tout-en-un utilisé pour le test MeltPro XDR-TB (figure S1) : un boîtier blanc avec un écran tactile en haut et une ouverture frontale, portant le nom Zeesan.",
        "ru": "Фотография настольного прибора «всё в одном» Sanity 2.0, используемого для теста MeltPro XDR-TB (рисунок S1): белый корпус с сенсорным экраном сверху и фронтальным отсеком, с надписью Zeesan."
      },
      "state": "draft"
    },
    {
      "id": "img-p676-1",
      "file": "images/img-p676-1.webp",
      "page": 676,
      "narratives": {
        "en": "Forest plots of MeltPro XDR-TB sensitivity and specificity on sputum against pDST (Figure S2), from a single study (Zeesan 2020), in six panels for isoniazid, fluoroquinolone and amikacin resistance, each in rifampicin-susceptible and rifampicin-resistant patients. Each row gives a study's TP, FP, FN and TN counts and sensitivity and specificity with 95% CI, plotted as squares with CI lines on 0–1 scales. Sensitivities range from 0.79 to 0.91 and specificities from 0.86 to 0.98.",
        "ar": "مخططات غابية لحساسية ونوعية اختبار MeltPro XDR-TB على البلغم مقابل pDST (الشكل S2)، من دراسة واحدة (Zeesan 2020)، في ست لوحات لمقاومة الإيزونيازيد والفلوروكينولون والأميكاسين، لدى المرضى الحساسين للريفامبيسين والمقاومين له. يعرض كل صف أعداد الإيجابيات الحقيقية والإيجابيات الكاذبة والسلبيات الكاذبة والسلبيات الحقيقية لدراسة ما، والحساسية والنوعية مع فترات ثقة 95%، ممثلة بمربعات وخطوط فترات الثقة على مقياس من 0 إلى 1. تتراوح الحساسية بين 0.79 و0.91 والنوعية بين 0.86 و0.98.",
        "zh": "MeltPro XDR-TB对痰标本以pDST为参照的灵敏度和特异性森林图（图S2），来自单项研究（Zeesan 2020），分六组展示异烟肼、氟喹诺酮和阿米卡星耐药，分别针对利福平敏感和利福平耐药患者。每行列出一项研究的真阳性、假阳性、假阴性和真阴性数，以及灵敏度和特异性（95%置信区间），以方块和置信区间线绘于0–1刻度上。灵敏度为0.79至0.91，特异性为0.86至0.98。",
        "es": "Diagramas de bosque (forest plots) de la sensibilidad y especificidad de MeltPro XDR-TB en esputo frente a pDST (figura S2), de un único estudio (Zeesan 2020), en seis paneles para la resistencia a la isoniazida, las fluoroquinolonas y la amikacina, en pacientes sensibles y resistentes a la rifampicina. Cada fila presenta los VP, FP, FN y VN de un estudio y la sensibilidad y especificidad con IC del 95 %, representadas como cuadrados con líneas de IC en escalas de 0 a 1. Las sensibilidades oscilan entre 0,79 y 0,91 y las especificidades entre 0,86 y 0,98.",
        "fr": "Graphiques en forêt (forest plots) de la sensibilité et de la spécificité de MeltPro XDR-TB sur expectorations par rapport au pDST (figure S2), issus d'une seule étude (Zeesan 2020), en six panneaux pour la résistance à l'isoniazide, aux fluoroquinolones et à l'amikacine, chez les patients sensibles et résistants à la rifampicine. Chaque ligne indique les VP, FP, FN et VN d'une étude ainsi que la sensibilité et la spécificité avec IC à 95 %, représentées par des carrés et des barres d'IC sur des échelles de 0 à 1. Les sensibilités vont de 0,79 à 0,91 et les spécificités de 0,86 à 0,98.",
        "ru": "Форест-диаграммы чувствительности и специфичности MeltPro XDR-TB в мокроте по сравнению с pDST (рисунок S2) по данным одного исследования (Zeesan 2020) в шести панелях: устойчивость к изониазиду, фторхинолонам и амикацину у пациентов, чувствительных и устойчивых к рифампицину. В каждой строке приведены число ИП, ЛП, ЛО и ИО в исследовании, а также чувствительность и специфичность с 95% ДИ, показанные квадратами с линиями ДИ на шкалах от 0 до 1. Чувствительность — от 0,79 до 0,91, специфичность — от 0,86 до 0,98."
      },
      "state": "draft"
    },
    {
      "id": "img-p677-1",
      "file": "images/img-p677-1.webp",
      "page": 677,
      "narratives": {
        "en": "Forest plots of Xpert MTB/XDR sensitivity and specificity for diagnosing pulmonary TB on sputum against culture, in three panels: adults (6 studies), children under 15 (no data) and people with HIV (3 studies). Each row gives a study's TP, FP, FN and TN counts and sensitivity and specificity with 95% CI, plotted as squares with CI lines on 0–1 scales. Sensitivity is high (0.86–0.99), while specificity in adults varies widely (0.00–1.00) with very wide intervals.",
        "ar": "مخططات غابية لحساسية ونوعية اختبار Xpert MTB/XDR في تشخيص السل الرئوي على البلغم مقابل المزرعة، في ثلاث لوحات: البالغون (6 دراسات)، والأطفال دون 15 عامًا (لا توجد بيانات)، والمصابون بفيروس العوز المناعي البشري (3 دراسات). يعرض كل صف أعداد الإيجابيات الحقيقية والإيجابيات الكاذبة والسلبيات الكاذبة والسلبيات الحقيقية لدراسة ما، والحساسية والنوعية مع فترات ثقة 95%، ممثلة بمربعات وخطوط فترات الثقة على مقياس من 0 إلى 1. الحساسية مرتفعة (0.86–0.99)، بينما تتفاوت النوعية لدى البالغين تفاوتًا كبيرًا (0.00–1.00) مع فترات واسعة جدًا.",
        "zh": "Xpert MTB/XDR对痰标本以培养为参照诊断肺结核的灵敏度和特异性森林图，分三组：成人（6项研究）、15岁以下儿童（无数据）和艾滋病毒感染者（3项研究）。每行列出一项研究的真阳性、假阳性、假阴性和真阴性数，以及灵敏度和特异性（95%置信区间），以方块和置信区间线绘于0–1刻度上。灵敏度较高（0.86–0.99），而成人的特异性差异很大（0.00–1.00），置信区间非常宽。",
        "es": "Diagramas de bosque (forest plots) de la sensibilidad y especificidad de Xpert MTB/XDR para diagnosticar la TB pulmonar en esputo frente al cultivo, en tres paneles: adultos (6 estudios), menores de 15 años (sin datos) y personas con VIH (3 estudios). Cada fila presenta los VP, FP, FN y VN de un estudio y la sensibilidad y especificidad con IC del 95 %, representadas como cuadrados con líneas de IC en escalas de 0 a 1. La sensibilidad es alta (0,86–0,99), mientras que la especificidad en adultos varía mucho (0,00–1,00), con intervalos muy amplios.",
        "fr": "Graphiques en forêt (forest plots) de la sensibilité et de la spécificité de Xpert MTB/XDR pour le diagnostic de la TB pulmonaire sur expectorations par rapport à la culture, en trois panneaux : adultes (6 études), enfants de moins de 15 ans (aucune donnée) et personnes vivant avec le VIH (3 études). Chaque ligne indique les VP, FP, FN et VN d'une étude ainsi que la sensibilité et la spécificité avec IC à 95 %, représentées par des carrés et des barres d'IC sur des échelles de 0 à 1. La sensibilité est élevée (0,86–0,99), tandis que la spécificité chez les adultes varie fortement (0,00–1,00), avec des intervalles très larges.",
        "ru": "Форест-диаграммы чувствительности и специфичности Xpert MTB/XDR при диагностике легочного ТБ в мокроте по сравнению с посевом в трех панелях: взрослые (6 исследований), дети до 15 лет (нет данных) и люди с ВИЧ (3 исследования). В каждой строке приведены число ИП, ЛП, ЛО и ИО в исследовании, а также чувствительность и специфичность с 95% ДИ, показанные квадратами с линиями ДИ на шкалах от 0 до 1. Чувствительность высокая (0,86–0,99), а специфичность у взрослых сильно варьирует (0,00–1,00) при очень широких интервалах."
      },
      "state": "draft"
    },
    {
      "id": "img-p691-1",
      "file": "images/img-p691-1.webp",
      "page": 691,
      "narratives": {
        "en": "PRISMA flow diagram (Figure 1): records from PubMed (n = 17), Web of Science (n = 38) and Embase (n = 72); 31 duplicate articles removed, giving 96 unique articles; 89 excluded after screening title and abstract, leaving 7 screened articles; 2 unpublished trials/studies added, for 9 articles/trials included.",
        "ar": "مخطط PRISMA الانسيابي (الشكل 1): سجلات من PubMed (العدد = 17) وWeb of Science (العدد = 38) وEmbase (العدد = 72)؛ أُزيلت 31 مقالة مكررة، فبقيت 96 مقالة فريدة؛ استُبعدت 89 بعد فرز العنوان والملخص، فبقيت 7 مقالات؛ وأضيفت تجربتان/دراستان غير منشورتين، ليصبح المجموع 9 مقالات/تجارب مدرجة.",
        "zh": "PRISMA流程图（图1）：来自PubMed（n = 17）、Web of Science（n = 38）和Embase（n = 72）的记录；删除31篇重复文章，得到96篇独立文章；筛选标题和摘要后排除89篇，剩余7篇；另纳入2项未发表的试验/研究，共纳入9篇文章/试验。",
        "es": "Diagrama de flujo PRISMA (figura 1): registros de PubMed (n = 17), Web of Science (n = 38) y Embase (n = 72); se eliminaron 31 artículos duplicados, quedando 96 artículos únicos; 89 se excluyeron tras el cribado de título y resumen, quedando 7; se añadieron 2 ensayos/estudios no publicados, con un total de 9 artículos/ensayos incluidos.",
        "fr": "Diagramme de flux PRISMA (figure 1) : enregistrements issus de PubMed (n = 17), Web of Science (n = 38) et Embase (n = 72) ; 31 articles en double supprimés, soit 96 articles uniques ; 89 exclus après examen du titre et du résumé, laissant 7 articles ; 2 essais/études non publiés ajoutés, soit 9 articles/essais inclus.",
        "ru": "Блок-схема PRISMA (рисунок 1): записи из PubMed (n = 17), Web of Science (n = 38) и Embase (n = 72); удалена 31 дублирующая статья, осталось 96 уникальных статей; 89 исключены после скрининга заголовков и аннотаций, осталось 7; добавлены 2 неопубликованных испытания/исследования, всего включено 9 статей/испытаний."
      },
      "state": "draft"
    },
    {
      "id": "img-p695-1",
      "file": "images/img-p695-1.webp",
      "page": 695,
      "narratives": {
        "en": "Forest plot of Nipro PZA LPA sensitivity and specificity for pyrazinamide (PZA) resistance against phenotypic DST, with two studies: Mitarai (sensitivity 1.00 [0.40, 1.00], specificity 1.00) and Sekiguchi (sensitivity not estimable, specificity 1.00). Each row gives a study's TP, FP, FN and TN counts and sensitivity and specificity with 95% CI, plotted as squares with CI lines on 0–1 scales.",
        "ar": "مخطط غابي لحساسية ونوعية اختبار Nipro PZA LPA لمقاومة البيرازيناميد (PZA) مقابل اختبار الحساسية الظاهري، بدراستين: Mitarai (الحساسية 1.00 [0.40، 1.00]، النوعية 1.00) وSekiguchi (الحساسية غير قابلة للتقدير، النوعية 1.00). يعرض كل صف أعداد الإيجابيات الحقيقية والإيجابيات الكاذبة والسلبيات الكاذبة والسلبيات الحقيقية لدراسة ما، والحساسية والنوعية مع فترات ثقة 95%، ممثلة بمربعات وخطوط فترات الثقة على مقياس من 0 إلى 1.",
        "zh": "Nipro PZA LPA以表型药敏试验为参照检测吡嗪酰胺（PZA）耐药的灵敏度和特异性森林图，含两项研究：Mitarai（灵敏度1.00 [0.40, 1.00]，特异性1.00）和Sekiguchi（灵敏度不可估计，特异性1.00）。每行列出一项研究的真阳性、假阳性、假阴性和真阴性数，以及灵敏度和特异性（95%置信区间），以方块和置信区间线绘于0–1刻度上。",
        "es": "Diagrama de bosque (forest plot) de la sensibilidad y especificidad de Nipro PZA LPA para la resistencia a la pirazinamida (PZA) frente a la PSF fenotípica, con dos estudios: Mitarai (sensibilidad 1,00 [0,40; 1,00], especificidad 1,00) y Sekiguchi (sensibilidad no estimable, especificidad 1,00). Cada fila presenta los VP, FP, FN y VN de un estudio y la sensibilidad y especificidad con IC del 95 %, representadas como cuadrados con líneas de IC en escalas de 0 a 1.",
        "fr": "Graphique en forêt (forest plot) de la sensibilité et de la spécificité du Nipro PZA LPA pour la résistance au pyrazinamide (PZA) par rapport au TPM phénotypique, avec deux études : Mitarai (sensibilité 1,00 [0,40 ; 1,00], spécificité 1,00) et Sekiguchi (sensibilité non estimable, spécificité 1,00). Chaque ligne indique les VP, FP, FN et VN d'une étude ainsi que la sensibilité et la spécificité avec IC à 95 %, représentées par des carrés et des barres d'IC sur des échelles de 0 à 1.",
        "ru": "Форест-диаграмма чувствительности и специфичности Nipro PZA LPA для устойчивости к пиразинамиду (PZA) по сравнению с фенотипическим ТЛЧ, два исследования: Mitarai (чувствительность 1,00 [0,40; 1,00], специфичность 1,00) и Sekiguchi (чувствительность не поддается оценке, специфичность 1,00). В каждой строке приведены число ИП, ЛП, ЛО и ИО в исследовании, а также чувствительность и специфичность с 95% ДИ, показанные квадратами с линиями ДИ на шкалах от 0 до 1."
      },
      "state": "draft"
    },
    {
      "id": "img-p695-2",
      "file": "images/img-p695-2.webp",
      "page": 695,
      "narratives": {
        "en": "Forest plot of Nipro PZA LPA sensitivity and specificity for PZA resistance against genotypic DST, with one study (Driesen: TP 14, FN 0, TN 7; sensitivity 1.00 [0.77, 1.00], specificity 1.00 [0.59, 1.00]). Each row gives a study's TP, FP, FN and TN counts and sensitivity and specificity with 95% CI, plotted as squares with CI lines on 0–1 scales.",
        "ar": "مخطط غابي لحساسية ونوعية اختبار Nipro PZA LPA لمقاومة PZA مقابل اختبار الحساسية الجيني، بدراسة واحدة (Driesen: الإيجابيات الحقيقية 14، السلبيات الكاذبة 0، السلبيات الحقيقية 7؛ الحساسية 1.00 [0.77، 1.00]، النوعية 1.00 [0.59، 1.00]). يعرض كل صف أعداد الإيجابيات الحقيقية والإيجابيات الكاذبة والسلبيات الكاذبة والسلبيات الحقيقية لدراسة ما، والحساسية والنوعية مع فترات ثقة 95%، ممثلة بمربعات وخطوط فترات الثقة على مقياس من 0 إلى 1.",
        "zh": "Nipro PZA LPA以基因型药敏试验为参照检测PZA耐药的灵敏度和特异性森林图，含一项研究（Driesen：真阳性14，假阴性0，真阴性7；灵敏度1.00 [0.77, 1.00]，特异性1.00 [0.59, 1.00]）。每行列出一项研究的真阳性、假阳性、假阴性和真阴性数，以及灵敏度和特异性（95%置信区间），以方块和置信区间线绘于0–1刻度上。",
        "es": "Diagrama de bosque (forest plot) de la sensibilidad y especificidad de Nipro PZA LPA para la resistencia a la PZA frente a la PSF genotípica, con un estudio (Driesen: VP 14, FN 0, VN 7; sensibilidad 1,00 [0,77; 1,00], especificidad 1,00 [0,59; 1,00]). Cada fila presenta los VP, FP, FN y VN de un estudio y la sensibilidad y especificidad con IC del 95 %, representadas como cuadrados con líneas de IC en escalas de 0 a 1.",
        "fr": "Graphique en forêt (forest plot) de la sensibilité et de la spécificité du Nipro PZA LPA pour la résistance au PZA par rapport au TPM génotypique, avec une étude (Driesen : VP 14, FN 0, VN 7 ; sensibilité 1,00 [0,77 ; 1,00], spécificité 1,00 [0,59 ; 1,00]). Chaque ligne indique les VP, FP, FN et VN d'une étude ainsi que la sensibilité et la spécificité avec IC à 95 %, représentées par des carrés et des barres d'IC sur des échelles de 0 à 1.",
        "ru": "Форест-диаграмма чувствительности и специфичности Nipro PZA LPA для устойчивости к PZA по сравнению с генотипическим ТЛЧ, одно исследование (Driesen: ИП 14, ЛО 0, ИО 7; чувствительность 1,00 [0,77; 1,00], специфичность 1,00 [0,59; 1,00]). В каждой строке приведены число ИП, ЛП, ЛО и ИО в исследовании, а также чувствительность и специфичность с 95% ДИ, показанные квадратами с линиями ДИ на шкалах от 0 до 1."
      },
      "state": "draft"
    },
    {
      "id": "img-p697-1",
      "file": "images/img-p697-1.webp",
      "page": 697,
      "narratives": {
        "en": "Table of risk of bias (patient selection, index test, reference standard, flow and timing) and applicability concerns (patient selection, index test, reference standard) for seven Nipro PZA LPA studies: Ando, Sekiguchi, Mitarai, Rienthong, Driesen, Matsumoto and Burhan trial, using red, yellow and green markers. Several studies are rated high risk for patient selection and the index test. Key: red = high, yellow '?' = unclear, green = low.",
        "ar": "جدول خطر التحيز (اختيار المرضى، والاختبار المؤشر، والمعيار المرجعي، والتدفق والتوقيت) والمخاوف المتعلقة بقابلية التطبيق (اختيار المرضى، والاختبار المؤشر، والمعيار المرجعي) لسبع دراسات لاختبار Nipro PZA LPA: Ando وSekiguchi وMitarai وRienthong وDriesen وMatsumoto وBurhan trial، باستخدام علامات حمراء وصفراء وخضراء. صُنفت عدة دراسات بخطر مرتفع في اختيار المرضى والاختبار المؤشر. المفتاح: الأحمر = مرتفع، الأصفر '?' = غير واضح، الأخضر = منخفض.",
        "zh": "Nipro PZA LPA七项研究的偏倚风险（患者选择、待评价试验、参考标准、流程和时间）和适用性问题（患者选择、待评价试验、参考标准）表，研究包括Ando、Sekiguchi、Mitarai、Rienthong、Driesen、Matsumoto和Burhan trial，使用红、黄、绿标记。数项研究在患者选择和待评价试验方面被评为高风险。图例：红色=高，黄色“?”=不明确，绿色=低。",
        "es": "Tabla de riesgo de sesgo (selección de pacientes, prueba índice, patrón de referencia, flujo y cronología) y problemas de aplicabilidad (selección de pacientes, prueba índice, patrón de referencia) de siete estudios de Nipro PZA LPA: Ando, Sekiguchi, Mitarai, Rienthong, Driesen, Matsumoto y Burhan trial, con marcadores rojos, amarillos y verdes. Varios estudios se califican de alto riesgo en selección de pacientes y prueba índice. Leyenda: rojo = alto, amarillo «?» = incierto, verde = bajo.",
        "fr": "Tableau du risque de biais (sélection des patients, test index, norme de référence, flux et chronologie) et des problèmes d'applicabilité (sélection des patients, test index, norme de référence) pour sept études du Nipro PZA LPA : Ando, Sekiguchi, Mitarai, Rienthong, Driesen, Matsumoto et Burhan trial, avec des marqueurs rouges, jaunes et verts. Plusieurs études sont jugées à risque élevé pour la sélection des patients et le test index. Légende : rouge = élevé, jaune « ? » = incertain, vert = faible.",
        "ru": "Таблица риска систематической ошибки (отбор пациентов, индексный тест, эталонный стандарт, последовательность и сроки) и проблем применимости (отбор пациентов, индексный тест, эталонный стандарт) для семи исследований Nipro PZA LPA: Ando, Sekiguchi, Mitarai, Rienthong, Driesen, Matsumoto и Burhan trial, с красными, желтыми и зелеными маркерами. Ряд исследований оценен как имеющие высокий риск по отбору пациентов и индексному тесту. Обозначения: красный — высокий, желтый «?» — неясный, зеленый — низкий."
      },
      "state": "draft"
    },
    {
      "id": "img-p697-2",
      "file": "images/img-p697-2.webp",
      "page": 697,
      "narratives": {
        "en": "Forest plot of Nipro PZA LPA sensitivity and specificity for PZA resistance in seven studies: Ando, Burhan trial, Driesen, Matsumoto, Mitarai, Rienthong and Sekiguchi. Each row gives a study's TP, FP, FN and TN counts and sensitivity and specificity with 95% CI, plotted as squares with CI lines on 0–1 scales. Sensitivity ranges from 0.36 (Rienthong) and 0.39 (Burhan trial) to 1.00; specificity is 0.93–1.00.",
        "ar": "مخطط غابي لحساسية ونوعية اختبار Nipro PZA LPA لمقاومة PZA في سبع دراسات: Ando وBurhan trial وDriesen وMatsumoto وMitarai وRienthong وSekiguchi. يعرض كل صف أعداد الإيجابيات الحقيقية والإيجابيات الكاذبة والسلبيات الكاذبة والسلبيات الحقيقية لدراسة ما، والحساسية والنوعية مع فترات ثقة 95%، ممثلة بمربعات وخطوط فترات الثقة على مقياس من 0 إلى 1. تتراوح الحساسية من 0.36 (Rienthong) و0.39 (Burhan trial) إلى 1.00؛ والنوعية بين 0.93 و1.00.",
        "zh": "Nipro PZA LPA检测PZA耐药的灵敏度和特异性森林图，涉及七项研究：Ando、Burhan trial、Driesen、Matsumoto、Mitarai、Rienthong和Sekiguchi。每行列出一项研究的真阳性、假阳性、假阴性和真阴性数，以及灵敏度和特异性（95%置信区间），以方块和置信区间线绘于0–1刻度上。灵敏度从0.36（Rienthong）和0.39（Burhan trial）到1.00；特异性为0.93–1.00。",
        "es": "Diagrama de bosque (forest plot) de la sensibilidad y especificidad de Nipro PZA LPA para la resistencia a la PZA en siete estudios: Ando, Burhan trial, Driesen, Matsumoto, Mitarai, Rienthong y Sekiguchi. Cada fila presenta los VP, FP, FN y VN de un estudio y la sensibilidad y especificidad con IC del 95 %, representadas como cuadrados con líneas de IC en escalas de 0 a 1. La sensibilidad va de 0,36 (Rienthong) y 0,39 (Burhan trial) a 1,00; la especificidad es de 0,93–1,00.",
        "fr": "Graphique en forêt (forest plot) de la sensibilité et de la spécificité du Nipro PZA LPA pour la résistance au PZA dans sept études : Ando, Burhan trial, Driesen, Matsumoto, Mitarai, Rienthong et Sekiguchi. Chaque ligne indique les VP, FP, FN et VN d'une étude ainsi que la sensibilité et la spécificité avec IC à 95 %, représentées par des carrés et des barres d'IC sur des échelles de 0 à 1. La sensibilité va de 0,36 (Rienthong) et 0,39 (Burhan trial) à 1,00 ; la spécificité est de 0,93–1,00.",
        "ru": "Форест-диаграмма чувствительности и специфичности Nipro PZA LPA для устойчивости к PZA в семи исследованиях: Ando, Burhan trial, Driesen, Matsumoto, Mitarai, Rienthong и Sekiguchi. В каждой строке приведены число ИП, ЛП, ЛО и ИО в исследовании, а также чувствительность и специфичность с 95% ДИ, показанные квадратами с линиями ДИ на шкалах от 0 до 1. Чувствительность — от 0,36 (Rienthong) и 0,39 (Burhan trial) до 1,00; специфичность — 0,93–1,00."
      },
      "state": "draft"
    },
    {
      "id": "img-p698-1",
      "file": "images/img-p698-1.webp",
      "page": 698,
      "narratives": {
        "en": "A QUADAS-2 style table of risk of bias (patient selection, index test, reference standard, flow and timing) and applicability concerns (patient selection, index test, reference standard) for six studies: Ando, Sekiguchi, Mitarai, Rienthong, Driesen and ITM trial. Each cell holds a coloured marker: green for low, red for high and yellow for unclear concern.",
        "ar": "جدول على نمط QUADAS-2 لخطر التحيز (اختيار المرضى، والاختبار المؤشر، والمعيار المرجعي، والتدفق والتوقيت) ومخاوف قابلية التطبيق (اختيار المرضى، والاختبار المؤشر، والمعيار المرجعي) لست دراسات: Ando وSekiguchi وMitarai وRienthong وDriesen وITM trial. تحتوي كل خلية على علامة ملونة: الأخضر للخطر المنخفض، والأحمر للخطر المرتفع، والأصفر للخطر غير الواضح.",
        "zh": "QUADAS-2式表格，列出六项研究（Ando、Sekiguchi、Mitarai、Rienthong、Driesen和ITM trial）的偏倚风险（患者选择、待评价试验、参考标准、流程和时间）及适用性问题（患者选择、待评价试验、参考标准）。每个单元格有一个彩色标记：绿色表示低风险，红色表示高风险，黄色表示不明确。",
        "es": "Tabla de tipo QUADAS-2 sobre el riesgo de sesgo (selección de pacientes, prueba índice, patrón de referencia, flujo y cronología) y los problemas de aplicabilidad (selección de pacientes, prueba índice, patrón de referencia) de seis estudios: Ando, Sekiguchi, Mitarai, Rienthong, Driesen e ITM trial. Cada celda contiene un marcador de color: verde para riesgo bajo, rojo para alto y amarillo para incierto.",
        "fr": "Tableau de type QUADAS-2 du risque de biais (sélection des patients, test index, norme de référence, flux et chronologie) et des préoccupations d’applicabilité (sélection des patients, test index, norme de référence) pour six études : Ando, Sekiguchi, Mitarai, Rienthong, Driesen et ITM trial. Chaque cellule contient un repère de couleur : vert pour un risque faible, rouge pour élevé et jaune pour incertain.",
        "ru": "Таблица в формате QUADAS-2 с оценкой риска систематической ошибки (отбор пациентов, индексный тест, эталонный стандарт, ход исследования и сроки) и сомнений в применимости (отбор пациентов, индексный тест, эталонный стандарт) для шести исследований: Ando, Sekiguchi, Mitarai, Rienthong, Driesen и ITM trial. В каждой ячейке цветная метка: зелёная — низкий риск, красная — высокий, жёлтая — неясный."
      },
      "state": "draft"
    },
    {
      "id": "img-p698-2",
      "file": "images/img-p698-2.webp",
      "page": 698,
      "narratives": {
        "en": "A forest plot listing six studies (Ando, Driesen, ITM trial, Mitarai, Rienthong, Sekiguchi) with TP, FP, FN and TN counts and sensitivity and specificity with 95% CI, plotted on 0–1 scales. Sensitivity ranges from 0.79 (Ando) to 1.00, and specificity is 1.00 in all studies where it is estimable (not estimable for Ando).",
        "ar": "مخطط شجري يسرد ست دراسات (Ando وDriesen وITM trial وMitarai وRienthong وSekiguchi) مع أعداد الإيجابيات الحقيقية والإيجابيات الكاذبة والسلبيات الكاذبة والسلبيات الحقيقية، والحساسية والنوعية مع فاصل ثقة 95%، مرسومة على مقياس من 0 إلى 1. تتراوح الحساسية بين 0.79 (Ando) و1.00، وتبلغ النوعية 1.00 في جميع الدراسات التي أمكن تقديرها فيها (غير قابلة للتقدير في Ando).",
        "zh": "森林图列出六项研究（Ando、Driesen、ITM trial、Mitarai、Rienthong、Sekiguchi）的真阳性、假阳性、假阴性和真阴性数，以及灵敏度和特异度（95%置信区间），绘制在0–1刻度上。灵敏度从0.79（Ando）到1.00不等；在可估计的所有研究中特异度均为1.00（Ando无法估计）。",
        "es": "Diagrama de bosque con seis estudios (Ando, Driesen, ITM trial, Mitarai, Rienthong, Sekiguchi) con los recuentos de VP, FP, FN y VN y la sensibilidad y especificidad con IC del 95%, representadas en escalas de 0 a 1. La sensibilidad va de 0,79 (Ando) a 1,00, y la especificidad es 1,00 en todos los estudios en que puede estimarse (no estimable en Ando).",
        "fr": "Graphique en forêt présentant six études (Ando, Driesen, ITM trial, Mitarai, Rienthong, Sekiguchi) avec les nombres de VP, FP, FN et VN ainsi que la sensibilité et la spécificité avec IC à 95 %, sur des échelles de 0 à 1. La sensibilité va de 0,79 (Ando) à 1,00 et la spécificité est de 1,00 dans toutes les études où elle est estimable (non estimable pour Ando).",
        "ru": "Лесовидный график по шести исследованиям (Ando, Driesen, ITM trial, Mitarai, Rienthong, Sekiguchi) с числом ИП, ЛП, ЛО и ИО, а также чувствительностью и специфичностью с 95% ДИ на шкалах от 0 до 1. Чувствительность составляет от 0,79 (Ando) до 1,00, специфичность равна 1,00 во всех исследованиях, где её можно оценить (для Ando не оценивается)."
      },
      "state": "draft"
    },
    {
      "id": "img-p698-3",
      "file": "images/img-p698-3.webp",
      "page": 698,
      "narratives": {
        "en": "A forest plot listing seven studies (Ando, Driesen, ITM trial, Mitarai, Rienthong, Sekiguchi, Willby) with TP, FP, FN and TN counts and sensitivity and specificity with 95% CI on 0–1 scales. Sensitivity ranges from 0.93 (Willby) to 1.00, and specificity from 0.86 (Driesen) to 1.00.",
        "ar": "مخطط شجري يسرد سبع دراسات (Ando وDriesen وITM trial وMitarai وRienthong وSekiguchi وWillby) مع أعداد الإيجابيات الحقيقية والإيجابيات الكاذبة والسلبيات الكاذبة والسلبيات الحقيقية، والحساسية والنوعية مع فاصل ثقة 95% على مقياس من 0 إلى 1. تتراوح الحساسية بين 0.93 (Willby) و1.00، والنوعية بين 0.86 (Driesen) و1.00.",
        "zh": "森林图列出七项研究（Ando、Driesen、ITM trial、Mitarai、Rienthong、Sekiguchi、Willby）的真阳性、假阳性、假阴性和真阴性数，以及灵敏度和特异度（95%置信区间），刻度为0–1。灵敏度从0.93（Willby）到1.00，特异度从0.86（Driesen）到1.00。",
        "es": "Diagrama de bosque con siete estudios (Ando, Driesen, ITM trial, Mitarai, Rienthong, Sekiguchi, Willby) con los recuentos de VP, FP, FN y VN y la sensibilidad y especificidad con IC del 95% en escalas de 0 a 1. La sensibilidad va de 0,93 (Willby) a 1,00 y la especificidad de 0,86 (Driesen) a 1,00.",
        "fr": "Graphique en forêt présentant sept études (Ando, Driesen, ITM trial, Mitarai, Rienthong, Sekiguchi, Willby) avec les nombres de VP, FP, FN et VN ainsi que la sensibilité et la spécificité avec IC à 95 % sur des échelles de 0 à 1. La sensibilité va de 0,93 (Willby) à 1,00 et la spécificité de 0,86 (Driesen) à 1,00.",
        "ru": "Лесовидный график по семи исследованиям (Ando, Driesen, ITM trial, Mitarai, Rienthong, Sekiguchi, Willby) с числом ИП, ЛП, ЛО и ИО, а также чувствительностью и специфичностью с 95% ДИ на шкалах от 0 до 1. Чувствительность составляет от 0,93 (Willby) до 1,00, специфичность — от 0,86 (Driesen) до 1,00."
      },
      "state": "draft"
    },
    {
      "id": "img-p699-1",
      "file": "images/img-p699-1.webp",
      "page": 699,
      "narratives": {
        "en": "A QUADAS-2 style table of risk of bias (patient selection, index test, reference standard, flow and timing) and applicability concerns (patient selection, index test, reference standard) for seven studies: Ando, Sekiguchi, Mitarai, Rienthong, Driesen, Willby and ITM trial. Cells hold green (low), red (high) or yellow (unclear) markers.",
        "ar": "جدول على نمط QUADAS-2 لخطر التحيز (اختيار المرضى، والاختبار المؤشر، والمعيار المرجعي، والتدفق والتوقيت) ومخاوف قابلية التطبيق (اختيار المرضى، والاختبار المؤشر، والمعيار المرجعي) لسبع دراسات: Ando وSekiguchi وMitarai وRienthong وDriesen وWillby وITM trial. تحتوي الخلايا على علامات خضراء (منخفض) أو حمراء (مرتفع) أو صفراء (غير واضح).",
        "zh": "QUADAS-2式表格，列出七项研究（Ando、Sekiguchi、Mitarai、Rienthong、Driesen、Willby和ITM trial）的偏倚风险（患者选择、待评价试验、参考标准、流程和时间）及适用性问题（患者选择、待评价试验、参考标准）。单元格中为绿色（低）、红色（高）或黄色（不明确）标记。",
        "es": "Tabla de tipo QUADAS-2 sobre el riesgo de sesgo (selección de pacientes, prueba índice, patrón de referencia, flujo y cronología) y los problemas de aplicabilidad (selección de pacientes, prueba índice, patrón de referencia) de siete estudios: Ando, Sekiguchi, Mitarai, Rienthong, Driesen, Willby e ITM trial. Las celdas contienen marcadores verdes (bajo), rojos (alto) o amarillos (incierto).",
        "fr": "Tableau de type QUADAS-2 du risque de biais (sélection des patients, test index, norme de référence, flux et chronologie) et des préoccupations d’applicabilité (sélection des patients, test index, norme de référence) pour sept études : Ando, Sekiguchi, Mitarai, Rienthong, Driesen, Willby et ITM trial. Les cellules contiennent des repères verts (faible), rouges (élevé) ou jaunes (incertain).",
        "ru": "Таблица в формате QUADAS-2 с оценкой риска систематической ошибки (отбор пациентов, индексный тест, эталонный стандарт, ход исследования и сроки) и сомнений в применимости (отбор пациентов, индексный тест, эталонный стандарт) для семи исследований: Ando, Sekiguchi, Mitarai, Rienthong, Driesen, Willby и ITM trial. В ячейках зелёные (низкий), красные (высокий) или жёлтые (неясный) метки."
      },
      "state": "draft"
    },
    {
      "id": "img-p730-1",
      "file": "images/img-p730-1.webp",
      "page": 730,
      "narratives": {
        "en": "A flow chart of study selection: 1754 records identified through database searching; 878 duplicates removed; 876 records screened by titles, of which 867 were excluded; 9 full-text articles (datasets) assessed for eligibility, of which 6 did not meet inclusion criteria; 3 studies included from the literature review. Together with 1 published study obtained by corresponding with experts and 6 unpublished studies from a WHO call for data, 10 studies were included in total.",
        "ar": "مخطط انسيابي لاختيار الدراسات: حُدد 1754 سجلاً عبر البحث في قواعد البيانات؛ وأزيل 878 سجلاً مكرراً؛ وفُحص 876 سجلاً حسب العنوان واستُبعد منها 867؛ وقُيّمت أهلية 9 مقالات كاملة النص (مجموعات بيانات) لم تستوفِ 6 منها معايير الإدراج؛ وأُدرجت 3 دراسات من استعراض الأدبيات. ومع دراسة منشورة واحدة حُصل عليها بالتواصل مع الخبراء و6 دراسات غير منشورة من دعوة المنظمة إلى تقديم البيانات، بلغ مجموع الدراسات المدرجة 10 دراسات.",
        "zh": "研究筛选流程图：通过数据库检索识别出1754条记录；剔除878条重复记录；按标题筛查876条记录，排除867条；评估9篇全文文章（数据集）的合格性，其中6篇不符合纳入标准；从文献综述中纳入3项研究。加上通过与专家联系获得的1项已发表研究和来自世卫组织数据征集的6项未发表研究，共纳入10项研究。",
        "es": "Diagrama de flujo de la selección de estudios: 1754 registros identificados mediante búsqueda en bases de datos; 878 duplicados eliminados; 876 registros cribados por título, de los cuales se excluyeron 867; 9 artículos a texto completo (conjuntos de datos) evaluados para determinar su elegibilidad, de los cuales 6 no cumplían los criterios de inclusión; 3 estudios incluidos de la revisión bibliográfica. Junto con 1 estudio publicado obtenido mediante contacto con expertos y 6 estudios inéditos procedentes de una convocatoria de datos de la OMS, se incluyeron 10 estudios en total.",
        "fr": "Organigramme de la sélection des études : 1754 enregistrements identifiés par recherche dans les bases de données ; 878 doublons supprimés ; 876 enregistrements examinés sur le titre, dont 867 exclus ; 9 articles en texte intégral (jeux de données) évalués pour l’éligibilité, dont 6 ne répondaient pas aux critères d’inclusion ; 3 études incluses à partir de la revue de la littérature. Avec 1 étude publiée obtenue en contactant des experts et 6 études non publiées issues d’un appel à données de l’OMS, 10 études ont été incluses au total.",
        "ru": "Блок-схема отбора исследований: в базах данных выявлено 1754 записи; удалено 878 дубликатов; по заголовкам проверено 876 записей, из них исключено 867; на соответствие критериям оценено 9 полнотекстовых статей (наборов данных), из которых 6 не отвечали критериям включения; из обзора литературы включено 3 исследования. Вместе с 1 опубликованным исследованием, полученным при переписке с экспертами, и 6 неопубликованными исследованиями из запроса данных ВОЗ всего включено 10 исследований."
      },
      "state": "draft"
    },
    {
      "id": "img-p783-1",
      "file": "images/img-p783-1.webp",
      "page": 783,
      "narratives": {
        "en": "A PRISMA flow diagram for the systematic review: 100 studies imported for screening, 21 duplicates removed; 79 studies screened, 68 irrelevant; 11 full-text studies assessed for eligibility, 1 excluded for wrong intervention; 0 studies ongoing and 0 awaiting classification; 10 studies included.",
        "ar": "مخطط PRISMA الانسيابي للاستعراض المنهجي: استُورد 100 دراسة للفحص، وأزيلت 21 دراسة مكررة؛ وفُحصت 79 دراسة، منها 68 غير ذات صلة؛ وقُيّمت أهلية 11 دراسة كاملة النص، واستُبعدت دراسة واحدة لخطأ في التدخل؛ ولا توجد دراسات جارية (0) ولا دراسات بانتظار التصنيف (0)؛ وأُدرجت 10 دراسات.",
        "zh": "系统综述的PRISMA流程图：导入100项研究进行筛查，剔除21项重复；筛查79项研究，68项不相关；评估11项全文研究的合格性，1项因干预措施不符被排除；0项研究正在进行，0项等待分类；纳入10项研究。",
        "es": "Diagrama de flujo PRISMA de la revisión sistemática: 100 estudios importados para cribado, 21 duplicados eliminados; 79 estudios cribados, 68 irrelevantes; 11 estudios a texto completo evaluados para determinar su elegibilidad, 1 excluido por intervención errónea; 0 estudios en curso y 0 pendientes de clasificación; 10 estudios incluidos.",
        "fr": "Diagramme de flux PRISMA de la revue systématique : 100 études importées pour le tri, 21 doublons supprimés ; 79 études triées, 68 non pertinentes ; 11 études en texte intégral évaluées pour l’éligibilité, 1 exclue pour intervention inadaptée ; 0 étude en cours et 0 en attente de classification ; 10 études incluses.",
        "ru": "Блок-схема PRISMA систематического обзора: импортировано для скрининга 100 исследований, удалено 21 дубликат; проверено 79 исследований, 68 нерелевантны; на соответствие критериям оценено 11 полнотекстовых исследований, 1 исключено из-за неподходящего вмешательства; текущих исследований 0, ожидающих классификации 0; включено 10 исследований."
      },
      "state": "draft"
    },
    {
      "id": "img-p784-1",
      "file": "images/img-p784-1.webp",
      "page": 784,
      "narratives": {
        "en": "A PRISMA flow diagram for the scoping review: 1054 studies imported for screening, 246 duplicates removed; 808 studies screened, 790 irrelevant; 18 full-text studies assessed for eligibility, 5 excluded for wrong outcomes; 0 studies ongoing and 0 awaiting classification; 13 studies included.",
        "ar": "مخطط PRISMA الانسيابي لاستعراض النطاق: استُوردت 1054 دراسة للفحص، وأزيلت 246 دراسة مكررة؛ وفُحصت 808 دراسات، منها 790 غير ذات صلة؛ وقُيّمت أهلية 18 دراسة كاملة النص، واستُبعدت 5 دراسات لخطأ في النتائج؛ ولا توجد دراسات جارية (0) ولا دراسات بانتظار التصنيف (0)؛ وأُدرجت 13 دراسة.",
        "zh": "范围综述的PRISMA流程图：导入1054项研究进行筛查，剔除246项重复；筛查808项研究，790项不相关；评估18项全文研究的合格性，5项因结局不符被排除；0项研究正在进行，0项等待分类；纳入13项研究。",
        "es": "Diagrama de flujo PRISMA de la revisión exploratoria: 1054 estudios importados para cribado, 246 duplicados eliminados; 808 estudios cribados, 790 irrelevantes; 18 estudios a texto completo evaluados para determinar su elegibilidad, 5 excluidos por resultados erróneos; 0 estudios en curso y 0 pendientes de clasificación; 13 estudios incluidos.",
        "fr": "Diagramme de flux PRISMA de la revue exploratoire : 1054 études importées pour le tri, 246 doublons supprimés ; 808 études triées, 790 non pertinentes ; 18 études en texte intégral évaluées pour l’éligibilité, 5 exclues pour résultats inadaptés ; 0 étude en cours et 0 en attente de classification ; 13 études incluses.",
        "ru": "Блок-схема PRISMA обзорного исследования: импортировано для скрининга 1054 исследования, удалено 246 дубликатов; проверено 808 исследований, 790 нерелевантны; на соответствие критериям оценено 18 полнотекстовых исследований, 5 исключены из-за неподходящих исходов; текущих исследований 0, ожидающих классификации 0; включено 13 исследований."
      },
      "state": "draft"
    },
    {
      "id": "img-p828-1",
      "file": "images/img-p828-1.webp",
      "page": 828,
      "narratives": {
        "en": "A linear workflow diagram of targeted next-generation sequencing (tNGS) with four steps joined by arrows: DNA extraction, library preparation, sequencing and data analysis.",
        "ar": "مخطط خطي لسير عمل تحديد التسلسل الموجَّه من الجيل التالي (tNGS) يتألف من أربع خطوات تربطها أسهم: استخلاص الحمض النووي الريبي المنقوص الأكسجين (DNA)، وإعداد المكتبة، وتحديد التسلسل، وتحليل البيانات.",
        "zh": "靶向二代测序（tNGS）的线性工作流程图，由箭头连接四个步骤：DNA提取、文库制备、测序和数据分析。",
        "es": "Diagrama lineal del flujo de trabajo de la secuenciación dirigida de nueva generación (tNGS) con cuatro pasos unidos por flechas: extracción de ADN, preparación de la biblioteca, secuenciación y análisis de datos.",
        "fr": "Schéma linéaire du flux de travail du séquençage ciblé de nouvelle génération (tNGS) en quatre étapes reliées par des flèches : extraction de l’ADN, préparation de la banque, séquençage et analyse des données.",
        "ru": "Линейная схема рабочего процесса таргетного секвенирования нового поколения (tNGS) из четырёх этапов, соединённых стрелками: выделение ДНК, подготовка библиотеки, секвенирование и анализ данных."
      },
      "state": "draft"
    },
    {
      "id": "img-p858-1",
      "file": "images/img-p858-1.webp",
      "page": 858,
      "narratives": {
        "en": "A PRISMA flow diagram of search and screening with two parallel streams. The systematic search found 3 records, all reviewed in full text and excluded for wrong method, leaving 0 eligible records. The open, hand and expert search found 27 records, excluded for wrong method or being out of scope, leaving 0 eligible records.",
        "ar": "مخطط PRISMA الانسيابي للبحث والفحص يضم مسارين متوازيين. أسفر البحث المنهجي عن 3 سجلات رُوجعت نصوصها الكاملة واستُبعدت لخطأ في المنهج، فلم يبقَ أي سجل مؤهل (0). وأسفر البحث المفتوح واليدوي وعن طريق الخبراء عن 27 سجلاً استُبعدت لخطأ في المنهج أو لخروجها عن النطاق، فلم يبقَ أي سجل مؤهل (0).",
        "zh": "检索和筛查的PRISMA流程图，包含两条平行路径。系统检索发现3条记录，经全文审阅后均因方法不符被排除，合格记录为0。开放检索、手工检索和专家检索发现27条记录，因方法不符或超出范围被排除，合格记录为0。",
        "es": "Diagrama de flujo PRISMA de la búsqueda y el cribado con dos vías paralelas. La búsqueda sistemática encontró 3 registros, todos revisados a texto completo y excluidos por método erróneo, con 0 registros elegibles. La búsqueda abierta, manual y por expertos encontró 27 registros, excluidos por método erróneo o por estar fuera del ámbito, con 0 registros elegibles.",
        "fr": "Diagramme de flux PRISMA de la recherche et du tri avec deux circuits parallèles. La recherche systématique a trouvé 3 enregistrements, tous examinés en texte intégral et exclus pour méthode inadaptée, soit 0 enregistrement éligible. La recherche ouverte, manuelle et auprès d’experts a trouvé 27 enregistrements, exclus pour méthode inadaptée ou hors champ, soit 0 enregistrement éligible.",
        "ru": "Блок-схема PRISMA поиска и скрининга с двумя параллельными потоками. Систематический поиск выявил 3 записи; все они изучены в полном тексте и исключены из-за неподходящего метода, подходящих записей — 0. Открытый, ручной и экспертный поиск выявил 27 записей, исключённых из-за неподходящего метода или несоответствия тематике; подходящих записей — 0."
      },
      "state": "draft"
    },
    {
      "id": "img-p868-1",
      "file": "images/img-p868-1.webp",
      "page": 868,
      "narratives": {
        "en": "An inverted pyramid showing the hierarchy of reference standards for tests of TB infection, with an arrow running from Weaker at the bottom to Stronger at the top. From top to bottom the levels are: efficacy of TPT based on results of test for TB infection; predictive value for TB disease; correlation with exposure gradient; sensitivity/specificity using surrogate reference standards; and concordance with existing tests.",
        "ar": "هرم مقلوب يبيّن تسلسل المعايير المرجعية لاختبارات العدوى بالسل، مع سهم يمتد من «أضعف» في الأسفل إلى «أقوى» في الأعلى. والمستويات من الأعلى إلى الأسفل هي: نجاعة العلاج الوقائي من السل استناداً إلى نتائج اختبار العدوى بالسل؛ والقيمة التنبؤية لمرض السل؛ والارتباط بتدرّج التعرّض؛ والحساسية/النوعية باستخدام معايير مرجعية بديلة؛ والتوافق مع الاختبارات القائمة.",
        "zh": "倒金字塔图，显示结核感染检测参考标准的等级，箭头从底部的“较弱”指向顶部的“较强”。从上到下各层依次为：基于结核感染检测结果的结核病预防性治疗效力；对结核病的预测价值；与暴露梯度的相关性；使用替代参考标准的灵敏度/特异度；与现有检测的一致性。",
        "es": "Pirámide invertida que muestra la jerarquía de patrones de referencia para las pruebas de infección tuberculosa, con una flecha que va de «Más débil» abajo a «Más fuerte» arriba. De arriba abajo, los niveles son: eficacia del TPT basado en los resultados de la prueba de infección tuberculosa; valor predictivo de la enfermedad tuberculosa; correlación con el gradiente de exposición; sensibilidad/especificidad con patrones de referencia sustitutivos; y concordancia con las pruebas existentes.",
        "fr": "Pyramide inversée montrant la hiérarchie des normes de référence pour les tests de l’infection tuberculeuse, avec une flèche allant de « Plus faible » en bas à « Plus fort » en haut. De haut en bas, les niveaux sont : efficacité du TPT fondé sur les résultats du test de l’infection tuberculeuse ; valeur prédictive de la tuberculose maladie ; corrélation avec le gradient d’exposition ; sensibilité/spécificité à l’aide de normes de référence de substitution ; et concordance avec les tests existants.",
        "ru": "Перевёрнутая пирамида, показывающая иерархию эталонных стандартов для тестов на туберкулёзную инфекцию; стрелка идёт от «Слабее» внизу к «Сильнее» вверху. Уровни сверху вниз: эффективность ПЛТ на основе результатов теста на туберкулёзную инфекцию; прогностическая ценность в отношении туберкулёза; корреляция с градиентом контакта; чувствительность/специфичность по суррогатным эталонным стандартам; согласованность с существующими тестами."
      },
      "state": "draft"
    },
    {
      "id": "img-p876-1",
      "file": "images/img-p876-1.webp",
      "page": 876,
      "narratives": {
        "en": "A PRISMA flow diagram of study selection with two streams. Via databases and registers, records were identified from Medline (853), EMBASE (1317), CKNI (565), CBLD (282) and e-library (405); 746 duplicates were removed, 2676 records screened, 2651 excluded, 25 reports sought, 2 not retrieved, 23 assessed and 19 excluded, giving 7 studies from the updated search. Via other methods (WHO public call 20, manufacturers 15), 21 reports were assessed and 19 excluded. Combined with studies from the review by Krutikov et al, the review included 5 C-Tb, 4 C-TST, 34 Diaskintest and 1 DPPD studies.",
        "ar": "مخطط PRISMA الانسيابي لاختيار الدراسات يضم مسارين. في مسار قواعد البيانات والسجلات، حُددت سجلات من Medline (853) وEMBASE (1317) وCKNI (565) وCBLD (282) وe-library (405)؛ وأزيل 746 سجلاً مكرراً، وفُحص 2676 سجلاً واستُبعد 2651، وطُلب 25 تقريراً لم يُسترجع منها تقريران، وقُيّم 23 واستُبعد 19، فنتجت 7 دراسات من البحث المحدَّث. وفي مسار الطرق الأخرى (الدعوة العامة للمنظمة 20، والجهات المصنِّعة 15)، قُيّم 21 تقريراً واستُبعد 19. وبضمّ الدراسات الواردة في استعراض Krutikov وزملائه، شمل الاستعراض 5 دراسات عن C-Tb و4 عن C-TST و34 عن Diaskintest ودراسة واحدة عن DPPD.",
        "zh": "研究筛选的PRISMA流程图，包含两条路径。通过数据库和登记册，从Medline（853）、EMBASE（1317）、CKNI（565）、CBLD（282）和e-library（405）识别记录；剔除746条重复记录，筛查2676条，排除2651条，寻求获取25份报告，2份未获取，评估23份，排除19份，从更新检索中纳入7项研究。通过其他方法（世卫组织公开征集20份，制造商15份），评估21份报告，排除19份。连同Krutikov等人综述中的研究，本综述共纳入C-Tb研究5项、C-TST 4项、Diaskintest 34项和DPPD 1项。",
        "es": "Diagrama de flujo PRISMA de la selección de estudios con dos vías. Mediante bases de datos y registros se identificaron registros de Medline (853), EMBASE (1317), CKNI (565), CBLD (282) y e-library (405); se eliminaron 746 duplicados, se cribaron 2676 registros y se excluyeron 2651, se solicitaron 25 informes, 2 no se obtuvieron, se evaluaron 23 y se excluyeron 19, con 7 estudios procedentes de la búsqueda actualizada. Mediante otros métodos (convocatoria pública de la OMS 20, fabricantes 15) se evaluaron 21 informes y se excluyeron 19. Junto con los estudios de la revisión de Krutikov et al., la revisión incluyó 5 estudios de C-Tb, 4 de C-TST, 34 de Diaskintest y 1 de DPPD.",
        "fr": "Diagramme de flux PRISMA de la sélection des études avec deux circuits. Via les bases de données et registres, des enregistrements ont été identifiés dans Medline (853), EMBASE (1317), CKNI (565), CBLD (282) et e-library (405) ; 746 doublons ont été supprimés, 2676 enregistrements triés et 2651 exclus, 25 rapports recherchés, 2 non obtenus, 23 évalués et 19 exclus, soit 7 études issues de la recherche actualisée. Via d’autres méthodes (appel public de l’OMS 20, fabricants 15), 21 rapports ont été évalués et 19 exclus. Avec les études de la revue de Krutikov et al., la revue a inclus 5 études sur C-Tb, 4 sur C-TST, 34 sur Diaskintest et 1 sur DPPD.",
        "ru": "Блок-схема PRISMA отбора исследований с двумя потоками. Через базы данных и регистры выявлены записи в Medline (853), EMBASE (1317), CKNI (565), CBLD (282) и e-library (405); удалено 746 дубликатов, проверено 2676 записей и исключено 2651, запрошено 25 отчётов, 2 не получены, оценено 23 и исключено 19, что дало 7 исследований из обновлённого поиска. Другими методами (открытый запрос ВОЗ — 20, производители — 15) оценён 21 отчёт и исключено 19. Вместе с исследованиями из обзора Krutikov и соавт. в обзор включены 5 исследований C-Tb, 4 — C-TST, 34 — Diaskintest и 1 — DPPD."
      },
      "state": "draft"
    },
    {
      "id": "img-p885-1",
      "file": "images/img-p885-1.webp",
      "page": 885,
      "narratives": {
        "en": "A forest plot of test sensitivity (%) in two head-to-head studies (Starshinova 2019 (a) and Starshinova 2018) for four tests, with random-effects pooled estimates: TST 5mm 88.24% (78.20–94.01), IGRA (QFT) 89.66% (78.83–95.28), IGRA (T-SPOT.TB) 90.91% (79.95–96.16) and Diaskintest 5mm 91.18% (81.72–95.98). Heterogeneity is I² = 0% for each test.",
        "ar": "مخطط شجري لحساسية الاختبارات (%) في دراستين للمقارنة المباشرة (Starshinova 2019 (a) وStarshinova 2018) لأربعة اختبارات، مع تقديرات مجمّعة بنموذج التأثيرات العشوائية: TST 5 مم 88.24% (78.20–94.01)، وIGRA (QFT) 89.66% (78.83–95.28)، وIGRA (T-SPOT.TB) 90.91% (79.95–96.16)، وDiaskintest 5 مم 91.18% (81.72–95.98). وتبلغ قيمة عدم التجانس I² = 0% لكل اختبار.",
        "zh": "森林图显示两项头对头研究（Starshinova 2019 (a)和Starshinova 2018）中四种检测的灵敏度（%），以及随机效应合并估计值：TST 5mm 88.24%（78.20–94.01），IGRA（QFT）89.66%（78.83–95.28），IGRA（T-SPOT.TB）90.91%（79.95–96.16），Diaskintest 5mm 91.18%（81.72–95.98）。各检测的异质性均为I² = 0%。",
        "es": "Diagrama de bosque de la sensibilidad (%) de cuatro pruebas en dos estudios de comparación directa (Starshinova 2019 (a) y Starshinova 2018), con estimaciones combinadas por modelo de efectos aleatorios: TST 5 mm 88,24% (78,20–94,01), IGRA (QFT) 89,66% (78,83–95,28), IGRA (T-SPOT.TB) 90,91% (79,95–96,16) y Diaskintest 5 mm 91,18% (81,72–95,98). La heterogeneidad es I² = 0% para cada prueba.",
        "fr": "Graphique en forêt de la sensibilité (%) de quatre tests dans deux études de comparaison directe (Starshinova 2019 (a) et Starshinova 2018), avec les estimations groupées par modèle à effets aléatoires : TST 5 mm 88,24 % (78,20–94,01), IGRA (QFT) 89,66 % (78,83–95,28), IGRA (T-SPOT.TB) 90,91 % (79,95–96,16) et Diaskintest 5 mm 91,18 % (81,72–95,98). L’hétérogénéité est I² = 0 % pour chaque test.",
        "ru": "Лесовидный график чувствительности (%) четырёх тестов в двух исследованиях прямого сравнения (Starshinova 2019 (a) и Starshinova 2018) с объединёнными оценками по модели случайных эффектов: TST 5 мм 88,24% (78,20–94,01), IGRA (QFT) 89,66% (78,83–95,28), IGRA (T-SPOT.TB) 90,91% (79,95–96,16) и Diaskintest 5 мм 91,18% (81,72–95,98). Гетерогенность I² = 0% для каждого теста."
      },
      "state": "draft"
    },
    {
      "id": "img-p886-1",
      "file": "images/img-p886-1.webp",
      "page": 886,
      "narratives": {
        "en": "A forest plot of percentage agreement between tests in two studies (Losovskaya 2014 and 2016), with random-effects pooled estimates: Diaskintest vs. IGRA 87.16% (79.47–92.24), Diaskintest vs. TST 5mm 55.45% (46.08–64.45) and IGRA vs. TST 5mm 51.38% (42.05–60.60). Agreement is much higher between Diaskintest and IGRA than between either test and TST.",
        "ar": "مخطط شجري لنسبة التوافق بين الاختبارات في دراستين (Losovskaya 2014 و2016)، مع تقديرات مجمّعة بنموذج التأثيرات العشوائية: Diaskintest مقابل IGRA 87.16% (79.47–92.24)، وDiaskintest مقابل TST 5 مم 55.45% (46.08–64.45)، وIGRA مقابل TST 5 مم 51.38% (42.05–60.60). والتوافق بين Diaskintest وIGRA أعلى بكثير منه بين أيٍّ منهما وTST.",
        "zh": "森林图显示两项研究（Losovskaya 2014和2016）中检测之间的一致率（%），以及随机效应合并估计值：Diaskintest对IGRA为87.16%（79.47–92.24），Diaskintest对TST 5mm为55.45%（46.08–64.45），IGRA对TST 5mm为51.38%（42.05–60.60）。Diaskintest与IGRA之间的一致性远高于二者与TST之间的一致性。",
        "es": "Diagrama de bosque de la concordancia porcentual entre pruebas en dos estudios (Losovskaya 2014 y 2016), con estimaciones combinadas por modelo de efectos aleatorios: Diaskintest frente a IGRA 87,16% (79,47–92,24), Diaskintest frente a TST 5 mm 55,45% (46,08–64,45) e IGRA frente a TST 5 mm 51,38% (42,05–60,60). La concordancia es mucho mayor entre Diaskintest e IGRA que entre cualquiera de ellas y la TST.",
        "fr": "Graphique en forêt du pourcentage de concordance entre tests dans deux études (Losovskaya 2014 et 2016), avec les estimations groupées par modèle à effets aléatoires : Diaskintest vs IGRA 87,16 % (79,47–92,24), Diaskintest vs TST 5 mm 55,45 % (46,08–64,45) et IGRA vs TST 5 mm 51,38 % (42,05–60,60). La concordance est bien plus élevée entre Diaskintest et IGRA qu’entre l’un ou l’autre et le TST.",
        "ru": "Лесовидный график процента согласованности тестов в двух исследованиях (Losovskaya 2014 и 2016) с объединёнными оценками по модели случайных эффектов: Diaskintest и IGRA — 87,16% (79,47–92,24), Diaskintest и TST 5 мм — 55,45% (46,08–64,45), IGRA и TST 5 мм — 51,38% (42,05–60,60). Согласованность между Diaskintest и IGRA значительно выше, чем между любым из них и TST."
      },
      "state": "draft"
    },
    {
      "id": "img-p888-1",
      "file": "images/img-p888-1.webp",
      "page": 888,
      "narratives": {
        "en": "A forest plot of test sensitivity (%) in four head-to-head studies (Ruhwald 2017, Aggerbeck 2018, Aggerbeck 2019, Hoff 2016), with random-effects pooled estimates: TST 15mm 77.18% (66.44–85.25), TST 5mm 82.68% (74.91–88.42), TST 5mm HIV+/15mm HIV− 78.18% (67.75–85.94), IGRA 71.67% (63.44–78.68) and C-Tb 74.52% (70.39–78.25). Heterogeneity is high for TST 15mm (I² = 81%), TST 5mm/15mm (84%) and IGRA (78%) and 0% for C-Tb.",
        "ar": "مخطط شجري لحساسية الاختبارات (%) في أربع دراسات للمقارنة المباشرة (Ruhwald 2017 وAggerbeck 2018 وAggerbeck 2019 وHoff 2016)، مع تقديرات مجمّعة بنموذج التأثيرات العشوائية: TST 15 مم 77.18% (66.44–85.25)، وTST 5 مم 82.68% (74.91–88.42)، وTST 5 مم لمن لديهم فيروس العوز المناعي البشري/15 مم لمن ليس لديهم 78.18% (67.75–85.94)، وIGRA 71.67% (63.44–78.68)، وC-Tb 74.52% (70.39–78.25). وعدم التجانس مرتفع في TST 15 مم (I² = 81%) وTST 5/15 مم (84%) وIGRA (78%)، ويبلغ 0% في C-Tb.",
        "zh": "森林图显示四项头对头研究（Ruhwald 2017、Aggerbeck 2018、Aggerbeck 2019、Hoff 2016）中的检测灵敏度（%），以及随机效应合并估计值：TST 15mm 77.18%（66.44–85.25），TST 5mm 82.68%（74.91–88.42），TST 5mm（艾滋病毒阳性）/15mm（艾滋病毒阴性）78.18%（67.75–85.94），IGRA 71.67%（63.44–78.68），C-Tb 74.52%（70.39–78.25）。TST 15mm（I² = 81%）、TST 5mm/15mm（84%）和IGRA（78%）的异质性较高，C-Tb为0%。",
        "es": "Diagrama de bosque de la sensibilidad (%) en cuatro estudios de comparación directa (Ruhwald 2017, Aggerbeck 2018, Aggerbeck 2019, Hoff 2016), con estimaciones combinadas por modelo de efectos aleatorios: TST 15 mm 77,18% (66,44–85,25), TST 5 mm 82,68% (74,91–88,42), TST 5 mm VIH+/15 mm VIH− 78,18% (67,75–85,94), IGRA 71,67% (63,44–78,68) y C-Tb 74,52% (70,39–78,25). La heterogeneidad es alta para TST 15 mm (I² = 81%), TST 5/15 mm (84%) e IGRA (78%), y del 0% para C-Tb.",
        "fr": "Graphique en forêt de la sensibilité (%) dans quatre études de comparaison directe (Ruhwald 2017, Aggerbeck 2018, Aggerbeck 2019, Hoff 2016), avec les estimations groupées par modèle à effets aléatoires : TST 15 mm 77,18 % (66,44–85,25), TST 5 mm 82,68 % (74,91–88,42), TST 5 mm VIH+/15 mm VIH− 78,18 % (67,75–85,94), IGRA 71,67 % (63,44–78,68) et C-Tb 74,52 % (70,39–78,25). L’hétérogénéité est élevée pour TST 15 mm (I² = 81 %), TST 5/15 mm (84 %) et IGRA (78 %), et de 0 % pour C-Tb.",
        "ru": "Лесовидный график чувствительности (%) в четырёх исследованиях прямого сравнения (Ruhwald 2017, Aggerbeck 2018, Aggerbeck 2019, Hoff 2016) с объединёнными оценками по модели случайных эффектов: TST 15 мм — 77,18% (66,44–85,25), TST 5 мм — 82,68% (74,91–88,42), TST 5 мм при ВИЧ+/15 мм при ВИЧ− — 78,18% (67,75–85,94), IGRA — 71,67% (63,44–78,68), C-Tb — 74,52% (70,39–78,25). Гетерогенность высокая для TST 15 мм (I² = 81%), TST 5/15 мм (84%) и IGRA (78%), для C-Tb — 0%."
      },
      "state": "draft"
    },
    {
      "id": "img-p889-1",
      "file": "images/img-p889-1.webp",
      "page": 889,
      "narratives": {
        "en": "A forest plot of test specificity (%) in two studies in low-incidence settings (Aggerbeck 2013 and Ruhwald 2017), with random-effects pooled estimates: TST 15mm 93.31% (90.22–95.48), IGRA 99.15% (79.66–99.97) and C-Tb 97.85% (93.96–99.25). The x-axis runs from 80 to 100.",
        "ar": "مخطط شجري لنوعية الاختبارات (%) في دراستين أُجريتا في أماكن منخفضة معدل الوقوع (Aggerbeck 2013 وRuhwald 2017)، مع تقديرات مجمّعة بنموذج التأثيرات العشوائية: TST 15 مم 93.31% (90.22–95.48)، وIGRA 99.15% (79.66–99.97)، وC-Tb 97.85% (93.96–99.25). ويمتد المحور الأفقي من 80 إلى 100.",
        "zh": "森林图显示两项在低发病率环境中开展的研究（Aggerbeck 2013和Ruhwald 2017）中的检测特异度（%），以及随机效应合并估计值：TST 15mm 93.31%（90.22–95.48），IGRA 99.15%（79.66–99.97），C-Tb 97.85%（93.96–99.25）。横轴范围为80至100。",
        "es": "Diagrama de bosque de la especificidad (%) en dos estudios realizados en entornos de baja incidencia (Aggerbeck 2013 y Ruhwald 2017), con estimaciones combinadas por modelo de efectos aleatorios: TST 15 mm 93,31% (90,22–95,48), IGRA 99,15% (79,66–99,97) y C-Tb 97,85% (93,96–99,25). El eje x va de 80 a 100.",
        "fr": "Graphique en forêt de la spécificité (%) dans deux études menées dans des contextes de faible incidence (Aggerbeck 2013 et Ruhwald 2017), avec les estimations groupées par modèle à effets aléatoires : TST 15 mm 93,31 % (90,22–95,48), IGRA 99,15 % (79,66–99,97) et C-Tb 97,85 % (93,96–99,25). L’axe des abscisses va de 80 à 100.",
        "ru": "Лесовидный график специфичности (%) в двух исследованиях в условиях низкой заболеваемости (Aggerbeck 2013 и Ruhwald 2017) с объединёнными оценками по модели случайных эффектов: TST 15 мм — 93,31% (90,22–95,48), IGRA — 99,15% (79,66–99,97), C-Tb — 97,85% (93,96–99,25). Ось X — от 80 до 100."
      },
      "state": "draft"
    },
    {
      "id": "img-p890-1",
      "file": "images/img-p890-1.webp",
      "page": 890,
      "narratives": {
        "en": "A forest plot of percentage agreement between tests in three studies (Aggerbeck 2018, Aggerbeck 2019, Hoff 2016), with random-effects pooled estimates for seven comparisons: C-Tb vs. IGRA 79.80%, C-Tb vs. TST 5mm HIV+/15mm HIV− 78.92%, C-Tb vs. TST 5mm (HIV+) 83.85%, C-Tb vs. TST 15mm (HIV−) 76.39%, IGRA vs. TST 5mm HIV+/15mm HIV− 74.67%, IGRA vs. TST 5mm (HIV+) 79.54% and IGRA vs. TST 15mm (HIV−) 74.74%. Pooled agreement lies between about 75% and 84% in all comparisons.",
        "ar": "مخطط شجري لنسبة التوافق بين الاختبارات في ثلاث دراسات (Aggerbeck 2018 وAggerbeck 2019 وHoff 2016)، مع تقديرات مجمّعة بنموذج التأثيرات العشوائية لسبع مقارنات: C-Tb مقابل IGRA 79.80%، وC-Tb مقابل TST 5 مم (إيجابيو فيروس العوز المناعي البشري)/15 مم (سلبيوه) 78.92%، وC-Tb مقابل TST 5 مم (إيجابيو الفيروس) 83.85%، وC-Tb مقابل TST 15 مم (سلبيو الفيروس) 76.39%، وIGRA مقابل TST 5/15 مم 74.67%، وIGRA مقابل TST 5 مم (إيجابيو الفيروس) 79.54%، وIGRA مقابل TST 15 مم (سلبيو الفيروس) 74.74%. ويتراوح التوافق المجمّع بين نحو 75% و84% في جميع المقارنات.",
        "zh": "森林图显示三项研究（Aggerbeck 2018、Aggerbeck 2019、Hoff 2016）中检测之间的一致率（%），以及七组比较的随机效应合并估计值：C-Tb对IGRA 79.80%，C-Tb对TST 5mm（艾滋病毒阳性）/15mm（艾滋病毒阴性）78.92%，C-Tb对TST 5mm（艾滋病毒阳性）83.85%，C-Tb对TST 15mm（艾滋病毒阴性）76.39%，IGRA对TST 5mm/15mm 74.67%，IGRA对TST 5mm（艾滋病毒阳性）79.54%，IGRA对TST 15mm（艾滋病毒阴性）74.74%。所有比较的合并一致率约在75%至84%之间。",
        "es": "Diagrama de bosque de la concordancia porcentual entre pruebas en tres estudios (Aggerbeck 2018, Aggerbeck 2019, Hoff 2016), con estimaciones combinadas por modelo de efectos aleatorios para siete comparaciones: C-Tb frente a IGRA 79,80%, C-Tb frente a TST 5 mm VIH+/15 mm VIH− 78,92%, C-Tb frente a TST 5 mm (VIH+) 83,85%, C-Tb frente a TST 15 mm (VIH−) 76,39%, IGRA frente a TST 5 mm VIH+/15 mm VIH− 74,67%, IGRA frente a TST 5 mm (VIH+) 79,54% e IGRA frente a TST 15 mm (VIH−) 74,74%. La concordancia combinada se sitúa entre el 75% y el 84% aproximadamente en todas las comparaciones.",
        "fr": "Graphique en forêt du pourcentage de concordance entre tests dans trois études (Aggerbeck 2018, Aggerbeck 2019, Hoff 2016), avec les estimations groupées par modèle à effets aléatoires pour sept comparaisons : C-Tb vs IGRA 79,80 %, C-Tb vs TST 5 mm VIH+/15 mm VIH− 78,92 %, C-Tb vs TST 5 mm (VIH+) 83,85 %, C-Tb vs TST 15 mm (VIH−) 76,39 %, IGRA vs TST 5 mm VIH+/15 mm VIH− 74,67 %, IGRA vs TST 5 mm (VIH+) 79,54 % et IGRA vs TST 15 mm (VIH−) 74,74 %. La concordance groupée se situe entre environ 75 % et 84 % pour toutes les comparaisons.",
        "ru": "Лесовидный график процента согласованности тестов в трёх исследованиях (Aggerbeck 2018, Aggerbeck 2019, Hoff 2016) с объединёнными оценками по модели случайных эффектов для семи сравнений: C-Tb и IGRA — 79,80%, C-Tb и TST 5 мм при ВИЧ+/15 мм при ВИЧ− — 78,92%, C-Tb и TST 5 мм (ВИЧ+) — 83,85%, C-Tb и TST 15 мм (ВИЧ−) — 76,39%, IGRA и TST 5/15 мм — 74,67%, IGRA и TST 5 мм (ВИЧ+) — 79,54%, IGRA и TST 15 мм (ВИЧ−) — 74,74%. Объединённая согласованность во всех сравнениях составляет примерно от 75% до 84%."
      },
      "state": "draft"
    },
    {
      "id": "img-p900-1",
      "file": "images/img-p900-1.webp",
      "page": 900,
      "narratives": {
        "en": "A forest plot of sensitivity (%) in six head-to-head studies grouped by test, with random-effects pooled estimates: TST 81.61% (72.34–88.27), IGRA (QFT) 77.04% (66.36–85.10) and TBST 78.10% (70.61–84.11). The test for subgroup differences is not significant (p = 0.74).",
        "ar": "مخطط شجري للحساسية (%) في ست دراسات للمقارنة المباشرة مصنّفة حسب الاختبار، مع تقديرات مجمّعة بنموذج التأثيرات العشوائية: TST 81.61% (72.34–88.27)، وIGRA (QFT) 77.04% (66.36–85.10)، وTBST 78.10% (70.61–84.11). واختبار الفروق بين المجموعات الفرعية غير دالّ (p = 0.74).",
        "zh": "森林图按检测分组显示六项头对头研究的灵敏度（%），随机效应合并估计值为：TST 81.61%（72.34–88.27），IGRA（QFT）77.04%（66.36–85.10），TBST 78.10%（70.61–84.11）。亚组差异检验无统计学意义（p = 0.74）。",
        "es": "Diagrama de bosque de la sensibilidad (%) en seis estudios de comparación directa agrupados por prueba, con estimaciones combinadas por modelo de efectos aleatorios: TST 81,61% (72,34–88,27), IGRA (QFT) 77,04% (66,36–85,10) y TBST 78,10% (70,61–84,11). La prueba de diferencias entre subgrupos no es significativa (p = 0,74).",
        "fr": "Graphique en forêt de la sensibilité (%) dans six études de comparaison directe regroupées par test, avec les estimations groupées par modèle à effets aléatoires : TST 81,61 % (72,34–88,27), IGRA (QFT) 77,04 % (66,36–85,10) et TBST 78,10 % (70,61–84,11). Le test des différences entre sous-groupes n’est pas significatif (p = 0,74).",
        "ru": "Лесовидный график чувствительности (%) в шести исследованиях прямого сравнения, сгруппированных по тестам, с объединёнными оценками по модели случайных эффектов: TST — 81,61% (72,34–88,27), IGRA (QFT) — 77,04% (66,36–85,10), TBST — 78,10% (70,61–84,11). Различия между подгруппами незначимы (p = 0,74)."
      },
      "state": "draft"
    },
    {
      "id": "img-p901-1",
      "file": "images/img-p901-1.webp",
      "page": 901,
      "narratives": {
        "en": "A forest plot of TBST sensitivity (%) in individuals with HIV-negative or unknown status, grouped by test: DST (any induration size) 66.37% (59.03–72.99), DST (induration ≥5mm) 88.41% (78.49–94.09), C-Tb (≥5mm) 75.78% (70.37–80.47) and C-TST (≥5mm) 86.29% (82.77–89.19). The overall random-effects pooled sensitivity is 75.96% (70.32–80.82) across 1276 participants.",
        "ar": "مخطط شجري لحساسية اختبارات TBST (%) لدى الأفراد السلبيين لفيروس العوز المناعي البشري أو مجهولي الحالة، مصنّفة حسب الاختبار: DST (أي حجم للتصلّب) 66.37% (59.03–72.99)، وDST (تصلّب ≥5 مم) 88.41% (78.49–94.09)، وC-Tb (≥5 مم) 75.78% (70.37–80.47)، وC-TST (≥5 مم) 86.29% (82.77–89.19). وتبلغ الحساسية المجمّعة الإجمالية بنموذج التأثيرات العشوائية 75.96% (70.32–80.82) لدى 1276 مشاركاً.",
        "zh": "森林图显示艾滋病毒阴性或状况不明者中TBST的灵敏度（%），按检测分组：DST（任何硬结大小）66.37%（59.03–72.99），DST（硬结≥5mm）88.41%（78.49–94.09），C-Tb（≥5mm）75.78%（70.37–80.47），C-TST（≥5mm）86.29%（82.77–89.19）。1276名参与者的总体随机效应合并灵敏度为75.96%（70.32–80.82）。",
        "es": "Diagrama de bosque de la sensibilidad (%) de las TBST en personas VIH-negativas o con estado desconocido, agrupada por prueba: DST (cualquier tamaño de induración) 66,37% (59,03–72,99), DST (induración ≥5 mm) 88,41% (78,49–94,09), C-Tb (≥5 mm) 75,78% (70,37–80,47) y C-TST (≥5 mm) 86,29% (82,77–89,19). La sensibilidad combinada global por modelo de efectos aleatorios es del 75,96% (70,32–80,82) en 1276 participantes.",
        "fr": "Graphique en forêt de la sensibilité (%) des TBST chez les personnes VIH-négatives ou de statut inconnu, par test : DST (toute taille d’induration) 66,37 % (59,03–72,99), DST (induration ≥5 mm) 88,41 % (78,49–94,09), C-Tb (≥5 mm) 75,78 % (70,37–80,47) et C-TST (≥5 mm) 86,29 % (82,77–89,19). La sensibilité groupée globale par modèle à effets aléatoires est de 75,96 % (70,32–80,82) sur 1276 participants.",
        "ru": "Лесовидный график чувствительности (%) TBST у лиц с ВИЧ-отрицательным или неизвестным статусом по тестам: DST (любой размер инфильтрата) — 66,37% (59,03–72,99), DST (инфильтрат ≥5 мм) — 88,41% (78,49–94,09), C-Tb (≥5 мм) — 75,78% (70,37–80,47), C-TST (≥5 мм) — 86,29% (82,77–89,19). Общая объединённая чувствительность по модели случайных эффектов — 75,96% (70,32–80,82) у 1276 участников."
      },
      "state": "draft"
    },
    {
      "id": "img-p902-1",
      "file": "images/img-p902-1.webp",
      "page": 902,
      "narratives": {
        "en": "A forest plot of TBST sensitivity (%) in HIV-positive individuals, grouped by test: DST (≥5mm) 70.27% (53.87–82.71), DST (any induration size) 39.77% (30.11–50.30) and C-Tb (≥5mm) 68.75% (61.85–74.91). The overall random-effects pooled sensitivity is 63.49% (52.60–73.16) across 317 participants.",
        "ar": "مخطط شجري لحساسية اختبارات TBST (%) لدى المصابين بفيروس العوز المناعي البشري، مصنّفة حسب الاختبار: DST (≥5 مم) 70.27% (53.87–82.71)، وDST (أي حجم للتصلّب) 39.77% (30.11–50.30)، وC-Tb (≥5 مم) 68.75% (61.85–74.91). وتبلغ الحساسية المجمّعة الإجمالية بنموذج التأثيرات العشوائية 63.49% (52.60–73.16) لدى 317 مشاركاً.",
        "zh": "森林图显示艾滋病毒阳性者中TBST的灵敏度（%），按检测分组：DST（≥5mm）70.27%（53.87–82.71），DST（任何硬结大小）39.77%（30.11–50.30），C-Tb（≥5mm）68.75%（61.85–74.91）。317名参与者的总体随机效应合并灵敏度为63.49%（52.60–73.16）。",
        "es": "Diagrama de bosque de la sensibilidad (%) de las TBST en personas VIH-positivas, agrupada por prueba: DST (≥5 mm) 70,27% (53,87–82,71), DST (cualquier tamaño de induración) 39,77% (30,11–50,30) y C-Tb (≥5 mm) 68,75% (61,85–74,91). La sensibilidad combinada global por modelo de efectos aleatorios es del 63,49% (52,60–73,16) en 317 participantes.",
        "fr": "Graphique en forêt de la sensibilité (%) des TBST chez les personnes VIH-positives, par test : DST (≥5 mm) 70,27 % (53,87–82,71), DST (toute taille d’induration) 39,77 % (30,11–50,30) et C-Tb (≥5 mm) 68,75 % (61,85–74,91). La sensibilité groupée globale par modèle à effets aléatoires est de 63,49 % (52,60–73,16) sur 317 participants.",
        "ru": "Лесовидный график чувствительности (%) TBST у ВИЧ-положительных лиц по тестам: DST (≥5 мм) — 70,27% (53,87–82,71), DST (любой размер инфильтрата) — 39,77% (30,11–50,30), C-Tb (≥5 мм) — 68,75% (61,85–74,91). Общая объединённая чувствительность по модели случайных эффектов — 63,49% (52,60–73,16) у 317 участников."
      },
      "state": "draft"
    },
    {
      "id": "img-p902-2",
      "file": "images/img-p902-2.webp",
      "page": 902,
      "narratives": {
        "en": "A forest plot of TBST sensitivity (%) in children, grouped by test: DST AI (Aksenova 2011, Nikitina 2019, Borodulina 2014) pooled at 94.74% (70.61–99.26) and DST 5mm (Starshinova 2018) at 100.00%. The overall random-effects pooled sensitivity is 97.06% (81.86–99.59) across 34 participants.",
        "ar": "مخطط شجري لحساسية اختبارات TBST (%) لدى الأطفال، مصنّفة حسب الاختبار: DST AI (Aksenova 2011 وNikitina 2019 وBorodulina 2014) بقيمة مجمّعة 94.74% (70.61–99.26)، وDST 5 مم (Starshinova 2018) بنسبة 100.00%. وتبلغ الحساسية المجمّعة الإجمالية بنموذج التأثيرات العشوائية 97.06% (81.86–99.59) لدى 34 مشاركاً.",
        "zh": "森林图显示儿童中TBST的灵敏度（%），按检测分组：DST AI（Aksenova 2011、Nikitina 2019、Borodulina 2014）合并值为94.74%（70.61–99.26），DST 5mm（Starshinova 2018）为100.00%。34名参与者的总体随机效应合并灵敏度为97.06%（81.86–99.59）。",
        "es": "Diagrama de bosque de la sensibilidad (%) de las TBST en niños, agrupada por prueba: DST AI (Aksenova 2011, Nikitina 2019, Borodulina 2014), con una estimación combinada del 94,74% (70,61–99,26), y DST 5 mm (Starshinova 2018), del 100,00%. La sensibilidad combinada global por modelo de efectos aleatorios es del 97,06% (81,86–99,59) en 34 participantes.",
        "fr": "Graphique en forêt de la sensibilité (%) des TBST chez l’enfant, par test : DST AI (Aksenova 2011, Nikitina 2019, Borodulina 2014), groupée à 94,74 % (70,61–99,26), et DST 5 mm (Starshinova 2018), à 100,00 %. La sensibilité groupée globale par modèle à effets aléatoires est de 97,06 % (81,86–99,59) sur 34 participants.",
        "ru": "Лесовидный график чувствительности (%) TBST у детей по тестам: DST AI (Aksenova 2011, Nikitina 2019, Borodulina 2014) — объединённая 94,74% (70,61–99,26), DST 5 мм (Starshinova 2018) — 100,00%. Общая объединённая чувствительность по модели случайных эффектов — 97,06% (81,86–99,59) у 34 участников."
      },
      "state": "draft"
    },
    {
      "id": "img-p903-1",
      "file": "images/img-p903-1.webp",
      "page": 903,
      "narratives": {
        "en": "A forest plot of percentage agreement between TBST and IGRA in studies including participants without active TB, grouped by test pair: C-Tb 5mm vs QFT 90.45%, DST AI vs QFT 90.67%, DST 5mm vs QFT 97.18%, DST papule 7+mm vs T-SPOT.TB 60.93% and C-TST 5mm vs T-SPOT 85.48%. The overall random-effects pooled agreement is 88.96% (82.60–93.19) across 2510 participants, with significant subgroup differences (p < 0.01).",
        "ar": "مخطط شجري لنسبة التوافق بين اختبارات TBST وIGRA في الدراسات التي شملت مشاركين غير مصابين بالسل النشط، مصنّفة حسب زوج الاختبارات: C-Tb 5 مم مقابل QFT 90.45%، وDST AI مقابل QFT 90.67%، وDST 5 مم مقابل QFT 97.18%، وحطاطة DST ≥7 مم مقابل T-SPOT.TB 60.93%، وC-TST 5 مم مقابل T-SPOT 85.48%. ويبلغ التوافق المجمّع الإجمالي 88.96% (82.60–93.19) لدى 2510 مشاركين، مع فروق دالّة بين المجموعات الفرعية (p < 0.01).",
        "zh": "森林图显示纳入无活动性结核病参与者的研究中TBST与IGRA的一致率（%），按检测组合分组：C-Tb 5mm对QFT 90.45%，DST AI对QFT 90.67%，DST 5mm对QFT 97.18%，DST丘疹7+mm对T-SPOT.TB 60.93%，C-TST 5mm对T-SPOT 85.48%。2510名参与者的总体随机效应合并一致率为88.96%（82.60–93.19），亚组差异有统计学意义（p < 0.01）。",
        "es": "Diagrama de bosque de la concordancia porcentual entre las TBST y los IGRA en estudios con participantes sin TB activa, agrupada por par de pruebas: C-Tb 5 mm frente a QFT 90,45%, DST AI frente a QFT 90,67%, DST 5 mm frente a QFT 97,18%, pápula DST 7+ mm frente a T-SPOT.TB 60,93% y C-TST 5 mm frente a T-SPOT 85,48%. La concordancia combinada global es del 88,96% (82,60–93,19) en 2510 participantes, con diferencias significativas entre subgrupos (p < 0,01).",
        "fr": "Graphique en forêt du pourcentage de concordance entre TBST et IGRA dans les études incluant des participants sans TB active, par paire de tests : C-Tb 5 mm vs QFT 90,45 %, DST AI vs QFT 90,67 %, DST 5 mm vs QFT 97,18 %, papule DST 7+ mm vs T-SPOT.TB 60,93 % et C-TST 5 mm vs T-SPOT 85,48 %. La concordance groupée globale est de 88,96 % (82,60–93,19) sur 2510 participants, avec des différences significatives entre sous-groupes (p < 0,01).",
        "ru": "Лесовидный график процента согласованности TBST и IGRA в исследованиях с участниками без активного ТБ по парам тестов: C-Tb 5 мм и QFT — 90,45%, DST AI и QFT — 90,67%, DST 5 мм и QFT — 97,18%, папула DST 7+ мм и T-SPOT.TB — 60,93%, C-TST 5 мм и T-SPOT — 85,48%. Общая объединённая согласованность — 88,96% (82,60–93,19) у 2510 участников; различия между подгруппами значимы (p < 0,01)."
      },
      "state": "draft"
    },
    {
      "id": "img-p904-1",
      "file": "images/img-p904-1.webp",
      "page": 904,
      "narratives": {
        "en": "A forest plot of percentage agreement between TBST and IGRA in studies including people with active TB, grouped by test pair: C-Tb 5mm vs QFT 79.59%, DST AI vs QFT 97.28%, DST 5mm vs QFT 97.01% and C-TST 5mm vs T-SPOT 85.42%. The overall random-effects pooled agreement is 85.71% (79.53–90.26) across 870 participants, with significant subgroup differences (p < 0.01).",
        "ar": "مخطط شجري لنسبة التوافق بين اختبارات TBST وIGRA في الدراسات التي شملت مصابين بالسل النشط، مصنّفة حسب زوج الاختبارات: C-Tb 5 مم مقابل QFT 79.59%، وDST AI مقابل QFT 97.28%، وDST 5 مم مقابل QFT 97.01%، وC-TST 5 مم مقابل T-SPOT 85.42%. ويبلغ التوافق المجمّع الإجمالي 85.71% (79.53–90.26) لدى 870 مشاركاً، مع فروق دالّة بين المجموعات الفرعية (p < 0.01).",
        "zh": "森林图显示纳入活动性结核病患者的研究中TBST与IGRA的一致率（%），按检测组合分组：C-Tb 5mm对QFT 79.59%，DST AI对QFT 97.28%，DST 5mm对QFT 97.01%，C-TST 5mm对T-SPOT 85.42%。870名参与者的总体随机效应合并一致率为85.71%（79.53–90.26），亚组差异有统计学意义（p < 0.01）。",
        "es": "Diagrama de bosque de la concordancia porcentual entre las TBST y los IGRA en estudios con personas con TB activa, agrupada por par de pruebas: C-Tb 5 mm frente a QFT 79,59%, DST AI frente a QFT 97,28%, DST 5 mm frente a QFT 97,01% y C-TST 5 mm frente a T-SPOT 85,42%. La concordancia combinada global es del 85,71% (79,53–90,26) en 870 participantes, con diferencias significativas entre subgrupos (p < 0,01).",
        "fr": "Graphique en forêt du pourcentage de concordance entre TBST et IGRA dans les études incluant des personnes atteintes de TB active, par paire de tests : C-Tb 5 mm vs QFT 79,59 %, DST AI vs QFT 97,28 %, DST 5 mm vs QFT 97,01 % et C-TST 5 mm vs T-SPOT 85,42 %. La concordance groupée globale est de 85,71 % (79,53–90,26) sur 870 participants, avec des différences significatives entre sous-groupes (p < 0,01).",
        "ru": "Лесовидный график процента согласованности TBST и IGRA в исследованиях с лицами с активным ТБ по парам тестов: C-Tb 5 мм и QFT — 79,59%, DST AI и QFT — 97,28%, DST 5 мм и QFT — 97,01%, C-TST 5 мм и T-SPOT — 85,42%. Общая объединённая согласованность — 85,71% (79,53–90,26) у 870 участников; различия между подгруппами значимы (p < 0,01)."
      },
      "state": "draft"
    },
    {
      "id": "img-p905-1",
      "file": "images/img-p905-1.webp",
      "page": 905,
      "narratives": {
        "en": "A forest plot of percentage agreement between TBST and TST in studies including participants without active TB, grouped by test pair: C-Tb5mm vs TST5mm 85.95%, C-Tb5mm vs TST15mm 81.61%, DST AI vs TST5mm 47.38%, DST5mm vs TST5mm 41.90% and C-TST vs TST 5mm 59.59%. The overall random-effects pooled agreement is 59.42% (45.34–72.10) across 4857 participants, with wide variation among DST studies.",
        "ar": "مخطط شجري لنسبة التوافق بين اختبارات TBST وTST في الدراسات التي شملت مشاركين غير مصابين بالسل النشط، مصنّفة حسب زوج الاختبارات: C-Tb 5 مم مقابل TST 5 مم 85.95%، وC-Tb 5 مم مقابل TST 15 مم 81.61%، وDST AI مقابل TST 5 مم 47.38%، وDST 5 مم مقابل TST 5 مم 41.90%، وC-TST مقابل TST 5 مم 59.59%. ويبلغ التوافق المجمّع الإجمالي 59.42% (45.34–72.10) لدى 4857 مشاركاً، مع تباين واسع بين دراسات DST.",
        "zh": "森林图显示纳入无活动性结核病参与者的研究中TBST与TST的一致率（%），按检测组合分组：C-Tb5mm对TST5mm 85.95%，C-Tb5mm对TST15mm 81.61%，DST AI对TST5mm 47.38%，DST5mm对TST5mm 41.90%，C-TST对TST 5mm 59.59%。4857名参与者的总体随机效应合并一致率为59.42%（45.34–72.10），DST各研究间差异很大。",
        "es": "Diagrama de bosque de la concordancia porcentual entre las TBST y la TST en estudios con participantes sin TB activa, agrupada por par de pruebas: C-Tb 5 mm frente a TST 5 mm 85,95%, C-Tb 5 mm frente a TST 15 mm 81,61%, DST AI frente a TST 5 mm 47,38%, DST 5 mm frente a TST 5 mm 41,90% y C-TST frente a TST 5 mm 59,59%. La concordancia combinada global es del 59,42% (45,34–72,10) en 4857 participantes, con gran variación entre los estudios de DST.",
        "fr": "Graphique en forêt du pourcentage de concordance entre TBST et TST dans les études incluant des participants sans TB active, par paire de tests : C-Tb 5 mm vs TST 5 mm 85,95 %, C-Tb 5 mm vs TST 15 mm 81,61 %, DST AI vs TST 5 mm 47,38 %, DST 5 mm vs TST 5 mm 41,90 % et C-TST vs TST 5 mm 59,59 %. La concordance groupée globale est de 59,42 % (45,34–72,10) sur 4857 participants, avec une grande variabilité entre les études DST.",
        "ru": "Лесовидный график процента согласованности TBST и TST в исследованиях с участниками без активного ТБ по парам тестов: C-Tb 5 мм и TST 5 мм — 85,95%, C-Tb 5 мм и TST 15 мм — 81,61%, DST AI и TST 5 мм — 47,38%, DST 5 мм и TST 5 мм — 41,90%, C-TST и TST 5 мм — 59,59%. Общая объединённая согласованность — 59,42% (45,34–72,10) у 4857 участников, с большим разбросом между исследованиями DST."
      },
      "state": "draft"
    },
    {
      "id": "img-p906-1",
      "file": "images/img-p906-1.webp",
      "page": 906,
      "narratives": {
        "en": "A forest plot of percentage agreement between TBST and TST in studies including people with active TB, grouped by test pair: C-Tb5mm vs TST5mm 80.84%, C-Tb5mm vs TST15mm 76.39%, DST AI vs TST5mm 92.56%, DST5mm vs TST5mm 95.36% and C-TST vs TST 5mm 81.25%. The overall random-effects pooled agreement is 88.29% (82.14–92.51) across 2260 participants.",
        "ar": "مخطط شجري لنسبة التوافق بين اختبارات TBST وTST في الدراسات التي شملت مصابين بالسل النشط، مصنّفة حسب زوج الاختبارات: C-Tb 5 مم مقابل TST 5 مم 80.84%، وC-Tb 5 مم مقابل TST 15 مم 76.39%، وDST AI مقابل TST 5 مم 92.56%، وDST 5 مم مقابل TST 5 مم 95.36%، وC-TST مقابل TST 5 مم 81.25%. ويبلغ التوافق المجمّع الإجمالي 88.29% (82.14–92.51) لدى 2260 مشاركاً.",
        "zh": "森林图显示纳入活动性结核病患者的研究中TBST与TST的一致率（%），按检测组合分组：C-Tb5mm对TST5mm 80.84%，C-Tb5mm对TST15mm 76.39%，DST AI对TST5mm 92.56%，DST5mm对TST5mm 95.36%，C-TST对TST 5mm 81.25%。2260名参与者的总体随机效应合并一致率为88.29%（82.14–92.51）。",
        "es": "Diagrama de bosque de la concordancia porcentual entre las TBST y la TST en estudios con personas con TB activa, agrupada por par de pruebas: C-Tb 5 mm frente a TST 5 mm 80,84%, C-Tb 5 mm frente a TST 15 mm 76,39%, DST AI frente a TST 5 mm 92,56%, DST 5 mm frente a TST 5 mm 95,36% y C-TST frente a TST 5 mm 81,25%. La concordancia combinada global es del 88,29% (82,14–92,51) en 2260 participantes.",
        "fr": "Graphique en forêt du pourcentage de concordance entre TBST et TST dans les études incluant des personnes atteintes de TB active, par paire de tests : C-Tb 5 mm vs TST 5 mm 80,84 %, C-Tb 5 mm vs TST 15 mm 76,39 %, DST AI vs TST 5 mm 92,56 %, DST 5 mm vs TST 5 mm 95,36 % et C-TST vs TST 5 mm 81,25 %. La concordance groupée globale est de 88,29 % (82,14–92,51) sur 2260 participants.",
        "ru": "Лесовидный график процента согласованности TBST и TST в исследованиях с лицами с активным ТБ по парам тестов: C-Tb 5 мм и TST 5 мм — 80,84%, C-Tb 5 мм и TST 15 мм — 76,39%, DST AI и TST 5 мм — 92,56%, DST 5 мм и TST 5 мм — 95,36%, C-TST и TST 5 мм — 81,25%. Общая объединённая согласованность — 88,29% (82,14–92,51) у 2260 участников."
      },
      "state": "draft"
    },
    {
      "id": "img-p907-1",
      "file": "images/img-p907-1.webp",
      "page": 907,
      "narratives": {
        "en": "A forest plot of percentage agreement between TBST and IGRA in children without active TB, by test pair: C-Tb vs QFT 89.52%, DST AI vs QFT 90.67%, DST 5mm vs QFT 97.18% and DST papule 7+mm vs T-SPOT.TB 60.93%. The overall random-effects pooled agreement is 89.26% (79.25–94.76) across 779 participants.",
        "ar": "مخطط شجري لنسبة التوافق بين اختبارات TBST وIGRA لدى الأطفال غير المصابين بالسل النشط، حسب زوج الاختبارات: C-Tb مقابل QFT 89.52%، وDST AI مقابل QFT 90.67%، وDST 5 مم مقابل QFT 97.18%، وحطاطة DST ≥7 مم مقابل T-SPOT.TB 60.93%. ويبلغ التوافق المجمّع الإجمالي بنموذج التأثيرات العشوائية 89.26% (79.25–94.76) لدى 779 مشاركاً.",
        "zh": "森林图显示无活动性结核病儿童中TBST与IGRA的一致率（%），按检测组合：C-Tb对QFT 89.52%，DST AI对QFT 90.67%，DST 5mm对QFT 97.18%，DST丘疹7+mm对T-SPOT.TB 60.93%。779名参与者的总体随机效应合并一致率为89.26%（79.25–94.76）。",
        "es": "Diagrama de bosque de la concordancia porcentual entre las TBST y los IGRA en niños sin TB activa, por par de pruebas: C-Tb frente a QFT 89,52%, DST AI frente a QFT 90,67%, DST 5 mm frente a QFT 97,18% y pápula DST 7+ mm frente a T-SPOT.TB 60,93%. La concordancia combinada global por modelo de efectos aleatorios es del 89,26% (79,25–94,76) en 779 participantes.",
        "fr": "Graphique en forêt du pourcentage de concordance entre TBST et IGRA chez l’enfant sans TB active, par paire de tests : C-Tb vs QFT 89,52 %, DST AI vs QFT 90,67 %, DST 5 mm vs QFT 97,18 % et papule DST 7+ mm vs T-SPOT.TB 60,93 %. La concordance groupée globale par modèle à effets aléatoires est de 89,26 % (79,25–94,76) sur 779 participants.",
        "ru": "Лесовидный график процента согласованности TBST и IGRA у детей без активного ТБ по парам тестов: C-Tb и QFT — 89,52%, DST AI и QFT — 90,67%, DST 5 мм и QFT — 97,18%, папула DST 7+ мм и T-SPOT.TB — 60,93%. Общая объединённая согласованность по модели случайных эффектов — 89,26% (79,25–94,76) у 779 участников."
      },
      "state": "draft"
    },
    {
      "id": "img-p908-1",
      "file": "images/img-p908-1.webp",
      "page": 908,
      "narratives": {
        "en": "A forest plot of percentage agreement between TBST and TST in children without active TB, by test pair: DST AI vs TST 5mm 39.21% (seven studies ranging from 6.25% to 85.71%), DST 5mm vs TST 5mm 76.74% and C-Tb vs TST 15mm 90.37%. The overall random-effects pooled agreement is 56.73% (30.85–79.40) across 2202 participants.",
        "ar": "مخطط شجري لنسبة التوافق بين اختبارات TBST وTST لدى الأطفال غير المصابين بالسل النشط، حسب زوج الاختبارات: DST AI مقابل TST 5 مم 39.21% (سبع دراسات تتراوح بين 6.25% و85.71%)، وDST 5 مم مقابل TST 5 مم 76.74%، وC-Tb مقابل TST 15 مم 90.37%. ويبلغ التوافق المجمّع الإجمالي 56.73% (30.85–79.40) لدى 2202 مشارك.",
        "zh": "森林图显示无活动性结核病儿童中TBST与TST的一致率（%），按检测组合：DST AI对TST 5mm 39.21%（七项研究，范围为6.25%至85.71%），DST 5mm对TST 5mm 76.74%，C-Tb对TST 15mm 90.37%。2202名参与者的总体随机效应合并一致率为56.73%（30.85–79.40）。",
        "es": "Diagrama de bosque de la concordancia porcentual entre las TBST y la TST en niños sin TB activa, por par de pruebas: DST AI frente a TST 5 mm 39,21% (siete estudios, entre el 6,25% y el 85,71%), DST 5 mm frente a TST 5 mm 76,74% y C-Tb frente a TST 15 mm 90,37%. La concordancia combinada global es del 56,73% (30,85–79,40) en 2202 participantes.",
        "fr": "Graphique en forêt du pourcentage de concordance entre TBST et TST chez l’enfant sans TB active, par paire de tests : DST AI vs TST 5 mm 39,21 % (sept études allant de 6,25 % à 85,71 %), DST 5 mm vs TST 5 mm 76,74 % et C-Tb vs TST 15 mm 90,37 %. La concordance groupée globale est de 56,73 % (30,85–79,40) sur 2202 participants.",
        "ru": "Лесовидный график процента согласованности TBST и TST у детей без активного ТБ по парам тестов: DST AI и TST 5 мм — 39,21% (семь исследований, от 6,25% до 85,71%), DST 5 мм и TST 5 мм — 76,74%, C-Tb и TST 15 мм — 90,37%. Общая объединённая согласованность — 56,73% (30,85–79,40) у 2202 участников."
      },
      "state": "draft"
    },
    {
      "id": "img-p908-2",
      "file": "images/img-p908-2.webp",
      "page": 908,
      "narratives": {
        "en": "A forest plot of percentage agreement between TBST and TST in children with active TB, by test pair: DST AI vs TST5mm 97.04% (three studies) and DST 5mm vs TST 5mm 98.85% (one study). The overall random-effects pooled agreement is 97.39% (96.39–98.12) across 1342 participants.",
        "ar": "مخطط شجري لنسبة التوافق بين اختبارات TBST وTST لدى الأطفال المصابين بالسل النشط، حسب زوج الاختبارات: DST AI مقابل TST 5 مم 97.04% (ثلاث دراسات)، وDST 5 مم مقابل TST 5 مم 98.85% (دراسة واحدة). ويبلغ التوافق المجمّع الإجمالي 97.39% (96.39–98.12) لدى 1342 مشاركاً.",
        "zh": "森林图显示活动性结核病儿童中TBST与TST的一致率（%），按检测组合：DST AI对TST5mm 97.04%（三项研究），DST 5mm对TST 5mm 98.85%（一项研究）。1342名参与者的总体随机效应合并一致率为97.39%（96.39–98.12）。",
        "es": "Diagrama de bosque de la concordancia porcentual entre las TBST y la TST en niños con TB activa, por par de pruebas: DST AI frente a TST 5 mm 97,04% (tres estudios) y DST 5 mm frente a TST 5 mm 98,85% (un estudio). La concordancia combinada global es del 97,39% (96,39–98,12) en 1342 participantes.",
        "fr": "Graphique en forêt du pourcentage de concordance entre TBST et TST chez l’enfant atteint de TB active, par paire de tests : DST AI vs TST 5 mm 97,04 % (trois études) et DST 5 mm vs TST 5 mm 98,85 % (une étude). La concordance groupée globale est de 97,39 % (96,39–98,12) sur 1342 participants.",
        "ru": "Лесовидный график процента согласованности TBST и TST у детей с активным ТБ по парам тестов: DST AI и TST 5 мм — 97,04% (три исследования), DST 5 мм и TST 5 мм — 98,85% (одно исследование). Общая объединённая согласованность — 97,39% (96,39–98,12) у 1342 участников."
      },
      "state": "draft"
    },
    {
      "id": "img-p910-1",
      "file": "images/img-p910-1.webp",
      "page": 910,
      "narratives": {
        "en": "A forest plot of percentage agreement between TBST and TST in children aged under 5 years without active TB: DST AI vs TST 5mm 76.57% (Dovgalyuk 2012) and C-Tb vs TST 15mm 88.51% (Aggerbeck 2018). The overall random-effects pooled agreement is 81.97% (71.38–89.23) across 484 participants.",
        "ar": "مخطط شجري لنسبة التوافق بين اختبارات TBST وTST لدى الأطفال دون سن الخامسة غير المصابين بالسل النشط: DST AI مقابل TST 5 مم 76.57% (Dovgalyuk 2012)، وC-Tb مقابل TST 15 مم 88.51% (Aggerbeck 2018). ويبلغ التوافق المجمّع الإجمالي 81.97% (71.38–89.23) لدى 484 مشاركاً.",
        "zh": "森林图显示5岁以下无活动性结核病儿童中TBST与TST的一致率（%）：DST AI对TST 5mm为76.57%（Dovgalyuk 2012），C-Tb对TST 15mm为88.51%（Aggerbeck 2018）。484名参与者的总体随机效应合并一致率为81.97%（71.38–89.23）。",
        "es": "Diagrama de bosque de la concordancia porcentual entre las TBST y la TST en niños menores de 5 años sin TB activa: DST AI frente a TST 5 mm 76,57% (Dovgalyuk 2012) y C-Tb frente a TST 15 mm 88,51% (Aggerbeck 2018). La concordancia combinada global es del 81,97% (71,38–89,23) en 484 participantes.",
        "fr": "Graphique en forêt du pourcentage de concordance entre TBST et TST chez l’enfant de moins de 5 ans sans TB active : DST AI vs TST 5 mm 76,57 % (Dovgalyuk 2012) et C-Tb vs TST 15 mm 88,51 % (Aggerbeck 2018). La concordance groupée globale est de 81,97 % (71,38–89,23) sur 484 participants.",
        "ru": "Лесовидный график процента согласованности TBST и TST у детей младше 5 лет без активного ТБ: DST AI и TST 5 мм — 76,57% (Dovgalyuk 2012), C-Tb и TST 15 мм — 88,51% (Aggerbeck 2018). Общая объединённая согласованность — 81,97% (71,38–89,23) у 484 участников."
      },
      "state": "draft"
    },
    {
      "id": "img-p910-2",
      "file": "images/img-p910-2.webp",
      "page": 910,
      "narratives": {
        "en": "A forest plot of percentage agreement between TBST and IGRA in BCG-vaccinated individuals without active TB: DST 5mm vs QFT 97.18% (Starshinova 2018, children) and C-TST vs T-SPOT.TB 97.44% (Xu 2021, adults). The overall random-effects pooled agreement is 97.22% (93.96–98.75) across 216 participants.",
        "ar": "مخطط شجري لنسبة التوافق بين اختبارات TBST وIGRA لدى الأفراد الملقَّحين بلقاح BCG غير المصابين بالسل النشط: DST 5 مم مقابل QFT 97.18% (Starshinova 2018، أطفال)، وC-TST مقابل T-SPOT.TB 97.44% (Xu 2021، بالغون). ويبلغ التوافق المجمّع الإجمالي 97.22% (93.96–98.75) لدى 216 مشاركاً.",
        "zh": "森林图显示接种卡介苗且无活动性结核病者中TBST与IGRA的一致率（%）：DST 5mm对QFT为97.18%（Starshinova 2018，儿童），C-TST对T-SPOT.TB为97.44%（Xu 2021，成人）。216名参与者的总体随机效应合并一致率为97.22%（93.96–98.75）。",
        "es": "Diagrama de bosque de la concordancia porcentual entre las TBST y los IGRA en personas vacunadas con BCG sin TB activa: DST 5 mm frente a QFT 97,18% (Starshinova 2018, niños) y C-TST frente a T-SPOT.TB 97,44% (Xu 2021, adultos). La concordancia combinada global es del 97,22% (93,96–98,75) en 216 participantes.",
        "fr": "Graphique en forêt du pourcentage de concordance entre TBST et IGRA chez les personnes vaccinées par le BCG sans TB active : DST 5 mm vs QFT 97,18 % (Starshinova 2018, enfants) et C-TST vs T-SPOT.TB 97,44 % (Xu 2021, adultes). La concordance groupée globale est de 97,22 % (93,96–98,75) sur 216 participants.",
        "ru": "Лесовидный график процента согласованности TBST и IGRA у вакцинированных БЦЖ лиц без активного ТБ: DST 5 мм и QFT — 97,18% (Starshinova 2018, дети), C-TST и T-SPOT.TB — 97,44% (Xu 2021, взрослые). Общая объединённая согласованность — 97,22% (93,96–98,75) у 216 участников."
      },
      "state": "draft"
    },
    {
      "id": "img-p911-1",
      "file": "images/img-p911-1.webp",
      "page": 911,
      "narratives": {
        "en": "A forest plot of percentage agreement between TBST and QFT in BCG-vaccinated children with active TB: DST 5mm vs QFT 97.01% (Starshinova 2018) and DST AI vs QFT 100.00% (Nakonechnaya 2020). The overall random-effects pooled agreement is 97.65% (93.90–99.11) across 170 participants.",
        "ar": "مخطط شجري لنسبة التوافق بين اختبارات TBST وQFT لدى الأطفال الملقَّحين بلقاح BCG والمصابين بالسل النشط: DST 5 مم مقابل QFT 97.01% (Starshinova 2018)، وDST AI مقابل QFT 100.00% (Nakonechnaya 2020). ويبلغ التوافق المجمّع الإجمالي 97.65% (93.90–99.11) لدى 170 مشاركاً.",
        "zh": "森林图显示接种卡介苗的活动性结核病儿童中TBST与QFT的一致率（%）：DST 5mm对QFT为97.01%（Starshinova 2018），DST AI对QFT为100.00%（Nakonechnaya 2020）。170名参与者的总体随机效应合并一致率为97.65%（93.90–99.11）。",
        "es": "Diagrama de bosque de la concordancia porcentual entre las TBST y la QFT en niños vacunados con BCG con TB activa: DST 5 mm frente a QFT 97,01% (Starshinova 2018) y DST AI frente a QFT 100,00% (Nakonechnaya 2020). La concordancia combinada global es del 97,65% (93,90–99,11) en 170 participantes.",
        "fr": "Graphique en forêt du pourcentage de concordance entre TBST et QFT chez l’enfant vacciné par le BCG atteint de TB active : DST 5 mm vs QFT 97,01 % (Starshinova 2018) et DST AI vs QFT 100,00 % (Nakonechnaya 2020). La concordance groupée globale est de 97,65 % (93,90–99,11) sur 170 participants.",
        "ru": "Лесовидный график процента согласованности TBST и QFT у вакцинированных БЦЖ детей с активным ТБ: DST 5 мм и QFT — 97,01% (Starshinova 2018), DST AI и QFT — 100,00% (Nakonechnaya 2020). Общая объединённая согласованность — 97,65% (93,90–99,11) у 170 участников."
      },
      "state": "draft"
    },
    {
      "id": "img-p911-2",
      "file": "images/img-p911-2.webp",
      "page": 911,
      "narratives": {
        "en": "A forest plot of percentage agreement between TBST and TST in BCG-vaccinated individuals without active TB: DST 5mm vs TST 5mm 52.30% (Starshinova 2018 28.34%, Yablonskiy 2013 76.74%) and C-TST vs TST 5mm 16.67% (Xu 2021). The overall random-effects pooled agreement is 38.76% (14.09–70.94) across 519 participants.",
        "ar": "مخطط شجري لنسبة التوافق بين اختبارات TBST وTST لدى الأفراد الملقَّحين بلقاح BCG غير المصابين بالسل النشط: DST 5 مم مقابل TST 5 مم 52.30% (Starshinova 2018 بنسبة 28.34%، وYablonskiy 2013 بنسبة 76.74%)، وC-TST مقابل TST 5 مم 16.67% (Xu 2021). ويبلغ التوافق المجمّع الإجمالي 38.76% (14.09–70.94) لدى 519 مشاركاً.",
        "zh": "森林图显示接种卡介苗且无活动性结核病者中TBST与TST的一致率（%）：DST 5mm对TST 5mm为52.30%（Starshinova 2018为28.34%，Yablonskiy 2013为76.74%），C-TST对TST 5mm为16.67%（Xu 2021）。519名参与者的总体随机效应合并一致率为38.76%（14.09–70.94）。",
        "es": "Diagrama de bosque de la concordancia porcentual entre las TBST y la TST en personas vacunadas con BCG sin TB activa: DST 5 mm frente a TST 5 mm 52,30% (Starshinova 2018 28,34%, Yablonskiy 2013 76,74%) y C-TST frente a TST 5 mm 16,67% (Xu 2021). La concordancia combinada global es del 38,76% (14,09–70,94) en 519 participantes.",
        "fr": "Graphique en forêt du pourcentage de concordance entre TBST et TST chez les personnes vaccinées par le BCG sans TB active : DST 5 mm vs TST 5 mm 52,30 % (Starshinova 2018 28,34 %, Yablonskiy 2013 76,74 %) et C-TST vs TST 5 mm 16,67 % (Xu 2021). La concordance groupée globale est de 38,76 % (14,09–70,94) sur 519 participants.",
        "ru": "Лесовидный график процента согласованности TBST и TST у вакцинированных БЦЖ лиц без активного ТБ: DST 5 мм и TST 5 мм — 52,30% (Starshinova 2018 — 28,34%, Yablonskiy 2013 — 76,74%), C-TST и TST 5 мм — 16,67% (Xu 2021). Общая объединённая согласованность — 38,76% (14,09–70,94) у 519 участников."
      },
      "state": "draft"
    },
    {
      "id": "img-p912-1",
      "file": "images/img-p912-1.webp",
      "page": 912,
      "narratives": {
        "en": "A forest plot of the difference in specificity (%) between TBST and IGRA, by test pair: DST 5mm vs QFT 4.50 (−13.13 to 22.12), C-Tb vs QFT 0.70 (−7.02 to 8.42) and C-TST vs T-SPOT.TB 3.54 (−1.37 to 8.44). The overall random-effects pooled difference is 2.29 (−1.60 to 6.18), with confidence intervals crossing zero.",
        "ar": "مخطط شجري للفرق في النوعية (%) بين اختبارات TBST وIGRA، حسب زوج الاختبارات: DST 5 مم مقابل QFT 4.50 (−13.13 إلى 22.12)، وC-Tb مقابل QFT 0.70 (−7.02 إلى 8.42)، وC-TST مقابل T-SPOT.TB 3.54 (−1.37 إلى 8.44). ويبلغ الفرق المجمّع الإجمالي بنموذج التأثيرات العشوائية 2.29 (−1.60 إلى 6.18)، وتتقاطع فواصل الثقة مع الصفر.",
        "zh": "森林图显示TBST与IGRA特异度的差值（%），按检测组合：DST 5mm对QFT为4.50（−13.13至22.12），C-Tb对QFT为0.70（−7.02至8.42），C-TST对T-SPOT.TB为3.54（−1.37至8.44）。总体随机效应合并差值为2.29（−1.60至6.18），置信区间跨越零。",
        "es": "Diagrama de bosque de la diferencia de especificidad (%) entre las TBST y los IGRA, por par de pruebas: DST 5 mm frente a QFT 4,50 (−13,13 a 22,12), C-Tb frente a QFT 0,70 (−7,02 a 8,42) y C-TST frente a T-SPOT.TB 3,54 (−1,37 a 8,44). La diferencia combinada global por modelo de efectos aleatorios es de 2,29 (−1,60 a 6,18), con intervalos de confianza que incluyen el cero.",
        "fr": "Graphique en forêt de la différence de spécificité (%) entre TBST et IGRA, par paire de tests : DST 5 mm vs QFT 4,50 (−13,13 à 22,12), C-Tb vs QFT 0,70 (−7,02 à 8,42) et C-TST vs T-SPOT.TB 3,54 (−1,37 à 8,44). La différence groupée globale par modèle à effets aléatoires est de 2,29 (−1,60 à 6,18), les intervalles de confiance incluant zéro.",
        "ru": "Лесовидный график разницы в специфичности (%) между TBST и IGRA по парам тестов: DST 5 мм и QFT — 4,50 (от −13,13 до 22,12), C-Tb и QFT — 0,70 (от −7,02 до 8,42), C-TST и T-SPOT.TB — 3,54 (от −1,37 до 8,44). Общая объединённая разница по модели случайных эффектов — 2,29 (от −1,60 до 6,18); доверительные интервалы включают ноль."
      },
      "state": "draft"
    },
    {
      "id": "img-p913-1",
      "file": "images/img-p913-1.webp",
      "page": 913,
      "narratives": {
        "en": "A forest plot of the difference in specificity (%) between TBST and IGRA, by test pair: DST 5mm vs T-SPOT.TB −9.49 (−34.96 to 15.98), C-Tb vs QFT 0.70 (−7.02 to 8.42) and C-TST vs T-SPOT.TB 3.54 (−1.37 to 8.44). The overall random-effects pooled difference is −2.21 (−10.27 to 5.86).",
        "ar": "مخطط شجري للفرق في النوعية (%) بين اختبارات TBST وIGRA، حسب زوج الاختبارات: DST 5 مم مقابل T-SPOT.TB −9.49 (−34.96 إلى 15.98)، وC-Tb مقابل QFT 0.70 (−7.02 إلى 8.42)، وC-TST مقابل T-SPOT.TB 3.54 (−1.37 إلى 8.44). ويبلغ الفرق المجمّع الإجمالي بنموذج التأثيرات العشوائية −2.21 (−10.27 إلى 5.86).",
        "zh": "森林图显示TBST与IGRA特异度的差值（%），按检测组合：DST 5mm对T-SPOT.TB为−9.49（−34.96至15.98），C-Tb对QFT为0.70（−7.02至8.42），C-TST对T-SPOT.TB为3.54（−1.37至8.44）。总体随机效应合并差值为−2.21（−10.27至5.86）。",
        "es": "Diagrama de bosque de la diferencia de especificidad (%) entre las TBST y los IGRA, por par de pruebas: DST 5 mm frente a T-SPOT.TB −9,49 (−34,96 a 15,98), C-Tb frente a QFT 0,70 (−7,02 a 8,42) y C-TST frente a T-SPOT.TB 3,54 (−1,37 a 8,44). La diferencia combinada global por modelo de efectos aleatorios es de −2,21 (−10,27 a 5,86).",
        "fr": "Graphique en forêt de la différence de spécificité (%) entre TBST et IGRA, par paire de tests : DST 5 mm vs T-SPOT.TB −9,49 (−34,96 à 15,98), C-Tb vs QFT 0,70 (−7,02 à 8,42) et C-TST vs T-SPOT.TB 3,54 (−1,37 à 8,44). La différence groupée globale par modèle à effets aléatoires est de −2,21 (−10,27 à 5,86).",
        "ru": "Лесовидный график разницы в специфичности (%) между TBST и IGRA по парам тестов: DST 5 мм и T-SPOT.TB — −9,49 (от −34,96 до 15,98), C-Tb и QFT — 0,70 (от −7,02 до 8,42), C-TST и T-SPOT.TB — 3,54 (от −1,37 до 8,44). Общая объединённая разница по модели случайных эффектов — −2,21 (от −10,27 до 5,86)."
      },
      "state": "draft"
    },
    {
      "id": "img-p913-2",
      "file": "images/img-p913-2.webp",
      "page": 913,
      "narratives": {
        "en": "A forest plot of the difference in specificity (%) between TBST and TST, by test pair: DST 5mm vs TST 5mm 57.26, DST AI vs TST 5mm 29.93, C-Tb vs TST 15mm 4.61, C-Tb vs TST 5/15mm −2.00 and C-TST vs TST 5mm 39.90. The overall random-effects pooled difference is 33.47 (18.16 to 48.78), favouring higher specificity for TBST, with high residual heterogeneity (I² = 96%).",
        "ar": "مخطط شجري للفرق في النوعية (%) بين اختبارات TBST وTST، حسب زوج الاختبارات: DST 5 مم مقابل TST 5 مم 57.26، وDST AI مقابل TST 5 مم 29.93، وC-Tb مقابل TST 15 مم 4.61، وC-Tb مقابل TST 5/15 مم −2.00، وC-TST مقابل TST 5 مم 39.90. ويبلغ الفرق المجمّع الإجمالي 33.47 (18.16 إلى 48.78) لصالح نوعية أعلى لاختبارات TBST، مع عدم تجانس متبقٍّ مرتفع (I² = 96%).",
        "zh": "森林图显示TBST与TST特异度的差值（%），按检测组合：DST 5mm对TST 5mm为57.26，DST AI对TST 5mm为29.93，C-Tb对TST 15mm为4.61，C-Tb对TST 5/15mm为−2.00，C-TST对TST 5mm为39.90。总体随机效应合并差值为33.47（18.16至48.78），显示TBST特异度更高，残余异质性高（I² = 96%）。",
        "es": "Diagrama de bosque de la diferencia de especificidad (%) entre las TBST y la TST, por par de pruebas: DST 5 mm frente a TST 5 mm 57,26, DST AI frente a TST 5 mm 29,93, C-Tb frente a TST 15 mm 4,61, C-Tb frente a TST 5/15 mm −2,00 y C-TST frente a TST 5 mm 39,90. La diferencia combinada global es de 33,47 (18,16 a 48,78), a favor de una mayor especificidad de las TBST, con una heterogeneidad residual alta (I² = 96%).",
        "fr": "Graphique en forêt de la différence de spécificité (%) entre TBST et TST, par paire de tests : DST 5 mm vs TST 5 mm 57,26, DST AI vs TST 5 mm 29,93, C-Tb vs TST 15 mm 4,61, C-Tb vs TST 5/15 mm −2,00 et C-TST vs TST 5 mm 39,90. La différence groupée globale est de 33,47 (18,16 à 48,78), en faveur d’une spécificité plus élevée des TBST, avec une hétérogénéité résiduelle élevée (I² = 96 %).",
        "ru": "Лесовидный график разницы в специфичности (%) между TBST и TST по парам тестов: DST 5 мм и TST 5 мм — 57,26, DST AI и TST 5 мм — 29,93, C-Tb и TST 15 мм — 4,61, C-Tb и TST 5/15 мм — −2,00, C-TST и TST 5 мм — 39,90. Общая объединённая разница — 33,47 (от 18,16 до 48,78) в пользу более высокой специфичности TBST при высокой остаточной гетерогенности (I² = 96%)."
      },
      "state": "draft"
    },
    {
      "id": "img-p915-1",
      "file": "images/img-p915-1.webp",
      "page": 915,
      "narratives": {
        "en": "A forest plot of the difference in specificity (%) between TBST and QFT in children: DST 5mm vs QFT 10.60 (2.30 to 18.90; Starshinova 2018a) and C-Tb vs QFT 6.50 (−5.25 to 18.25; Aggerbeck 2018). The overall random-effects pooled difference is 9.21 (−15.46 to 33.88).",
        "ar": "مخطط شجري للفرق في النوعية (%) بين اختبارات TBST وQFT لدى الأطفال: DST 5 مم مقابل QFT 10.60 (2.30 إلى 18.90؛ Starshinova 2018a)، وC-Tb مقابل QFT 6.50 (−5.25 إلى 18.25؛ Aggerbeck 2018). ويبلغ الفرق المجمّع الإجمالي بنموذج التأثيرات العشوائية 9.21 (−15.46 إلى 33.88).",
        "zh": "森林图显示儿童中TBST与QFT特异度的差值（%）：DST 5mm对QFT为10.60（2.30至18.90；Starshinova 2018a），C-Tb对QFT为6.50（−5.25至18.25；Aggerbeck 2018）。总体随机效应合并差值为9.21（−15.46至33.88）。",
        "es": "Diagrama de bosque de la diferencia de especificidad (%) entre las TBST y la QFT en niños: DST 5 mm frente a QFT 10,60 (2,30 a 18,90; Starshinova 2018a) y C-Tb frente a QFT 6,50 (−5,25 a 18,25; Aggerbeck 2018). La diferencia combinada global por modelo de efectos aleatorios es de 9,21 (−15,46 a 33,88).",
        "fr": "Graphique en forêt de la différence de spécificité (%) entre TBST et QFT chez l’enfant : DST 5 mm vs QFT 10,60 (2,30 à 18,90 ; Starshinova 2018a) et C-Tb vs QFT 6,50 (−5,25 à 18,25 ; Aggerbeck 2018). La différence groupée globale par modèle à effets aléatoires est de 9,21 (−15,46 à 33,88).",
        "ru": "Лесовидный график разницы в специфичности (%) между TBST и QFT у детей: DST 5 мм и QFT — 10,60 (от 2,30 до 18,90; Starshinova 2018a), C-Tb и QFT — 6,50 (от −5,25 до 18,25; Aggerbeck 2018). Общая объединённая разница по модели случайных эффектов — 9,21 (от −15,46 до 33,88)."
      },
      "state": "draft"
    },
    {
      "id": "img-p915-2",
      "file": "images/img-p915-2.webp",
      "page": 915,
      "narratives": {
        "en": "A forest plot of the difference in specificity (%) between TBST and TST in children: DST 5mm vs TST 5mm 70.70 (Starshinova 2018a), DST AI vs TST 5mm 12.30 (Dovgalyuk 2013) and C-Tb vs TST 15mm −2.00 (Aggerbeck 2018). The overall random-effects pooled difference is 27.15 (−68.57 to 122.87), with significant subgroup differences (p < 0.01).",
        "ar": "مخطط شجري للفرق في النوعية (%) بين اختبارات TBST وTST لدى الأطفال: DST 5 مم مقابل TST 5 مم 70.70 (Starshinova 2018a)، وDST AI مقابل TST 5 مم 12.30 (Dovgalyuk 2013)، وC-Tb مقابل TST 15 مم −2.00 (Aggerbeck 2018). ويبلغ الفرق المجمّع الإجمالي 27.15 (−68.57 إلى 122.87)، مع فروق دالّة بين المجموعات الفرعية (p < 0.01).",
        "zh": "森林图显示儿童中TBST与TST特异度的差值（%）：DST 5mm对TST 5mm为70.70（Starshinova 2018a），DST AI对TST 5mm为12.30（Dovgalyuk 2013），C-Tb对TST 15mm为−2.00（Aggerbeck 2018）。总体随机效应合并差值为27.15（−68.57至122.87），亚组差异有统计学意义（p < 0.01）。",
        "es": "Diagrama de bosque de la diferencia de especificidad (%) entre las TBST y la TST en niños: DST 5 mm frente a TST 5 mm 70,70 (Starshinova 2018a), DST AI frente a TST 5 mm 12,30 (Dovgalyuk 2013) y C-Tb frente a TST 15 mm −2,00 (Aggerbeck 2018). La diferencia combinada global es de 27,15 (−68,57 a 122,87), con diferencias significativas entre subgrupos (p < 0,01).",
        "fr": "Graphique en forêt de la différence de spécificité (%) entre TBST et TST chez l’enfant : DST 5 mm vs TST 5 mm 70,70 (Starshinova 2018a), DST AI vs TST 5 mm 12,30 (Dovgalyuk 2013) et C-Tb vs TST 15 mm −2,00 (Aggerbeck 2018). La différence groupée globale est de 27,15 (−68,57 à 122,87), avec des différences significatives entre sous-groupes (p < 0,01).",
        "ru": "Лесовидный график разницы в специфичности (%) между TBST и TST у детей: DST 5 мм и TST 5 мм — 70,70 (Starshinova 2018a), DST AI и TST 5 мм — 12,30 (Dovgalyuk 2013), C-Tb и TST 15 мм — −2,00 (Aggerbeck 2018). Общая объединённая разница — 27,15 (от −68,57 до 122,87); различия между подгруппами значимы (p < 0,01)."
      },
      "state": "draft"
    },
    {
      "id": "img-p916-1",
      "file": "images/img-p916-1.webp",
      "page": 916,
      "narratives": {
        "en": "A forest plot of the difference in specificity (%) between TBST and T-SPOT.TB in BCG-vaccinated individuals: DST 5mm vs T-SPOT.TB −12.61 (Starshinova 2018a, adults −5.90 and children −18.70) and C-TST vs T-SPOT.TB −2.60 (Xu 2021, adults). The overall random-effects pooled difference is −9.67 (−31.12 to 11.79).",
        "ar": "مخطط شجري للفرق في النوعية (%) بين اختبارات TBST وT-SPOT.TB لدى الأفراد الملقَّحين بلقاح BCG: DST 5 مم مقابل T-SPOT.TB −12.61 (Starshinova 2018a، البالغون −5.90 والأطفال −18.70)، وC-TST مقابل T-SPOT.TB −2.60 (Xu 2021، بالغون). ويبلغ الفرق المجمّع الإجمالي −9.67 (−31.12 إلى 11.79).",
        "zh": "森林图显示接种卡介苗者中TBST与T-SPOT.TB特异度的差值（%）：DST 5mm对T-SPOT.TB为−12.61（Starshinova 2018a，成人−5.90，儿童−18.70），C-TST对T-SPOT.TB为−2.60（Xu 2021，成人）。总体随机效应合并差值为−9.67（−31.12至11.79）。",
        "es": "Diagrama de bosque de la diferencia de especificidad (%) entre las TBST y la T-SPOT.TB en personas vacunadas con BCG: DST 5 mm frente a T-SPOT.TB −12,61 (Starshinova 2018a, adultos −5,90 y niños −18,70) y C-TST frente a T-SPOT.TB −2,60 (Xu 2021, adultos). La diferencia combinada global es de −9,67 (−31,12 a 11,79).",
        "fr": "Graphique en forêt de la différence de spécificité (%) entre TBST et T-SPOT.TB chez les personnes vaccinées par le BCG : DST 5 mm vs T-SPOT.TB −12,61 (Starshinova 2018a, adultes −5,90 et enfants −18,70) et C-TST vs T-SPOT.TB −2,60 (Xu 2021, adultes). La différence groupée globale est de −9,67 (−31,12 à 11,79).",
        "ru": "Лесовидный график разницы в специфичности (%) между TBST и T-SPOT.TB у вакцинированных БЦЖ лиц: DST 5 мм и T-SPOT.TB — −12,61 (Starshinova 2018a: взрослые −5,90, дети −18,70), C-TST и T-SPOT.TB — −2,60 (Xu 2021, взрослые). Общая объединённая разница — −9,67 (от −31,12 до 11,79)."
      },
      "state": "draft"
    },
    {
      "id": "img-p916-2",
      "file": "images/img-p916-2.webp",
      "page": 916,
      "narratives": {
        "en": "A forest plot of the difference in specificity (%) between TBST and TST 5mm in BCG-vaccinated individuals: DST 5mm vs TST 5mm 60.12 (Starshinova 2018a, adults 48.30 and children 70.70) and C-TST vs TST 5mm 83.30 (Xu 2021, adults). The overall random-effects pooled difference is 67.39 (24.04 to 110.73).",
        "ar": "مخطط شجري للفرق في النوعية (%) بين اختبارات TBST وTST 5 مم لدى الأفراد الملقَّحين بلقاح BCG: DST 5 مم مقابل TST 5 مم 60.12 (Starshinova 2018a، البالغون 48.30 والأطفال 70.70)، وC-TST مقابل TST 5 مم 83.30 (Xu 2021، بالغون). ويبلغ الفرق المجمّع الإجمالي 67.39 (24.04 إلى 110.73).",
        "zh": "森林图显示接种卡介苗者中TBST与TST 5mm特异度的差值（%）：DST 5mm对TST 5mm为60.12（Starshinova 2018a，成人48.30，儿童70.70），C-TST对TST 5mm为83.30（Xu 2021，成人）。总体随机效应合并差值为67.39（24.04至110.73）。",
        "es": "Diagrama de bosque de la diferencia de especificidad (%) entre las TBST y la TST 5 mm en personas vacunadas con BCG: DST 5 mm frente a TST 5 mm 60,12 (Starshinova 2018a, adultos 48,30 y niños 70,70) y C-TST frente a TST 5 mm 83,30 (Xu 2021, adultos). La diferencia combinada global es de 67,39 (24,04 a 110,73).",
        "fr": "Graphique en forêt de la différence de spécificité (%) entre TBST et TST 5 mm chez les personnes vaccinées par le BCG : DST 5 mm vs TST 5 mm 60,12 (Starshinova 2018a, adultes 48,30 et enfants 70,70) et C-TST vs TST 5 mm 83,30 (Xu 2021, adultes). La différence groupée globale est de 67,39 (24,04 à 110,73).",
        "ru": "Лесовидный график разницы в специфичности (%) между TBST и TST 5 мм у вакцинированных БЦЖ лиц: DST 5 мм и TST 5 мм — 60,12 (Starshinova 2018a: взрослые 48,30, дети 70,70), C-TST и TST 5 мм — 83,30 (Xu 2021, взрослые). Общая объединённая разница — 67,39 (от 24,04 до 110,73)."
      },
      "state": "draft"
    },
    {
      "id": "img-p917-1",
      "file": "images/img-p917-1.webp",
      "page": 917,
      "narratives": {
        "en": "A forest plot of TBST specificity (%) in healthy individuals with negative IGRA results, by test pair: DST 5mm vs QFT 99.06% (Starshinova 2018), C-Tb vs QFT 98.01% (three studies, 91.43% to 99.32%) and C-TST vs T-SPOT.TB 95.48% (Xu 2021). The x-axis runs from 80 to 100; subgroup differences are not significant (p = 0.18).",
        "ar": "مخطط شجري لنوعية اختبارات TBST (%) لدى الأفراد الأصحاء ذوي نتائج IGRA السلبية، حسب زوج الاختبارات: DST 5 مم مقابل QFT 99.06% (Starshinova 2018)، وC-Tb مقابل QFT 98.01% (ثلاث دراسات، من 91.43% إلى 99.32%)، وC-TST مقابل T-SPOT.TB 95.48% (Xu 2021). ويمتد المحور الأفقي من 80 إلى 100، والفروق بين المجموعات الفرعية غير دالّة (p = 0.18).",
        "zh": "森林图显示IGRA结果阴性的健康人群中TBST的特异度（%），按检测组合：DST 5mm对QFT为99.06%（Starshinova 2018），C-Tb对QFT为98.01%（三项研究，91.43%至99.32%），C-TST对T-SPOT.TB为95.48%（Xu 2021）。横轴范围为80至100；亚组差异无统计学意义（p = 0.18）。",
        "es": "Diagrama de bosque de la especificidad (%) de las TBST en personas sanas con resultados negativos de IGRA, por par de pruebas: DST 5 mm frente a QFT 99,06% (Starshinova 2018), C-Tb frente a QFT 98,01% (tres estudios, del 91,43% al 99,32%) y C-TST frente a T-SPOT.TB 95,48% (Xu 2021). El eje x va de 80 a 100; las diferencias entre subgrupos no son significativas (p = 0,18).",
        "fr": "Graphique en forêt de la spécificité (%) des TBST chez les personnes en bonne santé ayant un IGRA négatif, par paire de tests : DST 5 mm vs QFT 99,06 % (Starshinova 2018), C-Tb vs QFT 98,01 % (trois études, de 91,43 % à 99,32 %) et C-TST vs T-SPOT.TB 95,48 % (Xu 2021). L’axe des abscisses va de 80 à 100 ; les différences entre sous-groupes ne sont pas significatives (p = 0,18).",
        "ru": "Лесовидный график специфичности (%) TBST у здоровых лиц с отрицательным результатом IGRA по парам тестов: DST 5 мм и QFT — 99,06% (Starshinova 2018), C-Tb и QFT — 98,01% (три исследования, от 91,43% до 99,32%), C-TST и T-SPOT.TB — 95,48% (Xu 2021). Ось X — от 80 до 100; различия между подгруппами незначимы (p = 0,18)."
      },
      "state": "draft"
    },
    {
      "id": "img-p917-2",
      "file": "images/img-p917-2.webp",
      "page": 917,
      "narratives": {
        "en": "A forest plot of TBST specificity (%) in healthy children with negative IGRA results: DST 5mm vs QFT 99.06% (Starshinova 2018) and C-Tb vs QFT 91.43% (Aggerbeck 2018). The overall random-effects pooled specificity is 96.74% (85.52–99.33) across 176 participants.",
        "ar": "مخطط شجري لنوعية اختبارات TBST (%) لدى الأطفال الأصحاء ذوي نتائج IGRA السلبية: DST 5 مم مقابل QFT 99.06% (Starshinova 2018)، وC-Tb مقابل QFT 91.43% (Aggerbeck 2018). وتبلغ النوعية المجمّعة الإجمالية بنموذج التأثيرات العشوائية 96.74% (85.52–99.33) لدى 176 مشاركاً.",
        "zh": "森林图显示IGRA结果阴性的健康儿童中TBST的特异度（%）：DST 5mm对QFT为99.06%（Starshinova 2018），C-Tb对QFT为91.43%（Aggerbeck 2018）。176名参与者的总体随机效应合并特异度为96.74%（85.52–99.33）。",
        "es": "Diagrama de bosque de la especificidad (%) de las TBST en niños sanos con resultados negativos de IGRA: DST 5 mm frente a QFT 99,06% (Starshinova 2018) y C-Tb frente a QFT 91,43% (Aggerbeck 2018). La especificidad combinada global por modelo de efectos aleatorios es del 96,74% (85,52–99,33) en 176 participantes.",
        "fr": "Graphique en forêt de la spécificité (%) des TBST chez les enfants en bonne santé ayant un IGRA négatif : DST 5 mm vs QFT 99,06 % (Starshinova 2018) et C-Tb vs QFT 91,43 % (Aggerbeck 2018). La spécificité groupée globale par modèle à effets aléatoires est de 96,74 % (85,52–99,33) sur 176 participants.",
        "ru": "Лесовидный график специфичности (%) TBST у здоровых детей с отрицательным результатом IGRA: DST 5 мм и QFT — 99,06% (Starshinova 2018), C-Tb и QFT — 91,43% (Aggerbeck 2018). Общая объединённая специфичность по модели случайных эффектов — 96,74% (85,52–99,33) у 176 участников."
      },
      "state": "draft"
    },
    {
      "id": "img-p917-3",
      "file": "images/img-p917-3.webp",
      "page": 917,
      "narratives": {
        "en": "A forest plot of TBST specificity (%) in BCG-vaccinated individuals with negative IGRA results from three studies: Xu 2021 (C-TST vs T-SPOT.TB) 97.44%, Starshinova 2018 (DST 5mm vs QFT) 99.06% and Aggerbeck 2013 (C-Tb vs QFT) 99.32%. The random-effects pooled specificity is 98.97% (96.86–99.67) across 292 participants.",
        "ar": "مخطط شجري لنوعية اختبارات TBST (%) لدى الأفراد الملقَّحين بلقاح BCG ذوي نتائج IGRA السلبية من ثلاث دراسات: Xu 2021 (C-TST مقابل T-SPOT.TB) 97.44%، وStarshinova 2018 (DST 5 مم مقابل QFT) 99.06%، وAggerbeck 2013 (C-Tb مقابل QFT) 99.32%. وتبلغ النوعية المجمّعة بنموذج التأثيرات العشوائية 98.97% (96.86–99.67) لدى 292 مشاركاً.",
        "zh": "森林图显示三项研究中IGRA结果阴性的卡介苗接种者TBST的特异度（%）：Xu 2021（C-TST对T-SPOT.TB）97.44%，Starshinova 2018（DST 5mm对QFT）99.06%，Aggerbeck 2013（C-Tb对QFT）99.32%。292名参与者的随机效应合并特异度为98.97%（96.86–99.67）。",
        "es": "Diagrama de bosque de la especificidad (%) de las TBST en personas vacunadas con BCG con resultados negativos de IGRA, en tres estudios: Xu 2021 (C-TST frente a T-SPOT.TB) 97,44%, Starshinova 2018 (DST 5 mm frente a QFT) 99,06% y Aggerbeck 2013 (C-Tb frente a QFT) 99,32%. La especificidad combinada por modelo de efectos aleatorios es del 98,97% (96,86–99,67) en 292 participantes.",
        "fr": "Graphique en forêt de la spécificité (%) des TBST chez les personnes vaccinées par le BCG ayant un IGRA négatif, dans trois études : Xu 2021 (C-TST vs T-SPOT.TB) 97,44 %, Starshinova 2018 (DST 5 mm vs QFT) 99,06 % et Aggerbeck 2013 (C-Tb vs QFT) 99,32 %. La spécificité groupée par modèle à effets aléatoires est de 98,97 % (96,86–99,67) sur 292 participants.",
        "ru": "Лесовидный график специфичности (%) TBST у вакцинированных БЦЖ лиц с отрицательным результатом IGRA в трёх исследованиях: Xu 2021 (C-TST и T-SPOT.TB) — 97,44%, Starshinova 2018 (DST 5 мм и QFT) — 99,06%, Aggerbeck 2013 (C-Tb и QFT) — 99,32%. Объединённая специфичность по модели случайных эффектов — 98,97% (96,86–99,67) у 292 участников."
      },
      "state": "draft"
    },
    {
      "id": "img-p946-1",
      "file": "images/img-p946-1.webp",
      "page": 946,
      "narratives": {
        "en": "A PRISMA flow diagram of study selection for the safety review. Via databases and registers (Medline 853, EMBASE 1317, CKNI 565, CBLD 282, e-library 405), 746 duplicates were removed, 2676 records screened, 2322 excluded, 354 reports sought, 27 not retrieved, 327 assessed and 304 excluded (mostly for no safety data, n = 261). Via other methods (WHO public call 20, manufacturers 26), 46 reports were sought and 38 assessed; the right edge of the image is cut off. In total 29 studies were included: 15 reports in English, 10 in Russian and 1 in Ukrainian.",
        "ar": "مخطط PRISMA الانسيابي لاختيار الدراسات في استعراض المأمونية. في مسار قواعد البيانات والسجلات (Medline 853، وEMBASE 1317، وCKNI 565، وCBLD 282، وe-library 405)، أزيل 746 سجلاً مكرراً، وفُحص 2676 سجلاً واستُبعد 2322، وطُلب 354 تقريراً لم يُسترجع منها 27، وقُيّم 327 واستُبعد 304 (معظمها لعدم وجود بيانات عن المأمونية، العدد = 261). وفي مسار الطرق الأخرى (الدعوة العامة للمنظمة 20، والجهات المصنِّعة 26)، طُلب 46 تقريراً وقُيّم 38؛ والحافة اليمنى من الصورة مقطوعة. وأُدرجت إجمالاً 29 دراسة: 15 تقريراً بالإنكليزية و10 بالروسية وتقرير واحد بالأوكرانية.",
        "zh": "安全性综述研究筛选的PRISMA流程图。通过数据库和登记册（Medline 853、EMBASE 1317、CKNI 565、CBLD 282、e-library 405），剔除746条重复记录，筛查2676条，排除2322条，寻求获取354份报告，27份未获取，评估327份，排除304份（大多因无安全性数据，n = 261）。通过其他方法（世卫组织公开征集20份，制造商26份），寻求获取46份报告，评估38份；图像右侧边缘被截断。共纳入29项研究：英文报告15份，俄文10份，乌克兰文1份。",
        "es": "Diagrama de flujo PRISMA de la selección de estudios para la revisión de seguridad. Mediante bases de datos y registros (Medline 853, EMBASE 1317, CKNI 565, CBLD 282, e-library 405) se eliminaron 746 duplicados, se cribaron 2676 registros y se excluyeron 2322, se solicitaron 354 informes, 27 no se obtuvieron, se evaluaron 327 y se excluyeron 304 (la mayoría por falta de datos de seguridad, n = 261). Mediante otros métodos (convocatoria pública de la OMS 20, fabricantes 26) se solicitaron 46 informes y se evaluaron 38; el borde derecho de la imagen está cortado. En total se incluyeron 29 estudios: 15 informes en inglés, 10 en ruso y 1 en ucraniano.",
        "fr": "Diagramme de flux PRISMA de la sélection des études pour la revue de l’innocuité. Via les bases de données et registres (Medline 853, EMBASE 1317, CKNI 565, CBLD 282, e-library 405), 746 doublons ont été supprimés, 2676 enregistrements triés et 2322 exclus, 354 rapports recherchés, 27 non obtenus, 327 évalués et 304 exclus (surtout faute de données d’innocuité, n = 261). Via d’autres méthodes (appel public de l’OMS 20, fabricants 26), 46 rapports ont été recherchés et 38 évalués ; le bord droit de l’image est coupé. Au total, 29 études ont été incluses : 15 rapports en anglais, 10 en russe et 1 en ukrainien.",
        "ru": "Блок-схема PRISMA отбора исследований для обзора безопасности. Через базы данных и регистры (Medline 853, EMBASE 1317, CKNI 565, CBLD 282, e-library 405) удалено 746 дубликатов, проверено 2676 записей и исключено 2322, запрошено 354 отчёта, 27 не получены, оценено 327 и исключено 304 (в основном из-за отсутствия данных о безопасности, n = 261). Другими методами (открытый запрос ВОЗ — 20, производители — 26) запрошено 46 отчётов и оценено 38; правый край изображения обрезан. Всего включено 29 исследований: 15 отчётов на английском, 10 на русском и 1 на украинском языке."
      },
      "state": "draft"
    },
    {
      "id": "img-p947-1",
      "file": "images/img-p947-1.webp",
      "page": 947,
      "narratives": {
        "en": "A forest plot of risk ratios (TBST vs TST) for any injection site reaction, from five C-Tb studies (pooled RR 1.05) and one DST study (Streltsova 2011, RR 3.00). The overall random-effects pooled risk ratio is 1.09 (0.74–1.61).",
        "ar": "مخطط شجري لنسب الخطر (TBST مقابل TST) بالنسبة إلى أي تفاعل في موضع الحقن، من خمس دراسات عن C-Tb (نسبة الخطر المجمّعة 1.05) ودراسة واحدة عن DST (Streltsova 2011، نسبة الخطر 3.00). وتبلغ نسبة الخطر المجمّعة الإجمالية بنموذج التأثيرات العشوائية 1.09 (0.74–1.61).",
        "zh": "森林图显示任何注射部位反应的风险比（TBST对TST），来自五项C-Tb研究（合并风险比1.05）和一项DST研究（Streltsova 2011，风险比3.00）。总体随机效应合并风险比为1.09（0.74–1.61）。",
        "es": "Diagrama de bosque de los cocientes de riesgos (TBST frente a TST) de cualquier reacción en el lugar de inyección, en cinco estudios de C-Tb (cociente combinado 1,05) y un estudio de DST (Streltsova 2011, cociente 3,00). El cociente de riesgos combinado global por modelo de efectos aleatorios es de 1,09 (0,74–1,61).",
        "fr": "Graphique en forêt des rapports de risques (TBST vs TST) pour toute réaction au site d’injection, dans cinq études sur C-Tb (rapport groupé 1,05) et une étude sur DST (Streltsova 2011, rapport 3,00). Le rapport de risques groupé global par modèle à effets aléatoires est de 1,09 (0,74–1,61).",
        "ru": "Лесовидный график отношений рисков (TBST и TST) для любой реакции в месте введения, по пяти исследованиям C-Tb (объединённое ОР 1,05) и одному исследованию DST (Streltsova 2011, ОР 3,00). Общее объединённое отношение рисков по модели случайных эффектов — 1,09 (0,74–1,61)."
      },
      "state": "draft"
    },
    {
      "id": "img-p948-1",
      "file": "images/img-p948-1.webp",
      "page": 948,
      "narratives": {
        "en": "A forest plot of risk ratios (TBST vs TST) for itching/pruritus, from four C-Tb studies (pooled RR 0.87), one C-TST study (Li 2016b, RR 1.00) and one DST study (Dotsenko 2015, RR 0.43). The overall random-effects pooled risk ratio is 0.86 (0.78–0.96).",
        "ar": "مخطط شجري لنسب الخطر (TBST مقابل TST) بالنسبة إلى الحكة، من أربع دراسات عن C-Tb (نسبة الخطر المجمّعة 0.87) ودراسة واحدة عن C-TST (Li 2016b، نسبة الخطر 1.00) ودراسة واحدة عن DST (Dotsenko 2015، نسبة الخطر 0.43). وتبلغ نسبة الخطر المجمّعة الإجمالية بنموذج التأثيرات العشوائية 0.86 (0.78–0.96).",
        "zh": "森林图显示瘙痒的风险比（TBST对TST），来自四项C-Tb研究（合并风险比0.87）、一项C-TST研究（Li 2016b，风险比1.00）和一项DST研究（Dotsenko 2015，风险比0.43）。总体随机效应合并风险比为0.86（0.78–0.96）。",
        "es": "Diagrama de bosque de los cocientes de riesgos (TBST frente a TST) de el prurito, en cuatro estudios de C-Tb (cociente combinado 0,87), un estudio de C-TST (Li 2016b, cociente 1,00) y un estudio de DST (Dotsenko 2015, cociente 0,43). El cociente de riesgos combinado global por modelo de efectos aleatorios es de 0,86 (0,78–0,96).",
        "fr": "Graphique en forêt des rapports de risques (TBST vs TST) pour le prurit, dans quatre études sur C-Tb (rapport groupé 0,87), une étude sur C-TST (Li 2016b, rapport 1,00) et une étude sur DST (Dotsenko 2015, rapport 0,43). Le rapport de risques groupé global par modèle à effets aléatoires est de 0,86 (0,78–0,96).",
        "ru": "Лесовидный график отношений рисков (TBST и TST) для зуда, по четырём исследованиям C-Tb (объединённое ОР 0,87), одному исследованию C-TST (Li 2016b, ОР 1,00) и одному исследованию DST (Dotsenko 2015, ОР 0,43). Общее объединённое отношение рисков по модели случайных эффектов — 0,86 (0,78–0,96)."
      },
      "state": "draft"
    },
    {
      "id": "img-p948-2",
      "file": "images/img-p948-2.webp",
      "page": 948,
      "narratives": {
        "en": "A forest plot of risk ratios (TBST vs TST) for pain, from four C-Tb studies (pooled RR 1.05) and one C-TST study with no events (Li 2016b). The overall random-effects pooled risk ratio is 1.05 (0.88–1.25).",
        "ar": "مخطط شجري لنسب الخطر (TBST مقابل TST) بالنسبة إلى الألم، من أربع دراسات عن C-Tb (نسبة الخطر المجمّعة 1.05) ودراسة واحدة عن C-TST بلا أحداث (Li 2016b). وتبلغ نسبة الخطر المجمّعة الإجمالية بنموذج التأثيرات العشوائية 1.05 (0.88–1.25).",
        "zh": "森林图显示疼痛的风险比（TBST对TST），来自四项C-Tb研究（合并风险比1.05）和一项无事件的C-TST研究（Li 2016b）。总体随机效应合并风险比为1.05（0.88–1.25）。",
        "es": "Diagrama de bosque de los cocientes de riesgos (TBST frente a TST) de el dolor, en cuatro estudios de C-Tb (cociente combinado 1,05) y un estudio de C-TST sin eventos (Li 2016b). El cociente de riesgos combinado global por modelo de efectos aleatorios es de 1,05 (0,88–1,25).",
        "fr": "Graphique en forêt des rapports de risques (TBST vs TST) pour la douleur, dans quatre études sur C-Tb (rapport groupé 1,05) et une étude sur C-TST sans événement (Li 2016b). Le rapport de risques groupé global par modèle à effets aléatoires est de 1,05 (0,88–1,25).",
        "ru": "Лесовидный график отношений рисков (TBST и TST) для боли, по четырём исследованиям C-Tb (объединённое ОР 1,05) и одному исследованию C-TST без событий (Li 2016b). Общее объединённое отношение рисков по модели случайных эффектов — 1,05 (0,88–1,25)."
      },
      "state": "draft"
    },
    {
      "id": "img-p949-1",
      "file": "images/img-p949-1.webp",
      "page": 949,
      "narratives": {
        "en": "A forest plot of risk ratios (TBST vs TST) for rash, from four C-Tb studies (Aggerbeck 2018, Aggerbeck 2019, Hoff 2016, Ruhwald 2017). The overall random-effects pooled risk ratio is 0.80 (0.52–1.23).",
        "ar": "مخطط شجري لنسب الخطر (TBST مقابل TST) بالنسبة إلى الطفح الجلدي، من أربع دراسات عن C-Tb (Aggerbeck 2018 وAggerbeck 2019 وHoff 2016 وRuhwald 2017). وتبلغ نسبة الخطر المجمّعة الإجمالية بنموذج التأثيرات العشوائية 0.80 (0.52–1.23).",
        "zh": "森林图显示皮疹的风险比（TBST对TST），来自四项C-Tb研究（Aggerbeck 2018、Aggerbeck 2019、Hoff 2016、Ruhwald 2017）。总体随机效应合并风险比为0.80（0.52–1.23）。",
        "es": "Diagrama de bosque de los cocientes de riesgos (TBST frente a TST) de la erupción cutánea, en cuatro estudios de C-Tb (Aggerbeck 2018, Aggerbeck 2019, Hoff 2016, Ruhwald 2017). El cociente de riesgos combinado global por modelo de efectos aleatorios es de 0,80 (0,52–1,23).",
        "fr": "Graphique en forêt des rapports de risques (TBST vs TST) pour l’éruption cutanée, dans quatre études sur C-Tb (Aggerbeck 2018, Aggerbeck 2019, Hoff 2016, Ruhwald 2017). Le rapport de risques groupé global par modèle à effets aléatoires est de 0,80 (0,52–1,23).",
        "ru": "Лесовидный график отношений рисков (TBST и TST) для сыпи, по четырём исследованиям C-Tb (Aggerbeck 2018, Aggerbeck 2019, Hoff 2016, Ruhwald 2017). Общее объединённое отношение рисков по модели случайных эффектов — 0,80 (0,52–1,23)."
      },
      "state": "draft"
    },
    {
      "id": "img-p950-1",
      "file": "images/img-p950-1.webp",
      "page": 950,
      "narratives": {
        "en": "A forest plot of risk ratios (TBST vs TST) for erythema, from four C-Tb studies, with Hoff 2016 carrying 83% of the weight. The overall random-effects pooled risk ratio is 0.82 (0.67–1.00).",
        "ar": "مخطط شجري لنسب الخطر (TBST مقابل TST) بالنسبة إلى الحُمامى، من أربع دراسات عن C-Tb، تحمل فيها دراسة Hoff 2016 نسبة 83% من الوزن. وتبلغ نسبة الخطر المجمّعة الإجمالية بنموذج التأثيرات العشوائية 0.82 (0.67–1.00).",
        "zh": "森林图显示红斑的风险比（TBST对TST），来自四项C-Tb研究，其中Hoff 2016占权重的83%。总体随机效应合并风险比为0.82（0.67–1.00）。",
        "es": "Diagrama de bosque de los cocientes de riesgos (TBST frente a TST) de el eritema, en cuatro estudios de C-Tb, en los que Hoff 2016 tiene el 83% del peso. El cociente de riesgos combinado global por modelo de efectos aleatorios es de 0,82 (0,67–1,00).",
        "fr": "Graphique en forêt des rapports de risques (TBST vs TST) pour l’érythème, dans quatre études sur C-Tb, Hoff 2016 représentant 83 % du poids. Le rapport de risques groupé global par modèle à effets aléatoires est de 0,82 (0,67–1,00).",
        "ru": "Лесовидный график отношений рисков (TBST и TST) для эритемы, по четырём исследованиям C-Tb, из которых на Hoff 2016 приходится 83% веса. Общее объединённое отношение рисков по модели случайных эффектов — 0,82 (0,67–1,00)."
      },
      "state": "draft"
    },
    {
      "id": "img-p951-1",
      "file": "images/img-p951-1.webp",
      "page": 951,
      "narratives": {
        "en": "A forest plot of risk ratios (TBST vs TST) for swelling/oedema, from three C-Tb studies (Aggerbeck 2018, Hoff 2016, Ruhwald 2017). The overall random-effects pooled risk ratio is 1.04 (0.68–1.59).",
        "ar": "مخطط شجري لنسب الخطر (TBST مقابل TST) بالنسبة إلى التورّم/الوذمة، من ثلاث دراسات عن C-Tb (Aggerbeck 2018 وHoff 2016 وRuhwald 2017). وتبلغ نسبة الخطر المجمّعة الإجمالية بنموذج التأثيرات العشوائية 1.04 (0.68–1.59).",
        "zh": "森林图显示肿胀/水肿的风险比（TBST对TST），来自三项C-Tb研究（Aggerbeck 2018、Hoff 2016、Ruhwald 2017）。总体随机效应合并风险比为1.04（0.68–1.59）。",
        "es": "Diagrama de bosque de los cocientes de riesgos (TBST frente a TST) de la tumefacción/el edema, en tres estudios de C-Tb (Aggerbeck 2018, Hoff 2016, Ruhwald 2017). El cociente de riesgos combinado global por modelo de efectos aleatorios es de 1,04 (0,68–1,59).",
        "fr": "Graphique en forêt des rapports de risques (TBST vs TST) pour le gonflement/l’œdème, dans trois études sur C-Tb (Aggerbeck 2018, Hoff 2016, Ruhwald 2017). Le rapport de risques groupé global par modèle à effets aléatoires est de 1,04 (0,68–1,59).",
        "ru": "Лесовидный график отношений рисков (TBST и TST) для отёка, по трём исследованиям C-Tb (Aggerbeck 2018, Hoff 2016, Ruhwald 2017). Общее объединённое отношение рисков по модели случайных эффектов — 1,04 (0,68–1,59)."
      },
      "state": "draft"
    },
    {
      "id": "img-p951-2",
      "file": "images/img-p951-2.webp",
      "page": 951,
      "narratives": {
        "en": "A forest plot of risk ratios (TBST vs TST) for vesicle/blister, from four C-Tb studies, with study risk ratios from 0.47 to 1.24. The overall random-effects pooled risk ratio is 0.75 (0.36–1.56).",
        "ar": "مخطط شجري لنسب الخطر (TBST مقابل TST) بالنسبة إلى الحويصلات/النفطات، من أربع دراسات عن C-Tb، تتراوح نسب الخطر فيها بين 0.47 و1.24. وتبلغ نسبة الخطر المجمّعة الإجمالية بنموذج التأثيرات العشوائية 0.75 (0.36–1.56).",
        "zh": "森林图显示水疱的风险比（TBST对TST），来自四项C-Tb研究，各研究风险比为0.47至1.24。总体随机效应合并风险比为0.75（0.36–1.56）。",
        "es": "Diagrama de bosque de los cocientes de riesgos (TBST frente a TST) de las vesículas/ampollas, en cuatro estudios de C-Tb, con cocientes de riesgos por estudio de 0,47 a 1,24. El cociente de riesgos combinado global por modelo de efectos aleatorios es de 0,75 (0,36–1,56).",
        "fr": "Graphique en forêt des rapports de risques (TBST vs TST) pour les vésicules/phlyctènes, dans quatre études sur C-Tb, les rapports de risques par étude allant de 0,47 à 1,24. Le rapport de risques groupé global par modèle à effets aléatoires est de 0,75 (0,36–1,56).",
        "ru": "Лесовидный график отношений рисков (TBST и TST) для везикул/пузырей, по четырём исследованиям C-Tb с ОР в отдельных исследованиях от 0,47 до 1,24. Общее объединённое отношение рисков по модели случайных эффектов — 0,75 (0,36–1,56)."
      },
      "state": "draft"
    },
    {
      "id": "img-p952-1",
      "file": "images/img-p952-1.webp",
      "page": 952,
      "narratives": {
        "en": "A forest plot of risk ratios (TBST vs TST) for induration, from three C-Tb studies (Aggerbeck 2018, Aggerbeck 2019, Ruhwald 2017), indicating more induration events with TBST. The overall random-effects pooled risk ratio is 1.78 (1.36–2.32).",
        "ar": "مخطط شجري لنسب الخطر (TBST مقابل TST) بالنسبة إلى التصلّب، من ثلاث دراسات عن C-Tb (Aggerbeck 2018 وAggerbeck 2019 وRuhwald 2017)، مما يشير إلى أحداث تصلّب أكثر مع اختبارات TBST. وتبلغ نسبة الخطر المجمّعة الإجمالية بنموذج التأثيرات العشوائية 1.78 (1.36–2.32).",
        "zh": "森林图显示硬结的风险比（TBST对TST），来自三项C-Tb研究（Aggerbeck 2018、Aggerbeck 2019、Ruhwald 2017），显示TBST的硬结事件更多。总体随机效应合并风险比为1.78（1.36–2.32）。",
        "es": "Diagrama de bosque de los cocientes de riesgos (TBST frente a TST) de la induración, en tres estudios de C-Tb (Aggerbeck 2018, Aggerbeck 2019, Ruhwald 2017), lo que indica más casos de induración con las TBST. El cociente de riesgos combinado global por modelo de efectos aleatorios es de 1,78 (1,36–2,32).",
        "fr": "Graphique en forêt des rapports de risques (TBST vs TST) pour l’induration, dans trois études sur C-Tb (Aggerbeck 2018, Aggerbeck 2019, Ruhwald 2017), indiquant davantage d’indurations avec les TBST. Le rapport de risques groupé global par modèle à effets aléatoires est de 1,78 (1,36–2,32).",
        "ru": "Лесовидный график отношений рисков (TBST и TST) для инфильтрата, по трём исследованиям C-Tb (Aggerbeck 2018, Aggerbeck 2019, Ruhwald 2017), что указывает на большее число случаев инфильтрата при TBST. Общее объединённое отношение рисков по модели случайных эффектов — 1,78 (1,36–2,32)."
      },
      "state": "draft"
    },
    {
      "id": "img-p953-1",
      "file": "images/img-p953-1.webp",
      "page": 953,
      "narratives": {
        "en": "A summary forest plot of pooled risk ratios (TBST vs PPD) for any injection site reaction and individual reactions: any ISR 1.09 (6 studies), itching/pruritus 0.87, pain 1.05, rash 0.80, erythema 0.82, swelling/oedema 1.04, vesicle/blister 0.75 and induration 1.78 (1.36–2.32). Only induration has a confidence interval entirely above 1, and only itching one entirely below 1.",
        "ar": "مخطط شجري موجز لنسب الخطر المجمّعة (TBST مقابل PPD) لأي تفاعل في موضع الحقن وللتفاعلات المنفردة: أي تفاعل 1.09 (6 دراسات)، والحكة 0.87، والألم 1.05، والطفح الجلدي 0.80، والحُمامى 0.82، والتورّم/الوذمة 1.04، والحويصلات/النفطات 0.75، والتصلّب 1.78 (1.36–2.32). والتصلّب وحده فاصل ثقته أعلى من 1 بالكامل، والحكة وحدها فاصل ثقتها أدنى من 1 بالكامل.",
        "zh": "汇总森林图显示任何注射部位反应及各类反应的合并风险比（TBST对PPD）：任何注射部位反应1.09（6项研究），瘙痒0.87，疼痛1.05，皮疹0.80，红斑0.82，肿胀/水肿1.04，水疱0.75，硬结1.78（1.36–2.32）。只有硬结的置信区间完全高于1，只有瘙痒的置信区间完全低于1。",
        "es": "Diagrama de bosque resumido de los cocientes de riesgos combinados (TBST frente a PPD) de cualquier reacción en el lugar de inyección y de cada reacción: cualquier reacción 1,09 (6 estudios), prurito 0,87, dolor 1,05, erupción 0,80, eritema 0,82, tumefacción/edema 1,04, vesícula/ampolla 0,75 e induración 1,78 (1,36–2,32). Solo la induración tiene un intervalo de confianza totalmente por encima de 1, y solo el prurito uno totalmente por debajo de 1.",
        "fr": "Graphique en forêt récapitulatif des rapports de risques groupés (TBST vs PPD) pour toute réaction au site d’injection et chaque réaction : toute réaction 1,09 (6 études), prurit 0,87, douleur 1,05, éruption 0,80, érythème 0,82, gonflement/œdème 1,04, vésicule/phlyctène 0,75 et induration 1,78 (1,36–2,32). Seule l’induration a un intervalle de confiance entièrement au-dessus de 1, et seul le prurit un intervalle entièrement en dessous de 1.",
        "ru": "Сводный лесовидный график объединённых отношений рисков (TBST и PPD) для любой реакции в месте введения и отдельных реакций: любая реакция — 1,09 (6 исследований), зуд — 0,87, боль — 1,05, сыпь — 0,80, эритема — 0,82, отёк — 1,04, везикулы/пузыри — 0,75, инфильтрат — 1,78 (1,36–2,32). Только для инфильтрата доверительный интервал целиком выше 1, и только для зуда — целиком ниже 1."
      },
      "state": "draft"
    },
    {
      "id": "img-p953-2",
      "file": "images/img-p953-2.webp",
      "page": 953,
      "narratives": {
        "en": "A forest plot of the proportion (%) of participants with any systemic adverse event after TBST: five C-Tb studies pooled at 36.1% (26.8–46.4), ranging from 28.5% to 53.0%, and one C-TST study (Li 2016a) with 0 of 6. The overall random-effects pooled proportion is 35.0% (26.4–44.7) across 3033 participants.",
        "ar": "مخطط شجري لنسبة (%) المشاركين الذين تعرّضوا لأي حدث ضائر جهازي بعد اختبارات TBST: خمس دراسات عن C-Tb بنسبة مجمّعة 36.1% (26.8–46.4) تتراوح بين 28.5% و53.0%، ودراسة واحدة عن C-TST (Li 2016a) بلا أحداث من أصل 6. وتبلغ النسبة المجمّعة الإجمالية 35.0% (26.4–44.7) لدى 3033 مشاركاً.",
        "zh": "森林图显示TBST后发生任何全身性不良事件的参与者比例（%）：五项C-Tb研究合并为36.1%（26.8–46.4），范围为28.5%至53.0%；一项C-TST研究（Li 2016a）6人中0人发生。3033名参与者的总体随机效应合并比例为35.0%（26.4–44.7）。",
        "es": "Diagrama de bosque de la proporción (%) de participantes con algún evento adverso sistémico tras las TBST: cinco estudios de C-Tb con una proporción combinada del 36,1% (26,8–46,4), entre el 28,5% y el 53,0%, y un estudio de C-TST (Li 2016a) con 0 de 6. La proporción combinada global es del 35,0% (26,4–44,7) en 3033 participantes.",
        "fr": "Graphique en forêt de la proportion (%) de participants présentant un événement indésirable systémique après TBST : cinq études sur C-Tb groupées à 36,1 % (26,8–46,4), allant de 28,5 % à 53,0 %, et une étude sur C-TST (Li 2016a) avec 0 sur 6. La proportion groupée globale est de 35,0 % (26,4–44,7) sur 3033 participants.",
        "ru": "Лесовидный график доли (%) участников с любым системным нежелательным явлением после TBST: пять исследований C-Tb — объединённая доля 36,1% (26,8–46,4), от 28,5% до 53,0%; одно исследование C-TST (Li 2016a) — 0 из 6. Общая объединённая доля — 35,0% (26,4–44,7) у 3033 участников."
      },
      "state": "draft"
    },
    {
      "id": "img-p954-1",
      "file": "images/img-p954-1.webp",
      "page": 954,
      "narratives": {
        "en": "A forest plot of the proportion (%) of participants with fever after TBST, grouped by test: C-Tb 2.6% (three studies), C-TST 0.0% (two studies with no events) and DST 2.7% (six studies, 0.0% to 7.0%). The overall random-effects pooled proportion is 2.6% (2.0–3.4) across 2478 participants.",
        "ar": "مخطط شجري لنسبة (%) المشاركين الذين أصيبوا بالحمى بعد اختبارات TBST، حسب الاختبار: C-Tb 2.6% (ثلاث دراسات)، وC-TST 0.0% (دراستان بلا أحداث)، وDST 2.7% (ست دراسات، من 0.0% إلى 7.0%). وتبلغ النسبة المجمّعة الإجمالية 2.6% (2.0–3.4) لدى 2478 مشاركاً.",
        "zh": "森林图显示TBST后发热的参与者比例（%），按检测分组：C-Tb 2.6%（三项研究），C-TST 0.0%（两项研究，无事件），DST 2.7%（六项研究，0.0%至7.0%）。2478名参与者的总体随机效应合并比例为2.6%（2.0–3.4）。",
        "es": "Diagrama de bosque de la proporción (%) de participantes con fiebre tras las TBST, por prueba: C-Tb 2,6% (tres estudios), C-TST 0,0% (dos estudios sin eventos) y DST 2,7% (seis estudios, del 0,0% al 7,0%). La proporción combinada global es del 2,6% (2,0–3,4) en 2478 participantes.",
        "fr": "Graphique en forêt de la proportion (%) de participants ayant de la fièvre après TBST, par test : C-Tb 2,6 % (trois études), C-TST 0,0 % (deux études sans événement) et DST 2,7 % (six études, de 0,0 % à 7,0 %). La proportion groupée globale est de 2,6 % (2,0–3,4) sur 2478 participants.",
        "ru": "Лесовидный график доли (%) участников с лихорадкой после TBST по тестам: C-Tb — 2,6% (три исследования), C-TST — 0,0% (два исследования без событий), DST — 2,7% (шесть исследований, от 0,0% до 7,0%). Общая объединённая доля — 2,6% (2,0–3,4) у 2478 участников."
      },
      "state": "draft"
    },
    {
      "id": "img-p955-1",
      "file": "images/img-p955-1.webp",
      "page": 955,
      "narratives": {
        "en": "A forest plot of the proportion (%) of participants with headache after C-Tb in six studies, ranging from 3.8% (Aggerbeck 2013) to 17.2% (Aggerbeck 2019). The random-effects pooled proportion is 11.3% (7.8–16.0) across 2723 participants, with high heterogeneity (I² = 79%).",
        "ar": "مخطط شجري لنسبة (%) المشاركين الذين أصيبوا بالصداع بعد اختبار C-Tb في ست دراسات، تتراوح بين 3.8% (Aggerbeck 2013) و17.2% (Aggerbeck 2019). وتبلغ النسبة المجمّعة بنموذج التأثيرات العشوائية 11.3% (7.8–16.0) لدى 2723 مشاركاً، مع عدم تجانس مرتفع (I² = 79%).",
        "zh": "森林图显示六项研究中C-Tb后出现头痛的参与者比例（%），范围为3.8%（Aggerbeck 2013）至17.2%（Aggerbeck 2019）。2723名参与者的随机效应合并比例为11.3%（7.8–16.0），异质性高（I² = 79%）。",
        "es": "Diagrama de bosque de la proporción (%) de participantes con cefalea tras C-Tb en seis estudios, del 3,8% (Aggerbeck 2013) al 17,2% (Aggerbeck 2019). La proporción combinada por modelo de efectos aleatorios es del 11,3% (7,8–16,0) en 2723 participantes, con heterogeneidad alta (I² = 79%).",
        "fr": "Graphique en forêt de la proportion (%) de participants ayant des céphalées après C-Tb dans six études, de 3,8 % (Aggerbeck 2013) à 17,2 % (Aggerbeck 2019). La proportion groupée par modèle à effets aléatoires est de 11,3 % (7,8–16,0) sur 2723 participants, avec une hétérogénéité élevée (I² = 79 %).",
        "ru": "Лесовидный график доли (%) участников с головной болью после C-Tb в шести исследованиях — от 3,8% (Aggerbeck 2013) до 17,2% (Aggerbeck 2019). Объединённая доля по модели случайных эффектов — 11,3% (7,8–16,0) у 2723 участников при высокой гетерогенности (I² = 79%)."
      },
      "state": "draft"
    },
    {
      "id": "img-p1056-1",
      "file": "images/img-p1056-1.webp",
      "page": 1056,
      "narratives": {
        "en": "Model diagram (Figure 1) of the TB infection care cascade. From a starting node 'Tested for TB infection', arrows branch to 'No TBI tested' (leading to 'No TBI treated', 'No TBI untreated' and 'No TBI Treatment interrupted') and 'TBI tested' (leading to 'TBI treated', 'TBI untreated' and 'TBI Treatment interrupted'). 'TBI treated' and 'TBI Treatment interrupted' both point to 'TBI untreated', which leads by a dashed arrow to 'Active TB'; each end state ends in a green triangle terminal node.",
        "ar": "مخطط النموذج (الشكل 1) لسلسلة الرعاية الخاصة بعدوى السل. من عقدة البداية «خضع لاختبار عدوى السل» تتفرع الأسهم إلى «اختبار بلا عدوى سل» (ويؤدي إلى «بلا عدوى سل ومعالَج» و«بلا عدوى سل وغير معالَج» و«بلا عدوى سل وانقطع العلاج») وإلى «اختبار مع عدوى سل» (ويؤدي إلى «عدوى سل معالَجة» و«عدوى سل غير معالَجة» و«عدوى سل وانقطع علاجها»). وتشير كل من «عدوى سل معالَجة» و«عدوى سل وانقطع علاجها» إلى «عدوى سل غير معالَجة» التي تؤدي بسهم متقطع إلى «السل النشط»؛ وتنتهي كل حالة نهائية بعقدة طرفية على شكل مثلث أخضر.",
        "zh": "结核感染关护级联的模型图（图1）。从起始节点“接受结核感染检测”出发，箭头分为“检测为无结核感染”（通向“无结核感染已治疗”“无结核感染未治疗”和“无结核感染治疗中断”）和“检测为结核感染”（通向“结核感染已治疗”“结核感染未治疗”和“结核感染治疗中断”）。“结核感染已治疗”和“结核感染治疗中断”均指向“结核感染未治疗”，后者经虚线箭头通向“活动性结核病”；每个终末状态以绿色三角形终端节点结束。",
        "es": "Diagrama del modelo (figura 1) de la cascada de atención de la infección tuberculosa. Desde el nodo inicial «Sometido a prueba de infección tuberculosa», las flechas se ramifican hacia «Prueba sin ITB» (que lleva a «Sin ITB tratado», «Sin ITB no tratado» y «Sin ITB tratamiento interrumpido») y «Prueba con ITB» (que lleva a «ITB tratada», «ITB no tratada» e «ITB tratamiento interrumpido»). «ITB tratada» e «ITB tratamiento interrumpido» apuntan a «ITB no tratada», que conduce mediante una flecha discontinua a «TB activa»; cada estado final termina en un nodo triangular verde.",
        "fr": "Schéma du modèle (figure 1) de la cascade de soins de l’infection tuberculeuse. À partir du nœud initial « Testé pour l’infection tuberculeuse », des flèches mènent à « Testé sans ITB » (vers « Sans ITB traité », « Sans ITB non traité » et « Sans ITB traitement interrompu ») et à « Testé avec ITB » (vers « ITB traitée », « ITB non traitée » et « ITB traitement interrompu »). « ITB traitée » et « ITB traitement interrompu » renvoient toutes deux à « ITB non traitée », qui mène par une flèche en pointillés à « TB active » ; chaque état final aboutit à un nœud terminal en triangle vert.",
        "ru": "Схема модели (рисунок 1) каскада помощи при туберкулезной инфекции. От начального узла «Обследован на туберкулезную инфекцию» стрелки ведут к «Обследован, ТБИ нет» (далее «Нет ТБИ, лечение проведено», «Нет ТБИ, без лечения» и «Нет ТБИ, лечение прервано») и к «Обследован, ТБИ есть» (далее «ТБИ, лечение проведено», «ТБИ без лечения» и «ТБИ, лечение прервано»). «ТБИ, лечение проведено» и «ТБИ, лечение прервано» указывают на «ТБИ без лечения», откуда пунктирная стрелка ведет к «Активному ТБ»; каждое конечное состояние завершается зеленым треугольным терминальным узлом."
      },
      "state": "draft"
    },
    {
      "id": "img-p1063-1",
      "file": "images/img-p1063-1.webp",
      "page": 1063,
      "narratives": {
        "en": "Incremental cost-effectiveness plane for Brazil (part of Figure 2): a scatter plot of Monte Carlo simulations with Incremental QALYs on the x-axis (−2 to 2) and Incremental Costs on the y-axis (about −20 to 20), comparing DiaskinTest versus PPD-TST (blue) and DiaskinTest versus IGRA (green). Both clouds overlap and are centred near zero QALYs with mostly small positive incremental costs.",
        "ar": "مستوى الفعالية من حيث التكلفة الإضافية في البرازيل (جزء من الشكل 2): مخطط انتشار لمحاكاة مونت كارلو يبيّن على المحور الأفقي سنوات العمر المعدّلة حسب الجودة الإضافية (من −2 إلى 2) وعلى المحور الرأسي التكاليف الإضافية (about −20 to 20)، مع مقارنة DiaskinTest باختبار التوبركولين PPD-TST (بالأزرق) وDiaskinTest باختبار IGRA (بالأخضر). تتداخل السحابتان وتتمركزان قرب الصفر على محور سنوات العمر المعدّلة حسب الجودة مع تكاليف إضافية موجبة صغيرة في الغالب.",
        "zh": "巴西的增量成本效果平面（图2的一部分）：蒙特卡洛模拟散点图，x轴为增量质量调整生命年（−2至2），y轴为增量成本（about −20 to 20），比较DiaskinTest与PPD-TST（蓝色）以及DiaskinTest与IGRA（绿色）。两组点云相互重叠，集中在质量调整生命年接近零处，增量成本大多为较小的正值。",
        "es": "Plano de costo-efectividad incremental para Brasil (parte de la figura 2): diagrama de dispersión de simulaciones de Monte Carlo con los AVAC incrementales en el eje x (−2 a 2) y los costos incrementales en el eje y (about −20 to 20), que compara DiaskinTest frente a PPD-TST (azul) y DiaskinTest frente a IGRA (verde). Ambas nubes se superponen y se centran cerca de cero AVAC, con costos incrementales mayoritariamente positivos y pequeños.",
        "fr": "Plan coût-efficacité incrémental pour le Brésil (partie de la figure 2) : nuage de points de simulations de Monte Carlo avec les QALY incrémentaux en abscisse (−2 à 2) et les coûts incrémentaux en ordonnée (about −20 to 20), comparant DiaskinTest au PPD-TST (bleu) et DiaskinTest à l’IGRA (vert). Les deux nuages se chevauchent et sont centrés près de zéro QALY, avec des coûts incrémentaux surtout faiblement positifs.",
        "ru": "Плоскость дополнительной затратной эффективности для Бразилии (часть рисунка 2): диаграмма рассеяния симуляций Монте-Карло; по оси x — дополнительные QALY (от −2 до 2), по оси y — дополнительные затраты (about −20 to 20); сравниваются DiaskinTest и PPD-TST (синий) и DiaskinTest и IGRA (зеленый). Оба облака точек перекрываются и сосредоточены около нуля QALY, с преимущественно небольшими положительными дополнительными затратами."
      },
      "state": "draft"
    },
    {
      "id": "img-p1063-2",
      "file": "images/img-p1063-2.webp",
      "page": 1063,
      "narratives": {
        "en": "Incremental cost-effectiveness plane for South Africa (part of Figure 2): a scatter plot of Monte Carlo simulations with Incremental QALYs on the x-axis (−2 to 2) and Incremental Costs on the y-axis (about −50 to 100), comparing DiaskinTest versus PPD-TST (blue) and DiaskinTest versus IGRA (green). The green points (versus IGRA) lie mostly above zero cost, around 50, while the blue points (versus PPD-TST) are centred near zero cost.",
        "ar": "مستوى الفعالية من حيث التكلفة الإضافية في جنوب أفريقيا (جزء من الشكل 2): مخطط انتشار لمحاكاة مونت كارلو يبيّن على المحور الأفقي سنوات العمر المعدّلة حسب الجودة الإضافية (من −2 إلى 2) وعلى المحور الرأسي التكاليف الإضافية (about −50 to 100)، مع مقارنة DiaskinTest باختبار التوبركولين PPD-TST (بالأزرق) وDiaskinTest باختبار IGRA (بالأخضر). تقع النقاط الخضراء (مقابل IGRA) في الغالب فوق الصفر على محور التكلفة، حول 50، بينما تتمركز النقاط الزرقاء (مقابل PPD-TST) قرب الصفر.",
        "zh": "南非的增量成本效果平面（图2的一部分）：蒙特卡洛模拟散点图，x轴为增量质量调整生命年（−2至2），y轴为增量成本（about −50 to 100），比较DiaskinTest与PPD-TST（蓝色）以及DiaskinTest与IGRA（绿色）。绿色点（对比IGRA）大多位于零成本之上、约50附近，而蓝色点（对比PPD-TST）集中在零成本附近。",
        "es": "Plano de costo-efectividad incremental para Sudáfrica (parte de la figura 2): diagrama de dispersión de simulaciones de Monte Carlo con los AVAC incrementales en el eje x (−2 a 2) y los costos incrementales en el eje y (about −50 to 100), que compara DiaskinTest frente a PPD-TST (azul) y DiaskinTest frente a IGRA (verde). Los puntos verdes (frente a IGRA) se sitúan mayoritariamente por encima de cero en costos, en torno a 50, mientras que los azules (frente a PPD-TST) se centran cerca de cero.",
        "fr": "Plan coût-efficacité incrémental pour l’Afrique du Sud (partie de la figure 2) : nuage de points de simulations de Monte Carlo avec les QALY incrémentaux en abscisse (−2 à 2) et les coûts incrémentaux en ordonnée (about −50 to 100), comparant DiaskinTest au PPD-TST (bleu) et DiaskinTest à l’IGRA (vert). Les points verts (contre IGRA) se situent surtout au-dessus de zéro en coût, autour de 50, tandis que les points bleus (contre PPD-TST) sont centrés près de zéro.",
        "ru": "Плоскость дополнительной затратной эффективности для Южной Африки (часть рисунка 2): диаграмма рассеяния симуляций Монте-Карло; по оси x — дополнительные QALY (от −2 до 2), по оси y — дополнительные затраты (about −50 to 100); сравниваются DiaskinTest и PPD-TST (синий) и DiaskinTest и IGRA (зеленый). Зеленые точки (против IGRA) располагаются в основном выше нуля по затратам, около 50, а синие (против PPD-TST) сосредоточены около нуля."
      },
      "state": "draft"
    },
    {
      "id": "img-p1064-1",
      "file": "images/img-p1064-1.webp",
      "page": 1064,
      "narratives": {
        "en": "Incremental cost-effectiveness plane for the UK (part of Figure 2): a scatter plot of Monte Carlo simulations with Incremental QALYs on the x-axis (−2 to 2) and Incremental Costs on the y-axis (about −400 to 400), comparing DiaskinTest versus PPD-TST (blue) and DiaskinTest versus IGRA (green). The blue points (versus PPD-TST) sit mostly at or above zero cost, while the green points (versus IGRA) sit mostly at or below zero cost.",
        "ar": "مستوى الفعالية من حيث التكلفة الإضافية في المملكة المتحدة (جزء من الشكل 2): مخطط انتشار لمحاكاة مونت كارلو يبيّن على المحور الأفقي سنوات العمر المعدّلة حسب الجودة الإضافية (من −2 إلى 2) وعلى المحور الرأسي التكاليف الإضافية (about −400 to 400)، مع مقارنة DiaskinTest باختبار التوبركولين PPD-TST (بالأزرق) وDiaskinTest باختبار IGRA (بالأخضر). تقع النقاط الزرقاء (مقابل PPD-TST) في الغالب عند الصفر أو فوقه على محور التكلفة، بينما تقع النقاط الخضراء (مقابل IGRA) في الغالب عند الصفر أو تحته.",
        "zh": "英国的增量成本效果平面（图2的一部分）：蒙特卡洛模拟散点图，x轴为增量质量调整生命年（−2至2），y轴为增量成本（about −400 to 400），比较DiaskinTest与PPD-TST（蓝色）以及DiaskinTest与IGRA（绿色）。蓝色点（对比PPD-TST）大多位于零成本或其上方，而绿色点（对比IGRA）大多位于零成本或其下方。",
        "es": "Plano de costo-efectividad incremental para el Reino Unido (parte de la figura 2): diagrama de dispersión de simulaciones de Monte Carlo con los AVAC incrementales en el eje x (−2 a 2) y los costos incrementales en el eje y (about −400 to 400), que compara DiaskinTest frente a PPD-TST (azul) y DiaskinTest frente a IGRA (verde). Los puntos azules (frente a PPD-TST) se sitúan mayoritariamente en cero o por encima en costos, mientras que los verdes (frente a IGRA) se sitúan mayoritariamente en cero o por debajo.",
        "fr": "Plan coût-efficacité incrémental pour le Royaume-Uni (partie de la figure 2) : nuage de points de simulations de Monte Carlo avec les QALY incrémentaux en abscisse (−2 à 2) et les coûts incrémentaux en ordonnée (about −400 to 400), comparant DiaskinTest au PPD-TST (bleu) et DiaskinTest à l’IGRA (vert). Les points bleus (contre PPD-TST) se situent surtout à zéro ou au-dessus en coût, tandis que les points verts (contre IGRA) se situent surtout à zéro ou en dessous.",
        "ru": "Плоскость дополнительной затратной эффективности для Соединенного Королевства (часть рисунка 2): диаграмма рассеяния симуляций Монте-Карло; по оси x — дополнительные QALY (от −2 до 2), по оси y — дополнительные затраты (about −400 to 400); сравниваются DiaskinTest и PPD-TST (синий) и DiaskinTest и IGRA (зеленый). Синие точки (против PPD-TST) находятся в основном на нуле или выше по затратам, а зеленые (против IGRA) — в основном на нуле или ниже."
      },
      "state": "draft"
    },
    {
      "id": "img-p1087-1",
      "file": "images/img-p1087-1.webp",
      "page": 1087,
      "narratives": {
        "en": "PRISMA flow chart (Figure A1, Review A) in two panels. English/Chinese literature: 1317 records in EMBASE, 1424 in Medline, 282 in the Chinese Biomedical Literature Database and 565 in China National Knowledge Infrastructure databases give 2271 records after removing duplicates; 2168 that do not report new skin tests are excluded, leaving 103 records for second screening and 0 records eligible. Russian literature: 405 records in e-library, 141 deemed not relevant, 264 for full-text review, all 264 excluded, giving 0 records potentially eligible; separately, 1 paper from a WHO public call for data yields 1 record eligible.",
        "ar": "مخطط PRISMA الانسيابي (الشكل A1، الاستعراض A) في لوحتين. المؤلفات الإنكليزية/الصينية: 1317 سجلًا في EMBASE و1424 في Medline و282 في قاعدة بيانات المؤلفات الطبية الحيوية الصينية و565 في قواعد بيانات البنية التحتية الوطنية الصينية للمعرفة، تعطي 2271 سجلًا بعد حذف المكرر؛ ويُستبعد 2168 سجلًا لا تتناول اختبارات جلدية جديدة، فيتبقى 103 سجلات للفرز الثاني و0 سجل مؤهل. المؤلفات الروسية: 405 سجلات في e-library، و141 اعتُبرت غير ذات صلة، و264 لمراجعة النص الكامل، استُبعدت جميعها، فيكون عدد السجلات المؤهلة المحتملة 0؛ وبشكل منفصل، ورقة واحدة من دعوة المنظمة العامة لتقديم البيانات تعطي سجلًا واحدًا مؤهلًا.",
        "zh": "PRISMA流程图（图A1，综述A），分为两部分。英文/中文文献：EMBASE中1317条记录、Medline中1424条、中国生物医学文献数据库中282条、中国知网数据库中565条，去重后为2271条；排除2168条未报告新型皮肤试验的记录，剩余103条进入第二轮筛选，0条符合条件。俄文文献：e-library中405条记录，141条被认为不相关，264条进行全文审查，全部264条被排除，0条可能符合条件；另外，世卫组织公开征集数据获得的1篇论文产生1条符合条件的记录。",
        "es": "Diagrama de flujo PRISMA (figura A1, revisión A) en dos paneles. Literatura en inglés/chino: 1317 registros en EMBASE, 1424 en Medline, 282 en la Chinese Biomedical Literature Database y 565 en las bases de datos China National Knowledge Infrastructure dan 2271 registros tras eliminar duplicados; se excluyen 2168 que no informan sobre nuevas pruebas cutáneas, quedan 103 registros para el segundo cribado y 0 registros elegibles. Literatura en ruso: 405 registros en e-library, 141 considerados no pertinentes, 264 para revisión del texto completo, los 264 excluidos, con 0 registros potencialmente elegibles; por separado, 1 artículo de la convocatoria pública de datos de la OMS da 1 registro elegible.",
        "fr": "Diagramme de flux PRISMA (figure A1, revue A) en deux volets. Littérature anglaise/chinoise : 1317 enregistrements dans EMBASE, 1424 dans Medline, 282 dans la Chinese Biomedical Literature Database et 565 dans les bases China National Knowledge Infrastructure donnent 2271 enregistrements après suppression des doublons ; 2168 ne portant pas sur de nouveaux tests cutanés sont exclus, il reste 103 enregistrements pour le second tri et 0 enregistrement éligible. Littérature russe : 405 enregistrements dans e-library, 141 jugés non pertinents, 264 pour examen du texte intégral, tous exclus, soit 0 enregistrement potentiellement éligible ; séparément, 1 article issu de l’appel public à données de l’OMS donne 1 enregistrement éligible.",
        "ru": "Блок-схема PRISMA (рисунок A1, обзор A) из двух панелей. Литература на английском/китайском языках: 1317 записей в EMBASE, 1424 в Medline, 282 в Китайской биомедицинской литературной базе данных и 565 в базах China National Knowledge Infrastructure дают 2271 запись после удаления дубликатов; исключены 2168 записей, не сообщающих о новых кожных тестах, на второй скрининг отобраны 103 записи, отвечающих критериям — 0. Литература на русском языке: 405 записей в e-library, 141 признана нерелевантной, 264 — для полнотекстового анализа, все 264 исключены, потенциально подходящих — 0; отдельно 1 статья из открытого запроса данных ВОЗ дает 1 подходящую запись."
      },
      "state": "draft"
    },
    {
      "id": "img-p1087-2",
      "file": "images/img-p1087-2.webp",
      "page": 1087,
      "narratives": {
        "en": "PRISMA flow chart (Figure A1, Review B): 123 studies identified from MEDLINE, EMBASE, CINAHL and PsychInfo; 88 records after duplicates removed, of which 69 were deemed irrelevant; 19 full-text studies assessed for eligibility, with 16 excluded (11 wrong study design, 4 wrong intervention, 1 wrong publication type); 3 studies in final inclusion.",
        "ar": "مخطط PRISMA الانسيابي (الشكل A1، الاستعراض B): حُددت 123 دراسة من MEDLINE وEMBASE وCINAHL وPsychInfo؛ و88 سجلًا بعد حذف المكرر، اعتُبر 69 منها غير ذي صلة؛ وقُيّمت أهلية 19 دراسة بنصها الكامل، واستُبعدت 16 (11 تصميم دراسة غير مناسب، و4 تدخل غير مناسب، و1 نوع نشر غير مناسب)؛ وأُدرجت 3 دراسات في النهاية.",
        "zh": "PRISMA流程图（图A1，综述B）：从MEDLINE、EMBASE、CINAHL和PsychInfo中识别出123项研究；去重后88条记录，其中69条被认为不相关；19项全文研究接受资格评估，排除16项（11项研究设计不符、4项干预措施不符、1项出版类型不符）；最终纳入3项研究。",
        "es": "Diagrama de flujo PRISMA (figura A1, revisión B): 123 estudios identificados en MEDLINE, EMBASE, CINAHL y PsychInfo; 88 registros tras eliminar duplicados, de los cuales 69 se consideraron no pertinentes; 19 estudios a texto completo evaluados para elegibilidad, con 16 excluidos (11 por diseño de estudio inadecuado, 4 por intervención inadecuada, 1 por tipo de publicación inadecuado); 3 estudios incluidos finalmente.",
        "fr": "Diagramme de flux PRISMA (figure A1, revue B) : 123 études identifiées dans MEDLINE, EMBASE, CINAHL et PsychInfo ; 88 enregistrements après suppression des doublons, dont 69 jugés non pertinents ; 19 études en texte intégral évaluées pour l’éligibilité, dont 16 exclues (11 plan d’étude inadéquat, 4 intervention inadéquate, 1 type de publication inadéquat) ; 3 études incluses au final.",
        "ru": "Блок-схема PRISMA (рисунок A1, обзор B): 123 исследования выявлены в MEDLINE, EMBASE, CINAHL и PsychInfo; 88 записей после удаления дубликатов, из них 69 признаны нерелевантными; 19 полнотекстовых исследований оценены на соответствие критериям, 16 исключены (11 — неподходящий дизайн, 4 — неподходящее вмешательство, 1 — неподходящий тип публикации); в итоге включены 3 исследования."
      },
      "state": "draft"
    },
    {
      "id": "img-p1091-1",
      "file": "images/img-p1091-1.webp",
      "page": 1091,
      "narratives": {
        "en": "Diagram of themes and subthemes (Figure A2) arranged in three columns of labelled circles with different shading. Acceptability: Consumer demographics, Consumer experience, Accuracy / certainty of results, Suitability in specific subgroups. Feasibility: Consumer experience, Cost, Resource requirements, Health system setting. Equity: Access and transport issues, Scalability for large scale screening / suitability for subgroups.",
        "ar": "مخطط للمواضيع والمواضيع الفرعية (الشكل A2) مرتب في ثلاثة أعمدة من الدوائر المعنونة بتظليل مختلف. المقبولية: الخصائص الديمغرافية للمستهلكين، وتجربة المستهلك، ودقة النتائج/اليقين منها، والملاءمة لفئات فرعية محددة. الجدوى: تجربة المستهلك، والتكلفة، والاحتياجات من الموارد، وسياق النظام الصحي. الإنصاف: قضايا الوصول والنقل، وقابلية التوسع للتحري على نطاق واسع/الملاءمة للفئات الفرعية.",
        "zh": "主题和次主题示意图（图A2），以三列不同底纹的带标签圆圈排列。可接受性：消费者人口学特征、消费者体验、结果的准确性/确定性、对特定亚组的适用性。可行性：消费者体验、成本、资源需求、卫生系统环境。公平性：可及性和交通问题、大规模筛查的可扩展性/对亚组的适用性。",
        "es": "Diagrama de temas y subtemas (figura A2) organizado en tres columnas de círculos rotulados con distintos sombreados. Aceptabilidad: características demográficas del consumidor, experiencia del consumidor, exactitud/certeza de los resultados, idoneidad en subgrupos específicos. Factibilidad: experiencia del consumidor, costo, necesidades de recursos, entorno del sistema de salud. Equidad: problemas de acceso y transporte, escalabilidad para el cribado a gran escala/idoneidad para subgrupos.",
        "fr": "Schéma des thèmes et sous-thèmes (figure A2) disposé en trois colonnes de cercles étiquetés, avec des trames différentes. Acceptabilité : caractéristiques démographiques des consommateurs, expérience des consommateurs, exactitude/certitude des résultats, adéquation à des sous-groupes spécifiques. Faisabilité : expérience des consommateurs, coût, besoins en ressources, contexte du système de santé. Équité : problèmes d’accès et de transport, possibilité de passage à l’échelle pour un dépistage à grande échelle/adéquation aux sous-groupes.",
        "ru": "Схема тем и подтем (рисунок A2) в виде трех столбцов подписанных кругов с разной штриховкой. Приемлемость: демографические характеристики потребителей, опыт потребителей, точность/достоверность результатов, пригодность для отдельных подгрупп. Осуществимость: опыт потребителей, стоимость, потребности в ресурсах, условия системы здравоохранения. Справедливость: проблемы доступа и транспорта, масштабируемость для крупномасштабного скрининга/пригодность для подгрупп."
      },
      "state": "draft"
    },
    {
      "id": "img-p1091-2",
      "file": "images/img-p1091-2.webp",
      "page": 1091,
      "narratives": {
        "en": "Diagram titled 'End user values and preferences' (part of Figure A2) with five labelled circles: Accuracy / certainty of results, Convenience, Consumer experience, Cost and Resource requirements.",
        "ar": "مخطط بعنوان «قيم المستخدمين النهائيين وأفضلياتهم» (جزء من الشكل A2) يضم خمس دوائر معنونة: دقة النتائج/اليقين منها، والملاءمة، وتجربة المستهلك، والتكلفة، والاحتياجات من الموارد.",
        "zh": "题为“终端用户的价值观和偏好”的示意图（图A2的一部分），包含五个带标签的圆圈：结果的准确性/确定性、便利性、消费者体验、成本和资源需求。",
        "es": "Diagrama titulado «Valores y preferencias de los usuarios finales» (parte de la figura A2) con cinco círculos rotulados: exactitud/certeza de los resultados, comodidad, experiencia del consumidor, costo y necesidades de recursos.",
        "fr": "Schéma intitulé « Valeurs et préférences des utilisateurs finaux » (partie de la figure A2) comportant cinq cercles étiquetés : exactitude/certitude des résultats, commodité, expérience des consommateurs, coût et besoins en ressources.",
        "ru": "Схема под названием «Ценности и предпочтения конечных пользователей» (часть рисунка A2) с пятью подписанными кругами: точность/достоверность результатов, удобство, опыт потребителей, стоимость и потребности в ресурсах."
      },
      "state": "draft"
    },
    {
      "id": "img-p1100-1",
      "file": "images/img-p1100-1.webp",
      "page": 1100,
      "narratives": {
        "en": "Diagram of end-user values and preferences (Figure B2) shown as five labelled circles: Accuracy / certainty of results, Convenience, Consumer experience, Cost and Resource requirements.",
        "ar": "مخطط لقيم المستخدمين النهائيين وأفضلياتهم (الشكل B2) في صورة خمس دوائر معنونة: دقة النتائج/اليقين منها، والملاءمة، وتجربة المستهلك، والتكلفة، والاحتياجات من الموارد.",
        "zh": "终端用户价值观和偏好示意图（图B2），以五个带标签的圆圈表示：结果的准确性/确定性、便利性、消费者体验、成本和资源需求。",
        "es": "Diagrama de los valores y preferencias de los usuarios finales (figura B2) representados como cinco círculos rotulados: exactitud/certeza de los resultados, comodidad, experiencia del consumidor, costo y necesidades de recursos.",
        "fr": "Schéma des valeurs et préférences des utilisateurs finaux (figure B2) représentées par cinq cercles étiquetés : exactitude/certitude des résultats, commodité, expérience des consommateurs, coût et besoins en ressources.",
        "ru": "Схема ценностей и предпочтений конечных пользователей (рисунок B2) в виде пяти подписанных кругов: точность/достоверность результатов, удобство, опыт потребителей, стоимость и потребности в ресурсах."
      },
      "state": "draft"
    },
    {
      "id": "img-p1102-1",
      "file": "images/img-p1102-1.webp",
      "page": 1102,
      "narratives": {
        "en": "Diagram of people-related factors in test acceptability (Figure B3) shown as seven grey circles: Consumer demographics, Consumer experience, Perceptions of skin tests, Knowledge, Familiarity, Usefulness and Provider-consumer communication.",
        "ar": "مخطط للعوامل المتعلقة بالأشخاص في مقبولية الاختبار (الشكل B3) في صورة سبع دوائر رمادية: الخصائص الديمغرافية للمستهلكين، وتجربة المستهلك، والتصورات عن الاختبارات الجلدية، والمعرفة، والألفة، والفائدة، والتواصل بين مقدم الخدمة والمستهلك.",
        "zh": "检测可接受性中与人相关的因素示意图（图B3），以七个灰色圆圈表示：消费者人口学特征、消费者体验、对皮肤试验的看法、知识、熟悉程度、有用性以及提供者与消费者的沟通。",
        "es": "Diagrama de los factores relacionados con las personas en la aceptabilidad de la prueba (figura B3), representados como siete círculos grises: características demográficas del consumidor, experiencia del consumidor, percepciones de las pruebas cutáneas, conocimientos, familiaridad, utilidad y comunicación entre proveedor y consumidor.",
        "fr": "Schéma des facteurs liés aux personnes dans l’acceptabilité du test (figure B3), représentés par sept cercles gris : caractéristiques démographiques des consommateurs, expérience des consommateurs, perceptions des tests cutanés, connaissances, familiarité, utilité et communication prestataire-consommateur.",
        "ru": "Схема факторов, связанных с людьми, влияющих на приемлемость теста (рисунок B3), в виде семи серых кругов: демографические характеристики потребителей, опыт потребителей, восприятие кожных тестов, знания, привычность, полезность и коммуникация между поставщиком услуг и потребителем."
      },
      "state": "draft"
    },
    {
      "id": "img-p1106-1",
      "file": "images/img-p1106-1.webp",
      "page": 1106,
      "narratives": {
        "en": "Diagram of test-related factors in test acceptability (Figure B4) shown as five labelled circles: Accuracy, Reliability, Time to receive result, Suitability in specific subgroups and Ability to differentiate latent and active TB.",
        "ar": "مخطط للعوامل المتعلقة بالاختبار في مقبولية الاختبار (الشكل B4) في صورة خمس دوائر معنونة: الدقة، والموثوقية، والوقت اللازم لتلقي النتيجة، والملاءمة لفئات فرعية محددة، والقدرة على التمييز بين السل الكامن والسل النشط.",
        "zh": "检测可接受性中与检测相关的因素示意图（图B4），以五个带标签的圆圈表示：准确性、可靠性、获得结果的时间、对特定亚组的适用性，以及区分潜伏性结核和活动性结核的能力。",
        "es": "Diagrama de los factores relacionados con la prueba en su aceptabilidad (figura B4), representados como cinco círculos rotulados: exactitud, fiabilidad, tiempo hasta obtener el resultado, idoneidad en subgrupos específicos y capacidad de diferenciar la TB latente de la activa.",
        "fr": "Schéma des facteurs liés au test dans son acceptabilité (figure B4), représentés par cinq cercles étiquetés : exactitude, fiabilité, délai d’obtention du résultat, adéquation à des sous-groupes spécifiques et capacité à distinguer la TB latente de la TB active.",
        "ru": "Схема факторов, связанных с самим тестом, влияющих на его приемлемость (рисунок B4), в виде пяти подписанных кругов: точность, надежность, время получения результата, пригодность для отдельных подгрупп и способность различать латентный и активный ТБ."
      },
      "state": "draft"
    },
    {
      "id": "img-p1108-1",
      "file": "images/img-p1108-1.webp",
      "page": 1108,
      "narratives": {
        "en": "Diagram of contextual factors in test acceptability (Figure B5) shown as three labelled circles: Test environment, Provider perceptions of the test and Infrastructure for test follow-up.",
        "ar": "مخطط للعوامل السياقية في مقبولية الاختبار (الشكل B5) في صورة ثلاث دوائر معنونة: بيئة الاختبار، وتصورات مقدمي الخدمة عن الاختبار، والبنية التحتية لمتابعة الاختبار.",
        "zh": "检测可接受性中的背景因素示意图（图B5），以三个带标签的圆圈表示：检测环境、提供者对检测的看法以及检测后续跟进的基础设施。",
        "es": "Diagrama de los factores contextuales en la aceptabilidad de la prueba (figura B5), representados como tres círculos rotulados: entorno de la prueba, percepciones de los proveedores sobre la prueba e infraestructura para el seguimiento de la prueba.",
        "fr": "Schéma des facteurs contextuels dans l’acceptabilité du test (figure B5), représentés par trois cercles étiquetés : environnement du test, perceptions du test par les prestataires et infrastructure pour le suivi du test.",
        "ru": "Схема контекстуальных факторов, влияющих на приемлемость теста (рисунок B5), в виде трех подписанных кругов: условия проведения теста, восприятие теста поставщиками услуг и инфраструктура для последующего наблюдения."
      },
      "state": "draft"
    },
    {
      "id": "img-p1109-1",
      "file": "images/img-p1109-1.webp",
      "page": 1109,
      "narratives": {
        "en": "Diagram of people factors in test feasibility (Figure B6): a central grey circle 'Consumer experience' surrounded by four boxed labels: Transport, Healthcare setting, Return visits and Timeliness of results.",
        "ar": "مخطط للعوامل المتعلقة بالأشخاص في جدوى الاختبار (الشكل B6): دائرة رمادية مركزية بعنوان «تجربة المستهلك» تحيط بها أربع تسميات في مربعات: النقل، وموقع الرعاية الصحية، والزيارات المتكررة، وتوقيت النتائج.",
        "zh": "检测可行性中与人相关的因素示意图（图B6）：中央灰色圆圈“消费者体验”，周围有四个方框标签：交通、医疗卫生场所、复诊以及结果的及时性。",
        "es": "Diagrama de los factores relacionados con las personas en la factibilidad de la prueba (figura B6): un círculo gris central «Experiencia del consumidor» rodeado de cuatro etiquetas en recuadros: transporte, entorno de atención de salud, visitas de seguimiento y puntualidad de los resultados.",
        "fr": "Schéma des facteurs liés aux personnes dans la faisabilité du test (figure B6) : un cercle gris central « Expérience des consommateurs » entouré de quatre étiquettes encadrées : transport, cadre de soins, visites de retour et rapidité des résultats.",
        "ru": "Схема факторов, связанных с людьми, влияющих на осуществимость теста (рисунок B6): центральный серый круг «Опыт потребителей», окруженный четырьмя подписями в рамках: транспорт, медицинское учреждение, повторные визиты и своевременность результатов."
      },
      "state": "draft"
    },
    {
      "id": "img-p1110-1",
      "file": "images/img-p1110-1.webp",
      "page": 1110,
      "narratives": {
        "en": "Diagram of test factors in test feasibility (Figure B7) shown as four labelled circles: Cost, Time to receive result, Portability and Ease of administration.",
        "ar": "مخطط للعوامل المتعلقة بالاختبار في جدوى الاختبار (الشكل B7) في صورة أربع دوائر معنونة: التكلفة، والوقت اللازم لتلقي النتيجة، وسهولة النقل، وسهولة الإجراء.",
        "zh": "检测可行性中与检测相关的因素示意图（图B7），以四个带标签的圆圈表示：成本、获得结果的时间、便携性和操作简便性。",
        "es": "Diagrama de los factores relacionados con la prueba en su factibilidad (figura B7), representados como cuatro círculos rotulados: costo, tiempo hasta obtener el resultado, portabilidad y facilidad de administración.",
        "fr": "Schéma des facteurs liés au test dans sa faisabilité (figure B7), représentés par quatre cercles étiquetés : coût, délai d’obtention du résultat, portabilité et facilité d’administration.",
        "ru": "Схема факторов, связанных с тестом, влияющих на его осуществимость (рисунок B7), в виде четырех подписанных кругов: стоимость, время получения результата, портативность и простота проведения."
      },
      "state": "draft"
    },
    {
      "id": "img-p1112-1",
      "file": "images/img-p1112-1.webp",
      "page": 1112,
      "narratives": {
        "en": "Diagram of contextual factors in test feasibility (Figure B8) shown as three labelled circles: Resource requirements, COVID-19 and Health system setting.",
        "ar": "مخطط للعوامل السياقية في جدوى الاختبار (الشكل B8) في صورة ثلاث دوائر معنونة: الاحتياجات من الموارد، وكوفيد-19، وسياق النظام الصحي.",
        "zh": "检测可行性中的背景因素示意图（图B8），以三个带标签的圆圈表示：资源需求、2019冠状病毒病和卫生系统环境。",
        "es": "Diagrama de los factores contextuales en la factibilidad de la prueba (figura B8), representados como tres círculos rotulados: necesidades de recursos, COVID-19 y entorno del sistema de salud.",
        "fr": "Schéma des facteurs contextuels dans la faisabilité du test (figure B8), représentés par trois cercles étiquetés : besoins en ressources, COVID-19 et contexte du système de santé.",
        "ru": "Схема контекстуальных факторов, влияющих на осуществимость теста (рисунок B8), в виде трех подписанных кругов: потребности в ресурсах, COVID-19 и условия системы здравоохранения."
      },
      "state": "draft"
    },
    {
      "id": "img-p1114-1",
      "file": "images/img-p1114-1.webp",
      "page": 1114,
      "narratives": {
        "en": "Diagram of equity factors (Figure B9) shown as five grey circles: Access and transport issues, Suitability to low-income country setting, Scalability for large scale screening programmes, Affected by the infrastructure required and Suitability to subgroups.",
        "ar": "مخطط لعوامل الإنصاف (الشكل B9) في صورة خمس دوائر رمادية: قضايا الوصول والنقل، والملاءمة لسياق البلدان المنخفضة الدخل، وقابلية التوسع لبرامج التحري على نطاق واسع، والتأثر بالبنية التحتية المطلوبة، والملاءمة للفئات الفرعية.",
        "zh": "公平性因素示意图（图B9），以五个灰色圆圈表示：可及性和交通问题、对低收入国家环境的适用性、大规模筛查规划的可扩展性、受所需基础设施的影响以及对亚组的适用性。",
        "es": "Diagrama de los factores de equidad (figura B9) representados como cinco círculos grises: problemas de acceso y transporte, idoneidad para el contexto de países de ingreso bajo, escalabilidad para programas de cribado a gran escala, dependencia de la infraestructura necesaria e idoneidad para subgrupos.",
        "fr": "Schéma des facteurs d’équité (figure B9) représentés par cinq cercles gris : problèmes d’accès et de transport, adéquation au contexte des pays à faible revenu, possibilité de passage à l’échelle pour des programmes de dépistage à grande échelle, dépendance à l’infrastructure requise et adéquation aux sous-groupes.",
        "ru": "Схема факторов справедливости (рисунок B9) в виде пяти серых кругов: проблемы доступа и транспорта, пригодность для условий стран с низким уровнем дохода, масштабируемость для крупномасштабных программ скрининга, зависимость от необходимой инфраструктуры и пригодность для подгрупп."
      },
      "state": "draft"
    },
    {
      "id": "img-p1122-1",
      "file": "images/img-p1122-1.webp",
      "page": 1122,
      "narratives": {
        "en": "World map of DCE respondent locations (Figure C1), with countries shaded by number of respondents and labelled with counts. The darkest shading is the United States of America (38); India (26), South Africa (20) and a neighbouring country (17), and Pakistan (18) are also shaded more darkly, while many other countries are labelled with 1 to 10 respondents and grey countries have none.",
        "ar": "خريطة عالمية لمواقع المستجيبين لتجربة الاختيار المنفصل (الشكل C1)، تظلَّل فيها البلدان بحسب عدد المستجيبين وتحمل أعدادهم. أغمق تظليل للولايات المتحدة الأمريكية (38)؛ وتظلَّل أيضًا بلون أغمق الهند (26) وجنوب أفريقيا (20) وبلد مجاور لها (17) وباكستان (18)، بينما تحمل بلدان كثيرة أخرى أعدادًا من 1 إلى 10 مستجيبين، والبلدان الرمادية لا مستجيبين فيها.",
        "zh": "离散选择实验受访者所在地世界地图（图C1），各国按受访者人数着色并标注人数。颜色最深的是美利坚合众国（38）；印度（26）、南非（20）及其一个邻国（17）以及巴基斯坦（18）颜色也较深，许多其他国家标注为1至10名受访者，灰色国家无受访者。",
        "es": "Mapa mundial de la ubicación de los encuestados del EED (figura C1), con los países sombreados según el número de encuestados y rotulados con las cifras. El sombreado más oscuro corresponde a los Estados Unidos de América (38); la India (26), Sudáfrica (20) y un país vecino (17), y el Pakistán (18) también aparecen más oscuros, mientras que muchos otros países se rotulan con 1 a 10 encuestados y los países en gris no tienen ninguno.",
        "fr": "Carte du monde de la localisation des répondants à l’expérience de choix discrets (figure C1), les pays étant colorés selon le nombre de répondants et annotés de ces nombres. La teinte la plus foncée correspond aux États-Unis d’Amérique (38) ; l’Inde (26), l’Afrique du Sud (20) et un pays voisin (17), ainsi que le Pakistan (18) sont aussi plus foncés, tandis que de nombreux autres pays portent 1 à 10 répondants et les pays en gris n’en ont aucun.",
        "ru": "Карта мира с распределением респондентов ДЭВ (рисунок C1); страны окрашены по числу респондентов и подписаны числами. Самый темный цвет — Соединенные Штаты Америки (38); Индия (26), Южная Африка (20) и соседняя с ней страна (17), а также Пакистан (18) также выделены темнее, многие другие страны подписаны числами от 1 до 10, серые страны респондентов не имеют."
      },
      "state": "draft"
    }
  ],
  "tables": [
    {
      "label": "Table 1",
      "caption": "Table 1. Xpert Ultra: Characteristics of included studies",
      "pages": [
        17,
        18,
        19
      ],
      "columns": [
        {
          "titles": "Study"
        },
        {
          "titles": "Reference standard"
        },
        {
          "titles": "Study design"
        },
        {
          "titles": "Proportion of PLHIV"
        },
        {
          "titles": "Clinical setting"
        },
        {
          "titles": "Age group"
        },
        {
          "titles": "Country"
        },
        {
          "titles": "High TB burden?"
        },
        {
          "titles": "Specimen type"
        },
        {
          "titles": "Xpert Ultra non-determinate for detection of MTBᵃ % (number/total)"
        }
      ],
      "rows": [
        [
          "Aguilera-Alonso 2022",
          "Solid & liquid – 1 to 3 specimens",
          "Prospective Cohort",
          "None",
          "Inpatient",
          "Adolescents",
          "Spain",
          "No",
          "Fresh sputum",
          "NR"
        ],
        [
          "Berhanu 2018",
          "Solid (LJ) & liquid",
          "Prospective cohort",
          "62% (147/237)",
          "Outpatient",
          "Adults",
          "RSA",
          "Yes",
          "Fresh sputum",
          "NR"
        ],
        [
          "Boyles 2020",
          "Liquid culture - 2 specimens",
          "Cohort",
          "100% (207/207)",
          "Outpatient",
          "Adults",
          "RSA",
          "Yes",
          "Fresh sputum",
          "0% (0/207)"
        ],
        [
          "Calderwood 2023",
          "Liquid culture",
          "Cohort",
          "42% (376/896)",
          "Outpatient",
          "Adults",
          "RSA",
          "Yes",
          "Fresh sputum",
          "NR"
        ],
        [
          "Chakravorty 2017",
          "Solid (LJ) & liquid (MRS based on MGIT only)",
          "Cross-sectional",
          "NR",
          "NR",
          "Adults",
          "Georgia, India, Peru, Vietnam, RSA",
          "Yes",
          "Fresh and frozen sputum",
          "NR"
        ],
        [
          "Chien 2020",
          "Solid & liquid",
          "Cross-sectional",
          "0% (0/165)",
          "NR",
          "Adults",
          "Taiwan",
          "No",
          "BAL/bronchial wash (fresh)",
          "NR"
        ],
        [
          "Chilukutu 2022",
          "Solid & liquid",
          "Cross-sectional",
          "43% (319/737)",
          "Outpatient",
          "Adults",
          "Zambia",
          "Yes",
          "Fresh sputum",
          "NR"
        ],
        [
          "Dorman 2018",
          "Solid (LJ) & liquid",
          "Prospective cohort",
          "44% (633/1439)",
          "Inpatient & outpatient",
          "Adults",
          "Belarus, Brazil, China, Georgia, India, Kenya, RSA, Uganda",
          "Yes",
          "Fresh sputum",
          "<1% (2/1439)"
        ],
        [
          "Jaganath 2021",
          "Solid & liquid - 2 specimens",
          "Cross-sectional",
          "None for 10-14 yrs",
          "Inpatient & outpatient",
          "Adolescents",
          "Uganda",
          "Yes",
          "Fresh sputum",
          "NR"
        ],
        [
          "Li 2023",
          "Liquid- 3 samples combined",
          "Cohort",
          "0% (0/368)",
          "Outpatient",
          "Adults",
          "China",
          "Yes",
          "Fresh sputum",
          "0% (0/368)"
        ],
        [
          "Liu 2021",
          "Liquid",
          "Prospective cohort",
          "None",
          "Inpatient",
          "Adolescents",
          "China",
          "Yes",
          "Fresh & frozen sputum",
          "NR"
        ],
        [
          "MacLean 2023",
          "Liquid",
          "Cross-sectional",
          "1%",
          "Outpatient",
          "Adults",
          "Peru",
          "Yes",
          "Fresh sputum",
          "<1% (1/590)"
        ],
        [
          "Mishra 2020a",
          "Liquid",
          "Prospective cohort",
          "20% (48/239)",
          "Outpatient",
          "Adults",
          "RSA",
          "Yes",
          "Fresh sputum",
          "NR"
        ],
        [
          "Mishra 2020b",
          "Liquid",
          "Cross-sectional",
          "44% (152/346)",
          "Unknown",
          "Adults",
          "RSA",
          "Yes",
          "Fresh sputum",
          "NR"
        ],
        [
          "Moodley 2022",
          "Liquid",
          "Cross-sectional",
          "38% (298/789)",
          "Outpatient",
          "Adults",
          "RSA",
          "Yes",
          "Fresh sputum",
          "<1% (1/789)"
        ],
        [
          "Mukoka 2023",
          "Solid & liquid",
          "RCT",
          "100% (319/319)",
          "Outpatient",
          "Adults",
          "Malawi",
          "Yes",
          "Fresh sputum",
          "NR"
        ],
        [
          "Opota 2019",
          "Liquid",
          "Retrospective cohort",
          "NR",
          "Inpatient",
          "NR",
          "Switzerland",
          "No",
          "Fresh and frozen sputum",
          "NR"
        ],
        [
          "Park 2019",
          "Liquid",
          "Cohort",
          "7% (20/282)",
          "Inpatient & outpatient",
          "Adolescents and adults",
          "United Kingdom",
          "No",
          "BAL - fresh",
          "NR"
        ],
        [
          "Penn-Nicholson 2021",
          "Solid & liquid",
          "Cross-sectional",
          "3% (7/261)",
          "Outpatient",
          "Adults",
          "Peru",
          "Yes",
          "Fresh sputum",
          "None (0/378)"
        ],
        [
          "Pereira 2020",
          "Solid",
          "Cross-sectional",
          "2% (4/180)",
          "Outpatient",
          "Adults",
          "Brazil",
          "Yes",
          "Fresh sputum",
          "NR"
        ],
        [
          "Piersimoni 2019",
          "Liquid",
          "Cross-sectional",
          "NR",
          "Inpatient & outpatient",
          "Adults (2 of 254 < 15 years)",
          "Italy",
          "No",
          "Frozen sputum",
          "<1% (3/266)"
        ],
        [
          "Saavedra 2021",
          "Solid & liquid",
          "Cross-sectional",
          "NR",
          "Inpatient & outpatient",
          "Adults",
          "Mozambique",
          "Yes",
          "Fresh sputum",
          "NR"
        ],
        [
          "Sabi 2018",
          "Solid & liquid",
          "Prospective cohort",
          "31% (12/39)",
          "Outpatient",
          "Adolescents",
          "Tanzania",
          "Yes",
          "Frozen sputum",
          "10% (4/39)"
        ],
        [
          "Sabi 2022",
          "Solid & liquid",
          "Cross-sectional",
          "NR",
          "Outpatient",
          "Adolescents",
          "The Gambia, Tanzania",
          "Yes",
          "Fresh sputum",
          "NR"
        ],
        [
          "Sava 2023",
          "Solid",
          "Cross-sectional",
          "0% (0/730)",
          "Inpatient & outpatient",
          "Adolescents & adults",
          "Romania",
          "No",
          "Sputum & BAL/bronchial wash - all fresh",
          "NR"
        ],
        [
          "Sessolo 2023",
          "Liquid - 2 specimens",
          "Cross-sectional",
          "38% (68/177)",
          "Outpatient",
          "Adults",
          "Uganda",
          "Yes",
          "Fresh sputum",
          "None (0/177)"
        ],
        [
          "Ssengooba 2020",
          "Solid & liquid",
          "Cross-sectional",
          "NR",
          "Outpatient",
          "Adolescents",
          "Uganda",
          "Yes",
          "Frozen sputum",
          "NR"
        ],
        [
          "Ssengooba 2024",
          "Liquid",
          "Cross-sectional",
          "44% (109/249)",
          "Outpatient",
          "Adults",
          "Uganda",
          "Yes",
          "Fresh sputum",
          "None"
        ],
        [
          "Theron 2024",
          "Liquid",
          "Cross-sectional",
          "53% (203/384)",
          "Outpatient",
          "Adults",
          "RSA",
          "Yes",
          "Fresh sputum",
          "None – eligibility required positive or negative Xpert Ultra"
        ],
        [
          "Wang 2019",
          "Liquid",
          "Prospective cohort",
          "0% (0/292)",
          "Inpatient",
          "Adolescents & adults",
          "China",
          "Yes",
          "Fresh and frozen sputum",
          "<1% (5/292)"
        ],
        [
          "Wang 2022",
          "Liquid",
          "Cross-sectional",
          "0% (0/1079)",
          "Inpatient",
          "Adolescents & adults",
          "China",
          "Yes",
          "Fresh sputum",
          "<0.1% (4/1079)"
        ],
        [
          "Zar 2019",
          "Liquid - 2 specimens",
          "Prospective cohort",
          "0% (0/5)",
          "Inpatient",
          "Adolescents",
          "RSA",
          "Yes",
          "Frozen sputum",
          "NR"
        ],
        [
          "Zhang 2021",
          "Solid & liquid",
          "Cohort",
          "100% (99/99)",
          "Inpatient",
          "Adults",
          "China",
          "Yes",
          "BAL/bronchial wash (fresh",
          "NR"
        ]
      ],
      "notes": "LJ: Löwenstein-Jensen medium (solid culture); MGIT: Mycobacteria Growth Indicator Tube; NR: not reported; PLHIV: people living with HIV; RSA: Republic of South Africa. [Draft note: the Wang 2019 row is split across pages 18–19 in the source ('Prospective / cohort', 'Adolescents / & adults', 'Fresh and frozen / sputum'); joined here. Footnote 'a' is not printed under the table.]",
      "narratives": {
        "en": "Characteristics of the studies included in the review of Xpert Ultra. Each row is a study; columns give the reference standard, study design, proportion of people living with HIV, clinical setting, age group, country, whether the country has a high TB burden, specimen type, and the proportion of non-determinate Xpert Ultra results for detection of MTB.",
        "ar": "خصائص الدراسات المشمولة في استعراض اختبار Xpert Ultra. يمثل كل صف دراسة؛ وتبيّن الأعمدة المعيار المرجعي، وتصميم الدراسة، ونسبة المتعايشين مع فيروس العوز المناعي البشري، والبيئة السريرية، والفئة العمرية، والبلد، وما إذا كان البلد يتحمل عبئاً مرتفعاً من السل، ونوع العينة، ونسبة نتائج Xpert Ultra غير الحاسمة للكشف عن المتفطرة السلية.",
        "zh": "纳入Xpert Ultra综述的研究特征。每一行为一项研究；各列列出参考标准、研究设计、艾滋病毒感染者比例、临床环境、年龄组、国家、是否为结核病高负担国家、标本类型，以及Xpert Ultra检测结核分枝杆菌结果不确定的比例。",
        "es": "Características de los estudios incluidos en la revisión de Xpert Ultra. Cada fila es un estudio; las columnas indican el patrón de referencia, el diseño del estudio, la proporción de personas con el VIH, el entorno clínico, el grupo de edad, el país, si el país tiene una carga alta de tuberculosis, el tipo de muestra y la proporción de resultados no determinados de Xpert Ultra para la detección de MTB.",
        "fr": "Caractéristiques des études incluses dans l’examen de Xpert Ultra. Chaque ligne correspond à une étude ; les colonnes indiquent la norme de référence, le plan d’étude, la proportion de personnes vivant avec le VIH, le cadre clinique, la tranche d’âge, le pays, si le pays présente une forte charge de tuberculose, le type d’échantillon et la proportion de résultats Xpert Ultra non déterminés pour la détection de MTB.",
        "ru": "Характеристики исследований, включенных в обзор Xpert Ultra. Каждая строка — исследование; в столбцах указаны референсный стандарт, дизайн исследования, доля людей, живущих с ВИЧ, клинические условия, возрастная группа, страна, относится ли страна к странам с высоким бременем ТБ, тип образца и доля неопределенных результатов Xpert Ultra при выявлении МБТ."
      },
      "csv": "tables/table-1.csv"
    },
    {
      "label": "Table 2",
      "caption": "Table 2. Truenat assays: Characteristics of included studies",
      "pages": [
        20
      ],
      "columns": [
        {
          "titles": "Study"
        },
        {
          "titles": "Reference standard"
        },
        {
          "titles": "Study design"
        },
        {
          "titles": "Proportion of PLHIV"
        },
        {
          "titles": "Clinical setting"
        },
        {
          "titles": "Age group"
        },
        {
          "titles": "Country"
        },
        {
          "titles": "High TB burden"
        },
        {
          "titles": "Specimen type"
        },
        {
          "titles": "Truenat non-determinate % (number/total)"
        }
      ],
      "rows": [
        [
          "Jose 2024",
          "LJ & MGIT",
          "Cross- sectional (Retrospective)",
          "Not reported",
          "Outpatients & inpatients from tertiary care hospital",
          "Adolescents & adults",
          "India",
          "Yes",
          "Fresh",
          "Not reported"
        ],
        [
          "Gomathi 2020",
          "MGIT",
          "Cross-sectional",
          "Not reported",
          "Outpatients from all settings",
          "Adults",
          "India",
          "Yes",
          "Fresh and stored sputum",
          "Not reported"
        ],
        [
          "Ngangue 2022",
          "LJ & MGIT",
          "Prospective cohort",
          "37% (352)",
          "Outpatients from tertiary & secondary care",
          "Adults",
          "Cameroon",
          "Yes",
          "Fresh sputum",
          "136/1353 (10%) - before repeat testing; 166/1353 (1 after repeat testing"
        ],
        [
          "Theron 2024",
          "MGIT",
          "Cross-sectional",
          "54% (269/384)",
          "Outpatients",
          "Adults",
          "RSA",
          "Yes",
          "Frozen sputum",
          "86/501 (17.1%) before repeat testing; 34/501 (6.7%) after repeat testing"
        ],
        [
          "Penn Nicholson 2021",
          "LJ & MGIT",
          "Prospective Cohort",
          "2.7% (48/1762)",
          "Outpatients from all settings",
          "Adults",
          "India, Peru, Ethiopia, Papua New-Guinea",
          "Yes",
          "Fresh sputum",
          "89/1405 (6%) before repeat testing; 25/1405 (2%) after repeat testing"
        ]
      ],
      "notes": "LJ: Löwenstein-Jensen medium (solid culture); MGIT: Mycobacteria Growth Indicator Tube (Liquid culture). PLHIV: people living with HIV",
      "narratives": {
        "en": "Characteristics of the studies included in the review of Truenat assays. Each row is a study; columns give the reference standard, study design, proportion of people living with HIV, clinical setting, age group, country, high TB burden status, specimen type, and the proportion of non-determinate Truenat results.",
        "ar": "خصائص الدراسات المشمولة في استعراض مقايسات Truenat. يمثل كل صف دراسة؛ وتبيّن الأعمدة المعيار المرجعي، وتصميم الدراسة، ونسبة المتعايشين مع فيروس العوز المناعي البشري، والبيئة السريرية، والفئة العمرية، والبلد، ووضع العبء المرتفع للسل، ونوع العينة، ونسبة نتائج Truenat غير الحاسمة.",
        "zh": "纳入Truenat检测综述的研究特征。每一行为一项研究；各列列出参考标准、研究设计、艾滋病毒感染者比例、临床环境、年龄组、国家、是否为结核病高负担国家、标本类型以及Truenat结果不确定的比例。",
        "es": "Características de los estudios incluidos en la revisión de las pruebas Truenat. Cada fila es un estudio; las columnas indican el patrón de referencia, el diseño del estudio, la proporción de personas con el VIH, el entorno clínico, el grupo de edad, el país, la condición de país con carga alta de tuberculosis, el tipo de muestra y la proporción de resultados no determinados de Truenat.",
        "fr": "Caractéristiques des études incluses dans l’examen des tests Truenat. Chaque ligne correspond à une étude ; les colonnes indiquent la norme de référence, le plan d’étude, la proportion de personnes vivant avec le VIH, le cadre clinique, la tranche d’âge, le pays, le statut de pays à forte charge de tuberculose, le type d’échantillon et la proportion de résultats Truenat non déterminés.",
        "ru": "Характеристики исследований, включенных в обзор тестов Truenat. Каждая строка — исследование; в столбцах указаны референсный стандарт, дизайн исследования, доля людей, живущих с ВИЧ, клинические условия, возрастная группа, страна, статус страны с высоким бременем ТБ, тип образца и доля неопределенных результатов Truenat."
      },
      "csv": "tables/table-2.csv"
    },
    {
      "label": "Table 3",
      "caption": "Table 3. Diagnostic accuracy of LC-aNAATs for pulmonary TB and rifampicin resistance in adults and adolescents",
      "pages": [
        23,
        24
      ],
      "columns": [
        {
          "titles": "No."
        },
        {
          "titles": "Analysis"
        },
        {
          "titles": "Number of studies"
        },
        {
          "titles": "Number of participants (cases)"
        },
        {
          "titles": "Summary sensitivity (95% CI)"
        },
        {
          "titles": "Summary specificity (95% CI)"
        },
        {
          "titles": "PPV (95% CI)¹"
        },
        {
          "titles": "NPV (95% CI)¹"
        }
      ],
      "rows": [
        [
          "Detection of pulmonary TB",
          "",
          "",
          "",
          "",
          "",
          "",
          ""
        ],
        [
          "1",
          "LC-aNAATs, MRS, All",
          "34",
          "14840 (3636)",
          "90.4 (88.0 to 92.4)",
          "94.9 (93.0 to 96.3)",
          "66.3 (58.3 to 73.5)",
          "98.9 (98.6 to 99.1)"
        ],
        [
          "2",
          "LC-aNAATs, MRS, PLHIV",
          "12",
          "2016 (474)",
          "87.4 (83.8 to 90.3)",
          "95.2 (92.7 to 96.9)",
          "67.0 (55.9 to 76.4)",
          "98.6 (98.1 to 98.9)"
        ],
        [
          "3",
          "LC-aNAATs, MRS, HIV negative",
          "6",
          "1700 (497)",
          "92.2 (87.6 to 95.2)",
          "95.0 (92.3 to 96.9)",
          "67.4 (55.7 to 77.1)",
          "99.1 (98.5 to 99.5)"
        ],
        [
          "4",
          "LC-aNAATs, MRS, smear positive²",
          "18",
          "1501 (1426)",
          "98.6 (97.8 to 99.1)",
          "-",
          "-",
          "-"
        ],
        [
          "5",
          "LC-aNAATs, MRS, smear negative",
          "18",
          "7563 (965)",
          "79.8 (74.9 to 84.0",
          "94.3 (92.0 to 96.0)",
          "60.9 (51.0 to 69.9)",
          "97.7 (97.1 to 98.2)"
        ],
        [
          "6",
          "LC-aNAATs, MRS, history of TB",
          "10",
          "944 (175)",
          "86.3 (80.4 to 90.7)",
          "87.2 (80.8 to 91.8)",
          "42.9 (31.7 to 55.0)",
          "98.3 (97.4 to 98.9)"
        ],
        [
          "7",
          "LC-aNAATs, MRS, no history of TB",
          "10",
          "4233 (1345)",
          "92.8 (90.2 to 94.8)",
          "95.2 (92.3 to 97.0)",
          "68.1 (56.6 to 77.9)",
          "99.2 (98.8 to 99.4)"
        ],
        [
          "8",
          "LC-aNAATs, MRS, adults only",
          "22",
          "11508 (2681)",
          "90.0 (86.7 to 92.6)",
          "94.9 (93.1 to 96.2)",
          "66.1 (58.2 to 73.0)",
          "98.8 (98.4 to 99.2)"
        ],
        [
          "9",
          "Xpert Ultra, MRS, All",
          "32",
          "12529 (3130)",
          "90.7 (88.2 to 92.7)",
          "94.8 (92.8 to 96.3)",
          "66.1 (57.7 to 73.6)",
          "98.9 (98.6 to 99.2)"
        ],
        [
          "10",
          "Xpert Ultra, MRS, PLHIV",
          "11",
          "1664 (409)",
          "87.7 (82.0 to 91.7)",
          "95.3 (92.2 to 97.2)",
          "67.5 (53.9 to 78.6)",
          "98.6 (97.9 to 99.1)"
        ],
        [
          "11",
          "Xpert Ultra, MRS, HIV negative",
          "4",
          "928 (248)",
          "90.4 (85.4 to 93.8)",
          "96.2 (91.4 to 98.4)",
          "72.8 (52.6 to 86.7)",
          "98.9 (98.3 to 99.3)"
        ],
        [
          "12",
          "Xpert Ultra, MRS, smear positive²",
          "16",
          "1295 (1222)",
          "98.8 (98.0 to 99.3)",
          "-",
          "-",
          "-"
        ],
        [
          "13",
          "Xpert Ultra, MRS, smear negative",
          "16",
          "6460 (905)",
          "80.7 (75.4 to 85.0)",
          "94.0 (91.3 to 95.9)",
          "59.9 (49.2 to 69.6)",
          "97.8 (97.1 to 98.3)"
        ],
        [
          "14",
          "Xpert Ultra, MRS, history of TB",
          "9",
          "809 (152)",
          "84.8 (78.2 to 89.7)",
          "86.2 (78.9 to 91.3)",
          "40.7 (29.1 to 53.5)",
          "98.1 (97.0 to 98.8)"
        ],
        [
          "15",
          "Xpert Ultra, MRS, no history of TB",
          "9",
          "3423 (1134)",
          "91.5 (87.9 to 94.1)",
          "95.1 (91.6 to 97.1)",
          "67.4 (53.9 to 78.5)",
          "99.0 (98.6 to 99.3)"
        ],
        [
          "16",
          "Xpert Ultra, MRS, adults only",
          "21",
          "9585 (2277)",
          "90.7 (87.5 to 93.1)",
          "95.0 (93.1 to 96.4)",
          "66.9 (58.5 to 74.2)",
          "98.9 (98.5 to 99.2)"
        ],
        [
          "17",
          "Xpert Ultra, MRS, adolescents only³",
          "6",
          "160 (35)",
          "80.0 (63.6 to 90.2)",
          "93.6 (87.7 to 96.8)",
          "58.1 (36.5 to 75.6)",
          "97.7 (95.6 to 98.9)"
        ],
        [
          "18",
          "Xpert Ultra, CRS, All",
          "10",
          "2127 (809)",
          "69.9 (52.7 to 82.9",
          "98.8 (96.2 to 99.7)",
          "87.0 (60.5 to 96.4)",
          "96.7 (94.8 to 98.1)"
        ],
        [
          "19",
          "Truenat MTB Plus, MRS, All",
          "4",
          "3073 (750)",
          "90.6 (83.7 to 94.8)",
          "95.7 (94.7 to 96.5)",
          "70.1 (63.7 to 75.1)",
          "98.9 (98.1 to 99.4)"
        ],
        [
          "20",
          "Truenat MTB Plus, MRS, PLHIV",
          "2",
          "555 (135)",
          "-",
          "-",
          "-",
          "-"
        ],
        [
          "21",
          "Truenat MTB Plus, MRS, HIV negative",
          "2",
          "772 (249)",
          "-",
          "-",
          "-",
          "-"
        ],
        [
          "22",
          "Truenat MTB Plus, MRS, smear positive⁴",
          "3",
          "304 (298)",
          "-",
          "-",
          "-",
          "-"
        ],
        [
          "23",
          "Truenat MTB Plus, MRS, smear negative",
          "3",
          "1388 (117)",
          "76.1 (67.5 to 82.9)",
          "96.4 (94.4 to 97.7)",
          "70.2 (57.4 to 80.0)",
          "97.3 (96.3 to 98.1)"
        ],
        [
          "24",
          "Truenat MTB Plus, MRS, history of TB",
          "1",
          "135 (23)",
          "-",
          "-",
          "-",
          "-"
        ],
        [
          "25",
          "Truenat MTB Plus, MRS, no history of TB",
          "1",
          "810 (211)",
          "-",
          "-",
          "-",
          "-"
        ],
        [
          "Detection of rifampicin resistance",
          "",
          "",
          "",
          "",
          "",
          "",
          ""
        ],
        [
          "26",
          "LC-aNAATs, MRS, RR",
          "11",
          "2,540 (487)",
          "95.1 (83.1 to 98.7)",
          "98.1 (97.0 to 98.7)",
          "84.5 (75.6 to 89.7)",
          "99.5 (98.1 to 99.9)"
        ],
        [
          "27",
          "LC-aNAATs, MRS, RR, sensitivity analysis⁵",
          "10",
          "1,906 (428)",
          "95.5 (89.7 to 98.1)",
          "98.2 (96.9 to 99.0)",
          "85.4 (76.2 to 91.2)",
          "99.5 (98.8 to 99.8)"
        ],
        [
          "28",
          "LC-aNAATs, MRS, RR, smear positive",
          "5",
          "1692 (368)",
          "92.3 (75.8 to 97.9)",
          "97.8 (96.7 to 98.5)",
          "82.1 (71.6 to 88.0)",
          "99.1 (97.3 to 99.8)"
        ],
        [
          "29",
          "LC-aNAATs, MRS, RR, smear negative",
          "5",
          "550 (53)",
          "91.5 (38.4 to 99.5)",
          "99.6 (90.7 to 100.0)",
          "96.1 (31.5 to 99.8)",
          "99.1 (93.0 to 99.9)"
        ],
        [
          "30",
          "Xpert Ultra, MRS, RR",
          "10",
          "1644 (383)",
          "95.8 (93.2 to 97.4)",
          "98.3 (97.0 to 99.0)",
          "86.0 (77.8 to 91.4)",
          "99.5 (99.2 to 99.7)"
        ],
        [
          "31",
          "Xpert Ultra, MRS, RR, smear positive",
          "4",
          "1117 (315)",
          "95.5 (91.3 to 97.8)",
          "98.4 (94.8 to 99.5)",
          "87.1 (66.0 to 96.0)",
          "99.5 (99.0 to 99.8)"
        ],
        [
          "32",
          "Xpert Ultra, MRS, RR, smear negative",
          "4",
          "491 (47)",
          "94.2 (76.1 to 98.8)",
          "99.9 (72.7 to 100.0)",
          "99.1 (23.6 to 100.0)",
          "99.4 (96.5 to 99.9)"
        ],
        [
          "33",
          "Truenat MTB-RIF Dx, MRS, RR",
          "2",
          "966 (111)",
          "-",
          "-",
          "-",
          "-"
        ]
      ],
      "notes": "¹Predictive values were determined at a pre-test probability of 10% using the summary estimates of sensitivity and specificity and their 95% CIs. ²We performed meta-analysis of sensitivity using univariate fixed effect logistic regression because there was little variation in estimates of sensitivity between studies and in many studies, there were zero false positives and true negatives (i.e. zero non-cases) so a bivariate meta-analysis was not feasible. ³Same results for LC-aNAATs because no adolescent only data for Truenat MTB Plus. ⁴Specificity was not estimable for one study, 0% for one study and 75% for the third study. Meta-analysis was not performed. ⁵Excluding Gomathi 2020 due to very low sensitivity. Abbreviations: CI: confidence interval; CRS: composite reference standard; LC-aNAATs: low complexity automated nucleic acid tests; MRS: microbiological reference standard (culture); RR: rifampicin resistance. For analysis with two studies without summary estimates in the table, meta-analysis was not performed due to substantial heterogeneity. See Appendix 3 for the forest plots showing the 2x2 tables Two studies (Penn-Nicholson 2021 and Theron 2024) compared the accuracy of Xpert Ultra and Truenat MTB Plus. Note that for the class level meta-analyses of LC-aNAATs presented in the table, to avoid double counting, we selected the data for Truenat MTB Plus for inclusion in the meta-analyses because Truenat assays were the index tests evaluated in the studies. [Footnotes continue on page 25.]",
      "narratives": {
        "en": "Summary results of meta-analyses of the diagnostic accuracy of low-complexity automated NAATs (LC-aNAATs), Xpert Ultra and Truenat assays for detecting pulmonary TB and rifampicin resistance in adults and adolescents. Each numbered row is an analysis (test, reference standard and subgroup), with the number of studies and participants (cases), summary sensitivity and specificity, and PPV and NPV with 95% CIs.",
        "ar": "النتائج الموجزة للتحليلات التلوية للدقة التشخيصية للاختبارات الآلية منخفضة التعقيد لتضخيم الحمض النووي (LC-aNAATs) وXpert Ultra ومقايسات Truenat في الكشف عن السل الرئوي ومقاومة الريفامبيسين لدى البالغين والمراهقين. يمثل كل صف مرقّم تحليلاً (الاختبار والمعيار المرجعي والفئة الفرعية)، مع عدد الدراسات والمشاركين (الحالات)، والحساسية والنوعية الموجزتين، والقيمتين التنبؤيتين الإيجابية والسلبية مع فترات الثقة 95%.",
        "zh": "低复杂度自动化核酸扩增检测（LC-aNAATs）、Xpert Ultra和Truenat检测在成人和青少年中检测肺结核和利福平耐药的诊断准确性荟萃分析汇总结果。每个编号行为一项分析（检测、参考标准和亚组），列出研究数和参与者数（病例数）、汇总敏感性和特异性，以及阳性和阴性预测值及其95%置信区间。",
        "es": "Resultados resumidos de los metanálisis de la exactitud diagnóstica de las NAAT automatizadas de baja complejidad (LC-aNAAT), Xpert Ultra y las pruebas Truenat para detectar la tuberculosis pulmonar y la resistencia a la rifampicina en adultos y adolescentes. Cada fila numerada es un análisis (prueba, patrón de referencia y subgrupo), con el número de estudios y participantes (casos), la sensibilidad y especificidad resumidas, y el VPP y el VPN con IC del 95%.",
        "fr": "Résultats résumés des méta-analyses de l’exactitude diagnostique des TAAN automatisés de faible complexité (LC-aNAAT), de Xpert Ultra et des tests Truenat pour la détection de la tuberculose pulmonaire et de la résistance à la rifampicine chez l’adulte et l’adolescent. Chaque ligne numérotée correspond à une analyse (test, norme de référence et sous-groupe), avec le nombre d’études et de participants (cas), la sensibilité et la spécificité résumées, ainsi que la VPP et la VPN avec IC à 95 %.",
        "ru": "Сводные результаты метаанализов диагностической точности автоматизированных МАНК низкой сложности (LC-aNAAT), Xpert Ultra и тестов Truenat для выявления туберкулеза легких и устойчивости к рифампицину у взрослых и подростков. Каждая пронумерованная строка — анализ (тест, референсный стандарт и подгруппа) с числом исследований и участников (случаев), сводной чувствительностью и специфичностью, а также ПЦПР и ПЦОР с 95% ДИ."
      },
      "csv": "tables/table-3.csv"
    },
    {
      "label": "Table 4",
      "caption": "Table 4. CRS Definitions",
      "pages": [
        28
      ],
      "columns": [
        {
          "titles": "Study"
        },
        {
          "titles": "CRS Definition"
        }
      ],
      "rows": [
        [
          "Aguilera-Alonso 2022",
          "Adolescents; CRS definition: (1) Confirmed TB: ≥1 respiratory specimen positive for MTB (culture or PCR); (2) Unconfirmed TB: without bacteriological evidence who met ≥1 (if immunological evidence of MTB) or 2 (immunological evidence absent) criteria: symptoms/signs suggestive of TB, CXR consistent with TB, close TB exposure, response to TB treatment. Immunological evidence of MTB infection defined as positive TST or IGRA."
        ],
        [
          "Berhanu 2018",
          "Adult patients with clinical diagnosis of TB by X ray or other method."
        ],
        [
          "Chien 2020",
          "Adolescents with either bacteriologically confirmed TB (culture-confirmed TB) or diagnosed with active TB by a clinician who decided to give the patient a full course of TB treatment."
        ],
        [
          "Jaganath 2021",
          "Adolescents with confirmed intrathoracic TB (positive culture) or unconfirmed TB (negative cultures with signs and symptoms of TB and clinical evidence of TB including response to anti-TB treatment)."
        ],
        [
          "Opota 2019",
          "Primarily adults although at least one participant was 15 years of age. CRS based on “clinical and radiological findings.”"
        ],
        [
          "Park 2019",
          "Adolescents and adult participants had 3 month follow up with clinical data including any imaging. The final diagnosis of each patient was determined by consensus among 3 respiratory consultants masked to the Xpert Ultra results. CRS included category 1: culture confirmed TB directly from the BAL or EBUS sample or category 2: highly probable TB with clinical and radiological features suggestive of TB, response to TB treatment and cytological evidence of granulomatous disease if available."
        ],
        [
          "Sabi 2018",
          "Adolescent participants with CRS based on sputum culture confirmed TB, highly probable TB (CXR consistent with TB, histology/cytology typical for TB, or fluorescent/acid-fast bacilli on microscopy), or probable TB (clinically suspected TB without objective findings as above)."
        ],
        [
          "Wang 2022",
          "Primarily adults although adolescents included. CRS defined as: Definite pulmonary TB- microbiologically confirmed TB, with positive smear and/or culture outcome excluding nontuberculous mycobacteria; Probable TB, defined as smear and culture negative but patient was clinically diagnosed with TB based on clinical findings, radiologic imaging, other molecular tests, or response to empirical anti-TB treatment."
        ],
        [
          "Zar 2019",
          "Adolescents; CRS: microbiologic evidence or \"unconfirmed TB\" based on a clinical diagnosis"
        ],
        [
          "Zhang 2021",
          "Adults who met the CRS definition of TB were: 1) Confirmed PTB: BAL samples positive for MTB cultures; 2) Suspected PTB: BAL samples culture negative, but clinical symptoms and radiological findings suggestive of PTB, and response to anti-TB therapy."
        ]
      ],
      "narratives": {
        "en": "Definitions of the composite reference standard (CRS) used in each included study. Each row names a study and describes the population and the criteria it used to classify participants as having TB under the CRS.",
        "ar": "تعاريف المعيار المرجعي المركّب المستخدمة في كل دراسة مشمولة. يذكر كل صف دراسةً ويصف الفئة السكانية والمعايير التي استخدمتها لتصنيف المشاركين على أنهم مصابون بالسل وفق المعيار المرجعي المركّب.",
        "zh": "各纳入研究所采用的复合参考标准（CRS）定义。每一行列出一项研究，并描述其人群以及按复合参考标准将参与者判定为结核病的标准。",
        "es": "Definiciones del patrón de referencia compuesto (CRS) utilizadas en cada estudio incluido. Cada fila nombra un estudio y describe la población y los criterios que utilizó para clasificar a los participantes como casos de tuberculosis según el CRS.",
        "fr": "Définitions de la norme de référence composite (CRS) utilisées dans chaque étude incluse. Chaque ligne nomme une étude et décrit la population et les critères utilisés pour classer les participants comme atteints de tuberculose selon la CRS.",
        "ru": "Определения составного референсного стандарта (CRS), использованные в каждом включенном исследовании. В каждой строке указано исследование и описаны популяция и критерии, по которым участники классифицировались как больные ТБ согласно CRS."
      },
      "csv": "tables/table-4.csv"
    },
    {
      "label": "Table 5",
      "caption": "Table 5. Starting volumes and concentration for pleural fluid and diagnostic accuracy",
      "pages": [
        121
      ],
      "columns": [
        {
          "titles": "Study, year"
        },
        {
          "titles": "Pleural fluid volume"
        },
        {
          "titles": "Concentration"
        },
        {
          "titles": "Sensitivity (95% CI)"
        },
        {
          "titles": "Specificity (95% CI)"
        }
      ],
      "rows": [
        [
          "Meldau 2019*",
          "1 mL",
          "Yes",
          "Uses CRS*",
          ""
        ],
        [
          "Minnies 2023",
          "20 mL",
          "Yes",
          "100 (74 – 100)",
          "87 (76 – 94)"
        ],
        [
          "Peñata 2021",
          "> 2 mL",
          "Yes",
          "100 (29 – 100)",
          "93 (86 – 98)"
        ],
        [
          "Wang 2019",
          "> 3 mL",
          "No",
          "81 (69 – 90)",
          "65 (50 – 78)"
        ],
        [
          "Wang 2020",
          "1 mL",
          "No",
          "84 (71 – 92)",
          "99 (94 – 100)"
        ],
        [
          "Wu 2019",
          "If > 5 mL",
          "Yes",
          "74 (52 – 90)",
          "71 (61 – 79)"
        ]
      ],
      "notes": "Sensitivity and specificity are presented as percentages. *Uses CRS",
      "narratives": {
        "en": "Pleural fluid starting volume, use of a concentration step, and sensitivity and specificity (95% CI) reported by each study of LC-aNAATs on pleural fluid. One study used a composite reference standard and has no estimates in the table.",
        "ar": "حجم البدء للسائل الجنبي، واستخدام خطوة التركيز، والحساسية والنوعية (بفترة ثقة 95%) كما أبلغت عنها كل دراسة للاختبارات الآلية منخفضة التعقيد لتضخيم الحمض النووي على السائل الجنبي. استخدمت دراسة واحدة معياراً مرجعياً مركّباً ولا ترد لها تقديرات في الجدول.",
        "zh": "各项胸腔积液LC-aNAAT研究报告的胸腔积液起始体积、是否进行浓缩步骤，以及敏感性和特异性（95%置信区间）。其中一项研究使用复合参考标准，表中未列出其估计值。",
        "es": "Volumen inicial de líquido pleural, uso de un paso de concentración y sensibilidad y especificidad (IC del 95%) notificadas por cada estudio de LC-aNAAT en líquido pleural. Un estudio utilizó un patrón de referencia compuesto y no tiene estimaciones en la tabla.",
        "fr": "Volume initial de liquide pleural, recours à une étape de concentration, et sensibilité et spécificité (IC à 95 %) rapportées par chaque étude des LC-aNAAT sur liquide pleural. Une étude a utilisé une norme de référence composite et ne présente pas d’estimations dans le tableau.",
        "ru": "Исходный объем плевральной жидкости, использование этапа концентрирования и чувствительность и специфичность (95% ДИ), представленные в каждом исследовании LC-aNAAT на плевральной жидкости. В одном исследовании использовался составной референсный стандарт, и оценки для него в таблице не приведены."
      },
      "csv": "tables/table-5.csv"
    },
    {
      "label": "Table 6",
      "caption": "Table 6. Diagnostic accuracy of LC-aNAATs for detection of rifampicin resistance in adults and adolescents",
      "pages": [
        122
      ],
      "columns": [
        {
          "titles": "Number of studies"
        },
        {
          "titles": "Number of participants (cases)"
        },
        {
          "titles": "Sensitivity (95% CI)"
        },
        {
          "titles": "Specificity (95% CI)"
        },
        {
          "titles": "Positive predictive value (95% CI)"
        },
        {
          "titles": "Negative predictive value (95% CI)"
        }
      ],
      "rows": [
        [
          "13",
          "446 (54)",
          "100.0 (93.4 to 100.0)",
          "99.4 (92.1 to 100.0)",
          "94.6 (56.7 to 100.0)",
          "100.0 (99.2 to 100.0)"
        ]
      ],
      "notes": "Sensitivity, specificity, and predictive values are presented as percentages.",
      "narratives": {
        "en": "Pooled diagnostic accuracy of LC-aNAATs for detecting rifampicin resistance in extrapulmonary specimens from adults and adolescents: number of studies and participants (cases), sensitivity, specificity and positive and negative predictive values with 95% CIs.",
        "ar": "الدقة التشخيصية المجمّعة للاختبارات الآلية منخفضة التعقيد لتضخيم الحمض النووي في الكشف عن مقاومة الريفامبيسين في عينات خارج الرئة لدى البالغين والمراهقين: عدد الدراسات والمشاركين (الحالات)، والحساسية، والنوعية، والقيمتان التنبؤيتان الإيجابية والسلبية مع فترات الثقة 95%.",
        "zh": "LC-aNAAT在成人和青少年肺外标本中检测利福平耐药的合并诊断准确性：研究数和参与者数（病例数）、敏感性、特异性以及阳性和阴性预测值及其95%置信区间。",
        "es": "Exactitud diagnóstica agrupada de las LC-aNAAT para detectar la resistencia a la rifampicina en muestras extrapulmonares de adultos y adolescentes: número de estudios y participantes (casos), sensibilidad, especificidad y valores predictivos positivo y negativo con IC del 95%.",
        "fr": "Exactitude diagnostique groupée des LC-aNAAT pour la détection de la résistance à la rifampicine dans des échantillons extrapulmonaires chez l’adulte et l’adolescent : nombre d’études et de participants (cas), sensibilité, spécificité et valeurs prédictives positive et négative avec IC à 95 %.",
        "ru": "Объединенная диагностическая точность LC-aNAAT для выявления устойчивости к рифампицину во внелегочных образцах у взрослых и подростков: число исследований и участников (случаев), чувствительность, специфичность, а также положительная и отрицательная прогностическая ценность с 95% ДИ."
      },
      "csv": "tables/table-6.csv"
    },
    {
      "label": "Table 7",
      "caption": "Table 7: Subgroup comparisons of interest for assessing heterogeneity",
      "pages": [
        272
      ],
      "columns": [
        {
          "titles": "Variable"
        },
        {
          "titles": "Definition"
        },
        {
          "titles": "Population"
        },
        {
          "titles": "Comparison"
        }
      ],
      "rows": [
        [
          "Age",
          "Age groups (0-4 years/5-9 years)",
          "Children with and without HIV",
          "Children with and without HIV 0-4 years vs 5-9 years"
        ],
        [
          "Sample Type",
          "Nasopharyngeal aspirate collection",
          "Children with and without HIV",
          "Nasopharyngeal aspirate versus other respiratory specimens"
        ],
        [
          "Clinical setting",
          "Inpatient or outpatient",
          "Children with and without HIV",
          "Inpatient versus outpatient"
        ],
        [
          "CD4 Cell Count",
          "Low as <200 cells/mm3",
          "Children with HIV ≥5 years old",
          "Low CD4 Cell count versus higher"
        ],
        [
          "CD4 Percentage",
          "Low as <25%",
          "Children with HIV <5 years old",
          "Low CD4 Cell count versus higher"
        ],
        [
          "Advanced HIV disease",
          "Children ≥5 years old: CD4 cell count <200 cells/mm3 or WHO clinical stage 3 or 4 at presentation of care All children <5 years old",
          "Children with HIV",
          "Advanced HIV versus non-advanced HIV"
        ],
        [
          "Serious Illness",
          "A seriously ill child is defined as having any of the following danger signs: lethargy or unconsciousness; convulsions; unable to drink or breastfeed; and repeated vomiting. Other clinical conditions such as body temperature ≥39°C and age-defined tachycardia and/or tachypnoea are considered based on clinical judgement",
          "Children with HIV",
          "Serious versus non-serious illness"
        ]
      ],
      "narratives": {
        "en": "Subgroup comparisons planned to investigate heterogeneity in the review of tests for TB in children. Each row is a variable (such as age, sample type, clinical setting, CD4 count or percentage, advanced HIV disease and serious illness) with its definition, the population it applies to and the comparison made.",
        "ar": "مقارنات الفئات الفرعية المخطط لها لاستقصاء عدم التجانس في استعراض اختبارات السل لدى الأطفال. يمثل كل صف متغيراً (مثل العمر ونوع العينة والبيئة السريرية وعدد خلايا CD4 أو نسبتها المئوية ومرض فيروس العوز المناعي البشري المتقدم والمرض الخطير) مع تعريفه والفئة السكانية التي ينطبق عليها والمقارنة المُجراة.",
        "zh": "为探究儿童结核病检测综述中的异质性而计划的亚组比较。每一行为一个变量（如年龄、样本类型、临床环境、CD4计数或百分比、晚期艾滋病毒疾病和重症），列出其定义、适用人群及所作比较。",
        "es": "Comparaciones de subgrupos previstas para investigar la heterogeneidad en la revisión de pruebas de tuberculosis en niños. Cada fila es una variable (como la edad, el tipo de muestra, el entorno clínico, el recuento o porcentaje de CD4, la enfermedad avanzada por el VIH y la enfermedad grave) con su definición, la población a la que se aplica y la comparación realizada.",
        "fr": "Comparaisons en sous-groupes prévues pour étudier l’hétérogénéité dans l’examen des tests de la tuberculose chez l’enfant. Chaque ligne correspond à une variable (âge, type d’échantillon, cadre clinique, numération ou pourcentage de CD4, maladie à VIH à un stade avancé, maladie grave) avec sa définition, la population concernée et la comparaison effectuée.",
        "ru": "Сравнения подгрупп, запланированные для изучения неоднородности в обзоре тестов на ТБ у детей. Каждая строка — переменная (возраст, тип образца, клинические условия, количество или процент CD4, продвинутая стадия ВИЧ-инфекции и тяжелое заболевание) с ее определением, популяцией, к которой она относится, и проводимым сравнением."
      },
      "csv": "tables/table-7.csv"
    },
    {
      "label": "Table 8",
      "caption": "Table 8. Eligible comparisons",
      "pages": [
        334
      ],
      "columns": [
        {
          "titles": "Comparison #"
        },
        {
          "titles": "Index test A"
        },
        {
          "titles": "Index test B (comparator)"
        },
        {
          "titles": "If no IPD available: data on the following tests should be reported"
        },
        {
          "titles": "If IPD available*: data on following tests should be available"
        }
      ],
      "rows": [
        [
          "Population: adults and adolescents with HIV",
          "",
          "",
          "",
          ""
        ],
        [
          "1",
          "Respiratory LC-aNAAT + Urinary LF-LAM",
          "Respiratory LC-aNAAT",
          "Respiratory LC-aNAAT + Urinary LF-LAM; Respiratory LC-aNAAT",
          "Respiratory LC-aNAAT; Urinary LF-LAM; Reference standard test"
        ],
        [
          "2",
          "Respiratory LC-aNAAT + Urinary LF-LAM",
          "Urinary LF-LAM",
          "Respiratory LC-aNAAT + Urinary LF-LAM; Urinary LF-LAM",
          "Respiratory LC-aNAAT; Urinary LF-LAM; Reference standard test"
        ]
      ],
      "notes": "Abbreviations: IPD: individual participant data; LC-aNAAT: Low-complexity automated nucleic acid amplification testing; LF-LAM: lateral flow lipoarabinomannan testing. *only applicable to fully paired designs. [Draft note: in the last two columns each test is printed on its own line; lines are joined here with '; '.]",
      "narratives": {
        "en": "Comparisons eligible for the review of parallel testing in adults and adolescents with HIV. For each comparison, the table gives index test A (respiratory LC-aNAAT plus urinary LF-LAM), the comparator index test B, and the test data required when individual participant data are or are not available.",
        "ar": "المقارنات المؤهلة لاستعراض الاختبار المتوازي لدى البالغين والمراهقين المتعايشين مع فيروس العوز المناعي البشري. يبيّن الجدول لكل مقارنة الاختبار الدليلي A (الاختبار الآلي منخفض التعقيد لتضخيم الحمض النووي على عينة تنفسية مع اختبار LF-LAM في البول)، والاختبار الدليلي المقارن B، وبيانات الاختبارات المطلوبة عند توافر بيانات المشاركين الفردية أو عدم توافرها.",
        "zh": "艾滋病毒感染成人和青少年平行检测综述的合格比较。对每项比较，表中列出指标检测A（呼吸道LC-aNAAT加尿液LF-LAM）、对照指标检测B，以及在有或无个体参与者数据时需报告的检测数据。",
        "es": "Comparaciones admisibles para la revisión de las pruebas en paralelo en adultos y adolescentes con el VIH. Para cada comparación, la tabla indica la prueba índice A (LC-aNAAT respiratoria más LF-LAM en orina), la prueba índice comparadora B y los datos de pruebas requeridos cuando se dispone o no de datos de participantes individuales.",
        "fr": "Comparaisons éligibles pour l’examen des tests en parallèle chez l’adulte et l’adolescent vivant avec le VIH. Pour chaque comparaison, le tableau indique le test index A (LC-aNAAT respiratoire plus LF-LAM urinaire), le test index comparateur B et les données de test requises selon que des données individuelles des participants sont disponibles ou non.",
        "ru": "Сравнения, подходящие для обзора параллельного тестирования у взрослых и подростков с ВИЧ. Для каждого сравнения в таблице указаны индексный тест A (респираторный LC-aNAAT плюс LF-LAM мочи), индексный тест сравнения B и данные тестов, требуемые при наличии или отсутствии индивидуальных данных участников."
      },
      "csv": "tables/table-8.csv"
    },
    {
      "label": "Table 9",
      "caption": "Table 9. Summary accuracy by presence of symptoms. Pooled test accuracy along with summary difference between the parallel use (LC-aNAAT and LF-LAM) versus LC-aNAAT alone for detection of tuberculosis using a microbiological reference standard.",
      "pages": [
        354
      ],
      "columns": [
        {
          "titles": "Participants"
        },
        {
          "titles": "Studies (participants)"
        },
        {
          "titles": "Pooled sensitivity (95% CrI)"
        },
        {
          "titles": "Pooled specificity (95% CrI)"
        }
      ],
      "rows": [
        [
          "Symptomatic",
          "",
          "",
          ""
        ],
        [
          "LF-LAM",
          "23 (8644)",
          "40.0% (32.5 to 48.1)",
          "91.9% (87.9 to 94.7)"
        ],
        [
          "LC-aNAAT",
          "23 (8644)",
          "68.1% (59.7 to 75.9)",
          "96.7% (95.6 to 97.7)"
        ],
        [
          "Parallel",
          "23 (8644)",
          "78.5% (73.8 to 82.8)",
          "89.3% (85.1 to 92.6)"
        ],
        [
          "Summary difference between parallel and LC-aNAAT",
          "",
          "7.0% (3.8 to 11.7)",
          "-6.8% (-10.1 to -4.4)"
        ],
        [
          "Asymptomatic",
          "",
          "",
          ""
        ],
        [
          "LF-LAM",
          "8 (1370)",
          "11.5% (4.1 to 25.2)",
          "97.3% (94.1 to 99.0)"
        ],
        [
          "LC-aNAAT",
          "8 (1370)",
          "47.4% (27.8 to 67.8)",
          "98.9% (97.9 to 99.5)"
        ],
        [
          "Parallel",
          "8 (1370)",
          "53.5% (34.8 to 71.7)",
          "96.1% (92.7 to 98.2)"
        ],
        [
          "Summary difference between parallel and LC-aNAAT",
          "",
          "4.9% (1.0 to 14.9)",
          "-2.5% (-5.4 to -0.9)"
        ]
      ],
      "narratives": {
        "en": "Pooled accuracy of LF-LAM, LC-aNAAT and parallel testing (LC-aNAAT plus LF-LAM) for detecting tuberculosis against a microbiological reference standard, in people with HIV with and without symptoms. Rows give each test with the number of studies (participants) and pooled sensitivity and specificity (95% CrI), followed by the summary difference between parallel testing and LC-aNAAT.",
        "ar": "الدقة المجمّعة لاختبار LF-LAM والاختبار الآلي منخفض التعقيد لتضخيم الحمض النووي (LC-aNAAT) والاختبار المتوازي (LC-aNAAT مع LF-LAM) في الكشف عن السل مقارنةً بمعيار مرجعي ميكروبيولوجي، لدى المتعايشين مع فيروس العوز المناعي البشري المصحوبين بأعراض وغير المصحوبين بأعراض. تبيّن الصفوف كل اختبار مع عدد الدراسات (المشاركين) والحساسية والنوعية المجمّعتين (بفترة موثوقية 95%)، إضافةً إلى الفرق الموجز بين الاختبار المتوازي وLC-aNAAT.",
        "zh": "在有症状和无症状的艾滋病毒感染者中，LF-LAM、LC-aNAAT及平行检测（LC-aNAAT加LF-LAM）以微生物学参考标准检测结核病的合并准确性。各行列出每项检测的研究数（参与者数）、合并敏感性和特异性（95%可信区间），以及平行检测与LC-aNAAT之间的汇总差异。",
        "es": "Exactitud agrupada de LF-LAM, LC-aNAAT y las pruebas en paralelo (LC-aNAAT más LF-LAM) para detectar la tuberculosis frente a un patrón de referencia microbiológico, en personas con el VIH con y sin síntomas. Las filas muestran cada prueba con el número de estudios (participantes), la sensibilidad y especificidad agrupadas (ICr del 95%) y la diferencia resumida entre las pruebas en paralelo y LC-aNAAT.",
        "fr": "Exactitude groupée de LF-LAM, des LC-aNAAT et des tests en parallèle (LC-aNAAT plus LF-LAM) pour la détection de la tuberculose par rapport à une norme de référence microbiologique, chez les personnes vivant avec le VIH présentant ou non des symptômes. Les lignes présentent chaque test avec le nombre d’études (participants), la sensibilité et la spécificité groupées (ICr à 95 %) et la différence résumée entre les tests en parallèle et LC-aNAAT.",
        "ru": "Объединенная точность LF-LAM, LC-aNAAT и параллельного тестирования (LC-aNAAT плюс LF-LAM) для выявления туберкулеза по сравнению с микробиологическим референсным стандартом, у людей с ВИЧ с симптомами и без симптомов. В строках указаны каждый тест с числом исследований (участников), объединенными чувствительностью и специфичностью (95% интервал достоверности) и сводная разница между параллельным тестированием и LC-aNAAT."
      },
      "csv": "tables/table-9.csv"
    },
    {
      "label": "Table 10",
      "caption": "Table 10: Summary accuracy by CD4. Pooled test accuracy along with difference between the parallel use (LC-aNAAT and LF-LAM) versus LC-aNAAT alone for detection of tuberculosis using a microbiological reference standard.",
      "pages": [
        355
      ],
      "columns": [
        {
          "titles": "Participants"
        },
        {
          "titles": "Studies (participants)"
        },
        {
          "titles": "Pooled sensitivity (95% CrI)"
        },
        {
          "titles": "Pooled specificity (95% CrI)"
        }
      ],
      "rows": [
        [
          "CD4 ≤ 200",
          "",
          "",
          ""
        ],
        [
          "LF-LAM",
          "13 (2798)",
          "49.7% (39.5 to 59.4)",
          "88.1% (81.5 to 92.7)"
        ],
        [
          "LC-aNAAT",
          "13 (2798)",
          "65.8% (54.7 to 76.0)",
          "95.5% (93.2 to 97.2)"
        ],
        [
          "Parallel",
          "13 (2798)",
          "78.7% (72.9 to 83.8)",
          "85.6% (78.5 to 90.8)"
        ],
        [
          "Summary difference between parallel and LC-aNAAT",
          "",
          "9.2% (4.0 to 17.4)",
          "-9.4% (-14.7 to -5.6)"
        ],
        [
          "CD4 > 200",
          "",
          "",
          ""
        ],
        [
          "LF-LAM",
          "2 (148)",
          "19.7% (4.1 to 53.7)",
          "89.2% (72.7 to 96.5)"
        ],
        [
          "LC-aNAAT",
          "2 (148)",
          "52.6% (20.2 to 83.1)",
          "97.1% (88.4 to 99.3)"
        ],
        [
          "Parallel",
          "2 (148)",
          "61.5% (25.5 to 88.4)",
          "88.6% (71.4 to 96.4)"
        ],
        [
          "Summary difference between parallel and LC-aNAAT",
          "",
          "9.1% (0.8 to 38.0)",
          "-9.3% (-24.2 to -2.4)"
        ]
      ],
      "narratives": {
        "en": "Pooled accuracy of LF-LAM, LC-aNAAT and parallel testing (LC-aNAAT plus LF-LAM) for detecting tuberculosis against a microbiological reference standard, in people with HIV with CD4 counts of 200 or below and above 200. Rows give each test with the number of studies (participants) and pooled sensitivity and specificity (95% CrI), followed by the summary difference between parallel testing and LC-aNAAT.",
        "ar": "الدقة المجمّعة لاختبار LF-LAM والاختبار الآلي منخفض التعقيد لتضخيم الحمض النووي (LC-aNAAT) والاختبار المتوازي (LC-aNAAT مع LF-LAM) في الكشف عن السل مقارنةً بمعيار مرجعي ميكروبيولوجي، لدى المتعايشين مع فيروس العوز المناعي البشري الذين يبلغ عدد خلايا CD4 لديهم 200 أو أقل وأكثر من 200. تبيّن الصفوف كل اختبار مع عدد الدراسات (المشاركين) والحساسية والنوعية المجمّعتين (بفترة موثوقية 95%)، إضافةً إلى الفرق الموجز بين الاختبار المتوازي وLC-aNAAT.",
        "zh": "在CD4计数≤200和>200的艾滋病毒感染者中，LF-LAM、LC-aNAAT及平行检测（LC-aNAAT加LF-LAM）以微生物学参考标准检测结核病的合并准确性。各行列出每项检测的研究数（参与者数）、合并敏感性和特异性（95%可信区间），以及平行检测与LC-aNAAT之间的汇总差异。",
        "es": "Exactitud agrupada de LF-LAM, LC-aNAAT y las pruebas en paralelo (LC-aNAAT más LF-LAM) para detectar la tuberculosis frente a un patrón de referencia microbiológico, en personas con el VIH con recuentos de CD4 de 200 o menos y superiores a 200. Las filas muestran cada prueba con el número de estudios (participantes), la sensibilidad y especificidad agrupadas (ICr del 95%) y la diferencia resumida entre las pruebas en paralelo y LC-aNAAT.",
        "fr": "Exactitude groupée de LF-LAM, des LC-aNAAT et des tests en parallèle (LC-aNAAT plus LF-LAM) pour la détection de la tuberculose par rapport à une norme de référence microbiologique, chez les personnes vivant avec le VIH dont la numération des CD4 est inférieure ou égale à 200 et supérieure à 200. Les lignes présentent chaque test avec le nombre d’études (participants), la sensibilité et la spécificité groupées (ICr à 95 %) et la différence résumée entre les tests en parallèle et LC-aNAAT.",
        "ru": "Объединенная точность LF-LAM, LC-aNAAT и параллельного тестирования (LC-aNAAT плюс LF-LAM) для выявления туберкулеза по сравнению с микробиологическим референсным стандартом, у людей с ВИЧ с количеством CD4 200 и менее и более 200. В строках указаны каждый тест с числом исследований (участников), объединенными чувствительностью и специфичностью (95% интервал достоверности) и сводная разница между параллельным тестированием и LC-aNAAT."
      },
      "csv": "tables/table-10.csv"
    },
    {
      "label": "Table 11",
      "caption": "Table 11: Summary accuracy by clinical setting. Pooled test accuracy along with difference between the parallel use (LC-aNAAT and LF-LAM) versus LC-aNAAT alone for detection of tuberculosis using a microbiological reference standard.",
      "pages": [
        355
      ],
      "columns": [
        {
          "titles": "Participants"
        },
        {
          "titles": "Studies (participants)"
        },
        {
          "titles": "Pooled sensitivity (95% CrI)"
        },
        {
          "titles": "Pooled specificity (95% CrI)"
        }
      ],
      "rows": [
        [
          "Inpatients",
          "",
          "",
          ""
        ],
        [
          "LF-LAM",
          "10 (3951)",
          "49.7% (40.2 to 59.9)",
          "89.0% (83.4 to 92.9)"
        ],
        [
          "LC-aNAAT",
          "10 (3951)",
          "63.5% (47.0 to 79.1)",
          "96.9% (95.3 to 98.2)"
        ],
        [
          "Parallel",
          "10 (3951)",
          "77.7% (68.5 to 85.9)",
          "87.2% (81.3 to 91.6)"
        ],
        [
          "Summary difference between parallel and LC-aNAAT",
          "",
          "11.7% (4.6 to 23.0)",
          "-9.5% (-14.5 to -5.9)"
        ],
        [
          "Outpatients",
          "",
          "",
          ""
        ],
        [
          "LF-LAM",
          "11 (5892)",
          "28.8% (21.1 to 38.3)",
          "94.3% (89.5 to 96.9)"
        ],
        [
          "LC-aNAAT",
          "11 (5892)",
          "71.7% (65.0 to 77.9)",
          "97.1 (95.4 to 98.1)"
        ],
        [
          "Parallel",
          "11 (5892)",
          "76.0% (69.8 to 81.7)",
          "92.0% (86.2 to 95.4)"
        ],
        [
          "Summary difference between parallel and LC-aNAAT",
          "",
          "3.6% (1.9 to 5.8)",
          "-4.4% (-8.2 to -2.3)"
        ]
      ],
      "narratives": {
        "en": "Pooled accuracy of LF-LAM, LC-aNAAT and parallel testing (LC-aNAAT plus LF-LAM) for detecting tuberculosis against a microbiological reference standard, in inpatients and outpatients with HIV. Rows give each test with the number of studies (participants) and pooled sensitivity and specificity (95% CrI), followed by the summary difference between parallel testing and LC-aNAAT.",
        "ar": "الدقة المجمّعة لاختبار LF-LAM والاختبار الآلي منخفض التعقيد لتضخيم الحمض النووي (LC-aNAAT) والاختبار المتوازي (LC-aNAAT مع LF-LAM) في الكشف عن السل مقارنةً بمعيار مرجعي ميكروبيولوجي، لدى المرضى الداخليين والخارجيين المتعايشين مع فيروس العوز المناعي البشري. تبيّن الصفوف كل اختبار مع عدد الدراسات (المشاركين) والحساسية والنوعية المجمّعتين (بفترة موثوقية 95%)، إضافةً إلى الفرق الموجز بين الاختبار المتوازي وLC-aNAAT.",
        "zh": "在住院和门诊艾滋病毒感染者中，LF-LAM、LC-aNAAT及平行检测（LC-aNAAT加LF-LAM）以微生物学参考标准检测结核病的合并准确性。各行列出每项检测的研究数（参与者数）、合并敏感性和特异性（95%可信区间），以及平行检测与LC-aNAAT之间的汇总差异。",
        "es": "Exactitud agrupada de LF-LAM, LC-aNAAT y las pruebas en paralelo (LC-aNAAT más LF-LAM) para detectar la tuberculosis frente a un patrón de referencia microbiológico, en pacientes hospitalizados y ambulatorios con el VIH. Las filas muestran cada prueba con el número de estudios (participantes), la sensibilidad y especificidad agrupadas (ICr del 95%) y la diferencia resumida entre las pruebas en paralelo y LC-aNAAT.",
        "fr": "Exactitude groupée de LF-LAM, des LC-aNAAT et des tests en parallèle (LC-aNAAT plus LF-LAM) pour la détection de la tuberculose par rapport à une norme de référence microbiologique, chez les patients hospitalisés et ambulatoires vivant avec le VIH. Les lignes présentent chaque test avec le nombre d’études (participants), la sensibilité et la spécificité groupées (ICr à 95 %) et la différence résumée entre les tests en parallèle et LC-aNAAT.",
        "ru": "Объединенная точность LF-LAM, LC-aNAAT и параллельного тестирования (LC-aNAAT плюс LF-LAM) для выявления туберкулеза по сравнению с микробиологическим референсным стандартом, у стационарных и амбулаторных пациентов с ВИЧ. В строках указаны каждый тест с числом исследований (участников), объединенными чувствительностью и специфичностью (95% интервал достоверности) и сводная разница между параллельным тестированием и LC-aNAAT."
      },
      "csv": "tables/table-11.csv"
    },
    {
      "label": "Table 12",
      "caption": "Table 12. Summary accuracy for screening positive. Pooled test accuracy along with difference between the parallel use (LC-aNAAT and LF-LAM) versus LC-aNAAT alone for detection of tuberculosis using a microbiological reference standard.",
      "pages": [
        356
      ],
      "columns": [
        {
          "titles": "Participants"
        },
        {
          "titles": "Studies (participants)"
        },
        {
          "titles": "Pooled sensitivity (95% CrI)"
        },
        {
          "titles": "Pooled specificity (95% CrI)"
        }
      ],
      "rows": [
        [
          "Screening positive",
          "",
          "",
          ""
        ],
        [
          "LF-LAM",
          "6 (1901)",
          "34.4% (22.9 to 48.7)",
          "89.1% (76.0 to 95.5)"
        ],
        [
          "LC-aNAAT",
          "6 (1901)",
          "71.2% (54.1 to 83.9)",
          "95.2% (91.3 to 97.3)"
        ],
        [
          "Parallel",
          "6 (1901)",
          "80.8% (67.2 to 90.2)",
          "84.5% (72.0 to 91.9)"
        ],
        [
          "Summary difference between parallel and LC-aNAAT",
          "",
          "7.3% (2.1 to 18.0)",
          "-9.1% (-19.8 to -3.8)"
        ]
      ],
      "narratives": {
        "en": "Pooled accuracy of LF-LAM, LC-aNAAT and parallel testing (LC-aNAAT plus LF-LAM) for detecting tuberculosis against a microbiological reference standard, in people with HIV who screened positive for tuberculosis. Rows give each test with the number of studies (participants) and pooled sensitivity and specificity (95% CrI), followed by the summary difference between parallel testing and LC-aNAAT.",
        "ar": "الدقة المجمّعة لاختبار LF-LAM والاختبار الآلي منخفض التعقيد لتضخيم الحمض النووي (LC-aNAAT) والاختبار المتوازي (LC-aNAAT مع LF-LAM) في الكشف عن السل مقارنةً بمعيار مرجعي ميكروبيولوجي، لدى المتعايشين مع فيروس العوز المناعي البشري الذين جاءت نتيجة تحرّي السل لديهم إيجابية. تبيّن الصفوف كل اختبار مع عدد الدراسات (المشاركين) والحساسية والنوعية المجمّعتين (بفترة موثوقية 95%)، إضافةً إلى الفرق الموجز بين الاختبار المتوازي وLC-aNAAT.",
        "zh": "在结核病筛查阳性的艾滋病毒感染者中，LF-LAM、LC-aNAAT及平行检测（LC-aNAAT加LF-LAM）以微生物学参考标准检测结核病的合并准确性。各行列出每项检测的研究数（参与者数）、合并敏感性和特异性（95%可信区间），以及平行检测与LC-aNAAT之间的汇总差异。",
        "es": "Exactitud agrupada de LF-LAM, LC-aNAAT y las pruebas en paralelo (LC-aNAAT más LF-LAM) para detectar la tuberculosis frente a un patrón de referencia microbiológico, en personas con el VIH con un resultado positivo en el tamizaje de la tuberculosis. Las filas muestran cada prueba con el número de estudios (participantes), la sensibilidad y especificidad agrupadas (ICr del 95%) y la diferencia resumida entre las pruebas en paralelo y LC-aNAAT.",
        "fr": "Exactitude groupée de LF-LAM, des LC-aNAAT et des tests en parallèle (LC-aNAAT plus LF-LAM) pour la détection de la tuberculose par rapport à une norme de référence microbiologique, chez les personnes vivant avec le VIH ayant obtenu un résultat positif au dépistage de la tuberculose. Les lignes présentent chaque test avec le nombre d’études (participants), la sensibilité et la spécificité groupées (ICr à 95 %) et la différence résumée entre les tests en parallèle et LC-aNAAT.",
        "ru": "Объединенная точность LF-LAM, LC-aNAAT и параллельного тестирования (LC-aNAAT плюс LF-LAM) для выявления туберкулеза по сравнению с микробиологическим референсным стандартом, у людей с ВИЧ с положительным результатом скрининга на туберкулез. В строках указаны каждый тест с числом исследований (участников), объединенными чувствительностью и специфичностью (95% интервал достоверности) и сводная разница между параллельным тестированием и LC-aNAAT."
      },
      "csv": "tables/table-12.csv"
    },
    {
      "label": "Table 13",
      "caption": "Table 13: Summary accuracy for advanced HIV. Summary accuracy by test with the difference between the parallel use (LC-aNAAT and LF-LAM) versus LC-aNAAT alone for detection of tuberculosis against a microbiological reference standard",
      "pages": [
        356
      ],
      "columns": [
        {
          "titles": "Participants"
        },
        {
          "titles": "Studies (participants)"
        },
        {
          "titles": "Pooled sensitivity (95% CrI)"
        },
        {
          "titles": "Pooled specificity (95% CrI)"
        }
      ],
      "rows": [
        [
          "Advanced HIV",
          "",
          "",
          ""
        ],
        [
          "LF-LAM",
          "12 (2945)",
          "44.9% (35.1 to 55.2)",
          "89.8% (82.2 to 94.5)"
        ],
        [
          "LC-aNAAT",
          "12 (2945)",
          "73.6% (64.2 to 82.4)",
          "96.5% (94.4 to 98.0)"
        ],
        [
          "Parallel",
          "12 (2945)",
          "81.9% (75.5 to 87.6)",
          "87.1% (78.4 to 92.8)"
        ],
        [
          "Summary difference between parallel and LC-aNAAT",
          "",
          "8.1% (3.8 to 14.0)",
          "-8.4% (-15.2 to -4.2)"
        ]
      ],
      "narratives": {
        "en": "Pooled accuracy of LF-LAM, LC-aNAAT and parallel testing (LC-aNAAT plus LF-LAM) for detecting tuberculosis against a microbiological reference standard, in people with advanced HIV disease. Rows give each test with the number of studies (participants) and pooled sensitivity and specificity (95% CrI), followed by the summary difference between parallel testing and LC-aNAAT.",
        "ar": "الدقة المجمّعة لاختبار LF-LAM والاختبار الآلي منخفض التعقيد لتضخيم الحمض النووي (LC-aNAAT) والاختبار المتوازي (LC-aNAAT مع LF-LAM) في الكشف عن السل مقارنةً بمعيار مرجعي ميكروبيولوجي، لدى المصابين بمرض فيروس العوز المناعي البشري المتقدم. تبيّن الصفوف كل اختبار مع عدد الدراسات (المشاركين) والحساسية والنوعية المجمّعتين (بفترة موثوقية 95%)، إضافةً إلى الفرق الموجز بين الاختبار المتوازي وLC-aNAAT.",
        "zh": "在晚期艾滋病毒疾病患者中，LF-LAM、LC-aNAAT及平行检测（LC-aNAAT加LF-LAM）以微生物学参考标准检测结核病的合并准确性。各行列出每项检测的研究数（参与者数）、合并敏感性和特异性（95%可信区间），以及平行检测与LC-aNAAT之间的汇总差异。",
        "es": "Exactitud agrupada de LF-LAM, LC-aNAAT y las pruebas en paralelo (LC-aNAAT más LF-LAM) para detectar la tuberculosis frente a un patrón de referencia microbiológico, en personas con enfermedad avanzada por el VIH. Las filas muestran cada prueba con el número de estudios (participantes), la sensibilidad y especificidad agrupadas (ICr del 95%) y la diferencia resumida entre las pruebas en paralelo y LC-aNAAT.",
        "fr": "Exactitude groupée de LF-LAM, des LC-aNAAT et des tests en parallèle (LC-aNAAT plus LF-LAM) pour la détection de la tuberculose par rapport à une norme de référence microbiologique, chez les personnes atteintes de maladie à VIH à un stade avancé. Les lignes présentent chaque test avec le nombre d’études (participants), la sensibilité et la spécificité groupées (ICr à 95 %) et la différence résumée entre les tests en parallèle et LC-aNAAT.",
        "ru": "Объединенная точность LF-LAM, LC-aNAAT и параллельного тестирования (LC-aNAAT плюс LF-LAM) для выявления туберкулеза по сравнению с микробиологическим референсным стандартом, у людей с продвинутой стадией ВИЧ-инфекции. В строках указаны каждый тест с числом исследований (участников), объединенными чувствительностью и специфичностью (95% интервал достоверности) и сводная разница между параллельным тестированием и LC-aNAAT."
      },
      "csv": "tables/table-13.csv"
    },
    {
      "label": "Table 14",
      "caption": "Table 14: Summary accuracy for seriously ill. Summary accuracy by test with the difference between the parallel use (LC-aNAAT and LF-LAM) versus LC-aNAAT alone for detection of tuberculosis against a microbiological reference standard",
      "pages": [
        356,
        357
      ],
      "columns": [
        {
          "titles": "Participants"
        },
        {
          "titles": "Studies (participants)"
        },
        {
          "titles": "Pooled sensitivity (95% CrI)"
        },
        {
          "titles": "Pooled specificity (95% CrI)"
        }
      ],
      "rows": [
        [
          "Seriously ill",
          "",
          "",
          ""
        ],
        [
          "LF-LAM",
          "6 (577)",
          "47.8% (30.6 to 67.0)",
          "82.4% (71.4 to 90.6)"
        ],
        [
          "LC-aNAAT",
          "6 (577)",
          "67.9% (47.8 to 85.0)",
          "94.0% (89.4 to 97.1)"
        ],
        [
          "Parallel",
          "6 (577)",
          "78.7% (62.8 to 90.7)",
          "79.7% (68.7 to 88.5)"
        ],
        [
          "Summary difference between parallel and LC-aNAAT",
          "",
          "13.3% (4.4 to 25.4)",
          "-14.4% (-24.2 to -7.4)"
        ]
      ],
      "notes": "[Draft note: caption is on page 356; the table body is on page 357.]",
      "narratives": {
        "en": "Pooled accuracy of LF-LAM, LC-aNAAT and parallel testing (LC-aNAAT plus LF-LAM) for detecting tuberculosis against a microbiological reference standard, in seriously ill people with HIV. Rows give each test with the number of studies (participants) and pooled sensitivity and specificity (95% CrI), followed by the summary difference between parallel testing and LC-aNAAT.",
        "ar": "الدقة المجمّعة لاختبار LF-LAM والاختبار الآلي منخفض التعقيد لتضخيم الحمض النووي (LC-aNAAT) والاختبار المتوازي (LC-aNAAT مع LF-LAM) في الكشف عن السل مقارنةً بمعيار مرجعي ميكروبيولوجي، لدى المتعايشين مع فيروس العوز المناعي البشري المصابين بمرض خطير. تبيّن الصفوف كل اختبار مع عدد الدراسات (المشاركين) والحساسية والنوعية المجمّعتين (بفترة موثوقية 95%)، إضافةً إلى الفرق الموجز بين الاختبار المتوازي وLC-aNAAT.",
        "zh": "在病情严重的艾滋病毒感染者中，LF-LAM、LC-aNAAT及平行检测（LC-aNAAT加LF-LAM）以微生物学参考标准检测结核病的合并准确性。各行列出每项检测的研究数（参与者数）、合并敏感性和特异性（95%可信区间），以及平行检测与LC-aNAAT之间的汇总差异。",
        "es": "Exactitud agrupada de LF-LAM, LC-aNAAT y las pruebas en paralelo (LC-aNAAT más LF-LAM) para detectar la tuberculosis frente a un patrón de referencia microbiológico, en personas con el VIH gravemente enfermas. Las filas muestran cada prueba con el número de estudios (participantes), la sensibilidad y especificidad agrupadas (ICr del 95%) y la diferencia resumida entre las pruebas en paralelo y LC-aNAAT.",
        "fr": "Exactitude groupée de LF-LAM, des LC-aNAAT et des tests en parallèle (LC-aNAAT plus LF-LAM) pour la détection de la tuberculose par rapport à une norme de référence microbiologique, chez les personnes vivant avec le VIH gravement malades. Les lignes présentent chaque test avec le nombre d’études (participants), la sensibilité et la spécificité groupées (ICr à 95 %) et la différence résumée entre les tests en parallèle et LC-aNAAT.",
        "ru": "Объединенная точность LF-LAM, LC-aNAAT и параллельного тестирования (LC-aNAAT плюс LF-LAM) для выявления туберкулеза по сравнению с микробиологическим референсным стандартом, у тяжелобольных людей с ВИЧ. В строках указаны каждый тест с числом исследований (участников), объединенными чувствительностью и специфичностью (95% интервал достоверности) и сводная разница между параллельным тестированием и LC-aNAAT."
      },
      "csv": "tables/table-14.csv"
    },
    {
      "label": "Table 15",
      "caption": "Table 15. Summary accuracy for Xpert Ultra only. Summary accuracy by test with the difference between the parallel use (Xpert Ultra and LF-LAM) versus Xpert Ultra alone for detection of tuberculosis against a microbiological reference standard",
      "pages": [
        357
      ],
      "columns": [
        {
          "titles": "Participants"
        },
        {
          "titles": "Studies (participants)"
        },
        {
          "titles": "Pooled sensitivity (95% CrI)"
        },
        {
          "titles": "Pooled specificity (95% CrI)"
        }
      ],
      "rows": [
        [
          "Xpert Ultra",
          "",
          "",
          ""
        ],
        [
          "LF-LAM",
          "9 (5752)",
          "34.4% (22.9 to 48.7)",
          "89.1% (76.0 to 95.5)"
        ],
        [
          "Xpert Ultra",
          "9 (5752)",
          "67.8% (51.3 to 81.1)",
          "96.8% (95.2 to 98.0)"
        ],
        [
          "Parallel",
          "9 (5752)",
          "77.1% (66.4 to 85.8)",
          "88.5% (82.0 to 93.1)"
        ],
        [
          "Summary difference between parallel and LC-aNAAT",
          "",
          "7.5% (3.0 to 15.2)",
          "-7.4% (-13.1 to -3.8)"
        ]
      ],
      "narratives": {
        "en": "Pooled accuracy of LF-LAM, LC-aNAAT and parallel testing (LC-aNAAT plus LF-LAM) for detecting tuberculosis against a microbiological reference standard, restricted to studies using Xpert Ultra as the LC-aNAAT. Rows give each test with the number of studies (participants) and pooled sensitivity and specificity (95% CrI), followed by the summary difference between parallel testing and LC-aNAAT.",
        "ar": "الدقة المجمّعة لاختبار LF-LAM والاختبار الآلي منخفض التعقيد لتضخيم الحمض النووي (LC-aNAAT) والاختبار المتوازي (LC-aNAAT مع LF-LAM) في الكشف عن السل مقارنةً بمعيار مرجعي ميكروبيولوجي، مع الاقتصار على الدراسات التي استخدمت Xpert Ultra بوصفه الاختبار الآلي منخفض التعقيد. تبيّن الصفوف كل اختبار مع عدد الدراسات (المشاركين) والحساسية والنوعية المجمّعتين (بفترة موثوقية 95%)، إضافةً إلى الفرق الموجز بين الاختبار المتوازي وLC-aNAAT.",
        "zh": "仅限于使用Xpert Ultra作为LC-aNAAT的研究，LF-LAM、LC-aNAAT及平行检测（LC-aNAAT加LF-LAM）以微生物学参考标准检测结核病的合并准确性。各行列出每项检测的研究数（参与者数）、合并敏感性和特异性（95%可信区间），以及平行检测与LC-aNAAT之间的汇总差异。",
        "es": "Exactitud agrupada de LF-LAM, LC-aNAAT y las pruebas en paralelo (LC-aNAAT más LF-LAM) para detectar la tuberculosis frente a un patrón de referencia microbiológico, limitada a los estudios que utilizaron Xpert Ultra como LC-aNAAT. Las filas muestran cada prueba con el número de estudios (participantes), la sensibilidad y especificidad agrupadas (ICr del 95%) y la diferencia resumida entre las pruebas en paralelo y LC-aNAAT.",
        "fr": "Exactitude groupée de LF-LAM, des LC-aNAAT et des tests en parallèle (LC-aNAAT plus LF-LAM) pour la détection de la tuberculose par rapport à une norme de référence microbiologique, limitée aux études ayant utilisé Xpert Ultra comme LC-aNAAT. Les lignes présentent chaque test avec le nombre d’études (participants), la sensibilité et la spécificité groupées (ICr à 95 %) et la différence résumée entre les tests en parallèle et LC-aNAAT.",
        "ru": "Объединенная точность LF-LAM, LC-aNAAT и параллельного тестирования (LC-aNAAT плюс LF-LAM) для выявления туберкулеза по сравнению с микробиологическим референсным стандартом, только в исследованиях, где в качестве LC-aNAAT использовался Xpert Ultra. В строках указаны каждый тест с числом исследований (участников), объединенными чувствительностью и специфичностью (95% интервал достоверности) и сводная разница между параллельным тестированием и LC-aNAAT."
      },
      "csv": "tables/table-15.csv"
    },
    {
      "label": "Table 16",
      "caption": "Table 16. Within study comparison of Xpert vs Ultra",
      "pages": [
        357
      ],
      "columns": [
        {
          "titles": ""
        },
        {
          "titles": "Point",
          "group": "Absolute difference in sensitivity"
        },
        {
          "titles": "Lower 95% CI",
          "group": "Absolute difference in sensitivity"
        },
        {
          "titles": "Upper 95% CI",
          "group": "Absolute difference in sensitivity"
        },
        {
          "titles": "Point",
          "group": "Absolute difference in sensitivity"
        },
        {
          "titles": "Lower 95% CI",
          "group": "Absolute difference in sensitivity"
        },
        {
          "titles": "Upper 95% CI",
          "group": "Absolute difference in sensitivity"
        }
      ],
      "rows": [
        [
          "Study: Gils 2023",
          "",
          "",
          "",
          "",
          "",
          ""
        ],
        [
          "Parallel (Xpert Ultra) vs Xpert Ultra",
          "0.07",
          "-0.08",
          "0.21",
          "-0.09",
          "-0.12",
          "-0.06"
        ],
        [
          "Parallel (Xpert MTB/Rif) vs Xpert MTB/Rif",
          "0.07",
          "-0.09",
          "0.22",
          "-0.09",
          "-0.12",
          "-0.06"
        ],
        [
          "P for interaction",
          "0.944 (no evidence of a difference between Xpert Ultra and Xpert MTB/Rif)",
          "",
          "",
          "0.719 (no evidence of a difference between Xpert Ultra and Xpert MTB/Rif)",
          "",
          ""
        ],
        [
          "Study: Reeve 2023",
          "",
          "",
          "",
          "",
          "",
          ""
        ],
        [
          "Parallel (Xpert Ultra) vs Xpert Ultra",
          "0.01",
          "-0.10",
          "0.12",
          "-0.01",
          "-0.03",
          "-0.01"
        ],
        [
          "Parallel (Xpert MTB/Rif) vs Xpert MTB/Rif",
          "0.00",
          "-0.13",
          "0.13",
          "-0.01",
          "-0.02",
          "-0.00"
        ],
        [
          "P for interaction",
          "0.919 (no evidence of a difference between Xpert Ultra and Xpert MTB/Rif)",
          "",
          "",
          "0.411 (no evidence of a difference between Xpert Ultra and Xpert MTB/Rif)",
          "",
          ""
        ]
      ],
      "notes": "[Draft note: the table is an embedded image (no text layer); values read from the image. Both column groups are headed 'Absolute difference in sensitivity' as printed; the second group's values are negative and may refer to specificity.]",
      "narratives": {
        "en": "Within-study comparisons from two studies (Gils 2023 and Reeve 2023) of the absolute difference in accuracy between parallel testing with LF-LAM and the LC-aNAAT alone, separately for Xpert Ultra and Xpert MTB/RIF. Columns give the point estimate and lower and upper 95% CI for each of two difference measures, with a P value for interaction between the two Xpert assays.",
        "ar": "مقارنات داخل الدراسة من دراستين (Gils 2023 وReeve 2023) للفرق المطلق في الدقة بين الاختبار المتوازي مع LF-LAM والاختبار الآلي منخفض التعقيد وحده، بشكل منفصل لكل من Xpert Ultra وXpert MTB/RIF. تبيّن الأعمدة التقدير النقطي والحدين الأدنى والأعلى لفترة الثقة 95% لكل من مقياسي الفرق، مع قيمة P للتفاعل بين مقايستي Xpert.",
        "zh": "两项研究（Gils 2023和Reeve 2023）的研究内比较，分别针对Xpert Ultra和Xpert MTB/RIF，比较与LF-LAM平行检测和单独使用LC-aNAAT之间准确性的绝对差异。各列给出两个差异指标的点估计值及95%置信区间下限和上限，并列出两种Xpert检测之间交互作用的P值。",
        "es": "Comparaciones dentro de dos estudios (Gils 2023 y Reeve 2023) de la diferencia absoluta de exactitud entre las pruebas en paralelo con LF-LAM y la LC-aNAAT sola, por separado para Xpert Ultra y Xpert MTB/RIF. Las columnas indican la estimación puntual y los límites inferior y superior del IC del 95% para cada una de dos medidas de diferencia, con un valor de p de interacción entre las dos pruebas Xpert.",
        "fr": "Comparaisons intra-étude, dans deux études (Gils 2023 et Reeve 2023), de la différence absolue d’exactitude entre les tests en parallèle avec LF-LAM et le LC-aNAAT seul, séparément pour Xpert Ultra et Xpert MTB/RIF. Les colonnes donnent l’estimation ponctuelle et les bornes inférieure et supérieure de l’IC à 95 % pour chacune de deux mesures de différence, avec une valeur p d’interaction entre les deux tests Xpert.",
        "ru": "Внутрисследовательские сравнения в двух исследованиях (Gils 2023 и Reeve 2023) абсолютной разницы в точности между параллельным тестированием с LF-LAM и одним LC-aNAAT, отдельно для Xpert Ultra и Xpert MTB/RIF. В столбцах приведены точечная оценка и нижняя и верхняя границы 95% ДИ для каждой из двух мер разницы, а также значение P для взаимодействия между двумя тестами Xpert."
      },
      "csv": "tables/table-16.csv"
    },
    {
      "label": "Table 17",
      "caption": "Table 17. Summary accuracy for sensitivity analysis. Summary accuracy by test with the difference between the parallel use (Xpert Ultra and LF-LAM) versus Xpert Ultra alone for detection of tuberculosis against a microbiological reference standard",
      "pages": [
        358
      ],
      "columns": [
        {
          "titles": "Participants"
        },
        {
          "titles": "Studies (participants)"
        },
        {
          "titles": "Pooled sensitivity (95% CrI)"
        },
        {
          "titles": "Pooled specificity (95% CrI)"
        }
      ],
      "rows": [
        [
          "Excluding studies with high risk of bias",
          "",
          "",
          ""
        ],
        [
          "LF-LAM",
          "8 (4304)",
          "41.9% (30.3 to 55.0)",
          "LF-LAM"
        ],
        [
          "LC-aNAAT",
          "8 (4304)",
          "63.7% (52.5 to 73.5)",
          "LC-aNAAT"
        ],
        [
          "Parallel",
          "8 (4304)",
          "74.9% (66.5 to 82.1)",
          "Parallel"
        ],
        [
          "Summary difference between parallel and LC-aNAAT",
          "",
          "10.0% (4.9 to 17.6)",
          "-10.8% (-20.6 to -5.4)"
        ],
        [
          "Excluding participants with at least one unavailable or non-determinate index test result",
          "",
          "",
          ""
        ],
        [
          "LF-LAM",
          "27 (10685)",
          "38.7% (32.5 to 45.2)",
          "91.9% (88.7 to 94.4)"
        ],
        [
          "LC-aNAAT",
          "27 (10685)",
          "75.1% (70.7 to 79.3)",
          "96.2% (95.1 to 97.2)"
        ],
        [
          "Parallel",
          "27 (10685)",
          "80.4% (76.8 to 83.6)",
          "89.3% (85.7 to 92.2)"
        ],
        [
          "Summary difference between parallel and LC-aNAAT",
          "",
          "4.4% (2.8 to 6.5)",
          "-6.9% (-9.1 to -4.5)"
        ],
        [
          "Alternative priors",
          "",
          "",
          ""
        ],
        [
          "LF-LAM",
          "27 (12651)",
          "38.8% (31.6 to 46.3)",
          "92.2% (88.5 to 94.8)"
        ],
        [
          "LC-aNAAT",
          "27 (12651)",
          "68.2% (60.2 to 75.8)",
          "96.8% (95.7 to 97.7)"
        ],
        [
          "Parallel",
          "27 (12651)",
          "77.5% (73.3 to 81.6)",
          "89.6% (85.7 to 92.7)"
        ],
        [
          "Summary difference between parallel and LC-aNAAT",
          "",
          "6.1% (3.1 to 10.6)",
          "-6.6% (-9.6 to -4.3)"
        ]
      ],
      "notes": "[Draft note: the batch caption for this job was garbled body text; the table on page 358 is Table 17. In the first block the specificity column repeats the test names (LF-LAM, LC-aNAAT, Parallel) instead of values, as printed.]",
      "narratives": {
        "en": "Pooled accuracy of LF-LAM, LC-aNAAT and parallel testing (LC-aNAAT plus LF-LAM) for detecting tuberculosis against a microbiological reference standard, in sensitivity analyses (excluding studies at high risk of bias, excluding participants with an unavailable or non-determinate index test result, and using alternative priors). Rows give each test with the number of studies (participants) and pooled sensitivity and specificity (95% CrI), followed by the summary difference between parallel testing and LC-aNAAT.",
        "ar": "الدقة المجمّعة لاختبار LF-LAM والاختبار الآلي منخفض التعقيد لتضخيم الحمض النووي (LC-aNAAT) والاختبار المتوازي (LC-aNAAT مع LF-LAM) في الكشف عن السل مقارنةً بمعيار مرجعي ميكروبيولوجي، في تحليلات الحساسية (باستبعاد الدراسات المعرّضة لخطر تحيّز مرتفع، واستبعاد المشاركين الذين لديهم نتيجة اختبار دليلي غير متاحة أو غير حاسمة، واستخدام توزيعات مسبقة بديلة). تبيّن الصفوف كل اختبار مع عدد الدراسات (المشاركين) والحساسية والنوعية المجمّعتين (بفترة موثوقية 95%)، إضافةً إلى الفرق الموجز بين الاختبار المتوازي وLC-aNAAT.",
        "zh": "在敏感性分析中（排除高偏倚风险研究、排除指标检测结果缺失或不确定的参与者，以及使用替代先验分布），LF-LAM、LC-aNAAT及平行检测（LC-aNAAT加LF-LAM）以微生物学参考标准检测结核病的合并准确性。各行列出每项检测的研究数（参与者数）、合并敏感性和特异性（95%可信区间），以及平行检测与LC-aNAAT之间的汇总差异。",
        "es": "Exactitud agrupada de LF-LAM, LC-aNAAT y las pruebas en paralelo (LC-aNAAT más LF-LAM) para detectar la tuberculosis frente a un patrón de referencia microbiológico, en análisis de sensibilidad (excluyendo los estudios con alto riesgo de sesgo, excluyendo a los participantes con un resultado de la prueba índice no disponible o no determinado y utilizando distribuciones a priori alternativas). Las filas muestran cada prueba con el número de estudios (participantes), la sensibilidad y especificidad agrupadas (ICr del 95%) y la diferencia resumida entre las pruebas en paralelo y LC-aNAAT.",
        "fr": "Exactitude groupée de LF-LAM, des LC-aNAAT et des tests en parallèle (LC-aNAAT plus LF-LAM) pour la détection de la tuberculose par rapport à une norme de référence microbiologique, dans des analyses de sensibilité (exclusion des études à risque élevé de biais, exclusion des participants ayant un résultat de test index indisponible ou non déterminé, et utilisation d’a priori alternatifs). Les lignes présentent chaque test avec le nombre d’études (participants), la sensibilité et la spécificité groupées (ICr à 95 %) et la différence résumée entre les tests en parallèle et LC-aNAAT.",
        "ru": "Объединенная точность LF-LAM, LC-aNAAT и параллельного тестирования (LC-aNAAT плюс LF-LAM) для выявления туберкулеза по сравнению с микробиологическим референсным стандартом, в анализах чувствительности (исключение исследований с высоким риском систематической ошибки, исключение участников с недоступным или неопределенным результатом индексного теста и использование альтернативных априорных распределений). В строках указаны каждый тест с числом исследований (участников), объединенными чувствительностью и специфичностью (95% интервал достоверности) и сводная разница между параллельным тестированием и LC-aNAAT."
      },
      "csv": "tables/table-17.csv"
    },
    {
      "label": "Table 18",
      "caption": "Table 18. Comparison of mortality in randomized trials evaluating interventions that included respiratory LC-aNAATs and urine LF-LAM in adult inpatients with HIV.",
      "pages": [
        361
      ],
      "columns": [
        {
          "titles": "Study"
        },
        {
          "titles": "Population"
        },
        {
          "titles": "Illness severity metrics"
        },
        {
          "titles": "Design"
        },
        {
          "titles": "Time of mortality assessment"
        },
        {
          "titles": "Mortality analysis"
        },
        {
          "titles": "Mortality in intervention"
        },
        {
          "titles": "Mortality in control"
        },
        {
          "titles": "Other key findings"
        }
      ],
      "rows": [
        [
          "Peter 2016",
          "1609 HIV-positive adults, inpatients (with TB symptoms)",
          "Median CD4 84 cells per µL, Karnofksy score 50, BMI 18.8, median haemoglobin 9.2 g/dL",
          "Randomized controlled trial",
          "8 weeks",
          "ARR 4% (1 to 7%)",
          "17.4% (139/798)",
          "21.9% (178/811)",
          "Greatest mortality reduction in those with CD4 < 50 cells per µL. Length of hospital stay and tuberculosis-related morbidity were not decreased."
        ],
        [
          "Gupta-Wright 2018",
          "2574 HIV-positive adults, inpatients (unselected)",
          "Median CD4 222 cells per µL, Karnofksy score 60, BMI 21.7, median haemoglobin 10.4 g/dL",
          "Randomized controlled trial",
          "56 days",
          "aRD –2.8%, 95% CI: -5.8 to 0.3; P = 0.074",
          "18% (235/1287)",
          "21% (272/1287)",
          "Subgroups - severe anaemia, CD4 < 100 cells per µL, clinically suspected tuberculosis"
        ],
        [
          "Åhsberg 2023",
          "422 HIV-positive adults, inpatients (symptoms, severe illness, or advanced HIV)",
          "Median CD4 87 cells per µL,",
          "Cluster randomized trial (3 clusters)",
          "8 weeks",
          "No effect measure reported, log-rank test: P = .088",
          "32.4% (56/173)",
          "25.2% (62/246)",
          "19/41 (46%) patients with positive LAM test died compared with 31/120 (26%) patients with negative LAM test (log-rank test: P = .026)"
        ]
      ],
      "narratives": {
        "en": "Mortality results of three randomized trials in adult inpatients with HIV that evaluated interventions including respiratory LC-aNAATs and urine LF-LAM. For each trial the table gives the population, illness severity metrics, design, time of mortality assessment, mortality analysis, mortality in the intervention and control groups, and other key findings.",
        "ar": "نتائج الوفيات في ثلاث تجارب معشّاة أُجريت على مرضى بالغين داخليين متعايشين مع فيروس العوز المناعي البشري وقيّمت تدخلات تشمل الاختبارات الآلية منخفضة التعقيد لتضخيم الحمض النووي على عينات تنفسية واختبار LF-LAM في البول. يبيّن الجدول لكل تجربة الفئة السكانية، ومقاييس شدة المرض، والتصميم، وتوقيت تقييم الوفيات، وتحليل الوفيات، والوفيات في مجموعتي التدخل والمقارنة، والنتائج الرئيسية الأخرى.",
        "zh": "三项针对成年住院艾滋病毒感染者的随机试验的死亡率结果，这些试验评估了包括呼吸道LC-aNAAT和尿液LF-LAM在内的干预措施。表中列出每项试验的人群、疾病严重程度指标、设计、死亡率评估时间、死亡率分析、干预组和对照组死亡率以及其他主要发现。",
        "es": "Resultados de mortalidad de tres ensayos aleatorizados en pacientes adultos hospitalizados con el VIH que evaluaron intervenciones que incluían LC-aNAAT respiratorias y LF-LAM en orina. Para cada ensayo, la tabla indica la población, los indicadores de gravedad de la enfermedad, el diseño, el momento de evaluación de la mortalidad, el análisis de mortalidad, la mortalidad en los grupos de intervención y de control, y otros resultados clave.",
        "fr": "Résultats de mortalité de trois essais randomisés menés chez des adultes hospitalisés vivant avec le VIH, évaluant des interventions comprenant des LC-aNAAT respiratoires et le LF-LAM urinaire. Pour chaque essai, le tableau indique la population, les indicateurs de gravité de la maladie, le plan d’étude, le moment de l’évaluation de la mortalité, l’analyse de mortalité, la mortalité dans les groupes intervention et témoin, et d’autres résultats clés.",
        "ru": "Результаты по смертности трех рандомизированных исследований у взрослых стационарных пациентов с ВИЧ, в которых оценивались вмешательства, включавшие респираторные LC-aNAAT и LF-LAM мочи. Для каждого исследования приведены популяция, показатели тяжести заболевания, дизайн, сроки оценки смертности, анализ смертности, смертность в группах вмешательства и контроля и другие ключевые результаты."
      },
      "csv": "tables/table-18.csv"
    },
    {
      "label": "Table 2a",
      "caption": "Table 2a: Diagnostic accuracy of each index test- TB detection",
      "pages": [
        530
      ],
      "columns": [
        {
          "titles": "Parameter"
        },
        {
          "titles": "Point estimate"
        },
        {
          "titles": "CI"
        },
        {
          "titles": "TB+"
        },
        {
          "titles": "TB -"
        }
      ],
      "rows": [
        [
          "Overall (N = 29)",
          "",
          "",
          "",
          ""
        ],
        [
          "Overall sens",
          "93.0",
          "90.9 to 94.7",
          "4767",
          "9085"
        ],
        [
          "Overall spec",
          "97.7",
          "95.6 to 98.8",
          "",
          ""
        ],
        [
          "Abbott RealTime MTB (N= 12)",
          "",
          "",
          "",
          ""
        ],
        [
          "Pooled sens",
          "96.1",
          "89.9 to 98.5",
          "1274",
          "4162"
        ],
        [
          "Pooled spec",
          "97.6",
          "94.8 to 98.9",
          "",
          ""
        ],
        [
          "FluoroType MTB (N= 6)",
          "",
          "",
          "",
          ""
        ],
        [
          "Pooled sens",
          "91.3",
          "89.0 to 93.0",
          "755",
          "2502"
        ],
        [
          "Pooled spec",
          "98.4",
          "91.9 to 99.7",
          "",
          ""
        ],
        [
          "FluoroType MTBDR (N= 4)",
          "",
          "",
          "",
          ""
        ],
        [
          "Pooled sens",
          "91.7",
          "86.2 to 95.1",
          "976",
          "677"
        ],
        [
          "Pooled spec",
          "99",
          "95.8 to 99.8",
          "",
          ""
        ],
        [
          "BD Max MTB (N= 5)",
          "",
          "",
          "",
          ""
        ],
        [
          "Pooled sens",
          "93.0",
          "89.7 to 95.3",
          "1098",
          "1207"
        ],
        [
          "Pooled spec",
          "95.1*",
          "73.2 to 99.3",
          "",
          ""
        ],
        [
          "Roche Cobas MTB (N= 2)**",
          "",
          "",
          "",
          ""
        ],
        [
          "Sens",
          "93.3",
          "87.4 to 97.3",
          "664",
          "537"
        ],
        [
          "Spec",
          "96.7",
          "92.9 to 98.6",
          "",
          ""
        ]
      ],
      "notes": "CI: Confidence interval; # = number of; sens: sensitivity; spec: specificity. *A study (Paradis 2019) reported low specificity of 87%, but that study also had low specificity in Xpert and on BD Max, when a head-to-head comparison was done [72% (Bd Max) vs 73% (Xpert)]. ** For Roche Cobas MTB assay, we present the results as median sensitivity and specificity. For individual studies, the sensitivity was 91.7% (92.0-97.3) and 94.9% (87.4- 94.6). the specificty was 95.6% (92.9-98.6) and 97.9% (96.2-97.8).",
      "narratives": {
        "en": "Diagnostic accuracy of moderate-complexity automated NAATs for TB detection, overall and for each index test (Abbott RealTime MTB, FluoroType MTB, FluoroType MTBDR, BD Max MTB and Roche Cobas MTB). For each, the table gives sensitivity and specificity point estimates with confidence intervals and the numbers of TB-positive and TB-negative specimens.",
        "ar": "الدقة التشخيصية لاختبارات تضخيم الحمض النووي الآلية متوسطة التعقيد في الكشف عن السل، إجمالاً ولكل اختبار دليلي (Abbott RealTime MTB وFluoroType MTB وFluoroType MTBDR وBD Max MTB وRoche Cobas MTB). يبيّن الجدول لكل منها التقديرات النقطية للحساسية والنوعية مع فترات الثقة، وأعداد العينات الإيجابية والسلبية للسل.",
        "zh": "中等复杂度自动化核酸扩增检测在结核病检测中的诊断准确性，包括总体及各指标检测（Abbott RealTime MTB、FluoroType MTB、FluoroType MTBDR、BD Max MTB和Roche Cobas MTB）。表中列出各检测敏感性和特异性的点估计值及置信区间，以及结核病阳性和阴性标本数。",
        "es": "Exactitud diagnóstica de las NAAT automatizadas de complejidad moderada para detectar la tuberculosis, en conjunto y para cada prueba índice (Abbott RealTime MTB, FluoroType MTB, FluoroType MTBDR, BD Max MTB y Roche Cobas MTB). Para cada una, la tabla indica las estimaciones puntuales de sensibilidad y especificidad con intervalos de confianza y el número de muestras positivas y negativas para tuberculosis.",
        "fr": "Exactitude diagnostique des TAAN automatisés de complexité modérée pour la détection de la tuberculose, globalement et pour chaque test index (Abbott RealTime MTB, FluoroType MTB, FluoroType MTBDR, BD Max MTB et Roche Cobas MTB). Pour chacun, le tableau donne les estimations ponctuelles de sensibilité et de spécificité avec intervalles de confiance et le nombre d’échantillons positifs et négatifs pour la tuberculose.",
        "ru": "Диагностическая точность автоматизированных МАНК средней сложности для выявления ТБ в целом и для каждого индексного теста (Abbott RealTime MTB, FluoroType MTB, FluoroType MTBDR, BD Max MTB и Roche Cobas MTB). Для каждого приведены точечные оценки чувствительности и специфичности с доверительными интервалами и число ТБ-положительных и ТБ-отрицательных образцов."
      },
      "csv": "tables/table-2a.csv"
    },
    {
      "label": "Table 2b",
      "caption": "Table 2b: Diagnostic accuracy for TB detection by smear status",
      "pages": [
        530,
        531
      ],
      "columns": [
        {
          "titles": "Parameter"
        },
        {
          "titles": "Point estimate",
          "group": "Smear positive (N = 26; 2880 specimens)"
        },
        {
          "titles": "CI",
          "group": "Smear positive (N = 26; 2880 specimens)"
        },
        {
          "titles": "Point estimate",
          "group": "Smear negative (N = 26; 9947 specimens)"
        },
        {
          "titles": "CI",
          "group": "Smear negative (N = 26; 9947 specimens)"
        }
      ],
      "rows": [
        [
          "Overall sens",
          "98.8%",
          "93.7 to 99.7",
          "86.1%",
          "73.4 to 93.2"
        ],
        [
          "Overall spec",
          "-",
          "-",
          "96.4%",
          "93.6 to 98.0"
        ],
        [
          "Abbott RealTime MTB(N= 11)",
          "",
          "",
          "",
          ""
        ],
        [
          "Pooled sens",
          "99.7%",
          "97.3 to 99.9",
          "85.7%",
          "65.5 to 95.0"
        ],
        [
          "Pooled spec",
          "-",
          "-",
          "99.2%",
          "96.4 to 99.1"
        ],
        [
          "FluoroType MTB (N= 4)",
          "",
          "",
          "",
          ""
        ],
        [
          "Pooled sens",
          "87.0%",
          "83 to 91",
          "84.0%",
          "80 to 89"
        ],
        [
          "Pooled spec",
          "-",
          "-",
          "97.0%",
          "96 to 98"
        ],
        [
          "FluoroType MTBDR (N= 4)",
          "",
          "",
          "",
          ""
        ],
        [
          "Pooled sens",
          "97%",
          "95 to 99",
          "79.1%",
          "62.9 to 89.4"
        ],
        [
          "Pooled spec",
          "-",
          "-",
          "99.3%",
          "96.2 to 99.8"
        ],
        [
          "BD Max MTB (N= 4)",
          "",
          "",
          "",
          ""
        ],
        [
          "Pooled sens",
          "97%",
          "93 to 99",
          "79.6%",
          "68.7 to 87.4"
        ],
        [
          "Pooled spec",
          "-",
          "-",
          "97.2%",
          "76.6 to 99.7"
        ],
        [
          "Roche Cobas MTB (N= 2)*",
          "",
          "",
          "",
          ""
        ],
        [
          "Sens",
          "99%",
          "97 to 100",
          "80.0%",
          "61.2 to 92.4"
        ],
        [
          "Spec",
          "-",
          "-",
          "97.0%",
          "96.2 to 98.6"
        ]
      ],
      "notes": "CI: Confidence interval; # = number of; sens: sensitivity; spec: specificity. *For Roche Cobas MTB assay, data are presented as median sensitivity and specificity. For individual studies, the sensitivity in semar positive was 99% (97-99) and 99% (97-100). For smear negative the sensitivity was 73% (61.2 to 82.3), 87% (80.1 to 92.4). The specificity was 96% (96.2 to 98.6) and 98% (92.0 to 98.1). [Draft note: caption is at the foot of page 530; the table is on page 531. The 'Smear positive' / 'Smear negative' labels are printed as a shaded row under the column headings; treated here as column groups.]",
      "narratives": {
        "en": "Diagnostic accuracy of moderate-complexity automated NAATs for TB detection by smear status, overall and for each index test. Columns give point estimates and confidence intervals for smear-positive and smear-negative specimens; specificity is not reported for smear-positive specimens.",
        "ar": "الدقة التشخيصية لاختبارات تضخيم الحمض النووي الآلية متوسطة التعقيد في الكشف عن السل بحسب حالة اللطاخة، إجمالاً ولكل اختبار دليلي. تبيّن الأعمدة التقديرات النقطية وفترات الثقة للعينات الإيجابية اللطاخة والسلبية اللطاخة؛ ولا ترد النوعية للعينات الإيجابية اللطاخة.",
        "zh": "中等复杂度自动化核酸扩增检测按涂片状态检测结核病的诊断准确性，包括总体及各指标检测。各列给出涂片阳性和涂片阴性标本的点估计值和置信区间；涂片阳性标本未报告特异性。",
        "es": "Exactitud diagnóstica de las NAAT automatizadas de complejidad moderada para detectar la tuberculosis según el resultado de la baciloscopia, en conjunto y para cada prueba índice. Las columnas indican las estimaciones puntuales y los intervalos de confianza para muestras con baciloscopia positiva y negativa; no se notifica la especificidad para las muestras con baciloscopia positiva.",
        "fr": "Exactitude diagnostique des TAAN automatisés de complexité modérée pour la détection de la tuberculose selon le statut de l’examen microscopique des frottis, globalement et pour chaque test index. Les colonnes donnent les estimations ponctuelles et les intervalles de confiance pour les échantillons à frottis positif et négatif ; la spécificité n’est pas indiquée pour les échantillons à frottis positif.",
        "ru": "Диагностическая точность автоматизированных МАНК средней сложности для выявления ТБ в зависимости от результата микроскопии мазка, в целом и для каждого индексного теста. В столбцах приведены точечные оценки и доверительные интервалы для мазок-положительных и мазок-отрицательных образцов; специфичность для мазок-положительных образцов не приводится."
      },
      "csv": "tables/table-2b.csv"
    },
    {
      "label": "Table 3a",
      "caption": "Table 3a: Diagnostic accuracy of each index test - resistance detection with phenotypic DST as reference standard",
      "pages": [
        532
      ],
      "columns": [
        {
          "titles": ""
        },
        {
          "titles": ""
        },
        {
          "titles": ""
        },
        {
          "titles": ""
        }
      ],
      "rows": [
        [
          "Overall Pooled RIF (N = 18)",
          "",
          "Overall Pooled INH (N = 18)",
          ""
        ],
        [
          "Pooled Sens",
          "96.7 (93.1 to 98.4)",
          "Pooled sens",
          "86.4 (82.8 to 89.3)"
        ],
        [
          "Pooled Spec",
          "98.9 (97.5 to 99.5)",
          "Pooled spec",
          "99.2 (98.1 to 99.7)"
        ],
        [
          "Abbott (RIF) N = 9",
          "",
          "Abbott (INH) N = 9",
          ""
        ],
        [
          "Pooled sens",
          "94% (91 to 96)",
          "Pooled sens",
          "89% (86 to 92)"
        ],
        [
          "Pooled spec",
          "99% (99 to 100)",
          "Pooled spec",
          "98% (98 to 100)"
        ],
        [
          "FluoroType MTBDR (RIF) N= 3",
          "",
          "FluroType MTBDR (INH) N= 3",
          ""
        ],
        [
          "Sens",
          "97 (82 – 100); 99 (94 – 100) ; 100 (93-100)",
          "Sens",
          "70 (46 – 88); 92 (84 – 97); 79 (67-88)"
        ],
        [
          "Spec",
          "100 (85 – 100); 100 (96- 100) ; 95 (90-98)",
          "Spec",
          "100 (84 – 100); 100 (96-100); 99 (94-100)"
        ],
        [
          "BD Max MDR-TB (RIF) N= 4",
          "",
          "BD Max MDR-TB (INH) N= 4",
          ""
        ],
        [
          "Pooled Sens",
          "99.1 (96.2-100)",
          "Pooled Sens",
          "90.0 (64.6 – 97.8)"
        ],
        [
          "Pooled Spec",
          "98.2 (96.4 - 99.2)",
          "Pooled Spec",
          "99.8 (98.2 – 99.9)"
        ],
        [
          "Roche Cobas MTB RIF/INH (RIF) N= 2",
          "",
          "Roche Cobas MTB RIF/INH (INH) N = 2",
          ""
        ],
        [
          "Sens",
          "91 (85-96); 100 (54-100)",
          "Sens",
          "80 (28- 99); 97 (91- 100)"
        ],
        [
          "Spec",
          "96 (94-98); 100 (95-100)",
          "spec",
          "98 (96-100); 97 (91- 100)"
        ]
      ],
      "notes": "Data are presented as point estimate with 95% CI. Sens: sensitivity; spec: specificity. [Draft note: the table has no column header row; the left half reports rifampicin (RIF) and the right half isoniazid (INH) resistance, each block headed by a test label row.]",
      "narratives": {
        "en": "Diagnostic accuracy of moderate-complexity automated NAATs for detecting rifampicin (left) and isoniazid (right) resistance against phenotypic DST, overall and for each test (Abbott, FluoroType MTBDR, BD Max MDR-TB and Roche Cobas MTB RIF/INH). Each block gives pooled or study-level sensitivity and specificity with 95% CIs.",
        "ar": "الدقة التشخيصية لاختبارات تضخيم الحمض النووي الآلية متوسطة التعقيد في الكشف عن مقاومة الريفامبيسين (يساراً) والإيزونيازيد (يميناً) مقارنةً باختبار الحساسية للأدوية بالنمط الظاهري، إجمالاً ولكل اختبار (Abbott وFluoroType MTBDR وBD Max MDR-TB وRoche Cobas MTB RIF/INH). تبيّن كل مجموعة الحساسية والنوعية المجمّعتين أو على مستوى الدراسة مع فترات الثقة 95%.",
        "zh": "以表型药敏试验为参考标准，中等复杂度自动化核酸扩增检测利福平（左）和异烟肼（右）耐药的诊断准确性，包括总体及各检测（Abbott、FluoroType MTBDR、BD Max MDR-TB和Roche Cobas MTB RIF/INH）。每个区块列出合并或单项研究的敏感性和特异性及95%置信区间。",
        "es": "Exactitud diagnóstica de las NAAT automatizadas de complejidad moderada para detectar la resistencia a la rifampicina (izquierda) y a la isoniazida (derecha) frente a las PSF fenotípicas, en conjunto y para cada prueba (Abbott, FluoroType MTBDR, BD Max MDR-TB y Roche Cobas MTB RIF/INH). Cada bloque indica la sensibilidad y especificidad agrupadas o por estudio con IC del 95%.",
        "fr": "Exactitude diagnostique des TAAN automatisés de complexité modérée pour la détection de la résistance à la rifampicine (à gauche) et à l’isoniazide (à droite) par rapport à l’antibiogramme phénotypique, globalement et pour chaque test (Abbott, FluoroType MTBDR, BD Max MDR-TB et Roche Cobas MTB RIF/INH). Chaque bloc indique la sensibilité et la spécificité groupées ou par étude avec IC à 95 %.",
        "ru": "Диагностическая точность автоматизированных МАНК средней сложности для выявления устойчивости к рифампицину (слева) и изониазиду (справа) по сравнению с фенотипическим ТЛЧ, в целом и для каждого теста (Abbott, FluoroType MTBDR, BD Max MDR-TB и Roche Cobas MTB RIF/INH). В каждом блоке приведены объединенные или по отдельным исследованиям чувствительность и специфичность с 95% ДИ."
      },
      "csv": "tables/table-3a.csv"
    },
    {
      "label": "Table 3b",
      "caption": "Table 3b : Diagnostic accuracy of each index test - resistance detection with composite reference standard",
      "pages": [
        533
      ],
      "columns": [
        {
          "titles": ""
        },
        {
          "titles": ""
        },
        {
          "titles": ""
        },
        {
          "titles": ""
        }
      ],
      "rows": [
        [
          "Overall Pooled RIF (N = 9)",
          "",
          "Overall Pooled INH (N = 8)",
          ""
        ],
        [
          "Pooled sens",
          "96.7 (92.9 to 98.5)",
          "Pooled sens",
          "86.4 (82.1 to 89.8)"
        ],
        [
          "Pooled spec",
          "98.7 (97.1 to 99.4)",
          "Pooled spec",
          "99.8 (98.3 to 99.8)"
        ]
      ],
      "notes": "Data are presented as point estimate with 95% CI. Sens: sensitivity; spec: specificity. [Draft note: the table has no column header row.]",
      "narratives": {
        "en": "Overall pooled sensitivity and specificity (95% CI) of moderate-complexity automated NAATs for detecting rifampicin and isoniazid resistance against a composite reference standard.",
        "ar": "الحساسية والنوعية المجمّعتان الإجماليتان (بفترة ثقة 95%) لاختبارات تضخيم الحمض النووي الآلية متوسطة التعقيد في الكشف عن مقاومة الريفامبيسين والإيزونيازيد مقارنةً بمعيار مرجعي مركّب.",
        "zh": "以复合参考标准为对照，中等复杂度自动化核酸扩增检测利福平和异烟肼耐药的总体合并敏感性和特异性（95%置信区间）。",
        "es": "Sensibilidad y especificidad agrupadas globales (IC del 95%) de las NAAT automatizadas de complejidad moderada para detectar la resistencia a la rifampicina y a la isoniazida frente a un patrón de referencia compuesto.",
        "fr": "Sensibilité et spécificité groupées globales (IC à 95 %) des TAAN automatisés de complexité modérée pour la détection de la résistance à la rifampicine et à l’isoniazide par rapport à une norme de référence composite.",
        "ru": "Общие объединенные чувствительность и специфичность (95% ДИ) автоматизированных МАНК средней сложности для выявления устойчивости к рифампицину и изониазиду по сравнению с составным референсным стандартом."
      },
      "csv": "tables/table-3b.csv"
    },
    {
      "label": "Table 7A",
      "caption": "Table 7A. Output from Included tNGS Studies for the Systematic Review: Diagnostic Cost per Sample",
      "pages": [
        792
      ],
      "columns": [
        {
          "titles": "Manuscript"
        },
        {
          "titles": "Illumina MiSeq (15,000x coverage)",
          "group": "Diagnostic Cost per Sample¹,²,³ / Diagnostic Intervention (tNGS)"
        },
        {
          "titles": "Nanopore MinION",
          "group": "Diagnostic Cost per Sample¹,²,³ / Diagnostic Intervention (tNGS)"
        }
      ],
      "rows": [
        [
          "Tafess K et al (2020)",
          "$69.64",
          "$73.47"
        ]
      ],
      "notes": "1. Values are written in USD 2021 unless otherwise specified 2. Value looks at Illumina MiSeq and for lower and upper values, respectively, both at 15,000x coverage 3. Only studies with published data for each outcome were included",
      "narratives": {
        "en": "Diagnostic cost per sample of targeted next-generation sequencing (tNGS) reported by an included study, for Illumina MiSeq and Nanopore MinION platforms (2021 USD).",
        "ar": "تكلفة التشخيص لكل عينة باستخدام التسلسل الجيني الموجَّه من الجيل التالي (tNGS) كما أبلغت عنها دراسة مشمولة، لمنصتي Illumina MiSeq وNanopore MinION (بدولارات الولايات المتحدة لعام 2021).",
        "zh": "一项纳入研究报告的靶向二代测序（tNGS）每份样本诊断成本，分别列出Illumina MiSeq和Nanopore MinION平台（2021年美元）。",
        "es": "Costo diagnóstico por muestra de la secuenciación dirigida de nueva generación (tNGS) notificado por un estudio incluido, para las plataformas Illumina MiSeq y Nanopore MinION (USD de 2021).",
        "fr": "Coût diagnostique par échantillon du séquençage ciblé de nouvelle génération (tNGS) rapporté par une étude incluse, pour les plateformes Illumina MiSeq et Nanopore MinION (USD de 2021).",
        "ru": "Стоимость диагностики на один образец при таргетном секвенировании нового поколения (tNGS) по данным включенного исследования для платформ Illumina MiSeq и Nanopore MinION (в долларах США 2021 г.)."
      },
      "csv": "tables/table-7a.csv"
    },
    {
      "label": "Table 7B",
      "caption": "Table 7B. Output from Included tNGS Studies for the Systematic Review: Component Costs",
      "pages": [
        792
      ],
      "columns": [
        {
          "titles": "Manuscript"
        },
        {
          "titles": "Illumina MiSeq Instrument",
          "group": "Component costs¹,⁴ / Diagnostic Intervention (tNGS)"
        },
        {
          "titles": "Illumina NextSeq Instrument",
          "group": "Component costs¹,⁴ / Diagnostic Intervention (tNGS)"
        },
        {
          "titles": "ONT MinION Instrument",
          "group": "Component costs¹,⁴ / Diagnostic Intervention (tNGS)"
        },
        {
          "titles": "Reagents and consumables",
          "group": "Component costs¹,⁴ / Diagnostic Intervention (tNGS)"
        },
        {
          "titles": "Reagents (Nanopore MinION, 24-plex workflow)",
          "group": "Component costs¹,⁴ / Diagnostic Intervention (tNGS)"
        },
        {
          "titles": "Consumables",
          "group": "Component costs¹,⁴ / Diagnostic Intervention (tNGS)"
        }
      ],
      "rows": [
        [
          "Colman RE et al (2019)",
          "",
          "",
          "",
          "$6.20-15.32²",
          "",
          ""
        ],
        [
          "Chan WS et al (2020)",
          "",
          "",
          "",
          "",
          "$67.02",
          ""
        ],
        [
          "Gliddon HD et al (2021)",
          "",
          "",
          "",
          "",
          "",
          "$138.68²"
        ],
        [
          "Rowlinson MC and Musser KA (2022)³",
          "$125,000",
          "$210,000 - $275,000",
          "$1,000",
          "",
          "",
          ""
        ]
      ],
      "notes": "1. Values are written in 2021 USD unless otherwise specified 2. Value includes: £9.70 Moyi DNA extraction; £2.50 RPA reagents; £5.20 FFPE DNA repair mix & buffer; £7.20 Ultra II End prep mix & buffer; £7.60 blunt/TA ligase master mix; £2.15 quick ligation module; £6.66 ligation sequencing kit; £3.26 native barcoding kit; £52.92 flow cell; and £1.20 agencourt beads 3. Cost was calculated as a rough estimation, which includes flow cell ($900.00), barcoding kit ($1200.00), ligation sequencing kit ($599.00), and other reagents. It does not include salary and other fixed costs 4. Only studies with published data were for each outcome were included",
      "narratives": {
        "en": "Component costs of targeted next-generation sequencing (tNGS) reported by four included studies: sequencing instruments (Illumina MiSeq, Illumina NextSeq, ONT MinION), reagents and consumables (2021 USD).",
        "ar": "تكاليف مكونات التسلسل الجيني الموجَّه من الجيل التالي (tNGS) كما أبلغت عنها أربع دراسات مشمولة: أجهزة التسلسل (Illumina MiSeq وIllumina NextSeq وONT MinION)، والكواشف والمستهلكات (بدولارات الولايات المتحدة لعام 2021).",
        "zh": "四项纳入研究报告的靶向二代测序（tNGS）各组成部分成本：测序仪器（Illumina MiSeq、Illumina NextSeq、ONT MinION）、试剂和耗材（2021年美元）。",
        "es": "Costos por componente de la secuenciación dirigida de nueva generación (tNGS) notificados por cuatro estudios incluidos: instrumentos de secuenciación (Illumina MiSeq, Illumina NextSeq, ONT MinION), reactivos y consumibles (USD de 2021).",
        "fr": "Coûts par composante du séquençage ciblé de nouvelle génération (tNGS) rapportés par quatre études incluses : instruments de séquençage (Illumina MiSeq, Illumina NextSeq, ONT MinION), réactifs et consommables (USD de 2021).",
        "ru": "Стоимость компонентов таргетного секвенирования нового поколения (tNGS) по данным четырех включенных исследований: секвенаторы (Illumina MiSeq, Illumina NextSeq, ONT MinION), реагенты и расходные материалы (в долларах США 2021 г.)."
      },
      "csv": "tables/table-7b.csv"
    },
    {
      "label": "Table 7C",
      "caption": "Table 7C. Output from Included tNGS Studies for the Systematic Review: Costs per step",
      "pages": [
        793
      ],
      "columns": [
        {
          "titles": "Manuscript"
        },
        {
          "titles": "Target Enrichment Multiplex PCR",
          "group": "Costs per step¹,³ / Diagnostic Intervention (tNGS Illumina MiSeq)"
        },
        {
          "titles": "Library Prep",
          "group": "Costs per step¹,³ / Diagnostic Intervention (tNGS Illumina MiSeq)"
        },
        {
          "titles": "Quality Control",
          "group": "Costs per step¹,³ / Diagnostic Intervention (tNGS Illumina MiSeq)"
        },
        {
          "titles": "Sequencing",
          "group": "Costs per step¹,³ / Diagnostic Intervention (tNGS Illumina MiSeq)"
        },
        {
          "titles": "DNA Extraction",
          "group": "Costs per step¹,³ / Diagnostic Intervention (tNGS Illumina MiSeq)"
        },
        {
          "titles": "Target Enrichment Multiplex PCR",
          "group": "Costs per step¹,³ / Diagnostic Intervention (Nanopore MinION)"
        },
        {
          "titles": "Library Prep",
          "group": "Costs per step¹,³ / Diagnostic Intervention (Nanopore MinION)"
        },
        {
          "titles": "Quality Control",
          "group": "Costs per step¹,³ / Diagnostic Intervention (Nanopore MinION)"
        },
        {
          "titles": "Sequencing",
          "group": "Costs per step¹,³ / Diagnostic Intervention (Nanopore MinION)"
        },
        {
          "titles": "DNA Extraction",
          "group": "Costs per step¹,³ / Diagnostic Intervention (Nanopore MinION)"
        }
      ],
      "rows": [
        [
          "Tafess K et al (2020)²",
          "$4.15",
          "$28.56",
          "$13.78",
          "$19.52",
          "$3.64",
          "$4.15",
          "$16.11",
          "$2.52",
          "$47.08",
          "$3.64"
        ]
      ],
      "notes": "1. Values are written in 2021 USD unless otherwise specified 2. Value looks at Illumina MiSeq and Nanopore MinION for lower and upper values, respectively, both at 15,000x coverage 5. Only studies with published data for each outcome were included [Draft note: footnote numbered '5' as printed although the header cites footnote 3.]",
      "narratives": {
        "en": "Costs per laboratory step (target enrichment by multiplex PCR, library preparation, quality control, sequencing and DNA extraction) of targeted next-generation sequencing on Illumina MiSeq and Nanopore MinION, from one included study (2021 USD).",
        "ar": "تكاليف كل خطوة مختبرية (الإثراء المستهدف بتفاعل البوليميراز المتسلسل المتعدد، وتحضير المكتبة، ومراقبة الجودة، والتسلسل، واستخلاص الحمض النووي) للتسلسل الجيني الموجَّه من الجيل التالي على Illumina MiSeq وNanopore MinION، من دراسة مشمولة واحدة (بدولارات الولايات المتحدة لعام 2021).",
        "zh": "一项纳入研究中，在Illumina MiSeq和Nanopore MinION上进行靶向二代测序各实验室步骤（多重PCR靶向富集、文库制备、质量控制、测序和DNA提取）的成本（2021年美元）。",
        "es": "Costos por etapa de laboratorio (enriquecimiento dirigido por PCR múltiple, preparación de bibliotecas, control de calidad, secuenciación y extracción de ADN) de la secuenciación dirigida de nueva generación en Illumina MiSeq y Nanopore MinION, según un estudio incluido (USD de 2021).",
        "fr": "Coûts par étape de laboratoire (enrichissement ciblé par PCR multiplex, préparation des banques, contrôle de la qualité, séquençage et extraction de l’ADN) du séquençage ciblé de nouvelle génération sur Illumina MiSeq et Nanopore MinION, d’après une étude incluse (USD de 2021).",
        "ru": "Стоимость каждого лабораторного этапа (таргетное обогащение мультиплексной ПЦР, подготовка библиотеки, контроль качества, секвенирование и экстракция ДНК) таргетного секвенирования нового поколения на Illumina MiSeq и Nanopore MinION по данным одного включенного исследования (в долларах США 2021 г.)."
      },
      "csv": "tables/table-7c.csv"
    },
    {
      "label": "Table 8A",
      "caption": "Table 8A. Output from Included tNGS and WGS Studies for the Systematic Review: Costing Data, Cates et al. (2022)",
      "pages": [
        793
      ],
      "columns": [
        {
          "titles": "Manuscript"
        },
        {
          "titles": "Labor",
          "group": "Diagnostic cost per sample¹,² / Diagnostic Intervention (tNGS Illumina iSeq100) / SSM+ or Xpert+, excluding Xpert/RIF-"
        },
        {
          "titles": "Equipment",
          "group": "Diagnostic cost per sample¹,² / Diagnostic Intervention (tNGS Illumina iSeq100) / SSM+ or Xpert+, excluding Xpert/RIF-"
        },
        {
          "titles": "Reagents & Consumables",
          "group": "Diagnostic cost per sample¹,² / Diagnostic Intervention (tNGS Illumina iSeq100) / SSM+ or Xpert+, excluding Xpert/RIF-"
        },
        {
          "titles": "Training",
          "group": "Diagnostic cost per sample¹,² / Diagnostic Intervention (tNGS Illumina iSeq100) / SSM+ or Xpert+, excluding Xpert/RIF-"
        },
        {
          "titles": "Maintenance",
          "group": "Diagnostic cost per sample¹,² / Diagnostic Intervention (tNGS Illumina iSeq100) / SSM+ or Xpert+, excluding Xpert/RIF-"
        },
        {
          "titles": "Total",
          "group": "Diagnostic cost per sample¹,² / Diagnostic Intervention (tNGS Illumina iSeq100) / SSM+ or Xpert+, excluding Xpert/RIF-"
        },
        {
          "titles": "Labor",
          "group": "Diagnostic cost per sample¹,² / Diagnostic Intervention (tNGS Illumina iSeq100) / All SSM+ or Xpert+"
        },
        {
          "titles": "Equipment",
          "group": "Diagnostic cost per sample¹,² / Diagnostic Intervention (tNGS Illumina iSeq100) / All SSM+ or Xpert+"
        },
        {
          "titles": "Reagents & Consumables",
          "group": "Diagnostic cost per sample¹,² / Diagnostic Intervention (tNGS Illumina iSeq100) / All SSM+ or Xpert+"
        },
        {
          "titles": "Training",
          "group": "Diagnostic cost per sample¹,² / Diagnostic Intervention (tNGS Illumina iSeq100) / All SSM+ or Xpert+"
        },
        {
          "titles": "Maintenance",
          "group": "Diagnostic cost per sample¹,² / Diagnostic Intervention (tNGS Illumina iSeq100) / All SSM+ or Xpert+"
        },
        {
          "titles": "Total",
          "group": "Diagnostic cost per sample¹,² / Diagnostic Intervention (tNGS Illumina iSeq100) / All SSM+ or Xpert+"
        },
        {
          "titles": "Labor",
          "group": "Diagnostic cost per sample¹,² / Diagnostic Intervention (tNGS Illumina iSeq100) / All SSM+ or Xpert+, plus pDST"
        },
        {
          "titles": "Equipment",
          "group": "Diagnostic cost per sample¹,² / Diagnostic Intervention (tNGS Illumina iSeq100) / All SSM+ or Xpert+, plus pDST"
        },
        {
          "titles": "Reagents & Consumables",
          "group": "Diagnostic cost per sample¹,² / Diagnostic Intervention (tNGS Illumina iSeq100) / All SSM+ or Xpert+, plus pDST"
        },
        {
          "titles": "Training",
          "group": "Diagnostic cost per sample¹,² / Diagnostic Intervention (tNGS Illumina iSeq100) / All SSM+ or Xpert+, plus pDST"
        },
        {
          "titles": "Maintenance",
          "group": "Diagnostic cost per sample¹,² / Diagnostic Intervention (tNGS Illumina iSeq100) / All SSM+ or Xpert+, plus pDST"
        },
        {
          "titles": "Total",
          "group": "Diagnostic cost per sample¹,² / Diagnostic Intervention (tNGS Illumina iSeq100) / All SSM+ or Xpert+, plus pDST"
        }
      ],
      "rows": [
        [
          "Cates L et al (2022)",
          "$1.40",
          "$19.34",
          "$97.94",
          "$0.70",
          "$20.74",
          "$140.12",
          "$0.64",
          "$8.84",
          "$71.93",
          "$0.36",
          "$9.48",
          "$91.17",
          "$7.10",
          "$18.58",
          "$99.19",
          "$0.96",
          "$10.93",
          "$136.63"
        ]
      ],
      "notes": "1. Values are written in 2021 USD unless otherwise specified 2. Component costs determined by multiplying proportions with cost per sample, verified by authors",
      "narratives": {
        "en": "Diagnostic cost per sample reported by Cates et al. (2022), broken down into labour, equipment, reagents and consumables, training, maintenance and total (2021 USD), for three testing scenarios: SSM+ or Xpert+, excluding Xpert/RIF- (Diagnostic Intervention (tNGS Illumina iSeq100)); All SSM+ or Xpert+ (Diagnostic Intervention (tNGS Illumina iSeq100)); All SSM+ or Xpert+, plus pDST (Diagnostic Intervention (tNGS Illumina iSeq100)).",
        "ar": "تكلفة التشخيص لكل عينة كما أبلغ عنها Cates وآخرون (2022)، مفصّلة إلى العمالة والمعدات والكواشف والمستهلكات والتدريب والصيانة والإجمالي (بدولارات الولايات المتحدة لعام 2021)، لثلاثة سيناريوهات اختبار: SSM+ or Xpert+, excluding Xpert/RIF- (Diagnostic Intervention (tNGS Illumina iSeq100)); All SSM+ or Xpert+ (Diagnostic Intervention (tNGS Illumina iSeq100)); All SSM+ or Xpert+, plus pDST (Diagnostic Intervention (tNGS Illumina iSeq100)).",
        "zh": "Cates等（2022）报告的每份样本诊断成本，按人工、设备、试剂和耗材、培训、维护及合计分列（2021年美元），涵盖三种检测情景：SSM+ or Xpert+, excluding Xpert/RIF- (Diagnostic Intervention (tNGS Illumina iSeq100)); All SSM+ or Xpert+ (Diagnostic Intervention (tNGS Illumina iSeq100)); All SSM+ or Xpert+, plus pDST (Diagnostic Intervention (tNGS Illumina iSeq100))。",
        "es": "Costo diagnóstico por muestra notificado por Cates et al. (2022), desglosado en mano de obra, equipo, reactivos y consumibles, capacitación, mantenimiento y total (USD de 2021), para tres escenarios de pruebas: SSM+ or Xpert+, excluding Xpert/RIF- (Diagnostic Intervention (tNGS Illumina iSeq100)); All SSM+ or Xpert+ (Diagnostic Intervention (tNGS Illumina iSeq100)); All SSM+ or Xpert+, plus pDST (Diagnostic Intervention (tNGS Illumina iSeq100)).",
        "fr": "Coût diagnostique par échantillon rapporté par Cates et al. (2022), ventilé en main-d’œuvre, équipement, réactifs et consommables, formation, maintenance et total (USD de 2021), pour trois scénarios de test : SSM+ or Xpert+, excluding Xpert/RIF- (Diagnostic Intervention (tNGS Illumina iSeq100)); All SSM+ or Xpert+ (Diagnostic Intervention (tNGS Illumina iSeq100)); All SSM+ or Xpert+, plus pDST (Diagnostic Intervention (tNGS Illumina iSeq100)).",
        "ru": "Стоимость диагностики на один образец по данным Cates и соавт. (2022) с разбивкой на оплату труда, оборудование, реагенты и расходные материалы, обучение, техническое обслуживание и итог (в долларах США 2021 г.) для трех сценариев тестирования: SSM+ or Xpert+, excluding Xpert/RIF- (Diagnostic Intervention (tNGS Illumina iSeq100)); All SSM+ or Xpert+ (Diagnostic Intervention (tNGS Illumina iSeq100)); All SSM+ or Xpert+, plus pDST (Diagnostic Intervention (tNGS Illumina iSeq100))."
      },
      "csv": "tables/table-8a.csv"
    },
    {
      "label": "Table 8B",
      "caption": "Table 8B. Output from Included tNGS and WGS Studies for the Systematic Review: Costing Data, Cates et al. (2022)",
      "pages": [
        793
      ],
      "columns": [
        {
          "titles": "Manuscript"
        },
        {
          "titles": "Labor",
          "group": "Diagnostic cost per sample¹,² / Diagnostic Intervention (tNGS Illumina iSeq100) / All culture+"
        },
        {
          "titles": "Equipment",
          "group": "Diagnostic cost per sample¹,² / Diagnostic Intervention (tNGS Illumina iSeq100) / All culture+"
        },
        {
          "titles": "Reagents & Consumables",
          "group": "Diagnostic cost per sample¹,² / Diagnostic Intervention (tNGS Illumina iSeq100) / All culture+"
        },
        {
          "titles": "Training",
          "group": "Diagnostic cost per sample¹,² / Diagnostic Intervention (tNGS Illumina iSeq100) / All culture+"
        },
        {
          "titles": "Maintenance",
          "group": "Diagnostic cost per sample¹,² / Diagnostic Intervention (tNGS Illumina iSeq100) / All culture+"
        },
        {
          "titles": "Total",
          "group": "Diagnostic cost per sample¹,² / Diagnostic Intervention (tNGS Illumina iSeq100) / All culture+"
        },
        {
          "titles": "Labor",
          "group": "Diagnostic cost per sample¹,² / Diagnostic Intervention (tNGS Illumina iSeq100) / All culture+ excluding Xpert/RIF-"
        },
        {
          "titles": "Equipment",
          "group": "Diagnostic cost per sample¹,² / Diagnostic Intervention (tNGS Illumina iSeq100) / All culture+ excluding Xpert/RIF-"
        },
        {
          "titles": "Reagents & Consumables",
          "group": "Diagnostic cost per sample¹,² / Diagnostic Intervention (tNGS Illumina iSeq100) / All culture+ excluding Xpert/RIF-"
        },
        {
          "titles": "Training",
          "group": "Diagnostic cost per sample¹,² / Diagnostic Intervention (tNGS Illumina iSeq100) / All culture+ excluding Xpert/RIF-"
        },
        {
          "titles": "Maintenance",
          "group": "Diagnostic cost per sample¹,² / Diagnostic Intervention (tNGS Illumina iSeq100) / All culture+ excluding Xpert/RIF-"
        },
        {
          "titles": "Total",
          "group": "Diagnostic cost per sample¹,² / Diagnostic Intervention (tNGS Illumina iSeq100) / All culture+ excluding Xpert/RIF-"
        },
        {
          "titles": "Labor",
          "group": "Diagnostic cost per sample¹,² / Diagnostic Intervention (tNGS Illumina iSeq100) / All culture+, plust pDST"
        },
        {
          "titles": "Equipment",
          "group": "Diagnostic cost per sample¹,² / Diagnostic Intervention (tNGS Illumina iSeq100) / All culture+, plust pDST"
        },
        {
          "titles": "Reagents & Consumables",
          "group": "Diagnostic cost per sample¹,² / Diagnostic Intervention (tNGS Illumina iSeq100) / All culture+, plust pDST"
        },
        {
          "titles": "Training",
          "group": "Diagnostic cost per sample¹,² / Diagnostic Intervention (tNGS Illumina iSeq100) / All culture+, plust pDST"
        },
        {
          "titles": "Maintenance",
          "group": "Diagnostic cost per sample¹,² / Diagnostic Intervention (tNGS Illumina iSeq100) / All culture+, plust pDST"
        },
        {
          "titles": "Total",
          "group": "Diagnostic cost per sample¹,² / Diagnostic Intervention (tNGS Illumina iSeq100) / All culture+, plust pDST"
        }
      ],
      "rows": [
        [
          "Cates L et al (2022)",
          "$0.51",
          "$7.59",
          "$68.74",
          "$0.26",
          "$8.10",
          "$85.28",
          "$1.04",
          "$14.16",
          "$85.17",
          "$0.46",
          "$15.20",
          "$116.03",
          "$7.01",
          "$15.90",
          "$92.24",
          "$0.88",
          "$9.26",
          "$125.16"
        ]
      ],
      "notes": "1. Values are written in 2021 USD unless otherwise specified 2. Component costs determined by multiplying proportions with cost per sample, verified by authors",
      "narratives": {
        "en": "Diagnostic cost per sample reported by Cates et al. (2022), broken down into labour, equipment, reagents and consumables, training, maintenance and total (2021 USD), for three testing scenarios: All culture+ (Diagnostic Intervention (tNGS Illumina iSeq100)); All culture+ excluding Xpert/RIF- (Diagnostic Intervention (tNGS Illumina iSeq100)); All culture+, plust pDST (Diagnostic Intervention (tNGS Illumina iSeq100)).",
        "ar": "تكلفة التشخيص لكل عينة كما أبلغ عنها Cates وآخرون (2022)، مفصّلة إلى العمالة والمعدات والكواشف والمستهلكات والتدريب والصيانة والإجمالي (بدولارات الولايات المتحدة لعام 2021)، لثلاثة سيناريوهات اختبار: All culture+ (Diagnostic Intervention (tNGS Illumina iSeq100)); All culture+ excluding Xpert/RIF- (Diagnostic Intervention (tNGS Illumina iSeq100)); All culture+, plust pDST (Diagnostic Intervention (tNGS Illumina iSeq100)).",
        "zh": "Cates等（2022）报告的每份样本诊断成本，按人工、设备、试剂和耗材、培训、维护及合计分列（2021年美元），涵盖三种检测情景：All culture+ (Diagnostic Intervention (tNGS Illumina iSeq100)); All culture+ excluding Xpert/RIF- (Diagnostic Intervention (tNGS Illumina iSeq100)); All culture+, plust pDST (Diagnostic Intervention (tNGS Illumina iSeq100))。",
        "es": "Costo diagnóstico por muestra notificado por Cates et al. (2022), desglosado en mano de obra, equipo, reactivos y consumibles, capacitación, mantenimiento y total (USD de 2021), para tres escenarios de pruebas: All culture+ (Diagnostic Intervention (tNGS Illumina iSeq100)); All culture+ excluding Xpert/RIF- (Diagnostic Intervention (tNGS Illumina iSeq100)); All culture+, plust pDST (Diagnostic Intervention (tNGS Illumina iSeq100)).",
        "fr": "Coût diagnostique par échantillon rapporté par Cates et al. (2022), ventilé en main-d’œuvre, équipement, réactifs et consommables, formation, maintenance et total (USD de 2021), pour trois scénarios de test : All culture+ (Diagnostic Intervention (tNGS Illumina iSeq100)); All culture+ excluding Xpert/RIF- (Diagnostic Intervention (tNGS Illumina iSeq100)); All culture+, plust pDST (Diagnostic Intervention (tNGS Illumina iSeq100)).",
        "ru": "Стоимость диагностики на один образец по данным Cates и соавт. (2022) с разбивкой на оплату труда, оборудование, реагенты и расходные материалы, обучение, техническое обслуживание и итог (в долларах США 2021 г.) для трех сценариев тестирования: All culture+ (Diagnostic Intervention (tNGS Illumina iSeq100)); All culture+ excluding Xpert/RIF- (Diagnostic Intervention (tNGS Illumina iSeq100)); All culture+, plust pDST (Diagnostic Intervention (tNGS Illumina iSeq100))."
      },
      "csv": "tables/table-8b.csv"
    },
    {
      "label": "Table 8C",
      "caption": "Table 8C. Output from Included tNGS and WGS Studies for the Systematic Review: Costing Data, Cates et al. (2022)",
      "pages": [
        794
      ],
      "columns": [
        {
          "titles": "Manuscript"
        },
        {
          "titles": "Labor",
          "group": "Diagnostic cost per sample¹,² / Diagnostic Intervention (tNGS Illumina iSeq100) / All culture+ excluding Xpert/RIF-, plus pDST"
        },
        {
          "titles": "Equipment",
          "group": "Diagnostic cost per sample¹,² / Diagnostic Intervention (tNGS Illumina iSeq100) / All culture+ excluding Xpert/RIF-, plus pDST"
        },
        {
          "titles": "Reagents & Consumables",
          "group": "Diagnostic cost per sample¹,² / Diagnostic Intervention (tNGS Illumina iSeq100) / All culture+ excluding Xpert/RIF-, plus pDST"
        },
        {
          "titles": "Training",
          "group": "Diagnostic cost per sample¹,² / Diagnostic Intervention (tNGS Illumina iSeq100) / All culture+ excluding Xpert/RIF-, plus pDST"
        },
        {
          "titles": "Maintenance",
          "group": "Diagnostic cost per sample¹,² / Diagnostic Intervention (tNGS Illumina iSeq100) / All culture+ excluding Xpert/RIF-, plus pDST"
        },
        {
          "titles": "Total",
          "group": "Diagnostic cost per sample¹,² / Diagnostic Intervention (tNGS Illumina iSeq100) / All culture+ excluding Xpert/RIF-, plus pDST"
        },
        {
          "titles": "Labor",
          "group": "Diagnostic cost per sample¹,² / Diagnostic Intervention (WGS Illumina MiSeq) / All culture+"
        },
        {
          "titles": "Equipment",
          "group": "Diagnostic cost per sample¹,² / Diagnostic Intervention (WGS Illumina MiSeq) / All culture+"
        },
        {
          "titles": "Reagents & Consumables",
          "group": "Diagnostic cost per sample¹,² / Diagnostic Intervention (WGS Illumina MiSeq) / All culture+"
        },
        {
          "titles": "Training",
          "group": "Diagnostic cost per sample¹,² / Diagnostic Intervention (WGS Illumina MiSeq) / All culture+"
        },
        {
          "titles": "Maintenance",
          "group": "Diagnostic cost per sample¹,² / Diagnostic Intervention (WGS Illumina MiSeq) / All culture+"
        },
        {
          "titles": "Total",
          "group": "Diagnostic cost per sample¹,² / Diagnostic Intervention (WGS Illumina MiSeq) / All culture+"
        },
        {
          "titles": "Labor",
          "group": "Diagnostic cost per sample¹,² / Diagnostic Intervention (WGS Illumina MiSeq) / All culture+ excluding Xpert/RIF-"
        },
        {
          "titles": "Equipment",
          "group": "Diagnostic cost per sample¹,² / Diagnostic Intervention (WGS Illumina MiSeq) / All culture+ excluding Xpert/RIF-"
        },
        {
          "titles": "Reagents & Consumables",
          "group": "Diagnostic cost per sample¹,² / Diagnostic Intervention (WGS Illumina MiSeq) / All culture+ excluding Xpert/RIF-"
        },
        {
          "titles": "Training",
          "group": "Diagnostic cost per sample¹,² / Diagnostic Intervention (WGS Illumina MiSeq) / All culture+ excluding Xpert/RIF-"
        },
        {
          "titles": "Maintenance",
          "group": "Diagnostic cost per sample¹,² / Diagnostic Intervention (WGS Illumina MiSeq) / All culture+ excluding Xpert/RIF-"
        },
        {
          "titles": "Total",
          "group": "Diagnostic cost per sample¹,² / Diagnostic Intervention (WGS Illumina MiSeq) / All culture+ excluding Xpert/RIF-"
        }
      ],
      "rows": [
        [
          "Cates L et al (2022)",
          "$7.40",
          "$29.61",
          "$128.97",
          "$1.48",
          "$17.39",
          "$185.04",
          "$1.98",
          "$26.15",
          "$82.55",
          "$0.25",
          "$13.01",
          "$123.95",
          "$2.52",
          "$48.97",
          "$91.40",
          "$0.50",
          "$24.32",
          "$167.70"
        ]
      ],
      "notes": "1. Values are written in 2021 USD unless otherwise specified 2. Component costs determined by multiplying proportions with cost per sample, verified by authors",
      "narratives": {
        "en": "Diagnostic cost per sample reported by Cates et al. (2022), broken down into labour, equipment, reagents and consumables, training, maintenance and total (2021 USD), for three testing scenarios: All culture+ excluding Xpert/RIF-, plus pDST (Diagnostic Intervention (tNGS Illumina iSeq100)); All culture+ (Diagnostic Intervention (WGS Illumina MiSeq)); All culture+ excluding Xpert/RIF- (Diagnostic Intervention (WGS Illumina MiSeq)).",
        "ar": "تكلفة التشخيص لكل عينة كما أبلغ عنها Cates وآخرون (2022)، مفصّلة إلى العمالة والمعدات والكواشف والمستهلكات والتدريب والصيانة والإجمالي (بدولارات الولايات المتحدة لعام 2021)، لثلاثة سيناريوهات اختبار: All culture+ excluding Xpert/RIF-, plus pDST (Diagnostic Intervention (tNGS Illumina iSeq100)); All culture+ (Diagnostic Intervention (WGS Illumina MiSeq)); All culture+ excluding Xpert/RIF- (Diagnostic Intervention (WGS Illumina MiSeq)).",
        "zh": "Cates等（2022）报告的每份样本诊断成本，按人工、设备、试剂和耗材、培训、维护及合计分列（2021年美元），涵盖三种检测情景：All culture+ excluding Xpert/RIF-, plus pDST (Diagnostic Intervention (tNGS Illumina iSeq100)); All culture+ (Diagnostic Intervention (WGS Illumina MiSeq)); All culture+ excluding Xpert/RIF- (Diagnostic Intervention (WGS Illumina MiSeq))。",
        "es": "Costo diagnóstico por muestra notificado por Cates et al. (2022), desglosado en mano de obra, equipo, reactivos y consumibles, capacitación, mantenimiento y total (USD de 2021), para tres escenarios de pruebas: All culture+ excluding Xpert/RIF-, plus pDST (Diagnostic Intervention (tNGS Illumina iSeq100)); All culture+ (Diagnostic Intervention (WGS Illumina MiSeq)); All culture+ excluding Xpert/RIF- (Diagnostic Intervention (WGS Illumina MiSeq)).",
        "fr": "Coût diagnostique par échantillon rapporté par Cates et al. (2022), ventilé en main-d’œuvre, équipement, réactifs et consommables, formation, maintenance et total (USD de 2021), pour trois scénarios de test : All culture+ excluding Xpert/RIF-, plus pDST (Diagnostic Intervention (tNGS Illumina iSeq100)); All culture+ (Diagnostic Intervention (WGS Illumina MiSeq)); All culture+ excluding Xpert/RIF- (Diagnostic Intervention (WGS Illumina MiSeq)).",
        "ru": "Стоимость диагностики на один образец по данным Cates и соавт. (2022) с разбивкой на оплату труда, оборудование, реагенты и расходные материалы, обучение, техническое обслуживание и итог (в долларах США 2021 г.) для трех сценариев тестирования: All culture+ excluding Xpert/RIF-, plus pDST (Diagnostic Intervention (tNGS Illumina iSeq100)); All culture+ (Diagnostic Intervention (WGS Illumina MiSeq)); All culture+ excluding Xpert/RIF- (Diagnostic Intervention (WGS Illumina MiSeq))."
      },
      "csv": "tables/table-8c.csv"
    },
    {
      "label": "Table 8D",
      "caption": "Table 8D. Output from Included tNGS and WGS Studies for the Systematic Review: Costing Data, Cates et al. (2022)",
      "pages": [
        794
      ],
      "columns": [
        {
          "titles": "Manuscript"
        },
        {
          "titles": "Labor",
          "group": "Diagnostic cost per sample¹,² / All culture+, plust pDST"
        },
        {
          "titles": "Equipment",
          "group": "Diagnostic cost per sample¹,² / All culture+, plust pDST"
        },
        {
          "titles": "Reagents & Consumables",
          "group": "Diagnostic cost per sample¹,² / All culture+, plust pDST"
        },
        {
          "titles": "Training",
          "group": "Diagnostic cost per sample¹,² / All culture+, plust pDST"
        },
        {
          "titles": "Maintenance",
          "group": "Diagnostic cost per sample¹,² / All culture+, plust pDST"
        },
        {
          "titles": "Total",
          "group": "Diagnostic cost per sample¹,² / All culture+, plust pDST"
        },
        {
          "titles": "Labor",
          "group": "Diagnostic cost per sample¹,² / All culture+ excluding Xpert/RIF-, plus pDST"
        },
        {
          "titles": "Equipment",
          "group": "Diagnostic cost per sample¹,² / All culture+ excluding Xpert/RIF-, plus pDST"
        },
        {
          "titles": "Reagents & Consumables",
          "group": "Diagnostic cost per sample¹,² / All culture+ excluding Xpert/RIF-, plus pDST"
        },
        {
          "titles": "Training",
          "group": "Diagnostic cost per sample¹,² / All culture+ excluding Xpert/RIF-, plus pDST"
        },
        {
          "titles": "Maintenance",
          "group": "Diagnostic cost per sample¹,² / All culture+ excluding Xpert/RIF-, plus pDST"
        },
        {
          "titles": "Total",
          "group": "Diagnostic cost per sample¹,² / All culture+ excluding Xpert/RIF-, plus pDST"
        },
        {
          "titles": "Labor",
          "group": "Diagnostic cost per sample¹,² / Diagnostic Comparitor (pDST) / N/A"
        },
        {
          "titles": "Equipment",
          "group": "Diagnostic cost per sample¹,² / Diagnostic Comparitor (pDST) / N/A"
        },
        {
          "titles": "Reagents & Consumables",
          "group": "Diagnostic cost per sample¹,² / Diagnostic Comparitor (pDST) / N/A"
        },
        {
          "titles": "Training",
          "group": "Diagnostic cost per sample¹,² / Diagnostic Comparitor (pDST) / N/A"
        },
        {
          "titles": "Maintenance",
          "group": "Diagnostic cost per sample¹,² / Diagnostic Comparitor (pDST) / N/A"
        },
        {
          "titles": "Total",
          "group": "Diagnostic cost per sample¹,² / Diagnostic Comparitor (pDST) / N/A"
        }
      ],
      "rows": [
        [
          "Cates L et al (2022)",
          "$8.36",
          "$34.57",
          "$105.83",
          "$0.82",
          "$14.25",
          "$163.83",
          "$8.99",
          "$64.39",
          "$135.16",
          "$1.66",
          "$26.51",
          "$236.71",
          "$6.38",
          "$8.30",
          "$23.41",
          "$0.56",
          "$1.20",
          "$39.88"
        ]
      ],
      "notes": "1. Values are written in 2021 USD unless otherwise specified 2. Component costs determined by multiplying proportions with cost per sample, verified by authors [Draft note: the second header level is blank over the first two scenario blocks (presumably the WGS Illumina MiSeq intervention continued from Table 8C).]",
      "narratives": {
        "en": "Diagnostic cost per sample reported by Cates et al. (2022), broken down into labour, equipment, reagents and consumables, training, maintenance and total (2021 USD), for three testing scenarios: All culture+, plust pDST (); All culture+ excluding Xpert/RIF-, plus pDST (); N/A (Diagnostic Comparitor (pDST)).",
        "ar": "تكلفة التشخيص لكل عينة كما أبلغ عنها Cates وآخرون (2022)، مفصّلة إلى العمالة والمعدات والكواشف والمستهلكات والتدريب والصيانة والإجمالي (بدولارات الولايات المتحدة لعام 2021)، لثلاثة سيناريوهات اختبار: All culture+, plust pDST (); All culture+ excluding Xpert/RIF-, plus pDST (); N/A (Diagnostic Comparitor (pDST)).",
        "zh": "Cates等（2022）报告的每份样本诊断成本，按人工、设备、试剂和耗材、培训、维护及合计分列（2021年美元），涵盖三种检测情景：All culture+, plust pDST (); All culture+ excluding Xpert/RIF-, plus pDST (); N/A (Diagnostic Comparitor (pDST))。",
        "es": "Costo diagnóstico por muestra notificado por Cates et al. (2022), desglosado en mano de obra, equipo, reactivos y consumibles, capacitación, mantenimiento y total (USD de 2021), para tres escenarios de pruebas: All culture+, plust pDST (); All culture+ excluding Xpert/RIF-, plus pDST (); N/A (Diagnostic Comparitor (pDST)).",
        "fr": "Coût diagnostique par échantillon rapporté par Cates et al. (2022), ventilé en main-d’œuvre, équipement, réactifs et consommables, formation, maintenance et total (USD de 2021), pour trois scénarios de test : All culture+, plust pDST (); All culture+ excluding Xpert/RIF-, plus pDST (); N/A (Diagnostic Comparitor (pDST)).",
        "ru": "Стоимость диагностики на один образец по данным Cates и соавт. (2022) с разбивкой на оплату труда, оборудование, реагенты и расходные материалы, обучение, техническое обслуживание и итог (в долларах США 2021 г.) для трех сценариев тестирования: All culture+, plust pDST (); All culture+ excluding Xpert/RIF-, plus pDST (); N/A (Diagnostic Comparitor (pDST))."
      },
      "csv": "tables/table-8d.csv"
    },
    {
      "label": "Table 9A",
      "caption": "Table 9A. Output from Included tNGS and WGS Studies for the Systematic Review: BIA, Cates et al. (2022)",
      "pages": [
        794
      ],
      "columns": [
        {
          "titles": "Manuscript"
        },
        {
          "titles": "Year 1 (start-up)",
          "group": "Total Budget Impact Estimates¹ / pDST"
        },
        {
          "titles": "Year 2",
          "group": "Total Budget Impact Estimates¹ / pDST"
        },
        {
          "titles": "Year 3",
          "group": "Total Budget Impact Estimates¹ / pDST"
        },
        {
          "titles": "Year 4",
          "group": "Total Budget Impact Estimates¹ / pDST"
        },
        {
          "titles": "Year 5",
          "group": "Total Budget Impact Estimates¹ / pDST"
        },
        {
          "titles": "Total",
          "group": "Total Budget Impact Estimates¹ / pDST"
        },
        {
          "titles": "Year 1 (start-up)",
          "group": "Total Budget Impact Estimates¹ / tNGS for all culture+"
        },
        {
          "titles": "Year 2",
          "group": "Total Budget Impact Estimates¹ / tNGS for all culture+"
        },
        {
          "titles": "Year 3",
          "group": "Total Budget Impact Estimates¹ / tNGS for all culture+"
        },
        {
          "titles": "Year 4",
          "group": "Total Budget Impact Estimates¹ / tNGS for all culture+"
        },
        {
          "titles": "Year 5",
          "group": "Total Budget Impact Estimates¹ / tNGS for all culture+"
        },
        {
          "titles": "Total",
          "group": "Total Budget Impact Estimates¹ / tNGS for all culture+"
        },
        {
          "titles": "Year 1 (start-up)",
          "group": "Total Budget Impact Estimates¹ / tNGS for all culture+, excluding Xpert/RIF-"
        },
        {
          "titles": "Year 2",
          "group": "Total Budget Impact Estimates¹ / tNGS for all culture+, excluding Xpert/RIF-"
        },
        {
          "titles": "Year 3",
          "group": "Total Budget Impact Estimates¹ / tNGS for all culture+, excluding Xpert/RIF-"
        },
        {
          "titles": "Year 4",
          "group": "Total Budget Impact Estimates¹ / tNGS for all culture+, excluding Xpert/RIF-"
        },
        {
          "titles": "Year 5",
          "group": "Total Budget Impact Estimates¹ / tNGS for all culture+, excluding Xpert/RIF-"
        },
        {
          "titles": "Total",
          "group": "Total Budget Impact Estimates¹ / tNGS for all culture+, excluding Xpert/RIF-"
        }
      ],
      "rows": [
        [
          "Cates L et al (2022)",
          "$76,811.00",
          "$74,507.00",
          "$72,272.00",
          "$70,104.00",
          "$68,001.00",
          "$361,695.00",
          "$194,530.00",
          "$150,463.00",
          "$146,577.00",
          "$142,808.00",
          "$139,151.00",
          "$773,528.00",
          "$149,772.00",
          "$107,047.00",
          "$104,464.00",
          "$101,958.00",
          "$99,528.00",
          "$562,769.00"
        ]
      ],
      "notes": "1. Values are written in 2021 USD unless otherwise specified",
      "narratives": {
        "en": "Total budget impact estimates reported by Cates et al. (2022) for years 1 (start-up) to 5 and in total (2021 USD), for three testing strategies: pDST; tNGS for all culture+; tNGS for all culture+, excluding Xpert/RIF-.",
        "ar": "تقديرات الأثر الإجمالي على الميزانية كما أبلغ عنها Cates وآخرون (2022) للسنوات من 1 (بدء التشغيل) إلى 5 وبالإجمال (بدولارات الولايات المتحدة لعام 2021)، لثلاث استراتيجيات اختبار: pDST; tNGS for all culture+; tNGS for all culture+, excluding Xpert/RIF-.",
        "zh": "Cates等（2022）报告的第1年（启动）至第5年及合计的总预算影响估计（2021年美元），涵盖三种检测策略：pDST; tNGS for all culture+; tNGS for all culture+, excluding Xpert/RIF-。",
        "es": "Estimaciones del impacto presupuestario total notificadas por Cates et al. (2022) para los años 1 (puesta en marcha) a 5 y en total (USD de 2021), para tres estrategias de pruebas: pDST; tNGS for all culture+; tNGS for all culture+, excluding Xpert/RIF-.",
        "fr": "Estimations de l’impact budgétaire total rapportées par Cates et al. (2022) pour les années 1 (démarrage) à 5 et au total (USD de 2021), pour trois stratégies de test : pDST; tNGS for all culture+; tNGS for all culture+, excluding Xpert/RIF-.",
        "ru": "Оценки общего влияния на бюджет по данным Cates и соавт. (2022) за годы с 1-го (запуск) по 5-й и в целом (в долларах США 2021 г.) для трех стратегий тестирования: pDST; tNGS for all culture+; tNGS for all culture+, excluding Xpert/RIF-."
      },
      "csv": "tables/table-9a.csv"
    },
    {
      "label": "Table 9B",
      "caption": "Table 9B. Output from Included tNGS and WGS Studies for the Systematic Review: BIA, Cates et al. (2022)",
      "pages": [
        795
      ],
      "columns": [
        {
          "titles": "Manuscript"
        },
        {
          "titles": "Year 1 (start-up)",
          "group": "Total Budget Impact Estimates¹ / tNGS for all SSM+ or Xpert+"
        },
        {
          "titles": "Year 2",
          "group": "Total Budget Impact Estimates¹ / tNGS for all SSM+ or Xpert+"
        },
        {
          "titles": "Year 3",
          "group": "Total Budget Impact Estimates¹ / tNGS for all SSM+ or Xpert+"
        },
        {
          "titles": "Year 4",
          "group": "Total Budget Impact Estimates¹ / tNGS for all SSM+ or Xpert+"
        },
        {
          "titles": "Year 5",
          "group": "Total Budget Impact Estimates¹ / tNGS for all SSM+ or Xpert+"
        },
        {
          "titles": "Total",
          "group": "Total Budget Impact Estimates¹ / tNGS for all SSM+ or Xpert+"
        },
        {
          "titles": "Year 1 (start-up)",
          "group": "Total Budget Impact Estimates¹ / tNGS for all SSM+ or Xpert+, excluding Xpert/RIF-"
        },
        {
          "titles": "Year 2",
          "group": "Total Budget Impact Estimates¹ / tNGS for all SSM+ or Xpert+, excluding Xpert/RIF-"
        },
        {
          "titles": "Year 3",
          "group": "Total Budget Impact Estimates¹ / tNGS for all SSM+ or Xpert+, excluding Xpert/RIF-"
        },
        {
          "titles": "Year 4",
          "group": "Total Budget Impact Estimates¹ / tNGS for all SSM+ or Xpert+, excluding Xpert/RIF-"
        },
        {
          "titles": "Year 5",
          "group": "Total Budget Impact Estimates¹ / tNGS for all SSM+ or Xpert+, excluding Xpert/RIF-"
        },
        {
          "titles": "Total",
          "group": "Total Budget Impact Estimates¹ / tNGS for all SSM+ or Xpert+, excluding Xpert/RIF-"
        },
        {
          "titles": "Year 1 (start-up)",
          "group": "Total Budget Impact Estimates¹ / tNGS for all SSM+ or Xpert+, plus pDST"
        },
        {
          "titles": "Year 2",
          "group": "Total Budget Impact Estimates¹ / tNGS for all SSM+ or Xpert+, plus pDST"
        },
        {
          "titles": "Year 3",
          "group": "Total Budget Impact Estimates¹ / tNGS for all SSM+ or Xpert+, plus pDST"
        },
        {
          "titles": "Year 4",
          "group": "Total Budget Impact Estimates¹ / tNGS for all SSM+ or Xpert+, plus pDST"
        },
        {
          "titles": "Year 5",
          "group": "Total Budget Impact Estimates¹ / tNGS for all SSM+ or Xpert+, plus pDST"
        },
        {
          "titles": "Total",
          "group": "Total Budget Impact Estimates¹ / tNGS for all SSM+ or Xpert+, plus pDST"
        }
      ],
      "rows": [
        [
          "Cates L et al (2022)",
          "$180,787.00",
          "$137,132.00",
          "$133,646.00",
          "$130,265.00",
          "$126,985.00",
          "$708,816.00",
          "$136,029.00",
          "$93,717.00",
          "$91,534.00",
          "$89,416.00",
          "$87,361.00",
          "$498,057.00",
          "$255,837.00",
          "$209,931.00",
          "$204,261.00",
          "$198,762.00",
          "$193,427.00",
          "$1,062,218.00"
        ]
      ],
      "notes": "1. Values are written in 2021 USD unless otherwise specified",
      "narratives": {
        "en": "Total budget impact estimates reported by Cates et al. (2022) for years 1 (start-up) to 5 and in total (2021 USD), for three testing strategies: tNGS for all SSM+ or Xpert+; tNGS for all SSM+ or Xpert+, excluding Xpert/RIF-; tNGS for all SSM+ or Xpert+, plus pDST.",
        "ar": "تقديرات الأثر الإجمالي على الميزانية كما أبلغ عنها Cates وآخرون (2022) للسنوات من 1 (بدء التشغيل) إلى 5 وبالإجمال (بدولارات الولايات المتحدة لعام 2021)، لثلاث استراتيجيات اختبار: tNGS for all SSM+ or Xpert+; tNGS for all SSM+ or Xpert+, excluding Xpert/RIF-; tNGS for all SSM+ or Xpert+, plus pDST.",
        "zh": "Cates等（2022）报告的第1年（启动）至第5年及合计的总预算影响估计（2021年美元），涵盖三种检测策略：tNGS for all SSM+ or Xpert+; tNGS for all SSM+ or Xpert+, excluding Xpert/RIF-; tNGS for all SSM+ or Xpert+, plus pDST。",
        "es": "Estimaciones del impacto presupuestario total notificadas por Cates et al. (2022) para los años 1 (puesta en marcha) a 5 y en total (USD de 2021), para tres estrategias de pruebas: tNGS for all SSM+ or Xpert+; tNGS for all SSM+ or Xpert+, excluding Xpert/RIF-; tNGS for all SSM+ or Xpert+, plus pDST.",
        "fr": "Estimations de l’impact budgétaire total rapportées par Cates et al. (2022) pour les années 1 (démarrage) à 5 et au total (USD de 2021), pour trois stratégies de test : tNGS for all SSM+ or Xpert+; tNGS for all SSM+ or Xpert+, excluding Xpert/RIF-; tNGS for all SSM+ or Xpert+, plus pDST.",
        "ru": "Оценки общего влияния на бюджет по данным Cates и соавт. (2022) за годы с 1-го (запуск) по 5-й и в целом (в долларах США 2021 г.) для трех стратегий тестирования: tNGS for all SSM+ or Xpert+; tNGS for all SSM+ or Xpert+, excluding Xpert/RIF-; tNGS for all SSM+ or Xpert+, plus pDST."
      },
      "csv": "tables/table-9b.csv"
    },
    {
      "label": "Table 9C",
      "caption": "Table 9C. Output from Included tNGS and WGS Studies for the Systematic Review: BIA, Cates et al. (2022)",
      "pages": [
        795
      ],
      "columns": [
        {
          "titles": "Manuscript"
        },
        {
          "titles": "Year 1 (start-up)",
          "group": "Total Budget Impact Estimates¹ / tNGS for all culture+ plus pDST"
        },
        {
          "titles": "Year 2",
          "group": "Total Budget Impact Estimates¹ / tNGS for all culture+ plus pDST"
        },
        {
          "titles": "Year 3",
          "group": "Total Budget Impact Estimates¹ / tNGS for all culture+ plus pDST"
        },
        {
          "titles": "Year 4",
          "group": "Total Budget Impact Estimates¹ / tNGS for all culture+ plus pDST"
        },
        {
          "titles": "Year 5",
          "group": "Total Budget Impact Estimates¹ / tNGS for all culture+ plus pDST"
        },
        {
          "titles": "Total",
          "group": "Total Budget Impact Estimates¹ / tNGS for all culture+ plus pDST"
        },
        {
          "titles": "Year 1 (start-up)",
          "group": "Total Budget Impact Estimates¹ / tNGS for all culture+, excluding Xpert/RIF-, plus pDST"
        },
        {
          "titles": "Year 2",
          "group": "Total Budget Impact Estimates¹ / tNGS for all culture+, excluding Xpert/RIF-, plus pDST"
        },
        {
          "titles": "Year 3",
          "group": "Total Budget Impact Estimates¹ / tNGS for all culture+, excluding Xpert/RIF-, plus pDST"
        },
        {
          "titles": "Year 4",
          "group": "Total Budget Impact Estimates¹ / tNGS for all culture+, excluding Xpert/RIF-, plus pDST"
        },
        {
          "titles": "Year 5",
          "group": "Total Budget Impact Estimates¹ / tNGS for all culture+, excluding Xpert/RIF-, plus pDST"
        },
        {
          "titles": "Total",
          "group": "Total Budget Impact Estimates¹ / tNGS for all culture+, excluding Xpert/RIF-, plus pDST"
        },
        {
          "titles": "Year 1 (start-up)",
          "group": "Total Budget Impact Estimates¹ / WGS for all culture+"
        },
        {
          "titles": "Year 2",
          "group": "Total Budget Impact Estimates¹ / WGS for all culture+"
        },
        {
          "titles": "Year 3",
          "group": "Total Budget Impact Estimates¹ / WGS for all culture+"
        },
        {
          "titles": "Year 4",
          "group": "Total Budget Impact Estimates¹ / WGS for all culture+"
        },
        {
          "titles": "Year 5",
          "group": "Total Budget Impact Estimates¹ / WGS for all culture+"
        },
        {
          "titles": "Total",
          "group": "Total Budget Impact Estimates¹ / WGS for all culture+"
        }
      ],
      "rows": [
        [
          "Cates L et al (2022)",
          "$271,341.00",
          "$224,970.00",
          "$218,849.00",
          "$212,911.00",
          "$207,152.00",
          "$1,135,223.00",
          "$220,847.00",
          "$175,991.00",
          "$171,339.00",
          "$166,827.00",
          "$162,450.00",
          "$897,456.00",
          "$345,152.00",
          "$201,743.00",
          "$197,006.00",
          "$192,411.00",
          "$187,954.00",
          "$1,124,267.00"
        ]
      ],
      "notes": "1. Values are written in 2021 USD unless otherwise specified [Draft note: this table is rendered as an image on the page; its text layer appears under Table 9D in the PDF text.]",
      "narratives": {
        "en": "Total budget impact estimates reported by Cates et al. (2022) for years 1 (start-up) to 5 and in total (2021 USD), for three testing strategies: tNGS for all culture+ plus pDST; tNGS for all culture+, excluding Xpert/RIF-, plus pDST; WGS for all culture+.",
        "ar": "تقديرات الأثر الإجمالي على الميزانية كما أبلغ عنها Cates وآخرون (2022) للسنوات من 1 (بدء التشغيل) إلى 5 وبالإجمال (بدولارات الولايات المتحدة لعام 2021)، لثلاث استراتيجيات اختبار: tNGS for all culture+ plus pDST; tNGS for all culture+, excluding Xpert/RIF-, plus pDST; WGS for all culture+.",
        "zh": "Cates等（2022）报告的第1年（启动）至第5年及合计的总预算影响估计（2021年美元），涵盖三种检测策略：tNGS for all culture+ plus pDST; tNGS for all culture+, excluding Xpert/RIF-, plus pDST; WGS for all culture+。",
        "es": "Estimaciones del impacto presupuestario total notificadas por Cates et al. (2022) para los años 1 (puesta en marcha) a 5 y en total (USD de 2021), para tres estrategias de pruebas: tNGS for all culture+ plus pDST; tNGS for all culture+, excluding Xpert/RIF-, plus pDST; WGS for all culture+.",
        "fr": "Estimations de l’impact budgétaire total rapportées par Cates et al. (2022) pour les années 1 (démarrage) à 5 et au total (USD de 2021), pour trois stratégies de test : tNGS for all culture+ plus pDST; tNGS for all culture+, excluding Xpert/RIF-, plus pDST; WGS for all culture+.",
        "ru": "Оценки общего влияния на бюджет по данным Cates и соавт. (2022) за годы с 1-го (запуск) по 5-й и в целом (в долларах США 2021 г.) для трех стратегий тестирования: tNGS for all culture+ plus pDST; tNGS for all culture+, excluding Xpert/RIF-, plus pDST; WGS for all culture+."
      },
      "csv": "tables/table-9c.csv"
    },
    {
      "label": "Table 9D",
      "caption": "Table 9D. Output from Included tNGS and WGS Studies for the Systematic Review: BIA, Cates et al. (2022)",
      "pages": [
        795
      ],
      "columns": [
        {
          "titles": "Manuscript"
        },
        {
          "titles": "Year 1 (start-up)",
          "group": "Total Budget Impact Estimates¹ / WGS for all culture+ excluding Xpert/RIF-"
        },
        {
          "titles": "Year 2",
          "group": "Total Budget Impact Estimates¹ / WGS for all culture+ excluding Xpert/RIF-"
        },
        {
          "titles": "Year 3",
          "group": "Total Budget Impact Estimates¹ / WGS for all culture+ excluding Xpert/RIF-"
        },
        {
          "titles": "Year 4",
          "group": "Total Budget Impact Estimates¹ / WGS for all culture+ excluding Xpert/RIF-"
        },
        {
          "titles": "Year 5",
          "group": "Total Budget Impact Estimates¹ / WGS for all culture+ excluding Xpert/RIF-"
        },
        {
          "titles": "Total",
          "group": "Total Budget Impact Estimates¹ / WGS for all culture+ excluding Xpert/RIF-"
        },
        {
          "titles": "Year 1 (start-up)",
          "group": "Total Budget Impact Estimates¹ / WGS for all culture+, plus pDST"
        },
        {
          "titles": "Year 2",
          "group": "Total Budget Impact Estimates¹ / WGS for all culture+, plus pDST"
        },
        {
          "titles": "Year 3",
          "group": "Total Budget Impact Estimates¹ / WGS for all culture+, plus pDST"
        },
        {
          "titles": "Year 4",
          "group": "Total Budget Impact Estimates¹ / WGS for all culture+, plus pDST"
        },
        {
          "titles": "Year 5",
          "group": "Total Budget Impact Estimates¹ / WGS for all culture+, plus pDST"
        },
        {
          "titles": "Total",
          "group": "Total Budget Impact Estimates¹ / WGS for all culture+, plus pDST"
        },
        {
          "titles": "Year 1 (start-up)",
          "group": "Total Budget Impact Estimates¹ / WGS for all culture+, excluding Xpert/RIF-, plus pDST"
        },
        {
          "titles": "Year 2",
          "group": "Total Budget Impact Estimates¹ / WGS for all culture+, excluding Xpert/RIF-, plus pDST"
        },
        {
          "titles": "Year 3",
          "group": "Total Budget Impact Estimates¹ / WGS for all culture+, excluding Xpert/RIF-, plus pDST"
        },
        {
          "titles": "Year 4",
          "group": "Total Budget Impact Estimates¹ / WGS for all culture+, excluding Xpert/RIF-, plus pDST"
        },
        {
          "titles": "Year 5",
          "group": "Total Budget Impact Estimates¹ / WGS for all culture+, excluding Xpert/RIF-, plus pDST"
        },
        {
          "titles": "Total",
          "group": "Total Budget Impact Estimates¹ / WGS for all culture+, excluding Xpert/RIF-, plus pDST"
        }
      ],
      "rows": [
        [
          "Cates L et al (2022)",
          "$297,132.00",
          "$137,704.00",
          "$134,888.00",
          "$132,157.00",
          "$129,507.00",
          "$813,389.00",
          "$421,963.00",
          "$276,250.00",
          "$269,278.00",
          "$262,515.00",
          "$255,955.00",
          "$1,485,961.00",
          "$350,208.00",
          "$206,648.00",
          "$201,764.00",
          "$197,026.00",
          "$192,430.00",
          "$1,148,075.00"
        ]
      ],
      "notes": "1. Values are written in 2021 USD unless otherwise specified",
      "narratives": {
        "en": "Total budget impact estimates reported by Cates et al. (2022) for years 1 (start-up) to 5 and in total (2021 USD), for three testing strategies: WGS for all culture+ excluding Xpert/RIF-; WGS for all culture+, plus pDST; WGS for all culture+, excluding Xpert/RIF-, plus pDST.",
        "ar": "تقديرات الأثر الإجمالي على الميزانية كما أبلغ عنها Cates وآخرون (2022) للسنوات من 1 (بدء التشغيل) إلى 5 وبالإجمال (بدولارات الولايات المتحدة لعام 2021)، لثلاث استراتيجيات اختبار: WGS for all culture+ excluding Xpert/RIF-; WGS for all culture+, plus pDST; WGS for all culture+, excluding Xpert/RIF-, plus pDST.",
        "zh": "Cates等（2022）报告的第1年（启动）至第5年及合计的总预算影响估计（2021年美元），涵盖三种检测策略：WGS for all culture+ excluding Xpert/RIF-; WGS for all culture+, plus pDST; WGS for all culture+, excluding Xpert/RIF-, plus pDST。",
        "es": "Estimaciones del impacto presupuestario total notificadas por Cates et al. (2022) para los años 1 (puesta en marcha) a 5 y en total (USD de 2021), para tres estrategias de pruebas: WGS for all culture+ excluding Xpert/RIF-; WGS for all culture+, plus pDST; WGS for all culture+, excluding Xpert/RIF-, plus pDST.",
        "fr": "Estimations de l’impact budgétaire total rapportées par Cates et al. (2022) pour les années 1 (démarrage) à 5 et au total (USD de 2021), pour trois stratégies de test : WGS for all culture+ excluding Xpert/RIF-; WGS for all culture+, plus pDST; WGS for all culture+, excluding Xpert/RIF-, plus pDST.",
        "ru": "Оценки общего влияния на бюджет по данным Cates и соавт. (2022) за годы с 1-го (запуск) по 5-й и в целом (в долларах США 2021 г.) для трех стратегий тестирования: WGS for all culture+ excluding Xpert/RIF-; WGS for all culture+, plus pDST; WGS for all culture+, excluding Xpert/RIF-, plus pDST."
      },
      "csv": "tables/table-9d.csv"
    },
    {
      "label": "Table 10A",
      "caption": "Table 10A. Output from Included WGS Studies for the Systematic Review: Diagnostic Cost per Sample",
      "pages": [
        796
      ],
      "columns": [
        {
          "titles": "Manuscript"
        },
        {
          "titles": "Illumina NextSeq",
          "group": "Diagnostic cost per sample¹,⁷ / Diagnostic Intervention (WGS)"
        },
        {
          "titles": "Illumina MiSeq",
          "group": "Diagnostic cost per sample¹,⁷ / Diagnostic Intervention (WGS)"
        },
        {
          "titles": "Nanopore MinION",
          "group": "Diagnostic cost per sample¹,⁷ / Diagnostic Intervention (WGS)"
        },
        {
          "titles": "pDST",
          "group": "Diagnostic cost per sample¹,⁷ / Diagnostic Comparator"
        }
      ],
      "rows": [
        [
          "Cirillo DM et al (2016)¹⁰",
          "",
          "$185.77",
          "",
          ""
        ],
        [
          "Pankhurst LJ et al (2016)⁵",
          "",
          "$110.87 ($109.67-112.38)⁴",
          "",
          "$49.00 ($48.60-49.47)⁴"
        ],
        [
          "He G et al (2020)",
          "",
          "$71.61",
          "",
          "$45.47-102.30³"
        ],
        [
          "Vogel M et al (2021)",
          "",
          "$141.00 - $277.00⁶",
          "",
          ""
        ],
        [
          "Rowlinson MC and Musser KA (2022)²",
          "$68.00",
          "$130.00 - $150.00",
          "$63.00",
          ""
        ]
      ],
      "notes": "1. Values are written in 2021 USD unless otherwise specified. 2. Diagnostic costs per sample do not include DNA extraction, preparation costs, or labor costs. 3. First line drugs and second line drugs recorded as lower and upper ranges, respectively. 4. Range based on sensitivity analysis of 10% greater or fewer samples per year. 5. Component costs are calculated on a per sample basis. 6. Range based on first 174 sample ($277.00), and subsequent samples for 500-cycles ($167.00) and 600-cycles ($141.00). 7. Only studies with published data were for each outcome were included. [Draft note: footnote 10 cited for Cirillo is not printed.]",
      "narratives": {
        "en": "Diagnostic cost per sample of whole-genome sequencing (WGS) on Illumina NextSeq, Illumina MiSeq and Nanopore MinION, and of the phenotypic DST comparator, as reported by five included studies (2021 USD).",
        "ar": "تكلفة التشخيص لكل عينة لتسلسل الجينوم الكامل (WGS) على Illumina NextSeq وIllumina MiSeq وNanopore MinION، ولاختبار الحساسية للأدوية بالنمط الظاهري المقارن، كما أبلغت عنها خمس دراسات مشمولة (بدولارات الولايات المتحدة لعام 2021).",
        "zh": "五项纳入研究报告的全基因组测序（WGS）在Illumina NextSeq、Illumina MiSeq和Nanopore MinION上的每份样本诊断成本，以及对照表型药敏试验的成本（2021年美元）。",
        "es": "Costo diagnóstico por muestra de la secuenciación del genoma completo (WGS) en Illumina NextSeq, Illumina MiSeq y Nanopore MinION, y de las PSF fenotípicas utilizadas como comparador, según cinco estudios incluidos (USD de 2021).",
        "fr": "Coût diagnostique par échantillon du séquençage du génome entier (WGS) sur Illumina NextSeq, Illumina MiSeq et Nanopore MinION, et de l’antibiogramme phénotypique comparateur, d’après cinq études incluses (USD de 2021).",
        "ru": "Стоимость диагностики на один образец при полногеномном секвенировании (WGS) на Illumina NextSeq, Illumina MiSeq и Nanopore MinION, а также фенотипического ТЛЧ в качестве сравнения по данным пяти включенных исследований (в долларах США 2021 г.)."
      },
      "csv": "tables/table-10a.csv"
    },
    {
      "label": "Table 10B",
      "caption": "Table 10B. Output from Included WGS Studies for the Systematic Review: Component Costs",
      "pages": [
        796
      ],
      "columns": [
        {
          "titles": "Manuscript"
        },
        {
          "titles": "Equipment",
          "group": "Component costs¹,⁴ / Diagnostic Intervention (WGS)"
        },
        {
          "titles": "MiSeq",
          "group": "Component costs¹,⁴ / Diagnostic Intervention (WGS)"
        },
        {
          "titles": "iSeq100",
          "group": "Component costs¹,⁴ / Diagnostic Intervention (WGS)"
        },
        {
          "titles": "Maintenance",
          "group": "Component costs¹,⁴ / Diagnostic Intervention (WGS)"
        },
        {
          "titles": "Labor",
          "group": "Component costs¹,⁴ / Diagnostic Intervention (WGS)"
        },
        {
          "titles": "Training",
          "group": "Component costs¹,⁴ / Diagnostic Intervention (WGS)"
        },
        {
          "titles": "Overhead",
          "group": "Component costs¹,⁴ / Diagnostic Intervention (WGS)"
        },
        {
          "titles": "Reagents and consumables (Illumina MiSeq)",
          "group": "Component costs¹,⁴ / Diagnostic Intervention (WGS)"
        },
        {
          "titles": "Reagents and consumables (Illumina iSeq100)",
          "group": "Component costs¹,⁴ / Diagnostic Intervention (WGS)"
        },
        {
          "titles": "Equipment",
          "group": "Component costs¹,⁴ / Diagnostic Comparator (pDST)"
        },
        {
          "titles": "Labor",
          "group": "Component costs¹,⁴ / Diagnostic Comparator (pDST)"
        },
        {
          "titles": "Training",
          "group": "Component costs¹,⁴ / Diagnostic Comparator (pDST)"
        },
        {
          "titles": "Overhead",
          "group": "Component costs¹,⁴ / Diagnostic Comparator (pDST)"
        },
        {
          "titles": "Reagents and consumables",
          "group": "Component costs¹,⁴ / Diagnostic Comparator (pDST)"
        }
      ],
      "rows": [
        [
          "Pankhurst LJ et al (2016)³",
          "$10.48",
          "",
          "",
          "",
          "$18.72",
          "$0.68",
          "$18.48",
          "$62.51",
          "",
          "$3.12",
          "$17.61",
          "$0.42",
          "$8.17",
          "$19.68"
        ],
        [
          "Colman RE et al (2019)",
          "",
          "$106,820.31",
          "$20,500.87",
          "",
          "",
          "",
          "",
          "$15.08-$30.44²",
          "$74.93",
          "",
          "",
          "",
          "",
          ""
        ],
        [
          "Vogel M et al (2021)",
          "$222,065.00",
          "",
          "",
          "$8,462.00",
          "",
          "$48,250.00",
          "",
          "$60,995.66",
          "",
          "",
          "",
          "",
          "",
          ""
        ]
      ],
      "notes": "1. Values are written in 2021 USD unless otherwise specified. 2. Illumina MiSeq v3 2x300bp run - Illumina MiSeq v3 2x150bp run. 3. Component costs are calculated on a per sample basis. 4. Only studies with published data were for each outcome were included.",
      "narratives": {
        "en": "Component costs of whole-genome sequencing (equipment, sequencers, maintenance, labour, training, overhead, reagents and consumables) and of the phenotypic DST comparator, as reported by three included studies (2021 USD).",
        "ar": "تكاليف مكونات تسلسل الجينوم الكامل (المعدات، وأجهزة التسلسل، والصيانة، والعمالة، والتدريب، والنفقات العامة، والكواشف والمستهلكات) ولاختبار الحساسية للأدوية بالنمط الظاهري المقارن، كما أبلغت عنها ثلاث دراسات مشمولة (بدولارات الولايات المتحدة لعام 2021).",
        "zh": "三项纳入研究报告的全基因组测序各组成部分成本（设备、测序仪、维护、人工、培训、间接费用、试剂和耗材）以及对照表型药敏试验的成本（2021年美元）。",
        "es": "Costos por componente de la secuenciación del genoma completo (equipo, secuenciadores, mantenimiento, mano de obra, capacitación, gastos generales, reactivos y consumibles) y de las PSF fenotípicas utilizadas como comparador, según tres estudios incluidos (USD de 2021).",
        "fr": "Coûts par composante du séquençage du génome entier (équipement, séquenceurs, maintenance, main-d’œuvre, formation, frais généraux, réactifs et consommables) et de l’antibiogramme phénotypique comparateur, d’après trois études incluses (USD de 2021).",
        "ru": "Стоимость компонентов полногеномного секвенирования (оборудование, секвенаторы, техническое обслуживание, оплата труда, обучение, накладные расходы, реагенты и расходные материалы) и фенотипического ТЛЧ в качестве сравнения по данным трех включенных исследований (в долларах США 2021 г.)."
      },
      "csv": "tables/table-10b.csv"
    },
    {
      "label": "Table 10C",
      "caption": "Table 10C. Output from Included WGS Studies for the Systematic Review: Costs per step",
      "pages": [
        797
      ],
      "columns": [
        {
          "titles": "Manuscript"
        },
        {
          "titles": "DNA Extraction",
          "group": "Costs per step¹,³ / Diagnostic Intervention (WGS)"
        },
        {
          "titles": "Target Enrichment Multiplex PCR",
          "group": "Costs per step¹,³ / Diagnostic Intervention (WGS)"
        },
        {
          "titles": "Library Prep",
          "group": "Costs per step¹,³ / Diagnostic Intervention (WGS)"
        },
        {
          "titles": "Quality Control",
          "group": "Costs per step¹,³ / Diagnostic Intervention (WGS)"
        },
        {
          "titles": "Sequencing",
          "group": "Costs per step¹,³ / Diagnostic Intervention (WGS)"
        }
      ],
      "rows": [
        [
          "Vogel M et al (2021)²",
          "$4.05",
          "$1.31 - $2.88",
          "$59.61 - $91.25",
          "$3.83 - $14.70",
          "$64.53 - $156.32"
        ]
      ],
      "notes": "1. Values are written in 2021 USD unless otherwise specified. 2. Range based on first 174 sample ($277.00), and subsequent samples for 500-cycles ($167.00) and 600-cycles ($141.00). 3. Only studies with published data were for each outcome were included.",
      "narratives": {
        "en": "Costs per laboratory step of whole-genome sequencing (DNA extraction, target enrichment by multiplex PCR, library preparation, quality control and sequencing) from one included study (2021 USD).",
        "ar": "تكاليف كل خطوة مختبرية لتسلسل الجينوم الكامل (استخلاص الحمض النووي، والإثراء المستهدف بتفاعل البوليميراز المتسلسل المتعدد، وتحضير المكتبة، ومراقبة الجودة، والتسلسل) من دراسة مشمولة واحدة (بدولارات الولايات المتحدة لعام 2021).",
        "zh": "一项纳入研究中全基因组测序各实验室步骤（DNA提取、多重PCR靶向富集、文库制备、质量控制和测序）的成本（2021年美元）。",
        "es": "Costos por etapa de laboratorio de la secuenciación del genoma completo (extracción de ADN, enriquecimiento dirigido por PCR múltiple, preparación de bibliotecas, control de calidad y secuenciación) según un estudio incluido (USD de 2021).",
        "fr": "Coûts par étape de laboratoire du séquençage du génome entier (extraction de l’ADN, enrichissement ciblé par PCR multiplex, préparation des banques, contrôle de la qualité et séquençage) d’après une étude incluse (USD de 2021).",
        "ru": "Стоимость каждого лабораторного этапа полногеномного секвенирования (экстракция ДНК, таргетное обогащение мультиплексной ПЦР, подготовка библиотеки, контроль качества и секвенирование) по данным одного включенного исследования (в долларах США 2021 г.)."
      },
      "csv": "tables/table-10c.csv"
    },
    {
      "label": "Table 11A",
      "caption": "Table 11A. Output from Included Studies for the Scoping Review: Key Outcome(s) and Component Costs",
      "pages": [
        798
      ],
      "columns": [
        {
          "titles": "Manuscript"
        },
        {
          "titles": "Key outcome(s)"
        },
        {
          "titles": "Equipment",
          "group": "Component costs per sample¹,⁵ / Diagnostic Intervention"
        },
        {
          "titles": "Maintenance",
          "group": "Component costs per sample¹,⁵ / Diagnostic Intervention"
        },
        {
          "titles": "Staffing",
          "group": "Component costs per sample¹,⁵ / Diagnostic Intervention"
        },
        {
          "titles": "Overhead",
          "group": "Component costs per sample¹,⁵ / Diagnostic Intervention"
        },
        {
          "titles": "Reagents and consumables",
          "group": "Component costs per sample¹,⁵ / Diagnostic Intervention"
        },
        {
          "titles": "Quality Assurance",
          "group": "Component costs per sample¹,⁵ / Diagnostic Intervention"
        }
      ],
      "rows": [
        [
          "Gachogo et al (2020)",
          "To establish detailed cost profile for HIVDR testing and to identify cost drivers",
          "$105.56",
          "$2.44",
          "$48.25",
          "$15.14",
          "$104.61",
          "$4.12"
        ],
        [
          "Kunasol et al (2022)²",
          "Targeted Amplicon Deep sequencing (TADs) using Ion Torrent PGM with Illumina MiSeq reduced costs by 86% compared to conventional Sanger sequencing",
          "",
          "",
          "",
          "",
          "$62.72",
          ""
        ],
        [
          "Merel et al (2001)",
          "Reagent costs per sequencing reaction and sequencer capital costs were lower for CEQ 2000 than Prism-377 and TruGene",
          "",
          "",
          "",
          "",
          "$54.37",
          ""
        ],
        [
          "Riaz et al (2021)³",
          "Reagent cost per sample was less for Nanopore sequencing than for Illumina sequencing",
          "",
          "",
          "",
          "",
          "$33.49",
          ""
        ],
        [
          "Wales et al (2017)",
          "Reagent cost per sample",
          "",
          "",
          "",
          "",
          "$19.19 - $36.13⁴",
          ""
        ]
      ],
      "notes": "1. All costs are in USD unless stated otherwise. 2. Costs are for 6 drug resistance genes per sample, with 96 samples per sequencing run. 3. Intervention was Nanopore and comparator was Illumina Sequencing. 4. The range is based on number of samples, where 30 samples were $36.13 per sample and 96 samples were $19.19 per sample. 5. Only manuscripts with data were included.",
      "narratives": {
        "en": "Key outcomes and component costs per sample (equipment, maintenance, staffing, overhead, reagents and consumables, quality assurance) of sequencing-based diagnostic interventions reported by five studies in the scoping review (USD).",
        "ar": "النتائج الرئيسية وتكاليف المكونات لكل عينة (المعدات، والصيانة، والموظفون، والنفقات العامة، والكواشف والمستهلكات، وضمان الجودة) للتدخلات التشخيصية القائمة على التسلسل الجيني كما أبلغت عنها خمس دراسات في الاستعراض الاستكشافي (بدولارات الولايات المتحدة).",
        "zh": "范围综述中五项研究报告的基于测序的诊断干预措施的主要结果及每份样本各组成部分成本（设备、维护、人员、间接费用、试剂和耗材、质量保证）（美元）。",
        "es": "Resultados clave y costos por componente por muestra (equipo, mantenimiento, personal, gastos generales, reactivos y consumibles, garantía de la calidad) de las intervenciones diagnósticas basadas en secuenciación notificados por cinco estudios de la revisión exploratoria (USD).",
        "fr": "Principaux résultats et coûts par composante par échantillon (équipement, maintenance, personnel, frais généraux, réactifs et consommables, assurance qualité) des interventions diagnostiques fondées sur le séquençage rapportés par cinq études de l’examen de la portée (USD).",
        "ru": "Ключевые результаты и стоимость компонентов на один образец (оборудование, техническое обслуживание, персонал, накладные расходы, реагенты и расходные материалы, обеспечение качества) диагностических вмешательств на основе секвенирования по данным пяти исследований обзорного анализа (в долларах США)."
      },
      "csv": "tables/table-11a.csv"
    },
    {
      "label": "Table 11B",
      "caption": "Table 11B. Output from Included Studies for the Scoping Review: Costs per step",
      "pages": [
        799
      ],
      "columns": [
        {
          "titles": "Manuscript"
        },
        {
          "titles": "Sample collection",
          "group": "Costs per step¹,² / Diagnostic Intervention"
        },
        {
          "titles": "Target Enrichment Multiplex PCR",
          "group": "Costs per step¹,² / Diagnostic Intervention"
        },
        {
          "titles": "Sequencing",
          "group": "Costs per step¹,² / Diagnostic Intervention"
        },
        {
          "titles": "DNA or RNA Extraction",
          "group": "Costs per step¹,² / Diagnostic Intervention"
        },
        {
          "titles": "Gel electrophoresis",
          "group": "Costs per step¹,² / Diagnostic Intervention"
        },
        {
          "titles": "Sequencing analysis",
          "group": "Costs per step¹,² / Diagnostic Intervention"
        }
      ],
      "rows": [
        [
          "Dimitrov et al (2017)",
          "",
          "$55.29",
          "$56.40",
          "$5.53",
          "",
          ""
        ],
        [
          "Gachogo et al (2020)",
          "$2.48",
          "$57.86",
          "$165.88",
          "$23.49",
          "$10.66",
          "$19.75"
        ],
        [
          "Taylor et al (2013)",
          "",
          "$1.99",
          "$1093.49",
          "$1.99",
          "",
          ""
        ]
      ],
      "notes": "1. All costs are in USD unless stated otherwise. 2. Only manuscripts with data were included.",
      "narratives": {
        "en": "Costs per laboratory step (sample collection, target enrichment by multiplex PCR, sequencing, DNA or RNA extraction, gel electrophoresis and sequencing analysis) of sequencing-based diagnostic interventions reported by three studies in the scoping review (USD).",
        "ar": "تكاليف كل خطوة مختبرية (جمع العينات، والإثراء المستهدف بتفاعل البوليميراز المتسلسل المتعدد، والتسلسل، واستخلاص الحمض النووي الريبي أو منقوص الأكسجين، والرحلان الكهربائي الهلامي، وتحليل التسلسل) للتدخلات التشخيصية القائمة على التسلسل الجيني كما أبلغت عنها ثلاث دراسات في الاستعراض الاستكشافي (بدولارات الولايات المتحدة).",
        "zh": "范围综述中三项研究报告的基于测序的诊断干预措施各实验室步骤（样本采集、多重PCR靶向富集、测序、DNA或RNA提取、凝胶电泳和测序分析）的成本（美元）。",
        "es": "Costos por etapa de laboratorio (recogida de muestras, enriquecimiento dirigido por PCR múltiple, secuenciación, extracción de ADN o ARN, electroforesis en gel y análisis de secuencias) de las intervenciones diagnósticas basadas en secuenciación notificados por tres estudios de la revisión exploratoria (USD).",
        "fr": "Coûts par étape de laboratoire (prélèvement des échantillons, enrichissement ciblé par PCR multiplex, séquençage, extraction de l’ADN ou de l’ARN, électrophorèse sur gel et analyse des séquences) des interventions diagnostiques fondées sur le séquençage rapportés par trois études de l’examen de la portée (USD).",
        "ru": "Стоимость каждого лабораторного этапа (сбор образцов, таргетное обогащение мультиплексной ПЦР, секвенирование, экстракция ДНК или РНК, гель-электрофорез и анализ последовательностей) диагностических вмешательств на основе секвенирования по данным трех исследований обзорного анализа (в долларах США)."
      },
      "csv": "tables/table-11b.csv"
    },
    {
      "label": "Table 11C",
      "caption": "Table 11C. Output from Included Studies for the Scoping Review: ICERs, Cost per Sample and Component Costs Total",
      "pages": [
        800
      ],
      "columns": [
        {
          "titles": "Manuscript¹,⁷"
        },
        {
          "titles": "QALYs (months)",
          "group": "ICERs / Diagnostic Intervention"
        },
        {
          "titles": "QALYs sens analysis - effectiveness of HAART (months)",
          "group": "ICERs / Diagnostic Intervention"
        },
        {
          "titles": "Added QALYs sens analysis - maximum duration of HAART (months)",
          "group": "ICERs / Diagnostic Intervention"
        },
        {
          "titles": "Cost-effectiveness ratio (CER, $/QALY gained)",
          "group": "ICERs / Diagnostic Intervention"
        },
        {
          "titles": "CER sens analysis - effectiveness of HAART ($/QALY gained)",
          "group": "ICERs / Diagnostic Intervention"
        },
        {
          "titles": "CER sens analysis - maximum duration of HAART ($/QALY gained)",
          "group": "ICERs / Diagnostic Intervention"
        },
        {
          "titles": "Diagnostic intervention",
          "group": "Cost per Sample"
        },
        {
          "titles": "Diagnostic Comparator",
          "group": "Cost per Sample"
        },
        {
          "titles": "Equipment",
          "group": "Component costs total / Diagnostic intervention"
        },
        {
          "titles": "Equipment",
          "group": "Component costs total / Diagnostic Comparator"
        }
      ],
      "rows": [
        [
          "Chaturbhuj et al (2014)",
          "",
          "",
          "",
          "",
          "",
          "",
          "$128.19",
          "$343.37",
          "",
          ""
        ],
        [
          "Dimitrov et al (2017)",
          "",
          "",
          "",
          "",
          "",
          "",
          "$117.22",
          "",
          "",
          ""
        ],
        [
          "Dudley et al (2012)⁴",
          "",
          "",
          "",
          "",
          "",
          "",
          "$24.33",
          "$69.35",
          "",
          ""
        ],
        [
          "Ekici et al (2014)⁵",
          "",
          "",
          "",
          "",
          "",
          "",
          "$27.18-$36.83",
          "",
          "",
          ""
        ],
        [
          "Gachogo et al (2020)",
          "",
          "",
          "",
          "",
          "",
          "",
          "$280.12",
          "$391.10",
          "",
          ""
        ],
        [
          "Merel et al (2001)²",
          "",
          "",
          "",
          "",
          "",
          "",
          "",
          "",
          "$127,132.98",
          "$165,181.43"
        ],
        [
          "Patel et al (2016)",
          "",
          "",
          "",
          "",
          "",
          "",
          "$180.75",
          "$119.99-$270.36³",
          "",
          ""
        ],
        [
          "Weinstein et al (2001)⁶",
          "63.1-66.4",
          "60.9-66.3",
          "2.20-2.69",
          "$27,086 – 29,746",
          "$26,754 – 39,882",
          "$29,746 – 33,734",
          "",
          "",
          "",
          ""
        ]
      ],
      "notes": "1. All costs are in USD unless stated otherwise. 2. Equipment costs only include cost of sequencers; comparator only includes Prism-377 and not OpenGene. 3. Costs include HIV (79 GBP) and HCV (178 GBP) for Sanger sequencing, and 119 GBP for HIV/HCV for NGS. 4. Cost per sample assumes 48 samples multiplexed together. 5. Assumes pooling 24 samples per run. 6. Range presents data from two clinical trials. 7. Only manuscripts with data were included. [Draft note: the 'Cost per Sample' columns have no third-level header.]",
      "narratives": {
        "en": "Incremental cost-effectiveness results (QALYs and cost-effectiveness ratios with sensitivity analyses), cost per sample for the diagnostic intervention and comparator, and total equipment costs reported by eight studies in the scoping review (USD).",
        "ar": "نتائج فعالية التكلفة الإضافية (سنوات العمر المعدلة حسب الجودة ونسب فعالية التكلفة مع تحليلات الحساسية)، وتكلفة كل عينة للتدخل التشخيصي والمقارن، وإجمالي تكاليف المعدات كما أبلغت عنها ثماني دراسات في الاستعراض الاستكشافي (بدولارات الولايات المتحدة).",
        "zh": "范围综述中八项研究报告的增量成本效果结果（质量调整生命年和成本效果比及敏感性分析）、诊断干预措施和对照的每份样本成本以及设备总成本（美元）。",
        "es": "Resultados de costo-efectividad incremental (AVAC y razones de costo-efectividad con análisis de sensibilidad), costo por muestra de la intervención diagnóstica y del comparador, y costos totales de equipo notificados por ocho estudios de la revisión exploratoria (USD).",
        "fr": "Résultats coût-efficacité incrémentiels (QALY et ratios coût-efficacité avec analyses de sensibilité), coût par échantillon de l’intervention diagnostique et du comparateur, et coûts totaux d’équipement rapportés par huit études de l’examen de la portée (USD).",
        "ru": "Результаты анализа приростной экономической эффективности (QALY и коэффициенты затраты–эффективность с анализом чувствительности), стоимость одного образца для диагностического вмешательства и сравнения, а также общие затраты на оборудование по данным восьми исследований обзорного анализа (в долларах США)."
      },
      "csv": "tables/table-11c.csv"
    },
    {
      "label": "Table 12A",
      "caption": "Table 12A. Output from Included Studies for the Scoping Review: Cost per Sample, Alleweldt et al. (2021)",
      "pages": [
        801
      ],
      "columns": [
        {
          "titles": "Manuscript"
        },
        {
          "titles": "Avian influenza (APHA)",
          "group": "Cost per sample / WGS"
        },
        {
          "titles": "Avian influenza (FLI)",
          "group": "Cost per sample / WGS"
        },
        {
          "titles": "Influenza A+B (EMC)",
          "group": "Cost per sample / WGS"
        },
        {
          "titles": "Food-borne Pathogens (IZSLER)",
          "group": "Cost per sample / WGS"
        },
        {
          "titles": "Food-borne Pathogens (INEI-ANLIS)",
          "group": "Cost per sample / WGS"
        },
        {
          "titles": "Food-borne Pathogens (MDH)",
          "group": "Cost per sample / WGS"
        },
        {
          "titles": "Food-borne Pathogens (PHAC)",
          "group": "Cost per sample / WGS"
        },
        {
          "titles": "Food-borne Pathogens (PHE)",
          "group": "Cost per sample / WGS"
        },
        {
          "titles": "Avian influenza (APHA)",
          "group": "Cost per sample / Conventional"
        },
        {
          "titles": "Avian influenza (FLI)",
          "group": "Cost per sample / Conventional"
        },
        {
          "titles": "Influenza A+B (EMC)",
          "group": "Cost per sample / Conventional"
        },
        {
          "titles": "Food-borne Pathogens (IZSLER)",
          "group": "Cost per sample / Conventional"
        },
        {
          "titles": "Food-borne Pathogens (INEI-ANLIS)",
          "group": "Cost per sample / Conventional"
        },
        {
          "titles": "Food-borne Pathogens (MDH)",
          "group": "Cost per sample / Conventional"
        },
        {
          "titles": "Food-borne Pathogens (PHAC)",
          "group": "Cost per sample / Conventional"
        },
        {
          "titles": "Food-borne Pathogens (PHE)",
          "group": "Cost per sample / Conventional"
        }
      ],
      "rows": [
        [
          "Alleweldt et al (2021)¹",
          "$1320.60",
          "$698.73",
          "$126.40",
          "$483.51",
          "$62.85",
          "$193.5",
          "$273.26",
          "$161.84",
          "$376.81",
          "$ 1027.72",
          "$106.99",
          "$112.42",
          "$18.96",
          "$101.46",
          "$119.64",
          "$85.03"
        ]
      ],
      "notes": "1. Costs were obtained between 2016-2019 for all studies within Alleweldt et al (2021), with the majority of costs from 2017, which was used for costing conversions to 2021 USD.",
      "narratives": {
        "en": "Cost per sample reported by Alleweldt et al. (2021) for whole-genome sequencing (WGS) and conventional methods, for eight laboratory settings covering avian influenza, influenza A+B and food-borne pathogens (2021 USD).",
        "ar": "تكلفة كل عينة كما أبلغ عنها Alleweldt وآخرون (2021) لتسلسل الجينوم الكامل (WGS) والطرائق التقليدية، في ثمانية مختبرات تشمل إنفلونزا الطيور والإنفلونزا A+B ومسببات الأمراض المنقولة بالغذاء (بدولارات الولايات المتحدة لعام 2021).",
        "zh": "Alleweldt等（2021）报告的全基因组测序（WGS）和传统方法的每份样本成本，涵盖禽流感、甲型和乙型流感及食源性病原体的八个实验室（2021年美元）。",
        "es": "Costo por muestra notificados por Alleweldt et al. (2021) para la secuenciación del genoma completo (WGS) y los métodos convencionales, en ocho laboratorios que abarcan la gripe aviar, la gripe A+B y los patógenos transmitidos por los alimentos (USD de 2021).",
        "fr": "Coût par échantillon rapportés par Alleweldt et al. (2021) pour le séquençage du génome entier (WGS) et les méthodes conventionnelles, dans huit laboratoires couvrant la grippe aviaire, la grippe A+B et les agents pathogènes d’origine alimentaire (USD de 2021).",
        "ru": "Стоимость одного образца по данным Alleweldt и соавт. (2021) для полногеномного секвенирования (WGS) и традиционных методов в восьми лабораториях, охватывающих птичий грипп, грипп A+B и пищевые патогены (в долларах США 2021 г.)."
      },
      "csv": "tables/table-12a.csv"
    },
    {
      "label": "Table 12B",
      "caption": "Table 12B. Output from Included Studies for the Scoping Review: Component Costs, Alleweldt et al. (2021)",
      "pages": [
        801
      ],
      "columns": [
        {
          "titles": "Manuscript"
        },
        {
          "titles": "Equipment: Avian Influenza APHA",
          "group": "Component Costs / WGS"
        },
        {
          "titles": "Equipment: Avian Influenza FLI",
          "group": "Component Costs / WGS"
        },
        {
          "titles": "Equipment: Influenza A+B EMC",
          "group": "Component Costs / WGS"
        },
        {
          "titles": "Equipment: Food-borne pathogens IZSLER",
          "group": "Component Costs / WGS"
        },
        {
          "titles": "Equipment: Food-borne pathogens ARG",
          "group": "Component Costs / WGS"
        },
        {
          "titles": "Equipment: Food-borne pathogens MDH",
          "group": "Component Costs / WGS"
        },
        {
          "titles": "Equipment: Food-borne pathogens PHAC",
          "group": "Component Costs / WGS"
        },
        {
          "titles": "Equipment: Food-borne pathogens PHE",
          "group": "Component Costs / WGS"
        },
        {
          "titles": "Equipment: Avian Influenza APHA",
          "group": "Component Costs / Conventional Method"
        },
        {
          "titles": "Equipment: Avian Influenza FLI",
          "group": "Component Costs / Conventional Method"
        },
        {
          "titles": "Equipment: influenza A+B EMC",
          "group": "Component Costs / Conventional Method"
        },
        {
          "titles": "Equipment: Food-borne pathogens IZSLER",
          "group": "Component Costs / Conventional Method"
        },
        {
          "titles": "Equipment: Food-borne pathogens ARG",
          "group": "Component Costs / Conventional Method"
        },
        {
          "titles": "Equipment: Food-borne pathogens MDH",
          "group": "Component Costs / Conventional Method"
        },
        {
          "titles": "Equipment: Food-borne pathogens PHAC",
          "group": "Component Costs / Conventional Method"
        },
        {
          "titles": "Equipment: Food-borne pathogens PHE",
          "group": "Component Costs / Conventional Method"
        }
      ],
      "rows": [
        [
          "Alleweldt et al (2021)¹",
          "$76.03",
          "$259.04",
          "$3.21",
          "$200.05",
          "$17.50",
          "$36.92",
          "$96.31",
          "$45.76",
          "$102.04",
          "$168.85",
          "$3.41",
          "$31.86",
          "N/A",
          "$7.30",
          "$15.61",
          "$9.24"
        ]
      ],
      "notes": "1. Costs were obtained between 2016-2019 for all studies within Alleweldt et al (2021), with the majority of costs from 2017, which was used for costing conversions to 2021 USD.",
      "narratives": {
        "en": "Equipment component costs reported by Alleweldt et al. (2021) for whole-genome sequencing (WGS) and conventional methods, for eight laboratory settings covering avian influenza, influenza A+B and food-borne pathogens (2021 USD).",
        "ar": "تكاليف مكون المعدات كما أبلغ عنها Alleweldt وآخرون (2021) لتسلسل الجينوم الكامل (WGS) والطرائق التقليدية، في ثمانية مختبرات تشمل إنفلونزا الطيور والإنفلونزا A+B ومسببات الأمراض المنقولة بالغذاء (بدولارات الولايات المتحدة لعام 2021).",
        "zh": "Alleweldt等（2021）报告的全基因组测序（WGS）和传统方法的设备成本，涵盖禽流感、甲型和乙型流感及食源性病原体的八个实验室（2021年美元）。",
        "es": "Costos del componente de equipo notificados por Alleweldt et al. (2021) para la secuenciación del genoma completo (WGS) y los métodos convencionales, en ocho laboratorios que abarcan la gripe aviar, la gripe A+B y los patógenos transmitidos por los alimentos (USD de 2021).",
        "fr": "Coûts de la composante équipement rapportés par Alleweldt et al. (2021) pour le séquençage du génome entier (WGS) et les méthodes conventionnelles, dans huit laboratoires couvrant la grippe aviaire, la grippe A+B et les agents pathogènes d’origine alimentaire (USD de 2021).",
        "ru": "Затраты на оборудование по данным Alleweldt и соавт. (2021) для полногеномного секвенирования (WGS) и традиционных методов в восьми лабораториях, охватывающих птичий грипп, грипп A+B и пищевые патогены (в долларах США 2021 г.)."
      },
      "csv": "tables/table-12b.csv"
    },
    {
      "label": "Table 12C",
      "caption": "Table 12C. Output from Included Studies for the Scoping Review: Cost per Sample, Alleweldt et al. (2021)",
      "pages": [
        801
      ],
      "columns": [
        {
          "titles": "Manuscript"
        },
        {
          "titles": "Consumables: Avian influenza APHA",
          "group": "Component Costs / WGS"
        },
        {
          "titles": "Consumables: Avian influenza FLI",
          "group": "Component Costs / WGS"
        },
        {
          "titles": "Consumables: Influenza A+B EMC",
          "group": "Component Costs / WGS"
        },
        {
          "titles": "Consumables: Food-borne pathogens IZSLER",
          "group": "Component Costs / WGS"
        },
        {
          "titles": "Consumables: Food-borne pathogens ARG",
          "group": "Component Costs / WGS"
        },
        {
          "titles": "Consumables: Food-borne pathogens MDH",
          "group": "Component Costs / WGS"
        },
        {
          "titles": "Consumables: Food-borne pathogens PHAC",
          "group": "Component Costs / WGS"
        },
        {
          "titles": "Consumables: Food-borne pathogens PHE",
          "group": "Component Costs / WGS"
        },
        {
          "titles": "Consumables: Avian Influenza APHA",
          "group": "Component Costs / Conventional Method"
        },
        {
          "titles": "Consumables: Avian Influenza FLI",
          "group": "Component Costs / Conventional Method"
        },
        {
          "titles": "Consumables: influenza A+B EMC",
          "group": "Component Costs / Conventional Method"
        },
        {
          "titles": "Consumables: Food-borne pathogens IZSLER",
          "group": "Component Costs / Conventional Method"
        },
        {
          "titles": "Consumables: Food-borne pathogens ARG",
          "group": "Component Costs / Conventional Method"
        },
        {
          "titles": "Consumables: Food-borne pathogens MDH",
          "group": "Component Costs / Conventional Method"
        },
        {
          "titles": "Consumables: Food-borne pathogens PHAC",
          "group": "Component Costs / Conventional Method"
        },
        {
          "titles": "Consumables: Food-borne pathogens PHE",
          "group": "Component Costs / Conventional Method"
        }
      ],
      "rows": [
        [
          "Alleweldt et al (2021)¹",
          "$1079.43",
          "$313.34",
          "$43.02",
          "$202.35",
          "$42.56",
          "$130.51",
          "$88.53",
          "$70.04",
          "$28.46",
          "$443.65",
          "$44.14",
          "$24.68",
          "N/A",
          "$41.12",
          "$44.35",
          "$38.85"
        ]
      ],
      "notes": "1. Costs were obtained between 2016-2019 for all studies within Alleweldt et al (2021), with the majority of costs from 2017, which was used for costing conversions to 2021 USD. [Draft note: caption says 'Cost per Sample' but the table header reads 'Component Costs' (consumables).]",
      "narratives": {
        "en": "Consumables component costs reported by Alleweldt et al. (2021) for whole-genome sequencing (WGS) and conventional methods, for eight laboratory settings covering avian influenza, influenza A+B and food-borne pathogens (2021 USD).",
        "ar": "تكاليف مكون المستهلكات كما أبلغ عنها Alleweldt وآخرون (2021) لتسلسل الجينوم الكامل (WGS) والطرائق التقليدية، في ثمانية مختبرات تشمل إنفلونزا الطيور والإنفلونزا A+B ومسببات الأمراض المنقولة بالغذاء (بدولارات الولايات المتحدة لعام 2021).",
        "zh": "Alleweldt等（2021）报告的全基因组测序（WGS）和传统方法的耗材成本，涵盖禽流感、甲型和乙型流感及食源性病原体的八个实验室（2021年美元）。",
        "es": "Costos del componente de consumibles notificados por Alleweldt et al. (2021) para la secuenciación del genoma completo (WGS) y los métodos convencionales, en ocho laboratorios que abarcan la gripe aviar, la gripe A+B y los patógenos transmitidos por los alimentos (USD de 2021).",
        "fr": "Coûts de la composante consommables rapportés par Alleweldt et al. (2021) pour le séquençage du génome entier (WGS) et les méthodes conventionnelles, dans huit laboratoires couvrant la grippe aviaire, la grippe A+B et les agents pathogènes d’origine alimentaire (USD de 2021).",
        "ru": "Затраты на расходные материалы по данным Alleweldt и соавт. (2021) для полногеномного секвенирования (WGS) и традиционных методов в восьми лабораториях, охватывающих птичий грипп, грипп A+B и пищевые патогены (в долларах США 2021 г.)."
      },
      "csv": "tables/table-12c.csv"
    },
    {
      "label": "Table 12D",
      "caption": "Table 12D. Output from Included Studies for the Scoping Review: Cost per Sample, Alleweldt et al. (2021)",
      "pages": [
        802
      ],
      "columns": [
        {
          "titles": "Manuscript"
        },
        {
          "titles": "Staff (prof and tech): Avian influenza APHA",
          "group": "Component Costs / WGS"
        },
        {
          "titles": "Staff (prof and tech): Avian influenza FLI",
          "group": "Component Costs / WGS"
        },
        {
          "titles": "Staff (prof and tech): Influenza A+B EMC",
          "group": "Component Costs / WGS"
        },
        {
          "titles": "Staff (prof and tech): Food-borne pathogens IZSLER",
          "group": "Component Costs / WGS"
        },
        {
          "titles": "Staff (prof and tech): Food-borne pathogens ARG",
          "group": "Component Costs / WGS"
        },
        {
          "titles": "Staff (prof and tech): Food-borne pathogens MDH",
          "group": "Component Costs / WGS"
        },
        {
          "titles": "Staff (prof and tech): Food-borne pathogens PHAC",
          "group": "Component Costs / WGS"
        },
        {
          "titles": "Staff (prof and tech): Food-borne pathogens PHE",
          "group": "Component Costs / WGS"
        },
        {
          "titles": "Staff (prof and tech): Avian Influenza APHA",
          "group": "Component Costs / Conventional Method"
        },
        {
          "titles": "Staff (prof and tech): Avian Influenza FLI",
          "group": "Component Costs / Conventional Method"
        },
        {
          "titles": "Staff (prof and tech): influenza A+B EMC",
          "group": "Component Costs / Conventional Method"
        },
        {
          "titles": "Staff (prof and tech): Food-borne pathogens IZSLER",
          "group": "Component Costs / Conventional Method"
        },
        {
          "titles": "Staff (prof and tech): Food-borne pathogens ARG",
          "group": "Component Costs / Conventional Method"
        },
        {
          "titles": "Staff (prof and tech): Food-borne pathogens MDH",
          "group": "Component Costs / Conventional Method"
        },
        {
          "titles": "Staff (prof and tech): Food-borne pathogens PHAC",
          "group": "Component Costs / Conventional Method"
        },
        {
          "titles": "Staff (prof and tech): Food-borne pathogens PHE",
          "group": "Component Costs / Conventional Method"
        }
      ],
      "rows": [
        [
          "Alleweldt et al (2021)¹",
          "$165.14",
          "$126.37",
          "$75.44",
          "$81.10",
          "€ 6.85",
          "$25.73",
          "$88.45",
          "$46.05",
          "$ 246.33",
          "$415.22",
          "$59.44",
          "$35.98",
          "N/A",
          "$53.04",
          "$59.69",
          "$34.77"
        ]
      ],
      "notes": "1. Costs were obtained between 2016-2019 for all studies within Alleweldt et al (2021), with the majority of costs from 2017, which was used for costing conversions to 2021 USD. [Draft note: caption says 'Cost per Sample' but the table header reads 'Component Costs' (staff). One WGS value is printed in euros (€ 6.85).]",
      "narratives": {
        "en": "Staff (professional and technical) component costs reported by Alleweldt et al. (2021) for whole-genome sequencing (WGS) and conventional methods, for eight laboratory settings covering avian influenza, influenza A+B and food-borne pathogens (2021 USD).",
        "ar": "تكاليف مكون الموظفين (المهنيين والفنيين) كما أبلغ عنها Alleweldt وآخرون (2021) لتسلسل الجينوم الكامل (WGS) والطرائق التقليدية، في ثمانية مختبرات تشمل إنفلونزا الطيور والإنفلونزا A+B ومسببات الأمراض المنقولة بالغذاء (بدولارات الولايات المتحدة لعام 2021).",
        "zh": "Alleweldt等（2021）报告的全基因组测序（WGS）和传统方法的人员（专业和技术人员）成本，涵盖禽流感、甲型和乙型流感及食源性病原体的八个实验室（2021年美元）。",
        "es": "Costos del componente de personal (profesional y técnico) notificados por Alleweldt et al. (2021) para la secuenciación del genoma completo (WGS) y los métodos convencionales, en ocho laboratorios que abarcan la gripe aviar, la gripe A+B y los patógenos transmitidos por los alimentos (USD de 2021).",
        "fr": "Coûts de la composante personnel (professionnel et technique) rapportés par Alleweldt et al. (2021) pour le séquençage du génome entier (WGS) et les méthodes conventionnelles, dans huit laboratoires couvrant la grippe aviaire, la grippe A+B et les agents pathogènes d’origine alimentaire (USD de 2021).",
        "ru": "Затраты на персонал (профессиональный и технический) по данным Alleweldt и соавт. (2021) для полногеномного секвенирования (WGS) и традиционных методов в восьми лабораториях, охватывающих птичий грипп, грипп A+B и пищевые патогены (в долларах США 2021 г.)."
      },
      "csv": "tables/table-12d.csv"
    },
    {
      "label": "Table 12E",
      "caption": "Table 12E. Output from Included Studies for the Scoping Review: Cost per Sample, Alleweldt et al. (2021)",
      "pages": [
        802
      ],
      "columns": [
        {
          "titles": "Manuscript"
        },
        {
          "titles": "Other costs: Avian influenza APHA",
          "group": "Component Costs / WGS"
        },
        {
          "titles": "Other costs: Avian influenza FLI",
          "group": "Component Costs / WGS"
        },
        {
          "titles": "Other costs: Influenza A+B EMC",
          "group": "Component Costs / WGS"
        },
        {
          "titles": "Other costs: Food-borne pathogens IZSLER",
          "group": "Component Costs / WGS"
        },
        {
          "titles": "Other costs: Food-borne pathogens ARG",
          "group": "Component Costs / WGS"
        },
        {
          "titles": "Other costs: Food-borne pathogens MDH",
          "group": "Component Costs / WGS"
        },
        {
          "titles": "Other costs: Food-borne pathogens PHAC",
          "group": "Component Costs / WGS"
        },
        {
          "titles": "Other costs: Food-borne pathogens PHE",
          "group": "Component Costs / WGS"
        },
        {
          "titles": "Other costs: Avian Influenza APHA",
          "group": "Component Costs / Conventional Method"
        },
        {
          "titles": "Other costs: Avian Influenza FLI",
          "group": "Component Costs / Conventional Method"
        },
        {
          "titles": "Other costs: influenza A+B EMC",
          "group": "Component Costs / Conventional Method"
        },
        {
          "titles": "Other costs: Food-borne pathogens IZSLER",
          "group": "Component Costs / Conventional Method"
        },
        {
          "titles": "Other costs: Food-borne pathogens ARG",
          "group": "Component Costs / Conventional Method"
        },
        {
          "titles": "Other costs: Food-borne pathogens MDH",
          "group": "Component Costs / Conventional Method"
        },
        {
          "titles": "Other costs: Food-borne pathogens PHAC",
          "group": "Component Costs / Conventional Method"
        },
        {
          "titles": "Other costs: Food-borne pathogens PHE",
          "group": "Component Costs / Conventional Method"
        }
      ],
      "rows": [
        [
          "Alleweldt et al (2021)¹",
          "$0.00",
          "$0.00",
          "$4.72",
          "$0.00",
          "$0.00",
          "$0.00",
          "$0.00",
          "$0.00",
          "$0.00",
          "$0.00",
          "$0.00",
          "$19.91",
          "N/A",
          "N/A",
          "$0.00",
          "$2.17"
        ]
      ],
      "notes": "1. Costs were obtained between 2016-2019 for all studies within Alleweldt et al (2021), with the majority of costs from 2017, which was used for costing conversions to 2021 USD. [Draft note: caption says 'Cost per Sample' but the table header reads 'Component Costs' (other costs).]",
      "narratives": {
        "en": "Other component costs reported by Alleweldt et al. (2021) for whole-genome sequencing (WGS) and conventional methods, for eight laboratory settings covering avian influenza, influenza A+B and food-borne pathogens (2021 USD).",
        "ar": "تكاليف المكونات الأخرى كما أبلغ عنها Alleweldt وآخرون (2021) لتسلسل الجينوم الكامل (WGS) والطرائق التقليدية، في ثمانية مختبرات تشمل إنفلونزا الطيور والإنفلونزا A+B ومسببات الأمراض المنقولة بالغذاء (بدولارات الولايات المتحدة لعام 2021).",
        "zh": "Alleweldt等（2021）报告的全基因组测序（WGS）和传统方法的其他成本，涵盖禽流感、甲型和乙型流感及食源性病原体的八个实验室（2021年美元）。",
        "es": "Otros costos por componente notificados por Alleweldt et al. (2021) para la secuenciación del genoma completo (WGS) y los métodos convencionales, en ocho laboratorios que abarcan la gripe aviar, la gripe A+B y los patógenos transmitidos por los alimentos (USD de 2021).",
        "fr": "Autres coûts par composante rapportés par Alleweldt et al. (2021) pour le séquençage du génome entier (WGS) et les méthodes conventionnelles, dans huit laboratoires couvrant la grippe aviaire, la grippe A+B et les agents pathogènes d’origine alimentaire (USD de 2021).",
        "ru": "Прочие затраты по данным Alleweldt и соавт. (2021) для полногеномного секвенирования (WGS) и традиционных методов в восьми лабораториях, охватывающих птичий грипп, грипп A+B и пищевые патогены (в долларах США 2021 г.)."
      },
      "csv": "tables/table-12e.csv"
    },
    {
      "label": "Table A1.1",
      "caption": "Table A1.1. Search strategy for the primary systematic literature review (nov",
      "pages": [
        977
      ],
      "columns": [
        {
          "titles": ""
        },
        {
          "titles": "Search Term"
        }
      ],
      "rows": [
        [
          "1",
          "exp TUBERCULOSIS/ or tuberculosis.mp. or exp MYCOBACTERIUM TUBERCULOSIS/ or tb.mp."
        ],
        [
          "2",
          "exp Recombinant Proteins/ or (recombinant or novel or dppd or esat 6 or esat6 or cfp 10 or cfp10 or early secretory antigenic target* or culture filtrate protein* or rd* or region of difference or Rv0061 or recombinant tuberculosis allergen).mp."
        ],
        [
          "3",
          "skin test*.mp. or Skin Tests/"
        ],
        [
          "4",
          "(c tb or diaskintest or c-tst or dppd).mp."
        ],
        [
          "5",
          "1 and 2 and 3"
        ],
        [
          "6",
          "(recombinant and allergen).mp."
        ],
        [
          "7",
          "6 and 1"
        ],
        [
          "8",
          "4 or 5 or 7"
        ]
      ],
      "notes": "Other databases: e-library (www.e-library.ru) for Russian literature. Search Terms: Диаскинтест* или «Аллерген* туберкулезн* рекомбинантн*». The Chinese Biomedical Literature Database and the China National Knowledge Infrastructure databases. Search terms: “ESAT-6” and “CFP-10” or “ESAT6” and “CFP10”. [Draft note: the caption is truncated in the source ('(nov').]",
      "narratives": {
        "en": "Numbered search lines used in the primary systematic literature review of novel skin tests for TB infection, combining tuberculosis, recombinant antigen and skin-test terms with Boolean operators.",
        "ar": "أسطر البحث المرقّمة المستخدمة في الاستعراض المنهجي الأولي للأدبيات بشأن اختبارات الجلد الجديدة لعدوى السل، والتي تجمع بين مصطلحات السل والمستضدات المؤتلفة واختبارات الجلد باستخدام العوامل المنطقية.",
        "zh": "结核感染新型皮肤试验主要系统文献综述中使用的编号检索式，用布尔运算符组合结核病、重组抗原和皮肤试验相关检索词。",
        "es": "Líneas de búsqueda numeradas utilizadas en la revisión sistemática primaria de la literatura sobre las nuevas pruebas cutáneas para la infección tuberculosa, que combinan términos de tuberculosis, antígenos recombinantes y pruebas cutáneas mediante operadores booleanos.",
        "fr": "Lignes de recherche numérotées utilisées dans la revue systématique primaire de la littérature sur les nouveaux tests cutanés de l’infection tuberculeuse, combinant des termes relatifs à la tuberculose, aux antigènes recombinants et aux tests cutanés au moyen d’opérateurs booléens.",
        "ru": "Пронумерованные строки поиска, использованные в первичном систематическом обзоре литературы по новым кожным тестам на туберкулезную инфекцию, объединяющие термины о туберкулезе, рекомбинантных антигенах и кожных тестах с помощью булевых операторов."
      },
      "csv": "tables/table-a1-1.csv"
    },
    {
      "label": "Table A3",
      "caption": "Table A3: Data extraction results for all the entries from the secondary systematic review",
      "pages": [
        981,
        982,
        983,
        984,
        985,
        986,
        987,
        988,
        989,
        990
      ],
      "columns": [
        {
          "titles": "Study Characteristics"
        },
        {
          "titles": "Linas (2011)²²"
        },
        {
          "titles": "Pareek (2011)³⁸"
        },
        {
          "titles": "del Campo (2012)²⁵"
        }
      ],
      "rows": [
        [
          "Country Setting",
          "USA",
          "UK",
          "Spain"
        ],
        [
          "Year of Cost Valuation",
          "2011",
          "2010",
          "2012"
        ],
        [
          "Currency",
          "USD",
          "GBP",
          "Euros"
        ],
        [
          "Study Population",
          "1) Immigrant/Migrants 2) Immunocompromised 3) Vulnerable",
          "Recently arrived immigrants (<16y.o. and 16- 35y.o.)",
          "Healthcare workers."
        ],
        [
          "Index Diagnostic Test Strategies",
          "1. QFT 2. TST",
          "IGRA",
          "1. TST (10mm) 2. QFT 3. TST (5mm) + QFT"
        ],
        [
          "Alternatives Provided",
          "No screening.",
          "No screening",
          "TST (5mm)"
        ],
        [
          "Type of economic evaluation",
          "CUA",
          "CEA",
          "CEA"
        ],
        [
          "Source of costing",
          "Published Literature",
          "Empirical data collection",
          "Published Literature (tests) and Empirical data collection for other costs."
        ],
        [
          "Primary outcome",
          "ICER: $/QALYs gained",
          "ICER: £/active TB case averted.",
          "ICER: Euro/active TB case averted."
        ],
        [
          "Type of model",
          "Markov.",
          "Decision tree.",
          "Decision Tree"
        ],
        [
          "Time Horizon",
          "Lifetime.",
          "20 years.",
          "2 years."
        ],
        [
          "Discounting",
          "1.5%",
          "3.5%",
          "Not stated."
        ],
        [
          "Sensitivity analysis",
          "One-way, Two-way deterministic.",
          "One-way deterministic.",
          "One-way deterministic."
        ],
        [
          "Key scenarios/variables in sensitivity analysis.",
          "TST and QFT sensitivity, specificity, and test costs.",
          "Reactivation Rate, sensitivity, and specificity of tests.",
          "TST and QFT sensitivity, specificity and LTBI prevalence."
        ],
        [
          "WTP Threshold",
          "$100,000",
          "Not Stated.",
          "Not Stated."
        ],
        [
          "Study Characteristics",
          "Eralp. (2012)²⁶",
          "Shah (2012)³⁹",
          "Mandalakas (2013)²⁷"
        ],
        [
          "Country Setting",
          "UK",
          "USA",
          "South Africa"
        ],
        [
          "Year of Cost Valuation",
          "2011",
          "2012",
          "2009"
        ],
        [
          "Currency",
          "GBP",
          "USD",
          "USD"
        ],
        [
          "Study Population",
          "Healthcare Workers",
          "Individuals at primary health clinic with positive TST.",
          "Children (0-2 and 3- 5y.o.) contacts."
        ],
        [
          "Index Diagnostic Test Strategies",
          "1. QFT 2. TST",
          "TST + QFT-GIT",
          "1) TST 2) TST+QFT. 3) TST-QFT. 4) TST+ T-SPOT 5) TST- T-SPOT 6) QFT. 7) T-SPOT"
        ],
        [
          "Alternative Provided",
          "TST + QFT",
          "TST",
          "No Screening"
        ],
        [
          "Type of economic evaluation",
          "CEA",
          "CEA",
          "CEA"
        ],
        [
          "Source of costing",
          "Published Literature",
          "Data from Boston Health Dep.",
          "Published Literature."
        ],
        [
          "Primary outcome",
          "ICER: £/Life Year Gained.",
          "ICER: $/QALY gained.",
          "ICER: $/active TB case averted."
        ],
        [
          "Type of model",
          "Markov.",
          "Decision tree.",
          "Markov"
        ],
        [
          "Time Horizon",
          "20 years.",
          "1 year for those without LTBI and lifetime for those with LTBI.",
          "15 years."
        ],
        [
          "Discounting",
          "5%",
          "3%",
          "3%"
        ],
        [
          "Sensitivity analysis",
          "One-way deterministic and PSA.",
          "Two-way and PSA.",
          "One-way deterministic."
        ],
        [
          "Key scenarios/variables in sensitivity analysis.",
          "TST and QFT sensitivity, specificity, test costs and LTBI prevalence.",
          "QFT-GIT sensitivity, specificity and LTBI prevalence.",
          "TST and QFT sensitivity, specificity and LTBI prevalence."
        ],
        [
          "WTP Threshold",
          "£30,000",
          "$50,000",
          "Not Stated."
        ],
        [
          "Study Characteristics",
          "Pareek (2013)²⁹",
          "Steffen (2013)⁷",
          "Swaminath (2013)⁴⁰"
        ],
        [
          "Country Setting",
          "UK",
          "USA",
          "USA"
        ],
        [
          "Year of Cost Valuation",
          "2011",
          "2012",
          "Not stated."
        ],
        [
          "Currency",
          "GBP",
          "USD",
          "USD"
        ],
        [
          "Study Population",
          "Recently arrived immigrants (≤35 y.o.).",
          "35y.o. close contacts.",
          "Immunosuppressed with IBD"
        ],
        [
          "Index Diagnostic Test Strategies",
          "1. T-SPOT 2. QFT 3. TST + T-SPOT 4. TST + QFT",
          "1. QFT 2. TST + QFT",
          "QFT"
        ],
        [
          "Alternative Provided",
          "TST",
          "TST",
          "TST"
        ],
        [
          "Type of economic evaluation",
          "CEA",
          "CEA",
          "CEA"
        ],
        [
          "Source of costing",
          "Published Literature",
          "Published Literature.",
          "Published Literature."
        ],
        [
          "Primary outcome",
          "ICER: £/active TB case averted.",
          "ICER: $/active TB case averted.",
          "Cost and TB deaths."
        ],
        [
          "Type of model",
          "Decision Tree",
          "Decision tree.",
          "Decision Tree"
        ],
        [
          "Time Horizon",
          "20 years.",
          "2 years.",
          "1 year."
        ],
        [
          "Discounting",
          "3.5%",
          "None.",
          "None."
        ],
        [
          "Sensitivity analysis",
          "One-way deterministic.",
          "One-way and two-way and PSA.",
          "One-way deterministic."
        ],
        [
          "Key scenarios/variables in sensitivity analysis.",
          "TST and QFT sensitivity, specificity, test costs and LTBI prevalence.",
          "TST and QFT sensitivity, specificity, test costs and LTBI prevalence.",
          "TST and QFT sensitivity, specificity, test, and treatment. costs and LTBI prevalence."
        ],
        [
          "WTP Threshold",
          "Not Stated.",
          "$50,000",
          "Not Stated."
        ],
        [
          "Study Characteristics",
          "Verma (2013)³⁰",
          "Capocci, (2015)²¹",
          "Wingate (2015)³¹"
        ],
        [
          "Country Setting",
          "Canada",
          "UK",
          "USA"
        ],
        [
          "Year of Cost Valuation",
          "2012",
          "2012",
          "2012"
        ],
        [
          "Currency",
          "Canadian Dollars",
          "Euro",
          "USD"
        ],
        [
          "Study Population",
          ">65y.o. in long term care",
          "Adults living with HIV",
          "Pre arrival refugees to USA."
        ],
        [
          "Index Diagnostic Test Strategies",
          "TST",
          "1. QFT + TST 2. QFT (for higher risk) 3. QFT (for all)",
          "TST"
        ],
        [
          "Alternative Provided",
          "No screening",
          "No Screening",
          "No Screening"
        ],
        [
          "Type of economic evaluation",
          "CEA",
          "CEA/CUA",
          "CBA"
        ],
        [
          "Source of costing",
          "Published Literature",
          "Published Literature and clinic data.",
          "Published Literature and experts."
        ],
        [
          "Primary outcome",
          "ICER: $/active TB case averted.",
          "ICER: Euro/QALY gained or active TB case averted.",
          "Net benefit (Cost)"
        ],
        [
          "Type of model",
          "Markov",
          "Markov.",
          "Decision tree and Markov."
        ],
        [
          "Time Horizon",
          "4 years",
          "Lifetime",
          "20 years."
        ],
        [
          "Discounting",
          "3%",
          "3.5%",
          "3%"
        ],
        [
          "Sensitivity analysis",
          "One-way deterministic.",
          "PSA.",
          "One-way deterministic."
        ],
        [
          "Key scenarios/variables in sensitivity analysis.",
          "TST and QFT sensitivity, specificity and LTBI prevalence.",
          "TST and QFT sensitivity, specificity, test, and treatment. costs and LTBI prevalence.",
          "TST and QFT sensitivity, specificity, test costs and LTBI prevalence."
        ],
        [
          "WTP Threshold",
          "Not Stated.",
          "Euro 24,000",
          "Not Stated."
        ],
        [
          "Study Characteristics",
          "Auguste. (2016)¹⁹",
          "Nijhawan (2016)³²",
          "Campbell (2017)⁴¹"
        ],
        [
          "Country Setting",
          "UK",
          "USA",
          "Canada"
        ],
        [
          "Year of Cost Valuation",
          "2012",
          "2013",
          "2016"
        ],
        [
          "Currency",
          "Euro",
          "USD",
          "Canadian Dollars"
        ],
        [
          "Study Population",
          "1) Children 2) Immunocompromised 3) Recently Arrived Immigrants 4) General Population.",
          "Adults entering jail.",
          "Pre-arrival refugees to USA."
        ],
        [
          "Index Diagnostic Test Strategies",
          "1. IGRA 2. TST + IGRA 3. Simultaneous.",
          "QFT",
          "1. TST 2. IGRA 3. TST + IGRA"
        ],
        [
          "Alternative Provided",
          "TST",
          "TST",
          "No Screening"
        ],
        [
          "Type of economic evaluation",
          "CUA",
          "Cost Analysis.",
          "CUA"
        ],
        [
          "Source of costing",
          "Published Literature, NHS data and assumptions.",
          "Published Literature and empirical data collection.",
          "British Columbia Centre for Disease control"
        ],
        [
          "Primary outcome",
          "ICER: £/QALY gained",
          "Cost difference per active TB case detected.",
          "ICER: $/QALY gained."
        ],
        [
          "Type of model",
          "Decision tree and discrete event simulation.",
          "Decision tree.",
          "Discrete event simulation."
        ],
        [
          "Time Horizon",
          "Lifetime",
          "Not Stated.",
          "10 years."
        ],
        [
          "Discounting",
          "3.5%",
          "Not Stated.",
          "1.5%"
        ],
        [
          "Sensitivity analysis",
          "PSA.",
          "One-way.",
          "One-way and PSA."
        ],
        [
          "Key scenarios/variables in sensitivity analysis.",
          "TST and QFT sensitivity, specificity, test, and treatment. costs and LTBI prevalence.",
          "Cost of labour, unit cost of tests.",
          "TST and QFT sensitivity, specificity, test costs and LTBI prevalence."
        ],
        [
          "WTP Threshold",
          "£30,000",
          "Not Stated.",
          "$100,000"
        ],
        [
          "Study Characteristics",
          "Haukaas (2017)³³",
          "Mullie (2017)³⁴",
          "Tasillo, (2017)¹⁸"
        ],
        [
          "Country Setting",
          "Norway",
          "Canada",
          "USA"
        ],
        [
          "Year of Cost Valuation",
          "2013",
          "2015",
          "2015"
        ],
        [
          "Currency",
          "Euro",
          "Canadian Dollars",
          "USD"
        ],
        [
          "Study Population",
          "Recently arrived immigrants <35y.o.",
          "HCW with negative TST at time of employment.",
          "US-born or migrants living with or without comorbidities."
        ],
        [
          "Index Diagnostic Test Strategies",
          "1. QFT (for those with risk factors) 2. TST + QFT 3. QFT (for all)",
          "QFT-GIT",
          "1. TST 2. IGRA 3. IGRA + TST 4. IGRA - TST"
        ],
        [
          "Alternative Provided",
          "No Screening",
          "TST",
          "No Screening"
        ],
        [
          "Type of economic evaluation",
          "CEA",
          "CUA",
          "CUA"
        ],
        [
          "Source of costing",
          "Published Literature and expert opinion.",
          "Published Literature.",
          "Assumptions and published literature."
        ],
        [
          "Primary outcome",
          "ICER: £/QALY gained",
          "ICER: $/QALY gained.",
          "ICER: $/QALY gained."
        ],
        [
          "Type of model",
          "Decision Tree and Markov",
          "Decision tree.",
          "Decision tree and Markov."
        ],
        [
          "Time Horizon",
          "10 years.",
          "20 years.",
          "Lifetime"
        ],
        [
          "Discounting",
          "4%",
          "3%",
          "3%"
        ],
        [
          "Sensitivity analysis",
          "One-way.",
          "One-way and two scenario analyses.",
          "One-way and PSA."
        ],
        [
          "Key scenarios/variables in sensitivity analysis.",
          "TST and QFT sensitivity, specificity, test, costs and LTBI prevalence.",
          "TST and QFT sensitivities and specificities.",
          "TST and QFT sensitivity, specificity, test costs and LTBI prevalence."
        ],
        [
          "WTP Threshold",
          "28,400 Euros",
          "Not Stated.",
          "$100,000"
        ],
        [
          "Study Characteristics",
          "Abubakar (2018)²⁴",
          "Li (2018)⁴²",
          "Sohn (2018)³⁵"
        ],
        [
          "Country Setting",
          "UK",
          "Hong Kong",
          "Japan"
        ],
        [
          "Year of Cost Valuation",
          "Not Stated.",
          "Not stated.",
          "2015"
        ],
        [
          "Currency",
          "GBP",
          "USD",
          "USD"
        ],
        [
          "Study Population",
          "1. Recent immigrants. 2. Contacts",
          "Elderly (>65y.o.) at admission to residential care home.",
          "Adolescents (13- 18y.o.) contacts."
        ],
        [
          "Index Diagnostic Test Strategies",
          "1. T-SPOT.TB 2. QFT-GIT 3. TST (varying cut offs) 4. Confirm positive or negative T-SPOT or QFT-GIT after TST",
          "IGRA",
          "1. TST + QFT 2. QFT"
        ],
        [
          "Alternative Provided",
          "No Screening",
          "No screening.",
          "TST"
        ],
        [
          "Type of economic evaluation",
          "CUA",
          "CUA",
          "CEA"
        ],
        [
          "Source of costing",
          "Published literature and NHS Data.",
          "Estimation.",
          "Published literature."
        ],
        [
          "Primary outcome",
          "ICER: £/QALY gained.",
          "ICER: $/QALY gained.",
          "ICER: $/QALY gained."
        ],
        [
          "Type of model",
          "Decision Tree.",
          "Markov.",
          "Decision tree."
        ],
        [
          "Time Horizon",
          "Lifetime",
          "20 years.",
          "2 years."
        ],
        [
          "Discounting",
          "3.5%",
          "5%",
          "3% (overhead costs only)"
        ],
        [
          "Sensitivity analysis",
          "PSA.",
          "One-way and PSA.",
          "One-way and PSA."
        ],
        [
          "Key scenarios/variables in sensitivity analysis.",
          "Test sensitivity and specificity.",
          "TST and QFT sensitivities and specificities, reactivation rate.",
          "TST and QFT sensitivity, specificity, test costs and LTBI prevalence."
        ],
        [
          "WTP Threshold",
          "£20,000",
          "$50,000",
          "$50,000"
        ],
        [
          "Study Characteristics",
          "Campbell (2019a)³⁶",
          "Campbell (2019b)²³",
          "Loureiro (2019)³⁷"
        ],
        [
          "Country Setting",
          "Canada",
          "Canada",
          "Brazil"
        ],
        [
          "Year of Cost Valuation",
          "2016",
          "2016",
          "2016"
        ],
        [
          "Currency",
          "Canadian Dollars",
          "Canadian Dollars",
          "USD"
        ],
        [
          "Study Population",
          "Pre-arrival immigrants.",
          "Migrants with either late-stage CKD or beginning dialysis.",
          "Primary HCW."
        ],
        [
          "Index Diagnostic Test Strategies",
          "1. QFT-GIT 2. TST + QFT-GIT 3. TST (>10mm)",
          "1. QFT-GIT 2. TST (>10mm)",
          "1. TST (>10mm) 2. TST (>10mm) + QFT 3. TST (>5mm) + QFT QFT"
        ],
        [
          "Alternative Provided (Baseline for Incremental Analysis)",
          "No screening",
          "No screening",
          "TST (>5mm)"
        ],
        [
          "Type of economic evaluation",
          "CUA",
          "CUA",
          "CEA"
        ],
        [
          "Source of costing",
          "British Columbia Centre for Disease control and expert opinion.",
          "British Columbia Centre for Disease control and expert opinion.",
          "Ministry of Health and estimations."
        ],
        [
          "Primary outcome",
          "ICER: $/QALY gained",
          "ICER: $/QALY gained.",
          "ICER: $/active TB case averted."
        ],
        [
          "Type of model",
          "Discrete event simulation",
          "Markov.",
          "Decision tree."
        ],
        [
          "Time Horizon",
          "25 years.",
          "25 years.",
          "1 year."
        ],
        [
          "Discounting",
          "3%",
          "3%",
          "None."
        ],
        [
          "Sensitivity analysis",
          "PSA.",
          "PSA.",
          "One-way."
        ],
        [
          "Key scenarios/variables in sensitivity analysis.",
          "TST and QFT sensitivity and specificity, incidence rate of country of origin of immigrant, reactivation rate.",
          "TST and QFT sensitivities and specificities, cost of tests and reactivation rate.",
          "TST and QFT sensitivity, specificity, test costs and LTBI prevalence."
        ],
        [
          "WTP Threshold",
          "$50,000",
          "$50,000",
          "Not stated."
        ],
        [
          "Study Characteristics",
          "Png (2019)⁴³",
          "Al Abri (2020)⁴⁴",
          "Jo (2020)²⁰"
        ],
        [
          "Country Setting",
          "Singapore",
          "Oman",
          "USA"
        ],
        [
          "Year of Cost Valuation",
          "2016",
          "2020",
          "2018"
        ],
        [
          "Currency",
          "USD",
          "USD",
          "USD"
        ],
        [
          "Study Population",
          "HCW.",
          "20-year-old recent immigrants.",
          "(1) non–US-born, (2) living with diabetes, (3) HIV-positive, (4) experiencing recent homelessness, (5) incarcerated"
        ],
        [
          "Index Diagnostic Test Strategies",
          "QFT-GIT either annually or every three years for combination of 1) new hires 2) high risk 3) international 4) universal.",
          "1. QFT 2. TST 3. CXR All with varying treatments.",
          "IGRA"
        ],
        [
          "Alternative Provided (Baseline for Incremental Analysis)",
          "No Screening",
          "QFT (4-month RIF)",
          "Not Stated."
        ],
        [
          "Type of economic evaluation",
          "CUA",
          "CUA",
          "CUA"
        ],
        [
          "Source of costing",
          "National University Hospital and Published Literature.",
          "Not Stated.",
          "Published Literature."
        ],
        [
          "Primary outcome",
          "ICER: $/QALY gained",
          "ICER: $/QALY gained",
          "ICER: $/QALY gained."
        ],
        [
          "Type of model",
          "Decision Tree.",
          "Markov.",
          "Individual-based TB epidemiological model."
        ],
        [
          "Time Horizon",
          "3 years.",
          "Lifetime",
          "30 years."
        ],
        [
          "Discounting",
          "3%",
          "Not stated.",
          "3%"
        ],
        [
          "Sensitivity analysis",
          "PSA.",
          "One-way, Two-way and PSA.",
          "One-way and PSA."
        ],
        [
          "Key scenarios/variables in sensitivity analysis.",
          "TST and QFT sensitivity and specificity, incidence rate of country of origin of immigrant, reactivation rate.",
          "TST and QFT sensitivity and specificity, incidence rate of country of origin of immigrant, reactivation rate.",
          "Cost of tests, treatment, and completion of treatment probability."
        ],
        [
          "WTP Threshold",
          "$50,000",
          "$100,000",
          "Not stated."
        ],
        [
          "Study Characteristics",
          "Steffen (2020)¹²",
          "Kim (2018)²⁸",
          ""
        ],
        [
          "Country Setting",
          "Brazil",
          "South Africa",
          ""
        ],
        [
          "Year of Cost Valuation",
          "2020",
          "2016",
          ""
        ],
        [
          "Currency",
          "USD",
          "USD",
          ""
        ],
        [
          "Study Population",
          "Adults living with HIV",
          "HIV+ pregnant women",
          ""
        ],
        [
          "Index Diagnostic Test Strategies",
          "1. TST 2. QFT-GIT 3. EC Test",
          "1. TST",
          ""
        ],
        [
          "Alternative Provided (Baseline for Incremental Analysis)",
          "DiaskinTest",
          "QFT-GIT",
          ""
        ],
        [
          "Type of economic evaluation",
          "CUA",
          "CEA",
          ""
        ],
        [
          "Source of costing",
          "Ministry of Health and market value.",
          "National Health Laboratory service",
          ""
        ],
        [
          "Primary outcome",
          "ICER: $/QALY gained",
          "ICER: $/DALY averted",
          ""
        ],
        [
          "Type of model",
          "Markov.",
          "Decision tree",
          ""
        ],
        [
          "Time Horizon",
          "20 years.",
          "12 months",
          ""
        ],
        [
          "Discounting",
          "5%",
          "3%",
          ""
        ],
        [
          "Sensitivity analysis",
          "One-way, Two-way and PSA.",
          "One-way, Two-way and PSA.",
          ""
        ],
        [
          "Key scenarios/variables in sensitivity analysis.",
          "TST and DiaskinTest sensitivity and specificity, prevalence of LTBI.",
          "TST and QFT sensitivity and specificity, and other highly sensible parameters",
          ""
        ],
        [
          "WTP Threshold",
          "$7544",
          "$12,860/DALY",
          ""
        ]
      ],
      "notes": "[Draft note: the table runs over pages 981–990 ('Continuation of Table A3'); each continuation page has its own header row naming three different studies. Those header rows are kept as body rows beginning 'Study Characteristics', so the column titles apply only to the first block. The last page has two studies; the fourth column is empty there. Superscript numbers after study names are reference numbers.]",
      "narratives": {
        "en": "Data extracted from the economic evaluations of TST and IGRA included in the secondary systematic review. For each study (three per block), rows give the country, year of cost valuation, currency, study population, index test strategies, alternative, type of economic evaluation, source of costing, primary outcome, model type, time horizon, discounting, sensitivity analyses, key variables and willingness-to-pay threshold.",
        "ar": "البيانات المستخلصة من التقييمات الاقتصادية لاختبار التوبركولين الجلدي واختبارات إطلاق الإنترفيرون غاما المشمولة في الاستعراض المنهجي الثانوي. لكل دراسة (ثلاث دراسات في كل مجموعة)، تبيّن الصفوف البلد، وسنة تقييم التكاليف، والعملة، والفئة السكانية، واستراتيجيات الاختبار الدليلي، والبديل، ونوع التقييم الاقتصادي، ومصدر التكاليف، والنتيجة الأساسية، ونوع النموذج، والأفق الزمني، والخصم، وتحليلات الحساسية، والمتغيرات الرئيسية، وعتبة الاستعداد للدفع.",
        "zh": "二级系统综述纳入的结核菌素皮肤试验（TST）和γ干扰素释放试验（IGRA）经济学评价的提取数据。对每项研究（每组三项），各行列出国家、成本估值年份、货币、研究人群、指标检测策略、备选方案、经济学评价类型、成本来源、主要结局、模型类型、时间范围、贴现、敏感性分析、关键变量和支付意愿阈值。",
        "es": "Datos extraídos de las evaluaciones económicas de la PT y los IGRA incluidas en la revisión sistemática secundaria. Para cada estudio (tres por bloque), las filas indican el país, el año de valoración de los costos, la moneda, la población de estudio, las estrategias de pruebas índice, la alternativa, el tipo de evaluación económica, la fuente de los costos, el resultado principal, el tipo de modelo, el horizonte temporal, el descuento, los análisis de sensibilidad, las variables clave y el umbral de disposición a pagar.",
        "fr": "Données extraites des évaluations économiques du TCT et des IGRA incluses dans la revue systématique secondaire. Pour chaque étude (trois par bloc), les lignes indiquent le pays, l’année de valorisation des coûts, la monnaie, la population étudiée, les stratégies de tests index, l’alternative, le type d’évaluation économique, la source des coûts, le critère de jugement principal, le type de modèle, l’horizon temporel, l’actualisation, les analyses de sensibilité, les variables clés et le seuil de disposition à payer.",
        "ru": "Данные, извлеченные из экономических оценок ТКП и IGRA, включенных во вторичный систематический обзор. Для каждого исследования (по три в блоке) в строках указаны страна, год оценки затрат, валюта, исследуемая популяция, стратегии индексного тестирования, альтернатива, тип экономической оценки, источник данных о затратах, первичный исход, тип модели, временной горизонт, дисконтирование, анализ чувствительности, ключевые переменные и порог готовности платить."
      },
      "csv": "tables/table-a3.csv"
    },
    {
      "label": "Table A7",
      "caption": "Table A7. Drummond checklist for studies quality: Cost/Cost-effectiveness analyses for Novel skin tests for diagnosing TBI",
      "pages": [
        991,
        992,
        993,
        994,
        995,
        996,
        997,
        998,
        999,
        1000,
        1001
      ],
      "columns": [
        {
          "titles": "Drummond Checklist Questions"
        },
        {
          "titles": "Kulikov 2009"
        },
        {
          "titles": "Aksenova 2011"
        },
        {
          "titles": "Yagudina 2013"
        },
        {
          "titles": ""
        }
      ],
      "rows": [
        [
          "1. Was a well-defined question posed in answerable form?",
          "",
          "",
          "",
          ""
        ],
        [
          "1.1. Did the study examine both costs and effects of the service(s) or programme(s)?",
          "Yes",
          "No, only presents costs",
          "Yes",
          ""
        ],
        [
          "1.2. Did the study involve a comparison of alternatives?",
          "Yes",
          "Yes",
          "Yes",
          ""
        ],
        [
          "1.3. Was a viewpoint for the analysis stated and was the study placed in any decision-making context?",
          "Yes, children and adolescents",
          "Yes, children",
          "Yes",
          ""
        ],
        [
          "2. Was a comprehensive description of the competing alternatives given?",
          "",
          "",
          "",
          ""
        ],
        [
          "2.1. Were there any important alternatives omitted?",
          "No",
          "No",
          "No",
          ""
        ],
        [
          "2.2. Was (should) a do-nothing alternative be considered?",
          "No",
          "No",
          "No",
          ""
        ],
        [
          "3. Was the effectiveness of the programme or services established?",
          "",
          "",
          "",
          ""
        ],
        [
          "3.1. Was this done through a randomised, controlled clinical trial? If so, did the trial protocol reflect what would happen in regular practice?",
          "No",
          "No",
          "No",
          ""
        ],
        [
          "3.2. Was effectiveness established through an overview of clinical studies?",
          "Yes. Sensitivity and specificity of tests values from number of clinical studies.",
          "No, cost analysis, no CE",
          "Yes",
          ""
        ],
        [
          "3.3. Were observational data or assumptions used to establish effectiveness? If so, what are the potential biases in results?",
          "Yes. Observational data, no time horizon/discounting provided.",
          "N/A",
          "Assumption on the proportion of patients with a dubious and positive test with 2TE PPD-L and Diaskintest drug® to be equal to two different existing artiles, which might lead to biased conclusion depending on the settings analysed and population characteristics",
          ""
        ],
        [
          "4. Were all the important and relevant costs and consequences for each alternative identified?",
          "",
          "",
          "",
          ""
        ],
        [
          "4.1. Was the range wide enough for the research question at hand?",
          "Yes",
          "Yes",
          "Yes",
          ""
        ],
        [
          "4.2. Did it cover all relevant viewpoints?",
          "Yes",
          "Yes",
          "Yes",
          ""
        ],
        [
          "4.3. Were the capital costs, as well as operating costs, included?",
          "Test and treatment costs included, the rest is unclear",
          "Only research costs, sample analyses costs, preventive treatment, consultation and Xrays",
          "Yes, it included treatment, diagnostic, drugs and chemoteraphy costs, registering and operating costs, among others",
          ""
        ],
        [
          "5. Were costs and consequences measured accurately in appropriate physical units?",
          "",
          "",
          "",
          ""
        ],
        [
          "5.1. Were any of the identified items omitted from measurement? If so, does this mean that they carried no weight in the subsequent analysis?",
          "Outcome costs is missing",
          "The cost of test itself, it just measures the cost of diagnostic measures. And outcome costs",
          "No",
          ""
        ],
        [
          "5.2. Were there any special circumstances (e.g., joint use of resources) that made measurement difficult? Were these circumstances handled appropriately?",
          "No",
          "No",
          "No",
          ""
        ],
        [
          "6. Were the cost and consequences valued credibly?",
          "",
          "",
          "",
          ""
        ],
        [
          "6.1. Were the sources of all values clearly identified?",
          "Unclear, cost of valuation is not stated",
          "Unclear, but only stated on the Table 3",
          "Yes",
          ""
        ],
        [
          "6.2. Were market values employed for changes involving resources gained or depleted?",
          "Yes",
          "Yes",
          "Yes",
          ""
        ],
        [
          "6.3. Where market values were absent (e.g. volunteer labour), or market values did not reflect actual values (such as clinic space donated at a reduced rate), were adjustments made to approximate market values?",
          "N/A",
          "N/A",
          "N/A",
          ""
        ],
        [
          "6.4. Was the valuation of consequences appropriate for the question posed?",
          "Yes",
          "N/A",
          "Yes",
          ""
        ],
        [
          "7. Were costs and consequences adjusted for differential timing?",
          "",
          "",
          "",
          ""
        ],
        [
          "7.1. Were costs and consequences that occur in the future ‘discounted’ to their present values?",
          "No",
          "N/A",
          "Not stated",
          ""
        ],
        [
          "7.2. Was there any justification given for the discount rate used?",
          "Discounting rate No stated",
          "N/A",
          "N/A",
          ""
        ],
        [
          "8. Was an incremental analysis of costs and consequences of alternatives performed?",
          "",
          "",
          "",
          ""
        ],
        [
          "8.1. Were the additional (incremental) costs generated by one alternative over another compared to the additional effects, benefits, or utilities generated?",
          "Yes",
          "No",
          "Yes",
          ""
        ],
        [
          "9. Was allowance made for uncertainty in the estimates of costs and consequences?",
          "",
          "",
          "",
          ""
        ],
        [
          "9.1. If data on costs and consequences were stochastic (randomly determined sequence of observations), were appropriate statistical analyses performed?",
          "Yes",
          "N/A",
          "Yes",
          ""
        ],
        [
          "9.2. If sensitivity analysis was employed, was justification provided for the range of values (or for key study parameters)?",
          "Yes, for treatment and test costs",
          "N/A",
          "No explanation, just stated the parameters over which the SA was employed (test cost)",
          ""
        ],
        [
          "9.3. Were the study results sensitive to changes in the values?",
          "Not that much. The conclusion was robust to changes in key parameters with the cost of a second clinical visit being the most influential to the cost-effectiveness ratios",
          "N/A",
          "No, it was stable",
          ""
        ],
        [
          "10. Did the presentation and discussion of study results include all issues of concern to users?",
          "",
          "",
          "",
          ""
        ],
        [
          "10.1. Were the conclusions of the analysis based on some overall index or ratio of costs to consequences (e.g. cost-effectiveness ratio)?",
          "Yes (2.28 rubles compared to 3.42)",
          "",
          "Yes",
          ""
        ],
        [
          "10.2. Were the results compared with those of others who have investigated the same question? If so, were allowances made for potential differences in study methodology?",
          "No",
          "No",
          "No",
          ""
        ],
        [
          "10.3. Did the study discuss the generalisability of the results to other settings and patient/client groups?",
          "No",
          "Yes",
          "No",
          ""
        ],
        [
          "10.4. Did the study allude to, or take account of, other important factors in the choice or decision under consideration (e.g. distribution of costs and consequences, or relevant ethical issues)?",
          "No",
          "Yes",
          "Yes",
          ""
        ],
        [
          "10.5. Did the study discuss issues of implementation, such as the feasibility of adopting the ‘preferred’ programme given existing financial or other constraints, and whether any freed resources could be redeployed to other worthwhile programmes?",
          "Yes",
          "Yes",
          "No",
          ""
        ],
        [
          "Drummond Checklist Questions",
          "Moiseeva 2014",
          "Solodun 2017",
          "Sinitsyn 2018",
          "Chugaev 2020"
        ],
        [
          "1. Was a well-defined question posed in answerable form?",
          "",
          "",
          "",
          ""
        ],
        [
          "1.1. Did the study examine both costs and effects of the service(s) or programme(s)?",
          "Yes",
          "Yes",
          "Yes",
          "Yes"
        ],
        [
          "1.2. Did the study involve a comparison of alternatives?",
          "Yes",
          "Yes",
          "Yes",
          "Yes"
        ],
        [
          "1.3. Was a viewpoint for the analysis stated and was the study placed in any decision-making context?",
          "Yes",
          "Yes, children and adolescents",
          "Yes, HIV patients",
          "Yes, children"
        ],
        [
          "2. Was a comprehensive description of the competing alternatives given?",
          "",
          "",
          "",
          ""
        ],
        [
          "2.1. Were there any important alternatives omitted?",
          "No",
          "No",
          "Yes, the use of any other test rather than Diaskin solely",
          "Yes"
        ],
        [
          "2.2. Was (should) a do-nothing alternative be considered?",
          "No",
          "No",
          "Yes",
          "No"
        ],
        [
          "3. Was the effectiveness of the programme or services established?",
          "",
          "",
          "",
          ""
        ],
        [
          "3.1. Was this done through a randomised, controlled clinical trial? If so, did the trial protocol reflect what would happen in regular practice?",
          "No",
          "No",
          "No",
          "No"
        ],
        [
          "3.2. Was effectiveness established through an overview of clinical studies?",
          "Yes",
          "Yes",
          "Yes, CB analysis",
          "Yes"
        ],
        [
          "3.3. Were observational data or assumptions used to establish effectiveness? If so, what are the potential biases in results?",
          "Not clear CE method used",
          "Yes, it uses observational data from specific settings",
          "Yes, ICER is not computed and no other interventions were employed rather than do-nothing and Diaskintest",
          ""
        ],
        [
          "4. Were all the important and relevant costs and consequences for each alternative identified?",
          "",
          "",
          "",
          ""
        ],
        [
          "4.1. Was the range wide enough for the research question at hand?",
          "Yes",
          "Yes",
          "Yes",
          "Yes"
        ],
        [
          "4.2. Did it cover all relevant viewpoints?",
          "Yes",
          "Yes",
          "Yes",
          "Yes"
        ],
        [
          "4.3. Were the capital costs, as well as operating costs, included?",
          "unclear",
          "Yes, including staff costs, diagnostics, tests, operating costs, etc",
          "No",
          "No"
        ],
        [
          "5. Were costs and consequences measured accurately in appropriate physical units?",
          "",
          "",
          "",
          ""
        ],
        [
          "5.1. Were any of the identified items omitted from measurement? If so, does this mean that they carried no weight in the subsequent analysis?",
          "No",
          "No",
          "No",
          "No"
        ],
        [
          "5.2. Were there any special circumstances (e.g., joint use of resources) that made measurement difficult? Were these circumstances handled appropriately?",
          "No",
          "No",
          "No",
          "No"
        ],
        [
          "6. Were the cost and consequences valued credibly?",
          "",
          "",
          "",
          ""
        ],
        [
          "6.1. Were the sources of all values clearly identified?",
          "Unclear",
          "Yes, most costs coming from the State Treasure Healthcare institution",
          "Yes",
          ""
        ],
        [
          "6.2. Were market values employed for changes involving resources gained or depleted?",
          "Yes",
          "Yes",
          "Yes",
          "Yes"
        ],
        [
          "6.3. Where market values were absent (e.g. volunteer labour), or market values did not reflect actual values (such as clinic space donated at a reduced rate), were adjustments made to approximate market values?",
          "N/A",
          "N/A",
          "N/A",
          "N/A"
        ],
        [
          "6.4. Was the valuation of consequences appropriate for the question posed?",
          "Yes",
          "Yes",
          "Yes",
          "Yes"
        ],
        [
          "7. Were costs and consequences adjusted for differential timing?",
          "",
          "",
          "",
          ""
        ],
        [
          "7.1. Were costs and consequences that occur in the future ‘discounted’ to their present values?",
          "No",
          "Not stated",
          "Not stated",
          "No"
        ],
        [
          "7.2. Was there any justification given for the discount rate used?",
          "N/A",
          "N/A",
          "N/A",
          "N/A"
        ],
        [
          "8. Was an incremental analysis of costs and consequences of alternatives performed?",
          "",
          "",
          "",
          ""
        ],
        [
          "8.1. Were the additional (incremental) costs generated by one alternative over another compared to the additional effects, benefits, or utilities generated?",
          "Yes",
          "Yes",
          "Non ICER computed, comparison between two alternatives",
          "Yes Diaskin over TST, costs saved"
        ],
        [
          "9. Was allowance made for uncertainty in the estimates of costs and consequences?",
          "",
          "",
          "",
          ""
        ],
        [
          "9.1. If data on costs and consequences were stochastic (randomly determined sequence of observations), were appropriate statistical analyses performed?",
          "No",
          "N/A",
          "N/A",
          "N/A"
        ],
        [
          "9.2. If sensitivity analysis was employed, was justification provided for the range of values (or for key study parameters)?",
          "No sensitivity analyses carried out",
          "Yes",
          "Non sensitivity analyses employed",
          "Non sensitivity analyses employed"
        ],
        [
          "9.3. Were the study results sensitive to changes in the values?",
          "N/A",
          "No, 1% change",
          "N/A",
          "N/A"
        ],
        [
          "10. Did the presentation and discussion of study results include all issues of concern to users?",
          "",
          "",
          "",
          ""
        ],
        [
          "10.1. Were the conclusions of the analysis based on some overall index or ratio of costs to consequences (e.g. cost- effectiveness ratio)?",
          "No",
          "Not stated",
          "No",
          "No"
        ],
        [
          "10.2. Were the results compared with those of others who have investigated the same question? If so, were allowances made for potential differences in study methodology?",
          "No",
          "No",
          "No",
          "No"
        ],
        [
          "10.3. Did the study discuss the generalisability of the results to other settings and patient/client groups?",
          "No",
          "No",
          "No",
          "Yes"
        ],
        [
          "10.4. Did the study allude to, or take account of, other important factors in the choice or decision under consideration (e.g. distribution of costs and consequences, or relevant ethical issues)?",
          "No",
          "No",
          "No",
          "No"
        ],
        [
          "10.5. Did the study discuss issues of implementation, such as the feasibility of adopting the ‘preferred’ programme given existing financial or other constraints, and whether any freed resources could be redeployed to other worthwhile programmes?",
          "No",
          "No",
          "No",
          "Yes"
        ]
      ],
      "notes": "[Draft note: the table runs over pages 991–1001. Pages 991–996 assess Kulikov 2009, Aksenova 2011 and Yagudina 2013; 'Continuation of Table A7' (pages 997–1001) repeats the header for Moiseeva 2014, Solodun 2017, Sinitsyn 2018 and Chugaev 2020. That second header row is kept as a body row, so column titles apply only to the first block; the first block has no fifth column. A cell split across pages 994–995 (Kulikov 2009, question 9.3) is joined.]",
      "narratives": {
        "en": "Drummond checklist assessment of the quality of cost and cost-effectiveness analyses of novel skin tests for diagnosing TB infection. Rows are the checklist questions, grouped under ten main criteria; columns give each study's answer and comments, in two blocks of studies.",
        "ar": "تقييم جودة تحليلات التكلفة وفعالية التكلفة لاختبارات الجلد الجديدة لتشخيص عدوى السل باستخدام قائمة Drummond المرجعية. تمثل الصفوف أسئلة القائمة المرجعية مجمّعة تحت عشرة معايير رئيسية؛ وتبيّن الأعمدة إجابة كل دراسة وتعليقاتها، في مجموعتين من الدراسات.",
        "zh": "采用Drummond清单评估结核感染新型皮肤试验诊断的成本和成本效果分析的质量。各行为清单问题，归入十项主要标准；各列给出每项研究的回答和评述，分为两组研究。",
        "es": "Evaluación con la lista de verificación de Drummond de la calidad de los análisis de costos y de costo-efectividad de las nuevas pruebas cutáneas para diagnosticar la infección tuberculosa. Las filas son las preguntas de la lista, agrupadas en diez criterios principales; las columnas indican la respuesta y los comentarios de cada estudio, en dos bloques de estudios.",
        "fr": "Évaluation, au moyen de la liste de contrôle de Drummond, de la qualité des analyses de coût et de coût-efficacité des nouveaux tests cutanés pour le diagnostic de l’infection tuberculeuse. Les lignes correspondent aux questions de la liste, regroupées sous dix critères principaux ; les colonnes donnent la réponse et les commentaires de chaque étude, en deux blocs d’études.",
        "ru": "Оценка качества анализов затрат и экономической эффективности новых кожных тестов для диагностики туберкулезной инфекции по контрольному перечню Драммонда. Строки — вопросы перечня, сгруппированные по десяти основным критериям; в столбцах приведены ответы и комментарии по каждому исследованию в двух блоках исследований."
      },
      "csv": "tables/table-a7.csv"
    },
    {
      "label": "Table A8",
      "caption": "Table A8. Drummond Checklist for studies quality: Cost/Cost-effectiveness analyses for TST or IGRA for diagnosing TBI",
      "pages": [
        1002,
        1003,
        1004,
        1005,
        1006,
        1007,
        1008,
        1009,
        1010,
        1011,
        1012,
        1013,
        1014,
        1015,
        1016,
        1017,
        1018,
        1019,
        1020,
        1021,
        1022,
        1023,
        1024,
        1025,
        1026,
        1027,
        1028,
        1029,
        1030,
        1031,
        1032,
        1033,
        1034,
        1035,
        1036,
        1037,
        1038,
        1039,
        1040,
        1041,
        1042,
        1043
      ],
      "columns": [
        {
          "titles": "Drummond Checklist Questions"
        },
        {
          "titles": "Linas (2011)"
        },
        {
          "titles": "Pareek (2011)"
        },
        {
          "titles": "del Campo (2012)"
        },
        {
          "titles": "Eralp (2012)"
        },
        {
          "titles": "Shah (2012)"
        }
      ],
      "rows": [
        [
          "1. Was a well-defined question posed in answerable form?",
          "",
          "",
          "",
          "",
          ""
        ],
        [
          "1.1. Did the study examine both costs and effects of the service(s) or programme(s)?",
          "Yes",
          "Yes",
          "Yes",
          "Yes",
          "Yes"
        ],
        [
          "1.2. Did the study involve a comparison of alternatives?",
          "Yes",
          "Yes",
          "Yes",
          "Yes",
          "Yes"
        ],
        [
          "1.3. Was a viewpoint for the analysis stated and was the study placed in any decision-making context?",
          "Yes Immigrant/migrants, immunocompromised and vulnerable populations in the USA.",
          "Yes Recently arrived immigrants (<16y.o. and 16- 35y.o.) in the UK.",
          "Yes Healthcare workers in Spain.",
          "Yes Healthcare workers in the UK.",
          "Yes Individuals at primary health clinic with positive TST in the USA."
        ],
        [
          "2. Was a comprehensive description of the competing alternatives given?",
          "",
          "",
          "",
          "",
          ""
        ],
        [
          "2.1. Were there any important alternatives omitted?",
          "No",
          "No",
          "No",
          "No",
          "No"
        ],
        [
          "2.2. Was (should) a do- nothing alternative be considered?",
          "Yes, do nothing was included appropriately.",
          "Yes, do nothing was included appropriately.",
          "No",
          "No",
          "No"
        ],
        [
          "3. Was the effectiveness of the programme or services established?",
          "",
          "",
          "",
          "",
          ""
        ],
        [
          "3.1. Was this done through a randomised, controlled clinical trial? If so, did the trial protocol reflect what would happen in regular practice?",
          "No",
          "No",
          "No",
          "No",
          "No"
        ],
        [
          "3.2. Was effectiveness established through an overview of clinical studies?",
          "Yes. Sensitivity and specificity of tests values from number of clinical studies.",
          "Yes. Sensitivity and specificity of tests values from number of clinical studies.",
          "Yes. Sensitivity and specificity of tests values from number of clinical studies.",
          "Yes. Sensitivity and specificity of tests values from number of clinical studies.",
          "Yes. Sensitivity and specificity of tests values from number of clinical studies."
        ],
        [
          "3.3. Were observational data or assumptions used to establish effectiveness? If so, what are the potential biases in results?",
          "Yes. Assumed that quality of life with cured TB was the same as that for healthy individuals. All assumptions references/reasoned adequately.",
          "Yes. Prospective cohort analysis performed for LTBI prevalence. All assumptions references/reasoned adequately.",
          "Yes. Key assumption that no active cases of TB at the time of testing. All assumptions references/reasoned adequately.",
          "Yes Key assumption that “LTBI generates a positive result at same probability that active TB” for test. All effectiveness assumptions clearly identified and references/ reasoned adequately.",
          "Yes All effectiveness assumptions clearly identified and references/ reasoned adequately."
        ],
        [
          "4. Were all the important and relevant costs and consequences for each alternative identified?",
          "",
          "",
          "",
          "",
          ""
        ],
        [
          "4.1. Was the range wide enough for the research question at hand?",
          "Yes",
          "Yes",
          "Yes",
          "Yes",
          "Yes"
        ],
        [
          "4.2. Did it cover all relevant viewpoints?",
          "Yes",
          "Yes",
          "Yes",
          "Yes",
          "Yes"
        ],
        [
          "4.3. Were the capital costs, as well as operating costs, included?",
          "No. State only direct medical costs included.",
          "No.",
          "No.",
          "Yes, stated overheads included but no description provided.",
          "Yes, operating costs such as quality assurance, specimen transport, supply delivery, and estimates for rent and utilities included."
        ],
        [
          "5. Were costs and consequences measured accurately in appropriate physical units?",
          "",
          "",
          "",
          "",
          ""
        ],
        [
          "5.1. Were any of the identified items omitted from measurement? If so, does this mean that they carried no weight in the subsequent analysis?",
          "No",
          "Yes. Excluded drug- resistant strains and HIV infection. Assumed minimal impact.",
          "No",
          "No",
          "No"
        ],
        [
          "5.2. Were there any special circumstances (e.g., joint use of resources) that made measurement difficult? Were these circumstances handled appropriately?",
          "No",
          "No",
          "No",
          "No",
          "No"
        ],
        [
          "6. Were the cost and consequences valued credibly?",
          "",
          "",
          "",
          "",
          ""
        ],
        [
          "6.1. Were the sources of all values clearly identified?",
          "Yes",
          "Yes",
          "Yes",
          "Yes",
          "Yes"
        ],
        [
          "6.2. Were market values employed for changes involving resources gained or depleted?",
          "Yes",
          "Yes",
          "Yes",
          "Yes",
          "Yes"
        ],
        [
          "6.3. Where market values were absent (e.g. volunteer labour), or market values did not reflect actual values (such as clinic space donated at a reduced rate), were adjustments made to approximate market values?",
          "N/A",
          "N/A",
          "N/A",
          "N/A",
          "N/A"
        ],
        [
          "6.4. Was the valuation of consequences appropriate for the question posed?",
          "Yes",
          "Yes",
          "Yes",
          "Yes",
          "Yes"
        ],
        [
          "7. Were costs and consequences adjusted for differential timing?",
          "",
          "",
          "",
          "",
          ""
        ],
        [
          "7.1. Were costs and consequences that occur in the future ‘discounted’ to their present values?",
          "Yes, 3%.",
          "Yes, 3.5%.",
          "No.",
          "Yes, 5%.",
          "Yes, 3%."
        ],
        [
          "7.2. Was there any justification given for the discount rate used?",
          "Yes, following Siegel et al. 1997 guidelines.",
          "Yes, following NICE recommendations.",
          "N/A",
          "State “standard rate” with no reference in supplementary material.",
          "No justification for discount rate of costs provided."
        ],
        [
          "8. Was an incremental analysis of costs and consequences of alternatives performed?",
          "",
          "",
          "",
          "",
          ""
        ],
        [
          "8.1. Were the additional (incremental) costs generated by one alternative over another compared to the additional effects, benefits, or utilities generated?",
          "Yes",
          "Yes",
          "Yes",
          "Yes",
          "Yes"
        ],
        [
          "9. Was allowance made for uncertainty in the estimates of costs and consequences?",
          "",
          "",
          "",
          "",
          ""
        ],
        [
          "9.1. If data on costs and consequences were stochastic (randomly determined sequence of observations), were appropriate statistical analyses performed?",
          "Yes",
          "Yes",
          "Yes",
          "Yes",
          "Yes"
        ],
        [
          "9.2. If sensitivity analysis was employed, was justification provided for the range of values (or for key study parameters)?",
          "Yes",
          "Yes",
          "Yes",
          "Yes",
          "Yes"
        ],
        [
          "9.3. Were the study results sensitive to changes in the values?",
          "Yes – many conclusions for different populations sensitive to key parameters.",
          "No",
          "No",
          "No",
          "No"
        ],
        [
          "10. Did the presentation and discussion of study results include all issues of concern to users?",
          "",
          "",
          "",
          "",
          ""
        ],
        [
          "10.1. Were the conclusions of the analysis based on some overall index or ratio of costs to consequences (e.g. cost- effectiveness ratio)?",
          "Yes",
          "Yes",
          "Yes",
          "Yes",
          "Yes"
        ],
        [
          "10.2. Were the results compared with those of others who have investigated the same question? If so, were allowances made for potential differences in study methodology?",
          "No",
          "Yes",
          "Yes",
          "No",
          "No"
        ],
        [
          "10.3. Did the study discuss the generalisability of the results to other settings and patient/client groups?",
          "No",
          "Yes",
          "No",
          "No",
          "Yes"
        ],
        [
          "10.4. Did the study allude to, or take account of, other important factors in the choice or decision under consideration (e.g. distribution of costs and consequences, or relevant ethical issues)?",
          "No",
          "Yes",
          "No",
          "Yes",
          "No"
        ],
        [
          "10.5. Did the study discuss issues of implementation, such as the feasibility of adopting the ‘preferred’ programme given existing financial or other constraints, and whether any freed resources could be redeployed to other worthwhile programmes?",
          "No",
          "Yes",
          "No",
          "Yes",
          "Yes"
        ],
        [
          "Drummond Checklist Questions",
          "Mandalakas (2013)",
          "Pareek (2013)",
          "Steffen (2013)",
          "Swaminath (2013)",
          "Verma (2013)"
        ],
        [
          "1. Was a well-defined question posed in answerable form?",
          "",
          "",
          "",
          "",
          ""
        ],
        [
          "1.1. Did the study examine both costs and effects of the service(s) or programme(s)?",
          "Yes",
          "Yes",
          "Yes",
          "Yes",
          "Yes"
        ],
        [
          "1.2. Did the study involve a comparison of alternatives?",
          "Yes",
          "Yes",
          "Yes",
          "Yes",
          "Yes"
        ],
        [
          "1.3. Was a viewpoint for the analysis stated and was the study placed in any decision-making context?",
          "Yes Children (0-2 and 3- 5y.o.) contacts in South Africa.",
          "Yes Recently arrived immigrants (≤35 y.o.) in the UK.",
          "Yes 35y.o. close contacts of active TB cases in Brazil.",
          "Yes Immunosuppressed with IBD in the USA.",
          "Yes >65y.o. in long term care in Canada."
        ],
        [
          "2. Was a comprehensive description of the competing alternatives given?",
          "",
          "",
          "",
          "",
          ""
        ],
        [
          "2.1. Were there any important alternatives omitted?",
          "No",
          "No",
          "No",
          "No",
          "No"
        ],
        [
          "2.2. Was (should) a do- nothing alternative be considered?",
          "Yes, do nothing was included appropriately.",
          "No",
          "No",
          "No",
          "Yes, do nothing was included appropriately."
        ],
        [
          "3. Was the effectiveness of the programme or services established?",
          "",
          "",
          "",
          "",
          ""
        ],
        [
          "3.1. Was this done through a randomised, controlled clinical trial? If so, did the trial protocol reflect what would happen in regular practice?",
          "No",
          "No",
          "No",
          "No",
          "No"
        ],
        [
          "3.2. Was effectiveness established through an overview of clinical studies?",
          "Yes. Sensitivity and specificity of tests values from number of clinical studies.",
          "Yes. Sensitivity and specificity of tests values from number of clinical studies.",
          "Yes. Sensitivity and specificity of tests values from number of clinical studies.",
          "Yes. Sensitivity and specificity of tests values from number of clinical studies.",
          "Yes Sensitivity and specificity of tests values from number of clinical studies."
        ],
        [
          "3.3. Were observational data or assumptions used to establish effectiveness? If so, what are the potential biases in results?",
          "Yes All effectiveness assumptions are said to be derived from published data obtained in high- burden settings, but no reference provided.",
          "Yes Observational study performed to estimate LTBI prevalence.",
          "Yes Many assumptions effecting effectiveness with no references/reasoning.",
          "Yes Many assumptions to estimate effectiveness with only a small number with references/reasoning.",
          "Yes Key assumption is TST characteristics used are for general population despite evidence of lower specificity and sensitivity for elderly. Could introduce overestimation of effectiveness hence underestimate of cost-effectiveness ratio."
        ],
        [
          "4. Were all the important and relevant costs and consequences for each alternative identified?",
          "",
          "",
          "",
          "",
          ""
        ],
        [
          "4.1. Was the range wide enough for the research question at hand?",
          "Yes",
          "Yes",
          "Yes",
          "Yes",
          "Yes"
        ],
        [
          "4.2. Did it cover all relevant viewpoints?",
          "Yes",
          "Yes",
          "Yes",
          "Yes",
          "Yes"
        ],
        [
          "4.3. Were the capital costs, as well as operating costs, included?",
          "Unclear. Outpatient hospitalisation costs included but no description provided.",
          "No, state only direct medical costs included and clearly state breakdown of hospitalisation costs.",
          "No.",
          "No, authors use Linas 2011 hospitalisation costs.",
          "No. Hospitalisation costs breakdown do not state any overheads/operating costs."
        ],
        [
          "5. Were costs and consequences measured accurately in appropriate physical units?",
          "",
          "",
          "",
          "",
          ""
        ],
        [
          "5.1. Were any of the identified items omitted from measurement? If so, does this mean that they carried no weight in the subsequent analysis?",
          "Yes Excluded adverse reaction costs as very rare events. Assumed no impact.",
          "No",
          "No",
          "Yes. Excluded MDR-TB due to low prevalence and secondary reactivation of TB. Also did not include patient data for those who did not attend second clinic visit for TST reading. Assumed no impact.",
          "No"
        ],
        [
          "5.2. Were there any special circumstances (e.g., joint use of resources) that made measurement difficult? Were these circumstances handled appropriately?",
          "No",
          "No",
          "No",
          "No",
          "No"
        ],
        [
          "6. Were the cost and consequences valued credibly?",
          "",
          "",
          "",
          "",
          ""
        ],
        [
          "6.1. Were the sources of all values clearly identified?",
          "Yes",
          "Yes",
          "Yes",
          "Yes but no year of valuation stated.",
          "Yes"
        ],
        [
          "6.2. Were market values employed for changes involving resources gained or depleted?",
          "Yes",
          "Yes",
          "Yes",
          "Yes",
          "Yes"
        ],
        [
          "6.3. Where market values were absent (e.g. volunteer labour), or market values did not reflect actual values (such as clinic space donated at a reduced rate), were adjustments made to approximate market values?",
          "N/A",
          "N/A",
          "N/A",
          "N/A",
          "N/A"
        ],
        [
          "6.4. Was the valuation of consequences appropriate for the question posed?",
          "Yes",
          "Yes",
          "Yes",
          "Yes",
          "Yes"
        ],
        [
          "7. Were costs and consequences adjusted for differential timing?",
          "",
          "",
          "",
          "",
          ""
        ],
        [
          "7.1. Were costs and consequences that occur in the future ‘discounted’ to their present values?",
          "Yes, 3%.",
          "Yes, 3.5%.",
          "No.",
          "No.",
          "Yes, 3%."
        ],
        [
          "7.2. Was there any justification given for the discount rate used?",
          "Yes, state “standard rate” and referenced.",
          "Yes, reference NICE recommendations.",
          "N/A",
          "N/A",
          "No."
        ],
        [
          "8. Was an incremental analysis of costs and consequences of alternatives performed?",
          "",
          "",
          "",
          "",
          ""
        ],
        [
          "8.1. Were the additional (incremental) costs generated by one alternative over another compared to the additional effects, benefits, or utilities generated?",
          "Yes",
          "Yes",
          "Yes",
          "Yes",
          "Yes"
        ],
        [
          "9. Was allowance made for uncertainty in the estimates of costs and consequences?",
          "",
          "",
          "",
          "",
          ""
        ],
        [
          "9.1. If data on costs and consequences were stochastic (randomly determined sequence of observations), were appropriate statistical analyses performed?",
          "Yes",
          "Yes",
          "Yes",
          "Yes",
          "Yes"
        ],
        [
          "9.2. If sensitivity analysis was employed, was justification provided for the range of values (or for key study parameters)?",
          "No Stated “reasonable range” but no reference.",
          "Yes",
          "Yes",
          "Yes",
          "Yes"
        ],
        [
          "9.3. Were the study results sensitive to changes in the values?",
          "Yes Sensitive to LTBI rate.",
          "Yes Sensitive to specificity of QFT-GIT.",
          "Yes Sensitive to QFT costs and TST specificity.",
          "No",
          "Yes Sensitive to TB re-activation rate."
        ],
        [
          "10. Did the presentation and discussion of study results include all issues of concern to users?",
          "",
          "",
          "",
          "",
          ""
        ],
        [
          "10.1. Were the conclusions of the analysis based on some overall index or ratio of costs to consequences (e.g. cost- effectiveness ratio)?",
          "Yes",
          "Yes",
          "Yes",
          "No No cost-effectiveness ratio was used. Conclusions were based on “highest benefits” and “lowest cost” strategy.",
          "Yes"
        ],
        [
          "10.2. Were the results compared with those of others who have investigated the same question? If so, were allowances made for potential differences in study methodology?",
          "No",
          "Yes",
          "Yes",
          "No",
          "No"
        ],
        [
          "10.3. Did the study discuss the generalisability of the results to other settings and patient/client groups?",
          "No",
          "Yes",
          "Yes",
          "Yes",
          "Yes"
        ],
        [
          "10.4. Did the study allude to, or take account of, other important factors in the choice or decision under consideration (e.g. distribution of costs and consequences, or relevant ethical issues)?",
          "Yes",
          "Yes",
          "Yes",
          "Yes",
          "Yes"
        ],
        [
          "10.5. Did the study discuss issues of implementation, such as the feasibility of adopting the ‘preferred’ programme given existing financial or other constraints, and whether any freed resources could be redeployed to other worthwhile programmes?",
          "Yes",
          "Yes",
          "Yes",
          "No",
          "No"
        ],
        [
          "Drummond Checklist Questions",
          "Capocci, (2015)",
          "Wingate (2015)",
          "Auguste. (2016)",
          "Nijhawan (2016)",
          "Campbell (2017)"
        ],
        [
          "2. Was a well-defined question posed in answerable form?",
          "",
          "",
          "",
          "",
          ""
        ],
        [
          "1.1. Did the study examine both costs and effects of the service(s) or programme(s)?",
          "Yes",
          "Yes",
          "Yes",
          "Yes",
          "Yes"
        ],
        [
          "1.2. Did the study involve a comparison of alternatives?",
          "Yes",
          "Yes",
          "Yes",
          "Yes",
          "Yes"
        ],
        [
          "1.3. Was a viewpoint for the analysis stated and was the study placed in any decision-making context?",
          "Yes Adults living with HIV in the UK.",
          "Yes Pre arrival refugees to USA.",
          "Yes Children, immunocompromised people and recently Arrived immigrants and General Population in the UK.",
          "Yes Adults entering jail in the USA.",
          "Yes Pre-arrival refugees to Canada."
        ],
        [
          "2. Was a comprehensive description of the competing alternatives given?",
          "",
          "",
          "",
          "",
          ""
        ],
        [
          "2.1. Were there any important alternatives omitted?",
          "No",
          "No",
          "No",
          "No",
          "No"
        ],
        [
          "2.2. Was (should) a do- nothing alternative be considered?",
          "Yes, do nothing was included appropriately.",
          "Yes, do nothing was included appropriately.",
          "No",
          "No",
          "Yes, do nothing was included appropriately."
        ],
        [
          "3. Was the effectiveness of the programme or services established?",
          "",
          "",
          "",
          "",
          ""
        ],
        [
          "3.1. Was this done through a randomised, controlled clinical trial? If so, did the trial protocol reflect what would happen in regular practice?",
          "No",
          "No",
          "No",
          "No",
          "No"
        ],
        [
          "3.2. Was effectiveness established through an overview of clinical studies?",
          "Somewhat. Sensitivity of IGRA used from one clinical study.",
          "Yes Sensitivity and specificity of TST values from number of clinical studies",
          "Yes Systematic review carried out to establish sensitivity and specificity of tests.",
          "Yes Sensitivity and specificity of test values from clinical studies and systematic review.",
          "Yes Sensitivity and specificity of test values from clinical studies and systematic reviews."
        ],
        [
          "3.3. Were observational data or assumptions used to establish effectiveness? If so, what are the potential biases in results?",
          "Yes Both observational data from clinic and referenced assumptions used. Unclear method of calculating effectiveness outcomes.",
          "Yes Key assumption is proportions of population with/without BCG vaccination with adequate references/reasoning. Authors use this assumption and one clinical study to estimate TST sensitivity.",
          "Yes Many assumptions for effectiveness with no references/reasoning.",
          "No",
          "Yes Many assumptions for effectiveness all with adequate references/reasoning."
        ],
        [
          "4. Were all the important and relevant costs and consequences for each alternative identified?",
          "",
          "",
          "",
          "",
          ""
        ],
        [
          "4.1. Was the range wide enough for the research question at hand?",
          "Yes",
          "Yes",
          "Yes",
          "Yes",
          "Yes"
        ],
        [
          "4.2. Did it cover all relevant viewpoints?",
          "Yes",
          "Yes",
          "Yes",
          "Yes",
          "Yes"
        ],
        [
          "4.3. Were the capital costs, as well as operating costs, included?",
          "Unclear breakdown of costs provided.",
          "No. Includes labour but no indication of other operating/capital costs.",
          "No. Clear breakdown provided and capital/overheads not included.",
          "Yes. For QFT-GIT laboratory operations included.",
          "No."
        ],
        [
          "5. Were costs and consequences measured accurately in appropriate physical units?",
          "",
          "",
          "",
          "",
          ""
        ],
        [
          "5.1. Were any of the identified items omitted from measurement? If so, does this mean that they carried no weight in the subsequent analysis?",
          "No",
          "No",
          "No",
          "Yes Treatment and outcome costs. Potential underestimate of benefits of QFT-GIT.",
          "No"
        ],
        [
          "5.2. Were there any special circumstances (e.g., joint use of resources) that made measurement difficult? Were these circumstances handled appropriately?",
          "No",
          "No",
          "No",
          "No",
          "No"
        ],
        [
          "6. Were the cost and consequences valued credibly?",
          "",
          "",
          "",
          "",
          ""
        ],
        [
          "6.1. Were the sources of all values clearly identified?",
          "Yes",
          "Yes",
          "Yes",
          "Yes",
          "Yes"
        ],
        [
          "6.2. Were market values employed for changes involving resources gained or depleted?",
          "Yes",
          "Yes",
          "Yes",
          "Yes",
          "Yes"
        ],
        [
          "6.3. Where market values were absent (e.g. volunteer labour), or market values did not reflect actual values (such as clinic space donated at a reduced rate), were adjustments made to approximate market values?",
          "N/A",
          "N/A",
          "N/A",
          "N/A",
          "N/A"
        ],
        [
          "6.4. Was the valuation of consequences appropriate for the question posed?",
          "Yes",
          "Yes",
          "Yes",
          "Yes",
          "Yes"
        ],
        [
          "7. Were costs and consequences adjusted for differential timing?",
          "",
          "",
          "",
          "",
          ""
        ],
        [
          "7.1. Were costs and consequences that occur in the future ‘discounted’ to their present values?",
          "Yes, 3.5%",
          "Yes, 3%",
          "Yes, 3.5%",
          "No",
          "Yes, 1.5%"
        ],
        [
          "7.2. Was there any justification given for the discount rate used?",
          "Yes, reference NICE recommendations.",
          "Yes, reference Haddix et al. 2003.",
          "Yes, reference NICE recommendations.",
          "N/A",
          "Yes, reference Canadian Agency for Drugs and Technologies in Health recommendations."
        ],
        [
          "8. Was an incremental analysis of costs and consequences of alternatives performed?",
          "",
          "",
          "",
          "",
          ""
        ],
        [
          "8.1. Were the additional (incremental) costs generated by one alternative over another compared to the additional effects, benefits, or utilities generated?",
          "Yes",
          "Yes",
          "Yes",
          "Yes",
          "Yes"
        ],
        [
          "9. Was allowance made for uncertainty in the estimates of costs and consequences?",
          "",
          "",
          "",
          "",
          ""
        ],
        [
          "9.1. If data on costs and consequences were stochastic (randomly determined sequence of observations), were appropriate statistical analyses performed?",
          "Yes",
          "Yes",
          "Yes",
          "Yes",
          "Yes"
        ],
        [
          "9.2. If sensitivity analysis was employed, was justification provided for the range of values (or for key study parameters)?",
          "Yes",
          "Yes",
          "Yes",
          "No",
          "Yes"
        ],
        [
          "9.3. Were the study results sensitive to changes in the values?",
          "No",
          "No",
          "No",
          "No",
          "Yes Sensitive to treatments received."
        ],
        [
          "10. Did the presentation and discussion of study results include all issues of concern to users?",
          "",
          "",
          "",
          "",
          ""
        ],
        [
          "10.1. Were the conclusions of the analysis based on some overall index or ratio of costs to consequences (e.g. cost- effectiveness ratio)?",
          "Yes",
          "Yes",
          "Yes",
          "No",
          "Yes"
        ],
        [
          "10.2. Were the results compared with those of others who have investigated the same question? If so, were allowances made for potential differences in study methodology?",
          "No",
          "Yes",
          "Yes",
          "Yes",
          "Yes"
        ],
        [
          "10.3. Did the study discuss the generalisability of the results to other settings and patient/client groups?",
          "Yes",
          "No",
          "Yes",
          "Yes",
          "Yes"
        ],
        [
          "10.4. Did the study allude to, or take account of, other important factors in the choice or decision under consideration (e.g. distribution of costs and consequences, or relevant ethical issues)?",
          "Yes",
          "No",
          "Yes",
          "Yes",
          "Yes"
        ],
        [
          "10.5. Did the study discuss issues of implementation, such as the feasibility of adopting the ‘preferred’ programme given existing financial or other constraints, and whether any freed resources could be redeployed to other worthwhile programmes?",
          "Yes",
          "No",
          "Yes",
          "Yes",
          "Yes"
        ],
        [
          "Drummond Checklist Questions",
          "Haukaas (2017)",
          "Mullie (2017)",
          "Tasillo, (2017)",
          "Abubakar (2018)",
          "Li (2018)"
        ],
        [
          "1. Was a well-defined question posed in answerable form?",
          "",
          "",
          "",
          "",
          ""
        ],
        [
          "1.1. Did the study examine both costs and effects of the service(s) or programme(s)?",
          "Yes",
          "Yes",
          "Yes",
          "Yes",
          "Yes"
        ],
        [
          "1.2. Did the study involve a comparison of alternatives?",
          "Yes",
          "Yes",
          "Yes",
          "Yes",
          "Yes"
        ],
        [
          "1.3. Was a viewpoint for the analysis stated and was the study placed in any decision-making context?",
          "Yes Recently arrived immigrants <35y.o to Norway",
          "Yes HCW with negative TST at time of employment.",
          "Yes US-born or migrants living with or without comorbidities.",
          "Yes Recent immigrants and contacts in the UK.",
          "Yes Elderly (>65y.o.) at admission to residential care home in Hong Kong."
        ],
        [
          "2. Was a comprehensive description of the competing alternatives given?",
          "",
          "",
          "",
          "",
          ""
        ],
        [
          "2.1. Were there any important alternatives omitted?",
          "No",
          "No",
          "No",
          "No",
          "No"
        ],
        [
          "2.2. Was (should) a do- nothing alternative be considered?",
          "Yes, do nothing was included appropriately.",
          "No",
          "Yes, do nothing was included appropriately.",
          "Yes, do nothing was included appropriately.",
          "Yes, do nothing was included appropriately."
        ],
        [
          "3. Was the effectiveness of the programme or services established?",
          "",
          "",
          "",
          "",
          ""
        ],
        [
          "3.1. Was this done through a randomised, controlled clinical trial? If so, did the trial protocol reflect what would happen in regular practice?",
          "No",
          "No",
          "No",
          "",
          "No"
        ],
        [
          "3.2. Was effectiveness established through an overview of clinical studies?",
          "Somewhat. Sensitivity and specificity of TST values from only one study.",
          "Yes Sensitivity and specificity of tests values from number of clinical studies.",
          "Yes Sensitivity and specificity of tests values from number of clinical studies.",
          "No",
          "Yes Sensitivity and specificity of tests values from number of clinical studies."
        ],
        [
          "3.3. Were observational data or assumptions used to establish effectiveness? If so, what are the potential biases in results?",
          "Yes Expert opinion and estimation used for multiple key effectiveness parameter. Other assumptions provided with no references/reasoning.",
          "Yes Key assumption is no loss of QALYs with uncomplicated treatment of LTBI. All other assumptions references/reasoned adequately.",
          "Yes Key assumption is that LTBI treatment without adverse effects causes no change in quality of life. Other assumptions provided with no references/reasoning.",
          "Yes Cohort trial used to estimate sensitivity and specificity of tests. Reporting and selection bias possible.",
          "Yes Many assumptions for effectiveness all with adequate references/reas oning."
        ],
        [
          "4. Were all the important and relevant costs and consequences for each alternative identified?",
          "",
          "",
          "",
          "",
          ""
        ],
        [
          "4.1. Was the range wide enough for the research question at hand?",
          "Yes",
          "Yes",
          "Yes",
          "Yes",
          "Yes"
        ],
        [
          "4.2. Did it cover all relevant viewpoints?",
          "Yes",
          "Yes",
          "Yes",
          "Yes",
          "Yes"
        ],
        [
          "4.3. Were the capital costs, as well as operating costs, included?",
          "Unclear. Hospitalisation costs included but no breakdown provided.",
          "Unclear. Hospitalisation costs included but no breakdown provided.",
          "Unclear. Treatment costs included but no breakdown provided.",
          "No. Clear breakdown provided and capital/overheads not included",
          "No. Clear breakdown provided and capital/overhea ds not included"
        ],
        [
          "5. Were costs and consequences measured accurately in appropriate physical units?",
          "",
          "",
          "",
          "",
          ""
        ],
        [
          "5.1. Were any of the identified items omitted from measurement? If so, does this mean that they carried no weight in the subsequent analysis?",
          "Yes VAT, MDR-TB assumed minimal effect on analysis.",
          "No",
          "No",
          "No",
          "Yes. Costs of minor adverse events or additional radiologic tests. Underestimatio n of costs."
        ],
        [
          "5.2. Were there any special circumstances (e.g., joint use of resources) that made measurement difficult? Were these circumstances handled appropriately?",
          "No",
          "No",
          "No",
          "No",
          "No"
        ],
        [
          "6. Were the cost and consequences valued credibly?",
          "",
          "",
          "",
          "",
          ""
        ],
        [
          "6.1. Were the sources of all values clearly identified?",
          "Yes",
          "Yes",
          "Yes",
          "Yes, but year of valuation not stated.",
          "Yes, but year of valuation not stated."
        ],
        [
          "6.2. Were market values employed for changes involving resources gained or depleted?",
          "Yes",
          "Yes",
          "Yes",
          "Yes",
          "Yes"
        ],
        [
          "6.3. Where market values were absent (e.g. volunteer labour), or market values did not reflect actual values (such as clinic space donated at a reduced rate), were adjustments made to approximate market values?",
          "N/A",
          "N/A",
          "N/A",
          "N/A",
          "N/A"
        ],
        [
          "6.4. Was the valuation of consequences appropriate for the question posed?",
          "Yes",
          "Yes",
          "Yes",
          "Yes",
          "Yes"
        ],
        [
          "7. Were costs and consequences adjusted for differential timing?",
          "",
          "",
          "",
          "",
          ""
        ],
        [
          "7.1. Were costs and consequences that occur in the future ‘discounted’ to their present values?",
          "Yes, 4% Only costs discounted in base case analysis.",
          "Yes, 3%",
          "Yes, 3%",
          "Yes, 3.5%",
          "Yes, 5%"
        ],
        [
          "7.2. Was there any justification given for the discount rate used?",
          "Yes, reference Norwegian Directorate of Health recommendations.",
          "Yes, reference Sanders et al. 2016 recommendations.",
          "State current recommendations.",
          "State current recommendations.",
          "Yes, reference Drummond et al. 2005."
        ],
        [
          "8. Was an incremental analysis of costs and consequences of alternatives performed?",
          "",
          "",
          "",
          "",
          ""
        ],
        [
          "8.1. Were the additional (incremental) costs generated by one alternative over another compared to the additional effects, benefits, or utilities generated?",
          "Yes",
          "Yes",
          "Yes",
          "Yes",
          "Yes"
        ],
        [
          "9. Was allowance made for uncertainty in the estimates of costs and consequences?",
          "",
          "",
          "",
          "",
          ""
        ],
        [
          "9.1. If data on costs and consequences were stochastic (randomly determined sequence of observations), were appropriate statistical analyses performed?",
          "Yes",
          "Yes",
          "Yes",
          "Yes",
          "Yes"
        ],
        [
          "9.2. If sensitivity analysis was employed, was justification provided for the range of values (or for key study parameters)?",
          "No",
          "Yes",
          "Yes",
          "Yes",
          "Yes"
        ],
        [
          "9.3. Were the study results sensitive to changes in the values?",
          "Yes. Sensitive to IGRA cost.",
          "No",
          "Yes Sensitive to LTBI rate and TST sensitivity.",
          "No",
          "No."
        ],
        [
          "10. Did the presentation and discussion of study results include all issues of concern to users?",
          "",
          "",
          "",
          "",
          ""
        ],
        [
          "10.1. Were the conclusions of the analysis based on some overall index or ratio of costs to consequences (e.g. cost-effectiveness ratio)?",
          "Yes",
          "Yes",
          "Yes",
          "Yes",
          "Yes"
        ],
        [
          "10.2. Were the results compared with those of others who have investigated the same question? If so, were allowances made for potential differences in study methodology?",
          "Yes",
          "Yes",
          "No",
          "No",
          "Yes"
        ],
        [
          "10.3. Did the study discuss the generalisability of the results to other settings and patient/client groups?",
          "No",
          "Yes",
          "No",
          "Yes",
          "Yes"
        ],
        [
          "10.4. Did the study allude to, or take account of, other important factors in the choice or decision under consideration (e.g. distribution of costs and consequences, or relevant ethical issues)?",
          "Yes",
          "Yes",
          "Yes",
          "Yes",
          "Yes"
        ],
        [
          "10.5. Did the study discuss issues of implementation, such as the feasibility of adopting the ‘preferred’ programme given existing financial or other constraints, and whether any freed resources could be redeployed to other worthwhile programmes?",
          "Yes",
          "No",
          "No",
          "Yes",
          "Yes"
        ],
        [
          "Drummond Checklist Questions",
          "Sohn (2018).",
          "Campbell (2019a).",
          "Campbell (2019b).",
          "Loureiro (2019).",
          "Png (2019)."
        ],
        [
          "1. Was a well-defined question posed in answerable form?",
          "",
          "",
          "",
          "",
          ""
        ],
        [
          "1.1. Did the study examine both costs and effects of the service(s) or programme(s)?",
          "Yes",
          "Yes",
          "Yes",
          "Yes",
          "Yes"
        ],
        [
          "1.2. Did the study involve a comparison of alternatives?",
          "Yes",
          "Yes",
          "Yes",
          "Yes",
          "Yes"
        ],
        [
          "1.3. Was a viewpoint for the analysis stated and was the study placed in any decision-making context?",
          "Yes Adolescents (13-18y.o.) contacts in Japan.",
          "Yes Pre-arrival immigrants to Canada",
          "Yes Migrants with either late-stage CKD or beginning dialysis.",
          "Yes Primary HCW in Brazil.",
          "Yes HCW in Singapore."
        ],
        [
          "2. Was a comprehensive description of the competing alternatives given?",
          "",
          "",
          "",
          "",
          ""
        ],
        [
          "2.1. Were there any important alternatives omitted?",
          "No",
          "No",
          "No",
          "No",
          "No"
        ],
        [
          "2.2. Was (should) a do- nothing alternative be considered?",
          "No",
          "Yes",
          "Yes, do nothing was included appropriately.",
          "No",
          "Yes, do nothing was included appropriately."
        ],
        [
          "3. Was the effectiveness of the programme or services established?",
          "",
          "",
          "",
          "",
          ""
        ],
        [
          "3.1. Was this done through a randomised, controlled clinical trial? If so, did the trial protocol reflect what would happen in regular practice?",
          "No",
          "No",
          "No",
          "No",
          "No"
        ],
        [
          "3.2. Was effectiveness established through an overview of clinical studies?",
          "Yes Sensitivity and specificity of tests values from number of clinical studies and systematic reviews.",
          "Yes Sensitivity and specificity of tests values from number of clinical studies.",
          "Yes Sensitivity and specificity of tests values from number of clinical studies.",
          "Yes Sensitivity and specificity of tests values from number of clinical studies.",
          "Yes"
        ],
        [
          "3.3. Were observational data or assumptions used to establish effectiveness? If so, what are the potential biases in results?",
          "Yes Key assumption is the proportion of recent infection among contacts with LTBI. All assumptions for effectiveness all have adequate references/reasoning.",
          "Yes All assumptions for effectiveness all have adequate references/reasoning.",
          "Yes Key assumption is that no individuals had active TB at the time of LTBI screening. All assumptions for effectiveness all have adequate references/reasoning.",
          "Yes Multiple assumptions for effectiveness all with no references/reasonin g.",
          "Yes Assumed 100% specificity and sensitivity of QFT- G with reasoning and references. All assumptions are stated to be from “published literature or expert opinion”"
        ],
        [
          "4. Were all the important and relevant costs and consequences for each alternative identified?",
          "",
          "",
          "",
          "",
          ""
        ],
        [
          "4.1. Was the range wide enough for the research question at hand?",
          "Yes",
          "Yes",
          "Yes",
          "Yes",
          "Yes"
        ],
        [
          "4.2. Did it cover all relevant viewpoints?",
          "Yes",
          "Yes",
          "Yes",
          "Yes",
          "Yes"
        ],
        [
          "4.3. Were the capital costs, as well as operating costs, included?",
          "Yes. Includes overheads and vehicle operations.",
          "Unclear. Hospitalisation costs included but no breakdown provided.",
          "Unclear. Hospitalisation costs included but no breakdown provided.",
          "Yes. No capital costs stated but equipment use costs clearly included.",
          "Yes. State that hospitalisation and testing costs include labour and overhead costs."
        ],
        [
          "5. Were costs and consequences measured accurately in appropriate physical units?",
          "",
          "",
          "",
          "",
          ""
        ],
        [
          "5.1. Were any of the identified items omitted from measurement? If so, does this mean that they carried no weight in the subsequent analysis?",
          "Yes Cost of referral to clinic assumed relatively minimal impact.",
          "No",
          "No",
          "Yes MDR-TB due to low prevalence. Assumed minimal impact.",
          "No"
        ],
        [
          "5.2. Were there any special circumstances (e.g., joint use of resources) that made measurement difficult? Were these circumstances handled appropriately?",
          "No",
          "No",
          "No",
          "No",
          "No"
        ],
        [
          "6. Were the cost and consequences valued credibly?",
          "",
          "",
          "",
          "",
          ""
        ],
        [
          "6.1. Were the sources of all values clearly identified?",
          "Yes",
          "Yes",
          "Yes",
          "No",
          "Yes"
        ],
        [
          "6.2. Were market values employed for changes involving resources gained or depleted?",
          "Yes",
          "Yes",
          "Yes",
          "No",
          "Yes"
        ],
        [
          "6.3. Where market values were absent (e.g. volunteer labour), or market values did not reflect actual values (such as clinic space donated at a reduced rate), were adjustments made to approximate market values?",
          "N/A",
          "N/A",
          "N/A",
          "N/A",
          "N/A"
        ],
        [
          "6.4. Was the valuation of consequences appropriate for the question posed?",
          "Yes",
          "Yes",
          "Yes",
          "Yes",
          "Yes"
        ],
        [
          "7. Were costs and consequences adjusted for differential timing?",
          "",
          "",
          "",
          "",
          ""
        ],
        [
          "7.1. Were costs and consequences that occur in the future ‘discounted’ to their present values?",
          "No",
          "Yes, 3%",
          "Yes, 1.5%",
          "No",
          "Yes, 3%"
        ],
        [
          "7.2. Was there any justification given for the discount rate used?",
          "State due to short horizon of analysis.",
          "Yes, reference Sanders et al. 2016.",
          "Yes, reference Canadian Agency for Drugs and Technologies in Health recommendations.",
          "State due to short horizon of analysis.",
          "Only state “commonly used rate”."
        ],
        [
          "8. Was an incremental analysis of costs and consequences of alternatives performed?",
          "",
          "",
          "",
          "",
          ""
        ],
        [
          "8.1. Were the additional (incremental) costs generated by one alternative over another compared to the additional effects, benefits, or utilities generated?",
          "Yes",
          "Yes",
          "Yes",
          "Yes",
          "Yes"
        ],
        [
          "9. Was allowance made for uncertainty in the estimates of costs and consequences?",
          "",
          "",
          "",
          "",
          ""
        ],
        [
          "9.1. If data on costs and consequences were stochastic (randomly determined sequence of observations), were appropriate statistical analyses performed?",
          "Yes",
          "Yes",
          "Yes",
          "Yes",
          "Yes"
        ],
        [
          "9.2. If sensitivity analysis was employed, was justification provided for the range of values (or for key study parameters)?",
          "Yes",
          "Yes",
          "Yes",
          "Yes",
          "Yes"
        ],
        [
          "9.3. Were the study results sensitive to changes in the values?",
          "Yes Sensitive to QFT-GIT cost.",
          "Yes For migrants from low incidence conclusion only cost-effective 50% of time in probabilistic sensitivity analysis.",
          "No",
          "No",
          "No"
        ],
        [
          "10. Did the presentation and discussion of study results include all issues of concern to users?",
          "",
          "",
          "",
          "",
          ""
        ],
        [
          "10.1. Were the conclusions of the analysis based on some overall index or ratio of costs to consequences (e.g. cost-effectiveness ratio)?",
          "Yes",
          "Yes",
          "Yes",
          "Yes",
          "Yes"
        ],
        [
          "10.2. Were the results compared with those of others who have investigated the same question? If so, were allowances made for potential differences in study methodology?",
          "Yes",
          "Yes",
          "Yes",
          "Yes",
          "Yes"
        ],
        [
          "10.3. Did the study discuss the generalisability of the results to other settings and patient/client groups?",
          "Yes",
          "Yes",
          "Yes",
          "No",
          "Yes"
        ],
        [
          "10.4. Did the study allude to, or take account of, other important factors in the choice or decision under consideration (e.g. distribution of costs and consequences, or relevant ethical issues)?",
          "Yes",
          "Yes",
          "Yes",
          "Yes",
          "No"
        ],
        [
          "10.5. Did the study discuss issues of implementation, such as the feasibility of adopting the ‘preferred’ programme given existing financial or other constraints, and whether any freed resources could be redeployed to other worthwhile programmes?",
          "Yes",
          "Yes",
          "Yes",
          "Yes",
          "Yes"
        ],
        [
          "Drummond Checklist Questions",
          "Al Abri (2020).",
          "Jo (2020).",
          "Steffen (2020)",
          "Kim (2018)",
          ""
        ],
        [
          "1.Was a well-defined question posed in answerable form?",
          "",
          "",
          "",
          "",
          ""
        ],
        [
          "1.1. Did the study examine both costs and effects of the service(s) or programme(s)?",
          "Yes",
          "Yes",
          "Yes",
          "Yes",
          ""
        ],
        [
          "1.2. Did the study involve a comparison of alternatives?",
          "Yes",
          "Yes",
          "Yes",
          "Yes",
          ""
        ],
        [
          "1.3. Was a viewpoint for the analysis stated and was the study placed in any decision-making context?",
          "Yes 20-year-old recent immigrants in Oman.",
          "Yes General population with vulnerable sub- populations.",
          "Yes Adults living with HIV in Brazil.",
          "Yes HIV+ Pregnant women",
          ""
        ],
        [
          "2. Was a comprehensive description of the competing alternatives given?",
          "",
          "",
          "",
          "",
          ""
        ],
        [
          "2.1. Were there any important alternatives omitted?",
          "No",
          "Unclear alternatives provided.",
          "No",
          "No",
          ""
        ],
        [
          "2.2. Was (should) a do-nothing alternative be considered?",
          "No",
          "No",
          "No",
          "No",
          ""
        ],
        [
          "3. Was the effectiveness of the programme or services established?",
          "",
          "",
          "",
          "",
          ""
        ],
        [
          "3.1. Was this done through a randomised, controlled clinical trial? If so, did the trial protocol reflect what would happen in regular practice?",
          "No",
          "No",
          "No",
          "No",
          ""
        ],
        [
          "3.2. Was effectiveness established through an overview of clinical studies?",
          "Yes Sensitivity and specificity of tests values from number of clinical studies and systematic reviews.",
          "Yes Sensitivity and tests values from a single systematic review.",
          "Yes Sensitivity and specificity of tests values from number of systematic reviews.",
          "Yes Sensitivity and specificity of tests values from number of systematic reviews.",
          ""
        ],
        [
          "3.3. Were observational data or assumptions used to establish effectiveness? If so, what are the potential biases in results?",
          "Yes No clear assumptions stated. TB incidence and the LTBI rate, BCG vaccination rate, (MDR- TB) rate, TB mortality, and rate of adherence to treatment were imputed from Omani data.",
          "Yes Most assumptions for effectiveness all have adequate references/reasoning.",
          "Yes All assumptions for effectiveness all have adequate references/reasoning.",
          "Yes All assumptions for effectiveness all have adequate references/reasoning.",
          ""
        ],
        [
          "4. Were all the important and relevant costs and consequences for each alternative identified?",
          "",
          "",
          "",
          "",
          ""
        ],
        [
          "4.1. Was the range wide enough for the research question at hand?",
          "Yes",
          "No",
          "Yes",
          "Yes",
          ""
        ],
        [
          "4.2. Did it cover all relevant viewpoints?",
          "Yes",
          "Yes",
          "Yes",
          "Yes",
          ""
        ],
        [
          "4.3. Were the capital costs, as well as operating costs, included?",
          "Unclear breakdown of costs provided.",
          "Unclear breakdown of costs provided.",
          "Yes. No capital costs stated but equipment use costs clearly included.",
          "Yes Costs of overheads, building space, equipment, staff, and consumables included.",
          ""
        ],
        [
          "5. Were costs and consequences measured accurately in appropriate physical units?",
          "",
          "",
          "",
          "",
          ""
        ],
        [
          "5.1. Were any of the identified items omitted from measurement? If so, does this mean that they carried no weight in the subsequent analysis?",
          "No",
          "No",
          "No",
          "No",
          ""
        ],
        [
          "5.2. Were there any special circumstances (e.g., joint use of resources) that made measurement difficult? Were these circumstances handled appropriately?",
          "No",
          "No",
          "No",
          "No",
          ""
        ],
        [
          "6. Were the cost and consequences valued credibly?",
          "",
          "",
          "",
          "",
          ""
        ],
        [
          "6.1. Were the sources of all values clearly identified?",
          "No",
          "Yes",
          "Yes",
          "Yes",
          ""
        ],
        [
          "6.2. Were market values employed for changes involving resources gained or depleted?",
          "No",
          "Yes",
          "Yes",
          "Yes",
          ""
        ],
        [
          "6.3. Where market values were absent (e.g. volunteer labour), or market values did not reflect actual values (such as clinic space donated at a reduced rate), were adjustments made to approximate market values?",
          "N/A",
          "N/A",
          "N/A",
          "N/A",
          ""
        ],
        [
          "6.4. Was the valuation of consequences appropriate for the question posed?",
          "No",
          "Yes",
          "Yes",
          "Yes",
          ""
        ],
        [
          "7. Were costs and consequences adjusted for differential timing?",
          "",
          "",
          "",
          "",
          ""
        ],
        [
          "7.1. Were costs and consequences that occur in the future ‘discounted’ to their present values?",
          "No",
          "Yes, 3%",
          "Yes, 3%",
          "Yes, 3%",
          ""
        ],
        [
          "7.2. Was there any justification given for the discount rate used?",
          "No",
          "Yes, reference Sassi 2006.",
          "Yes, reference Brazilian Ministry of Health recommendations.",
          "No",
          ""
        ],
        [
          "8. Was an incremental analysis of costs and consequences of alternatives performed?",
          "",
          "",
          "",
          "",
          ""
        ],
        [
          "8.1. Were the additional (incremental) costs generated by one alternative over another compared to the additional effects, benefits, or utilities generated?",
          "Yes",
          "Yes",
          "Yes",
          "Yes",
          ""
        ],
        [
          "9. Was allowance made for uncertainty in the estimates of costs and consequences?",
          "",
          "",
          "",
          "",
          ""
        ],
        [
          "9.1. If data on costs and consequences were stochastic (randomly determined sequence of observations), were appropriate statistical analyses performed?",
          "Yes",
          "Yes",
          "Yes",
          "Yes",
          ""
        ],
        [
          "9.2. If sensitivity analysis was employed, was justification provided for the range of values (or for key study parameters)?",
          "No",
          "Yes",
          "Yes",
          "Yes",
          ""
        ],
        [
          "9.3. Were the study results sensitive to changes in the values?",
          "Yes Sensitive to treatments received.",
          "Yes Specificity of QFT-GIT.",
          "Yes Cost of DiaskinTest.",
          "Yes Sensitive to the probability of developing TB and LTBI prevalence",
          ""
        ],
        [
          "10. Did the presentation and discussion of study results include all issues of concern to users?",
          "",
          "",
          "",
          "",
          ""
        ],
        [
          "10.1. Were the conclusions of the analysis based on some overall index or ratio of costs to consequences (e.g. cost-effectiveness ratio)?",
          "Yes",
          "Yes",
          "Yes",
          "Yes",
          ""
        ],
        [
          "10.2. Were the results compared with those of others who have investigated the same question? If so, were allowances made for potential differences in study methodology?",
          "Yes",
          "Yes",
          "Yes",
          "Yes",
          ""
        ],
        [
          "10.3. Did the study discuss the generalisability of the results to other settings and patient/client groups?",
          "No",
          "Yes",
          "Yes",
          "Yes",
          ""
        ],
        [
          "10.4. Did the study allude to, or take account of, other important factors in the choice or decision under consideration (e.g. distribution of costs and consequences, or relevant ethical issues)?",
          "No",
          "Yes",
          "Yes",
          "Yes",
          ""
        ],
        [
          "10.5. Did the study discuss issues of implementation, such as the feasibility of adopting the ‘preferred’ programme given existing financial or other constraints, and whether any freed resources could be redeployed to other worthwhile programmes?",
          "No",
          "Yes",
          "Yes",
          "Yes",
          ""
        ]
      ],
      "notes": "[Draft note: the table runs over pages 1002–1043 in six blocks of studies, each with its own header row ('Drummond Checklist Questions' followed by the study names). Column titles are those of the first block (Linas 2011 to Shah 2012); the header rows of the later blocks (Mandalakas 2013 to Verma 2013; Capocci 2015 to Campbell 2017; Haukaas 2017 to Li 2018; Sohn 2018 to Png 2019; Al Abri 2020, Jo 2020, Steffen 2020, Kim 2018) are kept as body rows. The last block has only five columns, so its sixth column is empty. Pages 1015, 1023, 1030 and 1038 show only 'Continuation of Table A8' and page 1037 is blank. Cells split across pages are joined. In the third block the first criterion is printed '2. Was a well-defined question posed in answerable form?' and is kept as printed.]",
      "narratives": {
        "en": "Drummond checklist assessment of the quality of cost and cost-effectiveness analyses of the tuberculin skin test (TST) or interferon-gamma release assays (IGRA) for diagnosing TB infection. Rows are the checklist questions, grouped under ten main criteria; columns give each study's answer and comments, in six successive blocks of studies.",
        "ar": "تقييم جودة تحليلات التكلفة وفعالية التكلفة لاختبار التوبركولين الجلدي (TST) أو مقايسات إطلاق الإنترفيرون غاما (IGRA) لتشخيص عدوى السل باستخدام قائمة Drummond المرجعية. تمثل الصفوف أسئلة القائمة المرجعية مجمّعة تحت عشرة معايير رئيسية؛ وتبيّن الأعمدة إجابة كل دراسة وتعليقاتها، في ست مجموعات متتالية من الدراسات.",
        "zh": "采用Drummond清单评估结核菌素皮肤试验（TST）或γ干扰素释放试验（IGRA）诊断结核感染的成本和成本效果分析的质量。各行为清单问题，归入十项主要标准；各列给出每项研究的回答和评述，分为六组连续的研究。",
        "es": "Evaluación con la lista de verificación de Drummond de la calidad de los análisis de costos y de costo-efectividad de la prueba cutánea de la tuberculina (PT) o de los ensayos de liberación de interferón gamma (IGRA) para diagnosticar la infección tuberculosa. Las filas son las preguntas de la lista, agrupadas en diez criterios principales; las columnas indican la respuesta y los comentarios de cada estudio, en seis bloques sucesivos de estudios.",
        "fr": "Évaluation, au moyen de la liste de contrôle de Drummond, de la qualité des analyses de coût et de coût-efficacité de l’intradermoréaction à la tuberculine (IDR) ou des tests de libération d’interféron gamma (IGRA) pour le diagnostic de l’infection tuberculeuse. Les lignes correspondent aux questions de la liste, regroupées sous dix critères principaux ; les colonnes donnent la réponse et les commentaires de chaque étude, en six blocs successifs d’études.",
        "ru": "Оценка качества анализов затрат и экономической эффективности туберкулиновой кожной пробы (ТКП) или тестов высвобождения гамма-интерферона (IGRA) для диагностики туберкулезной инфекции по контрольному перечню Драммонда. Строки — вопросы перечня, сгруппированные по десяти основным критериям; в столбцах приведены ответы и комментарии по каждому исследованию в шести последовательных блоках исследований."
      },
      "csv": "tables/table-a8.csv"
    },
    {
      "label": "Table A9",
      "caption": "Table A9. Summary of the proportion of articles accomplishing each of the Drummond’s criteria",
      "pages": [
        1044,
        1045,
        1046
      ],
      "columns": [
        {
          "titles": "Drummond Checklist Questions"
        },
        {
          "titles": "All articles",
          "group": "% Of papers accomplishing each criterion"
        },
        {
          "titles": "DiaskinTest-related",
          "group": "% Of papers accomplishing each criterion"
        },
        {
          "titles": "TST or IGRA",
          "group": "% Of papers accomplishing each criterion"
        }
      ],
      "rows": [
        [
          "1. Was a well-defined question posed in answerable form?",
          "",
          "",
          ""
        ],
        [
          "1.1. Did the study examine both costs and effects of the service(s) or programme(s)?",
          "97.1%",
          "87.5%",
          "100.0%"
        ],
        [
          "1.2. Did the study involve a comparison of alternatives?",
          "100.0%",
          "100.0%",
          "100.0%"
        ],
        [
          "1.3. Was a viewpoint for the analysis stated and was the study placed in any decision-making context?",
          "100.0%",
          "100.0%",
          "100.0%"
        ],
        [
          "2. Was a comprehensive description of the competing alternatives given?",
          "",
          "",
          ""
        ],
        [
          "2.1. Were there any important alternatives omitted?",
          "5.7%",
          "25.0%",
          "0.0%"
        ],
        [
          "2.2. Was (should) a do-nothing alternative be considered?",
          "42.9%",
          "12.5%",
          "50.0%"
        ],
        [
          "3. Was the effectiveness of the programme or services established?",
          "",
          "",
          ""
        ],
        [
          "3.1. Was this done through a randomised, controlled clinical trial? If so, did the trial protocol reflect what would happen in regular practice?",
          "0.0%",
          "0.0%",
          "0.0%"
        ],
        [
          "3.2. Was effectiveness established through an overview of clinical studies?",
          "91.4%",
          "87.5%",
          "92.9%"
        ],
        [
          "3.3. Were observational data or assumptions used to establish effectiveness? If so, what are the potential biases in results?",
          "85.7%",
          "62.5%",
          "92.9%"
        ],
        [
          "4. Were all the important and relevant costs and consequences for each alternative identified?",
          "",
          "",
          ""
        ],
        [
          "4.1. Was the range wide enough for the research question at hand?",
          "97.1%",
          "100.0%",
          "96.4%"
        ],
        [
          "4.2. Did it cover all relevant viewpoints?",
          "100.0%",
          "100.0%",
          "100.0%"
        ],
        [
          "4.3. Were the capital costs, as well as operating costs, included?",
          "31.4%",
          "62.5%",
          "25.0%"
        ],
        [
          "5. Were costs and consequences measured accurately in appropriate physical units?",
          "",
          "",
          ""
        ],
        [
          "5.1. Were any of the identified items omitted from measurement? If so, does this mean that they carried no weight in the subsequent analysis?",
          "25.7%",
          "25.0%",
          "25.0%"
        ],
        [
          "5.2. Were there any special circumstances (e.g., joint use of resources) that made measurement difficult? Were these circumstances handled appropriately?",
          "0.0%",
          "0.0%",
          "0.0%"
        ],
        [
          "6. Were the cost and consequences valued credibly?",
          "",
          "",
          ""
        ],
        [
          "6.1. Were the sources of all values clearly identified?",
          "82.9%",
          "50.0%",
          "92.9%"
        ],
        [
          "6.2. Were market values employed for changes involving resources gained or depleted?",
          "94.3%",
          "100.0%",
          "92.9%"
        ],
        [
          "6.3. Where market values were absent (e.g. volunteer labour), or market values did not reflect actual values (such as clinic space donated at a reduced rate), were adjustments made to approximate market values?",
          "0.0%",
          "0.0%",
          "0.0%"
        ],
        [
          "6.4. Was the valuation of consequences appropriate for the question posed?",
          "94.3%",
          "87.5%",
          "96.4%"
        ],
        [
          "7. Were costs and consequences adjusted for differential timing?",
          "",
          "",
          ""
        ],
        [
          "7.1. Were costs and consequences that occur in the future ‘discounted’ to their present values?",
          "60.0%",
          "12.5%",
          "75.0%"
        ],
        [
          "7.2. Was there any justification given for the discount rate used?",
          "60.0%",
          "12.5%",
          "75.0%"
        ],
        [
          "8. Was an incremental analysis of costs and consequences of alternatives performed?",
          "",
          "",
          ""
        ],
        [
          "8.1. Were the additional (incremental) costs generated by one alternative over another compared to the additional effects, benefits, or utilities generated?",
          "94.3%",
          "75.0%",
          "100.0%"
        ],
        [
          "9. Was allowance made for uncertainty in the estimates of costs and consequences?",
          "",
          "",
          ""
        ],
        [
          "9.1. If data on costs and consequences were stochastic (randomly determined sequence of observations), were appropriate statistical analyses performed?",
          "77.1%",
          "37.5%",
          "89.3%"
        ],
        [
          "9.2. If sensitivity analysis was employed, was justification provided for the range of values (or for key study parameters)?",
          "71.4%",
          "37.5%",
          "82.1%"
        ],
        [
          "9.3. Were the study results sensitive to changes in the values?",
          "34.3%",
          "12.5%",
          "42.9%"
        ],
        [
          "10. Did the presentation and discussion of study results include all issues of concern to users?",
          "",
          "",
          ""
        ],
        [
          "10.1. Were the conclusions of the analysis based on some overall index or ratio of costs to consequences (e.g. cost-effectiveness ratio)?",
          "77.1%",
          "50.0%",
          "85.7%"
        ],
        [
          "10.2. Were the results compared with those of others who have investigated the same question? If so, were allowances made for potential differences in study methodology?",
          "40.0%",
          "12.5%",
          "50.0%"
        ],
        [
          "10.3. Did the study discuss the generalisability of the results to other settings and patient/client groups?",
          "57.1%",
          "37.5%",
          "64.3%"
        ],
        [
          "10.4. Did the study allude to, or take account of, other important factors in the choice or decision under consideration (e.g. distribution of costs and consequences, or relevant ethical issues)?",
          "62.9%",
          "37.5%",
          "71.4%"
        ],
        [
          "10.5. Did the study discuss issues of implementation, such as the feasibility of adopting the ‘preferred’ programme given existing financial or other constraints, and whether any freed resources could be redeployed to other worthwhile programmes?",
          "62.9%",
          "50.0%",
          "67.9%"
        ]
      ],
      "notes": "[Draft note: the caption is on page 1044; the table itself is on pages 1045–1046. Criterion rows (1.–10.) have empty value cells.]",
      "narratives": {
        "en": "Percentage of the reviewed economic evaluations that met each Drummond checklist criterion, for all articles, for DiaskinTest-related articles and for TST or IGRA articles. Rows are the checklist questions, grouped under ten main criteria.",
        "ar": "النسبة المئوية للتقييمات الاقتصادية المستعرضة التي استوفت كل معيار من معايير قائمة Drummond المرجعية، لجميع المقالات وللمقالات المتعلقة باختبار DiaskinTest وللمقالات المتعلقة باختبار التوبركولين الجلدي أو مقايسات إطلاق الإنترفيرون غاما. تمثل الصفوف أسئلة القائمة المرجعية مجمّعة تحت عشرة معايير رئيسية.",
        "zh": "所审查的经济学评价中符合Drummond清单各项标准的百分比，分为全部文章、DiaskinTest相关文章以及TST或IGRA文章。各行为清单问题，归入十项主要标准。",
        "es": "Porcentaje de las evaluaciones económicas examinadas que cumplieron cada criterio de la lista de verificación de Drummond, para todos los artículos, para los artículos relacionados con DiaskinTest y para los artículos sobre la PT o los IGRA. Las filas son las preguntas de la lista, agrupadas en diez criterios principales.",
        "fr": "Pourcentage des évaluations économiques examinées qui satisfont à chaque critère de la liste de contrôle de Drummond, pour l’ensemble des articles, pour les articles portant sur le DiaskinTest et pour ceux portant sur l’IDR ou les IGRA. Les lignes correspondent aux questions de la liste, regroupées sous dix critères principaux.",
        "ru": "Доля рассмотренных экономических оценок (в %), соответствующих каждому критерию контрольного перечня Драммонда, для всех статей, для статей, касающихся Диаскинтеста, и для статей о ТКП или IGRA. Строки — вопросы перечня, сгруппированные по десяти основным критериям."
      },
      "csv": "tables/table-a9.csv"
    },
    {
      "label": "Table B1",
      "caption": "Table B1. Calculation of the TBI progression",
      "pages": [
        1070
      ],
      "columns": [
        {
          "titles": "ISO code"
        },
        {
          "titles": "LTBI estimates 2014 1"
        },
        {
          "titles": "Population estimates 2014 9"
        },
        {
          "titles": "LTBI/population (%)"
        }
      ],
      "rows": [
        [
          "BRA",
          "26,900,000 [19,100,000 - 36,700,000]",
          "202,763,744",
          "13.27 [9.4 – 18.1]"
        ],
        [
          "GBR",
          "1,150,000 [ 867,000 - 1,790,000]",
          "65,423,048",
          "1.76 [1.3 – 2.7]"
        ],
        [
          "ZAF",
          "17,200,000 [15,700,000 - 19,700,000]",
          "54,544,184",
          "31.53 [28.8 – 36.1]"
        ]
      ],
      "notes": "[Draft note: the '1' and '9' after the year in the headers are superscript reference numbers.]",
      "narratives": {
        "en": "Estimated number of people with latent TB infection (LTBI) in 2014, total population in 2014 and the resulting LTBI prevalence (%) with uncertainty ranges, for Brazil (BRA), the United Kingdom (GBR) and South Africa (ZAF).",
        "ar": "العدد التقديري للأشخاص المصابين بعدوى السل الكامنة في عام 2014، وإجمالي عدد السكان في عام 2014، ونسبة انتشار عدوى السل الكامنة الناتجة (%) مع نطاقات عدم اليقين، للبرازيل (BRA) والمملكة المتحدة (GBR) وجنوب أفريقيا (ZAF).",
        "zh": "巴西（BRA）、英国（GBR）和南非（ZAF）2014年潜伏性结核感染估计人数、2014年总人口以及据此得出的潜伏性结核感染患病率（%）及其不确定性范围。",
        "es": "Número estimado de personas con infección tuberculosa latente (ITBL) en 2014, población total en 2014 y prevalencia resultante de la ITBL (%) con sus intervalos de incertidumbre, para el Brasil (BRA), el Reino Unido (GBR) y Sudáfrica (ZAF).",
        "fr": "Nombre estimé de personnes atteintes d’une infection tuberculeuse latente (ITL) en 2014, population totale en 2014 et prévalence de l’ITL qui en résulte (%) avec les intervalles d’incertitude, pour le Brésil (BRA), le Royaume-Uni (GBR) et l’Afrique du Sud (ZAF).",
        "ru": "Оценочное число людей с латентной туберкулезной инфекцией (ЛТИ) в 2014 г., общая численность населения в 2014 г. и полученная распространенность ЛТИ (%) с интервалами неопределенности для Бразилии (BRA), Соединенного Королевства (GBR) и Южной Африки (ZAF)."
      },
      "csv": "tables/table-b1.csv"
    },
    {
      "label": "Table B2",
      "caption": "Table B2. Progression from LTBI to active TB: population estimates",
      "pages": [
        1070,
        1071
      ],
      "columns": [
        {
          "titles": "Progression from LTBI to active TB, by treatment received"
        },
        {
          "titles": "Coeff probability (95% CI)"
        },
        {
          "titles": "Source"
        }
      ],
      "rows": [
        [
          "General population",
          "",
          ""
        ],
        [
          "Evolution of recent TBI to TB, without treatment for TBI",
          "0.08 (0.05–0.10)",
          "5-7"
        ],
        [
          "Evolution of remote TBI to TB, without treatment for TBI",
          "0.04 (0.025–0.05)",
          "5-7"
        ],
        [
          "HIV status",
          "",
          ""
        ],
        [
          "Proportion of TST or IGRA positive, untreated, HIV negative individuals progressing to active TB (post-exposure TB) over 20 years",
          "0.05 (0.025-0.15)",
          "22,24"
        ],
        [
          "Proportion of TST or IGRA positive, untreated, HIV positive individuals progressing to active TB (post-exposure TB) over 20 years",
          "0.40 (0.20-0.80)",
          "22,24"
        ]
      ],
      "notes": "Notes: All individuals in the model are assumed to belong to the general population with recent TBI infection. Differentiation between HIV status or duration of infection are not included in the model but these values are reported in this table to show how the model could be adapted to study different scenarios by modifying its parametrisation.",
      "narratives": {
        "en": "Probabilities (with 95% CI) of progression from latent TB infection to active TB used as model parameters, for recent and remote infection in the general population and by HIV status, with the reference sources.",
        "ar": "احتمالات (مع فترات ثقة 95%) التطور من عدوى السل الكامنة إلى السل النشط المستخدمة كمعلمات في النموذج، للعدوى الحديثة والقديمة لدى عامة السكان وحسب حالة فيروس العوز المناعي البشري، مع المراجع.",
        "zh": "作为模型参数使用的从潜伏性结核感染进展为活动性结核病的概率（含95%置信区间），按一般人群中的近期感染和既往感染以及艾滋病毒感染状况分列，并附参考来源。",
        "es": "Probabilidades (con IC del 95%) de progresión de la infección tuberculosa latente a tuberculosis activa utilizadas como parámetros del modelo, para la infección reciente y remota en la población general y según el estado serológico respecto del VIH, con las fuentes de referencia.",
        "fr": "Probabilités (avec IC à 95 %) de progression de l’infection tuberculeuse latente vers la tuberculose active utilisées comme paramètres du modèle, pour l’infection récente et ancienne dans la population générale et selon le statut VIH, avec les sources de référence.",
        "ru": "Вероятности (с 95% ДИ) прогрессирования латентной туберкулезной инфекции в активный туберкулез, используемые как параметры модели, для недавнего и давнего инфицирования в общей популяции и в зависимости от ВИЧ-статуса, с указанием источников."
      },
      "csv": "tables/table-b2.csv"
    },
    {
      "label": "Table B3",
      "caption": "Table B3. Costs per TBI treatment, by country (not inflated, different currencies)",
      "pages": [
        1071,
        1072
      ],
      "columns": [
        {
          "titles": "Cost per TBI treatment regime, by country"
        },
        {
          "titles": "Drug costs"
        },
        {
          "titles": "Staff costs (medical and nurse follow-up consultations) a"
        },
        {
          "titles": "Source"
        }
      ],
      "rows": [
        [
          "Brazil",
          "",
          "",
          ""
        ],
        [
          "3H",
          "$36.09",
          "$12.9",
          "2010 costs 17. Single cost per medical consultation= $4.3 Single cost Follow-up check= $4.3"
        ],
        [
          "6H",
          "$72.18",
          "$25.8",
          ""
        ],
        [
          "9H",
          "$108.27",
          "$38.7",
          ""
        ],
        [
          "12H",
          "$144.36",
          "$51.6",
          ""
        ],
        [
          "South Africa",
          "",
          "",
          ""
        ],
        [
          "3H",
          "$2.7",
          "$2.52",
          "2016 costs,18. Single cost per medical consultation= $0.98 Single cost Follow-up check= $0.77"
        ],
        [
          "6H",
          "$5.4",
          "$4.83",
          ""
        ],
        [
          "9H",
          "$8.1",
          "$7.14",
          ""
        ],
        [
          "12H",
          "$10.8",
          "$9.45",
          ""
        ],
        [
          "United Kingdom*",
          "",
          "",
          ""
        ],
        [
          "3H",
          "£173",
          "£254",
          "2015 costs 19 Single cost per medical consultation= £126 Single cost Follow-up check= £64"
        ],
        [
          "6H",
          "£341",
          "£446",
          ""
        ],
        [
          "9H",
          "£681",
          "£638",
          ""
        ],
        [
          "12H",
          "£693",
          "£830",
          ""
        ]
      ],
      "notes": "Notes: 3H= three months of treatment with isoniazid (300 mg/day), 6H= 6 months treatment with isoniazid, 9H= = 9 months treatment with isoniazid, 12= 12 months treatment with isoniazid, 2. a Calculated considering one medical check plus the number of follow-up checks administered by nurses depending upon the regimen, it is as follows: 3H: 2 nurse consultations; 6H: 5; 9H: 8; 12H: 11. *Drug costs were obtained from the NHS drug tariff (2014) (for H and R) and British National Formulary (2013) (for Pz); quantities of drugs used for each regimen were supplied by NICE. Staff costs were calculated from the amounts of staff time required for administration of LTBI treatment, based on GDG advice, and the cost of that time according to NHS reference costs (Curtis 2013). [Draft note: the notes run onto page 1072. In the Source column each country's text is printed as one block beside the four regimens; the numbers after the cost years (17, 18, 19) are superscript references.]",
      "narratives": {
        "en": "Drug costs and staff (medical and nurse follow-up consultation) costs of isoniazid preventive treatment regimens of 3, 6, 9 and 12 months (3H–12H) in Brazil, South Africa and the United Kingdom, in local currency and cost year, with the source and unit consultation costs.",
        "ar": "تكاليف الأدوية وتكاليف الموظفين (استشارات المتابعة الطبية والتمريضية) لنُظم العلاج الوقائي بالأيزونيازيد لمدة 3 و6 و9 و12 شهراً (3H–12H) في البرازيل وجنوب أفريقيا والمملكة المتحدة، بالعملة المحلية وسنة التكلفة، مع المصدر وتكاليف الاستشارة الواحدة.",
        "zh": "巴西、南非和英国3、6、9和12个月异烟肼预防性治疗方案（3H–12H）的药品费用和人员费用（医生和护士随访咨询），以当地货币和成本年份表示，并列出来源及单次咨询费用。",
        "es": "Costos de medicamentos y de personal (consultas médicas y de seguimiento de enfermería) de los regímenes de tratamiento preventivo con isoniazida de 3, 6, 9 y 12 meses (3H–12H) en el Brasil, Sudáfrica y el Reino Unido, en moneda local y año de costo, con la fuente y los costos unitarios de las consultas.",
        "fr": "Coûts des médicaments et du personnel (consultations médicales et de suivi infirmier) des schémas de traitement préventif par l’isoniazide de 3, 6, 9 et 12 mois (3H–12H) au Brésil, en Afrique du Sud et au Royaume-Uni, en monnaie locale et par année de coût, avec la source et le coût unitaire des consultations.",
        "ru": "Затраты на лекарственные препараты и на персонал (врачебные и сестринские контрольные консультации) для схем профилактического лечения изониазидом продолжительностью 3, 6, 9 и 12 месяцев (3H–12H) в Бразилии, Южной Африке и Соединенном Королевстве в местной валюте и ценах соответствующего года, с указанием источника и стоимости одной консультации."
      },
      "csv": "tables/table-b3.csv"
    },
    {
      "label": "Table B4",
      "caption": "Table B4. Cost of the Diaskin Test per vial for different delivery volumes and considering that 1 vial is used for 15 patients",
      "pages": [
        1072
      ],
      "columns": [
        {
          "titles": "Volume"
        },
        {
          "titles": "Price per vial"
        },
        {
          "titles": "Delivery costs Brazil"
        },
        {
          "titles": "Delivery costs UK"
        },
        {
          "titles": "Delivery costs South Africa"
        }
      ],
      "rows": [
        [
          "667 pack",
          "$ 24.3",
          "$ 7,405",
          "$ 5,227",
          "$ 5,676"
        ],
        [
          "6,667 pack",
          "$ 22.3",
          "$ 18,560",
          "$ 7,948",
          "$ 18,199"
        ],
        [
          "30,000 pack",
          "$ 19.3",
          "-",
          "-",
          "-"
        ],
        [
          "60,000 pack",
          "$ 19.3",
          "-",
          "-",
          "-"
        ],
        [
          "150,000 and more pack",
          "$ 17.8",
          "-",
          "-",
          "-"
        ]
      ],
      "notes": "Notes: All prices are indicated for 1 vial (for 15 patients). The 100% shelf life of Diaskintest is 2 years. Data provided by the test manufacturer.",
      "narratives": {
        "en": "Price per vial of the Diaskin Test by order volume (from 667 to 150,000 or more packs), and delivery costs to Brazil, the UK and South Africa for the two smallest volumes.",
        "ar": "سعر القارورة الواحدة من اختبار Diaskin حسب حجم الطلبية (من 667 إلى 150000 عبوة أو أكثر)، وتكاليف التوصيل إلى البرازيل والمملكة المتحدة وجنوب أفريقيا لأصغر حجمين.",
        "zh": "按订购量（667包至150 000包及以上）列出的Diaskin试验每瓶价格，以及两个最小订购量运往巴西、英国和南非的运输费用。",
        "es": "Precio por vial de la prueba Diaskin según el volumen del pedido (de 667 a 150 000 o más envases) y costos de envío al Brasil, el Reino Unido y Sudáfrica para los dos volúmenes más pequeños.",
        "fr": "Prix par flacon du test Diaskin selon le volume de commande (de 667 à 150 000 conditionnements ou plus) et coûts de livraison au Brésil, au Royaume-Uni et en Afrique du Sud pour les deux plus petits volumes.",
        "ru": "Цена одного флакона Диаскинтеста в зависимости от объема поставки (от 667 до 150 000 и более упаковок) и затраты на доставку в Бразилию, Соединенное Королевство и Южную Африку для двух наименьших объемов."
      },
      "csv": "tables/table-b4.csv"
    },
    {
      "label": "Table B5",
      "caption": "Table B5. Full costs including delivery, and cost per patient by country",
      "pages": [
        1072
      ],
      "columns": [
        {
          "titles": "Volume"
        },
        {
          "titles": "Full price excluding delivery"
        },
        {
          "titles": "Number of patients treated"
        },
        {
          "titles": "Full costs + delivery Brazil"
        },
        {
          "titles": "Full costs + delivery UK"
        },
        {
          "titles": "Full costs + delivery South Africa"
        }
      ],
      "rows": [
        [
          "667 pack",
          "$16,208.1",
          "10,005",
          "$ 7,405",
          "$ 5,227",
          "$ 5,676"
        ],
        [
          "6,667 pack",
          "$148,674.1",
          "100,005",
          "$ 18,560",
          "$ 7,948",
          "$ 18,199"
        ],
        [
          "Price per patient:",
          "",
          "",
          "",
          "",
          ""
        ],
        [
          "667 pack",
          "$ 1.62",
          "-",
          "$ 2.36",
          "$ 2.14",
          "$ 2.19"
        ],
        [
          "6,667 pack",
          "$ 1.49",
          "-",
          "$ 1.67",
          "$ 1.57",
          "$ 1.67"
        ]
      ],
      "notes": "Notes. The 100% shelf life of Diaskintest is 2 years. Data provided by the test manufacturer.",
      "narratives": {
        "en": "Full Diaskin Test costs for 667-pack and 6,667-pack orders, excluding delivery and including delivery to Brazil, the UK and South Africa, with the number of patients treated and the resulting price per patient.",
        "ar": "التكاليف الكاملة لاختبار Diaskin لطلبيات من 667 عبوة و6667 عبوة، بدون التوصيل ومع التوصيل إلى البرازيل والمملكة المتحدة وجنوب أفريقيا، مع عدد المرضى المعالَجين والسعر الناتج لكل مريض.",
        "zh": "667包和6 667包订购量的Diaskin试验全部费用（不含运输费，以及含运往巴西、英国和南非的运输费），并列出治疗患者人数和由此得出的每名患者价格。",
        "es": "Costos totales de la prueba Diaskin para pedidos de 667 y 6667 envases, sin envío y con envío al Brasil, el Reino Unido y Sudáfrica, con el número de pacientes tratados y el precio resultante por paciente.",
        "fr": "Coûts complets du test Diaskin pour des commandes de 667 et 6 667 conditionnements, hors livraison et avec livraison au Brésil, au Royaume-Uni et en Afrique du Sud, avec le nombre de patients traités et le prix par patient qui en résulte.",
        "ru": "Полные затраты на Диаскинтест при заказе 667 и 6667 упаковок без учета доставки и с доставкой в Бразилию, Соединенное Королевство и Южную Африку, с числом пролеченных пациентов и полученной ценой на одного пациента."
      },
      "csv": "tables/table-b5.csv"
    },
    {
      "label": "Table B6",
      "caption": "Table B6: Drummond checklist for the quality of our study: Cost-effectiveness analyses for Novel skin tests for diagnosing TBI",
      "pages": [
        1073,
        1074,
        1075
      ],
      "columns": [
        {
          "titles": "Drummond Checklist Questions"
        },
        {
          "titles": "Our study"
        }
      ],
      "rows": [
        [
          "1.Was a well-defined question posed in answerable form?",
          ""
        ],
        [
          "1.1. Did the study examine both costs and effects of the service(s) or programme(s)?",
          "Yes"
        ],
        [
          "1.2. Did the study involve a comparison of alternatives?",
          "Yes"
        ],
        [
          "1.3. Was a viewpoint for the analysis stated and was the study placed in any decision-making context?",
          "Yes Adult population"
        ],
        [
          "2. Was a comprehensive description of the competing alternatives given?",
          ""
        ],
        [
          "2.1. Were there any important alternatives omitted?",
          "No"
        ],
        [
          "2.2. Was (should) a do-nothing alternative be considered?",
          "No"
        ],
        [
          "3. Was the effectiveness of the programme or services established?",
          ""
        ],
        [
          "3.1. Was this done through a randomised, controlled clinical trial? If so, did the trial protocol reflect what would happen in regular practice?",
          "No"
        ],
        [
          "3.2. Was effectiveness established through an overview of clinical studies?",
          "Yes Sensitivity and specificity of tests values from number of clinical studies and systematic reviews"
        ],
        [
          "3.3. Were observational data or assumptions used to establish effectiveness? If so, what are the potential biases in results?",
          "Yes All assumptions for effectiveness all have adequate references/reasoning."
        ],
        [
          "4. Were all the important and relevant costs and consequences for each alternative identified?",
          ""
        ],
        [
          "4.1. Was the range wide enough for the research question at hand?",
          "Yes"
        ],
        [
          "4.2. Did it cover all relevant viewpoints?",
          "Yes"
        ],
        [
          "4.3. Were the capital costs, as well as operating costs, included?",
          "Diagnostic, treatment, staff, laboratory, material, and operating costs included"
        ],
        [
          "5. Were costs and consequences measured accurately in appropriate physical units?",
          ""
        ],
        [
          "5.1. Were any of the identified items omitted from measurement? If so, does this mean that they carried no weight in the subsequent analysis?",
          "No"
        ],
        [
          "5.2. Were there any special circumstances (e.g., joint use of resources) that made measurement difficult? Were these circumstances handled appropriately?",
          "No"
        ],
        [
          "6. Were the cost and consequences valued credibly?",
          ""
        ],
        [
          "6.1. Were the sources of all values clearly identified?",
          "Yes"
        ],
        [
          "6.2. Were market values employed for changes involving resources gained or depleted?",
          "Yes"
        ],
        [
          "6.3. Where market values were absent (e.g. volunteer labour), or market values did not reflect actual values (such as clinic space donated at a reduced rate), were adjustments made to approximate market values?",
          "No"
        ],
        [
          "6.4. Was the valuation of consequences appropriate for the question posed?",
          "No"
        ],
        [
          "7. Were costs and consequences adjusted for differential timing?",
          ""
        ],
        [
          "7.1. Were costs and consequences that occur in the future ‘discounted’ to their present values?",
          "Yes"
        ],
        [
          "7.2. Was there any justification given for the discount rate used?",
          "Yes"
        ],
        [
          "8. Was an incremental analysis of costs and consequences of alternatives performed?",
          ""
        ],
        [
          "8.1. Were the additional (incremental) costs generated by one alternative over another compared to the additional effects, benefits, or utilities generated?",
          "Yes"
        ],
        [
          "9. Was allowance made for uncertainty in the estimates of costs and consequences?",
          ""
        ],
        [
          "9.1. If data on costs and consequences were stochastic (randomly determined sequence of observations), were appropriate statistical analyses performed?",
          "Yes"
        ],
        [
          "9.2. If sensitivity analysis was employed, was justification provided for the range of values (or for key study parameters)?",
          "Yes"
        ],
        [
          "9.3. Were the study results sensitive to changes in the values?",
          "Yes Sensitive to treatments received."
        ],
        [
          "10. Did the presentation and discussion of study results include all issues of concern to users?",
          ""
        ],
        [
          "10.1. Were the conclusions of the analysis based on some overall index or ratio of costs to consequences (e.g. cost-effectiveness ratio)?",
          "Yes"
        ],
        [
          "10.2. Were the results compared with those of others who have investigated the same question? If so, were allowances made for potential differences in study methodology?",
          "Yes"
        ],
        [
          "10.3. Did the study discuss the generalisability of the results to other settings and patient/client groups?",
          "Yes"
        ],
        [
          "10.4. Did the study allude to, or take account of, other important factors in the choice or decision under consideration (e.g. distribution of costs and consequences, or relevant ethical issues)?",
          "Yes"
        ],
        [
          "10.5. Did the study discuss issues of implementation, such as the feasibility of adopting the ‘preferred’ programme given existing financial or other constraints, and whether any freed resources could be redeployed to other worthwhile programmes?",
          "Yes"
        ]
      ],
      "notes": "[Draft note: the table runs over pages 1073–1075.]",
      "narratives": {
        "en": "Self-assessment of the review's own cost-effectiveness analysis of novel skin tests for diagnosing TB infection against the Drummond checklist. Rows are the checklist questions, grouped under ten main criteria; the single column gives the answer and comments for this study.",
        "ar": "تقييم ذاتي لتحليل فعالية التكلفة الذي أجرته المراجعة نفسها لاختبارات الجلد الجديدة لتشخيص عدوى السل وفقاً لقائمة Drummond المرجعية. تمثل الصفوف أسئلة القائمة المرجعية مجمّعة تحت عشرة معايير رئيسية؛ ويبيّن العمود الوحيد الإجابة والتعليقات الخاصة بهذه الدراسة.",
        "zh": "按照Drummond清单对本研究自身开展的结核感染新型皮肤试验诊断成本效果分析进行的自我评估。各行为清单问题，归入十项主要标准；唯一一列给出本研究的回答和评述。",
        "es": "Autoevaluación, con la lista de verificación de Drummond, del propio análisis de costo-efectividad de las nuevas pruebas cutáneas para diagnosticar la infección tuberculosa. Las filas son las preguntas de la lista, agrupadas en diez criterios principales; la única columna indica la respuesta y los comentarios para este estudio.",
        "fr": "Auto-évaluation, au moyen de la liste de contrôle de Drummond, de la propre analyse coût-efficacité des nouveaux tests cutanés pour le diagnostic de l’infection tuberculeuse. Les lignes correspondent aux questions de la liste, regroupées sous dix critères principaux ; l’unique colonne donne la réponse et les commentaires pour cette étude.",
        "ru": "Самооценка собственного анализа экономической эффективности новых кожных тестов для диагностики туберкулезной инфекции по контрольному перечню Драммонда. Строки — вопросы перечня, сгруппированные по десяти основным критериям; в единственном столбце приведены ответ и комментарии по данному исследованию."
      },
      "csv": "tables/table-b6.csv"
    },
    {
      "label": "Table A1",
      "caption": "Table A1: Systematic Reviews A and B- Characteristics of Included Studies",
      "pages": [
        1090
      ],
      "columns": [
        {
          "titles": "Study ID"
        },
        {
          "titles": "Publication type"
        },
        {
          "titles": "TBI Tests"
        },
        {
          "titles": "Country"
        },
        {
          "titles": "Facility Type"
        },
        {
          "titles": "Public/ Private"
        },
        {
          "titles": "Rural/ Urban"
        },
        {
          "titles": "Participants"
        },
        {
          "titles": "Programmatic features"
        },
        {
          "titles": "Comparators"
        },
        {
          "titles": "Data collection"
        },
        {
          "titles": "Study duration"
        },
        {
          "titles": "Method of data analysis"
        },
        {
          "titles": "Conceptual framework"
        },
        {
          "titles": "Conflicts of Interest"
        }
      ],
      "rows": [
        [
          "Review A findings on TBST",
          "",
          "",
          "",
          "",
          "",
          "",
          "",
          "",
          "",
          "",
          "",
          "",
          "",
          ""
        ],
        [
          "Aksenova 2021 (Review A)",
          "Report (WHO call for data)",
          "Diaskintest",
          "Russian Federation",
          "Not reported",
          "Not reported",
          "Not reported",
          "Parents of children and adolescents undergoing TB screening. Demographic data not reported.",
          "Tests were administered as part of a large-scale screening program for TBI in children and adolescents in the Penza region of the Russian Federation.",
          "No comparator",
          "Not reported",
          "Not reported",
          "Not reported",
          "N/A",
          "Not reported"
        ],
        [
          "Review B findings on TST and IGRA",
          "",
          "",
          "",
          "",
          "",
          "",
          "",
          "",
          "",
          "",
          "",
          "",
          "",
          ""
        ],
        [
          "Kerrigan 2018 (Review B)",
          "Peer-reviewed article",
          "IGRA (QuantiFERON TB Gold In-Tube [QGIT])",
          "South Africa",
          "14 primary care clinics",
          "Public",
          "Not reported",
          "28 HIV patients and 28 clinical care providers (12 TB nurses, 11 professional nurses, 3 counsellors, 1 operational manager, 1 community health worker). Mean age of patients 38.4 years. 50% male patients.",
          "Clinics were participating in the TEKO trial (investigating cost-effectiveness of the IGRA during routine CD4 count blood draws in HIV-infected adults compared to the TST).",
          "TST",
          "Individual interviews using a semi-structured guide",
          "2 months (April – June, 2014)",
          "Thematic content analysis",
          "No formal framework. Interviews followed a semi-structured guide.",
          "None to declare"
        ],
        [
          "Pascopella 2014 (Review B)",
          "Peer-reviewed article",
          "IGRA",
          "United States",
          "4 clinics (2 hospital-based; 1 private clinic; 1 health department clinic)",
          "Public",
          "Urban",
          "20 clinic staff. Demographic data not reported.",
          "All clinics took part in the Health Resources & Services Administration (HRSA) quality assurance program for persons with low-income living with HIV/AIDS. Two clinics were part C funded by the Ryan White HIV/AIDS Program of the HRSA.",
          "TST",
          "Individual interviews using a semi-structured guide",
          "2 years (2008 – 2010)",
          "Not explicitly reported (describes using data to inform themes but does not describe the analytic process)",
          "N/A",
          "None to declare"
        ],
        [
          "Spruijt 2019 (Review B)",
          "Peer-reviewed article",
          "IGRA (QuantiFERON TB Gold Plus [QFT-Plus])",
          "The Netherlands",
          "5 Public Health Services",
          "Public",
          "Both urban and rural",
          "5 PHS teams (each comprised of at least 1 Medical Technical Assistant, 1 TB nurse, 1 TB physician). No demographic data reported.",
          "Public Health Services focused on treating new immigrants (not applying for asylum) from non-EU countries with a TB incidence of >50/100,000 population.",
          "TST",
          "Semi- structured group interviews",
          "6 months (March – September, 2016)",
          "Thematic analysis (although not explicitly reported; describes development of a coding scheme refined through author agreement)",
          "Levesque’s conceptual framework for access to care",
          "Qiagen provided the IGRA kits free of charge but did not contribute to study design or analysis."
        ]
      ],
      "notes": "[Draft note: words hyphenated at line ends in narrow cells (e.g. 'Comparato-rs', 'QuantiFER-ON', 'Septemb-er') are joined.]",
      "narratives": {
        "en": "Characteristics of the four qualitative studies included in Systematic Review A (TBST) and Systematic Review B (TST and IGRA): publication type, tests, country, facility type and setting, participants, programmatic features, comparators, data collection, study duration, method of analysis, conceptual framework and conflicts of interest.",
        "ar": "خصائص الدراسات النوعية الأربع المشمولة في المراجعة المنهجية A (اختبارات الجلد القائمة على مستضدات السل) والمراجعة المنهجية B (اختبار التوبركولين الجلدي ومقايسات إطلاق الإنترفيرون غاما): نوع المنشور، والاختبارات، والبلد، ونوع المرفق وموقعه، والمشاركون، والسمات البرنامجية، والمقارنات، وجمع البيانات، ومدة الدراسة، وطريقة التحليل، والإطار المفاهيمي، وتضارب المصالح.",
        "zh": "系统综述A（基于结核抗原的皮肤试验）和系统综述B（TST和IGRA）所纳入的四项定性研究的特征：出版物类型、检测方法、国家、机构类型和环境、参与者、规划特点、对照、数据收集、研究持续时间、分析方法、概念框架和利益冲突。",
        "es": "Características de los cuatro estudios cualitativos incluidos en la revisión sistemática A (pruebas cutáneas basadas en antígenos de M. tuberculosis) y la revisión sistemática B (PT e IGRA): tipo de publicación, pruebas, país, tipo y entorno del establecimiento, participantes, características programáticas, comparadores, recopilación de datos, duración del estudio, método de análisis, marco conceptual y conflictos de intereses.",
        "fr": "Caractéristiques des quatre études qualitatives incluses dans la revue systématique A (tests cutanés à base d’antigènes de M. tuberculosis) et la revue systématique B (IDR et IGRA) : type de publication, tests, pays, type et cadre de l’établissement, participants, caractéristiques programmatiques, comparateurs, collecte des données, durée de l’étude, méthode d’analyse, cadre conceptuel et conflits d’intérêts.",
        "ru": "Характеристики четырех качественных исследований, включенных в систематический обзор A (кожные тесты на основе антигенов M. tuberculosis) и систематический обзор B (ТКП и IGRA): тип публикации, тесты, страна, тип учреждения и местность, участники, особенности программы, тесты сравнения, сбор данных, продолжительность исследования, метод анализа, концептуальная основа и конфликт интересов."
      },
      "csv": "tables/table-a1.csv"
    },
    {
      "label": "Table C1",
      "caption": "Table C1: List of attributes and levels included in both provider and consumer DCEs",
      "pages": [
        1120
      ],
      "columns": [
        {
          "titles": "Attribute",
          "group": "Provider DCE"
        },
        {
          "titles": "Levels",
          "group": "Provider DCE"
        },
        {
          "titles": "Description",
          "group": "Consumer DCE"
        },
        {
          "titles": "Levels",
          "group": "Consumer DCE"
        }
      ],
      "rows": [
        [
          "Cost to healthcare practice",
          "USD 100",
          "Time required for test results to come back",
          "1 day"
        ],
        [
          "",
          "USD 50",
          "",
          "3 days"
        ],
        [
          "",
          "USD 25",
          "",
          "7 days"
        ],
        [
          "If a follow-up appointment is needed to get test results",
          "In-person follow-up appointment needed",
          "If a follow-up appointment is needed to get test results",
          "In-person follow-up appointment needed to get results"
        ],
        [
          "",
          "No follow-up appointment required",
          "",
          "No follow-up appointment required"
        ],
        [
          "Chance of the test wrongly saying you have TB infection when you do not 27,28",
          "1% chance you will get treatment you don’t need",
          "Chance of the test wrongly saying you have TB infection when you do not 27,28",
          "1% chance you will get treatment you don’t need"
        ],
        [
          "",
          "5% chance you will get treatment you don’t need",
          "",
          "5% chance you will get treatment you don’t need"
        ],
        [
          "",
          "10% chance you will get treatment you don’t need",
          "",
          "10% chance you will get treatment you don’t need"
        ],
        [
          "Chance of the test wrongly telling you that you do not have TB infection when you do 27,28",
          "15% chance you will not get treatment when you need it",
          "Chance of the test wrongly telling you that you do not have TB infection when you do 27,28",
          "15% chance you will not get treatment when you need it"
        ],
        [
          "",
          "20% chance you will not get treatment when you need it",
          "",
          "20% chance you will not get treatment when you need it"
        ],
        [
          "",
          "25% chance you will not get treatment when you need it",
          "",
          "25% chance you will not get treatment when you need it"
        ],
        [
          "Ease of administration and interpretation",
          "Does not require specialist staff or equipment to administer or interpret",
          "Where you can get the test",
          "Hospital only"
        ],
        [
          "",
          "Requires specialist staff or equipment to administer or interpret",
          "",
          "Primary care (e.g. family doctor, GP, pharmacy)"
        ],
        [
          "",
          "",
          "",
          "Community (e.g. workplace or your house)"
        ],
        [
          "",
          "",
          "How the test is performed",
          "Skin prick and blood drawn"
        ],
        [
          "",
          "",
          "",
          "Skin prick and injection under the skin"
        ]
      ],
      "notes": "NB. Shaded cells denote attributes common across the provider and consumer DCEs. [Draft note: the shaded (common) attributes are the follow-up appointment and the two test-error attributes (body rows 4–11). '27,28' after the error attributes is a superscript reference. The provider side ends after row 13; the consumer side continues to row 16.]",
      "narratives": {
        "en": "Attributes and their levels used in the discrete choice experiments (DCEs) for providers and for consumers, side by side; attributes common to both DCEs are shaded.",
        "ar": "السمات ومستوياتها المستخدمة في تجارب الاختيار المنفصل لمقدمي الخدمات وللمستهلكين، جنباً إلى جنب؛ والسمات المشتركة بين التجربتين مظللة.",
        "zh": "并列列出用于医疗服务提供者和消费者离散选择实验（DCE）的属性及其水平；两项DCE共有的属性以阴影标示。",
        "es": "Atributos y sus niveles utilizados en los experimentos de elección discreta (EED) para proveedores y para consumidores, uno al lado del otro; los atributos comunes a ambos EED están sombreados.",
        "fr": "Attributs et niveaux utilisés dans les expériences de choix discrets (ECD) auprès des prestataires et des consommateurs, présentés côte à côte ; les attributs communs aux deux ECD sont grisés.",
        "ru": "Атрибуты и их уровни, использованные в экспериментах с дискретным выбором (ЭДВ) для поставщиков услуг и для потребителей, в сопоставлении; атрибуты, общие для обоих ЭДВ, выделены заливкой."
      },
      "csv": "tables/table-c1.csv"
    }
  ],
  "coverage": [
    {
      "kind": "contents",
      "state": "not-extracted",
      "note": "split one section per page; no contents was trusted"
    },
    {
      "kind": "sections",
      "state": "partial",
      "count": 1169,
      "note": "one per page, not by heading"
    },
    {
      "kind": "figures",
      "state": "found",
      "count": 278
    },
    {
      "kind": "tables",
      "state": "found",
      "count": 57
    },
    {
      "kind": "references",
      "state": "not-extracted",
      "note": "a references section is in the text (p36); its entries are not extracted"
    },
    {
      "kind": "glossary",
      "state": "not-extracted",
      "note": "a glossary section is in the text (p381); its entries are not extracted"
    },
    {
      "kind": "footnotes",
      "state": "not-extracted"
    },
    {
      "kind": "summaries",
      "state": "found",
      "count": 1169,
      "note": "1169 of 1169 sections"
    }
  ],
  "links": {
    "repo": "litlfred/who-iris",
    "branch": "main",
    "dir": "library/10665-381036"
  }
}
